Final Program

Final Program

Interscience Conference on Antimicrobial Agents and Chemotherapy

ASM’s Premier Annual Conference on Infectious Diseases and Antimicrobial Agents Moscone Convention Center | San Francisco, CA www.icaac.org

COMING THIS NOVEMBER

Official Peer-Reviewed Highlights

Want to know more?

Peer-Rev

iewed INFECTIO

Clinica l Trial Highlig hts

US DISE

ASE

OFFICIAL PEER-REVI EWED HIGHLIGH TS FROM THE

52 nd Inters cience Co on Antim nfe icrobial Ag rence ents and Chemoth erapy

Translatio nal Resear ch

Therap eutic Updates

Infectio New Op us Disease Ge

Scan for the ICAAC 2011 edition

Distribution

of this inde is support pendent report ed by

September San Francis 9 - 12, 2012 co, Califor nia, USA

nomics: Techno portunitite logical Individu advanc s million al Varia es now genetic bility, enable variants A large compar number in subjec isons of immune of mo -related novel genetic ts with diseas e and pop re than a hal bowel disease, diseases, such loci involved f a ulation in sus as rheum studies. hav control More rec e been ide s. atoid arth ceptibility to ntif identify com ently, this ied riti loc methodol through gen s and inflam mon Immuno i involved in matory ome-w ogy has infectio l Rev 201 ide ass been suc us 1]. See cessfully ociation page 4. disease suscep applied tibility [Vannb to erg FO et al. t Hot

ALSO IN THIS

ISSUE

Topics in Vaccines t Clinical Tria Behind Infe l Highlights – The Science ctious Dis t Novel ease Approache s to Antiba cterial Dru

g Discov

ery

7RSUHVHDUFKNH\ILQGLQJVDQGSUDFWLFHFKDQJLQJXSGDWHV &RQWHQWJXLGHGE\,&$$&3URJUDP&RPPLWWHH $UWLFOHVZULWWHQVWULFWO\IURPSULPDU\VRXUFHGDWD 3HHUUHYLHZHGE\LQGHSHQGHQWH[SHUWV

Produced by:

Distribution supported by:

>Table of Contents ICAAC Program Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Welcome Letter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Corporate Supporters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 ICAAC Mobile App . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Schedule-at-a-Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 ICAAC Awards and Lectures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Opening Keynote Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 ICAAC Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Cubist-ICAAC Award and Lecture . . . . . . . . . . . . . . . . . . . . . . 8 ICAAC Program Committee Awards . . . . . . . . . . . . . . . . . . . . . 9 ICAAC Young Investigator Awards . . . . . . . . . . . . . . . . . . . . . 10 Poster Walks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Grant and Travel Grant Recipients . . . . . . . . . . . . . . . . . . . . . . . . 13 ICAAC ID Fellows Grant Program . . . . . . . . . . . . . . . . . . . . . 13 ASM Infectious Diseases (ID) Fellow Travel Grants . . . . . . 14 ASM Student and Post-Doctoral Fellow Travel Grants . . . . 15 American Society for Microbiology Products and Services . . . . 17 Career Connections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 ASM Journals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 ASM Press Bookstore . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Membership . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Press Room and ICAAC Live . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Convention Center Floor Plans . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Hotel Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Hotel Map. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Shuttle Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Abstract Compilations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Abstracts on CD-ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Americans with Disabilities Act . . . . . . . . . . . . . . . . . . . . . . 23 ATM Machines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Badge Policies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Business Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 Cameras and Recordings . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 Certificate of Attendance . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 Child Safety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 Coat and Baggage Check . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 Cooperating Organizations. . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 E-Central . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 Exhibit Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 ExpoCard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 First Aid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Food and Beverage Services . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Future Meetings Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Housing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Information Booths . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Lost and Found . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Multimedia Sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Nursing Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Parking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Poster Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Poster Walks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

Program Changes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Registration Hours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Satellite Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Sessions and Room Capacity . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Shipping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Shuttle Service . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Smoking Policy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Telephone Numbers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Transportation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Continuing Education . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 Glossary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 Scientific Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 Sunday . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 Monday . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 Tuesday . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127 Wednesday . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183 Indices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207 Abstract Authors Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207 Keyword Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261 Program Grid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 279 Late-breakers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295 Late-breaker Presentations . . . . . . . . . . . . . . . . . . . . . . . . . . 295 Late-breaker Abstracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . .305 Late-breaker Author Index . . . . . . . . . . . . . . . . . . . . . . . . . . 339 Late-breaker Keyword Index . . . . . . . . . . . . . . . . . . . . . . . . . 345

Final Program

ICAAC Headquarters: American Society for Microbiology Meetings & Exhibits 1752 N Street, NW Washington, DC 20036-2904 Telephone: (202) 737-3600 Fax: (202) 942-9340 E-mail: [email protected] Internet: www.icaac.org Copyright © 2012 American Society for Microbiology Printed in the United States of America ISBN: 978-1-55581-873-9 ISSN: 0733-6373

3

> ICAAC 2012 Program Committee M. Lindsay Grayson, MD, Chair Austin Hospital, Melbourne, Australia

Craig E. Rubens, MD, PhD, Vice Chair Seattle Children’s Hospital Research Institute, Seattle, WA

Judith A. Aberg, MD

Alan Magill, MD

New York University School of Medicine, New York, NY

Walter Reed Army Medical Institute of Research, Silver Spring, MD

David Michael Aronoff, MD

Lesley McGee, PhD

University of Michigan Health System, Ann Arbor, MI

Centers for Disease Control and Prevention, Atlanta, GA

Emily Blumberg, MD

Jean-Michel Molina, MD, PhD

University of Pennsylvania, Philadelphia, PA

Hospital Saint Louis, Paris, France

Guy Boivin, MD

Patrice Nordmann, PhD

Laval University, Quebec, Canada

Hospital Bicetre, Paris, France

Robert A. Bonomo, MD

Malcolm G. P. Page, PhD

VA Medical Center, Cleveland, OH

Basilea Pharmaceuticia, Basel, Switzerland

Patricia A. Bradford, PhD

Robin Patel, MD

AstraZeneca Pharmaceuticals, Waltham, MA

Mayo Clinic College of Medicine, Rochester, MN

Angela M. Caliendo, MD, PhD

John Perfect, MD

Emory University Hospital, Atlanta, GA

Duke University Medical Center, Durham, NC

Karen Carroll, MD

Laura J.V. Piddock, PhD

Johns Hopkins University School of Medicine, Baltimore, MD

University of Birmingham, Birmingham, United Kingdom

Morven S. Edwards, MD

Liise-anne Pirofski, MD

Baylor College of Medicine, Houston, TX

Albert Einstein College of Medicine, Bronx, NY

Joseph J. Eron, Jr., MD

Johann Pitout, MD

University of North Carolina, Chapel Hill, NC

Calgary Laboratory Services, Calgary, Canada

Niels Fridmodt-Moller, MD

Didier Pittet, MD

Statens Serum Institute, Copenhagen, Denmark

University of Geneva, Geneva, Switzerland

Carlo Giaquinto, MD

Michael J. Pucci, PhD

University of Padova, Padova, Italy

Achillion Pharmaceuticals, New Haven, CT

Loreen Herwaldt, MD

Vincent Racaniello, PhD

University of Iowa College of Medicine, Iowa City, IA

Columbia University Medical Center, New York, NY

Stephen G. Jenkins, PhD

Jesús Rodriguez Baño, MD, PhD

Weill Cornell Medical College, New York, NY

Hospital Universitario Virgen Macarena, Sevilla, Spain

John A. Jernigan, MD

Keith A. Rodvold, PhD

Centers for Disease Control and Prevention, Atlanta, GA

University of Illinois, Chicago, IL

Kevin C. Kain, MD

Wing-Hong Seto, MD

University of Toronto, Toronto, Canada

Queen Mary Hospital, Hong Kong, China

Laurent Kaiser, MD

Shiranee Sriskandan, FRCP, PhD

University Hospitals of Geneva, Geneva, Switzerland

Imperial College Faculty of Medicine, London, United Kingdom

Tania C. Sorrell, MD University of Sydney, Westmead, Australia

4

September 9-12 |

Dear Colleagues, Welcome to San Francisco! On behalf of the Program Committee for the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, we invite you to take full advantage of all that ICAAC has to offer. Scheduled throughout the four days of ICAAC, the premier conference on antimicrobial agents and infectious diseases, is a line-up of oral and poster presentations showcasing the latest-breaking science and lectures from top researchers from around the globe.

M. Lindsay Grayson

Craig E. Rubens

The ICAAC Program Committee has designed a program of the highest quality to facilitate the exchange of new information among healthcare professionals, particularly physicians, clinical microbiologists, researchers, pharmacists and trainees specializing in infectious diseases. Two hundred and fifty-five sessions have been scheduled including: the Opening Keynote session, covering cutting edge issues related to diagnostics, viral hepatitis, and new drug discovery; the ICAAC Lecture “Fungal Disease in the 21st Century”; the Cubist-ICAAC Award Lecture “Antiviral Chemotherapy: Astonishing Progress and Formidable Pushback—The Ying and Yang of Host-Viral Interactions”; ten interactive symposia; 36 Meet-the-Experts sessions; and 70 didactic symposia. In addition, on Sunday afternoon there will be a Poster Summary reporting on Early New Antimicrobial Agents and a Literature Review to provide an update on infectious diseases. From over 1,700 accepted abstract submissions, the Program Committee has organized 107 poster sessions, 26 slide sessions and seven state-of-the-art mini-lectures. Late-breaker abstracts will be presented during applicable slide and poster sessions rather than in separate Late-breaker sessions. The Late-breaker abstracts and presentation times have been printed on page 295 of this and are posted online at www.icaac.org. The complement of abstract sessions and invited sessions allow for the presentation of new and important developments in the therapy, prevention, pathogenesis, epidemiology, immunology and diagnosis of both established and emerging infectious diseases. Detailed session descriptions are included in this Final Program. The Program Committee welcomes your feedback regarding all aspects of the meeting. This feedback will be used to plan future ICAACs that meet all of your expectations. Surveys for individual sessions are available at E-Central. These surveys will also be available online for one year after the meeting. In addition, you will receive via e-mail, an evaluation survey composed of questions that cover many aspects of the conference. Your responses are vital in assisting the Program Committee with their preparations for ICAAC 2013, which will be held September 10-13, 2013, in Denver, CO. We hope that you enjoy your time in San Francisco and at ICAAC 2012. We are certain you will return home with new information that you can immediately put to use in your offices, classrooms and laboratories to improve healthcare and the management of infectious diseases.

M. Lindsay Grayson, MD Chair, ICAAC Program Committee

Final Program

Craig E. Rubens, MD, PhD Vice-Chair, ICAAC Program Committee

5

> ICAAC 2012 Supporters ICAAC would like to acknowledge the following companies for their support of ICAAC 2012. On behalf of our leadership, we thank them for their continued commitment and appreciate their generous contributions.

Booth 1001

ID Fellows Grant Program

Aisle Signs ICAAC 2012 Peer Reviewed Highlights Report Booth 700 Abstracts on CD-ROM iPosters™

Booth 1101 ID Fellows Grant Program Booth 1301

Booth 1300 Expocards



INTRODUCING THE ICAAC 2012 APP!

NOW AVAILABLE!

DOWNLOADING THE APP IS EASY For iPhone, iPod Touch, and iPad users:

ICAAC 2012

Scan above using your device’s barcode scanner application for easy download.

From your handheld device, go to the iTunes App Store and search for “ICAAC” or “ICAAC 2012” to locate the app. Click on the “free” button, which will take you to the install screen. Next, download the ICAAC 2012 App as you would any other application from the iTunes App Store. It’s that easy.

For BlackBerry, Android, and all other web-enabled smartphones: Point your browser to m.core-apps.com/TriStar-ICAAC12. On this web-based mobile site, you will be directed to the proper download version for your device type.

The ICAAC 2012 App is compatible with iPhone, BlackBerry, and Android smartphones, as well as iPad and most tablets.

6

September 9-12 |

Get 24-hour access to unique, on-the-go meeting information, maps, and networking. Features include: tInteractive program & course schedules tCustomizable calendar & itinerary builder tExhibitor listing with interactive booth map tSocial media interaction tMeeting alerts

> Schedule-at-a-Glance

Saturday

Sunday

Monday

Tuesday

Wednesday

September 8

September 9

September 10

September 11

September 12

Registration

12:00 p.m. - 5:00 p.m.

6:30 a.m. - 5:00 p.m.

6:30 a.m. - 5:00 p.m.

6:30 a.m. - 5:00 p.m.

6:30 a.m. - 9:00 a.m.

Workshops*

8:30 a.m. - 4:30 p.m.

7:00 a.m. - 8:15 a.m. 5:45 p.m. - 7:00 p.m.

7:00 a.m. - 8:15 a.m. 5:45 p.m. - 7:00 p.m.

7:00 a.m. - 8:15 a.m.

8:30 a.m. - 10:30 a.m.

8:30 a.m. - 10:30 a.m.

9:15 a.m. - 11:15 a.m.

Infectious Diseases 101 for Fellows Ages 18-88

7:00 a.m. - 9:00 a.m.

Keynote Session

9:30 a.m. - 11:30 a.m.

Meet-the-Experts

Symposia

4:00 p.m. - 6:00 p.m.

11:15 a.m. - 12:45 p.m.

11:15 a.m. - 12:45 p.m.

2:00 p.m. - 4:00 p.m.

2:00 p.m. - 4:00 p.m.

Slide Sessions

4:00 p.m. - 6:30 p.m.

8:30 a.m. - 11:00 a.m. 1:30 p.m. - 4:00 p.m.

8:30 a.m. - 11:00 a.m. 1:30 p.m. - 4:00 p.m.

9:15 a.m. - 11:45 a.m.

Poster Sessions

11:30 a.m. - 1:30 p.m.

11:15 a.m. - 1:15 p.m.

11:15 a.m. - 1:15 p.m.

9:15 a.m. - 11:15 a.m.

Exhibits and Posters

11:30 a.m. - 4:30 p.m.

10:30 a.m. - 4:30 p.m.

10:30 a.m. - 4:30 p.m.

Special Lectures and Award Presentations

1:45 p.m. - 3:45 p.m.

4:30 p.m. - 5:30 p.m.

4:30 p.m. - 5:30 p.m.

8:00 a.m. - 9:00 a.m.

Literature Review Session & Poster Summary Session

ICAAC Lecture

Cubist-ICAAC Award Lecture

Plenary Session

After 7:00 p.m.

After 7:00 p.m.

Commercially-Supported Educational Activities Satellite Symposia

After 5:00 p.m.

After 7:00 p.m.

*Registration for workshops begins at 7:30 a.m.

Final Program

7

> ICAAC Awards and Lectures Keynote Session

ICAAC Lecture

Sunday, September 9 | 9:30 a.m. - 11:30 a.m. | Hall E

Monday, September 10 | 4:30 p.m.– 5:30 p.m. | Room 103

Emerging New Issues in the Management of Hepatitis C Infection Charles M. Rice, PhD

Fungal Disease in the 21st Century Arturo Casadevall, MD, PhD Albert Einstein Coll. of Med., Bronx, NY

The Rockefeller Univ., New York-Presbyterian Hosp., Weill Cornell Med. Coll., New York, NY

The Impact of Emerging New Diagnostic Laboratory Techniques on Clinical Infectious Disease Franklin R. Cockerill III, MD Mayo Clinic, Rochester, MN

Prospects for New Antibiotics Christopher T. Walsh, PhD Harvard Med. Sch., Boston, MA

Cubist-ICAAC Award and Lecture Tuesday, September 11 | 4:30 p.m. - 5:30 p.m. | Room 103 Supported by Cubist Pharmaceuticals Antiviral Chemotherapy: Astonishing Progress and Formidable Pushback— The Ying and Yang of Host-Viral Interactions Lawrence Corey, MD Fred Hutchinson Cancer Research Center, Seattle, WA

ASM’s premier award honoring outstanding accomplishment in antimicrobial research is presented to Lawrence Corey. An internationally renowned expert in virology, immunology and vaccine development, Corey’s research focuses on herpes viruses, HIV, and other viral infections, particularly those associated with cancer. Corey is the President and Director of the Fred Hutchinson Cancer Research Center. He earned his bachelor’s and medical degrees from the University of Michigan, and completed infectious diseases training at the University of Washington School of Medicine. He joined the faculty of the University of Washington in 1978, where he remains today as a Professor of Laboratory Medicine and holder of the Lawrence Corey Endowed Chair in Medical Virology. Corey is also an infectious disease physician at Seattle Cancer Care Alliance and the principal investigator of the Hutchinson Center-based HIV Vaccine Trials Network (HVTN), an international collaboration of scientists and institutions that combines clinical trials and laboratory-based studies to accelerate the development of HIV vaccines. Corey will deliver the Cubist-ICAAC Award Lecture, “Antiviral Chemotherapy: Astonishing Progress and Formidable Pushback—The Ying and Yang of Host-Viral Interactions,” on September 11 at 4:30 p.m.

8

September 9-12 |

ICAAC Program Committee Awards Presentation Will be honored during the ICAAC Lecture. Monday, September 10 | 4:30 p.m. – 5:30 p.m. | Room 103 These awards were established for the purpose of encouraging the presentation of quality research through outstanding abstract preparation. Following the review of all submitted abstracts, the ICAAC Program Committee has a meeting to discuss the most interesting submissions and is pleased to announce the following six recipients. You are encouraged to attend their presentations.

Pathogenesis of Microbial Diseases Ana García-Reyne, MD, PhD Univ. Hosp. 12 Octubre, Madrid, Spain

Influence of Cytomegalovirus (CMV) Disease in the Development of Cardiac Allograft Vasculopathy (CAV) in Heart Transplants Recipients (HTR) through the Application of the New ISHLT (International Society of Heart Transplantation) Coronary Angiographic Criteria Slide Session 116, Presentation T-1071 Epidemiology of Infection David J. Templeton, PhD Kirby Inst., Univ. of New South Wales, Sydney, Australia

Prevalence and Correlates of Vaccine-Preventable Anal Human Papillomavirus Genotypes in Australian Homosexual Men Poster Session 027, Presentation L2-301 Therapy and Prevention of Microbial Disease Au H. Duong, BS Univ. California San Francisco, San Francisco, CA

Efficacy of Human Intravenous Immunoglobulin (IVIG) for the Treatment of Lethal Necrotizing Pneumonia Caused by Hypervirulent Community-Associated MethicillinResistant Staphylococcus aureus Slide Session 196, Presentation B-1735 Clinical Microbiology and Diagnosis Stefano Giulieri, MD Univ. of Lausanne, Lausanne, Switzerland

Is CSF Lactate the Best Parameter for Discriminating Bacterial from Viral Community Acquired Meningitis? Slide Session 158, Presentation L1-1221 Resistance: Mechanisms and Consequences Alicia E. Farinati, Sr., MD Salvador Univ., Buenos Aires, Argentina

Prevalence of Naturally Occurring Hepatitis C Virus (HCV) Variants with Primary Resistance to the Direct-Acting Antivirals (DAA): Analysis of 722 Complete Genome Sequences and 307 NS3/4A and NS5B Partial Sequences Slide session 160, Presentation V-1237 Immunology of Infection Emmanuel Faure, PhD Lille 2 Univ. Hosp., Lille, France

IPAF-Inflammasome Null Mice are Protected from Pseudomonas aeruginosa-Induced Acute Lung Infection Poster Session 005, Presentation B-060

Final Program

9

> ICAAC Awards and Lectures continued…

ICAAC Young Investigator Awardees Will be honored during the Cubist-ICAAC Lecture. Tuesday, September 11 | 4:30 p.m. - 5:30 p.m. | Room 103 The 2012 ICAAC Young Investigator Awards recognize and reward five early-career scientists for their research excellence and potential in microbiology and infectious diseases. Two awards have been supported by Merck, U.S. Human Health Division since 1983, while two are sponsored by the ASM. In 2007, an additional award from Merck, U.S. Human Health Division was added to recognize excellence in HIV research. William P. Hanage and David M. Tobin are the 2012 laureates for the Merck-sponsored awards, and Andrew Lee Lovering and María Soledad Ramírez are the 2012 laureates for the ASM-sponsored awards. Mario L. Santiago is the 2012 laureate for the Merck-sponsored award for HIV research.

William P. Hanage, PhD

Mario L. Santiago, PhD

Harvard School of Public Health, Boston, MA

University of Colorado, Denver

Honored for his work studying the epidemiology and evolution of infectious disease, Hanage received his PhD from Imperial College London where he studied host microbial interactions. Hanage continued to the University of Oxford and later Imperial College London, where he studied the molecular epidemiology of bacterial pathogens. Especially interested in subjects that combine clinical importance with fundamental biological questions, Hanage looks at questions like how pathogens respond to novel selective pressures in the form of antimicrobials and vaccines.

Santiago’s outstanding work in virology includes fieldbased HIV epidemiology studies and manipulating innate immunity in his efforts to explore innovative new ways to approach the challenge of the HIV vaccine. Before receiving his PhD in Microbiology at the University of AlabamaBirmingham, Santiago worked at the NIH-sponsored Tropical Medicine Research Center in the Philippines and as a Fogarty AIDS International Research fellow at Brown University. He completed postdoctoral fellowships at the University of AlabamaBirmingham and the University of California, San Francisco. He now works on the interplay between innate retroviral restriction and adaptive immunity in mice, monkeys and humans, with a conceptual focus on HIV vaccine development, host genetics of retrovirus resistance, and interferon-based antiretroviral therapy.

Andrew Lee Lovering, PhD University of Birmingham, Edgbaston, Birmingham, United Kingdom

Lovering is recognized for his seminal work on the structural biology and biochemistry of the proteins that synthesize and modify cell walls in bacteria. Lovering earned his PhD in Biosciences from Birmingham University, where he used x-ray crystallography to detail the mechanism of action of two enzymes involved in cancer therapies— one a bacterial nitroreductase used in gene therapy of solid tumors, and the other a target for a cell differentiation approach tackling acute myeloid leukemia. He then took a postdoctoral position at the University of British Columbia working on antibacterial research. Lovering now focuses on deciphering the molecular basis of bacterial predation by Bdellovibrio bacteriovorus, a phenomenon that may lead to its exploitation as a “living antibiotic.” María Soledad Ramírez, PhD National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina

Ramírez is honored for her outstanding work in the area of integron participation in gene capture and dissemination. Before earning her PhD at the University of Buenos Aires, Ramírez underwent clinical research training at the Fundación Favaloro. After receiving her PhD, Ramírez received a CONICET Postdoctoral Fellowship, followed by a Fulbright-CONICET Research Fellowship. She has extensive experience in the study of the mechanisms of antimicrobial resistance, both in the biochemical characterization and the genetic analysis of the structures associated with the encoding genes.

10

September 9-12 |

David M. Tobin, PhD Duke University School of Medicine, Durham, NC

Tobin is recognized for his work in infectious disease therapeutics. He received his PhD at the University of California, San Francisco, where he defined the role of a set of TRPV-related ion channels in behaviors. He completed his postdoctoral studies at the University of Washington, developing a genetic screen in zebrafish to probe the host genetic determinants of susceptibility to mycobacterial infection. Tobin currently studies the host response to mycobacterial infection using zebrafish, bacterial, and human genetics.

> Poster Walk Presentations Poster Walk presentations, selected by the ICAAC Program Committee, are designed to give poster presenters an opportunity to give brief informal presentations and answer questions on their research. Lead by pioneers in the field, these topic-based walks will tour the Poster Hall discussing the most intriguing posters and latest discoveries from particular areas of interest. Poster Walks will take place in Halls A-C.

Efficacy and Use of PI vs EFV in Treatment Naive HIV+ Men and Women J. Patel; Rush Univ. Med. Ctr., Chicago, IL

Safety and Efficacy of Once Daily Raltegravir to Enhance Adherence and Efficacy of HAART in Vulnerable HIV-Infected Patients K. Stewart; Univ. of Saskatchewan, Saskatoon, Canada

Preemptive Therapy Prevents Cytomegalovirus End-Organ Disease in Treatment-Naïve Patients With Advanced HIV-1 Infection D. Mizushima; Natl. Ctr. for Global Hlth. and Med., Tokyo, Japan

Sunday, September 9 | 11:30 a.m. – 12:30 p.m.

Genotypic Algorithm for Predicting Elvitegravir Susceptibility: Clinical Validation and Correlation with Phenotype

Antibiotic Use and Resistance

M. Haddad; Monogram Biosciences, South San Francisco, CA

Convener: Stephan Harbarth, MD, MS Univ. of Geneva Hosp., Geneva, Switzerland

Persistent Low-Level Viraemia in HIV-1-Infected Patients: Swiss HIV Cohort Study N. Boillat Blanco; Univ., Lausanne, Switzerland

Presentations:

Do Antibiotic Combinations with Rifampin for Osteoarticular Infections Protect against Clostridium difficile-Associated Colitis?

Monday, September 10 | 11:15 a.m.-12:15 p.m.

C. Landelle; Univ. of Geneva Hosp., Geneva, Switzerland

Daily Infection Prevention and Control Issues

Outcome of Appropriate Empiric Combination versus Monotherapy for Pseudomonas aeruginosa Bacteremia D. R. Bowers; St. Luke’s Episcopal Hosp., Univ. of Houston, Houston, TX

Convener: Loreen Herwaldt, MD Univ. of Iowa, Coll. of Med., Iowa City, IA

Clinical Impact of KPC Status and Appropriate Treatment among Enterobacteriaceae (EB) and Pseudomonas aeruginosa (Pae) in a Multicenter Matched Control Cohort Study in Colombia

Presentations:

V. M. Blanco; CIDEIM, Cali, Colombia, Univ. del Valle, Cali, Colombia

M. E. Portillo; Reference Lab. of Catalunya, Barcelona, Spain

Inadequate Antibiotic Therapy is Associated with Decreased Survival in Patients with Extended-Spectrum BetaLactamase-Producing Enterobacteriaceae Bloodstream Infections

Hospital-Acquired Influenza in an Australian Sentinel Surveillance System

N. F. Dewhurst; St. Michael’s Hosp., Toronto, Canada, Univ. of Toronto, Toronto, Canada

Rapid Screening Tests for MRSA Did Not Decrease Postoperative MRSA Infections in Patients with Inflammatory Bowel Disease (IBD)

Control of the Prescription of Carbapenems in a French Hospital: Impact of the Hospital Antibiotic Management Team C. Couzigou; Hosp. Saint-Joseph, Paris, France

Prosthetic Joint Infection (PJI) Should Be Considered In Prosthetic Failure Within 2 Years of Implantation

N. Macesic; Alfred Hlth., Melbourne, Australia

Y. Takahashi; Hyogo Coll. of Med., Nishinomiya, Japan

What to Breathe? Performance Analysis of Air Samplers in Operating Rooms

Sunday, September 9 | 12:30 p.m.- 1:30 p.m.

L. Ummels; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands

The HIV Poster Rounds

Characteristics of Septic Arthritis: A Retrospective Study Over 11 Years

Conveners: Joseph Eron, Jr., MD Univ. of North Carolina, Chapel Hill, NC

L. N. Walti; Univ. Hosp., Lausanne, Switzerland

Jean-Michel G. Molina, MD Saint Louis Hosp. and Univ. of Sorbonne Paris Cité, Paris, France Presentations:

Impact of Seven Nucleotide Polymorphisms and Haplotypes of CYP2B6 on Plasma Efavirenz Level in HIV/Tuberculosis Co-Infected Thai Patients Receiving Rifampicin S. Sungkanuparph; Faculty of Med. Ramathibodi Hosp., Mahidol Univ., Bangkok, Thailand

Final Program

11

> Poster Walk Presentations continued…

Monday, September 10 | 12:15 p.m. - 1:15 p.m.

Resistance Genes Have No Boundaries! Conveners: Lesley McGee, PhD CDC, Atlanta, GA

H. Y. Chu; Univ. of Washington, Seattle, WA

Diagnosis of Invasive Aspergillosis and Mucormycosis Guided by PCR Assays from Bronchoalveolar Lavage Fluid in Allogenic Stem Cell Recipients

Johann D. Pitout, MD Univ. of Calgary, Calgary, Canada

H. Lellek; Univ. Hosp. Hamburg-Eppendorf, Hamburg, Germany

Presentations:

Molecular Characterization of Multidrug-Resistant Mycobacterium tuberculosis from Asian Countries C. Nakajima; Hokkaido Univ. Res. Ctr. for Zoonosis Control, Sapporo, Japan

Tuesday, September 11 | 12:15 p.m. - 1:15 p.m.

Fungal Infections at the Bedside

Extended-Spectrum Beta-Lactamase (ESBL) Producing GramNegative Bacteria from Pets, Buffalos and Psittacines, Brazil

Convener: John Perfect, MD Duke Univ. Med. Ctr., Durham, NC

L. Barbato; USP, São Paulo, Brazil

Presentations:

Accessory Gene Regulator (AGR) Function, rpoB Mutations and Vancomycin (VA) Susceptibility in Methicillin-Resistant Staphylococcus aureus (MRSA) Blood Isolates

The Clinical Course Following the Use of Corticosteroids for Symptomatic Relief of Primary Pulmonary Coccidioidomycosis in Immunocompetent Persons

M. Camoez; Hosp. Univ Bellvitge. UB. IDIBELL, Barcelona, Spain

N. Azadeh; Mayo Clinic, Phoenix, AZ

Lack of Impact of Infant PCV Vaccination on Rates of Adult Invasive Pneumococcal Disease in Ontario, Canada

Effectiveness of Posaconazole Vs Fluconazole as Antifungal Prophylaxis in Hematology-Oncology Patients at Duke University Hospital (DUH) 2004-2010

K. Wong; Mount Sinai Hosp., Toronto, Canada

Current Status of Group B Streptococci (GBS) in Japan -Penicillin-Resistant GBS is Emerging in Japan? H. Mikamo; Aichi Med. Univ., Aichi, Japan

Dissemination of Diverse Plasmids Bearing blaKPC Among Carbapenem-Resistant Enterobacteriaceae (CRE) Different from Klebsiella spp. in a Hospital System in Cleveland F. Perez; VAMC, CWRU, Cleveland, OH

Tuesday, September 11 | 11:15 a.m. - 12:15 p.m.

New Developments in Transplantation Convener: Emily A. Blumberg, MD Perelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA Presentations:

Refractory KPC Carbapenemase-Producing Klebsiella pneumoniae Bacteremia is Tolerated by Solid Organ Transplant Patients (SOT Pts) C. Clancy; Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA

Chronic High EBV Load Carriage has Low Predictive Value to Detect Post-Transplant Lymphoproliferative Disorder (PTLD) in Solid-Organ Transplant Recipients C. Gardiol; Univ. Hosp. Ctr. of Lausanne, Lausanne, Switzerland

Risk Factors and Outcomes of Bacteremia Caused by Drug-Resistant ESKAPE Pathogens in Solid Organ Transplant (SOT) Recipients M. Bodro; IDIBELL Biomedical Res. Inst., Hosp. Llobregat, Barcelona, Spain

12

The Molecular Epidemiology of a Respiratory Syncytial Virus Outbreak Among Oncology and Hematopoietic Stem Cell Transplant (HSCT) Patients

September 9-12 |

H. C. Kung; Duke Clinical Res. Inst., Durham, NC

Pilot Prospective Study of High Dose (10 mg/kg/d) Liposomal Amphotericin B (L-AmB) for the Initial Treatment of Mucormycosis: AMBIZYGO Trial F. Lanternier; Hosp. Necker Enfants Malades, Paris, France; Inst. Pasteur, Paris, France

Systemic Candidiasis Increased Mortality in ICU Infected Patients with Cirrhosis H. Dupont; Pole d’Anesthesie-Reanimation, CHU d’Amiens, Amiens, France

The Tolerability of Amphotericin B Lipid Complex Formulation in Patients With Severe Infusion Reactions to Liposomal Amphotericin B D. Farmakiotis; MD Anderson Cancer Ctr., Houston, TX

> ICAAC ID Fellows Grant Program Supported by educational grants from ASM, Gilead US, Pfizer Australia, and 3M. The American Society for Microbiology has long been committed to the educational development of young professionals within the infectious disease arena. This year, the ASM is please to host again the ID fellows Grant Program supported by educational grants from ASM, Gilead US, Pfizer Australia, and 3M. This program offers ID Fellows a unique opportunity to attend ICAAC 2012 and participate in an educational experience specifically tailored to their educational development needs. This select group of Fellows was nominated by their Program Directors and will have the opportunity to hear a targeted keynote talk and an overview of recommended sessions for attendance, interact with ICAAC Program Committee members and ASM Officers, and be offered personalized attention and daily discussion. ICAAC 2012 ID Fellows Grant Program Recipients: Albornoz, Ezequiel, Inst. Natl. de Enfermedades Infecciosas ANLIS Dr. G. Malbran,

Kwa, Andrea, Univ. of Pittsburgh, Pittsburgh, PA

Alraddadi, Basem, Tufts Med. Ctr., Medford, MA

Poster Session 015, Presentation E-195; Poster Session 094, Presentation E-791; Poster Session 174, Presentation E-1476

Poster Session 113, Presentation T-1025

Lee, Yu-Mi, Asan Med. Ctr., Seoul, Korea, Republic of

Beyda, Nicholas, Univ. of Houston Coll. of Pharmacy, Houston, TX

Poster Session 091, Presentation D-741

Poster Session 028, Presentation M-316

Lee, Yeon Joo, Memorial Sloan-Kettering Cancer Ctr., New York, NY

Bhalla, Preeti, Oregon Hlth. & Sci. Univ., Portland, OR



Leistner, Rasmus, Charité Univ., Berlin, Germany

Bhalodi, Amira, Hartford Hosp., Hartford, CT Poster Session 003, Presentation A-020; Poster Session 083, Presentation A-625; Poster Session 163, Presentation A-1287

Bhargava, Ashish, Detroit Med. Ctr., Wayne State Univ., Detroit, MI

Phee, Lynette, Barts Hlth. NHS Trust, London, United Kingdom

Briggs, Heather, Univ. of Texas Hlth. Sci. Ctr. at San Antonio, TX

Poster Session 092, Presentation D-761; Poster Session 094, Presentation E-797


Pittet, Laure, Univ. Hosp. of Geneva, Switzerland

Butterfield, Jill, Albany Coll. of Pharmacy and Hlth. Sci., Albany, NY

Poster Session 178, Presentation G3-1556

Poster Session 082, Presentation A-606

Pupaibool, Jakrapun, Mayo Clinic, Rochester, MN

Chen, Hong, Ctr. for Hlth. Protection, Hong Kong, China

Poster Session 096, Presentation F-813

Poster Session 021, Presentation K-243

Rao, Gauri, SUNY, Buffalo, NY

Cheng, Ying, Natl. Inst. for Communicable Disease Control and Prevention, Sklid, China Poster Session 105, Presentation K-936



Reuland, Elien Ascelijn, VU Univ. Med. Ctr., Amsterdam, Netherlands

Commons, Robert, Royal Darwin Hosp., Northern Territory, Australia

Poster Session 009, Presentation C2-104

Poster Session 165, Presentation B-1313

Sadarangani, Manish, Univ. of British Columbia and BC Children’s Hosp.,

Dilworth, Thomas, Univ. of New Mexico Coll. of Pharmacy, Albuquerque, NM Poster Session 174, Presentation E-1472

Frere, Julie, CHU Sainte-Justine, Montreal, Canada


Gillis, Louise-Marie, Univ. of Pittsburgh Med. Ctr., Pittsburgh, PA

Schmitt, Bryan, Mayo Clinic, Rochester, MI

Poster Session 094, Presentation E-786; Poster Session 183, Presentation K-1605

Slide Session 201, Presentation D-1774

Gillman, Jason, UT Southwestern Med. Ctr., Dallas, Texas

Sharff, Katie, Oregon Hlth. and Sci. Univ., Portland, OR



Goldblatt, Jennifer, Imperial Coll. London, London, United Kingdom

Sheth, Prameet, Univ. of Toronto, Toronto, Canada

Poster Session 165, Presentation B-1311


Housman, Seth, Ctr. Anti-Infect. Res. & Devel., Hartford Hosp., Hartford, CT

Poster Session 030, Presentation V-376 Poster Session 105, Presentation K-928

Karadag Oncel, Eda, Hacettepe Univ. Med. Faculty, Ankara, Turkey Poster Session 240, Presentation A-1941

Kasper, Douglas, Med. Coll. of Wisconsin, Milwuakee, WI

Vancouver, Canada Poster Session 178, Presentations G3-1542, G3-1544

Satyanarayana, Gowri, Beth Israel Deaconess Med. Ctr., Boston, MA

Poster Session 178, Presentation G3-1554

Jacobson, Shauna, West Virginia Univ. Hosp., Morgantown, WV

Poster Session 004, Presentation A-024; Poster Session 094, Presentation E-785

Rao, Krishna, Univ. of Michigan Hlth. Systems, Ann Arbor, MI

Chu, Helen, Univ. of Washington, Seattle, WA



Luther, Megan, Veterans Affarirs Med. Ctr., Providence, RI Poster Session 173, Presentations E-1464, E-1469


Jaber, Mohammad, Chu Sainte Justine, Montreal, QC, Canada

Kestler Hernandez, Martha, Hosp. Gen. Univ. Gregorio Marañon, Madrid, Spain Poster Session 023, Presentation K-263; Poster Session 106, Presentation K-940

Buenos Aires, Argentina Poster Session 087, Presentation C2-701

Soltani, Banafsheh, Temple Univ. Hosp., Philadelphia, PA Poster Session 188, Presentation L1-1656

Soon, Rachel L., Univ. at Buffalo, Buffalo, NY Poster Session 015, Presentation E-201; Poster Session 082, Presentation A-605; Slide Session 200, Presentation A-1762

Stevens, Vanessa, SUNY Buffalo Sch. of Pharmacy and Pharmacutical Sci., Buffalo, NY Poster Session 082, Presentation A-617

Suwantarat, Nuntra, Case Western Reserve Univ., Cleveland, OH Poster Session 087, Presentation C2-686


Kelesidis, Theodoros, David Geffen Sch. of Med., Los Angeles, CA Poster Session 024, Presentation K-280; Poster Session 169, Presentation C2-1401

Final Program

13

> ID Fellows Grant Program Recipients continued… Teh, Benjamin, Royal Melbourne Hosp., Parkville, Australia Poster Session 113, Presentation T-1027

Wongkulab, Panuwat, Chiang Mai Univ., Chiang Mai, Thailand Poster Session 170, Presentation D-1406

Tulliano, Gianfranco, NYU School of Medicine, New York, NY Poster Session 024, Presentation K-273

Xu, Hua, ShanDong Provincial Hosp., Jinan, China Poster Session 023, Presentation K-268

Werth, Brian, Wayne State Univ., Detroit, MI

Zhou, Qing, Zhongshan Hosp. Fudan Univ., Shanghai, China



Williamson, Deborah, Department of Clin. Microbiology, Auckland, New Zealand Poster Session 178, Presentation G3-1555; Slide Session 237, Presentation C2-1908

Zimmerman, Ofer, Tel Aviv Sourasky Med. Ctr., Tel Aviv, Israel Slide Session 115, Presentation M-1059

Wilmer, Amanda, Univ. of British Columbia, Vancouver, British Columbia, Canada Poster Session 011, Presentation D-161; Poster Session 182, Presentation K-1593

> ASM Infectious Diseases (ID) Fellow Travel Grants The ASM ID Fellows Travel Grant program was established to support the travel of ID Fellows to the annual Interscience Conference on Antimicrobial Agents and Chemotherapy. The ICAAC Program Committee is pleased to announce that the following individuals were awarded travel grants. All of this year’s recipients have been designated as George McCracken Infectious Disease Fellows, in recognition of Dr. McCracken’s efforts to facilitate financial support for these grants. ICAAC 2012 George McCracken ID Fellows Grant Recipients: Achermann, Yvonne, Univ. Hosp. Zurich, Switzerland Slide Session 129, Presentation K-1125

Slide Session 160, Presentation V-1239

Albur, Mahableshwar, North Bristol NHS Trust, Bristol, United Kingdom Poster Session 092, Presentation D-763; Poster Session 094, Presentation E-793

Amit, Sharon, Tel-Aviv Sourasky Med. Ctr., Tel-Aviv, Israel Poster Session 184, Presentation K-1609

Morency-Potvin, Philippe, Univ. de Montreal, Montreal, Canada Poster Session 090, Presentation D-730

Munier, Anne-Lise, Hosp. Saint Louis, Paris, France Poster Session 019, Presentation H-219; Poster Session 169, Presentation C2-1399

Asuphon, Orarik, Nareasuan Univ. Meung Pitsanulok, Phayao, Thailand Poster Session 162, Presentation A-1279

Munita, Jose, Univ. of Texas at Houston Med. Sch., Houston, TX Poster Session 166, Presentation C1-1345

Ballesté Delpierre, Clara, Ctr. en Salut Internacional de Barcelona, Barcelona, Spain Poster Session 087, Presentation C2-696

Cubero, Meritxell, Hosp. Univ. de Bellvitge, Barcelona, Spain Poster Session 087, Presentation C2-690

Muvunyi, Mambo-Claude, National Univ. of Rwanda, National Reference Laboratory, Huye, Rwanda Poster Session 092, Presentation D-775

Pascual, Vanesa, Hosp. Univ. Mutua de Terrassa, Barcelona, Spain

Daniels, Kelly, The Univ. of Texas, San Antonio, TX Poster Session 026, Presentation L1-297


Pino, Marylu, Facultad de Farmacia y Bioquimica, Buenos Aires, Argentina

Duval, Raphael, Univ. de Lorraine, Nancy, France Poster Session 177, Presentation F-1527

Slide Session 047, Presentation C1-466; Poster Session 086, Presentation C1-678

Pouch, Stephanie, NY Presbyterian, Columbia Univ. Med. Ctr., NY

Espinal, Paula, Hosp. Clinic-CEK, Barcelona, Spain Poster Session 016, Presentation, B-1327; Slide Session 236, Presentation C2-1900

Farmakiotis, Dimitrios, Baylor Coll. of Med., MD Anderson Cancer Ctr., Houston, TX

Poster Session 113, Presentations T-1034, T-1036

Seyedmousavi Tasieh, Seyedmojtaba, Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands Poster Session 111, Presentation M-989

Poster Session 191, Presentation M-1705 Ghebremedhin, Beniam, Med. Mirobiol., Magdeburg, Germany Poster Session 009, Presentation C2-108

Shahrooei, Mohammad, Lab. for Experimental and Clin. Microbio., Leuven, Belgium

Girometti, Nicolo, Policlinico S. Orsola-Malpighi, Bologna, Italy

Shallcross, Laura, Univ. College London, London, United Kingdom


Poster Session 252, Presentation K-2094 Poster Session 186, Presentation L1-1645

Gomez, Sonia Alejandra, ANLIS-Dr Carlos G. Malbran, Buenos Aires, Argentina Poster Session 008, Presentation C2-084

Sivagnanam, Shobini, Nepean Hosp., Sydney, Australia Poster Session 190, Presentation M-1680

Goncalves Quiles, Milene, Federal Univ. of Sao Paulo, Brazil Poster Session 170, Presentation D-1412

Sole Guiu, Mar, CRESIB, Barcelona, Spain Poster Session 006, Presentation C1-075

Hung, Wei-Chun, Niigata Univ. Graduate Sch. of Med. and Dental Sciences, Niigata, Japan Poster Session 166, Presentation C1-1340

Tamayo-Legorreta, Elsa, Natl. Inst. Public Hlth., Cuernavaca, Morelos, Mexico Poster Session 006, Presentation C1-069

Khan, Adnan, Univ. of Karachi, Karachi, Pakistan Poster Session 243, Presentation C2-1981

Tsai, MaoSong, Natl. Taiwan Univ. Hosp., Taipei, Taiwan, Province of China Poster Session 180, Presentation H-1578

Kim, Chung-Jong, Seoul Natl. Univ. Hosp., Seoul, Korea, Republic of Poster Session 104, Presentation K-908

Valerio, Maricela, Hosp. Gen. Gregorio Marañon, Madrid, Spain Slide Session 159, Presentation M-1232; Poster Session 190, Presentation M-1684

King, Travis, Univ. of Mississippi Med. Ctr., Jackson, MI Poster Session 111, Presentation M-968

Vila, Xavier, Hosp. Clinic, Barcelona, Spain Poster Session 249, Presentation F-2068

Macesic, Nenad, Alfred Hlth., Prahran, Australia Poster Session 108, Presentation K-952

14

Moon, Song Mi, Asan Med. Ctr., Seoul, Korea, Republic of

September 9-12 |

> George McCracken ID Fellows Grant Recipients continued… Wainaina, Jane, Med. Col. of Wisconsin, Milwaukee, WI

Yoshizumi, Ayumi, Toho Univ., Ota-ku, Tokyo, Japan



Xue, Bai, Inst. for Clin. PharmacoDynamics (ICPD), Latham, NY

Zainah, Hadeel, Henry Ford Hosp., Detroit, MI

Poster Session 161, Presentations A-1261, A-1263


Yakubchyk, Yury, SUNY Stony Brook, SBUMC Pediatric ID, Stony Brook, NY Poster Session 112, Presentation P-997

> ASM Student & Post-Doctoral Fellow Travel Grants The ASM Student and Post-Doctoral Travel Grant program was established to support the travel of students and fellows to ASM meetings. Recipients are selected by the ICAAC Program Committee on the basis of the scientific quality of their submitted abstracts. ICAAC 2012 Student and Post-Doctoral Travel Grant Recipients: Baietto, Lorena, Univ. of Turin, Turin, Italy

Martins Bispo, Paulo Jose, Federal Univ. of Sao Paulo, Sao Paulo, Brazil

Slide Session 200, Presentation A-1769; Poster Session 090, Presentation A-1937

Poster Session 169, Presentation C2-1400; Poster Session 174, Presentation E-1481

Berti, Andrew, Univ. of Wisconsin, Sch. of Pharmacy, Madison, WI

Maya, Juan J., Intl. Natl. Ctr. for Med. Res. and Training, Cali, Colombia

Poster Session 174, Presentation E-1482

Blanco, Victor M., Intl. Ctr. for Med. Res. and Training (CIDEIM), Cali, Colombia Poster Session 092, Presentation D-747; Poster Session 104, Presentation K-903; Poster Session 255, Presentation L2-2108 Poster Session 024, Presentation K-275; Poster Session 106, Presentation K-946; Slide Session 129, Presentation K-1123

Slide Session 237, Presentation C2-1914 Poster Session 025, Presentation L1-285; Poster Session 172, Presentation D-1458; Poster Session 186, Presentation L1-1642


Cotton, Gemma, Univ. of Lincoln, Lincoln, United Kingdom

Muraleedharan, Chithra, Oakland Univ., Rochester, MI



Denisuik, Andrew, Univ. of Manitoba, Winnipeg, Canada

Nair, Rajeshwari, Univ. of Iowa, Coralville, IA

Poster Session 009, Presentation C2-103; Poster Session 015, Presentation E-194


Deslouches, Berthony, Univ. of Pittsburgh, Ctr. for Vaccine Res., Pittsburgh, PA

Peterson, Eliza, Univ. of North Carolina, Chapel Hill, NC Poster Session 177, Presentation F-1535


Dumkow, Lisa, Henry Ford Hosp., Detroit, MI

Rogers, Benjamin, The Univ. of Queensland, Herston, Brisbane, Australia



Fehlberg, Lorena Cristina, Univ. Federal de São Paulo, São Paulo, Brazil

Rojo, Andrea, Clin. Univ. de Navarra, Pamplona, Spain

Poster Session 090, Presentation D-731; Slide Session 156, Presentation C1-1207

Poster Session 171, Presentations D-1439, D-1440

Finn, Talya, Tel Aviv Med. Ctr., Tel Aviv, Israel

Ryan, Keenan, Univ. of New Mexico Coll. of Pharmacy, Albuquerque, NM


Slide Session 197, Presentation C1-1742

Ghantoji, Shashank, MD Anderson Cancer Ctr., Houston, TX

Serrano-Villar, Sergio, Hosp. Univ. Ramón y Cajal, Madrid, Spain


Poster Session 018, Presentation H-217; Poster Session 179, Presentation H-1567

Grare, Marion, Lab. de Bactériologie-Hygiène, Toulouse, France

Simner, Patricia, Mayo Clinic, Rochester, MN

Poster Session 092, Presentation D-758; Poster Session 177, Presentation F-1527


Hall, Ashley, Wayne State Univ., Detroit, MI

Trang, Michael, Univ. at Buffalo, Buffalo, NY

Poster Session 082, Presentations A-601, A-602


Heimann, Sebastian, Univ. Hosp. of Cologne, Clinic I for Internal Med., Div. of

Trivedi, Ashit, Univ. of Tennessee Hlth. Sci. Ctr., Memphis, TN Poster Session 161, Presentation A-1267

Infectious Disease, Cologne, Germany Slide Session 159, Presentation M-1230; Poster Session 191, Presentation M-1706

Walti, Laura, CHUV, Lausanne, Switzerland

Hoenigl, Martin, Med. Univ. of Graz, Section of Infectious Diseases, Graz, Austria Poster Session 170, Presentation D-1404; Poster Session 112, Presentation P-1009

Poster Session 012, Presentation D-168; Poster Session 022, Presentation K-250; Poster Session 250, Presentation K-2073

Wendel, Sarah, Natl. Inst. of Allergy and Infectious Diseases, Natl. Inst. of Hlth.,

Huang, En, The Ohio State Univ., Columbus, OH Poster Session 176, Presentation F-1508

Lin, Yu-Tzu, Dept. of Clin.Lab. Sci.and Med. Biotechnology, Taipei, Taiwan,


Milillo, Michael, Walter Reed Army Inst. of Res., Silver Spring, MD Montassier, Emmanuel, UFR Med., Univ. of Nantes, Nantes, France

Chan, Albert, UCLA, Los Angeles, CA

Ly, Neang, Univ. of Buffalo, Buffalo, NY

Melchers, Maria, Radboud Univ. Nijmegen Med. Centre, Nijmegen, Netherlands Poster Session 015, Presentation E-190; Poster Session 094, Presentation E-803

Casapao, Anthony, Wayne State Univ., Anti-Infective Res. Lab., Detroit, MI

Province of China Poster Session 166, Presentation C1-1339

Poster Session 092, Presentation D-747; Poster Session 104, Presentation K-903; Poster Sesion 255, Presentation L2-2108

Baltimore, MD Poster Session 180, Presentation H-1580

Winkler, Marisa, Case Western Reserve Univ., Cleveland, OH Slide Session 047, Presentation C1-463; Slide Session 156, Presentation C1-1209

Zhao, Yuyun, Tsinghua Univ., Beijing, China Poster Session 246, Presentation F-2002

Mahajan, Sminil, UT MD Anderson Cancer Ctr., Houston, TX Slide Session 117, Presentation V-1075

Final Program

15

16

September 9-12 |

> American Society for Microbiology Products and Services

ASM Career Connections ASM Career Connections will be onsite at ICAAC. Leverage your meeting attendance by searching job postings and applying for jobs as a candidate, or post job openings and contact qualified candidates as an employer. Identify candidates and employers attending the meeting and schedule onsite interviews. Learn more at www.asmcareerconnections.org.

ASM Journals ASM journals, available in both online and print formats, remain a critical source of high-quality clinical microbial content. Our journals are some of the most-cited serials within their disciplines, covering antimicrobial agents, immunology, chemotherapy, clinical microbiology, molecular biology, pharmacology, virology, and more. For more information about publishing in an ASM journal, please visit the ASM Journals Booth #1513 in the Exhibit Hall. Additional submission information is available on the Authors tab at www.journals.asm.org.

ASM Press Bookstore ASM Press, the book publishing division of the American Society for Microbiology, will be selling a broad selection of textbooks, references, manuals, and general interest titles in the ASM Press Bookstore, located in the main entrance of the South Lobby. ASM Members receive a 20-50% discount on all purchases made at the meeting. Non-members receive a 10% discount on all purchases made at the meeting.

Membership Advance with ASM Membership In 2013 ASM will change its member categories to address the needs of an increasingly diverse scientific audience—including infectious disease and other clinical professionals. For more information about the new member types and benefits, visit asm.org/advance or stop by the Membership Booth (#1106) on the exhibit floor. ICAAC attendees can join or renew for 2013 onsite. For additional information on membership in ASM, call (202) 942-9319 or e-mail [email protected].

Press Room and ICAAC Live Media representatives interested in obtaining releases on selected papers and scheduling interviews can do so in the Press Room, Esplanade Ballroom 301. Daily press conferences and media interviews of researchers will also take place as part of ICAAC Live in Esplanade Ballroom 303. ICAAC Live will be moderated by Dr. Jeff Fox, Features Editor for Microbe magazine. The ICAAC Live schedule and live webcasts of interviews are available at http://www.microbeworld.org/icaaclive. All registered attendees of ICAAC are invited to attend the ICAAC Live interviews.

Final Program

17

> Convention Center Maps

18

September 9-12 |

Final Program

19

> ICAAC 2012 Hotel Information

20

1.

Hotel Abri 127 Ellis Street San Francisco, CA 94102 (415) 392-8800

10. JW Marriott San Francisco Union Square 500 Post Street San Francisco, CA 94102 (415) 771-8600

19. Serrano Hotel (Kimpton) 405 Taylor Street San Francisco, CA 94102 (415) 885-2500

2.

Courtyard by Marriott Downtown 299 Second Street San Francisco, CA 94105 (415) 947-0700

11. King George Hotel 334 Mason Street San Francisco, CA 94102 (415) 781-5050

20. Sir Francis Drake Hotel (Kimpton) 450 Powell Street San Francisco, CA 94102 (415) 392-7755

3.

Fairmont San Francisco 950 Mason Street San Francisco, CA 94108 (415) 772-5000

12. Marriott Union Square-San Francisco 480 Sutter Street San Francisco, CA 94108 (415) 398-8900

21. Hotel Union Square 114 Powell Street San Francisco, CA 94102 (415) 397-3000

4.

Galleria Park Hotel, a Joie De Vivre Hotel 191 Sutter Street San Francisco, CA 94104 (415) 781-3060

13. Hotel Nikko San Francisco 222 Mason Street San Francisco, CA 94102 (415) 394-1111

22. Villa Florence Hotel 225 Powell Street San Francisco, CA 94102 (415) 397-7700

5.

Grand Hyatt San Francisco 345 Stockton Street San Francisco, CA 94108 (415) 398-1234

14. Palace Hotel 2 New Montgomery Street San Francisco, CA 94105 (415) 512-1111

23. W San Francisco 181 3rd Street San Francisco, CA 94103 (415) 777-5300

6.

Handlery Union Square Hotel 351 Geary Street San Francisco, CA 94102 (415) 781-7800

15. Hotel Palomar 12 4th Street San Francisco, CA 94503 (415) 348-1111

24. The Westin San Francisco Market Street 50 Third Street San Francisco, CA 94103 (415) 974-6400

7.

Hilton San Francisco Union Square 333 O’Farrell Street San Francisco, CA 94102 (415) 771-1400

16. Parc 55 Wyndham San Francisco – Union Square 55 Cyril Magnin Street San Francisco, CA 94102 (415) 392-8000

25. The Westin St. Francis 335 Powell Street San Francisco, CA 94102 (415) 397-7000

8.

Holiday Inn Civic Center 50 8th Street San Francisco, CA 94103 (415) 626-6103

17. The Powell Hotel 28 Cyril Magnin Street San Francisco, CA 94102 (415) 398-3200

9.

InterContinental San Francisco 888 Howard Street San Francisco, CA 94103 (415) 616-6500

18. San Francisco Marriott Marquis 55 4th Street San Francisco, CA 94102 (415) 896-1600

September 9-12 |

ICAAC - Hotel Key 1 - Hotel Abri 2 - Courtyard by Marriott Marriot San Francisco Downtown 3 - The Fairmont San Francisco Fra 4 - Galleria Parkk Hotel, a Joie de Vivre hotel 5 - Grand Hyatt San Francisco Fran 6 - Handlery Union Squa Square Hotel 7 - Hilton Hilto Hi lton n San Sa Francisco Union Square 8 - Holidayy Inn Inn Civic Civi Center Cen 9 - InterContinental InterContinent ntal al San San Francisco 10 - JW Marriott San Francisco Union Square Fra 11 - King George Hotel 12 - Marriott Union Square Squa – San Francisco 13 - Hotel Nikko San Francisco Fra

Final Program

14 - Palace Hotel 15 - Hotel Palomar 16 - Parc 55 Wyndham San Francisco-Union Square 17 - The Powell Hotel 18 - San Francisco Marriott Marquis 19 - Serrano Hotel 20 - Sir Francis Drake Hotel 21 - Hotel Union Square 22 - Villa Florence Hotel 23 - W San Francisco 24 - The Westin San Francisco Market Street 25 - The Westin St. Francis

21

> Shuttle Information Complimentary shuttle service is provided between the Moscone Convention Center and the official ICAAC hotels. Shuttle information signs will be posted in the lobby of each hotel. Check the sign in your hotel lobby for additional information and changes.

Hotels and Boarding Locations Please allow for adequate travel time to accommodate for possible delays due to distance, traffic conditions, etc.

> Route #1 . . . . . . . . . . . . . . . . . . . . . . . . Boarding Location

Hilton Union Square San Francisco . . . . . Curbside on Taylor Street Holiday Inn Civic Center . . . . . . . . . . . . . . Curbside on 8th Street Hotel Nikko . . . . . . . . . . . . . . . . . . . . . . . . . . At Hilton Union Square King George Hotel . . . . . . . . . . . . . . . . . . . At Hilton Union Square Serrano Hotel . . . . . . . . . . . . . . . . . . . . . . . . At Hilton Union Square Villa Florence Hotel . . . . . . . . . . . . . . . . . . At Hilton Union Square Service every 15-20 minutes at all times.

> Route #2 . . . . . . . . . . . . . . . . . . . . . . . . Boarding Location

Galleria Park Hotel . . . . . . . . . . . . . . . . . . . At Westin St. Francis Grand Hyatt San Francisco . . . . . . . . . . . . At Westin St. Francis Handlery Union Square . . . . . . . . . . . . . . . At Westin St. Francis JW Marriott San Francisco Union Sq. . . . At Westin St. Francis Marriott Union Square . . . . . . . . . . . . . . . . At Westin St. Francis Sir Francis Drake . . . . . . . . . . . . . . . . . . . . . . At Westin St. Francis Westin St. Francis . . . . . . . . . . . . . . . . . . . . . Curbside on Post Service every 15-20 minutes at all times.

The following hotels are located within walking distance of Moscone Convention Center, therefore, shuttle service is NOT provided. Hotel Abri Courtyard by Marriott Downtown Hotel Palomar Hotel Union Square InterContinental San Francisco Marriott Marquis San Francisco Palace - Luxury Starwood Parc 55 Wyndham Powell Hotel W Hotel San Francisco Westin San Francisco Market Street

> Route #3 . . . . . . . . . . . . . . . . . . . . . . . . Boarding Location Fairmont San Francisco . . . . . . . . . . . . . . . . Curbside on Mason Service every 15-20 minutes at all times.

Convention Center Shuttle Hours Moscone Convention Center Service is every 15-20 minutes at all times. Saturday, September 8 . . . . . . . . . . . . . . . . 7:30 a.m. – 5:30 p.m.* Sunday, September 9 . . . . . . . . . . . . . . . . . 6:00 a.m. – 7:00 p.m.* Monday, September 10 . . . . . . . . . . . . . . . 6:00 a.m. – 7:30 p.m.* Tuesday, September 11 . . . . . . . . . . . . . . . 6:00 a.m. – 7:30 p.m.* Wednesday, September 12 . . . . . . . . . . . . 6:30 a.m. – 12:30 p.m.*

*Indicates last time shuttle departs Moscone Convention Center returning to hotels. Last shuttle departs hotels coming to Moscone approximately 45 minutes prior to this time.

22

September 9-12 |

Satellite Symposia Shuttle Hours Symposia will be located at the Marriott Marquis and the Intercontinental. SHUTTLE SERVICE WILL NOT BE PROVIDED.

If you have questions about the shuttle or if you need to make an advance reservation for a wheelchair-accessible shuttle, please see the supervisor at the Moscone Convention Center or call KUSHNER & ASSOCIATES at (310) 274-8819 ext. 213.

> General Information for ICAAC 2012 Abstract Compilations

Badge Policies

Exhibiting companies that distribute abstract compilations onsite of any of the ICAAC 2012 abstract presentations must have received prior approval from the Program Committee and ASM. Compilations most accurately reflect the abstracts and cannot contain promotional information. Pre-approved distribution is allowed from a specially designated literature rack in Halls A-C at the Poster Information booth. Abstract compilations distributed in an unapproved area will be removed by ASM staff.

For security reasons, all attendees are required to wear a badge to attend sessions or enter the Exhibit Hall. Please note that badges are the property of ASM and must be relinquished at any time at the request of ASM staff or security.

Abstracts on CD-ROM Supported by Merck & Co, Inc. All ICAAC 2012 Abstracts have been compiled on a fully searchable CD-ROM that will be included in each registration bag.

Americans with Disabilities Act Special Services at Moscone North and South Persons requiring special services at the convention center (wheelchair-accessible transportation, sign interpreters, etc.) are asked to stop by ASM Headquarters in Room 220. Since requests were due as part of the registration process, on-site requests will be fulfilled based on availability.

ATM There is an ATM located in Moscone North near the entrance to Hall D, and one in Moscone South outside of Hall B.

Attendee Badges > Access into all scientific sessions > Access to the Exhibit Hall and Poster Sessions during operating hours > Unlimited use of the courtesy shuttle > Access to Continuing Education Credits Guest Badges > Access to the Exhibit Hall and Poster Sessions during operating hours > Unlimited use of the courtesy shuttle > Attendees wearing guest badges will not be permitted into scientific session rooms. Exhibitor Badges > Entrance into the Exhibit Hall during installation and dismantling hours > Entrance into the Hall 2 hours before the Hall opens and one hour after it closes > Unlimited use of the courtesy shuttle > Attendees wearing exhibitor badges will not be permitted into scientific session rooms. Press Badges > Access into all scientific sessions > Access to the Exhibit Hall and Poster Sessions during operating hours > Unlimited use of the courtesy shuttle > To receive continuing education credit, members of the press must register for the meeting and pay the appropriate registration fee Badge Replacement Policy Replacement badges are $100. Please return any found badges to the Registration Assistance Counter located in Hall A-B, Exhibit Level of Moscone Convention Center South. Security and Badge Duplication or Sharing Strict badge policies are in effect for ICAAC to provide a safe and secure meeting. Photocopying, duplicating, or sharing badges to avoid paying meeting registration fees is strictly prohibited. Security will be closely examining badges and anyone possessing a fraudulent meeting badge will be escorted from the premises.

Final Program

23

> General Information continued…

Business Center The Business Center in Moscone South offers numerous services, including digital printing, packing & shipping, packaging materials, and last-minute office supplies, to meet your needs. Location Moscone South, near the entrance to Hall C Phone: (415) 974-4067 Fax: (415) 974-4052 Hours: Sunday, September 9 Monday, September 10 Tuesday, September 11 Wednesday, September 12

> > > >

10:30 a.m. – 4:30 p.m. 9:30 a.m. – 4:30 p.m. 9:30 a.m. – 4:30 p.m. 9:00 a.m. – 12:00 p.m.

Cameras and Recording Cassette recorders, cameras (including camera phones, and video cameras) are NOT allowed in session rooms or in the exhibit and poster areas. Attendees who wish to purchase a digital recording of a session may stop by the Multimedia Booth located in the South Lobby.

Certificate of Attendance A Certificate of Attendance will be available beginning Monday, September 10 at all attendee registration counters.

Child Safety Children are not permitted entry into session rooms. Also, children under the age of 18 are not permitted on the Exhibit Hall floor during setup or dismantling hours. During scheduled show hours, exceptions are made when parents or guardians complete and sign a Minor Release Form. This form is available in the ICAAC Information Booth in the South Lobby and in the ICAAC Headquarters Office in Room 220. Strollers are not allowed in the Exhibit Hall and may be checked at the coat and baggage check.

Coat and Baggage Check A coat and baggage check is located on the Mezzanine level, just below the South Lobby. Hours: Sunday, September 9 Monday, September 10 Tuesday, September 11 Wednesday, September 12

24

> > > >

7:00 a.m. – 6:30 p.m. 7:00 a.m. – 7:00 p.m. 7:00 a.m. – 7:00 p.m. 7:00 a.m. – 12:00 p.m.

September 9-12 |

Cooperating Organizations > American Society of Tropical Medicine and Hygiene (ASTMH) > European Organisation for Research and Treatment of Cancer (EORTC-IDG) > European Society of Clinical Microbiology and Infectious Diseases (ESCMID) > Global Chinese Association of Clinical Microbiology and Infectious Diseases (GCACMID) > Infectious Diseases Society of America (IDSA) > Infectious Diseases Society of Obstetrics and Gynecology (IDSOG) > International Antiviral Society-USA (IAS-USA) > International Society of Anti-Infective Pharmacology (ISAP) > International Society of Chemotherapy (ISC) > Mycology Study Group (MSG) > Pediatric Infectious Diseases Society (PIDS) > Society of Infectious Diseases Pharmacists (SIDP) > Surgical Infection Society (SIS)

E-Central The following services and information are available: > > > >

Obtain a continuing education certificate ASM CE Portal access Locate presenters, sessions and topics E-mail access

Locations : E -Central #1 | Hall E Foyer Saturday, September 8 > 12:00 p.m. – 5:00 p.m. Sunday, September 9 > 6:30 a.m. – 6:30 p.m. Monday, September 10 > 6:30 a.m. – 7:00 p.m. Tuesday, September 11 > 6:30 a.m. – 7:00 p.m. Wednesday, September 12 > 6:30 a.m. – 12:00 p.m. E-Central #2 | Halls A-C Sunday, September 9 > 11:30 a.m. – 4:30 p.m. Monday, September 10 > 10:30 a.m. – 4:30 p.m. Tuesday, September 11 > 10:30 a.m. – 4:30 p.m.

Exhibit Hall

ExpoCard

Outside of the educational sessions, the Exhibit Hall is the most exciting place to be! With more than 70 exhibitors assembled in The Moscone Center for one of the largest exhibitions in antimicrobial agents and chemotherapy. These exhibitors will have the latest in the field of infectious disease from vaccines, diagnostic equipment and services, scientific publications, research, and new drugs and the latest information on existing drugs.

Supported by Elsevier – Clinical Key.

Please schedule time to walk through the Exhibit Hall and take advantage of this rare grouping of exhibitors. The Exhibit Hall is located in Moscone South A-C. The Exhibit Hall is open: Sunday, September 9 > 11:30 a.m. – 4:30 p.m. Monday, September 10 > 10:30 a.m. – 4:30 p.m. Tuesday, September 11 > 10:30 a.m. – 4:30 p.m.

The ExpoCard has your name, address, and demographic information electronically encoded. Several services are accessible when the ExpoCard is used: In the Exhibit Hall: the ExpoCard serves as an electronic business card, allowing you to easily and quickly leave your address information for follow-up with companies exhibiting products that interest you. E-Central: you may gain access to the services outlined on page 24 with the swipe of your ExpoCard.

First Aid A First Aid Station will be staffed at Moscone Center in Hall C Foyer during meeting hours. If you feel ill or need a place to lie down, go to the First Aid Station. In case of a medical emergency at Moscone Center, please dial 511 from any house phone.

Exhibit Hall Attractions: > Poster Sessions > Poster Walks > iPosters > E-Central > Food Court

Food and Beverage Full service food stands will be available Saturday–Tuesday, throughout Moscone North and South.

Refer to the Meeting & Exhibit Guide for detailed information on specific exhibitors, their products and locations, as well as additional information on their industry-sponsored symposia.

Future Meetings Booth A bulletin board for posting notices concerning future meetings will be located at the Future Meetings Booth in the South Lobby. Announcements displayed elsewhere will be discarded.

Housing Any changes to hotel reservations should be made directly with the hotel. If you have any problems with your reservation or need to change hotels, please visit the Housing Assistance Counter located at Registration Assistance in Halls A-C.

Information Booth The ICAAC Information Booth will be located in the South Lobby. The following information will be available: > Meeting Information > Approved Affiliated Events > Program Changes and Updates > Minor Release Forms for Exhibit Hall Entrance > Satellite Symposia Information

Final Program

25

> General Information continued…

Lost and Found

Poster Walks

Unattended personal belongings will be removed and taken to the ICAAC Headquarters Office located in Room 220.

Poster Walk presentations, selected by the ICAAC Program Committee, are designed to give poster presenters an opportunity to give brief informal presentations and answer questions on their research. Lead by pioneers in the field, these topic-based walks will tour the Poster Hall discussing the most intriguing posters and latest discoveries from particular areas of interest. Poster Walks will take place in Halls A-C. For more information see page 11.

Messages Mail and other forms of communication can be directed to the individual at the hotel where he or she is registered.

Multimedia Sales Digital recordings from ICAAC sessions are available for purchase in the South Lobby at the multimedia sales booth.

Nursing Room A Nursing Room will be available for use during ICAAC 2012. Please visit Headquarters in Room 220 for additional information.

Parking Moscone Center encourages the use of public transit first. However, parking facilities do exist close to Moscone. For more information about nearby garages as well as a parking map, please visit www.moscone.com/directions/parking.shtml.

Poster Information Call4Posters™ The Call4Posters™ Booth is located outside Halls A-C. iPosters™ iPosters is a free of charge service that allows you to include your poster in the online poster database. iPosters™ online poster database will be available for viewing during and after the meeting. iPosters™ kiosks for poster viewing and printing will be available on-site in Halls A-C. To include your poster in this educational database, please go to www. call4posters.com/icaac or visit the iPosters™ kiosks located in Halls A-C, where staff will be available to accept electronic submissions of your final poster. Attendees can view iPosters™ online by visiting the iPosters™ kiosks. Poster Storage Complimentary poster storage, for posters and poster containers only, will be located inside Halls A-C. Posters not removed from the Poster Storage area will be discarded at the conclusion of the meeting. All items are stored at your own risk. ASM is not responsible for lost or stolen items.

26

September 9-12 |

Program Changes Daily updates and changes to the Final Program will be reflected in the ICAAC 2012 Mobile App.

Registration Hours Saturday, September 8 Sunday, September 9 Monday, September 10 Tuesday, September 11 Wednesday, September 12

> > > > >

12:00 p.m. – 5:00 p.m. 6:30 a.m. – 5:00 p.m. 6:30 a.m. – 5:00 p.m. 6:30 a.m. – 5:00 p.m. 6:30 a.m. – 9:00 a.m.

Satellite Symposia Satellite Symposia are non-commercially-focused scientific sessions developed by organizing agencies and supported by ICAAC exhibiting companies. Satellite Symposia are not part of the official ICAAC program. Details about the satellite symposia can be found in the ICAAC Meeting & Exhibit Guide located in each registration bag.

Sessions and Room Capacity All scientific sessions will be held at Moscone North and South. A map of Moscone Center is located in the Meeting & Exhibit Guide and this Final Program. Poster Sessions will be held in Halls A-C Sunday, September 9 – Wednesday, September 12. An ICAAC 2012 attendee badge is required to access the Poster Sessions. The ICAAC Program Committee attempts to determine the popularity and estimated attendance level for each session. Please accept our apologies in advance should the demand exceed the number of seats in a particular session. For safety reasons, ASM must adhere to all room capacity regulations prescribed by the Moscone Convention Center and the Fire Marshall of California. Attendance is on a first-come, firstserved basis. ASM requests that attendees use every available seat before resorting to standing. Sitting in aisles is a hazard, and ASM requests that you not do so.

Shipping

Transportation

If you need to have a package shipped from San Francisco, please visit your hotel’s business center or the Business Center in Moscone South near the entrance to Hall C.

Shuttle Service Please see page 22 for complete shuttle details including boarding locations and hours of operation. A shuttle bus flyer and signage will also be placed in each hotel.

Smoking Policy Smoking is prohibited in all areas of the Moscone Center.

Speaker Ready Room Speakers may preview their presentation in the Speaker Ready Room in Room 204 of the Moscone Center. ASM requests that speakers submit their electronic presentation files to the AV operator in the Speaker Ready Room at least 4 hours prior to their presentation time. Hours: Saturday, September 8 Sunday, September 9 Monday, September 10 Tuesday, September 11 Wednesday, September 12

> > > > >

7:30 a.m. – 5:00 p.m. 6:00 a.m. – 7:00 p.m. 6:00 a.m. – 6:00 p.m. 6:00 a.m. – 6:00 p.m. 6:00 a.m. – 9:30 a.m.

Telephone Numbers ICAAC Headquarters Office — 415-978-3700 First Aid — 415-974-4090 Press Room — 415-978-3709 Shuttle Bus — 310-274-8819, ext. 213

Airports San Francisco International Airport (SFO) offers non-stop flights to more than 31 international points on 29 international carriers. The Bay Area’s largest airport offers service to more than 70 non-stop cities in the U.S. on 16 domestic airlines. Public Transportation from the Airport > BART Rapid Rail: BART operates rapid rail service to northern San Mateo County, San Francisco and the East Bay directly from SFO. The SFO BART Station is located on the Departures/Ticketing Level of the International Terminal (Boarding Area G side). BART is easily accessed from any terminal by riding SFO’s AirTrain to the Garage G/BART Station stop. There is no charge to board AirTrain. BART provides a connection to Caltrain at the Millbrae station. > Caltrain Commuter Rail: Caltrain provides rail service between San Francisco and San Jose, with weekday commute-hour service to Gilroy. BART connects SFO to the Caltrain rail system at the Millbrae Station. Weekday express trains serve select stations during commute hours. > SamTrans Public Bus Service: SamTrans provides 24hour service connecting SFO to San Mateo County and parts of San Francisco and Palo Alto. Shuttle from the Airport Charter services are available to most Bay Area locations and must be pre-arranged with the service operator. Charter pick-up areas are located in the courtyards on the Arrivals/ Baggage Claim Level. Please visit www.flysfo.com for a list of operators serving SFO. Taxicabs from the Airport Taxis depart from the designated taxi zones located at the roadway center islands, on the Arrivals/Baggage Claim Level of all terminals. Uniformed taxi coordinators are stationed at the taxi zones from 7:00 a.m. to 1:00 a.m. to assist passengers with questions or concerns. Taxi Service 24-hour dependable service is available to and from all destinations. Taxi cabs are also easily accessible at the Moscone Center, major hotels, and other downtown locations.

Final Program

27

> Continuing Education Information Intended Audience

Continuing Education (CE) Credit

The ICAAC 2012 is designed to meet the needs of health care professionals, particularly physicians, clinical microbiologists, researchers, and pharmacists, specializing in infectious diseases. Current trends will be covered regarding:

The following session types will offer continuing education credit.

> > > > > > > > > > > > > >

Antimicrobial Resistance Clinical Trials Community-Acquired Infections Epidemiology HIV/AIDS and other Retroviruses Laboratory Diagnostics Microbial Pathogenesis Mycology Nosocomial Infections Parasitology Pharmacology Susceptibility Studies Vaccines and Immunology Virology

Session Type

Contact Hours or AMA PRA Category 1 Credits™ per session

Keynote Session, Poster Summary and Literature Review

>

Interactive Symposia and Symposia

> 1.5 - 2

Slide Sessions

>

2.5

Meet-the-Experts

>

1.25

ICAAC Lecture and Plenary Session

>

1

Workshops (Full-Day)

>

7

Workshops (Half-Day)

>

3.5

2

Objectives Participation in the ICAAC 2012 should allow attendees to: > Investigate the pathogenesis and epidemiology of old and new microbes; > Utilize new data from the research of basic microbiological sciences related to human disease to improve their clinical practice and patient outcomes; > Evaluate the spread of infectious diseases throughout the world; > Review state-of-the-art developments in the field, including timely reviews of recent advances in clinical care and research and original reports of clinical, translational, and basic research; > Identify the most recent trends in health care management; > Incorporate the knowledge gained to assist with bridging any gaps among the fields of infectious diseases clinical practice, clinical research, epidemiological and health services research, translational research, and basic research; > Recognize and better understand recent new antimicrobial agents; > Understand and discuss updates on clinical diagnoses, preventative modalities and therapeutics; > Analyze the developing resistance of pathogens to diverse therapeutics; and > Engage in networking and collaboration among clinicians and investigators to facilitate advances in the prevention, diagnosis, and treatment of infectious diseases.

28

September 9-12 |

Continuing Medical Education The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The France Foundation designates this live activity for a maximum of 33.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The American Medical Association (AMA) has determined that physicians not licensed in the U.S. who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Diplomates of the American Board of Medical Microbiology, Diplomates of the American Board of Medical Laboratory Immunology, and Registrants of the National Registry of Certified Microbiologists who are MDs and DOs may earn AMA PRA Category 1 Credits™ toward recertification. All other Diplomates and Registrants may claim Participation, CA or FL credits toward recertification. Each professional should claim credit commensurate with their level of participation in the activity.

Continuing Pharmacy Education The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award up to 33.25 contact hours or 3.325 CEUs to pharmacists who attend the activities and complete the registration and evaluation forms. All sessions at ICAAC 2012 are knowledge-based activities. Sessions approved for CE credit will have a corresponding Universal Activity Number (UAN). California Clinical Laboratory Scientists (CLS) ASM is accredited by the California Department of Health Services to offer continuing education for California Clinical Laboratory Scientists. All sessions designated for CME credit will also qualify for California CE credit toward CLS license renewal. Florida Clinical Laboratory Personnel ASM is accredited by the Florida Department of Health to offer continuing education for Florida Clinical Laboratory Personnel. All sessions designated for CME credit will also qualify for Florida CE credit toward license renewal. Other CE Licenses You may obtain a Participation Statement of Credit by completing the activity evaluation. This is a detailed statement that documents your participation in the activity. Education Disclaimer The primary purpose of the sessions at ICAAC 2012 is education. Information presented, as well as publications, technologies, products, and/or services discussed, are intended to inform you about the knowledge, techniques, and experiences of professionals who are willing to share such information with colleagues. A diversity of professional opinions exists in the fields discussed at ICAAC and the views of the ICAAC faculty are offered solely for educational purposes. Faculty’s views neither represent those of ASM nor constitute endorsement by the association. The ASM disclaims any and all liabilities for damages to any individual attending ICAAC and for all claims which may result from the use of this information, publications, technologies, products, and/or services at ICAAC.

Disclosure The France Foundation adheres to ACCME Essential Areas, Standards, and Policies regarding industry support of continuing medical education. Disclosure of the planning committee, content reviewers, and faculty’s commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations. A listing of faculty disclosures is available in the Online Program Planner and will be made available at the start of each session. This policy is intended to make you aware of faculty disclosure so that you may form your own judgments about material discussed during ICAAC. If you have concerns (e.g., commercially-biased presentations, promotional materials distributed by presenters and/or participants, etc.), please visit the ICAAC Headquarters Office and ask to speak to an ASM staff person so that ASM can respond immediately to your concerns. The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Claim CE Credits To claim credits for the ICAAC 2012, visit the ASM CE Portal, http://ce.asm.org. The ASM CE Portal allows individuals to: > Evaluate the activities they attend, > Print their own CE or participation certificate for the activity, > Browse the library of available ASM CE activities, > Participate in online learning activities. How to Claim CE Credit 1. Keep your badge! You will need your registration confirmation number or badge ID to claim your credits. 2. Login to the CE Portal with your ASM eStore user name and password. If you do not have a user name and password, select the “Need Help Logging In?” link. 3. Once logged in, you will be directed to your “My Activities” page. 4. Click on the “Claim Credits for Live Meetings” button on the right side of the screen. 5. Select “ICAAC 2012” under the Available Activities table. If you are claiming credit for a workshop, please select “Workshops –ICAAC 2012.” 6. On the Activities Overview Page, scroll to the bottom of the page to enter your badge ID. The badge ID may be obtained from your printed badge or from your emailed confirmation letter. 7. Choose what type of credit you would like to claim. The ICAAC 2012 offers five types of continuing education credit. Please choose the certificate that is applicable to your needs: - Continuing Medical Education (CME) certificate - Continuing Pharmacy Education (CPE) certificate - Florida (FL) certificate - California (CA) certificate - Participation certificate > After selecting your certificate type you will be directed to the “Claim Credits” page. Select each session attended, indicate how many credits you are requesting, and complete the evaluation for each session. (To view more sessions please click the page numbers at the bottom of the Claim Credits screen. Do not press Next until you have finished claiming credits for all your sessions.) 8. Once you have claimed credit for ALL of your sessions, you may review your credits summary and print your certificate.

When completing your online evaluation, PLEASE DO NOT PRESS PRINT until you have entered your information for each session attended at ICAAC. Once you print, your Statement of Credit is considered final and sessions cannot be added or changed. Please email [email protected] with questions or visit the ICAAC Headquarters Office.

Final Program

29

> Glossary

Continuing education available for physicians, microbiologists, and others

Icon legend >>>>>>

Recipient of an ICAAC Program Committee Award

Conveners Conveners are invited faculty who have contributed to the planning of an invited symposium or interactive cases and serve as a chair. Interactive Symposia Seven invited symposia have been scheduled that involve the audience in their own learning. Faculty present clinical case studies and pose relevant questions. Using hand-held keypads, the audience participants select a response, and the audience’s collective data are then displayed. Subsequently, there is an open discussion of the responses. Late-Breaker Presentations Late-breaker presentations highlight break-through scientific research results only recently discovered since the original ICAAC abstract submission deadline. Late-breaker abstracts have been added to previously programmed slide and poster sessions as appropriate. Please see page 295 for details. Literature Review Scheduled for Sunday afternoon, the conveners of this session present a general overview of the past year’s most noteworthy publications related to infectious diseases. Abstracts of the articles discussed are posted at www.icaac.org. Meet-the-Experts Thirty-six clinically-oriented Meet-the-Experts sessions are scheduled. These sessions permit attendees to interact directly with two specialists on a topic. After short presentations, the experts open the session for questions and answers during this 1-1/4 hour session. Moderators Moderators are selected individuals who serve as chairs of abstract slide sessions. Poster Sessions Eighty-five percent of accepted abstracts will be presented as posters, on display in Exhibit Hall, Halls A-C from Sunday – Wednesday. Each poster stays on display for an entire day, and each presenter is available at his or her poster for a two hour time period, as published. Specially-designed literature racks provided by ASM are located near the Poster Information booth, where exhibiting companies may place their pre-approved abstract and poster compilations. Poster Summary Session This session on new drugs will be held Sunday afternoon. The conveners of this session review all poster presentations that deal with new drug research and present an overview of the data presented. This session consistently receives outstanding reviews. Poster Walks Poster Walk presentations are selected by the ICAAC Program Committee are designed to give poster presenters an opportunity to discuss informally their research with colleagues. These brief oral presentations allow poster presenters to present their research and answer questions from the audience. Poster walks will take place in Exhibit Hall, Halls A-C. Slide Sessions Fifteen percent of this year’s accepted abstracts are scheduled for slide (PowerPoint) presentation. State-of-the-Art Mini-Lecture Seven slide sessions include a 30-minute, invited State-of-the-Art Mini-Lecture to complement the abstract presentations by offering attendees an overview, background, or summary of the science in that slide session. Symposia Symposia are classic 1 ½ - 2 hour sessions in which three to four speakers, invited by the ICAAC Program Committee, discuss the topic at hand. A number of symposia conclude with a 30-minute roundtable discussion to allow for additional audience participation.

30

Continuing education available for pharmacists

September 9-12 |

Topical Categories To assist you with your use of the Final Program, please note the following topical categories that are referenced in parentheses following session numbers. A1. Antimicrobial Pharmacokinetics A2. Antimicrobial Pharmacodynamics B. Therapy in Animal Models, Pathogenesis of Infectious Diseases, Molecular Basis for Pathogenicity, and Host Defenses C1. Antibacterials: Mechanisms of Action, Biochemistry and Genetics of Resistance (Antibacterial, not Viral or Fungal) C2. Antibacterials: Surveys and/or Molecular Epidemiology of Resistance and Resistance Genes, Strains or Serotypes (Bacterial, not Viral or Fungal Resistance) D. Laboratory Tests for Diagnosing Infections; Methods for Antibacterial Susceptibility Testing E. In Vitro Antibacterial Susceptibility Studies and DrugCombination Interactions F1. New Antimicrobial Agents (i.e. pre-US IND or prior to the start of any clinical therapeutic studies) F2. New Research Technologies and Methodologies (in early stages of drug discovery) G1. Bacterial, Viral and Other Vaccine Development Trials G2. Antigen Discovery or Delivery and Adjuvants or Immunomodulators to Augment Immune Responses G3. Studies Relating to Aspects of Pediatric Infections H1. HIV Epidemiology, Natural History, Pathogenesis and HIVRelated Morbidities Including Outcomes and Pharmacoepidemiological Studies H2. Antiretroviral Agents for Treatment and Prevention Including Preclinical and All Phases of Clinical Trials and resistance H3. Co-Infections in HIV (eg HCV, HBV, Other Agents) K. Healthcare-Associated and Surgical Infections and Clinical Epidemiology L1. Clinical Trials of Adults with Community-Acquired Infections L2. STD, Urinary Tract and Ob-Gyn Infections M. Mycology, Including Resistance and Mechanisms of Action of Antifungals P.

Global Health, Travel Medicine and Parasitology

T.

Transplantation Infectious Diseases

V.

Virology (Non-HIV), Including Resistance, and Non-HIV Viral Opportunistic Infections in HIV-Infected Patients

Saturday

> 8:30 a.m. - 12:00 p.m. Workshops 52-01 Basics of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents Esplanade Ballroom 306 52-03 Introduction to PK/PD Modeling of Anti-InfectiveAgents Esplanade Ballroom 305

> 8:30 a.m. - 4:30 p.m. Workshops 52-05 PK/PD Full-Day Workshop Combining 52-01 and 52-02 52-06 PK/PD Full-Day Workshop Combining 52-03 and 52-04 52-07 PK/PD Full-Day Workshop Combining 52-04 and 52-01 52-08 PK/PD Full-Day Workshop Combining 52-03 and 52-02 52-10 Antibiotic Resistance Among Bacterial Pathogens: Mechanisms, Detection, and Molecular Epidemiology Esplanade Ballroom 307 52-11 Antimicrobial Stewardship in Hospitals Esplanade Ballroom 304 52-12 A Year in Review: Critical Analysis and Application of Infectious Diseases Practice Guidelines and Pharmacotherapy Literature Esplanade Ballroom 308 52-13 New Clinical Microbiology Diagnostics: What is (or Could be) in Your Lab? Esplanade Ballroom 309 52-14 Transplant Infectious Diseases: Prevention and Resistance: Challenges for the 21st Century Esplanade Ballroom 310

Sunday

> 7:00 a.m. - 9:00 a.m. Interactive ID Fellows Session 001 Infectious Diseases 101: For Fellows Age 18-88 Room 104

> 9:30 a.m. - 11:30 a.m. Keynote Session 002 Opening Keynote Session Hall E

017 (H) Adherence to HIV Therapy and Care Halls A-C 018 (H) Hepatitis B and C Coinfection in HIV Halls A-C 019 (H) Opportunistic Infections and CoMorbid Conditions in HIV-I Halls A-C 020 (K) Antibiotic Stewardship and Usage Halls A-C 021 (K) Infection Control and the Environment Halls A-C

Poster Walk

022 (K) Prosthetic Joint Infections Halls A-C

Antibiotic Use and Resistance Halls A-C

> 11:30 a.m. - 1:30 p.m. Poster Sessions 003 (A) PK/PD of Carbapenems With or Without Beta-Lactamase Inhibitors Halls A-C 004 (A) Polymyxins and Aminoglycosides: Optimizing PK/PD and Dosing Halls A-C 005 (B) Immune Response to Microbial Infection Halls A-C 006 (C1) Carbapenemases and Expanded Spectrumơ-Lactamases: Enterobacteriaceae, S. aeruginosa, A. bumannii Halls A-C 007 (C2) AmpCs: Not Going Away! Halls A-C 008 (C2) Carbapenemases: Will They Ever End! Halls A-C

Workshops

009 (C2) ESBLs: Still Relevant Halls A-C

52-04 Advanced PK/PD Modeling of AntiInfective Agents with Practical Examples Esplanade Ballroom 305

016 (E) In Vitro Activity of Fluoroquinolones Halls A-C

> 11:30 a.m. - 12:30 p.m.

> 1:00 p.m. - 4:30 p.m. 52-02 Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents Esplanade Ballroom 306

015 (E) In Vitro Activity of Beta-Lactamase Inhibitor Combinations Halls A-C

010 (C2) Multi-Center Surveillance Studies Halls A-C 011 (D) Clostridium difficile Diagnostics Halls A-C 012 (D) Diagnosis of Infections of Implantable Devices and Biofilms Halls A-C 013 (D) Diagnosis of Respiratory Tract Infections Halls A-C 014 (D) Serologic Methods for Detection of Infectious Diseases Halls A-C

023 (K) Surgical Site Infections Halls A-C 024 (K) Vancomyoin-Resistant Enterococci Halls A-C 025 (L1) Antimicrobial Stewardship and OPAT Halls A-C 026 (L1) Respiratory Tract Infection Halls A-C 027 (L2) Studies in Sexually Transmitted Infection Halls A-C 028 (M) Fungal Epidemiology Halls A-C 029 (T) Infections in Transplant Recipients: Viruses and Fungi Halls A-C 030 (V) Non-HIV Virology Halls A-C

> 12:30 p.m. - 1:30 p.m. Poster Walk The HIV Poster Rounds Halls A-C

> 1:45 p.m. - 3:45 p.m. Literature Review 031 Literature Review Room 103

Poster Summary Session 032 (F) Early New Antimicrobial Agents Room 104

Saturday/Sunday

> Saturday/Sunday Schedule at-a-Glance

> Saturday/Sunday Schedule at-a-Glance continued… > 4:00 p.m. - 6:00 p.m. Interactive Symposia 033 (P) What’s Hot Where it’s Hot: Interactive Cases in Tropical Medicine Room 103 034 (V, D) Transplantation and the ID Physician: Management Strategies for the 21st Century Room 104

Symposia 035 (A) Pharmacodynamics of Antifungal Agents Esplanade Ballroom 306 036 (B) Microbial Factors Modulating Host Responses: New Frontiers Esplanade Ballroom 309 037 (C1) Multidrug Resistance in Emerging Countries Esplanade Ballroom 302 038 (C2) Whole Genome Sequencing and Molecular Epidemiology: The New Frontier? Esplanade Ballroom 308 039 (D) Best Practices: Diagnosis of Viral Causes of Hepatitis Esplanade Ballroom 305 040 (E, C2) Origins and Ecology of Antibiotic Resistance Esplanade Ballroom 310 041 (F) New Treatments for Mycobacterium tuberculosis Infections Room 122 042 (G) Vaccine Conquests and Challenges Room 120 043 (H) Update on HIV-Associated Co-Morbidities Room 121 044 (L) An Update on Novel & Important Tickborne Diseases Room 102 045 (L2) An Update on Perinatal Infections Room 130 046 (M) Mycology 2012: Top Papers Room 132

> 4:00 p.m. - 6:30 p.m. Slide Session 047 (C1) Structure/Function Esplanade Ballroom 300 048 (K) Difficulties of Clostridium difficile Room 254

ICAAC 2012 WORKSHOPS

Workshops All workshops will be held in the Moscone South (Convention Center).

-----------------------------------------------------------------------52-01

-----------------------------------------------------------------------52-02

Basics of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents

Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents

Saturday, 8:30 a.m. - 12:00 p.m. . . . . Esplanade Ballroom 306 UAN: 0391-9999-12-179-L04-P

Saturday, 1:00 p.m. - 4:30 p.m. . . . . . Esplanade Ballroom 306 UAN: 0391-9999-12-180-L04-P

Conveners: Johan W. Mouton, MD, PhD - Professor Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands. Hartmut Derendorf, PhD - Distinguished Professor Univ. of Florida, Gainesville, FL.

Conveners: Johan W. Mouton, MD, PhD - Professor Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands. Ursula Theuretzbacher, PhD - Principal Ctr. for Anti-Infective Agents, Vienna, Austria.

Faculty: Hartmut Derendorf, PhD - Distinguished Professor Univ. of Florida, Gainesville, FL. Johan W. Mouton, MD, PhD - Professor Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands. William A. Craig, MD - Emeritus Professor Univ. of Wisconsin, Madison, WI. Alasdair P. MacGowan, MD - Professor of Clinical Microbiology and Antimicrobial Therapeutics Bristol Ctr. for Antimicrobial Res. and Evaluation, Bristol, United Kingdom. Ursula Theuretzbacher, PhD - Principal Ctr. for Anti-Infective Agents, Vienna, Austria. Roger L. Nation, PhD - Professor of Drug Disposition and Dynamics Monash Univ., Melbourne, Australia.

Faculty: Johan W. Mouton, MD, PhD - Professor Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands. Markus Zeitlinger, MD - Assoc. Professor Med. Univ. of Vienna, Vienna, Austria. Sujata M. Bhavnani, PharmD - Vice-President, Translational Medicine Inst. for Clinical Pharmacodynamics, Latham, NY. David R. Andes, MD - Associate Professor Univ. of Wisconsin, Madison, WI. Ursula Theuretzbacher, PhD - Principal Ctr. for Anti-Infective Agents, Vienna, Austria. Paul M. Tulkens, MD - Professor Univ. Louvain, Bruxelles, Belgium.

Objectives: Upon completion of this Workshop, the participant should be able to: > Identify pharmacokinetic and pharmacodynamic concepts of antimicrobial efficacy; > Apply in vitro models and animal models in pharmacodynamic research; > Recognize the limitations and use of serum and tissue concentrations; > Calculate pharmacokinetic and pharmacodynamic parameters and interpret the results; and > Assess drug resistance in vitro. Intended Audience: Medical microbiologists, infectious diseases specialists, pharmacologists, drug development scientists, and other interested.

Objectives: Upon completion of this Workshop, the participant should be able to: > Gain insight in the clinical significance of PK/PD modeling of antimicrobials; > Extrapolate preclinical PK/PD information into clinical drug development; > Determine PK/PD of antibacterials and antifungals; > Assess drug exposure at the site of infection; and > Recognize and evaluate clinical drug resistance. Intended Audience: Infectious diseases specialists, pharmacologists, medical microbiologists, clinical drug development specialists, and others interested. Course Level: Beginning

Course Level: Beginning

Final Program

31

> Saturday WORKSHOPS -----------------------------------------------------------------------52-03 Introduction to PK/PD Modeling of Anti-Infective Agents Saturday, 8:30 a.m. - 12:00 p.m. . . . . Esplanade Ballroom 305 UAN: 0391-9999-12-181-L04-P Conveners: Vincent Tam, PharmD - Associate Professor Univ. of Houston Coll. of Pharmacy, Houston, TX. Alexander A. Vinks, PharmD, PhD - Professor Univ. of Cincinnati, Cincinnati, OH. Faculty: Alasdair P. MacGowan, MD - Professor of Clinical Microbiology and Antimicrobial Therapeutics Bristol Ctr. for Antimicrobial Res. and Evaluation, Bristol, United Kingdom. Vincent H. Tam, PharmD - Associate Professor Univ. of Houston Coll. of Pharmacy, Houston, TX. Alexander A. Vinks, PharmD, PhD - Professor Univ. of Cincinnati, Cincinnati, OH. Alan Forrest, PharmD - Research Professor; Senior Director Pharmacometrics SUNY Univ. of Buffalo, Buffalo, NY. Sujata M. Bhavnani, PharmD - Vice-President, Translational Medicine Inst. for Clinical Pharmacodynamics, Latham, NY. Jared L. Crandon, PharmD - Associate Director Hartford Hosp., Hartford, CT. Objectives: Upon completion of this Workshop, the participant should be able to: > Apply MIC based PK/PD modeling in vitro and in animals; > Perform PK/PD analysis based on kill curves; > Employ population PK/PD of anti-infective agents; > Design and evaluate Monte Carlo Simulations; and > Integrate preclinical and clinical PK/PD. Intended Audience: Drug development specialists, pharmacologists, medical microbiologists, infectious diseases specialists, and others interested. Course Level: Intermediate

-----------------------------------------------------------------------52-04 Advanced PK/PD Modeling of Anti-Infective Agents with Practical Examples Saturday, 1:00 p.m. - 4:30 p.m. . . . . . Esplanade Ballroom 305 UAN: 0391-9999-12-182-L04-P Conveners: George L. Drusano, MD - Professor Univ. of Florida, Orlando, FL. Hartmut Derendorf, PhD - Distinguished Professor Univ. of Florida, Gainesville, FL. Faculty: Hartmut Derendorf, PhD - Distinguished Professor Univ. of Florida, Gainesville, FL. Alan Forrest, Pharm D - Research Professor; Senior Director, Pharmacometrics SUNY Univ. of Buffalo, Buffalo, NY. Jurgen Bulitta, PhD - Senior Research Fellow & Adjunct Assistant Professor Monash Univ., Buffalo, NY. George Drusano, MD - Professor Univ. of Florida, Gainesville, FL.

32

September 9-12 |

Objectives: Upon completion of this Workshop, the participant should be able to: > Employ sophisticated kill curve modeling; > Design PK/PD models to predict and avoid resistance development; > Integrate modeling and simulation in to the overall drug development activities; and > Identify the integration of preclinical and clinical PK/PD to streamline decision making in drug development. Intended Audience: Pharmacometricians, PK/PD analysts, and drug development specialists. Course Level: Advanced

-----------------------------------------------------------------------52-05 PK/PD Full-Day Workshop Combining 52-01 and 52-02 Saturday, 8:30 a.m. - 4:30 p.m.




ICAAC 2012 WORKSHOPS -----------------------------------------------------------------------52-10

-----------------------------------------------------------------------52-11

Antibiotic Resistance Among Bacterial Pathogens: Mechanisms, Detection, and Molecular Epidemiology

Antimicrobial Stewardship in Hospitals

Saturday, 8:30: a.m. - 4:30 p.m. . . . . . Esplanade Ballroom 307 UAN: 0391-9999-12-183-L04-P Conveners: Stephen G. Jenkins, PhD - Professor of Pathology and Laboratory Medicine Weill Cornell Med. Coll., New York, NY. Stephen M. Brecher, PhD - Director of Microbiology VA Boston Healthcare System, West Roxbury, MA. Faculty: Stephen G. Jenkins, PhD - Professor of Pathology and Laboratory Medicine Weill Cornell Med. Coll., New York, NY. Stephen M. Brecher, PhD - Director of Microbiology VA Boston Healthcare System, West Roxbury, MA. Audrey N. Schuetz, MD, MPH - Assistant Professor of Pathology and Laboratory Medicine Weill Cornell Med. Coll., New York, NY. David P. Nicolau, PharmD - Dir., Ctr for Anti-Infective Res & Dev Hartford Hosp., Ctr. for Anti-Infective Res. and Dev., Hartford, CT. Objectives: Upon completion of this Workshop, the participant should be able to: > Describe the nuances and problems associated with susceptibility testing of staphylococci; > Recognize the problems associated with detection of antibiotic resistance in Enterobacteriaceae and other gram-negative pathogens, and methods employed to overcome such difficulties; > Detect Clostridium difficile with significantly increased accuracy; > Describe how to use molecular typing tools in the clinical laboratory to solve epidemiologic problems; and > Explain the PK/PD parameters used to evaluate antimicrobial agents in the light of evolving resistance. Intended Audience: Clinical microbiologists, infectious disease physicians, clinical pharmacists with expertise and interest in infectious diseases, and infection control practitioners. Course Level: Intermediate

Saturday, 8:30 a.m. - 4:30 p.m. . . . . . Esplanade Ballroom 304 UAN: 0391-9999-12-184-L04-P Developed in Cooperation with ESCMID Study Group for Antibiotic Policies (ESGAP) Conveners: Inge C. Gyssens, MD, PhD - Professor Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands. Richard H. Drew, PharmD, MS - Professor of Pharmacy, Associate Professor of Medicine Duke Univ. Med. Ctr., Durham, NC. Faculty: Stephan Harbarth, MD, MS - Associate Professor Hôpitaux Univ. de Genève, Geneva, Switzerland. Inge C. Gyssens, MD, PhD - Professor Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands. Elizabeth S. D. Ashley, PharmD - Associate Director of Clinical Pharmacy Services Univ. of Rochester Med. Ctr., Rochester, NY. Robert Gaynes, MD - Professor Emory Univ. Sch. of Med., Atlanta, GA. Richard H. Drew, PharmD, MS - Professor of Pharmacy, Associate Professor of Medicine Duke Univ. Med. Ctr., Durham, NC. Harold C. Standiford, MD - Clinical Professor of Medicine Univ. of Maryland Sch. of Med., Baltimore, MD. Objectives: Upon completion of this Workshop, the participant should be able to: > Select proper measurement units to describe the volume of antimicrobial use; > Interpret antimicrobial use data locally and within a multicenter network (Benchmarking); > Choose and to apply an audit methodology for monitoring the quality of antimicrobial prescriptions; > Identify possible intervention strategies and their relative advantages and disadvantages which could be implemented in a hospital; > Identify the electronic antimicrobial drug prescribing aids and the advantages and disadvantages of each; > Describe how an individual hospital can determine if its antimicrobial management program was economically successful and if it had an impact on bacterial resistance; > Describe the use of biomarkers of infection that may be useful to guide the duration of therapy; and > Describe the elements needed to launch a stewardship program in community hospitals. Intended Audience: Infectious diseases pharmacists, infection control practitioners involved in antimicrobial management, and infectious diseases physicians. Course Level: Intermediate

Final Program

33

> Saturday WORKSHOPS -----------------------------------------------------------------------52-12

-----------------------------------------------------------------------52-13

A Year in Review: Critical Analysis and Application of Infectious Diseases Practice Guidelines and Pharmacotherapy Literature

New Clinical Microbiology Diagnostics: What is (or Could be) in Your Lab?

Saturday, 8:30 a.m. - 4:30 p.m. . . . . . Esplanade Ballroom 308 UAN: 0391-9999-12-185-L04-P Conveners: Scott J. Bergman, PharmD - Associate Professor Southern Illinois Univ. Edwardsville, Springfield, IL. Jeannie McKinnon, PharmD - Pharmacist Mayo Clinic, Jacksonville, FL. Punit J. Shah, PharmD - Infectious Diseases Pharmacy Resident St. John’s Hosp., Springfield, IL. Faculty: Jessica Cottreau, Pharm D - Assistant Professor Univ. of Houston, Houston, TX. Ian McNicholl, PharmD - Clinical Associate Professor Univ. of California, San Francisco, CA. Russell Lewis, PharmD - Senior Researcher S’Orsola-Malpighi Hosp., Univ. of Bologna, Bologna, Italy. Christopher R. Frei, PharmD, MS - Assistant Professor The Univ. of Texas at Austin and The Univ. of Texas Hlth. Sci. Ctr. at San Antonio, Austin, TX. David J. Weber, MD, MPH - Professor of Medicine, Pediatrics & Epidemiology Univ. of North Carolina, Chapel Hill, NC. Ellie J. C. Goldstein, MD - Director R.M. Alden Res. Lab., Santa Monica, CA. Objectives: Upon completion of this Workshop, the participant should be able to: > Summarize the most relevant infectious diseases practice guidelines published in the last year; > Discuss the recent literature surrounding anti-infective therapy and how this may influence treatment guidelines and clinical practice; > Assess the efficacy, safety, and economics of anti-infective therapy recommended; and > Develop evidence-based treatment strategies for patients with infections. Intended Audience: Physicians, pharmacists, microbiologists, and industry scientists. Course Level: Intermediate

34

September 9-12 |

Saturday, 8:30 a.m. - 4:30 p.m. . . . . . Esplanade Ballroom 309 UAN: 0391-9999-12-186-L04-P Conveners: Robin Patel, MD - Professor of Medicine and Microbiology Mayo Clinic, Rochester, MN. Karen C. Carroll, MD - Professor of Pathology Johns Hopkins Univ. Sch. of Med., Baltimore, MD. Faculty: Robin Patel, MD - Professor of Medicine and Micorbiology Mayo Clinic, Rochester, MN. Karen C. Carroll, MD - Professor of Pathology Johns Hopkins Univ. Sch. of Med., Baltimore, MD. Alexandra Valsamakis, MD, PhD - Associate Professor Johns Hopkins Univ. Sch. of Med., Baltimore, MD. Nathan A. Ledeboer, PhD - Assistant Professor of Pathology Med. Coll. of Wisconsin, Milwaukee, WI. Esther Babady, PhD - Assistant Director of Microbiology Mem. Sloan-Kettering Cancer Ctr., New York, NY. Objectives: Upon completion of this Workshop, the participant should be able to: > State the potential benefits to patient care (if any) realized by adopting the discussed technologies; > Discuss the strengths and limitations of the discussed diagnostic tests; > Apply the discussed diagnostic techniques to their clinical practice; and > Assess workflow changes, if any, surrounding use of these new technologies. Intended Audience: Clinical microbiologists, infectious diseases clinicians, laboratory technologists, and industry. Course Level: Intermediate

ICAAC 2012 WORKSHOPS -----------------------------------------------------------------------52-14 Transplant Infectious Diseases: Prevention and Resistance: Challenges for the 21st Century Saturday, 8:30 a.m. - 4:30 p.m. . . . . . Esplanade Ballroom 310 UAN: 0391-9999-12-187-L04-P Developed in Cooperation with the International Society of Heart and Lung Transplantation (ISHLT) Conveners: Emily A. Blumberg, MD - Professor of Medicine Perelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA. Lara Danziger-Isakov, MD, MPH - Assistant Professor of Pediatrics Cleveland Clinic Lerner Coll. of Med., Case Western Reserve Univ., Cleveland, OH. Faculty: Atul Humar, MD - Professor, Director Alberta Transplant Institute Univ. of Alberta, Edmonton, Canada. Shahid Husain, MS, MBBS, MD - Associate Professor of Medicine , Director of Transplant Infectious Diseases Univ. of Toronto, Toronto, Canada. Lara Danziger-Isakov, MD, MPH - Assistant Professor of Pediatrics Cleveland Clinic Lerner Coll. of Med., Case Western Reserve Univ., Cleveland, OH. David R. Snydman, MD, FACP, FIDSA - Chief, Division of Geographic Medicine and Infectious Diseases Tufts Univ., Sch. of Med., Boston, MA. Todd D. Barton, MD - Associate Professor of Clinical Medicine Perelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA. Ajit P. Limaye, MD - Professor Univ. of Washington, Seattle, WA. Laurent Kaiser, MD - Professor, Head of the Laboratory of clinical virology Univ. Hosp. of Geneva, Geneva, Switzerland. Emily A. Blumberg, MD - Professor of Medicine Perelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA. Wing Hong Seto, MD - Director, WHO Collaborating Centre for Infection Control Hosp. Authority, Hong Kong, China. Guy Boivin, MD - Professor CHUL, Quebec, Canada. Objectives: Upon completion of this Workshop, the participant should be able to: > Determine the impact of antimicrobials on prevention of infection; > Identify adjunctive prevention strategies, including immunization and infection control strategies; > Appraise the impact of viral infections on transplant outcomes; and > Assess issues related to diagnosis and treatment for multiple difficult to treat infections in transplant recipients, including resistant viruses, bacteria and mycobacteria. Intended Audience: Infectious diseases physicians, pharmacists, and microbiologists working in diagnostics. The audience may include those already working in transplantation as well as those who are familiar with infectious diseases but not with transplant specific issues. Course Level: Intermediate

Final Program

35

> NOTES

36

September 9-12 |

SUNDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------001 Interactive ID Fellows Session

-----------------------------------------------------------------------002 Keynote Session

Infectious Diseases 101: For Fellows Age 18-88

Opening Keynote Session

Sunday, 7:00 a.m.–9:00 a.m.. . . . . . . . . . . . . . . . . . . . . Room 104 UAN: 0391-9999-12-033-L04-P

Sunday, 9:30 a.m.–11:30 a.m. . . . . . . . . . . . . . . . . . . . . . . . . Hall E UAN: 0391-9999-12-034-L04-P

conveners: Didier Pittet, MD, MS - Professor of Medicine Univ. of Geneva Hosp., Geneva, Switzerland. David Aronoff, MD - Associate Professor Univ. of Michigan, Ann Arbor, MI.

Speakers: 9:30 a.m. 005 Emerging New Issues in the Management of Hepatitis C Infection

Speakers: 001 Treatment Challenges in Multidrug-Resistant Infections Yohei Doi, MD, PhD Univ. of Pittsburgh Med. Ctr., Pittsburgh, PA.

Charles M. Rice, PhD - Maurice R. and Corinne P. Greenberg Professor; Head, Laboratory of Virology and Infectious Disease The Rockefeller Univ., New York-Presbyterian Hosp., Weill Cornell Med. Coll., New York, NY. 9:30 a.m. 006 The Impact of Emerging New Diagnostic Laboratory Tech-

002 Important Topics in Vaccines

niques on Clinical Infectious Disease

Kathryn M. Edwards, MD Vanderbilt Univ., Nashville, TN. 003 Treating HIV Infection in 2012 Joel Gallant, MD - Professor of Medicine & Epidemiology, Associate Director, John Hopkins AIDS Service Johns Hopkins Univ. Sch. of Med., Baltimore.

Franklin R. Cockerill, III, MD - Ann and Leo Markin Professor of Microbiology and Medicine, Mayo Graduate School of Medicine; Chair, Department of Laboratory Medicine and Pathology Mayo Clinic, Rochester, MN. 9:30 a.m. 007 Prospects for New Antibiotics Christopher T. Walsh, PhD - Hamilton Kuhn Professor Harvard Med. Sch., Boston, MA.

004 Important Issues in Global Health David Heymann, MD - Professor Imperial Coll., London, United Kingdom. Objectives: Upon completion of this Interactive ID Fellows Session, the participant should be able to: > Integrate new knowledge regarding vaccine-preventable infections into their practice or research; > Identify critical knowledge gaps in microbiology, infectious diseases and infection prevention; > Discuss global burden of diseases and global health; and > Discuss novel diagnostic and therapeutic aspects of infectious diseases.

Objectives: Upon completion of this Keynote Session, the participant should have a greater understanding regarding emerging new issues related to: > The pathogenesis and management of hepatitis C; > Emerging new technologies in diagnostic microbiology and their likely impact on clinical infectious diseases; and > The development of new classes of antimicrobial agents. Intended Audience: Clinicians, scientists, researchers, microbiologists, virologists, pharmacists and public health physicians. Level: All Levels

-----------------------------------------------------------------------------------------------------------------------------------------------------POSTER WALK Antibiotic Use and Resistance | Sunday, September 9, 11:30 a.m. – 12:30 p.m. | Halls A-C Convener: Stephan Harbarth, MD, MS - Professor Univ. of Geneva Hosp., Geneva, Switzerland. Presentations:

Do Antibiotic Combinations with Rifampin for Osteoarticular Infections Protect against Clostridium difficile-Associated Colitis? C. Landelle; Univ. of Geneva Hosp., Geneva, Switzerland.

Outcome of Appropriate Empiric Combination versus Monotherapy for Pseudomonas aeruginosa Bacteremia D. R. Bowers; St. Luke’s Episcopal Hosp., Univ. of Houston, Houston, TX.

Clinical Impact of KPC Status and Appropriate Treatment among Enterobacteriaceae (EB) and Pseudomonas aeruginosa (Pae) in a Multicenter Matched Control Cohort Study in Colombia V. M. Blanco; CIDEIM, Cali, Colombia.

Inadequate Antibiotic Therapy is Associated with Decreased Survival in Patients with Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Bloodstream Infections N. F. Dewhurst; St. Michael’s Hosp., Univ. of Toronto, Toronto, Canada.

Control of the Prescription of Carbapenems in a French Hospital: Impact of the Hospital Antibiotic Management Team C. Couzigou; Hosp. Saint Joseph, Paris, France.

Final Program

37

> Sunday SCIENTIFIC SESSIONS -----------------------------------------------------------------------------------------------------------------------------------------------------POSTER WALK The HIV Poster Rounds | Sunday, September 9, 12:30 p.m. – 1:30 p.m. | Halls A-C Conveners: Joseph Eron, Jr., MD - Professor of Medicine Univ. of North Carolina, Chapel Hill, NC. Jean-Michel G. Molina, MD - Professor Saint Louis Hosp. and Univ. of Sorbonne Paris Cité, Paris, France. Presentations:

Impact of Seven Nucleotide Polymorphisms and Haplotypes of CYP2B6 on Plasma Efavirenz Level in HIV/Tuberculosis Co-Infected Thai Patients Receiving Rifampicin S. Sungkanuparph; Faculty of Med. Ramathibodi Hosp., Mahidol Univ., Bangkok, Thailand.

Efficacy and Use of PI vs EFV in Treatment Naive HIV+ Men and Women J. Patel; Rush Univ. Med. Ctr., Chicago, IL.

Safety and Efficacy of Once Daily Raltegravir to Enhance Adherence and Efficacy of HAART in Vulnerable HIV-Infected Patients K. Stewart; Univ. of Saskatchewan, Saskatoon, Canada.

Preemptive Therapy Prevents Cytomegalovirus End-Organ Disease in Treatment-Naïve Patients With Advanced HIV-1 Infection D. Mizushima; Natl. Ctr. for Global Hlth. and Med., Tokyo, Japan.

Genotypic Algorithm for Predicting Elvitegravir Susceptibility: Clinical Validation and Correlation with Phenotype M. Haddad; Monogram Biosciences, South San Francisco, CA.

Persistent Low-Level Viraemia in HIV-1-Infected Patients: Swiss HIV Cohort Study N. Boillat Blanco; Univ., Lausanne, Switzerland.

-----------------------------------------------------------------------003(A) Poster Session PK/PD of Carbapenems With or Without Beta-Lactamase Inhibitors Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . Halls A-C Presentations:

Combined with Tobramycin (TOB) against a Hypermutating Pseudomonas aeruginosa (PA) Strain J. B. Bulitta 1, R. E. D’Hondt 2, A. Oliver 3, A. Mena 3, C. B. Landersdorfer 1, D. Brown 4, B. VanScoy 4, R. Kulawy 4, A. Louie 4, G. L. Drusano 4; 1Ctr. for Med. Use and Safety, Monash Univ., Melbourne, Australia, 2Ordway Res. Inst., Albany, NY, 3Hosp. Univ. Son Espases, Palma de Mallorca, Spain, 4Inst. for Therapeutic Innovation, Univ. Florida, Albany, NY. A-012 Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation

A-008 MK-7655, A Novel ơ-Lactamase Inhibitor (BLI), Elicits a

Prolonged Post-Inhibitor Effect in P. aeruginosa K. Young 1, M. Motyl 1, M. Rizk 2, J. Deane 3, D. Sahm 3, M. Knechtel 4, G. Zuerenko 5, C. Pillar 4, D. Shinabarger 4; 1Merck Res. Lab., Kenilworth, NJ, 2 Merck Res. Lab., West Point, PA, 3Eurofins, Global Central Lab., Chantilly, VA, 4Micromyx, Kalamazoo, MI, 5Micromyx, Kalmazoo, MI. A-009 A Phase I Study Evaluating the Single-Dose Safety, Toler-

ability, and Pharmacokinetics of an Intravenous Beta-Lactamase Inhibitor in Healthy Elderly Male, Elderly Female and Young Female Volunteers P. Jumes 1, M. L. Rizk 1, M. Gutierrez 2, X. Li 1, S. A. Stoch 1, J. A. Wagner 1 , J. R. Butterton 1; 1Merck Sharp & Dohme Corp., Whitehouse Station, NJ, 2 Comprehensive Phase One, Miramar, FL. A-010 Pharmacokinetics of MK-7655, a Novel Beta-Lactamase In-

hibitor (BLI), in Combination with Imipenem/Cilastatin (IPM/ CIL) in Subjects with Impaired Renal Function M. L. Rizk 1, P. Jumes 1, K. Lassetter 2, T. Marbury 3, E. Mangin 1, Y. Liu 1, J. Wagner1, J. Butterton 1; 1Merck Sharp & Dohme Corp., Whitehouse Station, NJ, 2Clinical Pharmacology of Miami, Miami, FL, 3The Orlando Clinical Res. Ctr., Orlando, FL.

38

A-011 Synergistic Prevention of Resistance by Meropenem (MER)

September 9-12 |

of the Efficacy & Efficiency (Ef ) of Meropenem (M) Dosing Regimens M. Trang, A. Forrest; SUNY Sch. of Pharmacy, Buffalo, NY. A-013 Impact of Various Conditions on the Efficacy of Dual Car-

bapenem Therapy against KPC Producing Klebsiella pneumoniae D. E. Wiskirchen 1, J. L. Crandon 2, D. P. Nicolau 2; 1Univ. of St. Joseph, Sch. of Pharm., Hartford, CT, 2Ctr. Anti-Infect. Res. & Devel., Hartford Hosp., Hartford, CT. A-014 Impact of Resistance Mechanisms on Predicting In Vivo Ac-

tivity of Carbapenems against Klebsiella pneumoniae with Similar MICs M. Hagihara 1, J. L. Crandon 1, C. Urban 2, D. P. Nicolau 1; 1Ctr. Anti-Infect. Res. & Dev., Hartford Hosp., Hartford, CT, 2Infect. Dis. Res. Lab, New York Hosp. Queens, Flushing, NY. A-015 KPC Presence in Pseudomonas aeruginosa (PSA) has Minimal

Impact on the In Vivo Efficacy of Carbapenem Therapy M. Haihara 1,2, J. L. Crandon 1, C. Urban 3, D. P. Nicolau 1; 1Ctr. Anti-Infect. Res. and Dev., Hartford Hosp., Hartford, CT, 2Aichi Med. Univ., Aichi, Japan, 3Infec Dis. Res. Lab., New York Hosp. Queens, Flushing, NY.

SUNDAY SCIENTIFIC SESSIONS A-016 Comparison of Methods for Doripenem (D) Population

Pharmacodynamic (PPD) Analysis & Optimization of Dosing Regimens Using Monte Carlo Simulation (MCS) N. S. Ly, G. G. Rao, R. L. Soon, L. Wollenberg, K. Yang, B. T. Tsuji, A. Forrest; SUNY, Buffalo, NY. A-017 Pharmacokinetics and Pharmacodynamics of Doripenem in

Obese, Hospitalized Patients 1

2

3

4

M. B. Kays , S. C. Cheatham , M. R. Fleming , J. M. Juenke , C. E. K. Chung 1; 1Purdue Univ. Coll. of Pharmacy, Indianapolis, IN, 2St. Francis Hosp., Indianapolis, IN, 3Methodist Dallas Med. Ctr., Dallas, TX, 4ARUP, Salt Lake City, UT.

M. Hagihara 1,2, S. T. Housman 1, D. P. Nicolau 1, J. L. Kuti 1; 1Ctr. AntiInfect. Res. and Dev., Hartford Hosp., Hartford, CT, 2Aichi Med. Univ., Aichi, Japan. A-024 Polymyxin B (PB) in Combination (Combo) with Doripenem

(D) against Acinetobacter baumannii (Ab) Demonstrates High Synergy and Suppression of Resistance G. G. Rao1, N. S. Ly 1, R. L. Soon 1, M. D. San Roman 1, P. A. Kelchlin 1, P. N. Holden 1, P. Bergen 2, J. B. Bulitta 2,1, A. Forrest 1, R. L. Nation 2, J. Li 2, B. T. Tsuji 1; 1SUNY, Buffalo, NY, 2Monash Univ., Melbourne, Australia. A-025 Pulmonary Target Delivery of Polymyxin B for Enhanced

Efficacy J. He, K. Abdelraouf, K. R. Ledesma, D. S. L. Chow, V. H. Tam; Univ. of Houston, Houston, TX.

A-018 Pharmacokinetics and Monte Carlo Simulations of

Doripenem in Patients with Febrile Neutropenia G. E. Stein, G. Kulhanek, C. Smith, J. Kuti, D. Nicolau, A. Scharmen, C. Farnum, M. Tran, A. Kalra, D. Havlichek; Michigan State Univ., East Lansing, MI. A-019 PK/PD Target Attainment of Doripenem in Pediatric

Patients Using Monte-Carlo Simulation

A-026 Clinical Pharmacokinetics of Intravenous Polymyxin B1 and B2 C. J. Kubin1, E. Broun 1, K. M. Abildskov 1, J. Horan 2, T. A. Thomas 1, M. T. Yin 1, S. Cremers 1; 1Columbia Univ. Med. Ctr., New York, NY, 2Duke Univ., Durham, NC. A-027 Steady-State (SS) Pharmacokinetics (PK) of Polymyxin B (PB)

Y. Matsuo, M. Tsuji, T. Ishibashi, T. Katsube, T. Wajima; Shionogi & Co. Ltd., Osaka, Japan. A-020 Comparative Pharmacokinetics (PK) of Doripenem (DOR)

in Infected Patients Treated In- and Out-Side the Intensive Care Unit (ICU) A. A. Bhalodi 1, R. A. Keel 1, R. Quintiliani 2, T. P. Lodise 3, D. P. Nicolau 1, J. L. Kuti 1; 1Ctr. for Anti-Infect. Res. & Dev., Harford Hosp., Hartford, CT, 2 CT Multispecialty Group, Hartford Hosp., Hartford, CT, 3Albany Coll. of Pharmacy and Hlth. Sci., Albany, NY. A-021 Population Pharmacokinetics (PopPK) of Imipenem (IMP)

in Intensive Care Unit (ICU) Patients with Ventilator-Associated Pneumonia (VAP) C. Couffignal 1,2, O. Pajot 3, L. Massias 1, L. Armand-lefevre 1, A. Foucrier 1, C. Laouénan 1,2, M. Wolff 1,4, F. Mentré 1,2; 1AP-HP, Hop BICHAT, Paris, France, 2Univ. Paris Diderot, Sorbonne Paris Cité and Inserm, UMR 738, Paris, France, 3Hop V Dupouy, Argenteuil, France, 4Univ. Paris Diderot, Sorbonne Paris Cité, EA 3964, Paris, France. A-022 In Vitro Pharmacodynamics (IVPD) of Human Simulated

Exposures of Ampicillin/Sulbactam (SAM), Doripenem (DOR), or Tigecycline (TGC) Alone and in Combination against Multidrug-Resistant (MDR) Acinetobacter baumanii (ACB) S. T. Housman, M. Hagihara, D. P. Nicolau, J. L. Kuti; Ctr. Anti-Infect. Res. & Devel., Hartford Hosp., Hartford, CT. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------004(A) Poster Session Polymyxins and Aminoglycosides: Optimizing PK/PD and Dosing Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-023 In Vitro Pharmacodynamics of Polymyxin B (PMB) and

in Critically Ill Patients A. M. Sandri 1,2, C. B. Landersdorfer 3, J. Jacob 4, M. M. Boniatti 5, M. G. Dalarosa 5, D. R. Falci 5, T. F. Behle 6, J. Wang 4, A. Forrest 7, R. L. Nation 4, A. P. Zavascki 1,6, J. Li 4; 1Univ. Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Hosp. Sao Lucas da PUCRS, Porto Alegre, Brazil, 3Ctr. for Med. Use & Safety, Monash Univ., Melbourne, Australia, 4Monash Inst. of Pharmaceutical Sci., Monash Univ., Melbourne, Australia, 5Hosp. Nossa Senhora da Conceição, Porto Alegre, Brazil, 6Hosp. de Clín. de Porto Alegre, Porto Alegre, Brazil, 7Sch. of Pharmacy & Pharmaceutical Sci., SUNY, Buffalo, NY. A-028 Pharmacokinetics and Renal Disposition of Polymyxin B K. Abdelraouf, J. He, K. R. Ledesma, M. Hu, V. H. Tam; Univ. of Houston, Houston, TX. A-029 Polymyxin B Dosing Adjustment in Renal Insufficiency V. H. Tam, J. He, K. Abdelraouf, K. R. Ledesma, M. Hu; Univ. of Houston, Houston, TX. A-030 Colistin, Tigecycline and Daptomycin Combinations

Improves Bacterial Kill of Acinetobacter baumannii P. Komp Lindgren 1, H. Seifert 2, O. Cars 1; 1ARunit, Uppsala, Sweden, 2 IMMIH, Cologne, Germany. A-031 Synergistic Killing of Colistin (COL) Combination (COM-

BO) Therapy against Multidrug-Resistant (MDR) Acinetobacter baumannii (Ab) in Mouse Lung and Thigh Infection Models H. J. Lee 1, J. Wang 1, C. Ku 1, B. T. Tsuji 2, A. Forrest 2, J. B. Bulitta 1,2, J. Li 1 , R. L. Nation 1; 1Monash Univ., Melbourne, Australia, 2Univ. at Buffalo, Buffalo, NY. A-032 Optimal Design (OD) of a Colistin Sparse Sampling Schedule

for Individual PK-Parameter Estimation A. N. Kristoffersson, J. Nyberg, L. E. Friberg; Uppsala Univ., Uppsala, Sweden. A-033 Whole Body Physiologically-Based Pharmacokinetic

Model of Colistin and Colistimethate Sodium (CMS) in Healthy Volunteers S. Bouchene1, L. E. Friberg 1, S. Björkman 1, W. Couet 2, M. O. Karlsson 1; 1 Uppsala Univ., Uppsala, Sweden, 2Poitiers Univ., Poitiers, France.

Tigecycline (TGC) Alone and in Combination against Multidrug-Resistant (MDR) Acinetobacter baumannii (ACB)

Final Program

39

> Sunday SCIENTIFIC SESSIONS ---------------------------------------------------------------------------------005(B) Poster Session

A-034 Risk Factors for and Incidence of Nephrotoxicity

Associated with Intravenous Colistin in the Modern Era: A Systematic Review H. Pulluru, K. S. Kaye, J. M. Pogue, D. Marchaim, K. Hayakawa; Detroit Med. Ctr., Wayne State Univ., Detroit, MI.

Immune Response to Microbial Infection

A-035 Pharmacokinetics of Colistin Methanesulfonate and Colistin

after Lung Transplantion in Cystic Fibrosis Patients

Presentations:

N. Grégoire 1, F. Périn-Dureau 2, P. Gobin 3, C. Cerf 4, D. Grenet 2, F. Parquin 2, O. Mimoz 3, W. Couet 1,5; 1Univ. of Poitiers, Poitiers, France, 2 Hosp. Foch, Suresnes, France, 3CHU Poitiers, Poitiers, France, 4Hosp. Foch, Suresnes, France, 5Inserm, Poitiers, France.

B-043 Staphylococcus aureus Nasal Carriage Might be Associated with

Vitamin D Receptor Polymorphisms in Type 2 Diabetes D. Dimopoulou, I. Messaritakis, G. Samonis, G. Goulielmos, J. Papadakis, G. Brentzos, C. Choulaki, M. Fragaki, A. Valachis, D. P. Kofteridis; Univ. Hosp. of Heraklion, Heraklion, Greece.

A-036 Plasma Pharmacokinetics and Sputum Concentrations of

Colistin After Nebulisation or Intravenous Administration of Colistin Methansulphonate (CMS) to Ambulatories Cystic Fibrosis Patients 1

2

1

1

2

B-044 Pattern Recognition Receptor Polymorphisms and the Suscep-

tibility to Complicated Skin and Skin Structure Infections 1,3

S. Marchand , A. Henriet , N. Grégoire , P. Gobin , P. Diot , W. Couet ; 1 Univ. of Poitiers, Poitiers, France, 2CHU Tours, Tours, France, 3Inserm, Poitiers, France. A-037 Plasma Pharmacokinetics and Epithelial Lining Fluid (ELF)

Concentrations of Colistin after Nebulisation or Intravenous Administration of Colistin Methanesulfonate (CMS) in Critical Care Patients M. Boisson 1, S. Marchand 2, N. Grégoire 2, P. Gobin 1, O. Mimoz 1, W. Couet 2,3; 1CHU Poitiers, Poitiers, France, 2Univ. of Poitiers, Poitiers, France, 3 Inserm, Poitiers, France. A-038 Penetration of Arbekacin Sulfate to the Lung Tissue Y. Funatsu, N. Hasegawa, H. Nahmgunn, H. Fujiwara, T. Asami, T. Betsuyaku, S. Iwata; Keio Univ., Shinjuku-Ku, Japan. A-039 Pharmacologic Assessment of Guidelines on Gentamicin

Use in Infective Endocarditis G. Beraud, A. Elsendoorn, C. Landron, C. Plouzeau, G. Le Moal, C. Godet, C. Burucoa, F. Roblot; Univ. Hosp. of Poitiers, Poitiers, France. A-040 Plazomicin (PLZ) Compared with Cefepime, Ciprofloxacin,

Meropenem, Piperacillin-Tazobactam and Aminoglycosides for the Empiric Treatment of Gram-Negative, including MultidrugResistant (MDR), Pathogens Causing Infections in Hospitals 1

2

1

Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C

1 1

S. Zelenitsky , R. Ariano , C. Lawson , G. Zhanel ; Univ. of Manitoba, Winnipeg, Canada, 2St. Boniface Gen. Hosp., Winnipeg, Canada. A-041 Pharmacodynamics of Plazomicin in a Neutropenic Murine

Pneumonia Model against Klebsiella pneumoniae (Kpn) A. Louie1, S. Fikes 1, W. Liu 1, B. VanScoy 1, R. Cirz 2, G. Drusano 1; 1Univ. of Florida, Orlando, FL, 2Achaogen, Inc., South San Francisco, CA. A-042 Dose-Response Efficacy of Plazomicin in the Treatment of

Murine Pneumonia Due to 7 Strains of Klebsiella pneumoniae (Kpn) Including Strains Resistant to Legacy Aminoglycosides A. Louie 1, W. Liu 1, S. Fikes 1, B. VanScoy 1, R. Cirz 2, R. Cass 2, J. McKinnell 2, P. Nordmann 3, G. Drusano 1; 1Univ. of Florida, Orlando, FL, 2Achaogen, Inc., South San Francisco, CA, 3South Paris Med. Sch., Hosp. Bicetre, Paris, France.

M. H. T. Stappers 1,2, Y. Thys 1,3, M. Oosting 1, T. S. Plantinga 1, M. Ioana 1, P. Reimnitz 4, J. W. Mouton 1,2, M. G. Netea 1, L. A. B. Joosten 1, I. C. Gyssens 1,2,3; 1Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 2Canisius Wilhelmina Hosp., Nijmegen, Netherlands, 3Hasselt Univ., Diepenbeek, Belgium, 4Bayer Healthcare Pharmaceuticals, Wuppertal, Germany. B-045 Role of Mannose-Binding Lectin (MBL) in Hospitalized-

Children Infected with H1N1 2009 Virus in Argentina S. D. Ruvinsky, J. Gurevich, A. Monaco, G. Perez, L. Sen, R. Bologna, A. Mangano; Hosp. de Pediatria Dr. Juan P. Garrahan, Buenos Aires, Argentina. B-046 Immunization of Rats with Recombinant Lactococcus lactis

Expressing ClfA Protects from Staphylococcus aureus Experimental Endocarditis Induced by Low-Grade Bacteremia T. R. Veloso, Y. A. Que, M. Giddey, J. Vouillamoz, P. Moreillon, J. Entenza; Univ. of Lausanne, Lausanne, Switzerland. B-047 Leptin-Stat3 Signaling Axis Enhances Colonic Inflammation

During Clostridium difficile Infection Withdrawn B-048 Macrolides Inhibit Fusobacterium nucleatum-Induced

MUC5AC Induction in Human Airway Epithelial Cells K. Nagaoka, K. Yanagihara, Y. Harada, K. Yamada, Y. Migiyama, Y. Morinaga, S. Kohno; Nagasaki Univ. Hosp., Nagasaki, Japan. B-049 Azithromycin Inhibit Muc5ac Induction by Multidrug-

Resistant Acinetobacter baumannii in Airway Epithelial Cells K. Yamada, K. Yanagihara, Y. Harada, Y. Migiyama, K. Nagaoka, Y. Morinaga, K. Izumikawa, H. Kakeya, Y. Yamamoto, S. Kohno; Nagasaki Univ., Nagasaki, Japan. B-050 Lung Sensitization by Candida Albicans Protects from

Pseudomonas aeruginosa-Induced Lung Injury Through Expression of Antimicrobial Peptides J. B. Méar1, E. Faure 1, E. Kipnis 1, P. Gosset 2, G. Schurtz 1, K. Faure 1, B. Guery 1; 1Faculte de Med. de Lille, Lille, France, 2Inserm U1019, Team 8, Lille, France. B-051 Natural Killer Cells are Critical in Controlling Pseudomonas

aeruginosa Strain PAO1 in a Mice Pneumonia Infection Model A. H. Broquet1, A. Roquilly 1,2, C. Jacqueline 1, J. Caillon 1, G. Potel 1, K. Asehnoune 1,2; 1UPRES EA3826, Nantes, France, 2CHU Nantes, Pôle Anesthésie Réanimations, Service d’Anesthésie Réanimation Chirurgicale, Hôtel Dieu, Nantes, France.

40

September 9-12 |

SUNDAY SCIENTIFIC SESSIONS B-052 T-Cells from Chronic Bone Infection Show Reduced Prolif-

Presentations:

eration and a High Proportion of CD28 Negative CD4 T-Cells

C1-061 Characterization of OXA-204, a Carbapenem-Hydrolyzing

G. Kumar1, M. Ticchioni 2, E. Bernard 2, C. Trojani 2, P. Roger 2; 1Univ. of Nice Sophia Antipolis, Nice, France, 2Hopital L’Archet 1, Nice, France.

Class D Beta-Lactamase from a Klebsiella pneumoniae Clinical Isolate

B-053 Keyhole Limpet Hemocyanin (KLH) N-Glycans Share Similar

L. Poirel, A. Potron, P. Nordmann; Hosp. de Bicetre, Le Kremlin Bicetre, France.

Structural Features with Saccharides of Schistosoma, Trypanosoma, Leishmania, Cryptococcus, Aspergillis, Candida, E. coli, Salmonella, Clostridium and Hepatitis C Virus (HCV) J. S. Sundsmo, H. Chow, M. Sagermann; Stellar Biotechnologies, Inc., Port Hueneme, CA. B-054 Monophosphoryl Lipid a Modulates the Cross-Talk Between

Dendritic Cells and Natural Killer Cells in a Murine Model of Hemorrhage-Induced Immune Dysfunction A. Roquilly, A. Broquet, C. Jacqueline, R. Cinotti, X. Ambrosi, G. Potel, J. Caillon, K. Asehnoune; Univ. de Nantes, Laboratoire EA UPRES 3826, Nantes, France. B-055 Endotoxemia in Humans Induces Alterations in the T-Cell

Compartment and is Associated with Impaired Production of Proinflammatory Cytokines A. Ronit, R. P. Plovsing, J. C. Gaardbo, R. M. Berg, H. J. Hartling, H. Ullum, K. Moller, S. D. Poulsen; Copenhagen Univ. Hosp. Rigshospitalet, Osterbro, Denmark. B-056 Critical Roles of IL-17 in Lethality of Community-Associated

C1-062 Intercontinental Transfer of an OXA-48-Producing Multi-

Resistant Klebsiella pneumoniae B. A. Espedido1,2, J. A. Steen 3,4, I. B. Gosbell 1,2,5, H. Ziochos 5, M. A. Cooper 4, S. M. Grimmond 3,4, S. J. van Hal 1,5, S. O. Jenson 1,2; 1ARMEG, SoM, Univ. W. Sydney, Liverpool, Australia, 2Ingham Inst. Applied Med. Res., Liverpool, Australia, 3Qld Ctr. for Med. Genomics, Univ. Qld, Brisbane, Australia, 4Inst. Mol. Biosc. Univ. Qld, Brisbane, Australia, 5Sydney South West Pathology Service, NSW Pathology, Liverpool, Australia. C1-063 Emergence of OXA-232, a Carbapenem-Hydrolyzing Class

Dơ-Lactamase from Indian Isolates L. Poirel, E. Rondinaud, A. Potron, P. Nordmann; Hosp. de Bicetre, Le Kremlin Bicetre, France. C1-064 A Direct-Link Between blaNDM-1 Harbouring Plasmids

Isolated in Chennai, India and pNDM-HK Isolated in Hong Kong M. A. Toleman1, M. D. Krepps 2, H. S. Gibbons 2, T. R. Walsh 1; 1Cardiff Univ., Cardiff, United Kingdom, 2U.S. Army Edgewood Biological Chemical Ctr., Baltimore, MD. C1-065 Biochemical Characterization of the Metallo-Beta-Lactamase

MRSA Pneumonia in Mice Y. Shibue 1,2, S. Kimura1, C. Kajiwara 1, K. Tateda 1, M. Nishimura 2, K. Yamaguchi 1; 1Toho Univ. Faculty of Med., Tokyo, Japan, 2Hokkaido Univ. Sch. of Med., Hokkaido, Japan. B-057 Chemokine Induction of Biofilm in Staphylococcus aureus S. C. Yung, K. Chen, P. M. Murphy; NIH, Bethesda, MD. B-058 Distinctive Cytokines as Biomarkers Predicting Fatal Out-

come of Severe Staphylococcus aureus Bacteremia in Mice S. van den Berg 1, J. D. Laman 1, L. Boon 2, M. T. ten Kate 1, G. J. de Knegt 1, R. M. Verdijk 1, H. A. Verbrugh 1, J. L. Nouwen 1, I. A. BakkerWoudenberg 1; 1Erasmus Univ. Med. Ctr., Rotterdam, Netherlands, 2Bioceros BV, Utrecht, Netherlands. B-059 Modulation of Inflammatory Mediators MicroRNA-21 and

MicroRNA-19b in Human Coronavirus-229E Infected Cells A. R. Collins, SUNY at Buffalo, Buffalo, NY. B-060 IPAF-Inflammasome Null Mice are Protected from

Pseudomonas aeruginosa-Induced Acute Lung Infection E. Faure, J. Mear, B. Guery, K. Faure, E. Kipnis; Lille 2 Univ. Hosp., Lille, France. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------006(C1) Poster Session Carbapenemases and Expanded Spectrumơ. Lactamases: Enterobacteriaceae, S. aeruginosa, A. bumannii Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C

IMP-30 K. M. Pegg 1, E. M. Liu 2, P. Oelschlaeger2; 1California State Polytechnic Univ., Pomona, CA, 2Western Univ. of Hlth. Sci., Pomona, CA. C1-066 Covalent Docking and Molecular Dynamics of Serine Active

Carbapenemases T. Naas1, P. Nordmann 1, B. I. Iorga 2; 1INSERM U914, Le Kremlin Bicetre, France, 2ICSN, CNRS UPR 2301, Gif-sur-Yvette, France. C1-067 Characterization of Pseudomonas aeruginosa Clinical Isolates

from Mexico Producing Novel Carbapenemases (ß-Lactamases Ges-19 and Ges-20, and Imp-36) J. Silva-Sanchez 1, H. Barrios 1, U. Garza-Ramos 1, A. Sánchez 1, F. Reyna 1, J. C. Catalan 1, R. Morfin 2, E. Rodriguez 2, P. Volkow 3, P. Cornejo 3, M. Vázquez 4, V. Rodríguez 4, J. Gaytan 5, I. G. Lorenzo 5, R. Gonzalez 6, L. Vazquez 6; 1INSP, Cuernavaca, Mexico, 2Hosp. Civil de Guadalajara, Jalisco, Mexico, 3Inst. Natl. de Cancerología, DF, Mexico, 4Inst. Natl. de Cardiología, DF, Mexico, 5Hosp. de Infectología CMN La Raza, DF, Mexico, 6UMAE. IMSS #71, Torreon, Mexico. C1-068 Characterization of OXA-210, a Novel Carbapenem-Hydro-

lyzing Class Dơ-Lactamase from Pseudomonas aeruginosa J. H. Lee, J. J. Lee, X. Wu, B. Selenge, S. H. Lee; Myongji Univ., Yongin, Korea, Republic of. C1-069 Identification of Carbapenemase OXA-23 Group in

Acinetobacter baumannii: OXA-239, a Novel Oxacillinase Identified in Mexico E. M. Tamayo-Legorreta1, H. Barrios 1, U. Garza-Ramos 1, A. Sanchez 1, A. Galicia 2, A. Meza 3, J. Silva-Sanchez 1; 1Inst. Natl. de Salud Publ.a, Cuernavaca, Mexico, 2Hosp. de Oncologia, IMSS-CMN-Siglo XXI, DF, Mexico, 3 Hosp. de Cardiologia, IMSS-CMN-Siglo XXI, DF, Mexico.

Final Program

41

> Sunday SCIENTIFIC SESSIONS C1-070 OXA-237, a Novel Class D Beta-Lactamase Involved in

Resistance to Carbapenems in Acinetobacter baumannii P. G. Higgins1, F. J. Perez-Llarena 2, E. Zander 1, A. Fernandez 2, G. Bou 2, H. Seifert 1; 1Univ. of Cologne, Cologne, Germany, 2C.H.Univ. A Coruña, A Coruña, Spain. C1-071 Endemicity of GES-Type Carbapenemase among

Producing Different CMYơ-Lactamases from a Cystic Fibrosis Patient L. Cremet1, N. Caroff 1, C. Giraudeau 2, A. Reynaud 1, J. Caillon 1, S. Corvec 1; 1Univ., Nantes, France, 2Nantes Hosp., Nantes, France. C2-081 Genotyping Plasmid Mediated ampC Genes By Real-Time

Acinetobacter baumannii Clinical Isolates in Kuwait

PCR and High Resolution Melt Analysis

R. Bonnin1, V. Rotimi 2, P. Nordmann 1, M. Al Hubail2, N. Al Sweih 3, L. Poirel 1; 1Hosp. de Bicetre, Le Kremlin Bicetre, France, 2Faculty of Med., Kuwait-City, Kuwait, 3Hosp. de Bicetre, Kuwait-City, Kuwait.

B. Y. Y. Tse 1, G. L. Vanstone 2, I. Balakrishnan 2; 1Univ. Coll., London, United Kingdom, 2Royal Free Hosp., London, United Kingdom.

C1-072 Role of Position 169 in Penicillin-Hydrolysis Activity of

Class A ESBLs T. Naas1, B. I. Iorga 2, L. Djamdjian 1, P. Nordmann 1; 1INSERM U914, Le Kremlin Bicetre, France, 2ICSN, CNRS UPR 2301, Gif-Yvette, France. C1-073 N148G and -S Substitutions in ADC-7ơ-Lactamase of

Acinetobacter baumannii (ACB) Cause Selective Changes in Substrate and Inhibitor Specificity B. C. Conklin, M. J. Skalweit; VAMC/CWRU, Cleveland, OH. C1-074 Description of Novel Allelic Variants of the Chromosomal

Gene Blaoxa-114-Like in Achromobacter xylosoxidans Clinical Isolates G. Traglia1, M. Almuzara 2, A. K. Merkier 1, M. Papalia2, M. Radice 2, C. Vay 2, D. Centrón 1, M. Ramirez 1; 1Sch. of Med., Buenos Aires, Argentina, 2Facultad de Farmacia y Bioquimica, Buenos Aires, Argentina. C1-075 CMY-88: A Novel Chromosomally-Encoded Cephamycinase

in an Escherichia coli Clinical Isolate M. Solé 1, N. Cobos 2, I. Roca 1, J. Martínez 2, J. Vila 1; 1CRESIB-Hosp. Clinic/UB, Barcelona, Spain, 2Hosp. Clinic/UB, Barcelona, Spain. C1-076 The Contribution of Ambler Position P167 in Ceftazidime

(TAZ) Resistance in PenI of Burkholderia pseudomallei (Bp) K. M. Papp-Wallace1, M. Nukaga 2, R. A. Bonomo 1; 1LSCDVAMC & CWRU, Cleveland, OH, 2Josai Intl. Univ., Togane City, Chiba, Japan. C1-077 Kinetic Characterization of a Novel VIM (VIM-28) Metallo-

Beta-Lactamase in Pseudomonas aeruginosa Isolates from Egypt A. Yoshizumi1, Y. Ishii 1, T. S. El-Mahdy 2, N. D. Hanson 3, K. Tateda 1; 1 Toho Univ., Tokyo, Japan, 2Helwan Univ., Cairo, Egypt, 3Creighton Univ., Omaha, NE. C1-078 Rapid Detection of Carbapenemase Production in

Pseudomonas P. Nordmann, L. Poirel, L. Dortet; Hosp. de Bicetre, Le Kremlin Bicetre, France.

-----------------------------------------------------------------------007(C2) Poster Session AmpCs: Not Going Away! Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: C2-079 Identification of Plasmid Mediated AmpCơ-Lactamases in

Clinical Isolates of Escherichia coli and Klebsiella pneumoniae at a Tertiary Hospital of Muscat, Oman Withdrawn

42

C2-080 Detection of Clonally-Related Escherichia coli Isolates

September 9-12 |

C2-082 Plasmid-Mediated AmpCơ-Lactamases: Moving From

Hospitals to the Community? A. Conen 1, R. Frei 2,3, H. Adler 2, C. A. Fux 1, A. F. Widmer 3; 1Infectious Diseases and Hosp. Epidemiology, Aarau, Switzerland, 2Clinical Microbiol., Basel, Switzerland, 3Infectious Diseases and Hosp. Epidemiology, Basel, Switzerland.

-----------------------------------------------------------------------008(C2) Poster Session Carbapenemases: Will They Ever End! Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: C2-083 A Novel IMP Metallo-ơ-Lactamase, IMP-38, from an Out-

break of a K. pneumonia Clone Strain in a University Hospital in Central China W. Liu, Z. Jian, H. Li, Y. Li, Y. Li, Y. Liu, X. Gu, W. Peng; Xiangya Hosp., Central South Univ., Changsha, China. C2-084 Klebsiella pneumoniae Producing a New Variant Derived from

OXA-163: Case Report S. Gomez, F. Pasteran, D. Faccone, M. Bettiol, O. Veliz, M. Rapoport, B. Gatti, A. Petroni, A. Corso; INEI-ANLIS-MALBRAN, Buenos Aires, Argentina. C2-085 Emergence of Serratia marcescens Harbouring the Class A

Carbapenemase SME in Canada L. F. Mataseje 1, D. A. Boyd 1, M. Imperial 2, B. Lefebvre 3, P. Van Caeseele 4, B. Willey 5, M. R. Mulvey 1; 1Natl. Microbiol. Lab., Winnipeg, Canada, 2 BCCDC, Vancouver, Canada, 3Lab. de Santé Publique du Québec, SainteAnne-de-Bellevue, Canada, 4Natl. Microbiol. Lab., Cadam Provincial Lab., Canada, 5Mount Sinai Hosp., Toronto, Canada. C2-086 Emergence of Polymyxin B-Resistant KPC-2-Producing

Klebsiella pneumoniae ST11 Clone in an University Hospital in Brazil L. N. Andrade1, L. Vitali 2, G. G. Gaspar 2, R. Martinez 2, A. C. Darini 1; 1 Faculdade de Ciências Farmacêuticas de Ribeirão Preto - USP, Ribeirão Preto, Brazil, 2Hosp. das Clínicas - Faculdade de Med. de Ribeirão Preto USP, Ribeirão Preto, Brazil. C2-087 Fosfomycin Susceptibility of BlaKPC-2 in Brazil F. F. Tuon1, J. L. L. Rocha 2, J. Camilotti 1, M. S. Formighieri 1, S. Sfair 1, M. B. Bertoldi 1, J. K. Palmeiro 3, L. M. Dalla-Costa 3; 1Hosp. Univ. Evangélico de Curitiba, Curitiba, Brazil, 2Frischmann Aisengart/DASA Medicina Diagnóstica, Curitiba, Brazil, 3Hosp. de Clínicas, Univ. Federal do Paraná (UFPR), Curitiba, Brazil.

SUNDAY SCIENTIFIC SESSIONS C2-088 Two Cases of NDM-Producing Klebsiella pneumoniae:

Transmission or Coincidence - If the Molecular Biology is Surprising, Do You Trust the Epidemiology? D. Morris 1, K. Burns 2, C. Collins 2, V. Passet 3, S. Brisse 3, M. Cormican 1; 1 Natl. Univ. of Ireland, Galway, Ireland, 2Beaumont Hosp., Dublin, Ireland, 3 Institut Pasteur, Paris, France. C2-089 Surveillance of KPC-Producing Enterobacteriaceae in ON,

Canada, 2008-2011 N. Tijet, P. M. Sheth, O. Lastovetska, C. Chung, S. Lo, D. J. Farrell, D. E. Low, S. N. Patel, R. G. Melano; Publ. Hlth. Ontario Lab., Toronto, Canada. C2-090 Detection of IMP-27 Metallo-ß-Lactamase in Proteus

mirabilis, ON, Canada N. Tijet, S. Lo, H. Siebert, M. MacNeill, P. Rawte, D. J. Farrell, D. E. Low, S. N. Patel, R. G. Melano; Publ. Hlth. Ontario Lab., Toronto, Canada. C2-091 Persistence Of NDM-1-Producing Enterobacteria Over a

6-Month Period in a French Community Patient C. Arpin1, P. Noury 2, F. M’Zali 1, C. Andre 1, L. Coulange 1, C. Quentin 1; 1 UMR CNRS 5234, Univ. de Bordeaux 2, Bordeaux, France, 2Lab. EXALAB, Villenave d’Ornon, France. C2-092 Dissemination of Diverse Plasmids Bearing blaKPC Among

Carbapenem-Resistant Enterobacteriaceae (CRE) Different from Klebsiella spp. in a Hospital System in Cleveland

S. Ruiz 1, F. Perez 2, A. M. Hujer 2, S. Rudin 2, S. H. Marshall 2, S. Bajaksouszian 3, M. V. Villegas 1, R. A. Bonomo 2, M. R. Jacobs 3; 1CIDEIM, Cali, Colombia, 2VAMC, Cleveland, OH, 3CWRU, Cleveland, OH. C2-093 Emergence of Four Different OXA-48-Type Carbapenemase-

Producing Enterobacteriaceae Species Isolated in One Patient A. Mischnik, N. T. Mutters, S. Klein, B. Lehner, S. Zimmermann; Heidelberg Univ. Hosp., Heidelberg, Germany. C2-094 Emergence of MDR KPC-2-Producing Escherichia coli in Italy A. Piazza 1, M. Caltagirone 1, V. Repetto 1, E. Nucleo 1, M. Spalla, 1, M. Balzaretti 2, E. Casari 3, L. Pagani 1, R. Migliavacca 1; 1Univ. of Pavia, Pavia, Italy, 2ASP Piero Redaelli, Milan, Italy, 3IRCCS Clinical Inst. Humanitas, Rozzano, Italy. C2-095 Assessing the Prevalence of Enterobacteriaceae Harboring

Klebsiella pneumoniae Carbapenemases (KPC) in Maryland J. K. Johnson1, L. E. Wilson 2, L. Zhao 1, K. A. Thom 1, A. D. Harris 1, Maryland MDRO Prevention Collaborative; 1Univ. of Maryland, Baltimore, Baltimore, 2Maryland Dept. of Hlth. and Mental Hygiene, Baltimore. C2-096 Epidemiology of Carbapenem-Resistant Enterobacteriaceae

(CRE) Colonization Among Patients with Exposure to LongTerm Acute Care Centers (LTACs) A. Bhargava 1, K. Hayakawa 1, K. C. Alluri 2, S. Haider 2, S. Datla 3, S. Diviti 2, V. Kuchipudi 2, K. Muppavarapu 2, D. Marchaim 1, T. Chopra 1, K. Kaye 1; 1 WSU, Detroit, MI, 2Detroit Med. Ctr., Detroit, MI, 3DMC, Detroit, MI. C2-097 Carbapenem-Nonsusceptible Enterobacteriaceae Infection:

Impact of Carbapenemases Production and In Vitro Susceptibility to Tigecycline and Colistin on Mortality U. Wu1, J. Wang 1, Y. Chen 1, C. Yang 2, C. Lin 3, S. Chang 1; 1Natl. Taiwan Univ. Hosp., Taipei, Taiwan, 2Far Eastern Mem. Hosp., Taipei, Taiwan, 3Natl. Taiwan Univ. Hosp., Yun-Lin Branch, Dao-Liou, Taiwan.

C2-098 Whole Genome Sequencing to Track a Hospital Outbreak of Carbapenem-Resistant Klebsiella pneumoniae Withdrawn Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------009(C2) Poster Session ESBLs: Still Relevant Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: C2-099 In Vitro Activity of Tigecycline against Enterobacteriaceae

with Emphasis on ESBL Producing Isolates in India and Israel: Test 2007-2012 M. Renteria, S. Bouchillon, B. Johnson, M. Hackel, J. Johnson; IHMA, Inc., Schaumburg, IL. C2-100 Trends in Susceptibility and ESBL Production for Escherichia

coli from Intra-Abdominal Infections: SMART 2002-2011 S. Lob, S. Bouchillon, M. Hackel, D. Hoban, A. Johnson, R. Badal; IHMA, Inc., Schaumburg, IL. C2-101 Extended Spectrum Beta-Lactamases and Class I Integron:

Multidrug Modulators in Clinical Isolates of Escherichia coli and Salmonella spp from Eastern Cape, South Africa M. A. Bisi-Johnson 1,2, C. L. Obi 1, T. Hattori 3, K. A. Baba 4, S. D. Vasaikar 1, I. Morobe 1; 1Walter Sisulu Univ., Mthatha, South Africa, 2Obafemi Awolowo Univ., Ile-Ife, Nigeria, 3Tohoku Univ., Sendai, Japan, 4Univ. of Pretoria, Pretoria, South Africa. C2-102 Molecular Epidemiology and Antimicrobial Resistance of

Escherichia coli Infections in East London, UK H. Ciesielczuk 1, D. W. Wareham 1, R. Hope 2, N. Woodford 2,1; 1Queen Mary’s Coll. Univ. of London, London, United Kingdom, 2Hlth. Protection Agency, London, United Kingdom. C2-103 Dramatic Increase in the Prevalence of ESBL-Producing

Escherichia coli (EC) in Canadian Hospitals Over a 5-Year Period A. Denisuik 1, P. Simner 2, F. Tailor 1, H. Adam 1,3, P. Lagacé-Wiens 1,3, M. Mulvey 1,4, M. Baxterer 1, D. J. Hoban 1,3, G. G. Zhanel 1; 1Univ. of Manitoba, Winnipeg, Canada, 2Mayo Clinic, Rochester, MN, 3Diagnostic Services of Manitoba, Winnipeg, Canada, 4Natl. Microbiol. Lab., Winnipeg, Canada. C2-104 High Prevalence of ESBL-Producing Enterobacteriaceae

(ESBL-E) in the Dutch Community E. A. Reuland 1, N. Al Naiemi 1,2, M. C. Rijnsburger 1, M. Van Keulen 1, P. H. M. Savelkoul 1, P. J. M. Elders 1, C. M. J. Vandenbroucke-Grauls 1; 1 VU Univ. Med. Ctr., Amsterdam, Netherlands, 2Lab. for Med. Microbiol., Enschede, Netherlands. C2-105 Emergence of ESBL-Producing Enterobacter cloacae in a

University Hospital in Northern Spain J. Calvo, M. Cano, M. Aranzamendi, E. Román, B. Ruiz, L. MartinezMartinez; Hosp. Univ. Marqués de Valdecilla, Santander, Spain. C2-106 Complex Class 1 Integrons Harboring blaCTX-M-2 Genes

in Different Clinical Enterobacteriaceae Species from a Hospital in Brazil M. Dropa, L. C. Balsalobre, N. Lincopan, G. R. Matte, M. H. Matte; Univ. of Sao Paulo, Sao Paulo, Brazil. C2-107 Prevalence of ESBL-Producing E. coli and K. pneumoniae in

Fecal Carriage in Children in Guinea-Bissau J. Isendahl1, A. Turlej-Rogacka 1, A. Rodrigues 2, C. Manjuba 3, C. Giske 1, P. Nauclér 1; 1Karolinska Inst., Stockholm, Sweden, 2Natl. Inst. of Publ. Hlth. in Guinea-Bissau, Bissau, Guinea-Bissau, 3Natl. Hosp. Simão Mendes, Bissau, Guinea-Bissau.

Final Program

43

> Sunday SCIENTIFIC SESSIONS C2-108 ESBL-Producing Klebsiella pneumoniae Isolates of Different

Phylogenetic Lineages from Southwest Nigeria B. Ghebremedhin1, I. Aibinuer 2, T. Odugbemier 2, W. Koenig 1; 1Clinical Microbiol., Magdeburg, Germany, 2Med. Microbiol. & Parasitol., Lagos, Nigeria. C2-109 Transmission Dynamics of ESBL-Producing E. coli Clones in

Rehabilitation Wards A. Adler 1, M. Gniadkowski 2, A. Baraniak 2, R. Izdebski 2, J. Fiett 2, W. Hryniewicz 2, S. Malhotra-Kumar 3, H. Goossens 3, C. Lammens 3, Y. Lerman 1, M. Kazma 1, T. Kotlovsky 1, Y. Carmeli 1, MOSAR WP5 & WP2 study groups; 1Tel-Aviv Med. Ctr., Tel-Aviv, Israel, 2Warsaw Natl. Med. Inst., Warsaw, Poland, 3Univ. of Antwerp, Antwerp, Belgium. C2-110 Molecular Epidemiology of ESBL-Producing Escherichia coli

from Community Onset and Hospital Associated Blood Stream Infections in Bucharest A. Hristea 1, I. D. Olaru 2, M. Popoiu 2, M. Nica, 3,4, M. Buzea 5, M. Ion 2, S. Adams-Sapper 6, L. W. Riley 6; 1Natl. Inst. of Infectious Diseases, Univ. of Med. and Pharmacy, Bucharest, Romania, 2Natl. Inst. of Infectious Diseases, Bucharest, Romania, 3Victor Babes Hosp. of Tropical and Infectious Disease, Bucharest, Romania, 4Univ. of Med. and Pharmacy, Bucharest, Romania, 5 Univ. Emergency Hosp. Elias, Bucharest, Romania, 6Univ. of California, Berkeley, CA. C2-111 High Prevalence of CTX-M-15 Escherichia coli ST131

Causing Community-Onset Healthcare Associated Bacteremic Urinary Tract Infection in Spain I. Merino 1, E. Cercenado 2, N. Benito 3, M. Pallarés 4, J. Gómez 5, M. Xercavins 6, L. Martínez-Martínez 7, M. De Cueto 8, E. Shaw 9, J. Horcajada 9, R. Cantón 1, P. Ruiz-Garbajosa 1, ITUBRAS-GEIH-SEIMC Group; 1Hosp. Ramón y Cajal, Madrid, Spain, 2Hosp. Gregorio Marañón, Madrid, Spain, 3Hosp. Santa Creu i Sant Pau, Barcelona, Spain, 4Complexo Hosp. Pontevedra, Pontevedra, Spain, 5Lab. de Referència de Catalunya, Barcelona, Spain, 6Hosp. Mútua de Terrassa, Terrassa, Spain, 7Hosp. Marqués de Valdecilla, Madrid, Spain, 8Hosp. Virgen Macarena, Sevilla, Spain, 9Hosp. del Mar, Barcelona, Spain. C2-112 Community-Associated Extended-Spectrum-ơ-Lactamase

(ESBL)-Producing Escherichia coli Infection in the United States Y. Doi 1, Y. Park 2, J. I. Rivera 1, J. M. Adams-Haduch 1, A. Hingwe 3, M. C. Kilayko 4, J. S. Lewis, Jr 5, W. J. Howard 6, L. E. Johnson 3, E. Sordillo 4, B. Poskly 4, J. H. Jorgensen 5, S. S. Richter 7, K. A. Shutt 1, D. L. Paterson 8; 1 Univ. of Pittsburgh Med. Ctr., Pittsburgh, PA, 2Gachon Univ. Gil Hosp., Incheon, Korea, Republic of, 3Henry Ford Hosp., Detroit, MI, 4St. Luke’s Roosevelt Hosp. Ctr., New York, NY, 5Univ. of Texas Hlth. Sci. Ctr., San Antonio, TX, 6Univ. of Iowa Hlth. Care, Iowa City, IA, 7Cleveland Clinic, Cleveland, OH, 8Univ. of Queensland, Brisbane, Australia. C2-113 Risk Factors and Molecular Epidemiology of Extended-

Spectrumơ-Lactamases-Producing Escherichia coli in Urinary Tract Infections in a Mexican Naval Hospital M. D. Alcántar-Curiel1, H. J. Varona-Bobadilla 2, C. Gayosso-Vázquez 1, M. D. Jarillo-Quijada 1, M. Frías-Mendivil 3, L. Sanjuan-Padrón 2, J. I. Santos-Preciado 1; 1Univ. Nacional Autónoma de México (UNAM), México D.F., Mexico, 2Hosp. Gen. Naval de Alta Especialidad (HOSGENAES), México D.F., Mexico, 3Escuela Nacional de Enfermeria, UNAM, México D.F., Mexico.

C2-114 Molecular Characteristics of Extended-Spectrum

ơ-Lactamases in Clinical Isolates of Escherichia coli at a Japanese Tertiary Hospital H. Yano, S. Endo, H. Kanamori, S. Inomata, R. Kakuta, N. Ishibashier, T. Aoyagi, M. Hatta, Y. Gu, M. Yamada, K. Tokuda, H. Kunishima, M. Kitagawa, Y. Hirakata, M. Kaku; Tohoku Univ. Graduate Sch. of Med., Sendai, Japan. C2-115 Evaluation of blaCTXM14 and blaCTXM15 Identifies Differential

Gene Expression Among Sequence Type 131 (ST131) and Non-ST131 (NST131) E. coli (Ec)

C. Geyer 1, S. Weissman 2, P. Hawkey 3, N. D. Hanson 1; 1Creighton Univ., Omaha, NE, 2Univ. of WA, Seattle, WA, 3Univ. of Birm, Edgbaston, United Kingdom. C2-116 Characterization of Extended-Spectrum Cephalosporins-

Resistant (ESC-R) Escherichia coli (Ec) Isolates Detected in Bern, Switzerland M. Hilty, S. Aebi, S. Droz, V. Perreten, K. Mühlemann, A. Endimiani; Univ. of Bern, Bern, Switzerland. C2-117 Clonal Dissemination of Extended Spectrum Beta-Lacta-

mase Producing E. coli and Klebiellae among Patients Presenting to Community Hospitals in Southeastern United States L. F. Chen1, B. Nicholson 2, A. Keiger 2, C. W. Woods 2, D. J. Sexton1, D. J. Anderson1; 1Duke Univ. Med. Ctr., Durham, NC, 2Durham VA Med. Ctr., Durham, NC. C2-118 High Prevalence of ST131 Strains among Escherichia coli

Urinary Isolates with Decreased Carbapenem Susceptibilities in Southern Taiwan J. Yan1, J. Wu 2; 1Natl. Cheng Kung Univ. Coll. of Med. and Hosp., Tainan, Taiwan, 2Natl. Cheng Kung Univ. Coll. of Med., Tainan, Taiwan. C2-119 Changes In Dominant Extended Spectrumơ-Lactamase

Producing E. coli in a Nursing Home Over a Seven Year Period C. Ludden1, E. Mc Garry 1, B. Hanahoe 2, M. Cormican 1,2, D. Morris 1; 1 Natl. Univ. of Ireland, Galway, Galway, Ireland, 2Univ. Hosp. Galway, Galway, Ireland. C2-122 E. coli O25b:ST131 Accounts for a Significantly Higher

Proportion of Nursing Home Isolates Compared with Hospital Isolates of CTX-M Producing E. coli C. Ludden 1, F. Boyle 1, B. Hanahoe 2, B. Kanagaratnam 1, M. Cormican 1,2, D. Morris 1; 1Natl. Univ. of Ireland, Galway, Ireland, 2Galway Univ. Hosp., Galway, Ireland. C2-120 Global Susceptibility and ESBL+ Rates of K. pneumoniae

from Intra-Abdominal Infections: SMART 2011 R. Badal 1, S. Bouchillon 1, M. Hackel 1, D. Hoban 1, A. Johnson 1, S. Hawser 2; 1IHMA, Inc., Schaumburg, IL, 2IHMA Europe, Sarl, Epalinges, Switzerland. C2-121 Point Prevalence and Genetic Characterization of Extended-

Spectrumơ-Lactamase Genes Harbored by Invasive Isolates of Enterobacteriaceae in a Teaching Hospital in Lagos, Nigeria M. A. Raji 1,2, O. Ojemhen 3, U. Umejiburu 4, W. Jamal 5, O. Rotimi 5; 1Lagos State Univ. Coll. of Med., I, Lagos State, Nigeria, 2Lagos State Univ. Teaching Hosp.,, Ikeja, Nigeria, 3Lagos State Univ. Teaching Hosp.,, Lagos State, Nigeria, 4Lagos State Univ. Coll. of Med., Lagos State, Nigeria, 5Faculty of Med., Kuwait Univ., Kuwait, United Arab Emirates. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

44

September 9-12 |

SUNDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------010(C2) Poster Session Multi-Center Surveillance Studies Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: C2-123 Ceftaroline Activity Tested against Pathogens Associated

With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Isolated From Latin American Medical Centers (2010) D. J. Biedenbach, H. S. Sader, R. K. Flamm, R. N. Jones; JMI Lab., Inc., N Liberty, IA. C2-124 Antimicrobial Activity of Ceftaroline and Comparator

Agents Tested against Contemporary (2010) Pathogens Associated with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Isolated from the Asia-Pacific Region (APAC) and South Africa (SAF) P. R. Rhomberg, R. K. Flamm, R. N. Jones, H. S. Sader; JMI Lab., N Liberty, IA. C2-125 Comparative In Vitro Activity of Sitafloxacin (SIT) Relative

to Other Fluoroquinolones against Clinically Important Bacteria Isolated in Asia and Europe J. Deane, A. Simenauer, D. Sahm; Eurofins, Chantilly, VA.

C2-132 Oritavancin Activity Tested against Staphylococcus aureus

andơ-Hemolytic Streptococci Causing Skin and Skin Structure Infections in the USA (2010−2012) R. E. Mendes, H. S. Sader, R. K. Flamm, R. N. Jones; JMI Lab., N Liberty, IA. C2-133 Monitoring Cross-Resistance Trends Between Tigecycline

and Minocycline in Gram-Positive Blood Isolates (Test 2008 2011) S. Hawser1, C. Zampaloni1, F. Monti 1, S. Bouchillon 2; 1IHMA Europe Sàrl, Epalinges, Switzerland, 2IHMA, Inc., Schaumburg, IL. C2-134 Comparative In Vitro Activity of Dalbavancin (DAL) and

Other Gram-Positive Agents against a Recent Collection of European Bacterial Isolates J. Deane 1, A. Simenauer 1, M. Dunne 2, B. P. Goldstein 3, D. Sahm 1; 1 Eurofins Medinet, Chantilly, VA, 2Durata Therapeutics, Morristown, NJ, 3 None, Morristown, NJ. C2-135 Antimicrobial Susceptibility of 27,123 Pathogens Isolated

from Patients in Canadian Hospitals: CANWARD Study 20072011 G. G. Zhanel1, H. Adam 2, M. Baxter 1, K. Nichol 2, A. Denisuik 1, P. Lagace-Wiens 2, A. Walkty 2, J. A. Karlowsky 2, F. Schweizer 1, Canadian Antimicrobial Resistance Alliance-CARA, D. J. Hoban 2; 1Univ. of Manitoba, Winnipeg, Canada, 2Diagnostic Services of Manitoba, Winnipeg, Canada. C2-136 Emerging Markets Resistance Surveillance (EMRS) Program

C2-126 In Vitro Activity of Ceftaroline against Staphylococcus aureus

(SA) from Consecutive U.S. Nationwide Surveillance Program 2009 and 2011 G. Doern 1, S. Richter 2, K. Heilmann 1, C. Dohrn 1, F. Riahi 1, D. Diekema1; 1 Univ. of Iowa, Iowa City, IA, 2Cleveland Clinic, Cleveland, OH. C2-127 Comparative In Vitro Activity of Ceftaroline, Daptomycin,

Linezolid, and Vancomycin against 512 Bacteremic MethicillinResistant Staphylococcus aureus Isolated Over a Period of 9 Years (2004-2012) in Madrid, Spain E. Cercenado, B. Gama, C. Sánchez-Carrillo, M. Marín, M. RodríguezCréixe, E. Bouza; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain. C2-128 A Five Year Comparison of Vancomycin (VAN) and Orita-

vancin (ORI) In Vitro Activities against Staphylococci J. Deane 1, A. Simenauer 1, G. Moeck 2, F. F. Arhin 2, D. Sahm 1; 1Eurofins, Chantilly, VA, 2The Med. Company, Parsippany, NJ. C2-129 Antimicrobial Susceptibility of S. aureus from USA Hospitals

According to the Site of Infection: Data from the Ceftaroline AWARE Surveillance Program (2008-2011) H. S. Sader, R. K. Flamm, R. N. Jones; JMI Lab., Inc., N Liberty, IA. C2-130 Activity of Ceftaroline Tested against Staphylococcus Collected

from a Nationwide Study in Spain, 2010 E. Cercenado, B. Gama, O. Cuevas, M. Marín, E. Bouza, Staphylococcus Study Group; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain. C2-131 Ceftaroline and Comparator Agent Activity against Con-

temporary (2010) Staphylococcus aureus Isolates from Asia-Pacific (APAC) Region and South Africa Hospitals P. R. Rhomberg, R. K. Flamm, R. N. Jones, H. S. Sader; JMI Lab., Inc., N Liberty, IA.

Report for Eastern European (EEU) Nations R. N. Jones, M. G. Stilwell, R. K. Flamm, H. S. Sader; JMI Lab., N Liberty, IA. C2-137 Nationwide Surveillance on the Antimicrobial Resistance

among Blood Isolates Causing Bacteremia: A 2011 Korean Network for Study on Infectious Diseases (KONSID) Study K. Huh, S. Y. Park, S. Y. Cho, C. I. Kang, D. R. Chung, N. Y. Lee, K. R. Peck, J. H. Song, Korean Network for Study on Infectious Diseases (KONSID); Samsung Med. Ctr., Seoul, Korea, Republic of. C2-138 Update of Dalbavancin (DAL) Activity in the USA: Report

from the SENTRY Program (2011) R. N. Jones R. K. Flamm, H. S. Sader; JMI Lab., N Liberty, IA. C2-139 Linezolid Experience and Accurate Determination of Resis-

tance (LEADER) Program for 2011: USA Surveillance Report J. E. Ross, R. E. Mendes, R. K. Flamm, R. N. Jones; JMI Lab., N Liberty, IA. C2-140 Trends in Activity of Tigecycline against Bacteroides spp. from

Cardiovascular Sources (TEST 2008 - 2011) S. Hawser 1, C. Zampaloni1, F. Monti 1, S. Bouchillon 2; 1IHMA Europe Sàrl, Epalinges, Switzerland, 2IHMA, Inc., Schaumburg, IL. C2-141 Comparison of Tigecycline Activity against Aerobic Intra-

Abdominal Pathogens in Eastern and Western European Countries: TEST 2008-2011 S. Lob, S. Bouchillon, M. Hackel, D. Hoban, J. Johnson; IHMA, Inc., Schaumburg, IL. C2-142 In Vitro Activity of Tedizolid and Radezolid against Line-

zolid-Resistant Gram-Positive Clinical Isolates with Genetically Characterized Resistance Mechanisms E. Cercenado, M. Marín, B. Gama, C. Iglesias, E. Bouza; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain.

Final Program

45

> Sunday SCIENTIFIC SESSIONS C2-143 Susceptibility of Gram-Positive Wound Pathogens in Eastern

Europe: A Multi-Year Update of the TEST Study M. Hackel1, S. Bouchillon 1, D. Hoban1, R. Badal 1, J. Johnson 1, S. Hawser 2; 1 IHMA, Inc., Schaumburg, IL, 2IHMA Europe Sàrl, Epalinges, Switzerland. C2-144 Monitoring of Tigecycline In Vitro Activity in Nosocomial

Pneumonia Isolates from North American Intensive Care Units: TEST Data 2006-2011 D. Hoban, M. Hackel, R. Badal, S. Bouchillon, B. Johnson; IHMA, Inc., Schaumburg, IL. C2-145 Activity of Ceftaroline (CPT) and Comparator Agents Tested

against Contemporary (2010) Pathogens Commonly Associated with Respiratory Tract Infections (RTI) in Asia-Pacific (APAC) Countries and South Africa (SAF) D. J. Biedenbach, R. K. Flamm, D. J. Farrell, H. S. Sader, R. N. Jones; JMI Lab., N Liberty, IA. C2-146 Antimicrobial Activity of Ceftaroline Tested against Bacteria

Collected from Patients with Community-Acquired Respiratory Tract Infections (CARTI) in the USA (2008-2011) R. N. Jones, R. K. Flamm, P. R. Rhomberg, H. S. Sader; JMI Lab., Inc., N Liberty, IA. C2-147 Extended-Spectrum ß-Lactamase (ESBL) In Vitro Activity

in Urinary Tract Infections: European TEST Program Results, 2004-2011 S. Bouchillon, M. Hackel, B. Johnson, D. Hoban, J. Johnson; IHMA, Inc., Schaumburg, IL. C2-148 Epidemiology and Antimicrobial Susceptibility of Pathogens

Clostridium difficile Diagnostics Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: D-153 Evaluation of the Accuracy and Cost Effectiveness of Strate-

gies of Testing for Clostridium difficile J. N. Wainaina1, M. A. Beilke 1, T. Wisniewski 2, J. Winner 2, P. Sohnle 1; 1 Clement J. Zablocki Med. Ctr., Med. Coll. of Wisconsin, Milwaukee, WI, 2 Clement J. Zablocki Med. Ctr., Milwaukee, WI. D-154 Does a Rapid Diagnosis of Clostridium difficile Infection (CDI)

Impact on Quality of Patient’s Management? F. Barbut 1,2, C. Eckert 1,2, L. Surgers 1, V. Lalande 1, for the GRCn°2 EPIDIFF; 1Hosp. Saint-Antoine, Paris, France, 2Univ. Pierre et Marie Curie, Paris, France. D-155 The Efficient Use of Laboratory Testing in Support of Clos-

tridium difficile Infection, Diagnosis, and Prevention: Comparing Antigen, Nucleic Acid Amplification, and GDH: What is the Most Efficient Testing Algorithm? M. J. Bankowski 1,2, A. Hose 1, A. LeClaire 1, T. Goo 1, T. Koyamatsu 1, W. Kim 1; 1Diagnostic Lab. Services (The Queen’s Med. Ctr.), Aiea, HI, 2John A. Burns Sch. of Med., Honolulu, HI. D-156 Evaluation of a New Glutamatedehydrogenase Immuno Assay

Associated with Bacterial Empyema: TEST 2004-2011

in a Two Step Algorithm for the Diagnosis of Clostridium difficile Infection

S. Bouchillon, R. Badal, B. Johnson, M. Hackel, D. Hoban; IHMA, Inc., Schaumburg, IL.

J. Van Broeck, E. R. Icyeza, M. Delmée; Univ. Catholique de Louvain, Brussels, Belgium.

C2-149 In Vitro Activity of Ceftazidime-Avibactam (formerly

D-157 Performances of a New Test to Detect GDH in Stool Samples

CAZ104) against Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals in 2009-2011: CANWARD Surveillance Study P. Lagacé-Wiens, H. Adam, A. Denisuik, J. Karlowsky, A. Walkty, D. Hoban, G. G. Zhanel; Univ. of Manitoba, Winnipeg, Canada. C2-150 In Vitro Activity of Tigecycline and Comparators against

Gram-Negatives in Africa-Middle East: TEST 2007-2012 1

1

1

1

2

M. Renteria , S. Bouchillon , B. Johnson , M. Hackel , N. Raghubir ; 1 IHMA, Inc., Schaumburg, IL, 2Pfizer, Inc., Dubai, United Arab Emirates. C2-151 Dynamics of Susceptibility to Tigecycline and to an Extended

Panel of Antimicrobials of Gram-Positive and Gram-Negative Bacteria in Portugal (2005-2011) C. Silva-Costa, A. Friaes, M. D. Pinho, M. Ramirez, J. Melo-Cristino; Faculdade de Med. de Lisboa, Lisboa, Portugal. C2-152 Enterobacteriaceae in the UK and Ireland 2011: Susceptibility

to Old and New Agents R. Reynolds1, S. Mushtaq2, A. Kidney 3, BSAC Working Party on Resistance Surveillance; 1Southmead Hosp., Bristol, United Kingdom, 2Hlth. Protection Agency, London, United Kingdom, 3Quotient Bioresearch, Microbiol., Fordham, United Kingdom.

46

---------------------------------------------------------------------------------011(D) Poster Session

September 9-12 |

C. Eckert1,2, C. Rambaud 1,2, V. Lalande 3,2, F. Barbut 1,2; 1Saint-Antoine Hosp., Paris, France, 2UPMC Univ. Paris 06, GRC n°2, Epidiff, Paris, France, 3Saint-Antoine Hosp., AP-HP, Paris, France. D-158 Development and Evaluation of a Double Multiplex Real-

Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of C. difficile from Stool Samples A. Kilic 1,2, M. J. Alam 2, N. L. Tisdel 3, D. N. Shah 2,3, M. Yapar 1, T. M. Lasco 3, K. W. Garey2,3; 1Gulhane Military Med. Academy, Ankara, Turkey, 2 Univ. of Houston Coll. of Pharmacy, Houston, TX, 3St Luke’s Episcopal Hosp., Houston, TX. D-159 Improvement in Patient Management through the Use of a

Clostridium difficile PCR Real-Time Stand Alone Test in Acute Hospital Setting E. Casari 1, A. Ferrario1, C. De Luca 1, M. Calabrò 1, S. Allibardi 2, M. Lagioia 1; 1IRCCS Ist. Clinico Humanitas, Rozzano (Milan), Italy, 2Cepheid Europe, Milano, Italy. D-160 Clinical Validation of Clostidium difficile Infection (CDI)

Diagnostics: Importance of Toxin Detection T. D. Planche 1, K. A. Davies 2, P. Coen 3, D. Crook 4, N. Shetty 3, M. Wrener 3, M. H. Wilcox 2; 1St. George’s, Univ. of London, London, United Kingdom, 2Leeds Teaching Hosp. NHS Trust, Leeds, United Kingdom, 3 UCLH NHS Fndn. Trust, London, United Kingdom, 4Oxford Radcliffe NHS Trust, Oxford, United Kingdom.

SUNDAY SCIENTIFIC SESSIONS D-161 PCR Assay to Detect Clostridium difficile tcdC Mutants is

Valuable in Characterizing Hospital Epidemiology A. Wilmer1, E. Lloyd-Smith 2, V. Leung 2, T. Wong 1, G. Ritchie 3, S. Champagne 3, M. Romney 3; 1Univ. of British Columbia, Vancouver, Canada, 2St. Paul’s Hosp., Vancouver, Canada, 3St. Paul’s Hosp., Vancouver, Canada. D-162 Elevated Fecal Lactoferrin Levels Correlate with the Presence

of Clostridium difficile Toxin

D-170 Anaerobic Thioglycollate Broth Culture for Recovery of

Propionibacterium Acnes (PA) from Shoulder Fluid and Tissue Specimens S. K. Shannon, J. Mandrekar, D. R. Gustafson, S. L. Rucinski, A. L. Dailey, R. E. Segner, M. K. Burman, K. J. Boelman, D. T. Lynch, J. E. Rosenblatt, R. Patel; Mayo Clinic, Rochester, MN. D-171 Detection of Biofilm Formation Among the Clinical Isolates

H. R. Totty1, J. H. Boone 1, R. J. Carman 1, T. M. Kerkering 2, D. M. Lyerly 1; 1 Techlab, Inc., Blacksburg, VA, 2Carilion Clinic, Roanoke, VA. D-163 Higher Lactoferrin, Increased WBC, Stool Toxin and 027

Infection are Associated with More Severe C. difficile Disease J. H. Boone1, C. McCoy 1, J. DiPersio 2, M. Tan 2, S. Salstrom 2, K. Wickham 1, R. Carman 1, D. Lyerly 1; 1TechLab, Inc., Blacksburg, VA, 2 Summa Hlth. System, Akron, OH.

of Acinetobacter baumanii A. Hassan; Natl. Univ. of Scienecs and Technology, Army Med. Coll., Rawalpindi, Pakistan.

---------------------------------------------------------------------------------013(D) Poster Session

-----------------------------------------------------------------------012(D) Poster Session

Diagnosis of Respiratory Tract Infections

Diagnosis of Infections of Implantable Devices and Biofilms

D-172 Genomic Load from Sputum to Diagnose Pneumococcal

Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: D-164 A Novel, Direct Susceptibility Testing Method of Vascular

Prosthetic Grafts by E-Tests L. Stecken 1, A. San Miguel 1, F. M’zali 2, A. Quinart 1, X. Berard 1, F. Sztark 1; 1Bordeaux Teaching Hosp., Bordeaux, France, 2Univ. of Bordeaux, Bordeaux, France. D-165 Sonication of Cardiac Devices and their Components: Mi-

Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations:

Pneumonia W. C. Albrich1,2, S. A. Madhi 2,3, P. V. Adrian 2,3, P. Zhaoer 4, M. Sidhu 5, J. Telles 6, G. Paranhos-Baccala 6, K. U. Jansen 4, G. Vernet 6, K. P. Klugman 2,7; 1 Kantonsspital Aarau, Aarau, Switzerland, 2Vaccine Preventable Diseases & Respiratory and Meningeal Pathogens Res. Unit, MRC, Univ. of the Witwatersrand, Johannesburg, South Africa, 3Natl. Inst. for Communicable Diseases, Faculty of Hlth. Sci., Johannesburg, South Africa, 4Pfizer Vaccine Res., Pearl River, NY, 5Pfizer, Pearl River, NY, 6Emerging Pathogens Lab., Fondation Mérieux, Lyon, France, 7Rollins Sch. of Publ. Hlth. & Div. of Infect. Dis., Emory Univ., Atlanta, GA. D-173 Multiplex PCR on Bronchoalveolar Lavage (BAL) Markedly

crobiological and Pathogenetic Implication in Cardiac Device Infections

Improves the Microbiological Documentation of Severe Pneumonia for Patients with Ongoing Antimicrobial Treatment

A. Oliva1, B. Nguyen 1, M. T. Mascellino 1, M. Iannetta 1, A. D’Abramo 1, V. Malagnino 1, A. Ciccaglioni 1, V. Vullo 1, C. M. Mastroianni 2; 1Sapienza Univ., Rome, Italy, 2Sapienza Univ., Latina, Italy.

J. Baudel, J. Tankovic, F. Carrat, R. Dahoumane, A. Galbois, H. Ait Oufella, G. Offenstadt, B. Guidet, E. Maury; Univ. Hosp. Saint-Antoine, Paris, France.

D-166 Diagnosis of Venous Access Port Colonization Requires Cul-

tures from Multiple Sites M. Guembe, P. Martín-Rabadán, A. Echenagusia, F. Camúñez, G. Rodríguez-Rosales, G. Simó, M. Echenagusia, E. Bouza; Hosp. G.U. Gregorio Marañón, Univ. of Madrid, Madrid, Spain.

D-174 Direct Comparison of Real-Time PCR Using Roche Analyte

Specific Reagents with Shell Vial Culture for Detection of Cytomegalovirus in Lower Respiratory Specimens K. R. Hawkins1, M. J. Binnicker 2, B. S. Pritt 2; 1Univ. of Warwick, Norfolk, United Kingdom, 2Mayo Clinic, Rochester, MN.

D-167 Diagnosis of Intravascular Catheter Colonization and Central

D-175 Dichromatic at-a-Glance Real-Time PCR Discrimination

Venous Catheter-Related Infection: A Prospective Comparison of the Roll-Plate and Sonication Technique in 975 Central Venous Catheters

of Macrolide Sensitive/Resistant Mycoplasma pneumoniae from Clinical Specimens

S. Erb, K. Schrengenberger, M. Dangel, R. Frei, A. F. Widmer; Univ. Hosp. of Basel, Switzerland, Basel, Switzerland. D-168 Sonication of Cerebrospinal Fluid Catheter Tips for Improved

Detection of Microorganism in Device Associated Infections L. N. Walti1, G. Jost 2, L. Mariani 2, A. Trampuz 1; 1Univ. Hosp., Lausanne, Switzerland, 2Univ. Hosp., Basel, Switzerland. D-169 Diagnostic Tests for Prosthetic Joint Infection (PJI) M. Fernandez-Sampedro1, C. Fariñas-Alvarez 2, C. Salas-Venero 1, M. Sumillera 1, M. Fakkas Fernández 1, J. Gómez-Román 1, L. Martínez-Martínez 1, M. Fariñas 1; 1Valdecilla Univ. Hosp., Santander, Spain, 2Sierrallana Hosp., Torrelavega, Spain.

I. Miyata, I. Miyairi; Natl. Ctr. for Child Hlth. and Dev., Tokyo, Japan. D-176 Diagnosis of Respiratory Infections Due to Mycoplasma

pneumoniae: Serology or PCR? S. Sunder, D. Bouvet, M. Alves, F. Bastides, C. De Gialluly, R. Quentin, A. Goudeau, L. Bernard; CHRU de Tours, Tours, France. D-177 Multiplex Real-Time PCR: Efficacy in Diagnosis and Treat-

ment of Lower Respiratory Tract Infections H. Chaussade, D. Bouvet, S. Sunder, G. Gras, A. Goudeau, L. Bernard; CHRU de Tours, Tours, France.

Final Program

47

> Sunday SCIENTIFIC SESSIONS D-178 Comparative Evaluation of 8 Commercial Multiplex PCR Kits

for the Diagnosis of Respiratory Infection M. Lardeux 1, S. Pillet1, J. Dina 2, F. Grattard 1, P. O. Verhoeven 1, J. Legoff 3, A. Vabret 2, B. Pozzetto 1; 1Univ. Hosp. of Saint Etienne, Saint Etienne, France, 2 Univ. Hosp. of Caen, Caen, France, 3Saint-Louis Hosp., Paris, France. D-179 Prevalence of Respiratory Viruses in the Community of

Northern Saxony and Saxony-Anhalt, Germany N. H. Zaiss, M. Kunze, G. Ackermann; Alphaomega Labor, Delitzsch, Germany. D-180 Prognostic Value of Serum Albumin Levels at Admission in

Hospitalized Adults with Community-Acquired Pneumonia D. Viasus, C. Garcia-Vidal, J. Dorca, F. Gudiol, J. Carratalà; Hosp. de Bellvitge - IDIBELL, Univ. of Barcelona, Barcelona, Spain. D-181 Prevalence of Bacterial Otitis Media and Antimicrobial Sus-

ceptibility Pattern in Ethiopia 1

2

3 1

2

D. S. Fentaw , Y. Bekele , T. Getachew ; UIO, Oslo, Norway, AHRI, Addis Ababa, Ethiopia, 3EHNRI, Addis Ababa, Ethiopia.

-----------------------------------------------------------------------014(D) Poster Session Serologic Methods for Detection of Infectious Diseases Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C

In Vitro Activity of Beta-Lactamase Inhibitor Combinations Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: E-186 Antimicrobial Activity of Ceftaroline-Avibactam (CPA)

Tested against Contemporary Clinical Isolates from USA Medical Centers (2011) H. S. Sader, R. K. Flamm, J. M. Streit, R. N. Jones; JMI Lab., Inc., N Liberty, IA. E-187 Avibactam Reverts the Ceftazidime (CAZ) MIC90 of a Recent

Set of European Clinical Isolates of Gram-Negative Bacteria Back to the Epidemiological Cut-Off Value (ECOFF)

R. K. Flamm1, W. W. Nichols 2, H. S. Sader 1, R. N. Jones 1; 1JMI Lab., N Liberty, IA, 2AstraZeneca Pharmaceuticals LP, Waltham, MA. E-188 Quality Control Parameters for Ceftaroline-Avibactam Disk

Diffusion, Anaerobic Broth Microdilution and Agar Dilution Quality Control S. D. Brown, M. M. Traczewski; Clinical Microbiol. Inst., Inc., Wilsonville, OR. E-189 Antimicrobial Spectrum and Potency of Ceftaroline-Avibactam

Presentations: D-182 Optimal Cutoff Value of Serum Adenosine Deaminase Activ-

ity for Diagnosing Acute Scrub Typhus J. Lee1, J. Cho 2, E. Choi 3; 1Inst. of Wonkwang Med. Sci., Iksan, Korea, Republic of, 2Wonkwang Univ. Hosp., Iksan, Korea, Republic of, 3Mirawomen Pedriatric Hosp., Iksan, Korea, Republic of. D-183 Diagnostic Cutoffs for Increases and Absolute Values of Im-

munoglobulin G Antibodies against Pertussis Toxin S. C. de Greeff 1, P. Teunis 1, H. E. de Melker 1, F. R. Mooi 1, D. Notermans 1, B. Elvers 1, J. F. P. Schellekens2; 1Natl. Inst. for Publ. Hlth. and the Environment, Bilthoven, Netherlands, 2Lab. for Infectious Diseases, Groningen, Netherlands. D-184 A Comparison of Three Anti-HEV IgG EIA Screening

Kits and One Confirmatory Immunodot Assay in Blood Donor Samples in Switzerland A. Schnegg 1, P. Bürgisser 2, C. André 2, A. Kenfak-Foguena 2, G. Canellini 3, D. Moradpour 2, M. Cavassini 2, K. E. Darling 2; 1Univ. of Lausanne, Lausanne, Switzerland, 2Ctr. Hosp. Univ. Vaudois, Univ. of Lausanne, Lausanne, Switzerland, 3Service Régional Vaudois de Transfusion Sanguine, Epalinges, Switzerland. D-185 Optimizing the Positive Predictive Value of the Focus HSV-2

ELISA in Hepatitis C Infected Veterans at the Jackson VAMC M. Burton1, E. Swiatlo 1, I. Sunesara 2, A. Penman 2, C. Young 1, E. W. Hook, III 3; 1G.V. Sonny Montgomery VAMC, Jackson, 2Univ. of Mississippi Med. Ctr., Jackson, 3Univ. of Alabama, Birmingham, AL.

48

---------------------------------------------------------------------------------015(E) Poster Session

September 9-12 |

Tested against ESBL-Phenotype and Carbapenem-Resistant Enterobacteriaceae Collected from USA Hospitals (2009-2011) H. S. Sader, M. Castanheira, R. K. Flamm, R. N. Jones; JMI Lab., Inc., N Liberty, IA. E-190 In Vitro Activity of Ceftazidime Alone and in Combination

with Avibactam against Resistant Pseudomonas aeruginosa and Enterobacteriaceae M. J. B. Melchers1, C. H. van Mil 2, J. W. Mouton 1; 1Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 2Canisius Wilhelmina Hosp., Nijmegen, Netherlands. E-191 In Vitro Activity of Ceftaroline-Avibactam against Frequently

Isolated Bacterial Pathogens from Patients in Canadian Hospitals J. Karlowsky1, A. Walkty 1, M. Baxter 2, H. Adam 1, P. Lagace-Wiens 1, D. Hoban 1, G. G. Zhanel 2; 1Diagnostic Services of Manitoba, Winnipeg, Canada, 2Univ. of Manitoba, Winnipeg, Canada. E-192 Activity of MK-7655 with Imipenem vs.ơ-Lactamase

Producers D. M. Livermore, M. Warner, S. Mushtaq; UK Hlth. Protection Agency, London, United Kingdom. E-193 Antimicrobial Activity of BAL30072, Alone and in Combina-

tion with Meropenem Tested against Gram-Negative Bacteria Causing Serious Infections in Hospitals from China, India, Latin America and South East Asia-Pacific P. R. Rhomberg, K. A. Fedler, R. K. Flamm, R. N. Jones, H. S. Sader; JMI Lab., Inc., N Liberty, IA.

SUNDAY SCIENTIFIC SESSIONS E-194 Avibactam (NXL104) in Combination with Selectơ-Lactams

and Meropenem Greatly Improves In Vitro Activity against ESBL-, AmpC-, and KPC-Producing Escherichia coli (EC) and Klebsiella pneumoniae (KPN) from Canadian Hospitals A. Denisuik1, F. Tailor1, P. Lagacé-Wiens 1,2, H. J. Adam 1,2, D. J. Hoban 1,2, G. G. Zhanel 1, The Canadian Antimicrobial Resistance Alliance (CARA); 1 Univ. of Manitoba, Winnipeg, Canada, 2Diagnostic Services of Manitoba, Winnipeg, Canada. E-195 In Vitro Activity of Piperacillin-Tazobactam (PT) in Combi-

nation (combi) with Various Antibiotics (ABX) against Extreme Drug-Resistant (XDR) Enterobacteriaceae (EB) with Reduced Susceptibilities to Polymyxin B (PB) T. P. Lim 1,2, S. Sasikala 1, W. Lee 1, N. Tahir 1, Y. Cai 1, T. H. Koh 1, T. Y. Tan 3, L. Y. Hsu 2, T. T. Tan 1, A. L. Kwa1; 1Singapore Gen. Hosp., Singapore, Singapore, 2Natl. Univ. Hosp. System, Singapore, Singapore, 3Changi Gen. Hosp., Singapore, Singapore. E-196 In Vitro Susceptibility Among Enterobacteriaceae to a Novel

ơ-Lactam/ơ-Lactam Inhibitor Combination: Cefpime-Tazobactam A. Manoharan, M. Sugumar, G. S. Barla, D. Kumar, D. Mathai; Christian Med. Coll., Vellore, Tamil Nadu, India. E-197 Utilizing Population Analysis to Investigate Piperacillin/

Tazobactam Differences Between Broth Microdilution and Agar Dilution for a Set of Escherichia coli C. Shubert1, J. Slaughter 1, D. Creely 1, G. Zambardi 2, D. Shortridge 1; 1 bioMerieux, Inc., Hazelwood, MO, 2bioMerieux, Inc., La Balme, France. E-198 In Vitro Activity of Ceftolozane Alone and in Combination

with Tazobactam against Extended Spectrum Beta-Lactamase Harbouring Enterobacteriaceae M. J. B. Melchers1, C. H. van Mil 2, J. W. Mouton 1; 1Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 2Canisius Wilhelmina Hosp., Nijmegen, Netherlands. E-199 Activity of the Novel Antimicrobial Ceftolozane/Tazobactam

Tested against Contemporary Clinical Strains from USA Hospitals (2011) H. S. Sader, R. K. Flamm, J. M. Streit, R. N. Jones; JMI Lab., Inc., N Liberty, IA. E-200 In Vitro Activity of Ceftolozane/Tazobactam Tested against

1,705 Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals in 2011: CANWARD Surveillance Study G. G. Zhanel1, H. Adam 2,1, A. Walkty 2, P. R. S. Lagace-Wiens 2, D. J. Hoban 2,1, J. A. Karlowsky 2; 1Univ. of Manitoba, Winnipeg, Canada, 2 Diagnostic Services of Manitoba, Winnipeg, Canada. E-201 In Vitro Pharmacodynamics (PD) of Ceftolozane (TOL)/

Tazobactam (TAZ) againstơ-Lactamase (BL) Producing Eschericia coli (Ec)

-----------------------------------------------------------------------016(E) Poster Session In Vitro Activity of Fluoroquinolones Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: E-203 In Vitro Bactericidal Activity of KPI-10, a Next Generation

Fluoroquinolone (FQ), against FQ-Susceptible (FQ-S) and FQResistant (FQ-R) Gram-Negative and Gram-Positive Isolates C. Jacqueline 1, C. Desessard 2, M. Davieau 1, Y. Ge 3, G. Potel 1, J. Caillon 1; 1 UPRES EA 3826, Nantes, France, 2Atlangram, Nantes, France, 3Kalidex Pharmaceuticals Inc, Menlo Park, CA. E-204 Ozenoxacin. Activity against Gram-Positive Bacteria (GPB)

Causing Skin and Soft Tissue Infections (SSTI) Collected in 2009-10 I. Morrissey1, R. Janes 1, J. Dallow 1, A. Leakey 1, A. Guglietta 2, D. Gargallo-Viola 2; 1Quotient Bioresearch, Ltd., Fordham, United Kingdom, 2 Ferrer, R&D Ctr., Barcelona, Spain. E-205 Ozenoxacin: Characterization of Variables that May Influence

Susceptibility Testing, Including MIC and MBC Values M. Tato1, Y. López 2, A. Moreno-Bofarull 1, M. I. Morosinier 1, D. Gargallo-Viola 3, A. Guglietta 3, J. Vila 2, R. Cantón 1; 1Ramón y Cajal Univ. Hosp., Madrid, Spain, 2Hosp. Clinic, Barcelona, Spain, 3Ferrer, R&D Ctr., Barcelona, Spain. E-206 In Vitro Activity of Nemonoxacin, a Novel Quinolone

Antibiotic, against Chlamydia trachomatis K. Chotikanatis, S. A. Kohlhoff, M. R. Hammerschlag; SUNY Downstate Med. Ctr., Brooklyn, NY. E-207 Activity of the Novel Fluoroquinolone KPI-10 vs. Atypical

Bacteria P. B. Eckburg1, Y. Ge 1, H. Windsor2, M. Donati 3, R. Cevenini 3; 1Kalidex Pharmaceuticals, Inc., Menlo Park, CA, 2Mycoplasma Experience, Ltd., Reigate, United Kingdom, 3Univ. of Bologna, Bologna, Italy. E-208 Characterization and In Vitro Activity of Delafloxacin (DLX)

against Isolates from a Phase 2 Study of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) L. E. Lawrence1, S. Hopkins 1, D. Sahm 2, J. Deane 2, J. Longcor 1; 1Rib-X Pharmaceuticals Inc., New Haven, CT, 2Eurofins Medinet, Chantilly, VA. E-209 In Vitro Activity of Sitafloxacin against Multidrug-Resistant

(MDR) Acinetobacter baumannii V. Thamlikitkul, S. Tiengrim; Siriraj Hosp., Bangkok, Thailand. E-210 Ozenoxacin: Bactericidal Activity against Gram-Positive

Bacteria

R. L. Soon, A. Forrest, P. N. Holden, P. Kelchlin, B. T. Tsuji; Univ. at Buffalo, Buffalo, NY. E-202 In Vitro Imipenem -Sulbactam Activity against Multidrug-

I. Morrissey1, R. Janes, MRes 1, J. Dallow 1, A. Leakey 1, A. Guglietta 2, D. Gargallo-Viola 2; 1Quotient Bioresearch, Ltd., Fordham, United Kingdom, 2 Ferrer, R&D Ctr., Barcelona, Spain.

Resistant Acinetobacter baumannii Complex (ABC) by Time-Kill Assay M. G. Quinteros, A. Miquelarena, Jr, A. Dorronzoro, J, J. Toran, M. Santalucía, Jr, A. E. Farinati; Salvador Univ., Buenos Aires, Argentina.

Final Program

49

> Sunday SCIENTIFIC SESSIONS -----------------------------------------------------------------------017(H) Poster Session Adherence to HIV Therapy and Care Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: H-211 Association Between Selective Adherence to Antiretroviral

Therapy and Hospitalization Risk in an HIV Population C. Cohen1, K. Davis 2, J. Meyers 2; 1Community Res. Initiative of New England, Boston, MA, 2RTI Hlth. Solutions, Research Triangle Park, NC. H-212 Affects on Medication Adherence in HIV-Infected Patients

by a Part D Style Medication Therapy Management (MTM) Program C. Holtzer, Holtzer, E. Ndzerem, C. Higgs; Ramsell Corp., Oakland, CA. H-213 Barriers to Healthcare Engagement in Hospitalized HIV-

Infected Patients A. P. Liappis1,2, B. Yoon 1, S. D. McIntosh1,2, A. D. Castel 2, S. Silver 2, P. J. Poppen 2; 1VA Med. Ctr., Washington, DC, 2George Washington Univ., Washington, DC.

-----------------------------------------------------------------------018(H, V) Poster Session Hepatitis B and C Coinfection in HIV Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: H-214 Genotyping and Phylogenetic Analysis of HCV Isolates

H-218 Clinical and Virologic Outcomes after Switch to Tenofovir/

Lamivudine of HIV-Infected Patients with Hepatitis B Virus (HBV) Resistance to Lamivudine in an Hyperendemic Area for HBV Infection K. Lee, S. Chang, Y. Su, W. Liu, C. Hung, S. Chang; Natl. Taiwan Univ. Hosp., Taipei, Taiwan.

-----------------------------------------------------------------------019(H) Poster Session Opportunistic Infections and Co-Morbid Conditions in HIV-I Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: H-219 Risk Factors of Invasive Pneumococcal Disease in HIV-

Infected Patients in France from 2000-2011 A. Munier1, V. De Lastours 1, R. Porcher 1, E. Varon 2, J. Donay 1, J. Molina 1; 1 Saint-Louis Hosp., Paris, France, 2HEGP Hosp., Paris, France. H-220 Cryptococcal Meningitis in Patients with AIDS: Clinical

Experience in a Tertiary Care Teaching Hospital of Panama E. González, A. B. Arauz, A. Rodriguez-French; Hosp. Santo Tomás, Panama, Panama. H-221 Hepatotoxicity Related to Use of Trimethoprim-Sulfamethox-

azole in Treatment of Pneumocystis jirovecii Pneumonia in HIVInfected Patients: Incidence and Associated Factors J. Yang, K. Lee, M. Tsai, C. Hung, S. Chang; Natl. Taiwan Univ. Hosp., Taipei, Taiwan. H-222 Leishmaniasis as Cause of Immune Activation in HIV-Infect-

among People Living with HIV/AIDS in Cameroon

ed Patients

M. Djuidje Ngounoue 1,2, A. Djikeng 3, D. Spiro 4, P. F. Moundipa 1, L. Kaptue 5,2; 1Univ. of Yaounde I, Yaounde, Cameroon, 2Cameroon Natl. Ethics Committee, Yaoundé, Cameroon, 3Biosciences central and eastern Africa (BECA) and Intl. Livestock Res. Inst. (ILRI), Nairobi, Kenya, 4Natl. Inst. of Hlth. (NIAID/NIH/DHHS), Bethesda, 5Univ. des Montagnes, Bangangté, Cameroon.

J. L. Casado, M. Abad, M. Del Palacio, M. J. Perez-Elías, A. Moreno, S. Moreno, A. Vallejo; Ramon y Cajal Hosp., Madrid, Spain.

H-215 Prevalence of Genotypic Resistance of Hepatitis C Virus to

Protease Inhibitors in HIV-Infected Patients In Taiwan S. Chang, Z. Yang, W. Liu, C. Hung, S. Chang; Natl. Taiwan Univ. Hosp., Taipei, Taiwan. H-216 A Comparative Meta-Analysis Report of Retreatment with

Pegylated Interferon and Ribavirin in HIV-HCV Coinfected Patients M. Bassoer 1, S. G. Parisi1, C. Mengoli 1, M. Fiscon 1, M. Cruciani 2, S. Nardi 2, G. Palù 1; 1Padova Univ., Padova, Italy, 2ULSS20, Verona, Italy. H-217 Neutropenia During Therapy with PegIFN and RBV and the

Risk of Infections in HIV-Infected Subjects with Chronic Hepatitis C (CHC) S. Serrano-Villar, C. Quereda, A. Moreno, M. Pérez-Elías, J. Martín, J. Casado, F. Dronda, E. Navas, J. Hermida, S. Moreno; Hosp. Ramón y Cajal, Madrid, Spain.

H-223 AIDS Related Toxoplasmic Encephalitis in the Era of Antiret-

roviral Therapy in Japan T. Kobayashi, K. Watanabe, K. Nishijima, H. Gatanaga, Y. Kikuchi, S. Oka; Natl. Ctr. for Global Hlth. and Med., Shinjuku-ku, Japan. H-224 Preemptive Therapy Prevents Cytomegalovirus End-Organ Dis-

ease in Treatment-Naïve Patients with Advanced HIV-1 Infection D. Mizushima, T. Nishijima, H. Gatanaga, K. Tsukada, K. Teruya, Y. Kikuchi, S. Oka; Natl. Ctr. for Global Hlth. and Med., Tokyo, Japan. H-225 Impact of an Antimicrobial Stewardship Team (AST) in the

Management of Hospitalized Patients with HIV A. Kunapuli, J. Nagel, T. Gandhi; Univ. of Michigan, Ann Arbor, MI. H-226 Etiologies of Pulmonary Complications of HIV-Infected

Patients in Taiwan in the Era of Combination Antiretroviral Therapy: A Prospective Observational Study K. Lee1, D. Ji 2, C. Hung 1, S. Chang 1; 1Natl. Taiwan Univ. Hosp., Taipei, Taiwan, 2Ctr.s for Disease Control, Taipei, Taiwan. H-227 Etiology and Prognostic Factors of HIV-Infected Patients

Admitted to an Intensive Care Unit in a 20-year Period A. Santos1, S. Xerinda 1, C. Alves 1, P. Figueiredo 1, R. Poinhos 2, M. Santos 1, A. Sarmento 1; 1Hosp. S. João, Porto, Portugal, 2Faculdade Ciências Nutrição, Porto, Portugal.

50

September 9-12 |

SUNDAY SCIENTIFIC SESSIONS H-228 In-Hospital Mortality from Acute Myocardial Infarction: HIV

K-237 How Carbapenems are Used in French Health-Care Settings

Sero-Positive vs. Sero-Negative Individuals

in 2011?

D. D. Pearce1, C. Ani 2, Y. Espinosa-Silva 3, R. Clark 3, K. Fatima 3, M. Rahman 3, E. Diebolt 3, B. Ovbiagele 4; 1Loma Linda Univ., Loma Linda, CA, 2Charles Drew Univ., Compton, CA, 3Western Univ. of Hlth. Sci., Coll. of Osteopathic Med. of the Pacific, Pomona, CA, 4Univ. of California, San Diego, San Diego, CA.

R. Gauzit1, Y. Pean 2, S. Alfandari 3, J. Bru 4, J. P. Bedos 5, C. Rabaud 6, J. Robert 7, SPILF, ONERBA; 1Hotel-Dieu, Paris, France, 2L’IMM, Paris, France, 3CH, Tourcoing, France, 4CH, Annecy, France, 5CH, Versailles, France, 6CHU, Nancy, France, 7Faculte P&M Curie, Paris, France.

H-229 Early Onset and Late Diagnosis of CAD in HIV+ Persons C. Kaiser 1, T. Chin 1, S. Napravnik 2, L. Yang 1, M. Tipton 2, J. Eron 2, C. Hicks1; 1Duke Univ. Med. Ctr., Durham, NC, 2UNC, Chapel Hill, NC. H-230 Comparison of Predicted Cardiovascular Disease Risk Be-

tween HIV-Infected and Non-Infected Koreans

K-238 Optimal Antibiotic Treatment in Hospitals- Meta-Analysis

and Models P. Abel Zur Wiesch1, R. D. Kouyos 2, S. Abel 1, L. Laser 3, S. Bonhoeffer 3; 1 Brigham and Women’s Hosp., Harvard Med. Sch., Boston, MA, 2Princeton Univ., Princeton, NJ, 3ETH Zurich, Zurich, Switzerland. K-239 Costs of Outpatient Parenteral Antibiotic Therapy (OPAT)

S. Kim, Y. Kim, M. Kim, J. Song, D. Oh, J. Ahn, N. Ku, H. Kim, S. Jeong, S. Han, C. Kim, Y. Song, J. Choi, J. Kim; Yonsei Univ. Coll. of Med., Seoul, Korea, Republic of. H-231 An Observational Study of Bone Status in HIV-Infected

Patients

for the Management of Gram+ Acute Bacterial Skin and Soft Tissue Infections (abSSTIs) A. Khachatryan1, V. Ektare 1, M. Xue 1, M. Dunne 2, J. Stephens 1; 1 Pharmerit Intl., Bethesda, 2Durata Therapeutics, Morristown, NJ. K-240 Implementation of a Collaborative Antimicrobial Culture

L. Lemeunier1, N. Viget 1, E. Biver 2, B. Cortet 2, E. Senneville 1; 1Tourcoing Hosp., Tourcoing, France, 2CHRU Lille, Lille, France. H-232 Psychiatric Disorders among HIV Patients in Southern Israel:

A Comparison between African-Origin and Caucasian Populations I. Dotan, R. Toledano, D. Buskila, F. Schlaeffer, R. Smolyakov, L. SaidelOdes, V. Novack, A. Borer, K. Riesenberg; Soroka Univ. Med. Ctr. (SUMC) and Faculty of Hlth. Sci., Ben Gurion Univ. of the Negev, Beer Sheva, Israel.

-----------------------------------------------------------------------020(K) Poster Session Antibiotic Stewardship and Usage Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: K-233 Regional Antibiogram (ABG) of ESKAPE Pathogens: A New

Direction for Resistance Trends in Antimicrobial Stewardship (AMS) A. R. Caffrey1,2, H. J. Morrill 3, K. M. Babcock 3, J. Dworkin 4, K. L. LaPlante 3,2; 1Univ. of Rhode Island Coll. of Pharmacy, Kingston, RI, 2Univ. of Rhode Island, Coll. of Pharmacy, Kingston, RI, 3Providence VA ID Res. Program, Providence, RI, 4Brown Univ., Providence, RI. K-234 Control of the Prescription of Carbapenems in a French Hos-

pital: Impact of the Hospital Antibiotic Management Team C. Couzigou, J. C. Nguyen, B. Vidal, I. Tersen, J. Loriau, M. D. Kitzis; Hosp. Saint-Joseph, Paris, France. K-235 The Role of an Anti-Microbial Stewardship Program (ASP) in

an Adult Renal Department Y. Cai, ASP Team (SGH), M. P. Chlebicki, A. L. Kwa; Singapore Gen. Hosp., Singapore, Singapore. K-236 Little Steps Towards Infection Control: Where There is a Will,

There is a Way- Even in the NDM-1 Era!! A. Ghafur, V. P. R. Lakshmi, K. Chandra, S. Bharadwaj, M. Anna; Apollo Hosp., Chennai, India.

Follow-Up Program in the Emergency Department (ED) L. E. Dumkow1, R. M. Chambers 1, N. C. MacDonald 1, J. J. Carreno 1,2, M. K. Malhotra 1, S. L. Davis 1,2; 1Henry Ford Hosp., Detroit, MI, 2Wayne State Univ., Detroit, MI. K-241 Impact of a Pharmacy Driven Intervention to Reduce Time to

Initiation of Empiric Antibiotic Therapy in Bacteremic Patients T. E. Bias1,2, W. Vincent 2,1, N. Trustman 2, L. Berkowitz 1, V. Venugopalan 1,2; 1 The Brooklyn Hosp. Ctr., Brooklyn, NY, 2Arnold & Marie Schwartz Coll. of Pharmacy and Hlth. Sci. Long Island Univ., Brooklyn, NY. K-242 Early Intervention of Piperacillin/Tazobactam in the Accident

and Emergency Department at Sultan Qaboos University Hospital in Oman: A Boon or an Anathema? R. Vaishnav1, R. S. H. Al-Buridi 2,3; 1Coll. of Med. & Hlth. Sci., Sultan Qaboos Univ., Al-Khod, Muscat, Oman, 2Coll. of Med. & Hlth. Sci., Al-Khod, Muscat, Oman, 3Coll. of Med. & Hlth. Sci., Sultan Qaboos Univ., Muscat, Oman.

-----------------------------------------------------------------------021(K) Poster Session Infection Control and the Environment Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: K-243 Will Environmental Disinfection Decrease Healthcare-

Associated Infection (HAI)?: A Systematic Review H. Chen1, C. Yau 1, A. Wong 1, P. Ching 2, W. Seto 2; 1CHP, HKSAR, Hong Kong, 2WHO Collaborative Ctr., HKSAR, Hong Kong. K-244 What to Breath?: Performance Analysis of Air Samplers in

Operating Rooms L. Ummels1, D. Van de Vegt 1, A. Voss 1,2, J. Hopman 1; 1Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 2Canisius Wilhemina Hosp., Nijmegen, Netherlands.

Final Program

51

> Sunday SCIENTIFIC SESSIONS K-245 The Effect of Copper-Coated Surfaces on the Environmental

Contamination by Pathogenic Bacteria in a Greek ICU: A Comparative Trial M. Souli 1, A. Antoniadou 1, M. Droggari 1, I. Mavrou1, A. Antonopoulou1, G. Poulakou1, E. Papadomichelakis1, P. Efstathiou 2, H. Giamarellou 3, A. Armaganidis 1, G. Petrikkos 1; 1Univ. Gen. Hosp. ATTIKON, Chaidari, Greece, 2Hellenic Copper Dev. Inst., Athens, Greece, 3Hygeia Hosp., Marousi, Greece. K-246 Burden of Environmental Contamination by Pathogenic M. Souli1, A. Antoniadou 1, T. Panagea 1, G. Petrikkos 1, H. Giamarellou 2, A. Armaganidis 1; 1Univ. Gen. Hosp. ATTIKON, Chaidari, Greece, 2Hygeia Hosp., Marousi, Greece.

-----------------------------------------------------------------------022(K) Poster Session Prosthetic Joint Infections Presentations: K-247 Targeted Use of Vancomycin (VAN) Perioperative Prophylaxis

in Revision Total Knee Arthroplasty (RTKA) Reduces Surgical Site Infections (SSI) C. Liu, L. Block, A. Kakis A. Nichols, S. Takemoto, K. Bozic; Univ. of California, San Francisco, CA. K-248 Characteristics of Prosthetic Joint Infections Leading to

Bacteremia F. A. Dauchy 1, H. Dutronc 1, S. Lawson-Ayayi 2, P. Hofmann 1, T. Fabre 1, B. de Barbeyrac 1, M. Dupon1; 1Bordeaux Univ. Hosp., Bordeaux, France, 2 INSERM U897, ISPED, Bordeaux, France. K-249 Not Following the Surgical Zimmerli’S Algorithm in Patients

with Methicillin-Susceptible S. aureus Prosthetic Joint Infection (Hip and Knee) is a Risk Factor for Treatment Failure at LongTerm Follow Up 1

1

2

2

A. Bouaziz , I. Uçkay , S. Lustig , A. Boibieux , D. Lew , P. Hoffmeyer , P. Neyret 1, C. Chidiac 1, T. Ferry1; 1Hospices Civils de Lyon, Lyon, France, 2 Hosp. Univ. de Genève, Geneva, Switzerland. K-250 Infection and Functional Outcome of Hip and Knee Prosthet-

ic Joint Infection: A Retrospective Multicenter Study L. N. Walti1, C. Cattelan2, R. Baalbaki1, M. Veuthey 1, S. Meriem 1, O. Borens 1, A. Trampuz 1; 1Univ. Hosp., Lausanne, Switzerland, 2Univ. Hosp., Basel, Switzerland. K-251 Impact of Interdisciplinary Septic Unit: On Treatment

Outcome of Hip and Knee Prosthetic Joint Infection T. Tkhilaishvili, L. N. Walti, R. Balbaaki, M. Veuthey, S. Meriem, O. Borens, A. Trampuz; Univ. Hosp., Lausanne, Switzerland. K-252 Tissue Expander-Related Infections: Perioperative and

Empiric Antimicrobial Therapy G. M. Viola, K. V. Rolston, D. P. Baumann; MD Anderson Cancer Ctr., Houston, TX. K-253 Microbiological Markers Suggesting High Inoculum Size

at Time of Surgery are Risk Factors for Relapse in Patients with Methicillin-Susceptible or -Resistant S. aureus Prosthetic Joint Infection

52

September 9-12 |

Arthroplasties (ITHA): Differences in Clinical Characteristics and Prognosis J. Lora-T, G. Euba, O. Murillo, A. Ribera, S. Pedrero, F. Tubau, M. Pujol, X. Cabo, J. Ariza; Hosp. U Bellvitge, Barcelone, Spain.

Background Comparison Between Nasal Carriage and Prosthetic Joint Infection Isolates G. G. Aubin1,2, C. Lasserre 1,2, N. Caroff 2, D. Lepelletier 1,2, A. Reynaud 1,2, J. Lavigne. 3, S. Corvec 1,2; 1Nantes Univ. Hosp., Nantes, France, 2Med. Sch., Nantes, France, 3Montpellier Univ., Nîmes, France. K-256 Acute Prosthetic Joint Infections (PJI): Current Etiology,

Treatment, Outcome and Functional Results N. Benito, M. Franco, M. Jordán, V. Pomar, J. López-Contreras, P. Coll, J. Monllau, M. Gurguí; Hosp. de la Santa Creu i Sant Pau, Barcelona, Spain. K-257 Risk Factors Associated with Unfavorable Clinical Outcome


2

K-254 Infected Hip Hemiarthroplasties (IHHA) and Total Hip

K-255 Methicillin-Susceptible Staphylococcus aureus ST398: Genetic

Bacteria in an ICU Setting

1

A. Bouaziz 1, I. Uçkay 2, S. Lustig 1, A. Boibieux 1, D. Lew 2, P. Hoffmeyer 2, P. Neyret 1, C. Chidiac 1, T. Ferry1; 1Hospices Civils de Lyon, Lyon, France, 2 Hosp. Univ. de Genève, Geneva, Switzerland.

(UCO) During Hospitalization for Initial Treatment of Primary Total Hip Arthroplasty Infection (PHAI) in Brazil J. A. Matos, C. A. S. Schmaltz, N. M. Mesquita, I. Barauna, J. H. Carijó, R. W. Beranger; Inst. Nacional de Traumatologia e Ortopedia, Rio de Janeiro, Brazil. K-258 Prosthetic Joint Infection (PJI) Should be Considered in

Prosthetic Failure Within 2 Years of Implantation M. E. Portillo1, A. Alier 2, S. Martinez 2, L. Sorli 2, J. Horcajada 2, M. Salvado 1, L. Puig 2; 1Reference Lab. of Catalunya, Barcelona, Spain, 2Hosp. del Mar, Barcelona, Spain.

-----------------------------------------------------------------------023(K) Poster Session Surgical Site Infections Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: K-259 Characterizing Staphylococcus aureus Infections Following

Elective Surgeries in U.S. Hospitals H. Yu, J. Mardekian, D. Strutton, D. Girgenti; Pfizer, Inc., Collegeville, PA. K-260 Utilising Routine Electronic Data to Develop Syndromic Sur-

veillance of Surgical Site Infections in Coronary Artery Bypass Graft Patients Withdrawn K-261 Microbiology of Postoperative Spine Infections: A Retrospec-

tive Study of 239 Cases C. Liu, A. Abdul-Jabbar, S. Takemoto, S. Hu, S. Berven; Univ. of California, San Francisco, CA. K-262 Surgical-Site Infections Following Gender Reassignment

Surgeries J. J. Zhao, D. Marchaim, M. Palla, K. Hayakawa, R. Tansek, J. Moshos, A. Muthusamy, H. Kotra, P. R. Lephart, A. N. Wilson, K. S. Kaye; Wayne State Univ., Detroit, MI.

SUNDAY SCIENTIFIC SESSIONS K-263 Risk Factors for Abdominal Prosthetic Aortic Graft Infections

(APAGI) M. Kestler, P. Gijón, M. Izquierdo, A. Apodaka, T. Cervera, E. Bouza; Hosp. G. U. Gregorio Marañon., Univ. of Madrid, Madrid, Spain. K-264 A Prospective Study to Determine the Incidence and Micro-

bial Etiology of Surgical Site Infections at a Private Hospital in Mumbai, India Withdrawn K-265 Rapidly Growing Mycobacterial Infections Complicating

K-273 Characteristics of Enterococcus Species Isolated from Patients

at a Solid Organ Transplant Unit in a Tertiary Care University Hospital Between 2000 and 2011 G. Tulliano, P. M. Tierno, L. W. Teperman, R. A. Press, A. Safdar; New York Univ. Sch. of Med. and Langone Med. Ctr., New York, NY. K-274 An Analysis of the Use of Ampicillin for Urinary Tract Infec-

tions Caused by Vancomycin-Resistant Enterococcus J. Shultz 1, K. Klinker1, S. Borgert 1, R. Ramphal 2; 1Shands at the Univ. of Florida, Gainesville, FL, 2Univ. of Florida, Gainesville, FL. K-275 High-Dose Daptomycin for Treatment of Enterococcal Infec-

Laparoscopic Adjustable Gastric Banding D. G. McLellan1, S. Watson 2, J. Dyer 1, V. D’Abrera 2; 1Fremantle Hosp., Fremantle, Australia, 2St. John of God Healthcare Murdoch, Perth, Australia. K-266 Emergence of a Dominant Healthcare-Associated Clone of

Mycobacterium abscessus subsp. bolletii at a Medical Center A. Cheng, H. Sun, Y. Chuang, S. C. Chang, Y. C. Chen; Natl. Taiwan Univ. Hosp. and Far Eastern Mem. Hosp., Taipei, Taiwan. K-267 Success in Preventing Staphylococcus aureus Mediastinitis after

Coronary By-Pass Surgery

tions: Multicenter, Retrospective Study A. M. Casapao 1, S. L. Davis 1, D. P. Levine 2, J. J. Zhao 2, B. A. Potoski 3, D. A. Goff 4, C. W. Crank 5, J. Segreti 5, G. Sakoulas 6, S. E. Cosgrove 7, M. J. Rybak 1; 1Wayne State Univ., Anti-Infective Res. Lab., Detroit, MI, 2Detroit Med. Ctr., Detroit, MI, 3Univ. of Pittsburgh, Pittsburgh, PA, 4Ohio State Univ., Columbus, OH, 5Rush Univ., Chicago, IL, 6Univ. of California, La Jolla, CA, 7Johns Hopkins, Baltimore, MD. K-276 Daptomycin (D) with or without Concomitant Beta-lactams

(BL) for Vancomycin-Resistant Enterococcus (VRE) Bacteremia

J. Chapplain, M. Revest, E. Flecher, P. Donnio, C. Michelet, A. Leguerrier; Rennes Univ. Hosp., Rennes, France. K-268 Surgical Site Infection Surveillance of Esophageal and Lung

Cancer in Thoracic Surgery

P. A. Moise1, K. C. Lamp 1, D. D. DePestel 1, M. J. Yoon 1, M. Zervos 2 1 ; Cubist Pharmaceuticals, Lexington, MA, 2Henry Ford Hlth. System, Detroit, MI. K-277 Daptomycin Experience for Enterococcal Endocarditis

H. Xu, W. Li, Y. Wang, Q. Zhu, L. Jia, A. M. Gu; Provincial Hosp. Affiliated to Shandong Univ., Jinan, China. K-269 Effects of Antimicrobial-Coated Sutures in Reducing Surgical

Site Infection: A Meta-Analysis of Randomized Controlled Trials Q. Zhou1, X. Gao 2, B. Hu 2; 1Zhongshan Hosp., Fudan Univ., Shanghai, China, 2Zhongshan Hosp., Fudan Univ., Need, China.

J. C. Gallagher 1, P. White 2, J. Kishel 2, T. Chung 2; 1Temple Univ. Sch. of Pharmacy, Philadelphia, PA, 2Cubist Pharmaceuticals, Lexington, MA. K-278 Identification of Risk Factors Associated with the Develop-

ment of Daptomycin Nonsusceptible Enterococcus A. M. Pavell 1,2, C. W. Crank 1, S. Wang 1,2, K. S. Singh 1; 1Rush Univ. Med. Ctr., Chicago, IL, 2Midwestern Univ., Downers Grove, IL.

-----------------------------------------------------------------------024(K) Poster Session

K-279 Reduced Daptomycin Susceptibility (MIC 3-4 mcg/ml)

Vancomyoin-Resistant Enterococci

K-280 Case Series of Daptomycin Nonsusceptible Enterococcus

Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: K-270 Incidence of and Risk Factors for Patients in Intensive Care

Units to Acquire Infection or Colonization of Vancomycin-Resistant Enterococci S. Pan, J. Wang, Y. Chen, S. Chang; Natl. Taiwan Univ. Hosp., Taipei, Taiwan. K-271 De-Escalation of Broad Spectrum Antibiotics in Enterococcal

Among Vancomycin-Resistant Enterococci Blood-Stream Isolates N. Pettit, B. Brielmaier, J. Pisano, E. Landon; Univ. of Chicago Med. Ctr., Chicago, IL.

Urinary Tract Infections in a Tertiary Center T. Kelesidis1, S. Tsiodras 2, R. Humphries1; 1UCLA, Los Angeles, CA 2Univ. of Athens Med Sch., Athens, Greece. K-281 Selection of Vancomycin Resistance from vanA-Containing

Enterococcus faecium Susceptible to Vancomycin A. Loughborough1, B. M. Willey 1,2, M. Kissoon 1, S. Patel 3,4, A. McGeer 1,4, D. E. Low 1,4,2, S. M. Poutanen 1,2,4; 1Mount Sinai Hosp., Toronto, Canada, 2 Univ. Hlth. Network, Toronto, Canada, 3Publ. Hlth. Ontario, Toronto, Canada, 4Univ. of Toronto, Toronto, Canada.

Bloodstream Infections According to VRE Colonization E. Short1, M. Griffith 2,1, J. Esterly 1,3, M. Postelnick 1; 1Northwestern Mem. Hosp., Chicago, IL, 2Midwestern Univ., Downers Grove, IL, 3Chicago State Univ., Chicago, IL. K-272 The Impact of Different Antimicrobial Therapies on Clini-

cal and Fiscal Outcomes of Patients with Bacteremia Due to Vancomycin-Resistant Enterococci K. Hayakawa, D. Marchaim, U. M. Gudur, D. Dalle, K. Alshabani, S. Mohin, F. Jaydev, P. R. Sundaragiri, P. Bathina, S. D. Rajuri, K. S. Muppavarapu, J. K. Khatri, P. R. Lephart, E. T. Martin, J. M. Pogue, M. J. Rybak, K. S. Kaye; Detroit Med. Ctr. (DMC), Wayne State Univ., Detroit, MI.

Final Program

53

> Sunday SCIENTIFIC SESSIONS -----------------------------------------------------------------------025(L1) Poster Session Antimicrobial Stewardship and OPAT Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: L1-282 Use of Conditional and Cumulative Susceptibility Reporting

to Improve Antibiotic Prescribing and Rates of Initial Appropriate Antibiotic Therapy S. C. Cheatham1, S. S. Utley 1, M. R. Fleming 2; 1St. Francis Health, Indianapolis, IN, 2Methodist Dallas Med. Ctr., Dallas, TX. L1-283 De-Escalation of Antibacterial Therapy in Urinary Tract

Infections: A Neglected Opportunity to Save Broad-Spectrum Agents E. Montassier, E. Duchene, J. Caillon, G. Potel, E. Batard; Univ. de Nantes, Nantes, France. L1-284 The Incidence of Antimicrobial Associated Adverse Events

During Outpatient Parenteral Antimicrobial Therapy (OPAT): A One Year Retrospective Review I. El Lakkis, J. Mackey, M. Albrecht, R. Jambeih, E. Ablah, M. Sandid, K. Konda, M. Assi; Univ. of Kansas Sch. of Med. Wichita, KS. L1-285 Antibiotic Consumption in the Emergency Department: A

10-Year Survey

L1-286 Antibiotic Algorithm Use in Sepsis: Adherence and Effective-

ness in the Emergency Department 1

1

1,2

1,3 1

T. C. Kam , A. M. Cook , J. L. Lock , W. E. Swigart , C. P. Bunce ; St. Vincent Hosp., Indianapolis, IN, 2St. Vincent Emergency Physicians, Inc., Indianapolis, IN, 3Infectious Disease of Indiana, Carmel, IN. L1-287 A Comparison of Ertapenem Versus Ceftriaxone for the

Treatment of Cellulitis in the OPAT Setting R. Santos 1, A. Mayhew 1, D. Andrews 2, A. L. Chapman 2, M. Torok3; 1 Cambridge Univ. Hosp. NHS Fndn. Trust, Cambridge, United Kingdom, 2 Royal Hallamshire Hosp., Sheffield, United Kingdom, 3Univ. of Cambridge, Cambridge, United Kingdom. L1-288 Outpatient Parenteral Antibiotic Therapy (OPAT): Experi-

ence from a UK Teaching Hospital S. V. Coggle1, E. Nickerson 1, T. Gouliouris 1, T. Corrah 1, A. Mayhew 1, R. Santos 1, S. H. Aliyu 1, A. J. Carmichael 1, M. E. Torok 2; 1Cambridge Univ. Hosp. NHS Fndn. Trust, Cambridge, United Kingdom, 2Univ. of Cambridge, Cambridge, United Kingdom.

-----------------------------------------------------------------------026(L1) Poster Session Respiratory Tract Infection Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations:

Diagnoses for CAP in Hospitalized Patients: Results from the European REACH Study F. Blasi 1, J. Garau2, J. Medina 3, M. Ávila 4, K. McBride 5, H. Ostermann6; 1 Univ.ersità degli Studi di Milano, Milan, Italy, 2Hosp. Univ.ersitari Mutua de Terrassa, Barcelona, Spain, 3AstraZeneca, Madrid, Spain, 4AstraZeneca Europe, Zaventem, Belgium, 5Instat Services, Inc., Chatham, NJ, 6Univ. Hosp. Munich, Munich, Germany. L1-291 Better Impact of Combination Therapy with Macrolides in

ICU Patients with Community-Acquired Pneumonia J. Y. Mootien, C. Fuchs, D. Narbey, M. Egard, P. Guiot; Hosp E. Muller, Mulhouse, France. L1-292 Clinical Response Rate at Day 4 of Therapy in Hospitalized

Adult Patients with Community-Acquired Bacterial Pneumonia (CABP): An Interim Analysis of a Chart Review Study R. Luo 1, C. B. Lipkin 1, F. R. Ernst 1, X. Huang 2; 1Premier, Charlotte, NC, 2 Forest Res. Inst., Jersey City, NJ. L1-293 Rainfall is a Risk Factor for Legionella pneumophila Pneumo-

nia M. Labori, C. Garcia-Vidal, D. Viasus, L. Molero, D. Garcia-Somoza, J. Dorca, F. Gudiol , J. Carratala; Hosp. Univ. de Bellvitge, Barcelona, Spain.

center, Comparative Study of Zabofloxacin vs Moxifloxacin in the Treatment of Mild to Moderate Community-Acquired Pneumonia D. Choi1, Y. S. Kim 2, M. J. Kim 3, K. R. Back 4, C. H. Lim 1, J. A. Rock 5, S. K. Seoung 1; 1Dong-Wha Pharm., Yongin-si, Gyunggi-do, Korea, Republic of, 2Asan Med. Ctr., Pungnap 2-dong, Songpa-gu, Seoul, Korea, Republic of, 3 Korea Univ. Anam Hosp., Anam-Dong 5-Ga, Seongbuk-Gu, Seoul, Korea, Republic of, 4Samsung Med. Ctr., Irwon-dong, Gangnam-gu, Seoul, Korea, Republic of, 5IASO Pharma Inc., San Diego, CA. L1-295 Is it Possible to Identify Legionella pneumophila Pneumonia

from Initial Presentation on Emergency Room? C. Garcia-Vidal, D. Viasus, M. Labori, L. Molero, D. Garcia-Somoza, J. Dorca, F. Gudiol , J. Carratala; Hosp. Univ. De Bellvitge, Barcelona, Spain. L1-296 Dichotomy between In Vitro Activity and Clinical Outcome:

Does Azithromycin (AZM) Demonstrate Clinical Efficacy in Macrolides Resistant Pneumococcal Pneumonia? K. Tateda, S. Kohno, M. Nagashima; AZM Studies Data Review Committee, Tokyo, Japan. L1-297 The Impact of Statins on the Incidence of Bacteremia and

Pneumonia in Military Personnel K. R. Daniels1, I. A. Mansi 2, J. P. Magulick 2, C. U. Oramasionwu3, E. M. Mortensen 4, M. V. Pugh 5, C. R. Frei 1; 1UT Austin & UT Hlth. Sci. Ctr., San Antonio, TX, 2San Antonio Military Med. Ctr., San Antonio, TX, 3Univ. North Carolina, Chapel Hill, NC, 4UT Southwestern, Dallas, TX, 5VERDICT, South TX Vet. Hlth. Care Syst, San Antonio, TX. L1-298 Usefulness of IDSA/ATS Guidelines Recommendations for

Diagnostic Testing in Community-Acquired Pneumonia

L1-289 In Routine Hospital Practice: Ertapenem in Comparison with

Other Parenteral Antibiotics in the Treatment of CommunityAcquired Pneumonia

54

L1-290 Inter-Country Differences in Microbiological Testing and

L1-294 A Phase 2, Multi-Dose, Double-Blind, Randomized, Multi-

E. Montassier, D. Navas, N. Goffinet, C. Gras-Le Guen, G. Potel, E. Batard; Ctr. Hosp. Univ. de Nantes, Nantes, France.

1

C. Hidalgo Tenorio, C. Santiago, A. Fernandez, C. Gil, V. Sotorrio, I. Sanchez, C. Merin, A. Caballero, R. Javier, J. Pasquau Liaño; Univ. Hosp Virgen de las Nieves, Granada, Spain.

September 9-12 |

D. Viasus, C. Garcia-Vidal, J. Dorca, F. Gudiol, J. Carratalà; Hosp. de Bellvitge - IDIBELL, Univ. of Barcelona, L`Hosp. de Llobregat, Barcelona, Spain.

SUNDAY SCIENTIFIC SESSIONS L1-299 A Randomized Comparative Study of 7-Days Courses of

L2-306 Vaginitis Co-Infections Based on DNA Homology: 2 Yrs

Fuzafungine vs. Fuzafungine and Clarithromycin in Patients with Acute Laryngitis V. V. Rafalskiy1, A. S. Gurevitch 2, I. V. Otvagin 1, E. V. Dovgan 1; 1Smolensk State Med. Academy, Smolensk, Russian Federation, 2Bryansk Clinical and Diagnostic Ctr., Bryansk, Russian Federation. L1-300 Effect of LactoBacillus Rhamnosus LGG and Bifidobacterium

Experience at a Tertiary Medical Center A. Bhargava1, R. Mitchell 2, T. Painter 2, P. Lephart 2, A. Salimnia 1, N. Balic 1, M. Fairfax 1, H. Salimnia 2, J. Sobel 1; 1WSU, Detroit, MI, 2Detroit Med. Ctr. Univ. Lab., Detroit, MI. L2-307 Epidemiology of Genital Varicella Zoster and Herpes Simplex

Viruses

animalis ssp Lactis BB-12 on Health-Related Quality of Life in College Students with Upper Respiratory Infections

K. Choong1, C. Henderson 2, J. M. Robson 2; 1Nambour Hosp., Nambour, Australia, 2Sullivan Nicolaides Pathology, Brisbane, Australia.

T. J. Smith, D. Rigassio-Radler, R. Denmark, R. Touger-Decker; Univ. of Med. and Dentistry of New Jersey, Newark, NJ.

L2-308 Genetic and Molecular Epidemiologic Correlates of Cephalo-

Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------027(L2) Poster Session Studies in Sexually Transmitted Infection Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: L2-301 Prevalence and Correlates of Vaccine-Preventable Anal Hu-

man Papillomavirus Genotypes in Australian Homosexual Men 1

2

1

1

1

D. J. Templeton , S. N. Tabrizi , D. A. Machalek , F. Jin , I. M. Poynten , T. Tabone 2, S. M. Garland 2, R. J. Hillman 3, C. K. Fairley 2, J. Roberts 4, A. Farnsworth 4, A. E. Grulich 1, on behalf of the SPANC Research Team; 1 Kirby Inst., Univ. of New South Wales, Sydney, Australia, 2Univ. of Melbourne, Melbourne, Australia, 3Univ. of Sydney, Sydney, Australia, 4Douglass Hanly Moir, Sydney, Australia. L2-302 Oropharyngeal Squamous Cell Carcinoma and Human

Papillomavirus-Associated Cancers in Women J. Guillet 1, S. Bevilacqua2, P. Bravetti 3, J. Merlin 4, T. May 2, G. Dolivet 1; 1 Ctr. Alexis Vautrin, Vandoeuvre Les Nancy, France, 2CHU Nancy, Vandoeuvre Les Nancy, France, 3Faculté d’Odontologie, Nancy, France, 4Faculté Pharmacie, Nancy, France.

sporin Resistance in Neisseria gonorrhoeae, California 2011 S. Gose1, C. J. Kong 2, S. Guerry 3, M. Pandori 4; 1Univ. of California, Berkeley, Berkeley, CA, 2California Dept. of Publ. Health, Richmond, CA, 3 Los Angeles Dept. of Publ. Health, Los Angeles, CA, 4San Francisco Dept. of Publ. Health, San Francisco, CA. L2-309 Molecular Epidemiology of Chlamydia trachomatis Infection

Among Clients Seeking Voluntary Counseling and Testing for HIV in Taiwan P. Wu1, C. Yang 2, S. Chang 3, W. Liu 1, C. Hung, MSc 1; 1Natl. Taiwan Univ. Hosp., Taipei, Taiwan, 2Far Eastern Mem. Hosp., New Taipei City, Taiwan, 3 Natl. Taiwan Univ. Coll. of Med., Taipei, Taiwan. L2-310 Effect of Sexual Intercourse on Vaginal Microbiome of Infer-

tile Couples’ Women (Data of Illumina Sequencing) R. Mändar1,2, J. Truu 1,2, N. Borovkova 1,2, M. Punab 1,2,3; 1Univ. of Tartu, Tartu, Estonia, 2Competence Ctr. on Reproductive Med. and Biology, Tartu, Estonia, 3Tartu Univ. Hosp., Tartu, Estonia.

-----------------------------------------------------------------------028(M) Poster Session Fungal Epidemiology Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations:

L2-303 Antimicrobial Susceptibility and Molecular Characterization

M-311 Antifungal Susceptibility Profile and Predominance of Non-

of Neisseria gonorrhoeae Strains Isolated in 2011 from Barcelona, Spain

Candida albicans Isolates in Bloodstream Yeasts Isolated from Peruvian Patients

J. Serra 1, G. Roig 2, R. Juve 3, J. Gonzalez-Lopez1, C. Paz, Technician 1, D. Viu, Technician 1, A. Andreuer 1, M. Barberà 4; 1Hosp. Vall d’Hebron, Barcelona, Spain, 2Manso Primary Care Ctr., Barcelona, Spain, 3Manso Primary Care Ctr. 2, Barcelona, Spain, 4Sexually Transmitted Infectious Unit, Barcelona, Spain.

B. Bustamante 1, M. A. Martins 2, L. X. Bonfietti 2, M. W. Szeszs 2, J. Jacobs 3, M. S. C. Melhemer2; 1I Tropical Alexander von Humboldt-Univ. Peruana Cayetano Heredia, Lima, Peru, 2Instituto Adolfo Lutz, Sao Paulo, Brazil, 3Central Lab. of Clinical Biology, Dept. of Clinical Sci. Tropical Prince Leopold,, Amberes, Belgium.

L2-304 Evaluation of HPV Infection in Adolescent Girls Aged 13-19

M-312 Increase of Candidemia Due to Non-albicans Candida Species

Years

in Oncohematological (OH) Patients in Spain

S. Esposito1, E. Tanzi 2, V. Montinaro 1, S. Bosari 1, P. Bertuccio, BSc 3, G. Rizzardini 4, G. Tisi 5, M. Tinelli 6, N. Manca 7, M. Gramegna 8, G. Orlando 4, Valhidate Study Group; 1Fondazione IRCCS Policlinico, Univ. degli Studi di Milano, Milan, Italy, 2Univ. Milan, Milan, Italy, 3Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, 4Infectious Diseases II, L. Sacco Univ. Hosp, Milan, Italy, 5Gynecol Oncol Unit, Univ. of Brescia, Brescia, Italy, 6Infect Dis Unit, Lodi Hosp, Lodi, Italy, 7Microbiol Unit, Brescia, Italy, 8 Hlth. Gen. Director, Regione Lombardia, Milan, Italy.

I. Ruiz-Camps, Mireia Puig, Patricia Muñoz, Mario Fernández-Ruiz, Alberto Delgado-Iribarren, Maricela Valerio, José M Aguado; on behalf of CANDIPOP Project, GEIH-GEMICOMED (SEIMC) and REIPI., Barcelona, Spain.

L2-305 Once a Day Versus Twice a Day Sitafloxacin (STFX) for

Microbiological Cure of Women with Cervicitis by Chlamydia trachomatis

M-313 The Epidemiology of Nosocomial Candidemia in Nonneutro-

penic, Nonintensive Care-Based Patients A. T. L. Ong1, C. C. Blyth 2, E. G. Playford 3, S. C. Chen 1, T. C. Sorrell 1; 1 Westmead Hosp., Sydney, Australia, 2Univ. of Western Australia, Sydney, Australia, 3Princess Alexandra Hosp., Brisbane, Australia.

H. Mikamo, Y. Yamagishi; Aichi Med. Univ., Aichi, Japan.

Final Program

55

> Sunday SCIENTIFIC SESSIONS M-314 Geographic Distribution and Co-Morbidities of Cryptococcal

Trichosporonemia: Result Epidemiological Study in Japan

V. Pyrgos, A. E. Seitz , R. Prevots, P. R. Williamson; NIH, Bethesda, MD.

I. Tokimatsu, H. Kushima, S. Toba, J. Kadota, Japan Trichosporonosis Study Group; Oita Univ. Faculty of Med., Yufu, Japan.

M-315 Electronic Surveillance of Invasive Fungal Diseases in Hema-

tology-Oncology Patients Using Natural Language Processing of Computed Tomography Reports: Towards Real-Time Prospective Surveillance

M-325 Risk Factors and Epidemiology of Candidemia by Candida

M. Ananda-Rajah1, D. Martinez 2, H. Suominen 3, K. Thursky, FRACP 4, M. Slavin, FRACP 4, L. Cavedon 2; 1Alfred Hlth., Melbourne, Australia, 2 NICTA, Melbourne, Australia, 3NICTA, Canberra, Australia, 4Melbourne Hlth., Melbourne, Australia.

M-326 The Defined Daily Dose (DDD) of Micafungin Usage Didn’t

M-316 Molecular Epidemiology and Fluconazole Susceptibility of

Candida glabrata Candidemia at a University Affiliated Medical Center N. D. Beyda1,2, A. Kilic Scientist 1, M. J. Alam 1, T. M. Lasco 2, K. W. Garey 1,2; 1 Univ. of Houston Coll. of Pharmacy, Houston, TX, 2St. Luke’s Episcopal Hosp., Houston, TX. M-317 Candidemia in Internal Medicine Wards (iIMW): Epidemiol-

ogy, Time to Initiate Antifungal Treatment and Outcome M. Bassetti1, E. Righi 1, E. Nicco 2, L. Taramasso 2, C. Viscoli 2; 1Santa Maria Misericordia Hosp., Udine, Italy, 2San Martino Hosp., Genova, Italy. M-318 National Surveillance of Fungemia in Denmark 2010-11 M. C. Arendrup, Danish Fungaemia Study Group; Statens Serum Inst., Copenhagen, Denmark. M-319 Continued Increase of Azole Resistance in Aspergillus fumiga-

guilliermondii Y. Yamagishi, H. Mikamo; Aichi Med. Univ., Aichi, Japan.

Affect Incidence of Candida parapsilosis Candidemia at Tertiary Hospital in Japan Y. Hirai, S. Asahata, Y. Ainoda, H. Konishi, K. Okada, T. Fujita, K. Totsuka; Tokyo Women’s Med. Univ., Tokyo, Japan. M-327 Species Distribution and Susceptibility Profile of Yeasts

Isolated from Blood Cultures: Preliminary Results of a Multicenter Study for Latin America S. Córdoba 1, M. Melhem 2, M. Dolande 3, A. Puimé 4, G. Martínez 5, S. Zurita 6, M. Cuenca-Estrella 7, J. Rodríguez-Tudela 7, J. Gabastou 8, RLN; 1 INEI, Buenos Aires, Argentina, 2IAL, SP, Brazil, 3INHRR, Caracas, Venezuela, Bolivarian Republic of, 4DLSP, Montevideo, Uruguay, 5IPK, LH, Cuba, 6INS, Lima, Peru, 7ISC III, Majadahonda, Spain, 8PAHO, SJO, Trinidad and Tobago. M-328 Investigation on Isolation of Trichosporon Species in Clinical

Practice Y. Yamagishi1, N. Kawasumi 1, M. Hagihara 1, T. Sugita 2, H. Mikamo 1; 1 Aichi Med. Univ., Aichi, Japan, 2Meiji Pharmaceutical Univ., Tokyo, Japan. M-329 Effect of Statin Use on the Outcomes of Adults with

tus (Af ) in Dutch Hospitals D. Versteeg, E. Snelders, T. Rijs, BSc - research, W. Melchers, P. Verweij; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands. M-320 Development of Resistance to Agricultural Azole Antifungal

Compounds: Emergence of Multidrug Cross-Resistance Among Human Fungal Pathogens Candida, Cryptococcus and Aspergillus I. Faria-Ramos 1, S. Farinha 1, P. Tavares 1, J. Maia 1, E. Ricardo 1,2, I. M. Miranda 1,2, C. Pina-Vaz 1,2,3, A. G. Rodrigues1,2,3; 1Univ. of Porto, Oporto, Portugal, 2Cardiovascular Res. & Dev. Unit, Faculty of Med., Univ. of Porto, Porto, Portugal, 3Hosp. S. João, Porto, Portugal. M-321 Population-Based Program of Aspergillus spp. Antifungal

Candidemia G. Cuervo, C. Garcia-Vidal, M. Nucci, F. Puchades, M. Fernandez-Ruiz, A. Mykietiuk, A. Manzur, C. Gudiol, J. Peman, J. Ayats, J. Carratala; Hosp. de Bellvitge, Barcelona, Spain. M-330 New CLSI Clinical Breakpoints (CBPs) and Epidemiological

Cutoff Values (ECVs) Applied to Characterize Resistance (R) in the SENTRY Antifungal Surveillance Program (2010-2011) M. A. Pfaller, S. A. Messer, R. N. Jones, M. Castanheira; JMI Lab., N Liberty, IA. M-331 In Vitro Activity of Isavuconazole against Cryptococcus

Resistance in Spain (FILPOP STUDY )

Isolates: A Pooled Analysis from 3 Studies

A. Alastruey-Izquierdo 1, E. Mellado 1, T. Pelaez 2, J. Peman 3, S. Zapico 4, M. Alvarez 5, M. Cuenca-Estrella1, FILPOP Study Group; 1Centro Nacional de Microbiologia, ISCIII, Majadahonda. Madrid, Spain, 2Hosp. Gregorio Marañón, Madrid, Spain, 3Hosp. La Fe, Valencia, Spain, 4Hosp. de Donostia, Guipuzcoa, Spain, 5Hosp. Central de Asturias, Oviedo, Spain.

J. I. Smart 1, M. E. Jones 2, L. L. Kovanda, N/A 1; 1Astellas Pharma Global Dev., Inc, Deerfield, IL, 2Basilea Pharmaceutica Intl. Ltd., Basel, Switzerland.

M-322 Epidemiology of Otomycosis in a Large Teaching Hospital

Over a 24-Year Period: Is There Any Difference Between Adult and Pediatric Patients? T. Peláez, S. Álvarez-Pérez, L. Alcalá, B. Gama, BSc, F. Romero, E. Bouza; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain. M-323 Emerging Trends in Candidemia by C. glabrata: A Better Out-

come in a Worse Setting Withdrawn

56

M-324 Influence of Voriconazole (VRC) on Survival Outcome of

Meningitis in the U.S., 1997-2009

September 9-12 |

M-332 In Vitro Activity of Isavuconazole against a Worldwide Col-

lection of 237 Aspergillus Section Terrei Isolates and Compared with 7 Other Aspergillus Active Antifungal Drugs Tested with EUCAST and CLSI Methodology J. F. Meisant1,2, J. W. Mouton 2, J. P. Bouchara 3, A. Chakrabarti 4, P. Gaustad 5, J. V. Guinea-Ortega 6, J. Houbraken 7, R. A. Samson 7, K. Grif 8, C. Lass-Floerl 9, C. H. Klaassen 1; 1Canisius-Wilhelmina Hosp., Nijmegen, Netherlands, 2Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 3 Univ. Angers, Angers, France, 4Postgrad. Inst. Med.Res., Chandigarh, India, 5 Univ. Hosp. Oslo, Oslo, Norway, 6Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain, 7CBS-KNAW Fungal Biodiversity Ctr., Utrecht, Netherlands, 8Med. Univ. Innsbruck, Innsbruck, Austria, 9Med. Univ. Innsbruck, Innsbruck, Austria.

SUNDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------029(T, V) Poster Session

M-333 Absence of Pneumocystis DHPS Mutants in Brittany,

Western France S. Le Gal 1, F. Gangneux 2, C. Damiani 3, M. Virmaux 1, A. Totet 3, J. Gangneux 2, G. Nevez1; 1Univ. de Brest, Brest, France, 2Univ. de Rennes, Rennes, France, 3Univ. de Picardie, Amiens, France.

Infections in Transplant Recipients: Viruses and Fungi

M-334 In Vitro Activity of Micafungin Compared with Five other


Antifungal Agents against 273 Prospectively Collected Clinical Aspergillus Isolates from The Netherlands

Presentations:

I. Curfs 1, P. J. Haas. PhD 2, M. Wolfhagen 3, K. Verduin 4, C. Bens 1, C. H. Klaassen 1, J. F. Meis1,5, Dutch Mica Study Group; 1Canisius-Wilhelmina Hosp., Nijmegen, Netherlands, 2Univ. Med. Ctr. Utrecht, Utrecht, Netherlands, 3Isala Hosp., Zwolle, Netherlands, 4PAMM, Veldhoven, Netherlands, 5 Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.

promised Patients, Azole Resistant Clinical and Environmental Isolates for Aspergillus Fumigatus Cyp51A Key Mutations Using Sensitive PCR Assays and Consecutive DNA Sequence Analysis 1

2

3

3

4

B. Spiess , M. Reinwald , S. J. Howard , U. Gross , O. Bader , P. M. Rath , W. Seifarth1, S. Will, TA 1, M. Lauten 5, W. K. Hofmann 1, D. Buchheidt 1; 1 Mannheim Univ. Hosp., 3rd Dept. of Internal Med., Mannheim, Germany, 2 Univ. of Liverpool, Translational Med., Liverpool, United Kingdom, 3Inst. of Med. Microbiol., Göttingen Univ. Hosp., Göttingen, Germany, 4Inst. of Med. Microbiol., Essen Univ. Hosp., Essen, Germany, 5Pediatric Hematology and Oncology, Univ. Hosp. Schleswig-Holstein, Campus Lübeck, Lübeck, Germany. M-336 Molecular Epidemiology of Cryptococcosis in Thailand Re-

vealed a Greater Genetic Diversity as Known Previously and the Presence of the Low Virulent Vancouver Island Outbreak C. gattii Genotype VGIIb P. Ngamskulrungroj 1, A. Chindamporn 2, A. Chaiprasert 1, N. Poonwan 3, W. Meyer 4; 1Faculty of Med. Siriraj Hosp. Mahidol Univ., Bangkok, Thailand, 2 Mycology Lab., Faculty of Med., Chulalongkorn Univ., Bangkok, Thailand, Bangkok, Thailand, 3Mycology Lab., NIH, Nonthaburi, Thailand, Bangkok, Thailand, 4Molecular Mycology Lab., CIDM, Westmead Millennium Inst., Sydney Med. Sch.- Westmead Hosp., The Univ. of Sydney, Westmead, NSW, Australia, Westmead, Australia. M-337 Airway Invasive Pulmonary Aspergillosis (IPA) vs Angio-IPA

Have Distinct Risk Factors and Outcomes in Lung Transplant Recipients N. Singh 1, M. Wagener 1, J. Suarez 2, R. Avery 3, C. Lass Floerl 4, A. C. Pasqualotto 5, G. M. Lyon 6, M. Barron 7, S. Husain - 8, J. G. Montoya 2; 1 UPitt, Pitt, PA, 2Stanford, PaloAlto, CA, 3CCF, Cleveland, OH, 4 U Innsbruck, Innsbruck, Austria, 5UFCSPA, PortoAlegre, Brazil, 6Emory U, Atlanta, GA, 7U CO, Denver, CO, 8UHN, Toronto, Canada. M-338 Fungiscope: A Global Database for Emerging Fungal Infections M. J. Vehreschild 1, K. Wahlers1, A. Hamprecht 1, G. Fischer 2, S. de Hoog 3, J. Vehreschild 1, M. Karthaus 4, O. A. Cornely 1, The Fungiscope ECMM/ ISHAM Working Group; 1Univ. Hosp. Cologne, Koeln, Germany, 2Hlth. Authorities, Stuttgart, Germany, 3CBS, Utrecht, Netherlands, 4Klin. Neuperlach, Munich, Germany. M-339 Patterns and Dynamics of Colonization with Candida spp. in

the Neonatal Intensive Care Unit (NICU) E. Leibovitz, T. Taraboulos-Klein, I. Livshiz-Riven, A. Borer, E. Shani, A. Golan; Ben-Gurion Univ., Beer-Sheva, Israel.

Risk Transplant Recipients: Data from RESITRA-REIPI Cohort Y. Meije, J. Aguado, A. Moreno, J. Gavaldá, J. Cisneros, M. Gurguí, J. Carratalá, P. Muñoz, M. Montejo, M. Blanes, G. Bou, J. Pérez, J. TorreCisneros, A. Ramos, A. Pahissa, J. Fortún; GESITRA-REIPI, Spain, Spain. T-341 Plasma Exchange (PE) Therapy (Rituximab Apheresis) for

M-335 Investigation of Primary Clinical Samples of Immunocom-

1

T-340 Universal Prophylaxis vs Pre-Emptive Therapy in CMV High

Rituximab (R) Induced Progressive Multifocal Leukoencephalopathy (PML) in Hematologic Disorders A. Burchardt1, S. Wienzek-Lischka 2, H. Hackstein2, M. Rummel1; 1Hosp. of Justus-Liebieg Univ., Giessen, Germany, 2Transfusion Med., Justus-Liebieg Univ., Giessen, Germany. T-342 Central Nervous System Infections Due to Herpes Simplex

and Varicella-Zoster Viruses in Natalizumab-Treated Patients: Post-Market Data from the FDA Adverse Event Reporting System A. Fine, A. Sorbello; U.S. FDA., Silver Spring, MD. T-343 Fungal Infections in Solid Organ Transplant Recipients in the

Swiss Transplant Cohort Study T. Lecompte 1, C. Garzoni 2, N. Mueller 3, G. Kralidis 4, O. Manuel 5, M. Weiser 4, C. Berger 3, K. Boggian 6, P. Meylan 5, H. Hirsch 4, D. Vu-Cantero 1, C. Van Delden1, STCS; 1Univ. Hosp., Geneva, Switzerland, 2Clinica Luganese, Lugano, Switzerland, 3Univ. Hosp., Zurich, Switzerland, 4Univ. Hosp., Basel, Switzerland, 5Univ. Hosp., Lausanne, Switzerland, 6Cantonal Hosp., St. Gallen, Switzerland. T-344 Incidence of Invasive Fungal Infections in Pediatric Hematol-

ogy and Oncology Patients in Period 2002 - 2010 V. Chrenkova1, P. Hubacek, Ph.D. 2, P. Sedlacek 2, P. Keslova 2, E. Kabickova 2, E. Mejstrikova 2, V. Smelhaus 2, E. Bebrova 2, O. Nyc 2, J. Stary 2; 1Motol Univ. Hosp., Prague, Czech Republic, 2Charles Univ. 2nd Faculty of Med. and Motol Univ. Hosp., Prague, Czech Republic. T-345 Cryptococcus gattii Infection in Solid Organ Transplant

Recipients: Clinical Characteristics and Outcomes P. Bhalla, D.O. 1, E. E. DeBess, DVM, MPVM 2, L. N. Fitzgibbons, M.D. 3, K. L. Winthrop 1, G. N. Forrest 1, P. R. Cieslak 2; 1Oregon Hlth. & Sci. Univ., Portland, OR, 2Oregon Hlth. Authority, Publ. Hlth. Div., Portland, OR, 3Kaiser Sacramento Med. Ctr., Northern California Kaiser Permanente, Sacramento, CA. T-346 Posaconazole (POS) Serum Troughs, Clinical Responses and

Tolerance among Cardiothoracic Transplant Patients (CT pts) R. K. Shields, M. H. Nguyen, E. J. Kwak, F. P. Silveira, C. J. Clancy; Univ. of Pittsburgh, Pittsburgh, PA. T-347 Diagnosis of Invasive Aspergillosis and Mucormycosis Guided

by PCR Assays from Bronchoalveolar Lavage Fluid in Allogenic Stem Cell Recipients H. Lellek 1, R. Bialek 2, H.Rohde, H.J.Baumann, H.K.Klose, S.Kluge, N.Kröger, H. Rohde 1, H. Baumann 1, H. Klose 1, S. Kluge 1, N. Kröger 1; 1 Univ. Hosp. Hamburg-Eppendorf, Hamburg, Germany, 2Labor Dr Krause, Hamburg, Germany.

Final Program

57

> Sunday SCIENTIFIC SESSIONS T-348 Diseases Due to Scedosporium in the First Year Following

Posthematopoietic Cell Transplantation (HCT) is Associated with Significant Morbidity and Resource Utilization

L. Johnson, R. K. Shields, C. Clancy; Univ. of Pittsburgh, Pittsburgh, PA.

H. Mommeja-Marin, S. Godkin, T. Brundage, W. Painter, D. Margolskee; Chimerix, Durham, NC.

T-349 The Epidemiology and Outcomes of Candidemia in Hemato-

T-359 Impact of Adjuvanted Pandemic (H1N1) 2009 Influenza Vac-

poietic Cell Transplantation L. Gold J. Kriengkauykiat, B. Tegtmeier, S. Dadwal, J. Ito; City of Hope, Duarte, CA. T-350 Posaconazole (PCZ) Serum Levels for Treatment (Tx) and

Prophylaxis (Px) in Immunocompromised Patients M. Rhee1, J. Ito 2, S. Dadwal 2, B. Tegtmeier 2, J. Kriengkauykiat 2; 1Western Univ. of Hlth. Sci., Pomona, CA, 2City of Hope, Duarte, CA. T-351 Human Herpesvirus Type-6 (HHV6) Reactivation in Patients

(pts) with Unrelated Donor Hematopoietic Cell Transplantation (HCT): Comparison of Outcomes amongst Treated and Untreated T. Bui, J. Kriengkauykiat, J. Ito, B. Tegtmeier, S. Dadwal; City of Hope, Duarte, CA. T-352 Chronic High EBV Load Carriage Has Low Predictive Value

to Detect Post-Transplant Lymphoproliferative Disorder (PTLD) in Solid-Organ Transplant Recipients C. Gardiol, P. Meylan, M. Pascual, O. Manuel; Univ. Hosp. Ctr. of Lausanne, Lausanne, Switzerland. T-353 The Molecular Epidemiology of a Respiratory Syncytial Virus

Outbreak Among Oncology and Hematopoietic Stem Cell Transplant (HSCT) Patients H. Y. Chu, S. Podczervinski, J. Kuypers, A. P. Campbell, M. Boeckh, J. Englund, C. Casper; Univ. of Washington, Seattle, WA. T-354 BK Virus (BKV) Infection after Reduced Intensity Double

Umbilical Cord Blood Stem-Cell Transplantation (dUCBT) G. Satyanarayana 1, S. Hammond 2, T. A. Broge Jr. 1, R. Viscidi 3, I. Politikos 1, I. J. Koralnik 1, C. Cutler 4, K. Ballen 5, V. A. Boussiotis 1, F. Marty 2, S. Tan 1; 1 Beth Israel Deaconess Med. Ctr., Boston, MA, 2Brigham and Women’s Hosp., Boston, MA, 3Johns Hopkins Univ., Baltimore, 4Dana Farber Cancer Inst., Boston, MA, 5Massachusetts Gen. Hosp., Boston, MA. T-355 CMV Antigenemia and Quantitative Viral Load Assessments

in Hematopoietic Stem Cell Transplant Recipients L. Cardeñoso 1, B. Pinsky 2, I. Lautenschlager 3, S. Aslam 4, B. Cobb 4, R. Vilchez 4, H. Hirsch5; 1Hosp. Univ.ersitario de la Princesa, Madrid, Spain, 2 Stanford Univ. Sch. of Med., Stanford, CA, 3Helsinki Univ. Hosp., Univ. of Helsinki, Helsinki, Finland, 4Roche Molecular SysteInc., Pleasanton, CA, 5 Univ. of Basel, Basel, Switzerland. T-356 Letermovir (AIC246) for the Prevention of CMV Infections

Meets Primary Endpoint in Phase 2b Trial in Human Blood Precursor Cell Transplant (HBPCT) Recipients 1

2

1

R. F. Chemaly , G. Ehninger , R. Champlin , for the AIC246 Study Team, M. Richard 3, H. Zimmermann 3, P. Lischka 3, S. Stoelben 3, D. McCormick 3, H. Ruebsamen-Schaeff 3; 1UT MD Anderson Cancer Ctr., Houston, TX, 2 Univ. Dresden, Dresden, Germany, 3AiCuris GmbH & Co. KG, Wuppertal, Germany. T-357 Treatment of RSV in Adult Transplant Recipients with Palivi-

zumab 7.5mg/kg, Inhaled Ribavirin, IVIG, and Steroids J. Gillman, P. Mohazabnia, R. Portinari, Pharm.D, W. Tharpe, B. De Marco, F. Lee, B. M. Le; Univ. of Texas Southwestern Med. Ctr., Dallas, TX.

58

T-358 Preemptive Therapy (PrT) for Cytomegalovirus (CMV)

Transplant (Tx) Often Stem from Colonization or Surgical Seeding, and are Associated with High Mortality

September 9-12 |

cine on Acute Rejection Rate and Long-Term Graft Outcome after Kidney Transplantation (KT) M. Fernández-Ruiz 1, P. Arrazola 1, F. López-Medrano 1, J. M. Morales 1, A. Andrés 1, J. Gavaldà 2, J. M. Aguado 1, C. Lumbreras 1; 1Univ. Hosp. 12 de Octubre, Madrid, Spain, 2Univ. Hosp. Vall d´Hebron, Barcelona, Spain. T-360 Risk Factors and Prognosis of BK Virus-Associated Hemor-

rhagic Cystitis Following Allogeneic Hematopoietic Stem Cell Transplantation L. Gilis, N. Tedone, G. Billaud, M. Michallet, F. Ader; Hospices Civils de Lyon, Lyon, France. T-361 BK Polyomavirus (BKV) IgG is a Predictor of High Level BKV

Viruria after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Y. J. Lee1, D. Chung 1, C. Figueroa1, I. Amigues1, T. Son 1, J. Hester 2, A. Jakubowski 1, G. Papanicolaou 1; 1Mem. Sloan-Kettering Cancer Ctr., New York, NY, 2Viracor-IBT Lab., Lee’s Summit, MO. T-362 CMX001 is an Effective Treatment Option for Refractory

CMV Infection or Disease in HCT Recipients: A Single Center’s Experience G. Papanicolaou 1, H. Mommeja-Marin 2, M. Anderson 2, S. Godkin 2, G. Chittick 2, W. Painter 2; 1Mem. Sloan Kettering Cancer Ctr., New York, NY, 2 Chimerix, Inc., Durham, NC. T-363 Molecular Decryption of a Group C Adenovirus Epidemic in

Pediatric Recipients of Hematopoietic Stem Cells L. Feghoul 1, P. Roques 2, J. Dalle 3, J. Cherot 1, M. Ouachée 1, C. Doit 1, M. Rodier 1, A. Baruchel 3, F. Simon 1, J. Le Goff1; 1Univ. Paris Diderot, Hôpital Saint-Louis, APHP, Paris, France, 2IMETI, CEA, Fontenay-aux-Roses, France, 3Univ. Paris Diderot, Hôpital Robert Debré, APHP, Paris, France. T-364 Good Outcomes Among Hepatitis C (HCV)-Infected Heart

and Lung Transplant Recipients: A Single-Center Experience M. Nguyen 1, K. Chopra 1, E. J. Kwak 1, F. Silveira 1, R. Abdel-Massih 2, Y. Toyoda 2, N. Shigemura 2, J. Pilewski 1, M. Crespo 2, C. Bermudez 1, J. Bahma 2, C. Clancy2; 1Univ. of Pittsburgh, Pittsburgh, PA, 2Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA. T-365 Looking into the Crystal Ball: Can We Foresee CMV? A. J. Jamal1, S. Husain 1,2, Y. Li 1, O. Famure 1, J. S. Kim 1,2; 1Univ. Hlth. Network, Toronto, Canada, 2Univ. of Toronto, Toronto, Canada. T-366 Safety and Efficacy of a Strategy for Discontinuing Preemptive

Ganciclovir Therapy after One Negative Antigenemia Test Result in Kidney Transplantation S. Park, Y. Lee, H. Hong, H. Park, S. Moon, H. Sung, Y. Kim, D. Han, S. Park, J. Park, S. Kim, S. Choi, Y. Kim, J. Woo, S. Lee; Asan Med. Ctr., Seoul, Korea, Republic of. T-367 Acyclovir Resistant Herpes Simplex Virus (HSV) among Hema-

topoietic Stem Cell Transplant (HSCT) Recipients: Case-CaseControl Investigation D. Patel 1, D. Marchaim 2, G. Marcus2, R. Gayathri 1, P. R. Lephart 1, C. Pranatharthi 1; 1Wayne State Univ., Detroit, MI, 2Assaf Harofeh Med. Ctr., Zerifin, Israel.

SUNDAY SCIENTIFIC SESSIONS T-368 Impact of Cytomegalovirus (CMV) Infection in Rapid

Progression to Fibrosis and 5-Year Mortality in Liver Transplant Recipients (LTR) Infected with Hepatitis C Virus (HCV) O. Len, M. Puig, L. Castells, N. Fernández-Sabé, A. García-Reyne, M. Montejo, R. Lara, G. Bou, J. Gavaldà, A. Pahissa; REIPI (Spanish Network for Res. in Infectious Diseases), Barcelona, Spain. T-369 Use of Electronic Estimation of Renal Function (eGFR) to

Guide Valganciclovir (VGCV) Dosing in Solid-Organ Transplant Recipients (SOT-R) Commonly Results in Sub-Therapeutic Ganciclovir (GCV) Levels J. Trevillyan1, P. Angus 1,2, E. Shelton 1, J. Whitlam 1, F. Ierino 1,2, J. Pavlovic 1, D. Gregory 1, K. Urbancic 1, J. Torresi1,2, A. Testro 1, L. Grayson 1,2; 1Austin Health, Melbourne., Australia, 2Melbourne Univ., Melbourne, Australia. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------030(V) Poster Session Non HIV Virology Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: V-370 Fluorescent Primuline Derivatives Inhibit Hepatitis C Virus

NS3- Catalyzed RNA unwinding, Peptide Hydrolysis and Viral Replicase Formation J. Ndjomou 1, R. Kolli 1, S. Mukherjee 1, K. Li 2, F. J. Schoenen 2, D. N. Frick 1; 1Univ. of Wisconsine, Milwaukee, WI, 2Univ. of Kansas Specialized Chemistry Ctr., Lawrence, KS. V-371 Long-Term Follow-Up of Inner City Populations Treated for

HCV Infection

V-376 Hepatitis E Seroprevalence in an Immunocompromised Pedi-

atric Population M. J. Jaber, C. Buteau, C. Rousseau, S. Cellot, U. Halac, F. Alvarez; CHU Sainte Justine, Montreal, Canada. V-377 HCV RNA Replication is Sensitive to Perturbations in Des-

mosterol Homeostasis V. A. Villareal 1, M. A. Rodgers 1,2, E. A. Schaefer 3, L. F. Peng 3, K. E. Corey 3, R. T. Chung 3, P. L. Yang 1; 1Harvard Med. Sch., Boston, MA, 2USC, Los Angeles, CA, 3Massachusetts Gen. Hosp., Boston, MA. V-378 Association Between Chemokine Receptor 5 Mutation and

Hepatitis C Infection Susceptibility and Outcomes in Shistosomiasis-Infected Patients Withdrawn V-379 The Seroprevalence of Hepatitis B and C in Northeastern

Region of Turkey G. Arvas 1, Y. Akkoyunlu 2, B. Kaya 3, I. Hakyemez 4, M. Berktas 5, T. Aslan2; 1 Igdir Univ., Med. Technology Vocational and Training Sch., Igdir, Turkey, 2 Bezmialem Vakif Univ., Istanbul, Turkey, 3Igdir State Hosp., Igdir, Turkey, 4 Abant Izzet Baysal Univ., Bolu, Turkey, 5100. Yil Univ., Van, Turkey. V-380 Efficacy of Peramivir on the Outcome of Severe Pneumococcal

Pneumonia Induced By Co-Infection with Influenza Virus in Comparison with Oseltamivir in Mice A. Tanaka 1, S. Nakamura 1, N. Iwanaga 1, T. Kajihara 1, M. Kitano 2, Y. Imamura 1, T. Miyazaki 1, M. Seki 3, K. Izumikawa 1, H. Kakeya 1, Y. Yamamoto 1, K. Yanagihara 1, T. Tashiro 1, S. Kohno 1; 1Nagasaki Univ. Hosp., Nagasaki, Japan, 2Shionogi & Co., LTD. Medicinal Res. Lab., Osaka, Japan, 3 Osaka Univ. Hosp., Suita, Japan. V-381 Genotypic Resistance Assessment in a Phase II Clinical Study

Assessing DAS181 Antiviral Activity against Influenza R. L. Sanders, C. Tjoeng, R. Moss; NexBio Inc., San Diego, CA.

H. Tossonian 1, L. Gallagher 1, S. Nouch 2, F. Duncan 2, O. Alenezi 1, B. Conway 1; 1Univ. of British Columbia, Vancouver, Canada, 2Pender Community Hlth. Ctr., Vancouver Coastal Hlth., Vancouver, Canada. V-372 Relationship Between Apolipoprotein E Genotypes and Anti-

Viral Response in Hepatitis C Virus Infection W. Lee, Y. Kim, K. Lee; Kyungpook Natl. Univ. Hosp., Daegu, Korea, Republic of. V-373 Virologic Response and Emergence of Mutant Strains on

Antiviral Monotherapy and Combination Therapy in Hepatitis B Virus Related Chronic Liver Disease M. Srivastava, A. Jain, V. Dixit, S. Shukla, G. Nath; Inst. of Med. Sci.,BHU, Varanasi, India. V-374 A Cross-Sectional Survey of Genotypes and Viral Mutations

in Veterans with Chronic Hepatitis B Infection M. Burton1, D. Sullivan 2; 1G.V. Sonny Montgomery VAMC, Jackson, 2Univ. of Mississippi Med. Ctr., Jackson, MS. V-375 Impact of Free HBV Vaccination and/or Healthcare Workers

Training on Vaccine Acceptability in High Risk Subjects O. Launay 1, Y. Le Strat 2, W. Tosini 3, L. Kara 1, S. Quelet 4, S. Lévy 5, E. Bouvet 3, D. Lévy-Bruhl 2, ANRSFORMVAC Study Group; 1CIC de Vaccinologie Cochin Pasteur, Paris, France, 2Institut de Veille Sanitaire, Paris, France, 3Service des Maladies Infectieuses et Tropicales Hôpital Bichat, Paris, France, 4Direction de l’action sociale, de l’enfance et de la Santé, Paris, France, 5Ctr. Régional d’information et de Prévention du Sida, Paris, France.

V-382 Inhibition of Clinical Isolates of Human Parainfluenza Virus

by DAS181 in Cell Culture and in a Cotton Rat Model J. L. Hurwitz 1, B. Jones 2, R. Moss 3, R. L. Sanders 3; 1St. Judes Children’s Res. hospital, Memphis, TN, 2St. Jude Children’s Res. Hosp., San Diego, CA, 3 NexBio Inc, San Diego, CA. V-383 Correlation of Housekeeping Gene Expression with Respira-

tory Swab Sample Quality in Healthy Volunteers J. D. Hoopes 1, R. Coon 2, M. Balansay-Ames 2, L. Hua 3, M. Hughes 3, C. Myers 2, D. Faix 2, P. Blair 2, J. Nguyen 1, NIAID Influenza Research Collaboration; 1Adamas Pharmaceuticals, Emeryville, CA, 2Naval Hlth. Res. Ctr., San Diego, CA, 3Harvard Sch. of Publ. Health, Boston, MA. V-384 Prevalence and Predictors for the Presence of Heterosubtypic

Antibodies against Influenza A in Humans I. Kohler 1, A. U. Scherrer 2, B. Ledergerber 2, H. F. Guenthard 2, L. Hangartner 1; 1Univ. of Zurich, Zurich, Switzerland, 2Univ. Hosp. Zurich, Zurich, Switzerland. V-385 Barrier-Forming Formulation Containing Cetylpyridinium

Chloride (fCPC) Possesses Anti-Infective Activity against Influenza Virus F. Esper1, P. K. Mukherjee 2, A. M. Ghannoum 3, R. A. Salata 1, M. A. Ghannoum 4; 1Univ. Hosp. Case Med. Ctr., Cleveland, OH, 2Case Western Reserve Univ., Cleveland, OH, 3Oasis Consumer Healthcare LLC, Cleveland, OH, 4Univ. Hosp. Case Med. Ctr. and Case Western Reserve Univ., Cleveland, OH.

Final Program

59

> Sunday SCIENTIFIC SESSIONS V-386 Use of Data Integration of Alberta Laboratory (DIAL), A

Web-Based Platform, to Analyze Mixed Infections Among Human Metapneumovirus and Other Respiratory Viruses Circulating in Alberta, Canada (2009-2012) S. Fathima. 1, J. May-Hadford 2, B. Lee 3, S. Mukhi 3,4, S. J. Drews 1,5; 1 Provincial Lab. for Publ. Health, Calgary, Canada, 2Publ. Hlth. Agency of Canada, Calgary, Canada, 3Univ. of Alberta, Calgary, Canada, 4Canadian Network for Publ. Hlth. Intelligence, Winnipeg, Canada, 5Univ. of Calgary, Calgary, Canada. V-387 Risk Factors for Infection with the Pandemic Influenza A/

H1N1 Virus in the General Population: A Representative Cohort Study in France R. M. Delabre1, N. Lapidus 1, N. Salez 2, M. Leruez 3, L. Andreoletti. 4, A. Flahault 5, X. De Lamballerie. 2, F. Carrat. 1; 1Inserm U707, Paris, France, 2 UMR-D 190, Aix-Marseille Univ. and IRD, Marseille, France, 3Hosp. Necker, Paris, France, 4Unité de Virologie Médicale et Moléculaire, CHU, ReiFrance, 5EHESP, Rennes, France. V-388 Arbidol-Oseltamivir Combination Therapy for A Influenza

Virus Infection in Cell Culture and in Mice 1

2 1

I. A. Leneva , I. Fedyakina ; The I. Mechnikov Res. Inst. of Vaccines and Sera, Moscow, Russian Federation, 2 D.I. Ivanovsky Inst. of Virology, Moscow, Russian Federation. V-389 Influenza-Like Illness Hospitalizations with Prospective Viro-

logic Assessment During a Mixed Influenza A and B Season 1

2

1

3

4

R. Gilca , R. Amini , M. Douville-Fradet , H. Charest , J. Dubuque , V. Lajoie 2, N. Boulianne 1, A. Thuot 5, D. Lauzon 5, A. Poirier 6, D. Grimard 7, R. Savard 7, E. Simoneau 8, G. De Serres 1; 1INSPQ, Quebec, Canada, 2 CHUL-CHUQ, Quebec, Canada, 3INSPQ, Montreal, Canada, 4MSSS, Montreal, Canada, 5Hosp. Haut-Richelieu, Saint-Jean-sur-Richelieu, Canada, 6CSSSTR, Trois-Rivières, Canada, 7Hôpital de Chicoutimi, Chicoutimi, Canada, 8Cité de la santé, Laval, Canada. V-390 The Effectiveness of Neuraminidase Inhibitors for the

Pediatric Patients with Influenza K. Oda, Kawasaki Hosp., Okayama, Japan. V-391 AIC316, a Potent Non-Nucleosidic Inhibitor of Herpes

Simplex Virus (HSV), Exhibits a Favorable Pharmacokinetic/ Pharmacodynamic (PK/PD) Profile in a Successfully Completed Proof-of-Concept and Dose Finding Trial A. Birkmann, D. McCormick, B. Timmler, S. Stoelben, M. P. Richard, H. Zimmermann, H. Ruebsamen-Schaeff; AiCuris GmbH & Co. KG, Wuppertal, Germany. V-392 Novel Method for Generating Recombinant Human

Cytomegalovirus (HCMV) Mutants with a Reporter Luciferase for Drug Susceptibility Testing E. Drouot, J. Piret, G. Boivin; Laval Univ., Quebec, Canada. V-393 Relationship Between Cytomegalovirus (CMV) Infection of

Peripheral Blood Leukocytes (PBL) and Bone Marrow (BM) Cells in Hematopoietic Stem Cell Transplant (HSCT) Recipients A. Capobianchi, A. Iori, A. Micozzi, G. Torelli, C. Girmenia, S. Santilli, G. Antonelli, R. Foà, G. Gentile; Sapienza Univ., Rome, Italy. V-394 The Importance of Serum Adipokine Levels in Patients with

Crimean-Congo Hemorrhagic Fever G. Yilmaz, A. Mentese , H. Yilmaz, I. Koksal; Karadeniz Technical Univ. Faculty of Med., Trabzon, Turkey.

60

September 9-12 |

V-395 Blurred Vision and Myopic Shift in Puumala Virus Infection

are Independent of Disease Severity G. Theiler, B. Langner-Wegscheider, I. Zollner-Schwetz, T. Valentin, M. Hönigl, R. Krause; Med. Univ. Graz, Graz, Austria. V-396 Modeling the Efficacy of Post-Event Mass Vaccination and

Antiviral Prophylaxis and Treatment in Response to a Smallpox Outbreak E. Graeden , K. Steinhouse, R. Fielding; Gryphon Scientific, Takoma Park. V-397 Efficacy and Safety of Acyclovir 5%/Hydrocortisone 1% Cream

in Immunocompromised Patients with Recurrent Herpes Simplex Labialis S. K. Tyring1, T. Lin 2, L. Handiwala 2, J. T. Olin 2, C. M. Hull3; 1Univ. of Texas Med. Sch. at Houston, Houston, TX, 2Valeant Pharmaceuticals North America LLC, Bridgewater, NJ, 3Univ. of Utah, Salt Lake City, UT. V-398 Comparison of Clinical Characteristics and Laboratory Values

Between PCR Confirmed H1N1 Influenza and PCR Negative Influenza Like Illnesses M. Hoenigl, J. Prattes, M. Drescher, K. Tovilo, K. Vander, H. Kessler, R. B. Raggam, T. Valentin J. Wagner, K. Seeber, I. Zollner-Schwetz, R. Krause, H. Flick; Med. Univ. of Graz, Austria, Graz, Austria. V-399 Immunomodulating Effect of Protease-Activated Receptor

Type 1 (PAR-1) on Human Metapneumovirus Infection L. Aerts1, M. Hamelin 1, C. Rhéaume 1, C. Couture 1, B. Riteau 2, G. Boivin 1; 1 Univ. Laval, Quebec, Canada, 2Univ. C. Bernard, Lyon, France. V-400 First Prospective, Randomized, Clinical Study Evaluating

Combination of Oseltamivir Phosphate and Azithromycin Extended Release Formulation for Influenza H. Kakeya1, M. Seki 2, K. Izumikawa 1, S. Kohno 1; 1Nagasaki Univ. Hosp., Nagasaki, Japan, 2Osaka Univ. Hosp., Osaka, Japan. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

SUNDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------031 Literature Review

-----------------------------------------------------------------------033(P) Interactive Symposium

Literature Review

What’s Hot Where It’s Hot: Interactive Cases in Tropical Medicine

Sunday, 1:45 p.m.–3:45 p.m. . . . . . . . . . . . . . . . . . . . . Room 103 UAN: 0391-9999-12-035-L04-P Conveners: Robert A. Bonomo, MD - Professor Louis Stokes Cleveland Dept. of VA Med. Ctr., Cleveland, OH. Jean-Michel G. Molina, MD - Professor Saint Louis Hosp. and Univ. of Sorbonne Paris Cité, Paris, France. David Paterson, PhD - Professor of Medicine Univ. of Queensland Ctr. for Clinicial Res., Brisbane, Australia. Morven S. Edwards, MD - Professor of Pediatrics Baylor Coll. of Med., Houston, TX. Emily Blumberg, MD - Professor of Medicine Univ. of Pennsylvania, Philadelphia, PA. Angela M. Caliendo, MD, PhD - Professor Path. and Lab. Med., Emory Univ. Hosp., Atlanta, GA.

Sunday, 4:00 p.m.–6:00 p.m. . . . . . . . . . . . . . . . . . . . . Room 103 UAN: 0391-9999-12-037-L04-P Developed in Cooperation with the American Society of Tropical Medicine and Hygiene (ASTHM) Conveners: Wesley C. Van Voorhis, MD, PhD - Professor of Medicine and Head of

Allergy and ID Division Univ. of Washington, Seattle, WA. Panelists: 401 Stephen D. Shafran, MD - Professor and Director, Division of Infectious Diseases Medicine, Univ. of Alberta, Edmonton, Canada.

Objectives: Upon completion of this Literature Review, the participant should be able to: > Review the past year’s most noteworthy publications; > Restate recent advances in infectious diseases epidemiology, pathogenesis, diagnostics, and therapeutics; and > Summarize and analyze recent advances relating to HIV infection. Intended Audience: All Attendees Level: Intermediate

-----------------------------------------------------------------------032 Poster Summary Session Early New Antimicrobial Agents Sunday, 1:45 p.m.–3:45 p.m. . . . . . . . . . . . . . . . . . . . . Room 104 UAN: 0391-9999-12-036-L04-P Developed in Cooperation with the Japanese Antibiotic Research Association ( JARA) and the Japanese Society for Chemotherapy ( JSC) Conveners: Michael J. Pucci, PhD - Excutive Director Achillion Pharmaceuticals, New Haven, CT. Malcolm G. P. Page, PhD - Professor Basilea Pharmaceutica, Basel, Switzerland. Kazuhiro Tateda, MD, PhD - Professor Toho Univ. Sch. of Med., Tokyo, Japan.

402 Eric Caumes, MD - Professor Hosp. Pitié-Salpêtrière, Univ. Pierre-et-Marie-Curie, Paris, France. 403 Michael D. Libman, MD - Associate Professor McGill Univ. Hlth. Ctr., Montreal, Canada. 404 Andrea Boggild, MD - Associate Professor Univ. of Toronto, Toronto, Canada. 406 Christina M. Coyle, MD, MS - Professor of Clinical Medicine Albert Einstein Coll. of Med., Bronx, NY. Objectives: Upon completion of this Interactive Symposium Session, the participant should be able to: > Cite some of the latest significant literature of travelers medicine, parasitology, and tropical medicine; > Discuss the epidemiology of travelers’ illnesses and issues in management and prevention of these illnesses; and > Discuss issues in management and prevention of common tropical illnesses. Intended Audience: ID MDs, fellows, travel MDs, mid-levels, pharmacists, and general physicians. Level: Intermediate

Objectives: Upon completion of this Poster Summary Session, the participant should be able to: > Identify some key preclinical or early stage compounds in drug development that have not yet entered therapeutic (Phase 2) clinical trials; > Describe selected new antimicrobial agents or new screening technologies that are being presented in Category F sessions at this meeting; and > Gain insights into the potential antibiotic pipeline for the near future.

Final Program

61

> Sunday SCIENTIFIC SESSIONS -----------------------------------------------------------------------034(V, D) Interactive Symposium

-----------------------------------------------------------------------035(A) Symposium

Transplantation and the ID Physician: Management Strategies for the 21st Century

Pharmacodynamics of Antifungal Agents

Sunday, 4:00 p.m.–6:00 p.m. . . . . . . . . . . . . . . . . . . . . Room 104 UAN: 0391-9999-12-038-L04-P Conveners: Emily A. Blumberg, MD - Professor of Medicine Perelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA. Jay A. Fishman, MD - Professor of Medicine Massachusetts Gen. Hosp., Harvard Med. Sch., Boston, MA. Speakers:

Developed in Cooperation with the International Society of Anti-Infective Pharmacology (ISAP) Conveners: David R. Andes, MD - Professor Univ. of Wisconsin, Madison, WI. William Hope, MD, PhD - Professor of Therapeutics and Infectious Diseases The Univ. of Liverpool, Liverpool, United Kingdom. Speakers:

4:00 p.m. 407 Viral Molecular Diagnostics: Pitfalls & Challenges Ajit P. Limaye, MD- Professor Univ. of Washington, Seattle, WA. 4:30 p.m. 408 Laboratory Monitoring for Fungi in Transplantation: Advan-

tages and Limitations Barbara D. Alexander, MD, MHS - Associate Professor of Medicine and Pathology Duke Univ., Durham, NC. 5:00 p.m. 409 Functional Immune Assays and the Individualization of Care Atul Humar, MD - Professor, Director Alberta Transplant Institute Univ. of Alberta, Edmonton, Canada. 5:30 p.m. 410 Immunologically Based Prophylactic Strategies in Transplant

Recipients Jay A. Fishman, MD - Professor of Medicine Massachusetts Gen. Hosp., Harvard Med. Sch., Boston, MA. Objectives: Upon completion of this Interactive Symposium Session, the participant should be able to: > Analyze the utility and limitations of viral diagnostics in transplant recipients; > Assess the optimal use of fungal diagnostics in the management of transplant recipients; > Identify when to use immune monitoring assays in transplant recipients; and > Demonstrate how diagnostic assays may impact on prophylactic strategies in transplant recipients. Intended Audience: Physicians, pharmacists, and clinical microbiologists/ virologists.

4:00 p.m. 411 The Antifungal Pharmacodynamic Target: Impact of Organism,

Host, and Infection William W. Hope, MD, PhD - Professor of Therapeutics and Infectious Diseases The Univ. of Manchester, Manchester, United Kingdom. 4:30 p.m. 412 Antifungal Pharmacodynamics: Beyond Candida Nathan P. Wiederhold, PharmD - Associate Professor Univ. of Texas at Austin Coll. of Pharmacy, Univ. of Texas Hlth. Sci. Ctr., San Antonio, TX. 5:00 p.m. 413 Analysis of Clinical Pharmacodynamic Data of Antifungal

Agents David R. Andes, MD - Professor Univ. of Wisconsin, Madison, WI. 5:30 p.m. 414 Using Pharmacodynamics to Set Antifungal Susceptibility

Breakpoints Russell Lewis, PharmD - Senior Researcher Univ. of Bologna, Bologna, Italy. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Recognize the challenges in making dosage selections of antifungal agents; > Describe pharmacokinetic/pharmacodynamic methods involved in optimal dose selection; and > Identify issues and difficulties in estimating the optimal effect in vitro and in vivo of antifungal agents. Intended Audience: Physicians, pharmacists, and microbiologists. Level: Intermediate

Level: Intermediate

62

Sunday, 4:00 p.m.–6:00 p.m. . . . . . . . Esplanade Ballroom 306 UAN: 0391-9999-12-039-L04-P

September 9-12 |

SUNDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------036(B) Symposium

-----------------------------------------------------------------------037(C1) Symposium

Microbial Factors Modulating Host Responses: New Frontiers

Multidrug-Resistance in Emerging Countries

Sunday, 4:00 p.m.–6:00 p.m. . . . . . . . Esplanade Ballroom 309 UAN: 0391-9999-12-040-L04-P Conveners: Victor Nizet, MD - Professor Univ. of California, San Diego Sch. of Med. and Skaggs Sch. of Pharmacy & Pharmaceutical Sci., La Jolla, CA. Julie Magarian Blander, PhD - Associate Professor Mount Sinai Sch. of Med., New York, NY. Speakers:

Sunday, 4:00 p.m.–6:00 p.m. . . . . . . . Esplanade Ballroom 302 UAN: 0391-9999-12-041-L04-P Conveners: Patrice L. Nordmann, MD, PhD - Professor Hosp. Bicetre, South Paris Med. Sch., Kremlin-Bicetre, France. Ana C. Gales, MD, PhD - Professor of Medicine Univ. Federal de São Paulo, Escola Paulista de Med. (UNIFESP, EPM), São Paulo, Brazil. Speakers: 4:00 p.m. 419 India

4:00 p.m. 415 A Commensal Microbe Coordinates Host Immunity to Establish

Symbiosis June Round, PhD- Assistant Professor of Pathology, Division of Microbiology and Immunology Univ. of Utah, Salt Lake City, UT. 4:30 p.m. 416 Food from the Fire: How the Host Response Feeds Salmonella

Camilla Rodrigues, MD - Consultant Microbiologist Hinduja Hosp., Mumbai, India. 4:30 p.m. 420 Bacterial Resistance: The Brazilian Scenario Ana C. Gales, MD, PhD - Professor of Medicine Univ. Federal de São Paulo, Escola Paulista de Med. (UNIFESP, EPM), São Paulo, Brazil. 5:00 p.m.

Andreas Baumler, PhD - Professor Univ. of California, Davis Sch. of Med., Davis, CA.

421 Bacterial Resistance: The South African Scenario

5:00 p.m.

Adrian J. Brink, MD, MMed - Doctor Ampath Natl. Lab. Services, Milpark Hosp., Johannesburg, South Africa.

417 Vita-PAMPs: Signatures of Microbial Viability Julie Magarian Blander, PhD - Associate Professor Mount Sinai Sch. of Med., New York, NY.

5:30 p.m. 422 Epidemiology and Characteristics of Antibacterial Resistance

in China

5:30 p.m. 418 Bacterial Glycans and Glycosidases: That Subvert Host Phago-

cyte Function Victor Nizet, MD - Professor Univ. of California, San Diego, La Jolla, CA. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe how the commensal flora of the human intestine shape developmental aspects of the adaptive immune responses in both health and pathologies such as inflammatory bowel disease; > Identify how inflammatory responses induced by the intestinal pathogen Salmonella actually promote the pathogens own survival over the normal flora through unique metabolic adaptations; > Assess how the host innate immune system discriminates viable from nonviable bacteria in order to mount a response only in the circumstance of a true infectious threat; and > Describe how sugar molecules (glycans) on the surface of both bacterial and host cells regulate immune responses, and how streptococcal pathogens have learned to mimic or degrade host sugars to avoid phagocyte killing.

Yong-Hong Xiao, MD, PhD - Professor Zhejiang Univ., Hangzhou, China. Objectives: Upon completion of this Symposium Session, participants should be able to: > Assess the extent of the antibiotic resistance problem in several emerging countries; > Identify the main mechanisms of resistance behind resistance rates; and > Identify antibiotic resistance rates and first line therapy. Intended Audience: ID physicians, pharmacists, and industry clinical microbiologists. Level: Intermediate

Intended Audience: Microbiologists and immunologists interested in hostpathogen interactions and/or innate immunity, infectious disease physicians and physicians-in-training, and pharmaceutical scientists interested in novel targets for infectious disease therapeutics Level: Intermediate/Advanced

Final Program

63

> Sunday SCIENTIFIC SESSIONS -----------------------------------------------------------------------038(C2) Symposium

-----------------------------------------------------------------------039(D) Symposium

Whole Genome Sequencing and Molecular Epidemiology: The New Frontier?

Best Practices: Diagnosis of Viral Causes of Hepatitis

Sunday, 4:00 p.m.–6:00 p.m. . . . . . . . Esplanade Ballroom 308 UAN: 0391-9999-12-042-L04-P Developed in Cooperation with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Conveners: Mark J. Pallen, MD, PhD - Professor Univ. of Birmingham, Birmingham, United Kingdom. Johann Pitout, MD - Professor Univ. of Calgary, Calgary, Canada. Speakers:

Conveners: David A. Anderson, PhD - Deputy Director Macfarlane Burnet Inst. for Med. Res. and Publ. Hlth., Melbourne, Australia. Marie Landry, MD - Professor Yale Univ. Sch. of Med. and Yale New Haven Hosp., New Haven, CT. Speakers: 4:00 p.m. 427 Hepatitis A and E

4:00 p.m. 423 High-Throughput Sequencing and Molecular Epidemiology:

Progress, Opportunities and Challenges Mark J. Pallen, MD, PhD - Professor Univ. of Birmingham, Birmingham, United Kingdom. 4:30 p.m. 424 Next Generation Sequencing Technology and Gram-Negatives:

Escherichia coli O104:H4 Nicholas J. Loman, MB BS, PhD - Research Fellow Univ. of Birmingham, Birmingham, United Kingdom. 5:00 p.m. 425 Next Generation Sequencing Technology and Gram-Positives:

Methicillin-Resistant Staphylococcus aureus Patrice Francois, PhD - Microbiologist Univ. Hosp. of Geneva, Geneva, Switzerland. 5:30 p.m. 426 Clostridium difficile: Functional Genomics Studies Yung-Fu Chang, DVM, PhD - Professor Cornell Univ., Ithaca, NY. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the progress, opportunities and challenges of high-throughput sequencing in molecular epidemiology; > Recognize the role of next generation sequencing in the Escherichia coli O104:H4 outbreak; > Evaluate the role of next generation sequencing in the molecular epidemiology of MRSA; and > Evaluate the role of next generation sequencing in the molecular epidemiology of Clostridium difficile. Intended Audience: Clinical microbiologists, infectious disease physicians, infection control practitioners, clinical pathologists, medical technologists, and epidemiologists. Level: Advanced

64


September 9-12 |

David A. Anderson, PhD - Deputy Director Macfarlane Burnet Inst. for Med. Res. and Publ. Hlth., Melbourne, Australia. 4:30 p.m. 428 Diagnosis of Hepatitis B and Monitoring of Antiviral Therapy Fabien Zoulim, MD, PhD - Professor INSERM, Lyon, France. 5:00 p.m. 429 Diagnostic Testing for Hepatitis C Virus in the Era of Direct-

Acting Antiviral Therapy Alexandra Valsamakis, MD, PhD - Associate Professor Johns Hopkins Hosp., Baltimore. 5:30 p.m. 430 Herpes Viruses (CMV, EBV, HSV) Marie L. Landry, MD - Professor Yale Univ. Sch. of Med. and Yale New Haven Hosp., New Haven, CT. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Identify the best tests to diagnose viral causes of hepatitis; > Describe the types and uses of nucleic acid tests for diagnosis and monitoring treatment of viral hepatitis; > Describe the genetic markers that have been defined to be associated with infection and treatment outcome; and > Assess the impact of viral genome variability on the clinical outcome of chronic hepatitis. Intended Audience: Clinical microbiologists and infectious diseases clinicians. Level: Intermediate

SUNDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------040(E, C2) Symposium

-----------------------------------------------------------------------041(F) Symposium

Origins and Ecology of Antibiotic Resistance

New Treatments for Mycobacterium tuberculosis Infections


Sunday, 4:00 p.m.– 6:00 p.m.. . . . . . . . . . . . . . . . . . . . Room 122 UAN: 0391-9999-12-045-L04-P

Conveners: Laura V. Piddock, PhD- Professor Univ. of Birmingham, Birmingham, United Kingdom. Gautam Dantas, PhD - Assistant Professor Washington Univ. Sch. of Med., St. Louis, MO.

Conveners: Michael J. Pucci, PhD - Executive Director Achillion Pharmaceuticals, New Haven, CT. Carol A. Nacy, PhD - CEO Sequella, Inc., Rockville, MD. Speakers:

Speakers:

4:00 p.m.

4:00 p.m.

435 Discovery and Development of SQ609: A Novel Dipiperidine for

431 Antibiotic Resistance Genes in Probiotic Foods Giorgio Giraffa, PhD - Research Centre Director Consiglio per la Ricerca e la Sperimentazione in Agricoltura, Lodi, Italy. 4:30 p.m.

Treatment of TB and TB Meningitis Carol A. Nacy, PhD - CEO Sequella, Inc., Rockville, MD. 4:30 p.m.

432 Antibiotic Resistance Genes in Environmental Bacteria Gautam Dantas, PhD - Assistant Professor Washington Univ. Sch. of Med., St. Louis, MO.

436 Efficacy of Antimicrobial Peptoids against M. tuberculosis Annelise E. Barron, Ph.D. - Associate Professor Stanford Univ., Stanford, CA.

5:00 p.m.

5:00 p.m.

433 Antibiotic Resistance in Commensal Bacteria Bruno Fantin, MD, PhD - Professor Univ. Paris Diderot Med. Sch., Paris, France.

437 Dry Powder Aerosols for Treatment of Tuberculosis Anthony J. Hickey, PhD, DSc - Program Leader Inhalation Therapeutics Res. Triangle Inst., ResearchTriangle Park, NC.

5:30 p.m. 434 Antibiotic Resistance Genes in Bacteria of Ancient Origin Gerry Wright, PhD - Professor McMaster Univ., Hamilton, Canada. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Identify the contribution of reservoirs of antibiotic resistance genes in non-pathogenic bacteria; > Describe the potential importance of antimicrobial resistance genes in probiotic foods > Discuss the impact of antibiotic resistance genes in commensal microbiota; and > Discuss the types of antibitic resistance genes reported in bacteria of ancient origin.

5:30 p.m. 438 TBA-354: A Next Generation Nitroimidazole for Treatment of

Drug- Sensitive and Drug-Resistant Tuberculosis Anna M. Upton, PhD - Senior Project Leader, Discovery TB Alliance, New York, NY. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss the current need for new treatments for tuberculosis; > Gain insights into the drug discovery process for this disease; and > Discuss several early new approaches for future treatment of Mycobacterium tuberculosis infections. Intended Audience: Microbiologists, pharmaceutical and academic scientists. Level: Intermediate

Intended Audience: Researchers and physicians wishing to broaden their understanding of how antibiotic resistance genes arise and their prevalence in the environment’s other than humans. Level: Beginning

Final Program

65

> Sunday SCIENTIFIC SESSIONS -----------------------------------------------------------------------042(G) Symposium

-----------------------------------------------------------------------043(H) Symposium

Vaccine Conquests and Challenges

Update on HIV-Associated Co-Morbidities

Sunday, 4:00 p.m.–6:00 p.m. . . . . . . . . . . . . . . . . . . . . Room 120 UAN: 0391-9999-12-046-L04-P


Conveners: Andrew J. Pollard, FRCPCH PhD - Professor Univ. of Oxford, Oxford, United Kingdom. Janet A. Englund, MD - Professor Univ. of Washington, Seattle, WA. Speakers:

Conveners: Judith A. Aber, MD - Professor of Medicine; Director Division of Infectious Diseases and Immunology New York Univ. Sch. of Med., New York, NY. Esteban Martínez, MD - Associate Professor of Medicine Univ. of Barcelona, Barcelona, Spain. Speakers:

4:00 p.m. 439 Pneumococcal Conjugates: Impact of Expanded Valent Vaccines Anne Vergison, MD, PhD - Associate Professor ULB-HUDERF, Brussels, Belgium. 4:30 p.m. 440 Meningococcal Conjugate Vaccines: Africa and Beyond Andrew J. Pollard, FRCPCH, PhD - Professor Univ. of Oxford, Oxford, United Kingdom. 5:00 p.m.

4:00 p.m. 443 Epidemiology and Outcomes of Organ Transplantation in HIV Peter Stock, MD, PhD - Professor of Surgery Univ. of California San Francisco, San Francisco, CA. 4:30 p.m. 444 Central Nervous System Complications of HIV Serena S. Spudich, MD, MA - Associate Professor Yale Univ. Sch. of Med., New Haven, CT. 5:00 p.m.

441 HPV Vaccine for Girls and Boys! Janet A. Englund, MD - Professor Univ. of Washington,Seattle Children’s Hosp., Seattle, WA. 5:30 p.m. 442 Global Measles: What’s Next? Jane F. Seward, MBBS, MPH - Deputy Director, Division of Viral Diseases CDC, Atlanta, GA. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss the impact of expanded valent pneumococcal conjugate vaccines; > Discuss the impact of implementation of meningococcal conjugate vaccines in specific locales; > Discuss the expected outcomes after introduction of HPV vaccines in boys; and > Discuss goals by region, impact of importation and challenges remaining in global measles control. Intended Audience: Infectious disease physicians and physician extenders, public health officials and healthcare providers involved in vaccine development, advances and administration. Level: Intermediate

445 Syphilis and HIV: A Case Based Discussion Kimberly Workowski, MD - Professor of Medicine Emory Univ., Atlanta, GA. 5:30 p.m. 446 Update from the World AIDS Conference Esteban Martínez, MD - Associate Professor of Medicine Univ. of Barcelona, Barcelona, Spain. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss the epidemiology and outcomes of persons with HIV infection who receive organ transplants; > Review current knowledge of CNS complications associated with HIV infection; Identify the new diagnostic and treatment guidelines for of syphilis in HIV-infected persons; and > Review the data presented on co-morbidities at the World AIDS Conference 2012. Intended Audience: HIV and HCV clinicians including MD, pharmacists, pharmacologists, physician extenders and other clinician, HIV and HCV clinical and translational s including those involved in all phases of antiviral research. Level: Intermediate

66

September 9-12 |

SUNDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------044(L) Symposium

-----------------------------------------------------------------------045(L2) Symposium

An Update on Novel & Important Tickborne Diseases

An Update on Perinatal Infections



Conveners: Didier Raoult, MD, PhD - Professor WHO Collaborative Ctr. for Rickettsial Reference and Res., Marseille, France. Bobbi S. Pritt, MD - Laboratory Director Mayo Clinic and Mayo Clinic Coll. of Med., Rochester, MN.

Developed in Cooperation with the Infectious Diseases Society of Obstetrics and Gynecology (IDSOG)

Speakers:

Conveners: Catherine Nelson-Piercy, FRCP - Physician St. Thomas’ Hosp., London, United Kingdom. Michael G. Gravett, MD - Professor Univ. of Washington Sch. of Med., Seattle, WA.

4:00 p.m.

Speakers:

447 Emergence of a New Pathogenic Ehrlichia Species, Wisconsin

and Minnesota

4:00 p.m. 452 Safe Use of Antimicrobials in Pregnancy Catherine Nelson-Piercy, FRCP - Physician St. Thomas’ Hosp., London, United Kingdom.

Bobbi S. Pritt, MD - Associate Professor Mayo Clinic and Mayo Clinic Coll. of Med., Rochester, MN. 4:25 p.m.

4:30 p.m.

448 Human Infections Caused by Borrelia miyamotoi

453 Influenza During Pregnancy Richard Beigi, MD, MSc - Physician Magee-Womens Hosp. of the Univ. of Pittsburgh Med. Ctr., Pittsburgh, PA.

Peter J. Krause, MD - Senior Research Scientist Yale Sch. of Publ. Hlth. and Yale Sch. of Med., New Haven, CT. 4:50 p.m.

5:00 p.m.

449 Diverse Rickettsiae Across the Globe Didier Raoult, MD, PhD - Professor WHO Collaborative Ctr. for Rickettsial Reference and Res., Marseille, France. 5:15 p.m.

454 Beyone TORCH: The New Paradigm for Pesky Perinatal Infec-

tions Michael G. Gravett, MD - Professor Univ. of Washington Sch. of Med., Seattle, WA. 5:30 p.m.

450 Transfusion-Associated Babesiosis Barbara L. Herwaldt, MD, MPH - Medical Epidemiologist CDC, Atlanta, GA.

455 Malaria and Other Parasitic Infections During Pregnancy R. Philips Heine, MD - Associate Professor Duke Univ. Med. Ctr., Durham, NC.

5:40 p.m. 451 Emergence of Deer Tick Virus as a Human Pathogen Gary P. Wormser, MD - Professor New York Med. Coll., Valhalla, NY. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Identify major tickborne pathogens; > Define diagnostic and therapeutic aspects of tickborne infections; > Analyze features of emerging deer tick virus encephalitis; and > Improve knowledge about new tick-associated infections.

Objectives: Upon completion of this Symposium Session, the participant should be able to: > Define important infections that complicate pregnancy; > Determine which antimicrobials are safe for use in pregnancy; and > Improve the care of pregnant women with infection or at risk for infection. Intended Audience: Healthcare providers and investigators with an interest in perinatal maternal and child health. Level: Intermediate

Intended Audience: Healthcare practitioners and investigators with an interest in vector transmitted infections. Level: Intermediate

Final Program

67

> Sunday SCIENTIFIC SESSIONS -----------------------------------------------------------------------046(M) Symposium Mycology 2012: Top Papers Sunday, 4:00 p.m.– 6:00 p.m.. . . . . . . . . . . . . . . . . . . . Room 132 UAN: 0391-9999-12-050-L04-P Convener: Dimitrios P. Kontoyiannis, MD - Frances King Black Endowed Professor Univ. of Texas MD Anderson Cancer Ctr., Houston, TX.

C1-459 Crystal Structure of the Class A Beta-Lactamase from Bacil-

lus licheniformis BS3 Inhibited by Tazobactam P. Power, PhD - Researcher1, P. Mercuri, PhD - Researcher 2, R. Herman, BSc - Research Assistant 2, F. Kerff, PhD - Researcher 2, G. Gutkind, PhD Researcher 1, M. Galleni, PhD - Researcher 2, P. Charlier, PhD - Researcher 2, E. Sauvage, PhD - Researcher 2; 1Univ. of Buenos Aires, Buenos Aires, Argentina, 2Univ. of Liege, Liege, Belgium. 4:30 p.m. C1-460 Crystal Structures of the Penơ-Lactamases of Burkholderia

cepacia (Bc) and Burkholderia pseudomallei (Bp)

Experts: 456 Thomas F. Patterson, MD - Professor and Chief, Infectious Disease Univ. of Texas Hlth. Sci. Ctr., San Antonio, TX. 457 David Denning, MD - Professor Univ. Hosp. of South Manchester, Manchester, United Kingdom. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Analyze major findings in fungal diseases; > Understand new insights into the diagnosis and management of invasive fungal infections; and > Identify epidemiology features and understand pathogenesis of invasive fungal infections. Intended Audience: Clinicians, trainees, mycologists and researchers. Level: Advanced

-----------------------------------------------------------------------047(C1) Slide Session Structure/Function Sunday, 4:00 p.m.–6:30 p.m. . . . . . . . Esplanade Ballroom 300 UAN: 0391-9999-12-051-L04-P Moderators: Timothy G. Palzkill, PhD - Professor Baylor Coll. of Med., Houston, TX. Laurent Poirel, PhD - Senior Scientist Hop. de Bicetre, Le Kremlin Bicetre, France. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Identify molecular mechanisms of resistance; > Discuss the general properties that govern the relationship between antibiotic and resistance proteins; and > Discuss the correlation of 3D structure with mechanistic activity of resistance protien. Presentations: 4:00 p.m. C1-458 Structural and Functional Characterization of Aminoglycoside

N-Acetyltransferases AAC(6’)-Ig and -Ih from Acinetobacter spp P. J. Stogios, PhD - Research Scientist 1,2, D. Meziane-Cherif, PhD - Research Scientist3, E. Evdokimova, MSc - Research Technician 1,2, A. Savchenko, PhD - Professor 1,2, P. Courvalin, MD, FRCP - Professor 3; 1Univ. of Toronto, Toronto, Canada, 2Ctr. for Structural Genomics of Infectious Diseases, Toronto, Canada, 3Inst. Pasteur, Paris, France.

68

4:15 p.m.

September 9-12 |

K. M. Papp-Wallace, PhD - Research Scientist and Instructor 1, R. A. Bonomo, MD - Professor 1, N. Ohuchi, PhD - Research Associate 2, M. Nukaga, PhD - Associate Professor2; 1Cleveland VAMC and CWRU, Cleveland, OH, 2Josai Intl. Univ., Togane City, Chiba, Japan. 4:45 p.m. C1-461 Evolutionary Mechanisms for Metallo-Beta-Lactamases M. R. Meini, BS - PhD, M. M. Gonzalez, BS - PhD, P. E. Tomatis, PhD Research Assistant, A. J. Vila, ScD - Professor; IBR, Rosario, Argentina. 5:00 p.m. C1-462 Structural and Biochemical Characterization of Substrate

Specificity Determining Residues in CTX-M-14 A. Cardenas, BS - Graduate Student, N. G. Brown, PhD - Research Associate, L. B. Horton, PhD - Research Associate, T. G. Palzkill, PhD - Professor; Baylor Coll. of Med., Houston, TX. 5:15 p.m. C1-463 Unraveling a Final Common Pathway: The K234R Sub-

stitution in SHV Mediates Amoxicillin/Clavulanic Acid (A/C) Resistance M. L. Winkler, BA - Student1, E. Rodkey, BS - Student 1, M. Taracila, MS - Research Assistant 1, C. R. Bethel, MS - Research Assistant 2, S. M. Drawz, PhD - Student 1, K. Papp-Wallace, PhD - Investigator 2, F. van den Akker, PhD - Professor 1, R. A. Bonomo, MD - Professor 3; 1CWRU, Cleveland, OH, 2 VAMC, Cleveland, OH, 3CWRU, VAMC, Cleveland, OH. 5:30 p.m. C1-464 Defining the Role of D179 in the Substrate Profile of KPC-2

ơ-Lactamase P. S. Levitt, B.A. - MD/PhD student1, K. M. Papp-Wallace, PhD - Instructor 1,2 , R. A. Bonomo, MD - Professor 3; 1CWRU, Cleveland, OH, 2Cleveland VAMC, Cleveland, OH, 3VAMC, Cleveland, OH. 5:45 p.m. C1-465 The Crystal Structure of the DIM-1 Metallo-Beta-Lacta-

mase from Pseudomonas stutzeri M. P. S. Booth, PhD - Research Assistant 1, L. Poirel, PhD - Associate Researcher 2, P. Nordmann, MD, PhD - Professor 2, J. Spencer, PhD - Lecturer1; 1 Univ. of Bristol, Bristol, United Kingdom, 2Hosp. de Bicêtre, Paris, France. 6:00 p.m. C1-466 INQ-1: Preliminary Characterization of aơ-Lactamase from

Inquilinus limosus M. Pino, Lic. - Reseacher, P. Power, PhD - Reseacher, J. Di Conza, PhD Professor, M. Ruggiero, Lic. - Researcher, G. Gutkind, PhD - Professor; Fac. Farm. y Bioq., UBA, Buenos Aires, Argentina.

SUNDAY SCIENTIFIC SESSIONS 6:15 p.m.

5:00 p.m.

C1-467 Substrate Specificity in Class Dơ-Lactamases: A Structure

Based Comparison of OXA-1 and OXA-24 with Oxacillin Bound C. M. June, MS - Research Assistant 1, B. C. Vallier, undergraduate - Student 1 , R. A. Bonomo, MD - Professor 2, D. A. Leonard, PhD - Professor 1, R. A. Powers, PhD - Professor1; 1Grand Valley State Univ., Allendale, MI, 2Cleveland VAMC, Cleveland, OH.

-----------------------------------------------------------------------048(K) Slide Session Difficulties of Clostridium difficile Sunday, 4:00 p.m.–6:30 p.m. . . . . . . . . . . . . . . . . . . . . Room 254 UAN: 0391-9999-12-052-L04-P

K-471 A U.S. Based National Sentinel Surveillance Study for the

Susceptibility and Epidemiology of Clostridium difficile Associated Diarrheal Isolates D. R. Snydman, MD - Chief1, L. A. McDermott, MT (ASCP) - Research Associate 1, N. V. Jacobus, MS, MPH - Research Associate 1, E. J. C. Goldstein, MD - Director 2, L. Harrell, MD - Professor 3, R. Patel, MD, FRCP, FIDSA, FACP - Chair, Division of Clinical Microbiology 4, S. G. Jenkins, PhD - Professor of Pathology and Laboratory Medicine 5, S. J. Johnson, MD, DTM&H - Staff Physician, Medicine Service 6, D. N. Gerding, MD - Chief, Medical Service 6; 1Tufts Med. Ctr., Boston, MA, 2RM Alden Res. Lab., Culver City, CA, 3Duke Univ., Durham, NC, 4Mayo Clinic, Rochester, MN, 5New York Presbyterian Hosp., NY, NY, 6VA Chicago Hlth. Care System, Chicago, IL. 5:15 p.m. K-472 Mortality of Nosocomial Clostridium difficile Infections: A

Multicenter Cohort Study

Moderator: Dale N. Gerding, MD Edward Hines Jr. VA Hosp., Hines, IL. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Describe current epidemiology of Clostridium difficile stain type C; > Identify factors associated with outcome of C. difficile infection; and > Discuss clinical and economic consequences of vancomycin and fidaxomicin in the treatment of C. difficile infection.

M. Hensgens, MD 1, A. Goorhuis, MD - PhD 2, O. Dekkers, MD - PhD 1, B. van Benthem, PhD - PhD 3, E. Kuijper, MD - PhD 1; 1LUMC, Leiden, Netherlands, 2AMC, Amsterdam, Netherlands, 3Natl. Inst. for Publ. Hlth. and the Environment, Bilthoven, Netherlands. 5:30 p.m. K-473 Clinical and Economic Consequences of Vancomycin and

Fidaxomicin for the Treatment of Clostridium difficile Infection in Canada M. Wagner, PhD - Director, Research Application, L. Lavoie, PhD - Senior Research Application Associate, M. Goetghebeur, PhD - Vice-President Operations; BioMedCom Consultants Inc., Montreal, Canada.

Presentations: 4:00 p.m.

State-of-the-Art Minilecture 468 Update on C.difficile Infection

5:45 p.m. K-474 Genomic Stability of Clostridium difficile NAP1/027 within a

Dale N. Gerding, MD Edward Hines Jr. VA Hosp., Hines, IL.

Human Gut Model

4:30 p.m. K-469 Clostridium difficile Strain Types from United States Hospitals F. C. Tenover, PhD - Executive Director1, M. Donnellan, MS - Research Assistant 2, I. A. Tickler, BS - Scientist 1, D. H. Persing, MD, Ph.D. - Chief Medical and Technology Officer 1, R. V. Goering, Ph.D. - Professor 2, HAI Consortium; 1Cepheid, Sunnyvale, CA, 2Creighton Univ., Omaha, NE.

M. H. Wilcox, MD - Professor1, D. W. Eyre, BM, BCh - Research Fellow 2, R. Bowden, PhD - Senior Researcher 2, W. N. Fawley, PhD - Researcher 1, C. H. Chilton, Ph.D - Researcher 1, J. Freeman, PhD - Researcher 1, T. E. A. Peto, D.Phil - Professor 2; 1Univ. of Leeds, Leeds Teaching Hosp. & HPA, Leeds, United Kingdom, 2NIHR Oxford Biomedical Res. Ctr., Oxford, United Kingdom.

4:45 p.m. K-470 Characterisation of Swine Isolates of Clostridium difficile in

Spain: A Potential Source of Hypervirulent Multidrug-Resistant Strains? T. Pelaez, PhD - Professor1, L. Alcala, PharmD - Researcher 1, J. L. Blanco, PhD - Professor 2, M. Marin, PhD - Researcher 1, A. Martin-Lopez, PhD Researcher 1, S. Alvarez-Perez, PhD - Researcher 2,3, M. E. Garcia, PhD - Professor 2, E. Bouza, PhD - Professor 1; 1Hosp. Gen. Gregorio Marañon, Madrid, Spain, 2Facultad Veterinaria UCM, Madrid, Spain, 3Hosp. Gen. Gregorio Marañon, Madrid, Spain.

Final Program

69

> NOTES

70

September 9-12 |

> Monday Schedule at-a-Glance > 7:00 a.m. - 8:15 a.m. Meet-the-Experts 049 (A) Surgical Prophylaxis: Dosage Recommendations, Tissue Penetration, and Pharmacokinetic Considerations Esplanade Ballroom 305

051 (G) Antibiotic Shortages, Antibiotic Stewardship and the Sick Child Esplanade Ballroom 309 052 (H) How Do I Treat HCV in HIV/HCV Co-Infected Patients? Room 121 053 (K) Infection Prevention and Control in Low- and -Middle-Resource Settings Esplanade Ballroom 308 054 (K) Top Papers in Infection Prevention and Control, 2011-2012 Room 120 055 (L) Challenging Infections in Older Adults Esplanade Ballroom 310 056 (L1) Difficult to Manage Cutaneous Infections in Adults and Children Esplanade Ballroom 302 057 (M) Fungal Infections Involving the Eye Room 102 058 (P) Top Ten Papers in Travel and Tropical Medicine Esplanade Ballroom 306 059 (V) Persistent Herpes Virus Viremia: What Does it Mean? Esplanade Ballroom 300

> 8:30 a.m. - 10:30 a.m. Interactive Symposium 060 (D) Cases in Clinical Microbiology Room 103

Symposia 061 (A, L) Targeting Gram-Negative Superbugs with Polymyxins: From Lab-Bench to Bedside Esplanade Ballroom 305 062 (B) Malnutrition, Microbiome & Mucosal Immunity Esplanade Ballroom 308 063 (B) Pathogenesis, Diagnosis and Treatment of Urinary Tract Infection Room 130 064 (C1) Plasmid-Mediated Quinolone Resistance Esplanade Ballroom 302 065 (C2) Population Dynamics in Streptococcus pneumoniae Esplanade Ballroom 310

067 (G) Hot Topics in Vaccines Room 120 068 (K) Preventing Spread of M. tuberculosis in Healthcare Facilities Room 122 069 (L) New Issues in the Management of MDR/XDR TB Esplanade Ballroom 306 070 (L1) New Insights in Diabetic Foot Infections and Osteomyelitis Room 121 071 (L2) An Update on the Treatment and Prevention of UTIs Room 102 072 (M) Research in Mycology: Hot Topics Room 132

Slide Session 081 (C1) Carbapenemase in Enterobacteriaceae and P. aeruginosa Room 122

> 11:15 a.m. - 1:15 p.m. Poster Sessions 082 (A) Glycopeptides and Lipopeptides: What’s New in PK/PD and Safety Halls A-C 083 (A) Improving Pharmacodynamics of Beta-Lactams and Beta-Lactamase Inhibitors Halls A-C 084 (B) Antimicrobial Therapy in Animal Models I Halls A-C 085 (C1) Genetics and Resistance Halls A-C

> 8:30 a.m. - 11:00 a.m.

086 (C1) Resistance by Efflux/Quinolone Resistance Halls A-C

Slide Sessions

087 (C2) Diverse Resistance Issues in Enterobacteriaceae Halls A-C

073 (H) New Antiretroviral Therapy: Bench to Bedside Room 104 074 (K) Multidrug-Resistant Organisms: and Catheter-Related Infections Room 254 075 (P) Parasitology, Global Health and Travel Medicine Esplanade Ballroom 309

> 11:15 a.m. -12:15 p.m. Poster Walk Daily Infection Prevention and Control Issues Halls A-C

> 11:15 a.m. - 12:45 p.m. Interactive Symposium 076 (K) Challenges in Infection Control Room 104

Symposia 077 (G, H) Vaccine Innovations Esplanade Ballroom 305 078 (L, F) 50 Years of Fluoroquinolones: Past, Present and Future Room 132 079 (L) An Update on Streptococcal Pharyngitis and Rheumatic Fever Esplanade Ballroom 302 080 (V, H) Hot Topics in Viral Hepatitis Room 130

088 (C2) Food, Animals and Environment Reservoirs for Gram-Negative Organisms Halls A-C 089 (C2) Pseudomonas aeruginosa: An Overview of Survelliance Data Halls A-C 090 (D) MALDI-ToF Mass Spectrometry and Identification and Susceptibility Testing Halls A-C 091 (D) Mycobacteria: Diagnostics and Susceptibility Testing Halls A-C 092 (D) Phenotypic Susceptibility Testing Methods Halls A-C 093 (E) Cornucopia of in Vitro Activity Halls A-C 094 (E) In Vitro Activity Against MultidrugResistant Gram-Negative Bacteria Halls A-C 095 (E) In Vitro Activity Versus Anaerobes Halls A-C 096 (F) New Antifungal Agents Halls A-C 097 (F) New Antiviral Agents Halls A-C 098 (F) New Approaches in Mycobacterial Therapy Halls A-C

Monday

050 (D) Syphilis Diagnostics: Traditional Versus “New” Algorithm Room 122

066 (F) Host Defense (Antimicrobial) Peptides: Major Players in Health and Novel Therapeutics Esplanade Ballroom 300

> Monday Schedule at-a-Glance continued… > 11:15 a.m. - 1:15 p.m. 099 (F) Targeting the Bacterial Cell Wall: New Beta-Lactams and Beta-Lactamase Inhibitor Combinations Halls A-C 100 (G) Impact of Expanded Valent: Pneumococcal Vaccines Halls A-C 101 (G) Updates in Vaccines Halls A-C 102 (H) Antiretroviral Therapy Outcomes Including Select Populations Halls A-C 103 (H) Safety and Toxicity of Antiretroviral Therapy Halls A-C 104 (K) Blood Stream Infections Halls A-C 105 (K) Clostridium difficile Infections Halls A-C 106 (K) Endocarditis Halls A-C 107 (K) Fungal Infections Halls A-C 108 (K) Influenza Halls A-C 109 (L1) An Update on Tuberculosis Halls A-C 110 (L1) Zoonotic Infections Halls A-C 111 (M) Experimental Mycology Halls A-C 112 (P) Global Health, Parasitology and Travel Medicine Halls A-C 113 (T) Infections in Transplant Recipients and Patients with Malignancies Halls A-C

> 12:15 p.m. - 1:15 p.m. Poster Walk Resistance Genes Have No Boundaries! Halls A-C

> 1:30 p.m. - 4:00 p.m. Slide Sessions 114 (G) Vaccines: Innovations, Impact and Safety Room 121 115 (M) Sleuthing in Mycology Esplanade Ballroom 310 116 (T) Infections in Transplant Recipients Room 120 117 (V) Respiratory Viruses and Measles Esplanade Ballroom 309

> 2:00 p.m. - 4:00 p.m.

> 5:45 p.m. - 7:00 p.m.

Interactive Symposia

Meet-the-Experts

118 (K) Evidence-Based Infection Prevention and Control: Answering Key Questions Room 104

131 (A) Top Papers in Anti-Infective and Antiretroviral PK/PD Esplanade Ballroom 310

119 (P) Clinical Problem Solving: Interactive Cases in Travel and Tropical Medicine Room 103

132 (C2) Detecting, Controlling, and Treating Carbapenemase-Producing Enterobacteriaceae Esplanade Ballroom 302

Symposia 120 ICAAC Live Esplanade Ballroom 303 This Week in Microbiolgy with Vincent Racaniello 121 (A) Aerosol Drug Delivery: Getting AntiInfective Agents to the Lung Room 130 122 (B) Bacterial and Viral Infections in Patients Treated with Novel Biologic Agents: What Do I Need to Know? Esplanade Ballroom 300 123 (C2) Antibiotic Combinations against Gram-Negatives in the XDR Era: From Bench to Bedside Room 122 124 (D) Epidemiology and Diagnosis of Febrile Illness in the Era of Global Climate Change Room 102 125 (F) Alternative Approaches to Inhibiting Gram-Negative Bacteria Esplanade Ballroom 308 126 (H) Current Issues in HIV-Associated Opportunistic Diseases Esplanade Ballroom 306 127 (L) New Issues in the Management of Multidrug-Resistant (MDR) Endocarditis Esplanade Ballroom 305 128 (M) Fungal Infections in High-Risk Groups: Current and Future Strategies for Control Esplanade Ballroom 302

Slide Session 129 (K) Staphylococcus aureus: Tough Bug, Tough Treatment Room 132

> 4:30 p.m. - 5:30 p.m. ICAAC Lecture 130 ICAAC Lecture Room 103

133 (D) MALDI-ToF and PCR/ESI Mass Spectrometry: Implementation and Impact on Patient Care Room 121 134 (H, V) Prevention of Anal Cancer in HIV-Infection: From Early Detection to Vaccination Esplanade Ballroom 309 136 (K) Preventing Line-Associated Bloodstream Infection: Which Measures are Essential? Esplanade Ballroom 308 137 (P) Controversies in Pre-Travel Preparation Room 122 138 (V, H) New Strategies for Transplantation of HIV Infected Individuals Esplanade Ballroom 300

> 5:45 p.m. - 7:15 p.m. Symposium 130a ICAAC-GCACMID Symposium Room 102

MONDAY SCIENTIFIC SESSIONS ---------------------------------------------------------------------------------049(A) Meet-the-Experts

-----------------------------------------------------------------------051(G) Meet-the-Experts

Surgical Prophylaxis: Dosage Recommendations, Tissue Penetration, and Pharmacokinetic Considerations

Antibiotic Shortages, Antibiotic Stewardship and the Sick Child

Monday, 7:00 a.m.–8:15 a.m. . . . . . . . Esplanade Ballroom 305 UAN: 0391-9999-12-053-L04-P


Convener: Joseph S. Solomkin, MD - Professor of Surgery Univ. of Cincinnati Coll. of Med., Cincinnati, OH.

Experts: 479 Jason G. Newland, MD - Associate Professor of Pediatrics Univ. of Missouri, Kansas City Sch. of Med. and Children’s Mercy Hosp., Kansas City, MO.

Experts: 475 Douglas N. Fish, PharmD - Professor

480 Mike Sharland, MD - Professor

Univ. of Colorado Sch. of Pharmacy, Aurora, CO.

St. George’s Hosp., London, United Kingdom.

476 Kevin W. Garey, PharmD, MS - Associate Professor and Chair Univ. of Houston, Coll. of Pharmacy, Houston, TX.

Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Discuss the basis for shortages of antibiotics employed in the care of sick children; > Assess the importance of antibiotic stewardship to the care of children; and > Apply principles of antibiotic stewardship relevant to the care of children.

Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > List the current dosage recommendations of antimicrobial agents commonly used for surgical prophylaxis; > Describe the pharmacokinetic/pharmacodynamic and tissue penetration considerations of antimicrobial agents for surgical prophylaxis; and > Evaluate current dosing recommendations for surgical prophylaxis in obese patients.

Intended Audience: Physicians, public health practitioners, epidemiologists, pharmacists and all with an interest in issues pertaining to antimicrobial stewardship and shortages.

Intended Audience: Physicians, pharmacists, and microbiologists.

Level: Beginning/Intermediate

Level: Intermediate

-----------------------------------------------------------------------050(D) Meet-the-Experts Syphilis Diagnostics: Traditional Versus “New” Algorithm Monday, 7:00 a.m.–8:15 a.m. . . . . . . . . . . . . . . . . . . . . Room 122 UAN: 0391-9999-12-054-L04-P

How Do I Treat HCV in HIV/HCV Co-Infected Patients? Monday, 7:00 a.m.–8:15 a.m. . . . . . . . . . . . . . . . . . . . . Room 121 UAN: 0391-9999-12-056-L02-P Experts: 481 Charles W. Flexner, MD - Professor Johns Hopkins Univ. Sch. of Med., Baltimore, MD.

Experts: 477 Kimberly Workowski, MD - Professor of Medicine Emory Univ. Sch. of Med., Atlanta, GA.

482 Vincent Soriano, MD, PhD - Associate Professor of Medicine Hosp. Carlos III & Univ. Complutense of Madrid, Madrid, Spain.

478 Khalil G. Ghanem, MD, PhD - Associate Professor of Medicine Johns Hopkins Univ. Sch. of Med., Baltimore, MD. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Describe the traditional and reverse sequence algorithm for the diagnosis of syphilis; > Identify the strengths and weaknesses of each approach; and > Assess the impact of the algorithm on patient care and public health practice. Intended Audience: Clinical microbiologists and infectious diseases clinicians. Level: Intermediate

-----------------------------------------------------------------------052(H) Meet-the-Experts

Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Review recent data with direct acting anti-HCV drugs for the treatment of HCV-infection; > Discuss the unsettled issues and pitfalls of using DAAs for the treatment of HCV-infection in HIV-infected patients; and > Describe the most significant drug-drug interactions between anti-HCV and HIV drugs. Intended Audience: HIV treating physicians, ID professionals, clinical virologists, primary care physicians, hepatologists, pharmacologists, and industry professionals. Level: Intermediate/Advanced

Final Program

71

> Monday SCIENTIFIC SESSIONS -----------------------------------------------------------------------053(K) Meet-the-Experts

-----------------------------------------------------------------------055(L) Meet-the-Experts

Infection Prevention and Control in Low- and MiddleResource Settings

Challenging Infections in Older Adults

Monday, 7:00 a.m.–8:15 a.m. . . . . . . . Esplanade Ballroom 308 UAN: 0391-9999-12-057-L04-P Experts: 483 Benedetta Allegranzi, MD – Physician World Health Organization, Geneva, Switzerland. 484 Shaheen Mehtar, MD - Professor Fac of Hlth. Sci., Stellenbosch Univ., Cape Town, South Africa. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Measure the importance of infection prevention in countries with limited resources; > Discuss possible surveillance strategies to be implemented in countries with limited resources; > Identify the most frequent healthcare-associated infections in countries with limited resources; and > Discuss the barriers to infection control in countries with limited resources. Intended Audience: ID specialists, infection control professionals, hospital epidemiologists, public health professionals, and hospital administrators. Level: Beginning/Intermediate

-----------------------------------------------------------------------054(K) Meet-the-Experts Top Papers in Infection Prevention and Control, 20112012 Monday, 7:00 a.m.–8:15 a.m. . . . . . . . . . . . . . . . . . . . . Room 120 UAN: 0391-9999-12-058-L04-P Experts: 485 Andreas Voss, MD, PhD - Professor of Infection Control Canisius-Wilhelmina Hosp. & RUNMC, Nijmegen, Netherlands. 486 Loreen Herwaldt, MD - Professor, Hospital Epidemiologist Univ. of Iowa Coll. of Med., Iowa City, IA. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Provide a critical review of recently published papers in the field; > Prioritize information in the literature; and > Summarize changes in practice and novel discoveries in the field. Intended Audience: ID specialists, infection control professionals, and hospital epidemiologists. Level: Beginning/Intermediate

72

September 9-12 |

Monday, 7:00 a.m.–8:15 a.m. . . . . . . . Esplanade Ballroom 310 UAN: 0391-9999-12-059-L04-P Experts: 487 Ebbing Lautenbach, MD, MPH, MSCE - Professor of Medicine and Epidemiology Univ. of Pennsylvania Sch. of Med., Philadelphia, PA. 488 Preeti N. Malani, MD, MSJ - Associate Professor Univ. of Michigan, Ann Arbor, MI. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Identify important infectious diseases in older adults; > Describe the impact of infections on older adults; and > Improve their care of older adults with infections. Intended Audience: Healthcare providers and investigators interested in infections of older adults. Level: Intermediate

-----------------------------------------------------------------------056(L1) Meet-the-Experts Difficult to Manage Cutaneous Infections in Adults and Children Monday, 7:00 a.m.–8:15 a.m. . . . . . . . Esplanade Ballroom 302 UAN: 0391-9999-12-060-L04-P Experts: 489 John W. Baddley, MD, MSPH - Associate Professor Univ. of Alabama, Birmingham, AL. 490 Clarence B. Creech, MD, MPH - Assistant Professor Vanderbilt Univ. Sch. of Med., Nashville, TN. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Discriminate important infections of skin and soft tissue; > Describe the approach to diagnosing and managing challenging skin and soft tissue infections; and > Improve their care of patients with cutaneous infections. Intended Audience: Healthcare practitioners and investigators with an interest in skin and soft tissue infections. Level: Intermediate

MONDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------057(M) Meet-the-Experts

-----------------------------------------------------------------------059(V) Meet-the-Experts

Fungal Infections Involving the Eye

Persistent Herpes Virus Viremia: What Does it Mean?

Monday, 7:00 a.m.–8:15 a.m. . . . . . . . . . . . . . . . . . . . . Room 102 UAN: 0391-9999-12-061-L04-P


Experts:

Experts:

491 Carol A. Kauffman, MD - Professor Univ. of Michigan, Ann Arbor, MI.

494 Upton D. Allen, MD, MBBS - Professor Hosp. for Sick Children, Univ. of Toronto, Toronto, Canada.

492 Grant Comer, MD - Assistant Professor Kellogg Eye Ctr., Ann Arbor, MI.

495 Paul Griffiths, MD, DSc - Professor Univ. Coll. London, UCL Med. Sch., London, United Kingdom.

Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Apply the principles of PK/PD to antifungal drug use in eye infections; > Integrate, and interpret the results of, current diagnostics in the management of eye infections; > Discuss the scope and presentations of the problem in a resource poor country; and > Apply this experience-based knowledge to clinical practice. Intended Audience: Mycology researchers, ID physicians and trainees. Level: Intermediate

-----------------------------------------------------------------------058(P) Meet-the-Experts Top Ten Papers in Travel and Tropical Medicine Monday, 7:00 a.m.–8:15 a.m. . . . . . . . Esplanade Ballroom 306 UAN: 0391-9999-12-062-L04-P Developed in Cooperation with the American Society of Tropical Medicine and Hygiene (ASTMH) Experts: 493 Eric Caumes, MD - Professor Hosp. Pitié-Salpêtrière, Univ. Pierre-et-Marie-Curie, Paris, France. 494 Phil Coyne, MD, MSPH - Assistant Professor, Tropical Public Health Uniformed Services Univ. of Hlth. Sci., Bethesda, MD. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Cite the latest significant literature on travel medicine; > Describe the epidemiology of travel related illnesses; and > Identify issues in prevention of these illnesses. Intended Audience: ID MDs, fellows, travel MDs, mid-levels, pharmacists, and general physicians. Level: Intermediate

Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Identify what is a relevant persisting viremia for CMV and EBV; > Identify the clinical relevance of this viremia; and > Discuss the different monitoring tools and the treatment options. Intended Audience: Clinical microbiologists, ID physicians and transplant specialists. Level: Intermediate/Advanced

-----------------------------------------------------------------------060(D) Interactive Symposium Cases in Clinical Microbiology Monday, 8:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . Room 103 UAN: 0391-9999-12-064-L04-P Convener: Deirdre Church, MD, PhD, FRCPC - Professor Univ. of Calgary and Calgary Lab. Services, Calgary, Canada. Speakers: 496 Cases 1 and 2 Deirdre Church, MD, PhD, FRCPC - Professor Univ. of Calgary, Calgary Lab. Services, Calgary, Canada. 497 Cases 3 and 4 Duane W. Newton, PhD - Director, Clinical Microbiology Laboratories Univ. of Michigan Hosp. and Hlth. Ctr., Ann Arbor, MI. 498 Cases 5 and 6 Dominic E. Dwyer, MD - Professor Westmead Hosp. at the Univ. of Sydney, Sydney, Australia. 499 Cases 7 and 8 Guy Thwaites, MD, PhD - Consultant in Infectious Diseases and Microbiology Kings Coll. London, London, United Kingdom. Objectives: Upon completion of this Interactive Symposium Session, the participant should be able to: > Describe the advantages and limitations of certain conventional and contemporary diagnostic methods used for the identification of microbial pathogens; > Describe laboratory investigations in sick travelers returning from tropical regions; and > Assess the laboratory approach to the diagnosis of infectious diseases.

Final Program

73

> Monday SCIENTIFIC SESSIONS Intended Audience: Clinical microbiologists and infectious diseases clinicians. Level: Intermediate

-----------------------------------------------------------------------061(A, L) Symposium Targeting Gram-Negative Superbugs with Polymyxins: From Lab-Bench to Bedside

Malnutrition, Microbiome & Mucosal Immunity Monday, 8:30 a.m.–10:30 a.m. . . . . . Esplanade Ballroom 308 UAN: 0391-9999-12-066-L04-P

Developed in Cooperation with the Society of Infectious Diseases Pharmacists

Conveners: William A. Petri, Jr, MD, PhD - Professor and Chief, Division of Infectious Diseases Univ. of Virginia, Charlottesville, VA. Cecil Czerkinsky, DMD, PhD - Professor Intl. Vaccine Inst., Seoul, Korea, Republic of.

(SIDP) and International Society Anti-Infective Pharmacology (ISAP)

Speakers:

Monday, 8:30 a.m.–10:30 a.m. . . . . . Esplanade Ballroom 305 UAN: 0391-9999-12-065-L04-P

Conveners: Jian Li, PhD - Associate Professor Monash Inst. of Pharmaceutical Sci., Monash Univ., Parkville, Australia. Keith Kaye, MD, MPH - Professor of Medicine Wayne State Univ. and Detroit Med. Ctr., Detroit, MI. Speakers: 8:30 a.m.

8:30 a.m. 504 Characterization of the Immune System of Children in the

Developing World Mark M. Davis, PhD - Burt and Marion Avery Family Professor of Immunology Stanford Univ., Palo Alto, CA. 9:00 a.m.

500 Mechanisms of Activity of Polymyxins and Resistance Jian Li, PhD - Associate Professor Monash Inst. of Pharmaceutical Sci., Monash Univ., Parkville, Australia. 9:00 a.m.

505 Growth and Malnutrition in Children in the Gambia Andrew M. Prentice, PhD - Director, MRC International Nutrition Group London Sch. of Hygiene and Tropical Med., London, United Kingdom. 9:30 a.m.

501 Polymyxin Therapy: What Does Combination Therapy Offer in

the Clinical Setting?

506 Functional Studies of the Gut Microbiomes of Malawian Twin

Pairs Discordant for Kwashiorkor

Keith Kaye, MD, MPH - Professor of Medicine Wayne State Univ. and Detroit Med. Ctr., Detroit, MI.

Michelle I. Smith, PhD - Postdoctoral Research Fellow Washington Univ., St. Louis, MO.

9:30 a.m.

10:00 a.m.

502 Inhaled Polymyxins in Patients with Pneumonia and Cystic

Fibrosis

507 Oral Polio Vaccine Failure in Bangladesh and its Relationship to

Malnutrition and Tropical Enteropathy

William Couet, PhD - Professor Univ. de Poitiers, Poitiers, France.

William A. Petri, Jr., MD, PhD - Professor and Chief, Division of Infectious Diseases Univ. of Virginia, Charlottesville, VA.

10:00 a.m. 503 Polymyxin Nephrotoxicity: What Do We Know and How Might

Understanding its Mechanism Help? Vincent H. Tam, PharmD - Associate Professor Univ. of Houston Coll. of Pharmacy, Houston, TX. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Identify the mechanisms of activity and resistance of polymyxin agents; > Recognize the role of inhaled polymyxins in patients with pneumonia and cystic fibrosis; > Evaluate recommendations for combination therapy with polymyxin agents; and > Describe the mechanisms of nephrotoxicity and dose-limiting adverse effects of polymyxins. Intended Audience: Physicians, pharmacists, and microbiologists. Level: Intermediate

74

-----------------------------------------------------------------------062(B) Symposium

September 9-12 |

Objectives: Upon completion of this Workshop, the participant should be able to: > Discuss the broad concepts of induction of mucosal immunity, including the role of macro- and micronutrients, microbiome and vaccination strategies; > Assess how malnutrition is the most common cause of immunodeficiency in children; > Describe tropical (aka environmental) enteropathy; and Assess how the microbiome enables nutrition. Intended Audience: Scientists, physicians and public health professionals interested in the immune system of the intestine and elucidation of how it is different in children exposed to multiple enteric infections in the developing world. Level: Intermediate/Advanced

MONDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------063(B) Symposium Pathogenesis, Diagnosis and Treatment of Urinary Tract Infection Monday, 8:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . Room 130 UAN: 0391-9999-12-067-L04-P Conveners: Scott J. Hultgren, PhD - Helen L. Stoever Professor of Molecular Microbiology; Director Center for Women’s Infectious Disease Research Washington Univ. Sch. of Med., St. Louis, MO. Thomas M. Hooton, MD - Professor Univ. of Miami Miller Sch. of Med., Miami, FL. Speakers:

-----------------------------------------------------------------------064(C1) Symposium Plasmid-Mediated Quinolone Resistance Monday, 8:30 a.m.–10:30 a.m. . . . . . Esplanade Ballroom 302 UAN: 0391-9999-12-068-L04-P Conveners: Patricia Bradford, PhD - Associate Researcher AstraZeneca Pharmaceuticals, Waltham, MA. Laurent Poirel, PhD - Senior Scientist Hosp. Bicetre, South Paris Med. Sch., Kremlin-Bicetre, France. Speakers: 8:30 a.m. 513 QNR Update

8:30 a.m. 508 Innate Immunity, Genetics and Susceptibility to Urinary Tract

George A. Jacoby, MD - Research Associate Lahey Clinic, Burlington, MA. 9:00 a.m.

Infection

514 The Genetics and Function of Qep

Catharina M. Svanborg, MD, PhD - Professor Lund Univ., Lund, Sweden.

Laurent Poirel, PhD - Associate Researcher Hosp. Bicetre, South Paris Med. Sch., Kremlin-Bicetre, France.

8:50 a.m. 509 The Pathogenesis of Chronic and Recurrent Cystitis Thomas J. Hannan, DVM, PhD - Research Instructor in Immunobiology Washington Univ. Sch. of Med., Saint Louis, MO. 9:10 a.m.

9:30 a.m. 515 Genetics and Function of aac(6’)-Ib-cr David C. Hooper, MD - Professor Massachusetts Gen. Hosp., Harvard Med. Sch., Boston, MA. 10:00 a.m.

510 Global Spread of Multidrug-Resistance in UTI Marie-Helene Nicolas-Chanoine, MD, PhD - Professor Hopital Beaujon, Clichy, France.

516 Epidemiology of Plasmid-Mediated Quinolone-Resistance

Genes Luis Martinez-Martinez, MD, PhD - Professor Univ. Hosp. Marqués de Valdecilla, Univ. of Cantabria, Santander, Spain.

9:30 a.m. 511 Treatment Guidelines for UTI Thomas M. Hooton, MD - Professor of Clinical Medicine Univ. of Miami, Miami, FL. 9:50 a.m. 512 Development of Novel Therapeutics for Treatment of UTI Scott J. Hultgren, PhD - Helen L. Stoever Professor of Molecular Microbiology; Director, Center for Women’s Infectious Disease Research Washington Univ. Sch. of Med., St. Louis, MO. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the epidemiology of UTI and the increasing prevalence of MDR uropathogens; > Discuss basic concepts of innate immunity relevant to UTI; > Identify basic concepts of molecular pathogenesis of UTI; > Utilize recent guidelines for the treatment of UTI; and > Analyze novel approaches under study to prevent UTI.

Objectives: Upon completion of this Symposium Session, the participant should be able to: > Recognize the names of genes causing plasmid-mediated resistance (PMQR) to quinolones; > Review the mechanisms by which these elements cause resistance to fluoroquinolones; > Describe the fluoroquinolone antibiotics affected by these genes and the MIC values that might indicate the presence of a PMQR gene; and > Assess the spread of these genes both geographically and the scope of bacterial pathogens involved. Intended Audience: Physicians and microbiologists. Level: Intermediate

Intended Audience: Infectious disease scientist/clinician, urologist, internal medicine, microbiologists, pediatricians, immunologists, and pharmacologists. Level: Advanced

Final Program

75

> Monday SCIENTIFIC SESSIONS -----------------------------------------------------------------------065(C2) Symposium

-----------------------------------------------------------------------066(F) Symposium

Population Dynamics in Streptococcus pneumoniae

Host Defense (Antimicrobial) Peptides: Major Players in Health and Novel Therapeutics

Monday, 8:30 a.m.–10:30 a.m. . . . . . Esplanade Ballroom 310 UAN: 0391-9999-12-069-L04-P Conveners: Lesley McGee, PhD - Principal Scientist CDC, Atlanta, GA. Stephen D. Bentley, PhD - Principal Scientist Wellcome Trust Sanger Inst., Hinxton, United Kingdom. Speakers:

Conveners: Michael J. Pucci, PhD - Executive Director Achillion Pharmaceuticals, Inc., New Haven, CT. Robert Hancock, PhD - Professor Univ. of British Columbia, Vancouver, Canada.

8:30 a.m.

Speakers:

517 Status Update on Invasive Pneumococcal serotype and Clone

Distribution Post-PCV13 in USA

8:30 a.m. 521 Development of Innate Defense Regulator Peptides as Therapies

Bernard Beall, PhD - Head, Streptococcus Laboratory CDC, Atlanta, GA. 9:00 a.m. 518 Viewing the Evolution of Pneumococci Through Their Genome

Sequences

for Infections and Inflammation Robert Hancock, PhD - Professor Univ. of British Columbia, Vancouver, Canada. 9:00 a.m. 522 Peptides in Health and Disease

Stephen D. Bentley, PhD - Principal Scientist Wellcome Trust Sanger Inst., Hinxton, United Kingdom. 9:30 a.m.

Richard L. Gallo, MD, PhD - Professor Univ. of California, San Diego, CA. 9:30 a.m.

519 Streptococcus pneumoniae: Virulence Factors and Variation Tim J. Mitchell, PhD - Professor Univ. of Birmingham, Birmingham, United Kingdom. 10:00 a.m.

523 Peptides as Components of Advanced Adjuvants Volker Gerdts, DVM, PhD - Associate Director - Research VIDO-InterVac, Univ. of Saskatchewan, Saskatoon, Canada. 10:00 a.m.

520 PneuCarriage Project: Identifying the Best Method(s) to Detect

Carriage of Multiple Pneumococcal serotypes Catherine Satzke, PhD - Senior Research Officer Murdoch Childrens Res. Inst., Melbourne, Australia. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Provide an update on the serotype and clonal distribution post-PCV13 in USA; > Recognize the role of next generation sequencing in the molecular epidemiology of S. pneumoniae; > Describe the importance of different virulence factors in infections due to S. pneumoniae; and > Recommend the most appropriate serotyping methodologies for Streptococcus pneumoniae. Intended Audience: Clinical microbiologists, infectious disease physicians, infection control practitioners, clinical pathologists, medical technologists, epidemiologists and research scientists. Level: Intermediate

76

Monday, 8:30 a.m.–10:30 a.m. . . . . . Esplanade Ballroom 300 UAN: 0391-9999-12-070-L04-P

September 9-12 |

524 Nonpeptidic mimics of Host Defense Peptides Richard W. Scott, PhD - Vice President, Research PolyMedix, Inc., Radnor, PA. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the role of host defense proteins in the disease process; > Discuss the use of host defense peptides and peptidomimetics in the treatment of infections and inflammation; and > Gain an appreciation opportunities and challenges of peptides as antiinfective agents. Intended Audience: Microbiologists, pharmaceutical and academic scientists. Level: Intermediate

MONDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------067(G) Symposium

-----------------------------------------------------------------------068(K) Symposium

Hot Topics in Vaccines

Preventing Spread of M. tuberculosis in Healthcare Facilities

Monday, 8:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . Room 120 UAN: 0391-9999-12-071-L04-P Developed in Cooperation with the Pediatric Infectious Diseases Society (PIDS)

Monday, 8:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . Room 122 UAN: 0391-9999-12-072-L04-P

Conveners: Sarah S. Long, MD - Professor of Pediatrics, Chief of Infectious Diseases Drexel Univ. Coll. of Med., St. Christopher’s Hosp. for Children, Philadelphia, PA. Ron Dagan, MD - Professor Ben-Gurion Univ. of the Negev and Soroka Univ. Med. Ctr., Beer-Sheva, Israel.

Conveners: Loreen Herwaldt, MD - Professor, Hospital Epidemiologist Univ. of Iowa Coll. of Med., Iowa City, IA. Arthur L. Reingold, MD- Professor and Chair Univ. of California, Berkeley, CA.

Panelists:

8:30 a.m.

8:30 a.m. 525 Carol J. Baker, MD - Professor of Pediatrics, Molecular Virology & Microbiology Baylor Coll. of Med., Houston, TX. 9:00 a.m. 526 Kathleen M. Neuzil, MD, MPH - Director, Vaccine Access and Delivery PATH, Seattle, WA. 9:30 a.m.

529 TB Infection Control Reconsidered Edward Nardell, MD - Associate Professor Harvard Med. Sch., Harvard Sch. of Publ. Health, Brigham & Women’s Hosp., Boston, MA. 9:00 a.m. 530 Rapid Diagnostics: State-of-the-Art Lucien Davis, MD - Assistant Professor of Medicine Univ. of California, San Francisco, CA. 9:30 a.m.

527 Kathryn M. Edwards, MD - Professor of Pediatrics Vanderbilt Univ., Nashville, TN.

531 Thinking Out of the Box: Using Giant Gambian Pouched

Rats for Second-Line Screening in Low- and Medium-Income Countries

10:00 a.m.

Amanda D. Mahoney, MS APOPO, Warren, MI.

528 Jan Bonhoeffer, MD - Assistant Professor Brighton Collaboration, Basel, Switzerland. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Analyze the year’s important advances and biomedical discoveries in vaccinology; > Assimilate the context of new scientific findings by discussion with experts in the field; > Anticipate the potential impact of discoveries on the prevention of infection; and > Plan strategies to apply new advances to further discovery or clinical practice. Intended Audience: Infectious disease physicians and physician extenders, public health officials and healthcare providers involved in vaccine development, advances and administration. Level: Beginning/Intermediate

Speakers:

10:00 a.m. 532 Heathcare Worker’s Risk of Acquiring Tuberculosis and Screen-

ing Healthcare Workers for Tuberculosis Arthur L. Reingold, MD - Professor and Chair Sch. of Publ. Health, Univ. of California, Berkeley, CA. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe two approaches that will be essential for controlling spread of M. tuberculosis in the 21st century; > Describe the pros and cons of current rapid diagnostic tools; > Describe a possible method for second-line screening for M. tuberculosis in resource limited countries; and > Describe the pros and cons of different methods for screening healthcare workers for tuberculosis. Intended Audience: Clinical microbiologists, especially those working with Mycobacteria, infectious disease physicians, physicians and microbiologists involved in infection prevention, and public health professionals. Level: All Levels

Final Program

77

> Monday SCIENTIFIC SESSIONS -----------------------------------------------------------------------069(L) Symposium

-----------------------------------------------------------------------070(L1) Symposium

New Issues in the Management of MDR/XDR TB

New Insights in Diabetic Foot Infections and Osteomyelitis

Monday, 8:30 a.m.–10:30 a.m. . . . . . Esplanade Ballroom 306 UAN: 0391-9999-12-073-L04-P Conveners: William Bishai, MD, PhD - Director of K-RITH Kwa-Zulu-Natal Res. Inst. for Tuberculosis and HIV (K-RITH) and Johns Hopkins Ctr. for Tuberculosis Res., Durban, South Africa. Shiranee Sriskandan, MD, PhD - Professor Imperial Coll., London, United Kingdom. Speakers:

Conveners: Anthony R. Berendt, BM, BCh, FRCP - Consultant Physician Nuffield Orthopaedic Ctr., Headington, United Kingdom. Adolf W. Karchmer, MD - Professor of Medicine, Harvard Medical School Beth Israel Deaconess Med. Ctr., Boston, MA. Speakers:

8:30 a.m.

8:30 a.m.

533 MDR TB: View from the Frontline William R. Bishai, Doctor, MD, PhD - Director of K-RITH Kwa-Zulu-Natal Res. Inst. for Tuberculosis and HIV (K-RITH) and Johns Hopkins Ctr. for Tuberculosis Res., Durban, South Africa. 8:50 a.m.

538 Do Clinical Guideline Help Us Manage DFIs Caused by

Multidrug-Resistant Organisms? Anthony R. Berendt, FRCP - Deputy Medical Director Oxford Univ. Hosp. NHS Trust, Oxford, United Kingdom. 8:55 a.m.

534 New Diagnostics for MDR TB Mark Perkins, MD - Chief Scientific Officer Fndn. for Innovative Diagnostics (FIND), Geneva, Switzerland. 9:10 a.m.

539 Drug Dosing for Complicated DFIs: Maximizing PK/PD David P. Nicolau, PharmD - Dir., Ctr for Anti-Infective Res & Dev Hartford Hosp., Hartford, CT. 9:20 a.m.

535 MDR TB: View from WHO and Updated Recommended

Regimen TBD 9:30 a.m. 536 Surgery for MDR and Difficult to Treat TB John D. Mitchell, MD - Associate Professor Univ. of Colorado Sch. of Med., Natl. Jewish Health, Denver, CO. 9:50 a.m. 537 New Drugs in the Clinical Pipeline for TB Mel Spigelman, MD - President and Chief Executive Officer Global Alliance for TB Drug Dev., New York, NY. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Identify new diagnostic approaches for resistance testing in Mycobacterium tuberculosis; > Identify internationally-accepted management standards for treating cases of MDR and XDR M. tuberculosis; and > Identify options for alternative medical and surgical options in difficult to treat cases. Intended Audience: Infectious diseases physicians, medical microbiologists, tropical ID, and pharmaceutical development. Level: Intermediate

78


540 New Diagnostic Approaches to Diabetic Foot Osteomyelitis Benjamin A. Lipsky, MD - Professor, Department of Medicine VA Puget Sound Healthcare System, Seattle, WA and Univ. of Washington, Seattle, WA. 9:45 a.m. 541 Medical Management of Osteomyelitis: How to Prevent

Amputations Adolf W. Karchmer, MD - Professor of Medicine, Harvard Medical School Beth Israel Deaconess Med. Ctr., Boston, MA. 10:10 a.m.

Roundtable Discussion Objectives: Upon completion of this Symposium Session, the participant should be able to: > Define the impact of multidrug resistant pathogens to the management of diabetic foot infections; > Analyze options for diagnosing bone infections in the diabetic foot; > Determine the optimal dosing for antimicrobials used in the treatment of infections in diabetic feet; and > Manage diabetic foot infections in a more rational way. Intended Audience: Healthcare providers and investigators interested in diabetic foot infections. Level: Intermediate

September 9-12 |

MONDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------071(L2) Symposium

-----------------------------------------------------------------------072(M) Symposium

An Update on the Treatment and Prevention of UTIs

Research in Mycology: Hot Topics



Conveners: Lindsay E. Nicolle, MD - Professor Univ. of Manitoba, Winnipeg, Canada. Suzanne E. Geerlings, MD, PhD - Infectious Disease Specialist Univ. Med. Ctr. Utrecht, Utrecht, Netherlands.

Conveners: Tania C. Sorrell, MB, BS, MD, FRACP - Professor Univ. of Sydney, Sydney, Australia. John Perfect, MD - Interim Chief, Division of Infectious Diseases and International Health Duke Univ. Med. Ctr., Durham, NC.

Speakers:

Speakers:

8:30 a.m. 542 Do Cranberries or Other Natural Products Prevent UTIs?

546 Multicentre Collaborative Studies: How Do They Work and Why?

Suzanne E. Geerlings, MD, PhD - Infectious Disease Specialist Academic Med. Ctr., Amsterdam, Netherlands.

Peter G. Pappas, MD - Professor of Medicine Univ. of Alabama, Birmingham, AL.

9:00 a.m.

9:00 a.m.

543 Empiric UTI Therapy in the Era of the ESBLs

547 Cell-Based Therapies for IFIs in Haematology Patients David J. Gottlieb, MD PhD - Professor Univ. of Sydney, Sydney, Australia.

Barbara K. Hasse, MD - Attending Physician Univ. Hosp. Zurich, Zurich, Switzerland. 9:30 a.m. 544 Developments in Asymptomatic Bacteriuria and UTI in Older

9:30 a.m. 548 What the Site of a Fungal Infection Means for Outcome Michail Lionakis, MD, ScD - Assistant Clinical Investigator NIAID, Bethesda, MD.

Populations Lindsay E. Nicolle, MD - Professor Univ. of Manitoba, Winnipeg, Canada.

10:00 a.m.

10:00 a.m. 545 Effective Strategies to Prevent Catheter-Associated UTIs Barbara W. Trautner, MD, PhD - Associate Professor Baylor Coll. of Med., Houston, TX. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the role of cranberries and other natural products in UTI prevention; > Improve their care of patients with UTIs caused by multidrug resistant pathogens; > Analyze the state of knowledge regarding asymptomatic bacteriuria; and > Improve prevention of catheter related UTIs. Intended Audience: Healthcare practitioners and investigators interested in urinary tract infections. Level: Intermediate

8:30 a.m.

549 What are the Possibilities for Use of Radioimmunotherapy for

Fungal Infections: The Data and the Reality Joshua Nosanchuk, MD - Associate Professor Albert Einstein Coll. of Med., Bronx, NY. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Debate issues and participate constructively in planning and execution of multicentre collaborative studies; > Discuss the status and potential of two non-drug experimental approaches to therapy of invasive fungal infections; and > Translate information on the relationship between site of a fungal infection and outcome into clinical practice. Intended Audience: Mycology researchers, ID physicians and trainees. Level: Intermediate

Final Program

79

> Monday SCIENTIFIC SESSIONS -----------------------------------------------------------------------073(H) Slide Session New Antiretroviral Therapy: Bench to Bedside Monday, 8:30 a.m.–11:00 a.m. . . . . . . . . . . . . . . . . . . Room 104 UAN: 0391-9999-12-077-L04-P Moderators: Douglas J. Ward, MD - Physician Dupont Circle Physicians Group, Washington, DC. Joseph Eron, Jr., MD - Professor of Medicine Univ. of North Carolina, Chapel Hill, NC.

H-553 Preferential Expansion of Transitional (T TM) and Central

Memory (TCM) CD4 T-Cells following Adoptive Transfer of ZFN CCR5 Modified Autologous CD4 T-Cells (SB-728-T)

J. Zeidan, PhD - Fellow1, R. Bordi, PhD - Fellow 1, S. Deeks, MD - Professor 2, R. Mitsuyasu, MD - Professor 3, J. Lalezari, MD - Director 4, G. Lee, PhD - Assoc Director 5, S. Wang, MD - Director 5, W. W. Tang, MD - VP 5, G. Nichol, MD - EVP 5, M. Giedlin, PhD - VP 5, R. Sekaly, PhD - Director 1 , D. Ando, MD - CMO 5; 1VGTI, Port St Lucie, FL, 2UCSF, San Francisco, CA, 3UCLA, Los Angeles, CA, 4Quest Clin Res, San Francisco, CA, 5Sangamo Biosciences Inc, Richmond, CA. 9:30 a.m.

Objectives: Upon the completion of this Slide Session, the participant should be able to: > Describe mechanisms of action of new antiretroviral therapy; > Assess the antiretroviral response to fixed dose combination therapy; and > Discuss the advantages and disadvantages on switching antiretroviral therapy. Presentations: 8:30 a.m. H-550 Antiviral Characteristics of S/GSK1265744, an HIV Integrase

Inhibitor (INI) Dosed by Oral or Long-Acting Parenteral Injection 1

9:15 a.m.

1

T. Yoshinaga, PhD - Section Head , M. Kobayashi, MS - Section Head , T. Seki, PhD - Team Leader 1, T. Kawasuji, MS - Section Head 1, T. Taishi, MS Team Leader 1, A. Sato, PhD - Department Head 1, T. Fujiwara, PhD - Project Leader 1, B. Johns, PhD - Medicinal Chemist 2, R. Hazen, PhD - Virology 2, R. Ferris, PhD - Virology 2, M. Underwood, PhD - Virology 2; 1Shionogi, Toyonaka, Japan, 2GlaxoSmithKline, Research Triangle Park, NC. 8:45 a.m. H-551 Antiviral Activity and In Vitro Mutation Development Path-

ways of MK-1439: A Novel Non-Nucleoside Reverse Transcriptase Inhibitor M. Lai, PhD- Program Lead1, M. Feng, MS - Research Assistant 1, M. Lu, MS - Research Assistant 1, E. Asante-Appiah, PhD - Program Lead 2, P. Tawa, MS - Research Assistant 2, M. Witmer, MS - Research Assistant 1, D. DiStefano, MS - Program Lead 1, E. Cauchon, MS - Research Assistant 3, L. Campeau, PhD - Program Lead 4, Y. Yan, PhD - Program Lead 1, M. Miller, PhD - Program Lead 1, D. Hazuda, PhD - Vice President 1; 1Merck & Co. Inc., West Point, PA, 2Merck & Co. Inc., Kenilworth, NJ, 3Merck & Co. Inc., Pointe Claire, Canada, 4Merck & Co. Inc., Rahway, NJ. 9:00 a.m. H-552 Virological Profiling of GS-7340, a Next-Generation Tenofo-

vir Prodrug with Superior Potency Over TDF C. Callebaut, PhD - Sr Scientist, N. Margot, MS - Associate Scientist, G. Stepan, BS - Associate Scientist, Y. Tian, PhD - Research Scientist, M. Miller, PhD - Sr Director; Gilead Sci., Foster City, CA.

H-554 Albuvirtide, the First Long-Acting HIV Fusion Inhibitor,

Suppressed Viral Replicaiton in HIV-Infected Adults H. Wu, MD - Division Chief 1, C. Yao, PhD - Medical Manager 2, R. J. Lu, PhD - Vice President 2, T. Zhang, MD - Professor 1, M. X. Wang, PhD Professor 1, H. X. Zhao, MD - Professor 3, H. Y. Peng, MS - Research Assistant 4 , Y. Xie, BS - Research Assistant 2, W. J. Min, MS - Research Assistant 2, H. Jiang, PhD - Professor 2, C. J. Wang, PhD - Professor 2, D. Xie, PhD - Chief Scientific Officer2, R. H. Jin, MD - Professor 1; 1Beijing You’an Hosp., Capital Med. Univ., Beijing, China, 2Chongqing Frontier Biotechnologies Co. Ltd., Chongqing, China, 3Beijing Ditan Hosp., Capital Med. Univ., Beijing, China, 4Beijing Kao Ke Rui Co., Beijing, China. 9:45 a.m. H-555 Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/

Tenofovir DF from an Integrated Analysis of Phase 2 and 3 Clinical Trials D. Ward, MD - Owner1, G. Crofoot, MD - Owner 2, D. Shamblaw, MD Owner 3, N. Bellos, MD - Owner 4, C. Kinder, MD - Owner 5, M. Rhee, MD - As. Dir. 6; 1Dupont Cir Physicians Gr, Wash, DC, 2Gordon E. Crofoot, MD, Houston, TX, 3La Playa Med and Clin Res, San Diego, CA, 4Southwest Infectious Disease Clin Res., Dallas, TX, 5Kinder Med Gr., Miami, FL, 6 Gilead, Foster City, CA. 10:00 a.m. H-556 Switching to the Single-Tablet Regimen (STR) Emtric-

itabine/Rilpivirine/Tenofovir DF (FTC/RPV/TDF) from a Ritonavir-Boosted Protease Inhibitor (PI+RTV) and Two Nucleoside Reverse Transcriptase Inhibitors Maintains HIV Suppression and is Well Tolerated in HIV-1 Subjects at Week 24 Regardless of Age: SPIRIT Study D. Shamblaw, MD1, F. Palella, MD2, P. Ruane, MD 3, P. Tebas4, B. Gazzard5, M. Fisher 6, J. van Lunzen7, J. Flamm 8, R. Ebrahimi9, K. White9, H. Graham 9 , B. Guyer, PharmD 9, T. Fralich9, S. K. Chuck9; 1La Playa Med. Group, San Diego, CA, 2Northwestern Univ. Feinberg Sch. of Med., Chicago, IL, 3Peter J. Ruane, MD, Inc., Los Angeles, CA, 4Univ. of Penn., Philadelphia, PA, 5 Chelsea and Westminster Hosp., London, United Kingdom, 6Brighton and Sussex Univ. Hosp., Brighton, United Kingdom, 7Univ. Med. Ctr HamburgEppendorf, Hamburg, Germany, 8Kaiser Permanente, Sacramento, CA, 9 Gilead Sci., Foster City, CA. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

80

September 9-12 |

MONDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------074(K) Slide Session Multidrug-Resistant Organisms and Catheter-Related Infections Monday, 8:30 a.m.–11:00 a.m. . . . . . . . . . . . . . . . . . . Room 254 UAN: 0391-9999-12-078-L04-P Moderator: Sylvia Munoz-Price, MD - Associate Professor of Medicine Jackson Mem. Hosp., Univ. of Miami, Miami, FL. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Understand the epidemiology of MDROs in longterm care facilities; > List factors associated with survival of Acinetobacter baumannii in desiccating conditions; and > Describe successful approaches to treating meningitis caused by multidrug resistant Acinetobacter. Presentations: 8:30 a.m.

9:30 a.m. K-561 Laboratory Investigation of the Nosocomial Transmission of

Multiple Multi-Resistant Gram Negative Bacilli at a Canadian Hospital from a Patient Transferred from a Foreign Hospital J. Ahmed-Bentley, MD - Microbiologist1,2, A. U. Chandran, MD - Hospital Epidemiologist 3,2, A. M. Joffe, MD - Infectious diseases physician 3,2, A. Wolfe, BSc (MLS) - ICP 3, S. Manca, BSc (MLS) - ICP 3, K. Ng, BSc (MLS) Technologist 1, D. French, MLT - Technologist 1, D. Andrews, MLT - Technologist 1, T. Lloyd, MLT - Technologist 4, G. Peirano, PhD - Post-doc 4, J. Pitout, MD - Microbiologist 4,5; 1DynaLIFEDX, Edmonton, Canada, 2Univ. of Alberta, Edmonton, Canada, 3Royal Alexandra Hosp., Edmonton, Canada, 4 Calgary Lab. Services, Calgary, Canada, 5Univ. of Calgary, Calgary, Canada. 9:45 a.m. K-562 Successful Treatment of Extensive Drug-Resistant (XDR) A.

baumannii Meningitis with Intraventricular (IVR) Colistin (CST) after Application of a Loading Dose: A Case Series I. Karaiskos, MD - Attending Physician, L. Galani, MD - Infectious Disease specialist, F. Baziaka, PhD - Attending Physician, E. Katsouda, PhD - Intensivist, H. Paskalis, MD - Intensivist, I. Ioannidis, PhD - Interventional Neuroradiology, A. Andreou, PhD - Neurosurgery, H. Giamarellou, PhD - Professor of Internal Medicine; Hygeia Hosp., Athens, Greece. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

K-557 Prevention of Carbapenem-Resistant Enterobacteriaceae

(CRE) Spread in Long-Term Acute Care Facilities (LTACF) Via a National Intervention D. Ben-David, MD - Physician, S. Masarwa, MD - Nurse, A. Adler, MD - Microbiologist, S. Navon-Venezia, PhD - Microbiologist, G. Smollan, MD Microbiologist, B. Rubinovitch, MD - Physician, Y. Carmeli, MD - Physician, M. J. Schwaber, MD - Physician; Natl. Ctr. for Infection Control (NCIF), Israel Ministry of Health, Tel Aviv, Israel. 8:45 a.m. K-558 Prevalence and Risk Factors for Multidrug-Resistant Organ-

isms in Long-Term Care Facilities C. J. Lim, BPharm - PhD Student1,2, A. C. Cheng, MPH, PhD - Associate Professor of Infectious Diseases Epidemiology 1,2, J. Kennon - Manager of Infection Prevention and Healthcare Epidemiology 2, D. Spelman, MBBS, MPH - Head of Microbiology 2, D. Hale, BAS - Scientist of Microbiology 2, D. C. M. Kong, MPharm, PhD - Lecturer 1, A. Y. Peleg, MBBS, PhD - Senior Lecturer 1,2; 1 Monash Univ., Melbourne, Australia, 2Alfred Hlth., Melbourne, Australia. 9:00 a.m. K-559 Experimental and Proteomics Approach to Understand the

Survival of Acinetobacter baumannii in Desiccation Conditions C. Gayoso, PhD - Research Assistant, J. Mateos, PhD - Research Assistant, J. Méndez, MS - Student, P. Fernandez, PhD - Research Sssistant, M. Tomás, MD, PhD - Research Assistant, G. Bou, PhD; Univ. La Coruña, La Coruña, Spain.

-----------------------------------------------------------------------075(P) Slide Session Parasitology, Global Health and Travel Medicine Monday, 8:30 a.m.–11:00 a.m. . . . . . Esplanade Ballroom 309 UAN: 0391-9999-12-079-L04-P Moderator: Kevin Kain, MD, FRCPC - Professor of Medicine Univ. of Toronto, Toronto, Canada. Objectives: Upon completion of this Slide Session, the participant should be able to: > Describe a new molecular mechanism of resistance in Trichmonas vaginalis; > Compare the predictive utility of different clinical and laboratory features of severe dengue; > Contrast the differences between policy recommendations and the practice reality in malaria; and > Describe and recognize prognostic features severe malaria in non-immune adults. Presentations: 8:30 a.m. P-563 A Novel tvntr6 Polymorphism is Associated with Trichomonas

vaginalis Metronidazole Resistance

9:15 a.m. K-560 Prevalence of Extended Spectrum Beta-Lactamase-Producing

Enterobacteriaceae (ESBL-PE) in Chicken Meat and Food Handlers at a University Hospital Kitchen A. Stewardson, MD - Fellow1, G. Renzi, MS - Scientist 1, C. Vaudaux, MS - Food Safety Officer 1, C. Brossier, RN - Research Nurse 1, E. Fritsch, MD Physician 1, C. Bonfillon, MD - Physician 1, D. Pittet, MD - Professor 1, N. Maury, MS - Microbiologist 2, P. Edder, MS - Chemist 2, J. Schrenzel, MD - Professor 1, S. Harbarth, MD - Professor 1; 1Univ. of Geneva Hosp., Geneva, Switzerland, 2Dept. of Consumer & Vet. Affairs, Geneva, Switzerland.

S. E. Gygax, PhD - Director1, T. E. Miller, MS - Research Associate 1, P. Augostini, MS - Biologist 2, M. E. Adelson, PhD - Vice President 1, E. Mordechai, PhD - CEO 1, W. E. Secor, PhD - Research Microbiologist 2, D. W. Hilbert, PhD - Team Leader 1; 1FEMERIS Women’s Hlth. Res. Ctr., Med. Diagnostic Lab., L.L.C., Hamilton, NJ, 2CDC, Atlanta, GA.

Final Program

81

> Monday SCIENTIFIC SESSIONS 8:45 a.m. P-564 Attitude of Doctors Towards Infectious Disease Subspecialist:

A Report from South India P. Senthur Nambi, MD- Dr, R. Gopalakrishnan, MD - Doctor, A. Ghafur, MD - Doctor, P. Vidyalakshmi, MD - Doctor, C. Ashwini, MD - Doctor, V. Ramasubramanian, MD - Doctor; Apollo Hosp., Chennai, India. 9:00 a.m. P-565 Malaria Guidelines in India: Is it in Paper or in Practice? D. Sureshkumar, MD, MD- ID Fellow, K. Abdul Ghafur, MD - ID Consultant, V. Ramasubramanian, MD - ID Consultant, P. Vidyalakshmi, DNB ID Fellow, A. Tayade, DNB - ID Fellow; Apolo Hosp., Tamilnadu, India. 9:15 a.m. P-566 Hospitalized Adults with Measles in France in the 21st Century J. Stahl, MD- Professor1, M. Ojielska, MD - Assistant 2, A. Dinh, MD - Assistant 3, V. Corbin, MD - Assistant 4, E. Botelho-Nevers, MD - Assistant 5, C. Biron, MD - Assistant 6, S. Perin, MD - Assistant 7, S. Gallien, MD - Assistant 8, E. Curlier, MD - Assistant 9, T. Fraisse, MD - Head of department 10, C. Rabaud, PhD - Professor 11, Steering Comittee; 1Univ. Hosp., Grenoble, France, 2Univ. Hosp., Poitiers, France, 3Univ. Hosp., Garches, France, 4Univ. Hosp., Clermont-Ferrand, France, 5Univ. Hosp., Marseille, France, 6Univ. Hosp., Nantes, France, 7Univ. Hosp., Dijon, France, 8Univ. Hosp., Paris, France, 9Univ. Hosp., Besançon, France, 10Gen. Hosp., Alès, France, 11Univ. Hosp., Nancy, France. 9:30 a.m. P-567 Utility and Gaps of Warning Signs in Adult Dengue T. Thein, Research Fellow, Y. Leo, MRCP, FRCP, FAMS - Clinical Director, C. F. Yung, PhD - Consultant, V. C. Gan, MD - Medical Officer, J. G. Wong, BS - Medical Statistician, D. C. Lye, MBBS, FRACP, FAMS - Consultant; Tan Tock Seng Hosp., Singapore, Singapore. 9:45 a.m. P-568 Cerebral Malaria During Severe Imported Malaria in Adults:

Clinical Features, Prognostic Indices and Brain Imaging V. Laurent, MD - Doctor 1, F. Tubach, MD, PhD - Professor 2, M. Wolff, MD - Professor 2, J. P. Mira, MD, PhD - Professor 3, J. F. Timsit, MD, PhD - Professor 4, E. Azoulay, MD, PhD - Professor 5, C. Roy, PhD - Assistant 2, F. Bruneel, MD - Doctor1; 1Versailles Hosp., Versailles, France, 2Bichat Hosp. APHP, Paris, France, 3Cochin Hosp. APHP, Paris, France, 4Grenoble Hosp., Grenoble, France, 5Saint Louis Hosp. APHP, Paris, France. 10:00 a.m. P-569 Predictors of Bacteremia in Adult Dengue Y. Leo, FRCP - Associate Professor1,2, M. Yeang, NA - Medical Student 2, C. Yung, MPH - Doctor 1, T. Thein, MPH - Doctor 1, D. Lye, FRACP - Doctor 1,2 1 ; Tan Tock Seng Hosp., Singapore, Singapore, 2Natl. Univ. Singapore, Singapore. 10:15 a.m. P-570 Severe Imported Malaria in Adults: Multicenter Prospective

Physiopathological Study F. Bruneel, MD - Doctor1, F. Tubach, MD, PhD - Professor 2, J. P. Mira, MD, PhD - Professor 3, M. G. Huisse, MD - Doctor 2, S. Houze, MD - Doctor 2, S. Gibot, MD, PhD - Professor 4, S. Matheron, MD - Professor 2, M. Wolff, MD - Professor 2, SIMA-P Study Group; 1Versailles Hosp., Versailles, France, 2 Bichat Hosp. AP HP, Paris, France, 3Cochin Hosp. AP HP, Paris, France, 4 Nancy Central Hosp., Nancy, France.

82

September 9-12 |

-----------------------------------------------------------------------076(K) Interactive Symposium Challenges in Infection Control Monday, 11:15 a.m.–12:45 p.m. . . . . . . . . . . . . . . . . . Room 104 UAN: 0391-9999-12-080-L04-P Conveners: Didier Pittet, MD, MS - Professor of Medicine Univ. of Geneva Hosp., Geneva, Switzerland. Jean-Francois Timsit, MD, PhD - Professor CHU A. Michallon, Univ. Joseph Fourier, Grenoble, France. Speakers: 571 A) Reality Check for Mathematical Models: Is MRSA

Decolonization in the ICU a Viable Option? PRO Ben S. Cooper, PhD - Research Fellow Mahidol-Oxford Res. Unit, Bangkok, Thailand. 572 A) Reality Check for Mathematical Models: Is MRSA

Decolonization in the ICU a Viable Option? CON Stephan Harbarth, MD, MS - Professor Univ. of Geneva Hosp., Geneva, Switzerland. 573 B) Do Bundles of Infection Prevention Measures Produce

Sustained Reductions in Catheter-Associated Bloodstream Infections? PRO TBD 574 B) Do Bundles of Infection Prevention Measures Produce Sus-

tained Reductions in Catheter-Associated Bloodstream Infections? CON Jean-Francois Timsit, MD, PhD - Professor CHU A. Michallon, Univ. Joseph Fourier, Grenoble, France. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss the advantages/disadvantages of MRSA prevention strategies in the ICU setting; > Describe the concept of mathematical modeling, including its value and shortcomings in infection control; > Identify the concept of bundles and its role to help improve processes of care and patient outcomes; and > Identify the most effective components to be included in infection control bundles for a sustained effect. Intended Audience: ID specialists, infection control professionals, hospital epidemiologists, public health professionals, and hospital administrators. Level: Beginning/Intermediate

MONDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------077(G, H) Symposium

11:15 a.m. 578 New Novel Uses of Fluoroquinolones (Including Polyoma Virus,

Leprosy, MTB)

Vaccine Innovations

Ethan Rubinstein, MD - Professor Univ. of Manitoba, Winnipeg, Canada.

Monday, 11:15 a.m.–12:45 p.m. . . . . Esplanade Ballroom 305 UAN: 0391-9999-12-081-L04-P

11:45 a.m.

Conveners: Carlo Giaquinto, MD - Medical Doctor Paediatrician Azienda Ospedaliera-Univ., Padova, Italy. Richard Koup, MD - Senior Investigator NIH Vaccine Res. Ctr., Bethesda, MD.

Ian M. Gould, MD - Doctor Aberdeen Royal Infirmary, Aberdeen, United Kingdom. 12:15 p.m. 580 New Quinolones: What’s on the Horizon? David C. Hooper, MD - Professor Harvard Med. Sch., Boston, MA.

Speakers: 11:15 a.m. 575 Development of a Novel Multi-Antigen Vaccine to Prevent

Staphylococcus aureus Infection and Disease Annaliesa S. Anderson, PhD - Senior Director Vaccine Research Pfizer Vaccine Res., Pearl River, NY. 11:45 a.m. 576 A Universal Influenza Vaccine? Wendy A. Keitel, MD - Professor of Molecular Virology & Microbiology and Medicine Baylor Coll. of Med., Houston, TX. 12:15 p.m. 577 A Vaccine for HIV-1: Harnessing Cross-Reactive Antibodies Richard Koup, MD - Senior Investigator NIH Vaccine Res. Ctr., Bethesda, MD. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss progress toward and challenges remaining to development of a vaccine to prevent HIV-1 infection; > Discuss progress toward and challenges remaining to develop a prophylactic Staphylococcus aureus vaccine; and Discuss progress toward and challenges remaining to realization of a universal vaccine for influenza. Intended Audience: All attendees Level: Intermediate

-----------------------------------------------------------------------078(L, F) Symposium 50 Years of Fluoroquinolones: Past, Present and Future Monday, 11:15 a.m.–12:45 p.m. . . . . . . . . . . . . . . . . . Room 132 UAN: 0391-9999-12-082-L04-P Developed in Cooperation with the International Society of Chemotherapy (ISC) Conveners: David C. Hooper, MD - Professor Harvard Med. Sch., Boston, MA. Teresita Mazzei, MD - Professor of Chemotherapy Univ. of Florence, Florence, Italy. Speakers:

579 Use and Abuse: Why, How and So What?

Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss the fluoroquinolone drug class, including the emergence of resistance; > Describe how to effectively use fluoroquinolones for clinical care, including both efficacy and adverse reactions; and > Identify new fluoroquinolone agents that are under development. Intended Audience: Clinicians, scientists, researchers, microbiologists, and pharmacists. Level: All Levels

-----------------------------------------------------------------------079(L) Symposium An Update on Streptococcal Pharyngitis and Rheumatic Fever Monday, 11:15 a.m.–12:45 p.m. . . . . Esplanade Ballroom 302 UAN: 0391-9999-12-083-L04-P Conveners: Shiranee Sriskandan, MD, PhD - Professor Imperial Coll., London, United Kingdom. Andrew C. Steer, MD, PhD - Senior Research Fellow Univ. of Melbourne and Royal Children’s Hosp., Melbourne, Australia. Speakers: 11:15 a.m. 581 Group A Streptococcus Pathogenesis in Pharyngitis Michael Wessels, MD - Professor Children’s Hosp. Boston, Harvard Med. Sch., Boston, MA. 11:45 a.m. 582 Update on Diagnosis and Management of Streptococcal Phar-

yngitis Stanford T. Shulman, MD - Professor Northwestern Univ. Feinberg Sch. of Med., Chicago, IL. 12:15 p.m. 583 Rheumatic Fever 2012 and Beyond Andrew C. Steer, MD, PhD - Senior Research Fellow Univ. of Melbourne and Royal Children’s Hosp., Melbourne, Australia.

Final Program

83

> Monday SCIENTIFIC SESSIONS Objectives: Upon completion of this Symposium Session, the participant should be able to: > Identify key pathogenetic factors that enable S. pyogenes to cause pharyngeal infection; > Diagnose and manage Strep pharyngitis in the modern era; and > Discuss the epidemiology of strep pharyngitis and rheumatic fever. Intended Audience: Pediatric infectious diseases and outpatient ID specialists. Level: Intermediate

-----------------------------------------------------------------------080(V, H) Symposium Hot Topics in Viral Hepatitis Monday, 11:15 a.m.–12:45 p.m. . . . . . . . . . . . . . . . . . Room 130 UAN: 0391-9999-12-084-L04-P Conveners: Emily A. Blumberg, MD - Professor of Medicine Perelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA. Jean-Michel G. Molina, MD - Professor Hosp. Saint Louis and Univ. of Paris 7, Paris, France. Speakers:

Carbapenemase in Enterobacteriaceae and P. aeruginosa Monday, 11:15 a.m.–12:45 p.m. . . . . . . . . . . . . . . . . . Room 122 UAN: 0391-9999-12-085-L04-P Moderators: Patrice Nordmann, MD - Professor Hosp. Bicetre, Le-Kremlin-Bicetre, France. Mariana Castanheira, PhD - Associate Director JMI Lab., North Liberty, IA. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Discuss the most modern features of carbapenemases and their direction; > Decipher the genetics of carbapenemases; and > Explore the tools used to differentiate various carbapenemases. Presentations: 11:15 a.m. C1-587 Rapid Detection of Carbapenemase-Producing Enterobacte-

riaceae Using a Totally Novel Approach P. Nordmann, MD, PhD - Professor, L. Poirel, PhD - Associate Researcher, L. Dortet, PharmD - Assistant Professor; Hosp. de Bicetre, Le Kremlin Bicetre, France.

11:15 a.m. 584 Hepatitis C: Impact of New and Future Therapeutics Norah Terrault, MD, MPH - Professor of Medicine Univ. of California San Francisco, CA. 11:45 a.m. 585 Hepatitis B: Management of Mono and HIV Co-Infected

Individuals Douglas T. Dieterich, MD - Professor of Medicine Mount Sinai Sch. of Med., New York, NY. 12:15 p.m. 586 Epidemiology and Management of the Normal and

Immunosuppressed Host with Hepatitis E Nassim Kamar, MD, PhD - Professor Toulouse Univ. Hosp., Toulouse, France. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Differentiate treatment options for Hepatitis B and C for unique patient populations including HIV coinfected patients and transplant recipients; > Formulate appropriate treatment plans for Hepatitis viruses in different patient populations, recognizing the impact of drug interactions; and > Describe the epidemiology of Hepatitis E and assess treatment options in normal and immunosuppressed hosts. Intended Audience: Physicians, pharmacists, and clinical microbiologists/ virologists. Level: Intermediate

84

-----------------------------------------------------------------------081(C1) Slide Session

September 9-12 |

11:25 a.m. C1-588 Integron and Species Diversity in a Long-Term Outbreak of

GIM-1-Carrying Bacteria A. F. Wendel, MD- Resident1, A. H. B. Brodner, MD - Resident 1, B. Henrich, PhD - Professor 1, R. Deenen, PhD - Research Assistant 2, K. Köhrer, PhD - Professor 2, S. Ressina, BSc - Student 1, K. Pfeffer, MD - Professor 1, C. R. MacKenzie, MD - Professor 1; 1Inst. of Med. Microbiol. and Hosp. Hygiene, Heinrich-Heine Univ., Düsseldorf, Germany, 2Biologisch-Medizinisches Forschungszentrum, Heinrich-Heine Univ., Düsseldorf, Germany. 11:35 a.m. C1-589 Complete Nucleotide Sequence of blaKPC-4 and blaKPC-5

Harboring IncN and IncX Plasmids Isolated in New Jersey L. Chen, PhD- Research Associate1, K. D. Chavda, MS - Research Associate 1, J. R. Mediavilla, MS - Research Associate 1, H. S. Fraimow, MD - Professor 2, R. G. Melano, PhD - Professor 3, B. N. Kreiswirth, PhD - Research Associate 1; 1 Publ. Hlth. Res Ins, Uni of Med & Den of NJ, Newark, NJ, 2Cooper Uni Hosp, Camden, NJ, 3Publ. Hlth. Ontario, Toronto, Canada. 11:45 a.m. C1-590 ESBL-MBLs- Metallo-Beta-Lactamases with Extended-

Spectrum Beta-Lactamase (ESBL) Phenotypes? Defining the Role of Arg228 in Vim-2 and Vim-24 M. F. Mojica, MS - Research Assistant1, S. H. Marshall, MS - Research Assistant 2, C. J. Wallace, MS - Adjunct Professor 3, C. R. Bethel, MS - Research Assistant 2, M. A. Taracila, MS - Research Assistant 2, M. V. Villegas, MD - Scientific Director 1, R. A. Bonomo, MD - Professor 2; 1CIDEIM, Cali, Colombia, 2Cleveland VAMC, Cleveland, OH, 3Lakeland Community Coll., Kirtland, OH.

MONDAY SCIENTIFIC SESSIONS 11:55 a.m.

L. Poirel, PhD - Associate Researcher, E. Rondinaud, PharmD - Resident, A. Potron, PharmD - Assistant Professor, P. Nordmann, MD, PhD - Professor; Hosp. de Bicetre, Le Kremlin Bicetre, France.

PhD - Researcher 1, B. Aracil, PhD - Researcher 4, E. Cercenado, PhD - Researcher 5, E. Miro, PhD - Researcher 6, A. Oliver, PhD - Professor 2, J. Oteo, PhD - Professor 4, F. Navarro, PhD - Professor 6, G. Bou, PhD - Professor1; 1 Univ. La Coruña, La Coruña, Spain, 2HU Son Espases, Palma de Mallorca, Spain, 3Univ. de Liège, Liège, Belgium, 4Ctr. Natl. de Microbiología, Madrid, Spain, 5HGU Gregorio Marañón, Madrid, Spain, 6Hosp. de la Santa Creu i Sant Pa, Barcelona, Spain.

12:05 p.m.

12:25 p.m.

C1-591 Genetic Features of OXA-48-Producing Enterobacterial

Isolates

C1-592 Whole Genome Sequencing and Analysis of 12 blaNDM-1

Harbouring Isolates Including the Index Klebsiella pneumoniae blaNDM-1 Isolate H. S. Gibbons, PhD - Group Leader 1, M. D. Krepps, PhD - Research fellow 1 , T. R. Walsh, PhD - Prof 2, M. A. Toleman, PhD - Senior Research Fellow2; 1 US Army Edgewood Biological Chemical Ctr., Baltimore, MD, 2Cardiff Univ., Cardiff, United Kingdom. 12:15 p.m. C1-593 Characterization of a Novel IMP-28 Metallo-ơ-Lactamase

from a Spanish Klebsiella oxytoca Isolate F. Pérez-Llarena, PhD - Researcher 1, A. Fernández, student - PhD Student 1 , L. Zamorano, PhD - Researcher 2, F. Kerff, PhD - Researcher 3, A. Beceiro,

C1-594 IMP-33, a New IMP Variant Detected in Pseudomonas aerugi-

nosa (PSA) from Italy L. M. Deshpande, PhD - RSc 1, T. A. Davies, PhD - Principal Sci 2, G. Blandino, BS - MT 3, G. Nicoletti, PhD - Prof 3, R. N. Jones, MD - CEO 1, M. Castanheira, PhD - Dir1; 1JMI Lab., N Liberty, IA, 2Jansen R&D, Raritan, NJ, 3Univ. di Catania, Catania, Italy. 12:35 p.m. C1-595 Biochemical Characterization of OXA-240, a Novel Class D

Carbapenemase Identified in Pseudomonas aeruginosa J. J. Lee, MS - Research Assistant, J. H. Lee, MS - Research Assistant, X. Wu, MS - Research Assistant, D. B. Kwon, MS - Research Assistant, S. H. Lee, PhD - Professor; Myongji Univ., Yongin, Korea, Republic of.

-----------------------------------------------------------------------------------------------------------------------------------------------------POSTER WALK Monday, September 10 | 11:15 a.m.-12:15 p.m. | Halls A-C

Monday, September 10 | 12:15 p.m. - 1:15 p.m. | Halls A-C

Daily Infection Prevention and Control Issues

Resistance Genes Have No Boundaries!

Convener: Loreen Herwaldt, MD - Professor, Hospital Epidemiologist Univ. of Iowa Coll. of Med., Iowa City, IA. Presentations:

Prosthetic Joint Infection (PJI) Should Be Considered In Prosthetic Failure within 2 Years of Implantation M. E. Portillo; Reference Lab. of Catalunya, Barcelona, Spain. Hospital-Acquired Influenza in an Australian Sentinel Surveillance System N. Macesic; Alfred Health, Melbourne, Australia. Rapid Screening Tests for MRSA Did Not Decrease Postoperative MRSA Infections in Patients with Inflammatory Bowel Disease (IBD) Y. Takahashi; Hyogo Coll. of Med., Nishinomiya, Japan.

What to breath? Performance analysis of Air Samplers in Operating Rooms L. Ummels; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands. Characteristics of Septic Arthritis - A Retrospective Study Over 11 Years L. N. Walti; Univ. Hosp., Lausanne, Switzerland.

Conveners: Lesley McGee, PhD CDC, Atlanta, GA. Johann D. Pitout, MD Univ. of Calgary, Calgary, Canada. Presentations:

Molecular Characterization of Multidrug-Resistant Mycobacterium tuberculosis from Asian Countries C. Nakajima; Hokkaido Univ. Res. Ctr. for Zoonosis Control, Sapporo, Japan.

Extended-Spectrum Beta-Lactamase (ESBL) Producing GramNegative Bacteria from Pets, Buffalos and Psittacines, Brazil L. Barbato; USP, São Paulo, Brazil.

Accessory Gene Regulator (AGR) Function, rpoB Mutations and Vancomycin (VA) Susceptibility in Methicillin-Resistant Staphylococcus aureus (MRSA) Blood Isolates M. Camoez; Hosp. Univ Bellvitge. UB. IDIBELL, Barcelona, Spain. Lack of Impact of Infant PCV Vaccination on Rates of Adult Invasive Pneumococcal Disease in Ontario, Canada K. Wong; Mount Sinai Hosp., Toronto, Canada.

Current Status of Group B Streptococci (GBS) in Japan -Penicillin-resistant GBS is Emerging in Japan? H. Mikamo; Aichi Med. Univ., Aichi, Japan.

Dissemination of Diverse Plasmids Bearing blaKPC Among Carbapenem-Resistant Enterobacteriaceae (CRE) Different from Klebsiella spp. in a Hospital System in Cleveland F. Perez; VAMC, Cleveland, OH, 3CWRU, Cleveland, OH.

Final Program

85

> Monday SCIENTIFIC SESSIONS -----------------------------------------------------------------------082(A) Poster Session Glycopeptides and Lipopeptides: What’s New in PK/ PD and Safety Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-596 Menadione-Dependent Small-Colony Variants of MRSA are

Hypersusceptible toơ-Lactams Intracellularly Due to Cooperation Between Vacuolar Acidic pH and Oxidant Species L. G. Garcia 1, S. Lemaire 1, B. C. Kahl 2, K. Becker 2, R. A. Proctor 3, P. M. Tulkens1, F. Van Bambeke 1; 1Univ. Catholique de Louvain, Brussels, Belgium, 2Univ. Muenster, Muenster, Germany, 3Univ. Wisconsin, Madison, WI. A-597 Activity of Antibiotics against a Normal Phenotype MRSA

and its menD and hemB Mutants on Models of Bronchial Epithelial Cells Expressing Wild-Type, F508del or No CFTR 1

2

2

3

4

L. G. Garcia , B. C. Kahl , K. Becker , R. A. Proctor , O. Denis , P. M. Tulkens1, F. Van Bambeke1; 1Univ. Catholique de Louvain, Brussels, Belgium, 2Univ. Muenster, Muenster, Germany, 3Univ. Wisconsin, Madison, WI, 4 Univ. Libre de Bruxelles, Brussels, Belgium. A-598 Activity of Anti-Staphylococcal Antibiotics in an In Vitro

Model of Biofilm Using Clinical Isolates of S. aureus J. Bauer 1, M. Hallin 2, O. Denis2, P. M. Tulkens1, F. Van Bambeke1; 1Univ. Catholique de Louvain, Brussels, Belgium, 2Univ. Libre de Bruxelles, Brussels, Belgium. A-599 Influence of Oxidant Stress on the Activity of Antibiotics

against the Extracellular and Intracellular (THP-1 cells) Forms of S. aureus (SA) and its Small Colony Variants (SCV) Mutants 1

1

2

2

3

L. G. Garcia , S. Lemaire , B. C. Kahl , K. Becker , R. A. Proctor , P. M. Tulkens1, F. Van Bambeke1; 1Univ. Catholique de Louvain, Brussels, Belgium, 2Univ. Muenster, Muenster, Germany, 3Univ. Wisconsin, Madison, WI. A-600 Evaluation of the Daptomycin (DAP) Mutant Selection

mycin (HD-DAP) plus Trimethoprim/Sulfamethoxazole (TMP/ SMX) against Daptomycin Non-susceptible (DNS) MethicillinResistant Staphylococcus aureus (MRSA) Using an In Vitro Pharmacokinetic/Pharmacodynamic (PK/PD) Model of Simulated Endocardial Vegetations (SEVs) M. E. Steed, B. J. Werth , C. E. Ireland, M. J. Rybak; Anti-Infective Res. Lab., Wayne State Univ., Detroit, MI. A-604 Impact of High Dose Daptomycin in Preventing Resistance

Development in Viridans Group Streptococci R. L. Akins; Univ. of Louisiana Monroe, Monroe, LA. A-605 Pharmacokinetic (PK) / Pharmacodynamic (PD) / Toxicody-

namic (TD) Evaluation of Daptomycin (DAP) Efficacy & Safety against Staphylococcus aureus (SA) R. L. Soon, S. J. Turner, A. Forrest, B. T. Tsuji, J. Brown ; Univ. at Buffalo, Buffalo, NY. A-606 Daptomycin (D) Pharmacokinetics (PK) and Pharmacody-

namics (PD) in a Pooled Sample of Hemodialysis (HD) Patients (Pts) J. M. Butterfield1, N. Patel 1, B. A. Mueller 2, D. W. Grabe1, K. E. Cardone 1, N. N. Salama 3, T. P. Lodise1; 1Albany Coll. of Pharmacy and Hlth. Sci., Albany, NY, 2Univ. of Michigan Coll. of Pharmacy, Ann Arbor, MI, 3St. Louis Coll. of Pharmacy, St. Louis, MO. A-607 Optimal Loading Dose Regimen of Teicoplanin (TEIC) to

Achieve Higher Trough Level (Cmin) in Patients with Renal Dysfunction T. Ueda, Y. Takesue, K. Nakajima, K. Ichki, M. Komastu, Y. Wada, T. Tsuchida, Y. Takahashi, M. Ishihara; Hyogo Coll. of Med., Nishinomiya, Japan. A-608 New Target Trough Level (Cmin) of Teicoplanin (TEIC) in

Patients with Common MRSA Infections T. Ueda, Y. Takesue, K. Nakajima, K. Ichki, M. Komastu, Y. Wada, T. Tsuchida, Y. Takahashi, M. Ishihara; Hyogo Coll. of Med., Nishinomiya, Japan. A-609 Impact of High Inoculum of Heteroresistance Methicillin-

Window in Vancomycin Resistant Enterococci (VRE) in a Pharmacokinetic/Pharmacodynamic (PK/PD) Model of Simulated Endocardial Vegetations (SEV)

Susceptible Staphylococcus aureus on the Activities of Cefazolin Alone and in Combination with Vancomycin in an In Vitro Pharmacodynamic Model

B. J. Werth1, C. E. Ireland 1, M. E. Steed 2, M. J. Rybak1; 1Anti-Infective Res. Lab., Wayne State Univ., Detroit, MI, 2Univ. Kansas Med. Ctr., Kansas City, KS.

V. Huang1, M. J. Zervos 2,3; 1Mercer Univ. Coll. of Pharmacy and Hlth. Sci., Atlanta, GA, 2Henry Ford Hlth. System, Detroit, MI, 3Wayne State Univ. Sch. of Med., Detroit, MI.

A-601 Evaluation of Daptomycin (DAP) Plus Ceftriaxone (CTX)

A-610 Adjusted Vancomycin (VAN) Dosage to Reach an AUC/

against Vancomycin-Resistant Enterococcus faecium (VREFm) and faecalis (VREFs) in an In Vitro Pharmacokinetic/Pharmacodynamic (PK/PD) Simulated Endocardial Vegetation (SEV) Model

MIC Index 400 Did Not Improve the Outcome of Experimental Endocarditis (EE) Caused by Methicillin-Resistant Staphylococcus aureus (MRSA) Strains With Different VAN MICs

A. D. Hall1, G. Sakoulas 2, M. J. Rybak1; 1Wayne State Univ., Detroit, MI, 2 Univ of California San Diego, La Jolla, CA.

J. M. Miro, C. García-de-la-Maria, X. Castañeda, A. del-Rio, Y. Armero, C. Cervera, D. Soy, A. Moreno, J. M. Pericas, M. Almela, C. A. Mestres, C. Falces, S. Ninot, J. M. Gatell, F. Marco, Hospital Clinic Endocarditis Study Group; Hosp. Clinic, IDIBAPS, Barcelona, Spain.

A-602 A Preliminary Evaluation of the Novel Combination of Dap-

tomycin Plus Fosfomycin (FOS) against Vancomycin-Resistant Enterococcus Using an In Vitro Pharmacokinetic/Pharmacodynamic (PK/PD) Bacteremia Model A. D. Hall, B. J. Werth, J. P. McRoberts, M. J. Rybak; Wayne State Univ., Detroit, MI.

86

A-603 Evaluation of the Novel Combination of High Dose Dapto-

September 9-12 |

A-611 Population Pharmacokinetics (PK) of Vancomycin in Hospi-

talized Patients A. Chaturvedula 1, S. Mok 2, M. Chesson 1, M. J. Fossler 3, J. T. Jacob 4; 1 Mercer Univ., Atlanta, GA, 2Emory Healthcare, Atlanta, GA, 3GlaxoSmithKline, Prince of Prussia, PA, 4Emory Univ., Atlanta, GA.

MONDAY SCIENTIFIC SESSIONS A-612 Comparison of Vancomycin Dosing in Normal Body Habitus,

Overweight, and Obese Pediatric Patients M. P. Nelson1,2, D. E. Heble 2, D. A. Hunstad 3; 1Southern Illinois Univ. Edwardsville, Edwardsville, IL, 2St. Louis Children’s Hosp., St. Louis, MO, 3 Washington Univ., St. Louis, MO. A-613 Comparing Outpatient Parenteral Antimicrobial Therapy

(OPAT) for Methicillin-Sensitive Staphylococcus aureus (MSSA) Infection Using an In Vitro Pharmacodynamic Model (IPDM) H. Iacovides, C. Huang, S. Zelenitsky; Univ. of Manitoba, Winnipeg, Canada. A-614 Predictive Performance of Pharmacokinetic Models of Outpa-

tients Receiving Vancomycin Continuous Infusions T. M. Ng1, W. P. Lim 1, M. Chan 1, D. C. Lye 1, V. H. Tam2; 1Tan Tock Seng Hosp., Singapore, Singapore, 2Univ. of Houston, Houston, TX. A-615 Vancomycin Dose and Duration of Therapy as Risk Factors for

Nephrotoxicity in Adult Patients J. Brown 1, V. Stevens1, K. Brown 2, N. Onufrak 1; 1SUNY Buffalo Sch. of Pharmacy and Pharmaceutical Sci., Buffalo, NY, 2Univ. of Rochester Med. Ctr., Rochester, NY. A-616 Vancomycin Nephrotoxicity With or Without Administration

of Intravenous Contrast Media

A-622 Comparative Activity of Telavancin (TLV) Combined with

Nafcillin (NAF), Imipenem (IMP), and Gentamicin (GEN) against Staphylococcus aureus in an In Vitro Pharmacokinetic/ Pharmacodynamic (PK/PD) Model S. N. Leonard 1,2, M. E. Supple 1; 1Northeastern Univ., Boston, MA, 2 Brigham and Women’s Hosp., Boston, MA. A-623 A Single-Center, Randomized, Placebo- and Positive-Con-

trolled, Parallel-Group Study of the Electrocardiographic Effects of Dalbavancin in Healthy Male and Female Subjects M. Dunne1, S. R. Moriarty 1, C. R. Sprenger 2; 1Durata Therapeutics, Morristown, NJ, 2Cetero Res., Fargo, ND.

-----------------------------------------------------------------------083(A) Poster Session Improving Pharmacodynamics of Beta-Lactams and Beta-Lactamase Inhibitors Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-624 %fT>MIC Predicts Probability of Microbiological Outcome

A. Lee1, J. Joo 2, A. Jeng 2, P. Chan 1; 1Western Univ. of Hlth. Sci., Pomona, CA, 2Olive View-UCLA Med. Ctr., Sylmar, CA. A-617 Average 24-Hour Area Under the Vancomycin (V) Serum

Concentration-Time Curve (AUC), Degree of Nephrotoxicity (NT), and Need for Dialysis V. Stevens1, N. Onufrak 1, K. Brown 2, J. Brown 1; 1SUNY Buffalo Sch. of Pharmacy and Pharmaceutical Sci., Buffalo, NY, 2Univ. of Rochester Med. Ctr., Rochester, NY. A-618 Weight-Based Maintenance Dosing of Vancomycin in

Hemodialysis

in the Treatment of Nosocomial Pneumonia by Ceftobiprole A. E. Muller1, N. Punt 2, J. W. Mouton 1; 1UMC St Radboud, Nijmegen, Netherlands, 2Medimatics, Maastricht, Netherlands. A-624a Monte Carlo Simulations Based on Phase 1 Studies Predict

Target Attainment of Ceftobiprole in Nosocomial Pneumonia Patients: A Validation Study A. Muller1, A. H. Schmitt-Hoffmann2, N. Punt 3, J. W. Mouton; 1UMC St Radboud, Nijmegen, Netherlands, 2Basilea Pharmaceutica Intl. Ltd, Basel, CH, Basel, Switzerland, 3Medimatics, Maastricht, Netherlands. A-625 Efficacy of Ceftaroline Fosamil in the Staphylococcal Murine

D. Ezdon 1, M. Brown 1,2, M. Meshay 1, A. Brophy 1,3, R. Hickey 1,4, S. Aggarwal 1,5, R. Polisetty 1,6, B. Cuhaci 5, J. Mitchell 1, H. P. Schlecht 1,5; 1 Hahnemann Univ. Hosp., Philadelphia, PA, 2Nanticoke Mem. Hosp., Seaford, DE, 3Mercy St. Vincent Med. Ctr., Toledo, OH, 4Hosp. of the Univ. of Pennsylvania, Philadelphia, PA, 5Drexel Univ. Coll. of Med., Philadelphia, PA, 6Midwestern Univ., Chicago Coll. of Pharmacy, Downers Grove, IL. A-619 Pharmacokinetics of Vancomycin in Patients Undergoing

Continuous Venovenous Hemodialysis G. P. Mascara 1, R. Simpson 1, R. L. McGill 1,2, N. H. Chan-Tompkins1; 1 Allegheny Gen. Hosp., Pittsburgh, PA, 2Drexel Univ. Coll. of Med., Pittsburgh, PA. A-620 Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of

Oritavancin (ORI) against Staphylococcus aureus (SA) Using Data from a Murine-Thigh Infection Model 1

2

1

2

1

O. O. Okusanya , D. Lehoux , A. Forrest , G. Moeck , C. C. Bulik , P. G. Ambrose 1, S. M. Bhavnani 1; 1ICPD, Latham, NY, 2The Med. Company, St. Laurent, Canada. A-621 Effect of Telavancin (TEL) and Vancomycin (VAN) Clearance

on Staphylococcus aureus Activity in an In Vitro Pharmacokinetic/ Pharmacodynamic (PK/PD) Model of Varying Renal Function

Pneumonia Model A. A. Bhalodi 1, J. L. Crandon 1, D. Biek 2, D. P. Nicolau1; 1Ctr. for Anti-Infect. Res. & Dev., Hartford Hosp., Hartford, CT, 2Cerexa, Inc., Oakland, CA. A-626 An Evaluation of Ceftaroline (CPT) and Daptomycin (DAP)

or Vancomycin (VAN) Combination against an Isogenic Methicillin-Resistant Staphylococcus aureus (MRSA)/ Vancomycin Intermediate S. aureus (VISA) Pair in an In Vitro Pharmacokinetic/ Pharmacodynamic (PK/PD) Model B. J. Werth1, G. Sakoulas 2, W. E. Rose 3, M. J. Rybak1; 1Anti-Infective Res. Lab., Wayne State Univ, Detroit, MI, 2Univ. of California, La Jolla, CA, 3 Univ. of Wisconsin-Madison, Madison, WI. A-627 Evaluation of Ceftaroline (CPT) Activity against Heterore-

sistant Vancomycin Intermediate Staphylococcus aureus (hVISA) and VISA Methicillin-Resistant S. aureus (MRSA) Strains in an In Vitro Pharmacokinetic/Pharmacodynamic(PK/PD) Model: Exploring the “Seesaw Effect” B. J. Werth1, M. E. Steed 2, G. W. Kaatz 3,4, M. J. Rybak1; 1Anti-infective Res. Lab., Wayne State Univ., Detroit, MI, 2Univ. Kansas Med. Ctr., Kansas City, KS, 3Wayne State Univ., Detroit, MI, 4John D. Dingell VA Med. Ctr, Detroit, MI.

W. Rose1, T. Liebenstein 2, C. Vandevoorde1; 1Univ. of Wisconsin, Madison, WI, 2Univ. of Wisconsin Hosp. and Clinics, Madison, WI.

Final Program

87

> Monday SCIENTIFIC SESSIONS A-628 Assessment of the Antistaphylococcal Effect of Ceftaroline in

Long Duration Human Dose Simulations: Impact of MIC K. E. Bowker, A. R. Noel, S. Tomaselli, D. L. Nicholls, A. P. MacGowan; Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom. A-629 Pharmacodynamics of Ceftaroline against Enterobacteriaceae K. E. Bowker, A. R. Noel, S. G. Tomaselli, D. L. Nicholls, A. P. MacGowan; Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom. A-630 Efficacy of Humanized Ceftaroline-Fosamil/Avibactam Expo-

sures against Enterobacteriaceae Exhibiting MICs 1 μg/mL A. A. Bhalodi 1, J. L. Crandon1, G. Williams2, D. P. Nicolau 1; 1Ctr. for Anti-Infect. Res. & Dev., Hartford Hosp., Hartford, CT, 2Cerexa, Inc., Oakland, CA. A-631 The Pharmacodynamics of Avibactam (NXL104) in Combina-

for Betalactams, Aminosides, Glycopeptides and Other Antimicrobial Agents N. Lemaire, N. Gauthier, A. Le Joubioux, N. Van Grunderbeeck, S. Barrailler, B. Frimat; Lens Hosp., Lens, France. A-639 Integrating Pharmacodynamics and MIC Distributions to

Assess Changing Activity of Amikacin, Cefepime, Ciprofloxacin, Colistin, Gentamicin, Meropenem and Piperacillin-Tazobactam against Clinical Strains of Pseudomonas aeruginosa in Canadian Hospitals from 2007 to 2011 S. Zelenitsky1, E. Rubinstein 1, R. Ariano 2, G. Zhanel 1; 1Univ. of Manitoba, Winnipeg, Canada, 2St. Boniface Gen. Hosp., Winnipeg, Canada. A-640 Steady-State Pharmacokinetics/Pharmacodynamics of Cefo-

tion with Either Ceftaroline or Ceftazidime against Blactamase Producing Enterobacteriaceae

perazone/Sulbactam in Hospital-Acquired Pneumonia Patients Caused by Multidrug-Resistant Nonfermentative Bacilli

A. R. Noel1, S. G. Tomaselli 1, D. L. Nicholls 1, K. E. Bowker 1, G. Williams 2, A. P. MacGowan 1; 1Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom, 2Cerexa Inc, Oakland, CA, USA, a wholly-owned subsidiary of Forest Lab. Inc, Oakland, CA.

Y. J. Zhou, Y. Y. Zhang, B. N. Guo, X. J. Wu, J. F. Wu, Y. C. Chen, J. C. Yu, X. Y. Ye, J. Zhang, Y. G. Shi, M. G. Wang; Huashan Hosp., Fudan Univ., Shanghai, China.

A-632 In Vitro Efficacy of Simulated Human Exposures of Ceftazi-

dime-Avibactam against Pseudomonas aeruginosa in a Hollow Fiber Model V. Schuck, M. A. Tanudra, M. Beaudoin, K. Vishwanathan, W. Nichols; AstraZeneca, Waltham, MA. A-633 Comparative Efficacy of Human Simulated Exposures of

Ceftazidime (CAZ) and Ceftazidime-Avibactam (CAZ-AVI) against Clinical Pseudomonas aeruginosa Isolates J. L. Crandon, M. Banevicius, D. P. Nicolau; Ctr. for Anti-Infect. Res. & Dev., Hartford Hosp., Hartford, CT. A-634 Population Pharmacokinetic Modeling of Ceftazidime (CAZ)

and Avibactam (AVI) in Healthy Volunteers and Patients with Complicated Intra-Abdominal Infection (cIAI) 1

2

2

1

3

4 1

J. Li , W. Knebel , M. Riggs , D. Zhou , W. Nichols , S. Das ; AstraZeneca, Wilmington, DE, 2Metrum Res Gp, Tariffville, CT, 3AstraZeneca, Waltham, MA, 4AstraZeneca, Alderley Park, United Kingdom. A-635 Evaluation of Ceftazidime-Avibactam (CAZ-AVI) Dose

Regimens for Phase III Study in Patients with Different Renal Function J. Li 1, D. Zhou 1, W. Nichols2, S. Das 3; 1AstraZeneca, Wilmington, DE, 2 AstraZeneca, Waltham, MA, 3AstraZeneca, Alderley Park, United Kingdom. A-636 Mathematical Modeling of Ceftazidime for High-Flux Hemo-

dialysis Patients A. Loo1,2, M. Neely 3, E. Anderson 2,4, C. Ghossein 2,4, M. Griffith 1,2, M. Scheetz 1,2; 1Midwestern Univ., Downers Grove, IL, 2Northwestern Mem. Hosp., Chicago, IL, 3USC Keck Sch. of Med., Los Angeles, CA, 4Northwestern Univ. Feinberg Sch. of Med., Chicago, IL. A-637 Standard Dosage Regimens of Broad-Spectrum Beta-Lactams

are Inadequate to Treat Difficult-to-Treat Pathogens in Obese Non-Critically Ill Patients M. C. Hites, F. Wolff, F. S. Taccone, E. Maillart, G. Deprez, J. Araci, R. Surin, F. Cotton, F. Jacobs; Erasme Hosp., Free Univ. of Brussels, Brussels, Belgium.

88

A-638 Antibiotic Dosing in Adult Obese Patients: A Calculator

September 9-12 |

A-641 Safety and Pharmacokinetics (PK) of Intravenous (IV)

Ceftolozane/Tazobactam (C/T) 3 G Every 8 Hours (Q8h) and Cumulative Fraction of Response (CFR) in Plasma and Epithelial Lining Fluid (ELF) in a Simulated Ventilator-Associated Pneumonia (VAP) Population B. Miller, G. Chandorkar, O. Umeh, I. Friedland, E. Hershberger; Cubist Pharmaceuticals, Lexington, MA. A-642 Pharmacodynamics of Piperacillin/Tazobactam (P/T) against

Pseudomonas aeruginosa: Antibacterial Effect and Risk of Emergence of Resistance K. E. Bowker, A. R. Noel, S. G. Tomaselli, D. L. Nicholls, A. P. MacGowan; Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom. A-643 Piperacillin-Tazobactam (PT) Extended Infusion (EI)

Therapy to Treat Pulmonary Exacerbation in Patients with Cystic Fibrosis (CF) R. Kullar1, J. Garber 1, A. Alhadab1, A. Olyaei 1, G. Allada 2, J. Gold 2, M. Munar 1; 1Oregon State Univ/Oregon Hlth. & Sci. Univ, Portland, OR, 2 Oregon Hlth. & Sci. Univ, Portland, OR. A-644 Optimization of Piperacillin/Tazobactam (Pip/Taz) Dosing

Based on Population Pharmacokinetics (PK) & Pharmacodynamics (PD) G. Durica, A. Forrest; SUNY Sch. of Pharmacy, Buffalo, NY.

MONDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------084(B) Poster Session Antimicrobial Therapy in Animal Models I Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: B-645 Comparison of Six Generics Vancomycin (VAN) Products from

Europe and America in the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Experimental Endocarditis in Rabbits 1

2

2

3

4

P. Tattevin , A. Saleh-Mghir , B. Davido , I. Ghout , L. Massias , C. Garcia de la Maria 5, C. Muller-Serieys 4, J. M. Miro5, B. A. Diep 6, A. Crémieux2; 1Pontchaillou Univ. Hosp., Rennes, France, 2Raymond Poincaré Univ. Hosp., Garches, France, 3Ambroise Paré Univ. Hosp., Boulogne, France, 4 Bichat Univ. Hosp., Paris, France, 5Univ. Hosp. Clinic-IDIBAPS, Barcelona, Spain, 6SFGH, Univ. of California, San Francisco, CA. B-646 Relationship Between In Vitro Vancomycin Susceptibility in

Biofilms and Treatment Outcomes in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus W. Abdel Hady1, A. S. Bayer 1,2, K. Seidl 1,3, C. C. Nast 2,4, A. R. Horswill 5 , Y. Q. Xiong 1; 1LABioMed at Harbor-UCLA Med. Ctr., Torrance, CA, 2 David Geffen Sch. of Med. at UCLA, Los Angeles, CA, 3Univ. of Zurich, Zurich, Switzerland, 4Cedars-Sinai Med. Ctr., Los Angeles, CA, 5Univ. of Iowa, Iowa City, IA. B-647 Efficacy of the Combinations of Fosfomycin with Daptomycin

or Rifampin in an Experimental Foreign-Body Infection (FBI) by Methicillin-Resistant Staphylococcus aureus (MRSA) C. Garrigós, O. Murillo, J. Lora-Tamayo, M. Vivas, F. Tubau, Dr , J. Cabo, Dr , C. Cabellos, Dr , J. Ariza, Dr ; Hosp. Bellvitge, Barcelona, Spain. B-648 Effectiveness of Cloxacillin (CLO) Plus Vancomycin (VAN)

Compared to CLO, VAN, and Daptomycin (DAP) in the Treatment of Methicillin-Resistant (MRSA) or Methicillin-Susceptible (MSSA) Staphylococcus aureus in a Rabbit Model of Experimental Endocarditis (EE) X. Castañeda, C. García-de-la-Maria, A. del-Rio, D. Soy, Y. Armero, C. Cervera, A. Moreno, J. M. Pericas, M. Almela, C. A. Mestres, C. Falces, S. Ninot, J. M. Gatell, F. Marco, J. M. Miro, Hospital Clinic Endocarditis Study Group; Hosp. Clinic - IDIBAPS, Barcelona, Spain. B-649 Addition of Daptomycin (D) to Levofloxacin (LVX) Increased

the Efficacy of Levofloxacin Monotherapy against a MethicillinSensitive S. aureus (MSSA) Strain in Experimental Meningitis and Prevented Development of Levofloxacin-Induced Resistance 1

2

2

3

4 1

P. Cottagnoud , M. Cottagnoud , F. Acosta , A. Bizzini , S. Leib, ; Klinik Sonnenhof, Bern, Switzerland, 2Spitalnetzbern Ziegler, Bern, Switzerland, 3 CHUV, Lausanne, Switzerland, 4Inst. für Infektionskrankheiten, Bern, Switzerland. B-650 Inter-Laboratory Comparison of Treatment Response in a

Murine Model of Methicillin Resistant Staphylococcus aureus (MRSA) Bacteremia L. K. Najvar1,2, A. Ibrahim 3, N. P. Wiederhold4,1, G. Luo 3, R. A. Bocanegra 1,2 , T. Ghebremariam 3, W. R. Kirkpatrick 1,2, S. G. Filler 3, T. F. Patterson 1,2 1 ; UTHSCSA, San Antonio, TX, 2STVHCS, San Antonio, TX, 3HarborUCLA, Torrance, CA, 4UT Austin, Austin, TX.

B-651 Linezolid (LZD) Prevents the Development of Lung Damages

in a Murine Model of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia (PN) C. Jacqueline, A. Broquet, A. Roquilly, M. Davieau, G. Potel, J. Caillon, K. Asehnoune; UPRES EA 3826, Nantes, France. B-652 Comparative Activities of Vancomycin, Tigecycline and Ri-

fampin Alone and in Combination in a Rat Model of MethicillinResistant Staphylococcus aureus (MRSA) Foreign Body Osteomyelitis P. Vergidis, S. S. Schmidt, J. N. Mandrekar , J. M. Steckelberg, R. Patel; Mayo Clinic, Rochester, MN. B-653 Experimental Assessment of Calcium-Deficient Apatite

Delivering Daptomycin in Acute Osteomyelitis: A New Effective Approach? G. Amador1, H. Gautier2, C. Desessard 1, V. Le Mabecque 1, A. Miegeville 1, J. Bouler 2, P. Weiss, DDS 2, G. Potel1, J. Caillon1, C. Jacqueline 1; 1EA3826, Med. Sch., Nantes, France, 2INSERM U791, Nantes, France. B-654 Comparison of Linezolid and Daptomycin in an Experimen-

tal Murine Model of VRE Faecium Bacteremia: Emergence of Daptomycin-Nonsusceptibility During Daptomycin Treatment Y. Q. Xiong, W. Abdel Hardy, S. J. Eells, A. S. Bayer, J. A. McKinnell; LA Biomed Res. Inst., Torrance, CA. B-655 Murine Model of Acute Vancomycin-Resistant Enterococcal

(VRE) Bacteremia Y. Q. Xiong, W. Abdel Hardy, S. J. Eells, A. S. Bayer, J. A. McKinnell; LA Biomed Res. Inst., Torrance, CA. B-656 In Vivo Antibacterial Activity of Alpha-Melanocyte Stimulat-

ing Hormone against Staphylococcus aureus Withdrawn B-657 Effects of Dagibatran on a Murine Model of Staphylococcus

aureus Hematogenous Pulmonary Infection Y. Morinaga, K. Yanagihara, N. Kaku, Y. Migiyama, Y. Harada, K. Nagaoka, K. Yamada, K. Izumikawa, H. Kakeya, Y. Yamamoto, S. Kohno; Nagasaki Univ., Nagasaki, Japan. B-658 Experimental Study of the Efficacy of High Dose of Dapto-

mycin in the Therapy of Cephalosporin-Resistant Pneumococcal Meningitis M. Vivas, E. Force, C. Garrigós, F. Tubau, J. Liñares, I. Pelegrín, J. Ariza, C. Cabellos; Hosp. de Bellvitge, Hosp. del Llobregat, Spain. B-659 Synergism Between the Combination of Cpl-1 with Daptomy-

cin or Vancomycin against Streptococcus pneumoniae in Mice with Bacteremia J. Vouillamoz1, P. Moreillon1, M. Giddey 1, V. A. Fischetti 2, G. Resch1; 1 Univ. of Lausanne, Lausanne, Switzerland, 2The Rockefeller Univ., New York, NY. B-660 Impact of Reduced Susceptibility to Daptomycin in E. faecium

on the Activity of This Antibiotic In Vitro and In Vivo C. Richaud1, F. Chau 1, M. Sotier 2, A. Bleibtreu 3, B. Fantin1, V. Cattoir4, A. Lefort1; 1EA 3964, Univ. Paris Diderot, Paris, France, 2Lab de Toxicologie et Pharmacocinétique, Bichat Hosp., Paris, France, 3UMR 722, Univ. Paris Diderot, Paris, France, 4EA 4655, Univ. Caen Côte de Nacre, Caen, France. B-661 Prostaglandins Alter the Innate Immune Response to Group A

Streptococcus Infection Withdrawn

Final Program

89

> Monday SCIENTIFIC SESSIONS B-662 In Vitro Activity of Cadazolid (ACT-179811) against Clostridi-

um difficile and in an In Vitro Gut Model of C. difficile infection S. Baines, G. Crowther, S. Todhunter, J. Freeman, M. Wilcox; Leeds Teaching Hosp. & Univ. of Leeds, Leeds, United Kingdom. B-663 Effects of Vancomycin and Huo Xiang Zheng Qi Liquid on

Clostridium difficile Infection in C57BL Mice M. Chen 1,2, L. Zhai1, K. Schonning 3, L. P. Andersen1, W. A. Alpizar 4, O. D. Laerum4, A. Friis-Moeller3; 1Rigshospitalet, Copenhagen,, Denmark, 2 Sonderjylland Hosp., Aabenraa, Denmark, 3Univ. Hosp. Hvidovre, Copenhagen,, Denmark, 4The Finsen Ctr., Copenhagen,, Denmark. B-664 Efficacy Comparison between LFF571 and Fidaxomicin in the

Hamster Model of Clostridium difficile Infection D. McKenney1, A. Williams 2, M. LaMarche 2, J. Praestgaard 3, J. Leeds 1 1 ; Novartis Inst.s for BioMed. Res., Emeryville, CA, 2Novartis Inst. for BioMed. Res., Cambridge, MA, 3Novartis, East Hanover, NJ.

-----------------------------------------------------------------------085(C1) Poster Session Genetics and Resistance Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: C1-665 High Levels of Mobile Quinolone Resistance Genes Found

Near a Waste Water Treatment Plant Serving Antibiotic Manufacturers C. Rutgersson1, C. Flach 1, N. Marathe 1,2, E. Kristiansson 3, A. Janzon 1, J. Fick 4, Y. Shouche 2, E. Moore 5, D. G. J. Larsson 1; 1Inst. for Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg Univ., Gothenburg, Sweden, 2Natl. Ctr. for Cell Sci., Pune Univ., Pune, India, 3Chalmers Univ. of Tech., Gothenburg, Sweden, 4 Umeå Univ., Umeå, Sweden, 5The Sahlgrenska Univ. Hosp. Univ. of Gothenburg, Gothenburg, Sweden. C1-666 Regulation of Class 1 Integron Integrase Expression in

Biofilm E. Strugeon1,2, M. Ploy1,2,3, S. Da Re 1,2; 1Inserm, Limoges, France, 2Univ. de Limoges, Limoges, France, 3CHU, Limoges, France. C1-667 Mutator dnaQ Favors the Accumulation of a Double Muta-

tion in an E.coli gyrA Mutant in One Step to Yield High-Level Fluoroquinolone Resistance M. Petschulies, A. Heisig- Senior , P. Heisig; Univ. of Hamburg, Hamburg, Germany. C1-668 Mobile Element Tn1721 Associated to Resistance Genes and

Disseminated in Clinical and Sewage Samples L. C. Balsalobre, M. Dropa, D. E. Oliveira, G. Matté, M. Matté; Univ. of São Paulo, São Paulo, Brazil. C1-669 First Evidence of DNA Recombinant Activity of ISCR1 A. P. Porto 1, J. A. Ayala 2, G. O. Gutkind3, J. A. Di Conza 1,3; 1Univ. Nacional del Litoral, Santa Fe, Argentina, 2Univ. Autónoma de Madrid, Madrid, Spain, 3Univ. de Buenos Aires, Buenos Aires, Argentina. C1-670 Structural Variations in the Resistance Gene Regions of the

Integrative and Conjugative Element ICEPmu1 from Bovine Pasteurella multocida and Mannheimia haemolytica G. B. Michael 1, K. Kadlec 1, M. T. Sweeney 2, R. W. Murray 2, J. L. Watts 2, S. P. Schwarz1; 1Inst. of Farm Animal Genetics (FLI), Neustadt-Mariensee, Germany, 2Pfizer Animal Health, Kalamazoo, MI.

90

September 9-12 |

C1-671 Role of Transcriptional Regulators of the MarR Family (Mul-

tiple Antibiotic Resistance) in Bacteroides fragilis Susceptibility to Antimicrobial Drugs and Oxydative Stress L. A. Lobo1, N. L. P. Iorio2, F. L. Teixeira, BS1, D. N. S. Silva, BS1, E. O. Ferreira1, R. M. C. Domingues1; 1UFRJ, Rio de Janeiro, Brazil, 2UFF, Rio de Janeiro, Brazil. C1-672 Effect of the Transcriptional Activators SoxS, RobA and

RamA on the Expression of the Multidrug Efflux Pump AcrABTolC of Enterobacter cloacae A. Perez 1, M. Poza 1,2, J. Aranda 1,2, C. Latasa 3,4, M. Tomas 1,2, I. Lasa 3,4, G. Bou 1,2; 1Hosp. A Coruña, A Coruña, Spain, 2Univ. Hosp. A Coruña, A Coruña, Spain, 3Lab. of Microbial Biofilms-CSIC, Pamplona, Spain, 4Univ. of Pamplona, Pamplona, Spain. C1-673 Identification of Novel Antibacterials Inhibiting Biofilms in a

Broad-Spectrum Manner K. Sambanthamoorthy, N. Pattabiraman, C. Luo; Walter Reed Army Inst. of Res., Silver Spring, MD. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------086(C1) Poster Session Resistance by Efflux/Quinolone Resistance Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: C1-674 Chemical Inhibition of Multidrug-Resistance Efflux

Abolishes Biofilm Formation by Salmonella enterica Serovar Typhimurium S. Baugh, L. J. V. Piddock, M. A. Webber; Univ. of Birmingham, Birmingham, United Kingdom. C1-675 Susceptibility of Tetracyclines to TN1721- and Plasmid RP1d

Tet(A) Resistance is Dependent on Expression Level and Not Primary Structure C. Fyfe, J. A. Sutcliffe, T. H. Grossman; Tetraphase Pharmaceuticals, Watertown, MA. C1-676 Efflux Mediated Multiresistance in Clinical Isolates of Aci-

netobacter baumannii E. J. Yoon, P. Courvalin, C. Grillot-Courvalin; Inst. Pasteur, Paris, France. C1-677 Biofilm Regulator nuc in Staphylococus aureus is Differentially

Regulated and Expressed During In Vitro Antibiotic Treatment W. Rose1, S. Shukla2, Z. Ye 2; 1Univ. of Wisconsin, Madison, WI, 2Marshfield Clinic, Marshfield, WI. C1-678 Putative Mechanism of Resistance Detection of Inquilinus

limosus by a Full Genome Sequencing Approach M. Pino 1, J. Di Conza 1, S. Revale 2, G. Gutkind1; 1Fac. Farm. y Bioq.-UBA, Buenos Aires, Argentina, 2INDEAR, Rosario, Argentina. C1-679 First Identification of tet(31) among Tetracycline-Resistant

Porcine Bordetella bronchiseptica K. Kadlec 1, H. Kaspar, DVM 2, J. Mankertz 2, S. P. Schwarz1; 1Inst. of Farm Animal Genetics (FLI), Neustadt-Mariensee, Germany, 2Federal Office of Consumer Protection and Food Safety (BVL), Berlin, Germany.

MONDAY SCIENTIFIC SESSIONS C1-680 Cumulative Resistance to the Novel Lpxc Inhibitor Chir-090

C2-688 Regional Differences in Susceptibility of E. coli in

in Pseudomonas aeruginosa: Interplay of Efflux and Non Efflux Mechanisms

Community-Acquired Versus Hospital-Associated Intra-Abdominal Infections: SMART 2010/2011

A. K. Jones1, S. Barnes 2, K. Suefuji 1, L. Xie 1, J. R. Walker 2, C. R. Dean 1; 1 Novartis Inst. for Biomedical Res., Emeryville, CA, 2Genomics Inst. of the Novartis Res. Fndn., San Diego, CA.

R. Badal, S. Lob, S. Bouchillon, M. Hackel, D. Hoban; IHMA, Inc., Schaumburg, IL.

C1-681 Ozenoxacin. Selection of Resistant Mutants of Gram-Posi-

tive Cocci Y. López, Biologist1, M. Tato 2, R. Cantón 2, J. Vila 1; 1Hosp. Clinic, Barcelona, Spain, 2Ramón y Cajal Univ. Hosp., Madrid, Spain. C1-682 Ozenoxacin Impact of Mutations in the gyrA y parC Genes of

Clinical Gram-Positive Cocci in the MIC Y. López1, M. Tato 2, R. Cantón 2, J. Vila 1; 1Hosp. Clinic, Barcelona, Spain, 2 Ramón y Cajal Univ. Hosp., Madrid, Spain. C1-683 Prevalence and Molecular Characterization of Plasmid-Me-

diated Quinolone Resistance in Prospective Bacteremic Clinical Isolates of Enterobacter spp. from Spain J. Rodriguez-Martinez1, P. Díaz de Alba 1, C. Ruiz de Alegría 2, C. MartínGandul 3, O. Gasch 4, M. Cano 2, F. Tubau 4, J. Lepe3, R. Lara 5, F. Rodriguez 5, J. Rodriguez-Baño 1, L. Martinez-Martinez 2, M. Jiménez-Mejías 3, A. Pascual 1; 1Univ. of Seville, Seville, Spain, 2UH Marques de Valdecilla, Santander, Spain, 3UH Virgen del Rocio, Seville, Spain, 4UH Bellvitge, Barcelona, Spain, 5UH Reina Sofia, Cordoba, Spain. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------087(C2) Poster Session Diverse Resistance Issues in Enterobacteriaceae Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations:

C2-689 Risk Factors for 3rd Generation Cephalosporin Resistant

Community Onset E. coli Infections from Seven Centres in Low Prevalence Countries B. A. Rogers1,2, P. R. Ingram 2,3, N. Runnegar 2,4, J. T. Freeman 2,5, M. C. Pitman 2,6, E. Athan2,7, S. Havers 1, D. L. Paterson 1,2; 1Univ. of Queensland, UQCCR, Brisbane, Australia, 2The COOEE Study Group, ASID Clinical Res. Network, Qld, Australia, 3The Royal Perth Hosptial, Perth, Australia, 4 Princess Alexandra Hosp., Woolloongabba, Australia, 5Auckland District Hlth. Board, Auckland, New Zealand, 6The Royal Darwin Hosp., Tiwi, Australia, 7Barwon Hlth., Geelong, Australia. C2-690 Molecular Epidemiology of Non-Nosocomial Klebsiella

pneumoniae Bloodstream (KpB) Infections M. Cubero, I. Grau, R. Pallares, J. Ayats, M. Cisnal, J. Liñares, C. Ardanuy; Hosp. Univ. Bellvitge, L´Hospitalet de Llobregat (Barcelona), Spain. C2-691 New OXY-Variants from Klebisiella oxytoca (KOX) Bloodcul-

ture (BC) Clinical Isolates Collected in U.S.A. Hospitals M. Castanheira, L. M. Deshpande, R. E. Mendes, R. N. Jones; JMI Lab., N Liberty, IA. C2-692 OqxAB, a Quinolone and Olaquindox Efflux Pump, is

Widely Distributed Among Multidrug-Resistant (MDR) Klebsiella pneumoniae of Human Origin in the Northeast U.S.A. F. Perez1, S. Rudin 1, S. Marshall 1, L. Chen 2, P. Coakley 3, B. N. Kreiswirth 2 , D. van Duin 4, D. L. Paterson5, R. A. Bonomo 1; 1VAMC, Cleveland, OH, 2 UMDNJ, Newark, NJ, 3CWRU, Cleveland, OH, 4Cleveland Clinic, Cleveland, OH, 5Univ. of Queensland, Brisbane, Australia. C2-693 First Detection of Klebsiella pneumoniae Isolates Harboring

qnr Genes in Japan

C2-684 Host Risk Factors and Efflux Pump Gene Expressions

Among E.coli Strains Isolated From Community-Acquired Urinary Tract Infections F. Can 1, O. Kurt Azap 2, I. Dolapci 3, A. Yesilkaya 2, H. Arslan 2, O. Ergonul 1; 1Koc Univ., Istanbul, Turkey, 2Baskent Univ., Ankara, Turkey, 3 Ankara Univ., Ankara, Turkey. C2-685 Antimicrobial Resistance and Virulence Markers of E. coli

Isolated from Nosocomial Bloodstream Infection: A Study of the SCOPE Brazil Project A. C. Rochstroh, A. M. Doi, R. M. Silva, A. R. Marra, A. C. C. Pignatari; UNIFESP, Sao Paulo, Brazil. C2-686 Molecular Study of Escherichia coli Isolates from Outbreak of

Infections After Transrectal Ultrasound-Guided Prostate Biopsy N. Suwantarat1, S. Rudin 2, D. Dumford 1, S. Marshall 2, A. M. Hujer 2, K. M. Hujer 2, R. A. Bonomo 2, C. J. Donskey 2; 1Case Western Reserve Univ., Cleveland, OH, 2Louis Stokes VA Med. Ctr., Cleveland, OH. C2-687 Temporal Trends in Antibiotic Resistance among E. coli

ST131 Isolates, 1968-2012

H. Okade1,2, S. Nakagawa 2, N. Nomura 2, J. Mitsuyama 2, Y. Yamagishi 1, H. Mikamo 1; 1Aichi Med. Univ., Aichi, Japan, 2Res. Lab., Toyama Chemical Co., Ltd., Toyama, Japan. C2-694 Molecular Characterization ofơ-Lactam/ơ-Lactamase In-

hibitor Combinations (BL/BI) - Resistant Isolates from Colombia L. J. Rojas1, A. Correa 1, E. de La Cadena 1, M. F. Mojica 1, J. P. Quinn 2, R. A. Bonomo 3, M. V. Villegas 1, Colombian Nosocomial Resistance Study Group; 1CIDEIM, Cali, Colombia, 2AstraZeneca, Waltham, MA, 3VAMC Cleveland, Cleveland, OH. C2-695 Ceftriaxone Resistance among Salmonella Isolates from

Humans in the United States, 1996-2010 J. L. Reynolds1,2, J. M. Whichard 1, B. E. Karp 1; 1CDC, Atlanta, GA, 2 Atlanta Res. and Ed. Fndn., Decatur, GA. C2-696 Quinolone Resistance Mechanisms and Molecular Epidemi-

ology of Salmonella spp C. Ballesté-Delpierre1, A. Fàbrega 1, A. Dehn Lunn 2, M. Solé 1, M. Jiménez de Anta1, J. Vila1; 1CRESIB-Hosp. Clínic, UB, Barcelona, Spain, 2Univ. of Sheffield, Sheffield, United Kingdom.

B. Olesen 1,2, F. Scheutz2, J. Frimodt-Møller 1, B. Johnston 3, D. S. Hansen1, K. A. Krogfelt 2, J. R. Johnson3; 1Hillerød Hosp., Hillerød, Denmark, 2Statens Serum Inst., Copenhagen, Denmark, 3VA Med. Ctr., Minneapolis, MN.

Final Program

91

> Monday SCIENTIFIC SESSIONS C2-697 CTX-M-5-Coding Plasmids of Nosocomial Salmonella

Cattle (Ca), Pigs (P) and Chickens (Ch) in 10 EU Countries (EASSA study)

V. Kozyreva1, E. Ilina 2, A. Carattoli 3, M. Edelstein 1, R. Kozlov1; 1Inst. of Antimicrobial Chemotherapy, Smolensk, Russian Federation, 2Res. Inst. of Physical-Chemical Med., Moscow, Russian Federation, 3Inst. Superiore di Sanità, Rome, Italy.

A. de Jong 1, V. Thomas1, S. Simjee, Senior 1, F. El Garch1, H. Moyaert 1, D. Rigaut1, M. Vallé1, K. Maher 2, I. Morrissey2; 1EASSA Study Group, Brussels, Belgium, 2Q B, Fordham, United Kingdom.

C2-698 Characterisation of Antimicrobial Resistance Patterns and

Integrons among Salmonella enterica serovar Enteritidis Isolates in Taiwan and Development of Macroarray for Their Detection H. Tsen1, J. Pang 2,3; 1Hung-Kuang Univ., Taichung, Taiwan, 2Vanung Univ., Tao-Yuan, Taiwan, 3Vanung Univ., Tao Yuan, Taiwan. C2-699 A 3 Year Study of Changing Epidemiology, Seasonal Patterns,

Antibiotic Resistance and Racial Prediliction of Shigella at Qatar G. Wilson; Hamad Med. Corp., Doha, Qatar. C2-700 Prevalence of Plasmid-Mediated Quinolone Resistance

Determinants among Oxyiminocephalosporin Resistant Enterobacteriaceae 1,2

1

3

1

3

G. Rincón , M. Radice , S. Sennati, D , G. Santella , L. Pallecchi , G. M. Rossolini 3, J. Di Conza 1,4, G. Gutkind1; 1Fac de Farm UBA, Buenos Aires, Argentina, 2Univ. Industrial de Santander, Santander, Colombia, 3Univ. di Siena, Siena, Italy, 4Univ. del Litoral, Santa Fe, Argentina. C2-701 Prevalence of Plasmid-Mediated Quinolone Resistance

Mechanisms (PMQR) in Argentina E. Albornoz1, C. Lucero1, C. Rodriguez2, WHONET-Argentina Group, M. Galas 1, D. Centrón2, A. Corso1, A. Petroni1; 1Serv Antimicrobianos, INEIANLIS Malbran, Buenos Aires, Argentina, 2Fac de Med., Univ. de Bs As, Buenos Aires Argentina. C2-702 In Vitro Susceptibilities of E. coli and K. pneumoniae Isolated

from Patients with Intra-Abdominal Infections in China: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2002-2011 Y. Wang, Q. Yang, Y. Xu, SMART Study Group in China; Peking Union Med. Coll. Hosp., Beijing, China.

-----------------------------------------------------------------------088(C2) Poster Session Food, Animals and Environment Reservoirs for GramNegative Organisms Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C

C2-706 CTX-M E. coli is Common in Retail Chicken in Ireland but is

Not Closely Linked to Human Isolates C. Ludden1, A. Brennan1, S. Kelly 1, E. Burke 2, M. Cormican 1,2, D. Morris 1; 1 Natl. Univ. of Ireland, Galway, Galway, Ireland, 2Univ. Hosp. Galway, Galway, Ireland. C2-707 Characterization by pMLST of Plasmids Encoding SHV-12

in Escherichia coli Isolates from Human and Animal Food Sources in the South of Spain L. López-Cerero 1, P. Egea 1, E. Torres 1, M. Bellido 1, J. Rodríguez-Baño1, A. Pascual1,2; 1Univ. Hosp. Virgen Macarena, Seville, Spain, 2Sch. of Med., Seville, Spain. C2-708 Co-Selection May Explain High Rates of Ciprofloxacin Re-

sistant Escherichia coli from Retail Poultry Reared Without Prior Fluoroquinolone Exposure P. R. Ingram 1, B. A. Rogers 2, H. E. Sidjabat 2, J. S. Gibson 3, T. J. J. Inglis 1; 1 PathWest Lab., QEII Med. Ctr., Perth, Australia, 2The Univ. of Queensland, UQCCR, Brisbane, Australia, 3The Univ. of Queensland, Sch. of Vet. Sci., Brisbane, Australia. C2-709 Antimicrobial Susceptibility of Salmonella enterica (Se) from

Healthy Cattle (Ca), Pigs (P) and Chickens (Ch) Across the EU: European Antimicrobial Susceptibility Surveillance in Animals (EASSA) I. Morrissey1, A. de Jong 2, H. Moyaert 2, F. El Garch2, P. Butty2, U. Klein2, D. Rigaut2, S. Simjee2, V. Thomas2, M. Vallé2; 1Q B, Fordham, United Kingdom, 2EASSA Study Group, Brussels, Belgium. C2-710 Diversity of blaCMY-2 Carrying Plasmids from Bovine E. coli

Exposed to Antibiotic Agents J. L. Cottell1, N. Kanwar 2, G. H. Loneragan 3, H. M. Scott 2, P. Boerlin 1; 1 Univ. of Guelph, Guelph, Canada, 2Kansas State Univ., Manhattan, KS, 3 Texas Tech Univ., Lubbock, TX. C2-711 Detection of pO157-Free Escherichia coli Serotype O157 in

Surface Water Z. Hossain 1, K. Mohsina2, M. Fakruddin 1, K. R. Mahbub 1, M. M. Ahmed 1; 1 Bangladesh Council of Sci. and Industrial Res., Dhaka, Bangladesh, 2Shahjalal Univ. of Sci. and Tech., Sylhet, Bangladesh. C2-712 Characterization of Antimicrobial Resistance and Class 1 in-

tegrons in Escherichia coli Isolated from Shrimps and Environment

Presentations: C2-703 Molecular Analysis of Extended-Spectrum Beta-Lactamases

(ESBLs) Gene Sequences of Bacteria on Retail Lettuce and Relatedness to Clinical Isolates C. Muraleedharan1, N. Bhutani1, D. Talreja1, S. W. Rana 2, S. K. Walia 3, M. Sawani 4, A. Kumar 2, S. K. Walia1; 1Oakland Univ., Rochester, MI, 2KEI, Wayne State Univ., Detroit, MI, 3Henry Ford Helath System, Detroit, MI, 4 Crittenton Hosp. Med. Ctr., Rochester, MI. C2-704 Extended-Spectrum Beta-Lactamase (ESBL) Producing

92

C2-705 Antimicrobial Susceptibility of Escherichia coli (Ec) from

Typhimurium Clone Circulating for a Long Time in Russia, Belarus, and Kazakhstan

K. Changkaew1, F. Utrarachkij 2, K. Siripanichgon 2, C. Nakajima 1, O. Suthienkul 2, Y. Suzuki 1; 1Hokkaido Univ., Sapporo, Japan, 2Mahidol Univ., Bangkok, Thailand. C2-713 Antimicrobial Resistance in Salmonella enterica Serovars

Isolated from Retail Meat: An Update R. Figueiredo 1, A. Henriques2, R. Sereno 2, N. Mendonça 1, G. J. Da Silva1; 1 CEF, Univ. Coimbra, Coimbra, Portugal, 2ControlVet SA, Tondela, Portugal. C2-714 Seasonality and Geography Influence the Prevalence and

Gram-Negative Bacteria from Pets, Buffalos and Psittacines, Brazil

Resistance of Retail-Source Campylobacter

L. Barbato, L. C. Melo, C. P. Oresco, N. N. Oliveira, J. A. P. Abreu, A. F. P. Castro, N. Lincopan; USP, São Paulo, Brazil.

I. Forrester 1, E. Crarey 2, P. McDermott 2, H. Tate2; 1Univ. of Maryland, Baltimore, 2U.S. FDA, Laurel.

September 9-12 |

MONDAY SCIENTIFIC SESSIONS C2-715 16S rRNA Sequencing in Characterizing SXT-Positive

Vibrio owensii Isolated from Corals T. Bhotra, S. K. Das, D. V. Singh; Inst. of Life Sci., Bhubaneswar, India. C2-716 Presence of blaKPC Genes in Enterobacteriaceae Strains

Isolated from Sewage Treatment Plants in Brazil

C2-724 Response to Imipenem Plus MK-7655, a Novel ơ-Lactamase

Inhibitor, in a Surveillance Study Population of P. aeruginosa from SMART 2009 K. Young1, M. Hackel 2, C. Lascols 2, S. Bouchillon 2, R. Badal 2; 1Merck Res. Lab., Kenilworth, NJ, 2IHMA, Schaumburg, IL. C2-725 A Multi-Center Longitudinal Comparison of P. aeruginosa

Withdrawn

Antibiotic Resistance Profiles and Anatomical Sites

C2-717 Environmental Cc258 KPC-2-Producing Klebsiella

pneumoniae, Brazil R. Moura 1, S. Oliveira 1, K. Silva 1, M. Pavez 1, E. Hachich 2, M. Sato 1, E. Mamizuka 1, A. Pestana 1, N. Lincopan 1; 1Univ. of São Paulo, São Paulo, Brazil, 2CETESB, São Paulo, Brazil.

-----------------------------------------------------------------------089(C2) Poster Session

L. E. Nielsen, P. McGann, R. Clifford, L. Preston, Y. Kwak, P. Waterman, E. Lesho; WRAIR, US Army, Silver Spring, MD.

-----------------------------------------------------------------------090(D) Poster Session MALDI-ToF Mass Spectrometry and Identification and Susceptibility Testing

Pseudomonas aeruginosa: An Overview of Survelliance Data

Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C

Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C

D-726 Rapid Identification of Pathogens by MALDI-ToF MS in

Blood Culture Bottles

Presentations: C2-718 Prevalence of GESơ-Lactamases in P. aeruginosa in Lima,

Perú E. Gonzales 1, P. Maritza2, M. Radice 3, G. Gutkind3; 1Inst. Natl. de Salud del Niño, Lima, Peru, 2Univ. de Buenos Aires, Argentina, 3Fac de Farm Univ. de Buenos Aires, Argentina. C2-719 New Integron Encompassing blaVIM-2, qnrVC1 and Genes

Encoding Bacterial Group II Intron in Clonal Srains of Pseudomonas aeruginosa

C2-720 Metallo-ơ-Lactamases (MBLs) in the Heartland of the

United States: International Strain of VIM-2 Producing Pseudomonas aeruginosa (Pa) in a Community Hospital in Northeast Ohio (NEO) 1

2

2

D-727 Rapid Identification of Pathogens Directly from Blood Cul-

ture Bottles by Bruker MALDI-ToF Mass Spectrometry System V. O. Rotimi1, W. Jamal 1, R. Saleem 2, A. Pazhoor 2; 1Kuwait Univ., Safat, Kuwait, 2Mubarak Hosp., Jabriya, Kuwait.

in Gram-Negative Bacteria Isolated from Blood Cultures Using MALDI-ToF MS D. Kasper1, N. W. Anderson 1, B. W. Buchan 1,2, N. A. Ledeboer 1,2; 1Med. Coll. of Wisconsin, Milwaukee, WI, 2Dynacare Lab., Milwaukee, WI. D-729 Evaluation of Matrix-Assisted Laser-Desorption/Ionization

2

F. Perez , S. M. Marshall , A. J. Ray , D. Dumford , M. R. Jacobs , R. A. Bonomo1; 1VAMC, Cleveland, OH, 2CWRU, Cleveland, OH. C2-721 Pseudomonas aeruginosa in Pediatric Pneumonia: Activity of

Piperacillin-Tazobactam and Comparators: 2004-2011 D. Hoban1, M. Hackel 1, M. Renteria 1, R. Badal1, S. Bouchillon1, B. Johnson 1, J. Johnson1, S. Hawser 2; 1IHMA, Inc., Schaumburg, IL, 2 IHMA Europe Sàrl, Epalinges, Switzerland. C2-722 Impact of New CLSI Piperacillin/Tazobactam Breakpoints

on Reported Susceptibility of Pseudomonas aeruginosa in North America - TEST 2009-2011 S. Lob , S. Bouchillon , M. Hackel , D. Hoban , J. Johnson; IHMA, Inc., Schaumburg, IL. C2-723 Comparison of Variable Number Tandem Repeat Analysis

with Pulsed-Field Gel Electrophoresis for Multidrug-Resistant Pseudomonas aeruginosa Isolates from South Africa Withdrawn

B. Rodriguez-Sanchez, C. Sanchez-Carrillo , A. Ruiz, M. RodriguezCreixems, E. Bouza; Hosp. Gen. Univ. Gregorio Marañón, Univ. of Madrid. Spain., Madrid, Spain.

D-728 Rapid Identification of Antibiotic (Beta-Lactam) Hydrolysis

V. Dubois, L. Coulange, C. Andre, F. M’zali, C. Quentin-Noury; CNRSUniv. de Bordeaux 2, Bordeaux, France.

1

Presentations:

Time-of-Flight Mass Spectrometry (MALDI-ToF MS) for the Identification of Bacteria and Yeast in Clincial Specimens S. Robichaud 1, J. M. Blondeau 1, L. David 2, H. Deneer 1, O. Larios1, S. Sanche 1; 1Univ. of Saskatchewan, Saskatoon, Canada, 2Saskatoon Hlth. Region, Saskatoon, Canada. D-730 Comparison of Vitek MS and MALDI Biotyper for Rapid

Bacterial Identification by Matrix-Assisted Laser DesorptionIonization-Time of Flight Mass Spectrometry (MALDI-ToF MS) in a Pediatric Setting P. Morency-Potvin1,2, F. Rallu 1, M. Saint-Jean 1,2, M. Carrier 2, D. Sans 2, A. Demers 1,2, C. Laferrière 1,2; 1Sainte-Justine Univ. Hosp., Montréal, Canada, 2 Univ. of Montreal, Montréal, Canada. D-731 Rapid Identification of Burkholderia cepacia Complex (Bcc)

Species Using MALDI-ToF MS L. C. C. Fehlberg1, R. Cayô 1, L. H. S. Andrade1, D. M. Assis 1, R. H. V. Pereira 2, L. Juliano 1, A. C. Gales 1, E. A. Marques 2; 1UNIFESP, São Paulo, Brazil, 2UERJ, Rio de Janeiro, Brazil. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

Final Program

93

> Monday SCIENTIFIC SESSIONS -----------------------------------------------------------------------091(D) Poster Session Mycobacteria: Diagnostics and Susceptibility Testing Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C

I. Sauzullo 1, R. Scrivo 1, F. Mengoni 1, R. Marocco 2, G. Valesini 1, V. Vullo 1, C. M. Mastroianni2; 1Sapienza Univ., Rome, Italy, 2Sapienza Univ., Latina, Italy. D-741 Diagnostic Usefulness of a T-Cell-Based Assay in Patients Y. Lee, K. Park, S. Kim, S. Park, S. Lee, S. Choi, Y. Kim, J. Woo, S. Kim; Asan Med. Ctr., Seoul, Korea, Republic of.

D-732 Use of RT-PCR for the Detection of Mycobacterium

tuberculosis Complex DNA M. Rowlinson 1, S. R. Crowe 1, Y. Lee 1, P. Fiorella 1, R. Farah 1, M. Pedrosa 1, M. Salfinger 2; 1Florida Dept. of Hlth., Jacksonville, FL, 2Florida Dept. of Hlth., Tallahassee, FL. D-733 Comparative Evaluation of Conventional Methods and

Nested Polymerase Chain Reaction in the Diagnosis of ExtraPulmonary Tuberculosis D-734 Comparative Evaluation of Advansure Mycobacteria

Genoblot Assay Kit for the Identification of Nontuberculous Mycobacteria to the Species Level

D-735 Rapid Species Identification of Mycobacterium chelonae and

Mycobacterium abscessus Complex and Determination of Inducible Clarithromycin Resistance by High Resolution Melt Analysis (HRM) M. J. Tuohy, G. S. Hall, G. W. Procop, S. M. Harrington; Cleveland Clinic, Cleveland, OH. D-736 Evaluation of the TREK MIC MicroTiter Plate Method for

Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis Complex Isolates C. Tanner 1, P. Miles 1, M. Rowlinson1, S. Crowe 1, D. Willis 1, M. Salfinger 2; 1 Bureau of Lab., Florida Dept. of Hlth., Jacksonville, FL, 2Bureau of Lab., Florida Dept. of Hlth., Tallahassee, FL. D-737 Comparison of a Commercial MTB MIC Plate, Agar Propor-

tion Method, and DNA Sequence Analysis for Detection of Resistance to Isoniazid, Rifampin, and Ethambutol in Mycobacterium tuberculosis Complex D. Sikes, B. Metchock; CDC, Atlanta, GA. D-738 Drug Susceptibility Testing and Genotypes of Mycobacterium

tuberculosis Isolated from Extra-Pulmonary Clinical Specimens of Bangladesh Withdrawn D-739 Conversion of CO to CO2 by CO Dehydrogenase as a Highly

Selective Stable Isotope Breath Test Marker for Tuberculosis Diagnosis 2

1

1

2

S. Choi , M. Maiga , M. Maiga , V. Atudorei , Z. Sharp , W. Bishai , G. Timmins1; 1Univ. of New Mexico, Albuquerque, NM, 2Johns Hopkins Hosp., Baltimore, MD.

September 9-12 |

TST/IGRA Results I. Sauzullo 1, A. Ermocida 1, F. Mengoni 1, R. Rossi 1, M. Lichtner 2, V. Vullo 1, C. M. Mastroianni2; 1Sapienza Univ., Rome, Italy, 2Sapienza Univ., Latina, Italy. D-743 Extrapulmonary Tuberculosis: Epidemiological, Molecular

and Circulating Cytokines Markers

D-744 Approach to Latent Tuberculosis Among Occupational Health

H. Bae, G. Ryu, E. Lee; Green Cross Reference Lab., Yongin, Korea, Republic of.

2

D-742 Diagnosis of Latent Tuberculosis in Subjects with Discordant

J. Fortun, P. Martin-Davila, E. Gomez-Mampaso, A. Vallejo, I. Barbolla, P. Wikman, J. Ortíz, E. Navas, D. Gijon, I. Gomez-Garcia, A. Gonzalez, J. Rubi, E. Pallares, S. Moreno; Ramon Y Cajal Hosp., Madrid, Spain.

S. Sharma; Sgrdimsar, Amritsar, India.

94

Patients with TNF Blockers are not Associated with Tuberculosis Outcome

with Miliary Tuberculosis (TB)

Presentations:

1

D-740 Mycobacterial IGRA Variations in Long-Term Treated

Providers C. VinnardE 1, D. LinkinE 2, A. Behrman 2; 1Drexel Univ. Coll. of Med., Philadelphia, PA, 2Univ. of Pennsylvania, Philadelphia, PA.

-----------------------------------------------------------------------092(D) Poster Session Phenotypic Susceptibility Testing Methods Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: D-745 Evaluation of Two Etest MBL Strips for Detection of Metallo-

Carbapenemases in Enterobacteriaceae D. Halimi1, D. Girlich 2, P. Nordmann 2, S. Rivat1, G.Durand1, R.Martelin1, G. Zambardi1; 1bioMerieux, La Balme les Grottes, France, 2Hosp. Bicetre, Paris, France. D-746 Screening of Epidemiologically Challenging Carbapenemase

Producers Pseudomonas aeruginosa (CP-PA) by Agar Dilution (AD), Vitek 2C and Phoenix Systems: Are Current Breakpoints Enough? F. Pasteran1, C. Lucero 1, M. M. Peres 2, L. Errecalde 3, O. Veliz 1, M. Rapoport 1, E. Tuduri 1, A. Di Bella 4, S. Kaufman 3, D. Korbenfeld 2, A. Corso 1; 1Antimicrobianos, INEI-ANLIS, Buenos Aires, Argentina, 2BD Diagnostics Systems, Buenos Aires, Argentina, 3Hosp. Fernandez, Buenos Aires, Argentina, 4Hosp. Posadas, Buenos Aires, Argentina. D-747 Unreliability of the New CLSI 2012 Breakpoints for Cefepime

and Carbapenems to Detect KPCs M. V. Villegas1, A. Correa 1, E. De La Cadena 1, J. J. Maya 1, V. M. Blanco 1, L. J. Rojas 1, M. F. Mojica 1, R. Pacheco 1, C. Hernandez 1, M. E. Vallejo 1,2, J. P. Quinn 3, Colombian Nosocomial Resistance Study Group; 1CIDEIM, Cali, Colombia, 2Univ. Pontificia Bolivariana, Medellin, Colombia, 3AstraZeneca, Waltham, MA.

MONDAY SCIENTIFIC SESSIONS D-748 Evaluation of a New Eteststrip for KPC Detection in

D-758 Use of Oxoid Paper Disks Until 14 Days After Opening of the

Enterobacteriaceae D. Halimi1, D. Girlich 2, P. Nordmann2, S. Rivat1, G.Durand1, R.Martelin1, G. Zambardi1; 1bioMerieux, La Balme les Grottes, France, 2Hosp. Bicetre, Paris, France. D-749 Quantification of Modified Hodge Test: A New Approach to

Cartridge in Disk Diffusion Antimicrobial Susceptibility Testing Method M. Grare, A. Ayma, M. Auregan, N. Marty, C. Segonds; IFB, CHU Toulouse Purpan, Toulouse, France. D-759 Disk Diffusion-Based Algorithm Improves Detection of

Phenotypic Screening of KPC

aac(6’)-Ib-cr

V. B. Ribeiro1,2, A. R. Linhares 1, A. P. Zavascki 4, A. L. Barth 1,2; 1Univ. Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Hosp. de Clínicas de Porto Alegre, Porto Alegre, Brazil.

P. Andres, E. Albornoz, L. Guerriero, A. Corso, A. Petroni; INEI-ANLIS Malbran, Bs As, Argentina.

D-750 Carbapenem-Resistant Enterobacteriaceae Detection and

Prevention Practices, Michigan, 2012 B. M. Brennan, J. R. Coyle, M. S. Boehme, P. Boinapally, J. L. Finks; Michigan Dept. of Community Hlth., Lansing, MI. D-751 Comparison of Two Chromogenic Media and MacConkey

Agar with Carbapenem Disks for the Detection of Carpabenemase-Producing Gram Negative Rods in Simulated Stool Specimens J. Blackburn1, C. Tsimiklis 1, V. Lavergne 1, J. Pilotte 2, S. Grenier 2, A. Gilbert 2, B. Lefebvre 2, M. Domingo 2, C. Tremblay 2, A. Bourgault 2; 1Hosp. du Sacré-Coeur de Montréal, Montréal, Canada, 2Inst. Natl. de Santé Publique, Lab. de Santé Publique du Québec, Montréal, Canada. D-752 Performance of Ceftriaxone (CAX) Minimum Inhibitory

Concentration (MIC) > 1 μg/ml for Detection of ExtendedSpectrumơ-Lactamase (ESBL) Producing E. coli (EC) and K. pneumoniae (KP) N. K. Boyd1,2, K. S. Alvarez 1,2, L. Byrd 1, K. P. Bhavan 1,2; 1Parkland Hlth. and Hosp. System, Dallas, TX, 2Univ. of Texas Southwestern Med. Sch., Dallas, TX. D-753 Rapid Detection ofơ-Lactamase Hydrolyzing Extended-

Spectrum Cephalosporins in Enterobacteriaceae Using the New ChromogenicơLACTA Test M. Garcia-Castillo, M. Morosini, M. Tato, T. Curiao, D. Gijón, A. Valverde, P. Ruiz-Garbajosa, R. Canton; Hosp. Univ. Ramón y Cajal, Madrid, Spain. D-754 Implementation of the 2010 Clinical and Laboratory Stan-

dards Institute (CLSI) Guidelines: Effects on Antibiotic (Abx) Utilization in the Treatment of Presumed Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteriaceae (EB) J. Curello, C. MacDougall; UCSF Med. Ctr., San Francisco, CA. D-755 Evaluation of Vitek 2 and MicroScan WalkAway for Extended-

Spectrum ß-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolates against Cefepime, Cefotaxime and Ceftazidime W. Jang1, J. Yu 2, K. Park 2, Y. Park 2; 1St. Mary Hosp., Seoul, Korea, Republic of, 2Sch. of Med., The Catholic Univ. of Korea, Seoul, Korea, Republic of. D-756 Use of Combination Antibiograms to Determine Empiric

Double-Coverage of Gram-Negative Organisms J. J. Taylor, P. Pancholi, J. Balada-Llasat; The Ohio State Univ. Wexner Med. Ctr., Columbus, OH. D-757 Impact of EUCAST Breakpoints on the Management of

Infections Caused by Pseudomonas aeruginosa P. Bonfanti, B. Pini, C. Molteni, L. Principe, I. Caramma, S. Bracco, F. Luzzaro; 1A.Manzoni Hosp., Lecco, Italy.

D-760 Development of Disk Diffusion Testing for KPI-10, a Novel

Fluoroquinolone (FQ) with Potent, Broad-Spectrum Activity J. Deane 1, A. Simenauer1, Y. Ge 2, P. Eckburg 2, D. Sahm 1; 1Eurofins, Chantilly, VA, 2Kalidex Pharmaceuticals, Inc., Menlo Park, CA. D-761 Susceptibility of Multi-Drug Resistant Strains of Acinetobacter

baumannii to Colistin: A comparison of Disc Diffusion, Agar Dilution, Etest, Broth Microtitre Dilution, Automated and Time-Kill Methodologies L. Phee, M. Hornsey, D. Wareham; QMUL, London, United Kingdom. D-762 Development of a Disk Diffusion Assay for Oritavancin A. Belley, F. F. Arhin, , I. Sarmiento, G. Moeck; The Med. Company, StLaurent, Canada. D-763 Colistin MIC Testing: The Effect of Different Types of

Microtitre Trays and Surfactant Tween80 in Broth Microdilution Method M. S. Albur, K. E. Bowker, A. R. Noel, A. P. MacGowan; North Bristol NHS Trust, Bristol, United Kingdom. D-764 Various Test Method Parameters Have Minimal Impact on

In Vitro Minimal Inhibitory Concentration (MIC) Results Obtained with KPI-10 by Broth Microdilution Testing J. Deane 1, A. Simenauer 1, Y. Ge 2, P. B. Eckburg 3, D. Sahm1; 1Eurofins, Chantilly, VA, 2Kalidex Pharmaceuticals, Inc., Menlo Park, CA, 3Eurofins, Menlo Park, CA. D-765 Comparison of Two Gradient Diffusion Assays and Three

Testing Devices for Determination of MICs of Tigecycline against Multiresistant Isolates J. Calvo1, C. Rodríguez 1, L. Guzmán-Gómez 1, I. de Benito 2, A. Campo 2, L. Martínez-Martínez 1; 1HUM Valdecilla, Santander, Spain, 2Hosp. Sierrallana, Santander, Spain. D-766 An Equivalency Study of the Commercially Prepared Dried

MIC System Compared with the CLSI Broth Microdilution Reference Method for GSK2251052 D. Zollos1, C. Knapp 1, S. Killian 1, N. Holliday 1, N. Scangarella-Oman 2; 1 Thermo Fisher Scientific, Cleveland, OH, 2GlaxoSmithKline, Collegeville, PA. D-767 Broth Microdilution Quality Control Ranges for Testing

the Imipenem/MK-7655 Combination (IMK) against Key Organism Groups J. Deane1, A. Simenauer 1, K. Young 2, M. Motyl 2, D. Sahm 1; 1Eurofins, Chantilly, VA, 2Merck & Co., Inc., Kenilworth, NJ. D-768 Quality Control Parameters for LFF571 Aerobic & Anaerobic

Minimum Inhibitory Concentration (MIC) Susceptibility Tests M. M. Traczewski, S. D. Brown; The Clinical Microbiol. Inst., Wilsonville, OR.

Final Program

95

> Monday SCIENTIFIC SESSIONS D-769 Ozenoxacin. Checkerboard Interaction Studies with Other

Antibacterials against Gram-Positive Organisms I. Morrissey1, R. Janes 1, J. Dallow 1, A. Guglietta 2, D. Gargallo-Viola 2; 1 Quotient Bioresearch, Ltd., Fordham, United Kingdom, 2Ferrer, R&D Ctr., Barcelona, Spain. D-770 Effect of Testing Methodology on In Vitro Activity of Sodium

Oxychlorosene A. H. Stock1, S. S. Utley 1, S. C. Cheatham 1, M. R. Fleming 2, M. B. Kays 3 1 ; St. Francis Health, Indianapolis, IN, 2Methodist Dallas Med. Ctr., Dallas, TX, 3Purdue Univ., Indianapolis, IN. D-771 Multicenter Evaluation of Ceftaroline Etest Antimicrobial

Susceptibility Test for Enterobacteriaceae M. M. Traczewski1, S. D. Brown 1, W. M. Dunne 2,3, M. Tuohy 4, G. S. Hall 5, R. Collins 2; 1The Clinical Microbiol. Inst., Wilsonville, OR, 2Washington Univ. Sch. of Med., St. Louis, MO, 3bioMerieux, Inc, Durham, NC, 4Cleveland Clinic, Cleveland, OH, 5Cleveland Clinic, Wilsonville, OR. D-772 Screening of Hematological Patients for Intestinal Coloni-

Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals in 2011: CANWARD Surveillance Study G. G. Zhanel1, H. J. Adam 2, M. Baxter 1, A. Denisuik1, A. Walkty 2, P. R. S. Lagace-Wiens 2, F. Schweizer 1, D. J. Hoban 2, J. A. Karlowsky 2; 1Univ. of Manitoba, Winnipeg, Canada, 2Diagnostic Services of Manitoba, Winnipeg, Canada. E-780 A549 Cell Culture Supernatant Inactivates Carbapenem

Antibiotics H. Takemura, S. Terakubo, N. Okamura, J. Shimada, H. Nakashima; St. Marianna Univ., Kawasaki, Japan. E-781 Antimicrobial Activity of the Fluoroketolide, Solithromycin

(CEM-101), against Neisseria gonorrhoeae J. Mallegol1, P. Fernandes 2, C. Seah1, C. Guyard 1, R. G. Melano1; 1Publ. Hlth. Ontario Lab., Toronto, Canada, 2Cempra Pharmaceuticals, Inc., Chapel Hill, NC. E-782 In Vitro Interactions with Fractional Inhibitory Concentration

zation with Antibiotic-Resistant Enterobacteria is Helpful to Predict Susceptibility of Bacteremia Isolates

(FIC) Indices between 0.5 and 4 are In Vivo Important: A Need to Revisit FIC Index Cutoffs

P. Woerther, J. Micol, B. Gachot, J. Bourhis, S. de Botton, E. Chachaty; Inst. Gustave Roussy, Villejuif, France.

J. Meletiadis1, A. Elefanti 1, L. Zerva 1, P. E. Verweij 2, J. W. Mouton 2; 1 Attikon Univ. Gen. Hosp., Athens, Greece, 2Radboud Univ. Med. Ctr., Nijmegen, Netherlands.

D-773 Antimicrobial Resistance of Klebsiella pneumoniae and

Staphylococcus aureus at Sentinel Sites in South Africa O. Perovic, A. Singh-Moodley, M. Smith, W. Lowman; Natl. Hlth. Lab. Service, Johannesburg, South Africa. D-774 Detection of Amp C Beta Lactamase Producing Bacteria

Isolated from a Tertiary Care Hospitals A. Hassanil; Natl. Univ. of Scienecs and Tech., Army Med. Coll., Rawalpindi, Pakistan. D-775 Etiology and Antimicrobial Susceptibility Patterns of Acute

Uncomplicated Cystitis from Primary Care Settings in Rwanda C. Muvunyi, F. Masaisa, L. Mutesa, A. Musemakweri; Natl. Univ. of Rwanda/Faculty, Butare, Rwanda. D-776 Prevalence and Antimicrobial Susceptibility Pattern of

Propionibacterium Species Isolated from Indian Patients with Acne Vulgaris R. Chaudhry, R. Khan, N. Khanna; AIIMS, Delhi, India. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------093(E) Poster Session Cornucopia of In Vitro Activity Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: E-777 TP-434 is Active In Vitro against Biofilms Formed by Uro-

pathogenic Escherichia coli W. O’ Brien, J. A. Sutcliffe, T. H. Grossman; Tetraphase Pharmaceuticals, Watertown, MA. E-778 Comparison of Tedizolid (TZD) In Vitro Activity with That

of Other Key Gram Positive Agents against Recent Enterococcal and Streptococcal Isolates J. Deane 1, A. Simenauer 1, K. Bartizal 2, K. Shaw 2, D. F. Sahm1; 1Eurofins, Chantilly, VA, 2Trius Therapeutics, San Diego, CA.

96

E-779 In Vitro Activity of Plazomicin against Gram-Negative and

September 9-12 |

E-783 Does Pulmonary Surfactant Generally Affect Antimicrobial

Activity? R. Schwameis, S. Strommer, RT, M. A. Zeitlinger, R. Sauermann; Med. Univ. of Vienna, Vienna, Austria.

-----------------------------------------------------------------------094(E) Poster Session In Vitro Activity against Multidrug-Resistant GramNegative Bacteria Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: E-784 In Vitro Activity of Dioctadecyldimethylammonium Bromide

Bicelles (DDAb) and DDAb/Tigecycline against OxacillinaseProducing Acinetobacter baumannii P. R. Neves, M. Medeiros, E. Mamizuka, N. Lincopan; Univ.e de São Paulo, São Paulo, Brazil. E-785 An Evaluation of Polymyxin B (PB) and Tigecycline (TIG)

Combinations against Acinetobacter baumannii (Ab) G. G. Rao 1, N. S. Ly 1, R. L. Nation 2, A. Forrest 1, J. B. Bulitta 1,2, J. Li 2, B. T. Tsuji 1; 1SUNY, Buffalo, NY, 2Monash Univ., Melbourne, Australia. E-786 In Vitro and In Vivo Responses of Acinetobacter baumannii (Ab)

Isolates to Colistin (COL) and Doripenem (DOR) Following Previous Exposure L. M. Gillis, E. G. Press, M. H. Nguyen, C. J. Clancy , R. K. Shields; Univ. of Pittsburgh, Pittsburgh, PA. E-787 Minimal Inhibitory Concentrations (MICs) of Tigecycline

to Acinetobacter baumannii Vary Significantly as a Function of Testing Method D. Marchaim, O. Tzuman, K. Hayakawa, P. R. Lephart, J. M. Pogue, T. Lazarovitch, K. S. Kaye; Wayne State Univ., Detroit, MI.

MONDAY SCIENTIFIC SESSIONS E-788 Synergistic Activity of Polymyxin B Associated with

E-798 Novel Antibiotic Combinations with Enhanced Antibacterial

Vancomycin or Imipenem against OXA-143, OXA-23, OXA-58, and OXA-72-Producing Acinetobacter baumannii M. Medeiros, N. Lincopan; Univ. de São Paulo, São Paulo, Brazil. E-789 Seeking Active Agents against KPC-Producing Acinetobacter

baumannii (KPCAB) 1

2

2 1

K. S. Thomson , I. E. Robledo , G. J. Vázquez ; Creighton Univ. Sch. of Med., Omaha, NE, 2Univ. Puerto Rico, San Juan, PR. E-790 In Vitro Activity of Tobramycin and Polymyxin E against

E-791 Amikacin (A) & Meropenem (M) & Polymyxin B (P) is

1

3

nations against KPC-Producing K. pneumoniae: Comparison Between the Checkerboard and Etest Methods V. Papoutsaki, D. Lekkakou, I. Galani, M. Souli, L. Galani, I. Karaiskos, N. Vakalis, H. Giamarellou; Hygeia Hosp., Athens, Greece.

2

and NDM-Producing Klebsiella pneumoniae T. Tängdén1, R. A. Hickman 1, P. Forsberg 1, C. G. Giske 2, P. Lagerbäck 1, O. Cars1; 1Uppsala Univ., Uppsala, Sweden, 2Karolinska Inst., Stockholm, Sweden. E-801 Potential Antiseptic Properties of Dioctadecyldimethylam-

Bactericidal against Pandrug-Resistant (PDR) Pseudomonas aeruginosa (PA) & Suppress the Emergence of Resistance up to 120 hours in a Hollow Fiber Infection Model (HFIM) 1

E-799 In Vitro Activities of Tigecycline and Tigecycline Combi-

E-800 Synergistic Effect of Aztreonam Combinations against VIM-

Pseudomonas aeruginosa PAO1 and 25668 K. M. Tarquinio1,2, K. L. Confreda 1, K. L. LaPlante 3,4; 1Rhode Island Hosp. Pediatric Critical Care Med., Providence, RI, 2Brown Univ., Providence, RI, 3Providence VA ID Res. Program, Providence, RI, 4Univ. of Rhode Island Coll. of Pharmacy, Kingston, RI.

1,2

Effect against ESBL- Producing E.coli and Klebsiella pneumoniae R. A. Hickman, D. Hughes, C. Malmberg, O. Cars; Uppsala Univ., Uppsala, Sweden.

1

T. P. Lim , S. Sasikala , W. Lee , T. Y. Tan , L. Y. Hsu , T. T. Tan , A. L. Kwa1; 1Singapore Gen. Hosp., Singapore, Singapore, 2Natl. Univ. Hosp. System, Singapore, Singapore, 3Changi Gen. Hosp., Singapore, Singapore. E-792 Porin Expression Predicts Responses of Carbapenemase-

monium Bromide Cationic Bilayer Fragments (DDA-BF) against Carbapenemase-Producing Bacteria E. B. Gaspar1, A. S. Rosetti 2, H. G. Turano 2, M. Medeiros 2, P. R. Neves 2, N. Lincopan 2; 1Embrapa, Bagé, Brazil, 2São Paulo Univ., São Paulo, Brazil. E-802 The Effect of Urine, Lung Surfactant and Testing Parameter

Variations on the In Vitro Activity of GSK2251052 and Meropenem

Producing Klebsiella pneumoniae (KPC) to the Combination of Doripenem (DOR)+Ertapenem (ERT)+Colistin (COL) In Vitro

L. M. Koeth 1, J. DiFranco-Fisher 1, N. E. Scangarella-Oman2; 1Lab. Specialists, Inc., Westlake, OH, 2GlaxoSmithKline, Collegeville, PA.

J. H. Hong1, S. Cheng 2, R. Shields 1, Y. Doi 1, L. Chen 3, Y. Zhao 3, B. N. Kreiswirth 3, C. Clancy 1, M. H. Nguyen 1; 1Univ. of Pittsburgh Med. Ctr., Pittsburgh, PA, 2Univ. of Pittsburgh, Pittsburgh, PA, 3Publ. Hlth. Res Inst., Univ. of Med. & Den. of NJ, Newark, NJ.

E-803 Comparative In Vitro Activity of Doripenem, Meropenem and

E-793 Bactericidal Activity of Multiple Combinations of Fosfomycin

and Colistin against NDM-1 Producing Enterobacteriaceae M. S. Albur, A. R. Noel, K. E. Bowker, A. P. MacGowan; North Bristol NHS Trust, Bristol, United Kingdom. E-794 In Vitro Activity of Colistin Alone and in Combination with

Doripenem against KPC-Producing K. pneumoniae Isolates G. C. Lee1,2, D. S. Burgess 1,2; 1Univ. of Texas Col. of Pharmacy, Austin, Texas, 2UT Hlth. Sci. Ctr., San Antonio, Texas. E-795 Optimizing Polymyxin (POL) Combinations (Combos) with

‘Old’ Antibiotics against NDM-Producing Klebsiella pneumoniae (Kp) H. J. Lee 1, K. Davis1, C. Ku1, H. H. Yu1, A. Poudyal 1, J. Jacob 1, B. Y. Liu 2, J. Fu2, D. L. Paterson3, R. L. Nation 1, J. Li 1; 1Monash Inst. of Pharmaceutical Sci., Monash Univ., Melbourne, Australia, 2Monash Univ., Melbourne, Australia, 3Univ. of Queensland Ctr. for Clin. Res., Brisbane, Australia. E-796 Synergistic Activity of Colistin (COL) Plus Rifampin (RIF)

against COL-Resistant (R) and Susceptible (S) KPC-Producing Klebsiella pneumoniae (KPC-KP) Clinical Isolates E. Tagliaferri 1, C. Tascini 1, S. Flammini 1, T. Giani 2, A. Leonildi1, I. Ciullo 1, G. Rossolini 2, F. Menichetti 1; 1Azienda Ospedaliera Univ. Pisana, Pisa, Italy, 2 Univ. di Siena, Siena, Italy. E-797 In Vitro Activity of Daptomycin in Combination with Low-

Dose Colistin Versus a Diverse Collection of Gram-Negative Bacterial Pathogens L. Phee, M. Hornsey, D. Wareham; QMUL, London, United Kingdom.

Imipenem in a Prospective Multi-Centre Study M. J. B. Melchers, Other 1, A. Voss2, J. A. Kluytmans3, C. van Mil 2, J. W. Mouton1, the Design study group; 1Radboud Univ. Nijmegen Med. Ctr, Nijmegen, Netherlands, 2Canisius Wilhelmina Hosp., Nijmegen, Netherlands, 3 Amphia Hosp., Breda, Netherlands. E-804 Discrepancies Between Colistin (COL) MICs and Inhibition

of Acinetobacter (Ab) and Klebsiella (Kp) During Time-Kill Assays (TKA) R. K. Shields, C. J. Clancy , E. G. Press, J. Hong, C. A. Updike, M. H. Nguyen; Univ. of Pittsburgh, Pittsburgh, PA. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------095(E) Poster Session In Vitro Activity Versus Anaerobes Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: E-805 Patterns of Resistance in Bacteroides fragilis Group: Analysis of

Period 2010-2012 in a Teaching Hospital of Madrid (Spain) F. J. Candel, E. Baos, P. Merino, F. De la Torre, E. Culebras, J. J. Picazo; Hosp. Clinico San Carlos, Madrid, Spain. E-806 In Vitro Activity of Twelve Antianaerobic Agents against Clin-

ical Veillonella sp. Strains Isolated Over a 4-Year Period (2008-11) L. Alcalá , T. Peláez, P. Martín-Rabadán, E. Reigadas , E. Bouza; Hosp. GU Gregorio Marañón, Univ. Complutense de Madrid., Madrid, Spain.

Final Program

97

> Monday SCIENTIFIC SESSIONS E-807 Susceptibilities of Clostridium difficile to CB-183,315 and

Comparators L. Chesnel 1, A. E. Crist, Jr 2, R. M. Patti, JD 2, D. R. Snydman 3, J. Kishel1; 1 Cubist Pharmaceuticals, Lexington, MA, 2York Hosp., York, PA, 3Tufts Med. Ctr., Boston, MA. E-808 In Vitro Activity of Cadazolid against 209 Toxigenic Isolates of

Discovery of a Novel In Vitro Marker Correlated with In Vivo Anti-Aspergillus Efficacy T. Nakai, S. Matsumoto, S. Uchida, S. Takeda, S. Akamatsu, K. Maki; Astellas Pharma Inc., Tsukuba, Japan. F-818 ASP9726, A Unique 2nd Generation Echinocandin (2) -

Clostridium difficile

Synthesis and In Vitro Activity

D. W. Hecht1,2, D. N. Gerding 1,2, J. R. Osmolski 1, S. Sambol 1, A. Cheknis, BA 2; 1Loyola Univ. Med. Ctr., Maywood, IL, 2Hines Veterans Admin. Hosp., Hines, IL.

H. Morikawa, A. Okada, M. Tomishima, N. Kayakiri, D. Barrett, S. Akamatsu, S. Matsumoto, S. Uchida, T. Nakai, S. Takeda, K. Maki; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan.

-----------------------------------------------------------------------096(F) Poster Session

F-819 ASP9726, A Unique 2nd Generation Echinocandin (3) -

New Antifungal Agents

F-820 ASP9726, A Unique 2nd Generation Echinocandin (4) -

Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: F-809 Antifungal Activities of a Novel Arylamidine T-2307 against

Azole-Resistant Aspergillus Species, A. calidoustus K. Yamashita, E. Yamada, M. Kaeriyama, H. Nishikawa, N. Fujino, N. Nomura, J. Mitsuyama; Res. Lab., Toyama Chemical Co.,Ltd., Toyama, Japan. F-810 Antifungal Spectrum, In Vivo Efficacy and Structure Activity

Relationship of Ilicicolin H S. Singh, W. Liu, X. Li, T. Chen, A. Shafiee, D. Card, G. Abruzzo, A. Flattery, C. Gill, J. Thompson, M. Rosenbach, S. Dreikorn, V. Hornak, M. Meinz, R. Kelly, J. Onishi; Merck & Co., Inc., Rahway, NJ. F-811 Comparative In Vitro Activities of Fluconazole, Voriconazole,

and MXP-4509 against 256 Candida Isolates from Romanian Tertiary Hospitals 1

1

1

2

1 1

M. Mares , V. Nastasa , R. Moraru , B. Minea , L. Miron ; Ion Ionescu de la Brad Univ., IASI, Romania, 2Petru Poni Inst. of Macromolecular Chemistry, IASI, Romania. F-812 Sulphur Containing Acetamide, from an Endophytic Fungus

In Vitro and In Vivo Activity against Aspergillus spp. S. Akamatsu, S. Matsumoto, S. Uchida, T. Nakai, S. Takeda, K. Maki, A. Okada, N. Kayakiri, D. Barret; Astellas Pharma Inc.,, Tsukuba, Ibaraki, Japan.

In Vitro and In Vivo Activity against Candida spp. S. Akamatsu, S. Matsumoto, S. Uchida, T. Nakai, S. Takeda, K. Maki, H. Morikawa, M. Tomishima, D. Barrett; Astellas Pharma Inc.,, Tsukuba, Ibaraki, Japan. F-821 ASP9726, a Unique 2nd Generation Echinocandin (5) -In

Vitro and In Vivo Activity of Combination Therapy with Voriconazole against Aspergillus fumigatus S. Akamatsu, S. Matsumoto, S. Uchida, BS , T. Nakai, S. Takeda, K. Maki; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan. F-822 Evaluation of ASP9726 on Glucan Synthase Inhibition from

Echinocandin Susceptible and Resistant Fungi P. Paderu1, C. Jiménez-Ortigosa 1, S. Akamatsu2, S. Matsumoto2, D. Perlin 1; 1 Publ. Hlth. Res. Inst, Newark, NJ, 2Astellas Pharma Inc., Ibaraki, Japan. F-823 Efficacy and Pharmacokinetics of ASP9726 in a Guinea Pig

Model of Invasive Pulmonary Aspergillosis (IPA) W. R. Kirkpatrick1,2, N. P. Wiederhold3,1, L. K. Najvar 1,2, S. Matsumoto 4, R. A. Bocanegra 1,2, T. F. Patterson 1,2; 1UTHSCSA, San Antonio, TX, 2 STVHCS, San Antonio, TX, 3Univ. of Texas, Austin, TX, 4Astellas, Tsubuka, Japan.

Emericella sp. Isolated From Azadirachta indica


S. Mittal1,2, S. Kumar1, S. Gowil 1, D. Shrivastava 1; 1Jaipur Natl Univ, Jaipur, India, 2Amol Pharmaceuticals Pvt. Ltd., Jaipur, India.

-----------------------------------------------------------------------097(F) Poster Session

F-813 Biochemical Evaluation of Rtt109 Inhibitor as a Potential

Anti-Fungal Agent J. Pupaibool, T. J. Kottom, A. H. Limper; Mayo Clinic, Rochester, MN. F-814 Milbemycins: Not Just Fungal ABC-Transporter Inhibitors Withdrawn F-815 Antifungal Properties of 2-Adamantanamine, a Potentiator of

Azole Antifungals M. LaFleur1,2, L. Long 3, M. Ghannoum 3, J. North4, R. Lee 4, K. Lewis 2 1 ; Arietis Corp., Boston, MA, 2Northeastern Univ., Boston, MA, 3Case Western Reserve Univ., Cleveland, OH, 4St. Jude Children’s Res. Hosp., Memphis, TN. F-816 Potent Fungicidal Activity of Bis-Amidine Antibiotics T. J. Opperman, S. M. Kwasny, S. Nguyen, J. D. Williams, N. P. Peet, T. L. Bowlin; Microbiotix, Inc., Worcester, MA.

98

F-817 ASP9726, A Unique 2nd Generation Echinocandin (1),

September 9-12 |

New Antiviral Agents Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: F-824 Discovery of a Novel Antiviral against HSV-1 & HSV-2 N. Kapoor 1, R. Bhowmick 1, H. Sivaramakrishnn 1, S. Sharma 1, B. M. Thomas2; 1Piramal Life Sci. Limited, Mumbai, India, 2Piramal Healthcare Limited, Mumbai, India. F-825 New, Safe, Effective and Convenient Virucidal Agents Using

Amino Acid K. Tsujimoto 1, K. Ikeda2, Y. Suzuki2, H. Yamasaki.3, M. Nishide 1, M. Yoshida1, T. Arakawa 4, A. H. Koyama1,3; 1Shin-ai Women’s Jr. Coll., Wakayama, Japan, 2Wakayama Med. Univ. Sch. Hlth. & Nursing Sci., Wakayama, Japan, 3Wakayama Med. Univ. Grad. Sch. Med., Wakayama, Japan, 4Alliance Protein Lab., Thousand Oaks, CA.

MONDAY SCIENTIFIC SESSIONS F-826 Identification and Analysis of Hepatitis C virus NS3 Helicase

F-834 Anti-Tuberculosis In Vitro Activity of the Nitroimidazole

Inhibitors Using a Nucleic Acid Binding Assay

TBA-354

S. Mukherjee, A. M. Hanson, J. Ndjomou, D. Bartczak, L. A. Arnold, and D. N. Frick; Univ. of Wisconsin, Milwaukee, WI.

S. Franzblau 1, S. Cho 1, Y. Wang 1, Y. Lu 2, B. Wang 2, J. Xu 2, K. Mdluli 3, A. M. Upton 3, Z. Ma 3; 1Inst. for Tuberculosis Res., Univ. of Illinois, Chicago, IL, 2Beijing Tuberculosis and Thoracic Tumor Res. Inst., Beijing, China, 3Global Alliance for TB Drug Dev., New York, NY.

F-827 Identification of Novel Small Molecule Inhibitors against the

NS3/4A Serine Protease of Hepatitis C Virus by High-Throughput Screening H. Lee, T. Zhu, Y. Zhang, K. Patel, L. Truong, A. Sarkar, H. Jeong, M. E. Johnson; Univ. of Illinois, Chicago, IL. F-828 Discovery of a New Series of Pan-Genotypic NS5b Inhibitors

for Hepatitis C: The Indazole Amide Class of Site IV Polymerase Antivirals 1

1

1

1

1

1

A. G. Draffan , S. Bond , J. Cianci , B. Frey , M. Frazetto , R. Halim , S. Hamilton1, M. Harding1, R. Hufton 1, S. Jahangiri 1, T. Jeynes 1, M. Lilly 1, B. Lin 1, A. Luttick 1, C. Morton 1,2, T. Nero2, B. Pool 1, M. Parker 2, K. Porter1, M. Pryor 1, J. Thomas 1, S. Tucker 1, J. Wielens2, V. Wirth1; 1Biota Scientific Management, Melbourne, Australia, 2St. Vincent’s Inst. of Med. Res., Melbourne, Australia. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------098(F) Poster Session New Approaches in Mycobacterial Therapy Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations:

F-835 In Vivo Anti-Tuberculosis Activity of the Nitroimidazole

TBA-354 against Acute and Chronic Murine Tuberculosis S. G. Franzblau 1, Y. Wang 1, A. M. Upton 2, K. Mdluli 2, Z. Ma 2; 1Inst. for Tuberculosis Res., Univ. of Illinois, Chicago, IL, 2Global Alliance for TB Drug Dev., New York, NY. F-836 Activity of the Nitroimidazole TBA-354 Alone and in a Novel

Drug Regimen in Two Murine Models of Tuberculosis E. Nuermberger1, K. Williams 1, O. Amoabeng 1, R. Tasneen 1, A. Minkowski 1, K. Mdluli 2, A. M. Upton 2, Z. Ma 2; 1Johns Hopkins Univ., Baltimore, 2Global Alliance for TB Drug Dev., New York, NY. F-837 In Vitro and In Vivo Evaluation of the Phototoxic Potential of

the Nitroimidazole TBA-354 D. Severynse-Stevens1, A. M. Upton 2, A. M. Shadiack 2, Z. Ma 2; 1RTI Intl., Research Triangle Park, NC, 2Global Alliance for TB Drug Dev., New York, NY. F-838 TBA-354: Process Chemistry Optimization for Large Scale

API Production to Support IND-Enabling Development C. B. Cooper1, T. Kaneko 1, Q. Li 2, L. Zhang 2, S. Liu 2, Z. Ma 1; 1Global Alliance for TB Drug Dev., New York, NY, 2Shanghai ChemPartner, Shanghai, China. F-839 In Vitro Profiling of the Absorption, Distribution, Metabolism

F-829 Novo23: A Novel Antibiotic With Specific Activity against

Mycobacterium Tuberculosis E. Gavrish1, A. Peoples 2, A. Spoering2, A. Bissell 1, W. Millett 2, L. Ling 2, D. Hughes 2, K. Lewis 1; 1Northeastern Univ., Boston, MA, 2NovoBiotic Pharmaceuticals, LLC, Cambridge, MA. F-830 Enhanced Activity of 13C-Isoniazid Using Magnetic Isotope

Effect S. Choi1, R. Gupta2, L. Silks3, W. Bishai2, G. Timmins 1; 1Univ. of New Mexico, Albuquerque, NM, 2Johns Hopkins Hosp., Baltimore, 3Los Alamos Natl. Lab., Los Alamos, NM. F-831 The Search for New Antimicrobial Agents against Mycobacte-

rium abscessus, M. A. De Groote1, S. Cho 2, L. L. Klein 2, S. G. Franzblau 2; 1Colorado State Univ., Fort Collins, CO, 2Univ. of Illiniois at Chicago, Chicago, IL. F-832 Anti-Bacterial Activity and Postantibiotic Effect of Novel

Spectinamide Analogs against Mycobacterium Tuberculosis M. M. Butler1, D. F. Bruhn 2, H. I. M. Boshoff 3, J. Liu 2, T. L. Bowlin 1, R. E. Lee 2; 1Microbiotix, Inc., Worcester, MA, 2St. Jude Children’s Res. Hosp., Memphis, TN, 3NIAID, Bethesda, MD. F-833 Antimicrobial Activity of Five Essential Oils and Their

Compounds against Mycobacterium Tuberculosis S. Andrade Ochoa, K. F. Chacon Vargas, L. R. Hernández Ochoa, L. M. Rodriguez Valdez, G. V. Nevarez Moorillón, B. R. Rivera Chavira; Univ. Autonoma de Chihuahua, Chihuahua, Mexico.

and Excretion (ADME) Properties of the Nitroimidazole TBA-354 T. Yang 1, E. Pauli2, A. M. Upton 1, W. Wargin3, A. M. Shadiack 1, Z. Ma 1; 1 Global Alliance for TB Drug Dev., New York, NY, 2RTI Intl., Research Triangle Park, NC, 3PK-PM Associates, Chapel Hill, NC. F-840 Preclinical Pharmacokinetic Studies of the Nitroimidazole

TBA-354 in Mice, Rats and Dogs T. Yang1, E. Pauli 2, A. M. Upton 1, W. Wargin3, A. M. Shadiack 1, Z. Ma 1; 1 Global Alliance for TB Drug Dev., New York, NY, 2RTI Intl., Research Triangle Par, NC, 3PK-PM Associates, Chapel Hill, NC.

-----------------------------------------------------------------------099(F) Poster Session Targeting the Bacterial Cell Wall: New Beta-Lactams and Beta-Lactamase Inhibitor Combinations Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: F-841 In Vitro Activity of BAL30072 against Contemporary Clinical

Isolates of Gram-Negative Bacteria (GNB) from New York City including Multidrug-Resistant (MDR) Isolates D. Landman , M. Singh, B. El-Imad, E. Miller, T. Win, J. Quale; SUNY Downstate Med. Ctr., Brooklyn, NY.

Final Program

99

> Monday SCIENTIFIC SESSIONS F-842 Comparative Efficacy of BAL30072, Aztreonam, Meropenem

and Ceftazidime and Effects of Dose Fractionation in a Murine Thigh Infection Model J. K. Gould 1, A. Sattar 1, G. M. Daws 1, L. J. Payne 1, J. Spikermann 2, W. Stubbings 2, A. Schmitt-Hoffmann 2, M. G. P. Page 2, P. A. Warn1; 1Euprotec Ltd. Manchester, United Kingdom, 2Basilea Pharmaceutica Intl. Ltd. Basel, Switzerland. F-843 Broad Spectrum Cephalosporins with Urea-Substituted

Pyridinium Group at the C-3’ Position Exhibiting Potent Activity against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa Y. He, N. Yin, J. Romero, C. Abel, R. Busch, B. Wang, A. Pearson, P. Herradura, D. Keith, J. Rock, L. Chesnel, K. Cassidy C. Monahan, S. Zhang, J. Silverman, D. Alexander, C. Metcalf Y. Gu; Cubist Pharmaceuticals, Lexington, MA. F-844 Synthesis and Structure-Activity Relationships of Aminoalkyl-

RPX7009 in Preclinical Species D. C. Griffith, M. Sabet, Z. Tarazi, O. Lomovskaya S. J. Hecker, M. N. Dudley; Rempex Pharmaceuticals, San Diego, CA. F-852 Nonclinical Toxicology and Safety Profile of the Beta-Lacta-

mase Inhibitor RPX7009 D. C. Griffith, M. Sabet, Z. Tarazi, BS , R. Tsivkovski, O. Lomovskaya, S. J. Hecker M. N. Dudley; Rempex Pharmaceuticals, San Diego, CA. F-853 Activity of RPX2003 - RPX7009 Combinations against

Carbapenem-Resistant Enterobacteriaceae D. M. Livermore, S. Mushtaq, H. Dhanji; Hlth. Protection Agency, London, United Kingdom. F-854 In Vitro Activity of RPX2003/RPX7009, a Carbapenem Com-

bined with a Serineơ-Lactamase Inhibitor against Anaerobic Bacteria E. J. C. Goldstein, D. M. Citron; R.M. Alden Res. Lab., Culver City, CA.

N’-(Pyridin-4-yl) Benzohydrazide-Derived Cephalosporins with Broad Spectrum Activity against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa

F-855 Activity of Rpx2003/rpx7009 (RPX3/9), a Carbapenem Com-

J. Romero, Y. He, N. Yin, C. Abel, R. Busch, B. Wang, A. Pearson, P. Herradura, F. Epie, D. Keith, J. Rock, L. Chesnel, K. Cassidy, C. Monahan, S. Zhang, J. Silverman, D. Alexander, C. Metcalf-, Y. Gu; Cubist Pharmaceuticals, Lexington, MA.

M. Castanheira1, O. Lomovskaya 2, P. R. Rhomberg 1, R. N. Jones1; 1JMI Lab., N Liberty, IA, 2Rempex Pharmaceuticals, San Diego, CA.

F-845 Structure-Activity Relationship Studies of Novel Cephalo-

sporins with Substituted Pyrazolium Groups at the C-3’ Position against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa N. Yin1, Y. He 1, J. Romero 1, C. Abel1, R. Busch 1, B. Wang 1, A. Pearson2, P. Herradura 3, F. Epie 1, D. Keith 1, J. Rock 1, L. Chesnel 1, K. Cassidy 1, C. Monahan 1, Y. Li 1, C. Chuong1, S. Zhang 1, J. Silverman 1, D. Alexander1, C. Metcalf 1, Y. Gu 1; 1Cubist Pharmaceuticals, Lexington, MA, 2Biotech Generics LLC, Brooklyn, NY, 3Genentech, San Francisco, CA. F-846 In Vivo Efficacy of CB-027 against Methicillin-Resistant

Staphylococcus aureus, and Ceftazidime-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae Infections in Mice S. Zhang, L. I. Mortin, Y. Li, C. Chuong, H. Corkrey, C. Khang, A. Alsup, T. Li, A. Arya, Y. He, N. Yin, J. Rock, C. Abel, Y. Gu, D. Alexander, C. Metcalf, J. Silverman, C. Murphy; Cubist Pharmaceuticals, Lexington, MA. F-847 Versatile 6ơ-(hydroxymethyl) Penicillanic Acid Sulfone

(6ơ-HM-sulfone) Derivatives asơ-Lactamase Inhibitors J. D. Buynak1, M. Nottingham 1, C. Bethel 2, K. Papp-Wallace 2, D. McLeod1, S. R. R. Pagadala 1, M. Winkler3, R. A. Bonomo 2; 1SMU, Dallas, TX, 2VAMC, Cleveland, OH, 3CWRU, Cleveland, OH. F-848 Discovery of RPX7009, a Broad-Spectrum Beta-Lactamase

bined with a Novelơ-Lactamase Inhibitor (BLI) Tested against Clinical Isolates Producing Defined Enzymes

F-856 Pre-Clinical Evaluation of a Carbapenem/ơ-Lactamase Inhibi-

tor Combination (RPX2003/RPX7009) Tested against SerineCarbapenemase-Producing Pathogens M. Castanheira, H. K. Becker, P. R. Rhomberg, R. N. Jones; JMI Lab., N Liberty, IA. F-857 In Vivo Evaluation of a Novel Carbapenemase Inhibitor (CPI),

Rpx7009, in Combination with the Carbapenem Rpx2003 against 2 Kpc Producing K. pneumonia (KP) in a Neutropenic Murine Thigh Model A. Lepak, K. Marchillo, W. Craig, D. R. Andes; Univ. of Wisconsin, Madison, WI. F-858 In Vivo Efficacy of the Beta-Lactamase Inhibitor RPX7009

Combined with the Carbapenem RPX2003 against KPCProducing K. pneumoniae M. Sabet, Z. Tarazi , O. Lomovskaya, S. J. Hecke, M. N. DudleyO, D. C. Griffith; Rempex Pharmaceuticals, San Diego, CA. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------100(G) Poster Session

Inhibitor with Utility vs. Class A Serine Carbapenemases

Impact of Expanded Valent: Pneumococcal Vaccines

S. J. Hecker1, K. R. Reddy1, M. Totrov 2, G. C. Hirst1, O. Lomovskaya 1, D. C. Griffith 1, P. King 1, R. Tsivkovski1, D. Sun1, M. Sabet1, Z. Tarazi1, M. N. Dudley 1; 1Rempex Pharmaceuticals, Inc., San Diego, CA, 2Molsoft L.L.C., San Diego, CA.

Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: G-859 Lessons from Pneumococcal Conjugate Vaccines (PCV)

RPX7009

Efficacy Trials against Community-Acquired Pneumonia (CAP) and Acute Otitis Media (AOM)

O. Lomovskaya, R. Tsivkovsky, D. Sun, D. Griffith, S. J. Hecker M. N. Dudley; Rempex Pharmaceuticals, Inc, San Diego, CA.

F. L. P. Fierens, B. Hoet, W. P. Hausdorff; GlaxoSmithKline Biologicals, Wavre, Belgium.

F-849 Biochemical Characterization of the Beta-Lactamase Inhibitor

F-850 Microbiological Characterization of Beta-Lactamase Inhibitor

100

F-851 Pharmacokinetics of the New Beta-Lactamase Inhibitor

G-860 Cost-Effectiveness of 13-Valent Pneumococcal Vaccine in the

RPX7009

Adult Swiss Population

O. Lomovskaya, P. King, D. Sun, D. C. Griffith, S. J. Hecker, M. N. Dudley; Rempex Pharmaceuticals, Inc, San Diego, CA.

P. R. BlankBiology1, T. D. Szucs 2; 1Univ. of Zurich, Zurich, Switzerland, 2 Univ. of Basel, Basel, Switzerland.

September 9-12 |

MONDAY SCIENTIFIC SESSIONS G-861 Impact of the Ten-Pneumococcal Conjugate Vaccine (PCV10)

on Invasive Pneumococcal Infections of the Population Attending at University Hospital in Brazil S. R. Santos 1, L. F. Passadore1, E. H. Takagi 2, C. M. Fujii 1, A. E. Gilio1, M. B. Martinez2,1; 1HU-USP, Sao Paulo, SP, Brazil, 2FCF-USP, Sao Paulo, SP, Brazil. G-862 Impact of Pneumococcal Conjugate Vaccination on Hospital-

ization Rates for S. pneumoniae Invasive Disease in US Children: 1998-2009 R. M. Mera1, L. A. Miller 2, J. A. Suaya 2, H. A. Madsen 2, D. F. Sahm 3; 1 MSI, Washington, DC, 2GlaxoSmithKline, Upper Providence, PA, 3 Eurofins Medinet, Chantilly, VA. G-863 Effects of three Years of Immunization with Higher Valent

Pneumococcal Conjugate Vaccines on Serotype Distributions among Reported IPD Cases in German Children and Adults M. van der Linden1, R. von Kries 2, M. Imöhl 1; 1Inst. of Med. Microbiol., Aachen, Germany, 2Inst. of Social Pediatrics and Adolescent Med., Munich, Germany. G-864 Effect of 7-Valent and 13-Valent Pneumococcal Conjugate

Vaccines on Pneumococcal Meningitis in French Children Under 2 years C. Levy 1, E. Varon 2, E. Bingen 3, S. Béchet 4, Groupe des pédiatres et microbiologistes de l’Observatoire National des Méningites, R. Cohen1; 1Activ/ GPIP, Saint Maur des Fossés, France, 2CNRP APHP and GPIP, Paris, France, 3Denis Diderot Univ. and GPIP, Paris, France, 4Activ, Saint Maur des Fossés, France. G-865 Use of the 13-Valent Conjugate Vaccine has the Potential

to Eliminate Pilus Carrying Isolates as Causes of Invasive Pneumococcal Disease S. I. Aguiar, J. Melo-Cristino, M. Ramirez; Faculdade de Medicina de Lisboa, Lisboa, Portugal. G-866 Impact of Two Years of Non-Universal Pediatric Use of the

13-Valent Conjugate Vaccine (PCV13) in Portugal S. Aguiar 1, A. Horacio 1, J. Diamantino-Miranda 1, M. J. Brito 2, M. Ramirez 1, J. Melo-Cristino1, Microbiology and Pediatric Pneumococcal Working Group; 1Faculdade de Med. de Lisboa, Lisboa, Portugal, 2Centro Hosp. Lisboa Central, Lisboa, Portugal. G-867 Comparison of Serologic Responses to Primary Vaccination

-----------------------------------------------------------------------101(G) Poster Session Updates in Vaccines Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: G-868 Efficacy and Immunologic Mechanisms of NDV-3 Vaccine in

a Murine Model of Methicillin-Resistant Staphylococcus aureus (MRSA) Skin / Skin Structure Infection (SSSI) M. Yeaman1, S. Filler 2, S. Chaili 3, K. Barr 2, H. Wang 2, D. Kupferwasser 2 , Y. Fu 2, J. P. Hennessey, Jr. 4, C. Schmidt 4, J. Edwards, Jr. 2, Y. Xiong 2, A. Ibrahim 2; 1UCLA Shool of Med. & LABioMed at Harbor-UCLA Med. Ctr., Torrance, CA, 2LABioMed at Harbor-UCLA Med. Ctr., Torrance, CA, 3 Los Angeles Biomedical Res. Inst., Torrance, CA, 4NovaDigm Therapeutics, Inc., Grand Forks, ND. G-869 Comparison ofơ-Propiolactone and W805EC Nanoemulsion

for Inactivation of RSV Nasal Vaccination in a Mouse Challenge Model

T. Hamouda1, V. Bitko 1, A. Myc2, J. Simon 1, P. E. Makidon 2, D. M. Smith2, N. Lukacs 2, A. Fattom 1,2, J. R. Baker, Jr.1,2; 1NanoBio Corp, Ann Arbor, MI, 2Univ. of Mich., Ann Arbor, MI. G-870 Expression and Immune Response to Staphylococcus aureus

Virulence Factors in Human Disease W. Rozemeijer 1, P. Fink 2, E. Rojas 2, C. H. Jones 2, D. Pavliakova 2, P. Giardina 2, E. Murphy 2, P. Liberator 2, Q. Jiang 2, D. Q. Girgenti 2, R. P. H. Peters 1, P. Savelkoul 1, K. U. Jansen 2, A. S. Anderson2, J. Kluytmans 1; 1VU Univ. Med. Ctr., Amsterdam, Netherlands, 2Pfizer Vaccine Res., Pearl River, NY. G-871 Fully Human Monoclonal Antibody to IL-10RƠ Augments

HCV Antigen-Specific T Cell Responses In Vitro P. Rogers, L. Liou, E. Rodriguez, R. Soloff, K. Tomizuka, K. Ohgami; Kyowa Hakko Kirin California, Inc., La Jolla, CA. G-872 Effectiveness of Influenza Vaccine on the Prevention of

Hospitalization with Acute Lower Respiratory Infection and Exacerbation of Chronic Cardiopulmonary Disease in Korea During Year of 2010-2011

with 23-valent Pneumococcal Polysaccharide Vaccine vs 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Patients in the Era of Combination Antiretroviral Therapy

Y. Seo1, K. Hong 1, I. Kim 1, J. Baek 2, W. Choi 1, J. Lee 3, J. Song 1, J. Lee 2, H. Cheong 1, W. Kim 1; 1Korea Univ. Coll. of Med., Seoul, Korea, Republic of, 2Inha Univ. Coll. of Med., Incheon, Korea, Republic of, 3Hallym Univ. Coll. of Med., Seoul, Korea, Republic of.

J. Yang, C. Lu, W. Liu, Y. Su, S. Chang, DSc , C. Hung ; Natl. Taiwan Univ. Hosp., Taipei, Taiwan.

G-873 Safety, Tolerability and Lack of Immunogenicity in a Phase 1

Clinical Trial of TCN-032 (Anti-Influenza A mAb) E. Ramos1, J. Mitcham 1, P. Chan-Hui 1, M. Roberson 2, M. Al-Ibrahim 2; 1 Theraclone Sci., Seattle, WA, 2SNBL CPC, Baltimore. G-874 Cost-Effectiveness Analysis of Two Rotavirus Vaccines in

Argentina A. Urueña1, F. Virgilio, Economist 1, M. Betelu, Economist 1, T. Pippo, Economist 1, N. Giglio 2, A. Gentile 3, M. Diosque 1, S. García Giménez 4, C. Vizzotti 1; 1Ministerio de Salud de la Nación, Buenos Aires, Argentina, 2 Hosp. de Niños Ricardo Gutierrez, Buenos Aires, Argentina, 3Sociedad Argentina de Pediatría, Buenos Aires, Argentina, 4Organización Panamericana de la Salud, Buenos Aires, Argentina.

Final Program

101

> Monday SCIENTIFIC SESSIONS G-875 Protection against Experimental Aspergillosis by Heat-Killed

H-881 Meta Analysis of Differences in Viral Suppression by Race in

Yeast (HKY ) is not Antibody Dependent

Clinical Trials

V. Chen1, M. Martinez 1, M. Liu 1,2,3, H. Yun 1,3, K. V. Clemons 1,2,3, D. A. Stevens 1,2,3; 1California Inst. for Med. Res., San Jose, CA, 2Santa Clara Vly. Med. Ctr., San Jose, CA, 3Stanford Univ., Stanford, CA.

C. Evans1, H. Kwakwa 2, D. Spencer 3, L. Temme 4, I. Walker 4, M. Rawlings 4; 1 AIDS ARMS, Dallas, TX, 2Philadelphia Dept. of Publ. Health, Philadelphia, PA, 3Univ. of Maryland Sch. of Med., Baltimore, MD, 4Gilead Sci., Inc., Foster City, CA.

G-876 Genome-Wide Association Study Identifies Variants Near

IFNW1 and IFNB1 Associated with Host Susceptibility to Pneumococcal Disease 1

2

3

1

T. Benfield , M. Nørgaard , M. Hollegaard , L. N. Clausen , H. T. Sørensen2, H. M. David 3, H. B. Konradsen 3, Z. B. Harboe 1; 1Copenhagen Univ. Hosp., Hvidovre, Denmark, 2Århus Univ., Århus, Denmark, 3Staten Serum Inst., Copenhagen, Denmark. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------102(H) Poster Session Antiretroviral Therapy Outcomes Including Select Populations Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C

Receiving Atazanavir (ATV) Compared to ATV/Ritonavir (RTV), Each in Combination with Abacavir/Lamivudine (ABC/3TC), after Initial Suppression with ABC/3TC + ATV/RTV Through 144 Weeks on Therapy K. Squires1, B. Young 2, L. Santiago 3, R. Dretler 4, S. Walmsley 5, H. Zhao 6, B. Wine 6, L. L. Ross 6, M. Shaefer 7; 1T. Jefferson Univ, Philadelphia, PA, 2 Univ. of Colorado, Denver, Colorado, 3HOPE Clin Res, San Juan, Puerto Rico, 4ID Specialists of Atlanta, Decatur, GA, 5Univ Hlth. Network, Toronto, Canada, 6GlaxoSmithKline, Research Triangle Park, NC, 7ViiV Healthcare, Research Triangle Park, NC. H-883 Efficacy and Use of PI vs EFV in Treatment Naive HIV+ Men

and Women J. Patel1, B. Livak 2, J. Cole 1, S. Vibhakar 2, B. Max 2, K. Y. Smith 1; 1Rush Univ. Med. Ctr., Chicago, IL, 2Ruth M. Rothstein Core Ctr., Chicago, IL. H-884 Safety and Efficacy of Once Daily Raltegravir to Enhance

Presentations: H-877 Long-Term (96 And 144 Week) Efficacy and Safety from the

Verxve Trial Comparing Nevirapine Extended Release (NVP XR) 400 Mg Once a Day (qd) to Nevirapine Immediate Release (NVP IR) 200 Mg Twice a Day (bid) in Combination with Emtricitabine/Tenofovir in Treatment-Naïve HIV-1 Patients C. Brinson 1, A. Quinson 2, M. Drulak 2, J. Gathe, Jr.3; 1Central Texas Clinical Res.,, Austin, TX, 2Boehringer Ingelheim, Ridgefield, CT, 3Therapeutic Concepts, Houston, TX. H-878 Efficacy and Tolerability of Tenofovir/Emtricitabine Versus

Abacavir/lamivudine Based Antiretroviral Treatment for NaïVe HIV-1 Infected Patients: A Mixed Treatment Comparison J. Félix1, B. Vandewalle 1, S. Rabiais 1, M. J. Silva 1, D. Ferreira 1, J. Almeida 1, E. Teófilo 2; 1Exigo, Alhos Vedros, Portugal, 2Centro Hosp. Lisboa Central, Hosp. dos Capuchos, Lisboa, Portugal. H-879 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Quad)

Demonstrates Comparable Efficacy and Favorable Tolerability to Efavirenz/Emtricitabine/ Tenofovir DF in Patients 50 Years G. J. Richmond 1, P. Ruane 2, W. Robbins, F3, U. Bredeek 4, P. Shalit5, D. Hardy 6, K. Workowski7, M. Rhee8, D. Piontkowsky, JD 8; 1Gary Richmond MD PA, Fort Lauderdale, FL, 2Peter Ruane MD Inc., Los Angeles, CA, 3 Value Hlth. MD, Orlando, FL, 4Metropolis Med., San Francisco, CA, 5 Tribal Med, Seattle, WA, 6Cedars-Sinai Med. Ctr., Los Angeles, CA, 7 Emory Clinic, Atlanta, GA, 8Gilead Sci., Foster City, CA. H-880 Older Patients Showed Similar Efficacy and Safety Results

Compared to Younger Participants Over 96 Weeks in the Phase III ECHO and THRIVE Trials of Treatment-Naive HIV-1Infected Patients Treated with Rilpivirine or Efavirenz 1

H-882 Gender Stratification Analysis of HIV-1 Infected Patients

2

2

1

2 1

R. Ryan , Y. Dayaram , D. Schaible , B. Coate , D. Anderson ; Janssen Res. & Dev., Titusville, NJ, 2Janssen Services, LLC, Titusville, NJ.

Adherence and Efficacy of HAART in Vulnerable HIV-Infected Patients K. Stewart 1, B. Conway2, H. Tossonian 2; 1Univ. of Saskatchewan, Saskatoon, Canada, 2Univ. of British Columbia, Vancouver, Canada. H-885 Safety & Efficacy of Raltegravir (RAL) Over 3 Years in

Patients Co-Infected with HIV and Hepatitis B and/or C Virus (HBV/HCV) J. Rockstroh1, P. Sklar 2, J. Zhao2, H. Teppler 2, C. Harvey 2, K. Strohmaier 2, R. Leavitt2, B. Nguyen2; 1Univ. of Bonn, Bonn, Germany, 2Merck, Whitehouse Station, NJ. H-886 Virological Response to ARV in HIV-1 Group O Infected

Patients C. Charpentier 1,2, G. Unal 1, P. Cappy 1, M. Leoz 1, E. Alessandri 1, A. Depatureaux 1, I. Gueit1, F. Damond 2, J. Pavie 3, F. Barin 4,5, F. Simon6, J. C. Plantier 1; 1CHU Charles Nicolle, Rouen, France, 2Hôpital Bichat-Claude Bernard, Paris, France, 3Hosp. George Pompidou, Paris, France, 4Hosp. Bretonneau, Tours, France, 5Uni. François Rabelais, Tours, France, 6Hôpital Saint-Louis, Paris, France. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------103(H) Poster Session Safety and Toxicity of Antiretroviral Therapy Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: H-887 Prevalence and Risk Factors of Low Grade Proteinuria in

HIV-Infected Patients A. J. Zeder, R. Hilge, J. R. Bogner, U. Seybold; Ludwig-Maximilians-Univ., Munich, Germany.

102

September 9-12 |

MONDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------104(K) Poster Session

H-888 High Incidence of Renal Stones in HIV-Infected Patients on

Ritonavir-Boosted Atazanavir Than in Those on Other Protease Inhibitors-Containing Antiretroviral Therapy Y. Hamada1, T. Nishijima 1, K. Watanabe 1, H. Komatsu 2, K. Tsukada 1, H. Gatanaga 1, Y. Kikuchi 1, S. Oka 1; 1AIDS clinical Ctr., Natl. Ctr. for Global Hlth. and Med., Tokyo, Japan, 2Saku Central Hosp., Nagano, Japan.

Blood Stream Infections Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C

H-889 High ATZ and DRV Urine Concentrations and Cristalluria

Presentations:

in Asymptomatic Patients Receiving ATV and DRV-Based Regimens

K-896 Outcome of Appropriate Empiric Combination versus

Monotherapy for Pseudomonas aeruginosa Bacteremia

V. de Lastours1, E. Silva 1, M. Daudon 2, R. Porcher 1, H. Sauvageon 1, J. Molina 1; 1Saint-Louis Hosp., Paris, France, 2Tenon Hosp., Paris, France.

D. R. Bowers1,2, Y. X. Liew 3, D. C. Lye 4,5, A. L. Kwa 3, L. Y. Hsu 5, V. H. Tam1,2,5; 1St Luke’s Episcopal Hosp., Houston, TX, 2Univ. of Houston, Houston, TX, 3Singapore Gen Hosp., Singapore, Singapore, 4Tan Tock Seng Hosp, Singapore, Singapore, 5Natl. Univ. of Singapore, Singapore, Singapore.

H-890 Single Nucleotide Polymorphisms in ABCC2 Predict Teno-

fovir-Induced Kidney Tubular Dysfunction in Japanese Patients with HIV Infection: A Pharmacogenetic Study

K-897 Clinical and Microbiological Characteristics of Helicobacter

T. Nishijima1, H. Komatsu 2, K. Higasa 3, M. Takano, RN 1, T. Hayashida 1 , K. Tsuchiya 1, R. Yamada3, S. Oka 1, H. Gatanaga 1; 1Natl. Ctr. for Global Hlth. and Med., Tokyo, Japan, 2Saku Central Hosp., Saku, Japan, 3Kyoto Univ., Kyoto, Japan.

cinaedi Bacteremia in Japan H. Araoka, M. Baba, H. Inagawa, M. Kimura, A. Yoneyama; Toranomon Hosp., Tokyo, Japan. K-898 Inadequate Empiric Antibacterial Therapy (EAT) Affects the

H-891 Renal Safety Profile of Cobicistat-Boosted Elvitegravir or

Atazanavir plus Emtricitabine/Tenofovir DF in HIV Patients 1

2

3

4 1

P. Benson , C. Mayer, MO , J. Morales Ramirez , M. Rhee ; Be Well Med. Ctr., Berkley, MI, 2St. Joseph’s Comprehensive Res. Inst., Tampa, FL, 3 Clin. Res. Puerto Rico, San Juan, Puerto Rico, 4Gilead Sci., Foster City, CA.

baumannii Bacteremia Susceptible only to Polymyxin B: A CaseCase Control Study

Cytotoxicity of Tenofovir K. Stray, R. Bam, G. Birkus, J. Hao , I. Lepist , S. Yant , A. Ray, T. Cihlar; Gilead Sci., Foster City, CA.

T. M. Ng1, D. C. Lye 1, C. B. Tengarm 2; 1Tan Tock Seng Hosp., Singapore, Singapore, 2Natl. Univ. of Singapore, Singapore, Singapore.

H-893 Pharmacogenetic Aspects of HIV/AIDS and Tuberculosis

K-900 Clinical Outcomes of Staphylococcus aureus Blood Stream

Treatments: Emphasis on Ugandan Population

Infections in Latin America: A Prospective Multicenter Study

J. Mukonzo1,1, J. Ogwal-Okeng1, P. Waako2, L. L. Gustafsson3, E. Aklillu3; 1 Makerere Univ., Coll. of Hlth. Sci., Kampala, Uganda, 2 Makerere Univ., College of Hlth. Sci., Uganda, 3Karolinska Inst., Stockholm, Sweden.

C. Seas 1, C. Garcia 1, J. Zurita 2, C. Alvarez 3, M. Guzman 4, J. Reyes 5, C. Arias5, Latin America Working Group on Bacterial Resistance; 1Hosp. Natl. Cayetano Heredia, Lima, Peru, 2Hosp. Vozandes, Quito, Ecuador, 3Hosp. San Ignacio, Bogota, Colombia, 4Ctr. Med. de Caracas, Caracas, Venezuela, Bolivarian Republic of, 5Univ. del Bosque, Bogota, Colombia.

H-894 Impact of Seven Nucleotide Polymorphisms and Haplotypes

of CYP2B6 on Plasma Efavirenz Level in HIV/Tuberculosis Co-Infected Thai Patients Receiving Rifampicin W. Manosuthi 1, C. Sukasem 2, A. Lueangniyomkul 1, W. Mankatitham 1, S. Thongyen 1, S. Nilkamhang 1, S. Manosuthi 1, S. Sungkanuparph2; 1 Bamrasnaradura Infectious Dis. Inst., Ministry of Publ. Health, Nonthaburi, Thailand, 2Faculty of Med. Ramathibodi Hosp., Mahidol Univ., Bangkok, Thailand.

in North America and Reductions in Risk for Development of Abacavir Associated Hypersensitivity Reaction (ABC HSR) 3

3

3

K-901 Outcomes Following Carbapenem Therapy for Klebsiella Bac-

teremia: An Assessment of the Updated Susceptibility Breakpoints L. R. Biehle1,2, E. B. Hirsch 3, J. M. Cottreau 1,2; 1Univ. of Houston, Houston, TX, 2 St. Luke’s Episcopal Hosp., Houston, TX, 3Northeastern Univ., Boston, MA. K-902 Risk Factors Associated with Blood Stream Infection (BSI)

Due to Extensively Drug-Resistant (XDR) Acinetobacter baumannii (AB) in Immunocompromised Patients

H-895 Prevalence of HLA-B*5701 Allele in HIV-Infected Subjects

2

A. Micozzi, G. Colafigli, S. Santilli, D. Ballarò, C. Minotti, G. Gentile; Hematology, Rome, Italy. K-899 Risk Factors for Extensively Resistant Acinetobacter

H-892 Cobicistat Does Not Affect the In Vitro Renal Transport or

1

Outcome of High-Risk Hematological Patients (pts) with 126 E.coli (Ec) Bacteremia (B)

3

C. B. Small , D. Wohl , D. A. Margolis , L. L. Ross , B. Wine , H. Zhao , M. S. Shaefer 4; 1New York Med. Coll., Valhalla, NY, 2AIDS Clin Trials Unit, UNC CH, Chapel Hill, NC, 3GlaxoSmithKline, Research Triangle Park, NC, 4ViiV Healthcare, Research Triangle Park, NC.

I. K. Chalana, N. Davis, D. Marchaim, P. Johnson, R. Tansek, K. Chaudhry, N. Khandker, P. Lephart, J. Slim, J. Hothi, H. Ahmed, J. Pogue, J. J. Zhao, S. Dhar, A. O. Soubani, K. Hayakawa, A. Bhargava, K. S. Kaye, T. Chopra; Detroit Med. Ctr., Wayne State Univ., Detroit, MI. K-903 Clinical Impact of KPC Status and Appropriate Treatment

among Enterobacteriaceae (EB) and Pseudomonas aeruginosa (Pae) in a Multicenter Matched Control Cohort Study in Colombia R. Pacheco 1, L. E. Osorio 2, J. J. Maya 1, V. M. Blanco1, A. Correa 1, M. V. Villegas 1; 1CIDEIM, Cali, Colombia, 2Univ. del Valle, Cali, Colombia.

Final Program

103

> Monday SCIENTIFIC SESSIONS K-904 Outbreak of Burkholderia cepacia Complex Bacteremia in a

on the Treatment of Staphylococcus aureus Bacteremia at a Large Academic Medical Center

T. Singhal, S. Shah, R. Naik; Kokilaben Dhirubhai Ambani Hosp. and Med. Res. Inst., Mumbai, India.

C. Nguyen 1, J. Nguyen 1,2, T. Tsukamoto 1,2, C. Christensen 2,1, B. Heintz of Clinical Pharmacy 2,1; 1Univ. of California, San Francisco Sch. of Pharmacy, San Francisco, CA, 2Univ. of California, Davis Med. Ctr., Sacramento, CA.

K-905 Clinical Features of 119 Patients with Acinetobacter baumannii

K-916 Red Blood Cell Distribution Width is an Independent Predic-

Septicemia X. Lu, P. Zou; West China Hosp. of Sichuan Univ., Chengdu, China. K-906 Outcomes Associated with Vancomycin Intermediate Staphylo-

coccus aureus (VISA) Bloodstream Infections (BSI) K. E. Barber1, A. M. Casapao 2, J. M. Pogue 1, M. J. Rybak 2; 1Detroit Med. Ctr., Detroit, MI, 2Anti-Infective Res. Lab., Wayne State Univ., Detroit, MI. K-907 Assessment of Risk Factors Associated with Rapid Fatality in

Methicillin-Resistant Staphylococcus aureus Bacteremia T. Kim 1, H. Kim 2, E. Kim 2, S. Park 2, Y. Lee 1, S. Moon1, K. Park 1, Y. Chong 1, S. Kim1, S. Lee 1, S. Choi 1, J. Jeong 2, J. Woo1, Y. Kim1; 1Asan Med. Ctr., Seoul, Korea, Republic of, 2Asan Inst. of Life Sci., Seoul, Korea, Republic of. K-908 Burden of Nosocomial Staphylococcus aureus Bloodstream

Infection in Korea: A Prospective Nationwide Survey C. Kim1,2, A. Kim 2, K. Song 1, E. Kim 1, H. Kim 1, Y. Cho 3, Y. Choi 4, J. Park 5, B. Kim 6, N. Kim 1, K. Kim 7, M. Oh 1, Burden of Healthcare-associated infection Study Group; 1Seoul Natl. Univ., Seoul, Korea, Republic of, 2Natl. Evidence-based Healthcare Collaborating Agency, Seoul, Korea, Republic of, 3Gachon Univ, Incheon, Korea, Republic of, 4Ajou Univ., Suwon, Korea, Republic of, 5Boramae Hosp., Seoul, Korea, Republic of, 6Sangye-Paik Hosp., Seoul, Korea, Republic of, 7Pusan Natl. Univ., Pusan, Korea, Republic of. K-909 Early Experience with Ceftaroline fosamil Therapy at an Aca-

demic Hospital System A. M. Casapao 1, K. E. Barber 2, C. K. Wong 1, L. M. Steinke 2, R. P. Mynatt 2, S. L. Davis 1, K. S. Kaye 1, J. M. Pogue 2, M. J. Rybak 1; 1Wayne State Univ., Detroit, MI, 2Detroit Med. Ctr., Detroit, MI. K-910 Pitt Bacteremia Score and APACHE II in Predicting 30-Day

Mortality T. M. Ng, D. C. Lye; Tan Tock Seng Hosp., Singapore, Singapore. K-911 Epidemiology, Resistance Profile and Origin of Bacteremia in

Non-Neutropenic Patients with Solid Tumor M. Merad, E. Chachaty , B. Gachot, S. Antoun; Gustave Roussy Inst., Villejuif, France. K-912 Methicillin-Resistant S. aureus (MRSA) USA600 Lab Char-

acteristics and Association to Patient Mortality in Bloodstream Infections (BSI) and Pneumonia D. Moreno, S. Arshad, M. B. Perri, A. Shoyinka, P. Hartman, M. J. Zervos; Henry Ford Hlth. System, Detroit, MI. K-913 Risk Factors for KPC-Producing Klebsiella pneumonia Bacteremia J. L. L. Rocha1, F. F. Tuon 2, P. Toledo3, L. M. Arend 4, S. Penteado 2, C. H. Dias 2, T. M. Leite 2, A. P. Zavascki 5; 1Frischmann Aisengart/DASA Med. Diagnóstica, Curitiba, Brazil, 2Hosp. Univ. Evangélico de Curitiba, Curitiba, Brazil, 3Univ. Estadual de Ponta Grossa, Ponta Grossa, Brazil, 4Lab. Central do Estado LACEN-PR, Curitiba, Brazil, 5Hosp. de Clínicas de Porto Alegre, Curitiba, Brazil.

tor of Mortality in Patients with Gram-Negative Bacteremia N. Ku, H. Kim, H. Oh, Y. Kim-, M. Kim, J. Song, D. Oh, J. Ahn, S. Kim, S. Jeong, S. Han, C. Kim , Y. Song , J. Kim, J. Choi ; Yonsei Univ. Coll. of Med., Seoul, Korea, Republic of.

-----------------------------------------------------------------------105(K) Poster Session Clostridium difficile Infections Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: K-917 Assessing the Utility of Bedside Severity-of-illness Tools in the

Treatment of Patients with Clostridium difficile Infections C. Garibotto , T. Doan; Long Island Jewish Med. Ctr., New Hyde Park, NY. K-918 Molecular and Clinical Characterization of Clostridium difficile

Infections in a Japanese Teaching Hospital N. Mori, S. Yoshizawa, T. Saga, Y. Ishii, K. Tateda; Toho Univ. Faculty, Tokyo, Japan. K-919 Evaluation of Clinical Cure Rates of Clostridium difficile with

Different Oral Vancomycin Dosing Regimens Y. T. Garcia 1, T. D. Kish1,2; 1James J. Peters VA Med. Ctr., Bronx, NY, 2 Arnold and Marie Schwartz Coll. of Pharmacy and Hlth. Sci., Long Island Univ., Brooklyn, NY. K-920 Clinical Characteristics of Community-Associated Versus

Non-Community-Associated Clostridium difficile Infection in Hospitalized Patients D. N. Shah 1,2, V. R. K. Panchumarthi 3, L. S. Al-Jashaami 3, H. L. Koo 3,2,4, H. L. DuPont 3,2,1,4, K. W. Garey1,3,2; 1Univ. of Houston, Houston, TX, 2St. Luke’s Episcopal Hosp., Houston, TX, 3Univ. of Texas Sch. of Publ. Health, Houston, TX, 4Baylor Coll. of Med., Houston, TX. K-921 A Risk Index Based on Comorbid Conditions and Disease

Severity to Predict Mortality in Patients with Clostridium difficile Infection D. N. Shah 1,2, N. Bhatt3, E. Chen 3, H. L. Koo 3,2,4, H. L. DuPont 3,2,4,1, K. W. Garey1,2,3; 1Univ. of Houston, Houston, TX, 2St. Luke’s Episcopal Hosp., Houston, TX, 3Univ. of Texas Sch. of Publ. Health, Houston, TX, 4Baylor Coll. of Med., Houston, TX. K-922 Evaluation of Combination vs. Monotherapy for Clostridium

difficile Infection (CDI) J. C. Njoku1,2, T. C. VanSchooneveld 1,2, M. E. Rupp 1,2, K. M. Olsen 1,2, F. Qiu 2, J. L. Meza 2, E. D. Hermsen 1,2; 1The Nebraska Med. Ctr., Omaha, NE, 2Univ. of Nebraska Med. Ctr., Omaha, NE. K-923 Serum White Blood Cell Count of 15,000 Cells/mm3

Alternative to Time-Consuming Patient Chart Analysis

Predicts 30 Day All Cause Mortality Among Hemodialysis Patients with Clostridium difficile Infection

W. Zingg, M. Chraiti, D. Pittet, The HUG Infection Control Team; Univ. of Geneva Hosp. and Faculty of Med., Geneva, Switzerland.

A. A. Venugopal, S. Szpuna, L. B. Johnson; St John Hosp. and Med. Ctr., Grosse Pointe Woods, MI.

K-914 Electronic All-Cause Bloodstream Infection Surveillance: An

104

K-915 Impact of a Guideline and Educational Intervention Program

Chemotherapy Day Care Unit Due to Intrinsic Contamination of Granisetron

September 9-12 |

MONDAY SCIENTIFIC SESSIONS K-924 Successful Treatment of Simulated Clostridium difficile Infec-

tion in a Human Gut Model by Fidaxomycin After Vancomycin or Metronidazole Failure C. H. Chilton 1, G. Crowther 1, J. Freeman 1, S. Todhunter 1, S. Nicholson 1, C. Longshaw 2, M. H. Wilcox1; 1Univ. of Leeds & Leeds Teaching Hosp., Leeds, United Kingdom, 2Astellas Phama Europe Ltd, Staines, United Kingdom. K-925 Clostridium difficile in Ready-to-Eat Raw Vegetables, France C. Eckert1,2, B. Burghoffer 1,2, F. Barbut 1,2; 1Natl. Reference Lab. for C. difficile, Saint-Antoine Hosp., AP-HP, Paris, France, 2UPMC Univ Paris 06, Paris, France. K-926 Procalcitonin Levels Correlate with Severity in Cases of

Clostridium difficile Infection K. Rao, S. T. Walk, D. Micic, E. Chenoweth, L. Deng, MA Associate, R. Jain, I. Trivedi, M. Yu , C. Ring, V. B. Young , G. B. Huffnagle, D. M. Aronoff ; Univ. of Michigan, Ann Arbor, MI. K-927 Analysis of Sequential Isolates from Clostridium difficile Infec-

K-935 Prevalence of Diarrhea Associated with Antibiotics Use in Two

Concentration Hospitals in Mexico R. Figueroa Infectious Disease Hosp., IMSS, Mexico, D.,F., Mexico. K-936 MLST Analysis Investigation of 104 Clostridium difficile

Isolates from Various Areas and Hospitals of China Y. Cheng, Q. Yan, H. Zhou, C. Chen, R. Cen, W. Li, J. Lu; State Key Lab. for Infectious Disease Prevention and Control, Natl. Inst. for Communicable Disease Control and Prevention, Chinese Ctr. for Disease Control and Prevention, Beijing, China.

-----------------------------------------------------------------------106(K) Poster Session Endocarditis Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations:

tions by MLVA Subtyping S. Taori 1,2, A. Wroe 1, K. Templeton 2, A. Gibb 2, I. Poxton1; 1Univ. of Edinburgh, Edinburgh, United Kingdom, 2NHS Lothian, Edinburgh, United Kingdom.

K-937 In-Hospital and Long-Term Outcome of Left-Sided Infective

K-928 Evaluation of ATLAS Score in Predicting Clinical Cure and

N. Fernández-Hidalgo, B. Almirante, P. Tornos, M. T. González-Alujas, A. M. Planes, M. Galiñanes, A. Pahissa; Hosp. Vall d’Hebron, Barcelona, Spain.

Recurrence of Clostridium difficile Infection (CDI) S. Jacobson 1, D. Slain2; West Virginia Univ., Morgantown, WV.

Endocarditis (LSIE): The Influence of Methicillin-Resistant S. aureus Infection on Prognosis

K-938 Enterococcus faecalis Infective Endocarditis (EFIE): The Influ-

K-929 Do Antibiotic Combinations with Rifampin for Osteoarticular

Infections Protect against Clostridium difficile-Associated Colitis? C. Landelle , M. Schindler , W. Zingg , L. Pagani , I. Uckay, D. Pittet; Univ. of Geneva Hosp., Geneva, Switzerland. K-930 Case-Control Study of Community-Onset Clostridium difficile

Infections in the Netherlands M. Hensgens1, A. Demeulemeester 2, O. Dekkers 1, A. Buiting 3, P. Bloembergen 4, B. van Benthem 5, E. Kuijper 1; 1LUMC, Leiden, Netherlands, 2 SHL, Breda, Netherlands, 3Elisabeth Hosp., Tilburg, Netherlands, 4Isala, Zwolle, Netherlands, 5Natl. Inst. for Publ. Hlth. and the Environment, Bilthoven, Netherlands. K-931 Is There Any Correlation Between Microbiological Profile and

the Prognosis of Clostridium difficile Disease (CDD)? D. Rodriguez-Pardo, B. Almirante, R. Bartolomé, J. Vila, B. Mirelis, F. March, T. Cornejo, M. Español, M. Lung, A. Pahissa; Barcelona Clostridium difficile Project Study Group, Barcelona, Spain. K-932 Risk Factors Predictive of Recurrent C. difficile Infection P. Ty1, A. Wong-Beringer 2,1; 1Huntington Hosp., Pasadena, CA, 2Univ Southern California, Los Angeles, CA. K-933 Study on the Molecular Epidemiology and Antibiotic Resis-

tance of Clostridium difficile Isolates in Shijiazhuang of China J. Zhao 1, J. Yang 1, Y. Li1, S. Cui 2, J. Li 1, D. Shi 1, W. Song 1, H. Wei 1, X. Liu 1, C. Qiang 1, Z. Li 1, Q. Sun 1; 1The Second Hosp. of Hebei Med. Univ., Shijianzhuang, Hebei Province, China, 2Chinese Natl. Inst. for the Control of Pharmaceutical and Biological Products, Beijing, China. K-934 Comparison of Pulsed Xenon UV to Bleach for the Decontam-

ination of C. difficile from Surfaces in the Patient Environment S. S. Ghantoji1, M. Stibich 2, J. Stachowiak 2, B. Tanner 3, C. Perego 1, S. Cantu 1, R. F. Chemaly1; 1MD Anderson Cancer Ctr., Houston, TX, 2Xenex Healthcare Services, LLC, San Antonio, TX, 3Antimicrobial Test Lab., Austin, TX.

ence of Ampicillin + Gentamicin (AG) vs Ampicillin + Ceftriaxone (AC) on Outcome N. Fernández-Hidalgo,1,2, B. Almirante1,2, J. Gavaldà1,2, M. Gurgui2, C. Peña2, A. de Alarcón2, J. Ruiz2, M. Montejo2, N. Vallejo2, I. Vilacosta 2, F. López-Medrano2, A. Plata2, J. López2, C. Hidalgo2, J. Gálvez2, J. M. Lomas 2, M. Falcone 3, M. Noureddin2, X. Martínez-Lacasa2, A. Pahissa1,2; 1Hosp. Vall d’Hebron, Barcelona, Spain, 2Enterococcus Faecalis Infective Endocarditis Study Group, Spain, 3Enterococcus Faecalis Infective Endocarditis Study Group, Italy. K-939 Relationships Between Gender, Early Valve Surgery (EVS) and

Mortality in Patients with Infective Endocarditis (IE) Analyzed in a Multicenter Cohort C. Chirouze, F. Alla, C. Selton-Suty, L. Schubel, T. Doco-Lecompte, M. Erpelding, X. Duval, B. Hoen; AEPEI, PARIS, France. K-940 The Clinical Impact of Routine Performance of PET/CT in

Patients with Infectious Endocarditis (IE): Preliminary Results of a Prospective Ongoing Study M. Kestler, P. Muñoz, M. Rodriguez, F. Jimenez, A. Rotger, A. Marti, J. C. Alonso, J. Orcajo, E. Bouza; Hosp. G. U. Gregorio Marañon. Univ. of Madrid, Madrid, Spain. K-941 Influence of the Timing of Cardiac Surgery on the Prognosis

of Left-Sided Native Endocarditis: Prospective and Multicenter Cohort study (GAMES) J. Gálvez-Acebal1, P. Muñoz 2, J. M. Miró3, A. Alarcón 4, L. Castelo 5, J. Ruiz 6, A. Moreno 7, M. Montejo8, J. Lomas 9, S. Reus 10, E. Bouza 11, GAMES; 1Hosp. VMacarena, Seville, Spain, 2Hosp. GMarañón, Madrid, Spain, 3Hosp. Clinic, Barcelona, Spain, 4Hosp. VRocío, Seville, Spain, 5Hosp. JCanalejo, Coruña, Spain, 6Hosp. VVictoria, Malaga, Spain, 7Hosp. La Paz, Madrid, Spain, 8Hosp. Cruces, Bilbao, Spain, 9Hosp. JRJimenez, Huelva, Spain, 10Hosp. Alicante, Alicante, Spain, 11Hosp. GMarañón, Seville, Spain.

Final Program

105

> Monday SCIENTIFIC SESSIONS K-942 Valve Surgery in Infective Endocarditis: Determinants of

Based Surveillance for Candidemia in Spain

M. Martinez-Selles 1, A. Arnaiz 2, P. Muñoz1, J. Ruiz 3, M. Moreno 4, J. Reguera 5, J. Galvez 6, J. Portu 7, J. Oteo 8, J. dela Torre 9, E. Bouza- Prof 1, GAMES; 1H G.U. Gregorio Marañón. Univ. of Madrid, Madrid, Spain, 2 Hosp. Valdecilla, Santander, Spain, 3 Hosp. V Victoria, Málaga, Spain, 4 Hosp. La Paz, Madrid, Spain, 5 Hosp. Carlos Haya, Malaga, Spain, 6 Hosp. V Macarena, Seville, Spain, 7 Hosp. Txagorritxu, Barakaldo, Spain, 8 Hosp. San Pedro, La Rioja, Spain, 9 Hosp. Costa del Sol, Marbella, Spain.

M. Puig1, B. Padilla 2, J. Garnacho 3, R. Zaragoza 4, P. Muñoz 2, J. Aguado 5, M. Montejo 6, B. Almirante 1, CANDIPOP Project, GEIH-GEMICOMED (SEIMC) and REIPI.; 1Hosp. Vall d´Hebron, Barcelona, Spain, 2 Hosp. Gregorio Marañón, Madrid, Spain, 3Hosp. Virgen del Rocio, Sevilla, Spain, 4Hosp. Univ. Dr. Peset, Valencia, Spain, 5Hosp. 12 de Octubre, Madrid, Spain, 6Hosp. Cruces, Bilbao, Spain.

K-943 Short-Term and Long-Term Mortality Risk Factors in a

Prospective Cohort of 1000 Consecutive Infective Endocarditis in Spain (GAMES) P. Muñoz1, M. Fariñas 2, A. Alarcón 3, L. Castelo 4, J. Miró 5, M. Montejo 6, E. Navas 7, R. Ivanova 8, J. Paño 9, A. Moreno 10, C. Hidalgo-Tenorio 11, M. Goenaga 12, A. Plata 13, M. Rodríguez 1, E. Bouza 1, GAMES; 1 Hosp. G.U. Gregorio Marañón. Univ. of Madrid, Madrid, Spain, 2 Hosp. Valdecilla, Santander, Spain, 3 Hosp.V del Rocío, Sevilla, Spain, 4 Hosp. Juan Canalejo, Coruña, Spain, 5 Hosp. Clinic, Barcelona, Spain, 6 Hosp. Cruces, Bilbao, Spain, 7 Hosp. Ramón y Cajal, Madrid, Spain, 8 Hosp. V Victoria, Málaga, Spain, 9 Hosp. La Paz, Madrid, Spain, 10 Hosp. Central Asturias, Oviedo, Spain, 11H V Nieves, Granada, Spain, 12 Hosp. Donosti, San Sebastián, Spain, 13 Hosp. Carlos Haya, Málaga, Spain. K-944 Efficacy of Daptomycin in the Treatment of Enterococcal

Endocarditis: A 5-Year Perspective I. Ceron, P. Muñoz, M. Marin, M. Rodríguez-Créixems, B. Pinilla, A. Segado, J. Roda, H. Rodríguez, M. Valerio, A. Fernandez-Cruz, A. Burillo, E. Bouza- ID prof, GAME; Hosp. G.U. Gregorio Marañón, Univ. of Madrid, Madrid, Spain. K-945 Changes in the Antibiotic Treatment of Enterococcus faecalis

Infective Endocarditis (EF-IE) in the Last 15 Years J. M. Pericas, C. Cervera, A. del Río, C. García-De-La-Maria, Ph , A. Moreno, X. Castañeda, M. Almela, C. Falces, S. Ninot, Y. Armero, C. A. Mestres, D. Soy, J. M. Gatell, F. Marco, J. M. Miró, Hospital Clinic Endocarditis Study Group; Hosp. Clinic - IDIBAPS, Barcelona, Spain. K-946 Evaluation of Population Analysis Profile Susceptibility (PAP)

as a Predictor of Patient Outcomes with Methicillin-Resistant Staphylococcus aureus (MRSA) Infective Endocarditis (IE) A. M. Casapao, S. Patel , R. Kullar, S. L. Davis, M. J. Rybak; Wayne State Univ., Anti-Infective Res. Lab., Detroit, MI.

-----------------------------------------------------------------------107(K) Poster Session Fungal Infections Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: K-947 Candidaemia in Malaysia: Surprising Results from a National

Study Q. A. Nguyen1,2, D. J. E. Marriott 1, Malaysian Candidaemia Study (MaCaS) Group; 1St. Vincent’s Hosp. Sydney, Sydney, Australia, 2Garvan Inst. of Med. Res., Sydney, Australia.

106

K-948 Predictors of Poor Outcome in Candidemia: A Population-

In-Hospital Prognosis

September 9-12 |

K-949 Predictors of Candida sp. as a Causative Agent of Catheter-

Related Bloodstream Infections M. Nagao, G. Hotta, M. Yamamoto, Y. Matsumura, A. Matsushima, Y. Ito, S. Takakura, S. Ichiyama; Kyoto Univ. Hosp., Kyoto, Japan. K-950 Candida Bloodstream Infections (BSI) in the Intensive Care

Unit (ICU) Adult Patients M. Puig1, J. Garnacho 2, R. Zaragoza 3, J. Pemán 4, M. Valerio 5, E. MartinMazuelos 6, B. Almirante 1, CANDIPOP Project, GEIH-GEMICOMED and REIPI; 1Hosp. Vall d´Hebron, Barcelona, Spain, 2Hosp. Virgen del Rocio, sevilla, Spain, 3Hosp. Univ. Dr. Peset, Valencia, Spain, 4Hosp. La Fe, Valencia, Spain, 5Hosp. gregorio Marañon, Madrid, Spain, 6Hosp. de Valme, Sevilla, Spain. K-951 Outcome and Risk Factors for Mortality in Critically Ill

Patients with Invasive Pulmonary Aspergillosis S. Blot1, J. Rello 2, G. Dimopoulos 3, K. Vandewoude 1, D. Vogelaers 1, and the AspICU Study Investigators; 1Ghent Univ., Gent, Belgium, 2Vall d’hebron Univ. Hosp., Barcelona, Spain, 3Athens Attikon Univ. Hosp., Athens, Greece.

-----------------------------------------------------------------------108(K) Poster Session Influenza Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: K-952 Hospital-Acquired Influenza in an Australian Sentinel Sur-

veillance System N. Macesic1, T. Kotsimbos 1,2, P. M. Kelly 3, A. C. Cheng 1,2, FluCAN Investigators; 1Alfred Hlth., Melbourne, Australia, 2Monash Univ., Melbourne, Australia, 3Australian Natl. Univ., Canberra, Australia. K-953 Vaccination against Influenza at a European Pediatric Cancer

Center: Immunization Rates and Attitudes among Staff Members S. Jocham, A. Wiener, J. Groenefeld, A. Loecken, J. Kuehn, A. H. Groll; Univ. Hosp., Muenster, Germany. K-954 Nosocomial Outbreak of Seasonal Influenza in a Geriatric

Hospital L. Pagani 1, V. Sauvan 1, A. Iten1, L. Kaiser 2, S. Harbarth 1, D. Pittet 1; 1 Infection Control Program, Geneva, Switzerland, 2Lab. of Virology, Geneva, Switzerland. K-955 Risk For Death From Seasonal and Pandemic Influenza: A

Systematic Review D. Mertz1, T. Kim 1, J. Johnstone1, P. Lam 2, M. Science1, S. P. Kuster 3, S. A. Fadel2, D. Tran 2, N. Bathnagar1, M. Loeb1; 1McMaster Univ., Hamilton, Canada, 2Univ. of Toronto, Toronto, Canada, 3Univ. Hosp. Zurich, Zurich, Switzerland.

MONDAY SCIENTIFIC SESSIONS K-956 Epidemic of Seasonal Influenza in an Internal Medicine

L1-963 Chronic Q Fever: Clinical Data and Outcome

Service A. Iten, S. Manuel, L. Pagani, Y. Thomas, V. Camus, L. Kaiser, A. Perrier, D. Pittet; HUG, Geneva, Switzerland.

-----------------------------------------------------------------------109(L1) Poster Session An Update on Tuberculosis Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: L1-957 Use of Fluoroquinolons in Tuberculosis Regimen in Northern

Paris and Northern France, between 2004 and 2011 1

2

1

2

1

3

M. Amsilli , A. Blanc , H. Ferrand , E. Senneville , E. Papy , A. Vachée , R. Ruimy 1, E. Bouvet1, X. Lemaire 4, Y. Yazdanpanah1,2; 1Hosp. Bichat, Paris, France, 2Hosp. Gustave Dron, Tourcoing, France, 3Ctr. Hosp., Roubaix, France, 4Ctr. Hosp., Douai, France. L1-958 Tolerance and Safety of Intravenous Streptomycin Therapy in

Patients with Tuberculosis 1

1

2

R. Pérez Tanoira , R. Fernández-Roblas , F. Sánchez-Patán , A. Jiménez Girón 2, J. Esteban Moreno 1, M. Fernández Guerrero 1; 1Fundación Jiménez Díaz, Madrid, Spain, 2Inst. of Food Sci. Res., Madrid, Spain. L1-959 Predictors of Non-Adherence to a Pharmacist-Managed

Treatment Program for Latent Tuberculosis Infection (LTBI) Among Homeless Population A. F. Adesanya 1, A. Le 2, L. Nelson 3, J. Hirsch2, S. Lorentz2; 1Comprehensive Pharm Services, Memphis, TN, 2Univ. of California, San Diego, La Jolla, CA, 3Univ. of Louisville Hosp., Louisville, KY.

-----------------------------------------------------------------------110(L1) Poster Session Zoonotic Infections Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C

F. Laterza 1, A. Elsendoorn 1, S. Sunder 2, G. Beraud 1, G. Le Moal 1, S. Edouard 3, A. Riche 4, M. Texereau 5, D. Boutoille 6, C. Godet 1, F. Roblot1, GERICCO; 1Univ. Hosp., Poitiers, France, 2Univ. Hosp., Tours, France, 3 Natl. Reference Ctr., Univ. Aix-Marseille, Marseille, France, 4Gen. Hosp., Angoulême, France, 5General Hosp., Niort, France, 6Univ. Hosp., Nantes, France. L1-964 Phylogeography of Francisella tularensis Subspecies Holarc-

tica from the Country of Turkey Y. Ozsurekciship1, D. M. Wagner 2, M. Celikship 1, E. Karadag Oncelship 1, D. N. Birdsell 2, A. J. Vogler 2, P. Keim 2, A. Ozkaya Parlakayship 1, M. Ceyhan 1; 1Hacettepe Univ. Faculty of Med., Ankara, Turkey, 2Northern Arizona Univ., Arizona, AZ. L1-965 Diagnostic Value of FDG-PET/CT in Diagnosing Vascular

Chronic Q-Fever J. C. J. Hagenaars 1, A. W. Vlake1, N. H. M. Renders 1, A. S. van Petersen 2, M. G. L. de Jager-Leclercq 2, F. L. Moll 3, O. H. J. Koning 1, P. C. Wever1, C. J. Hoekstra 1; 1Jeroen Bosch Hosp., Hertogenbosch, Netherlands, 2Hosp. Bernhoven, Veghel/Oss, Netherlands, 3Univ. Med. Ctr. Utrecht, Netherlands.

-----------------------------------------------------------------------111(M) Poster Session Experimental Mycology Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: M-966 Polymorphism of Polyglutamine Proteins in Candida glabrata

and Role in Adaptation T. D. Edlind, S. K. Katiyar; Drexel Univ. Coll. of Med., Philadelphia, PA. M-967 Histopathology Following Polyene or Echinocandin Treat-

ment of Infection with Candida tropicalis Strain Having Unique Echinocandin-Resistant (ER) Genes J. Schwartz 1, H. Lee 2, J. Olson3, D. Hahka 3, N. Nguyen 3, A. Ibrahim 2, J. Adler-Moore 3; 1Charles River, Davis, CA, 2LA Biomed Res. Inst., Torrance, CA, 3Cal Poly, Pomona, CA. M-968 Disruption of Candida albicans Mitochondrial Function by

Presentations: L1-960 Imaging Techniques (Radyograph, Scintigraphy and Mag-

netic Rezonance Imaging) in Brucellar Sacroiliitis Can be Used as a Criteria for a Follow-Up in the Termination of Treatment A. Bilgeturk, H. C. Gul, A. Karakas, G. Mert, C. Artuk, C. P. Eyigun; Gulhane Military Med. Sch., Ankara, Turkey. L1-961 Brucella Melitensis (BM) Bacteremia in Adult Hospitalized

Patients in Southern Israel Y. Glick, E. Levin, L. Saidel-Odes, F. Schlaeffer, K. Riesenberg; Soroka Univ. Med. Ctr. (SUMC) and Faculty of Hlth. Sci., Ben Gurion Univ. of the Negev, Beer Sheva, Israel. L1-962 Timing of Antibiotic and Surgical Treatment of Q-Fever

Caspofungin S. T. King, K. R. Stover , S. Ferguson, J. P. Hosler, J. D. Cleary; Univ. of Mississippi Med. Ctr., Jackson, MS. M-969 Differential Expression of the Genes Encoding Erg11 and

Multidrug Efflux Transporters in Fluconazole Resistant Isolates of Non-Albicans Species of Candida E. L. Berkow, K. S. Barker, K. M. Brown, P. D. Rogers; Univ. of Tennessee Hlth. Sci. Ctr., Memphis, TN. M-970 Clinically-Derived Mutations in ERG11 Cause Decreased

Fluconazole Susceptibility When Expressed in a Susceptible Strain of C. albicans S. A. Flowers , K. S. Barker, P. D. Rogers; Univ. of Tennessee, Memphis, TN.

Endocarditis Y. Maor, A. Kogan, B. Orlov, H. Cohen, L. Sternik, A. Malachy, E. Raanani, G. Rahav; Sheba Med. Ctr., Tel Hashomer, Israel.

M-971 Cas5, Upc2, and Rpn4 Influence the Fungistatic Activity of

Fluconazole against Candida albicans E. M. Vasicek, E. L. Berkow, K. S. Barker, P. D. Rogers; Univ. of Tennessee Hlth. Sci. Ctr., Memphis, TN.

Final Program

107

> Monday SCIENTIFIC SESSIONS M-972 Hyperthermia Sensitizes Rhizopus oryzae (Ro) to Posacon-

azole (PCZ) and Itraconazole (ICZ) Action Through Apoptosis F. Shirazi1, M. Pontikos 1, R. Lewis 1, S. Achi 1, T. Walsh 2, N. Albert 1, D. Kontoyiannis1; 1UT MD Anderson Cancer Ctr., Houston, TX, 2Cornell Univ., New York, NY.

M. Martinez 1, V. Chen 1, K. V. Clemons 1, M. Johansen 1, T. Blaschke 1, L. Zhu 2, D. A. Stevens1; 1Stanford Univ., Stanford, CA, 2Fudan Univ., Shanghai, China. M-983 pH Signaling Inhibition in Candida albicans Leads to

Ferrioxamine Receptors

Enhanced Activity and Restore Fungicidal Effect of Ergosterol Synthesis Inhibitors

M. Liu1, T. Ghebremariam 1, C. Skory2, J. E. Edwards, Jr. 1, A. S. Ibrahim 1; 1 Habor-UCLA Med. Ctr., Torrance, CA, 2USDA, Peoria, IL.

S. Sahli 1, S. Boulahfa 1, M. Cornet1,2; 1Univ. Joseph Fourier, Grenoble, France, 2CHU, Grenoble, France.

M-973 CBS Domain-Containing Proteins are Rhizopus oryzae

M-974 Thermokinetic Evaluation of Fluconazole, Caspofungin,

Anidulafungin and Amphotericin B on Planktonic and Biofilm Candida spp. by Microcalorimetry E. Maiolo1, F. Ulrika 1, S. Dominique 2, T. Andrej 1; 1Univ. Hosp., Lausanne, Switzerland, 2Inst. of Microbio. Lausanne, Switzerland. M-975 Mutational Analysis of a Major Multi-Drug Transporter

Cdr1p of Pathogenic Candida albicans Reveals Novel Insights into Drug Binding and Transport M. Rawal Scholar, R. Prasad; Jawaharlal Nehru Univ., New Delhi, India. M-976 Impact of Iron Chelators on Growth and Expression of

Iron-Related Genes of Cryptococcus Species M. Chayakulkeeree, T. Tangkoskul Asistant, S. Tiengrim Associate, S. Onsomearng; Siriraj Hosp., Mahidol Univ., Bangkok, Thailand. M-977 The Antifungal Activity of an Abbreviated Regimen of

Amphotericin B Deoxycholate (DAmB) For Cryptococcal Meningitis is Due to Persistence of Drug in the Brain Rather Than T-Cell Recruitment J. Livermore1, A. Sharp1, C. Walker 1, W. Moser 1, L. Gregson 1, J. Goodwin1, T. W. Felton 1, S. J. Howard 1, W. Mueller 1, J. Perfect 2, W. W. Hope 1 1 ; The Univ. of Manchester, Manchester, United Kingdom, 2Duke Univ., Durham, NC. M-978 Caspofungin Induces Apoptosis of Candida albicans at

Minimum Inhibitory Concentration (MIC) and Causes Necrosis at > MIC B. Hao 1, S. Cheng 1, C. Clancy 2, M. Nguyen 1; 1Univ. of Pittsburgh, Pittsburgh, PA, 2Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA. M-979 Effects of Conditional Expression of Cell Wall Synthesis-

Encoding Genes in C. albicans (CA) in a Toll-Deficient Model of Invasive Candidiasis (IC) R. E. Lewis1, N. D. Albert 2, K. Young 3, C. M. Douglas 3, D. P. Kontoyiannis2; 1Univ. of Houston Coll. of Pharmacy, Houston, TX, 2The Unvi. of Texas M.D. Anderson Cancer Ctr., Houston, TX, 3Merck Res. Lab., Kenilworth, NJ. M-980 Evaluation of Arasertaconazole Nitrate Efficacy in a Vaginal

Candidiasis Rat Model F. Cabello, DVM , N. Marti, D. Gargallo, A. Guglietta; Res. and Dev. Ctr.. Ferrer Internacional SA, Barcelona, Spain. M-981 Antifungal Activity, Plasma Pharmacokinetics and Safety of

Second-Generation Echinocandin ASP9726 in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits V. Petraitis1, R. Petraitiene 1, K. A. Such 2, P. W. Moradi 1, G. E. Strauss 1, E. Petraityte 1, S. Fleener 3, S. Akamatsu 4, S. Matsumoto 4, T. J. Walsh, Transplantation 1; 1Weill Cornell Med. Coll. of Cornell Univ., New York, NY, 2The Rockefeller Univ., Weill Cornell Med. Coll., and Mem. Sloan-Kettering Cancer Ctr., New York, NY, 3Covance Res. Products, Denver, PA, 4Astellas Pharma Inc., Tukuba, Ibaraki, Japan.

108

M-982 P-Glycoprotein (Pgp) and Amphotericin B (AmB)

September 9-12 |

M-984 In Vitro Immunopharmacodynamics of Cell Wall Active

Antifungals against Candida albicans and Aspergillus fumigatus R. E. Lewis1, G. Liao 1, K. Young 2, C. M. Douglas 2, D. P. Kontoyiannis3; 1 Univ. of Houston Coll. of Pharmacy, Houston, TX, 2Merck & Co, Kenilworth, NJ, 3The Univ. of Texas M.D. Anderson Cancer Ctr., Houston, TX. M-985 Impaired Mitochondrial Function in Fluconazole (FLC)

Heteroresistant Candida glabrata T. Finn 1, A. Novikov1, O. Zimmerman 1, Y. Paran 1, N. Osherov 2, R. BenAmi 1; 1Tel Aviv Med. Ctr., Tel Aviv, Israel, 2Tel Aviv Univ., Tel Aviv, Israel. M-986 Isolation and Characterization of Small Colony Variants of

Pseudomonas aeruginosa from Monomicrobial and P. aeruginosaAspergillus fumigatus Mixed Microbial Biofilms E. K. Manavathu, D. L. Vager, J. A. Vazquez; Henry Ford Hosp., Detroit, MI. M-987 A Tale of Two Biofilms: A Comparative Study of the Charac-

teristics and Antifungal Drug Susceptibilities of Submerged and Surface Biofilms of Aspergillus fumigatus E. K. Manavathu, D. L. Vager, J. A. Vazquez; Henry Ford Hosp., Detroit, MI. M-988 Efficacy and Dose-Response Relationships of Liposomal

Amphotericin B (L-AmB) against Different Azole-Resistant Aspergillus fumigatus Isolates in a Non-Neutropenic Murine Model of Disseminated Aspergillosis S. Seyedmousavi1,2, W. J. G. Melchers 1,2, J. W. Mouton1,2, P. E. Verweij1,2; 1 Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 2Nijmegen Inst. for Infection, Inflammation and Immunity, Nijmegen, Netherlands. M-989 Pharmacodynamics of Anidulafungin (AFG) against Clinical

Aspergillus fumigatus Isolates in a Non-Neutropenic Murine Model of Disseminated Aspergillosis S. Seyedmousavi1,2, R. J. M. Brüggemann 1,2, W. J. G. Melchers 1,2, P. E. Verweij1,2, J. W. Mouton1,2; 1Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 2Nijmegen Inst. for Infection, Inflammation and Immunity, Nijmegen, Netherlands. M-990 Global Transcriptome Profiling of Human Endothelial Cells

in Response to Infection with Non-Mutant Morphological Forms of Candida albicans C. S. Y. Lim 1,2, Y. Tan 2, R. Rosli 2, H. Seow 2, P. Chong 2; 1UCSI Univ., Cheras, Malaysia, 2Univ. Putra Malaysia, Serdang, Malaysia. M-991 Itraconazole Induced Changes in Cardiac Function J. D. Cleary, K. Stover , J. Farley; Univ. of Mississippi Med. Ctr., Jackson, MS. M-992 Drug Concentrations in Urine Following Single, Multiple

or Intermittent Treatment with Increasing Doses of Liposomal Amphotericin B (LAmB) Versus Amphotericin B (Amp) N. Nguyen, J. A. Olson, J. Ruiz, J. Adler-Moore; Cal Poly Univ., Pomona, CA.

MONDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------112(P) Poster Session Global Health, Parasitology and Travel Medicine Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: P-993 First Detection of Encephalitozoon Spp. Spores in Stools Free-

Living Capybaras (Hydrochoerus Hydrochaeris) Withdrawn P-994 Serosurvey for Antibodies to Balamuthia mandrillaris in Mis-

sissippi Residents D. C. Sullivan, B. A. Chapman, H. H. Henderson, S. Molitorisz; Univ. of Mississippi Med. Ctr., Jackson, MS. P-995 Encephalitozoon and Enterocytozoon (Microsporidia) Spores

in Stool from Pigeons and Exotic Birds

P-1003 Sepsis Does Not Require High End Antibiotics Always: A

Study from South India P. Senthur Nambi, R. Gopalakrishnan, A. Ghafur, V. Ramasubramanian; Apollo Hosp., Chennai, India. P-1004 Melioidosis in India: Rare or Rarely Diagnosed? D. Sureshkumar, R. Gopalakrishnan, K. Abdul Ghafur, P. Vidyalakshmi, A. Tayade; Apollo Hosp., Tamilnadu, India. P-1005 Danish Travellers with Plasmodium ovale Curtisi and P. ovale

Wallikeri after Visiting Africa M. Chen1, P. Kjældgaard1, T. Christensen 2, R. Legarth 2, R. Legarth 2, N. Kirkby 2, L. Reinstrup 2, G. Gomme 2, J. A. L. Kurtzhals2; 1Sonderjylland Hosp., Sonderborg, Denmark, 2Rigshospital, Copenhagen, Denmark. P-1006 A Case of CNS Toxocariasis Presenting with Multiple

Sclerosis-Mimicking Recurrent Encephalomyelitis J. S. Moon, S. Lee, K. Jung, K. Chu; Seoul Natl. Univ. Hosp., Seoul, Korea, Republic of. P-1007 In Vitro Effects of Galactofuranoside Derivatives on

Withdrawn

Leishmania donovani

P-996 Vaccination Status of Young Adults in France J. Giraud 1, C. Chubilleau 1, S. Robin 1, B. Bouffard 1, M. Vivier-Darrigol 2 , C. Binet 3, P. Ingrand4, F. Roblot5; 1Regional Hlth. Observatory, Poitiers, France, 2Regional Hlth. Agency, Poitiers, France, 3Natl. Service Agency, Paris, France, 4Univ. of Med. and Pharmacy, Poitiers, France, 5Univ. Hosp., INSERM U1070, Poitiers, France. P-997 The Influence of TiO2 and ZnO Nanoparticles and UV Irra-

diation on Murine Macrophages Infectivity by Leishmania tropica Y. A. Yakubchyk, M. H. Rafailovich; SUNY Stony Brook, Stony Brook, NY. P-998 The Risk Areas of Malaria in Surin Province Thailand Using

M. Suleman 1, J. Gangneux2, L. Legentil 3, Y. Cabezas 3, O. Sergent 1, V. Ferrières 3, F. Robert-Gangneux4; 1INSERM U1085 IRSET, Rennes, France, 2CHU Pontchaillou - INSERM U1085 IRSET, Rennes, France, 3 Ecole Supérieure de Chimie de Rennes, Rennes, France, 4CHU Rennes INSERM U1085 IRSET, Rennes, France. P-1008 Comparative Study of the Diagnosis Methods in Human

Echinococcosis L. M. Junie, IV, P. T. Ciobanca, N. Constantea; Univ. of Med. and Pharmacy, Cluj Napoca, Romania. P-1009 Evaluation of Risk Factors for Autochthonous Leptospirosis

the Geographic Information System

in Austria

S. Kaewpitoon1, R. Rujiragul 2, N. Ueng-arporn 1, L. Matrakool 1, A. Sathapollatchaphum 2, W. Ratanasalink 2, A. GnamNuan 2, P. Saosri 2, N. Kaewpitoon 1; 1Inst. of Med., Suranaree Univ. of Tech., Muang Nakhon Ratchasima, Thailand, 2Parasitic Disease Res. Unit, Inst. of Med., Suranaree Univ. of Tech., Muang Nakhon Ratchasima, Thailand.

C. Wallner 1, H. Flick 1, T. Valentin 1, K. Seeber 1, I. Zollner-Schwetz 1, J. Wagner 1, A. Grisold 1, F. Allerberger 2, R. Krause 1, M. Hoenigl1; 1Med. Univ. of Graz, Austria, Graz, Austria, 2AGES Austria, Vienna, Austria.

P-999 The Carcinogenic Human Liver Fluke: Current Status of Op-

isthorchis viverrini Metacercariae in Northeastern Thailand N. Kaewpitoon 1, S. Kaewpitoon 1, N. Ueng-arporn 1, R. Rujiragul 1, S. Churproong 1, L. Matrakool 1, S. Auiwatanagul 1, B. Sripa 2; 1Inst. of Med., Suranaree Univ. of Tech., Muang Nakhon Ratchasima, Thailand, 2 Faculty of Med., Khon Kaen Univ., Khon Kaen, Thailand. P-1000 Side Effects of Amphotericin B of Colloidal Dispersion in the

Treatment of Cutaneous Leishmaniasis at the Central Military Hospital C. E. Perez1, C. Morales2; 1Hosp. Militar Central, Bogotá, Colombia, 2Hosp. Militar Central, Bogotá, Colombia. P-1001 Resurgence of Q Fever in Urban Areas, Israel 2000-2010 N. Carmi-Oren1, A. Keysary 2, S. Rzotkiewicz 2, Y. Atiya-Nasagi 2, M. Weinberger 1,3; 1Assaf Harofeh Med. Ctr., Zerifin, Israel, 2Israel Inst. for Biological Res. (IIBR), Ness Ziona, Israel, 3Sackler Sch. of Med., Tel Aviv Univ., Tel Aviv, Israel. P-1002 Antimicrobial Resistance and the Public Health Involvement L. C. Balsalobre, M. Dropa, G. Matté, M. Matté; Univ. of São Paulo, São Paulo, Brazil.

P-1010 Impact of Use of Antibiotics on Pathogenic Bacteria

Sensibility of Layer and Broiler Chicken in Ngaoundéré Town - Cameroon K. S. Tanedjeu1, D. Bakari 2, T. N. Leopold 2, M. Carl 2; 1Natl. Dairy Res. Inst., Karnal, India, 2Univ. of Ngaoundere, Ngaoundere, Cameroon. P-1011 Comparison of Clinical Features of Q Fever in French

Guiana and in Metropolitan France S. Edouard1, M. Demar 2, F. Djossou 2, P. Addoud 2, A. Mahamat 2, D. Raoult1; 1Unité de Recherche Sur les Maladies Infectieuses et Tropicales Émergentes URMITE, Marseille, France, 2Dept. of Infectious and Tropical Diseases, Cayenne, Guyana. P-1012 Coxiella burnetii in Ruminant Bulk Tank Milk Samples in

Portugal S. Anastacio 1,2, C. Cruz, Lic 2, D. Pessoa 2, G. J. Da Silva1; 1CEF, Univ. Coimbra, Coimbra, Portugal, 2Univ. Sch. Vasco da Gama, Coimbra, Portugal. P-1013 Efficacy of Liposomal Amphotericin B against Acute Chagas

Disease in Mice M. Martinez1, V. Chen 1, K. V. Clemons 1,2,3, D. A. Stevens 1,2,3; 1California Inst. for Med. Res., San Jose, CA, 2Santa Clara Vly. Med. Ctr., San Jose, CA, 3 Stanford Univ., Stanford, CA.

Final Program

109

> Monday SCIENTIFIC SESSIONS P-1014 Diagnosis of a Travel-Related Schistosoma haematobium

Middlemore Hospital, Auckland, New Zealand

P. H. P. Soentjens1,2, L. Cnops 1, T. Huyse 1,3, D. De Vos 4, C. P. Yansouni 1,5,6, M. Van Esbroeck 1; 1Inst. of Tropical Med., Antwerp, Belgium, 2Military Hosp. Queen Astrid, Brussels, Belgium, 3Lab. of Biodiversity and Evolutionary Genomics, Univ. of Leuven, Leuven, Belgium, 4Lab. for Molecular and Cellular Technology, Military Hosp. Queen Astrid, Brussels, Belgium, 5 JD MacLean Ctr. for Tropical Diseases, McGill Univ., Montreal, Canada, 6 Div. of Infectious Diseases and Med. Microbiol., McGill Univ. Hlth. Ctr., Montreal, Canada.

S. McBride1, J. Fulke 1, H. Giles 1, M. Hobbs 2, V. Sathyendran 2, E. Thompson 3, S. Taylor 1, D. Holland 1; 1Middlemore Hosp., Auckland, New Zealand, 2Auckland City Hosp., Auckland, New Zealand, 3North Shore Hosp., Auckland, New Zealand.

P-1015 Hepatitis A Virus Circulation after Universal Single Dose

Vaccination in Argentinean Children C. Vizzotti1, A. Gentile 2, J. González, Virologist 3, A. Rearte 1, M. Ramonet 2, M. Cañero 2, M. Pérez C. 1, A. Urueña1, M. Diosque 1, Argentinean Hepatitis A Working Group; 1Ministerio de Salud de la Nación, Buenos Aires, Argentina, 2Sociedad Argentina de Pediatría, Buenos Aires Argentina, 3 INEI-ANLIS Dr. Carlos Malbrán, Buenos Aires, Argentina. P-1016 High Persistence of Protective Antibodies against Hepatitis A

After Universal Single Dose Vaccination in Argentina C. Vizzotti1, A. Gentile 2, J. González, Virologist 3, A. Rearte 1, M. Ramonet 2, M. Cañero V. 2, M. Pérez C. 1, A. Urueña1, M. Diosque 1, Argentinean Hepatitis A Working Group; 1Ministerio de Salud de la Nación, Buenos Aires, Argentina, 2Sociedad Argentina de Pediatría, Buenos Aires, Argentina, 3INEI ANLIS Dr. Carlos Malbrán, Buenos Aires, Argentina. P-1017 Safety of Ferric Carboxymaltose Treatment for Experimental

Malaria J. Kirchhoff , L. Maretty, J. A. L. Kurtzhals ; Copenhagen Univ. Hosp., Copenhagen, Denmark. P-1018 Hydatid Disease in Cantabria (North of Spain) M. Gutiérrez-Cuadra, C. Amado, M. Cimas, C. Armiñanzas, M. C. Fariñas; Univ. Hosp. Marqués de Valdecilla, Santander, Spain. P-1019 5’ Methylthioadenosine Nucleosidase: A Novel Target for

P-1024 Trends in Colistin Use in 60 Countries, 2000-2010 Withdrawn Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

---------------------------------------------------------------------------------113(T) Poster Session Infections in Transplant Recipients and Patients with Malignancies Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: T-1025 Incidence, Risk Factors and Consequences of Severe Neutro-

penia Following Orthotopic Liver Transplantation B. Alraddadi1, N. E. Nierenberg 1, L. L. Price 1, J. K. L. Chow 1, R. J. Rohrer1, D. D. Poutsiaka1, J. T. Cooper 1, R. B. Freeman2, D. R. Snydamn1; 1 Tufts Med. Ctr., Boston, MA, 2Dartmouth-Hitchcock Med. Ctr., Lebanon, NH. T-1026 A Prospective Study of Fever in Solid Organ Transplant

Recipients (FEVERSOT) P. Muñoz1,2,3, A. Eworo 1, I. Ramírez 1, M. Valerio 1, A. Burillo 1, F. Anaya 1, M. Salcedo 1, A. Villa 1, E. Sarmiento 1, P. Lopez-Roa 1, E. Bouza 1,2,3, FEVERSOT; 1H G.U. Gregorio Marañón, Univ. of Madrid, Madrid, Spain, 2 CIBERES, Madrid, Spain, 3REIPI, Madrid, Spain. T-1027 Spectrum of Infections in Myeloma Patients Rreated Solely

Antiparasitic Drug Development in Giardia intestinalis and Entamoeba histolytica Infections

with Lenalidomide Based Regimens and Autologous Stem Cell Transplantation

K. Cornell; Boise State Univ., Boise, ID.

B. W. Teh, K. A. Thursky, R. Sedunary, A. Khot, M. A. Slavin, S. J. Harrison; Sonnenburg MacCallum Cancer Ctr, Melbourne, Australia.

P-1020 Mucocutanea Leishmanisis (ml): An Important Health

Problem in all the World P. Merino, I. Gestoso, J. Picazo- Chief; Clínico San Carlos Hosp., Madrid, Spain. P-1021 Enhanced Norovirus Surveillance and Detection

Capability with a New Filter Card Sampling Method Aboard U.S. Navy Vessels C. T. Coetzer 1, S. J. Maier 1, R. D. Hontz1, B. Espinosa 2, N. Gregoricus 3, J. Vinje 3, J. Dejli 1; 1Navy Environmental and Preventive Med. Unit Two, Norfolk, VA, 2Naval Med. Res. Ctr. BioDefense Res. Directorate, Frederick, 3 Natl. Calicivirus Lab., CDC, Atlanta, GA. P-1022 Low Serum Albumin in Rickettsial Infections in Southern

Israel, 2009-2011 L. Saidel-Odes, K. Riesenberg, A. Borer, R. Smolyakov, S. Novick, F. Schlaeffer; Soroka Univ. Med. Ctr. and Faculty of Hlth. Sci., Ben Gurion Univ. of the Negev, Beer Sheva, Israel.

110

P-1023 Epidemiology and Diagnosis of Meningitis, 2000 to 2009 at

-Schistosoma bovis Hybrid Cluster

September 9-12 |

T-1028 Feasibility of Very Early Discharge of Febrile Neutropenia

(FN) Patients (pts) Selected Using the Mascc Score: A Belgian Study A. Georgala, A. Loizidou, T. Berghmans , M. Aoun, V. Van Laethem, L. Dubreucq, J. Klastersky, M. Paesmans; Inst. Jules Bordet, Bruxelles, Belgium. T-1029 A Retrospective Review of Clostridium difficile Treatment in

Adult and Pediatric Intestinal Transplant Patients S. N. Nevrekar 1, L. A. Pote 1, K. A. Doan 1, A. P. Shah 2, R. S. Mangus 2, R. M. Vianna 2, A. J. Tector 2, S. A. Kubal 2; 1Indiana Univ. Hlth., Indianapolis, IN, 2IU Sch. of Med., Indianapolis, IN. T-1030 Risk Factors and Outcomes of Bacteremia Caused by Drug-

Resistant ESKAPE Pathogens in Solid Organ Transplant (SOT) Recipients M. Bodro1, N. Sabé2, C. Baliellas2, J. Roca2, J. Cruzado2, J. Carratalà 2; 1IDIBELL Biomedical Res. Inst., Barcelona, Spain, 2Hosp. Univ. de Bellvitge, Barcelona, Spain.

MONDAY SCIENTIFIC SESSIONS T-1031 Refractory KPC Carbapenemase-Producing Klebsiella

pneumoniae Bacteremia is Tolerated by Solid Organ Transplant Patients (SOT Pts) C. Clancy 1, R. K. Shields 2, Y. Zhao 3, L. Chen 3, B. N. Kreiswirth 3, E. J. Kwak 2, F. Silveira 2, K. Abu-Elmagd 2, G. Costa 2, M. Nguyen 2; 1Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA, 2Univ. of Pittsburgh, Pittsburgh, PA, 3Publ. Hlth. Res. Ins., UMDNJ, Newark, NJ. T-1032 Comparison of Three Methods for Detection of Latent TB in

Solid Organ Transplant Candidates S. Kusne1, T. M. Seville 1, H. R. Vikram 1, Y. H. Chang 1, A. E. McCullough 1, M. J. Binnicker 2, J. E. Blair 1; 1Mayo Clinic Arizona, Phoenix, AZ, 2Mayo Clinic Rochester, Rochester, MN. T-1033 Prevalence and Epidemiology of Positive QuantiFERON

T-1041 Pneumonia after Solid Organ Transplantation: A Multicenter

Prospective Study M. Giannella1, P. Munoz1, J. Martinez Alarcon 2, P. Grossi 3, E. Bouza1, on behalf of the PISOT Study Group; 1Hosp. Gregorio Maranon, Madrid, Spain, 2 Hosp. de Ciudad Real, Ciudad Real, Spain, 3Univ. of Insubria, Varese, Italy. T-1042 Opsonophagocytic Activity of Pneumococcal Antibodies in

Vaccinated Patients with B-Cell Malignancies J. Karlsson1,2, H. Hogevik 3, K. Andersson 2, B. Andréasson 4, C. Wennerås2,5; 1 Infectious Diseases, Trollhättan/Uddevalla, Sweden, 2Clinical Bacteriology, Göteborg, Sweden, 3Dev., Trollhättan/Uddevalla, Sweden, 4Hematology/Internal Med., Trollhättan/Uddevalla, Sweden, 5Hematology and Coagulation, Göteborg, Sweden. T-1043 Incidence and Burden of Infection-Related Hospitalizations

among Pre-Kidney Transplant Recipients

among Solid-Organ Transplant Recipients

J. Simkins, M. I. Morris; Univ. of Miami, Miller Sch. of Med., Miami, FL.

B. Hamandi, A. Morillo, C. Rotstein, L. G. Singer, E. Renner, S. J. Kim, H. Ross, S. Husain; Univ. Hlth. Network, Toronto, Canada.

T-1034 Epidemiology and Outcomes of Carbapenem-Resistant

Klebsiella pneumoniae (CRKP) Bacteriuria in Renal Transplant (RT) Recipients 1,2

1,2

1

2

2

S. M. Pouch , C. J. Kubin , D. Tsapepas , G. Dube , M. Pereira ; 1 NewYork-Presbyterian Hosp., New York, NY, 2Columbia Univ. Med. Ctr., New York, NY. T-1035 Extended Spectrum Beta Lactamase-Producing Enterobacte-

riaceae Associated Infections in Kidney Transplant Recipients: A Case-Control Study

T-1044 Infectious Complications of Central Venous Catheters in

Patients Undergoing Hematopoietic Stem Cell Transplantation G. Martinho, R. Romanelli, G. Teixeira, J. Chaia, A. Macedo, W. Trindade , V. Nobre; Univ. Federal de Minas Gerais, Belo Horizonte, Brazil. T-1045 Current Clinical Features and Outcomes of Early-Onset and

Late-Onset Bloodstream Infection (BSI) in Hematopoietic Stem Cell Transplant (HSCT) Recipients

E. Righi, M. Giannella, M. L. Balsamo, A. Colombo, D. Donati, A. Curto, N. Astuti, A. Tebini Project Leader, P. A. Grossi; Insubria Univ., Varese, Italy.

C. Gudiol1, C. Garcia-Vidal 1, M. Cisnal 1, M. Arnan 2, I. Sánchez-Ortega 2, R. Duarte 2, J. Carratalà1; 1Hosp. Univ. de Bellvitge, Barcelona, Spain, 2Hosp. Duran i Reynals, Barcelona, Spain.

T-1036 Epidemiology and Antimicrobial Resistance in Urine Isolates

T-1046 Surveillance Cultures (SC) and Microbiological Documenta-

Among Renal Transplant Recipients Over a 10-Year Period 1,2

1

1

2

2 1

C. J. Kubin , S. M. Pouch , D. Tsapepas , G. Dube , M. Pereira ; New York Presbyterian Hosp., New York, NY, 2Columbia Univ., New York, NY. T-1037 Clinical and Molecular Epidemiologic Characterization of

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Occurring Early after Lung Transplant (LTx)

tion of “Bad Bugs” Among Hematological Patients (HP) Presenting Febrile Neutropenia (FN) A. Georgala1, A. Dediste 2, M. Paesmans 1, M. Aoun 1; 1Inst. Jules Bordet, Bruxelles, Belgium, 2 Lab. de la Porte de Hal CHU St Pierre-Inst. Jules Bordet, Bruxelles, Belgium. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

M. Nguyen 1, M. Shelton, BA 1, R. K. Shields 1, J. Marsh 1, L. H. Harrison 1, E. J. Kwak 1, F. Silveira 1, Y. Toyoda 1, N. Shigemura 1, C. Bermudez, M.D.2, C. Clancy 2; 1Univ. of Pittsburgh, Pittsburgh, PA, 2Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA. T-1038 Low Incidence of Bacterial Resistance and Mortality in the

New Era of Haematopoietic Stem Cell Transplantation L. Yañez, A. Bermudez, A. Insunza; Hosp. Univ. Marques De Valdecilla, Santander, Spain. T-1039 Vancomycin-Resistant Enterococcus (VRE) Bacteremia in

Immunocompromised Patients Y. L. Song, J. I. Ito, B. Tegtmeier, S. S. Dadwal, J. Kriengkauykiat; City of Hope, Duarte, CA. T-1040 Risk Factors for Bacterial Infection After Liver Transplanta-

tion: A Retrospective Study in 195 Patients from Four Centers in Central Italy L. Tessitore, P. Piselli, M. Giannella, M. Antonini, L. Sollazzi, M. Dauri, F. Pugliese, V. Perilli, M. Polzoni, F. Ruperto, V. Puro, N. Petrosillo 2nd Division, on behalf of the NETWORK group; INMI L. Spallanzani, Rome, Italy.

Final Program

111

> Monday SCIENTIFIC SESSIONS -----------------------------------------------------------------------114(G) Slide Session Vaccines: Innovations, Impact and Safety Monday, 1:30 p.m.–4:00 p.m. . . . . . . . . . . . . . . . . . . . Room 121 UAN: 0391-9999-12-086-L04-P Moderators: Jan Bonhoeffer, MD - Assistant Professor Infectious Disease and Vaccines, Univ. Children’s Hosp., Basel, Switzerland. Penina Haber, MPH - Epidemiologist Immunization safety, CDC, Atlanta, GA. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Highlight new vaccine developments; > Provide updated information on vaccine impact and safety; and > Discuss the impact of newer vaccines. Presentations: 1:30 p.m. G-1047 Antibody Persistence and the Effect of a Booster Dose Given

5, 10 or 15 Years After Vaccination With a Recombinant Hepatitis B Vaccine V. Gilca, MD, PhD - Medical Epidemiologist1,2,3, N. Boulianne, MS - Medical Epidemiologist 1,2,3, M. Dionne, MD - Scientific Director 1,2,3, P. D. Wals, MD, PhD - Medical Epidemiologist 1,2,3, G. D. Serres, MD, PhD - Medical Epidemiologist 1,2,3; 1Quebec Publ. Hlth. Inst., Quebec, Canada, 2Laval Univ. Res. Hosp. Ctr., Quebec, Canada, 3Laval Univ., Quebec, Canada. 1:45 p.m. G-1048 Safety and Immunogenicity of an Intramuscular Bivalent

Norovirus VLP Vaccine 1

2

J. J. Treanor, MD - Prof Med , S. E. Frey, MD - Prof Med , R. Gormley, MD, PhD - Investigator 3, R. L. Atmar, MD - Prof Med 4, D. Topham, PhD - Prof Microbiol Immunol 1, W. Chen, MD - Assist Prof Med 5, J. Ferreira, ScM - Biostatistician 6, R. Bargatze, PhD - CSO 7, C. Richardson, PhD - VP R&D 8, P. Mendelman, MD - CMO 8; 1Univ. of Rochester, Rochester, NY, 2St. Louis Univ. Sch. of Med., St. Louis, MO, 3Navy Med. Res. Ctr., Silver Springs, MD, 4Baylor Coll. of Med., Houston, TX, 5Univ. of Maryland Sch. of Med., Baltimore, MD, 6Emmes Corporatiopn, Rockville, MD, 7Ligocyte Pharmceuticals, Bozeman, MT, 8Ligocyte Pharmaceuticals, Bozeman, MT. 2:00 p.m. G-1049 Nasopharyngeal Carriage in Healthy Children Before and

After 13-valent Pneumococcal Conjugate Vaccine Implementation R. Cohen, MD - Pediatric Infectious Disease Specialist, Scientific Director of a Research Institute on Pediatric Community-Acquired Infections (ACTIV)1, C. Levy, MD - Research MD 1, E. Bingen, PhD - Professor Microbiology 2, S. Béchet, MSc - Biostatistician 1, C. Bensoussan-Ambacher, MD - Pediatrician 3, F. Corrard, MD - Pediatrician 1, E. Varon, MD - Microbiologist 4; 1Activ, Saint Maur des Fossés, France, 2Denis Diderot Univ., Paris, France, 3AFPA, Vence, France, 4CNRP APHP, Paris, France.

2:15 p.m. G-1050 Rapid Reduction in the Incidence of Culture-Positive Non-

susceptible Streptococcus pneumoniae (NSSP) Otitis Media (AOM) Following Introduction of Pneumococcal Conjugate Vaccines (PCVs) in Southern Israel R. Dagan, MD - Professor, N. Givon-Lavi, PhD - Lecturer, E. Leibovitz, MD - Professor, S. Raiz, MD - Doctor, D. Greenberg, MD - Professor; BenGurion Univ. of the Negev and Soroka Univ. Med. Ctr., Beer-Sheva, Israel. 2:30 p.m. G-1051 Promoting Vaccination at Birth Improves Vaccination Coverage A. Gagneur, MD, PhD - Professor1, A. Farrands, Msc - Research Assistant 2, T. Lemaitre, Msc - Research Assistant 2, G. Petit, MD, PhD - Professor 1; 1 Univ. of Sherbrooke, Sherbrooke, Canada, 2Clinical Res. Ctr. CHU Sherbrooke, Sherbrooke, Canada. 2:45 p.m. G-1052 Safety of Live Attenuated Influenza Vaccine in Adults: U.S.,

Vaccine Adverse Event Reporting System (VAERS) P. Haber, MPH - Epidemilogist, P. Moro, MD - Medical Epidemilogist, K. Broder, MD - Medical Epidemilogist, P. Lewis, MSPH - Statistician, C. Vellozzi, MD, MPH - Medical Epidemilogist; CDC, Atlanta, GA. 3:00 p.m. G-1053 Safety and Immunogenicity of a Recombinant Hemagglutinin

(rHA) Pandemic H5N1 Influenza Vaccine J. J. Treanor, MD - Professor of Medicine1, R. Izikson, MD - Manager, Clinical Studies 2, L. Dunkle, MD - Chief Medical Officer 3, P. Patriarca, MD - Senior Consultant 4, K. Goldenthal, MD - Consultant 5, M. M. J. Cox, PhD - President and CEO 6; 1Univ. of Rochester, Rochester, NY, 2Protein Sci. Corp., Meriden, CT, 3Protein Sci. Corp, Meriden, CT, 4Biologics Consulting Group, Bethesda, MD, 5Bethesda, MD, 6Protein Sci., Meriden, CT. 3:15 p.m. G-1054 Exposure to Antibody-Stimulating Proteins and Polysaccha-

rides in Vaccines and Risk of Autism F. DeStefano, MD - Medical Officer1, C. S. Price, MS - Statisticians 2, E. S. Weintraub, MPH - Statistician 1; 1CDC, Atlanta, GA, 2Abt Associates Inc., Bethesda, MD. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------115(M) Slide Session Sleuthing in Mycology Monday, 1:30 p.m.–4:00 p.m. . . . . . . Esplanade Ballroom 310 UAN: 0391-9999-12-087-L04-P Moderators: John Perfect, MD - Interim Chief Duke Univ. Med. Ctr., Durham, NC. Michail Lionakis, MD, ScD - Assistant Clinical Investigator NIAID, NIH, Bethesda, MD. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Discuss mechanisms of drug resistance; > Identify host and fungal responses to disease; and > Describe the impact of environment on fungal infections.

112

September 9-12 |

MONDAY SCIENTIFIC SESSIONS 3:00 p.m.

Presentations:

M-1061 A Non-Echinocandin Compound Isolated from a Marine

1:30 p.m.

Sponge Mediates its Antifungal Activity by Targeting the Fungal Cell Wall

M-1055 Cx3cr1 is Important for Host Defense against Invasive

Candidiasis (IC) in Mice and Humans M. S. Lionakis, MD - Assistant Clinical Investigator1, M. Swamydas, PhD - Research Associate 1, B. G. Fischer, BS - Student 1, T. Plantinga, PhD - Postdoc 2, M. Jaeger, BS - Student 2, M. D. Johnson, PharmD - Assistant Professor 3, J. R. Perfect, MD - Professor 3, B. D. Alexander, MD - Associate Professor 3, B. Kullberg, MD - Professor 2, M. Netea, MD - Professor 2, P. M. Murphy, MD - Chief 1; 1NIH, Bethesda, MD, 2Radboud Univ., Nijmegen, Netherlands, 3Duke, Durham, NC. 1:45 p.m.

3:15 p.m. M-1062 Unmasking the Contribution of Oral Mycobiome to the

Biofilm Accretion-Endotrach Occlusion During Mechanical Ventilation Using 18S Detection

M-1056 Nanostring Analysis of Candida albicans Gene Expression

During Intra-Abdominal Candidiasis (IAC) Provides Insights into Pathogenesis and Reveals Rewiring of Regulatory Pathways S. Cheng, MD - Research Associate Professor 1, C. Clancy, MD - Associate Professor1, A. P. Mitchell, PhD - Professor 2, W. Xu, PhD - Fellow 1, S. Fanning, PhD - Fellow 2, N. Solis, MS - Research Associate 3, S. Filler, MD - Professor 3, M. Nguyen, MD - Professor 1; 1Univ. of Pittsburgh, Pittsburgh, PA, 2Carnegie Mellon Univ., Pittsburgh, PA, 3UCLA, Los Angeles, CA. 2:00 p.m. M-1057 Conditional Expression of Cell Wall Polysaccharide-Encod-

ing Genes in C. albicans and A. fumigatus Reproduces Immunopharmacologic Effects of Caspofungin and Nikkomycin Z Exposure R. E. Lewis, Pharm.D. - Professor1, G. Liao, PhD - Research Assistant 1, K. Young, MS - Researcher 2, C. M. Douglas, PhD - Researcher 2, D. P. Kontoyiannis, M.D. - Professor 3; 1Univ. of Houston Coll. of Pharmacy, Houston, TX, 2Merck & Co, Kenilworth, NJ, 3The Univ. of Texas M.D. Anderson Cancer Ctr., Houston, TX. 2:15 p.m. M-1058 Anidulafungin (ANF) Compared to Caspofungin (CAS) in

a Non-Neutropenic Mouse Model of Invasive Candidiasis (IC) Caused by ANF-Susceptible (S) C. parapsilosis (C.p) Isolates with Different Degrees of In Vitro Non-Susceptibility (NS) to CAS: MIC Does Not Tell the Whole Story D. Dimopoulou, MD - Research Fellow1, G. Hamilos, MD - Attending Physician 1, G. Samonis, MD - Professor 1, D. P. Kontoyiannis, MD, ScD, FACP - Professor 2; 1Univ. Hosp. of Heraklion, Heraklion,Crete, Greece, 2 The Univ. of Texas MD Anderson Cancer Ctr., Houston, TX. 2:30 p.m. M-1059 Candida glabrata Heteroresistance to Fluconazole is Associ-

ated with Aneuploidy and Chromosomal Translocations Involving the PDH1 Gene 1

S. Tripathi, PhD - Postdoctoral Associate, T. Xu, PhD - Postdoctoral Associate, Q. Feng, MS - Senior R & D Biologist, M. Jacob, PhD - Research Scientist, W. Xu, PhD - Postdoctoral Associate, X. Li, PhD - Senior Scientist, A. Clark, PhD - Professor, A. Agarwal, PhD - Senior Scientist; Univ. of Mississippi, University, MS.

1

O. Zimmerman, MD- Physician , A. Novikov, BSc - Research Assistant , T. Finn, MD- Physician 1, Y. Paran, MD- Physician 1, N. Osherov, PhD Researcher 2, R. Ben-Ami, MD- Physician 1; 1Tel Aviv Sourasky Med. Ctr., Tel Aviv, Israel, 2Tel Aviv Univ., Tel Aviv, Israel. 2:45 p.m. M-1060 Breath Volatile Organic Compound (VOC) Profiles for the

M. Ghannoum, PhD - Professor1, C. Waters, MS - Lead Tech 2, H. Motlagh, MPH - Research Associate 2, A. Wilson, MD - Director 2, J. Thomas, PhD - Professor 2; 1Case Western Reserve, Cleveland, OH, 2West Virginia Univ., Morgantown, WV. 3:30 p.m. M-1063 Neurological Disease After Mold Exposure, Immune Risks

& Response to Biofilm-Focused Antifungal Therapy J. F. Rini, MS, I. H. Grant, MD- Clinical Assistant Professor, Department of Family and Community Medicine; New York Med. Coll., Valhalla, NY.

-----------------------------------------------------------------------116(T) Slide Session Infections in Transplant Recipients Monday, 1:30 p.m.–4:00 p.m. . . . . . . . . . . . . . . . . . . . Room 120 UAN: 0391-9999-12-088-L04-P Moderators: Emily Blumberg, MD - Professor of Medicine Univ. of Pennsylvania, Philadelphia, PA. Shahid Husain, MD - Associate Professor of Medicine, Director of Transplant Infectious Diseases Univ. of Toronto, Toronto, Canada. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Identify the impact of respiratory viruses on transplant recipient; > Review newer diagnostic strategies for diagnosing post-transplant infections; and > Recognize the impact of CMV on post-transplant outcome. Presentations: 1:30 p.m. T-1064 Incidence of Viral Infections in Patients with Lung Trans-

plantation P. Bridevaux, MD, MS - Dr 1, J. Aubert, MD - Professor 2, G. Wagner, RN - Research assistant 1, L. Kaiser, MD - Professor1; 1Univ. Hosp. of Geneva, Geneva, Switzerland, 2Ctr. Hosp. Univ. Vaudois, Lausanne, Switzerland.

Diagnosis of Invasive Aspergillosis (IA) S. Koo, MD - Physician1,2, H. R. Thomas, AB - Res Asst 1, P. Rearden, PhD - Staff 3, J. Comolli, PhD - Staff 3, L. R. Baden, MD - Physician 1,2, F. M. Marty, MD - Physician 1,2; 1Brigham and Women’s Hosp., Boston, MA, 2 Harvard Med. Sch., Boston, MA, 3Draper Lab., Cambridge, MA.

Final Program

113

> Monday SCIENTIFIC SESSIONS 1:45 p.m.

3:15 p.m.

T-1065 Bronchiolitis obliterans following Respiratory Viral Infections

in Allogeneic Hematopoietic Stem Cell Transplant Recipients D. P. Shah, MD, MSPH - Pre-Doctoral Fellow, A. M. Alousi, MD - Assistant Professor, L. Bashoura, MD - Associate Professor, P. K. Shah, MD, MSPH - Research Assistant, S. Mahajan, MD - Graduate Research Assistant, V. E. Mulanovich, MD - Assistant Professor, E. Ariza-Heredia, MD Assistant Professor, R. F. Chemaly, MD, MPH, FACP - Associate Professor; MD Anderson Cancer Ctr., Houston, TX. 2:00 p.m. T-1066 Histoplasmosis Following Solid Organ Transplantation M. A. Assi, MD - Clinical Associate Professor1, S. I. Martin, MD - Assistant Professor 2, D. R. Kaul, MD - Associate Professor 3, M. S. Sandid, MD - Clinical Associate Professor 1, L. J. Wheat, MD - President and Director 4; 1 Univ. of Kansas, Wichita, KS, 2Ohio State Univ., Columbus, OH, 3Univ. of Michigan, Ann Arbor, MI, 4MiraVista Diagnostics, Indianapolis, IN. 2:15 p.m. T-1067 Utility of BAL Galactomannan (GM) and Culture Based Pre-

Emptive Antifungal Therapy (PET) Strategy in Lung Transplant Recipients (LTRs) S. Husain, MD - Associate Professor of Medicine, L. Singer, MD - Medical Director, Toronto Lung Transplant Program, Y. Akinlolu, MSc - Clinical Research Coordinator, C. Chaparro, MD - Assistant Professor of Medicine, C. Rotstein, MD - Professor of Medicine, S. Keshavjee, MD - Director, Lung Transplant Program; Univ. Hlth. Network, Toronto, Canada. 2:30 p.m. T-1068 Recurrent Clostridium difficile Infections (CDI) in Solid

Organ Transplant (SOT) Recipients M. A. Yu, PharmD - Pharmacist, S. T. Walk, PhD - Research Investigator, M. Tupps, PharmD - Pharmacist, C. Ring, MS - Research Coord, T. Horwedel, PharmD - Pharmacist, D. M. Aronoff, MD - Physician, J. L. Nagel, PharmD - Pharmacist; Univ. of Michigan Hlth. System, Ann Arbor, MI. 2:45 p.m. T-1069 Methicillin-Resistant S. aureus (MRSA) Screening and

Decolonization is Highly Cost-Effective Among Lung Transplant Recipients (LTR) in a Simulation Model C. Clancy, MD - Associate Professor1, R. K. Shields, PharmD - Professor 2, S. Bartsch, MS - Research Associate 2, B. Lee, MD - Assistant Professor 2, M. Nguyen, MD - Professor 1; 1Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA, 2Univ. of Pittsburgh, Pittsburgh, PA. 3:00 p.m. T-1070 An International Multicenter Performance Analysis of CMV

Viral Load Tests H. Hirsch, MD, MS, FAMH - Professor1, I. Lautenschlager, MD, PhD Director 2, B. A. Pinsky, MD, PhD - Director 3, L. Cardeñoso, MD Professor 4, S. Aslam, BS - Research Biostatistician 5, B. Cobb, PhD, FACMG - Director 5, R. Vilchez, MD, PhD - Director 5, A. Valsamakis, MD, PhD - Professor 6; 1Univ. of Basel, Basel, Switzerland, 2Helsinki Univ. Hosp., Univ. of Helsinki, Helsinki, Finland, 3Stanford Univ., Palo Alto, CA, 4 Hosp. Univ. de la Princesa, Madrid, Spain, 5Roche Molecular Systems, Inc., Pleasanton, CA, 6John Hopkins Univ., Baltimore, MD.

114

September 9-12 |

T-1071 Influence of Cytomegalovirus (CMV) Disease in the De-

velopment of Cardiac Allograft Vasculopathy (CAV) in Heart Transplants Recipients (HTR) through the Application of the New ISHLT (International Society of Heart Transplantation) Coronary Angiographic Criteria A. García-Reyne, MD, PhD - Research Assistant, S. de Dios, MD - Research Assistant, A. Jurado, MD - Research Assistant, F. López-Medrano, MD, PhD - Research Assistant, R. San-Juan, MD, PhD - Research Assistant, M. Fernández-Ruiz, MD - Research Assistant, J. Origüen, MD Research Assistant, M. Lizasoain, MD - Research Assistant, J. Aguado, MD PhD - Professor, J. Delgado, MD, PhD - Research Assistant, C. Lumbreras, MD, PhD - Research Assistant; Univ. Hosp. 12 Octubre, Madrid, Spain. 3:30 p.m. T-1072 The Time Course of Development and Impact from Viral

Resistance against Ganciclovir in Cytomegalovirus Infection Complicating Course after Transplantation C. D. Cunha-Bang, MD - Clinical Research Associate1, N. Kirkby, PhD - Consultant 2, M. Sønderholm, MS - Research Assistant 1, S. S. Sørensen, MD - Consultant 2, H. Sengeløv, MD - Consultant 2, M. Iversen, MD - Consultant 2, A. Rasmussen, MD - Consultant 2, F. Gustafson, MD Consultant 2, C. Frederiksen, PhD - Bioinformatic Scientist 1, J. Kjær, MSc - IT Manager 1, A. C. Lepri, PhD - Senior Lecturer 1, J. D. Lundgren, MD - Professor 1; 1Copenhagen HIV Programme, Copenhagen N, Denmark, 2 Rigshospitalet, Copenhagen N, Denmark.

-----------------------------------------------------------------------117(V) Slide Session Respiratory Viruses and Measles Monday, 1:30 p.m.–4:00 p.m. . . . . . . Esplanade Ballroom 309 UAN: 0391-9999-12-089-L04-P Moderators: Laurent Kaiser, MD - Professor, Head of the Laboratory of Clinical Urology Univ. Hosp. of Geneva, Geneva, Switzerland. Guy Boivin, MD Microbiology, Laval Univ., Sainte-Foy, Canada. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Evaluate incidence and impact of antiviral resistance of influenza infection; > Identify which viruses are associated with pneumonia requiring ICU admission; and > Review characteristics of current measles outbreak. Presentations: 1:30 p.m. V-1073 Measles Outbreak in a University Hospital in Paris M. Caseris, MD- Doctor, N. Houhou, MD- Doctor, P. Longuet, MDDoctor, R. Lepeule, MD- Doctor, C. Rioux, MD- Doctor, C. Choquet, MDD - Doctor, Y. Yazdanpanah, MD, PhD - Professor, P. Yeni, MD, PhD Professor, V. Joly, MD- Doctor; CHU Bichat Claude Bernard, Paris, France.

MONDAY SCIENTIFIC SESSIONS 1:45 p.m. V-1074 Viral Infection in Adult Patients with Severe Hospital-

Acquired Pneumonia Requiring Intensive Care Unit Admission H. Hong, MD- Fellow1, Y. Lee, MD- Fellow 1, S. Park, MD- Fellow 1, S. Moon, MD- Fellow 1, S. Park, MD- Professor 2, O. Cho, MD- Professor 3, S. Kim, MD- Professor 1, H. Sung, MD- Professor 1, S. Lee, MD- Professor 1, Y. Kim, MD- Professor 1, J. Woo, MD- Professor 1, S. Choi, MD- Professor 1 1 ; Asan Med. Ctr., Univ. of Ulsan Coll. of Med., Seoul, Korea, Republic of, 2 Dongguk Univ. Ilsan Hosp., Goyang, Korea, Republic of, 3Gyeongsang Natl. Univ. Hosp., Jinju, Korea, Republic of. 2:00 p.m. V-1075 Impact of RSV Infection in Patients with Lymphoma or

Multiple Myeloma (MM): A Single Center Study S. N. Mahajan, MD - Research Assistant 1, S. S. Ghantoji, MD,M.P.H. - Research Assistant, D. J. Shah, MD, MPH. - Research Assistant, V. E. Mulanovich, M.D. - Assistant Professor, E. Ariza Heredia, MD - Assistant Professor , R. F. Chemaly, MD, MPH, FACP - Associate Professor; M D Anderson Cancer Ctr., Houston, TX.

-----------------------------------------------------------------------118(K) Interactive Symposium Evidence-Based Infection Prevention and Control: Answering Key Questions Monday, 2:00 p.m.–4:00 p.m. . . . . . . . . . . . . . . . . . . . Room 104 UAN: 0391-9999-12-090-L04-P Conveners: Didier Pittet, MD - Professor of Medicine; Director, Infection Control Programme and WHO Collaborating Centre on Patient Safety Univ. of Geneva Hosp., Geneva, Switzerland. John Conly, MD - Professor of Medicine, Microbiology, Immunology and Infectious Diseases Univ. of Calgary, Calgary, Canada. Speakers: 2:00 p.m. 1081-1082 Effective Infection Prevention and Control Measures in

2:15 p.m. V-1076 Four-Year Prospective Evaluation of Host and Viral Factors

Affecting Clinical Performance of a Rapid RSV Test in Hospitalised Children J. Papenburg, MD - Graduate Student1, D. Buckeridge, MD - Professor 1, M. Ouakki, MSc - Statistician 2, G. De Serres, MD - Professor 2, G. Boivin, MD - Professor 2; 1McGill Univ., Montreal, Canada, 2Univ. Laval, Quebec, Canada.

Europe: An EU-Sponsored Meta-Analysis Alison Holmes, MD, MPH - Professor Imperial Coll., London, United Kingdom. Walter Zingg, MD - Senior Registrar Univ. of Geneva Hosp. and Faculty of Med., Geneva, Switzerland. 2:30 p.m. 1083 Isolation for Respiratory Viruses: The Cochrane Systematic

Review and Others

2:30 p.m. V-1077 Design of a Broadly Neutralizing Antibody Targeting

Influenza A Z. H. Shriver, PhD- Vice President, Research, K. Viswanathan, PhD Principal Scientist; Visterra, Inc., Cambridge, MA. 2:45 p.m. V-1078 Effects of Antiviral Treatment on Influenza-Associated

Complications During the 2009-2010 Pandemic Season P. Spagnuolo1, M. Zhang2, S. Liu2, J. Liu2, Y. Xu3, J. Han3, L. Shi2; 1Case Western Reserve Univ., Cleveland, OH, 2Tulane Univ., New Orleans, LA, 3 Genentech, Inc., South San Francisco, CA. 3:00 p.m. V-1079 Evaluation of Pandemic Influenza A/H1N1 Virus Mutations

Conferring Resistance to Zanamivir M. A. Pizzorno, MS - PhD Candidate, Y. Abed, PhD - Professor, X. Bouhy, Technician - Technician, G. Boivin, MD, MS - Professor; Laval Univ. and CHUQ, Quebec, Canada. 3:15 p.m. V-1080 Lack of Emergent Resistance to Oseltamivir Despite Antivi-

ral Efficacy in Type B Influenza Patients in the First 3 Years of the Influenza Resistance Information Study (IRIS) M. Schutten, C. Boucher 1, R. Dutkowski 2, K. Klumpp2, B. Lina3, A. Monto 4, A. Nist2, A. Osterhaus1, J. Nguyen-Van-Tam5, X. Tong2, R. J. Whitley6; 1 Erasmus MC, Rotterdam, Netherlands, 2Hoffmann-La Roche, Inc., Nutley, NJ, 3Univ. of Lyon, Lyon, France, 4Univ. of Michigan Sch. of Publ. Health, Ann Arbor, MI, 5Univ. of Nottingham, Nottingham, United Kingdom, 6Univ. of Alabama at Birmingham, AL.

Klara M. Posfay-Barbe, MD - Head of Pediatric Infectious Diseases Univ. of Geneva Hosp., Children’s Hosp. of Geneva, Geneva, Switzerland. 3:00 p.m. 1084 Aerosol-Generating Procedures: A Systematic Review John Conly, MD - Professor of Medicine, Microbiology, Immunology and Infectious Diseases Univ. of Calgary, Calgary, Canada. 3:30 p.m. 1085 The Role of Environmental Disinfection: A Systematic Review Wing Hong Seto, MD - Director, WHO Collaborating Centre for Infection Control Hosp. Authority, Hong Kong, China. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Identify the evidence base to determine which host, viral, or environmental characteristics increase or decrease the risk of infection in healthcare settings; > Analyze the efficacy of evidence-based management strategies used for key healthcare-associated infection outbreaks; > Review evidence-based changes in the epidemiology of key outbreaks; and > Summarize lessons learned from key outbreaks and their direct impact on infection control practices today. Intended Audience: Infection control physicians, infection control professionals, clinical laboratory personnel, microbiologists, and hospital epidemiologists. Level: Beginning/Intermediate


Final Program

115

> Monday SCIENTIFIC SESSIONS -----------------------------------------------------------------------119(P) Interactive Symposium

-----------------------------------------------------------------------120 Symposium

Clinical Problem Solving: Interactive Cases in Travel and Tropical Medicine

ICAAC Live

Monday, 2:00 p.m.– 4:00 p.m. . . . . . . . . . . . . . . . . . . . Room 103 UAN: 0391-9999-12-091-L04-P Developed in Cooperation with the American Society of Tropical Medicine and Hygiene (ASTMH) Conveners: Kevin Kain, MD - Professor of Medicine Univ. of Toronto, Toronto, Canada. Alan J. Magill, MD - Program Manager Defense Sci. Office (DSO), Defense Advanced Res. Programs Agency (DARPA), Arlington, VA. Speakers: 2:00 p.m.

Management Principles in Neurocyticercosis Christina M. Coyle, MD, MS - Professor of Clinical Medicine Albert Einstein Coll. of Med., Bronx, NY. 2:40 p.m. 1086 Tropical Dermatology Scott A. Norton, MD, MPH - Chief of Dermatology Children’s Natl. Med. Ctr., Washington, DC. 3:20 p.m. 1087 Immigrants and VFRs Rogelio López-Vélez, MD, DTM&H, PhD - Head Tropical Medicine Ramón y Cajal Hosp., Madrid, Spain. Objectives: Upon completion of this Interactive Symposium Session, the participant should be able to: > Cite some of the latest significant literature of travelers medicine, parasitology, and tropical medicine; > Discuss the epidemiology of travelers’ illnesses; and > Identify issues in management and prevention of these illnesses. Intended Audience: ID MDs, fellows, travel MDs, mid-levels, pharmacists, and general physicians.

ICAAC Live is a talk show that explores topics in infectious disease in a casual discussion format. Hosts Vincent Racaniello and Michael Schmidt will be joined by William Bishai, John Brownstein, and Victor Nizet. We’ll discuss the regulation of virulence factors in the pathogenesis of tuberculosis, the emerging role of social media in public health, and outside-the-box approaches to antibacterial therapy, such as targeting virulence factors or boosting innate immune function, with Streptococci and Staphylococci as the primary models. The conversational style of ICAAC Live promotes easy learning without the distraction of visual presentations. Upon completion of this Symposium Session, the participant should be able to: > Understand how social media tools such as HealthMap are playing increasingly important roles in public health; > Identify how the expression of tuberculosis virulence factors is regulated and how this impacts virulence; and > Become familiar with new approaches to antibacterial therapy that target virulence factors or boost innate immune function. Intended Audience: Clinician scientists or basic scientists involved in research on antimicrobial therapy or microbial virulence and epidemiologists and public health officials. Course Level: Intermediate Conveners: Vincent Racaniello, PhD Columbia Univ. Coll. of Physicians & Surgeons, New York, NY. Michael G. Schmidt, PhD Med. Univ. of South Carolina, Charleston, SC. Panelists: 1087a John Brownstein, PhD - Associate Professor Children’s Hosp. Boston & Harvard Med. Sch., Boston, MA. 1087b William Bishai, MD, PhD - Director of K-RITH Kwa-Zulu-Natal Res. Inst. for Tuberculosis and HIV (K-RITH) and Johns Hopkins Ctr. for Tuberculosis Res., Durban, South Africa. 1087c Victor Nizet, MD - Professor Univ. of California, San Diego Sch. of Med. and Skaggs Sch. of Pharmacy & Pharmaceutical Sci., La Jolla, CA.

Level: Intermediate

116

Monday, 2:00 p.m.–4:00 p.m. . . . . . . Esplanade Ballroom 303

September 9-12 |

MONDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------121(A) Symposium

-----------------------------------------------------------------------122(B) Symposium

Aerosol Drug Delivery: Getting Anti-Infective Agents to the Lung

Bacterial and Viral Infections in Patients Treated with Novel Biologic Agents: What Do I Need to Know?

Monday, 2:00 p.m.– 4:00 p.m. . . . . . . . . . . . . . . . . . . . Room 130 UAN: 0391-9999-12-092-L04-P

Monday, 2:00 p.m.–4:00 p.m. . . . . . . Esplanade Ballroom 300 UAN: 0391-9999-12-093-L04-P

Developed in Cooperation with the Society of Infectious Diseases Pharmacists (SIDP) Conveners: Michael Dudley, PharmD - Senior Vice President of R&D and Chief Scientific Officer Rempex Pharmaceuticals, San Diego, CA. Larry H. Danziger, PharmD - Professor of Pharmacy and Professor of Pharmacy in Medicine Univ. of Illinois, Coll. of Pharmacy and Med., Chicago, IL. Speakers: 2:00 p.m. 1088 Considerations for Aerosol Delivery of Anti-Infective Agents David E. Geller, MD - Associate Professor Florida State Univ., Orlando, FL.

Conveners: Henry Masur, MD NIH, Bethesda, MD. Leonard H. Calarese, DO - Professor Cleveland Clinic Lerner Coll. of Med., Cleveland, OH. Speakers: 2:00 p.m. 1092 Opportunistic Infections in Patients Treated with Anti-TNF Agents Deborah Symmons, MD FFPH FRCP - Professor Univ. of Manchester, Manchester, United Kingdom. 2:40 p.m. 1093 Infections Associated with Non-Anti-TNF Biologic Agents Kathryn Dao, MD - Associate Director of Clinical Rheumatology Baylor Res. Inst., Dallas, TX.

2:30 p.m. 1089 Pharmacokinetic/Pharmacodynamic Issues of Aerosol Anti-

Infective Agents Michael Dudley, PharmD - Senior Vice President of R&D and Chief Scientific Officer Rempex Pharmaceuticals, San Diego, CA. 3:00 p.m. 1090 Aerosolized Anti-Infective Agents for Cystic Fibrosis Patrick A. Flume, MD - Professor Med. Univ. of South Carolina, Charleston, SC. 3:30 p.m. 1091 Ventilator-Associated Pneumonia: Can Aerosol Drug Delivery

Help? Jean Chastre, MD - Professor Univ. Sch. of Med., Paris 6, Groupe Hosp. Pitié-Salpêtriére, Paris, France. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Recognize the advantages and disadvantages of devices used for aerosol delivery of anti-infective agents; > Describe the pharmacokinetic/pharmacodynamic issues associated with aerosol delivery of drugs; and > Evaluate the role of aerosolized anti-infective agents in patients with pneumonia and cystic fibrosis.

3:20 p.m. 1094 Viral Infections (HBV, HCV, PML) and Biologic Agents Leonard H. Calabrese, DO - Professor Cleveland Clinic Lerner Coll. of Med., Cleveland, OH. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the mechanism of action of biologic therapies approved for the treatment of rheumatologic, gastrointestinal, and dermatologic disease; > Assess the spectrum and risk of opportunistic infections in patients treated with anti-TNF and non-anti-TNF biologic agents; and > Describe the effect of biologic agents on viral infections, including HBV, HCV, PML. Intended Audience: ID fellows, ID practitioners, pharmacists, immunologists and basic researchers in immunology, virology, microbiology and mycology. Level: Intermediate/Advanced

Intended Audience: Physicians, pharmacists, and microbiologists. Level: Intermediate

Final Program

117

> Monday SCIENTIFIC SESSIONS -----------------------------------------------------------------------123(C2) Symposium

-----------------------------------------------------------------------124(D) Symposium

Antibiotic Combinations against Gram-Negatives in the XDR Era: From Bench to Bedside

Epidemiology and Diagnosis of Febrile Illness in the Era of Global Climate Change



Developed in Cooperation with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Conveners: Jesús Rodríguez-Baño, MD, PhD - Professor Hosp. Universitario Virgen Macarena and Univ. of Seville, Seville, Spain. Johann D. Pitout, MD - Professor Univ. of Calgary, Calgary, Canada. Speakers: 2:00 p.m. 1095 Truths and Half Truths About In Vitro Synergy against Gram-

Negatives

Conveners: Megan E. Reller, MD, PhD, MPH - Assistant Professor of Pathology The Johns Hopkins Univ. Sch. of Med., Baltimore, MD. Delia Enria, MD, MPH - Director Inst. Nacional de Enfermedades Virales Humanas, Pergamino, Argentina. Speakers: 2:00 p.m. 1098 Do We Have Good Data on Dengue? Delia A. Enria, MD, MPH - Director Instituto Nacional de Enfermedades Virales Humanas, Pergamino, Argentina. 2:20 p.m.

Shawn Aaron, MD - Professor The Ottawa Hosp. Res. Inst., Univ. of Ottawa, Ottawa, Canada. 2:40 p.m. 1096 Animal Modeling for Combined Therapy for Gram-Negative

Infections: A Critical Appraisal Vincent H. Tam, PharmD - Associate Professor Univ. of Houston Coll. of Pharmacy, Houston, TX. 3:20 p.m. 1097 Combination Antibiotics and Outcome of Life-Threatening

Bacterial Infections and Septic Shock

1099 Challenges for the Detection of Malaria Infections in Both

Endemic and Non-Endemic Countries at a Time of Changing Weather Patterns Colin J. Sutherland, PhD, MPH - Reader in Parasitology London Sch. of Hygiene and Tropical Med., London, United Kingdom. 2:40 p.m. 1100 Leptospirosis Albert I. Ko, MD - Associate Professor of Epidemiology and Medicine Yale Sch. of Publ. Health, New Haven, CT. 3:00 p.m.

Anand Kumar, MD - Associate Professor Univ. of Manitoba, Hlth. Sci. Ctr., Winnipeg, Canada.

1101 Rickettsial and Ehrlichial Infections

Objectives: Upon completion of this Symposium Session, the participant should be able to: > Recommend when in vitro synergy-testing of antimicrobial agents is indicated for gram- negatives; > Examine the role of animal modeling for combination therapy for gram negative infections; and > Describe if the combination of active antibiotics influences the outcome of infections due to multi-resistant gram-negative bacteria.

1102 Therapeutic Targets for Chikungunya Virus Mark Heise, PhD - Associate Professor Univ. of North Carolina, Chapel Hill, NC.

Intended Audience: Clinical microbiologists, infectious disease physicians, infection control practitioners, clinical pathologists, medical technologists, and epidemiologists. Level: Intermediate

Megan E. Reller, MD, PhD - Assistant Professor of Pathology The Johns Hopkins Univ. Sch. of Med., Baltimore, MD. 3:40 p.m.

Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the global reach of dengue, malaria, rickettsial diseases, Chikungunya virus and leptospirosis; > Recognize the clinical manifestations of each of the etiologies of febrile illness that are discussed; and > Assess the progress and limitations of diagnostic tests for each infection or syndrome. Intended Audience: Infectious Diseases specialists, Microbiologists, Epidemiologists, and Virologists Level: Intermediate

118

September 9-12 |

MONDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------125(F) Symposium

-----------------------------------------------------------------------126(H) Symposium

Alternative Approaches to Inhibiting Gram-Negative Bacteria

Current Issues in HIV-Associated Opportunistic Diseases



Conveners: Malcolm G. P. Page, PhD - Professor Basilea Pharmaceutica, Basel, Switzerland. Donald Moir, PhD - Chief Scientific Officer Microbiotix, Inc., Worcester, MA.

Conveners: Jean-Michel G. Molina, MD - Professor Saint Louis Hosp. and Univ. of Sorbonne Paris Cité, Paris, France. Richard E. Chaisson, MD - Professor John Hopkins Univ. Ctr. for Tuberculosis Res., Baltimore, MD.

Speakers:

Speakers:

2:00 p.m.

2:00 p.m.

1103 Small Molecule Inhibitors of Type III Secretion Donald Moir, PhD - Chief Scientific Officer Microbiotix, Inc., Worcester, MA.

1107 Diagnosis and Management of Castleman Disease Eric Oksenhendler, MD - Professor Univ. of Paris Diderot, Paris, France.

2:30 p.m.

2:30 p.m.

1104 SASP Delivery to Pseudomonas aeruginosa Heather Fairhead, PhD - CEO Phico Therapeutics Ltd., Cambridge, United Kingdom.

1108 Use of Antiretrovirals in Patients with Cryptococcal Meningitis David R. Boulware, MD, MPH - Distinguished Assistant Professor Univ of Minnesota, Minneapolis, MN.

3:00 p.m.

3:00 p.m.

1105 Alginate Oligosaccharides: OligoG for the Treatment of

1109 Prevention and Treatment of Tuberculosis in HIV Infected

Biofilms

Individuals

Edvar J. Onsoyen, MSc, PhD - Chief Scientific Officer, R&D Director AlgiPharma AS, Sandvika, Norway.

Richard E. Chaisson, MD - Professor John Hopkins Univ. Ctr. for Tuberculosis Res., Baltimore, MD.

3:30 p.m.

3:30 p.m.

1106 From the Natural Antibiotic Protegrin to the Clinical

1110 HIV and Malaria Johanna P. Daily, MD, MS - Associate Professor of Medicine and Microbiology and Immunology Albert Einstein Coll. of Med., Bronx, NY.

Candidate POL7080 Glenn E. Dale, PhD - Head of Pre-Clinical Development Polyphor AG, Basel, Switzerland. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the important problems in treating infections caused by gramnegative bacterial pathogens; > Discuss the gaps in the antimicrobial spectrum of currently available therapeutic agents and the limitations of conventional drug discovery approaches; and > Identify and distinguish new approaches to the discovery of novel agents acting against difficult to treat gram-negative bacteria. Intended Audience: Microbiologists working in academia and in the pharmaceutical industry. Level: Intermediate

Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss new data for the diagnosis and management of Castleman disease in patients with HIV-infection; > Discuss the challenges of using antiretrovirals for the treatment of cryptococcal meningitis; > Review current knowledge on the prophylaxis and management of tuberculosis in HIV-infection; and > Discuss the impact of HIV-infection on the incidence, clinical presentation and management of malaria. Intended Audience: HIV treating physicians, ID professionals, clinical virologists mycologists and parasitologists, primary care physicians, tropical medicine physicians, public health specialists and industry professionals. Level: Intermediate/Advanced

Final Program

119

> Monday SCIENTIFIC SESSIONS -----------------------------------------------------------------------127(L) Symposium

-----------------------------------------------------------------------128(M) Symposium

New Issues in the Management of Multidrug-Resistant (MDR) Endocarditis

Fungal Infections in High-Risk Groups: Current and Future Strategies for Control



Developed in Cooperation with the Infectious Diseases Society of America (IDSA)

Developed in Cooperation with the Mycology Study Group (MSG)

Conveners: M. Lindsay Grayson, MD - Professor Univ. of Melbourne, Austin Hlth., Melbourne, Australia. Henry F. Chambers, MD - Professor San Francisco Gen. Hosp., San Francisco, CA.

Conveners: Tania C. Sorrell, MB BS, MD, FRACP - Professor Univ. of Sydney, Sydney, Australia. John Edwards, Jr., MD - Chief, Division of Infectious Diseases Harbor UCLA Med. Ctr., Torrance, CA.

Speakers:

Speakers:

2:00 p.m.

2:00 p.m.

1111 MDR Staphylococcus aureus Endocarditis (MRSA, hVISA) Henry F. Chambers, MD - Professor San Francisco Gen. Hosp., San Francisco, CA. 2:30 p.m.

2:30 p.m.

1112 Endocarditis Due to VRE and Other Resistant Enterococci Robert C. Moellering, Jr., MD - Shields Warren-Mallinckrodt Professor of Medical Research Harvard Med. Sch., Boston, MA. 3:00 p.m. 1113 MDR Gram-Negative Endocarditis David Paterson, PhD - Professor of Medicine Univ. of Queensland Ctr. for Clinicial Res., Brisbane, Australia. 3:30 p.m.

1116 Candidemia in Neonates: Focus on an Indian Neonatal ICU Arunaloke Chakrabarti, MD - Professor Postgraduate Inst. of Med. Ed. & Res., Chandigarh, Chandigarh, India. 3:00 p.m. 1117 Candida Vaccination as a Therapeutic Strategy John Edwards, Jr., MDChief, Division of Infectious Diseases Harbor UCLA Med. Ctr., Torrance, CA. 3:30 p.m. 1118 HIV-Treatment Issues in Cryptococcal Meningitis

1114 Q Fever Endocarditis and Intravascular Infections Corine Delsing, MD Univ. Med. Ctr. St. Radbound, Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe how to diagnose multidrug-resistant intravascular infections; > Assess how to effectively treat multidrug resistant endocarditis and intravascular infections; and > Discuss the current development pathway for new agents and other approaches for endocarditis. Intended Audience: Clinicians, scientists, researchers, and microbiologists. Level: All Levels

120

1115 Invasive candidiasis in ICU Patients Philippe Eggimann, MD - Professor Ctr. Hosp. Univ. Vaudois, Lausanne, Switzerland.

September 9-12 |

Jeremy Day, MD PhD - Doctor Oxford Univ. Clinical Research Unit, Hosp. for Tropical Diseases, Ho Chi Minh City, Viet Nam. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Identify risk groups for invasive fungal infection; > Assess variability in resources for antifungal management; and > Provide guidelines for success in care of invasive fungal infections. Intended Audience: ID clinicians and trainees. Level: Advanced

MONDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------129(K) Slide Session Staphylococcus aureus: Tough Bug, Tough Treatment Monday, 2:00 p.m.–4:00 p.m. . . . . . . . . . . . . . . . . . . . Room 132 UAN: 0391-9999-12-100-L04-P Moderators: Vance Fowler, Jr., MD - Professor with Tenure Duke Univ., Durham, NC. John Jernigan, MD - Director, Office of Prevention Research and Evaluation CDC, Atlanta, GA. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Discuss the relationship between vancomycin MIC and clinical outcome; > Assess predictors and clinical success in the treatment of S.aureus infections; and > Assess predictors of success in treating MRSA pneumonia. Presentations: 2:00 p.m.

State-of-the-Art Minilecture 1119 Update on S. aureus Epidemiology, Resistance, and Treatment Vance Fowler, Jr., MD - Professor with Tenure Duke Univ., Durham, NC.

3:00 p.m. K-1122 Influence of Vancomycin (VAN) MIC on the Outcome of

Cloxacillin-Treated Methicillin-Susceptible Staphylococcus aureus (MSSA) Left-Sided Infective Endocarditis (IE) C. Cervera, MD, PhD - Physician, X. Castañeda, MD - Physician, A. del Río, MD, PhD - Physician, C. García de la María, MD, PhD - Physician, D. Soy, MD, PhD - Physician, A. Moreno, MD, PhD - Physician, C. Falces, MD, PhD - Physician, Y. Armero, MD - Physician, J. Pericas, MD - Physician, M. Almela, MD, PhD - Physician, S. Ninot, MD, PhD - Physician, J. Pare, MD, PhD - Physician, C. Mestres, MD, PhD - Physician, J. Gatell, MD, PhD - Physician, F. Marco, MD, PhD - Physician, J. M. Miro, MD, PhD - Physician; Hosp. Clinic - IDIBAPS, Barcelona, Spain. 3:15 p.m. K-1123 Clinical Outcomes in Patients with Heterogeneous Vancomy-

cin-Intermediate Staphylococcus aureus (hVISA) A. M. Casapao, PharmD - Post-Doc Fellow1, S. N. Leonard, PharmD - PostDoc Fellow 1, S. L. Davis, PharmD - Assistant Professor 1, T. P. Lodise, PharmD - Associate Professor 2, N. Patel, PharmD - Assistant Professor 2, D. A. Goff, PharmD - Associate Professor 3, K. L. LaPlante, PharmD - Assistant Professor 4, B. A. Potoski, PharmD - Associate Professor 5, M. J. Rybak, PharmD, MPH Professsor 1; 1Wayne State Univ., Anti-Infective Res. Lab., Detroit, MI, 2Albany Coll. of Pharmacy, Albany, NY, 3Ohio State Univ., Columbus, OH, 4Univ. of Rhode Island, Providence, RI, 5Univ. of Pittsburgh, Pittsburgh, PA. 3:30 p.m. K-1125 Methicillin-Sensitive Staphylococcus aureus Outbreak in a

Neonatal Ward: System Reengineering Warranted

2:30 p.m. K-1120 Predictors of Clinical Success Among a National Veterans

Affairs (VA) Cohort with Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia A. R. Caffrey, PhD, MS - Assistant Professor of Pharmacoepidemiology1,2, L. A. Puzniak, PhD - Regional Research Specialist 3, D. E. Myers, MPH Outcomes Research Scientist 3, K. L. LaPlante, PharmD - Associate Professor 4,2 1 ; Univ. of Rhode Island Coll. of Pharmacy, Kingston, RI, 2Univ. of Rhode Island, Coll. of Pharmacy, Kingston, RI, 3Pfizer, Inc., Collegeville, PA, 4 Providence VA ID Res. Program, Providence, RI.

Y. Achermann, MD- ID Physician, K. Seidl, PhD - Research Assistant, S. Karrer, None - Infection Control Practitioner, A. Holzmann, None - Lab Technician, G. Senn, None - Lab Technician, A. Zinkernagel, MD, PhD, MS - ID Physician, A. Leone, MD - Physician on Neonatal Ward, H. Bucher, MD - Professor, H. Sax, MD - Professor; Univ. Hosp. Zurich, Zurich, Switzerland.

2:45 p.m. K-1121 Daptomycin (DAP) Versus Vancomycin (VAN) for Methi-

cillin-Resistant Staphylococcus aureus Bacteremia (MRSAB) with VAN MIC > 1 mg/L: A Matched Cohort Study K. P. Murray, PharmD - Clinical Pharmacist1, J. J. Zhao, PharmD - Clinical Pharmacist Specialist 1, S. L. Davis, PharmD - Assistant Professor 2, K. S. Kaye, MD, MPH - Professor 1,3, M. J. Rybak, PharmD, MPH - Professor 1,3,2; 1Detroit Med. Ctr., Detroit, MI, 2Anti-Infective Res. Lab., Eugene Applebaum Coll. of Pharmacy and Hlth. Sci., Detroit, MI, 3Wayne State Univ. Sch. of Med., Detroit, MI.

Final Program

121

> Monday SCIENTIFIC SESSIONS -----------------------------------------------------------------------130 ICAAC Lecture

-----------------------------------------------------------------------130a Symposium

ICAAC Lecture

ICAAC-Global Chinese Association of Clinical Microbiology and Infectious Diseases (GCACMID) Symposium

Monday, 4:30 p.m.–5:30 p.m. . . . . . . . . . . . . . . . . . . . Room 103 UAN: 0391-9999-12-101-L04-P Conveners: M. Lindsay Grayson, MD - Professor Univ. of Melbourne, Austin Hlth., Melbourne, Australia. Craig E. Rubens, MD, PhD - Professor of Pediatrics & Global Health Univ. of Washington and Seattle Children’s, Seattle, WA. In this session, attendees will gain a greater understanding regarding emerging new issues related to fungal infections, new antibiotics, emerging antimicrobial resistance, and new laboratory diagnostic methods and approaches. Objectives: Upon completion of this Symposium Session, the participant should have a greater understanding regarding emerging new issues related to: > The pathogenesis and management of fungal infections; > Emerging new technologies in the diagnosis of fungal disease; > The development of new classes of antifungal agents; and > The emergence of antimicrobial resistance. Intended Audience: Chines clinicians, scientists, researchers, microbiologists, virologists, pharmacists and public health physicians.. Level: Beginning/intermediate. 4:30 p.m.

Award Presentations

Note: This session will be translated into Mandarin Conveners: M. Lindsay Grayson, MD Univ. of Melbourne, Austin Hlth., Melbourne, Australia. Wing Hong Seto, MD Hosp. Authority, Hong Kong, China. Po Ren Hsueh, MD Natl. Taiwan Univ. Coll. of Med., Taipei, Taiwan. Speakers: 5:50 p.m. 1126a Current Global Epidemiology of Gram-Negative Resistance Ronald Jones, MD JMI Lab., North Liberty, IA. 6:10 p.m. 1126b New Quinolones: What’s on the Horizon? David C. Hooper, MD Massachusetts Gen. Hosp., Boston, MA. 6:30 p.m.

4:45 p.m. 1126 Fungal Disease in the 21st Century Arturo Casadevall, MD, PhD - Professor of Microbiology and Immunology and Medicine; Chair, Department of Microbiology and Immunology Albert Einstein Coll. of Med., Bronx, NY. Objectives: Upon completion of the ICAAC Lecture, the participant should have a greater understanding regarding emerging new issues related to: > The pathogenesis and management of fungal infections; > Emerging new technologies in the diagnosis of fungal disease; and > The development of new classes of antifungal agents. Intended Audience: Clinicians, scientists, researchers, microbiologists, virologists, pharmacists and public health physicians. Level: All Levels

122

Monday, 5:45 p.m. - 7:15 p.m.. . . . . . . . . . . . . . . . . . . Room 102 UAN:

September 9-12 |

1126c Fungal Disease in the 21st Century Arturo Casadevall, MD, PhD Albert Einstein Coll. of Med. of Yeshiva Univ., Bronx, NY. 6:50 p.m. 1126d The Impact of Emerging New Diagnostic Laboratory Tech-

niques on Clinical Infectious Disease Franklin R. Cockerill, III, Mayo Clinic, Rochester, MN.

MONDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------131(A) Meet-the-Experts

-----------------------------------------------------------------------133(D) Meet-the-Experts

Top Papers in Anti-Infective and Antiretroviral PK/PD

MALDI-ToF and PCR/ESI Mass Spectrometry: Implementation and Impact on Patient Care

Monday, 5:45 p.m.–7:00 p.m. . . . . . . Esplanade Ballroom 310 UAN: 0391-9999-12-102-L04-P Developed in Cooperation with the Society of Infectious Diseases Pharmacists (SIDP) Convener: Keith A. Rodvold, PharmD - Professor Univ. of Illinois at Chicago, Chicago, IL.

Monday, 5:45 p.m.–7:00 p.m. . . . . . . . . . . . . . . . . . . . Room 121 UAN: 0391-9999-12-104-L04-P Experts: 1131 Nathan A. Ledeboer, PhD - Assistant Professor of Pathology Med. Coll. of Wisconsin, Milwaukee, WI.

Experts:

1132 Stefan Zimmermann, MD - Assistant Medical Director

1127 Johan W. Mouton, MD, PhD - Professor

Univ. Klinikum, Heidelberg, Germany.

Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands. 1128 Courtney V. Fletcher, PharmD - Dean and Professor Coll. of Pharmacy, Univ. of Nebraska Med. Ctr., Omaha, NE. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Describe the latest developments within the field of anti-infective PK/PD; > Describe the most recent findings of importance in anti-infective PK/PD and their consequences for dosing of such drugs; and > Identify the issues and difficulties in implementing recent PK/PD data in the clinic. Intended Audience: Physicians, pharmacists, and microbiologists. Level: Beginning/Intermediate

-----------------------------------------------------------------------132(C2) Meet-the-Experts Detecting, Controlling, and Treating CarbapenemaseProducing Enterobacteriaceae Monday, 5:45 p.m.–7:00 p.m. . . . . . . Esplanade Ballroom 302 UAN: 0391-9999-12-103-L04-P Experts: 1129 Rafael Canton, PhD - Professor Hosp. Univ. Ramón y Cajal. Inst. Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. 1130 David Landman, MD - Associate Professor SUNY Downstate Med. Ctr., Brooklyn, NY. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Describe which treatment options and control methods that are available for infections due to carbapenemase-producing Enterobacteriaceae; > Identify the changing epidemiology of carbapenemase-producing Enterobacteriaceae; and > Describe which control methods that are available to prevent infections due to carbapenemase-producing Enterobacteriaceae.

Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Describe how to implement mass spectrometry into the clinical microbiology laboratory; > Discuss the impact of mass spectrometry methods on workflow and laboratory costs; and > Assess the impact of MALDI-ToF mass spectrometry on patient care. Intended Audience: Clinical microbiologists, infection control practitioners, and infectious diseases physicians. Level: Intermediate

-----------------------------------------------------------------------134(H, V) Meet-the-Experts Prevention of Anal Cancer in HIV-Infection: From Early Detection to Vaccination Monday, 5:45 p.m.–7:00 p.m. . . . . . . Esplanade Ballroom 309 UAN: 0391-9999-12-105-L02-P Experts: 1133 Erna M. Kojic, MD - Assistant Professor of Medicine Warren Alpert Med. Sch. of Brown Univ., Providence, RI. 1134 Joel Palefsky, MD - Professor Univ. of California, San Francisco, CA. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Identify risk factors for anal dysplasia in HIV infection; > Discuss the role of HPV vaccination in HIV infected persons; and > Discuss the role of HPV vaccine as a therapeutic intervention for anal lesions. Intended Audience: HIV and HCV clinicians including MD, pharmacists, pharmacologists, physician extenders and other clinician, HIV and HCV clinical and translational scientists including those involved in all phases of antiviral research. Level: Intermediate/Advanced

Intended Audience: Clinical microbiologists, infectious disease physicians, infection control practitioners, and epidemiologists. Level: Intermediate

Final Program

123

> Monday SCIENTIFIC SESSIONS -----------------------------------------------------------------------136(K) Meet-the-Experts

-----------------------------------------------------------------------138(V, H) Meet-the-Experts

Preventing Line-Associated Bloodstream Infection: Which Measures are Essential?

New Strategies for Transplantation of HIV-Infected Individuals



Experts:

Experts:

1138 Dennis Maki, MD - Deputy Head, Div. of Infectious Diseases & Hospital Epidemiology, Head, Hosp. Epidemiology Univ. of Wisconsin Sch. of Med. and Publ. Hlth., Madison, WI. 1139 Andreas F. Widmer, MD, MS - Deputy Head of Div. Infectious Diseases & Hospital Epidemiology Univ. Hosp., Basel, Switzerland Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Identify the most effective measures to prevent bloodstream infection; > Explain the importance of adhering to evidence-based practice recommendations to prevent bloodstream infection; and > Discuss why a continuous monitoring of review of processes is essential to maintain a low infection rate. Intended Audience: Infectious disease specialists, infection control professionals, hospital epidemiologists, and hospital administrators. Level: Beginning/Intermediate

-----------------------------------------------------------------------137(P) Meet-the-Experts Controversies in Pre-Travel Preparation Monday, 5:45 p.m.–7:00 p.m. . . . . . . . . . . . . . . . . . . . Room 122 UAN: 0391-9999-12-108-L04-P Developed in Cooperation with the American Society of Tropical Medicine and Hygiene (ASTMH) Experts: 1140 Michael D. Libman, MD - Associate Professor Microbiology, McGill Univ., Montreal, Canada. 1141a Lin Chen, MD - Assistant Clinical Professor of Medicine Harvard University, Cambridge, MA. Objectives: Upon completion of this Meet-the-Expert session, the participant should be able to: > Cite some of the latest significant literature on travel medicine; > Discuss the epidemiology of travel related illnesses; and > Identify issues in prevention of these illnesses. Intended Audience: ID MDs, fellows, travel MDs, mid-levels, pharmacists, and general physicians. Level: Intermediate

124

September 9-12 |

1141 Linda Frassetto, MD - Professor Univ. of California, San Francisco, CA. 1142 Elmi Muller, MBChB, MRCS(Ed), FCS(SA) - Medical Doctor Univ. of Cape Town, Groote Schuur Hosp., Cape Town, South Africa. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Analyze the impact of drug interactions (with a focus on antiretrovirals and immunosuppressants) on patient management; > Assess the safety of HIV infected donor organs in HIV infected transplant recipients; and > Assess the pros and cons of solid organ transplantation in HIV-infected patients. Intended Audience: Physicians, pharmacists, and clinical microbiologists/ virologists. Level: Intermediate

NOTES

Final Program

125

> NOTES

126

September 9-12 |

> Tuesday Schedule at-a-Glance > 7:00 a.m. - 8:15 a.m. Meet-the-Experts 138a (K) MDRO Control: What to Do When Basic Prevention Measures Don’t Work? Room 102 139 (A) Intra- and Extracellular Activities of Anti-Infective Agents Esplanade Ballroom 310 140 (C2, K) Clostridium difficile: The Management of Severe and Recurrent Infections Esplanade Ballroom 308 141 (F) Too Few New Anti-Gram-Negative Agents: How to Change the Landscape? Room 122 142 (G) Healthy Mother, Healthy Baby Esplanade Ballroom 309

144 (K) Antimicrobial Resistance and Antimicrobial Stewardship in Non-Hospital Settings Room 120

> 8:30 a.m. - 10:30 a.m. Interactive Symposia 145 (G) Interactive Cases in Pediatric Infectious Diseases Room 103 146 (M) Challenging Cases in Mycology Room 104

Symposia 147 (A) Vancomycin: What Do We Know Now About Pharmacokinetics/Pharmacodynamics? Esplanade Ballroom 306 148 (B) New Concepts in Tuberculosis: Pathogenesis, Diagnostics, Treatment, and Prevention Esplanade Ballroom 308 149 (C1) Novel Techniques for the Diagnostic of the Emerging Antibiotic Resistances Esplanade Ballroom 302

> 8:30 a.m. - 11:00 a.m. Slide Sessions 156 (C1) Extended Spectrumơ-Lactamases Room 121 157 (C2) Carbapenemases Go Global Esplanade Ballroom 300 158 (L1) New Insights in Bacterial Meningitis Esplanade Ballroom 309 159 (M) Mycology for the Bedside Room 122 160 (V) Hepatitis and Herpes Viruses Room 254

> 11:15 a.m. - 12:15 p.m. Poster Walk New Developments in Transplantation Halls A-C

> 11:15 a.m. - 12:45 p.m. Symposia

> 11:15 a.m. - 1:15 p.m. Poster Sessions 161 (A) Clinical Pharmacology of Antiviral and Anti-Tuberculosis Agents Halls A-C 162 (A) Clinical Pharmacology of Novel AntiInfective Agents Halls A-C 163 (A) Pharmacokinetics/Pharmacodynamics of New and Old Oxazolidinones Halls A-C 164 (B) Antimicrobial Therapy in Animal Models II Halls A-C 165 (B) Microbial Determinants of Virulence Halls A-C 166 (C1) Resistance to Staphylococcus and Other Gram-Positive Halls A-C 167 (C2) Characterization of Streptococcus pneumoniae in the Era of Antibiotics and Vaccines Halls A-C 168 (C2) Drug-Resistant Mycobacterium tuberculosis Halls A-C

192 (B) Virulence Bags: Extracellular Vesicles that Modify Host-Pathogen Interactions Esplanade Ballroom 302

169 (C2) MRSA: A Bug with International Appeal and Great Sense Halls A-C

193 (K) Regional Approaches to Prevention of Healthcare-Associated Antimicrobial Resistance Esplanade Ballroom 300

170 (D) Detection of Bacteremia and Biomarkers for Sepsis Halls A-C

194 (L) Emerging and Current Challenges in Injecting Drug Users Room 102 195 (V) Influenza: Beyond the Headlines Room 130

Slide Sessions 196 (B) Novel Antibody Therapy of Difficult Infections Esplanade Ballroom 310 197 (C1) Resistance in Staphylococcus aureus Room 122

150 (D) Antimicrobial Susceptibility Update Room 120

198 (G) Global Pediatrics Esplanade Ballroom 309

151 (E, C1) Laboratory Approaches for Detection, Characterization, and Reporting of Important Resistance Mechanisms in GramNegatives Room 132

199 (K) Bloodstream Infections: Catheters, Cultures and Counts Room 121

171 (D) Diagnosis, Characterization and Antimicrobial Susceptibility Testing: GramPositive Cocci Halls A-C 172 (D) Molecular Methods for Pathogen Identification and Resistance Detection Halls A-C 173 (E) In Vitro Activity of Lipoglycopeptides and Related Compounds Halls A-C 174 (E) In Vitro Activity Versus Staphylococcal Halls A-C 175 (F) Antimicrobial Peptides and Peptidomimetics Halls A-C 176 (F) Compounds and Approaches for Combating Gram-Positive Infections Halls A-C

152 (H) What’s New in Antiretroviral Therapy Room 130

177 (F) Novel Antimicrobial Approaches and Agents Halls A-C

153 (L) Dangerous Pets and Other Animals Room 102

178 (G3) Pediatrics Halls A-C

154 (L, F) What Every Clinician Should Know About Emerging New Antimicrobials Esplanade Ballroom 305

Tuesday

143 (H) Management of Antiretroviral Therapy-Induced Bone Toxicity Room 121

155 (P) Update on Drug Resistance in Malaria Esplanade Ballroom 310

> Tuesday Schedule at-a-Glance continued… 179 (H) HIV-I Pathogenesis and Predictors of Antiretroviral Response in Treatment and Prevention Halls A-C 180 (H) HIV-I Resistance, Tropism and Novel Laboratory Methods Halls A-C 181 (K) Extended-Spectrumơ-Lactamase Enterobacteriaceae Halls A-C 182 (K) MRSA Infections Halls A-C 183 (K) Resistant Acinetobacter Infections Halls A-C 184 (K) Resistant Gram-Negative Infections Halls A-C 185 (K) Use of Vancomycin, Daptomycin and/ or Linezolid Halls A-C 186 (L1) Endocarditis and Other Invasive Infections Halls A-C 187 (L1) Meningitis and Central Nervous System Infections Halls A-C 188 (L1) Methicillin-Resistant Staphylococcus aureus: Clinical Aspects Halls A-C 189 (L1) Novel Agents and Insights in Skin and Soft Tissue Infections Halls A-C 190 (M) Clinical Mycology I Halls A-C 191 (M) Clinical Mycology II Halls A-C

> 12:15 p.m. - 1:15 p.m. Poster Walk Fungal Infections at the Bedside Halls A-C

> 1:30 p.m. - 4:00 p.m. Slide Sessions 200 (A) Maximizing PK/PD Modeling for Dosing, Prevention of Resistance and Clinical Outcomes Room 102 201 (D) Diverse Applications of Mass Spectrometry in Clinical Microbiology Room 120

> 2:00 p.m. - 4:00 p.m.

> 4:30 p.m. - 5:30 p.m.

Interactive Symposium


202 (H2, H3) Advances in HIV and HCV Management Room 103

Symposia 203 (C1) Bacterial Communication and Resistance Esplanade Ballroom 300 204 (C2, K) Global Spread of Antimicrobial Resistance: Mechanisms of Spread, Surveillance, and Control Room 121 205 (E) Selecting Antibiotic Resistant Mutants in the Laboratory: How Best to Mimic the Real World? Esplanade Ballroom 302

213 Cubist-ICAAC Award Lecture Room 103

> 5:45 p.m. - 7:00 p.m. Meet-the-Experts 214 (C1, C2) Top 10 ơ-Lactamase Papers in 2012 Esplanade Ballroom 305 215 (C2) Surveillance of Antimicrobial Resistance: Potential Sources of Bias Esplanade Ballroom 309 216 (F) Meeting the Challenge of Efflux from Gram-Negative Bacteria Esplanade Ballroom 302

206 (F) Iron Transport and Homeostasis: Are There Opportunities for New Drugs? Esplanade Ballroom 309

217 (K) Challenging Issues in Pediatric Infection Prevention and Control Room 122

207 (G) Hot Topics in Pediatric Infectious Disease: 2012 Room 122

218 (K) Issues in the Diagnosis and Management of Prosthetic Joint Infections Esplanade Ballroom 310

208 (K) Are Prevalence Surveys Still Useful for Healthcare-Associated Infection Surveillance? Esplanade Ballroom 305

219 (M, D) How Can the Mycology Lab Work for You? Room 121

209 ID Quiz Esplanade Ballroom 308 210 (L1) Potluck: The Latest on Foodborne Infections Room 132 211 (P) Global Health as an Academic Discipline Esplanade Ballroom 310 212 (V, G) Viruses and the Central Nervous System: Diagnostic, Treatment and Recent Outbreaks Room 130

TUESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------138a(K) Meet-the-Experts


MDRO Control: What to Do When Basic Prevention Measures Don’t Work?

-----------------------------------------------------------------------140(C2, K) Meet-the-Experts

Tuesday, 7:00 a.m.–8:15 a.m.. . . . . . . . . . . . . . . . . . . . Room 102 UAN: 0391-9999-12-106-L04-P

Clostridium difficile: The Management of Severe and Recurrent Infections

Experts:

Tuesday, 7:00 a.m.–8:15 a.m. . . . . . . . Esplanade Ballroom 308 UAN: 0391-9999-12-111-L04-P

1142a Alexander J. Kallen, MD, MPH - Medical Officer CDC, Atlanta, GA.

Experts:

1142b Po Ren Hsueh, MD - Professor Natl. Taiwan Univ. Hosp., Natl. Taiwan Univ. Coll. of Med., Taipei, Taiwan. 1142c Paul A. Tambyah, MD - Assistant Professor Natl. Univ. Hosp., Singapore, Singapore.

1145 Dale N. Gerding, MD - Professor Loyola Univ. Chicago Stritch Sch. of Med., Chicago, IL. 1146 Thomas Louie, MD - Professor Univ. of Calgary, Calgary, Canada.

Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Discuss the basic preventive measures which are generally taken as the first tier measures; > Identify possible measures which are generally taken as the second tier measures; and > Assess the strengths and weaknesses of the different second tier measures and when to apply them for the different MDROs. Intended Audience: ID specialists, infection control professionals, hospital epidemiologists, and clinical microbiologists. Level: Intermediate

---------------------------------------------------------------------------------139(A) Meet-the-Experts Intra- and Extracellular Activities of Anti-Infective Agents Tuesday, 7:00 a.m.–8:15 a.m. . . . . . . . Esplanade Ballroom 310 UAN: 0391-9999-12-110-L04-P Developed in Cooperation with the International Society of Anti-Infective Pharmacology (ISAP) Convener: Niels Frimodt-Møller, MD, DMSc - Professor, Senior Consultant Hvidovre Hosp., Copenhagen, Denmark.

Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Describe which treatment options are available for recurrent Clostridium difficile infection; > Identify the changing epidemiology of Clostridium difficile associated disease; and > Describe the management of severe infections due to Clostridium difficile. Intended Audience: Clinical microbiologists, infectious disease physicians, infection control practitioners, and epidemiologists. Level: Intermediate

-----------------------------------------------------------------------141(F) Meet-the-Experts Too Few New Anti-Gram-Negative Agents: How to Change the Landscape? Tuesday, 7:00 a.m.–8:15 a.m. . . . . . . . . . . . . . . . . . . . . Room 122 UAN: 0391-9999-12-112-L04-P Convener: Michael J. Pucci, PhD - Executive Director Achillion Pharmaceuticals, New Haven, CT. Experts: 1147 Robert A. Stavenger; MD- Team Leader GlaxoSmithKline, Collegeville, PA.

Experts: 1143 Francoise Van Bambeke, PharmD, Ph, PharmD - Professor Univ. Catholique de Louvain, Brussels, Belgium.

1148 David Shlaes, MD, PhD - President Anti-Infectives Consulting, Stonington, CT.

1144 Anne Sandberg-Schaal, PharmD, PhD - Post Doc Hvidovre Hosp., Copenhagen, Denmark. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Describe the importance of targeting both intra- and extracellular pathogens; > Describe the methodology available for estimating the intracellular penetration and activity of antimicrobials; and > Identify the issues and difficulties in estimating the intracellular activity in vitro and in vivo of antimicrobials.

1149 Otto Cars; MD, MPH- Professsor Infectious Diseases Uppsala University, Uppsala, Sweden. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Gain an understanding of the current environment for the development of new agents that target gram-negative pathogens; > Identify issues that have led to the current lack of new drugs to treat gram-negative bacterial infections; and > Discuss potential solutions to this crisis and understand their probabilities for success.

Final Program

127

> Tuesday SCIENTIFIC SESSIONS Intended Audience: Microbiologists, clinicians, and pharmaceutical and academic scientists. Level: Intermediate

-----------------------------------------------------------------------142(G) Meet-the-Experts

-----------------------------------------------------------------------144(K) Meet-the-Experts Antimicrobial Resistance and Antimicrobial Stewardship in Non-Hospital Settings

Healthy Mother, Healthy Baby

Tuesday, 7:00 a.m.–8:15 a.m. . . . . . . . . . . . . . . . . . . . . Room 120 UAN: 0391-9999-12-115-L04-P

Tuesday, 7:00 a.m.–8:15 a.m. . . . . . . . Esplanade Ballroom 309 UAN: 0391-9999-12-113-L04-P

1154 L. Silvia Munoz-Price, MD - Associate Professor of Medicine Jackson Mem. Hosp., Univ. of Miami, Miami, FL.

Experts:

1155 Maria Luisa Moro, MD - Doctor

1150 Claire Thorne, PhD - Lecturer Univ. Coll. London, London, United Kingdom. 1151 Saad B. Omer, MBBS, MPH, PhD - Assistant Professor Emory Univ., Sch. of Publ. Hlth. & Med., Atlanta, GA. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Cite important recent advances in prevention of perinatal transmission of HIV infection; > Discuss promising new strategies for prevention of influenza in pregnant women and young infants; and > Identify preventive strategies to the care of mothers and their infants. Intended Audience: Physicians, public health practitioners, epidemiologists, pharmacologists and all with an interest in maternal-infant health. Level: Beginning/Intermediate

-----------------------------------------------------------------------143(H) Meet-the-Experts Management of Antiretroviral Therapy-Induced Bone Toxicity Tuesday, 7:00 a.m.–8:15 a.m. . . . . . . . . . . . . . . . . . . . . Room 121 UAN: 0391-9999-12-114-L04-P Experts: 1152 Grace A. McComsey, MD - Professor of Medicine and Pediatrics Case Western Reserve Univ. Sch. of Med., Cleveland, OH. 1153 Pablo Tebas, MD - Professor of Medicine Univ. of Pennsylvania, Phhiladelphia, PA. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Describe bone complications resulting from HIV infection and its treatment; > Distinguish between osteoporosis and osteomalacia; > Discuss the role Vitamin D may play in the development of HIV associated bone disease; and > Discuss the management of HIV associated bone disease. Intended Audience: HIV and HCV clinicians including MD, pharmacists, pharmacologists, physician extenders and other clinician, HIV and HCV clinical and translational scientists including those involved in all phases of antiviral research. Level: Intermediate/Advanced

128

Experts:

September 9-12 |

Agenzia Sanitaria e Sociale Regione Emilia-Romagna, Bologna, Italy. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Identify issues regarding antimicrobial resistance and antimicrobial stewardship in non-hospital settings that are specific to these settings; > Identify resources that are helpful for addressing antimicrobial resistance and antimicrobial stewardship in non-hospital settings; and > Identify one intervention they can use in their own practice. Intended Audience: Physicians involved in infection control, particularly those working in non-hospital settings, physicians interested in controlling antimicrobial use in non-hospital settings, and microbiologists providing services to non-hospital settings. Level: Beginning/Intermediate

-----------------------------------------------------------------------145(G) Interactive Symposium Interactive Cases in Pediatric Infectious Diseases Tuesday, 8:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . Room 103 UAN: 0391-9999-12-116-L04-P Conveners: Jeffrey R. Starke, MD - Professor Baylor Coll. of Med., Houston, TX. Karina M. Butler, MB, DCh - Professor Our Lady’s Children’s Hosp. Crumlin, Dublin, Ireland. Panelists: 1156 Carol J. Baker, MD - Professor of Pediatrics, Molecular Virology & Microbiology Baylor Coll. of Med., Houston, TX. 1157 Mary Anne Jackson, MD - Professor of Pediatrics Children’s Mercy Hosp., Kansas City, MO. 1158 David Isaacs, MD - Professor of Pediatric Infectious Diseases The Children’s Hosp. at Westmead, Westmead, Australia. 1159 Anne Vergison, MD, PhD - Associate professor ULB-HUDERF, Brussels, Belgium. 1160 Pia S. Pannaraj, MD, MPH - Assistant Professor of Pediatrics Univ. of Southern California, Children’s Hosp. Los Angeles, Los Angeles, CA. Objectives: Upon completion of this Interactive Symposium, the participant should be able to:

TUESDAY SCIENTIFIC SESSIONS > Identify some common and not-so-common clinical manifestations of important infectious diseases in childhood; > Cite medical evidence and current expert opinion in management and prevention of infections in childhood; > Assess and compare knowledge anonymously with peers; and > Recognize and identify unusual infectious diseases. Intended Audience: Infectious disease physicians and physician extenders, public health personnel, microbiologists, pharmacologists and researchers. Level: Intermediate

-----------------------------------------------------------------------146(M) Interactive Symposium Challenging Cases in Mycology Tuesday, 8:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . Room 104 UAN: 0391-9999-12-117-L04-P Conveners: Andrew Ullmann, MD - Professor Klinikum der Johannes, Mainz, Germany. Jack D. Sobel, MD - Professor, Immunology Microbiology and Chief, Infectious Diseases Wayne State Univ. Sch. of Med., Detroit, MI. Speakers:

Tuesday, 8:30 a.m.–10:30 a.m. . . . . . Esplanade Ballroom 306 UAN: 0391-9999-12-118-L04-P Developed in Cooperation with the Society of Infectious Diseases Pharmacists (SIDP) Conveners: Annie Wong-Beringer, PharmD - Professor Univ. of Southern California Sch. of Pharmacy, Los Angeles, CA. Keith A. Rodvold, PharmD - Professor Univ. of Illinois, Coll. of Pharmacy and Med., Chicago, IL. Speakers: 8:30 a.m. 1165 Pharmacokinetic/Pharmacodynamic In Vitro Models: Lessons

from Glycopeptide- and Lipopeptide-Resistant Pathogens Michael J. Rybak, PharmD, MPH - Professor of Pharmacy & Medicine Wayne State Univ. Coll. of Pharmacy & Hlth. Sci., Detroit, MI. 9:00 a.m.

mycin? Natasha E. Holmes, MBBS (Hons) - PhD Research Scholar Austin Hlth., Dept. of Infectious Diseases, Heidelberg, Australia.

1161 Management Guidelines and Real Life Situations Andrew J. Ullmann, MD - Professor Julius-Maximilians Univ., Wuerzburg, Germany.

9:30 a.m.

9:00 a.m.

1167 Vancomycin-Associated Nephrotoxicity: A Critical Appraisal of

1162 Conundrums in Management Jack D. Sobel, MD - Professor, Immunology Microbiology and Chief, Infectious Diseases Wayne State Univ. Sch. of Med., Detroit, MI. 9:30 a.m.

Risk with High-Dose Therapy Annie Wong-Beringer, PharmD - Associate Professor Univ. of Southern California Sch. of Pharmacy, Los Angeles, CA. 10:00 a.m. 1168 When to Change Methicillin-Resistant Staphylococcus aureus

Therapy: Can Pharmacokinetic/Pharmacodynamic Indices Guide the Decision?

1163 A Difficult Case Patricia Muñoz, MD, PhD - Prof Hosp. G.U. Gregorio Maranon, Madrid, Spain.

Vance Fowler, Jr., MD - Professor with Tenure Duke Univ. Sch. of Med., Durham, NC.

10:00 a.m. 1164 Australia: When the Human Petri Dish Serves an Unusual

Guest Deborah J. E. Marriott, MBBS, BscMed, FRACP, FRCPA, MASM Professor St. Vincent’s Hosp., Sydney, Australia. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Manage complex cases; > Discuss the boundaries of diagnosis and treatment; and > Identify principles for the epidemiology and care of patients. Level: Advanced

Vancomycin: What Do We Know Now About Pharmacokinetics/Pharmacodynamics?

1166 Do High MIC Values Influence Clinical Outcomes of Vanco-

8:30 a.m.

Intended Audience: Clinicians and trainees.

-----------------------------------------------------------------------147(A) Symposium

Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe in vitro bactericidal activity of glycopeptide- and lipopeptideresistant pathogens; > Appraise whether high minimum inhibitory concentrations of vancomycin influence clinical outcomes; > Evaluate the risks of vancomycin-associated nephrotoxicity with highdose therapy; and > Recognize the role of pharmacokinetic-pharmacodynamic indices of vancomycin. Intended Audience: Physicians, pharmacists, and microbiologists. Level: Intermediate

Final Program

129

> Tuesday SCIENTIFIC SESSIONS -----------------------------------------------------------------------148(B) Symposium

-----------------------------------------------------------------------149(C1) Symposium

New Concepts in Tuberculosis: Pathogenesis, Diagnostics, Treatment, and Prevention

Novel Techniques for the Diagnostic of the Emerging Antibiotic Resistances

Tuesday, 8:30 a.m.–10:30 a.m. . . . . . Esplanade Ballroom 308 UAN: 0391-9999-12-119-L04-P

Tuesday, 8:30 a.m.–10:30 a.m. . . . . . Esplanade Ballroom 302 UAN: 0391-9999-12-120-L04-P

Conveners: John Chan, MD - Professor Albert Einstein Coll. of Med., Bronx, NY. Warwick J. Britton, PhD, MBBS, FRACP, FRCP, FRCPA - Bosch Professor of Medicine and Professor of Immunology Centenary Inst. and Univ. of Sydney, Sydney, Australia. Speakers:

Conveners: Jacques Schrenzel, MD - Professor Geneva Univ. Hosp., Geneva, Switzerland. Kenneth S. Thomson, PhD - Professor Creighton Univ., Omaha, NE. Speakers: 8:30 a.m.

8:30 a.m.

1173 Molecular/Protein-Based Techniques for Detection of

1169 New Concepts in Tuberculosis Diagnostics David Alland, MD - Professor New Jersey Med. Sch. (UMDNJ), Newark, NJ. 9:00 a.m.

Resistance in Gram-Negatives Kenneth Thomson, PhD - Professor Creighton Univ., Omaha, NE. 9:00 a.m.

1170 Adaptive Immunity in Tuberculosis: Friend and Foe Joel Ernst, MD - Professor of Medicine, Pathology, and Microbiology New York Univ., New York, NY. 9:30 a.m. 1171 New Approach to Tuberculosis Vaccine Design Warwick J. Britton, PhD, MBBS, FRACP, FRCP, FRCPA - Professor Centenary Inst. and Univ. of Sydney, Sydney, Australia. 10:00 a.m. 1172 B Cells and Humoral Immunity in Tuberculosis John Chan, MD - Professor Albert Einstein Coll. of Med., Bronx, NY. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the role of innate and adaptive immunity to pathogenesis of Tuberculosis; > Describe new findings relevant to Tuberculosis vaccine development; and > Incorporate new concepts for Tuberculosis diagnosis into future clinical practice. Intended Audience: ID clinicians, immunologists, microbiologists, and diagnostic developers.

1174 Molecular/Protein-Based Techniques for Diagnostic of

Resistance in Gram-Positives Frederic Laurent, PharmD, PhD - Associate Professor Hospices Civils de Lyon, Croix Rousse Hosp., Lyon, France. 9:30 a.m. 1175 Point-of-Care Technologies Michel Drancourt, MD, PhD - Professor Univ. of Marseilles, Marseille, France. 10:00 a.m. 1176 Future Techniques Jacques Schrenzel, MD - Professor Geneva Univ. Hosp., Geneva, Switzerland. Objectives: Upon completion of this Symposium Session, participants should be able to: > Describe the molecular and protein-based techniques useful for diagnostic of emerging antibiotic resistances; > Discuss the development of future technologies for diagnostic of antibiotic resistances; and > Identify the techniques that may be potentially implemented in a clinical lab. Intended Audience: ID physicians, pharmacists, scientists, and industry clinical microbiologists.

Level: Intermediate/Advanced

Level: Intermediate

130

September 9-12 |

TUESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------150(D) Symposium

-----------------------------------------------------------------------151(E, C1) Symposium

Antimicrobial Susceptibility Update

Laboratory Approaches for Detection, Characterization, and Reporting of Important Resistance Mechanisms in Gram-Negatives

Tuesday, 8:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . Room 120 UAN: 0391-9999-12-121-L04-P Conveners: Jean B. Patel, PhD - Deputy Director, Office of Antimicrobial Resistance CDC, Atlanta, GA. Rafael Canton, PhD - Professor Hosp. Univ. Ramón y Cajal. Inst. Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. Speakers: 8:30 a.m.

Tuesday, 8:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . Room 132 UAN: 0391-9999-12-122-L04-P Conveners: Stephen G. Jenkins, PhD - Professor of Pathology and Laboratory Medicine New York Presbyterian Hosp./Weill Cornell Med. Ctr., New York, NY. Melvin P. Weinstein, MD - Professor of Medicine and Pathology Robert Wood Johnson Med. Sch., New Brunswick, NJ. Speakers:

1177 CLSI and EUCAST Update

8:30 a.m.

Jean Patel, PhD, D(ABMM) - Deputy Director, Office of Antimicrobial Resistance CDC, Atlanta, GA. 9:00 a.m. 1178 New Challenges in Antimicrobial Susceptibility Testing in

Multidrug-Resistant Gram-Negative Rods

1181 Current Global Epidemiology of Gram-Negative Resistance Ronald N. Jones, MD - President, CEO JMI Lab., North Liberty, IA. 9:00 a.m. 1182 Phenotypic Detection of Resistance Mechanisms in Multidrug-

Resistant Enterobacteriaceae

Rafael Canton, PhD - Professor Hosp. Univ. Ramón y Cajal. Inst. Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.

Audrey N. Schuetz, MD - Assistant Professor Weill Cornell Med. Coll., New York, NY.

9:30 a.m.

9:30 a.m.

1179 Antifungal Susceptibility Testing Update: Yeast and Molds Annette W. Fothergill, MA, MBA - Assistant Professor Univ. of Texas Hlth. Sci. Ctr., San Antonio, TX. 10:00 a.m. 1180 Antimicrobial Susceptibility Testing of Non-Tuberculous

Mycobacteria and its Clinical Relevance

Mechanisms in Enterobacteriaceae Andrea Endimiani, MD, PhD - Clinical Microbiologist Univ. of Bern, Bern, Switzerland. 10:00 a.m. 1184 Reporting Antimicrobial Susceptibility Testing Results for

ESBL and KPC-Producing Gram-Negatives

Jakko van Ingen, MD, PhD - Resident in Clinical Microbiology Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Review current CLSI and EUCAST guidelines regarding antimicrobial susceptibility testing; > Assess what clinicians should know about and when to request antimicrobial susceptibility testing for clinical care; and > Review unsettled issues and pitfalls of current antimicrobial susceptibility testing, methods and their clinical application. Intended Audience: Clinical microbiologists, infection control practitioners, and infectious diseases physicians. Level: Intermediate

1183 Molecular Detection and Characterization of Resistance

David Paterson, PhD - Professor of Medicine Univ. of Queensland Ctr. for Clinical Res., Brisbane, Australia. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe variousơ-lactamase mediated resistance mechanisms among the Enterobacteriaceae and other clinically important gram-negatives; > Explain regional, national, and global patterns of antimicrobial resistance resulting from the various mechanisms described for various gram-negatives; > Recognize atypical antimicrobial susceptibility testing results with the Enterobacteriaceae for the parenteral cephalosporins and carbapenems that should lead to additional and/or confirmatory phenotypic and or molecular testing; and > Develop an approach to educate the end users (clinicians and hospital epidemiologists) on the impact these resistance mechanisms on the reporting of antimicrobial susceptibility testing results. Intended Audience: Infectious disease physicians, clinical microbiologists, clinical pharmacists with expertise and interest in infectious diseases, and infection control practitioners. Level: Intermediate

Final Program

131

> Tuesday SCIENTIFIC SESSIONS -----------------------------------------------------------------------152(H) Symposium

-----------------------------------------------------------------------153(L) Symposium

What’s New in Antiretroviral Therapy

Dangerous Pets and Other Animals

Tuesday, 8:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . Room 130 UAN: 0391-9999-12-123-L04-P

Tuesday, 8:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . Room 102 UAN: 0391-9999-12-124-L04-P

Conveners: Roy M. Gulick, MD - Professor of Medicine Weill Cornell Med. Coll., New York, NY. Joseph Eron, Jr., MD - Professor of Medicine Univ. of North Carolina, Chapel Hill, NC.

Conveners: Tara C. Smith, PhD - Assistant Professor Epidemiology, Univ. of Iowa, Iowa City, IA. David Aronoff, MD - Associate Professor Univ. of Michigan, Ann Arbor, MI.

Speakers:

Speakers:

8:30 a.m.

8:30 a.m.

1185 Antiretroviral Therapy 2012: What to Start? Joel E. Gallant, MD, MPH - Professor of Medicine & Epidemiology Johns Hopkins Univ. Sch. of Med., Baltimore, MD. 9:00 a.m. 1186 New Antiretrovirals and Novel Strategies for the Treatment of

HIV-1 Infection

Viruses Lin-Fa Wang, PhD - Professor CSIRO Australian Animal Hlth. Lab., Geelong, Australia. 9:00 a.m. 1190 Microbe Hunting: New Approaches to Pathogen Surveillance

Patrick G. Yeni, MD - Professor Hosp. Bichat-Claude Bernard and Xavier Bichat Med. Sch., Paris, France. 9:30 a.m. 1187 Pre-Exposure Prophylaxis (PrEP) for HIV-1: Where Have We

Been and Where are We Going? Jared Baeten, MD, PhD - Associate Professor Univ. of Washington, Seattle, WA. 10:00 a.m.

and Discovery W. I. Lipkin, MD - Professor Columbia Univ., New York, NY. 9:30 a.m. 1191 MRSA and Animals Tara C. Smith, PhD - Assistant Professor Univ. of Iowa, Iowa City, IA. 10:00 a.m.

1188 Top Papers in Antiretroviral Therapy: Including Key Presenta-

tions from the 2012 International AIDS Conference Roy M. Gulick, MD - Professor of Medicine Weill Cornell Med. Coll., New York, NY. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss several recommended initial antiretroviral regimens for the treatment of HIV-1 infection and identify potential patient types for which one regimen may be more suited than another; > Summarize information of new antiretroviral agents and antiretroviral treatment strategies that are in development for the treatment of HIV-1 infection; > Compare data from several large studies of pre-exposure prophylaxis studies using antiretrovirals for the prevention of HIV infection and consider which at risk individuals may benefit from PrEP for HIV prevention; and > Review the most important antiretroviral research studies that were published in 2012 or were presented at the 2012 International AIDS conference in Washington DC. Intended Audience: HIV clinicians including MD, pharmacists, pharmacologists, physician extenders and other clinician, HIV clinical and translational scientists including those involved in all phases of antiretroviral research, virologists, and drug developers. Level: All Levels

132

1189 The Role of Bats in the Transmission of Dangerous Zoonotic

September 9-12 |

1192 Once Bitten, Twice Shy: Animal Bites and Infectious Diseases David F. Looke, MD - Infectious Diseases Physician and Clinical Microbiologist Princess Alexandra Hosp., Univ. of Queensland, Brisbane, Australia. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss how to diagnose zoonotic infections; > Effectively treat infections related to animal bites; and > Identify new concepts regarding the epidemiology of newly recognized zoonotic infections. Intended Audience: Clinicians, scientists, researchers, microbiologists, and public health physicians. Level: All Levels

TUESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------154(L, F) Symposium

-----------------------------------------------------------------------155(P) Symposium

What Every Clinician Should Know About Emerging New Antimicrobials

Update on Drug Resistance in Malaria

Tuesday, 8:30 a.m.–10:30 a.m. . . . . . Esplanade Ballroom 305 UAN: 0391-9999-12-125-L04-P Conveners: M. Lindsay Grayson, MD - Professor Univ. of Melbourne, Austin Hlth., Melbourne, Australia. George M. Eliopoulos, MD - Professor of Medicine Beth Israel Deaconess Med. Ctr., Boston, MA.

Tuesday, 8:30 a.m.–10:30 a.m. . . . . . Esplanade Ballroom 310 UAN: 0391-9999-12-126-L04-P Conveners: Thomas E. Wellems, MD, PhD - Chief, LMVR NIAID, NIH, Bethesda, MD. Alan J. Magill, MD - Program Manager Defense Sci. Office (DSO), Defense Advanced Res. Programs Agency (DARPA), Arlington, VA. Speakers:

Speakers:

8:30 a.m.

8:30 a.m. 1193 Fidaxomicin and Other Macrocyclic Antibiotics Kathleen Mullane, DO, PharmD - Associate Professor of Medicine Univ. of Chicago, Chicago, IL. 8:50 a.m. 1194 New Oxazolidinones, Including Tedizolid (Torezolid, TR-700) George M. Eliopoulos, MD - Professor of Medicine Beth Israel Deaconess Med. Ctr., Boston, MA. 9:10 a.m. 1195 Ceftaroline: An Update Helen W. Boucher, MD, FACP - Associate Professor Tufts Med. Ctr., Boston, MA.

1199 What Can We Learn from the History of Resistance to Anti-

Malarial Drugs? Thomas E. Wellems, MD, PhD - Chief, LMVR NIAID, NIH, Bethesda, MD. 9:00 a.m. 1200 Emerging Artemisinin Resistance in Plasmodium falciparum

Malaria Rick M. Fairhurst, MD, PhD - Clinical Tenure-Track Investigator NIAID, NIH, Bethesda, MD. 9:30 a.m. 1200a Selection of Malaria Parasites with Decreased Sensitivity to

Artemisinin Partner Drugs

9:30 a.m. 1196 New Beta-Lactam/Beta-Lactamase Combinations (Including

Avibactam NKL104 and Tazobactam)

Philip J. Rosenthal, MD - Professor San Francisco Gen. Hosp., San Francisco, CA. 10:00 a.m.

David M. Livermore, PhD - Professor Univ. of East Anglia, Norwich, United Kingdom.

1201 Designing the Next Generation of Medicines for Malaria

Control and Elimination

9:50 a.m.

Tim Wells, PhD - Chief Scientific Officer Med. for Malaria Venture, Geneva, Switzerland.

1197 Plazomicin (ACHN-490) and Other Neoglycosides Karen Bush, PhD - Adjunct Professor Indiana Univ., Bloomington, IN. 10:10 a.m.

Waiting for replacement Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss the new emerging antimicrobial agents; > Recognize when these new agents may be of value in clinical practice; > Assess how to safely use these new agents; and > Identify the current development pathway for these new agents. Intended Audience: Clinicians, scientists, researchers, and microbiologists.

Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the current global distribution of genotypic and phenotypic markers associated with drug resistance to malaria; > Compare the difference between therapeutic failures and drug resistance; Recognize the technical and biologic difficulties in isolating and identifying the genetic correlates of acquired drug resistance in malaria; and > Interpret genotypic and phenotypic data acquired in the laboratory and apply to treatment recommendations. Intended Audience: Graduate students, MsC, and PhD, Public Health ID residents and trainees, ID Fellows and MDS. Level: Intermediate

Level: All Levels

Final Program

133

> Tuesday SCIENTIFIC SESSIONS -----------------------------------------------------------------------156(C1) Slide Session Extended Spectrumơ-Lactamases Tuesday, 8:30 a.m.–11:00 a.m. . . . . . . . . . . . . . . . . . . Room 121 UAN: 0391-9999-12-127-L04-P Moderators: Patrice Nordmann, MD - Professor Hosp. Bicetre, Le-Kremlin-Bicetre, France. Gian M. Rossolini, MD - Professor of Clinical Microbiology Siena Univ. Hosp., Siena, Italy. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Identify current epidemiology trend in emerging ESBLs; > Discuss genetic vectors of ESBLs; and > Understand the factors contributing to the spread of ESBLs. Presentations:

C1-1207 PER-2-Producing Enterobacter cloacae (PER-2-ECL): First

Report in Brazil K. S. Nogueira, PhD - PhD 1, L. C. C. Fehlberg, MS - PhD student2, R. Cayô, MS - PhD Student 2, A. G. Nicoletti, MS - PhD Student 2, J. K. Palmeiro, MS - PhD Student 1, A. C. Gales, MD - MD 2, L. M. Dalla-Costa, PhD - PhD 1; 1UFPR, Curitiba, Brazil, 2UNIFESP, São Paulo, Brazil. 10:00 a.m. C1-1208 Plasmid Sequencing of Four blaCTX-M Encoding

Plasmids, Including the Identification of a Novel blaCTX-M-32 IncX1 C. J. Boinett, MSc - PhD Student1,2, M. AbuOun, PhD - Research Scientist 1, M. J. Woodward, PhD - Professor of Human Gut Microbiome Studies 3, M. F. Anjum, PhD - Senior Scientist 1; 1Animal Hlth. and Vet. Lab. Agency, Surrey, United Kingdom, 2Royal Holloway, Univ. of London, Surrey, United Kingdom, 3Reading Univ., Reading, United Kingdom. 10:15 a.m. C1-1209 SHV-129: A Gateway to Global Suppressors (GSs) in the

SHVơ-Lactamase Family

8:30 a.m. C1-1202 How to Detect Extended-Spectrum Beta-Lactamase-

Producing Enterobacteriaceae: A New Paradigm P. Nordmann, MD, PhD - Professor, L. Poirel, PhD - Associate Researcher, L. Dortet, PharmD - Assistant Professor; Hosp. de Bicetre, Le Kremlin Bicetre, France. 8:45 a.m. C1-1203 Complete Nucleotide Sequence of a F33: A-: B- Type

Epidemic Plasmid Carrying blaCTX-M-65, fosA3 and rmtB, Spreading Both in Pets and a Pig Farm in China J. Liu, PhD - Associate Professor, L. He, MD - Master, Z. Chen, BD Professor; South China Agricultural Univ., Guangzhou, China. 9:00 a.m. C1-1204 Role of Amino Acid Variation on Activity and Evolution of

CTX-M Family ofơ-Lactamases B. Fryszczyn, BS - Graduate Student, T. Palzkill, PhD - Principal Investigator; Baylor Coll. of Med., Houston, TX. 9:15 a.m. C1-1205 Epidemic I1-Type Plasmid Responsible for the Emergence

and Wide Dissemination of CTX-M-9 Group ESBLs in Escherichia coli from the Intestinal Microbiota of Healthy Children in Bolivia E. Riccobono, MS - PhD Student1, L. Pallecchi, MD - Professor 1, T. Di Maggio, MS - Technician 1, V. Di Pilato, MS - PhD 1, A. Mantella, MS Professor 2, C. Trigoso, MD - Professor 3, A. Bartoloni, MD - Professor 2, G. M. Rossolini, MD - Professor 1; 1Univ. of Siena, Siena, Italy, 2Univ. of Florence, Florence, Italy, 3Univ. Mayor de San Andrés, La Paz, Bolivia, Plurinational State of. 9:30 a.m. C1-1206 Mutations in R220 In PER-2ơ-Lactamase Resulting in

A Decreased Susceptibility to Inhibitors Also Impact in the Catalytic Activity Towards Substrates M. Ruggiero, PhD student - Fellow1, E. Sauvage, PhD - Researcher 2, F. Troncoso, PhD - Researcher 1, L. Curto, PhD - Researcher 1, M. Galleni, PhD - Researcher 2, P. Power, PhD - Researcher 1, G. Gutkind, PhD - Researcher 1; 1 Fac. Farm. y Bioq - UBA, Buenos Aires, Argentina, 2CIP, Univ. de Liège, Liege, Belgium.

134

9:45 a.m.

September 9-12 |

M. L. Winkler, BA - Student1, A. M. Hujer, BS - Research Assistant 1, C. Lascols, MS - Molecular Microbiologist 2, M. Taracila, MS - Research Assistant 1, R. A. Bonomo, MD - Professor 3; 1CWRU, Cleveland, OH, 2IHMA, Schaumburg, IL, 3CWRU, VAMC, Cleveland, OH.

-----------------------------------------------------------------------157(C2) Slide Session Carbapenemases Go Global Tuesday, 8:30 a.m.–11:00 a.m. . . . . . Esplanade Ballroom 300 UAN: 0391-9999-12-128-L04-P Moderators: Johann Pitout, MD – Professor Univ. of Calgary, Calgary, Canada. Jesús Rodríguez-Baño, MD, PhD – Professor Hosp. Univ. Virgen Macarena, Seville, Spain. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Describe the molecular epidemiology of enterobacteria that produce carbapenemase; > Describe the virulence associated with enterobacteriaceae; and > Describe the worldwide emergence of enterobacteria carbapenemase. Presentations: 8:30 a.m. C2-1210 Molecular Epidemiology and Virulence Factors of Car-

bapenemase-Producing Klebsiella Pneumoniae (C-Kp), and First Report of blaOXA-48 in the U.S.A. C. Lascols, Masters (MS) - Molecular Microbiologist1, M. Hackel, PhD Lab Manager 1, G. Peirano, PhD - Research Associate 2, J. D. D. Pitout, MD Professor 2; 1IHMA, Schaumburg, IL, 2Univ. of Calgary, Calgary, Canada.

TUESDAY SCIENTIFIC SESSIONS 8:45 a.m.

10:15 a.m.

C2-1211 The Increasing Spread of KPC-Producing Klebsiella

C2-1217 Molecular Epidemiology of KPC-Producers Enterobacteria-

pneumoniae in Europe: Results from an Italian Nationwide Survey

ceae (ETB) in Argentina: An update 2006-2012

T. Giani, PhD - PhD 1, B. Pini, MD - MD 2, F. Arena, MD - MD 1, V. Conte, BS - St 1, L. Pagani, PhD - Professor 3, F. Luzzaro, MD - MD 2, G. M. Rossolini, MD - Professor1; 1Univ. of Siena, Siena, Italy, 2A. Manzoni Hosp., Lecco, Italy, 3Univ. of Pavia, Pavia, Italy.

S. Gomez, D. Faccone, M. Raporport, L. Guerriero, P. Ceriana, A. Petroni, F. Pasteran, Argentinean Kpc-Group, A. Corso; INEI-ANLIS-MALBRAN, Buenos Aires, Argentina.

9:00 a.m.

10:30 a.m. C2-1218 Molecular Epidemiology of KPC-2-Producing Klebsiella

C2-1212 Outbreak of Klebsiella pneumoniae Carbapenemase-2- Pro-

ducing K. pneumoniae Sequence Type 11 in Taiwan, 2011 C. Liu, MD - Visiting Staff1, C. Lee, MD - Visiting Staff 2, C. Liao, MD Visiting Staff 1, W. Lee, MD - Visiting Staff 3, Y. Liu, MD - Visiting Staff 4, J. Mu, PhD - Research Staff 5, M. Lee, MD - Visiting Staff 6, P. Hsueh, MD - Professor 7; 1Far Eastern Mem. Hosp., New Taipei City, Taiwan, 2Mackay Mem. Hosp., Taipei City, Taiwan, 3Wan Fang Hosp., Taipei City, Taiwan, 4 Shuang Ho Hosp., Taipei Med. Univ. and Sch. of Med., New Taipei City, Taiwan, 5Res. and Diagnostic Ctr., Ctr. for Disease Control, Taipei City, Taiwan, 6Chung Shan Med. Univ. Hosp., Taichung City, Taiwan, 7Natl. Taiwan Univ. Hosp., Natl. Taiwan Univ. Coll. of Med., Taipei City, Taiwan. 9:15 a.m. C2-1213 Surveillance and Enzyme Characterization of Carbapenem-

Resistant Enterobacteriaceae (CRE) in an Indiana Health Care Setting (2009-2012) K. Bush, PhD - Professor1, T. Davis, MS - Student 1, R. Lee, PhD Lecturer 1,2, R. Relich, PhD - Fellow 3, G. A. Denys, PhD - Clinical Director, Microbiology 3; 1Indiana Univ. Bloomington, Bloomington, IN, 2Dow Agro Sci., Indianapolis, IN, 3Indiana Univ. Hlth., Indianapolis, IN. 9:30 a.m. C2-1214 VIM-1-Producing Escherichia coli ST131 and Enterobacter

cloacae, Ontario, Canada, 2008-2011 N. Tijet, PhD 1, O. Lastovetska, MS 1, G. MacMullin, MS 1, C. Vermeiren, MS 2, P. Wenzel, MS 3, B. M. Willey, MS 4, D. J. Farrell, PhD 1, D. E. Low, MD 1, S. N. Patel, PhD 1, R. G. Melano, PhD 1; 1Publ. Hlth. Ontario Lab., Toronto, Canada, 2Shared Hosp. Labs, Toronto, Canada, 3Halton Healthcare Services, Oakville, Canada, 4Mt Sinai Hosp., Toronto, Canada. 9:45 a.m. C2-1215 Emergence of IMP-1 Producing Klebsiella pneumoniae in a

Tertiary Care Hospital in Korea H. Yang, MD - Assistant Professor1, J. Yoo, PhD - Research Staff 2, J. Chung, MD - Clinical Assistant Professor 3, J. Park, MD - Assistant Professor 1; 1Kosin Univ. Coll. of Med., Busan, Korea, Republic of, 2Korea NIH, Osong, Korea, Republic of, 3Dongguk Univ. Ilsan Hosp., Goyang, Korea, Republic of. 10:00 a.m.

pneumoniae in Brazil: Clonal Spread of CC11 (ST11, ST437, and ST340) and Dispersion of blaKPC-2 Associated with Tn4401 “a” P. S. Pereira, MS- PhD Student, C. F. M. Araújo, BSc - Student, L. M. Seki, PhD - Researcher, A. D. Carvalho-Assef, PhD - Researcher, M. D. Asensi, PhD - Researcher, Brazilian KPC Study Group; Oswaldo Cruz Inst. - IOCFIOCRUZ, Rio de Janeiro, Brazil. 10:45 a.m. C2-1219 First Reported Case of New Delhi Metallo (NDM)

Carbapenem-Positive Gene in Escherichia coli from Companion Animals in the United States B. W. Shaheen, DVM, MS, PhD - Post Doctoral Research Fellow 1, R. Nayak, MS, PhD - Research Scientist1, D. M. Boothe, DVM, MS, PhD - Professor 2; 1 U.S. FDA, Jefferson, AR, 2Auburn Univ., Auburn, AL.

-----------------------------------------------------------------------158(L1) Slide Session New Insights in Bacterial Meningitis Tuesday, 8:30 a.m.–11:00 a.m. . . . . . Esplanade Ballroom 309 UAN: 0391-9999-12-129-L04-P Moderators: Petter Brandtzag, MD, PhD - Professor Univ. of Oslo, Oslo, Norway. Stefano Giulieri, MD - Service of Infectious Diseases Univ. of Lausanne, Lausanne, Switzerland. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Improve clinical evaluation and management of patients with meningitis; > Critically evaluate information regarding the diagnosis and prognosis of acute bacterial meningitis; and > Integrate new knowledge regarding cerebrospinal fluid analysis into clinical decision making for patients with meningitis. Presentations: 8:30 a.m.

C2-1216 Clinical and Molecular Characterization of Carbapenemase-

Resistant K. pneumoniae (KPC) Strains from a Tertiary Center C. Clancy, MD - Associate Professor1, R. Shields, PharmD - Assistant Professor 2, J. Hong, MD - Fellow 2, L. Chen, PhD - Research Associate 3, Y. Zhao, PhD - Research Associate 3, B. N. Kreiswirth, PhD - Professor 3, S. Park, MD - Research Associate 3, D. S. Perlin, MD - Professor 3, Y. Doi, MD - Assistant Professor 2, E. Kwak, MD - Assistant Professor 2, F. Silveira, MD - Assistant Professor 1, W. Pasculle, PhD - Director Microbiology 2, M. Nguyen, MD Professor 2; 1Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA, 2Univ. of Pittsburgh, Pittsburgh, PA, 3Publ Hlth Res Ins, UMDNJ, Newark, NJ.

1220 State-of-the-Art Minilecture

Update on Neisseria meningitidis: Pathogenesis and Management Petter Brandtzag, MD, PhD - Professor Univ. of Oslo, Oslo, Norway. 9:00 a.m. L1-1221 Is CSF Lactate the Best Parameter for Discriminating

Bacterial from Viral Community-Acquired Meningitis? S. Giulieri, MD - Staff Physician, C. Chapuis, MD - Consultant, K. Jaton, PhD - Staff Microbiologist, J. Bille, MD - Professor, P. Meylan, MD Professor, O. Manuel, MD - Staff Physician, O. Marchetti, MD - Professor; Univ. of Lausanne, Lausanne, Switzerland.

Final Program

135

> Tuesday SCIENTIFIC SESSIONS 9:15 a.m.

8:45 a.m.

L1-1222 Listeria monocytogenes Meningitis: Implementation of

Adjunctive Dexamethasone Therapy and Risk Factors for Unfavorable Outcome

Aspergillosis (PIA)?

M. M. Koopmans, BS - Student, M. C. Brouwer, MD, PhD - Neurologist, A. van der Ende, PhD - Medical Microbiologist, D. van de Beek, MD, PhD Neurologist; Academic Med. Ctr., Amsterdam, The Netherlands.

K. Kyo, MD - Staff, T. Ochi, MD - Staff, T. Okatani, MD - Staff, M. Itagaki, MD - Staff, R. Imanaka, MD - Staff, Y. Katayama, MD - Staff, T. Kyo, MD - Chairman; Hiroshima Red Cross Atomic-Bomb Survivors Hosp., Hiroshima, Japan.

9:30 a.m.

9:00 a.m.

L1-1223 Delayed Cerebral Thrombosis in Bacterial Meningitis: A

M-1227 Invasive Aspergillosis -Associated Immune Reconstitution

Prospective Cohort Study

Syndrome in Lung Transplant Recipients

M. J. Lucas, MD - PhD student, M. C. Brouwer, MD, PhD - Neurologist, D. van de Beek, MD, PhD - Neurologist; Academic Med. Ctr., Amsterdam, The Netherlands.

Withdrawn

9:45 a.m.

9:15 a.m. M-1228 Environmental Variables Associated with an Increased Risk

of Invasive Aspergillosis

L1-1224 Acute Community-Acquired Meningitis in the ICU: Early

Treatment with Rifampicin is Associated with Lower Mortality C. Bretonnière, MD - Doctor1, M. Jozwiak, MD - Resident 1, C. Giraud, MD - Doctor 2, P. Beuret, MD - Doctor 3, J. Trouillet, MD - Professor 4, J. Teboul, MD - Professor 5, J. Caillon, PharmD - Doctor 1, G. Potel, MD Professor 6, D. Villers, MD - Professor 1, D. Boutoille, MD - Professor 1, C. Guitton, MD - Doctor 1; 1CHU, Nantes, France, 2CHU, Rouen, France, 3CH, Roanne, France, 4APHP-PSL, Paris, France, 5APHP-BCT, Bicêtre, France, 6 Faculté de Med., Nantes, France.

-----------------------------------------------------------------------159(M) Slide Session Mycology for the Bedside Tuesday, 8:30 a.m.–11:00 a.m. . . . . . . . . . . . . . . . . . . Room 122 UAN: 0391-9999-12-130-L04-P Moderators: Tania Sorrell, MB, BS, MD, FRACP - Professor Univ. of Sydney, Westmead, Australia. Raoul Herbrecht, MD - Professor Hosp. de Hautepierre, Strasbourg, France. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Identify specific aspects of clinical mycology; > Assess the impact of cost for fungal infections; > Discuss the epidemiology of fungal infections; and > Identify framing issues around guidelines and risk groups for fungal infections. Presentations: 8:30 a.m. M-1225 Application of the 2008 Definitions for Invasive Fungal

Diseases to the Voriconazole vs Amphotericin B for Therapy of Invasive Aspergillosis Trial: A Collaborative EORTC / MSG Study (MSG 05) R. Herbrecht, MD - Professor1, T. F. Patterson, MD - Professor 2, M. A. Slavin, MD - Professor 3, O. Marchetti, MD - Professor 4, J. Maertens, MD - Professor 5, H. T. Schlamm, MD - Medical Director 6, J. P. Donnelly, PhD - Professor 7, P. G. Pappas, MD - Professor 8; 1CHU, Strasbourg, France, 2UTHSC and STVHCS, San Antonio, TX, 3Peter MacCallum Cancer Ctr., Melbourne, Australia, 4 CHUV/Univ., Lausanne, Switzerland, 5UZ Gasthuisberg, K.U.Leuven, Leuven, Belgium, 6Pfizer, New York, NY, 7Radboud Univ Med Ctr, Nijmegen, Netherlands, 8Univ Alabama, Birmingham, AL.

136

M-1226 Is Halo Sign the Earliest Sign of Pulmonary Invasive

September 9-12 |

M. Labori, MD - Physician 1, C. Garcia-Vidal, PhD - Physician1, M. Peghin, MD - Physician 2, A. Moreno, PhD - Physician 3, I. Ruiz, PhD - Physician 2, C. Cervera, PhD - Physician 3, C. Gudiol, MD - Physician 1, E. Rossello, MD - Physician 2, J. Bellacasa, MD - Physician 3, J. Ayats, MD - Physician 1, P. Barba, MD - Physician 2, J. Carratalà, PhD - Professor 1; 1Hosp. Bellvitge, Barcelona, Spain, 2Hosp. VallHebron, Barcelona, Spain, 3Hosp. Clinic, Barcelona, Spain. 9:30 a.m. M-1229 Efficacy of Anidulafungin in 504 Patients with Invasive Can-

didiasis (IC) from a Pooled Clinical Trial Database B. Kullberg, MD - Professor of Medicine1, U. Conte, PharmD - Clinician 2, H. Schlamm, MD - Medical Development Lead 2, P. Biswas, PhD - Statistician 2, R. Swanson, PhD - Clinical Development Lead 2, M. Ruhnke, MD - Professor of Medicine 3; 1Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 2 Pfizer Inc., New York, NY, 3Charité Univ., Berlin, Germany. 9:45 a.m. M-1230 Cost-of-Illness Analysis of Candidemia in Patients on the

Intensive Care Unit S. Heimann, MS - Scientist, O. Cornely, Professor of Medicine - Scientist, H. Wisplinghoff, MD - Scientist, M. Vehreschild, MD - Scientist, B. Franke, data manager - Scientist, J. Glossmann, MD - Scientist, J. Vehreschild, MD Scientist; Univ. Hosp. of Cologne, Köln, Germany. 10:00 a.m. M-1231 Management Bundles for Invasive Candidiasis (IC): The

Impact of Compliance on Clinical Efficacy and Mortality Y. Takesue, MD - Professor1, S. Takakura, MD - Associate Professor 1, H. Mikamo, MD - Professor 1, S. Oda, MD - Professor 1, Y. Kitagawa, MD Professor 1, S. Kohno, MD - Professor 2; 1ACTION Project Committee, Tokyo, Japan, 2Mycoses Forum, Tokyo, Japan. 10:15 a.m. M-1232 Antifungal Stewardship: A Bedside Intervention Approach P. Muñoz, MD, PhD - ID Consultant, M. Valerio, MD - ID Consultant, B. Cáliz, PharmD - Pharmacist, C. Rodríguez, PharmD - Pharmacist, M. Sanjurjo, PharmD - Head of Pharmacy Dept, P. Escribano, PhD - Research, J. Guinea, PhD - Research, COMIC Study Group-PROMULGA, E. Reigadas, MD - Research, E. Bouza, MD, PhD - Head of Clin Microb and ID Dept; Hosp. Gen., Gregorio Marañón. Univ. of Madrid, Madrid, Spain.

TUESDAY SCIENTIFIC SESSIONS 10:30 a.m.

9:00 a.m.

M-1233 Longitudinal Clinical Findings and Outcome among

Cryptococcus gattii Patients in British Columbia P. Phillips, MD - Clinical Professor1, L. MacDougall, MSc - Epidemiologist 2, D. Thompson, PhD - Statistician 2, E. Galanis, MD - Assistant Professor, Epidemiologist 2,3; 1St. Paul’s Hosp., Univ. of British Columbia, Vancouver, Canada, 2British Columbia Ctr. for Disease Control, Vancouver, Canada, 3 Univ. of British Columbia, Vancouver, Canada. 10:45 a.m. M-1234 The Outcome of Invasive Fusariosis Has Improved in the

Last Decade M. Nucci, MD - Associate Professor1, M. Vehreschild, MD - Professor 2, E. Velasco, MD - Clinician 3, F. Queiroz-Telles, MD - Associate Professor 4, B. Simoes, MD - Associate Professor 5, C. A. Souza, MD - Professor of Medicine 6, S. Cesaro, MD - Professor 7, N. Hamerschlak, MD - Clinician 8, O. Cornely, MD - Professor 2, E. Anaissie, MD - Professor of Medicine 9; 1Federal Univ. of Rio de Janeiro, Rio de Janeiro, Brazil, 2Univ. Hosp. Cologne, Cologne, Germany, 3Natl. Cancer Inst., Rio de Janeiro, Brazil, 4Federal Univ. of Parana, Curitiba, Brazil, 5Univ. of Sao Paulo, Ribeirao Preto, Brazil, 6State Univ. of Campinas, Campinas, Brazil, 7Azienda Ospedaliera Univ. Integrata, Verona, Italy, 8Hosp. Albert Einstein, Sao Paulo, Brazil, 9Univ. of Arkansas for Med. Sci., Little Rock, AR.

-----------------------------------------------------------------------160(V) Slide Session Hepatitis and Herpes Viruses Tuesday, 8:30 a.m.–11:00 a.m. . . . . . . . . . . . . . . . . . . Room 254 UAN: 0391-9999-12-131-L04-P

Variants with Primary Resistance to the Direct-Acting Antivirals (DAA): Analysis of 722 Complete Genome Sequences and 307 NS3/4A and NS5B Partial Sequences M. B. Kolarovic, Junior, Assitant - School of Medicine, A. E. Farinati, Sr., MD - School of Medicine; Salvador Univ., Buenos Aires, Argentina. 9:15 a.m. V-1238 Seroepidemiology of Hepatitis E Virus Infection Among

Men Who Have Sex with Men in Taiwan W. Liu, MS - Research Assistant1, C. Lu, MD - Attending Physician 2, Z. Yang, MS - Student 3, S. Chang, DSc - Associate Professor 3, C. Hung, MD, MSc, PhD - Associate Professor 1, P. Chen, MD, PhD - Professor 1; 1Natl. Taiwan Univ. Hosp., Taipei, Taiwan, 2Natl. Taiwan Univ. Hosp. Hsin-Chu Branch, Hsin-Chun, Taiwan, 3Natl. Taiwan Univ. Coll. of Med., Taipei, Taiwan. 9:30 a.m. V-1239 Comparison of Central Nervous System Infection in Herpes

Simplex Virus Type 1 and Herpes Simplex Virus Type 2: the Clinical Manifestations and Cerebrospinal Fluid Findings S. Moon, MD - ID Fellow1,2, Y. Lee, MD - ID Fellow 1, H. Hong, MD ID Fellow 1, S. Park, MD - ID Fellow 1, S. Park, MD - Professor 3, K. Park, MD - Professor 1, Y. Chong, MD - Professor 1, S. Kim, MD - Professor 1, H. Sung, MD - Professor 1, S. Lee, MD - Professor 1, Y. Kim, MD - Professor 1, J. Woo, MD - Professor 1, S. Choi, MD - Professor 1; 1Asan Med. Ctr., Univ. of Ulsan Coll. of Med., Seoul, Korea, Republic of, 2Graduate Sch. of Kyung Hee Univ., Seoul, Korea, Republic of, 3Dongguk Univ. Ilsan Hosp., Goyang, Korea, Republic of. 9:45 a.m. V-1240 Varicella-Zoster Meningoencephalitis: 16 Years of Experience

Moderators: Paul D. Griffiths, MD, DSc - Professor Univ. Coll. Sch. of Med., London, United Kingdom. Vincent R. Racaniello, PhD - Professor Columbia Univ. Coll. of Physicians & Surgeons, New York, NY.

in the Era of PCR

Objectives: Upon the completion of this Slide Session, the participant should be able to: > Evaluate prospects for CMV vaccine; > Review new treatments for Hepatitis; and > Describe epidemiology and clinical presentation of herpes virus infections. Presentations: 8:30 a.m. 1235 State-of-the-Art Minilecture

CMV Vaccine: Is there a Future?

I. Pelegrin, MD - Fellow, I. Oriol, MS - Intern, J. Niubó, PhD - consultant, S. Martinez-Yelamos, PhD - Consultant, J. Ariza, PhD - Professor, P. FViladrich, PhD - Professor, C. Cabellos, PhD - Consultant; Hosp. Universitari de Bellvitge, Barcelona, Spain. 10:00 a.m. V-1241 Age-Specific Epstein-Barr Virus (EBV) Antibody (Ab)

Prevalence and Risk Factors for Early Acquisition of Infection L. M. Condon, MD - Attending Pediatrician1, M. D. Rabinovitch, MD Attending Pediatrician 1, L. E. Cederberg, MD - Attending Pediatrician 1, R. V. Liebo, MD - Attending Pediatrician 1, A. S. Delaney, MPH - Research Assistant 2, H. H. Balfour, jr, MD - Professor 2; 1HealthPartners, Minneapolis-St Paul, MN, 2Univ. of Minnesota, Minneapolis, MN. 10:15 a.m.

Paul D. Griffiths, MD, DSc Univ. Coll. London, London, United Kingdom.

V-1242 Diabetic Critical Patients Have a Higher Risk of Cytomega-

V-1236 Triple Therapy with TMC435, Peginterferon and Ribavirin in

HCV Genotype 1 Infected Treatment Experienced Patients: The ASPIRE Trial Withdrawn

V-1237 Prevalence of Naturally Occurring Hepatitis C Virus (HCV)

lovirus Disease P. López Roa, PharmD - Research Assistant1, M. Gónzalez del Vecchio, MD - Research Assistant 1, P. Muñoz, PhD - Professor 2, B. Padilla, MD - Research Assistant 1, P. Catalán, PharmD - Research Assistant 1, E. Bouza, PhD - Professor 1; 1Hosp. Gen. Univ. Gregorio Marañon. Univ. of Madrid., Madrid, Spain, 2 Hosp. Gen. Univ. Gregorio, Madrid, Spain.

Final Program

137

> Tuesday SCIENTIFIC SESSIONS -----------------------------------------------------------------------------------------------------------------------------------------------------POSTER WALK Tuesday, September 11 | 11:15 a.m. - 12:15 p.m. | Halls A-C

Tuesday, September 11 | 12:15 p.m. - 1:15 p.m. | Halls A-C

New Developments in Transplantation

Fungal Infections at the Bedside

Convener: Emily A. Blumberg, MD - Professor of Medicine Perelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA. Presentations:

Refractory KPC Carbapenemase-Producing Klebsiella pneumoniae Bacteremia is Tolerated by Solid Organ Transplant Patients (SOT Pts) C. Clancy; Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA.

Chronic High EBV Load Carriage Has Low Predictive Value to Detect Post-Transplant Lymphoproliferative Disorder (PTLD) in Solid-Organ Transplant Recipients C. Gardiol; Univ. Hosp. Ctr. of Lausanne, Lausanne, Switzerland.

Risk Factors and Outcomes of Bacteremia Caused by DrugResistant ESKAPE Pathogens in Solid Organ Transplant (SOT) Recipients M. Bodro; IDIBELL Biomedical Res. Inst., Hosp.Llobregat. Barcelona, Spain.

Presentations:

The Clinical Course Following the Use of Corticosteroids for Symptomatic Relief of Primary Pulmonary Coccidioidomycosis in Immunocompetent Persons N. Azadeh; Mayo Clinic Arizona, Phoenix, AZ.

Effectiveness of Posaconazole Vs Fluconazole as Antifungal Prophylaxis in Hematology-Oncology Patients at Duke University Hospital (DUH) 2004-2010 H. C. Kung; Duke Clinical Res. Inst., Durham, NC.

Pilot Prospective Study of High Dose (10 mg/kg/d) Liposomal Amphotericin B (L-AmB) for the Initial Treatment of Mucormycosis: “AMBIZYGO” Trial F. Lanternier; Hosp. Necker Enfants malades, Paris, France; Inst. Pasteur, Paris, France.

The Molecular Epidemiology of a Respiratory Syncytial Virus Outbreak Among Oncology and Hematopoietic Stem Cell Transplant (HSCT) Patients

Systemic Candidiasis Increased Mortality in ICU Infected Patients with Cirrhosis

H. Y. Chu; Univ. of Washington, Seattle, WA.

H. Dupont; Pole d’Anesthesie-Reanimation, CHU d’Amiens, Amiens, France.

Diagnosis of Invasive Aspergillosis and Mucormycosis guided by PCR Assays from Bronchoalveolar Lavage Fluid in Allogenic Stem Cell Recipients H. Lellek; Univ. Hosp. Hamburg-Eppendorf, Hamburg, Germany.


-----------------------------------------------------------------------161(A) Poster Session Clinical Pharmacology of Antiviral and Anti-Tuberculosis Agents Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-1243 Pharmacokinetic/Pharmacodynamic Model for Neuramini-

dase Inhibitor Oseltamivir in the Ferret K. Yang1,2, G. Rao 1,2, M. Reddy2, C. Pamulapati 2, B. M. Marathe 3, E. A. Govorkova3, C. R. Rayner 2, A. Forrest 1; 1SUNY Buffalo, Buffalo, NY, 2 Roche, Nutley, NJ, 3St. Jude Children’s Res. Hosp., Memphis, TN. A-1244 Population Pharmacokinetics (PPK) of Oseltamivir in Pedi-

atric and Adult Subjects M. A. Kamal1, S. A. Van Wart 2, C. R. Rayner 1, V. Subramoney 1, D. K. Reynolds 2, C. C. Bulik 2, P. F. Smith 1, S. M. Bhavnani 2, A. Forrest 2; 1 Hoffman-LaRoche, Nutley, NJ, 2ICPD, Latham, NY.

138

Convener: John Perfect, MD - Interim Chief, Division of Infectious Diseases and International Health Duke Univ. Med. Ctr., Durham, NC.

September 9-12 |

The Tolerability of Amphotericin B Lipid Complex Formulation in Patients With Severe Infusion Reactions to Liposomal Amphotericin B D. Farmakiotis; MD Anderson Cancer Ctr., Houston, TX.

A-1245 A Prospective, Open-Label Study of the Pharmacokinetics,

Safety and Pharmacodynamics of Oseltamivir in Infants Tuesday SCIENTIFIC SESSIONS A-1264 PK and Bactericidal Activity in Sputum and Blood of PNU-

100480 (Sutezolid, U-480) and its Major Metabolite (PNU101603, U-603) in Patients with Pulmonary TB R. S. Wallis1, S. O. Friedrich 2, A. H. Diacon 2, R. Dawson3, A. Venter 2, D. Paige 1, T. Zhu 1, A. Silvia 1, J. Gobey 1, C. Ellery 1, Y. Zhang 1; 1Pfizer, Groton, CT, 2Stellenbosch Univ., Stellenbosch, South Africa, 3Univ. Cape Town, Cape Town, South Africa. A-1265 Pharmacodynamics of PNU-100480 (U, Sutezolid), a New

Oxazolidinone, in Combination with its Active Metabolite in the Killing of Mycobacterium tuberculosis (Mtb) in an In Vitro Hollow Fiber Infection Model (HFIM) A. Louie, D. Brown, K. Files, M. Swift, S. Fikes, G. Drusano; Univ. of Florida, Orlando, FL. A-1266 A New Mathematical Model for Anti-Infective Pharma-

(PK/PD) of GSK2251052 (GSK052) against Gram-Negative Bacilli (GNB) Using Data from a Neutropenic MurinePneumonia Infection Model D. R. Andes1, O. O. Okusanya 2, C. C. Bulik 2, A. Lepak 1, S. M. Bhavnani 2, A. Forrest 2, J. L. Hoover 3, P. G. Ambrose 2; 1Univ. of Wisconsin, Madison, WI, 2ICPD, Latham, NY, 3GlaxoSmithKline, Collegeville, PA. A-1272 Pharmacokinetics and Safety of Oral GSK2251052, a Novel,

Boron-Containing Antimicrobial, in Healthy Subjects E. Dumont1, D. Tenero1, M. Barton 1, J. Bianco 2, S. Shakib 3, M. Kurtinecz 1, P. Patel 4, J. Tomayko 1; 1GlaxoSmithKline, Philadelphia, PA, 2GlaxoSmithKline, Abbotsford, Australia, 3CMAX, Adelaide, Australia, 4GlaxoSmithKline, RTP, NC. A-1273 Cadazolid, a Novel Antibiotic with Potent Activity against

cokinetics/Pharmacodynamics (PK/PD) which Accommodates Random Mutations

Clostridium difficile: Safety, Tolerability, and Pharmacokinetics in Healthy Subjects following Single and Multiple Oral Doses

A. Forrest1,2, O. O. Okusanya 1,2, J. B. Bulitta 3; 1SUNY Sch. of Pharmacy, Buffalo, NY, 2ICPD, Latham, NY, 3Monash Univ., Melbourne, Australia.

D. Baldoni1, M. Gutierrez1, J. Dingemanse1, W. Timmer2; 1Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, 2Clinical Res. Services Mannheim GmbH, Mannheim, Germany.

A-1267 Tissue Distribution and Macrophages Uptake for Novel

Spectinamide Drug Candidates against Tuberculosis

A-1274 Mutant Prevention Concentration of Fidaxomicin for

A. Trivedi1, D. Madhura 1, J. Liu 2, K. Kromke 1, C. Rathi 1, V. Loveless 1, R. E. Lee 2, B. Meibohm1; 1Univ. of Tennessee Hlth. Sci. Ctr., Memphis, TN, 2 St. Jude Children’s Res. Hosp., Memphis, TN.

A-1275 Pharmacokinetics/Pharmacodynamics (PK/PD) of Peptide

A-1268 Increasing Rifampicin Dosage in the Treatment of Murine

Tuberculosis Allows Reduction of Therapy Duration G. J. de Knegt1, R. E. Aarnoutse 2, M. T. Ten Kate 1, M. J. Boeree 2, D. van Soolingen3, I. A. Bakker-Woudenberg1, J. E. M. de Steenwinkel 1; 1Erasmus Univ. Med. Ctr., Rotterdam, Netherlands, 2Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 3Natl. Inst. of Publ. Hlth. and the Environment, Bilthoven, Netherlands. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------162(A) Poster Session Clinical Pharmacology of Novel Anti-Infective Agents Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-1269 Population Pharmacokinetic (PPK) and Pharmacokinetic/

Pharmacodynamic (PK/PD) Target Attainment (TA) Analyses for Solithromycin (SOL, CEM-101) to Support Intravenous (IV) Dose Selection in Patients with Community-Acquired Bacterial Pneumonia (CABP) O. O. Okusanya1, S. M. Bhavnani 1, A. Forrest 1, C. C. Bulik1, D. Oldach 2, P. Fernandes2, P. G. Ambrose 1; 1ICPD, Latham, NY, 2Cempra Pharmaceuticals, Chapel Hill, NC. A-1270 Evaluation of the Pharmacokinetics/Pharmacodynamics

(PK/PD) of GSK2251052 (GSK052) against Gram-Negative Bacilli (GNB) in a Murine-Thigh Infection Model C. C. Bulik1, O. O. Okusanya 1, S. M. Bhavnani 1, A. Lepak 2, A. Forrest 1, P. G. Ambrose1, J. L. Hoover 3, D. R. Andes 2; 1ICPD, Latham, NY, 2Univ. of Wisconsin, Madison, WI, 3GlaxoSmithKline, Collegeville, PA.

140

A-1271 Evaluation of the Pharmacokinetics/Pharmacodynamics

September 9-12 |

Clostridium difficile J. Seddon, F. Babakhani, P. Sears; Optimer Pharmaceuticals, San Diego, CA.

Deformylase (PDF) Inhibitor GSK1322322 (GSK322) against Streptococcus pneumoniae in a Mouse Pneumonia Model J. L. Hoover, R. J. Straub, S. J. Novick, O. J. Naderer, S. Rittenhouse; GlaxoSmithKline, Collegeville, PA. A-1276 Intravenous (IV) First Time in Human Safety and Phar-

macokinetics of GSK1322322 (GSK322), a Peptide Deformylase Inhibitor Antibacterial O. J. Naderer1, L. S. Jones 1, J. Z. Zhu 2, M. Kurtinecz 3, E. F. Dumont 3; 1 GlaxoSmithKline, Research Triangle Park, NC, 2GlaxoSmithKline, Upper Merion, PA, 3GlaxoSmithKline, Upper Providence, PA. A-1277 Penetration of GSK1322322 (GSK322) into Epithelial Lining

Fluid (ELF) and Alveolar Macrophages (AM) as Determined by Bronchoalveolar Lavage (BAL) O. J. Naderer1, K. A. Rodvold 2, L. S. Jones 1, J. Z. Zhu 3, E. F. Dumont 4; 1 GlaxoSmithKline, Research Triangle Park, NC, 2Univ. of Illinois at Chicago, IL, 3GlaxoSmithKline, Upper Merion, PA, 4GlaxoSmithKline, Upper Providence, PA. A-1278 The Monoclonal Antibody Panobacumab (KBPA101)

Improves Pseudomonas aeruginosa (PA) Opsonophagocytosis by THP-1 Monocytes H. Jacqmin, J. Buyck, P. M. Tulkens, F. Van Bambeke; Univ. Catholique de Louvain, Bruxelles, Belgium. A-1279 Optimizing Fosfomycin Dosing for Treatment of Pseudo-

monas aeruginosa Infections in Critically-Ill Patients Based on Pharmacokinetics/Pharmacodynamics (PK/PD) Target O. Asuphon1, P. Montakantikul2, J. Haungsaitong 2, P. Sonthisombat1, P. Kiratisin3; 1Naresaun Univ., Pitsanulok, Thailand, 2Mahidol Univ., Bangkok, Thailand, 3Siriraj Hosp., Mahidol Univ., Bangkok, Thailand.

TUESDAY SCIENTIFIC SESSIONS A-1280 Tigecycline and Enterobacter Invasive Infections: PK/PD

A-1289 Radezolid Demonstrates Favorable Safety Compared to

Parameters Using Monte Carlo Simulation

Linezolid in a Three-Month Rat Toxicology Study

J. Lepe1, C. Martín-Gandul 1, J. Rodríguez-Martínez2, O. Gasch3, C. Ruiz de Alegría4, R. Lara5, C. Fernández-Mazarrasa4, F. Tubau3, F. Rodríguez-López5, L. Martínez-Martínez4, M. Jiménez-Mejías1; 1Univ. Hosp. Virgen del Rocío, Sevilla, Spain, 2Univ. Hosp. Virgen Macarena, Sevilla, Spain, 3Univ. Hosp. Bellvitge, Barcelona, Spain, 4Univ. Hosp. Marqués de Valdecillas, Santander, Spain, 5Univ. Hosp. Reina Sofía, Córdoba, Spain.

C. Moore1, H. Dedhia 1, E. Duffy 2, J. Longcor 2, E. Burak 2, E. Bortolon 2, D. Molstad 2, Y. Wu 2, H. Jing 2, D. Li 2, R. Hanselmann2, M. Reeve 2, A. Marra2; 1 Covance Lab., Chandler, AZ, 2Rib-X Pharmaceuticals, New Haven, CT.

A-1281 Pharmacokinetics of [14c]-Labeled Omadacycline (PTK

0796) in Healthy Male Subjects H. Sun 1, L. Ting1, J. Flarakos1, K. Dole 1, J. Praestgaard 1, S. J. Kovacs1, D. S. Stein 1, G. Sunkara1, S. K. Tanaka2; 1Novartis, East Hanover, NJ, 2Paratek Pharmaceuticals, Boston, MA. A-1282 Pharmacokinetics of Omadacycline (PTK 0796) in Subjects

with Hepatic Impairment L. Ting1, S. J. Kovacs1, J. Praestgaard1, R. Maietta 2, D. S. Stein1, G. Sunkara1, M. P. Draper3, H. Sun 1; 1NIBR, Novartis Pharmaceuticals, East Hanover, NJ, 2NIBR, Novartis Pharmaceuticals, Cambridge, MA, 3Paratek Pharamaceuticals, Boston, MA. A-1283 Pharmacokinetics and Safety of Morinidazole in Patients

with Moderate Impaired Hepatic Function Compared with Healthy Volunteers X. Wu, Z. Chen, J. Wu, G. Cao, J. Yu, Bachelor, Y. Shi, Y. Zhang, J. Zhang; Inst. of Antibiotics, Huashan Hosp., Fudan Univ., Shanghai, China. A-1284 Metabolism and Excretion of PMX-30063: A Novel Class of

Antibiotics B. Korczak, D. Liu, R. Scott; Polymedix, Radnor, PA. A-1285 Urinary Antibacterial Activity of BAL30072 against Uro-

pathogens After IV Administration

Dose Study of Safety, and Pharmacokinetics (PK) of Radezolid (RDZ) in Healthy Subjects L. E. Lawrence1, A. Marra1, J. Longcor 1, R. Hoover 1, M. Benedict 2, C. Smith 2, Y. Cai 2, M. Medlock 2; 1Rib-X Pharmaceuticals Inc., New Haven, CT, 2PPD, Wilmington, NC. A-1291 Study of the Cellular Uptake and Subcellular Distribution

of the Oxazolidinone Tedizolid (TZD) in Murine J774 Macrophages: Lack of Association with Mitochondria D. Das, A. Lambert, G. Muccioli, P. M. Tulkens, F. Van Bambeke; Univ. Catholique de Louvain, Bruxelles, Belgium. A-1292 Safety and Pharmacokinetics after Single Oral and IV Ad-

ministration of Tedizolid Phosphate in Adolescent Patients K. A. Muñoz 1, H. Dreskin1, J. Bradley 2, A. Arrieta3, E. Capparelli 2, R. Jacobs4, S. L. Minassian 1, E. Fang 1, P. Prokocimer 1, S. Flanagan 1; 1Trius Therapeutics, Inc., San Diego, CA, 2UCSD, San Diego, CA, 3CHOC, Orange, CA, 4ACH, Little Rock, AR. A-1293 Safety and Pharmacokinetics of Single Oral Administration

of Tedizolid Phosphate in Healthy Elderly Subjects and Adult Control Subjects H. J. Dreskin1, K. Muñoz 1, E. Fang. 1, S. L. Minassian 1, D. Subich 2, S. Flanagan1, P. Prokocimer 1; 1Trius Therapeutics, Inc., San Diego, CA, 2Covance, Inc., Orlando, FL. A-1294 A Phase 1 Study of Intravenously Administered Tedizolid

F. M. E. Wagenlehner1, B. Blenk2, C. Wagenlehner 1, H. Blenk2, K. G. Naber3; 1Justus Liebig Univ., Giessen, Germany, 2Eukarion Inst., Nuernberg, Germany, 3Tech. Univ., Munich, Germany. A-1286 Systemic Safety Profile of Solithromycin in Phase 1 & 2

Clinical Trials D. Oldach, B. Jamieson, K. Clark, K. Keedy, P. Fernandes; Cempra, Inc., Chapel Hill, NC.

-----------------------------------------------------------------------163(A) Poster Session Pharmacokinetics/Pharmacodynamics of New and Old Oxazolidinones Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-1287 Pharmacokinetics (PK) of Intravenous (IV) Linezolid (LZD)

Phosphate in Subjects with Advanced Renal Impairment S. Flanagan1, D. Morris2, T. Boyea 1, H. Dreskin 1, S. L. Minassian 1, H. Alcorn, Jr 3, T. Marbury 4, M. Abdelhameed 2, E. Fang 1, P. Prokocimer 1; 1 Trius, San Diego, CA, 2Covance, Madison, WI, 3DaVita, Minneapolis, MN, 4 Orlando Clinical Res. Ctr., Orlando, FL. A-1295 A Phase 1 Study of Orally Administered Tedizolid Phosphate

in Subjects with Moderate or Severe Hepatic Impairment T. Boyea 1, H. Dreskin 1, S. L. Minassian 1, T. C. Marbury 2, H. J. Alcorn, Jr 3, E. Fang 1, P. Prokocimer1, S. Flanagan1; 1Trius Therapeutics, San Diego, CA, 2 Orlando Clinical Res. Ctr., Orlando, FL, 3DaVita Clinical Res., Minneapolis, MN. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------164(B) Poster Session Antimicrobial Therapy in Animal Models II Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C

in Moderately to Morbidly Obese Adults A. A. Bhalodi, P. K. Papasavas, D. S. Tishler, D. P. Nicolau, J. L. Kuti; Ctr. for Anti-Infect. Res. & Dev., Hartford Hosp., Hartford, CT. A-1288 Clinical Pharmacokinetic/Pharmacodynamic Profile of

Linezolid in Multidrug Resistant Gram Positive Infections H. Mikamo, Y. Yamagishi; Aichi Med. Univ., Aichi, Japan.

A-1290 A Phase 1, Single and Multiple Ascending Intravenous (IV)

Presentations: B-1296 Insights into the Activity of Pyrazinamide in Immune-Com-

petent and Immune-Deficient Murine Models of Tuberculosis D. V. Almeida1,2, P. Converse1, S. Tyagi1, S. Li1, N. Ammerman1,2, K. Wallengren 2, J. Grosset 1,2, W. Bishai 1,2; 1Johns Hopkins Univ., Baltimore, 2 K-RITH, Univ. of KwaZulu-Natal, Durban, South Africa.

Final Program

141

> Tuesday SCIENTIFIC SESSIONS B-1297 Effects of Recombinant Thrombomodulin in Combination

with Antibiotics on a Murine Legionella Pneumonia Model Y. Morinaga, K. Yanagihara, N. Kaku, Y. Migiyama, Y. Harada, K. Nagaoka, K. Yamada, K. Izumikawa, H. Kakeya, Y. Yamamoto, S. Kohno; Nagasaki Univ., Nagasaki, Japan. B-1298 Efficacy of Combination Therapy with Ciprofloxacin Plus

Cefotaxime against Vibrio vulnificus Sepsis in Mice H. Jang, S. Jung, K. Park, J. Shin, S. Kang; Chonnam Natl. Univ. Coll. of Med., Gwang-Ju, Korea, Republic of. B-1299 Activity of Telavancin in Combination with Colistin in a

Galleria mellonella Model of Acinetobacter baumannii Infection M. Horsney1, L. Phee 1, C. Longshaw2, D. Wareham 1; 1QMUL, London, United Kingdom, 2Astellas Europe, London, United Kingdom. B-1300 Activity of Tigecycline Combinations in Experimental

B-1308 GSK2251052, a Novel LeuRS Inhibitor, is Effective against

Multidrug-Resistant Pseudomonas aeruginosa in a Mouse Pneumonia Model J. L. Hoover, C. Mininger, S. Rittenhouse; GlaxoSmithKline, Collegeville, PA. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------165(B) Poster Session Microbial Determinants of Virulence Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: B-1309 Sequence Analysis of RepMP4 and RepMP2/3 Elements

Infections Caused by Nine KPC-Producing Enterobacteriaceae Clinical Isolates

of Mycoplasma pneumoniae P1 Gene During Four Outbreaks Between 2000 and 2011

G. Michail1, M. Labrou1, S. Manousaka1, A. Tsakris2, S. Pournaras1; 1Med. Sch., Univ. of Thessaly, Larissa, Greece, 2Med. Sch., Univ. of Athens, Athens, Greece.

J. Lee1, N. Yang2, K. Hong2, E. Choi3, H. Lee3; 1Kangwon Natl. Univ. Hosp., Chuncheon, Korea, Republic of, 2Seoul Natl. Univ. Children’s Hosp., Seoul, Korea, Republic of, 3Coll. of Med., Seoul Natl. Univ., Seoul, Korea, Republic of.

B-1301 Efficacy of Solithromycin for Treatment of Experimental

Syphilis Infection B. J. Molini, L. C. Tantalo, S. L. Brandt, S. K. Sahi, C. M. Marra, S. A. Lukehart; Univ. of Washington, Seattle, WA. B-1302 Efficacy of Plazomicin against Yersinia pestis in a Murine-

Aerosol Challenge Late-Treatment Model

B-1310 Identification of Mycobacterium avium ssp hominissuis (MAH)

Genes Related to the Formation of Microaggregates as Putative Targets for Prevention of Lung Infection L. Babrak, L. Bermudez; Oregon State Univ., Corvallis, OR. B-1311 Streptococcus pyogenes Protease, SpyCEP, Interrupts CXC

H. S. Heine1, L. Chuvala1, R. Riggins1, G. Hurteau1, R. Cass2, R. Cirz 2; 1 Univ. of Florida, Gainesville, FL, 2Achaogen Inc., San Francisco, CA.

Neutrophil Chemoattractant Signalling by Preventing CXCR1/2 Receptor Binding

B-1303 In Vitro and In Vivo Activity of Modithromycin (EDP-420)

J. Goldblatt, E. Wise, J. Viney, N. Lynskey, C. Turner, R. Edwards, J. Pease, S. Sriskandan; Imperial, London, United Kingdom.

against Neisseria gonorrhoeae X. Luo1, L. T. Phan1, O. Jones-Nelson2, M. Pilligua-Lucas2, D. J. J. Simon 2, A. E. Jerse2, Y. S. Or1; 1ENANTA Pharmaceuticals, Inc., Watertown, MA, 2 Uniformed Services Univ., Bethesda. B-1304 Efficacy of a Novel Mechanism Antibacterial GSK2251052

against Yersinia pestis in a Post-Exposure Prophylaxis MurineAerosol Challenge Model H. S. Heine1, L. Chuvala1, R. Riggins1, G. Hurteau1, C. Jakielaszek2; 1Univ. Florida, Gainesville, FL, 2GlaxoSmithKline, Collegeville, PA. B-1305 Colonization Characteristics of Quinolone-Resistant Esch-

erichia coli in the Faecal Microbiota of Healthy Volunteers V. de Lastours1, A. Bleibtreu2, F. Chau1, E. Denamur2, B. Fantin3; 1EA3964 Univ. Paris Diderot, Sorbonne Paris Cité, Paris, France, 2UMR U772 Univ. Paris Diderot, Sorbonne Paris Cité, Paris, France, 3EA3964 Univ. Paris Diderot, Sorbonne Paris Cité, Paris, France. B-1306 Clinical Impact of Aac(6’)-Ib-cr on Ciprofloxacin Treatment

in a Murine Model of Escherichia coli Pyelonephritis T. Guillard1, E. Cambau1, F. Chau1, C. de Champs2, B. Fantin1; 1Univ Paris Diderot-Paris 7, Paris, France, 2SFR CAP-Santé , URCA, Reims, France. B-1307 Mediation of the Development of Periodontitis by Amino-

guanidine P. Chang, Chang, L. Chong, S. Tsai; Natl. Univ. of Singapore, Singapore, Singapore.

142

September 9-12 |

B-1312 Toward a Functional Classification of Group A Streptococcus

M Protein P. R. Smeesters1,2,3, K. Sriprakash3, P. Dreze 1, T. Vu, 3, D. Bessen4, J. Guglielmini 5, A. Steer 2, J. Carapetis6, L. Van Melderen1, D. McMillan 3, M Protein Study Group; 1Univ. Libre de Bruxelles, Charleroi, Belgium, 2Murdoch Children Res. Inst., Melbourne, Australia, 3Queensland Inst. for Med. Res., Brisbane, Australia, 4New York Med. Coll., New-York, NY, 5Inst. Pasteur, Paris, France, 6Menzies Sch. of Hlth. Res., Darwin, Australia. B-1313 A Framework for Streptococcal Superantigen Nomenclature

and Disease Association R. Commons1, P. R. Smeesters2, N. Curtis 3; 1Royal Darwin Hosp., Northern Territory, Australia, 2Murdoch Children’s Res. Inst., Parkville, Australia, 3The Univ. of Melbourne and Murdoch Children’s Res. Inst., Royal Children’s Hosp. Melbourne, Parkville, Australia. B-1314 Genomic Comparison of Streptococcus mitis and Streptococcus

pneumoniae A. M. Mitchell1, A. Smith2, T. J. Mitchell1; 1Univ. of Birmingham, Birmingham, United Kingdom, 2Univ. of Glasgow, Glasgow, United Kingdom. B-1315 Comparison of Bengal Bay Clone ST772 with Bovine

Staphylococcus aureus Isolates from India G. Arakere1, B. Chakrakodi1, S. Prabhakara1, S. Isloor2, N. Hegde,3; 1Society for Innovation and Dev., Bangalore, India, 2Vet. Coll., Bangalore, India, 3Ella Fndn., Hyderabad, India.

TUESDAY SCIENTIFIC SESSIONS B-1316 Potential New Staphylococcal Chromosome Cassette (SCC)

and New LPXTG-Surface Protein Associated with the Transfer of Human Staphylococcus aureus CC8 to Cattle G. Resch1, M. Stojanov 1, O. Sakwinska 2, P. Moreillon1; 1Univ. of Lausanne, Lausanne, Switzerland, 2Nestlé Res. Ctr., Lausanne, Switzerland. B-1317 Alpha-Toxin Expression in Methicillin-Resistant Staphylococ-

B-1326 Comparative Virulence of KPC (+) and KPC (-) Klebsiella

pneumoniae in a Galleria mellonella Model M. Griffith1,2, M. Advincula1, M. Malczynski 2, G. Barajas 2, C. Qi2,3, M. Scheetz1,2; 1Midwestern Univ., Downers Grove, IL, 2Northwestern Mem. Hosp., Chicago, IL, 3Northwestern Univ., Chicago, IL. B-1327 Relationship Between Resistance Mechanisms and Potential

cus aureus (MRSA) is Not Associated with Cytotoxicity Following Invasion of Human Osteoblasts by MRSA

Virulence in Acinetobacter spp. Strains Using the Caenorhabditis elegans Model

J. Ranfaing 1, J. P. Rasigade2,1, S. Trouillet 1, J. Etienne2,1, F. Vandenesch2,1, F. Laurent2,1; 1Inserm U851, Lyon, France, 2Hospices Civils de Lyon, Lyon, France.

P. Espinal1,2, A. Pantel 2, J. Lavigne2, J. Vila1; 1Univ. of Barcelona Hosp. Clinic, Barcelona, Spain, 2INSERM, U1047, Montpellier 1 Univ., Nimes, France.

B-1318 Staphylococcus aureus Biofilm Formation Depends on MLST

Lineage in Bone and Joint Infections G. G. Aubin.1,2, C. Lasserre1,2, N. Caroff 2, D. Lepelletier 1,2, A. Reynaud1,2, J. Lavigne3, S. Corvec1; 1Nantes Univ. Hosp., Nantes, France, 2Med. Sch., Nantes, France, 3Montpellier Univ., Nîmes, France. B-1319 Intra-Osteoblastic Persistence of Methicillin-Susceptible

Staphylococcus aureus (MSSA): An Adaptative Mechanism of Bone and Joint Infections (BJI) Chronicity F. Valour, J. Rasigade, S. Trouillet, J. Gagnaire, A. Bouaziz, M. Bès, H. Meugnier, S. Lustig, F. Vandenesch, T. Ferry, F. Laurent; Hospices Civils de Lyon - INSERM U851, Lyon, France. B-1320 Increased Likelihood of Infective Endocarditis in Humans

but Attenuated Virulence of Clonal Complex 30 Genotype in Staphylococcus aureus is Associated with Distinct Genomic Architecture of its Genome B. K. Sharma-Kuinkel1, V. G. Fowler, Jr.1, S. Ahn1, T. H. Rude1, E. F. Mongodin 2, S. R. Gill3; 1Duke Univ., Durham, NC, 2Univ. of Maryland Sch. of Med. - IGS, Baltimore, 3Univ. of Rochester Sch. of Med. and Dentistry, Rochester, NY. B-1321 Antibiotic Resistance Due to Target Gene Mutations Affect-

ing Virulence in Klebsiella pneumoniae Y. Tsai, L. Siu; Natl. Inst. of Infectious Diseases and Vaccinology, Natl. Hlth. Res. Inst., Miaoli, Taiwan. B-1322 Pertussis Fimbrial Proteins Mediate Adherence to Primary

Human Airway Epithelial Cells: A Model to Study B. pertussis Fimbriae Adherence 1

1

1

1

2

C. P. Guevara , T. Starner , P. B. McCray, Jr , J. Zabner , F. R. Mooi , D. P. Greenberg 3, M. D. Decker4, O. G. Gomez-Duarte4; 1Univ. of Iowa Coll. of Med., Iowa City, IA, 2Ctr. for Infectious Disease Control, Bilthoven, Netherlands, 3Univ. of Pittsburgh Sch. of Med., Pittsburgh, PA, 4Vanderbilt Univ. Sch. of Med., Nashville, TN. B-1323 Delineating the Magnitude of Virulence in KPC (+) Organ-

isms M. Griffith1,2, M. Malczynski 2, G. Barajas 2, C. Qi2,3, M. Scheetz1,2; 1Midwestern Univ., Downers Grove, IL, 2Northwestern Mem. Hosp., Chicago, IL, 3 Northwestern Univ., Chicago, IL. B-1324 Sodium Salicylate Inhibited Hyper-Mucosity of Klebsiellae

Pneumoniae and Enhanced Leukocyte Phagocytosis and Bactericidal Activity C. Lee; Kaohsiung Chang Gung Mem. Hosp., Kaohsiung, Taiwan. B-1325 Sialic Acid Involved in Hypermucoviscosity Phenotype and

Resistance to Phagocytosis of Klebsiella pneumoniae by Neutrophils

B-1328 Comparison of Virulence Between Salmonella typhumurium

and S. choleraesuis by Proteomic and Cellular Microbiological Methods K. Huang1, K. Chien1, C. Chiu1,2; 1Chang Gung Univ., Tao-Yuan, Taiwan, 2 Chang Gung Children’s Hosp., Taoyuan, Taiwan. B-1329 Loss of Outer Membrane Protein A (OmpA) Affects the Fit-

ness and Virulence of Acinetobacter baumannii Y. Smani1, R. López-Rojas1, A. Fàbrega2, I. Roca2, J. Vila 2, J. Pachón 1; 1Inst. of Biomedicine of Seville, IBiS, Univ. Hosp. Virgen del Rocío, Seville, Spain, 2 Hosp. Clinic, Sch. of Med., Univ. of Barcelona, IDIBAPS, Barcelona, Spain. B-1330 Impact of Antibiotics on the Expression of the tra Genes and

on the Host Innate Immune Gene Activity during SXT Element Bearing Aeromonas salmonicida Infection in Atlantic Salmon (Salmo salar L.) L. Cantas1, F. L. Roux 2, D. Mazel 3, H. Sørum1; 1Norwegian Sch. of Vet. Sci., Oslo, Norway, 2IFREMER-UPMC Station Biologique de Roscoff, Roscoff, France, 3Inst. Pasteur, Paris, France. B-1331 Molecular Epidemiology of Virulence Factor Genes in Uro-

pathogenic Escherichia coli from Hospitalized Patients U. K. Frank1, K. Biehler 2, L. Goldberg2; 1Heidelberg Univ. Hosp., Heidelberg, Germany, 2Freiburg Univ. Hosp., Freiburg, Germany. B-1332 Comparison of Adhesin Genes Between Uropathogenic and

Intestinal Commensal Escherichia coli Strains X. Qin, X. Ye, D. Zhu, Y. Zhang, M. Wang; Huashan Hosp., Shanghai, China. B-1333 PA2226, a Novel Regulator of Quorum Sensing and Viru-

lence in Pseudomonas aeruginosa T. Kohler1, H. Ouertatani-Sakouhi2, P. Cosson2, C. van Delden1; 1Univ. Hosp. Geneva, Geneva, Switzerland, 2Univ. of Geneva, Geneva, Switzerland. B-1334 The Impact of Hypoxia on Infection of Pulmonary Epithelial

Cells by Pseudomonas aeruginosa B. Schaible1, S. McClean2, C. T. Taylor1, K. Schaffer 3; 1Conway Inst., Univ. Coll. Dublin, Dublin, Ireland, 2Inst. of Technology Tallaght, Dublin, Ireland, 3 St Vincent’s Univ. Hosp., Dublin, Ireland. B-1335 Acute Lung Injury Response to Pseudomonas aeruginosa

Infection in an Murine Pneumonia Model: Impact of the Type III Secretion System A. Broquet, C. Jacqueline, R. Cinotti, M. Davieau, C. Desessard, A. Roquilly, J. Caillon, G. Potel, K. Asehnoune; UPRES EA3826, Nantes, France. B-1336 Carbapenem Resistance is Not Associated with Virulence of

Pseudomonas aeruginosa (PA) Using the Dictyostelium discoideum (Dd) Virulence Model R. C. Fowler1, A. T. Weber2, N. D. Hanson1; 1Creighton Univ., Omaha, NE, 2 Univ. of Nebraska, Omaha, NE.

C. Lee; Kaohsiung Chang Gung Mem. Hosp., Kaohsiung, Taiwan.

Final Program

143

> Tuesday SCIENTIFIC SESSIONS B-1337 Impact of Ciprofloxacin (CIP) on the Expression of Genes

Involved in Pseudomonas aeruginosa (PA14) Persistence (P) in a Rabbit Model of Catheter Associated Urinary Tract Infection (CAUTI) M. Etienne, E. Fiaux, M. David, J. Peltier, I. El Meouche, L. Gibert, J. Didi, M. Pestel-Carom, F. Caron; Rouen Univ. Hosp., Rouen, France. B-1338 Pseudomonas aeruginosa (PA14) Catheter-Associated Urinary

C1-1345 Mutations in the liaFSR System Avoid Bactericidal Killing

of Daptomycin against Enterococci J. M. Munita1,2, T. T. Tran 1,3, D. Panesso 1,4, L. Diaz 1,4, J. Reyes 1,4, B. E. Murray 1, C. A. Arias1,4; 1Univ. of Texas Med. Sch., Houston, TX, 2Univ. del Desarrollo Clinica Alemana Sch. of Med., Santiago, Chile, 3Univ. of Houston Coll. of Pharm., Houston, TX, 4Univ. El Bosque, Bogota, Colombia. C1-1346 Cadazolid, a Novel Quinolonyl-Oxazolidinone Antibiotic

Tract Infection (CAUTI) in Rabbit: A Model to Explore In Vivo Bacterial Persistence in Biofilm (B) Infections

with Potent Activity against Clostridium difficile: In Vitro Antibacterial Activity and Propensity for Resistance Development

M. Etienne, M. David, E. Fiaux, J. Peltier, M. Pestel-Caron, F. Caron; Rouen Univ. Hosp., Rouen, France.

H. H. Locher, P. Pfaff, S. Schroeder, J. Specklin, C. Hubschwerlen, W. Keck; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.


-----------------------------------------------------------------------166(C1) Poster Session Resistance to Staphylococcus and Other Gram-Positive Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: C1-1339 A Novel Staphylococcal Chromosomal Cassette Containing

fusC in Methicillin-Resistant Staphylococcus aureus Y. T. Lin, H. J. Chen, L. J. Teng; Natl. Taiwan Univ. Med. Coll., Taipei City, Taiwan. C1-1340 A Unique IS1216V-Flanked Composite Mobile Element

from Enterococci is Distributed to ST59 Community-Acquired Methicillin-Resistant Staphylococcus aureus in Taiwan W. C. Hung1, T. Takano 1, Y. Iwao 1, L. J. Teng 2, T. Yamamoto1; 1Niigata Univ., Niigata, Japan, 2Natl. Taiwan Univ., Taipei, Taiwan. C1-1341 Characterization of the Staphylococcus aureus MepA Multi-

C1-1347 Cadazolid, a Novel Quinolonyl-Oxazolidinone Antibiotic:

Mode of Action and Effect on Clostridium difficile Toxin and Spore Formation H. H. Locher, S. Schroeder, D. Ritz, A. Knezevic, C. Hubschwerlen, W. Keck; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. C1-1348 Characterization of Mobile erm(X) And mef(A) Macrolide

Resistance Genes in Rhodococcus equi Isolates from Pneumonic Foals M. C. Roberts1, S. Giguere2, L. J. Berghaus 2, N. D. Cohen3, D. No 1, O. O. Soge 1; 1Univ. of Washington, Seattle, WA, 2Univ. of Georgia, Athens, GA, 3 Texas A & M Univ., College Station, TX. C1-1349 Characterization of a New VGA Gene Homologue in

Staphylococcus sciuri C. Hot, N. Berthet, O. Chesneau; Inst. Pasteur, Paris, France. C1-1350 Analysis of a Multi-Resistance Plasmid from Methicillin-

Resistant Staphylococcus epidermidis Isolates S. Weiß, A. T. Feßler, K. Kadlec, S. P. Schwarz; Inst. of Farm Animal Genetics (FLI), Neustadt-Mariensee, Germany. C1-1351 Correlation of icaA and Regulatory Genes agr and sarA

drug Efflux Pump Using Mutagenesis

Expression in Staphylococcus aureus Following Antibiotic Exposure in a Drip-Flow Biofilm Model

D. Patel1, S. M. Seo2, B. D. Schindler 2, G. W. Kaatz 2,1; 1Wayne State Univ. Sch. of Med., Detroit, MI, 2John D. Dingell VA Med. Ctr., Detroit, MI.

S. K. Shukla1, Z. Ye 1, W. Rose2; 1Marshfield Clin., Marshfield, WI, 2Univ. of Wisconsin, Madison, WI.

C1-1342 Rifampin Resistance in Propionibacterium acnes: In Vitro

Emergence and Molecular Characterization of Mutations in the RpoB Gene U. Furustrand Tafin1, A. Trampuz 1, S. Corvec 2; 1Univ. Hosp., Lausanne, Switzerland, 2Univ. Hosp., Nantes, France. C1-1343 Streptococcus sanguinis Displaying a Cross Resistance

Phenotype to Several Ribosomal RNA Targeting Agents, Including Linezolid R. E. Mendes1, L. M. Deshpande 1, J. Kim 2, D. Myers 2, J. E. Ross 1, R. N. Jones 1; 1JMI Lab., N Liberty, IA, 2Hershey Med. Ctr, Hershey, PA. C1-1344 Structure of Vancomycin Resistance Bifunctional D,D-

Dipeptidase/D,D-Carboxypeptidase VanXY from Enterococcus faecalis D. Meziane-Cherif1, P. J. Stogios2,3, E. Evdokimova 2,3, Z. Wawrzak4, A. Savchenko2,3, P. Courvalin1; 1Inst. Pasteur, Paris, France, 2Univ. of Toronto, Toronto, Canada, 3Ctr. for Structural Genomics of Infectious Diseases, Toronto, Canada, 4Northwestern Univ., Chicago, IL.


-----------------------------------------------------------------------167(C2) Poster Session Characterization of Streptococcus pneumoniae in the Era of Antibiotics and Vaccines Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: C2-1352 In Vitro Activity Efficacy of Comparative Antimicrobials

against Streptococcus pneumoniae from Respiratory Tract Sources from Europe: France, Germany, Italy, Spain And Sweden 20102011 D. Hoban, M. Hackel, R. Badal, S. Bouchillon, B. Johnson; IHMA, Inc., Schaumburg, IL. C2-1353 Relationship Between Genetic Beta-Lactam Resistance

and Capsular Type or Clonal Complex of Isolates from Invasive Pneumococcal Disease in Japan N. Chiba1, M. Shouji 2, M. Morozumi1, K. Ubukata1; 1Kitasato Inst. for Life Sci., Tokyo, Japan, 2Natl. Cancer Ctr. Hosp., Tokyo, Japan.

144

September 9-12 |

TUESDAY SCIENTIFIC SESSIONS C2-1354 Rapid Decrease in 7-Valent Conjugate Vaccine Coverage

for Invasive Pneumococcal Diseases (IPD) in Pediatric Patients in Japan K. Ubukata1, N. Chiba1, M. Morozumi1, H. Sakata 2, S. Iwata3; 1Kitasato Inst. for Life Sci.,Kitasato Univ., Tokyo, Japan, 2Asahikawa-Kosei Gen. Hosp., Asahikawa, Japan, 3Keio Univ. Sch. of Med., Tokyo, Japan. C2-1355 Quinolone-Nonsusceptible Streptococcus pneumoniae

Clinical Isolates in China Q. Guo, P. Wang, F. Hu, D. Zhu, F. Yang, M. Wang; Huashan Hosp., Shanghai, China. C2-1356 Laboratory Surveillance of Pneumococcal serotypes and Anti-

C2-1362 Surveillance for Antimicrobial Resistance in Streptococcus

pneumoniae, Canada, 1993-2011 K. A. Green, A. McGeer, A. Plevneshi, S. Pong-Porter, K. Wong, D. E. Low, Canadian Bacterial Surveillance Network (CBSN); Mount Sinai Hosp., Toronto, Canada. C2-1363 Lack of Impact of Infant PCV Vaccination on Rates of Adult

Invasive Pneumococcal Disease in Ontario, Canada K. Wong, A. McGeer, K. Green, A. Plevneshi, W. Rudnick, D. E. Low, Toronto Invasive Bacterial Diseases Network; Mount Sinai Hosp., Toronto, Canada. C2-1364 What will Happen to Antimicrobial Resistance in Adult

microbial Susceptibility Before and After Pcv7 in Mexico Sireva 2000-2011

Invasive Pneumococcal Disease in Canada after the Introduction of Infant PCV13 Vaccination?

G. Echaniz-Aviles1, M. Carnalla-Barajas 1, A. Soto-Noguerón 1, M. Velazquez-Meza 1, M. Sanchez-Alemán 1, M. Hernández-Salgado1, F. Solórzano-Sánchez 2, SIREVA-Mexico Network; 1Inst. Nacional de Salud Publ., Cuernavaca, Morelos, Mexico, 2Inst. Mexicano del Seguro Social, Mexico City, Mexico.

K. A. Green, A. McGeer, K. Wong, A. Plevneshi, S. Pong-Porter, W. Rudnick, D. E. Low, Canadian Bacterial Surveillance Network (CBSN); Mount Sinai Hosp., Toronto, Canada.

C2-1357 S19A and Coverage of Pneumococcal Conjugate Vaccines in

Mexico R. M. Hinojosa-Robles, M. J. De la Cruz-Váldez, P. A. HernándezRodríguez, C. Martínez-Longoria, L. Vera-Cabrera; Hosp. Univ., U.A.N.L., Monterrey, Mexico. C2-1358 Characteristics of Invasive Pneumococci Collected from

Adults Prior 13-Valent Conjugated Vaccine (pcv13) Introduction in Spain C. Ardanuy1, J. Marimón 2, E. Cercenado 3, N. Larrosa 4, D. Fontanals 5, M. Quesada 6, A. Fenoll 7, E. Pérez-Trallero2, J. Liñares1; 1Hosp Univ. BellvitgeIDIBELL, L’Hosp. de Llobregat, Spain, 2Hosp. Univ. Donostia, Donostia, Spain, 3Hosp. Univ. Gregorio Marañón, Madrid, Spain, 4Hosp. Univ. Vall d’Hebron, Barcelona, Spain, 5Hosp. Parc Taulí, Sabadell, Spain, 6Hosp. Germans Trias i Pujol, Badalona, Spain, 7Ctr. Natl. Microbiologia-ISCIII, Majadahonda, Spain. C2-1359 Changes in Epidemiology of Invasive Strains of Streptococcus

pneumoniae (Spn) in France Following Introduction of 13-Valent Conjugate Vaccine (PCV13) 7 years after PCV7 C. Janoir1, Reseau des Observatoires Regionaux du Pneumocoque, L. Gutmann 1, A. Lepoutre2, E. Varon1; 1AP-HP, Hosp. Europeen G-Pompidou - CNRP, Paris, France, 2InVS, St Maurice, France. C2-1360 Multidrug-Resistance in the Most Prevalent Invasive Strep-

tococcus pneumoniae (SPN) Serotypes (STs) Post PCV-13 Introduction in Canada H. Adam1,2,3, M. Gilmour 4,2, M. Baxter2,3, I. Martin 4, L. Scharikow 2, K. Nichol 1,3, W. Demczuk 4, J. Embree 2, D. Hoban 1,2,3, G. G. Zhanel2,3; 1 Diagnostic Services of Manitoba, Winnipeg, Canada, 2Univ. of Manitoba, Winnipeg, Canada, 3Canadian Antimicrobial Resistance Alliance (CARA), Winnipeg, Canada, 4Natl. Microbiol. Lab., Winnipeg, Canada. C2-1361 Epidemiology of Serotype 19A Streptococcus pneumoniae in

Adults Over the Past Decade B. E. Gonzalez1, K. G. Hulten 2, K. S. Sannes-Lowery 3, C. Washington3, C. Chen 3, S. Bajaksouzian1, A. R. Windau1, C. E. Good1, M. R. Jacobs1; 1Case Western Reserve U/U Hosp. Case Med Ctr, Cleveland, OH, 2Baylor Coll. of Med., Houston, TX, 3AthoGen, Carlsbad, CA.

C2-1365 Characterization of Spanish Isolates Presumptively

Identified as Atypical S. pneumoniae D. Rolo1, A. S. Simões1,2, A. Domenecher 1, A. Fenoll 3, J. Liñares1, H. de Lencastre2,4, C. Ardanuy1, R. Sá-Leão1,2; 1Hosp. Univ. Bellvitge, IDIBELLCIBERES, Barcelona, Spain, 2.ITQB/UNL, Oeiras, Portugal, 3CNMISCIII, Madrid, Spain, 4The Rockefeller Univ., New York, NY. C2-1366 Unique Pneumococcal Capsule Serotype of Serogroup 6 J. Y. Baek1, K. S. Ko2,1, S. H. Kim1, C. I. Kang 3, D. R. Chung 3,1, K. R. Peck 3, J. H. Song3,1; 1APFID, Seoul, Korea, Republic of, 2Sungkyunkwan Univ. Sch. of Med., Suwon, Korea, Republic of, 3Samsung Med. Ctr., Seoul, Korea, Republic of.

-----------------------------------------------------------------------168(C2, P) Poster Session Drug-Resistant Mycobacterium tuberculosis Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: C2-1367 Investigation of Extensively Drug Resistance in Multidrug

Resistance Tuberculosis Isolates B. Bektore1, T. Haznedaroglu1, O. Baylan1, M. Ozyurt1, N. Ozkutuk2, D. Satana 3, C. Cavusoglu 4, E. Seber5; 1Gulhane Military Med. Academy Haydarpasa Training Hosp., Istanbul, Turkey, 2Med. Sch. of Celal Bayar Univ., Manisa, Turkey, 3Istanbul Med. Sch. of Istanbul Univ., Istanbul, Turkey, 4 Med. Sch. of Ege Univ., Izmir, Turkey, 5Taksim Tuberculosis Dispensary, Istanbul, Turkey. C2-1368 Drug Resistance Pattern and Genotypic Characteristics of

Extremely Drug-Resistant Tuberculosis Strains from Nepalese Patients A. Poudel1, C. Nakajima 1, B. Maharjan2, B. D. Pandey3, Y. Suzuki1,4; 1Hokkaido Univ., Sapporo, Japan, 2German Nepal Tuberculosis Project (GENETUP), Kathmandu, Japan, 3Sukraraj Tropical and Infectious Disease Hosp., Kathmandu, Japan, 4JST/JICA-SATREPS, Tokyo, Japan.

Final Program

145

> Tuesday SCIENTIFIC SESSIONS C2-1369 Molecular Characterization of Multidrug-Resistant Myco-

bacterium tuberculosis from Asian Countries C. Nakajima1, Z. M. Rahim 2, A. Tamaru3, B. D. Pandey 4, B. Maharjan 5, K. S. Aye 6, A. Poudel1, Y. Suzuki1; 1Hokkaido Univ. Res. Ctr. for Zoonosis Control, Sapporo, Japan, 2ICDDR, B, Dhaka, Bangladesh, 3Osaka Prefectural Inst. of Publ. Health, Osaka, Japan, 4Sukraraj Tropical and Infectious Disease Hosp., Kathmandu, Nepal, 5GENETUP, Kathmandu, Nepal, 6Dept. of Med. Res., Yangon, Myanmar. C2-1370 Phenotypic Resistance Profiles and Gene Mutations Associ-

ated to Isoniazid and Rifampicin Resistance of Clinical Isolates of Mycobacterium tuberculosis from Guadalajara, México S. M. Flores-Treviño1, R. Morfin-Otero 2, E. Rodriguez-Noriega 2, G. Gonzalez1, Y. Hernandez2, N. Rodriguez2, E. Gonzalez-Diaz 2, E. GarzaGonzalez1; 1Univ. Autonoma de Nuevo Leon, San Nicolas de los Garza, Mexico, 2Univ. de Guadalajara, Guadalajara, Mexico. C2-1371 Molecular Detection of Multidrug-Resistant Mycobacte-

rium tuberculosis among HIV/TB Co-Infected Patients in Port Harcourt, Nigeria O. K. Obunge1, N. Onyejepu 2, P. Odeigah2; 1Univ. of Port Harcourt, Port Harcourt, Nigeria, 2Univ. of Lagos, Lagos, Nigeria. C2-1372 Changing Epidemiology of Mycobacterium tuberculosis

Complex (TB) Infections in a Tertiary Care Teaching Hospital in Riyadh Saudi Arabia: 8 Years Retrospective Study A. M. M. Somily, Jr., T. Naeem, Jr., A. Kambal; King Saud Univ., Riyadh, Saudi Arabia. C2-1373 Diabetes Mellitus is Important as HIV for Development of

Tuberculosis Control Programmes: Seven Years Experience in a Mexican Teaching Hospital C. Emanuela1, M. Lichtner1, E. González Díaz2, M. Morfin Otero2, E. Rodriguez Noriega 3, S. Savinelli 1, H. Perez Gomez 4, C. Mastroianni 1, V. Vullo 1; 1Sapienza Univ. of Rome, Roma, Italy, 2Univ. de Guadalajara Mexico, Hosp. Civil de Guadalajara, “Fray Antonio Alcalde, Guadalajara, Mexico, 3 Univ. de Guadalajara Mexico, Hosp. Civil de Guadalajara, Fray Antonio Alcalde, Roma, Mexico, 4Univ. de Guadalajara Mexico, Hosp. Civil de Guadalajara, Fray Antonio Alcalde, Guadalajara, Mexico. C2-1374 Tuberculosis Encephalitis in France E. Honnorat1, T. De Broucker2, A. Mailles 3, J. Stahl1; 1Univ. I, Grenoble, France, 2Hosp. Delafontaine, Saint-Denis, France, 3French Public Hlth. Inst., Saint-Maurice, France. C2-1375 Outbreak of Mycobacterium abcessus subsp. boletti in Rio

Grande do Sul State, Southern Brazil L. S. Nunes1, C. M. Cardoso 2, F. de Paris3, L. F. Baethgen 4, M. O. Ribeiro 2, V. Farias2, M. G. Silva5, R. S. Duarte5, A. L. Barth3,1; 1Programa de Pós Graduação Ciências Médicas , Univ. Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Lab. Central de Saúde Pública/RS, Porto Alegre, Brazil, 3 Hosp. de Clinc. de Porto Alegre, Porto Alegre, Brazil, 4Programa de Pós Graduação em Patologia, Univ. Fedd de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil, 5Univ. Fed. do Rio de Janeiro, Rio de Janeiro, Brazil.

-----------------------------------------------------------------------169(C2) Poster Session MRSA: A Bug with International Appeal and Great Sense Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: C2-1376 Displacement of the Brazilian Endemic Clone (BEC - SC-

Cmec III) by a Pediatric Clone (SCCmec II) Causing Shift in the Vancomycin MICs Among Methicillin-Resistant Staphylococcus aureus (MRSA) Isolated in Brazil E. A. M. Frigatto, C. G. Carvalhaes, B. Nonato, A. G. Souza, F. M. Inoue, V. G. S. Oliveira, R. Girardello, S. S. Andrade, A. M. O. Machado, A. C. Gales; UNIFESP, São Paulo, Brazil. C2-1377 Staphylococcus aureus International Clones Spread among

Inpatients Attending in an University Hospital in Rio De Janeiro, Brazil F. Aguiar-Alves1,2, T. M. Costa1,2, N. Iorio3,4, M. C. Ferguson1, D. Caldeira1, J. Carballito1, K. R. N. dos Santos4, S. Mondino1; 1UFF, Niteroi, Brazil, 2Federal Fluminense Univ., Niteroi, Brazil, 3UFF, Rio de Janeiro, Brazil, 4Federal Univ. of Rio de Janeiro, Rio de Janeiro, Brazil. C2-1378 Molecular Characterization of Methicillin Resistant Staphy-

lococcus aureus from a Teaching Hospital in South West Nigeria M. A. Raji1,2, O. Ojemhen2, P. Basset3, D. Blanc 3; 1Lagos State Univ. Coll. of Med., Ikeja, Lagos State, Nigeria, 2BT Hlth. Diagnostic Ctr., Ikeja, Nigeria, 3 CHUV, Lausanne, Switzerland. C2-1379 Continuing Evolution of USA300 (CMRSA10) Communi-

ty-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA) in Canadian Hospitals from 2007-2011 K. A. Nichol1, H. J. Adam 1,2, M. R. Mulvey3,2, M. McCracken3, M. Baxter2, A. Onio2, D. J. Hoban 1,2, G. G. Zhanel2, Canadian Antimicrobial Resistance Alliance (CARA); 1Diagnostic Services of Manitoba, Winnipeg, Canada, 2 Univ. of Manitoba, Winnipeg, Canada, 3Natl. Microbiol. Lab., Winnipeg, Canada. C2-1380 Characterization of Community-Onset Methicillin-

Resistant Staphylococcus aureus (COMRSA) Infections through Population-Based Surveillance in Canada G. Golding1, N. Vaid 2, M. Gale-Rowe 2, G. Jayaraman 2, J. MacDonald 3, L. Fang 2, J. Njihia 2, M. McCracken 1, C. Archibald 2, M. Mulvey 1, T. Wong 2, J. Embil 4, J. Conly 3, COMRSA Pilot Group; 1PHAC, Winnipeg, Canada, 2 PHAC, Ottawa, Canada, 3Alberta Hlth. Services, Calgary, Canada, 4Univ. of Manitoba, Winnipeg, Canada. C2-1381 Prospective Screening (S) for Vancomycin-Intermediate

Susceptibility (VISA) and Heteroresistance (hVISA) among Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Directly from Blood Culture (BC) Bottles S. Iyer, M. Sharma, L. B. Johnson, K. Riederer, S. Shemes, R. Khatib; St John Hosp. & Med. Ctr., Grosse Pointe Woods, MI. C2-1382 Characteristics of Staphylococcus aureus Nasal Carriage, Re-

sistance Patterns and Genetic Lineages in Healthy German Adults R. Köck1, P. Werner 2, A. W. Friedrich 3, C. Fegeler 2, Prevalence of Multiresistant Microorganisms (PMM)Study Group, K. Becker 1; 1Univ. Hosp. of Münster, Münster, Germany, 2Univ. Heilbronn, Heilbronn, Germany, 3Univ. Hosp. Groningen, Groningen, Netherlands.

146

September 9-12 |

TUESDAY SCIENTIFIC SESSIONS

C2-1383 Staphylococcal Isolates of Nasal Carriers May Share

C2-1394 High Level Mupirocin Resistance and In Vitro Activity of

Genetic Resistance Elements 1

1

Fusidic Acid among Staphylococcus aureus Clinical Isolates 1

2

2

R. Chamon , V. C. Salgueiro , M. Seixas , L. D. Falcão - , H. C. C. Póvoa , K. R. N. dos Santos1, N. L. P. Iorio 2; 1Rio de Janeiro Federal Univ., Rio de Janeiro, Brazil, 2Fluminense Federal Univ., Rio de Janeiro, Brazil. C2-1384 Molecular Epidemiology of Staphylococcus aureus Infection

T. Hosbul, B. Bektore, M. Ozyurt; Gulhane Military Med. Academy, Haydarpasa Training Hosp., Istanbul, Turkey. C2-1395 Accessory Gene Regulator (AGR) Function, rpoB

Isolates in Iowa

Mutations and Vancomycin (VA) Susceptibility in MethicillinResistant Staphylococcus aureus (MRSA) Blood Isolates

R. Nair1, S. Wardyn 2, M. Quick 2, J. Wu 2, T. Smith 2; 1Univ. of Iowa Coll. of Publ. Health, Coralville, IA, 2Univ. of Iowa, Coralville, IA.

M. Camoez, J. Sierra, F. Tubau, O. Gasch, M. Pujol, J. Liñares, R. Martín, M. Domínguez; Hosp. Univ. Bellvitge. UB. IDIBELL, Barcelona, Spain.

C2-1385 Diversity of SCCmec Elements in MRSA from Russia V. V. Gostev 1, A. E. Goncharov2, S. V. Sidorenko1,2; 1Res. Inst. of Children’s Infections, Saint Petersburg, Russian Federation, 2I.I. Mechnikov North West State Med. Univ., Saint- Petersburg, Russian Federation. C2-1386 Simultaneous Presence of SCCmec Types IV and V

Elements in a Clinical MRSA Isolate A. Romanov1, Y. Chernov1, M. Edelstein 1, E. Moskvitina 2, A. Dekhnich1; 1 Inst. of Antimicrobial Chemotherapy, Smolensk, Russian Federation, 2 Federal Med. Biological Agency Clinical Hosp. No. 81, Seversk, Russian Federation. C2-1387 Methicillin-Resistant Staphylococcus aureus Carrying the

PVL Gene with Reduced Sensibility to Vancomycin Isolated from a Newborn C. O. da Silva, R. C. Chamon, N. L. P. Iorio, F. S. Cavalcante, D. C. Ferreira, K. R. N. dos Santos; Federal Univ. of Rio de Janeiro, Rio de Janeiro, Brazil. C2-1388 Molecular and Phenotypic Characters of Methicillin-Resis-

tant Staphylococcus aureus Isolates from Patients with Empyema in Central Taiwan W. Wang1,2, T. Chiueh1, S. Tsao3; 1Natl. Defense Med. Ctr., Taipei, Taiwan, 2 Fong-Yuan Hosp., Taichung, Taiwan, 3Chung Shan Med. Univ. Hosp., Taichung, Taiwan. C2-1389 Cefazolin High-Iinoculum Effect in Methicillin-Susceptible

S. aureus (MSSA) from South American (SA) Hospitals

C2-1396 Molecular Epidemiology of Community-Acquired MRSA

Causing Skin and Skin Structure Infections in Argentina S. Fernandez1, N. Gardella 1, M. Lopez Furst 2, L. De Vedia 3, M. Stryjewski 4, M. Ganaha 5, S. Prieto 6, E. Carbone 7, N. Lista 3, F. Rotrying 8, M. Mollerach1; 1FFyB UBA, Caba, Argentina, 2S. Mendez, Caba, Argentina, 3Hosp. Muñiz, Caba Argentina, 4CEMIC, Caba, Argentina, 5 Hosp. V Lopez y Planes, Buenos Aires, Argentina, 6 Hosp. NS de Luján, Buenos Aires, Argentina, 7 Hosp. Aeronáutico, Caba, Argentina, 8 Hosp. UAI, Caba, Argentina. C2-1397 Molecular Epidemiology of Community-Acquired MRSA

Causing Invasive Disease in Argentina in 2010 and 2011 S. Fernandez1, N. Gardella1, S. Di Gregorio 1, M. Lopez Furst 2, L. De Vedia 3, M. Stryjewski 4, C. Ganaha5, S. Prieto 6, E. Carbone 7, N. Lista 3, F. Rotrying 8, M. Mollerach1; 1UBA, Caba, Argentina, 2S.Mendez, Caba, Argentina, 3Hosp. Muñiz, Caba, Argentina, 4CEMIC, Caba, Argentina, 5Hosp. V lopez y Planes, BA, Argentina, 6Hosp. NS de Luján, BA, Argentina, 7Hosp. Aeronautico, Caba, Argentina, 8UAI, Caba, Argentina. C2-1398 Acute Bacterial Skin and Skin Structure Infections

(Absssi) Caused by Community-Acquired Methicillin-Resistant Staphylococcus aureus: An Emerging Problem in Argentina A. Mykietiuk, P. Pessacq, M. Obed, B. Alcorta, G. Bertoni, P. Damico, E. Scaglione, J. Poggio, G. Guerrini, A. Calmaggi; HIGA ROSSI, La Plata, Argentina. C2-1399 Dynamics of the Emergence of Quinolone Resistance in

S. Rincon,1, J. Reyes 1, L. P. Carvajal1, B. E. Murray, 2, E. C. Nannini 3, C. A. Arias 2; 1Univ. El Bosque, Bogota, Colombia, 2Univ. of Texas Med. Sch. at Houston, Houston, TX, 3Univ. Nal de Rosario, Rosario, Argentina. C2-1390 Reversal of Vancomycin (VAN) MIC Creep in S. aureus (SA)

Strains Isolated from Blood E. L. Palavecino, J. W. Johnson, J. C. Williamson; Wake Forest Sch. of Med., Winston Salem, NC. C2-1391 Vancomycin Susceptibility in Methicillin-Resistant

Staphylococci from the Nasal Microbiota of Patients Treated by Fluoroquinolones A. Munier, V. de Lastours, F. Barbier, B. Fantin, R. Ruimy; EA3964 Univ. Paris Diderot, Paris, France. C2-1400 Distinct Frequency of Biofilm (BF)-Related Genes among

Ciprofloxacin (CIP) Susceptible and Resistant S. epidermidis (SEPI) agr Types I (tI) and II (tII) Isolates from Endophthalmitis (END)

Staphylococcus aureus (MRSA) Over 10 Years: MIC Decrease After a Transient Creep

P. J. Bispo1, D. Miller2; 1Federal Univ. of Sao Paulo, São Paulo, Brazil, 2 Bascom Palmer Eye Inst., Miami, FL.

R. Khatib, M. Sharma, L. B. Johnson, K. Riederer, S. Shemes, S. Iyer; St. John Hosp. & Med. Ctr., Grosse Pointe Woods, MI.

C2-1401 Microbiologic Features and Antimicrobial Susceptibilities

C2-1392 Low Prevalence of hVISA among S. aureus Bloodstream

Isolates and No Evidence of MIC Creep in the Cologne Metropolitan Area H. Seifert, D. Stefanik, A. Kaasch; Univ. of Cologne, Köln, Germany.

of Linezolid Resistant Coagulase Negative Staphylococcal Isolates in a Tertiary Center T. Kelesidis1, B. Gu1, S. Tsiodras2, R. Humphries 1; 1UCLA, Los Angeles, CA, CA, 2Univ. of Athens Med. Sch., Athens, Greece. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

C2-1393 A Plasmid-Borne System for Assessing the Excision and

Integration of Staphylococcal Cassette Chromosome Mec (SCCMec) Mediated By CcrA And CcrB L. Wang, G. Archer; Virginia Commonwealth Univ., Richmond, VA.

Final Program

147

> Tuesday SCIENTIFIC SESSIONS -----------------------------------------------------------------------170(D) Poster Session Detection of Bacteremia and Biomarkers for Sepsis Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: D-1402 Usefulness of Procalcitonin and C-Reactive Protein as

Diagnostic Markers of Bacterial Infection in Febrile Neutropenia M. Aimoto , H. Koh, M. Bingo , M. Yoshida, H. Okamura, T. Yoshimura , A. Inaba, S. Koh , S. Nanno , M. Nishimoto , Y. Hayashi , A. Hirose, M. Nakamae, K. Hagihara, Y. Terada, T. Nakane, H. Nakamae, , M. Hino; Graduate Sch. of Med., Osaka City Univ., Osaka, Japan. D-1403 Use of Monocyte Chemoattractant Protein 1-Alpha (MCP-

1Ơ), Soluble Tumor Necrosis Factor Receptor Type 1 (sTNFR-1) and C-Reactive Protein (CRP) in the Prediction of Fever in Neutropenic Patients A. V. Macedo, H. Bittencourt, A. S. Miranda, M. Marriel, V. C. S. Rocha, A. L. Teixeira, V. Nobre; Univ. Federal de Minas Gerais, Belo Horizonte, Brazil. D-1404 Soluble Urokinase Plasminogen Activator Receptor (suPAR)

Levels May Predict Positive Blood Cultures in Systemic Inflammatory Response Syndrome M. Hoenigl, R. B. Raggam, J. Wagner, A. J. Grisold, W. Krammer, K. Seeber, F. Prueller, E. Leitner, R. Krause; Med. Univ. of Graz, Austria, Graz, Austria. D-1405 Is Soluble Urokinase Plasminogen Activation Receptor

(SUPAR) A Valuable Tool in the Follow-Up Febrile Neutropenic Patients with Hematological Malignancy? S. Kaya1, G. Yılmaz1, A. Mentese 2, M. Sönmez3, A. Uzun Sümer 2, S. Sönmez Yıldırım1, &. Köksal 1; 1Karadeniz Tech. Univ. Faculty of Med., Trabzon, Turkey. D-1406 High Level of Autoantibody to Interferon-Gamma, a Major

Cause of Acquired Cell-Mediated Immune Deficiency in NonHIV Individuals in Northern Thailand P. Wongkulab, J. Wipasa, R. Chaiwarith, K. Supparatpinyo; Chiang Mai Univ., Chiang Mai, Thailand. D-1407 Serum Levels of Interferon Gamma in Patients with

Brucellosis in a Saudi Hospital M. M. A. Abo-Shadi1, A. I. H. Al-Harbi2, E. Ballal 3; 1Faculty of Sci.-Taibah Univ., Al-Madinah, Saudi Arabia, 2Taibah Univ., AlMadinah AlMunawarah, Saudi Arabia, 3Prince Sultan Armed Forces Hosp., AlMadinah AlMunawarah, Saudi Arabia. D-1408 Detection of Integrons in Blood Cultures: Predictive Value

for Acquired Resistance to Antibiotics? O. Barraud1,2,3, D. Chainier 1,2,3, J. Vignaud 3, M. Ploy1,2,3; 1INSERM, Limoges, France, 2Univ. Limoges, Limoges, France, 3CHU Limoges, Limoges, France. D-1409 Comparison of Charcoal-Containing Aerobic and Standard

Complicated Bloodstream Infections Caused by Gram-Positive Bacteria or Candida A. Fernandez-Cruz, M. Marín, M. Kestler, L. Alcalá, M. RodríguezCréixems, E. Bouza; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain. D-1412 Comparison of Conventional Blood Culture and Real-Time

PCR of Culture Bottles and Whole Blood for Diagnostic of Bloodstream Infections in Pediatric Oncologic Patients M. G. Quiles1, L. C. Menezes 1, K. C. Bauab 1, T. T. Rocchetti 1, F. S. Palomo 1, E. Gumpl3, F. Carlesse 2, A. C. C. Pignatari 1,; 1Federal Univ. of São Paulo, São Paulo, Brazil, 2Inst. of Pediatric Oncology, GRAACC/IPO/ UNIFESP, São Paulo, Brazil, 3UNIFESP, São Paulo, Brazil. D-1413 Clinical Impact of Matrix-Assisted Laser Desorption/Ion-

ization Time-of-Flight Mass Spectrometry (MALDI-ToF MS) Identifications from Positive Blood Cultures Bottles D. Martiny1, F. Debaugnies 1, D. Gateff 2, M. Gérard 2, A. Dediste 1, M. Chantrenne 1, C. Martin 2, D. Konopnicki 2, M. Aoun 3, A. Loizidou 3, A. Georgala 3, M. Hainaut 2, O. Vandenberg 1, S. Van Praet 2; 1Saint-Pierre Univ. Hosp. and Jules Bordet Inst., Brussels, Belgium, 2Saint-Pierre Univ. Hosp., Brussels, Belgium, 3Jules Bordet Inst., Brussels, Belgium. D-1414 Performance Characteristics of Rapid Prototype Immuno-

assays for the Detection of Staphylococcus aureus and Prediction of Susceptibility Directly from Blood Cultures C. V. Larka, G. W. Svanas, L. Robertson, S. Elagin; Meridian Bioscience, Inc., Cincinnati, OH. D-1415 Rapid Detection of Staphylococcus aureus and Methicillin-

Resistant S. aureus (MRSA) in Blood Cultures: Evaluation of the GenomEra MRSA/SA Assay E. Cercenado1, C. Sánchez-Carrillo1, M. Marín 1, A. Vindel 2, M. Rodríguez-Créixems1, E. Bouza 1; 1Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain, 2Inst. de Salud Carlos III, Madrid, Spain. D-1416 Evaluation of a Microarray Based Assay for Rapid Detection

of Gram-Positive Organisms and Resistance Markers in Positive Blood Cultures L. P. Samuel, R. J. Tibbetts, A. Agotesku, M. Fey, R. Hensley, F. A. Meier; Henry Ford Hlth. System, Detroit, MI. D-1417 Performance of the Nanosphere Verigene Gram-Positive

Blood Culture Nucleic Acid Test for Rapid Detection of S. aureus, S. epidermidis and mecA Directly from Positive Blood Cultures Withdrawn D-1418 Verification of a Commercial Signal Amplification Assay for

Rapid Identification of MRSA from Blood Culture Bottles G. A. Capraro; LSU Hlth. Sci. Ctr., Shreveport, LA. D-1419 Evaluation of Three Rapid Methods to Identify Staphylococcus

aureus and Determine Cloxacillin Susceptibility Directly from Positive Blood Culture S. Molinos, M. Quesada, L. Mateu, M. Colomer, C. Rodrigo, M. Gimenez; Hosp. Germans Trias i Pujol, Badalona, Spain.

Aerobic Blood Culture Media: Comparing Yield and Time to Detection

D-1420 Analysis of Sequential Time to Positivity of Blood Culture

G. N. Hartmeyer, T.Besser and R.B Dessau; Slagelse Sygehus Clinical Microbiol., Slagelse, Denmark.

Samples among Patients with Persistent Staphylococcus aureus Bacteremia

D-1410 Same-Day Blood Culture with Digital Microscopy S. Metzger1, C. S. Price 2, K. Hance 1, D. Howson 1; 1Accelr8, Denver, CO, 2 Denver Hlth. Med. Ctr., Denver, CO.

148

D-1411 The Value of Adding Septifast to a Prediction Score for

September 9-12 |

C. Liao; Far Eastern Mem. Hosp., New Taipei City, Taiwan.

TUESDAY SCIENTIFIC SESSIONS D-1421 Antimicrobial Resistance Profile of Salmonella Isolates from

Typhoid Fever Outbreak in Rwanda, May 2011 I. M. Uwimana1, T. Mukankwiro 1, N. Umulisa 2, E. Habyarimana 3, J. Flandin 4, O. Mukabayire1; 1RBC/IHDPC/Natl. Reference Lab., Kigali, Rwanda, 2 RBC/IHDPC/Malaria Div., Kigali, Rwanda, 3Ruhengeri District Hosp., Musanze, Rwanda, 4Natl. Reference Lab., Kigali, Rwanda. D-1422 Importance of Appropriate Antibiotic Usage in the Clearance

of Acinetobacter baumannii Bacteremia Y. Chuang1, S. Chang 1, W. Wang2; 1Natl. Taiwan Univ. Hosp., Taipei, Taiwan, 2John A. Burns Sch. of Med., Univ. of Hawaii at Manoa, Honolulu, HI. D-1423 MALDI-ToF MS and Direct Antimicrobial Susceptibility

Testing from Positive Blood Cultures: Comparison of the Bactalert and Bactec System H. Wisplinghoff1,2, T. Hoppe 2, A. Hamprecht 1, U. Aurbach 2; 1Univ. of Cologne, Cologne, Germany, 2Dres. Wisplinghoff & Colleagues, Cologne, Germany.

-----------------------------------------------------------------------171(D) Poster Session Diagnosis, Characterization and Antimicrobial Susceptibility Testing: Gram-Positive Cocci

D-1430Automated System Fails to Detect an Unusual Macrolide

Resistance Phenotype among Methicillin-Resistant Staphylococcus aureus T. Hosbul1, B. Bozdogan 2, T. Haznedaroglu 1, M. Ozyurt1; 1Gulhane Military Med. Academy, Haydarpasa Training Hosp., Istanbul, Turkey, 2Adnan Menderes Univ. Faculty of Med., Aydin, Turkey, Aydin, Turkey. D-1431 Reduced Activity of Clindamycin against Various Strepto-

cocci with Clindamycin-Inducible Resistance in the Neutropenic Thigh Infection Model A. J. Lepak 1, W. A. Craig1, D. R. Andes 2, K. Marchillo 3, J. van Hecker 3; 1 Univ. of Wisconsin, Madison, WI, 2Univ. of Wisconsin, William S Middleton Mem. VA Hosp., Madison, WI, 3William S Middleton Mem. VA Hosp., Madison, WI. D-1432 Use of DNA Microarray to Characterize Oxacillin-Susceptible,

mecA-Positive Staphylococcus aureus K. A. Sharff1, S. Slaughter 2, G. Forrest3, C. Pfeiffer3, S. Monecke 4, R. Ehricht 5, M. Oethinger2; 1Oregon Hlth. & Sci. Univ., Ptld, OR, 2Providence Med. Ctr., Portland, OR, 3VA Med. Ctr., Portland, OR, 4Inst. for Med. Microbiol. and Hygiene, Dresden, Germany, 5Alere Technologies, Jena, Germany. D-1433 Comparison of Etest and Broth Microdilution (BMD) MIC

Methods for Testing Staphylococcus aureus (SA) and Streptococcus agalactiae (GBS) with Ceftaroline

Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: D-1424 Evaluation of a Cost Effective Broth and Selective Agar

Combination for the Detection of MRSA and Staphylococcus aureus from Surveillance Specimens E. L. Chan, D. Seales; Trinity Med. Ctr., Birmingham, AL. D-1425 Droplet Digital PCR for Detection of Methicillin-Resistant

Staphylococcus aureus from Clinical Swabs

D. J. Diekema 1, J. H. Jorgensen 2, M. A. Lewinski 3, L. Boyken1, L. C. Fulcher 2, M. L. McElmeel 2, M. A. Tagarao 3, J. A. Hindler3; 1Univ. of Iowa Hosp. and Clinics, Iowa City, IA, 2Univ. of Texas Hlth. Sci. Ctr., San Antonio, TX, 3UCLA Hlth. System, Los Angeles, CA. D-1434 Onsite hVISA Detection: One Hospital’s Story M. Jeffres1,2 1 Roseman Univ. of Hlth. Sci., Henderson, NV, 2Univ. of Nevada Sch. of Med., Las Vegas, NV. D-1435 Prevalence and Relevance of Detecting Vancomycin Het-

D. C. Sullivan1, K. L. Kelley1, B. A. Chapman1, P. Belgrader2; 1Univ. of Mississippi Med. Ctr., Jackson, MS, 2BioRad Clin. Diag. Group, Hercules, CA. D-1426 Rapid Methicillin-Resistant Staphylococcus aureus (MRSA)

Screening on Admission to Pediatric and Neonatal Intensive Care Units in an Italian Pediatric Hospital R. Bandettini, M. Perotti, F. Risso, A. Moscatelli, M. Diana, L. Pescetto, L. Ricagni, E. Castagnola; Ist. G. Gaslni, Lab. Centrale, Genoa, Italy. D-1427 Evaluation of the Xpert Methicillin-Resistant Staphylococcus

aureus (MRSA) Assay for Rapid Detection of Nasal Carriage of MRSA Withdrawn. D-1428 A New Multiplex Pcr to Detect Sccmec Types in Methicillin-

Resistant Staphylococcus aureus of Nasal Carriage F. S. Cavalcante, D. C. Ferreira, Y. C. Lyra, F. Monteiro, E. D. Abad, K. R. N. dos Santos; Univ. Federal do Rio de Janeiro, Rio de Janeiro, Brazil. D-1429 Phage Open-Reading Frames Typing Method for Methi-

cillin-Resistant Staphylococcus aureus Outbreak Investigation in Neonatal Intensive Care Unit S. Matsushita, T. Shoji, K. Kinoshita, Y. Horikoshi; Tokyo Metropolitan Children’s Med. Ctr., Tokyo, Japan.

eroresistance among Methicillin-Resistant Staphylococcus aureus Bacteremia V. Huang, S. Sambhara, C. Bishop, J. Attardo; Mercer Univ. Coll. of Pharmacy and Hlth. Sci., Atlanta, GA. D-1436 Increased Cell Wall Stiffness in Vancomycin-Resistant Staph-

ylococcus aureus Measured by Atomic Force Microscopy L. Rio Marques1, G. Longo 2, S. Kasas 2, A. Trampuz 1, A. Bizzini 1; 1Univ. Hosp. Lausanne, Lausanne, Switzerland, 2Ecole Polytechnique Fédérale Lausanne, Switzerland. D-1437 Hexaplex PCR Assay for Detection of Staphylococcus aureus,

mecA, czrC, QacA/B and Pantone-Valentine Leucocidin Genes with Simultaneous Discrimination from Coagulase Negative Staphylococci S. Panda1, S. Kar 2, R. Choudhury 1, S. Sharma 2, D. V. Singh1; 1Inst. of Life Sci., Bhubaneswar, India, 2LV Prasad Eye Inst., Bhubaneswar, India. D-1438 The First Report of Daptomycin Susceptibility of 832 Strains

of Gram-Positive Cocci from an University Hospital in Japan (2009-2011) A. Yoshizumi1, M. Iwata 2, H. Murakami 2, S. Yumoto 2, K. Yasui 2, C. Maehara 2, S. Fukuzawa 2, K. Enokizono 2, A. Hikosaka 2, Y. Ishii 1, K. Tateda1; 1Toho Univ., Tokyo Japan, 2Toho Univ. Omori Med. Ctr., Tokyo, Japan.

Final Program

149

> Tuesday SCIENTIFIC SESSIONS D-1439 Staphylococcus aureus Enterotoxins Relevance in Atopic Der-

Enterobacteriaceae (C-Ent)

A. Rojo, A. Aguinaga, G. Gastaminza, J. R. Yustet, A. España; Clin. Univ. Navarra, Pamplona, Spain.

D. Doyle 1, G. Peirano 2, C. Lascols3, T. Lloyld 1, D. Church 2, J. Pitout2; 1 Calgary Lab Services, Calgary, Canada, 2Univ. of Calgary, Calgary, Canada, 3 IHMA, Inc, Schaumburg, IL.

D-1440 Staphylococcus aureus in Atopic Dermatitis: Different Geno-

typic Profile from Asymptomatic Atopic Carriers? A. Rojo1, A. Aguinaga1, S. Monecke2, G. Gastaminza 1, J. R. Yuste 1, A. España 1; 1Clin. Univ. Navarra, Pamplona, Spain, 2Ins. for Med. Microbiol. & Hyg., Jena, Germany. D-1441 Evaluation of the VITEK 2 AST-ST1 Card for Antibiotic

D-1449 Development of a Rapid Multiplex PCR Assay for Emerging

Carbapenemases and CMY-2 H. Briggs, M. Herrera, B. Wickes, J. Jorgensen; Univ. of Texas Hlth. Sci. Ctr. San Antonio, TX. D-1450 An Evaluation of Multiple Phenotypic Screening Methods

Susceptibility Testing of Oral, Group D, and Beta-Hemolytic Streptococci

for Klebsiella pneumoniae Carbapenemase (KPC)-Producing Enterobacteriaceae

R. Leclercq1, M. Auzou 1, F. Garnier 2, M. Ploy2, H. Poupet 3, C. Poyart3, V. Cattoir 1; 1CHU Caen, Caen, France, 2CHU Limoges, Limoges, France, 3 CHU Cochin, Paris, France.

E. B. Hirsch1, K. T. Chang 2, D. N. Francoeur 1, K. R. Ledesma2, V. H. Tam2,3, T. M. Lasco3; 1Northeastern Univ., Boston, MA, 2Univ. of Houston, Houston, TX, 3St. Luke’s Episcopal Hosp., Houston, TX.

D-1442 Comparison of Surveillance Culture to Xpert vanA Assay for

Detection of Vancomycin-Resistant Enterococci K. Gilhuley, D. Cianciminio-Bordelon, D. Reid, S. Tulumba, Y. Tang, N. E. Babady; Mem. Sloan-Kettering Cancer Ctr., New York, NY. D-1443 16S-23S Intergenic Spacer (ITS) Region Sequence Analysis

and Species Identification of the Genera Aerococcus, Abiotrophia, Granulicatella, Gemella and Leuconostoc D. Carkaci1,2, X. Nielsen, 1, J. Christensen1; 1Slagelse Hosp, Slagelse, Denmark, 2Roskilde Univ., Roskilde, Denmark. D-1444 Identification of the Bovis Group Streptococci and the Value

of Sequence Analysis of the 16S-23S Intergenic Spacer Region E. S. Marmolin1, G. N. Hartmeyer2, X. C. Nielsen2, R. Dargis 2, E. Knudsen 1, M. N. Skov 1, M. Kemp 1, J. J. Christensen2, U. S. Justesen1; 1Odense Univ. Hosp., Odense C, Denmark, 2Slagelse Hosp., Slagelse, Denmark.

-----------------------------------------------------------------------172(D) Poster Session Molecular Methods for Pathogen Identification and Resistance Detection Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C

D-1451 Development of Real-Time Multiplex PCR Assays for

Metalloơ-Lactamases, Other Carbapenemases, AmpC and CTX-M ESBLs R. L. Swayne 1, S. H. Aliyu1, M. J. Ellington 2, N. Woodford3, M. D. Curran 4; 1Cambridge Univ. Hosp. NHS Trust, Cambridge, United Kingdom, 2 Cambridge Microbiol. Lab Hlth. Protection Agency, Cambridge, United Kingdom, 3Antibiotic Resistance Monitoring and Ref Lab, Hlth. Protection Agency, London, United Kingdom, 4Cambridge Microbiol. Lab, Hlth. Protection Agency, Cambridge, United Kingdom. D-1452 Virulence Factor Gene cnf andơ-Lactamase Gene TEM are

Associated with an Increased Severity of Escherichia coli Blood Stream Infections M. Mora-Rillo, N. Fernández-Romero, C. Navarro San Francisco, M. P. Romero-Gómez, J. R. Paño-Pardo, J. R. Arribas-López, J. Mingorance; Hosp. Univ. La Paz, IdiPAZ, Madrid, Spain. D-1453 Real-Time PCR For Detection of Blaoxa-48 Genes From

Spiked Stools T. Naas, G. Cotellon, A. Ergani P. Nordmann; INSERM U914: Emerging Resistance to Antibiotics, Le Kremlin Bicetre, France. D-1454 Rapid Detection of Common Bacterial Antibiotic Resistance

Genes Using a Set of Locked Nucleic Acid (lna)-Based Quantitative PCR Assays Withdrawn

Presentations: D-1445 High Resolution Melting (HRM) Analysis Allows Rapid

Detection and Differentiation of blaKPC Alleles in Gram-Negative Pathogens A. L. Roth, M. Kovarik, N. D. Hanson; Creighton Univ., Omaha, NE. D-1446 Fast Identification of KPC-Type Genes by Pyrosequencing J. Monteiro1,2, R. Widen2, A. C. Pignatari 1, C. Kubasek 2, A. C. Gales 1, S. Silbert2; 1Federal Univ. of São Paulo, São Paulo, Brazil, 2Tampa Gen. Hosp., Tampa, FL. D-1447 Accreditation of Carbapenemase and ESBL Multiplex End-

Point PCRs According to ISO15189 P. Bogaerts, R. Rezende de Castro, Y. Glupczynski; CHU UCL MontGodinne, Yvoir, Belgium.

150

D-1448 The Laboratory Diagnosis of Carbapenemase-Producing

matitis: Clinical, Immunological and Microbiological Parameters

September 9-12 |

D-1455 A New OXA Variant from Achromobacter sp: A Species

Specific Marker M. Papalia 1, M. Almuzara1, G. Traglia, Lic 2, M. Ramírez1, A. Belmonte 2, A. Famiglietti1, C. Vay1, G. Gutkind1, M. Radice1; 1UBA, Buenos Aires, Argentina, 2 UNR, Rosario, Argentina. D-1456 New Lamp Method For Simple Screening of Plasmid-

Mediated Quinolone Resistance Genes, qepA K. Yamane1,2, A. Horino2, S. Suzuki2, J. Wachino2, M. Matsui2, K. Shibayama2, Y. Arakawa 3,2; 1Kawasaki Med. Sch., Kurashiki, Japan, 2Natl. Inst. of Infectious Diseases, Tokyo, Japan, 3Nagoya Univ. Graduate Sch. of Med., Nagoya, Japan. D-1457 Campylobacterosis; Changing Dynamics of Human Infection Withdrawn

TUESDAY SCIENTIFIC SESSIONS D-1458 Chemotherapy-Induced Changes of the Intestinal Micro-

biota Analyzed by High Throughput Pyrosequencing E. Montassier1, E. Batard1, J. Hardouin 2, J. Caillon1, T. Carton 3, N. Caroff1, T. Gastinne 1, P. Moreau 1, G. Potel1, M. De la Cochetière 2, F. Le Vacon 3; 1 Ctr. Hosp. Univ. de Nantes, Nantes, France, 2Faculté de Med. de Nantes, Nantes, France, 3Biofortis Res., Nantes, France. D-1459 Pyrotyping: A Practical Genotyping Method Compatible to

Multilocus Sequence Typing (MLST) by Pyrosequencing T. Saga, N. Aoike, Y. Ishii, K. Tateda; Toho Univ., Tokyo, Japan. D-1460 Rapid Identification of Causative Bacteria from Positive

Blood Culture Samples by DNA Pyrosequencing M. Yamada, K. Yanagihara, Y. Morinaga, S. Kohno, S. Kamihira; Nagasaki Univ., Nagasaki, Japan. D-1461 A Novel TM-Mapping Method that Enables Identification

of Pathogenic Microorganisms Within 3 Hours after Samples are Collected H. Niimi1, T. Ueno 1, S. Hayashi 1, M. Mori2, H. Tabata3, H. Minami3, S. Saito1, I. Kitajima1; 1Toyama Univ. Hosp., Toyama, Japan, 2Ishikawa Prefectural Univ., Ishikawa, Japan, 3Hokkaido Mitsui Chemicals Corp., Hokkaido, Japan. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------173(E) Poster Session In Vitro Activity of Lipoglycopeptides and Related Compounds Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: E-1462 In Vitro Activity of Oritavancin against Gram-Positive

Pathogens Isolated in Canadian Hospitals in 2011 J. A. Karlowsky1,2, H. Adam 1, M. Baxter2, D. Hoban 1,2, G. G. Zhanel2; 1 Diagnostic Services of Manitoba, Winnipeg, Canada, 2Univ. of Manitoba, Winnipeg, Canada. E-1463 A Multi-Site Study Comparing an 18-24h Commercially

Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Oritavancin Using Fastidious and Non-Fastidious Gram-Positive Organisms N. M. Holliday1, D. Zollos 1, C. C. Knapp1, S. B. Killian 1, F. F. Arhin 2, G. Moeck2, J. M. Streit 3, R. N. Jones 3, R. R. Prochaska 3, P. R. Rhomberg 3, L. Sykes 4; 1TREK Diagnostic Systems, Cleveland, OH, 2The Med. Company, Parsippany, NJ, 3JMI Lab., North Liberty, IA, 4Kaiser Permanente, Cleveland, OH. E-1464 Evaluating the Activity of Daptomycin (DAP) and Linezolid

(LND) in Combination with Rifampin (RIF) or Gentamicin (GENT) on Enterococcus faecium in an In Vitro Pharmacodynamic Model Using Simulated Endocardial Vegetations (SEV) 1

1

1,2

1,3 1

M. K. Luther , K. M. Babcock , K. L. LaPlante , A. R. Caffrey ; Providence VA ID Res. Program, Providence, RI, 2Univ. of Rhode Island, Kingston, RI, 3Univ. of Rhode Island Coll. of Pharmacy, Kingston, RI.

E-1465 In Vitro Development of Daptomycin Resistance (DAP-R)

After Exposure to DAP of Enterococcus faecalis (EF) Bloodstream Isolates from Patients with Infective Endocarditis (IE) C. Garcia-de-la-Maria, J. M. Pericas, A. del-Rio, Y. Armero, Biologist, X. Castañeda, C. Cervera, M. Almela, C. Falces, S. Ninot, C. A. Mestres, D. Soy, J. M. Gatell, A. Moreno, F. Marco, J. M. Miro, Hospital Clinic Endocarditis Study Group; Hosp. Clinic - IDIBAPS, Barcelona, Spain. E-1466 Efficacy of Daptomycin (DAP) and Ceftaroline (CPT) in

Methicillin- Resistant Staphylococcus aureus (MRSA)/ Candida glabrata (CG) Polymicrobial Biofilms J. M. Rybak1,2, J. A. Vazquez 2; 1Eugene Applebaum Coll. of Pharm. and Hlth. Sci., Detroit, MI, 2Henry Ford Hosp., Detroit, MI. E-1467 A Multi-Site Study Comparing an 18-24h Commercially

Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Dalbavancin Using Fastidious and Non-Fastidious Gram-Positive Organisms S. B. Killian1, N. M. Holliday 1, C. C. Knapp1, D. Zollos 1, M. Dunne 2, J. M. Streit 3, R. N. Jones 3, R. R. Prochaska 3, P. R. Rhomberg 3, L. Sykes4; 1 TREK Diagnostic Systems, Cleveland, OH, 2Durata Therapeutics, Inc., Morristown, NJ, 3JMI Lab., North Liberty, IA, 4Kaiser Permanente, Cleveland, OH. E-1468 Telavancin in the Therapy of Experimental Aortic Valve

Endocarditis in Rabbits Due to Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus (MRSA) Y. Q. Xiong1,2, W. A. Hady1, A. S. Bayer 1,2, L. Chen 3, S. Yang1,2; 1HarborUCLA, Torrance, CA, 2David Geffen Sch. of Med. UCLA, Los Angeles, CA, 3Publ. Hlth. Res. Inst. Tuberculosis Ctr., Newark, NJ. E-1469 Activity Of Telavancin (TLV), Daptomycin (DAP), Linezolid

(LND), and Vancomycin (VAN) against Clinical Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) in a Simulated In Vitro Pharmacodynamic (IVPD) Infection Model M. K. Luther1, K. M. Babcock1, A. R. Caffrey 1,2, K. L. LaPlante1,2; 1Providence VA ID Res. Program, Providence, RI, 2Univ. of Rhode Island Coll. of Pharmacy, Kingston, RI. E-1470 In Vitro Activity of Telavancin and Other Non-ß-Lactam An-

tibiotics in Methicillin Resistant Staphylococcus aureus (HospitalAcquired MRSA versus Community-Acquired MRSA) in Austria E. Leitner, G. Zarfel, G. Feierl, U. Wagner-Eibel, M. Gehrer, E. Marth, A. Grisold; Inst. of Hygiene, Microbio. and Environmental Med., Graz, Austria.

-----------------------------------------------------------------------174(E) Poster Session In Vitro Activity Versus Staphylococcal Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: E-1471 In Vitro Activity of Vancomycin, Linezolid and Tigecycline

against Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Isolates and Outcomes in Patients with MRSA Bacteremia of the Medical Hospital of Vienna From 2000-2011 C. Forstner, C. Dungl, S. Tobudic, H. Burgmann; Med. Univ. of Vienna, Vienna, Austria.

Final Program

151

> Tuesday SCIENTIFIC SESSIONS E-1472 Beta-Lactams (BL) Enhance Vancomycin Killing

Activity against Clinical Methicillin-Resistant Staphylococcus aureus (MRSA) In Vitro T. Dilworth, J. Sliwinski Candidate, K. Ryan Candidate, M. Dodd, R. C. Mercier; Univ. of New Mexico, Albuquerque, NM. E-1473 The Combination of Iron Chelation and Vancomycin is

Synergistic against Staphylococcus aureus In Vitro

E-1482 Seesaw Effect Between Daptomycin (DAP) and Macrolide-

Lincosamide-Streptogramin (MLS) Resistance in MRSA A. D. Berti1, W. Rose1, G. Sakoulas2; 1Univ. Wisconsin-, Madison, WI, 2 Univ. California, San Diego, CA. E-1483 In Vitro Susceptibility and Tolerance of Staphylococcus aureus

Small Colony Variants to Beta-Lactam Antibiotics

G. Luo, T. Ghebremariam, H. Lee, A. Bayer, A. S. Ibrahim; Harbor-UCLA Med. Ctr., Torrance, CA.

E. A. Idelevich1, A. Kriegeskorte 1, C. von Eiff 1,2, G. Peters 1, K. Becker 1; 1 Univ. Hosp. Münster, Münster, Germany, 2Pfizer Pharma GmbH, Berlin, Germany.

E-1474 Activity of PMX-30063 against Drug Resistant Staphylococci

E-1484 Retapamulin Activity against S. aureus Resistant to Various

R. Scott1, B. Korczak 1, D. Jorgensen 1, S. Hawser 2, M. Hackel 3, S. Bouchillon 3, Y. Xiong 4,5, A. Bayer5; 1PolyMedix, Inc., Radnor, PA, 2IHMA Europe, Epalinges, Switzerland, 3IHMA, Inc., Schaumberg, IL, 4LA Biomed Res. Inst, Torrance, CA, 5Geffen Sch. of Med., Torrance, CA. E-1475 Ceftaroline Activity against Community Associated (CA) and

Healthcare Associated (HA) Methicillin-Resistant Staphylococcus aureus (MRSA) Withdrawn E-1476 Daptomycin (D) & Tigecycline (T) is Bactericidal against

E-1485 Sequential Versus Simultaneous Exposure to Combination

Therapy for Methicillin-Resistant Staphylococcus aureus (mrsa) Biofilms S. J. Bergman 1, K. A. Luciano2, V. Sundareshan2; 1Southern Illinois Univ. Edwardsville, Springfield, IL, 2Southern Illinois Univ., Springfield, IL. E-1486 Phylogenetic Analysis of Enoyl-ACP Reductase (ENR)

a High Inoculum of Methicillin-Resistant Staphylococcus aureus (MRSA) with Reduced Susceptibilities to Vancomycin (V) Up to 120 Hours in a Hollow Fiber Infection Model (HFIM)

Protein Sequences from 123 Bacterial Species and Demonstration of Staphylococcal-Specific Inhibition by the FabI ENR Inhibitor AFN-1252 Using Reference In Vitro Susceptibility Testing

T. P. Lim 1,2, N. Tahir, Dip 1, W. Lee 1, S. Sasikala 1, Y. Cai 1, L. Y. Hsu2, T. Y. Tan 3, A. L. Kwa1; 1Singapore Gen. Hosp., Singapore, Singapore, 2Natl. Univ. Hosp. System, Singapore, Singapore, 3Changi Gen. Hosp., Singapore, Singapore.

J. A. Karlowsky1, N. Kaplan 2, B. Hafkin 2, D. J. Hoban1, G. G. Zhanel1; 1 Univ. of Manitoba, Winnipeg, Canada, 2Affinium Pharmaceuticals, Toronto, Canada.

E-1477 In Vitro Activity of Fosfomycin Alone and Combination

with Trimethoprim/Sulfamethoxazole against Blood Isolates of Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus A. Leelarasamee, T. Yungyuen, U. Kijsinthopchai, P. Disthaporn, A. Leelaporn; Mahidol Univ., Bangkok, Thailand. E-1478 Combination of Daptomycin withơ-Lactams Increases the

Antibacterial Efficacy against Clinically Relevant MRSA Strains and Prevents Selection of Dap-Resistant Derivatives C. Singh, K. B. Plata, P. Chanda, S. Riosa, R. Rosato, A. Rosato; The Methodist Res. Inst., Houston, TX. E-1479 In Vitro Activity Profile of Tedizolid (TZD) and Correlations

with Linezolid (LZD) Activity against Recent Staphylococcal Isolates J. Deane1, A. Simenauer 1, K. Bartizal 2, K. Shaw 2, D. Sahm 1; 1Eurofins, Chantilly, VA, 2Trius Therapeutics, San Diego, CA. E-1480 Biofilm Multiple Combination Bactericidal Test (MCBT) on

Methicillin-Resistant Staphylococcus aureus (MRSA) from Patients with Cystic Fibrosis (CF) R. Saginur1, W. Ferris 2, L. Hyde 2, R. Slinger2, F. Chan 2; 1The Ottawa Hosp., Civic Campus, Ottawa, Canada, 2CHEO, Ottawa, Canada. E-1481 Vancomycin MIC Creep among Ocular Staphylococcus aureus

Isolates P. J. Bispo, A. C. Pignatari, A. L. Hofling-Lima; Federal Univ. of Sao Paulo, São Paulo, Brazil.

152

Antimicrobial Agents L. D. Saravolatz, Sr., J. Pawlak, S. Saravolatz, L. B. Johnson; St John Hosp. and Med. Ctr., Grosse Pointe Woods, MI.

September 9-12 |

-----------------------------------------------------------------------175(F) Poster Session Antimicrobial Peptides and Peptidomimetics Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: F-1487 Antimicrobial Peptide Epidermicin Protects Galleria

Mellonella Larvae from Experimental Infection with S. aureus T. Gibreel, M. Upton; Univ. of Manchester, Manchester, United Kingdom. F-1488 Antimicrobial Activity of Native Human Defensins HNP1-3

Purified by a Biological Recycling Process L. Vossier1, F. Leon 1, C. Bachelier1, H. Marchandin 2, J. Coste 1, C. Fournier-Wirth1; 1Etablissement Français du Sang Pyrénées Méditerranée, Montpellier, France, 2UMR 5119 ECOSYM, Univ. Montpellier 1, Montpellier, France. F-1489 Novel Antimicrobial Peptides with Improved Bioavailability

and Reduced Cytotoxicity H. Kim, J. H. Jang, J. B. Yang, J. H. Cho; Gyeongsang Natl. Univ., Jinju, Korea, Republic of. F-1490 Determination of Structure-Activity Correlations for Ratio-

nal Design of Engineered Cationic Antimicrobial Peptides J. D. Steckbeck, B. Deslouches, J. K. Craigo, R. C. Montelaro; Univ. of Pittsburgh, Pittsburgh, PA.

TUESDAY SCIENTIFIC SESSIONS F-1491 Antimicrobial Activity of Two New Peptides (S2-P082090

and S5-P082090) against Gram-Positive and -Negative Bacteria: Comparison with Omiganan P. Maffia 1, D. Faccone2, O. Veliz 2, B. Bogado 1, L. Semorile 1, A. Corso 2; 1 Univ. Nacional de Quilmes, Buenos Aires, Argentina, 2Antimicrobianos, Inst. Natl. de Enfermedades Infecciosas-ANLIS, Bueno Aires, Argentina. F-1492 Antimicrobial Activity Upon Planktonic Cells and Biofilms

Of Polyethyleneimine 1

2

2

2

2

J. Barros , P. A. Ramalho , C. Pina-Vaz , A. G. Rodrigues , I. Pina-Vaz ; 1 Faculty of Dentistry, Porto, Portugal, 2Faculty of Med., Porto, Portugal. F-1493 Small, Nonpeptidic Mimics of Host Defense Proteins Exhibit

Potent Killing Activity against Gram-Positive and Gram-Negative Biofilm Cultures R. W. Scott, M. Corrigan; PolyMedix, Inc., Radnor, PA. F-1494 Nonpeptidic Mimics of Host Defense Proteins as Antimi-

crobial Agents for E. coli O104:H4, Campylobacter spp. and Other Foodborne Pathogens R. Scott1, S. Mithal 1, C. Chen 2; 1PolyMedix, Inc., Radnor, PA, 2USDA ARS, Wyndmoor, PA. F-1495 Nonpeptidic Mimics of Host Defense Proteins as Antimicro-

bial Agents for Category A and B Biowarefare Pathogens R. Scott1, S. Mithal 1, C. L. Marchand, III 2, S. Halasohoris 2, L. Miller 2; 1 PolyMedix, Inc., Radnor, PA, 2USAMRIID, Frederic, MD. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------176(F) Poster Session Compounds and Approaches for Combating GramPositive Infections Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: F-1496 M676, a Putative Inhibitor of Undecaprenyl Pyrophosphate

Synthase, Synergizes withơ-Lactam Antibiotics against MRSA L. Miesel1, J. Baysarowich 2, A. Caron 3, J. Huber 2, M. Kavana 1, J. Lafleur 3, P. T. Meinke 2, D. B. Olsen 4, R. E. Painter 1, M. J. Salvatore 2, M. Szymonifka 2, C. M. Tan1, S. T. Waddell 2, H. Wang 1, K. Young 1, S. Singh 2; 1Merck Res. Labs, Kenilworth, NJ, 2Merck Res. Labs, Rahway, NJ, 3Merck Res. Labs, Kirkland, Canada, 4Merck Res. Labs, West Point, PA. F-1497 Antibacterial Spectrum of Oxazolidinone MRX-I: Potent

Activity against Multidrug-Resistant Gram-Positive Pathogens D. M. Zhu1, W. Wang 2, Y. Q. Huang 3, Y. Y. Zhang 1; 1HuaShan Hosp., Fudan Univ., Shanghai, China, 2MicuRx Pharmaceuticals Inc., Hayward, CA, 3MicuRx Pharmaceuticals Inc., Shanghai, CA. F-1498 Antimicrobial Profile of MRX-I: Resistance and Drug Com-

bination Studies Y. Li 1, H. L. Wang 1, Y. H. Xu 1, W. Wang 2, Y. Q. Huang1, Q. Wang1, J. Liu2; 1MicuRx Pharmaceuticals Inc., Shanghai, China, 2MicuRx Pharmaceuticals Inc., Hayward, CA.

F-1499 Novel Oxazolidinone MRX-I is Efficacious in Mouse Models

of Gram-Positive Bacterial Infections C. R. Li1, G. Q. Li 1, X. X. Hu 1, W. X. Zhang 1, X. K. Wang 1, J. Pang 1, X. Lu 1, Q. Q. Zhai 1, H. Yuan 2, M. F. Gordeev 3, X. Y. Yang 1, X. F. You1; 1Inst. of Medicinal Biotechnology, Chinese Academy of Med. Sci. & Peking Union Med. Coll., Beijing, China, 2MicuRx Pharmaceuticals Inc., Shanghai, China, 3 MicuRx Pharmaceuticals Inc., Hayward, CA. F-1500 Pre-Clinical Pharmacokinetics of MRX-I in Rodents and Dogs X. Y. Chen 1, Z. W. Gao 1, H. Yuan 2, Z. Y. Yuan 3, D. F. Zhong 1; 1Shanghai Inst. of Materia Medica, Chinese Academy of Sci., Shanghai, China, 2 MicuRx Pharmaceuticals Inc., Shanghai, China, 3MicuRx Pharmaceuticals Inc., Hayward, CA. F-1501 In Vitro Safety Study of MRX-I, a Safer Oxazolidinone

Antibiotic Agent W. Wang1, Z. Wang 2, Y. Chang 2, H. Yuan 3, Z. Y. Yuan 1, J. L. Zhou 4, D. F. Zhong 4; 1MicuRx Pharmaceuticals Inc., Hayward, CA, 2Natl. Shanghai Ctr. For Drug Safety Evaluation & Res., Shanghai, China, 3MicuRx Pharmaceuticals Inc., Shanghai, China, 4Shanghai Inst. of Materia Medica, Chinese Academy of Sci., Shanghai, China. F-1502 Single-Dose and Repeat-Dose Toxicity of MRX-I in Rat Y. L. Qiu 1, J. Q. Jiang 1, H. X. Huang 1, C. H. Hsu 1, J. Ma -1, H. Yuan 2, M. F. Gordeev 3; 1Natl. Shanghai Ctr. For Drug Safety Evaluation & Res., Shanghai, China, 2MicuRx Pharmaceuticals Inc., Shanghai, China, 3MicuRx Pharmaceuticals Inc., Hayward, CA. F-1503 Single Oral Dose Pharmacokinetics of MRX-I in Healthy

Subjects J. Zhang1, X. J. Wu 1, J. Huang 1, J. C. Yu 1, B. N. Guo 1, G. Y. Cao 1, J. F. Wu 1, K. J. Zhang 2, H. Yuan 3, Z. Y. Yuan 4, Y. G. Shi 1, Y. Y. Zhang 1; 1 HuaShan Hosp., Fudan Univ., Shanghai, China, 2Sun Yat-Sen Univ., Guangzhou, China, 3MicuRx Pharmaceuticals Inc., Shanghai, China, 4 MicuRx Pharmaceuticals Inc., Hayward, CA. F-1504 Hematological Effect and Pharmacokinetics of Multiple Oral

Dose MRX-I in Healthy Subjects J. Zhang1, X. J. Wu 1, J. Huang 1, J. C. Yu 1, B. N. Guo 1, G. Y. Cao 1, J. F. Wu 1, H. Yuan 2, Z. Y. Yuan 3, Y. G. Shi 1, Y. Y. Zhang 1; 1HuaShan Hosp., Fudan Univ., Shanghai, China, 2MicuRx Pharmaceuticals Inc., Shanghai, China, 3MicuRx Pharmaceuticals Inc., Hayward, CA. F-1505 Pikromycin Derivative of Solithromycin: Discussion of Activity D. Pereira1, J. Li, P. Fernandes 1, S. Matsa 1; 1Cempra, Inc., Chapel Hill, NC, 2 Biolink, Morrisville, NC. F-1506 COT-303, A Novel Glycosylated Glycopeptide: I. In Vitro

Activity against Gram-Positive Bacteria H. Maki, H. Nakai, T. Hori, O. Yoshida, K. Matsui, Y. Yamano, J. Shimada; Shionogi & Co., Ltd., Osaka, Japan. F-1507 COT-303, A Novel Glycosylated Glycopeptide: II. In Vivo

Efficacy against Experimental Animal Infection Models H. Maki, R. Nakamur, M. Tsuji, O. Yoshida, K. Matsu, Y. Yamano, J. Shimada; Shionogi & Co., Ltd., Osaka, Japan. F-1508 Antimicrobial Spectrum and Biosynthesis of the New Lipo-

peptide Antibiotic, Paenibacterin E. Huang1, Y. Guo 2, A. E. Yousef1; 1The Ohio State Univ., Columbus, OH, 2 China Agricultural Univ., Beijing, China.

Final Program

153

> Tuesday SCIENTIFIC SESSIONS F-1509 In Vitro Antimicrobial Activity and In Vivo Efficacy in a

F-1518 Novel Biopolymer SYN01 Wound Treatment Reduces MRSA

Mouse Staphylococcal-Septicemia Model of Water-Soluble Tripropeptin C Analogs

Biofilms in a Partial Thickness Porcine Wound Model and Modulates the Production of IL-8 in Human Macrophages

S. Hirosawa1, H. Hashizume2, Y. Kobayashi1, R. Watabe1, K. Inoue 2, Y. Takahashi 2, S. Harada 2, S. Ohba 3, T. Masuda 3, R. Sawa2, Y. Takahashi1, T. Miyake 1, A. Nomotoector 2, M. Shibasaki2; 1Inst. of Microbial Chemistry, Hiyoshi, Kanagawa, Japan, 2Inst. of Microbial Chemistry, Tokyo, Japan, 3Inst. of Microbial Chemistry, Numazu, Shizuoka, Japan.

S. M. Townsend1, S. N. Garbers1, C. Perez1, J. Gil2, J. Valdes2, C. P. Smith1, S. C. Davis2, S. M. Baker1, W. P. Wiesman1; 1Synedgen, Inc., Claremont, CA, 2 Univ. of Miami, Miami, FL.

F-1510 Antimicrobial Activity of Six Seachaid Pharmaceuticals In-

vestigational Compounds Tested against Gram-Positive Strains R. E. Mendes1, D. J. Biedenbach 1, A. A. Watters 1, R. N. Jones 1, R. G. Sherrill 2, K. D. James 2; 1JMI Lab., N Liberty, IA, 2Seachaid Pharmaceuticals, Durham, NC. F-1511 Antimicrobial Activity and Spectrum of a Seachaid Phar-

maceuticals Investigational Compound (SP2078) Tested against Gram-Positive Pathogens R. E. Mendes, P. R. Rhomberg, M. Konrardy, R. N. Jones; JMI Lab., N Liberty, IA. F-1512 Time-Kill and Post-Antibiotic-Effect Studies of a Seachaid

Pharmaceuticals Investigational Compound (SP2078) against Wildtype and Multidrug-Resistant Pathogens R. E. Mendes, P. R. Rhomberg, D. M. Johnson, BS - MT, R. N. Jones; JMI Lab., N Liberty, IA. F-1513 Exploring Triazoles as Antimicrobials against Methicillin-

Resistant Staphylococcus aureus (MRSA) M. O. Abreu1,2, B. L. A. Ferreira2, D. Gonzaga 3, V. Ferreira3, H. C. Castro2, F. A. Alves1; 1Programa de Pós Graduação - HUAP, Rio de Janeiro, Brazil, 2 LABiEMOL - Inst. de Biologia, Rio de Janeiro, Brazil, 3Inst. de Química, Rio de Janeiro, Brazil. F-1514 CNH365.396, a Novel Marine-Derived Compound with

Potent Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) M. Hensler1, E. Soubih1, K. Jang 1, W. Thienphrapa 1, J. Locke2, M. Cunningham2, B. Kwan2, S. Nam1, C. Kauffman1, D. Beatty1, K. J. Shaw2, V. Nizet 1, W. Fenical1; 1Univ. Calif., San Diego, CA, 2Trius Therapeutics, San Diego, CA. F-1515 Antivirulence Agents against MRSA and Streptococcus pyo-

genes M. Shoham, G. Yu, B. Truitt, M. Pesho, V. Khodaverdian, L. Bollinger, A. Nash, R. Viswananthan; Case Western Reserve Univ., Cleveland, OH. F-1516 Killing and Lysis of Staphylococcus aureus and other Staphylo-

cocci by an Engineered Endolysin


-----------------------------------------------------------------------177(F) Poster Session Novel Antimicrobial Approaches and Agents Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: F-1519 Activity of HPi1, a Novel Quinoxaline, against Enterotoxigenic

Bacteroides fragilis A. Hachmann, M. LaFleur, K. Lewis; Northeastern Univ., Boston, MA. F-1520 In Vitro Activity of Sodium Oxychlorosene against Multi-

drug-Resistant (MDR) Pathogens A. H. Stock1, S. S. Utley 1, S. C. Cheatham 1, M. R. Fleming 2, D. W. Smith 3, M. F. Wack 4, M. B. Kays 5; 1St. Francis Hlth., Indianapolis, IN, 2Methodist Dallas Med. Ctr., Dallas, TX, 3Indiana Univ. Hlth. Methodist Hosp., Indianapolis, IN, 4Indiana Univ. Methodist Hosp., Indianapolis, IN, 5Purdue Univ., Indianapolis, IN. F-1521 Anti-Staphylococcal and Anti-Enterococcal Activity of Novel

Protein Synthesis Inhibitors from the RX-04 Program J. M. Remy1, J. A. DeVito 1, E. M. Duffy 1, D. F. Sahm 2; 1Rib-X Pharmaceuticals, Inc., New Haven, CT, 2Eurofins Medinet, Chantilly, VA. F-1522 Antibacterial Activity of Novel RX-04 Compounds against

Biodefense Pathogens J. Hershfield 1, L. Miller 1, S. Halasohoris, N.A. 1, C. Marchand, DVM1, J. Remy 2, M. Leggio 2, J. DeVito2, A. Marra 2, A. Bhattacharjee2, Z. Kanyo2, E. Duffy 2; 1USAMRIID, Fort Detrick, 2Rib-X Pharmaceuticals, Inc., New Haven, CT. F-1523 Novel Ribosome Inhibitors are Efficacious in a Murine Respi-

ratory Tract Infection Model Caused by Streptococcus pneumoniae A. Rey1, C. DelGorge 1, A. Marra2, E. Bortolon 2, D. Molstad2, E. Duffy 2; 1 Sanofi Pharmaceuticals, Toulouse, France, 2Rib-X Pharmaceuticals, New Haven, CT. F-1524 In Vitro Activity of E-101, a Rapidly Bactericidal Myeloper-

oxidase (MPO)-Based Agent, against Key Bacterial Pathogens

A. C. Fluit1, S. van Marm1, F. Eichenseher2, M. J. Loessner2, F. Pietersma 3, E. C. H. Boel1; 1Univ. Med. Ctr. Utrecht, Utrecht, Netherlands, 2ETH Zurich, Switzerland, 3Micreos BV, Wageningen, Netherlands. F-1517 Soluble High-Affinity T Cell Receptors for the Detection

and Treatment of Superantigen-Mediated Staphylococcal aureus Diseases A. S. Chervin1, D. M. Mattis 2, N. Wang 2, W. Salgado-Pabon 3, A. R. Spaulding3, O. N. Chuang-Smith 4, L. M. Breshears 4, M. L. Peterson4, A. R. Horswill3, C. L. Quinn 1, P. M. Schlievert3,1, D. M. Kranz2,1; 1ImmuVen, Inc., Champaign, IL, 2Univ. of Illinois, Urbana, IL, 3Univ. of Iowa, Iowa City, IA, 4 Univ. of Minnesota, Minneapolis, MN.

J. Deane1, A. Simenauer1, G. A. Denys 2, P. O’Hanley 3, J. T. Stephens3, D. F. Sahm1; 1Eurofins, Chantilly, VA, 2Indiana Univ. Hlth. Path Lab, Indianapolis, IN, 3Exoxemis, Inc., Little Rock, AR. F-1525 TP-271 is a Potent, Broad-Spectrum Fluorocycline with

Activity against Community-Acquired Bacterial Respiratory and Biothreat Pathogens T. H. Grossman1, C. Fyfe 1, W. O’ Brien 1, M. Hackel2, J. A. Sutcliffe 1; 1 Tetraphase Pharmaceuticals, Watertown, MA, 2IHMA, Schaumburg, IL. F-1526 Novel 8-Heterocycle Substituted Tetracyclines are Potent and

Broad Spectrum Antibacterial Agents with Oral Bioavailability X. Xiao, Y. Deng, C. Sun, C. Chen, D. Hunt, R. Clark, C. Fyfe, W. O’Brien, T. Grossman, J. Sutcliffe; Tetraphase Pharmaceuticals, Watertown, MA.

154

September 9-12 |

TUESDAY SCIENTIFIC SESSIONS F-1527 In Vitro Synergy Studies with a Promising New Compound,

F-1538 High-Throughput Screening for Novel Antimicrobial Agents

the Tetra-para-Guanidinoethylcalix[4]arene

Using a Whole Animal Infection Model

M. Grare 1, M. Mourer 1, J. Regnouf-de-Vains1, R. E. Duval1,2; 1UMR 7565, Univ. de Lorraine CNRS, Nancy, France, 2ABC Platform, Nancy, France.

B. Fuchs1, Y. Kim 1, J. Larkins-Ford1, A. Conery 1, F. Ausubel1, E. Mylonakis2; 1Massachusetts Gen. Hosp., Boston, MA, 2Brown Univ., Providence, RI.

F-1528 In Vitro Activity of C-101 Solution, a New Eosinophil Peroxi-

dase (EPO) Containing Enzyme System against Gram-Negative and Gram-Positive Pathogens G. A. Denys1, D. Shah 2, D. F. Sahm 2, R. C. Allen3, P. O’Hanley 4, J. T. Stephens 4; 1Indiana Univ. Hlth., Indianapolis, IN, 2Eurofins, Chantilly, VA, 3 Creighton Univ. Med. Ctr., Omaha, NE, 4Exoxemis, Inc., Little Rock, AR. F-1529 Identification of a Novel Anti-PcrV Antibody That Blocks

Type Three Secretion and Provides Superior Protection in Pseudomonas aeruginosa Animal Infection Models P. Warrener, R. Varkey, J. Zha, A. DiGiandomenico, M. Camara, P. Chowdury, B. Sellman, K. Stover; MedImmune LLC, Gaithersburg. F-1530 Disposition of MGB-BP-3, a New Class of Antibacterial

Agent, after Oral Administration in a Hamster Model of Severe Clostridium difficile Associated Diarrhoea (CDAD) M. Ravic1, C. Suckling2, I. Hunter2, C. Gemmell3, P. Warn 4, A. Sattar 4, M. Saunders5; 1MGB Biopharma, Glasgow, United Kingdom, 2Univ. of Strathclyde, Glasgow, United Kingdom, 3Univ. of Glasgow and Strathclyde, Glasgow, United Kingdom, 4Euprotec, Manchester, United Kingdom, 5Kuecept, Potters Bar, United Kingdom. F-1531 SRI-011225, a First-in-Class Bactericidal Antimicrobial

Active against Drug-Resistant Pathogens

F-1539 Inhibition of Cell Division Induced by External Guide Se-

quences Targeting ftsz C. Davies Sala1, A. Soler Bistué 1,2, L. Korprapun 1, A. Zorreguieta1, M. Tolmasky2; 1Fundación Inst. Leloir IIBBA CONICET UBA, Buenos Aires, Argentina, 2California State Univ. Fullerton, CA. F-1540 Residues of Phosphopantetheine Adenylyltransferase That

Determine Susceptibility to the Inhibitor N-Fmoc-L-glutamylD-histidine Isobutylamide A. R. Akin 1, M. F. Hollis-Symynkywicz 2, W. Shu 1, K. Suefuji 1, L. Xie 1, D. N. Chin 2, B. A. Appleton 1, C. J. Balibar1; 1Novartis Inst. BioMed. Res., Emeryville, CA, 2Novartis Inst. BioMed. Res., Cambridge, MA. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------178(G3) Poster Session Pediatrics Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: G3-1541 Bacterial Meningitis and Pneumococcal Serotype Distribu-

L. Jong, K. Mortelmans, C. Green, L. Hokama, T. Tran, D. Sahner; SRI Intl., Menlo Park, CA. F-1532 In Vitro Antimicrobial Effect of Diacetyl Rhein S. Nguon1,2, J. Novakova 2, L. Kokoska2; 1Royal Univ. of Agriculture, Phnom Penh, Cambodia, 2Czech Univ. of Life Sci. Prague, Czech Republic. F-1533 Antibacterial and Antifungal Activity of 2-S-Nitrobenzyl-

tion in Children in Cameroon A. Gervaix1, J. Taguebue2, B. Ninet Bescher 1, J. Corbeil3, F. Raymond 3, G. Alcoba 1, M. Kobela 2; 1Univ. Hosp. of Geneva, Geneva, Switzerland, 2 Mother and Child Hosp. of Chantal Biya Fndn., Yaounde, Cameroon, 3 Univ. of Laval, Quebec, Canada. G3-1542 Outcomes of Invasive Meningococcal Disease in Canada

Substituted Halogenobenzimidazoles

Between 2002 and 2010

A. E. Laudy 1, E. Swietochowska1, M. Kozlowska 2, Z. Kazimierczuk. 2, S. Tyski1,3; 1Med. Univ. of Warsaw, Warsaw, Poland, 2Warsaw Univ. of Life Sci., Warsaw, Poland, 3Natl. Med.s Inst., Warsaw, Poland.

M. Sadarangani1,2, S. A. Halperin 3, W. Vaudry 4, N. Le Saux 5, R. Tsang 6, D. W. Scheifele 1, J. A. Bettinger1, For the Canadian Immunization Monitoring Program, ACTive (IMPACT); 1Univ. of British Columbia, Vancouver, Canada, 2Univ. of Oxford, Oxford, United Kingdom, 3IWK Hlth. Ctr. & Dalhousie Univ., Halifax, Canada, 4Univ. of Alberta, Edmonton, Canada, 5 Children’s Hosp. of Eastern Ontario, Ottawa, Canada, 6Natl. Microbiol. Lab., Winnipeg, Canada.

F-1534 Computational Design of Staphylococcus aureus SrtA Enzyme

Inhibitors A. H. Chan1, E. M. Weiner1, J. Wereszczynski 2, J. A. McCammon2, R. T. Clubb1; 1Univ. of California, Los Angeles, Los Angeles, CA, 2Univ. of California, San Diego, CA. F-1535 Identifying and Characterizing Inhibitors of Streptococcus

pneumoniae Enda Using a Novel PicoGreen Nuclease Assay E. J. R. Peterson, D. Kireev, W. P. Janzen S. F. Singleton; Univ. of North Carolina, Chapel Hill, NC. F-1536 Screening for Broad Spectrum Antimicrobials with Unknown

G3-1543 Epidemiology of Bacterial Meningitis in Greece, in the Era

of Conjugate Vaccines: A 7 Years Review 2005-2011 T. Georgakopoulou 1, D. Menegas 1, G. Tzanakaki 2, E. Pipa 1, A. Vernardaki 1, P. Mavraganis 1, M. Theodoridou.1, J. Kremastinou. 1; 1Hellenic Ctr. for Disease Control & Prevention, Athens, Greece, 2Nat. Meningitis Ref. Lab, Athens, Greece. G3-1544 Childhood Meningitis in the UK in the Conjugate

Targets

Vaccine Era

L. Fleck1, G. Casadei 2, K. Lewis1; 1Northeastern Univ., Boston, MA, 2The Lombardy and E. Romagna Zootechnic Inst., Parma, Italy.

M. Sadarangani1,2, L. Willis 1, S. Kadambari 3, D. F. Kelly 1, P. T. Heath3, S. Nadel 4, A. J. Pollard1, For the UK Childhood Meningitis Study Group; 1 Univ. of Oxford, Oxford, United Kingdom, 2Univ. of British Columbia, Vancouver, Canada, 3St. George’s, Univ. of London, United Kingdom, 4St. Mary’s Hosp., London, United Kingdom.

F-1537 Developing Synthetic Antibodies against Clostridium difficile

Toxins as a Potential Therapeutic S. Wong1, P. Papatheodorou 2, T. Brummelkamp3, B. Nelson 1, D. van Dyk, K. Aktories2, S. Sidhu1, J. Moffat1; 1Univ. of Toronto, Toronto, Canada, 2Univ. of Freiburg, Freiburg, Germany, 3Netherlands Cancer Inst., Amsterdam, Netherlands.

Final Program

155

> Tuesday SCIENTIFIC SESSIONS G3-1545 Acute Childhood Encephalitis in Israel: Etiology,

Epidemiology and Clinical Characteristics G. Grisaru 1, N. Yanai 1, S. Reif 1, G. Paret 2; 1Dana Children’s Hosp. Sourasky Med. Ctr., Tel-Aviv, Israel, 2Safra Children’s Hosp., Tel-Aviv, Israel. G3-1546 The Betaherpesviruses in Children with Cancer J. Goldfarb1, N. Borges 2, L. K. Gowans 1, D. Kohn 3, S. Worley 4, B. YenLieberman 1, D. Lach 1, L. Danziger-Isakov 1, P. Pellett 5; 1Cleveland Clinic Children’s Hosp., Cleveland, OH, 2Children’s Hosp. Pittsburgh, PA, 3Cleveland Clinic, Cleveland, OH, 4Cleveland Clinic Biostatistics and Quanti, Cleveland, OH, 5Wayne State Univ. Sch. of Med., Cleveland, OH. G3-1547 Bloodstream Infections at a European Pediatric Cancer

Center: Trends in Epidemiology and Outcome between 2000 and 2010 M. Floeth, G. Lubritz, A. Tragiannidis, A. Kremer, G. Goletz, R. Koeck, K. Becker, A. H. Groll; Univ. Hosp., Muenster, Germany. G3-1548 Clinical and Epidemiological Aspects of Severe Form of the

Acute Respiratory Infection at Children Z. Djolbunova; Kyrgyz State Med. Academy Dept. of Child Infectious Diseases, Bishkek, Kyrgyzstan. G3-1549 Influenza C Virus (ICV) Infection in Children Aged Tuesday SCIENTIFIC SESSIONS H-1579 Tropism Correlates with Residual Viremia and Therapy but

K-1587 Risk Factors for Multidrug Resistance Among Community

Not with Cellular HIV DNA During Successful Therapy in Naïve Patients

Onset Extended-Spectrumơ-Lactamase-Producing Escherichia coli Infections

S. G. Parisi1, S. Andreis 1, R. Scaggiante1, M. Cruciani2, R. Ferretto3, V. Manfrin4, L. Sarmati 5, M. Basso 1, M. Andreoni 5, C. Mengoli 1, G. Palù 1 1 ; Univ., Padova, Italy, 2ULSS20, Verona, Italy, 3Hosp, Schio, Italy, 4Hosp., Vicenza, Italy, 5Univ, Roma, Italy.

S. Park1, C. Kang1, Y. Wi2, K. Huh 1, S. Cho1, D. Chung1, K. Peck 1, J. Song 1 1 ; Samsung Med. Ctr., Seoul, Korea, Republic of, 2Samsung Changwon Hosp., Seoul, Korea, Republic of.

H-1580 Effect of Natural and HAART-Induced Viral Suppression

and Viral Breakthrough on Anti-HIV Antibody Proportion and Avidity in Individuals with Clade B HIV Infection S. K. Wendel1, C. E. Mullis 2, S. H. Eshleman. 2, J. Blankson2, R. Moore 2, T. C. Quinn 1,2, O. Laeyendecker 1,2; 1NIAID, Baltimore, 2JHU, Baltimore. H-1581 Digital Droplet (DD) qPCR Allows Quantitation of HIV

Proviral DNA in Aviremic HIV+ Subjects on HAART Treated with ZFN CCR5 Modified Autologous CD4 T-cells (SB-728-T) 1

1

2

3

4

5

P. Tebas , C. June , D. Stein , R. Mitsuyasu , J. Lalezari , S. Wang , G. Lee 5, M. Giedlin 5, W. Tang 5, D. Ando5; 1PENN, Philadelphia, PA, 2Albert Einstein Coll. of Med., Bronx, NY, 3UCLA, Los Angeles, CA, 4Quest Clin. Res., San Francisco, CA, 5Sangamo BioSci., Richmond, CA. H-1582 Technical and Clinical Performance Evaluation of a Fourth-

Generation HIV Assay Y. Cho , J. Choi, H. Kim, G. Shin; Korea Univ. Med. Sch., Seoul, Korea, Republic of. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------181(K) Poster Session Extended-Spectrumơ-Lactamase Enterobacteriaceae Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: K-1583 Utility of a Clinical Risk-Factor Scoring Model in Predicting

Infection with Extended-Spectrumơ-Lactamase (ESBL)Producing Enterobacteriaceae Upon Hospital Admission 1,2

1,2

1,2

2 1

S. Johnson , R. Drew , D. May , D. Anderson ; Campbell Univ. Coll. of Pharmacy and Hlth. Sci., Buies Creek, NC, 2Duke Univ. Hosp., Durham, NC. K-1584 ESBL Producing Escherichia coli and Klebsiella pneumoniae:

Update From a Tertiary Care Lebanese Health Care System E. E. Azar1, E. Salem 2, M. Jallad 2, R. Nawfal1, J. Irani 2, Z. Daoud2; 1Saint George Hosp., Beirut, Lebanon, 2Univ. of Balamand, Beirut, Lebanon. K-1585 Impact of Institutional Gram Negative (GN) Susceptibility

with Use of Ertapenem as a First Line Treatment of Infections Caused by Extended Spectrum Beta-Lactamase (ESBL) Producing Enterobacteriaceae J. Fong1, W. Huang 2, E. Radigan 2; 1Massachusetts Coll. of Pharmacy and Hlth. Sci., Worcester, MA, 2Univ. of Mass. Mem. Med. Ctr., Worcester, MA. K-1586 ESBL-Producing E.coli vs. Klebsiella spp. Infections:

Differences in Epidemiology and Outcomes S. Voit1,2, R. Klevens2, P. Nieberg1, A. Wong-Beringer 2,1; 1Huntington Hosp., Pasadena, CA, 2Univ. So California, Los Angeles, CA.

K-1588 Risk Factors for Infection and Treatment Outcome of

Extended-Spectrumơ-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Bacteremia in Adult Cancer Patients S. Park, C. Kang, S. Cho, D. Chung, K. Peck, J. Song; Samsung Med. Ctr., Seoul, Korea, Republic of. K-1589 Differences Between Patients with Isolates of CTX-M Type

Extended-Spectrumơ-Lactamase (ESBL)-Producing Escherichia coli Compared to Non-CTX-M Type ESBL-Producing E. coli K. Hayakawa1, S. Gattu 2, D. Marchaim 1, A. Bhargava1, M. Palla 1, U. M. Gudur 1, K. Alshabani 1, P. Bathina1, S. Datla1, V. Kuchipudi1, S. Shahani1, V. Upputuri1, J. A. Moshos, MT1, P. R. Lephart, 1, K. Bush2, K. S. Kaye 1; 1 Detroit Med. Ctr. (DMC), Wayne State Univ., Detroit, MI, 2Indiana Univ., Bloomington, IN. K-1590 Piperacillin/Tazobactam is Not Associated with Reduced

Survival in Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Bloodstream Infections N. F. Dewhurst1,2, S. M. Poutanen 3,4,2, B. Hamandi 4,2, L. Dresser 4,2, M. Pitre 4, A. Lin 4, D. Lowe 4; 1St. Michael’s Hosp., Toronto, Canada, 2Univ. of Toronto, Toronto, Canada, 3Mt. Sinai Hosp., Toronto, Canada, 4Univ. Hlth. Network, Toronto, Canada. K-1591 Inadequate Antibiotic Therapy is Associated with Decreased

Survival in Patients with Extended-Spectrum Beta-LactamaseProducing Enterobacteriaceae Bloodstream Infections N. F. Dewhurstt1,2, S. M. Poutanen 3,4,2, B. Hamandi4,2, L. Dresser4,2, M. PitrePharm4, A. Lin4, D. Lowe4; 1St. Michael’s Hosp., Toronto, Canada, 2 Univ. of Toronto, Toronto, Canada, 3Mt. Sinai Hosp., Toronto, Canada, 4 Univ. Hlth. Network, Toronto, Canada. K-1592 Costs of an E.coli Bacteremia in a German University Hospital R. Leistner, E. Meyer, F. Schwab, P. Dem, C. Sakellariou, S. Kruse, P. Gastmeier; Charité Univ. Med. Berlin, Inst. for Hygiene and Environmental Med., Berlin, Germany.

-----------------------------------------------------------------------182(K) Poster Session MRSA Infections Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: K-1593 Reduction in Community-Onset Methicillin-Resistant

Staphylococcus aureus in an Urban Canadian Setting A. Wilmer1, E. Lloyd-Smith 2, M. Romney 3, S. Champagne 3, M. Hull 2; 1 Univ. of British Columbia, Vancouver, Canada, 2St. Paul’s Hosp., Vancouver, Canada, 3St. Paul’s Hosp., Vancouver, Canada. K-1594 Rapid Screening Tests for MRSA Did Not Decrease Postop-

erative MRSA Infections in Patients with Inflammatory Bowel Disease (IBD) Y. Takahashi, Y. Takesue, K. Ichiki, K. Nakajima, M. Uchino, H. Ikeuchi; Hyogo Coll. of Med., Nishinomiya, Japan.

158

September 9-12 |

TUESDAY SCIENTIFIC SESSIONS K-1595 Mupirocin Resistance in Methicillin-Resistant Staphylococcus

aureus (MRSA) in Singapore General Hospital (SGH) Burns Unit (BU) J. Teo, A. L. Kwa, W. Lee, Y. Liew, T. H. Koh, S. S. Goh, M. L. Ling, C. Song, M. P. Chlebicki; Singapore Gen. Hosp., Sg, Singapore. K-1596 A Neonatal MRSA Outbreak Investigation Using Rapid

Whole Genome Sequencing

K-1597 End Stage Renal Disease (ESRD) Patients with Methicillin-

Resistant Staphylococcus aureus (MRSA) Bacteremia Show No Increased Risk for Clinical Failure B. Bajoka1, S. Arshad 2, D. Moreno 2, A. Shoyinka 2, M. J. Zervos 2,3; 1Michigan State Univ., Sch. of Med., Lansing, MI, 2Henry Ford Hosp., Detroit, MI, 3 Wayne State Univ., Sch. of Med., Detroit, MI. K-1598 Clinical Response at Day 3 of Initial Antibiotic Treatment in

Hospitalized Adult Patients with Acute Bacterial Skin and Skin Structure Infections: A Patient Chart Review Study within a US Healthcare System 1

Intensive Care Unit E. Abdala, L. P. G. Duarte, M. P. Freire, K. Y. Ibrahim, A. S. K. Magri, C. P. Garcia, L. C. Pierrotti, P. P. Gutierrez, F. Rossi, M. Bellesso, J. Pereira, L. A. Hajjar, P. M. Hoff; Inst. do Câncer do Estado de São Paulo da FMUSP, São Paulo, Brazil. K-1604 Patients Infected with Acinetobacter baumannii and Treated

with Tigecycline: The Impact of Minimal Inhibitory Concentration (MIC) on Outcomes and the Role of Different Testing Methods

Withdrawn

1

K-1603 Carbapenem-Resistant A. baumannii Bacteremia in Oncologic

1

2 1

R. Adamson , I. Lew , S. Amara , X. Huang ; Barnabas Health, South Plainfield, NJ, 2Forest Res. Inst., Jersey City, NJ. K-1599 Molecular Epidemiology of Methicillin-Resistant

Staphylococcus aureus in a Neonatal Intensive Care Unit in Japan M. Nagao, M. Kawai, G. Hotta, M. Yamamoto, Y. Matsumura, A. Matsushima, Y. Ito, S. Takakura, S. Ichiyama; Kyoto Univ. Hosp., Kyoto, Japan. K-1600 Comparative Epidemiology of Bacteremia Due to Methicillin-

Resistant Staphylococcus aureus (MRSA) Between Older and Younger Adults: A Propensity Score Analysis R. Kullar1, M. J. Rybak 2, K. S. Kaye3; 1Wayne State Univ., Detroit, MI, 2 Wayne State Univ., Anti-Infective Res. Lab., Detroit, MI, 3Detroit Med. Ctr./Wayne State Univ., Detroit, MI. K-1601 Age and Pitt Score Predict Early Death in Methicillin-

Resistant Staphylococcus aureus (MRSA) Bacteremia V. P. Martins1, D. Otero 1,2, A. L. Ferreira 1, A. G. Magalhães 1, L. A. Mascarenhas 1,2, F. L. Cardoso 1, S. A. Nouér1; 1Univ. Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 2Inst. Natl. do Cancer, Rio de Janeiro, Brazil.

-----------------------------------------------------------------------183(K) Poster Session Resistant Acinetobacter Infections Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C

K. Hayakawa, D. Marchaim, P. Bathina, D. R. Abbadi, J. M. Pogue, A. Bhargava, P. R. Lephart, K. S. Kaye; Detroit Med. Ctr. (DMC), Wayne State Univ., Detroit, MI, Detroit, MI. K-1605 Predictors of Treatment Failure in Patients Infected with

Resistant Acinetobacter baumannii (Ab) Treated with Colistin (COL) Plus Doripenem (DOR) L. M. Gillis, M. H. Nguyen, C. J. Clancy, R. K. Shields; Univ. of Pittsburgh, Pittsburgh, PA. K-1606 Carbapenem-Resistant Strains of Acinetobacter baumannii

Isolated from an Intensive Care Unit in Brazil: The Importance of OXA-143 and OXA-23 F. C. Neves1, W. T. Clemente1, N. Lincopan2, R. Romanelli1, L. F. Paiva 1, L. A. Jesus1, V. Nobre1; 1Univ. Federal de Minas Gerais, Belo Horizonte, Brazil, 2 Univ. de São Paulo, São Paulo, Brazil. K-1607 Colistin with Carbapenem to Treat Extensively Drug Resis-

tant A. baumannii (XDRAB) Bacteremia Achieved Better Microbiological Outcomes Than Colistin with Tigecycline A. Cheng1,2, H. Sun 1, Y. Chuang 1, C. Yang 3, C. Yang 4, Y. C. Chen 1, S. C. Chang 1; 1NTUH, Taipei, Taiwan, 2FEMH, New Taipei City, Taiwan, 3 FEMH, Taipei, Taiwan, 4NTUH, Douliou, Taiwan.

-----------------------------------------------------------------------184(K) Poster Session Resistant Gram-Negative Infections Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: K-1608 Prevalence of and Risk Factors for Biliary Carriage of

Multidrug-Resistant Bacteria E. Maseda1, G. Maggi 1, R. Gomez-Gil 1, G. Ruiz1, R. Madero1, L. Aguilar 2, F. Gilsanz 1; 1Hosp. La Paz, Madrid, Spain, 2Univ. Complutense, Madrid, Spain. K-1609 Incidence and Predictors of Bloodstream Infections Among

Carbapenem-Resistant Klebsiella pneumoniae Carriers

Presentations: K-1602 Randomized Controlled Trial of Colistin (COL) vs. Colistin

plus Fosfomycin (COL + FOS) for Infections Caused by Carbapenem-Resistant (CR) Acinetobacter baumannii R. Sirijatuphat, P. Koomanachai, V. Thamlikitkul; Siriraj Hosp., Bangkok, Thailand.

S. Amit, T. Kotlovsky, H. Mishali, M. Shapiro, M. Schwaber, Y. Carmeli; Tel-Aviv Sourasky Med. Ctr., Tel-Aviv, Israel. K-1610 Bloodstream Infections Caused by Multidrug-Resistant

Proteus Mirabilis: Epidemiology, Risk Factors and Impact of Multidrug Resistance A. Korytny, K. Reisenberg, L. Saidel-Odes, F. Schlaeffer, A. Borer; Soroka Univ. Med. Ctr. and Faculty of Hlth. Sci., Ben Gurion Univ. of the Negev, Beer Sheva, Israel.

Final Program

159

> Tuesday SCIENTIFIC SESSIONS K-1611 Impact of Isolation for Resistant Pathogens on Barcode

Escherichia coli Producing AmpCơ-Lactamases (EC-AmpC)

E. J. Ernst1, P. M. Polgreen2, B. Johannsson3, T. Naughton 3, S. J. Johnson1; 1 Univ. of Iowa Coll. of Pharm., Iowa City, IA, 2Univ. of Iowa Carver Coll. of Med., Iowa City, IA, 3Univ. of Iowa Hosp. and Clinics, Iowa City, IA.

V. Pascual1, G. Ortiz 2, M. Simó 3, N. Alonso 4, M. C. Garcia 5, M. Xercavins 3 , A. Rivera 4, M. A. Morera 3, E. Miró 4, E. Espejo 5, F. Navarro 4, M. Gurgui4, J. Pérez 3, M. Rodríguez-Carballeira1, J. Garau1, E. Calbo1; 1Hosp. Mútua de Terrassa, Barcelona, Spain, 2Hosp. de Sant Pau, Barcelona, Spain, 3 Catlab, Barcelona, Spain, 4Hosp. de Sant Pau, Barcelona, Spain, 5Consorci de Terrassa, Barcelona, Spain.

K-1612 Prolongued Versus Bolus Meropenem Infusion Impact on

Mortality R. Rodil, M. Landecho, J. Beunza, J. Azanza, J. del Pozo; Clinica Univ. de Navarra, Pamplona, Spain. K-1613 Delineation of Specific Antibiotic (Abx) Exposures as

Risk Factors (RF) for Isolation of Carbapenem-Resistant Enterobacteriaceae (CRE): A Meta-Analysis J. Teo, Y. Cai, C. Lim, W. Lee, A. L. Kwa; Singapore Gen. Hosp., Singapore, Singapore. K-1614 Quantifying the Magnitude of Clinical Virulence of KPC

Through Translational Study M. Griffith1,2, M. Advincula1, M. Malczynski 2, G. Barajas 2, C. Qi2,3, M. Scheetz1,2; 1Midwestern Univ., Downers Grove, IL, 2Northwestern Mem. Hosp., Chicago, IL, 3Northwestern Univ., Chicago, IL. K-1615 Effect of Elevated Carbapenem MICs on Patient Mortality

in Gram-Negative Bloodstream Infections M. Griffith1,2, J. Wagner1, M. Advincula1, M. Scheetz1,2; 1Midwestern Univ., Downers Grove, IL, 2Northwestern Mem. Hosp., Chicago, IL. K-1616 Burkholderia cepacia Complex Isolated from Cystic Fibrosis

Patients: Identification, Epidemiology and Resistance J. Gonzalez-Lopez, P. Martinez de Salazar, M. T. Tórtola, A. Mirambell, A. Andreu, N. Larrosa, A. Ferrer; Hosp. Vall d’Hebron, Barcelona, Spain. K-1617 Selection of E.coli ST131 CTX-M-15 (E65) by Common

Antibiotics in the Mouse Intestinal Colonisation Model F. B. Hertz, Hertz1,2,3, A. Loebner-Olesen 4, F. Hansen 1, A. M. Hammerum 5, N. Frimodt-Moeller3; 1Statens Serum Inst., RUC and HVH, Amager, Copenhagen, Denmark, 2Roskilde Univ., Roskilde, Denmark, 3Hvidovre Hosp., Hvidovre, Denmark, 4Roskilde Univ., Amager, Copenhagen, Denmark, 5 Statens Serum Inst., Amager, Copenhagen, Denmark. K-1618 The First Clinical Study on the New Beta Lactam-Beta

Lactamase Inhibitor Combination: Cefepime-Tazobactam A. Ghafur, A. Tayade, K. Priyadarshini, K. Chandra; Apollo Hosp., Chennai, India. K-1619 Bacteremia Caused by Klebsiella pneumoniae Carbapenemase

(KPC)-Producing Organisms: An Analysis of Attributable Mortality and Risk Factors for Recurrence N. Girometti1, R. E. Lewis 1, F. Tumietto1, S. Ambretti2, M. Bartoletti 1, P. Viale 1; 1Clinic of Infectious Diseases - Sant’Orsola-Malpighi Hosp., Univ. of Bologna, Bologna, Italy, 2Operative Unit of Microbiol. - Sant’OrsolaMalpighi Hosp., Univ. of Bologna, Bologna, Italy. K-1620 Factors Associated with the Development of Polymyxin B

Resistance in Klebsiella pneumoniae S. R. Rosen1, C. J. Kubin 1, K. Wright 1, A. Lat 1, E. Y. Furuya2, M. T. Yin2; 1 NewYork, Presbyterian Hosp, New York, NY, 2Columbia Univ., New York, NY.

160

K-1621 Epidemiology and Clinical Features of Infections Caused by

Medication Administration Technology Utilization

September 9-12 |

K-1622 The Changing Face of Carbapenem Resistance Among

Gram-Negative Pathogens at a Tertiary Center R. K. Shields, L. G. Clarke, C. J. Clancy, M. H. Nguyen; Univ. of Pittsburgh, Pittsburgh, PA. K-1623 Sonication: The Clue in the Diagnosis of the Source of a

Carbapenem-Resistant Klebsiella pneumoniae Outbreak Related to a Duodenoscope L. Falgueras, M. Espasa, I. Fernández, S. Capilla, M. Píriz, G. Navarro, I. Sanfeliu, D. Fontanals, F. Segura; Corporació Sanitària Parc Taulí. Inst. Univ. Parc-Taulí-UAB., Sabadell, Spain. K-1624 Impact of Multidrug Resistance on Prognosis in Pseudomonas

aeruginosa Bacteriemia M. Montero, H. Knobel, R. Terrades, L. Sorlí, J. M. Nuñez, S. Grau, F. Alvarez Lerma, J. P. Horcajada, Ph D; Hosp. del Mar, Barcelona, Spain. K-1625 Transient Emergence of Carbapenemase-Producing Klebsiella

pneumoniae ST379 in Central NJ M. E. Rosenthal1, L. Chen 2, A. Rojtman 1, B. N. Kreiswirth2; 1Jersey Shore Univ. Med. Ctr., Neptune, NJ, 2Publ. Hlth. Res. Inst. UMDNJ, Newark, NJ.

-----------------------------------------------------------------------185(K) Poster Session Use of Vancomycin, Daptomycin and/or Linezolid Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: K-1626 Creatine Phosphokinase (CPK) Elevations in Patients on

Daptomycin With or Without a Statin J. Mordino 1, E. B. Hirsch2,1, M. Golik Mahoney 1; 1Beth Israel Deaconess Med. Ctr., Boston, MA, 2Northeastern Univ., Boston, MA. K-1627 Timing of Initial Therapeutic Drug Monitoring (TDM) in

Patients with Impaired Renal Function Treated with Once Daily Administration of Vancomycin (VCM) Y. Takahashi, Y. Takesue, K. Nakajima, T. Tsuchida, S. Takubo; Hyogo Coll. of Med., Nishinomiya, Japan. K-1628 Comparative Effectiveness of Linezolid and Vancomycin

Stratified by Obesity Status among a National Veterans Affairs (VA) Cohort with Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia A. R. Caffrey1,2, L. A. Puzniak 3, D. E. Myers 3, K. L. LaPlante4,2; 1Univ. of Rhode Island Coll. of Pharmacy, Kingston, RI, 2Univ. of Rhode Island, Coll. of Pharmacy, Kingston, RI, 3Pfizer, Inc., Collegeville, PA, 4Providence VA ID Res. Program, Providence, RI.

TUESDAY SCIENTIFIC SESSIONS K-1629 A Randomized Controlled Trial to Evaluate a Strategy to

Prevent Drug-Induced Nephrotoxicity in High-Risk Patients (STOP-NT) J. J. Carreno1,2, S. L. Davis1,2, R. M. Chambers 2, J. A. Vazquez2; 1Wayne State Univ. Coll. of Pharmacy, Detroit, MI, 2Henry Ford Hosp., Detroit, MI. K-1630 Outcomes of Methicillin-Resistant Staphylococcus aureus

Bacteremia and Vancomycin Minimum Inhibitory Concentration in Hemodialysis Patients G. A. Patel, R. Sharma; State Univ. of New York Downstate Med. Ctr., Brooklyn, NY. K-1631 Efficacy and Safety of Daptomycin (DAP) in the Treatment of

Gram-Positive Infections in Patients with Renal Impairment R. Kullar1, I. McClellan 2, M. Geriak 3, G. Sakoulas3; 1Oregon State Univ. Oregon Hlth. & Sci. Univ, Portland, OR, 2Oregon State Univ., Portland, OR, 3 Sharp Mem. Hosp., San Diego, CA. K-1632 Enterococcal Bloodstream Infection During Neutropenic

Fever: Impact of Vancomycin Resistance on Mortality S. Cho1, D. Lee1, J. Choi 1, J. Kwon 2, S. Kim 3, S. Choi1, S. Park1, J. Choi1, J. Yoo1; 1Coll. of Med., The Catholic Univ. of Korea, Seoul, Korea, Republic of, 2Ilsan Hosp., Goyang-si Gyeonggi-do, Korea, Seoul, Korea, Republic of, 3 Coll. of Med., The Korea Univ. of Korea, Seoul, Korea, Republic of. K-1633 Cost-Effectiveness Analysis of Linezolid (LIN), Daptomycin

(DAP) and Vancomycin (VAN) in Methicillin-Resistant Staphylococcus aureus (MRSA) Complicated Skin and Soft Tissue Infections (cSSTI) from a Spanish Perspective S. Grau1, M. M. Alonso-Socas 2, J. Rodríguez-Baño 3, A. Soriano 4, M. Trikic 5, M. De Salas-Cansado 5; 1Hosp. del Mar, Barcelona, Spain, 2Univ. Hosp. of Tenerife, Tenerife, Spain, 3Hosp. Virgen de la Macarena, Sevilla, Spain, 4Hosp. Clìnic, Barcelona, Spain, 5Pfizer, Madrid, Spain. K-1634 Treatment and Outcomes of Patients with Daptomycin

Non-Susceptible S. aureus Associated Infection N. Fattouh, B. Ostrowsky, Y. Guo; Montefiore Med. Ctr., Bronx, NY. K-1635 Daptomycin (DAP) Outcomes in Patients (Pts) with Severe

Sepsis Due to Staphylococcal Bacteremia (SB) with Vancomycin (VAN) MICs of 2 mg/L K. Holloway, K. C. Lamp, H. Anderson, M. J. Yoon; Cubist Pharmaceuticals, Lexington, MA. K-1636 Daptomycin Resistance Following Vancomycin Failure in

Invasive Methicillin-Resistant Staphylococcus aureus Bacteremia K. A. Bauer, J. Wong, J. Gaborcik Candidate, D. A. Goff; The Ohio State Univ. Med. Ctr., Columbus, OH.

-----------------------------------------------------------------------186(L1) Poster Session Endocarditis and Other Invasive Infections Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: L1-1637 Endocarditis from Enterococcus faecalis A. R. Cremona, Losinno Juan, Ramirez Santiago, Blanco Miriam, Cazzola Laura, Firpo Soledad, Yebara Analia; Hosp. Italiano, La Plata, Argentina. L1-1638 Comparison of High Dose Daptomycin (DAP) and Dose

Optimized Vancomycin (VAN) for MRSA Bacteremia and Infective Endocarditis (IE) S. L. Davis1,2, M. J. Rybak1,3,4, J. A. Vazquez2,4, E. Hershberger 5, P. Bernardo 5, D. P. Levine 4,3; 1Wayne State Univ. Coll. of Pharmacy, Detroit, MI, 2Henry Ford Hosp., Detroit, MI, 3Detroit Med. Ctr., Detroit, MI, 4Wayne State Univ. Sch. of Med., Detroit, MI, 5Cubist Pharmaceuticals, Lexington, MA. L1-1639 578 Endocarditis in French Region: Epidemiology,

Mortality and Cost S. Sunder1, S. Baron1, F. Bastides1, T. Prazuck2, Y. Guimard3, A. Valery2, M. Massot3, L. Bernard1; 1CHRU de Tours, Tours, France, 2CHR d’Orléans, Orléans, France, 3CH de Bourges, Bourges, France. L1-1640 Relation Between Specific Bacteria, Echocardiographic

Findings, and Surgical Findings in Patients Undergoing Cardiac Surgery Due to Infectious Endocarditis Y. Maor, A. Akuka, D. Ben David, N. Keller G. Rahav; Sheba Med. Ctr., Tel Hashomer, Israel. L1-1641 Morbidity and Mortality Associated with Invasive Pneumo-

coccal Disease (IPD) Among Adults During a 3 Year Surveillance in Belgium W. E. Peetermans 1, J. Flamaing1, J. Verhaegen1, W. De Backer2, B. Delaere 3, P. Van Damme2, K. Van Herck4, Y. Van Laethem5, F. Surmont 6; 1Univ. Hosp. Leuven, Leuven, Belgium, 2Univ. of Antwerp, Edegem, Belgium, 3Cliniques Universitaires Mont-Godinne, Mont Godinne, Belgium, 4Univ. of Ghent, Ghent, Belgium, 5Univ. Hosp. St Pierre, Brussels, Belgium, 6Pfizer, Brussels, Belgium. L1-1642 The Composition of the Intestinal Microbiota is a Risk

Factor for Escherichia coli Post-Chemotherapy Bacteremia E. Montassier1, E. Batard 1, J. Hardouin 2, J. Caillon 1, T. Carton 3, N. Caroff 1, T. Gastinne 1, P. Moreau 1, G. Potel 1, F. Le Vacon 3, M. De la Cochetière 2; 1 Ctr. Hosp. Univ. de Nantes, Nantes, France, 2Faculté de Med. de Nantes, Nantes, France, 3Biofortis Res., Nantes, France. L1-1643 Clinical Relevance of Community-Acquired Severe Sepsis

and Septic Shock in Adults: An Epidemiological PopulationBased Study J. Almirall, L. Campins, J. Capdevila, J. Yebenes, R. Bisbal, A. Albis, E. Güell, J. Mendez, M. Serra; Consorci Sanitari del Maresme, MATARO, Spain.

Final Program

161

> Tuesday SCIENTIFIC SESSIONS L1-1644 Beta-Haemolytic Streptococcal Infective Endocarditis

(BHIE): Characteristics and Outcomes from a Large, MultiNational Cohort N. Fernández-Hidalgo1,2, M. L. Aznar 1,2, Z. A. Kanafani 3,4, V. H. Chu 5, B. Almirante 1,2; 1Hosp. Vall d’Hebron, Barcelona, Spain, 2Intl. Collaboration on Endocarditis, ., Spain, 3American Univ. of Beirut Med. Ctr., Beirut, Lebanon, 4Intl. Collaboration on Endocarditis, Lebanon, 5Duke Univ. Med. Ctr., Durham, NC. L1-1645 Stable Incidence but Increasing Severity of Community-

Onset Boils and Abscesses Underlies Rising Hospital Admissions in England L. Shallcross, A. C. Hayward, A. M. Johnson, J. Rosenthal, I. Petersen; Univ. Coll. London, London, United Kingdom. L1-1646 Invasive Systemic Infection among Hospitalized Diabetic

Foot Ulcer Patients Following Discharge S. Chen, J. Giurini, A. Karchmer; Beth Israel Deaconess Med. Ctr., Boston, MA. L1-1647 Comparison of Once Versus Twice Daily Dose of Amikacin

in Neonatal Early Sepsis M. Rezai; Mazandaran Univ. of Med. Sci., Sari, Iran, Islamic Republic of.

-----------------------------------------------------------------------187(L1) Poster Session Meningitis and Central Nervous System Infections Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: L1-1648 Bacterial Meningitis in Patients with Absent or Dysfunc-

tional Spleen

L1-1653 Unusual Increase in Meningococcal Disease Associated with

Serogroup C ST11/ET37 CC in Mexico City L. E. Espinosa de los Montero1,2, L. V. Jimenez3, D. Gomez 3,4, N. A. Matias5, J. A. Vazquez6, R. Abad 6, V. Medina 6, Grupo Mexicano De Trabajo En Enfermedad Meningococcica; 1Hosp., Mexico City, Mexico, 2Investigation, Hosp. Manuel GeA Gonzalez, Mexico, 3Hosp. Infantil Federico Gomez, Mexico City, Mexico, 4Hosp. Infantil de México, Distrito Federal, Mexico, 5 Med. Ctr., Mexico City, Mexico, 6Inst. of Hlth. Carlos III, Majadahonda, Madrid, Spain.

-----------------------------------------------------------------------188(L1) Poster Session Methicillin Resistant Staphylococcus aureus: Clinical Aspects Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: L1-1654 Changing Epidemiology of the Community-Onset

Staphylococcus aureus Bacteremia: 9-Years Experience in a T aiwan Emergency Department S. Pan, S. Chen, J. Wang, S. Chang; Natl. Taiwan Univ. Hosp., Taipei, Taiwan. L1-1655 Early Concomitant Antimicrobial Therapy with Vancomycin

in Combination with Gentamicin in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Clinical Failure and Nephrotoxicity Rates S. Arshad1, D. Moreno 1, A. Shoyinka 1, M. J. Zervos 1,2; 1Henry Ford Hosp., Detroit, MI, 2Wayne State Univ., Sch. of Med., Detroit, MI. L1-1656 Clinical Experience with Telavancin for Treatment of

K. S. Adriani, M. C. Brouwer, A. van der Ende, D. van de Beek; AMC, Amsterdam, Netherlands.

Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infection

L1-1649 Specific Features in Encephalitis of Unknown Origin Can

B. Soltani, S. Chi, B. Laurence, C. Fernandes, B. Suh; Temple Univ. Hosp., Philadelphia, PA.

Help Raising Aetiological Hypothesis A. Mailles1, V. Vaillant1, J. Honnorat2, J. Stahl3; 1Inst. de Veille Sanitaire, Saint Maurice cedex, France, 2Lyon’s Neuroscience Res. Ctr. Inserm Unit U1028 / CNRS 5292, Lyon, France, 3Univ. I, Grenoble, France. L1-1650 Hospitalization for Central Nervous System Infection

among Individuals With and Without End Stage Renal Disease: A Danish Population-Based Study J. D. Gunst, S. Jensen-Fangel, B. Jespersen, L. Østergaard, O. S. Søgaard; Infectious Disease, Aarhus Univ. Hosp., Denmark. L1-1651 A Patient with Meningitis Due to a Lipopolysaccharide-

Deficient N. meningitidis J. R. Piet1, A. Zariri 2, F. Fransen2, K. Schipper 1, P. van der Ley 2, D. van de Beek 1, A. van der Ende1; 1Academic Med. Ctr., Amsterdam, Netherlands, 2 Lab. of Vaccine Res., Bilthoven, Netherlands. L1-1652 Intracranial Pressure Monitoring and Treatment of

Community-Acquired Bacterial Meningitis: A Ten Year Retrospective Survey U. Hjort, U. Hjort, P. Christensen, P. Soerensen; Aalborg Hosp., Aarhus Univ. Hosp., Aalborg, Denmark.

162

September 9-12 |

L1-1657 Clinical Manifestation and Molecular Characterization of

Community-Associated MRSA (CA-MRSA) in Japan T. Yamaguchi1, Y. Miura2, D. Kawamata 3, M. Sagisaka 3, T. Matsumoto1; 1 Tokyo Med. Univ., Tokyo, Japan, 2Bunkyo Gakuin Univ. Graduate Sch., Tokyo, Japan, 3Toda Central Med. Lab., Saitama, Japan. L1-1658 Is a High Vancomycin Mic Associated with Poor Prognosis

in Methicillin-Susceptible Staphylococcus aureus Bacteremia? L. López-Cortés, C. Velasco, J. Gálvez-Acebal, M. del Toro, M. De Cueto, F. Caballero, A. Dominguez-Castellano, M. Muniain, Á. Pascual, J. Rodríguez-Baño; Hosp. Univ. Virgen Macarena, Seville, Spain.

TUESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------189(L1) Poster Session Novel Agents and Insights in Skin and Soft Tissue Infections Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: L1-1659 Initial Analysis of the CAPTURE Study: Ceftaroline

Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Including Special Risk Groups P. Santos1, A. Davis 2, A. Jandourek 3, Y. Li 3, H. Friedland 3; 1Lakes Region Gen. Healthcare, Laconia, NH, 2Provena United Samaritans Med. Ctr., Danville, IL, 3Cerexa, Inc., Oakland, CA. L1-1660 Microbiological Activity and Outcome of the Pleuromutilin

BC-3781 in a Clinical Phase 2 Trial in Acute Bacterial Skin and Skin Structure Infections (ABSSSI) S. Paukner1, Z. Ivezic-Schoenfeld 1, K. J. Tack 2, D. F. Sahm 3, W. T. Prince 1; 1 Nabriva Therapeutics AG, Vienna, Austria, 2n.a., Brighton, MI, 3Eurofins Medinet Ltd, Chantilly, VA. L1-1661 Safety Among Hospitalized Patients Receiving Ceftaroline

Fosamil (CPT-F) Treatment: A USA Retrospective Analysis of a Large Hospital Claims Database Using ICD-9-CM Codes X. Huang, B.Pharm1, A. Jandourek 2, S. Laussucq2; 1Forest Res. Inst., Inc., Jersey City, NJ, 2Cerexa, Inc, Oakland, CA. L1-1662 A Phase 2 Randomized, Double-Blinded, Dose-Ranging,

Active Controlled Efficacy and Safety Evaluation of PMX-30063 for the Treatment of Acute Skin & Skin Structure Infections (ABSSSI) Caused by Staphylococcus aureus (SA) D. Jorgensen, R. Scott, B. Korczak; PolyMedix, Inc., Radnor, PA. L1-1663 Results of a Phase 2 Study of Delafloxacin (DLX) Compared

to Vancomycin (VAN) and Linezolid (LNZ) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI) L. E. Lawrence 1, J. Longcor 1, S. Hopkins1, S. Green2, P. Mehra2, W. Sears2, W. D. O’Riordan 2, P. Manos 2; 1Rib-X Pharmaceuticals Inc., New Haven, CT, 2eStudySite, San Diego, CA. L1-1664 Safety Profile of Tedizolid Phosphate Compared to Line-

zolid in a Phase 3 ABSSSI Study E. Fang1, C. De Anda 1, A. Das2, P. Prokocimer1; 1Trius Therapeutics, San Diego, CA, 2Axistat, San Francisco, CA. L1-1665 Comparison of Investigator Assessed Clinical Outcome

Over Time of Tedizolid Phosphate vs Linezolid in a Phase 3 Study in Patients with ABSSSI C. De Anda1, E. Fang1, S. Green2, P. Mehra3, P. Prokocimer1; 1Trius Therapeutics, San Diego, CA, 2eStudySite, La Mesa, CA, 3eStudySite, Chula Vista, CA. L1-1666 Inter-Country Differences in Microbiological Testing and

Diagnoses for cSSTI in Hospitalized Patients: Results from the European REACH Study

L1-1667 Skin Surface Temperature: An Objective Measure of Severity

and Treatment Response in Acute Skin and Soft Tissue Infection M. Montalto1,2, F. Davies 2, N. Marijanovic 2, A. Meads3; 1Epworth Hosp., Richmond, Australia, 2Royal Melbourne Hosp., Parkville, Australia, 3Pegasus Health, Christchurch, New Zealand. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------190(M) Poster Session Clinical Mycology I Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: M-1668 A Built-in Multiplex Protocol to Identify the Opportunistic

Fungal Pathogen Candida glabrata A. De Las Peñas, D. Barron, M. Cuellar, I. Castaño; Inst. Potosino de Investigacion Cientifica y Tecnologica, San Luis Potosi, San Luis Potosi, Mexico. M-1669 Clinical Characteristics of Candidemia in Adults with

Hematological Malignancy and Antimicrobial Susceptibilities of the Isolates at a Medical Center in Taiwan, 2001-2010 H. Y. Tsai1,2, Chien-Yuan Chen, Shang-Yi Huang, Woei Tsay, Ming Yao, Jih-Luh Tang, Bo-Sheng Ko, Wen-Chien Chou, Hwei-Fang Tien, Po-Ren Hsueh; 1Far Eastern Mem. Hosp., New Taipei City, Taiwan, 2Far Eastern Mem. Hosp., New Taipei City, Taiwan. M-1670 Neurological, Visual, and MRI Brain Scan Findings in

87 South African Patients with HIV-Associated Cryptococcal Meningoencephalitis A. Loyse1, A. Moodley2, P. Rich 3, W. Rae 4, A. Iqbal5, A. Michowicz6, L. Bishop6, D. Wilson 6, T. S. Harrison 1; 1St George’s Univ. of London, London, United Kingdom, 2Grey’s Hosp., Pietermaritzburg, South Africa, 3 St George’s Hosp., London, United Kingdom, 4Univ. of the Free State, Bloemfontein, South Africa, 5Univ. of Kwazulu-Natal, Durban, South Africa, 6 Edendale Hosp., Pietermaritzburg, South Africa. M-1671 Cost-Effectiveness of Caspofungin vs Liposomal

Amphotericin B for Empiric Therapy in Turkey S. J. Turner 1, E. Senol 2, A. Kara 3, D. Al-Badriyeh 4, D. C. M. Kong5, E. C. Dinleyici6; 1Univ. at Buffalo, Buffalo, NY, 2Gazi Univ., Ankara, Turkey, 3 Hacettepe Univ., Ankara, Turkey, 4Qatar Univ., Doha, Qatar, 5Monash Univ., Melbourne, Australia, 6Eskisehir Osmangazi Univ., Eskisehir, Turkey. M-1672 Pharmacoeconomics (PE) of Fluconazole (FLU) Versus (vs)

Posaconazole (POS) vs Voriconazole (VOR) for Antifungal Prophylaxis in Acute Myeloid Leukemia (AML) Patients Undergoing Consolidation Chemotherapy (CON-C) Withdrawn M-1673 Urinary Biomarkers of Acute Renal Injury in Patients with

Candiduria M. Gutiérrez-Cuadra1, J. P. Horcajada 2, B. A. Lavín 1, J. A. GómezGerique 1, M. T. García-Unzueta 1, M. C. Fariñas1; 1Univ. Hosp. Marqués de Valdecilla, Santander, Spain, 2Hosp. del Mar, Barcelona, Spain.

J. Garau1, F. Blasi 2, J. Medina 3, M. Ávila 4, K. McBride 5, H. Ostermann 6; 1 Hosp. Univ. Mutua de Terrassa, Barcelona, Spain, 2Univ. Degli Studi di Milano, Milan, Italy, 3AstraZeneca, Madrid, Spain, 4AstraZeneca Europe, Zaventem, Belgium, 5Instat Services, Inc., Chatham, NJ, 6Univ. Hosp. Munich, Munich, Germany.

Final Program

163

> Tuesday SCIENTIFIC SESSIONS M-1674 Detection of Multiple Candida Species in Oropharyngeal

M-1683 Efficacy of Anidulafungin in Patients with Invasive

Candidiasis (OPC) Patients Using Real Time PCR

Candidiasis (IC): Focus on Non-Albicans Candida spp

M. L. Herrera 1, N. P. Wiederhold2,1, W. R. Kirkpatrick 1,3, M. Olivo 1,3, S. D. Westbrook 1,3, D. K. Berg 1, S. W. Redding1, T. F. Patterson 1,3, B. L. Wickes1; 1UTHSCSA, San Antonio, TX, 2Univ. of Texas, Austin, TX, 3 STVHCS, San Antonio, TX.

U. Conte1, P. Hogan 1, H. Schlamm 1, P. Biswas 1, B. Kullberg2, M. Ruhnke 3; 1 Pfizer Inc., New York, NY, 2Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 3Charité Univ. Med., Berlin, Germany. M-1684 How Long Should Patients with Candidemia be Followed?

M-1675 Fks Mutation is a Risk Factor for Failure of Echinocandin

(EC) Therapy among Patients (pts) with Invasive Candidiasis (IC) Due to Candida glabrata (cg) but Not Other Candida Species R. K. Shields, M. H. Nguyen, E. G. Press, BS, A. L. Kwa, C. J. Clancy; Univ. of Pittsburgh, Pittsburgh, PA.

M-1685 Intra-Abdominal Candidiasis (IAC) is Under-Recognized,

but is the Most Common Type of Invasive Candidiasis (IC) and Results in Poor Outcomes

M-1676 Correlation between Circulating Fungal Biomarkers and

Clinical Outcome in Invasive Aspergillosis D. Neofytos1, K. Mullane2, D. Fredricks3, B. Granwehr 4, K. Marr 1, N. Almyroudis5, D. Kontoyiannis 4, J. Maertens 6, R. Fox 7, C. Douglas 7, R. Iannone 7, A. Kauh7, R. Railkar 7, N. Shire7; 1Johns Hopkins Univ., Baltimore, 2 Univ. of Chicago, Chicago, IL, 3Fred Hutchinson Ctr., Seattle, WA, 4Univ. of Texas Anderson, Houston, TX, 5Roswell Park Cancer Inst., SUNY, Buffalo, NY, 6UZ Leuven, Gasthuisberg, Belgium, 7Merck, Whitehouse Station, NJ. M-1677 Prevalence of Cryptococcal Antigenemia and Cost Effective-

ness of Cryptococcal Screening in Vietnam R. M. Smith1, T. A. Nguyen2, H. Ha 2, P. Thang 2, C. Thuy 3, L. X. Truong 4, H. T. Bui 5, T. H. Le 6, B. Struminger 5, M. McConnell 5, R. N. Fanfair 1, B. Park 1, J. R. Harris 1; 1CDC, Atlanta, GA, 2NIHE, Hanoi, Viet Nam, 3 NHTD, Hanoi, Viet Nam, 4PI, HCMC, Viet Nam, 5CDC, Hanoi, Viet Nam, 6CDC, HCMC, Viet Nam.

for Outcome in Hematological Malignancy Patients with Pulmonary Mucormycosis R. E. Lewis1, F. Sampsonas 2, S. Georgiadou 2, G. Chamilos 2, D. P. Kontoyiannis 2; 1Univ. of Houston Coll. of Pharmacy, Houston, TX, 2The Univ. of Texas MD Anderson Cancer Ctr., Houston, TX. M-1680 Thermomyces lanuginosus Endocarditis and Review of Endo-

carditis Due to Rare Molds

of Prognostic Factors Associated with Early Death Withdrawn M-1690 Earlier Diagnosis of Fusariosis with Aspergillus Serum

Galactomannan Testing A. Varon, M. L. S. Chiganer, M. Garnica, H. Reis, M. Paixao, G. Barreiros, T. Akiti, S. A. Nouer, M. Nucci; Federal Univ. of Rio de Janeiro, Rio de Janeiro, Brazil.

Fungal Assay on the PLEX-ID PCR-Electrospray Ionization Mass Spectrometry (ESI-MS) System

M-1681 Epidemiology, Clinical Manifestations, Management and

Outcome of 179 Cases of Aspergillus Osteomyelitis 4

M. Gamaletsou , M. Bueno , B. Moriyama , N. Sipsas , D. Kontoyiannis , E. Roilides 5, B. Brause 6,2, T. J. Walsh 2; 1Athens Univ. Med. Sch., Athens, Greece, 2Cornell Univ. Med. Sch., New York, NY, 3NIH, Bethesda, 4MD Anderson Cancer Ctr., Houston, TX, 5Aristotle Univ. Med. Sch., Thessaloniki, Greece, 6Hosp. for Special Surgery, New York, NY. M-1682 Inter-Laboratory and Inter-Study Reproducibility of a

Lateral Flow Device (LFD) for the Detection of Invasive Pulmonary Aspergillosis (IPA) N. P. Wiederhold1,2, L. K. Najvar 2,3, R. A. Bocanegra 2,3, W. R. Kirkpatrick 2,3, T. F. Patterson 2,3, C. R. Thornton4; 1Univ. of Texas, Austin, TX, 2UTHSCSA, San Antonio, TX, 3STVHCS, San Antonio, TX, 4Univ. Exeter, Exeter, United Kingdom.

September 9-12 |

(BD) in the Treatment of Invasive Candidiasis (IC)? K. Nakajima, Y. Takesue, K. Ichiki, T. Ueda, M. Komatsu, Y. Wada, T. Tsuchida, Y. Takahashi; Hyogo Coll. of Med., Nishinomiya, Japan.

M-1691 Detection and Identification of Fungi Using the Broad

S. Sivagnanam, S. Chen, C. Halliday, D. Packham; Ctr. for Infectious Diseases and Microbiol., Sydney, Australia.

164

M-1687 Does Treatment Affect the Levels of Serumơ-D-Glucan

M-1689 American Histoplasmosis in HIV-Infected Patients: A Study

M-1679 Absolute Lymphocyte Count (ALC) as a Prognostic Marker

1

Impacts its Prognosis P. Vironneau1, F. Lanternier2,3, D. Garcia-Hermoso3, G. Morizot3, C. Elie 2, F. Dromer 3, P. Herman1, R. Kania1, O. Lortholary2,3, French Mycosis Study Mycosis; 1Hosp. Lariboisiere, Paris, France, 2Hosp. Necker-Enfants Malades, Paris, France, 3Inst. Pasteur, Paris, France.

A. Fernandez-Cruz, P. Martín-Rabadán, M. Suárez, L. Rojas, M. Pérez, J. Guinea, M. Guembe, T. Peláez, C. Sánchez, E. Bouza, PROMULGA; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain.

Y. Zhao1, P. Paderu1, R. Fox 2, C. Douglas 2, R. Railkar 2, N. Shire 2, D. Perlin 1; 1PHRI Ctr., UMDNJ, Newark, NJ, 2Merck & Co., Inc., North Wales, PA.

3

M-1686 Radical Surgery of Rhino-Orbito-Cerebral Mucormycosis

without Catheter Withdrawal?

Alternative Biomarker for Invasive Aspergillosis

2

M. Nguyen 1, C. Clancy2; 1Univ. of Pittsburgh, Pittsburgh, PA, 2Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA.

M-1688 Is it Feasible to Diagnose Catheter-Related Fungemia

M-1678 Aspergillus RNA in the Blood of Patients is a Promising

1,2

P. Muñoz, M. Valerio, L. Córdova, M. Rodríguez-Creixéms, J. Guinea, P. Escribano, A. Fernández-Cruz, B. Cáliz, T. Peláez, E. Bouza, COMIC Study Group-PROMULGA; Hosp. Gen. Gregorio Marañón. Univ. of Madrid, Madrid, Spain.

P. J. Simner, J. R. Uhl, L. Hall, M. M. Weber, R. C. Walchakt, N. L. Wengenack; Mayo Clinic, Rochester, MN. M-1692 Quantitative PCR Detection of Circulating DNA in Serum

for Early Diagnosis of Mucormycosis L. Millon1,2, F. Grenouillet 1,2, F. Larosa 1, A. P. Bellanger1,2, F. Skana 1, S. Rocchi 1,2, J. Leroy 3, E. Deconinck1; 1Univ. Hosp., Besancon, France, 2UMR CNRS 6249, Besançon, France, 3Univ. Hosp., Besancon, France. M-1693 An Evaluation of Four Commercial Assays for the Detection

of Cryptococcal Antigen J. E. Bestrom, D. J. Jespersen, L. O. Rollins, M. J. Binnicker; Mayo Clinic, Rochester, MN.

TUESDAY SCIENTIFIC SESSIONS M-1694 Disseminated Histoplasmosis (DH) Before and After the

Implementation of Urine Antigen Detection Elisa (UADE) in an HIV Clinic in Guatemala B. Samayoa1,2, D. Mercado 1, E. Argueta1, C. Scheel 3, B. Guzman 1, I. Amado1, B. Gomez 3, R. Morales1, T. Chiller 3, E. Arathoon1; 1Asociacion de Salud Integral, Guatemala, Guatemala, 2Univ. de San Carlos, Guatemala, Guatemala, 3CDC, Atlanta, GA. M-1695 Correlation of Circulating Human Blood RNA Biomarkers

and Clinical Outcomes in an Observational Invasive Aspergillosis (IA) Trial N. J. Murgolo1, W. Ding 1, J. Li 1, R. A. Railkar 2, R. L. Fox2, C. M. Douglas 3, P. D. Mozley 3, E. A. Kauh4, R. Iannone 2, A. Loboda3, R. Cristescu 5, N. Shire2; 1Merck Res. Lab., Kenilworth, NJ, 2Merck Res. Lab., North Wales, PA, 3Merck Res. Lab., West Point, PA, 4Merck Res. Lab., Rahway, NJ, 5Merck Res. Lab., Boston, MA.

-----------------------------------------------------------------------191(M) Poster Session Clinical Mycology II Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: M-1696 Factors Influencing Non-Albicans Candidemia: A Case-

Case-Control Study D. P. Kofteridis, A. Valachis, D. Dimopoulou, A. Christidou, A. Adrianaki, G. Giourgouli, S. Maraki, G. Samonis; Univ. Hosp. of Heraklion, Heraklion, Greece. M-1697 The Clinical Course Following the Use of Corticosteroids for

Symptomatic Relief of Primary Pulmonary Coccidioidomycosis in Immunocompetent Persons N. Azadeh, S. Kusne, H. Vikram, M. Seville, R. Orenstein, DO, J. E. Blair; Mayo Clin. Phoenix, AZ. M-1698 Systemic Candidiasis Increased Mortality in ICU Infected

Patients with Cirrhosis H. Dupont, S. Huyard, N. Airapetian, F. Tinturier, M. Levrard, A. Seydi, Y. Mahjoub; Pole d’Anesthesie-Reanimation, CHU d’Amiens, Amiens, France. M-1699 Multicenter Evaluation of a Novel POC Assay for the Detec-

tion of Cryptococcal Antigen in HIV-Infected Persons D. Boulware1, D. Meya 2, N. Longley 3, N. Govender 4, J. Jarvis 3, B. Neary 5, K. Taseera 6, T. Chiller 7, T. Harrison 3, S. Bauman5; 1Univ. of Minn., Minneapolis, MN, 2Makerere Univ., Kampala, Uganda, 3St. George’s Univ. of London, London, United Kingdom, 4NICD, Johannesburg, South Africa, 5 IMMY, Norman, OK, 6Mbarara Univ of Sci and Tech, Mbarara, Uganda, 7 CDC, Atlanta, GA. M-1700 Fungal Intravascular Catheter Colonization without

Fungemia Should be Treated? Y. Meije, G. Fresco, P. Martín-Dávila, E. Loza, E. Gómez-GªPedrosa, J. Rodríguez, V. Pintado, J. Cobo, S. Moreno, J. Fortún; Hosp. Ramón y Cajal, Madrid, Spain. M-1701 Detection of (1,3)-Beta-D-Glucan in Bronchoalveolar

Lavage Fluid for the Diagnosis of Invasive Aspergillosis A. Atalay, G. Metan, A. N. Koc , L. G. Kaynar, H. Buyukoglan, I. Bozkurt, A. Yildirim, F. Elmali, B. Eser; Erciyes Univ., Kayseri, Turkey.

M-1702 The Use of In Vitro Lymphocyte Activation Testing to

Determine the Prevalence of Immunity to Coccidioides Among Healthy Arizona Residents without a History of Symptomatic Coccidioidomycosis J. E. Blair 1, Y. Ruiz 2, S. Duffy2, T. Pitta 1, D. Lake2; 1Mayo Clinic Arizona, Phoenix, AZ, 2Arizona State Univ., Phoenix, AZ. M-1703 Effectiveness of Posaconazole vs Fluconazole as Antifungal

Prophylaxis in Hematology-Oncology Patients at Duke University Hospital (DUH) 2004-2010 H. C. Kung1, M. D. Johnson2, R. H. Drew2, P. Saha-Chaudhuri 3, J. R. Perfect 2; 1Duke Clinical Res. Inst., Durham, NC, 2Duke Univ. Med. Ctr., Durham, NC, 3Duke Univ. Sch. of Med., Durham, NC. M-1704 Evaluation of an Aspergillus PCR Assay in Cerebrospinal

Fluid Samples of Immunocompromised Patients to Detect Cerebral Aspergillosis M. Reinwald1, M. Hummel 1, B. Spiess, 1, M. Duerken 1, H. Bertz 2, M. Barreto-Miranda 1, W. K. Hofmann 1, D. Buchheidt 1; 1Mannheim Univ. Hosp., Mannheim, Germany, 2Freiburg Univ. Hosp., Freiburg, Germany. M-1705 The Tolerability of Amphotericin B Lipid Complex Formu-

lation in Patients with Severe Infusion Reactions to Liposomal Amphotericin B D. Farmakiotis, F. P. Tverdek D. Kontoyiannis; MD Anderson Cancer Ctr., Houston, TX. M-1706 Development of Treatment Costs of Patients Undergoing

Remission Induction Chemotherapy: A Historical Comparison Before and After Introduction of Posaconazole Prophylaxis S. Heimann, O. Cornely, H. Wisplinghoff, M. Vehreschild, B. Franke, J. Glossmann, J. Vehreschild; Univ. Hosp. of Cologne, Cologne, Germany. M-1707 Pilot Prospective Study of High Dose (10 mg/kg/d) Lipo-

somal Amphotericin B (L-AmB) for the Initial Treatment of Mucormycosis: AMBIZYGO Trial F. Lanternier 1,2, S. Poiree1, C. Elie 1, P. Bakouboula 1, P. Ribaud3, M. Wolff4, E. Dannaoui 5, R. Herbrecht6, D. Garcia-Hermoso 2, O. Lortholary1,2; 1Hosp. Necker Enfants malades, Paris, France, 2Inst. Pasteur, Paris, France, 3Hosp. Saint Louis, Paris, France, 4Hosp. Bichat, Paris, France, 5Hosp. Europeen Georges Pompidou, Paris, France, 6Hosp. Hautepierre, Paris, France. M-1708 Characterization of the Cellular Immune Responses to

Rhizopus oryzae and Impact on Immunotherapeutic Strategies in Hematopoietic Stem Cell Transplantation T. Lehrnbecher1, L. Tramsen1, S. Perkhofer2, C. Lass-Flörl3, F. Roeger 1, R. Schubert1, S. Schmidt 1; 1Johann Wolfgang Goethe-Univ., Frankfurt, Germany, 2Univ. of Applied Sci. Tyrol, Innsbruck, Austria, 3Univ. of Innsbruck, Innsbruck, Austria. M-1709 Efficacy of Anidulafungin in 105 Patients with Deep Tissue

Candidiasis U. Conte1, H. Schlamm 1, P. Biswas 1, B. Kullberg2, M. Ruhnke 3; 1Pfizer Inc., New York, NY, 2Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 3Charité Univ., Berlin, Germany. M-1710 Evaluation of Caspofungin Susceptibility Testing by the New

VITEK 2 AST-YS06 Yeast Card Using a Unique Collection of FKS Wild Type and Hot Spot Mutant Isolates Including the Five Most Common Candida Species K. Astvad1, D. S. Perlin2, H. K. Johansen1, R. H. Jensen 3, M. C. Arendrup 3; 1 Rigshospitalet, Copenhagen, Denmark, 2Publ. Hlth. Res. Inst., Newark, NJ, 3 Statens Serum Inst., Copenhagen, Denmark.

Final Program

165

> Tuesday SCIENTIFIC SESSIONS M-1711 MGCD290, an Oral Fungal Hos2 Inhibitor, Enhances

the Antifungal Properties of Fluconazole following Multiple or Single Oral Dose Administration in Pre- and Post-Infection Settings J. Besterman, D. T. Nguyen, H. Ste-Croix; MethylGene Inc, Montreal, Canada. M-1712 Examination of Rhodamine 6G Accumulation in Multi-

Azoles Resistant Trichosporon asahii: Possible Role for Drug Efflux S. Toba; Oita Univ., Oita-Ken, Japan. M-1713 Effect of Combination Antimicrobial Therapy on C. albicans-

S. aureus Polymicrobial Biofilms A. Shoyinka1, N. Doyon-Reale 1, M. P. Ponniah 1, M. M. Harriot1,2, J. A. Vazquez 1; 1Henry Ford Hlth. System, Detroit, MI, 2Oakland Univ. William Beaumont Sch. of Med., Rochester, MI. M-1714 Activity of MK-3118, a New Oral Glucan Synthase Inhibitor,

Tested against Candida and Aspergillus spp. Using Two Reference Broth Microdilution (BMD) Methods M. A. Pfaller 1, S. A. Messer 1, M. R. Motyl 2, R. N. Jones 1, M. Castanheira1; 1 JMI Lab., N. Liberty, IA, 2Merck Sharp & Dohme Corp, Kenilworth, NJ. M-1715 In Vitro Susceptibility of MK-3118 against Candida and

Aspergillus Species Including Echinocandin and Azole Resistant Variants C. Jimenez-Ortigosa1, P. Paderu1, M. R. Motyl 2, D. S. Perlin1; 1Publ. Hlth. Res. Inst., Newark, NJ, 2Merck Sharp & Dohme Corp., Kenilworth, NJ. M-1716 Antimicrobial Monotherapy vs. Combination Therapy of

Aspergillus fumigatus and Pseudomonas aeruginosa Biofilms H. Zainah, E. Manavathu, D. Vager, J. A. Vazquez; Henry Ford Hosp., Detroit, MI. M-1717 In Vitro Synergy of Polymyxin B and Fluconazole against

Candida glabrata G. A. Pankey, D. S. Ashcraft; Ochsner Clin. Fndn., New Orleans, LA. M-1718 Antifungal Activity of Arasertaconazole Nitrate against

Fluconazole-Resistant Strains N. Marti1, A. Gomez-Lopez2, D. Gargallo-Viola 1, A. Guglietta 1, M. Cuenca-Estrella 2; 1Res. and Dev. Ctr. Ferrer Internacional SA, Barcelona, Spain, 2Inst. Carlos III, Madrid, Spain. M-1719 Activity of Antifungals and Their Combinations against

Aspergillus fumigatus and Aspergillus terreus by Isothermal Microcalorimetry U. Furustrand Tafin, A. Trampuz; Univ. Hosp., Lausanne, Switzerland. M-1720 Species-Specific Differences in Susceptibilities of Biofilms of

Less Common Candida Bloodstream Isolates to Echinocandins M. Simitsopoulou1, P. Peskova 1, E. Tasina 1, D. Kyrpitzi 1, A. Velegraki 2, T. Walsh 3, E. Roilides1; 1Aristotle Univ., Thessaloniki, Greece, 2Univ. of Athens, Athens, Greece, 3Cornell Univ., New York, NY.

166

September 9-12 |

-----------------------------------------------------------------------192(B) Symposium Virulence Bags: Extracellular Vesicles that Modify Host-Pathogen Interactions Tuesday, 11:15 a.m.– 12:45 p.m. . . . Esplanade Ballroom 302 UAN: 0391-9999-12-132-L04-P Conveners: Joshua D. Nosanchuk, MD - Associate Professor Albert Einstein Coll. of Med., Bronx, NY. Leonardo Nimrichter, PhD - Professor Cidade Univ., Rio de Janeiro, Brazil. Speakers: 11:15 a.m. 1721 Fungal Extracellular Exosomes: Weapons or Weakness Leonardo Nimrichter, PhD - Professor Cidade Univ., Rio de Janeiro, Brazil. 11:35 a.m. 1722 Viral Hijacking of Host Cell Exosomes for Communication Nancy Raab-Traub, PhD - Kenan Professor Univ. of North Carolina, Chapel Hill, NC. 11:55 a.m. 1723 Leishmania-Innate and Adaptive Immune Responses Dance to

Leishmania Exosomes Neil Reiner, MD - Professor of Medicine, Microbiology and Immunology Univ. of British Columbia, Vancouver, Canada. 12:15 p.m. 1724 Gene Silencing by Exosomes: A Remarkable Mechanisms for

Subverting Host Processes by Pathogens Jaap M. Middeldorp, PhD VU Univ. Med. Ctr., Amsterdam, Netherlands. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the processes of extracellular vesicle production/release; > Describe the components packaged within extracellular vesicles; and > Predict the impact of extracellular vesicles on microbial virulence. Intended Audience: Infectious diseases specialists, scientists and pharmacists of all levels of training and experience; those interested in mechanisms of microbial pathogenesis, cell communication, and host-pathogen interactions. Level: All Levels

TUESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------193(K) Symposium

------------------------------------------------------------------------

Regional Approaches to Prevention of HealthcareAssociated Antimicrobial Resistance

Emerging and Current Challenges in Injecting Drug Users

Tuesday, 11:15 a.m.–12:45 p.m. . . . . Esplanade Ballroom 300 UAN: 0391-9999-12-133-L04-P Convener: John Jernigan, MD - Director, Office of Prevention Research and Evaluation CDC, Atlanta, GA. Speakers: 11:15 a.m. 1725 Sharing Patients Among Healthcare Facilities in a Region:

Implications for Control of Multidrug-Resistant Organisms

194(L) Symposium

Tuesday, 11:15 a.m.–12:45 p.m. . . . . . . . . . . . . . . . . . Room 102 UAN: 0391-9999-12-134-L04-P Conveners: Shiranee Sriskandan, MD, PhD - Professor Imperial Coll., London, United Kingdom. Donald Levine, MD - Professor and Chief, Division of General Internal Medicine Wayne State Univ., Detroit, MI. Speakers: 11:15 a.m.

Susan S. Huang, MD, MPH - Associate Professor Univ. of California Irvine Sch. of Med., Orange, CA. 11:45 a.m. 1726 Using Local Epidemiology to Guide Control Strategies for

1728 Wound Botulism in Injecting Drug Users Duc J. Vugia, MD, MPH - Chief, Infectious Diseases Branch California Dept. of Pub. Hlth., Richmond, CA. 11:45 a.m.

Carbapenem-Resistant Enterobacteriaceae Mary Hayden, MD - Director, Division of Clinical MIcrobiology Rush Univ. Med. Ctr., Rush Med. Coll., Chicago, IL. 12:15 p.m. 1727 Follow-Up on the National Carbapenem-Resistant Enterobacte-

riaceae Intervention in Israel

1729 Anthrax in Heroin Users Tim J. Brooks, MA, MSc, FRCPath, FRSPH - Head of Rare & Imported Pathogens Department1, John Hood2, Colin Ramsay2; 1Hlth. Protection Agency, Porton Down, United Kingdom, 2Ctr. for Emergency Preparedness & Response, Salisbury, United Kingdom. 12:15 p.m.

Mitchell J. Schwaber, MD, MSc - Director Israel Ministry of Health, Tel Aviv, Israel. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss the scientific rationale for the regional approach to prevention of antimicrobial resistance; > Describe how certain healthcare facilities may serve as reservoirs of transmission to other facilities in a region; and > Review the national experience with prevention of carbapenem-resistant Enterobacteriaceae in Israel. Intended Audience: Infectious diseases clinicians and scientists, public health officials interested in healthcare-associated antimicrobial resistance and infection control.

1730 Update on Endocarditis in Drug Users Donald P. Levine, MD - Professor and Chief, Division of General Internal Medicine Wayne State Univ., Detroit, MI. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Identify new threats to injecting drug users; > Identify how such infections may present; and > Identify treatment options available. Intended Audience: Infectious diseases physicians and medical microbiologists. Level: Intermediate

Level: Intermediate/Advanced

Final Program

167

> Tuesday SCIENTIFIC SESSIONS -----------------------------------------------------------------------195(V) Symposium Influenza: Beyond the Headlines Tuesday, 11:15 a.m.–12:45 p.m. . . . . . . . . . . . . . . . . . Room 130 UAN: 0391-9999-12-135-L04-P

Presentations: 11:15 a.m.

Conveners: Guy Boivin, MD - Professor Laval Univ., Quebec, Canada. Vincent Racaniello, PhD - Professor Columbia Univ., New York, NY.

B-1734 Controlling Pseudomonas aeruginosa Infections Using a Novel

Anti-Psl/PcrV Multi-Specific Antibody Approach

Speakers: 11:15 a.m. 1731 Host Genetics of Severe Influenza Kenneth Baillie, BSc MRCP FRCA - Clinical Lecturer The Roslin Inst., Univ. of Edinburgh, Midlothian, United Kingdom. 11:45 a.m. 1732 H5N1 Influenza Viruses in Asia and Middle-East: Still a Threat? Malik Peiris, MBBS, PhD - Professor The Univ. of Hong Kong, Hong Kong. 12:15 p.m. 1733 Emergence of an Animal-Origin Influenza A H3N2 Virus in

the US Lyn Finelli, PhD - Lead, Influenza Surveillance and Outbreak Response, Influenza Division CDC, Atlanta, GA. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the epidemiological features of selected influenza virus threats; > Assess the mechanisms responsible for severe influenza diseases; > Identify risk factors for severe influenza infections; and > Discuss potential therapeutic and prophylactic modalities for specific influenza variants. Intended Audience: Infectious diseases specialists, virologists, clinical microbiologists, and pediatricians. Level: Intermediate/Advanced

-----------------------------------------------------------------------196(B) Slide Session Novel Antibody Therapy of Difficult Infections Tuesday, 11:15 a.m.–12:45 p.m. . . . . Esplanade Ballroom 310 UAN: 0391-9999-12-136-L04-P Moderators: Liise-anne Pirofski, MD - Chief, Division of Infectious Diseases, Albert Einstein College of Medicine and Montefiore Medical Center Albert Einstein Coll. of Med., Bronx, NY. Arturo Casadevall, MD, PhD - Professor of Microbiology and Immunology and Medicine; Chair, Department of Microbiology and Immunology Albert Einstein Coll. of Med. of Yeshiva Univ., Bronx, NY.

168

Objectives: Upon the completion of this Slide Session, the particpant should be able to: > Define antibody therapy; > Discuss the rationale for use of antibody therapy; > Discuss mechanisms by which antibody therapies work; and > Discuss the pathogens for which antibody therapies are being developed.

September 9-12 |

A. DiGiandomenico, PhD - Scientist II, A. Keller, BS - Research Associate II, C. Gao, PhD - Associate Scientist II, J. Hilliard, PhD - Scientist II, M. Camara, MS - Associate Scientist I, P. Warrener, MS - Scientist II, G. Rainey, PhD - Scientist II, C. Gao, PhD - Fellow, N. Dimasi, PhD - Senior Scientist, B. Sellman, PhD - Principal Scientist, C. Stover, PhD - Senior Director; MedImmune, LLC, Gaithersburg, MD. 11:30 a.m. B-1735 Efficacy of Human Intravenous Immunoglobulin (IVIG)

for the Treatment of Lethal Necrotizing Pneumonia Caused by Hypervirulent Community-Associated Methicillin-Resistant Staphylococcus aureus A. H. Duong, BS - Student1, C. Badiou, PhD - Researcher 2, H. N. Le, BA - Student 1, H. F. Chambers, MD - Professor 1, B. A. Diep, PhD - Assistant Professor 1, G. Lina, MD - Professor 2; 1Univ. California San Francisco, CA, 2 Univ. Lyon, Lyon, France. 11:45 a.m. B-1736 Anti-Alpha Toxin mAb Reduces CA-MRSA Disease Severity

an a Murine Dermonecrosis Model Through a Modulation of the Inflammatory Response B. Sellman, PhD- Principal Scientist, C. Tkaczyk, PhD - Sr. Scientist, M. Hamilton, MS - Associate Scientist, A. Datta, MD - Pathologist, T. O’Day, BS - Statistician, L. Hua, PhD - Scientist, A. Barnes, BS - Associate Scientist, C. Stover, PhD - Sr. Director; MedImmune, LLC, Gaithersburg, MD. 12:00 p.m. B-1737 Evaluation of Anti-Alpha Toxin mAb in Adjunctive Therapy

with Vancomycin in a MRSA-Induced Mouse Pneumonia Model J. J. Hilliard, PhD- Scientist II, R. Zinsou, MS - Associate Scientist I, C. Tkaczyk, PhD - Senior Scientist, L. Hua, PhD - Scientist I, Y. Shi, BS - Associate Scientist I, L. Cheng, DVM - Pathologist, B. Sellman, PhD - Principal Scientist, C. K. Stover, PhD - Senior Director; MedImmune, LLC, Gaithersburg, MD. 12:15 p.m. B-1738 Improved Antibody Therapies for the Treatment of

Clostridium difficile Infection D. P. Humphreys, PhD - Director, A. Moore, PhD - Senior Scientist, N. Fisher, BSc - Scientist, B. MacKenzie, BSc - Scientist, J. Compson, BSc Scientist, M. Oxbrow, BSc - Scientist, S. Cross, BSc - Senior Scientist, K. Tyson, PhD - Senior Scientist, D. Knight, BSc - Scientist, V. O’Dowd, BSc - Scientist, K. Herve, PhD - Scientist, D. Lightwood, PhD - Senior Group Leader; UCB Pharma, Slough, United Kingdom.

TUESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------197(C1) Slide Session Resistance in Staphylococcus aureus Tuesday, 11:15 a.m.–12:45 p.m. . . . . . . . . . . . . . . . . . Room 122 UAN: 0391-9999-12-137-L04-P Moderators: Frederic Laurent, MD, PhD - Associate Professor Hopsices Civils de Lyon, Inserm U851, Lyon, France. Rodrigo E. Mendes, PhD - Associated Director JMI Lab., North Liberty, IA.

11:45 a.m. C1-1743 Divergent Evolution of Methicillin-Resistant Staphylococcus

aureus (MRSA) ST239 in a Patient with Persistent Bacteremia S. J. van Hal, MBChB, FRACP, FRCPA - Associate Professor1,2, J. A. Steen, PhD - Researcher 3,4, I. B. Gosbell, PhD - Staff Specialist 1,5,2, B. A. Espedido, PhD - Scientist 1,5, M. A. Cooper, PhD - Professor 3, S. M. Grimmond, PhD - Professor 3,4, S. O. Jensen, PhD - Principal Scientist 1,5; 1Antibiotic Resistance Mobile Elements Group, Sch. of Med., Univ. of Western Sydney, Sydney, Australia, 2Liverpool Hosp., South West Sydney Local Hlth. District, Sydney, Australia, 3Inst. for Molecular Bioscience, Univ. of Queensland, Brisbane, Australia, 4Queensland Ctr. for Med. Genomics, Univ. of Queensland, Brisbane, Australia, 5Ingham Inst. for Applied Med. Res., Sydney, Australia. 11:55 a.m.

Objectives: Upon the completion of this Slide Session, the participant should be able to: > Discuss the emerging antibiotic resistance that’s in Staphylococcus aureus; > Discuss several biochemical based mechanisms of resistance; and > Understand impact of resistance mechanisms on therapeutic options for staphylococcal infections.

C1-1744 Cell Membrane (CM) Lipid Profiles Correlate with

Daptomycin (DAP) Resistance (R) in Methicillin-Resistant Staphylococcus aureus (MRSA)

Presentations:

N. N. Mishra, PhD - Senior Research Associate1, A. Rubio, PhD - Scientist 2, A. S. Bayer, MD - Professor 1,3; 1LA Biomedical Res. Inst. at Harbor UCLA, Torrance, CA, 2Cubist Pharmaceuticals, Lexington, MA, 3David Geffen Sch. of Med. UCLA, Los Angeles, CA.

11:15 a.m.

12:05 p.m.

C1-1739 Human Case of Invasive Osteitis: First Report of Severe

Infection Due to a Methicillin-Resistant Staphylococcus aureus Isolate Carrying the Novel mecaLGA251 Variant O. Barraud, PharmD, PhD - Biologist1,2,3, F. Laurent, PharmD, PhD Biologist 4,5, B. François, MD - Clinician 1,3, N. Hidri, MD - Biologist 1,3, C. Martin, PharmD, PhD - Biologist 1,3, M. Bes, Technician - Technician 4,5, M. Clavel, MD - Clinician 3, F. Garnier, PharmD, PhD - Biologist 1,3, M. Ploy, PharmD, PhD - Professor 1,2; 1INSERM, Limoges, France, 2Univ. Limoges, Limoges, France, 3CHU Limoges, Limoges, France, 4INSERM, Lyon, France, 5CNR Staphylocoques, Lyon, France. 11:25 a.m. C1-1740 Low Prevalence of Cassette Chromosome Recombinases

(ccr) Genes among Community-Associated Methicillin Susceptible Staphylococcus aureus (CA-MSSA)

C1-1745 Analysis of cfr-Carrying Plasmids in Staphylococcus epidermidis

and Staphylococcus aureus from Two Hospitals in Ohio R. E. Mendes, PhD - Dir1, L. M. Deshpande, PhD - Res Scientist 1, H. F. Bonilla, MD - Professor 2, M. D. Huband, BS - Senior Principal Scientist 3, R. N. Jones, MD - CEO 1, J. P. Quinn, MD - Senior Advisor 3; 1JMI Lab., North Liberty, IA, 2UPMC Mercy, Pittsburgh, PA, 3Pfizer Inc, Groton, CT. 12:15 p.m. C1-1746 Dynamics of Excision of the Staphylococcal Cassette Chro-

mosome mec (SCCmec) in Methicillin-Resistant Staphylococcus aureus (MRSA) M. Stojanov, Master of Science - PhD Student1, P. Moreillon, MD-PhD - Professor 1, O. Sakwinska, PhD - Researcher 2; 1UNIL, Lausanne Univ., Lausanne, Switzerland, 2Nestlé Res. Ctr., Lausanne, Switzerland. 12:25 p.m.

Withdrawn

C1-1747 Expression of Multidrug Resistance Efflux Pump

11:25 a.m. C1-1741 Biochemical Mechanisms of Sulfonamide Resistance in

Staphylococcus aureus E. C. Griffith, Pharm D - GHS, R. E. Lee, PhD - Member; St. Jude, Memphis, TN. 11:35 a.m. C1-1742 Thickened Cell Wall as a Mechanism for Increased

Telavancin Minimum Inhibitory Concentration (MIC) in Methicillin-Resistant Staphylococcus aureus (MRSA)

(MDR-EP) Genes in Clinical and Environmental Isolates of Staphylococcus aureus B. D. Schindler, PhD - Postdoctoral Fellow1, C. Kosmidis, MD - Fellow 2, P. L. Jacinto, MD - Fellow 2, D. Patel, MD - Fellow 2, K. Bains, MD Fellow 2, S. M. Seo, MT - Laboratory Associate 1, G. W. Kaatz, MD - Professor of Medicine 1; 1John D. Dingell VA Med. Ctr., Detroit, MI, 2Wayne State Univ. Sch. of Med., Detroit, MI. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

K. Ryan, PharmD Candidate - Research Assistant, S. Jett, PhD - Director, HSC EM Facility, R. C. Mercier, PharmD - Associate Professor; Univ. of New Mexico, Albuquerque, NM.

Final Program

169

> Tuesday SCIENTIFIC SESSIONS -----------------------------------------------------------------------198(G) Slide Session Global Pediatrics Tuesday, 11:15 a.m.–12:45 p.m. . . . . Esplanade Ballroom 309 UAN: 0391-9999-12-138-L04-P Moderators: Karina M. Butler, MB, DCh - Professor Our Lady’s Children’s Hosp., Dublin, Ireland. Mike Sharland, MD - Professor of Paediatric Infectious Diseases St. George’s Hosp. and Med. Sch., London, United Kingdom. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Discuss current epidemiology of pediatric infectious diseases on a global scale; > Discuss cutting-edge management issues in pediatric infections; and > Discuss aspects of the global impact of infections in children. Presentations: 11:15 a.m. G-1748 Multiplication of Coxsackie Bs and Other Non Polio

Enteroviruses on L20B Cell Line B. S. Oderinde, Mr, Masters in Medical Laborary Science (MMLS) Lecturer1,2, M. M. Baba, PhD - Lecturer 1,2, A. J. Williams, PhD - Microbiologist 3, D. N. Bukbuk, Masters - Lecturer 1, M. J. Bamaiyi, BSc - Technician 2, M. T. Akinola, BSc - Technologist 2, J. Dawurung, BSc- Technician 2, H. Adamu, HND / AIMLT - Technologist 2, T. Muhammed, Masters - Technologist 2; 1Univ. of Maiduguri , Maiduguri, Nigeria, 2WHO Natl. Polio/ ITB Lab., Univ. of Maiduguri Teaching Hosp., Maiduguri, Nigeria, 3CDC, Atlanta, GA. 11:30 a.m. G-1749 A Prospective Observational Study of the Safety and

Tolerability of Oseltamivir in Children Aged up to 24 Months B. Rath1, W. A. Blumentals 2, M. K. Miller. 3, K. A. Starzyk4, B. Tetiurka5, M. Wollenhaupt6; 1Charite Univ. Med. Ctr., Berlin, Germany, 2Hoffmann-La Roche, Inc., Nutley, NJ, 3Genentech, Inc., South San Francisco, CA, 4Outcome, Cambridge, MA, 5Niepubliczny Zaklad Opieki Zdrowotnej Salmed, Leczna, Poland, 6F. Hoffmann, La Roche Ltd., Basel, Switzerland. 11:45 a.m. G-1750 Appropriateness of Currently Recommended Antibiotics

(AB) in Treatment of Late Onset Sepsis (LOS) in Five European Countries I. Lutsar, MD, PhD - Professor, NeoMero Consortium; Univ. of Tartu, Tartu, Estonia.

12:00 p.m. G-1751 Multicenter Study of the Burden of Invasive Neonatal Group

B Streptococcal Disease L. Rivera, MD - Professor 1, X. Saez Llorenz, MD - Professor 2, J. Feris Iglesias, MD - Professor 3, M. Ip, MD - Professor4, S. Saha, MD - Professor 5, P. Adrian, PhD - Senior Researcher 6, I. Boudville, MD - Head Epidemiology, Region International 7, M. C. Cunnington, PhD - Epidemiologist 8, M. Kyaw, PhD - Associate Director 9, K. Slobod, MD - Head, Bacterial Advanced Program 10; 1Hosp. Nuestra Sra Altagracia, Santo Domingo, Dominican Republic, 2Hosp. del Nino, Panama City, Panama, 3Hosp. Infantil Dr Robert Reid, Santo Domingo, Dominican Republic, 4Chinese Univ. of Hong Kong, Hong Kong, China, 5Dhaka Shishu Hosp., Dhaka, Bangladesh, 6Univ. of Witwatersrand, Johannesberg, South Africa, 7NVD, Singapore, Singapore, 8 Novartis Vaccines & Diagnostics, London, United Kingdom, 9MedImmune, Washington, D.C., 10NVD, Cambridge, MA. 12:15 p.m. G-1752 Socioeconomic and Racial Disparities of Invasive Streptococcus

pneumoniae Infection among Children in Atlanta J. O. Spicer, MD, MPH - Medical Resident1, S. Thomas, MSPH - Epidemiologist 2, A. Holst, MPH - Epidemiologist 2, W. Baughman, MSPH - EIP Coordinator 2,3, M. M. Farley, MD - Professor 1,3; 1Emory Univ. Sch. of Med., Atlanta, GA, 2Emerging Infections Program, Atlanta, GA, 3VA Med. Ctr., Decatur, GA. 12:30 p.m. G-1753 Short Term Mortality Rates (STMRs), Long-Term Mortality

Rates (LTMRs), and Mortality Risk Factors (MRFs) among Children Presenting with Community-Acquired Pneumonia (CAAP) in Southern Israel D. Greenberg, MD - Professor1, N. Givon-Lavi, PhD - Lecturer 1, S. BenShimol, MD - Instructor 1, J. Bar-Ziv, MD - Professor 2, R. Dagan, MD Professor 1; 1Ben-Gurion Univ and Soroka Univ Med Ctr., Beer-Sheva, Israel, 2 Hadassah Univ Med Ctr., Jerusalem, Israel.

-----------------------------------------------------------------------199(K) Slide Session Bloodstream Infections: Catheters, Cultures and Counts Tuesday, 11:15 a.m.–12:45 p.m. . . . . . . . . . . . . . . . . . Room 121 UAN: 0391-9999-12-139-L04-P Moderators: Loreen Herwaldt, MD - Professor, Hospital Epidemiologist Univ. of Iowa Coll. of Med., Iowa City, IA. Jean-Francois Timsit, MD, PhD - Professor CHVA Michallon, Univ. Joseph Fowler Objectives: Upon the completion of this Slide Session, the participant should be able to: > Identify key epidemiologic characteristics of catheter-associated bloodstream infections; > Review the performance characteristics of electronic BSI surveillance methodologies; and > Describe the potential effect of blood culturing practice on reported bacteremia rates in children’s hospitals.

170

September 9-12 |

TUESDAY SCIENTIFIC SESSIONS Presentations: 11:15 a.m. K-1754 Resistance Prevalence in Community-Acquired and Hospi-

tal-Acquired Bloodstream Infections in European Children J. A. Bielicki, MD, MPH - Research Fellow, T. Planche, MD - Consultant Microbiologist, M. Sharland, MD - Professor, ARPEC Project Group; St. George’s Univ., London, United Kingdom. 11:30 a.m. K-1755 Evaluation of the Reporting Validity of CLABSI Data to a

Provincial Surveillance Program P. S. Fontela, MD, PhD - Professor1, I. Rocher, M.Sc. - Conseillerère en Soins Infirmiers 2, R. W. Platt, PhD - Professor 1, M. Pai, MD, PhD - Professor 1, D. L. Buckeridge, MD, PhD - Professor 1, C. Frenette, MD - Director of Infection Control 1, M. Dionne, MD - Scientific Director 2, C. Quach, MD, M.Sc. Professor 1; 1McGill Univ., Montreal, Canada, 2Inst. Natl. de Santé Publique du Québec, Montreal, Canada. 11:45 a.m. K-1756 The Validation of a Novel Surveillance System for Monitor-

ing Bloodstream Infections in the Calgary Health Region J. R. Leal, Masters- Surveillance Analyst1,2, D. B. Gregson, MD - Professor 2,1,3, T. Ross, BSc - Data Analyst 3, W. W. Flemons, MD - VP Quality, Safety and Health Information 1,2, D. L. Church, MD, PhD - Professor 2,3, K. B. Laupland, MD, MSc - Associate Professor 2,1,3; 1Alberta Hlth. Services, Calgary, Canada, 2Univ. of Calgary, Calgary, Canada, 3Calgary Lab. Services, Calgary, Canada. 12:00 p.m. K-1757 Randomized Controlled Trial of Chlorhexidine Dressing

and Highly Adhesive Dressing for Preventing Catheter-Related Infections in the ICU J. F. Timsit, MD, PhD - Head of the Medical Polyvalent ICU1, O. Mimoz, MD, PhD - Head of the Surgical ICU 2, J. C. Lucet, MD, PhD - Infection Control; Prevention 3, DRESSING2 Study Group, France; 1Univ. Hosp. Grenoble, Grenoble, France, 2Univ. Hosp. Poitiers, Poitiers, France, 3Univ. Hosp. Bichat, Paris, France. 12:15 p.m. K-1758 Epidemiology and Outcome of Hospital-Acquired Parenteral

Nutrition Catheter-Related Bacteremia (PN-CRB) D. Rodriguez-Pardo, MD, PhD - Professor, B. Almirante, MD, PhD Professor, N. Fernandez-Hidalgo, MD - Professor, C. Pigrau, MD, PhD - Professor, C. Ferrer, MS - Research Nurse, R. Sorde, MD - Research, A. M. Planes, MD,PhD - Professor, M. Palomar, MD,PhD - Professor, R. Burgos, MD, PhD - Professor, A. Pahissa, MD, PhD - Professor; Hosp. Univ. Vall d’Hebron, Barcelona, Spain. 12:30 p.m. K-1759 Variation in Paediatric Blood Culturing Strategies May

Influence Reported Rates of Bacteraemia in European Children’s Hospitals J. A. Bielicki, MD, MPH - Research Fellow, T. Planche, MD - Consultant Microbiologist, M. Sharland, MD - Professor, ARPEC Project Group; St George’s Univ., London, United Kingdom.

-----------------------------------------------------------------------200(A) Slide Session Maximizing PK/PD Modeling for Dosing, Prevention of Resistance and Clinical Outcomes Tuesday, 1:30 p.m.–4:00 p.m. . . . . . . . . . . . . . . . . . . . Room 102 UAN: 0391-9999-12-140-L04-P Moderators: George L. Drusano, MD - Director Ordway Res. Inst., Albany, NY. William W. Hope - Professor of Therapeutics and Infectious Diseases The Univ. of Manchester, Manchester, United Kingdom. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Describe novel PK/PD modeling techniques; > Illustrate methods to evaluate clinical outocmes related to PK/PD parameters; and > Discuss the application of PK/PD parameters for prevention of resistance. Presentations: 1:30 p.m. A-1760 A Threshold Concentration of Avibactam (AVI) During

the Pharmacokinetic Decline Phase, Below Whichơ-Lactamase Inhibition in Enterobacteriaceae Becomes Ineffective W. Nichols, PhD - Director1, P. Levasseur, PhD - Microbiology Consultant 2, J. Li, PhD – Sr. Scientist 3, S. Das, PhD – Sr. Scientist 4; 1AstraZeneca, Waltham, MA, 2AstraZeneca, Enghien les bains, France, 3AstraZeneca, Wilmington, DE, 4AstraZeneca, Alderley Park, United Kingdom. 1:45 p.m. A-1761 Infusion Duration Impact on Cell Kill for Combination of

Ceftaroline (CPT) & Avibactam (AVI) Against Two Klebsiella (KP) & One Enterobacter (EC) Strains A. Louie, MD - Professor 1, D. Bown, MS - Manager 1, J. McCauley, BS Tech 1, J. Rodriguez, BS - Tech 1, M. Swift, BS - Tech 1, G. Williams, PhD - Employee 2, G. L. Drusano, MD - Professor1; 1Univ. of Florida, Albany, NY, 2 Cerexa, Oakland, CA. 2:00 p.m. A-1762 A Novel Mathematical Modeling Approach to Characterize

the Pharmacodynamics (PD) of Ceftolozane (TOL)/Tazobactam (TAZ), aơ-Lactam &ơ-Lactamase Inhibitor (BLI) Combination R. L. Soon, PhD - Fellow1, A. Forrest, PharmD - Research Professor 1, J. B. Bulitta, PhD – Sr. Res. Fellow 2,1, B. T. Tsuji, PharmD – Asst. Professor 1; 1Univ. at Buffalo, Buffalo, NY, 2Monash Univ., Melb, Australia. 2:15 p.m. A-1763 A Semi-Mechanistic Pharmacokinetic/Pharmacodynamic

(PK/PD) Model for MK-7655, a Novel Beta-Lactamase Inhibitor (BLI) for Use in Combination with Imipenem/Cilastatin M. L. Rizk, PhD - Sr Research Pharmacokineticist1, G. F. Ahmed, BS - PhD Candidate 2, K. Young, MS - Biology Lead 1, M. Motyl, PhD - Biology Lead 1, J. Butterton, MD – Sr. Director 1, F. Racine, AS - Biology Member 1, J. Wu, PhD – Sr. Research Chemist 1, C. Li, PhD - Research Fellow 1, L. Wenning, PhD - Director 1; 1Merck Sharp & Dohme Corp., Whitehouse Station, NJ, 2 Univ. of Minnesota, Minneapolis, MN.

Final Program

171

> Tuesday SCIENTIFIC SESSIONS 2:30 p.m. A-1764 External Evaluation of a Mechanism-Based PK/PD Model:

Predicting Inoculum Effects E. I. Nielsen, PhD - Assistant Professor, D. Khan, MSc - PhD Student, S. Cao, PhD - Researcher, U. Lustig, MSc - Assistant, D. Hughes, PhD - P rofessor, D. I. Andersson, PhD - Professor, L. E. Friberg, PhD - Associate Professor; Uppsala Univ., Uppsala, Sweden. 2:45 p.m. A-1765 Impact of Administration of Piperacillin-Tazobactam by

Extended Infusion on Emergence of Resistance in an In Vitro Hollow Fiber Infection Model (HFIM) T. Felton, MD - Clinical Research Fellow, L. O’Connor, MRes - Medical Student, J. Goodwin, BSc - Research Assistant, A. Sharp, BSc - Research Assistant, L. Gregson, BSc - Research Technician, J. Livermore, PhD - Research Assistant, S. Howard, PhD - Research Associate, W. Hope, MD, PhD Professor; Univ. of Manchester, Manchester, United Kingdom. 3:00 p.m. A-1766 Prolonged Infusion of Piperacillin-Tazobactam for the

Treatment of Pseudomonas aeruginosa Infections G. Wu, PharMD - Clinical Pharmacy Coordinator, N. Saad, BS, PharmD Associate Director of Clinical Pharmacy and Residency Program, T. Abraham, BS, MS,, PharmD - Director of Clinical Pharmacy and Residency Program; New York Methodist Hosp., Brooklyn, NY. 3:15 p.m. A-1767 Appropriateness of Dosing Pre- and Post-Implementation of

Extended-Infusion Piperacillin/Tazobactam M. Mendez, PharmD - Infectious Diseases Clinical Pharmacist, N. Lu, PharmD - Clinical Pharmacist, S. Anderson, PharmD - Trauma Surgery Clinical Pharmacist, S. Munyaradzi, MS - Clinical Decision Support Analyst; Community Regional Med. Ctr., Fresno, CA. 3:30 p.m.

Diverse Applications of Mass Spectrometry in Clinical Microbiology Tuesday, 1:30 p.m.–4:00 p.m. . . . . . . . . . . . . . . . . . . . Room 120 UAN: 0391-9999-12-141-L04-P Moderator: Charlotte A. Gaydos, DrPH - Professor Infectious Diseases, Johns Hopkins Univ., Baltimore, MD. Objectives: Upon completion of this Slide Session, the participant should be able to: > Discuss techniques of mass spectrometry; > Review applications of mass spectrometry in clinical infectious disease diagnostics; and > Discuss MALDI-ToF and PCR-ESI mass spectrometry applications in clinical microbology. Presentations: 1:30 p.m. 1770 State-of-the-Art Minilecture

Overview of MALDI-ToF Mass Spectrometry Nathan A. Ledeboer, MD - Assistant Professor of Pathology Pathology, Med. Coll. of Wisconsin, Milwaukee, WI. 1:50 p.m. 1771 State-of-the-Art Minilecture

Overview of PCR-ESI-Mass Spectrometry Charlotte A. Gaydos, DrPH Univ., Baltimore, MD. 2:10 p.m.

A-1768 Vancomycin AUC24/MIC Ratio in Patients with Compli-

cated Bacteremia and Osteomyelitis Due to Methicillin-Resistant Staphylococcus aureus K. M. Gawronski, Pharm D - Specialty Practice Pharmacist1, J. E. Brown, PharmD, MS - Assistant Professor 2, D. A. Goff, PharmD - Specialty Practice Pharmacist Infectious Diseases 1, K. A. Bauer, PharmD - Specialty Practice Pharmacist Infectious Diseases 1; 1The Ohio State Univ. Med. Ctr., Columbus, OH, 2 State Univ. of New York, Buffalo, NY. 3:45 p.m. A-1769 Single Nucleotide Polymorphisms of ABCB1 Gene Influence

Daptomycin Pharmacokinetics in Adult Patients L. Baietto, Masters - PhD student, A. D’Avolio, BSc, MSc, SM - Researcher, F. G. De Rosa, MD - Associate Professor, J. Cusato, BSc, MSc - Biologist, S. Pace, BSc - Student, A. Calcagno, MD - Clinician, N. Pagani, MD - Clinician, C. Montrucchio, MD - Clinician, M. Simiele, BSc, MSc - PhD student, G. Di Perri, MD, DTM & H, PhD - Professor; Univ. of Turin, Turin, Italy.

172

-----------------------------------------------------------------------201(D) Slide Session

September 9-12 |

D-1772 Comparison between Matrix-Assisted Laser Desorption

Ionization-Time of Flight Mass Spectrometry (MALDI-ToF MS) and Sequencing of 16S rRNA Gene for the Identification of Difficult-to-Identify Bacterial Strains B. Rodriguez-Sanchez, PhD - Researcher, C. Sanchez-Carrillo, PharmD Researcher, E. Cercenado, PhD - Researcher, M. Marin, PhD - Researcher, A. Ruiz, PhD - Researcher, M. Rodriguez-Creixems, MD - Medical Doctor, E. Bouza, MD, PhD - Professor; Hosp. Gen. Univ. Gregorio Marañón. Univ.of Madrid. Spain., Madrid, Spain. 2:25 p.m. D-1773 Vitek-MS Mass Spectrometry is a New Accurate Technique

for the Routine Identification of Clinical Strains of Streptococcus pneumoniae P. D. Weber, PhD - Senior Microbiologist, M. Scotto, MS - MicrobiologyTechnician; BIO-VSM LAB Lab. of Clinical Microbiol., Vaires sur Marne, France.

TUESDAY SCIENTIFIC SESSIONS 2:40 p.m. D-1774 Identification of Anaerobic Bacteria by Bruker Biotyper

Matrix Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry with On-Plate Formic Acid Preparation B. Schmitt, DO- Clinical Microbiology Fellow, S. Cunningham, MT Development Technologist II, A. Dailey, MT - Clinical Lab Technologist, D. Gustafson, MT - Technical Specialist I, R. Patel, MD - Chair, Division of Clinical Microbiology; Mayo Clinic, Rochester, MN. 2:55 p.m. D-1775 Use of MALDI-ToF to Characterize Different Clonal Com-

plexes of Methicillin-Resistant Staphylococcus aureus (MRSA) 1

1

J. M. Sierra, PhD - Researcher , M. Camoez, MS - PhD Student , I. Roca, PhD - Researcher 2, J. Vila, PhD - Professor 2, M. A. Dominguez, PhD - Faculty 1; 1Hosp. Belvitge. IDIBELL, Hospitalet, Spain, 2Hosp. Clinic. CRESIB, Barcelona, Spain. 3:10 p.m.

-----------------------------------------------------------------------202(H2, H3) Interactive Symposium Advances in HIV and HCV Management Tuesday, 2:00 p.m.–4:00 p.m. . . . . . . . . . . . . . . . . . . . Room 103 UAN: 0391-9999-12-142-L02-P Developed in Cooperation with the International Antiviral Society-USA (IAS-USA) Speakers: 2:00 p.m. 1779 Update on Guidelines and Issues for Initiating Antiretroviral

Therapy in HIV Infection Ann C. Collier, MD - Professor of Medicine Univ. of Washington Sch. of Med., Seattle, WA. 2:40 p.m.

D-1776 Rapid Identification of Mycobacterium tuberculosis Resistance

1780 Clinical Management of Antiretroviral Therapy-Experienced

Using PCR and Mass Spectrometry

Patient

D. Florea, MD, PhD - Research Assist 1, D. Otelea, MD, PhD - Researcher 2, A. Hristea, MD, PhD - Lecturer3, O. Moldovan, PhD - Biologist 4, A. Macri, MD, PhD - Assistant Professor 4,5, S. Paraschiv, PhD - Biologist 2, C. Baicus, MD, PhD - Associate Professor 6,5, A. Streinu-Cercel, MD , PhD - Professor 2,5 1 ; Natl. Inst. of Infectious Diseases, Bucharest, Romania, 2Natl. Inst. of Infectious Diseases Professor Dr Matei Bals, Bucharest, Romania, 3Natl. Inst. of Infectious Diseases, Univ. of Med. and Pharmacy, Bucharest, Romania, 4 Marius Nasta Natl. Inst. of Pneumology, Bucharest, Romania, 5Univ. of Med. and Pharmacy, Bucharest, Romania, 6Colentina Clinical Hosp., Bucharest, Romania.

Pablo Tebas, MD - Professor of Medicine Univ. of Pennsylvania, Philadelphia, PA.

3:25 p.m. D-1777 Comparison of MALDI-ToF MS to Nucleic Acid Sequenc-

ing for the Identification of Clinical Isolates of Mycobacterium spp K. M. Riebe, M(ASCP) - Head Technologist, Microbiology 1, B. W. Buchan, PhD - Instructor2, M. Timke, PhD - Scientist 3, M. Kostrzewa, PhD - Scientist 3, N. A. Ledeboer, PhD - Assistant Professor 2; 1Dynacare Lab., Milwaukee, WI, 2Med. Coll. of Wisconsin, Milwaukee, WI, 3Bruker Daltonik GmbH, Bremen, Germany,. 3:40 p.m.

3:20 p.m. 1781 Clinical Management of HCV Infection: A New Paradigm David L. Wyles, MD - Associate Professor Univ. of California, San Diego, CA. Objectives: Upon completion of this Interactive Symposium Session, the participant should be able to: > Design, implement, and evaluate antiretroviral therapy in selected patients, including those who are pregnant, older, or treatment-experienced; > Design direct-acting antiviral regimens that effectively treat HCV infection in HIV/HCV coinfected patients; and > Discuss the pros and cons of antiretroviral therapy initiation. Intended Audience: Infectious diseases physicians, HIV and HCV specialists, and other clinical decision makers who are actively involved in the medical care of people with HIV/AIDS and Hepatitis C virus (HCV). Level: Advanced

D-1778 PCR-Electrospray Ionization/Mass Spectrometry as a Single

Tool for the Detection and Typing of Adenovirus in Routine Viral Diagnostics of Stem Cell Transplant Patient J. Le Goff, PharmD, PhD - Associate Professor1, L. Feghoul, PharmD Doctor 1, J. Dalle, MD, PhD - Professor 2, R. Peffault Delatour, MD, PhD - Associate Professor 1, F. Simon, MD, PhD - Professor 1; 1Univ. Paris Diderot, Hosp. Saint-Louis, Paris, France, 2Univ. Paris Diderot, Hosp. Robert Debré, Paris, France.

Final Program

173

> Tuesday SCIENTIFIC SESSIONS -----------------------------------------------------------------------203(C1) Symposium

-----------------------------------------------------------------------204(C2, K) Symposium

Bacterial Communication and Resistance

Global Spread of Antimicrobial Resistance: Mechanisms of Spread, Surveillance, and Control

Tuesday, 2:00 p.m.–4:00 p.m. . . . . . . Esplanade Ballroom 300 UAN: 0391-9999-12-143-L04-P Conveners: Patrice Courvalin, MD - Professor Inst. Pasteur, Paris, France. Emmanuelle M. Charpentier, PhD - Assoc. Professor MIMS, Umea Univ., Umea, Sweden. Speakers: 2:00 p.m. 1782 Conjugative Transfer in Human Cells

Tuesday, 2:00 p.m.–4:00 p.m. . . . . . . . . . . . . . . . . . . . Room 121 UAN: 0391-9999-12-144-L04-P Conveners: Didier Pittet, MD, MS - Professor of Medicine; Director, Infection Control Program and WHO Collaborating Centre on Patient Safety Univ. of Geneva Hosp., Geneva, Switzerland. Jesús Rodríguez-Baño, MD, PhD - Professor Hosp. Univ. Virgen Macarena and Univ. of Seville, Seville, Spain. Speakers: 2:00 p.m.

Christoph Dehio, PhD - Professor Univ. of Basel, Basel, Switzerland. 2:30 p.m. 1783 Bacterial Communication by Nanotubes Sigal Ben-Yehuda, PhD - Professor The Hebrew Univ. of Jerusalem, Jerusalem, Israel.

1786 Overview of Global Differences and Mechanisms for Spread Neil Woodford, PhD, FRCPath - Professor Hlth. Protection Agency, London, United Kingdom. 2:30 p.m. 1787 Building Capacity for Diagnosing Resistance Worldwide: Are

We Making Any Progress?

3:00 p.m. 1784 Promiscuous Cryptic Resistance Determinants Valerie W. Soo, PhD - Postdoctoral Research Fellow Massey Univ., Auckland, New Zealand.

Keith P. Klugman, MD, PhD - William H Foege Professor of Global Health Rollins Sch. of Publ. Hlth., Emory Univ., Atlanta, GA. 3:00 p.m. 1788 New Technologies: Towards Global Surveillance and Predic-

3:30 p.m. 1785 Transfer Limitations by CRISPRs Emmanuelle Charpentier, PhD - Associate Professor MIMS, Umea Univ., Umea, Sweden. Objectives: Upon completion of this Symposium Session, participants should be able to: > Assess the extent and limitations of resistance dissemination; > Identify the mechanisms of resistance spread recently elucidated; and > Identify the factors that favor dissemination of resistance. Intended Audience: ID physicians, pharmacists, scientists, and industry clinical microbiologists. Level: Advanced

tion? Hajo Grundmann, MD, PhD - Professor Univ. Med. Ctr. Groningen, Univ. of Groningen, Groningen, Netherlands. 3:30 p.m. 1789 Surveillance Spread and Control: Should We All Use the Euro-

pean Model? Dominique L. Monnet, PharmD, PhD ; ECDC, Stockholm, Sweden. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss the global differences and mechanisms for spread of antimicrobial resistance; > Describe the progress on recognizing antimicrobial resistance on a worldwide basis; > Review the role of new technologies in furthering or improving global surveillance; and > Evaluate the European model for antimicrobial surveillance and control. Intended Audience: Clinical microbiologists, infectious disease physicians, infection control practitioners, clinical pathologists, medical technologists, and epidemiologists. Level: Intermediate

174

September 9-12 |

TUESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------205(E) Symposium

-----------------------------------------------------------------------206(F) Symposium

Selecting Antibiotic Resistant Mutants in the Laboratory: How Best to Mimic the Real World?

Iron Transport and Homeostasis: Are There Opportunities for New Drugs?

Tuesday, 2:00 p.m.–4:00 p.m. . . . . . . Esplanade Ballroom 302 UAN: 0391-9999-12-145-L04-P


Conveners: Laura J. V. Piddock, PhD – Professor Univ. of Birmingham, Birmingham, United Kingdom. Joseph M. Blondeau, MSc, PhD - Head, Clinical Microbiology Univ. of Saskatchewan, Saskatoon, Canada.

Conveners: Malcolm G. P. Page, PhD - Professor Basilea Pharmaceutica, Basel, Switzerland. Marvin J. Miller, PhD - Professor Univ. of Notre Dame and PracticaChem, LLC, Notre Dame, IN.

Speakers:

Speakers:

2:00 p.m.

2:00 p.m.

1790 Selecting Resistant Bacteria in Liquid Media Roy Kishony, PhD - Professor Harvard Med. Sch., Boston, MA.

1794 Utilizing Iron Assimilation Processes for the Development of

New Antibiotics Marvin J. Miller, PhD - Professor Univ. of Notre Dame and PracticaChem, LLC, Notre Dame, IN.

2:30 p.m. 1791 Effect of Antioxidants and Oxygen Concentration on Antimi-

crobial Lethality and Resistance

2:30 p.m. 1795 Barriers and Possible Solutions to Iron Chelation Therapy for

Infections

Xilin Zhao, PhD - Assistant Professor UMDNJ, New Jersey Med. Sch., Newark, NJ.

Brad Spellberg, MD - Associate Professor of Medicine Harbor UCLA Med. Ctr., Torrance, CA.

3:00 p.m. 1792 Lethal and Non-Lethal Selection of Antibiotic Resistance Dan I. Andersson, PhD - Professor Uppsala Univ., Uppsala, Sweden. 3:30 p.m. 1793 In Infection Models: Ensuring the Output Accurately Reflects

the Population in the Model

3:00 p.m. 1796 Heme Aggregation Inhibitors as Anti-Malarial Agents David W. Wright, PhD - Associate Professor Vanderbilt Univ., Nashville, TN. 3:30 p.m. 1797 Siderophoreơ-Lactams

David P. Nicolau, PharmD - Dir., Ctr for Anti-Infective Res. & Dev. Hartford Hosp., Hartford, CT.

Eric Desarbre, PhD - Medicinal Chemist Basilea Pharmaceutica Intl. Ltd, Basel, Switzerland.

Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the strategies and experimental techniques used to select antibiotic resistant mutants that reflect those that can be selected by exposure to antibiotics in vivo; > Assess how to account for random mutation in ensuring statistical robustness as it relates to mutation rates and frequency of mutations; > Discuss how reactive oxygen species may influence both mutation rates and mechanisms of resistance; and > Ensure that in infection models the output accurately reflects the population in the model.

Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the role of iron homeostasis in the growth of microbial pathogens, including bacteria, fungi and protozoa; > Identify and distinguish new approaches to the discovery of agents exploiting iron-uptake systems in bacteria; and > Recognize the potential pitfalls in application of iron chelators in antimicrobial chemotherapy. Intended Audience: Microbiologists working in academia and in the pharmaceutical industry. Level: Intermediate

Intended Audience: Scientific and medical researchers, including postgraduate students. Level: Intermediate

Final Program

175

> Tuesday SCIENTIFIC SESSIONS -----------------------------------------------------------------------207(G) Symposium

-----------------------------------------------------------------------208(K) Symposium

Hot Topics in Pediatric Infectious Disease: 2012

Are Prevalence Surveys Still Useful for HealthcareAssociated Infection Surveillance?

Tuesday, 2:00 p.m.–4:00 p.m. . . . . . . . . . . . . . . . . . . . Room 122 UAN: 0391-9999-12-147-L04-P Conveners: Carlo Giaquinto, MD - Medical Doctor Paediatrician Azienda Ospedaliera-Univ., Padova, Italy. Jeffrey R. Starke, MD - Professor Baylor Coll. of Med., Houston, TX. Speakers: 2:00 p.m. 1798 TB or not TB? New Diagnostics and Treatment for

Tuesday, 2:00 p.m.–4:00 p.m. . . . . . . Esplanade Ballroom 305 UAN: 0391-9999-12-148-L04-P Conveners: Wing Hong Seto, MD - Director, WHO Collaborating Centre for Infection Control Hosp. Authority, Hong Kong, China. Gary L. French, MD - Professor King’s Coll., London, London, United Kingdom. Speakers: 2:00 p.m.

Childhood TB Jeffrey R. Starke, MD - Professor Baylor Coll. of Med., Houston, TX. 2:30 p.m. 1799 New Insights into Shiga Toxin-Associated HUS Marina Morigi, PhD - Head, Laboratory of Cell Biology and Xenotransplantation Mario Negri Inst. for Pharmacological Res., Bergamo, Italy.

1802 Period vs Point Prevalence Surveys: What is the Difference? Walter Zingg, MD - Senior Physician Univ. of Geneva Hosp., Geneva, Switzerland. 2:20 p.m. 1803 Prevalence Surveys: New Insights From the UK Experience Gary L. French, MD - Professor King’s Coll., London, London, United Kingdom. 2:40 p.m.

3:00 p.m. 1800 HBV and HCV Treatment in Children Giuseppe Indolfi, MD, PhD - Consultant Meyer Children’s Univ. Hosp., Florence, Italy.

1804 The Use of Prevalence Surveys in Europe Carl Suetens, MD - Senior Expert ECDC, Stockholm, Sweden. 3:00 p.m.

3:30 p.m. 1801 Impact of Expanded Valent Pneumococcal Vaccines Pia S. Pannaraj, MD, MPH - Assistant Professor of Pediatrics Univ. of Southern California, Children’s Hosp. Los Angeles, Los Angeles, CA. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss contemporary advances in pathogenesis, diagnosis and treatment of key pediatric infectious diseases and their importance to child health; > Summarize the potential impact of implementation of scientific advances to improve child health; and > Apply updated information to communication, decision-making and clinical practice. Intended Audience: Infectious disease physicians and physician extenders, clinical microbiologists, public health officials and pharmacologists. Level: Beginning/Intermediate

1805 Prevalence Surveys in Asia-Pacific: Effective Tracking of Care

Practices Benjamin J. Cowling, PhD - Assistant Professor The Univ. of Hong Kong, Hong Kong, Hong Kong. 3:20 p.m. 1806 New Prevalence Survey Tools from the CDC Shelley Magill, MD, PhD - Medical Officer CDC, Atlanta, GA. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Identify the most recent utilizations of the prevalence survey in HAI surveillance; > Discuss examples of effective application of the prevalence survey data in HAI surveillance; and > Identify the recent tools available to enhance the use of the prevalence survey. Intended Audience: ID specialists, infection control professionals, hospital epidemiologists, and public health professionals. Level: Intermediate/Advanced

176

September 9-12 |

TUESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------209 Symposium

-----------------------------------------------------------------------210(L1) Symposium

ID Quiz

Potluck: The Latest on Foodborne Infections


Tuesday, 2:00 p.m.–4:00 p.m. . . . . . . . . . . . . . . . . . . . Room 132 UAN: 0391-9999-12-150-L04-P

Conveners: Jonathan Cohen, MD - Professor Brighton and Sussex Med. Sch., Brighton, United Kingdom. Peter H. Gilligan, PhD - Professor, Pathology and Laboratory Medicine Univ. of North Carolina, Chapel Hill, NC.

Conveners: Hoonmo L. Koo, MD, MPH - Assistant Professor Baylor Coll. of Med., Houston, TX. Jakob P. Cramer, MD, MSC - Head Research Unit Physician Univ. Med. Ctr., Hamburg, Germany.

Speakers:

Speakers:

1807 Vance Fowler, Jr., MD - Professor with Tenure Duke Univ., Durham, NC.

2:00 p.m. 1816 Listeriosis: From Milk to Melons

1808 Stephen Harbarth, MD - Professor

Benjamin Silk, PhD - Staff Epidemiologist CDC, Atlanta, GA.

Univ. of Geneva Hosp., Geneva, Switzerland. 1809 Patricia Muñoz, MD, PhD - Professor of Infectious Diseases Hosp. Gregorio Marañón, Madrid, Spain.

2:20 p.m. 1817 Noroviruses: More Than a Cruise Ship Virus

1810 David L. Paterson, MD, PhD - Professor

Hoonmo L. Koo, MD, MPH - Assistant Professor Baylor Coll. of Med., Houston, TX.

Univ. of Queensland Ctr. for Clinicial Res., Brisbane, Australia. 1811 Guy Thwaites, MD - Consultant in Infectious Diseases and Microbiology Imperial Coll. London, United Kingdom.

Casey Barton Behravesh, MS, DVM, DrPH, DACVPM - Deputy Branch Chief, Outbreak Response and Prevention Branch CDC, Atlanta, GA.

1812 Helen W. Boucher, MD FACP - Associate Professor Tufts Med. Ctr., Boston, MA. 1813 Wendy Armstrong, MD - Associate Professor Infectious Disease, Emory Univ., Atlanta, GA.

3:00 p.m. 1819 Parasitic Infections in the Water Supply Julia W. Gargano, PhD - Epidemiologist CDC, NCEZID, Atlanta, GA.

1814 Yehuda Carmeli, MD - Professor Tel-Aviv Med. Ctr., Tel-Aviv, Israel. 1815 Ajit P. Limaye, MD - Professor

3:20 p.m.

Univ. of Washington, Seattle, WA. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Identify common and uncommon clinical manifestations of important infectious diseases; > Discuss important concepts in clinical microbiology; and > Discuss recent developments and emerging clinical problems in ID and clinical microbiology. Intended Audience: Clinicians, scientists, researchers, microbiologists, pharmacists, and public health physicians. Level: All levels

2:40 p.m. 1818 Salmonellosis: Recent Multistate Outbreak Investigations

1820 E. coli: Pathogenesis and Treatment of EHEC/HUS Jakob P. Cramer, MD, MSC - Head Research Unit Physician Univ. Med. Ctr., Hamburg, Germany. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Define possible foodborne infections in patients presenting with gastroenteritis; > Differentiate among the common etiologies of food-related infectious diseases; and > Summarize new information about the diagnosis and management of foodborne infectious diseases. Intended Audience: Healthcare providers and investigators with an interest in foodborne infections. Level: Intermediate

Final Program

177

> Tuesday SCIENTIFIC SESSIONS -----------------------------------------------------------------------211(P) Symposium Global Health as an Academic Discipline Tuesday, 2:00 p.m.–4:00 p.m. . . . . . . Esplanade Ballroom 310 UAN: 0391-9999-12-151-L04-P Developed in Cooperation with the American Society of Tropical Medicine and Hygiene (ASTMH) Conveners: Kevin Kain, MD - Professor of Medicine Univ. of Toronto, Toronto, Canada. Alan J. Magill, MD - Program Manager Defense Advanced Res. Programs Agency (DARPA), Arlington, VA. Speakers:

Viruses and the Central Nervous System: Diagnostic, Treatment and Recent Outbreaks Tuesday, 2:00 p.m.–4:00 p.m. . . . . . . . . . . . . . . . . . . . Room 130 UAN: 0391-9999-12-152-L04-P Conveners: Laurent Kaiser, MD - Professor, Head of the Laboratory of Clinical Virology Univ. Hosp. of Geneva, Geneva, Switzerland. Morven S. Edwards, MD - Professor Baylor Coll. of Med., Houston, TX. Speakers: 2:00 p.m.

2:00 p.m. 1821 Academic Institutions and Career Development in Global

Health Judith N. Wasserheit, MD, MDH - Professor Univ. of Washington, Seattle, WA.

1826 VZV CNS Complications Anne Gershon, MD - Professor Columbia Univ. Med. Ctr., New York, NY. 2:30 p.m. 1827 HHV6 Encephalitis in Immunocompetent and in Immuno-

compromised Hosts

2:20 p.m. 1822 CDC and Public Health Careers in Global Health Martin Cetron, MD - Director, DGMQ CDC, Atlanta, GA.

Danielle M. Zerr, MD, MPH - Professor Univ. of Washington and Seattle Children’s Hosp., Seattle, WA. 3:00 p.m. 1828 HSV Central Nervous System Infection in Neonates and Chil-

2:40 p.m. 1823 Uniformed Services Career Paths in Global Health Phil Coyne, Jr., MD, MSPH - Assistant Professor, Tropical Public Health Uniformed Services Univ. of Hlth. Sci., Bethesda, MD.

dren: Diagnostic and Treatment Monitoring David W. Kimberlin, MD - Professor of Pediatrics Univ. of Alabama, Birmingham, AL. 3:30 p.m.

3:00 p.m. 1824 Foundations and Opportunities in Global Health Regina Rabinovich, MD, MPH - Director, Department of Infectious Diseases and Tropical Medicine Bill and Melinda Gates Fndn., Seattle, WA. 3:20 p.m. 1825 European Perspective on Global Health Training and Career

Paths Johanna P. Daily, MD, MS - Associate Professor of Medicine and Microbiology and Immunology Albert Einstein Coll. of Med., Bronx, NY. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Assess the opportunities for pursuing an academic career in global health; > Discuss how to access resources and opportunities for further training in global health; and > Access websites and literature relevant to academic training and professional career development in global health. Intended Audience: Graduate students, MSc and PhD public health, ID residents and trainees, and ID fellows and MDs. Level: Beginning

178

-----------------------------------------------------------------------212(V, G) Symposium

September 9-12 |

1829 Enterovirus 71 and Brainstem Encephalitis in Asia Mong How Ooi, MRCP, PhD - Consultant Paediatrician Sarawak Gen. Hosp., Sarawak, Malaysia. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe clinical features of medically important herpes viruses and associated meningo-encephalitis; > Describe the potential advantages and limitation of available diagnostic procedures; > Discuss the role of the different treatment options; and > Describe the role of emerging enteroviruses. Intended Audience: ID physicians and specialists, clinical microbiologists, epidemiologist. Level: Intermediate/Advanced

TUESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------213 Cubist-ICAAC Award Lecture

-----------------------------------------------------------------------215(C2) Meet-the-Experts


Surveillance of Antimicrobial Resistance: Potential Sources of Bias

Tuesday, 4:30 p.m.–5:30 p.m. . . . . . . . . . . . . . . . . . . . Room 103 Conveners: M. Lindsay Grayson, MD - Professor Univ. of Melbourne, Austin Hlth., Melbourne, Australia. Craig E. Rubens, MD, PhD - Professor of Pediatrics & Global Health Univ. of Washington and Seattle Children’s, Seattle, WA. Award Lecturer:

Tuesday, 5:45 p.m.–7:00 p.m. . . . . . . Esplanade Ballroom 309 UAN: 0391-9999-12-154-L04-P Experts: 1833 Mitchell J. Schwaber, MD, MSc - Director Natl. Ctr. for Infection Control, Israel Ministry of Health, Tel Aviv, Israel.

1830 Antiviral Chemotherapy: Astonishing Progress and Formidable

1834 Kevin B. Laupland, MD - Associate Professor

Pushback - The Ying and Yang of Host-Viral Interactions

Univ. of Calgary, Calgary, Canada.

Lawrence Corey, MD - Professor, President, Director Fred Hutchinson Cancer Res. Ctr., Seattle, WA.

Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Describe which methods can be use to overcome bias in surveillance for antimicrobial resistance; > Identify the prevalence and rate data for the epidemiological interpretation of antimicrobial resistance studies; and > Identify potential bias in surveillance for antimicrobial resistance.

-----------------------------------------------------------------------214(C1, C2) Meet-the-Experts Top 10 ß-Lactamase Papers in 2012 Tuesday, 5:45 p.m.–7:00 p.m. . . . . . . Esplanade Ballroom 305 UAN: 0391-9999-12-153-L04-P

Intended Audience: Clinical microbiologists, infectious disease physicians, infection control practitioners, and epidemiologists. Level: Intermediate

Conveners: Robert A. Bonomo, MD - Professor Louis Stokes Cleveland Dep. of VA Med. Ctr., Cleveland, OH. Karen Bush, PhD - Adjunct Professor Indiana Univ., Bloomington, IN.

-----------------------------------------------------------------------216(F) Meet-the-Experts

Experts:

Meeting the Challenge of Efflux from Gram-Negative Bacteria

1831 Robert A. Bonomo, MD - Professor Louis Stokes Cleveland Dept. of VA Med. Ctr., Cleveland, OH.


1832 Karen Bush, PhD - Adjunct Professor Indiana Univ., Bloomington, IN.

Convener: Malcolm G. P. Page, PhD - Professor Basilea Pharmaceutica, Basel, Switzerland.

1832a Timothy G. Palzkill; PhD - Professor Baylor College of Medicine, Houston, TX.

Experts:

Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Discuss the changing epidemiology of beta-lactamase mediated resistance; > Recite the novel beta-lactamases that are described; and > Identify the new mechanistic developments in the fields of beta-lactamase enzymology and inhibitors.

1836 Klaas M. Pos, PhD - Professor Goethe Univ. Frankfurt, Frankfurt, Germany.

Intended Audience: Clinical microbiologists, infectious disease physicians, infection control practitioners, epidemiologists.

1837 Olga Lomovskaya, PhD - Vice President, Biology Rempex Pharmaceuticals, Inc., San Diego, CA.

Level: Intermediate

1835 Hiroshi Nikaido, MD - Professor Emeritus Univ. of California Berkeley, Berkeley, CA.

Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Describe the role of efflux in the resistance of microbial pathogens, especially Gram-negative bacteria; > Describe the mechanism of RND-type efflux pumps; and > Identify and distinguish new approaches to the discovery of agents acting against efflux systems in bacteria. Intended Audience: Microbiologists working in academia and in the pharmaceutical industry. Level: Advanced

Final Program

179

> Tuesday SCIENTIFIC SESSIONS -----------------------------------------------------------------------217(K) Meet-the-Experts

-----------------------------------------------------------------------219(M, D) Meet-the-Experts

Challenging Issues in Pediatric Infection Prevention and Control

How Can the Mycology Lab Work for You?

Tuesday, 5:45 p.m.–7:00 p.m. . . . . . . . . . . . . . . . . . . . Room 122 UAN: 0391-9999-12-156-L04-P

Tuesday, 5:45 p.m.–7:00 p.m. . . . . . . . . . . . . . . . . . . . Room 121 UAN: 0391-9999-12-158-L04-P Experts: 1842 Maiken C. Arendrup, MD, PhD - Head of Unit of Mycology Statens Serum Inst., Copenhagen, Denmark.

Experts: 1838 Walter Zingg, MD - Senior Physician Univ. of Geneva Hosp., Geneva, Switzerland. 1839 Lisa Saiman, MD, MPH - Professor of Clinical Pediatrics Columbia Univ. Med. Ctr., New York, NY. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Discuss the epidemiology of healthcare-associated infections in neonatal and pediatric patients; > Describe effective strategies for the prevention and control of infection in pediatric care settings; and > Describe the best evidence-based strategies to apply in the pediatric setting. Intended Audience: ID specialists, infection control professionals, hospital epidemiologists, public health professionals, hospital administrators, pediatric infectious diseases and infection control experts.

1843 Sean Zhang, PhD - Director, Mycology Laboratory/Assistant Professor Johns Hopkins Hosp., Johns Hopkins Sch. of Med., Baltimore, MD. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Determine when antifungal susceptibility testing is useful in clinical practice and the likely impact of introducing new antifungal susceptibility breakpoints in the diagnostic laboratory; > Recognize the advantages and pitfalls of in-house nucleic acid testing for fungal identification; and > Evaluate the cost-effectiveness and clinical use of multiplexed bacterial and fungal assays. Intended Audience: Mycology researchers, ID physicians and trainees. Level: Intermediate

Level: Beginning/Intermediate

-----------------------------------------------------------------------218(K) Meet-the-Experts Issues in the Diagnosis and Management of Prosthetic Joint Infections Tuesday, 5:45 p.m.–7:00 p.m. . . . . . . Esplanade Ballroom 310 UAN: 0391-9999-12-157-L04-P Experts: 1840 Andrej Trampuz, MD - Assistant Professor Infectious Diesases, Univ. Hosp. Lausanne, Lausanne, Switzerland. 1841 Adolf W. Karchmer, MD - Professor of Medicine, Harvard Medical School Beth Israel Deaconess Med. Ctr., Harvard Med. Sch., Boston, MA. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Discuss the latest understanding of the pathogenesis of prosthetic joint infection; > Identify the advantages and disadvantages of various diagnostic strategies; and > Assess optimal operative and non-operative management strategies for prosthetic joint infections. Intended Audience: Practicing clinicians who are often called upon to manage patients with prosthetic joint infections. Level: Intermediate/Advanced

180

September 9-12 |

---------------------------------------------------------------------------------220(C2) Meet-the-Experts Anaerobes and Surveillance: Neglected or Not? Wednesday, 7:00 a.m.–8:15 a.m. . . . Esplanade Ballroom 302 UAN: 0391-9999-12-159-L04-P Experts: 1844 Ellie J. C. Goldstein, MD - Clinical Professor of Medicine UCLA David Geffen Sch. of Med., Santa Monica, CA. 1845 David W. Hecht, MD, MS - Professor and Chair, Department of Medicine Loyola Univ. Med. Ctr., Chicago, IL. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Describe which mechanisms, species and antibiotics are the most appropriate to include for anaerobe surveillance studies; > Discuss when and the most appropriate method(s) that should be used to perform antimicrobial susceptibility testing on anaerobes; and > Describe the most appropriate method(s) that should be used for antimicrobial susceptibility testing on anaerobes. Intended Audience: Clinical microbiologists, infectious disease physicians, infection control practitioners, and epidemiologists. Level: Intermediate

NOTES

Final Program

181

> NOTES

182

September 9-12 |

> Wednesday Schedule at-a-Glance > 7:00 a.m. - 8:15 a.m. Meet-the-Experts 220 (C2) Anaerobes and Surveillance: Neglected or Not? Esplanade Ballroom 302 221 (D) Optimal Diagnostic Testing for Clostridium difficile in Clinical Practice Esplanade Ballroom 310 222 (H) Can We Safely Simplify Antiretroviral Therapy in Treatment-Experienced Patients? Esplanade Ballroom 300 223 (K) Environmental Cleaning and Infection Prevention Room 120 224 (M) Fungal Infections of the Central Nervous System Room 121

> 8:00 a.m. - 9:00 a.m. Plenary Session 225 The Use of Social Media and New Technologies in Healthcare Room 130

> 9:15 a.m. - 11:15 a.m. Interactive Symposium

Symposia 227 (A) Use of Pharmacokinetics/ Pharmacodynamics for Risk Reduction of Adverse Events Room 103

235 (V) Recognizing and Managing Antiviral Resistance Room 120

Poster Sessions 240 (A) Antifungals: Improving PK/PD and Safety Halls A-C 241 (A) Toxicokinetics and PK/PD of New and Old Fluoroquinolones Halls A-C 242 (C1) Mechanisms of Resistance to Novel Compounds Halls A-C

238 (H) Common Pathogens: Still a Problem in HIV-I Room 102 239 (K) Antimicrobial Stewardship: Perils of Prescribing Esplanade Ballroom 310

246 (F) New Ways with Old Friends: Repurposing and Novel Formulations Halls A-C 247 (F) Novel Inhibitors of Bacterial GyrB/ ParE Topoisomerase Subunits Halls A-C 248 (F) Quinolones and Beyond Halls A-C 249 (F) Targeting Gram-Negative Pathogens Halls A-C 250 (K) Bone Infections Halls A-C 251 (K) Hand Hygiene Halls A-C

253 (K) Ventilator-Associated Pneumonia Halls A-C

233 (M) Controversies in Clinical Mycology Esplanade Ballroom 300

237 (C2) MRSA: Pervasive, Persistent, and Pathogenic Esplanade Ballroom 305

245 (E) In Vitro Activity for Mycobacteria Halls A-C

229 (F) New Approaches in the Treatment of Fungal Infections Esplanade Ballroom 309

232 (L1, G) What’s New with Pneumococcus? Esplanade Ballroom 308

236 (C2) Acinetobacter: Challenges and Continued Emergence Room 132

244 (C2) Streptococcus and Enterococus Halls A-C

252 (K) Vascular Catheter and Device Related Infections Halls A-C

231 (K) A Multifaceted Approach to Preventing Surgical Site Infections Room 121

Slide Sessions

243 (C2) Antimicrobial Resistance of Miscellaneous Bacteria Halls A-C

228 (C1) Resistance in S. aureus Beyond MecA Esplanade Ballroom 302

230 (G, B) Interplay between Pathogen and Host: From Immune Deficiency to Infectious Disease Room 122

> 9:15 a.m. - 11:45 a.m.

254 (L1) Bone and Joint Infections Halls A-C 255 (L2) Urinary Tract Infection Halls A-C

Wednesday

226 (D) Challenges in the Diagnosis and Clinical Interpretation of Infections with Gram-Positive Rods Room 104

234 (P) Best Practices for Serologic Testing in Selected Parasitic Diseases Room 254

> Notes

WEDNESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------221(D) Meet-the-Experts Optimal Diagnostic Testing for Clostridium difficile in Clinical Practice Wednesday, 7:00 a.m.–8:15 a.m. . . . Esplanade Ballroom 310 UAN: 0391-9999-12-160-L04-P Experts:

Level: All Levels

-----------------------------------------------------------------------223(K) Meet-the-Experts Environmental Cleaning and Infection Prevention Wednesday, 7:00 a.m.–8:15 a.m. . . . . . . . . . . . . . . . . Room 120 UAN: 0391-9999-12-162-L04-P Experts:

1846 Mark H. Wilcox, MD - Professor

1850 John M. Boyce, MD - Hospital Epidemiologist

Leeds Teaching Hosp. NHS Trust, Leeds, United Kingdom.

Hosp. of Saint Raphael, New Haven, CT.

1847 Vivian G. Loo, MD, MSc - Associate Professor

1851 Markus Dettenkofer, MD - Professor

McGill Univ. Hlth. Ctr., Montreal, Canada.

Univ. Freiburg, Freiburg, Germany.

Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Describe the strengths and weaknesses of current methods for C. difficile testing; Evaluate data presented on comparative methods for C. difficile detection; and > Discuss the impact of molecular testing on C. difficile prevalence and infection control practice.

Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Discuss the evidence linking environmental contamination and HAIs; > Identify methods that assess environmental cleaning; and > Identify one intervention they can use in their own practice.

Intended Audience: Microbiologists, infection control practitioners, infectious diseases physicians.

Intended Audience: Physicians involved in infection prevention and control, microbiologists working in infection prevention and control or supporting infection prevention and control efforts and interested in the association of environmental contamination and HAIs.

Level: Intermediate

Level: All Levels

-----------------------------------------------------------------------222(H) Meet-the-Experts

-----------------------------------------------------------------------224(M) Meet-the-Experts

Can We Safely Simplify Antiretroviral Therapy in Treatment-Experienced Patients?

Fungal Infections of the Central Nervous System

Wednesday, 7:00 a.m.–8:15 a.m. . . . Esplanade Ballroom 300 UAN: 0391-9999-12-161-L04-P Experts:

Wednesday, 7:00 a.m.–8:15 a.m. . . . . . . . . . . . . . . . . Room 121 UAN: 0391-9999-12-163-L04-P Experts: 1852 David A. Stevens, MD - Professor Stanford Univ. and Sta. Clara Valley Med. Ctr., San Jose and Stanford, CA.

1848 Pedro Cahn, MD, PhD - Senior Scientist Fundación Huesped, Buenos Aires, Argentina. 1849 Sharon L. Walmsley, MD, MSc, FRCPC - Professor of Medicine Univ. Hlth. Network, Toronto, Canada. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Discuss several potential scenarios in which patients suppressed on effective but complicated antiretroviral therapy can have their regimen simplified without compromising the success of the treatment regimen; > Summarize information on new agents and new assays that may increase our ability to simplify antiretroviral therapy even in patients who have extensive previous treatment experience; > Assess the potential risks and benefits of therapy simplification for specific patient types; and > Evaluate the role of new fixed dose combination tablets in simplification of successful but cumbersome or complex regimens in treatment experienced patients.

1853 Thomas Walsh, MD - Director Transplantation in Oncology Infectious Diseases Program Weill Cornell Med. Coll., Cornell Univ., New York, NY. Objectives: Upon completion of this Meet-the-Experts Session, the participant should be able to: > Generate an appropriate differential diagnosis, diagnostic workup and management plan for CNS fungal infections; > Recognize the importance of travel history and underlying co-morbidities in predicting the likelihood of a fungal cause of CNS infections; and > Apply principles of PK/PD and an evidence-based approach to management. Intended Audience: Mycology researchers, ID physicians, and trainees. Level: Intermediate

Intended Audience: HIV clinicians including MD, pharmacists, pharmacologists, physician extenders and other clinician, HIV clinical and translational scientists including those involved in all phases of antiretroviral research, virologists, and drug developers.

Final Program

183

> Wednesday SCIENTIFIC SESSIONS -----------------------------------------------------------------------225 Plenary Session

-----------------------------------------------------------------------226(D) Interactive Symposium

The Use of Social Media and New Technologies in Healthcare

Challenges in the Diagnosis and Clinical Interpretation of Infections with Gram-Positive Rods

Wednesday, 8:00 a.m.–9:00 a.m. . . . . . . . . . . . . . . . . . Room 130 UAN: 0391-9999-12-164-L04-P

Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Room 104 UAN: 0391-9999-12-165-L04-P

Conveners: Vincent Racaniello, PhD - Professor Columbia Univ., New York, NY. David Aronoff, MD - Associate Professor Univ. of Michigan, Ann Arbor, MI.

Conveners: Guido Funke, MD - Professor Gartner and Colleagues Lab., Ravensburg, Germany. Patricia S. Conville, MS - Scientific Reviewer FDA, Silver Spring, MD.

Speakers:

Speakers:

8:00 a.m.

9:15 a.m.

1854 Novel Approaches to Spatial Modelling of Infectious Disease

Transmission Neil M. Ferguson, DPhil, MA - Head of Department and Professor Imperial Coll. London, London, United Kingdom. 8:30 a.m. 1855 The Emerging Role of Social Media in Public Health John Brownstein, PhD - Associate Professor Children’s Hosp. Boston & Harvard Med. Sch., Boston, MA. Objectives: Upon completion of this Plenary Session, the participant should have a greater understanding regarding emerging new technologies and their use in: > Mapping and modeling infectious diseases, especially outbreaks; > Planning and designing effective public health interventions; > Monitoring infectious diseases outbreaks; and > Improving health care communications. Intended Audience: Clinicians, scientists, researchers, microbiologists, virologists, pharmacists and public health physicians. Level: All Levels

1856 Corynebacteria Guido Funke, MD - Professor Gaertner and Colleagues Lab., Ravensburg, Germany. 9:45 a.m. 1857 Non-Tuberculous Mycobacteria Christine Y. Turenne, PhD - Director of Bacteriology Saskatchewan Disease Control Lab., Regina, Canada. 10:15 a.m. 1858 Branching Out: Insight into Current Nocardia Challenges Patricia S. Conville, MS - Scientific Reviewer FDA, Silver Spring, MD. 10:45 a.m. 1859 Diagnosis, Identification and Susceptibility Testing of Gordo-

nia & Tsukamurella Barbara A. Brown-Elliott, MS, MT (ASCP) - Research Assistant Professor/ Supervisor Mycobacteria/Nocardia Laboratory Univ. of Texas Hlth. Sci. Ctr. at Tyler, Tyler, TX. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the broad range of infections caused by the aerobic Actinomycetes; > Discuss the importance of accurate diagnosis of the various genera within this group; > Develop an approach to the diagnosis of the important pathogens; and > Identify the new technologies for identification of the aerobic grampositive rods. Intended Audience: Clinical microbiologists, infection control practitioners, and infectious diseases physicians. Level: Intermediate

184

September 9-12 |

WEDNESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------227(A) Symposium

-----------------------------------------------------------------------228(C1) Symposium

Use of Pharmacokinetics/Pharmacodynamics for Risk Reduction of Adverse Events

Resistance in S. aureus Beyond MecA

Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Room 103 UAN: 0391-9999-12-166-L04-P Developed in Cooperation with the International Society of Anti-Infective Pharmacology (ISAP) Conveners: Sujata M. Bhavnani, PharmD, MS - Vice-President, Translational Medicine Inst. for Clin. Pharmacodynamics, Latham, NY. Paul M. Tulkens, MD - Professor Univ. of Catholique de Louvain, Brussels, Belgium. Speakers:

Wednesday, 9:15 a.m.–11:15 a.m. . . Esplanade Ballroom 302 UAN: 0391-9999-12-167-L04-P Conveners: Patricia Bradford, PhD - Vice President, Discovery Biology AstraZeneca Pharmaceuticals, Waltham, MA. Jared A. Silverman, PhD - Sr. Vice President of Biology Cubist Pharmaceuticals, Lexington, MA. Speakers: 9:15 a.m. 1864 Cfr-Mediated Resistance to Linezolid and Other Antibiotics Karen J. Shaw, PhD - Sr. V. P. Biology Trius Therapeutics, San Diego, CA.

9:15 a.m.

9:45 a.m.

1860 Hepatic Safety of Antibiotics Paul M. Tulkens, MD - Professor Univ. Catholique de Louvain, Brussels, Belgium.

1865 Vga-Mediated Antimicrobial Resistance Stefan Schwarz, DVM - Professor Inst. of Farm Animal Genetics (FLI), Neustadt-Mariensee, Germany.

9:45 a.m. 1861 Pharmacodynamic Modeling the Risk of Myelosuppression

with Linezolid

10:15 a.m. 1866 Co-Evolution of Daptomycin Resistance with Resistance to

Alan Forrest, PharmD - Research Professor; Senior Director, Pharmacometrics SUNYBuffalo Sch. of Pharmacy, SUNY-Buffalo; Inst. of Clin. Pharmacodynamics, Buffalo and Albany, NY.

Host Defense Peptides Arnold Bayer, MD - Professor of Medicine UCLA Sch. of Med., LA Biomedical Res. Inst., Torrance, CA. 10:45 a.m.

10:15 a.m. 1862 Daptomycin Exposure and the Probability of Creatine Phos-

phokinase Elevations Sujata M. Bhavnani, PharmD, MS - Vice President, Translational Medicine Inst. for Clinical Pharmacodynamics, Latham, NY. 10:45 a.m. 1863 Case-Control Studies on the Safety of Timethoprim-Sulfa-

methoxazole Tony Antoniou, PharmD - Clinical Pharmacy Specialist, Assistant Professor Univ. of Toronto, St. Michael’s Hosp., Toronto, Canada. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe in hepatic safety issues associated with commonly used antibiotics; > Appraise the use pharmacodynamic modeling to assess adverse events associated with antibiotics; > Assess the relationships between antibiotic exposure and the probability of adverse events; and > Recognize trimethoprim-sulfamethoxazole induced adverse events in various patient populations.

1867 Staphylococcal Resistance to Anti-MRSA Cephalosporins Henry F. Chambers, MD - Professor UCSF, San Francisco, CA. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Recognize novel mechanisms of resistance affecting new anti-staphylococcal antibiotics; > Describe the mechanisms by which these genes cause resistance; and > Identify the spread of these resistance mechanisms. Intended Audience: Physicians and microbiologists. Level: Intermediate


Final Program

185

> Wednesday SCIENTIFIC SESSIONS -----------------------------------------------------------------------229(F) Symposium

-----------------------------------------------------------------------230(G, B) Symposium

New Approaches in the Treatment of Fungal Infections

Interplay Between Pathogen and Host: From Immune Deficiency to Infectious Disease

Wednesday, 9:15 a.m.–11:15 a.m. . . Esplanade Ballroom 309 UAN: 0391-9999-12-168-L04-P Conveners: Michael J. Pucci, PhD - Executive Director Achillion Pharmaceuticals, New Haven, CT. Eleftherios Mylonakis, MD, PhD - Associate Professor of Medicine Harvard Med. Sch. and Mass. Gen. Hosp., Boston, MA.


Speakers:

Conveners: Carlo Giaquinto, MD - Medical Doctor Pediatrician Azienda Ospedaliera Univ., Padova, Italy. Nigel J. Klein, MD, PhD - Professor of Infection and Immunity Inst. of Child Health, Univ. Coll. London, London, United Kingdom.

9:15 a.m.

Speakers:

1868 Antifungal Drug Discovery Through the Study of Invertebrate

Model Hosts

9:15 a.m. 1872 Immune Activation in HIV Infection

Eleftherios Mylonakis, MD, PhD - Associate Professor Harvard Med. Sch., Mass. Gen. Hosp., Boston, MA. 9:45 a.m. 1869 Screening for New Antifungal Agents Derek Law, PhD - Head of Microbiology F2G Ltd., Manchester, United Kingdom. 10:15 a.m. 1870 Role for Inhibition of Hsp90 Function in the Treatment of

Andrew Prendergast, MA, DPhil, MRCPCH - Senior Lecturer in Pediatric Infection and Immunity Queen Mary, Univ. of London, London, United Kingdom. 9:45 a.m. 1873 Immune Reconstitution Following Treatment of Immuno-

deficiencies Nigel J. Klein, MD, PhD - Professor of Infection and Immunity Inst. of Child Health, London, United Kingdom. 10:15 a.m.

Fungal Infections Stephanie Diezmann, PhD - Post-doctoral Fellow Univ. of Toronto, Toronto, Canada. 10:45 a.m. 1871 A Novel Class of Orally Active Antifungal Beta-1,3-D-Glucan

Synthase Inhibitors

1874 New Insights into Meningitis Pathogenesis Kwang Sik Kim, MD - Professor and Director Johns Hopkins Sch. of Med., Baltimore, MD. 10:45 a.m. 1875 Fungal Infection in the Immunodeficient Host

Todd A. Black, PhD – Director, Site Lead Merck Res. Labs., Kenilworth, NJ.

Emmanuel Roilides, MD - Professor Aristotle Univ. Sch. of Med., Thessaloniki, Greece.

Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the role of iron homeostasis in the growth of microbial pathogens, including bacteria, fungi and protozoa; > Identify and distinguish new approaches to the discovery of agents exploiting iron-uptake systems in bacteria; and > Recognize the potential pitfalls in application of iron chelators in anti-microbial chemotherapy.

Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss how immune activation adds to the challenges of treatment and prevention of HIV infection; > Discuss new insights into immune reconstitution following treatment of immunodeficiencies; > Apply new insights into meningitis pathogenesis to evaluation and management of patients with meningitis; and > Identify advances in fungal infection pathogenesis in the immunodeficient host.

Intended Audience: Microbiologists working in academia and in the pharmaceutical industry. Level: Intermediate

Intended Audience: Physician scientists, infectious disease clinicians, clinical microbiologists, clinical virologists, pharmacologists and those with an interest in the pathogenesis and treatment of infectious diseases. Level: Intermediate

186

September 9-12 |

WEDNESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------231(K) Symposium

-----------------------------------------------------------------------232(L1, G) Symposium

A Multifaceted Approach to Preventing Surgical Site Infections

What’s New with Pneumococcus?

Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Room 121 UAN: 0391-9999-12-170-L04-P Developed in Cooperation with the Surgical Infection Society (SIS) Conveners: Jan Kluytmans, MD, PhD - Professor Amphia Hosp., Breda, Netherlands. E. Patchen Dellinger, MD - Professor Univ. of Washington, Seattle, WA.

Wednesday, 9:15 a.m.–11:15 a.m. . . Esplanade Ballroom 308 UAN: 0391-9999-12-171-L04-P Conveners: Keith P. Klugman, MD, PhD - William F. Foege Professor of Global Health Rollins Sch. of Publ. Hlth., Emory Univ., Atlanta, GA. Patrick G. P. Charles, MBBS, PhD - Infectious Diseases Physician Austin Hlth., Heidelberg VIC, Australia. Speakers: 9:15 a.m.

Speakers:

1880 What is the Clinical Impact of Penicillin Non-Susceptibility on

9:15 a.m. 1876 Implementing a Bundle Strategy to Prevent Surgical Site Infections Jan Kluytmans, MD, PhD - Professor Amphia Hosp., Breda, Netherlands.

Treatment Outcomes for Meningitis and Invasive Pneumococcal Disease? Keith P. Klugman, MD, PhD - William H. Foege Professor of Global Health Rollins Sch. of Publ. Health, Emory Univ., Atlanta, GA. 9:35 a.m.

9:45 a.m. 1877 Meta-Analysis of Studies Evaluating Preoperative Screening

for S. aureus, Decolonization of Carriers, and Perioperative Antimicrobial Prophylaxis Marin Schweizer, PhD - Assistant Professor Carver Coll. of Med., Iowa City, IA.

1881 Extensive Genomic Diversity and Plasticity among

Streptococcus pneumonia Strains N. Luisa Hiller, PhD; Ctr. for Genomic Sciences, Allegheny Gen. Hosp., Pittsburgh, PA. 9:55 a.m. 1882 Does Penicillin Non-Susceptibility Really Matter When it

10:15 a.m.

Comes to Treating Pneumonia?

1878 Should Perioperative Prophylaxis for Non-Abdominal

Procedures Include Coverage for Gram-Negative Organisms and Data from the Swiss National Surveillance System? Andreas Widmer, MD, MS - Deputy Head of Div. Infectious Diseases & Hospital Epidemiology Univ. Hosp., Basel, Switzerland. 10:45 a.m. 1879 The New ASHP/SHEA/IDSA/SIS Guidelines for Surgical

Prophylaxis

Patrick G. P. Charles, MBBS, PhD - Infectious Diseases Physician Austin Hlth., Heidelberg VIC, Australia. 10:15 a.m. 1883 The Clinical Impact of Emerging Macrolide and Quinolone

Resistance in North America Thomas J. Marrie, MD - Professor Dalhousie Univ., Halifax, Canada. 10:45 a.m.

E. Patchen Dellinger, MD - Professor of Surgery Univ. of Washington, Seattle, WA.

1884 How Has the New Polyvalent Pneumococcal Vaccine Altered

Patterns of Clinical Disease?

Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss pros and cons of including specific interventions in a bundle to prevent SSIs; > Discuss the evidence supporting screening patients undergoing cardiac or orthopedic procedures for Staphylococcus aureus; > Discuss the evidence addressing whether perioperative prophylaxis for non-abdominal procedures should include coverage for gram-negative organisms; and > Discuss important changes in the ASHP/SHEA/IDSA/SIS guidelines for perioperative antimicrobial prophylaxis. Intended Audience: Clinical microbiologists, especially those whose laboratories may be asked to process preoperative screening tests for S. aureus; infectious disease physicians; physicians and microbiologists involved in infection prevention.

Peter R. Paradiso, PhD - Vaccine Consultant Paradiso Biologics Consulting, Radnor, PA. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Describe the impact of antimicrobial resistance to the management of S. pneumoniae infections; > Improve their clinical care of patients at risk for and infected with pneumococcus; > Critically analyze recent data regarding the global spread of antimicrobial resistance in pneumococcus; and > Define the impact of vaccination on global patterns of clinical disease. Intended Audience: Clinicians and investigators interested in pneumococcal infections. Level: Intermediate

Level: All Levels

Final Program

187

> Wednesday SCIENTIFIC SESSIONS -----------------------------------------------------------------------233(M) Symposium

-----------------------------------------------------------------------234(P) Symposium

Controversies in Clinical Mycology

Best Practices for Serologic Testing in Selected Parasitic Diseases

Wednesday, 9:15 a.m.–11:15 a.m. . . Esplanade Ballroom 300 UAN: 0391-9999-12-172-L04-P Developed in Cooperation with the Mycology Study Groug (MSG) and European Organisation for Research and Treatment of Cancer (EORTC-IDG) Conveners: John Perfect, MD - Interim Chief, Division of Infectious Diseases and International Health Duke Univ. Med. Ctr., Durham, NC. J.P. Donnelly, MD – Coordinator Studies Supportive Care Radboud Univ. Nijmegen Med. Ctr., Nijmegan Inst. for Infection, Nijmegen, Netherlands. Speakers: 9:15 a.m. 1885 Fungal Biomarkers and How to Use Them Elias Anaissie, MD - Infectious Disease Physician Univ. of Cincinnati, Cincinnati, OH.. 9:45 a.m. 1886 Do We Really Know How to Dose Antifungals William Hope, MD, PhD - Professor of Therapeutics and Infectious Diseases The Univ. of Liverpool, Liverpool, United Kingdom. 10:15 a.m. 1887 Fungal Infections and Diagnostic Guidelines: What is Right

and What is Strong J.P. Donnelly, PhD - Coordinator Studies Supportive Care Radboud Univ. Nijmegen Med. Ctr., Nijmegan Inst. for Infection, Nijmegen, Netherlands. 10:45 a.m. 1888 How Does the Clinical Mycologist Fit Into Antimicrobial

Stewardship Graeme Forrest, MD - Assistant Professor of Medicine, Division of Infectious Diseases VAMC Portland VA Med. Ctr., Portland, OR. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss the use of biomarkers; > Identify the importance of dosing antifungals; > Assess guidelines and their limitations; and > Describe issues around antifungal stewardship. Intended Audience: Clinicians, clinical microbiologists, trainees, and pharmacists. Level: Advanced

188

September 9-12 |

Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Room 254 UAN: 0391-9999-12-173-L04-P Conveners: Alan J. Magill, MD - Associate Professor Uniformed Services Univ. of the Hlth. Sci., Bethesda, MD. Patricia P. Wilkins, PhD - Chief, Reference Diagnostics Laboratory CDC, Atlanta, GA. Speakers: 9:15 a.m. 1889 The Serologic Diagnosis of Neurocysticercosis Hector H. Garcia, MD, PhD - Professor Univ. Peruana Cayetano Heredia and Inst. de Ciencias Neurologicas, Lima, Peru. 9:45 a.m. 1890 The Serologic Assessment of Filarial Infections Thomas B. Nutman, MD - Head, Helminth Immunology Section NIAID, NIH, Bethesda, MD. 10:15 a.m. 1891 The Serologic Diagnosis of Strongyloidiasis Jay S. Keystone, MD, MSc (CTM), FRCPC - Professor Toronto Gen. Hosp., Toronto, Canada. 10:45 a.m. 1892 The CDC Reference Laboratory and Serologic Diagnosis Patricia P. Wilkins, PhD - Chief, Reference Diagnostics Laboratory CDC, Atlanta, GA. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Update the clinical community on the appropriate use of currently available serologic testing for the diagnosis of three major infectious diseases using a case-based interactive format; > Discuss the advantages and limitations of serologic testing in the diagnosis and management of neurocysticercosis, schistosomiasis, and strongyloidiasis; and > Describe the reference capabilities for the CDC DPDM to support clinicians. Intended Audience: Clinical microbiologists, parasitologists, pathologists, researchers, public health and epidemiologists, quality improvement professionals and infectious disease physicians. Level: Intermediate

WEDNESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------235(V) Symposium

-----------------------------------------------------------------------236(C2) Slide Session

Recognizing and Managing Antiviral Resistance

Acinetobacter: Challenges and Continued Emergence



Conveners: Guy Boivin, MD - Professor of Microbiology Laval Univ., Quebec, Canada. Joseph Eron, Jr., MD - Professor of Medicine Univ. of North Carolina, Chapel Hill, NC.

Moderators: Jordi Vila, MD, PhD - Head of the Department of Clinical Microbiology Hosp. Clinic, Barcelona, Spain. Robert A. Bonomo, MD - Professor Louis Stokes Cleveland Dept. of VA Med. Ctr., Cleveland, OH.

Speakers:

Objectives: Upon the completion of this Slide Session, the participant should be able to: > Discuss the world wide dissemination of A. baumannii; > Identify information about predominant clones of A. baumannii; > Discuss the present challenge for antimicrobial treatment of Acinetobacter infections; and > Discuss genetic elements related to resistance.

9:15 a.m. 1893 Management of HIV Resistance: New Perspectives Ian Frank, MD - Professor of Medicine Univ. of Pennsylvania, Philadelphia, PA. 9:45 a.m. 1894 CMV: When to Think About Resistance and When to Switch

Therapy?

9:15 a.m.

Sunwen Chou, MD - Professor of Medicine Oregon Hlth. and Sci. Univ., Portland, OR.

C2-1897 Carbapenem-Resistant Acinetobacter baumannii: An Italian

Nationwide Problem

10:15 a.m. 1895 Influenza: How Resistance Emerges and the Role of Combina-

tion Therapy Maria Zambon, PhD - Director, Reference Microbiology Services Hlth. Protection Agency, London, United Kingdom.

F. Luzzaro, Doctor - Doctor 1, R. Migliavacca, PhD - Research 2, S. Bracco, PhD student - Doctor 1, A. Piazza, PhD Student - Doctor2, E. Nucleo, PhD - Research 2, G. Rossolini, Professor - Professor 3, L. Pagani, Professor of Clinical Microbiology - Professor 2; 1A. Manzoni Hosp., Lecco, Italy, 2Univ. of Pavia, Pavia, Italy, 3Univ. of Siena, Siena, Italy. 9:30 a.m.

10:45 a.m. 1896 How to Avoid Resistance When Treating Hepatitis B Lorne Tyrrell, MD/PhD - Professor and Director of the Li Ka Shing Institute of Virology Univ. of Alberta, Edmonton, Canada. Objectives: Upon completion of this Symposium Session, the participant should be able to: > Discuss the increasing problem of antiviral resistance; > Identify risk factors for selecting for drug-resistant viruses; > Discuss the consequences of drug-resistant infections; and > Propose potential alternate therapeutic strategies. Intended Audience: enteral infectious diseases specialists, HIV specialists, virologists, clinical microbiologists, and epidemiologists. Level: Intermediate/Advanced

Presentations:

C2-1898 Prevalence of Multidrug-Resistant Acinetobacter baumannii

in Southwest Nigeria Tertiary Hospitals W. E. Ike, MS - Doctoral Student1, B. A. Adeniyi, PhD - Professor 1, O. O. Soge, PhD - Research Scientist 2; 1Univ. of Ibadan, Ibadan, Nigeria, 2Univ. of Washington, Seattle, WA. 9:45 a.m. C2-1899 Spread of Carbapenem-Resistant Acinetobacter baumannii

Global Clone II in Asian Countries D. H. Kim, MS - Graduate Student1, J. Y. Choi, MS - Research Assistant 1, S. H. Kim, PhD - Project Manager 2, D. R. Chung, MD - Professor 3,2, J. H. Song, MD, PhD - Professor 3,2, K. S. Ko, PhD - Professor 1,2; 1Sungkyunkwan Univ. Sch. of Med., Suwon, Korea, Republic of, 2APFID, Seoul, Korea, Republic of, 3Sungkyunkwan Univ. Sch. of Med., Seoul, Korea, Republic of. 10:00 a.m. C2-1900 Carbapenem Resistant in Acinetobacter baumannii: An

Emerging Problem in Israel P. Espinal, MS - Research1, M. Kasma, MS - Research 2, Y. Lerman, MD Research 2, Y. Carmeli, PhD - Professor 2, J. Vila, PhD - Professor 1; 1Univ. of Barcelona, Hosp. Clinic, Barcelona, Spain, 2Sourasky Med. Ctr., Tel Aviv, Israel.

Final Program

189

> Wednesday SCIENTIFIC SESSIONS 10:15 a.m. C2-1901 Molecular Identification and Characterization of Acineto-

bacter Species Causing Bacteremia at a Japanese Tertiary Hospital S. Endo, MD - Assistant Professor, M. Sasano, MS - Research Assistant, H. Yano, MD - Lecture, H. Kanamori, MD - Assistant Professor, S. Inomata, MD - Assistant Professor, N. Ishibashi, MD - Assistant Professor, T. Aoyagi, MD Assistant Professor, M. Hatta, MD - Assistant Professor, Y. Gu, MD - Assistant Professor, M. Yamada, MD - Assistant Professor, K. Tokuda, MD - Lecture, M. Kitagawa, MS - Assistant Professor, H. Kunishima, MD - Associate Professor, M. Kaku, MD - Professor; Tohoku Univ., Sendai, Japan. 10:30 a.m. C2-1902 First Outbreak of Multiresistant Acinetobacter baumannii

Producing the Carbapenemase OXA 23 in Spain M. Merino, MSc - PhD Student, M. Poza, PhD - Researcher, M. J. Barba, CLT - Lab Assistant, S. Rumbo-Feal, MSc - PhD Student, A. Fernandez, MSc - PhD Student, M. Tomás, PhD - PhD Researcher, G. Bou, PhD Professor; Univ. La Coruña, La Coruña, Spain. 10:45 a.m. C2-1903 Clinical and Microbiological Characteristics of Bloodstream

Infection Caused by Acinetobacter baumannii Complex H. Lee, MD, MS - Attending Doctor and Lecturer, S. Wu, Bachelor Research Assistant, C. Chen, PhD - Assistant Professor, C. Chiu, MD, PhD Professor; Chang Gung Mem. Hosp., Taoyuan, Taiwan. 11:00 a.m. C2-1904 Application of Pyrosequencing Assay for Rapid Detection

of Epidemic Clonal Lineage of Acinetobacter baumannii M. Matsui, PhD - Reseacher1, S. Suzuki, MD, PhD - Senior Researcher 1, K. Shibayama, MD, PhD - Director 1, Y. Arakawa, MD, PhD - Professor 2; 1Natl. Inst. of Infectious Diseases, Japan, Tokyo, Japan, 2Nagoya Univ. Graduate Sch. of Med., Aichi, Japan. 11:15 a.m. C2-1905 High Prevalence of OXA-23-Producing Carbapenem-

Resistant Acinetobacter baumannii Among Hospitals from Porto Alegre, Brazil J. Barin, PharmD - Researcher 1, B. L. Heineck, Biomedicine Student Research Assistant 1, A. F. Martins, Ph.D. - Professor 2, A. P. Zavascki, PhDResearcher3,1; 1Univ. Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Ctr. Univ. Metodista, IPA, Porto Alegre, Brazil, 3Hosp. de Clinc. de Porto Alegre, Porto Alegre, Brazil.

-----------------------------------------------------------------------237(C2) Slide Session MRSA: Pervasive, Persistent, and Pathogenic Wednesday, 9:15 a.m.–11:45 a.m. . . Esplanade Ballroom 305 UAN: 0391-9999-12-176-L04-P Moderators: Emil P. Lesho, DO - Co-Founder and Director, MRSN Walter Reed Army Inst. of Res., Silver Spring, MD. Usha Stiefel, Stiefel, MD - Chief, Infectious Diseases Section Cleveland VA Med. Ctr., Cleveland Heights, OH. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Discuss hot topics in molecular epidemiology of MRSA; > Identify the clonal shifts in MRSA around the world; > Assess resistance epidemiology; and > Describe details about MRSA in animals as reservoirs. Presentations: 9:15 a.m. C2-1906 Agr Function and Mortality in Nosocomial Pneumonia Due

to Methicillin-Resistant Staphylococcus aureus D. S. Smyth, PhD – Research1, M. Wible, MS – Research 2, R. E. Mendes, PhD – Director 3, A. Labella, MD – Research 1, J. M. Kafer, BS – Research 1, V. J. Torres, PhD – Professor1, R. P. Novick, MD – Professor 1, B. Shopsin, MD, PhD – Professor1; 1Dept. of Med. and Microbiol., New York, NY, 2Pfizer Inc., Collegeville, PA, 3JMI Lab., North Liberty, IA. 9:30 a.m. C2-1907 Emergence of Different Lineages of MRSA Type IV and II

Substituting the BEC in Bloodstream Infections in Two Brazilian Hospitals R. C. Chamon, BA - Master Student, V. C. Salgueiro, BA - Master Student, S. S. Ribeiro, Graduate Student - Graduate Student, F. S. Cavalcante, MD - PhD Student, N. L. P. Iorio, PhD - Research, K. R. N. dos Santos, PhD Professor; Federal Univ. of Rio de Janeiro, Rio de Janeiro, Brazil. 9:45 a.m. C2-1908 Epidemiology of CA-MRSA in Auckland, New Zealand:

Emergence of ST5-IV as the Dominant CA-MRSA Clone D. A. Williamson, MD - Clinical Research Fellow1, S. A. Roberts, MD Clinical Microbiologist 2, S. R. Ritchie, MD PhD - Senior Lecturer 1, J. D. Fraser, PhD - Professor 1, G. Coombs, MS - Principal Scientist 3, H. Heffernan, MS - Senior Scientist 4; 1Univ. of Auckland, Auckland, New Zealand, 2 Auckland District Hlth. Board, Auckland, New Zealand, 3Australian Collaborating Ctr. for Enterococcus and Staphylococcus Species (ACCESS) Typing and Res., Perth, Australia, 4Inst. of Environmental Sci. and Res., Wellington, New Zealand.

190

September 9-12 |

WEDNESDAY SCIENTIFIC SESSIONS 10:00 a.m. C2-1909 MRSA USA300 Variant has Replaced the Chilean Clone in Latin American Hospitals J. Reyes, MA - Professor1,2, C. A. Arias, MD, MS, PhD - Professor 1,2, S. Rincon, MS - Professor 1, L. P. Carvajal, BSc - Research 1, N. Rojas, BSc Research 1, G. Ibarra, Medical Student - Research Assistant 1, C. Garcia, MD, PhD - Physician 3, C. A. Alvarez, MD - Physician 4, M. Guzman, MD - Physician 5, C. Seas, MD, MS - Physician 3, E. Gotuzzo, MD - Physician 3, Latin American Working Group on Bacterial Resistance; 1Univ. El Bosque, Bogotá, Colombia, 2Univ. of Texas Med. Sch., Houston, TX, 3Hosp. Nal Cayetano Heredia, Lima, Peru, 4Hosp. San Ignacio, Bogotá, Colombia, 5Ctr. Med. de Caracas, Caracas, Venezuela, Bolivarian Republic of. 10:15 a.m. C2-1910 New Patterns of Methicillin-Resistant Staphylococcus aureus

(MRSA) Clones in the Community and Hospital Setting, Argentina 2009

11:30 a.m. C2-1915 Oxacillin and Vancomycin Resistance Profile of Staphylococcus

aureus Strains Isolated from Medical Students I. A. Mendez, MA - Professor, D. F. Holguin, Student - Student, D. P. Pachon, MS - Professor, F. J. Africano, Student - Student, I. M. Gonzalez, Student - Student, N. A. Rojas, MS - Professor; Sch. of Med., Univ. Militar, Bogota, Colombia.

-----------------------------------------------------------------------238(H) Slide Session Common Pathogens: Still a Problem in HIV-I Wednesday, 9:15 a.m.–11:45 a.m. . . . . . . . . . . . . . . . . Room 102 UAN: 0391-9999-12-177-L02-P

C. Sola, PhD 1, A. Egea, MD 1, R. Lamberghini, MD 2, H. Paganini, MD 3, P. Gagetti, MD 4, D. Faccone, PhD 4, C. Lucero, MD 4, M. Galas, MD 4, CA-MRSA Argentina Group, J. L. Bocco, PhD, A. Corso, MD 4; 1CIBICI– CONICET. Fac. Cs. Químicas, UNC, Córdoba, Argentina, 2Hosp. G. Rawson, Córdoba, Argentina, 3Hosp. Dr. J. Garrahan, Buenos Aires, Argentina, 4 Antimicrobianos, INEI-ANLIS, Buenos Aires, Argentina.

Moderators: Sharon L. Walmsley, MD, MSc, FRCPC - Professor of Medicine Univ. of Toronto, Toronto, Canada. Judith Aberg, MD - Professor of Medicine; Director Division of Infectious Diseases and Immunology New York Univ., Bellevue Hosp. Ctr, New York, NY.

10:30 a.m.

Objectives: Upon the completion of this Slide Session, the participant should be able to: > Assesses the effect of HIV clinical malfunctions of common pathogens; > Discuss the utility of interferon gamma release assay HIV infection; and > Identify the impact of HSV-2 infection on HIV

C2-1911 Molecular Epidemiology of Healthcare-Associated

Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Isolated from Adult Patients in Russia Y. Chernov, MD - Research Assistant, A. Romanov, MD - Research Assistant, M. Edelstein, MD, PhD - Research Assistant, A. Dekhnich, MD, MSc, PhD - Research Assistant; Inst. of Antimicrobial Chemotherapy, Smolensk, Russian Federation. 10:45 a.m.

Presentations: 9:15 a.m. H-1916 Incidence and Risk Factors for Invasive Pneumococcal Dis-

ease in HIV Infected and Uninfected Individuals in Denmark

J. Rinsky, MPH - Student 1, M. Nadimpalli, MS - Student 1, D. Hall, Program Manager 2, D. Baron-Hall, Executive Director 2, J. Stewart, PhD, MS - Assistant Professor 1, S. Wing, PhD - Associate Professor 1, C. Heaney, PhD, MS Assistant Professor3; 1UNC, Chapel Hill, NC, 2REACH, Warsaw, NC, 3JHU, Baltimore, MD.

Z. B. Harboe, MD – Doctor 1, M. V. Larsen, MD – Doctor 2, S. Ladelund, MS - Statistician 2, G. Kronborg, MD - Doctor 2, R. Skov, MD - Doctor 3, H. Konradsen, MD - Doctor 3, N. Obel, MD - Doctor4, C. Shade, MD - Doctor 5, J. Gerstoft, MD - Doctor 4, T. L. V. Benfield, MD - Doctor2; 1Statens Serum Inst., Hvidovre Hosp., Copenhagen, Denmark, 2Hvidovre Hosp., Copenhagen, Denmark, 3Statens Serum Inst., Copenhagen, Denmark, 4Rigshospitalet, Copenhagen, Denmark, 5Aarhus Univ. Hosp., Aarhus, Denmark.

11:00 a.m.

9:30 a.m.

C2-1912 Carriage of Staphylococcus aureus CC398 Among Livestock

Workers and Household Members in NC

C2-1913 Prevalence and Characteristics of Methcillin-Resistant

H-1917 Comparison of the QuantiFERON TB Gold In-Tube Assay

Staphylococcus aureus Recovered from Raw Meats in Korea, 20102011

with Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection Among HIV Infected Children

H. Nam, PhD - Researcher, S. Lim, PhD - Researcher, G. Jang, MS - Researcher, M. Chae, MS - Researcher, S. Kim, MS - Researcher, S. Jung, PhD - Researcher; Animal, Plant, and Fisheries Quarantine and Inspection Agency, Anyang, Republic of Korea, Anyang, Korea, Republic of.

9:45 a.m.

R. M. Viani, MD - Associate Professor1, M. R. Araneta, PhD - Associate Professor 1, G. Lopez, MD - Associate Professor 2, S. A. Spector, MD - Professor 1; 1 Univ. of California, La Jolla, CA, 2Tijuana Gen. Hosp., Tijuana, Mexico. H-1918 Reversion and Conversion of Interferon-Gamma Release

11:15 a.m. C2-1914 Distribution of qacA/B And mupA Genes in Clinical Isolates

of Methicillin-Resistant Staphylococcus aureus M. Milillo, BSc - Research Assistant, R. Quintero, MS - Research Assistant, Y. Kwak, MS - Lab Manager, A. Mueller, BSc - Research Assistant, P. Waterman, MD - Deputy Director, P. McGann, PhD - Senior Microbiologist, E. Lesho, DO - Director; MRSN, WRAIR, Silver Spring, MD.

Assay Results in HIV-1-Infected Individuals M. C. Aichelburg, MD - Resident, F. Breitenecker, MD - Resident, T. Reiberger, MD - Associate Professor, A. Makristathis, MD - Associate Professor, A. Rieger, MD - Associate Professor; Med. Univ. of Vienna, Vienna, Austria.

Final Program

191

> Wednesday SCIENTIFIC SESSIONS 10:00 a.m.

Presentations:

H-1919 Six Year Follow Up of 590 Danish HIV Infected Patients

Screened for Tuberculosis Infection Copenhagen Soborg, MD,PhD - R1, M. Ruhwald, MD, PhD - R 2, P. Andersen, MD - C 3, P. Ravn, MD,PhD - C 4; 1 Copenhagen Univ. Hosp., Hvidovre, Copenhagen, Denmark, 2 Copenhagen Univ. Hosp., Hvidovre, Copenhagen, Denmark, 3SSI, Copenhagen, Denmark, 4Cph Univ. Hosp., Hillerod, Copenhagen, Denmark. 10:15 a.m. H-1920 No Impact of Suppressive Antiretroviral Therapy on

Mucosal Shedding of Herpes Simplex Virus Types 1 and 2 in HIV Co-Infected Adults D. H. S. Tan, MD - Clinician Scientist, J. M. Raboud, PhD - Associate Professor, R. Kaul, MD PhD - Associate Professor, S. L. Walmsley, MD MSc Professor; Univ. of Toronto, Toronto, Canada. 10:30 a.m.

9:15 a.m. 1922 State-of-the-Art Minilecture Neil O. Fishman, MD Univ. of Pennsylvania Med. Ctr., Philadelphia, PA. 9:45 a.m. K-1923 Impact of a Comprehensive Antimicrobial Stewardship Pro-

gram (ASP) on Antimicrobial Usage (AU) at a Large Community Hospital D. Patel, Pharm D - Clinical Pharmacy Specialist, Infectious Diseases1,2, V. Velmahos, MD - Medical Director, Antimicrobial Stewardship Program 2, C. A. Ewing, MD - Chairman, Department of Pathology 2, C. MacDougall, Pharm D - Associate Professor of Clinical Pharmacy 3; 1Comprehensive Pharmacy Services, Memphis, TN, 2John F. Kennedy Med. Ctr., Edison, NJ, 3UCSF Sch. of Pharmacy, San Francisco, CA. 10:0 a.m.

H-1921 Risk Factors in the Progression of Low Grade Intraepithelial

Neoplasia (LGAIN) to High Grade Intraepithelial Neoplasia (HGAIN) in a Cohort of HIV-MSM C. Hidalgo Tenorio, MD, PhD - Staff of Infectious Disease Unit, M. Rivero Rodriguez, MD - Staff of Infectious Disease Unit, C. Gil Anguita, MD Research Assitant of Infectious Disease Unit, A. Concha, MD, PhD - Chef of Pathology Anatomy Service, M. Lopez del Hierro, MD, PhD - Staff of General Service, P. Palma, MD, PhD - Staff of General Surgery Service, I. Segura, MD, PhD - Staff of General Surgery Service, M. Lopez Ruz, MD, PhD - Chef of Infectious Disease Unit, R. Javier, MD, PhD - Staff of Infectious Disease Unit, C. Garcia Vallecillos, Chem. - Research Assitant of Infectious Disease Unit, J. Pasquau Liaño, MD - Staff of Infectious Disease Unit; M. Álvarez, MD - Staff of Infectious Disease Unit, C. Diéguez, MD - Staff of Infectious Disease Unit, Univ. Hosp Virgen de las Nieves, Granada, Spain.

K-1924 High Impact of an Educational Antimicrobial Stewardship

Program on Prescribing Practice in a Tertiary Hospital Centre J. M. Cisneros, PhD - Assistant, M. Gil-Navarro, MD - Assistant, O. Net, PhD - Assistant, F. Jiménez-Parrila, MD - Assistant, J. Cano, MD - Assistant, E. Cordero, PhD - Assistant, J. Lepe, PhD - Assistant, M. J. Rodríguez-Hernández, PhD - Assistant, J. A. Márquez, MD - Assistant, M. Aguilar-Guisado, PhD - Assistant, R. Amaya, PhD - Assistant, C. Ferrándiz, MD - Assistant, J. Garnacho-Montero, PhD - Assistant, J. Palomino, PhD Assistant, E. Jiménez-Mejías, PhD - Assistant, M. Herrero, MD - Assistant, A. Gutiérrez, MD - Assistant, J. Molina, MD - Assistant; Hosp. Univ. Virgen del Rocio, Sevilla, Spain. 10:15 a.m. K-1925 Increased Antimicrobial Consumption in Denmark 2001 to


2010: Association with Demographic Factors

-----------------------------------------------------------------------239(K) Slide Session

K. Kuhn, PhD- Scientist, A. Hammerum, PhD- Head of Section, U. Jensen, MD - Scientist; Statens Serum Inst. Copenhagen, Denmark.

Antimicrobial Stewardship: Perils of Prescribing Wednesday, 9:15 a.m.–11:45 a.m. . . Esplanade Ballroom 310 UAN: 0391-9999-12-178-L04-P Moderator: Neil O. Fishman, MD Infectious Diseases, Univ. of Pennsylvania Med. Ctr., Philadelphia, PA. Objectives: Upon the completion of this Slide Session, the participant should be able to: > Identify the central components of a successful antimicrobial stewardship program; > Describe the relative role of measuring procalcitonin levels to guide therapy in patients with malignancies; and > Discuss demographic factors associated with antimicrobial consumption in Denmark.

192

September 9-12 |

10:30 a.m. K-1926 Early Antibiotic Discontinuation (E-DC) is Not Associated

with Increased Mortality in Patients with Clinically Suspected Ventilator Associated Pneumonia (VAP) and Negative Quantitative Bronchoalveolar Lavage (BAL) Cultures K. Raman, PharmD - PGY21,2, M. D. Nailor, PharmD - Ass. Prof. 2,1, D. P. Nicolau, PharmD – Dir. 3, J. Aslanzadeh, PhD - Dir. 1, J. L. Kuti, PharmD Ass. Dir. 3; 1Hartford Hosp., Hartford, CT, 2Univ. of CT, Storrs, CT, 3Ctr. for Anti-Infect. Res. & Dev., Hartford Hosp., Hartford, CT. 10:45 a.m. K-1927 Appropriateness of Antimicrobial Use in Hospitalized

Patients with Positive Urine Cultures S. J. Celetti, MSc - Student, A. Brooks, PharmD - Pharmacist, P. Delanghe, BSc - Student, D. Mertz, MD MSc - Physician; Hamilton Hlth. Sci., Hamilton, Canada.

WEDNESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------240(A) Poster Session Antifungals: Improving PK/PD and Safety Presentations: A-1928 Pharmacokinetic Rationale for Alternate Dosing Strategies

of Anidulafungin in Hematological Patients R. J. M. Brüggemann1, W. J. F. Van der Velden 1, A. Colbers 1, C. A. J. Knibbe 2, V. J. C. Lempers 1, D. M. Burger 1, N. M. A. Blijlevens 1, J. P. Donnelly 1; 1Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 2 Sint Antonius Ziekenhuis, Nieuwegein, Netherlands. A-1929 Pharmacodynamic (PD) Evaluation of 3 Echinocandins (E)

against C. glabrata (CG) with and without Fks Mutations in the Neutropenic Disseminated Candidiasis Model 2

3

3

kinetics of CYP3A4 Substrate Midazolam in Healthy Volunteers A. Desai, N. Zadeikis, H. Pearlman, D. Kowalski, R. Townsend; Astellas Pharma Global Dev., Deerfield, IL. A-1937 Influence of CYP2C19 and ABCB1 Genetic Polymorphisms

Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C

1

A-1936 Effect of Multiple Doses of Isavuconazole on the Pharmaco-

1

A. Lepak , M. Castanheira , M. Pfaller , D. Diekema , D. R. Andes ; 1 Univ. of Wisconsin, Madison, WI, 2JMI, North Liberty, IA, 3Univ. of Iowa, Madison, IA. A-1930 In Vivo Pharmacodynamic (PD) Evaluation of Combination

Triazole (T) and Echinocandin (E) Therapy against Susceptible and Resistant A. fumigatus (AF) A. Lepak1, D. R. Andes1, A. Forrest2; 1Univ. of Wisconsin, Madison, WI, 2 ICPD, Latham, NY. A-1931 Isavuconazole (ISA) Pharmacodynamic (PD) Target Deter-

mination for C. albicans (CA) in an In Vivo Neutropenic Murine Model of Invasive Candidiasis (IC) A. Lepak, K. Marchillo, J. Cabezas, D. R. Andes; Univ. of Wisconsin, Madison, WI. A-1932 Pharmacodynamic (PD) of Posaconazole (P) in a Murine

Invasive Pulmonary Aspergillosis (IPA) Model against Wild Type and Cyp51 Mutant Isolates A. Lepak, K. Marchillo, J. VanHecker, D. R. Andes; Univ. of Wisconsin, Madison, WI. A-1933 Intrapulmonary Penetration of Posaconazole in Immunosup-

on Voriconazole Levels in Haematological Patients L. Baietto, A. D’Avolio, J. Cusato, C. Marra, M. Simiele, F. G. De Rosa, G. Di Perri; Univ. of Turin, Turin, Italy. A-1938 An In Vitro Pharmacokinetic/Pharmacodynamic Model

Predicts In Vivo Outcome of Voriconazole Treatment against Aspergillus fumigatus Isolates with Reduced Azole Susceptibility M. Siopi1, E. Mavridou2, A. Elefanti1, P. E. Verweij2, J. W. Mouton2, J. Meletiadis1; 1Attikon Univ. Gen. Hosp., Athens, Greece, 2Radboud Univ. Med. Ctr., Nijmegen, Netherlands. A-1939 In Vitro Evaluation of the Efficacy of Voriconazole (VOR)

in Combination with Amphotericin B (AMB) against Aspergillus fumigatus (AFM) Using a Novel Pharmacokinetic/Pharmacodynamic (PK/PD) Model M. Siopi, A. Elefanti, N. Siafakas, L. Zerva, J. Meletiadis; Attikon Univ. Gen. Hosp., Athens, Greece. A-1940 Effect of Delay Exposure and Supra/Sub-MIC Concentra-

tions of Amphotericin B to Aspergillus Conidial, Hyphal and Mycelial Growth K. Krompa, N. Siafakas, L. Zerva, J. Meletiadis; Attikon Univ. Gen. Hosp., Athens, Greece. A-1941 Safety, Tolerance and Adverse Events of Treatment with

Lipozomal Amphotericin B in Pediatric Patients E. Karadag Oncel, A. Kara, Y. Ozsurekci, M. Celik, A. Ozkaya Parlakay, A. Cengiz, M. Ceyhan; Hacettepe Univ., Ankara, Turkey. A-1942 Pharmacokinetics (PK) and Pharmacodynamics (PD) of

Liposomal Amphotericin B (LAmB) and Flucytosine (5FC) against Cryptococcus neoformans in a Murine Model of Cryptococcal Meningitis L. O’Connor, J. Livermore, A. Sharp, J. Goodwin, T. W. Felton, S. J. Howard, W. W. Hope; The Univ. of Manchester, Manchester, United Kingdom. A-1943 Pharmacokinetics and Pharmacodynamics of Fluconazole

pressed Mice Receiving Oral Prophylactic Regimens S. Seyedmousavi1,2, R. J. M. Brüggemann1,2, W. J. G. Melchers1,2, P. E. Verweij1,2, J. W. Mouton1,2; 1Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands, 2Nijmegen Inst. for Infection, Inflammation and Immunity, Nijmegen, Netherlands. A-1934 Phase 1B Study of the Pharmacokinetics and Safety of

Posaconazole (POS) Solid Oral Tablet in Patients at Risk for Invasive Fungal Infection (IFI) R. F. Duarte1, J. López Jiménez 2, O. A. Cornely 3, L. Ma 4, M. P. S. van Iersel 5, H. Waskins 6; 1Catalan Inst. Oncol, Barcelona, Spain, 2Hosp Ramon y Cajal, Madrid, Spain, 3Univ. Hosp. Cologne, Cologne, Germany, 4Merck, Titusville, NJ, 5MSD, Oss, Netherlands, 6Merck, Whitehouse Station, NJ. A-1935 Effect of Concomitant Medications Affecting Gastric pH and

Motility on Posaconazole (POS) Tablet Pharmacokinetics (PK)

in a Murine Model of Cryptococcal Meningitis With Bridging to Humans: High Dosages are Required for Near-Maximal Antifungal Activity A. Sudan, J. Livermore, S. Howard, Z. Al-Nakeeb A. Sharp, J. Goodwin, L. Gregson, T. Wilkinson P. A. Warn, T. W. Felton, W. W. Hope; The Univ. of Manchester, Manchester, United Kingdom. A-1944 Pharmacokinetics and Pharmacodynamics of Liposomal

Amphotericin B (LAmB) for Cryptococcal Meningitis: A Single High Dose of Liposomal Amphotericin B is as Efficacious as Daily Dosing Regimens J. Livermore1, L. O’Connor 1, A. Sharp 1, L. Gregson 1, J. Goodwin 1, P. Warn 1, T. Felton 1, J. A. Schwartz 2, S. Howard1, W. W. Hope 1; 1The Univ. of Manchester, Manchester, United Kingdom, 2Charles River Lab., Davis, CA.

W. K. Kraft 1, P. Chang 1, M. P. S. van Iersel 2, H. Waskin3, G. Krishna 3, W. Kersemaekers 2; 1Thomas Jefferson Univ., Philadelphia, PA, 2Merck, Oss, Netherlands, 3Merck, Whitehouse Station, NJ.

Final Program

193

> Wednesday SCIENTIFIC SESSIONS A-1945 Standardization of a Murine Model of Systemic Candida albi-

and Oral (PO) KPI-10, a Novel Broad-Spectrum Fluoroquinolone (FQ)

J. M. Gonzalez, M. Agudelo, L. M. Leiva, C. A. Rodriguez, O. Vesga; Univ. of Antioquia, Medellin, Colombia.

Y. Ge1, P. B. Eckburg1, V. Jiang 1, D. Freeman 2, A. Kousba 3; 1Kalidex Pharmaceuticals, Inc., Menlo Park, CA, 2Ricerca Biosciences, LLC, Concord, OH, 3MicroConstants, Inc., San Diego, CA.

A-1946 Maximal Use PK Study of Luliconazole Solution 10% in

A-1954 Repeat-Dose Toxicity and Toxicokinetics (TK) of Oral KPI-

Subjects with Onychomycosis A. Tavakkol1, T. Jones 2; 1Topica Pharmaceuticals, Los Altos, CA, 2J & S Studies, Inc., College Station, TX. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------241(A) Poster Session Toxicokinetics and PK/PD of New and Old Fluoroquinolones Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-1947 In Vivo Pharmacodynamic (PD) Characterization of a New

Fluoroquinolone (FQ) Antibiotic, Kpi-10, against Gram-Positive (GP) and Gram-Negative (GN) Bacteria A. Lepak, K. Marchillo, J. Cabezas, W. Craig, D. R. Andes; Univ. of Wisconsin, Madison, WI. A-1948 Systemic Exposure Profile and Tissue Penetration (Lung,

Kidney, Bone Marrow, and Gallblader) of KPI-10 in Rabbits After Intravenous Administration C. Jacqueline1, V. Le Mabecque1, C. Desessard 2, A. F. Miegeville 1, Y. Ge 3 , G. Potel1, J. Caillon 1; 1UPRES EA 3826, Nantes, France, 2Atlangram, Nantes, France, 3Kalidex Pharmaceuticals Inc., Menlo Park, CA. A-1949 Absorption, Excretion, Tissue Distribution, and Protein

Binding of KPI-10, a New Broad-Spectrum Fluoroquinolone 1

1

2

3 1

Y. Ge , P. B. Eckburg , J. Enoru , E. Solon ; Kalidex Pharmaceuticals, Inc., Menlo Park, CA, 2Ricerca Biosciences, LLC, Concord, OH, 3QPS, LLC, Newark, DE. A-1950 In Vitro and In Vivo Metabolism of KPI-10, a New Broad-

Spectrum Fluoroquinolone Y. Ge1, P. B. Eckburg1, V. Jiang1, J. Enoru 2, R. Mc Clanahan 2, W. De Maio 2 , D. Johnson 3, A. Kousba 3; 1Kalidex Pharmaceuticals, Inc., Menlo Park, CA, 2Ricerca Biosciences, LLC, Concord, OH, 3MicroConstants, Inc., San Diego, CA. A-1951 Effect of KPI-10, a Novel, Broad-Spectrum Fluoroquino-

lone, on the Activity of Cytochrome P450 Isoenzymes in Human Hepatocytes J. Ge1, P. B. Eckburg1, J. Enoru 2, W. DeMaio 2; 1Kalidex Pharmaceuticals, Inc., Menlo Park, CA, 2Ricerca Biosciences, LLC, Concord, OH. A-1952 Safety & Pharmacokinetics of KPI-10, a Novel

Fluoroquinolone, in Healthy Adults Receiving Single Dose Oral Administrations P. B. Eckburg1, Y. Ge 1, V. Jiang1, T. Kilfoil 2, G. H. Talbot 3; 1Kalidex Pharmaceuticals, Inc., Menlo Park, CA, 2InClin, Inc., Los Altos, CA, 3Talbot Advisors LLC, Anna Maria, FL.

194

A-1953 Permeability and Pharmacokinetics (PK) of Intravenous (IV)

cans Infection to Study Therapeutic Equivalence (TE) of Fluconazole (FCZ) Generics

September 9-12 |

10, a Novel Fluoroquinolone, in Rats and Dogs P. B. Eckburg1, Y. Ge 1, L. Donald 2; 1Kalidex Pharmaceuticals, Inc., Menlo Park, CA, 2Intertek Cantox, Hoover, AL. A-1955 Lack of In Vitro or In Vivo Phototoxicity Associated with

KPI-10, a New Broad-Spectrum Fluoroquinolone P. B. Eckburg1, Y. Ge 1, K. Yasuhiro 2, D. B. Learn 3; 1Kalidex Pharmaceuticals, Inc., Menlo Park, CA, 2Wakunaga Pharmaceutical Co., Ltd., Hiroshima, Japan, 3Charles River Lab., Horsham, PA. A-1956 Metabolism and Mass Balance of Delafloxacin in Healthy

Human Volunteers Following Intravenous Administration A. McEwen1, L. Lawrence 2, S. Wood1, G. Ford 1, J. Longcor 2, D. Li 2, M. Reeve 2, R. Hoover 2; 1Quotient Bioresearch, Rushden, United Kingdom, 2 Rib-X Pharmaceuticals, New Haven, CT. A-1957 Pharmacokinetics (PK) of Delafloxacin (DLX), Vancomycin

(VAN), and Linezolid (LNZ) in a Phase 2 Exploratory Study in Subjects with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) R. Hoover1, L. Lawrence 1, J. Longcor 1, J. Greenfield 2; 1Rib-X Pharmaceuticals, New Haven, CT, 2PharmaNet/i3, The Woodlands, TX. A-1958 A Thorough Phase 1 QTc Study of Delafloxacin (DLX)

Compared with Placebo and Moxifloxacin (MXF) L. E. Lawrence1, M. Benedict 2, M. Medlock 2, J. Litwin 3, M. Thorn 4, S. Hopkins 1, J. Longcor 1; 1Rib-X Pharmaceuticals Inc., New Haven, CT, 2PPD Phase 1 Clinic, Austin, TX, 3ERT, Philadelphia, PA, 4Statistical Resources, Chapel Hill, NC. A-1959 Comparison of Postantibiotic Effects of Finafloxacin and

Other Fluoroquinolones C. Y. Goh 1, S. B. Ng 1, M. J. Everett 1, A. Vente2; 1MerLion Pharmaceuticals Pte Ltd, Singapore, Singapore, 2MerLion Pharmaceuticals GmbH, Berlin, Germany. A-1960 A Phase I Study to Determine Safety, Tolerability and

Pharmacokinetics (PK) of Intravenous Doses of Finafloxacin HCl (FIN) in Healthy Subjects M. Lückermann, L. Mooney, H. Patel, C. Fischer, S. Wohlert, A. Vente; MerLion Pharmaceuticals GmbH, Berlin, Germany. A-1961 Population Pharmacokinetic (PPK) and Pharmacokinetic/

Pharmacodynamic (PK/PD) Target Attainment (TA) Analyses to Support JNJ-Q2 Dose Selection for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) S. A. Van Wart1, M. Melhem1, J. M. Davenport 2, P. G. Ambrose 1, S. M. Bhavnani 1, D. R. Andes3, W. A. Craig3, G. F. Mc Intyre 2, C. M. Rubino1; 1 ICPD, Latham, NY, 2Furiex Pharmaceuticals, Morrisville, NC, 3Univ. of Wisconsin, Madison, WI.

WEDNESDAY SCIENTIFIC SESSIONS A-1962 Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis for

Efficacy of JNJ-Q2 Using Phase 2 Data from Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) S. M. Bhavnani1, J. P. Hammel1, S. A. Van Wart1, M. Melhem1, C. M. Rubino 1, J. M. Davenport 2, G. F. Mc Intyre 2, P. G. Ambrose 1; 1ICPD, Latham, NY, 2Furiex Pharmaceuticals, Morrisville, NC. A-1963 Decrease of Levofloxacin Fecal Concentrations in Experi-

mental Dogs Using DAV132, an Oral Adsorbent Delivered to the Ileum/Colon S. Sayah-Jeanne 1, E. Chachaty 2, T. Nguyen 3,4, V. Augustin 1, J. de Gunzburg 1, F. Mentré3,4, A. Andremont5,6; 1Da Volterra, Paris, France, 2Institut Gustave-Roussy, Villejuif, France, 3UMR738 INSERM, Paris, France, 4Univ. Paris Diderot, Paris, France, 5EA 3964 Univ. Paris Diderot, Paris, France, 6 Hosp. Bichat, AP-HP, Paris, France. A-1964 Levofloxacin (LVX) Penetration into Epithelial Lining Fluid

(ELF) Differs Between Infected and Uninfected Patients J. L. Kuti, D. P. Nicolau; Ctr. for Anti-Infect. Res. & Dev., Hartford Hosp., Hartford, CT. A-1965 Ciprofloxacin (CIP) PK/PD in Experimental Urinary Tract

Infection (UTI) Depends on Time>MIC and not AUC24/MIC L. Jakobsen1,2, K. S. Jensen 1, C. Vingsbo Lundberg 1, N. FrimodtMøller 1,2,3; 1Statens Serum Inst., Copenhagen, Denmark, 2Hvidovre Hosp., Hvidovre, Denmark, 3Hvidovre Univ. Hosp., Hvidovre, Denmark. A-1966 External Evaluation of a Mechanism-Based PKPD Model:

Predicting In Vitro Resistance Selection in Competition Experiments D. Khan, P. Lagerbäck, E. Gullberg, S. Cao, C. Malmberg, O. Cars, D. Hughes, D. I. Andersson, E. I. Nielsen, L. E. Friberg; Uppsala Univ., Uppsala, Sweden. A-1967 Testing the Mutant Selection Window Hypothesis with

Fluoroquinolone-Exposed Escherichia coli in an in Vitro Dynamic Model: Examination of Alternative Predictors of Resistance A. A. Firsov1, E. N. Strukova1, D. S. Shlykova 1, Y. A. Portnoy1, S. A. Dovzhenko1, M. B. Kobrin1, S. H. Zinner2; 1Gause Inst. of New Antibiotics, Moscow, Russian Federation, 2Mount Auburn Hosp., Cambridge, MA. A-1968 Pharmaceutical Equivalence (PE), Therapeutic Equivalence

(TE), and Resistance (R) Selection of 5 Generic Products of Ciprofloxacin (CIP) Compared with the Innovator against Pseudomonas aeruginosa C. A. Rodriguez, M. Agudelo, J. A. Perez, J. M. Gonzalez, O. Vesga; Univ. of Antioquia, Medellin, Colombia.

-----------------------------------------------------------------------242(C1) Poster Session Mechanisms of Resistance to Novel Compounds Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C Presentations: C1-1969 Structure of Plusbacin Bound to Bacterial Cell Walls S. Kim1, R. D. O’Connor 2, M. Singh 2, C. Cao 3, M. VanNiewenhze3, J. Schaefer2; 1Baylor Univ., Waco, TX, 2Washington Univ., St. Louis, MO, 3 Indiana Univ., Bloomington, IN. C1-1970 Dynamics and Mechanisms of Resistance Development to

Ceftazidime, Meropenem and Ceftolozane/Tazobactam in WildType and Mutator P.aeruginosa Strains G. Cabot, X. Mulet, B. Moyà, L. Zamorano., C. Juan, A. Oliver; Hosp. Son Espases, Palma de Mallorca, Spain. C1-1971 Single- and Multistep Resistance Selection with the Pleuro-

mutilin Antibiotic BC-3781 S. Paukner1, C. L. Clark, 2, Z. Ivezic-Schoenfeld 1, K. Kosowska-Shick2; 1 Nabriva Therapeutics AG, Vienna, Austria, 2Hershey Med. Ctr., Hershey, PA. C1-1972 Resistance Mechanism to Antisense Peptide-Phosphorodi-

amidate Morpholino Oligomers B. L. Geller1, K. A. Reese1, G. M. Mitev1, V. Mullen 1, K. R. Pomraning1, R. C. Johnson 1, P. L. Iversen 2, M. Freitag1; 1Oregon State Univ., Corvallis, OR, 2 AVI BioPharma, Inc., Corvallis, OR. C1-1973 Activity of the EF-G Inhibitor Argyrin B in Key Gram

Negative Pathogens: Spectrum and Resistance A. L. Woods, A. K. Jones, R. E. Caughlan, C. R. Dean; Novartis Inst. for Biomedical Res., Emeryville, CA. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------243(C2) Poster Session Antimicrobial Resistance of Miscellaneous Bacteria Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C Presentations: C2-1974 Oropharyngeal Colonization by Non-Typable Haemophilus

Influenzae (NTHi) among Healthy Children Attending Day Care Centers S. Marti1, C. Puig1, A. Fleites2, L. Calatayud1, C. Ardanuy1, J. Liñares1; 1 Hosp. Univ. Bellvitge, Barcelona, Spain, 2Hosp. Central, Oviedo, Spain. C2-1975 Genetic Diversity of ftsI Gene inơ-Lactamase Non-

Producing Ampicillin Resistant andơ-Lactamase Producing Amoxicillin-Clavulanic Acid Resistant Haemophilus influenzae Strains Isolated from the Nasopharyngeal Carriage of Children in South Korea C. Park1, J. Kang1, K. Kim2, D. Lee1, J. Lee1, H. Kwon1, E. Choi1; 1The Catholic Univ. of Korea, Seoul, Korea, Republic of, 2Ewha Univ., Seoul, Korea, Republic of.

Final Program

195

> Wednesday SCIENTIFIC SESSIONS C2-1976 Population-Based Surveillance of Haemophilus influenzae

Antimicrobial Resistance in the United States Withdrawn C2-1977 An Outbreak of Macrolide-Resistant Mycoplasma pneumoniae

(MRMP) Infection in 2011 Among Japanese Children 1,2

2

3

4

2

5

T. Okada , M. Morozumi , T. Tajima , M. Hasegawa , N. Chiba , S. Iwata , K. Ubukata2; 1Natl. Hosp. Organization Tokyo Med. Ctr., Tokyo, Japan, 2 Kitasato Inst. for Life Sci., Kitasato Univ., Tokyo, Japan, 3Hakujikai Mem. Hosp., Tokyo, Japan, 4Nihon Univ. Sch. of Med., Tokyo, Japan, 5Keio Univ. Sch. of Med., Tokyo, Japan. C2-1978 Increasing Prevalence of Macrolide-Resistance of Myco-

plasma pneumoniae Pneumonia in Korea, 2000-2011 N. Yang1, K. Hong 1, S. Lee 2, J. Lee3,4, Y. Ahn5, J. Lee6, E. Choi1, H. Lee1; 1 Seoul Natl. Univ. Hosp., Seoul, Korea, Republic of, 2Clinical Res. Inst., Seoul Natl. Univ. Hosp., Seoul, Korea, Republic of, 3Seoul Natl. Univ., Seoul, Korea, Republic of, 4Seoul Natl. Univ. Bundang Hosp., Seongnam, Korea, Republic of, 5Seoul Eulji Hosp., Seoul, Korea, Republic of, 6Kangwon Natl. Univ. Hosp., Seoul, Korea, Republic of. C2-1979 Characterisation of Antibiotic Resistant Determinants in

Moraxella osloensis, an Opportunistic Human Pathogen L. M. Bishop1, Muriel T. Mafura, Theresa Hunt, A. P. Roberts2, M. F. Anjum3; 1Animal Hlth. Vet. Lab. Agency, Weybridge, United Kingdom, 2 Eastman Dental Inst., Univ. Coll. London, London, United Kingdom, 3 Animal Hlth. Vet. Lab. Agency, Weybridge, United Kingdom. C2-1980 Antimicrobial Susceptibility and Genetic Diversity of 55

Turkish Bacillus Anthracis Strains M. Ortatatli1, A. Karagoz 2, D. Percin 3, L. Kenar1, S. Kilic2, R. Durmaz2; 1 GATA, Ankara, Turkey, 2RSNPHA, Ankara, Turkey, 3Erciyes Univ. Faculty of Med., Kayseri, Turkey. C2-1981 Antimicrobial Resistance Profile and Relatedness of cagA

Gene with Enhanced Metronidazole and Quinolone Resistance an Helicobacter pylori A. Khan1, A. Farooqui 2, H. Manzoor 3, S. S. Akhter 3, M. S. Qureshy3, S. U. Kazmi 1; 1Univ. of Karachi, Karachi, Pakistan, 2Intl. Inst. of Infection and Immunity, Shantou, China, 3Civil Hosp., Karachi, Pakistan. C2-1982 Ciprofloxacin Resistance in Neisseria meningitidis Serogroup

a Isolated from Invasive Meningococcal Meningitis from 2005 to 2012 in Delhi, India S. Dwivedi1, B. K. Das 1, A. Kapil1, S. Sood1, R. Chaudhry 1, M. Deb2, D. Nair2, S. Gupta3; 1AIIMS, Delhi, India, 2VMMC and Safdarjung Hosp., Delhi, India, 3Natl. Ctr. for Disease control, Delhi, India. C2-1983 Identification of Antibiotic Resistance Genes in the Human

Microflora Using 2 Different Approaches M. Anjum1, R. Card 1, P. Warburton 2, E. Allan2, P. Mullany2; 1Animal Hlth. and Vet. Lab. Agency, Surrey, United Kingdom, 2Univ. Coll. London, London, United Kingdom.

-----------------------------------------------------------------------244(C2) Poster Session Streptococcus and Enterococus Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C Presentations: C2-1984 Characterization of vanA type-Vancomycin-Susceptible

Enterococcus faecium Y. Jung, Y. Lee, S. Lee; KCDC, ChungCheongbuk-do, Korea, Republic of. C2-1985 Low Prevalence of Inc18-like vanA Plasmid Among

Prospectively-Collected Vancomycin-Resistant Enterococcus Isolates from Detroit Medical Center E. T. Martin1, A. M. Casapao1, J. McRoberts1, C. Archer1, K. Kaye1,2, M. J. Rybak1,2; 1Wayne State Univ., Detroit, MI, 2Detroit Med Ctr, Detroit, MI. C2-1986 Diversity of Multiple Antibiotic Resistant Enterococci from

Broiler Chicken Fed Antimicrobial Supplemented Diets M. S. Diarra1, H. Rempel 1, J. Champagne 2, L. Masson 2, E. Topp 3; 1Pacific Agri-Food Res. Ctr., Agassiz, Canada, 2Natl. Res. Council of Canada, Montreal, Canada, 3Southern Crop Protection and Food Res. Ctr., London, Canada. C2-1987 Conjugative Plasmids Carrying the Multiresistance Gene

cfr in Enterococcus faecalis and Enterococcus thailandicus from Swine and Farm Environment Y. Wang1, Y. Liu1, S. Schwarz2, C. Wu1, Z. Shen 3, Q. Zhang3, J. Shen1; 1 China Agricultural Univ., Beijing, China, 2Inst. of Farm Animal Genetics, FLI, Neustadt-Mariensee, Germany, 3Iowa State Univ., Ames, IA. C2-1988 Phenotypical and Genotypical Surveillance of Macrolide

and Lincosamide Resistance in Group B Streptococcus in Belgium J. Descy, Y. Ackermans, R. Boreux, C. Meex, L. Remont, G. Rodriguez Cuns, P. Melin; Natl. Reference Lab. for Group B Streptococci, Univ. Hosp., Leige, Belgium. C2-1989 Current Status of Group B Streptococci (GBS) in Japan

Penicillin-Resistant GBS is Emerging in Japan? T. Ohno1, H. Sawamura1, A. Yamada1, I. Koita1, H. Suematsu1, N. Nagano2, M. Toyama2, Y. Nagano2, K. Kimura3, Y. Arakawa3, Y. Yamagishi1, H. Mikamo1; 1Aichi Med. Univ., Aichi, Japan, 2Natl. Inst. of Infectious Diseases, Tokyo, Japan, 3Nagoya Univ., Aichi, Japan. C2-1990 Characteristics of Capsular and Multilocus Sequence

Types of Streptococcus agalactiae from Neonatal Invasive Infections in Japan K. Ubukata1, M. Morozumi1, N. Chiba1, T. Wajima1, H. Sakata 2, S. Iwata3; 1 Kitasato Inst. for Life Sci., Kitasato Univ., Tokyo, Japan, 2Asahikawa-Kosei Gen. Hosp., Asahikawa, Japan, 3Keio Univ. Sch. of Med., Tokyo, Japan. C2-1991 Change in the Prevalent emm Type and Increase in Mac-

rolide Resistance among Streptococcus pyogenes Isolated from Invasive Infections in Japan T. Wajima, M. Morozumi, N. Chiba, K. Ubukata; Kitasato Inst. for Life Sci., Kitasato Univ., Minato-ku, Japan.

196

September 9-12 |

WEDNESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------245(E) Poster Session In Vitro Activity for Mycobacteria Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C

Diflunisal to Target Methicillin-Resistant Staphylococcus aureus (MRSA) A. Salvioni1, N. Haste 1, W. Thienphrapa 1, V. Khodaverdian 2, G. Yu 2, M. Shoham2, V. Nizet1, M. Hensler1; 1Univ. Calif. San Diego, La Jolla, CA, 2 Case Western Reserve Univ., Cleveland, OH. F-2000 Benzamil Hydrochloride Has Antifungal Activity against

Presentations: E-1992 In Vitro Activities of PNU-100480 and Linezolid against

Mycobacterium tuberculosis (MTB) Isolates with Different Degrees of Anti-Tuberculosis Drug Resistance C. W. Yip1, K. M. Kam 1, T. K. Lam 1, C. Y. Chan2, W. W. Yew2; 1Publ. Hlth. Lab. Ctr., Dept. of Hlth., Kln, Hong Kong, 2The Chinese Univ. of Hong Kong, NT, Hong Kong. E-1993 Clinical Doses of PNU-100480 (U, Sutezolid) Plus Rifampin

(R) Synergistically Kills Mycobacterium tuberculosis (Mtb) while Linezolid (L) Plus R Does Not A. Louie, D. Brown, M. Swift, K. Files, S. Fikes, G. Drusano; Univ. of Florida, Orlando, FL. E-1994 Multidrug Resistance Among Newly Diagnosed Tuberculosis

Patients in Cross River State, Nigeria 1

F-1999 Re-Purposing the Non-Steroidal Anti-Inflammatory Drug

1

1

2

A. E. Asuquo , B. P. Thumamo , L. N. Abia-Bassey , N. O. Umoh , M. B. Idasa 3, F. O. Eko4; 1Univ. of Calabar, Calabar, Nigeria, 2Ministry of Hlth., Uyo, Nigeria, 3Univ. of Calabar Teaching Hosp., Calabar, Nigeria, 4Morehouse Sch. of Med., Atlanta, GA. E-1995 In Vitro Activities of Tedizolid Compared to Linezolid

against Mycobacterium fortuitum M. H. Cynamon, M. Sklaney; VA Med. Ctr., Syracuse, NY.

-----------------------------------------------------------------------246(F) Poster Session New Ways with Old Friends: Repurposing and Novel Formulations Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C Presentations: F-1996 Non-Steroidal Anti-Inflammatory Drugs: Antimicrobial

Activity and Influence on Efflux Mediated Resistance to Antibiotics of Gram-Negative Rods A. E. Laudy, J. Kalbarczyk, S. Tyski; Med. Univ. of Warsaw, Warsaw, Poland. F-1997 Antibacterial Spectrum and Structure-Activity Relationship

Candida albicans Biofilms In Vitro M. Jahng1, H. S. Rane1,2, S. M. Bernardo 1,2, S. A. Lee 1,2; 1New Mexico VA Healthcare System, Albuquerque, NM, 2Univ. of New Mexico, Albuquerque, NM. F-2001 Silver Nanoparticles: Antibacterial Potential and Applications G. C. Cotton, M. G. Baron, R. A. Dixon; Univ. of Lincoln, Lincoln, United Kingdom. F-2002 In Vivo Activity and Pharmacokinetics of Gold Nanoparticles

against Multidrug-Resistant Gram-Negative Bacteria Y. Zhao1, F. Long1, X. You2, W. Zhang1, X. Jiang1; 1Natl. Ctr. for Nanoscience and Technology, Beijing, China, 2Peking Union Med. Coll., Beijing, China. F-2003 Orally Administered DAV131, a Formulated Oral Adsorbent,

Inhibits Establishment of Intestinal Colonization by BetaLactamine Resistant Klebsiella pneumoniae in Mice Treated by Cefotaxime N. Grall1,2, N. Ducrot 1, M. Laurent 1, S. Sayah-Jeanne 3, E. Chachaty 4, T. Nguyen 2, J. De Gunzburg 3, A. Andremont1,2; 1Bichat Hosp., Paris, France, 2 Univ. Paris Diderot, Paris, France, 3Da Volterra, Paris, France, 4Inst. Gustave Roussy, Villejuif, France. F-2004 Enhancing Activity of Tigecycline to Metallo-Beta-Lac-

tamse-Producing Pseudomonas aeruginosa by Using DDA Bicelles: Synergistic Activity and Physico-Chemical Behavior J. Aliaga, H. Turano, N. Lincopan; Univ. de São Paulo, São Paulo, Brazil. F-2005 In Vitro Inhibition of Clostridium perfringens Epsilon Toxin

Using Beta-Cyclodextrin Derivatives Provides a Potential Strategy for Therapeutic Development M. Boley1, T. Robinson2, L. Jicsinszky2, V. Karginov 2, K. Langenbach 1; 1 ATCC, Manassas, VA, 2Innovative Biologics, Herndon, VA. F-2006 Development of an In Vitro Pharmacokinetic/Pharmaco-

dynamic Model for Studying Novel Nanoantibiotics: DextrinColistin Conjugates E. Azzopardi, E. Ferguson, D. Thomas; Cardiff Univ., Cardiff, United Kingdom. F-2007 Use of Small-Angle Neutron Scattering to Investigate the

of Tomatidine Analogs

Mechanism of Action of Bioresponsive Dextrin-Colistin Conjugates

I. Guay, F. Chagnon, G. Mitchell, K. Bouarab, É. Marsault, F. Malouin; Univ. de Sherbrooke, Sherbrooke, Canada.

E. Ferguson1, J. Roberts 1, R. Schweins 2, D. Thomas 1, P. Griffiths 1; 1Cardiff Univ., Cardiff, United Kingdom, 2Institut Laue-Langevin, Grenoble, France.

F-1998 Tomatidine is Bactericidal against Staphylococcus aureus in Co-

Culture with Pseudomonas aeruginosa Strains Producing HQNO S. Boulanger, G. Mitchell, E. Frost, É. Marsault, K. Bouarab, F. Malouin; Univ. de Sherbrooke, Sherbrooke, Canada.

F-2008 Comparative In Vitro Toxicity of Colistin, CMS and Dextrin-

Colistin Conjugates E. Ferguson, J. Roberts, D. Thomas; Cardiff Univ., Cardiff, United Kingdom. F-2009 DihomoƢ-Linolenic Acid (DGLA) Enhances the Antimicro-

bial Efficacy of Benzoyl Peroxide J. Rowe, D. Coughlan, M. Manku, J. Climax; Dignity Sci., Dublin, Ireland.

Final Program

197

> Wednesday SCIENTIFIC SESSIONS F-2010 Antimicrobial Activity of EDTA Containing Nanoemulsions

on MDR Acinetobacter baumannii K. Ramalingam1, Y. Y. Hwang 2, V. Lee 1, A. Rene 2; 1Univ. of Texas Hlth. Sci. Ctr., San Antonio, TX, 2Naval Med. Res. Unit, San Antonio, TX. F-2011 Antibacterial Activity of Daptomycin and Vancomycin-Load-

ed Polymeric Particulate Systems for Bone Infections Treatment I. S. Ferreira1, B. Betrisey 2, A. Bettencourt1, A. J. Almeida1, A. Trampuz 2; 1 Univ. of Lisbon, Lisbon, Portugal, 2Univ. Hosp., Lausanne, Switzerland. F-2012 Glyceryl Trinitrate (GTN) is Useful as a Novel Non-Antibi-

otic Catheter Lock for the Prevention of Intraluminal Catheter Biofilm Colonisation J. Rosenblatt, R. Y. Hachem, T. Dvorak, A. Chaftari, M. Alshuabi, I. I. Raad; U.T.M.D. Anderson Cancer Ctr., Houston, TX. F-2013 Augmenting Antibiotic-Coated Catheters (CVC) Activity

against Bacterial Biofilm Adherence by Impregnating the Cvc with Verapamil J. A. Mohamed, A. Chaftari, R. Y. Hachem, M. Alshuaibi, I. I. Raad; U.T.M.D. Anderson Cancer Ctr., Houston, TX. F-2014 Pathogenesis and Prevention of Ventilator-Associated Pneu-

monia (VAP): An in Vitro Model Using Antimicrobial-Coated Endotracheal Tube (ETT) J. Rosenblatt, R. Y. Hachem, R. Reitzel, A. Chaftari, I. I. Raad; U.T.M.D. Anderson Cancer Ctr., Houston, TX. F-2015 Barrier-Forming Oral Formulation Containing Cetylpyri-

dinium Chloride (fCPC) Exhibits Potent Activity against Oral Pathogens J. Chandra 1, P. K. Mukherjee1, F. Esper2, A. M. Ghannoum 3, B. Sokol 3, R. A. Salata2, M. A. Ghannoum4; 1Case Western Reserve Univ., Cleveland, OH, 2 Univ. Hosp. Case Med. Ctr., Cleveland, OH, 3Oasis Consumer Healthcare LLC, Cleveland, OH, 4Univ. Hosp. Case Med. Ctr. and Case Western Reserve Univ., Cleveland, OH. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------247(F) Poster Session Novel Inhibitors of Bacterial GyrB/ParE Topoisomerase Subunits Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . . . . . . . . . .

F-2017 Antibacterial Agents Targeting DNA Gyrase B and

Topoisomerase IV: Discovery of a New Class by Structure-Based Drug Design X. Li1, L. W. Tari 1, D. Bensen 1, M. Trzoss 1, T. Lam 1, J. Zhang 1, Z. Chen 1, S. J. Lee 1, M. Cunningham 1, K. Nelson 1, V. Brown-Driver 1, M. Stidham1, T. Nguyen 2, F. Lightstone 2, K. Shaw 1, J. Finn 1; 1Trius Therapeutics, Inc., San Diego, CA, 2Lawrence Livermore Natl. Lab., Livermore, CA. F-2018 Antibacterial Agents Targeting DNA Gyrase B and Topoi-

somerase IV: Optimization of Gram-Negative Antibacterial Activity and Drug Properties J. Finn1, M. Trzoss1, X. Li1, D. Bensen 1, T. Lam1, J. Zhang 1, Z. Chen1, S. Lee1, M. Cunningham1, K. Nelson1, A. Castellano 1, B. Kwan1 , M. Stidham1, V. Brown-Driver, T. Nguyen 2, F. Lightstone 2, S. Wong2, K. J. Shaw 1, L. W. Tari 1; 1Trius Therapeutics, Inc., San Diego, CA, 2Lawrence Livermore Natl. Lab., Livermore, CA. F-2018a Antibacterial Agents Targeting DNA Gyrase B and Topoi-

somerase IV: Design of Compounds with Broad-Spectrum GramNegative Antibacterial Activity L. Tar1, D. Bensen1, M. Trzoss1, X. Li1, T. Lam1, J. Zhang1, Z. Chen1, S. Lee1, M. Cunningham1, K. Nelson1, M. Stidham1, V. Brown-Driver1, T. Nguyen2, F. Lightstone2, S. Wong2, K. J. Shaw 1, J. Finn 1; 1Trius Therapeutics, San Diego, CA, 2Lawrence Livermore Natl. Lab., Livermore, CA. F-2019 Potent Activity of Novel Gyrase/Topoisomerase Inhibitors

against Gram-Negative and Gram-Positive Pathogens with Important Resistance Phenotypes C. M. Pillar, L. Stapert, M. Marchak, D. L. Shinabarger; Micromyx, LLC, Kalamazoo, MI. F-2020 Microbiological Profile of Novel Inhibitors of DNA Gyrase

and Topoisomerase IV against Gram-Negative Pathogens K. Nelson, A. Castellano, S. Farkas, V. Brown-Driver, K. J. Shaw; Trius Therapeutics, San Diego, CA. F-2021 In Vitro Activity of Novel Gyrase Inhibitor Antimicrobials

against Clinical Pseudomonas aeruginosa Isolates P. R. Tessier, D. P. Nicolau; Hartford Hosp., Hartford, CT. F-2022 Antimicrobial Activity and In Vivo Efficacy of Novel GyrB/

ParE Inhibitors versus Burkholderia pseudomallei V. Driver1, N. Podnecky 2, N. Marlenee 2, R. Bowen 2, X. Li 1, K. J. Shaw 1, H. P. Schweizer2; 1Trius Therapeutics, Inc., San Diego, CA, 2Colorado State Univ., Fort Collins, CO. F-2023 Broad Spectrum Activity of Novel, Dual Targeting Inhibitors

of Bacterial DNA Gyrase and Topoisomerase IV against Biodefense Pathogens

Halls A-C Presentations: F-2016 In Vitro and In Vivo Biology of Benzothiazole Urea-Based,

Dual-Targeting DNA Supercoiling Inhibitors for the Treatment of Bacterial Infections J. T. Palmer1, S. Barker 2, J. M. Bennett 2, J. Berry2, M. Blair 1, L. G. Czaplewski 2, I. Collins 2, D. Davies 2, D. J. Haydon 2, P. Lancett2, A. Logan 2, C. J. Lunniss 1, C. Morton 1, G. R. W. Pitt 1, D. Offermann 1, L. Offermann 1, S. Pommier 2, D. Price 2, N. Stokes 2, H. Thomaides-Brears 2, S. P. Tucker 1; 1 Biota Scientific Management, Notting Hill, Australia, 2Biota Europe, Begbroke, United Kingdom.

K. Montgomery 1, G. Vanier 1, K. Nelson 2, V. Brown-Driver2, K. J. Shaw 2, P. J. Jackson 1; 1Lawrence Livermore Natl. Lab., Livermore, CA, 2Trius Therapeutics, Inc., San Diego, CA. F-2024 Advanced Microbiological Profile of New DNA Gyrase/

Topoisomerase IV Inhibitors V. Brown-Driver, A. Castellano, K. Nelson, X. Li, T. Lam, M. Trzoss, J. Zhang, Z. Chen S. Lee, K. J. Shaw, J. Finn; Trius Therapeutics, San Diego, CA. F-2025 Selection and Characterization of E. coli Mutants with

Reduced Susceptibility to Novel DNA Gyrase/Topoisomerase IV Inhibitors A. Castellano, J. Locke, S. Farkus, V. Brown-Driver, K. J. Shaw; Trius Therapeutics, Inc., San Diego, CA.

198

September 9-12 |

WEDNESDAY SCIENTIFIC SESSIONS F-2026 Comparative Pharmacokinetics of Novel Inhibitors of DNA

Gyrase/Topoisomerase IV V. Ong, V. Brown-Driver, C. L. Hall, G. W. Hough, K. Nelson; Trius Therapeutics, Inc., San Diego, CA. F-2027 Use of Microdosing and Accelerator Mass Spectrometry to

Evaluate the Pharmacokinetics of a Novel GyrB/ParE Inhibitor M. A. Malfatti1, V. Lao 1, K. W. Turteltaub 1, C. L. Hall 2, V. S. Ong 2; 1 Lawrence Livermore Natl. Lab., Livermore, CA, 2Trius Therapeutics, Inc., San Diego, CA. F-2028 Activity of Novel, Dual Targeting Inhibitors of Bacterial

DNA Gyrase and Topoisomerase IV in Murine Infection Models T. M. Murphy1, M. A. Blair1, S. Little1, A. M. Slee1, V. Brown-Driver 2, K. J. Shaw 2; 1ViviSource Lab., Inc, Waltham, MA, 2Trius Therapeutics, Inc., San Diego, CA. F-2029 In Vitro Activity and Pharmacodynamic (PD) Evaluation of

Dual Targeting Inhibitors of Bacterial DNA Gyrase and Topoisomerase IV (DTIs) against Extracellular and Intracellular Forms of Ciprofloxacin-Susceptible (CIPS) and Ciprofloxacin-Resistant (CIPR) Pseudomonas aeruginosa (PA) and Staphylococcus aureus (SA) J. M. Buyck1, S. Lemaire 1, D. Pierard2, F. Van Bambeke1, P. M. Tulkens1; 1 Univ. Catholique de Louvain, Bruxelles, Belgium, 2Vrije Univ. Brussel, Bruxelles, Belgium.

-----------------------------------------------------------------------248(F) Poster Session Quinolones and Beyond Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C

F-2035 DS-8587, a New Generation of Broad Spectrum Quinolone:

Pharmacodynamic and Therapeutic Efficacy in Animal Infection Models Y. Kurosaka, S. Uoyama, C. Ishii, K. Hoshino; Daiichi Sankyo Co., Ltd., Tokyo, Japan. F-2036 DS-8587, a New Generation of Broad Spectrum Quinolone:

In Vitro Antibacterial Activities against Chinese Clinical Isolates D. Zhu1, Y. Kurosaka2, K. Hoshino 2; 1Huashan Hosp., Fudan Univ., Shanghai, China, 2Daiichi Sankyo, Co., Ltd., Tokyo, Japan. F-2037 DS-8587, a New Generation of Broad Spectrum Quinolone:

Antibacterial Spectrum and its In Vitro Activities against Clinical Isolates in Japan M. Chiba, K. Fujikawa, R. Okumura, K. Yuichi, K. Hoshino; Daiichi Sankyo, Co., Ltd., Tokyo, Japan. F-2038 DS-8587, a New Generation of Broad Spectrum Quinolone:

Mode of Action and Frequency of Resistant Mutants of Major Pathogens R. Okumura, Y. Onodera, M. Chiba, K. Fujikawa, K. Hoshino; Daiichi Sankyo, Co. Ltd., Tokyo, Japan. F-2039 DS-8587, a New Generation of Broad Spectrum Quinolone:

In Vitro Antibacterial Activities against A. baumannii S. Higuchi1,2, Y. Onodera 1, M. Chiba 1, K. Hoshino 1, N. Gotoh2; 1Daiichi Sankyo, Co. Ltd., Tokyo, Japan, 2Kyoto Pharmaceutical Univ., Kyoto, Japan. F-2040 DS-8587, a New Generation of Broad Spectrum Quinolone:

In Vitro Antibacterial Activity against Japanese Clinical Isolates of ESBL Producing Escherichia coli Y. Ishii1, M. Chiba2, K. Hoshino2, K. Tateda 1; 1Toho Univ. Sch. of Med., Tokyo, Japan, 2Daiichi Sankyo, Co., Ltd., Tokyo, Japan. F-2041 DS-8587, a New Generation of Broad Spectrum Quinolone:

Presentations: F-2030 Ev-035: Novel 2-Pyridone Based Topoisomerase Inhibitors

with Broad-Spectrum Activity against MDR Pathogens, Including Quinolone Resistance J. Heim, P. Roussel, D. Milligan, S. Goldman; Evolva, Reinach, Switzerland. F-2031 Ev-035: Synthesis and In Vitro Antibacterial Activity of a

New Series of 2-Pyridone Based Topoisomerase Inhibitors P. Roussel, G. Liu, D. Milligan, S. Goldman, J. Heim; Evolva SA, Reinach, Switzerland. F-2032 Ev-035: In Vitro ADMET, Mouse PK and Efficacy in Murine

Infection Models of a New Orally Available Class of Antibiotics G. Salerno, J. Heim, S. Goldman, D. Milligan, P. Roussel; Evolva, Reinach, Switzerland. F-2033 EV-035: Potent Antibiotic Series against Biothreat Agent

Burkholderia pseudomallei S. Goldman1, G. Salerno 1, D. Milligan 1, P. Roussel 1, N. Marlenee2, R. Bowen2, N. Podnecky 2, H. P. Schweizer2, J. Heim 1; 1Evolva, Reinach, Switzerland, 2Colorado State Univ., Fort Collins, CO. F-2034 Activity and Pharmacokinetics of Clinafloxacin for Bovine

and Swine Respiratory Disease

Nonclinical and Clinical Pharmacokinetic Profiles N. Kobayashi1, T. Shimizu 1, K. Toyama 1, E. Kamiyama1, E. Suzuki 1, T. Abiko1, H. Fukase 2, T. Tokui 1, T. Izumi 1; 1Daiichi Sankyo, Co. Ltd., Tokyo, Japan, 2CPC Clinical Trial Hosp., Kagoshima, Japan. F-2042 DS-8587, a New Generation of Broad Spectrum Quinolone:

Safety Profile in Preclinical Studies H. Miida, Y. Tsuchiya, S. Itoh, K. Noritake, T. Ishizaka, W. Takasaki; Daiichi Sankyo, Co. Ltd., Shizuoka, Japan. F-2043 DS-8587, a New Generation of Broad Spectrum Quinolone:

Pharmacodynamics and In Vivo Efficacy against Acinetobactor baumannii M. Pandya1, T. K. Barman 1, E. P. M. Rao 1, M. Kumar 1, S. Singhal 1, D. J. Upadhyay1, Y. Kurosaka2, S. Uoyama2, C. Ishii2, K. Hoshino2; 1Daiichi Sankyo Life Sci. Res. Ctr. Gurgaon, India, 2Daiichi Sankyo, Co. Ltd., Tokyo, Japan. F-2044 DS-8587, a New Generation of Broad Spectrum Quinolone:

In Vitro Antibacterial Activity against Clinical Isolates from Postoperative Intraabdominal Infections (IAIs) Y. Takesue1, M. Chiba2, K. Hoshino2; 1Hyogo Coll. of Med., Nishinomiya, Japan, 2Daiichi Sankyo, Co. Ltd., Tokyo, Japan.

M. T. Sweeney, R. Quesnell, R. Tiwari, M. LeMay, C. Benner, J. Watts; Pfizer, Kalamazoo, MI.

Final Program

199

> Wednesday SCIENTIFIC SESSIONS F-2045 DS-8587, a New Generation of Broad Spectrum Quinolone:

In Vitro Antibacterial Activity against 9 Major Anaerobic Species of Japanese Clinical Isolates H. Mikamo1, Y. Yamagishi1, H. Suematsu 1, H. Sawamura 1, M. Chiba2, R. Okumura2, K. Hoshino2; 1Aichi Med. Univ., Aichi, Japan, 2Daiichi Sankyo, Co. Ltd., Tokyo, Japan. F-2046 In Vitro Activity of KPI-10 against Clinically Important 1

2

2

1 1

J. Deane , A. Simenauer , Y. Ge , P. B. Eckburg , D. Sahm ; Eurofins, Chantilly, VA, 2Kalidex Pharmaceuticals, Inc., Menlo Park, CA. F-2047 In Vitro Activity of KPI-10 against Clinically Important

Gram-Positive Bacteria J. Deane 1, A. Simenauer1, Y. Ge 2, P. Eckburg 2, D. Sahm 1; 1Eurofins, Chantilly, VA, 2Kalidex Pharmaceuticals Inc., Menlo Park, CA. F-2048 Activity of Novel Fluoroquinolone, KPI-10, vs. Multidrug-

Resistant Bacteria, Including those with NDM-1 Carbapenemase D. M. Livermore, M. Warner, S. Mushtaq; Hlth. Protection Agency, London, United Kingdom. F-2049 In Vitro Activity and DNA Gyrase Inhibitory Activity of

KPI-10, a Novel Fluoroquinolone (FQ), against QuinoloneSusceptible (QS) and Quinolone-Resistant (QR) E. coli D. Kazamori, K. Sugimoto, Diploma, H. Aoi, K. Itoh, Y. Kuramoto, A. Yazaki; Wakunaga Pharmaceutical Co. Ltd., Hiroshima, Japan. F-2050 In Vitro Activity of KPI-10 Tested against a Global

Collection of Acinetobacter spp. Including Multidrug-Resistant (MDR) Strains R. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones; JMI Lab., N Liberty, IA. F-2051 KPI-10 In Vitro Activity Tested against Pathogens Common-

ly Associated with Community-Acquired Bacterial Pneumonia (CABP) Infections R. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones; JMI Lab., N Liberty, IA. F-2052 KPI-10, a Novel Flouroquinolone (FQ) Tested against

Neisseria gonorrhoeae Including Ciprofloxacin Non-Susceptible (CIP-NS) and Penicillin Non-Susceptible (PEN-NS) Strains R. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones; JMI Lab., N Liberty, IA. F-2053 In Vitro Activity of KPI-10 Tested against Pathogens

Commonly Associated with Urinary Tract infections (UTIs) R. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones; JMI Lab., N Liberty, IA. F-2054 Activity of KPI-10 against Highly Resistant E. coli and

K. pneumoniae from Various Countries M. A. Habeeb 1, P. Eckburg 2, J. Ge 3, C. G. Giske4; 1Natl. Inst. for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan, 2Kalidex Pharmaceutical Inc, Menlo Park, CA, 3Kalidex Pharmaceuticals, Menlo Park, CA, 4Karolinska Inst., Stockholm, Sweden. F-2055 In Vivo Activity of KPI-10, a Novel Fluoroquinolone (FQ),

in Mouse Systemic and Local Infection Models Caused by Multidrug- and FQ-Resistant Pathogens H. Amano, H. Aoi, K. Sakata, K. Inokuma, D. Kazamori, K. Itoh, Y. Kuramoto, A. Yazaki; Wakunaga Pharmaceutical Co. Ltd., Akitakata, Japan.

200

Treating Sepsis in Mice Due to Quinolone-Susceptible (QS) and Quinolone-Resistant (QR) Nosocomial Pathogens: Comparison with Ciprofloxacin (CIP) C. Jacqueline1, M. Davieau1, C. Desessard 2, A. F. Miegeville 1, Y. Ge 3, G. Potel1, J. Caillon 1; 1UPRES EA 3826, Nantes, France, 2Atlangram, Nantes, France, 3Kalidex Pharmaceuticals Inc, Menlo Park, CA. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

Gram-Negative Bacteria 1

F-2056 50% Effective Dose (ED50) Determination of KPI-10 for

September 9-12 |

-----------------------------------------------------------------------249(F) Poster Session Targeting Gram-Negative Pathogens Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C Presentations: F-2057 FimH Antagonists: A Selective and Highly Effective Novel

Therapeutic Approach for the Treatment of Urinary Tract Infection B. Ernst, D. Abgottspon, M. Scharenberg, X. Jiang, O. Schwardt; Inst. of Molecular Pharmacy, Basel, Switzerland. F-2058 N-Chlorotaurine, a Long-Lived Endogenous Oxidant, Inac-

tivates Shiga Toxin 2 of Enterohemorrhagic Escherichia coli M. Nagl1, C. Eitzinger1, S. Ehrlenbach 1, H. Lindner1, L. Kremser 1, W. Gottardi 1, D. Orth1, D. Debabov2, M. Anderson 2; 1Innsbruck Med. Univ., Innsbruck, Austria, 2Novabay, Emeryville, CA. F-2059 Activity of Novel Pyrrolocytosine Agents against Multidrug

and Carbapenem Resistant Klebsiella pneumoniae M. R. Jacobs1, S. Bajaksouzian1, A. R. Windau 1, A. N. Foster 1, K. M. Hujer 2, R. A. Bonomo2; 1CWRU/Univ. Hosp, Cleveland, OH, 2CWRU,VAMC, Cleveland, OH. F-2060 Antimicrobial Activity and Synergistic Effect of Synthetic

Peptides against Antibiotic Resistant Pseudomonas aeruginosa from Gallbladder Bile of Acute Cholecystitis Patients J. Chae1, B. Son2, Y. Park3, W. Choe1, S. Ahn2, S. Kim2, Y. Jo2, Y. Park2; 1Lab. Med., Eulji Univ. Coll. of Med., Eulji-Gen. Hosp., Seoul, Korea, Republic of, 2Internal Med., Eulji Univ. Coll. of Med., Eulji-Gen. Hosp., Seoul, Korea, Republic of, 3Biotechnology and Res. Ctr. for Proteineous Materials (RCPM), Chosun Univ., Kwangju, Korea, Republic of. F-2061 Rational Design of Engineered Antimicrobial Peptides

Consisting Exclusively of Arginine and Tryptophan B. Deslouches, J. D. Steckbeck, J. K. Craigo, R. C. Montelaro; Univ. of Pittsburgh, Pittsburgh, PA. F-2062 OligoG, a Novel Antimicrobial Alginate Oligosaccharide,

Impedes Biofilm Development by Inhibition of Bacterial Motility C. Emanuel1, S. Khan1, K. E. Hill 1, E. Onsøyen 2, R. Myrvold 2, A. Dessen 2, D. W. Thomas 1; 1Cardiff Univ., Cardiff, United Kingdom, 2Algipharma AS, Sandvika, Norway. F-2063 Nanoscale Characterisation of the Interaction of Alginate

Oligosaccharide Nanomedicines with the Bacterial Cell Surface of Pseudomonas aeruginosa L. C. Powell1,2, M. F. Pritchard 1,2, S. Khan1, C. Wright 2, E. Onsøyen3, R. Myrvold 3, K. E. Hill 1, D. W. Thomas 1; 1Cardiff Univ., Cardiff, United Kingdom, 2Swansea Univ., Swansea, United Kingdom, 3Algipharma AS, Sandvika, Norway.

WEDNESDAY SCIENTIFIC SESSIONS F-2064 Modification and Rheological Properties of Pseudomonal

Biofilms and Cystic Fibrosis Sputum M. F. Pritchard1,2, L. C. Powell1,2, S. Khan1, A. Sowedan2, C. J. Wright 2, K. Hawkins2, I. J. Doull 1, E. Onsøyen3, R. Myrvold 3, K. E. Hill 1, D. W. Thomas1; 1Cardiff Univ., Cardiff, United Kingdom, 2Swansea Univ., Swansea, United Kingdom, 3Algipharma AS, Sandvika, Norway. F-2065 SASP: In Vitro Characterisation of PT3.33 for the Treatment

of Multidrug-Resistant Pseudomonas aeruginosa S. Baines 1, M. Knetchel2, C. Pillar2, D. Shinabarger 2, A. Wilkinson 1, H. Fairhead1; 1Phico Therapeutics Ltd, Cambridge, United Kingdom, 2 Micromyx, Kalamazoo, MI. F-2066 SASP: Efficacy against Pseudomonas aeruginosa in a Murine

Pneumonia Model 1

1

1

2

2 1

J. Gould , L. Payne , P. Warn , A. Wilkinson , H. Fairhead ; Euprotec Ltd., Manchester, United Kingdom, 2Phico Therapeutics Ltd., Cambridge, United Kingdom. F-2067 Activity of FAB001 in Combination with Antimicrobial

Agents against Acinetobacter baumannii C. Soulama-Mouze1, C. Zampaloni2, F. Monti2, C. Siegmund2, S. Hawser2; 1 FAB Pharma, Paris, France, 2IHMA Europe Sàrl, Epalinges, Switzerland. F-2068 Mastoparan Analog, (mast-1) an Antimicrobial Peptide Ac-

tive against Pan-Resistant A. baumannii X. Vila-Farrés1, M. Teixidó 2, E. Giralt2, J. Vila1; 1CRESIB, Barcelona, Spain, 2 IRB, Barcelona, Spain. F-2069 Dual Inhibitors of Biofilm Formation and Beta-Lactam

Resistance

-----------------------------------------------------------------------250(K) Poster Session Bone Infections Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C Presentations: K-2073 Characteristics of Septic Arthritis: A Retrospective Study

Over 11 Years L. N. Walti1, L. Meyer2, T. Hugle 2, A. Trampuz1; 1Univ. Hosp., Lausanne, Switzerland, 2Univ. Hosp., Basel, Switzerland. K-2074 Prognostic Factors of Calcaneal Osteomyelitis A. Merlet, F. Dauchy, C. Cazanave, H. Dutronc, B. de Barbeyrac, D. Chauveaux, R. Weigert, M. Dupon; Univ. Hosp. Pellegrin, Bordeaux, France. K-2075 Epidemiology of Adverse Events Associated with Prolonged

Antibiotic Therapy for Osteoarticular Infections A. Iten, M. Schindler, W. Zingg, L. Pagani, I. Uckay, D. Pittet; HUG, Geneva, Switzerland. K-2076 Etiology and Choice of Empirical Antibiotics of Pyogenic

Spondylodiscitis in Patients with Invasive Spinal Procedures K. Kim1, J. Koh 1, J. Yi2, S. Lee1; 1Pusan Natl. Univ. Hosp., Busan, Korea, Republic of, 2Pusan Natl. Univ. Yangsan Hosp., Busan, Korea, Republic of. K-2077 Long-Term Oral Suppressive Antibiotic Therapy in Bone

and Joint Infections G. Fresco, C. Javier, Y. Meije, J. Rodríguez, V. Pintado, S. Alonso, P. MartínDávila, J. Fortún; Hosp. Ramon Y Cajal, Madrid, Spain.

C. Melander; North Carolina State Univ., Raleigh, NC. F-2070 A Novel Inhaled Anti-Infective Agent (NB-401) for CF

Lung Infections: Estimating In Vivo Airway Surface Liquid Concentrations in Humans C. F. Lange 1, S. I. Gracon2, J. R. Baker, Jr 2; 1Univ. of Alberta, Edmonton, Canada, 2NanoBio Corp., Ann Arbor, MI. F-2071 Quorum Sensing Inhibition of Chromobacterium violaceum

by Caffeoylquinic Acid- and Flavanol-Rich Fractions from Manuka Propolis A. T. Gemiarto, E. W. C. Chan, C. S. Y. Lim; UCSI Univ., Kuala Lumpur, Malaysia. F-2072 Structural Studies, SAR Analyses, and Antibacterial Testing

of a New Class of F. tularensis Enoyl Reductase (FabI) Inhibitors S. Mehboob1, J. Song 2, P. Su1, K. Hevener 1, T. Boci 1, J. Deng 1, M. Ghassemi 1, Y. Zhang 1, B. Santarsiero 1, H. Jeong 1, J. L. Cook 1, A. K. Ghosh 2, M. E. Johnson1; 1Univ. of Illinois Chicago, IL, 2Purdue Univ., West Lafayette, IN. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

K-2078 Experience with Daptomycin (DAP) for Treatment of

Device-Associated Osteomyelitis (DAO) E. D. Hermsen1, L. Mendez-Vigo 1, E. F. Berbari 2, T. Chung 1, M. J. Yoon 1, K. C. Lamp 1; 1Cubist Pharmaceuticals, Lexington, MA, 2Mayo Clinic, Rochester, MN. K-2079 Gram-Negative Pyogenic Vertebral Osteomyelitis: Is More

Difficult to Manage? O. Cho, Y. Suh, I. Bae, S. Kim; Gyeongsang Natl. Univ. Hosp., Jinju, Korea, Republic of.

-----------------------------------------------------------------------251(K) Poster Session Hand Hygiene Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C Presentations: K-2080 Hand Hygiene Compliance in ICU: Explanation by Socio-

Anthropological Observation M. Surska 1, A. Melbörde Kelmere 2, G. Freijs 2, V. Skultans 3, A. Luse 1, K. Sedlinieks 1, U. Dumpis2; 1Riga Stradins Univ., Riga, Latvia, 2Stradins Univ. Hosp., Riga, Latvia, 3Univ. of Bristol, Bristol, United Kingdom. K-2081 Validation of a User-Centered Infotainment Board Game in

Infection-Control and Hand Hygiene Withdrawn

Final Program

201

> Wednesday SCIENTIFIC SESSIONS K-2082 Novel Water Based Method of Impregnating Exam Gloves

with Gendine Antiseptic R. Reitzel, J. Rosenblatt, R. Y. Hachem, I. I. Raad; U.T.M.D. Anderson Cancer Ctr., Houston, TX. K-2083 Tracking the Progress of Hand Hygiene Indicators in Health-

care Facilities Worldwide B. Allegranzi1, A. Gayet-Ageron 2, H. Sax 3, S. Bagheri Nejad 1, A. Stewardson 2, D. Pittet2; 1WHO, Geneva, Switzerland, 2Univ. of Geneva Hosp., Geneva, Switzerland, 3Univ. Hosp. of Zurich, Zurich, Switzerland. K-2084 Infection Control Practices in a University Hospital Dental

Clinic: Do Dentists Follow the Recommendations? U. K. Frank1, U. Haegele 2; 1Heidelberg Univ. Hosp., Heidelberg, Germany, 2 Freiburg Univ. Dental Clinic, Freiburg, Germany. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

-----------------------------------------------------------------------252(K) Poster Session Vascular Catheter and Device Related Infections Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C Presentations:

the Number of Vascular Catheters and Catheter Lumens as a Tool for the Reduction of Catheter-Related Bacteremia A. Carretero, D. Díaz, C. Fuentes, J. González, M. Fernández-Ruiz, A. García-Reyne, J. Origüen, R. San Juan, M. Lizasoain, C. Lumbreras, J. Aguado, F. López-Medrano; Univ. Hosp. 12 de Octubre, Madrid, Spain. K-2092 Persistent Catheter-Related Staphylococcus aureus Bacteremia

after Catheter Removal and Initiation of Appropriate Antimicrobial Therapy: Incidence, Risk Factors, and Outcomes K. Park, Y. Chong, S. Kim, S. Lee, S. Choi, J. Jeong, J. Woo, Y. Kim; Asan Med. Cencer, Seoul, Korea, Republic of. K-2093 Endoluminal Catheter Colonization Surveillance Cultures

Reduce Catheter-Related Bloodstream Infections (CRBSI) in Hemodialysis P. Brañas, E. Morales, F. Rios, F. Sanz, E. Gutierrez, N. Quintanilla, M. Sanchez, M. A. Orellana, J. Otero, F. Chaves; Hosp. 12 de Octubre, Madrid, Spain. K-2094 Staphylococcus epidermidis LPXTG Surface Protein SesC is

Associated with Device-Related Infections M. Shahrooei, L. Khodaparast, L. Khodaparast, J. Van Eldere; KULeuven, Leuven, Belgium. K-2095 Daptomycin is Effective as First Line Treatment of Catheter-

K-2085 Daptomycin (Dapto) with or without 25% Ethanol Compared

to Combinations of Minocycline (Mino), EDTA, and 25% Ethanol (ETOH) against Biofilm Producing MRSA or MRSE Isolates K. M. Mullane, D.O., R. Estes, J. Theusch, A. Beck, D. L. Pitrak; Univ. of Chicago, Chicago, IL. K-2086 Non-Central Line Related Laboratory Confirmed Blood-

stream Infection (LCBI) M. M. De Vries, P. Mancos; Methodist Hosp., Gary, IN. K-2087 Prospective Study of Clinical Outcome After a Totally

Implantable Venous Access Port-Related Infection in Oncology D. Lebeaux, B. Larroque, J. Gellen-Dautremer, V. Leflon-Guibout, C. Dreyer, S. Bialek, A. Froissart, O. Hentic, C. Tessier, V. Zarrouk, B. Fantin; Hosp. Beaujon, Clichy, France. K-2088 Sustained Reduction of Catheter-Related Infections After

Introduction of Chlorhexidine (CHX)-Impregnated Dressings P. Eggimann, C. Joseph, M. Thévenin, P. Voirol, G. Zanetti, J. Revelly, Y. Que; Ctr. Hosp. Univ. Vaudois (CHUV), Lausanne, Switzerland. K-2089 Outcome and Predictive Factors of Treatment Failure in

Staphylococcal Vascular Graft Infection (SVGI): Impact of Rifampin (RIF) L. Legout 1, E. Senneville1, M. Valette 1, C. Rouyer 1, M. Massongo 1, P. Delia1, B. Sarraz-Bournet1, S. Haulon2, O. Leroy1; 1Dron Hosp., Tourcoing, France, 2Univ. Hosp. of Lille, Lille, France. K-2090 Catheter-Related Bloodstream Infections Caused by Unusual

Microorganisms E. Reigadas, M. Rodríguez-Créixems, C. Sánchez-Carrillo, P. MartínRabadán, E. Bouza; Hosp. Gen. Univ. Gregorio Marañón, Madrid, Spain.

202

K-2091 Hospital-Wide Objective Measurement of the Adequacy in

September 9-12 |

Related Bacteraemia: Results from The EUCORE Study P. Nikolaidis 1, M. Allen2, A. Robb 3, A. Beiras-Fernandez4, R. Utili5, B. Gragera6, A. Gonzalez-Ruiz7, N. Kröger8, K. Bouylout 9, R. Pathan 10, R. Chaves 9; 1Div. of Internal Med., Thessaloniki, Greece, 2Novartis, Frimley, United Kingdom, 3Camberley, Newcastle upon Tyne, United Kingdom, 4 Univ. of Munich, Munich, Germany, 5Monaldi, Napoli, Italy, 6Hosp. Univ. Vall d’Hebron, Barcelona, Spain, 7Darent Valley Hosp., Dartford, United Kingdom, 8Univ. Hosp. Hamburg-Eppendorf, Hamburg, Germany, 9Novartis, Basel, Switzerland, 10Novartis, HYD, India. K-2096 Efficacy of a Novel Gendine Coated Peripherally Inserted

Central Venous Catheters (picc) against Multidrug-Resistant Pathogens J. A. Mohamed, R. Y. Hachem, A. Chaftari, Y. Jiang, I. I. Raad; U.T.M.D. Anderson Cancer Ctr., Houston, TX. K-2097 In Vivo Activity of Antibiofilm/Antimicrobial-Treated

Central Venous Catheters against Colonization and Device-Associated Infection M. D. Mansouri, R. O. Darouiche; Baylor Coll. of Med., Houston, TX. K-2098 Targeting Biofilm Eradication in Totally Implanted Central

Venous Ports by Lock Solutions in an In Vitro Dynamic Model of Biofilm Formation L. Olivier1, C. Aumeran 1, O. Traore1, C. Forestier2; 1CHU ClermontFerrand, Clermont-Ferrand, France, 2Univ. Blaise Pascal, Clermont-Ferrand, France.

WEDNESDAY SCIENTIFIC SESSIONS -----------------------------------------------------------------------253(K) Poster Session Ventilator- Associated Pneumonia Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C Presentations: K-2099 Meta-Analysis of Linezolid vs. Glycopeptide for Treatment

of Proven Methicillin-Resistant Staphylococcus aureus (MRSA) Nosocomial Pneumonia (NP) Withdrawn K-2100 Comparative Patterns of Drug Regimens in Antipsychotic-

Receiving Geriatric Patients with Nosocomial Pneumonia J. Westphal1, F. Jehl 2, C. Nonnenmacher 3; 1Regional Agency for Hlth., Paris, France, 2Univ. Lab. for Microbiol., Strasbourg, France, 3Hosp. Ctr., Strasbourg-Brumath, France. K-2101 The Systematic Application of Intermitent Aspiration of

Subglottic Secretions (IASS) in a Major Heart Surgery (MHS)Intensive Care Unit is Feasible and Cost-Effective M. Perez Granda; Hosp. Gral Univ. Gregorio Marañon, Madrid, Spain.

-----------------------------------------------------------------------254(L1) Poster Session Bone and Joint Infections Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C Presentations: L1-2102 Streptococcal Vertebral Osteomyelitis (SVO): Multiple

Faces for the Same Disease O. Murillo1, A. Roset 1, B. Sobrino 2, J. Lora 1, R. Verdaguer 1, E. JimenezMejias 3, J. Nolla 1, J. Colmenero 2, J. Ariza 1; 1Hosp. Bellvitge, Barcelona, Spain, 2Hosp. Carlos Haya, Malaga, Spain, 3Hosp. Virgen Rocio, Sevilla, Spain. L1-2103 Which Duration of Decubitus in Vertebral Osteomyelitis? G. Gras 1, D. Mulleman1, H. Harrabi 1, K. Fevre 1, M. Dupon2, B. Marchou3, C. Marcelli4, L. Bernard1; 1CHRU de Tours, Tours, France, 2CHU de Bordeaux, Bordeaux, France, 3CHU de Toulouse, Toulouse, France, 4CHU de Caen, Caen, France. L1-2104 Vertebral Osteomyelitis Without Bacteremia: How to Ob-

tain Microbiological Diagnosis? R. Buzele 1, G. Gras 1, J. J. Parienti2, F. Debiais3, A. Dinh 4, C. Marcelli2, M. Dupon5, F. Roblot3, L. Bernard1; 1CHRU de Tours, Tours, France, 2CHU de Caen, Caen, France, 3CHU de Poitiers, Poitiers, France, 4AP-HP, Garches, France, 5CHU de Bordeaux, Bordeaux, France. L1-2105 Daptomycin Versus Comparator for Treatment of Prosthetic

Joint Infection (PJI): Prevalence and Susceptibility of Infecting Staphylococci G. M. Thorne, S. Rege, S. Yankelev, C. Gupta, D. Anastasiou, J. Steenbergen, E. Campanaro; Cubist Pharmaceuticals, Lexington, MA.

L1-2106 Efficacy of Clindamycin in Combination with Rifampin or

Fluoroquinolones for Therapy in Staphylococcal Osteoarticular Infections C. Saroufim, Y. El-Samad, F. Brazier., B. Brunschweiler, B. Canarelli, Y. Douadi, JP Lanoix. E. Justinien, JL Schmit; Amiens Univ. Hosp., Amiens, France.

-----------------------------------------------------------------------255(L2) Poster Session Urinary Tract Infection Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C Presentations: L2-2107 Surveillance of Antimicrobial Susceptibility of Aerobic and

Facultative Gram-Negative Bacilli Isolated from Patients with Urinary-Tract Infections in China: The 2010-2011 Study for Monitoring Antimicrobial Resistance Trends (SMART) Q. Yang1, H. Zhang 1, Y. Wang 1, M. Chen1, R. E. Badal 2, Y. Xu1; 1Peking Union Med. Coll. Hosp., Beijing, China, 2Intl. Hlth. Management Associates, Schaumburg, IL. L2-2108 Prevalence and Risk Factors (RF) of Extended-Spectrum

ơ-Lactamases (ESBLs) Producing E. coli (EC) in Community Onset (CO) Urinary Tract Infections (UTI) J. J. Maya1, A. Correa 1, R. Pacheco1, V. M. Blanco 1, H. Vargas2, A. Y. Celis2, C. M. Montoya 3, M. Garzón 3, F. Rosso 4, L. Matta 5, M. E. Vallejo 1,6, M. V. Villegas 1; 1CIDEIM, Cali, Colombia, 2Secret. Distr. Salud, Bogotá, Colombia, 3H. El Tunal, Bogotá, Colombia, 4Fund. Clin. Valle del Lili, Cali, Colombia, 5Corp. Comfenalco Valle – Univ. Libre., Cali, Colombia, 6Univ. Pontificia Bolivariana, Medellín, Colombia. L2-2109 Hospital Epidemiology of Urinary Tract Infections/Coloni-

zations Due to ESBL-Producing Escherichia coli R. Lepeule, V. Leflon, D. Vanjak, J. R. Zahar, M. Lafaurie, C. Besson, A. Lefort; Groupe des Référents en Infectiologie d’Ile de France (GRIF), Paris, France. L2-2110 Risk Factors of Bacteremia in Urinary Tract Infections A. Lalueza, N. Bermejo, R. García, O. Jiménez, B. Ponce, S. Bermejo, F. López-Medrano, A. G-Reyne, J. Aguado; Hosp. Madrid, Spain. L2-2111 Standardized, Low-Dose Daptomycin is Effective for the

Treatment of Urinary Tract Infections M. Moaddab, H. R. Palmer, K. Putney; St. Luke’s Episcopal Hosp., Houston, TX. L2-2112 A Micro-Patterned Surface Reduces Microbial Colonization

Associated with Catheter-Associated Urinary Tract Infection Withdrawn L2-2113 Increased ESBL Prevalence with Time in Escherichia coli

and Klebsiella spp from >50.000 Samples from the Community of a Large City as a Function of Age, Sex, and Location J. L. L. Rocha1,2, F. F. Tuon3, J. R. Johnson 4; 1Frischmann Aisengart/DASA Med. Diagnóstica, Curitiba, Brazil, 2Hosp. VITA, Curitiba, Brazil, 3Hosp. Univ. Evangélico, Curitiba, Brazil, 4VA Med. Ctr. and Univ. of Minnesota, Minneapolis, MN.

Final Program

203

> Wednesday SCIENTIFIC SESSIONS L2-2114 Prospective Study of Asymptomatic Bacteriuria in Female

Patients with Autoimmune Rheumatic Diseases S. Georgiadou, M. Gamaletsou, I. Mpanaka, A. Vlachou, V. Syriou, G. Kaltsas, M. Tektonidou, M. Manoussakis, N. Sipsas; Natl. and Kapodistrian Univ. of Athens, Athens, Greece. L2-2115 Economic Evaluation of Ceftibuten in the Treatment of

Uncomplicated Infection of Urinary Tract in Mexico M. V. Blandon1, A. Reyes 2; 1Merck Sharp & Dohme, Mexico, Mexico, 2 Hosp. Infantil de Mexico Federico Gomez, Mexico, Mexico. L2-2116 Selecting Empiric Treatment for Urinary Tract Infections

Due to Multidrug-Resistant Enterobacteriaceae T. Khawcharoenporn1, S. Vasoo 2, K. Singh 2; 1Thammasat Univ., Pathumthani, Thailand, 2Rush Univ. Med. Ctr., Chicago, IL. L2-2117 Empirical Therapy for Severe Urinary Tract Infection (UTI)

in an Era of Increasing ESBL-Producing Community-Acquired Enterobacteriaceae: A Model-Based Estimation of Effectiveness J. J. Parienti1,2, J. C. Lucet2, A. Lefort3, E. Casalino2, L. Armand-Lebèvre 2, M. Wolff2, F. Caron4, R. Leclercq1, Y. Yazdanpanah2; 1Côte de Nacre Univ., Caen, France, 2CHU Bichat, Paris, France, 3Beaujon, Paris, France, 4CHU Rouen, Rouen, France. L2-2118 National Trends in Antibiotic Prescribing for Uncompli-

cated Cystitis in Women J. C. McGregor1, M. R. Elman 1, C. Dent 2, D. T. Bearden 1; 1Oregon State Univ., Oregon Hlth. & Sci. Univ., Portland, OR, 2Oregon Publ. Hlth. Div., Portland, OR. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program.

204

September 9-12 |

NOTES

Final Program

205

> NOTES

206

September 9-12 |

> Notes

Indices

> Notes

AUTHOR INDEX Author

Presentation Number

A

Author

Presentation Number

Adesanya, A. F. . . . . . . . . . . . . . . . . . . L1-959, 109 Adler, A. . . . . . . . . . . . . . C2-109, 009; K-557, 074

Author

Presentation Number

Akkoyunlu, Y. . . . . . . . . . . . . . . . . . . . . V-379, 030 Aklillu, E. . . . . . . . . . . . . . . . . . . . . . . . H-893, 103

Aarnoutse, R. E. . . . . . . . . . . . . . . . . . 161, A-1268

Adler, F. . . . . . . . . . . . . . . . . . . . . . . . G3-1560, 178

Aktories, K. . . . . . . . . . . . . . . . . . . . . . F-1537, 177

Aaron, S. . . . . . . . . . . . . . . . . . . . . . . . . . 123, 1095 Abad, E. D. . . . . . . . . . . . . . . . . . . . . . 171, D-1428

Adler, H. . . . . . . . . . . . . . . . . . . . . . . . C2-082, 007 Adler-Moore, J. . . . . . . . . M-967, 111; M-992, 111

Akuka, A. . . . . . . . . . . . . . . . . . . . . . L1-1640, 186

Abad, M. . . . . . . . . . . . . .H-222, 019; H-1567, 179

Adler-Shohet, F. . . . . . . . . . . . . . . . . G3-1561, 178

Abad, R. . . . . . . . . . . . . . . . . . . . . . . L1-1653, 187

Adrian, P. . . . . . . . . . . . . . . . . . . . . . . . G-1751, 198 Adrian, P. V.. . . . . . . . . . . . . . . . . . . . . . D-172, 013 Adrianaki, A. . . . . . . . . . . . . . . . . . . . .M-1696, 191 Adriani, K. S.. . . . . . . . . . . . . . . . . . . L1-1648, 187

Al Sweih, N. . . . . . . . . . . . . . . . . . . . . C1-071, 006

Advincula, M. . . . . . . . . B-1326, 165; K-1614, 184; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1615, 184 Aebi, S. . . . . . . . . . . . . . . . . . . . . . . . . C2-116, 009 Aerts, L.. . . . . . . . . . . . . . . . . . . . . . . . . V-399, 030

Al-Harbi, A. I.. . . . . . . . . . . . . . . . . . . D-1407, 170

Abdel Hardy, W. . . . . . . . . B-654, 084; B-655, 084 Abdel-Massih, R. . . . . . . . . . . . . . . . . . T-364, 029 Abdelhameed, M. . . . . . . . . . . . . . . . . A-1294, 163 Abdelraouf, K. . . . . . . . . . .A-025, 004; A-028, 004; . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A-029, 004; Abdul Ghafur, K.. . . . . . . .P-565, 075; P-1004, 112

Africano, F. J. . . . . . . . . . . . . . . . . . . . C2-1915, 237 Agarwal, A. . . . . . . . . . . . . . . . . . . . . .M-1061, 115 Aggarwal, S. . . . . . . . . . . . . . . . . . . . . . A-618, 082

Abdul-Jabbar, A. . . . . . . . . . . . . . . . . . . K-261, 023

Agotesku, A. . . . . . . . . . . . . . . . . . . . . D-1416, 170

Abed, Y.. . . . . . . . . . . . . . . . . . . . . . . . V-1079, 117 Abel, C. . . . . . . . . . . . . . . . F-843, 099; F-844, 099; . . . . . . . . . . . . . . . . . . . .F-845, 099; F-846, 099 Abel, S. . . . . . . . . . . . . . . . . . . . . . . . . . K-238, 020

Aguado, J. M. . . . . . . . . . . T-340, 029; T-359, 029; . . . . . . . K-948, 107; T-1071, 116; K-2091, 252; . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2110, 255

Al-Nakeeb, Z. . . . . . . . . . . . . . . . . . . . A-1943, 240 Alam, M. J. . . . . . . . . . . . D-158, 011; M-316, 028 Alarcón, A. . . . . . . . . . . . . K-941, 106; K-943, 106 Alastruey-Izquierdo, A. . . . . . . . . . . . . .M-321, 028 Albert, N. D. . . . . . . . . . . M-972, 111; M-979, 111

Abadir, D. . . . . . . . . . . . . . . . . . . . . . . A-1245, 161 Abbadi, D. R. . . . . . . . . . . . . . . . . . . . K-1604, 183 Abdala, E. . . . . . . . . . . . . . . . . . . . . . . K-1603, 183 Abdel Hady, W.. . . . . . . . . . . . . . . . . . . B-646, 084

Abel zur Wiesch, P. . . . . . . . . . . . . . . . . K-238, 020 Abgottspon, D. . . . . . . . . . . . . . . . . . . F-2057, 249 Abia-Bassey, L. N.. . . . . . . . . . . . . . . . E-1994, 245 Abiko, T. . . . . . . . . . . . . . . . . . . . . . . . F-2041, 248 Abildskov, K. M. . . . . . . . . . . . . . . . . . . A-026, 004 Ablah, E. . . . . . . . . . . . . . . . . . . . . . . . L1-284, 025 Abo-Shadi, M. M.. . . . . . . . . . . . . . . . D-1407, 170 Abraham, T.. . . . . . . . . . . . . . . . . . . . . A-1766, 200 Abreu, J. A. . . . . . . . . . . . . . . . . . . . . . C2-704, 088 Abreu, M. O. . . . . . . . . . . . . . . . . . . . . F-1513, 176 Abruzzo, G. . . . . . . . . . . . . . . . . . . . . . . F-810, 096 Abu-Elmagd, K. . . . . . . . . . . . . . . . . . T-1031, 113 Abu Oun, M.. . . . . . . . . . . . . . . . . . . C1-1208, 156 Achermann, Y.. . . . . . . . . . . . . . . . . . . K-1125, 129 Achi, S. . . . . . . . . . . . . . . . . . . . . . . . . .M-972, 111 Ackermann, G. . . . . . . . . . . . . . . . . . . . D-179, 013 Ackermans, Y. . . . . . . . . . . . . . . . . . . C2-1988, 244 Acosta, F. . . . . . . . . . . . . . . . . . . . . . . . . B-649, 084 Adam, H. J. . . . . . . . . . .C2-103, 009; C2-135, 010; . . . . . . . .C2-149, 010; E-194, 015; 169; E-779, . . . . . . .E-191, 015; E-200, 015; C2-1360, 167; . . . . . . . . . . . . . . . . C2-1379, 093; E-1462, 173 Adams-Haduch, J. M. . . . . . . . . . . . . . C2-112, 009 Adams-Sapper, S. . . . . . . . . . . . . . . . . C2-110, 009 Adamson, R. . . . . . . . . . . . . . . . . . . . . K-1598, 182 Adamu, H.. . . . . . . . . . . . . . . . . . . . . . G-1748, 198 Addoud, P. . . . . . . . . . . . . . . . . . . . . . . P-1011, 112 Adelson, M. E. . . . . . . . . . . . . . . . . . . . P-563, 075 Adeniyi, B. A. . . . . . . . . . . . . . . . . . . C2-1898, 236 Ader, F. . . . . . . . . . . . . . . . . . . . . . . . . . T-360, 029

Agudelo, M. . . . . . . . . . A-1945, 240; A-1968, 241 Aguiar, B.. . . . . . . . . . . . . . . . . . . . . . . C2-716, 088 Aguiar, S. I. . . . . . . . . . . . .G-865, 100; G-866, 100 Aguiar-Alves, F.. . . . . . . . . . . . . . . . . C2-1377, 169 Aguilar, L. . . . . . . . . . . . . . . . . . . . . . . K-1608, 184 Aguilar-Guisado, M. . . . . . . . . . . . . . . K-1924, 239 Aguinaga, A. . . . . . . . . . D-1439, 171; D-1440, 171 Ahmed, G. F. . . . . . . . . . . . . . . . . . . . . A-1763, 200 Ahmed, H. . . . . . . . . . . . . . . . . . . . . . . K-902, 104 Ahmed, M. M. . . . . . . . . . . . . . . . . . . C2-711, 088 Ahmed-Bentley, J. . . . . . . . . . . . . . . . . . K-561, 074 Ahn, J. . . . . . . . . . . . . . . . . H-230, 019; K-916, 104 Ahn, S.. . . . . . . . . . . . . . B-1320, 165; F-2060, 249 Ahn, Y. . . . . . . . . . . . . . . . . . . . . . . . C2-1978, 243 Aibinu, I. . . . . . . . . . . . . . . . . . . . . . . . C2-108, 009 AIC246 Study Team, . . . . . . . . . . . . . . T-356, 029 Aichelburg, M. C. . . . . . . . . . . . . . . . . H-1918, 238 Aimoto, M. . . . . . . . . . . . . . . . . . . . . . D-1402, 170 Ainoda, Y. . . . . . . . . . . . . . . . . . . . . . . .M-326, 028 Airapetian, N. . . . . . . . . . . . . . . . . . . .M-1698, 191 Ait Oufella, H. . . . . . . . . . . . . . . . . . . . D-173, 013 Akamatsu, S. . . . . . . . . . . . F-817, 096; F-818, 096; . . . . . . . . . F-819, 096; F-820, 096; F-821, 096; . . . . . . . . . . . . . . . . . . . F-822, 096; M-981, 111 Akhter, S. S.. . . . . . . . . . . . . . . . . . . . C2-1981, 243 Akin, A. R. . . . . . . . . . . . . . . . . . . . . . F-1540, 177 Akinlolu, Y. . . . . . . . . . . . . . . . . . . . . . T-1067, 116 Akinola, M. T. . . . . . . . . . . . . . . . . . . . G-1748, 198 Akins, R. L. . . . . . . . . . . . . . . . . . . . . . . A-604, 082 Akiti, T. . . . . . . . . . . . . . . . . . . . . . . . .M-1690, 190

Final Program

Al Hubail, M. . . . . . . . . . . . . . . . . . . . C1-071, 006 Al Naiemi, N. . . . . . . . . . . . . . . . . . . . C2-104, 009 Al-Badriyeh, D. . . . . . . . . . . . . . . . . . .M-1671, 190 Al-Buridi, R. S. . . . . . . . . . . . . . . . . . . . K-242, 020 Al-Ghafri, S. S. . . . . . . . . . . . . . . . . . . C2-079, 007 Al-Hattali, H. S. . . . . . . . . . . . . . . . . . C2-079, 007 Al-Ibrahim, M. . . . . . . . . . . . . . . . . . . . G-873, 101 Al-Jashaami, L. S. . . . . . . . . . . . . . . . . . K-920, 105

Alberto Delgado-Iribarren . . . . . . . . . .M-312, 028 Albis, A. . . . . . . . . . . . . . . . . . . . . . . L1-1643, 186 Albornoz, E. . . . . . . . . . . C2-701, 087; D-759, 092 Albrecht, M. . . . . . . . . . . . . . . . . . . . . L1-284, 025 Albrich, W. C. . . . . . . . . . . . . . . . . . . . . D-172, 013 Albur, M. S. . . . . . . . . . . . . D-763, 092; E-793, 094 Alcalá, L. . . . . . . . . . . . . . M-322, 028; K-470, 048; . . . . . . . . . . . . . . . . . . . E-806, 095; D-1411, 170 Alcántar-Curiel, M. D. . . . . . . . . . . . . C2-113, 009 Alcoba, G. . . . . . . . . . . . . . . . . . . . . . G3-1541, 178 Alcorn, H. J. . . . . . . . . . A-1294, 163; A-1295, 163 Alcorta, B. . . . . . . . . . . . . . . . . . . . . . C2-1398, 169 Alenezi, O. . . . . . . . . . . . . . . . . . . . . . . V-371, 030 Alessandri, E. . . . . . . . . . . . . . . . . . . . . H-886, 102 Alexander, B. D. . . . . . . . . . 408, 034; M-1055, 115 Alexander, D.. . . . . . . . . . . F-843, 099; F-844, 099; . . . . . . . . . . . . . . . . . . . .F-845, 099; F-846, 099 Alfandari, S.. . . . . . . . . . . . . . . . . . . . . . K-237, 020 Alhadab, A. . . . . . . . . . . . . . . . . . . . . . . A-643, 083 Aliaga, J. . . . . . . . . . . . . . . . . . . . . . . . F-2004, 246 Alier, A. . . . . . . . . . . . . . . . . . . . . . . . . . K-258, 022 Aliyu, S. H. . . . . . . . . . . L1-288, 025; D-1451, 172 Alla, F. . . . . . . . . . . . . . . . . . . . . . . . . . . K-939, 106 Allada, G. . . . . . . . . . . . . . . . . . . . . . . . A-643, 083 Allan, E. . . . . . . . . . . . . . . . . . . . . . . C2-1983, 243 Alland, D. . . . . . . . . . . . . . . . . . . . . . . . . 1169, 148 Allegranzi, B.. . . . . . . . . . . . 483, 053; K-2083, 251 Allen, M. . . . . . . . . . . . . . . . . . . . . . . . K-2095, 252 Allen, R. C. . . . . . . . . . . . . . . . . . . . . . F-1528, 177 Allen, U. D. . . . . . . . . . . . . . . . . . . . . . . . . 494, 059 Allerberger, F. . . . . . . . . . . . . . . . . . . . P-1009, 112 Allibardi, S. . . . . . . . . . . . . . . . . . . . . . . D-159, 011

207

> Author INDEX Author

Presentation Number

Author

Presentation Number

Author

Presentation Number

Alluri, K. C.. . . . . . . . . . . . . . . . . . . . . C2-096, 008

Amsilli, M. . . . . . . . . . . . . . . . . . . . . . L1-957, 109

Antonelli, G. . . . . . . . . . . . . . . . . . . . . . V-393, 030

Almeida, A. J. . . . . . . . . . . . . . . . . . . . F-2011, 246 Almeida, D. V. . . . . . . . . . . . . . . . . . . . B-1296, 164

Anaissie, E. . . . . . . . . . . . . M-1234, 159; 1885, 233

Antoniadou, A. . . . . . . . . . K-245, 021; K-246, 021

Ananda-Rajah, M.. . . . . . . . . . . . . . . . .M-315, 028 Anastacio, S. . . . . . . . . . . . . . . . . . . . . P-1012, 112

Antonini, M. . . . . . . . . . . . . . . . . . . . . T-1040, 113 Antoniou, T. . . . . . . . . . . . . . . . . . . . . . . 1863, 227

Almela, M. . . . . . . . . . . . .A-610, 082; B-648, 084; . . . . . . . K-945, 106; K-1122, 129; E-1465, 173 Almirall, J. . . . . . . . . . . . . . . . . . . . . . L1-1643, 186

Anastasiou, D. . . . . . . . . . . . . . . . . . . L1-2105, 254

Antonopoulou, A. . . . . . . . . . . . . . . . . . K-245, 021

Almirante, B. . . . . . . . . . . .K-931, 105; K-937, 106; . . . . . . . . .K-938, 106; K-948, 107; K-950, 107; . . . . . . . . . . . . . . . . L1-1644, 186; K-1758, 199

Andersen, L. P. . . . . . . . . . . . . . . . . . . . B-663, 084 Andersen, P.. . . . . . . . . . . . . . . . . . . . . H-1919, 238

Almuzara, M. . . . . . . . . C1-074, 006; D-1455, 172

Anderson, A. S. . . . . . . . . . . . 575, 077; G-870, 101

Almyroudis, N. . . . . . . . . . . . . . . . . . .M-1676, 190 Alonso, J. C. . . . . . . . . . . . . . . . . . . . . . K-940, 106

Anderson, D. . . . . . . . . . . . . . . . . . . . . . H-880, 102 Anderson, D. A. . . . . . . . . . . . . . . . . . . . . 427, 039

Alonso, N. . . . . . . . . . . . . . . . . . . . . . . K-1621, 184

Anderson, D. . . . . . . . . . . . . . . . . . . . . K-1583, 181

Alonso, R. . . . . . . . . . . . . . . . . . . . . . . H-1577, 180 Alonso, S. . . . . . . . . . . . . . . . . . . . . . . K-2077, 250 Alonso-Socas, M. M. . . . . . . . . . . . . . K-1633, 185 Alousi, A. M.. . . . . . . . . . . . . . . . . . . . T-1065, 116 Alpizar, W. A. . . . . . . . . . . . . . . . . . . . . B-663, 084

Anderson, D. J. . . . . . . . . . . . . . . . . . . C2-117, 009 Anderson, E. . . . . . . . . . . . . . . . . . . . . . A-636, 083

Almeida, J. . . . . . . . . . . . . . . . . . . . . . . . H-878, 102

Alraddadi, B. . . . . . . . . . . . . . . . . . . . . T-1025, 113 Alshabani, K. . . . . . . . . . . K-272, 024; K-1589, 181 Alshuabi, M. . . . . . . . . . . . . . . . . . . . . F-2012, 246 Alshuaibi, M.. . . . . . . . . . . . . . . . . . . . F-2013, 246 Alsup, A. . . . . . . . . . . . . . . . . . . . . . . . . F-846, 099 Alvarez, C. A. . . . . . . . . K-900, 104; C2-1909, 237 Alvarez, F. . . . . . . . . . . . . . . . . . . . . . . . V-376, 030 Alvarez, K. S. . . . . . . . . . . . . . . . . . . . . . D-752, 092 Alvarez, M. . . . . . . . . . . . M-321, 028; M-323, 028 Álvarez, M. . . . . . . . . . . . . . . . . . . . . . H-1921, 238 Alvarez Lerma, F. . . . . . . . . . . . . . . . . K-1624, 184 Alvarez-Perez, S. . . . . . . . . . . . . . . . . . . K-470, 048 Álvarez-Pérez, S. . . . . . . . . . . . . . . . . . .M-322, 028 Alves, C. . . . . . . . . . . . . . . . . . . . . . . . . H-227, 019 Alves, F. A. . . . . . . . . . . . . . . . . . . . . . F-1513, 176 Alves, M. . . . . . . . . . . . . . . . . . . . . . . . . D-176, 013 Amado, C. . . . . . . . . . . . . . . . . . . . . . . P-1018, 112 Amado, I.. . . . . . . . . . . . . . . . . . . . . . .M-1694, 190 Amador, G. . . . . . . . . . . . . . . . . . . . . . . B-653, 084 Amano, H.. . . . . . . . . . . . . . . . . . . . . . F-2055, 248 Amara, S. . . . . . . . . . . . . . . . . . . . . . . . K-1598, 182 Amaya, R. . . . . . . . . . . . . . . . . . . . . . . K-1924, 239 Ambretti, S. . . . . . . . . . . . . . . . . . . . . . K-1619, 184 Ambrose, P. G. . . . . . . .A-1261, 161; A-1262, 161; . . . . . .A-1263, 161; A-1269, 162; A-1270, 162; . . . . . .A-1271, 162; A-1961, 241; A-1962, 241; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-620, 082 Ambrosi, X. . . . . . . . . . . . . . . . . . . . . . . B-054, 005 Amigues, I. . . . . . . . . . . . . . . . . . . . . . . T-361, 029 Amini, R.. . . . . . . . . . . . . . . . . . . . . . . . V-389, 030 Amit, S. . . . . . . . . . . . . . . . . . . . . . . . . K-1609, 184 Ammerman, N. . . . . . . . . . . . . . . . . . . B-1296, 164 Amoabeng, O. . . . . . . . . . . . . . . . . . . . . F-836, 098

208

Anastos, K. . . . . . . . . . . . . . . . . . . . . . H-1575, 180 Anaya, F. . . . . . . . . . . . . . . . . . . . . . . . T-1026, 113

Anderson, H. . . . . . . . . . . . . . . . . . . . . K-1635, 185 Anderson, M. . . . . . . . . . .T-362, 029; F-2058, 249 Anderson, N. W. . . . . . . . . . . . . . . . . . . D-728, 090 Anderson, S. . . . . . . . . . . . . . . . . . . . . A-1767, 200 Andersson, D. I. . . . . . . . . A-1764, 200; 1792, 205; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1966, 241 Andersson, K. . . . . . . . . . . . . . . . . . . . T-1042, 113 Andes, D. R. . . . . 413, 035; 857, 099; A-1270, 162; . . . . F-A-1271, 162; D-1431, 171;A-1929, 240; . . . . . .A-1930, 240; A-1931, 240; A-1932, 240; . . . . . . . . . . . . . . . . . A-1947, 241; A-1961, 241 Ando, D. . . . . . . . . . . . . .H-1581, 180; H-553, 073 Andrade, L. N. . . . . . . . . . . . . . . . . . . C2-086, 008 Andrade, L. H. . . . . . . . . . . . . . . . . . . . D-731, 090 Andrade, S. S. . . . . . . . . . . . . . . . . . . C2-1376, 169 Andrade Ochoa, S. . . . . . . . . . . . . . . . . F-833, 098 Andre, C. . . . . . . . . . . . . C2-091, 008; D-184, 014; . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-719, 089 Andréasson, B.. . . . . . . . . . . . . . . . . . . T-1042, 113 Andreis, S. . . . . . . . . . . . . . . . . . . . . . . H-1579, 180 Andrej, T.. . . . . . . . . . . . . . . . . . . . . . . .M-974, 111 Andremont, A. . . . . . . . A-1963, 241; F-2003, 246 Andreoletti, L. . . . . . . . . . . . . . . . . . . . . V-387, 030 Andreoni, M. . . . . . . . . . . . . . . . . . . . . H-1579, 180 Andreou, A. . . . . . . . . . . . . . . . . . . . . . . K-562, 074 Andrés, A. . . . . . . . . . . . . . . . . . . . . . . . T-359, 029 Andres, P.. . . . . . . . . . . . . . . . . . . . . . . . D-759, 092 Andreu, A. . . . . . . . . . . . L2-303, 027; K-1616, 184 Andrews, D. . . . . . . . . . . L1-287, 025; K-561, 074 Andrews, J. . . . . . . . . . . . . . . . . . . . . . A-1250, 161 Andries, K. . . . . . . . . . . . . . . . . . . . . . A-1259, 161 Angus, P. . . . . . . . . . . . . . . . . . . . . . . . . T-369, 029 Ani, C. . . . . . . . . . . . . . . . . . . . . . . . . . . H-228, 019 Anjum, M.. . . . . . . . . . . . . . . . . . . . . C2-1983, 243 Anjum, M. F. . . . . . . . . .K-236, 020; C1-1208, 156; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1979, 243 ANRSFORMVAC Study Group . . . . . V-375, 030

September 9-12 |

Antoun, S. . . . . . . . . . . . . . . . . . . . . . . . K-911, 104 Aoi, H.. . . . . . . . . . . . . . .F-2049, 248; F-2055, 248 Aoike, N. . . . . . . . . . . . . . . . . . . . . . . . D-1459, 172 Aoun, M. . . . . . . . . . . . .T-1028, 113; D-1413, 170; . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-1046, 113 Aoyagi, T.. . . . . . . . . . . C2-114, 009; C2-1901, 236 Apodaka, A.. . . . . . . . . . . . . . . . . . . . . . K-263, 023 Appleton, B. A. . . . . . . . . . . . . . . . . . . F-1540, 177 Aquino, A. . . . . . . . . . . . . . . . . . . . . . G3-1563, 178 Araci, J. . . . . . . . . . . . . . . . . . . . . . . . . . A-637, 083 Aracil, B. . . . . . . . . . . . . . . . . . . . . . . . C1-593, 081 Arakawa, T. . . . . . . . . . . . . . . . . . . . . . . F-825, 097 Arakawa, Y. . . . . . . . . D-1456, 172; C2-1904, 236; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1989, 244 Arakere, G. . . . . . . . . . . . . . . . . . . . . . B-1315, 165 Aranda, J.. . . . . . . . . . . . . . . . . . . . . . . C1-672, 085 Araneta, M. R.. . . . . . . . . . . . . . . . . . . H-1917, 238 Aranzamendi, M. . . . . . . . . . . . . . . . . C2-105, 009 Araoka, H. . . . . . . . . . . . . . . . . . . . . . . . K-897, 104 Arathoon, E. . . . . . . . . . . . . . . . . . . . .M-1694, 190 Araújo, C. F. . . . . . . . . . . . . . . . . . . . C2-1218, 157 Arauz, A. B.. . . . . . . . . . . . . . . . . . . . . . H-220, 019 Archer, C. . . . . . . . . . . . . . . . . . . . . . C2-1985, 244 Archer, G. . . . . . . . . . . . . . . . . . . . . . C2-1393, 169 Archibald, C. . . . . . . . . . . . . . . . . . . . C2-1380, 169 Ardanuy, C. . . . . . . . . .C2-690, 087; C2-1358, 167; . . . . . . . . . . . . . . . C2-1365, 167; C2-1974, 243 Ardic, N. . . . . . . . . . . . . . . . . . . . . . . . D-1427, 171 Arena, F. . . . . . . . . . . . . . . . . . . . . . . C2-1211, 157 Arend, L. M. . . . . . . . . . . . . . . . . . . . . . K-913, 104 Arendrup, M. C. . . . . . . . . M-318, 028; 1842, 219; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1710, 191 Argentinean Hepatitis A Working Group, . . . . . . . . . . . . . . . . . .P-1015, 112; P-1016, 112 Argentinean KPC-Group, .. . . . . . . . C2-1217, 157 Argueta, E. . . . . . . . . . . . . . . . . . . . . .M-1694, 190 Arhin, F. F. . . . . . . . . . . C2-128, 010; D-762, 092; . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-1463, 173 Ariano, R. . . . . . . . . . . . . . A-639, 083; A-040, 004 Arias, C. . . . . . . . . . . . . . . . . . . . . . . . . K-900, 104 Arias, C. A. . . . . . . . .C1-1345, 166; C2-1389, 169; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1909, 237 Ariza, J. . . . . . K-254, 022; B-647, 084; B-658, 084; . . . . . . . . . . . . . . . . V-1240, 160; L1-2102, 254 Ariza-Heredia, E. . . . . . T-1065, 116; V-1075, 117 Armaganidis, A. . . . . . . . . K-245, 021; K-246, 021 Armand-Lebèvre, L. . . . A-021, 003; L2-2117, 255

AUTHOR INDEX Author

Presentation Number

Armero, Y. . . . . . . . . . . . . .A-610, 082; B-648, 084; . . . . . . . K-945, 106; E-1465, 173; K-1122, 129 Armiñanzas, C. . . . . . . . . . . . . . . . . . . P-1018, 112 Armstrong, W.. . . . . . . . . . . . . . . . . . . . . 1813, 209

Author

Presentation Number

Baden, L. R. . . . . . . . . . . . . . . . . . . . .M-1060, 115

Attardo, J. . . . . . . . . . . . . . . . . . . . . . . D-1435, 171 Atudorei, V. . . . . . . . . . . . . . . . . . . . . . . D-739, 091

Bader, O. . . . . . . . . . . . . . . . . . . . . . . . .M-335, 028 Badiou, C. . . . . . . . . . . . . . . . . . . . . . . B-1735, 196

Aubert, J. . . . . . . . . . . . . . . . . . . . . . . . T-1064, 116

Bae, H.. . . . . . . . . . . . . . . . . . . . . . . . . . D-734, 091 Bae, I. . . . . . . . . . . . . . . . . . . . . . . . . . K-2079, 250 Baek, J.. . . . . . . . . . . . . . . . . . . . . . . . . . G-872, 101

Aubin, G. G. . . . . . . . . . . K-255, 022; B-1318, 165

Arnan, M. . . . . . . . . . . . . . . . . . . . . . . T-1045, 113 Aronoff, D. M. . . . . . . . . . . . . . . . . . . .K-926, 105; . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-1068, 116 Arnold, L. . . . . . . . . . . . . . . . . . . . . . . . F-826, 097 ARPEC project group . . K-1754, 199; K-1759, 199

Augostini, P. . . . . . . . . . . . . . . . . . . . . . P-563, 075 Augustin, V. . . . . . . . . . . . . . . . . . . . . . A-1963, 241

Arranz, J. . . . . . . . . . . . . . . . . . . . . . . . H-1576, 180 Arrazola, P. . . . . . . . . . . . . . . . . . . . . . . T-359, 029 Arribas-López, J. R. . . . . . . . . . . . . . . D-1452, 172 Arrieta, A. C.. . . . . . . A-1292, 163; G3-1560, 178; . . . . . . . . . . . . . . . . . . . . . . . . . . . G3-1561, 178

Presentation Number

Atmar, R. L. . . . . . . . . . . . . . . . . . . . . G-1048, 114

Arnaiz, A. . . . . . . . . . . . . . . . . . . . . . . . K-942, 106

Arpin, C. . . . . . . . . . . . . . . . . . . . . . . . C2-091, 008

Author

Auiwatanagul, S. . . . . . . . . . . . . . . . . . . P-999, 112 Aumeran, C. . . . . . . . . . . . . . . . . . . . . K-2098, 252 Aurbach, U. . . . . . . . . . . . . . . . . . . . . . D-1423, 170 Auregan, M. . . . . . . . . . . . . . . . . . . . . . D-758, 092 Ausubel, F. . . . . . . . . . . . . . . . . . . . . . . F-1538, 177 Autran, B. . . . . . . . . . . . . . . . . . . . . . . H-1568, 179 Auzou, M. . . . . . . . . . . . . . . . . . . . . . . D-1441, 171 Avery, R. . . . . . . . . . . . . M-337, 028; M-1227, 159 Avettand-Fenoël, V.. . . . . . . . . . . . . . . H-1568, 179

Baek, J. Y. . . . . . . . . . . . . . . . . . . . . . C2-1366, 167 Baeten, J. . . . . . . . . . . . . . . . . . . . . . . . . . 1187, 152 Baethgen, L. F. . . . . . . . . . . . . . . . . . C2-1375, 168 Baggi, E. . . . . . . . . . . G3-1549, 178; G3-1553, 178 Bagheri Nejad, S.. . . . . . . . . . . . . . . . . K-2083, 251 Bahma, J. . . . . . . . . . . . . . . . . . . . . . . . . T-364, 029 Baicus, C.. . . . . . . . . . . . . . . . . . . . . . . D-1776, 201 Baietto, L. . . . . . . . . . . . A-1769, 200; A-1937, 240 Baines, S. . . . . . . . . . . . . . B-662, 084; F-2065, 249 Bains, K. . . . . . . . . . . . . . . . . . . . . . . C1-1747, 197

Arshad, S. . . . . . . . . . . . .K-912, 104; K-1597, 182; . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1655, 188 Arslan, H. . . . . . . . . . . . . . . . . . . . . . . C2-684, 087 Arteaga, G. . . . . . . . . . . . . . . . . . . . . . H-1573, 180

Ávila, M. . . . . . . . . . . . L1-290, 026; L1-1666, 189 Aweeka, F. . . . . . . . . . . . . . . . . . . . . . . A-1256, 161 Ayala, J. A. . . . . . . . . . . . . . . . . . . . . . . C1-669, 085

Bajaksouzian, S. . . . . . .C2-092, 008; C2-1361, 167; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2059, 249 Bajoka, B. . . . . . . . . . . . . . . . . . . . . . . K-1597, 182

Artuk, C. . . . . . . . . . . . . . . . . . . . . . . . L1-960, 110

Ayats, J. . . C2-690, 087; M-329, 028; M-1228, 159

Arvas, G. . . . . . . . . . . . . . . . . . . . . . . . . V-379, 030 Arya, A. . . . . . . . . . . . . . . . . . . . . . . . . . F-846, 099 Arya, G.. . . . . . . . . . . . . . . . . . . . . . . G3-1562, 178 Arzate, P. . . . . . . . . . . . . . . . . . . . . . . G3-1563, 178

Aye, K. S.. . . . . . . . . . . . . . . . . . . . . . C2-1369, 168 Aylin, P. . . . . . . . . . . . . . . . . . . . . . . . . . K-260, 023 Ayma, A. . . . . . . . . . . . . . . . . . . . . . . . . D-758, 092 Azadeh, N. . . . . . . . . . . . . . . . . . . . . .M-1697, 191

Bakare, N. . . . . . . . . . . . . . . . . . . . . . . A-1259, 161 Bakari, D. . . . . . . . . . . . . . . . . . . . . . . P-1010, 112

Asahata, S. . . . . . . . . . . . . . . . . . . . . . . .M-326, 028 Asami, T. . . . . . . . . . . . . . . . . . . . . . . . . A-038, 004

Azanza, J.. . . . . . . . . . . . . . . . . . . . . . . K-1612, 184 Azar, E. E. . . . . . . . . . . . . . . . . . . . . . . K-1584, 181

Asante-Appiah, E.. . . . . . . . . . . . . . . . . H-551, 073 Asdamongkol, N.. . . . . . . . . . . . . . . . . H-1565, 179

Aznar, M. L. . . . . . . . . . . . . . . . . . . . L1-1644, 186 Azoulay, E. . . . . . . . . . . . . . . . . . . . . . . P-568, 075

Asehnoune, K. . . . . . . . . . . B-051, 005; B-054, 005; . . . . . . . . . . . . . . . . . . B-651, 084; B-1335, 165 Asensi, M. D. . . . . . . . . . . . . . . . . . . C2-1218, 157

Azzopardi, E.. . . . . . . . . . . . . . . . . . . . F-2006, 246

Ashcraft, D. S. . . . . . . . . . . . . . . . . . . .M-1717, 191 Ashouri, N. . . . . . . . . . . . . . . . . . . . . G3-1561, 178 Ashwini, C. . . . . . . . . . . . . . . . . . . . . . . P-564, 075 Aslam, F. . . . . . . . . . . . . . . . . . . . . . . . A-1252, 161 Aslam, S. . . . . . . . . . . . . . .T-355, 029; T-1070, 116 Aslan, T.. . . . . . . . . . . . . . . . . . . . . . . . . V-379, 030 Aslanzadeh, J. . . . . . . . . . . . . . . . . . . . K-1926, 239 AspICU Study Investigators . . . . . . . . . K-951, 107 ASP Team (SGH) . . . . . . . . . . . . . . . . . K-235, 020 Asshouri, N. . . . . . . . . . . . . . . . . . . . G3-1560, 178 Assi, M. A. . . . . . . . . . . L1-284, 025; T-1066, 116 Assis, D. M.. . . . . . . . . . . . . . . . . . . . . . D-731, 090 Astuti, N.. . . . . . . . . . . . . . . . . . . . . . . T-1035, 113 Astvad, K. . . . . . . . . . . . . . . . . . . . . . .M-1710, 191 Asuphon, O. . . . . . . . . . . . . . . . . . . . . A-1279, 162 Asuquo, A. E. . . . . . . . . . . . . . . . . . . . E-1994, 245 Atalay, A. . . . . . . . . . . . . . . . . . . . . . . .M-1701, 191 Athan, E. . . . . . . . . . . . . . . . . . . . . . . . C2-689, 087 Atiya-Nasagi, Y. . . . . . . . . . . . . . . . . . P-1001, 112

B B. Brunschweiler . . . . . . . . . . . . . . . . L1-2106, 254 B. Canarelli . . . . . . . . . . . . . . . . . . . . L1-2106, 254 Baalbaki, R. . . . . . . . . . . . . . . . . . . . . . . K-250, 022 Baba, K. A. . . . . . . . . . . . . . . . . . . . . . C2-101, 009 Baba, M. M. . . . . . . . . . . . . . . . . . . . . G-1748, 198 Baba, M. . . . . . . . . . . . . . . . . . . . . . . . . K-897, 104 Babady, N. E.. . . . . . . . . . . . . . . . . . . . D-1442, 171 Babakhani, F. . . . . . . . . . . . . . . . . . . . . A-1274, 162 Babcock, K. M. . . . . . . . .K-233, 020; E-1464, 173; . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-1469, 173 Babrak, L. . . . . . . . . . . . . . . . . . . . . . . B-1310, 165 Bacchus, C. . . . . . . . . . . . . . . . . . . . . . H-1568, 179 Bachelier, C. . . . . . . . . . . . . . . . . . . . . F-1488, 175 Back, K. R. . . . . . . . . . . . . . . . . . . . . . L1-294, 026 Badal, R. . . . . . . . . . . . .C2-100, 009; C2-120, 009; . . . . . .C2-143, 010; C2-144, 010; C2-148, 010; . . . . . .C2-688, 087; C2-721, 089; C2-724, 089; . . . . . . . . . . . . . . . C2-1352, 167; L2-2107, 255 Baddley, J. W. . . . . . . . . . . . . . . . . . . . . . . 489, 056

Final Program

Baker, C. J.. . . . . . . . . . . . . . . . 525, 067; 1156, 145 Baker, J. R. . . . . . . . . . . . . G-869, 101; F-2070, 249 Baker, M. G. . . . . . . . . . . . . . . . . . . . G3-1555, 178 Baker, S. M. . . . . . . . . . . . . . . . . . . . . . F-1518, 176 Bakker-Woudenberg, I. A. . . . . . . . . . . B-058, 005; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1268, 161 Bakouboula, P. . . . . . . . . . . . . . . . . . . .M-1707, 191 Balada-LLasat, J. . . . . . . . . . . . . . . . . . D-1417, 170 Balada-Llasat, J.. . . . . . . . . . . . . . . . . . . D-756, 092 Balakrishnan, I. . . . . . . . . . . . . . . . . . . C2-081, 007 Balansay-Ames, M. . . . . . . . . . . . . . . . . V-383, 030 Balbaaki, R. . . . . . . . . . . . . . . . . . . . . . . K-251, 022 Baldoni, D. . . . . . . . . . . . . . . . . . . . . . A-1273, 162 Balfour, H. H. . . . . . . . . . . . . . . . . . . . V-1241, 160 Balibar, C. J.. . . . . . . . . . . . . . . . . . . . . F-1540, 177 Balic, N.. . . . . . . . . . . . . . . . . . . . . . . . L2-306, 027 Baliellas, C. . . . . . . . . . . . . . . . . . . . . . T-1030, 113 Ballal, E. . . . . . . . . . . . . . . . . . . . . . . . D-1407, 170 Ballarò, D. . . . . . . . . . . . . . . . . . . . . . . . K-898, 104 Ballen, K. . . . . . . . . . . . . . . . . . . . . . . . . T-354, 029 Ballesté-Delpierre, C. . . . . . . . . . . . . . C2-696, 087 Ballow, C. H. . . . . . . . . . . . . . . . . . . . . A-1248, 161 Balsalobre, L. C. . . . . . . C1-668, 085; C2-106, 009 Balsamo, M. L. . . . . . . . . . . . . . . . . . . T-1035, 113 Balzaretti, M.. . . . . . . . . . . . . . . . . . . . C2-094, 008 Bam, R. . . . . . . . . . . . . . . . . . . . . . . . . . H-892, 103 Bamaiyi, M. J. . . . . . . . . . . . . . . . . . . . G-1748, 198 Bamford, C. . . . . . . . . . . . . . . . . . . . . . C2-723, 089 Bandara, K. . . . . . . . . . . . . . . . . . . . . . K-2081, 251 Bandettini, R. . . . . . . . . . . . . . . . . . . . D-1426, 171

209


Presentation Number

Banevicius, M. . . . . . . . . . . . . . . . . . . . . A-633, 083 Bani-Hashemi, T. . . . . . . . . . . . . . . . . . B-661, 084 Bankowski, M. J. . . . . . . . . . . . . . . . . . . D-155, 011 Baos, E. . . . . . . . . . . . . . . . . . . . . . . . . . E-805, 095 Bar-Ziv, J. . . . . . . . . . . . . . . . . . . . . . . G-1753, 198 Barajas, G. B-1323, 165; B-1326, 165; K-1614, 184 Baraniak, A.. . . . . . . . . . . . . . . . . . . . . C2-109, 009 Barauna, I. . . . . . . . . . . . . . . . . . . . . . . . K-257, 022 Barba, M. J. . . . . . . . . . . . . . . . . . . . . C2-1902, 236 Barba, P.. . . . . . . . . . . . . . . . . . . . . . . .M-1228, 159 Barbato, L.. . . . . . . . . . . . . . . . . . . . . . C2-704, 088 Barber, K. E. . . . . . . . . . . . K-906, 104; K-909, 104 Barberà, M. . . . . . . . . . . . . . . . . . . . . . L2-303, 027 Barbier, F. . . . . . . . . . . . . . . . . . . . . . C2-1399, 169 Barbolla, I. . . . . . . . . . . . . . . . . . . . . . . . D-743, 091 Barbut, F. . . . .D-154, 011; D-157, 011; K-925, 105 Bargatze, R. . . . . . . . . . . . . . . . . . . . . . G-1048, 114 Baril, J. . . . . . . . . . . . . . . . . . . . . . . . . . H-1571, 180 Barin, F. . . . . . . . . . . . . . . . . . . . . . . . . . H-886, 102 Barin, J. . . . . . . . . . . . . . . . . . . . . . . . C2-1905, 236

Author

Presentation Number

Beiras-Fernandez, A. . . . . . . . . . . . . . . K-2095, 252

Basset, P. . . . . . . . . . . . . . . . . . . . . . . C2-1378, 169 Bassetti, M. . . . . . . . . . . . . . . . . . . . . . .M-317, 028

Belgrader, P. . . . . . . . . . . . . . . . . . . . . . D-1425, 171 Bellacasa, J. . . . . . . . . . . . . . . . . . . . . .M-1228, 159

Basso, M. . . . . . . . . . . . . .H-216, 018; H-1579, 180

Bellanger, A. P. . . . . . . . . . . . . . . . . . .M-1692, 190

Bastides, F.. . . . . . . . . . . D-176, 013; L1-1639, 186 Basustaoglu, A. C. . . . . . . . . . . . . . . . . D-1427, 171 Batard, E. . . . . . . . . . . . L1-285, 025; L1-283, 025; . . . . . . . . . . . . . . . . D-1458, 172; L1-1642, 186 Bathina, P. . . . . . . . . . . . .K-272, 024; K-1589, 181; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1604, 183

Belley, A. . . . . . . . . . . . . . . . . . . . . . . . . D-762, 092 Belli, D. C. . . . . . . . . . . . . . . . . . . . . G3-1556, 178 Bellido, M.. . . . . . . . . . . . . . . . . . . . . . C2-707, 088

Bathnagar, N.. . . . . . . . . . . . . . . . . . . . . K-955, 108 Bauab, K. C. . . . . . . . . . . . . . . . . . . . . D-1412, 170 Baudel, J. . . . . . . . . . . . . . . . . . . . . . . . . D-173, 013 Bauer, J. . . . . . . . . . . . . . . . . . . . . . . . . . A-598, 082 Bauer, K. A. . . . . . . . . . . K-1636, 185; A-1768, 200 Baugh, S. . . . . . . . . . . . . . . . . . . . . . . . C1-674, 086 Baughman, W.. . . . . . . . . . . . . . . . . . . G-1752, 198 Bauman, S. . . . . . . . . . . . . . . . . . . . . .M-1699, 191 Baumann, D. P. . . . . . . . . . . . . . . . . . . . K-252, 022 Baumann, H. . . . . . . . . . . . . . . . . . . . . . T-347, 029 Baumann, R. . . . . . . . . . . . . . . . . . . . . H-1575, 180 Baumler, A. . . . . . . . . . . . . . . . . . . . . . . . . 416, 036

Barman, T. K. . . . . . . . . . . . . . . . . . . . F-2043, 248 Barnes, A. . . . . . . . . . . . . . . . . . . . . . . B-1736, 196 Barnes, S. . . . . . . . . . . . . . . . . . . . . . . . C1-680, 086

Baxter, M. . . . . . . . . . . .C2-103, 009; C2-135, 010; . . . . . . .E-191, 015; E-779, 093; C2-1360, 167; . . . . . . . . . . . . . . . . C2-1379, 169; E-1462, 173 Bayer, A. . . . E-1473, 174; E-1474, 174; 1866, 228

Baron, M. G. . . . . . . . . . . . . . . . . . . . . F-2001, 246 Baron, S. . . . . . . . . . . . . . . . . . . . . . . L1-1639, 186 Baron-Hall, D. . . . . . . . . . . . . . . . . . C2-1912, 237 Barr, K. . . . . . . . . . . . . . . . . . . . . . . . . . G-868, 101

Bayer, A. S. . . . . . . . . . . . . B-646, 084; B-654, 084; . . . . . . B-655, 084; C1-1744, 197; E-1468, 173 Baylan, O. . . . . . . . . . . . . . . . . . . . . . C2-1367, 168

Barron, A. E. . . . . . . . . . . . . . . . . . . . . . . . 436, 041 Barron, D. . . . . . . . . . . . . . . . . . . . . . .M-1668, 190 Barron, M. . . . . . . . . . . . M-337, 028; M-1227, 159 Barros, J. . . . . . . . . . . . . . . . . . . . . . . . F-1492, 175 Barry, M. . . . . . . . . . . . . . . . . . . . . . . . . . 1821, 211 Barth, A. L. . . . . . . . . . . D-749, 092; C2-1375, 168 Bartizal, K.. . . . . . . . . . . . E-778, 093; E-1479, 174 Bartczak, D.. . . . . . . . . . . . . . . . . . . . . . F-826, 097 Bartoletti, M. . . . . . . . . . . . . . . . . . . . . K-1619, 184 Bartolomé, R. . . . . . . . . . . . . . . . . . . . . K-931, 105 Bartoloni, A. . . . . . . . . . . . . . . . . . . . C1-1205, 156 Barton, M. . . . . . . . . . . . . . . . . . . . . . . A-1272, 162 Barton Behravesh, C.. . . . . . . . . . . . . . . . 1818, 210

210

Presentation Number

Bartsch, S. . . . . . . . . . . . . . . . . . . . . . . T-1069, 116 Baruchel, A.. . . . . . . . . . . . . . . . . . . . . . T-363, 029 Bashoura, L. . . . . . . . . . . . . . . . . . . . . T-1065, 116

Barker, K. S.. . . . . . . . . . .M-969, 111; M-970, 111; . . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-971, 111 Barker, S. . . . . . . . . . . . . . . . . . . . . . . . F-2016, 247 Barla, G. S. . . . . . . . . . . . . . . . . . . . . . . E-196, 015

Barrailler, S. . . . . . . . . . . . . . . . . . . . . . . A-638, 083 Barraud, O. . . . . . . . . . D-1408, 170; C1-1739, 197 Barreiros, G. . . . . . . . . . . . . . . . . . . . .M-1690, 190 Barreto-Miranda, M.. . . . . . . . . . . . . .M-1704, 191 Barrett, D. . . . . F-818, 096; F-819, 096; F-820, 096 Barrios, H. . . . . . . . . . . . C1-067, 006; C1-069, 006

Author

Baysarowich, J.. . . . . . . . . . . . . . . . . . . F-1496, 176 Baziaka, F. . . . . . . . . . . . . . . . . . . . . . . . K-562, 074 Beall, B. . . . . . . . . . . . . . . . . . . . . . . . . . . . 517, 065 Bearden, D. T. . . . . . . . . . . . . . . . . . . L2-2118, 255 Beatty, D.. . . . . . . . . . . . . . . . . . . . . . . F-1514, 176 Beaudoin, M. . . . . . . . . . . . . . . . . . . . . . A-632, 083 Bebrova, E. . . . . . . . . . . . . . . . . . . . . . . T-344, 029 Beceiro, A. . . . . . . . . . . . . . . . . . . . . . . C1-593, 081 Béchet, S.. . . . . . . . . . . . .G-1049, 114; G-864, 100 Beck, A. . . . . . . . . . . . . . . . . . . . . . . . . K-2085, 252 Becker, H. K. . . . . . . . . . . . . . . . . . . . . . F-856, 099 Becker, K. . . . . . . . . . . . . .A-596, 082; A-597, 082; . . . . . .A-599, 082; C2-1382, 169; E-1483, 174; . . . . . . . . . . . . . . . . . . . . . . . . . . . G3-1547, 178 Bedford, B. . . . . . . . . . . . . . . . . . . . . . A-1247, 161 Bedir, O. . . . . . . . . . . . . . . . . . . . . . . . D-1427, 171 Bedos, J. P. . . . . . . . . . . . . . . . . . . . . . . . K-237, 020 Behle, T. F.. . . . . . . . . . . . . . . . . . . . . . . A-027, 004 Behrman, A. . . . . . . . . . . . . . . . . . . . . . D-744, 091 Beigi, R.. . . . . . . . . . . . . . . . . . . . . . . . . . . 453, 045 Beilke, M. A. . . . . . . . . . . . . . . . . . . . . . D-153, 011

September 9-12 |

Bekele, Y. . . . . . . . . . . . . . . . . . . . . . . . . D-181, 013 Bektore, B. . . . . . . . . . C2-1367, 168; C2-1394, 169

Bellesso, M. . . . . . . . . . . . . . . . . . . . . . K-1603, 183

Bellos, N. . . . . . . . . . . . . . . . . . . . . . . . . H-555, 073 Belmonte, A. . . . . . . . . . . . . . . . . . . . . D-1455, 172 Ben David, D. . . . . . . . . . . . . . . . . . . L1-1640, 186 Ben-Ami, R. . . . . . . . . . M-985, 111; M-1059, 115 Ben-David, D. . . . . . . . . . . . . . . . . . . . . K-557, 074 Ben-Shimol, S. . . . . . . . . . . . . . . . . . . G-1753, 198 Ben-Yehuda, S. . . . . . . . . . . . . . . . . . . . . 1783, 203 Benedict, M. . . . . . . . . . A-1290, 163; A-1958, 241 Benfield, T. . . . . . . . . . . .G-876, 101; H-1916, 238 Benito, N. . . . . . . . . . . . . C2-111, 009; K-256, 022 Benner, C. . . . . . . . . . . . . . . . . . . . . . . F-2034, 248 Bennett, J. M. . . . . . . . . . . . . . . . . . . . F-2016, 247 Bens, C. . . . . . . . . . . . . . . . . . . . . . . . . .M-334, 028 Bensen, D. . . . . . . . . . . . F-2017, 247; F-2018, 247; . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2018a, 247 Benson, P. . . . . . . . . . . . . . . . . . . . . . . . H-891, 103 Bensoussan-Ambacher, C.. . . . . . . . . . G-1049, 114 Bentley, S. D. . . . . . . . . . . . . . . . . . . . . . . . 518, 065 Beranger, R. W. . . . . . . . . . . . . . . . . . . . K-257, 022 Berard, X. . . . . . . . . . . . . . . . . . . . . . . . D-164, 012 Beraud, G. . . . . . . . . . . . . A-039, 004; L1-963, 110 Berbari, E. F. . . . . . . . . . . . . . . . . . . . . K-2078, 250 Berendt, A. R. . . . . . . . . . . . . . . . . . . . . . . 538, 070 Berg, D. K. . . . . . . . . . . . . . . . . . . . . .M-1674, 190 Berg, R. M. . . . . . . . . . . . . . . . . . . . . . . B-055, 005 Berg, T. . . . . . . . . . . . . . . . . . . . . . . . . V-1236, 160 Bergen, P.. . . . . . . . . . . . . . . . . . . . . . . . A-024, 004 Berger, C.. . . . . . . . . . . . . . . . . . . . . . . . T-343, 029 Berghaus, L. J. . . . . . . . . . . . . . . . . . . C1-1348, 166 Berghmans, T. . . . . . . . . . . . . . . . . . . . T-1028, 113 Bergman, S. J. . . . . . . . . . . . . . . . . . . . E-1485, 174 Berkow, E. L.. . . . . . . . . . M-969, 111; M-971, 111 Berkowitz, L. . . . . . . . . . . . . . . . . . . . . . K-241, 020 Berktas, M. . . . . . . . . . . . . . . . . . . . . . . V-379, 030 Bermejo, N. . . . . . . . . . . . . . . . . . . . . L2-2110, 255 Bermejo, S. . . . . . . . . . . . . . . . . . . . . L2-2110, 255 Bermudez, A.. . . . . . . . . . . . . . . . . . . . T-1038, 113 Bermudez, C.. . . . . . . . . . .T-364, 029; T-1037, 113 Bermudez, L. . . . . . . . . . . . . . . . . . . . . B-1310, 165 Bernard, E. . . . . . . . . . . . . . . . . . . . . . . B-052, 005

AUTHOR INDEX Author

Presentation Number

Author

Presentation Number

Author

Presentation Number

Bernard, L. . . . . . . . . . . . D-176, 013; D-177, 013; . . . .L1-1639, 186; L1-2103, 254; L1-2104, 254

Bianco, J. . . . . . . . . . . . . . . . . . . . . . . . A-1272, 162 Bias, T. E. . . . . . . . . . . . . . . . . . . . . . . . K-241, 020

Blanco, V. M.. . . . . . . . . . D-747, 092; K-903, 104; . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2108, 255

Bernardo, P. . . . . . . . . . . . . . . . . . . . . L1-1638, 186 Bernardo, S. M. . . . . . . . . . . . . . . . . . . F-2000, 246

Bidet, P. . . . . . . . . . . . . . . . . . . . . . . . G3-1554, 178

Blandino, G. . . . . . . . . . . . . . . . . . . . . C1-594, 081

Biedenbach, D. J. . . . . . .C2-123, 010; C2-145, 010; . . . . . . F-1510, 176; F-2050, 248; F-2051, 248; . . . . . . . . . . . . . . . . . .F-2052, 248; F-2053, 248

Blandon, M. V. . . . . . . . . . . . . . . . . . L2-2115, 255 Blanes, M. . . . . . . . . . . . . . . . . . . . . . . . T-340, 029

Bernasconi, E. . . . . . . . . . . . . . . . . . . . H-1566, 179 Berry, J. . . . . . . . . . . . . . . . . . . . . . . . . F-2016, 247 Bertaina, C. . . . . . . . . . . . . . . . . . . . . G3-1559, 178

Blank, P. R. . . . . . . . . . . . . . . . . . . . . . . G-860, 100 Blankson, J. . . . . . . . . . . . . . . . . . . . . . H-1580, 180

Berti, A. D. . . . . . . . . . . . . . . . . . . . . . E-1482, 174

Biehle, L. R. . . . . . . . . . . . . . . . . . . . . . K-901, 104 Biehler, K. . . . . . . . . . . . . . . . . . . . . . . B-1331, 165 Biek, D. . . . . . . . . . . . . . . . . . . . . . . . . . A-625, 083

Blaschke, T. . . . . . . . . . . . . . . . . . . . . . .M-982, 111 Blasi, F. . . . . . . . . . . . . L1- L1-290, 026; 1666, 189

Bertoldi, M. B. . . . . . . . . . . . . . . . . . . C2-087, 008 Bertoni, G.. . . . . . . . . . . . . . . . . . . . . C2-1398, 169

Bielicki, J. . . . . . . . . . . . . . . . . . . . . . G3-1559, 178 Bielicki, J. A. . . . . . . . . . K-1754, 199; K-1759, 199

Blenk, B. . . . . . . . . . . . . . . . . . . . . . . . A-1285, 162

Bertuccio, P. . . . . . . . . . . . . . . . . . . . . . L2-304, 027

Bilgeturk, A. . . . . . . . . . . . . . . . . . . . . L1-960, 110 Billaud, G. . . . . . . . . . . . . . . . . . . . . . . . T-360, 029

Blenk, H. . . . . . . . . . . . . . . . . . . . . . . . A-1285, 162 Blijlevens, N. M. . . . . . . . . . . . . . . . . . A-1928, 240

Bille, J. . . . . . . . . . . . . . . . . . . . . . . . . L1-1221, 158

Block, L. . . . . . . . . . . . . . . . . . . . . . . . . K-247, 022

Binet, C. . . . . . . . . . . . . . . . . . . . . . . . . P-996, 112 Bingen, E. . . . . . . . . . . . G-864, 100; G-1049, 114; . . . . . . . . . . . . . . . . . . . . . . . . . . . G3-1554, 178 Bingo, M. . . . . . . . . . . . . . . . . . . . . . . D-1402, 170

Bloembergen, P. . . . . . . . . . . . . . . . . . . . K-930, 105 Blondeau, J. M. . . . . . . . . . . . . . . . . . . . D-729, 090 Blot, S. . . . . . . . . . . . . . . . . . . . . . . . . . . K-951, 107

Berthet, N.. . . . . . . . . . . . . . . . . . . . . C1-1349, 166

Bertz, H. . . . . . . . . . . . . . . . . . . . . . . .M-1704, 191 Bertz, R. J. . . . . . . . . . . . . . . . . . . . . . . A-1247, 161 Berven, S. . . . . . . . . . . . . . . . . . . . . . . . K-261, 023 Bès, M. . . . . . . . . . . . . B-1319, 165; C1-1739, 197 Bessen, D. . . . . . . . . . . . . . . . . . . . . . . B-1312, 165 Besser, T. . . . . . . . . . . . . . . . . . . . . . . . D-1409, 170 Besson, C. . . . . . . . . . . . . . . . . . . . . . L2-2109, 255 Besterman, J. . . . . . . . . . . . . . . . . . . . .M-1711, 191 Bestrom, J. E.. . . . . . . . . . . . . . . . . . . .M-1693, 190 Betelu, M. . . . . . . . . . . . . . . . . . . . . . . . G-874, 101 Bethel, C. R. . . . . . . . . .C1-463, 047; C1-590, 081; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-847, 099 Betrisey, B.. . . . . . . . . . . . . . . . . . . . . . F-2011, 246 Betsuyaku, T. . . . . . . . . . . . . . . . . . . . . . A-038, 004 Bettencourt, A. . . . . . . . . . . . . . . . . . . F-2011, 246 Bettinger, J. A. . . . . . . . . . . . . . . . . . . G3-1542, 178 Bettiol, M. . . . . . . . . . . . . . . . . . . . . . . C2-084, 008 Beumont-Mauviel, M.. . . . . . . . . . . . . V-1236, 160 Beunza, J.. . . . . . . . . . . . . . . . . . . . . . . K-1612, 184 Beuret, P. . . . . . . . . . . . . . . . . . . . . . . L1-1224, 158 Bevilacqua, S.. . . . . . . . . . . . . . . . . . . . L2-302, 027 Beyda, N. D. . . . . . . . . . . . . . . . . . . . . .M-316, 028 Bhalla, P. . . . . . . . . . . . . . . . . . . . . . . . . T-345, 029 Bhalodi, A. A. . . . . . . . . . .A-020, 003; A-625, 083; . . . . . . . . . . . . . . . . . . A-630, 083; A-1287, 163 Bharadwaj, S. . . . . . . . . . . . . . . . . . . . . . K-236, 020 Bhargava, A. . . . . . . . . .C2-096, 008; L2-306, 027; . . . . . . . K-902, 104; K-1589, 181; K-1604, 183 Bhatt, N. . . . . . . . . . . . . . . . . . . . . . . . . K-921, 105 Bhattacharjee, A. . . . . . . . . . . . . . . . . . F-1522, 177 Bhavan, K. P. . . . . . . . . . . . . . . . . . . . . . D-752, 092 Bhavnani, S. M. . . . . . . . .A-620, 082; A-1244, 161; . . . . . .A-1261, 161; A-1262, 161; A-1263, 161; . . . . . .A-1269, 162; A-1270, 162; A-1271, 162; . . . . . . . . 1862, 227; A-1961, 241; A-1962, 241 Bhotra, T.. . . . . . . . . . . . . . . . . . . . . . . C2-715, 088 Bhowmick, R. . . . . . . . . . . . . . . . . . . . . F-824, 097 Bhutani, N. . . . . . . . . . . . . . . . . . . . . . C2-703, 088 Bialek, R. . . . . . . . . . . . . . . . . . . . . . . . . T-347, 029 Bialek, S. . . . . . . . . . . . . . . . . . . . . . . . K-2087, 252

Binnicker, M. J. . . . . . . . . D-174, 013; T-1032, 113; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1693, 190 Birdsell, D. N. . . . . . . . . . . . . . . . . . . . L1-964, 110 Birkmann, A. . . . . . . . . . . . . . . . . . . . . . V-391, 030 Birkus, G. . . . . . . . . . . . . . . . . . . . . . . . H-892, 103 Biron, C. . . . . . . . . . . . . . . . . . . . . . . . . P-566, 075 Bisbal, R. . . . . . . . . . . . . . . . . . . . . . . L1-1643, 186 Bishai, W. . . D-739, 091; F-830, 098; B-1296, 164 Bishai, W. R. . . . . . . . . . . . . . .533, 069; 1087b, 120 Bishop, C. . . . . . . . . . . . . . . . . . . . . . . D-1435, 171 Bishop, L. . . . . . . . . . . . . . . . . . . . . . .M-1670, 190 Bishop, L. M. . . . . . . . . . . . . . . . . . . C2-1979, 243 Bisi-Johnson, M. A.. . . . . . . . . . . . . . . C2-101, 009 Bispo, P. J. . . . . . . . . . . C2-1400, 169; E-1481, 174 Bissell, A.. . . . . . . . . . . . . . . . . . . . . . . . F-829, 098 Biswas, P. . . . . . . . . . . .M-1229, 159; M-1683, 190; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1709, 191 Bitko, V.. . . . . . . . . . . . . . . . . . . . . . . . . G-869, 101 Bittencourt, H. . . . . . . . . . . . . . . . . . . D-1403, 170 Biver, E. . . . . . . . . . . . . . . . . . . . . . . . . . H-231, 019 Bizzini, A. . . . . . . . . . . . . B-649, 084; D-1436, 171 Björkman, S. . . . . . . . . . . . . . . . . . . . . . A-033, 004 Black, T. A. . . . . . . . . . . . . . . . . . . . . . . . 1871, 229 Blackburn, J. . . . . . . . . . . . . . . . . . . . . . D-751, 092 Blair, J. E. . . . . . . . . . . T-1032, 113; M-1697, 191; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1702, 191 Blair, M. . . . . . . . . . . . . . . . . . . . . . . . F-2016, 247 Blair, M. A. . . . . . . . . . . . . . . . . . . . . . F-2028, 247 Blair, P.. . . . . . . . . . . . . . . . . . . . . . . . . . V-383, 030 Blanc, A. . . . . . . . . . . . . . . . . . . . . . . . L1-957, 109 Blanc, C. . . . . . . . . . . . . . . . . . . . . . . . H-1568, 179 Blanc, D. . . . . . . . . . . . . . . . . . . . . . . C2-1378, 169 Blanco, J. L. . . . . . . . . . . . . . . . . . . . . . . K-470, 048

Final Program

Bleibtreu, A. . . . . . . . . . . B-660, 084; B-1305, 164

Blumentals, W. A. . . . . . . . . . . . . . . . . G-1749, 198 Blumer, J. L. . . . . . . . . . . . . . . . . . . . . A-1257, 161 Blyth, C. C. . . . . . . . . . . . . . . . . . . . . . .M-313, 028 Bo-Sheng Ko. . . . . . . . . . . . . . . . . . . .M-1669, 190 Bocanegra, R. A. . . . . . . . . B-650, 084; F-823, 096; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1682, 190 Bocco, J. L. . . . . . . . . . . . . . . . . . . . . C2-1910, 237 Boci, T. . . . . . . . . . . . . . . . . . . . . . . . . F-2072, 249 Bodro, M. . . . . . . . . . . . . . . . . . . . . . . T-1030, 113 Boeckh, M. . . . . . . . . . . . . . . . . . . . . . . T-353, 029 Boehme, M. S.. . . . . . . . . . . . . . . . . . . . D-750, 092 Boel, E. C. . . . . . . . . . . . . . . . . . . . . . . F-1516, 176 Boelman, K. J. . . . . . . . . . . . . . . . . . . . . D-170, 012 Boeree, M. J. . . . . . . . . . . . . . . . . . . . . A-1268, 161 Boerlin, P. . . . . . . . . . . . . . . . . . . . . . . C2-710, 088 Bogado, B. . . . . . . . . . . . . . . . . . . . . . . F-1491, 175 Bogaerts, P. . . . . . . . . . . . . . . . . . . . . . D-1447, 172 Boggian, K. . . . . . . . . . . . . . . . . . . . . . . T-343, 029 Boggild, A. . . . . . . . . . . . . . . . . . . . . . . . . 404, 033 Bogner, J. R. . . . . . . . . . . . . . . . . . . . . . H-887, 103 Boibieux, A. . . . . . . . . . . . . K-249, 022; K-253, 022 Boillat Blanco, N. . . . . . . . . . . . . . . . . H-1566, 179 Boinapally, P. . . . . . . . . . . . . . . . . . . . . . D-750, 092 Boinett, C. J. . . . . . . . . . . . . . . . . . . . C1-1208, 156 Boisson, M. . . . . . . . . . . . . . . . . . . . . . . A-037, 004 Boivin, G. . . . . . . . . . . . . . V-392, 030; V-399, 030; . . . . . . . . . . . . . . . . . V-1076, 117; V-1079, 117 Boley, M. . . . . . . . . . . . . . . . . . . . . . . . F-2005, 246 Bollinger, L.. . . . . . . . . . . . . . . . . . . . . F-1515, 176 Bologna, R. . . . . . . . . . . . . . . . . . . . . . . B-045, 005 Bond, S. . . . . . . . . . . . . . . . . . . . . . . . . . F-828, 097 Bonfanti, P. . . . . . . . . . . . . . . . . . . . . . . D-757, 092 Bonfietti, L. X.. . . . . . . . . . . . . . . . . . . .M-311, 028 Bonfillon, C. . . . . . . . . . . . . . . . . . . . . . K-560, 074

211


Presentation Number

Author

Presentation Number

Author

Presentation Number

Bonhoeffer, J. . . . . . . . . . . . . . . . . . . . . . . . 528, 067

Bourgault, A. . . . . . . . . . . . . . . . . . . . . . D-751, 092

Brinson, C. . . . . . . . . . . . . . . . . . . . . . . H-877, 102

Bonhoeffer, S. . . . . . . . . . . . . . . . . . . . . K-238, 020 Boniatti, M. M. . . . . . . . . . . . . . . . . . . . A-027, 004

Bourhis, J. . . . . . . . . . . . . . . . . . . . . . . . D-772, 092

Brisse, S. . . . . . . . . . . . . . . . . . . . . . . . C2-088, 008 Brito, M. J.. . . . . . . . . . . . . . . . . . . . . . . G-866, 100

Bonilla, H. F. . . . . . . . . . . . . . . . . . . . C1-1745, 197

Boussiotis, V. A. . . . . . . . . . . . . . . . . . . T-354, 029 Boutoille, D. . . . . . . . . L1-963, 110; L1-1224, 158

Bonnin, R. . . . . . . . . . . . . . . . . . . . . . . C1-071, 006

Bouvet, D. . . . . . . . . . . . . .D-176, 013; D-177, 013

Broder, K. . . . . . . . . . . . . . . . . . . . . . . G-1052, 114

Bonomo, R. A.. . . . . . . .C1-076, 006; C2-092, 008; . . . . . .C1-460, 047; C1-463, 047; C1-464, 047; . . . . . .C1-467, 047; C1-590, 081; C2-686, 087; . . . . . .C2-692, 087; C2-694, 087; C2-720, 089; . . . . . . . . F-847, 099; 1831, 214; C1-1209, 156; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2059, 249 Boon, L.. . . . . . . . . . . . . . . . . . . . . . . . . B-058, 005

Bouvet, E. . . . . . . . . . . . . V-375, 030; L1-957, 109 Bouylout, K. . . . . . . . . . . . . . . . . . . . . K-2095, 252

Brodner, A. H. . . . . . . . . . . . . . . . . . . . C1-588, 081 Broge Jr. T. A. . . . . . . . . . . . . . . . . . . . . T-354, 029

Bouza, E. . . . . . . . . . . . .C2-127, 010; C2-130, 010; . . . . . . . C2-142, 010; D-166, 012; K-263, 023; . . . . . . . M-322, 028; K-470, 048; D-726, 090; . . . . . . . . .E-806, 095; K-940, 106; K-941, 106; . . . . . . . . .K-942, 106; K-943, 106; K-944, 106; . . . . . .T-1026, 113; T-1041, 113; M-1232, 159; . . . . . V-1242, 160; D-1411, 170; D-1415, 170; . . . . H-1577, 180; M-1684, 190; M-1688, 190; . . . . . . . . . . . . . . . . . D-1772, 201; K-2090, 252

Brooks, A. . . . . . . . . . . . . . . . . . . . . . . K-1927, 239 Brooks, T. J. . . . . . . . . . . . . . . . . . . . . . . . 1729, 194

Boone, J. H. . . . . . . . . . . . .D-162, 011; D-163, 011 Booth, M. P. . . . . . . . . . . . . . . . . . . . . C1-465, 047 Boothe, D. M. . . . . . . . . . . . . . . . . . . C2-1219, 157 Bordi, R. . . . . . . . . . . . . . . . . . . . . . . . . H-553, 073 Borens, O. . . . . . . . . . . . . . K-250, 022; K-251, 022 Borer, A. . . . . . . . . . . . . . H-232, 019; M-339, 028; . . . . . . . . . . . . . . . . . P-1022, 112; K-1610, 184 Boreux, R. . . . . . . . . . . . . . . . . . . . . . C2-1988, 244 Borgert, S. . . . . . . . . . . . . . . . . . . . . . . . K-274, 024 Borges, N. . . . . . . . . . . . . . . . . . . . . . G3-1546, 178 Borovkova, N. . . . . . . . . . . . . . . . . . . . L2-310, 027 Bortolon, E. . . . . . . . . . . A-1289, 163; F-1523, 177 Bosari, S. . . . . . . . . . . . . . . . . . . . . . . . L2-304, 027 Boshoff, H. I.. . . . . . . . . . . . . . . . . . . . . F-832, 098 Bosis, S. . . . . . . . . . . . . . . . . . . . . . . . G3-1553, 178 Botelho-Nevers, E. . . . . . . . . . . . . . . . . P-566, 075 Bou, G. . . . . . . . . . . . . . . C1-070, 006; T-340, 029; . . . . . . . . T-368, 029; K-559, 074; C1-593, 081; . . . . . . . . . . . . . . . . C1-672, 085; C2-1902, 236 Bouarab, K. . . . . . . . . . . .F-1997, 246; F-1998, 246 Bouaziz, A. . K-249, 022; K-253, 022; B-1319, 165 Bouchami, O. . . . . . . . . . . . . . . . . . . C1-1740, 197 Bouchara, J. P. . . . . . . . . . . . . . . . . . . . .M-332, 028 Bouchene, S. . . . . . . . . . . . . . . . . . . . . . A-033, 004 Boucher, C. . . . . . . . . . . . . . . . . . . . . . V-1080, 117 Boucher, H. W. . . . . . . . . . . . .1195, 154; 1812, 209 Bouchillon, S. . . . . . . . .C2-099, 009; C2-100, 009; . . . . .C2-120, 009; C2-133, 010; C2-1352, 167; . . . . . .C2-140, 010; C2-141, 010; C2-143, 010; . . . . . .C2-144, 010; C2-147, 010; C2-148, 010; . . . . . .C2-150, 010; C2-688, 087; C2-721, 089; . . . . . . C2-722, 089; C2-724, 089; E-1474, 174 Boudville, I. . . . . . . . . . . . . . . . . . . . . . G-1751, 198 Bouffard, B. . . . . . . . . . . . . . . . . . . . . . . P-996, 112 Bouhy, X. . . . . . . . . . . . . . . . . . . . . . . . V-1079, 117 Boulahfa, S. . . . . . . . . . . . . . . . . . . . . . .M-983, 111 Boulanger, S. . . . . . . . . . . . . . . . . . . . . F-1998, 246 Bouler, J. . . . . . . . . . . . . . . . . . . . . . . . . B-653, 084 Boulianne, N.. . . . . . . . . . V-389, 030; G-1047, 114 Boulware, D. . . . . . . . . . . . . . . . . . . . .M-1699, 191 Boulware, D. R. . . . . . . . . . . . . . . . . . . . . 1108, 126

212

Bowden, R. . . . . . . . . . . . . . . . . . . . . . . K-474, 048 Bowen, R. . . . . . . . . . . . .F-2022, 247; F-2033, 248 Bowers, D. R. . . . . . . . . . . . . . . . . . . . . K-896, 104 Bowker, K. E. . . . . . . . . . .A-628, 083; A-629, 083; . . A-631, 083; A-642, 083; D-763, 092; E-793, 094 Bowlin, T. L. . . . . . . . . . . . .F-816, 096; F-832, 098 Bown, D. . . . . . . . . . . . . . . . . . . . . . . . A-1761, 200 Boyce, J. M. . . . . . . . . . . . . . . . . . . . . . . . 1850, 223 Boyd, D. A. . . . . . . . . . . . . . . . . . . . . . C2-085, 008 Boyd, N. K. . . . . . . . . . . . . . . . . . . . . . . D-752, 092 Boyea, T. . . . . . . . . . . . . A-1294, 163; A-1295, 163 Boyken, L. . . . . . . . . . . . . . . . . . . . . . . D-1433, 171 Boyle, F. . . . . . . . . . . . . . . . . . . . . . . . . C2-122, 009 Bozdogan, B. . . . . . . . . . . . . . . . . . . . . D-1430, 171 Bozic, K. . . . . . . . . . . . . . . . . . . . . . . . . K-247, 022 Bozkurt, I. . . . . . . . . . . . . . . . . . . . . . .M-1701, 191 Bracco, S. . . . . . . . . . . . . D-757, 092; C2-1897, 236 Bradley, J.. . . . . . . . . . . . . . . . . . . . . . . A-1292, 163 Brañas, P. . . . . . . . . . . . . . . . . . . . . . . . K-2093, 252 Brandt, S. L. . . . . . . . . . . . . . . . . . . . . B-1301, 164 Brause, B.. . . . . . . . . . . . . . . . . . . . . . .M-1681, 190 Bravetti, P. . . . . . . . . . . . . . . . . . . . . . . L2-302, 027 Brazier, F.. . . . . . . . . . . . . . . . . . . . . . L1-2106, 254 Brazilian KPC Study Group . . . . . . . C2-1218, 157 Bredeek, U. . . . . . . . . . . . . . . . . . . . . . . H-879, 102 Breitenecker, F. . . . . . . . . . . . . . . . . . . H-1918, 238 Brennan, A. . . . . . . . . . . . . . . . . . . . . . C2-706, 088 Brennan, B. M. . . . . . . . . . . . . . . . . . . . D-750, 092 Brenner, B.. . . . . . . . . . . . . . . . . . . . . . H-1571, 180 Brentzos, G.. . . . . . . . . . . . . . . . . . . . . . B-043, 005 Breshears, L. M. . . . . . . . . . . . . . . . . . F-1517, 176 Bretonnière, C. . . . . . . . . . . . . . . . . . L1-1224, 158 Bridevaux, P. . . . . . . . . . . . . . . . . . . . . T-1064, 116 Brielmaier, B.. . . . . . . . . . . . . . . . . . . . . K-279, 024 Briggs, H. . . . . . . . . . . . . . . . . . . . . . . D-1449, 172 Brink, A. . . . . . . . . . . . . . . . . . . . . . . . . . . 421, 037

September 9-12 |

Britton, W. J. . . . . . . . . . . . . . . . . . . . . . . 1171, 148

Brophy, A. . . . . . . . . . . . . . . . . . . . . . . . A-618, 082 Broquet, A. . . . . . . . . . . . . B-051, 005; B-054, 005; . . . . . . . . . . . . . . . . . . B-651, 084; B-1335, 165 Brossier, C. . . . . . . . . . . . . . . . . . . . . . . K-560, 074 Broun, E. . . . . . . . . . . . . . . . . . . . . . . . . A-026, 004 Brouwer, M. C. . . . . . . . . . . . . . . . . . L1-1223, 158; . . . . . . . . . . . . . . . L1-1222, 158; L1-1648, 187 Brown, D. . A-011, 003; A-1265, 161; E-1993, 245 Brown, J. . . . . A-605, 082; A-615, 082; A-617, 082 Brown, J. E. . . . . . . . . . . . . . . . . . . . . . A-1768, 200 Brown, K. . . . . . . . . . . . . . A-615, 082; A-617, 082 Brown, K. M.. . . . . . . . . . . . . . . . . . . . .M-969, 111 Brown, M. . . . . . . . . . . . . . . . . . . . . . . . A-618, 082 Brown, N. G. . . . . . . . . . . . . . . . . . . . . C1-462, 047 Brown, S. D. . E-188, 015; D-768, 092; D-771, 092 Brown-Driver, V. . . . . . . F-2017, 247; F-2018, 247; . . . . . F-2018a, 247; F-2020, 247; F-2023, 247; . . . . . . F-2024, 247; F-2025, 247; F-2026, 247; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2028, 247 Brownstein, J. . . . . . . . . . . . .1087a, 120; 1855, 225 Bru, J.. . . . . . . . . . . . . . . . . . . . . . . . . . . K-237, 020 Bruce, R. D.. . . . . . . . . . . . . . . . . . . . . A-1250, 161 Brüggemann, R. J. . . . . . M-989, 111; A-1928, 240; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1933, 240 Bruhn, D. F.. . . . . . . . . . . . . . . . . . . . . . F-832, 098 Brummelkamp, T. . . . . . . . . . . . . . . . . F-1537, 177 Brundage, T. . . . . . . . . . . . . . . . . . . . . . T-358, 029 Bruneel, F. . . . . . . . . . . . . . P-568, 075; P-570, 075 Brzostek, J.. . . . . . . . . . . . . . . . . . . . . . A-1245, 161 BSAC Working Party on Resistance Surveillance, . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-152, 010 Buchan, B. W. . . . . . . . . .D-1777, 201; D-728, 090 Bucher, H. . . . . . . . . . . . . . . . . . . . . . . K-1125, 129 Buchheidt, D. . . . . . . . . M-335, 028; M-1704, 191 Buckeridge, D. L. . . . . . V-1076, 117; K-1755, 199 Bueno, M. . . . . . . . . . . . . . . . . . . . . . .M-1681, 190 Bui, H. T.. . . . . . . . . . . . . . . . . . . . . . .M-1677, 190 Bui, T. . . . . . . . . . . . . . . . . . . . . . . . . . . T-351, 029 Buiting, A. . . . . . . . . . . . . . . . . . . . . . . . K-930, 105 Bukbuk, D. N. . . . . . . . . . . . . . . . . . . . G-1748, 198 Bulik, C. C. . . . . . . . . . . .A-620, 082; A-1244, 161; . . . . . .A-1261, 161; A-1262, 161; A-1263, 161; . . . . . . A-1269, 162; A-1270, 162; A-1271, 162

AUTHOR INDEX Author

Presentation Number

Bulitta, J. B. . . . . . . . . . . . .A-011, 003; A-024, 004; . . . . . . . .A-031, 004; E-785, 094; A-1266, 161; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1762, 200 Bunce, C. P. . . . . . . . . . . . . . . . . . . . . . L1-286, 025 Burak, E. . . . . . . . . . . . . . . . . . . . . . . . A-1289, 163 Burchardt, A. . . . . . . . . . . . . . . . . . . . . . T-341, 029 Burden of Healthcare-associated infection Study Group, . . . . . . . . . . . . . . . . . . . . . . . K-908, 104 Burger, D. M. . . . . . . . . . . . . . . . . . . . A-1928, 240 Burgess, D. S. . . . . . . . . . . . . . . . . . . . . E-794, 094 Burghoffer, B. . . . . . . . . . . . . . . . . . . . . K-925, 105 Bürgisser, P. . . . . . . . . . . . . . . . . . . . . . . D-184, 014 Burgmann, H. . . . . . . . . . . . . . . . . . . . E-1471, 174 Burgos, R. . . . . . . . . . . . . . . . . . . . . . . K-1758, 199 Burillo, A. . . . . . . . . . . . . K-944, 106; T-1026, 113 Burke, E. . . . . . . . . . . . . . . . . . . . . . . . C2-706, 088 Burke, E. E. . . . . . . . . . . . . . . . . . . . . . . B-661, 084 Burkett, A. . . . . . . . . . . . . . . . . . . . . . G3-1552, 178 Burman, M. K. . . . . . . . . . . . . . . . . . . . D-170, 012 Burns, K. . . . . . . . . . . . . . . . . . . . . . . . C2-088, 008 Burton, M.. . . . . . . . . . . . . D-185, 014; V-374, 030 Burucoa, C. . . . . . . . . . . . . . . . . . . . . . . A-039, 004 Busch, R. . . . . . F-843, 099; F-844, 099; F-845, 099 Bush, K. . . . . . . . . . . . . . . C2-1213, 157; 1197, 154; . . . . . . . . . . . . . . . . . . . K-1589, 181; 1832, 214 Buskila, D. . . . . . . . . . . . . . . . . . . . . . . . H-232, 019 Bustamante, B. . . . . . . . . . . . . . . . . . . .M-311, 028 Buteau, C. . . . . . . . . . . . . . . . . . . . . . . . V-376, 030 Butler, M. M.. . . . . . . . . . . . . . . . . . . . . F-832, 098 Butterfield, J. M. . . . . . . . . . . . . . . . . . . A-606, 082 Butterton, J. . . . . . . . . . . . .A-009, 003; A-010, 003; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1763, 200 Butty, P. . . . . . . . . . . . . . . . . . . . . . . . . C2-709, 088 Buyck, J.. . . . . . . . . . . . . A-1278, 162; F-2029, 247 Buynak, J. D. . . . . . . . . . . . . . . . . . . . . . F-847, 099 Buyukoglan, H. . . . . . . . . . . . . . . . . . .M-1701, 191 Buzea, M. . . . . . . . . . . . . . . . . . . . . . . C2-110, 009 Buzele, R. . . . . . . . . . . . . . . . . . . . . . L1-2104, 254 Byrd, L. . . . . . . . . . . . . . . . . . . . . . . . . . D-752, 092

C CA-MRSA Argentina Group . . . . . . C2-1910, 237 Caballero, A. . . . . . . . . . . . . . . . . . . . . L1-289, 026 Caballero, F.. . . . . . . . . . . . . . . . . . . . L1-1658, 188 Cabello, F. . . . . . . . . . . . . . . . . . . . . . . .M-980, 111 Cabellos, C. . B-647, 084; B-658, 084; V-1240, 160 Cabezas, J. . . . . . . . . . . . A-1931, 240; A-1947, 241 Cabezas, Y. . . . . . . . . . . . . . . . . . . . . . P-1007, 112 Cabo, J. . . . . . . . . . . . . . . . . . . . . . . . . . B-647, 084 Cabo, X.. . . . . . . . . . . . . . . . . . . . . . . . . K-254, 022 Cabot, G.. . . . . . . . . . . . . . . . . . . . . . C1-1970, 242

Author

Presentation Number

Caffrey, A. R.. . . . . . . . . .K-233, 020; K-1120, 129; . . . . . . E-1464, 173; E-1469, 173; K-1628, 185 Cahn, P. . . . . . . . . . . . . . . . . . . . . . . . . . . 1848, 222 Cai, Y. . . . . .E-195, 015; K-235, 020; A-1290, 163; . . . . . . . . . . . . . . . . . E-1476, 174; K-1613, 184

Author

Presentation Number

Cantón, R. . . . . . . . . . . . .C2-111, 009; E-205, 016; . . . . . . C1-681, 086; C1-682, 086; D-753, 092; . . . . . . . . . . . . . . . . . . . . . .1129, 132; 1178, 150 Cantu, S. . . . . . . . . . . . . . . . . . . . . . . . . K-934, 105 Cao, C. . . . . . . . . . . . . . . . . . . . . . . . C1-1969, 242

Caillon, J. . . . . . . . . . . . . . . B-051, 005; B-054, 005; . . . . . . . C2-080, 007; E-203, 016; L1-283, 025; . . . . . . . B-651, 084; B-653, 084; L1-1224, 158; . . . . . B-1335, 165; D-1458, 172; L1-1642, 186; . . . . . . . . . . . . . . . . . A-1948, 241; F-2056, 248 Calabrese, L. H.. . . . . . . . . . . . . . . . . . . . 1094, 122

Cao, G. Y. . . . . . . . . . . . .F-1503, 176; F-1504, 176

Calábria, P.. . . . . . . . . . . . . .P-993, 112; P-995, 112

Capobianchi, A.. . . . . . . . . . . . . . . . . . . V-393, 030

Calabrò, M. . . . . . . . . . . . . . . . . . . . . . . D-159, 011 Calatayud, L. . . . . . . . . . . . . . . . . . . . C2-1974, 243

Capparelli, E.. . . . . . . . . . . . . . . . . . . . A-1292, 163 Cappy, P. . . . . . . . . . . . . . . . . . . . . . . . . H-886, 102

Calbo, E. . . . . . . . . . . . . . . . . . . . . . . . K-1621, 184

Capraro, G. A. . . . . . . . . . . . . . . . . . . . D-1418, 170

Calcagno, A. . . . . . . . . . . . . . . . . . . . . A-1769, 200 Caldeira, D. . . . . . . . . . . . . . . . . . . . . C2-1377, 169

Caramma, I.. . . . . . . . . . . . . . . . . . . . . . D-757, 092 Carapetis, J. . . . . . . . . . . . . . . . . . . . . . B-1312, 165

Cáliz, B. . . . . . . . . . . . . M-1232, 159; M-1684, 190 Callebaut, C. . . . . . . . . . . . . . . . . . . . . . H-552, 073 Calmaggi, A. . . . . . . . . . . . . . . . . . . . C2-1398, 169

Caratozzolo, A. . . . . . . . . . . . . . . . . . G3-1552, 178 Carattoli, A.. . . . . . . . . . . . . . . . . . . . . C2-697, 087 Carballito, J.. . . . . . . . . . . . . . . . . . . . C2-1377, 169

Caltagirone, M. . . . . . . . . . . . . . . . . . . C2-094, 008 Calvo, J. . . . . . . . . . . . . . . C2-105, 009; D-765, 092 Camara, M. . . . . . . . . . . F-1529, 177; B-1734, 196

Carbone, E. . . . . . . . . C2-1396, 169; C2-1397, 169 Card, D.. . . . . . . . . . . . . . . . . . . . . . . . . F-810, 096 Card, R. . . . . . . . . . . . . . . . . . . . . . . . C2-1983, 243

Cambau, E. . . . . . . . . . . . . . . . . . . . . . B-1306, 164

Cardenas, A. . . . . . . . . . . . . . . . . . . . . C1-462, 047

Camilotti, J. . . . . . . . . . . . . . . . . . . . . . C2-087, 008 Camoez, M.. . . . . . . . . C2-1395, 169; D-1775, 201

Cardeñoso, L. . . . . . . . . . .T-355, 029; T-1070, 116 Cardone, K. E.. . . . . . . . . . . . . . . . . . . . A-606, 082 Cardoso, C. M. . . . . . . . . . . . . . . . . . C2-1375, 168

Campanaro, E.. . . . . . . . . . . . . . . . . . L1-2105, 254 Campbell, A. P. . . . . . . . . . . . . . . . . . . . T-353, 029 Campeau, L. . . . . . . . . . . . . . . . . . . . . . H-551, 073 Campins, L. . . . . . . . . . . . . . . . . . . . . L1-1643, 186 Campo, A. . . . . . . . . . . . . . . . . . . . . . . . D-765, 092 Camúñez, F.. . . . . . . . . . . . . . . . . . . . . . D-166, 012 Camus, V. . . . . . . . . . . . . . . . . . . . . . . . K-956, 108 Can, F. . . . . . . . . . . . . . . . . . . . . . . . . . C2-684, 087 Canadian Antimicrobial Resistance Alliance (CARA), . . . . . . . . C2-135, 010; C2-1379, 169 Canadian Bacterial Surveillance Network (CBSN), . . . . . . . . . . . . . . . C2-1362, 167; C2-1364, 167 Canadian Immunization Monitoring Program,ACTive (IMPACT), . . . G3-1542, 178 Candel, F. J. . . . . . . . . . . . . . . . . . . . . . . E-805, 095 CANDIPOP Project, GEIH-GEMICOMED (SEIMC) and REIPI. . . . . . . . . . . . . K-948, 107 CANDIPOP Project, GEIH-GEMICOMED and REIPI, . . . . . . . . . . . . . . . . . . . . K-950, 107 Canellini, G. . . . . . . . . . . . . . . . . . . . . . D-184, 014 Cañero, M. . . . . . . . . . . . . . . . . . . . . . P-1015, 112 Cañero V. M. . . . . . . . . . . . . . . . . . . . . P-1016, 112 Cano, J. . . . . . . . . . . . . . . . . . . . . . . . . K-1924, 239 Cano, M. . . . . . . . . . . . . C2-105, 009; C1-683, 086 Cantas, L. . . . . . . . . . . . . . . . . . . . . . . B-1330, 165 Cantin, R. . . . . . . . . . . . . . . . . . . . . . . H-1571, 180

Final Program

Cao, G. . . . . . . . . . . . . . . . . . . . . . . . . A-1283, 162 Cao, S. . . . . . . . . . . . . . . A-1764, 200; A-1966, 241 Capdevila, J.. . . . . . . . . . . . . . . . . . . . L1-1643, 186 Capilla, S. . . . . . . . . . . . . . . . . . . . . . . K-1623, 184

Cardoso, F. L. . . . . . . . . . . . . . . . . . . . K-1601, 182 Carijó, J. H. . . . . . . . . . . . . . . . . . . . . . . K-257, 022 Carkaci, D. . . . . . . . . . . . . . . . . . . . . . D-1443, 171 Carl, M. . . . . . . . . . . . . . . . . . . . . . . . . P-1010, 112 Carlesse, F.. . . . . . . . . . . . . . . . . . . . . . D-1412, 170 Carman, R. . . . . . . . . . . . . . . . . . . . . . . D-163, 011 Carman, R. J. . . . . . . . . . . . . . . . . . . . . . D-162, 011 Carmeli, Y. . . . . . . . . . . .C2-109, 009; K-557, 074; . . . . . . . K-1609, 184; 1814, 209; C2-1900, 236 Carmi-Oren, N.. . . . . . . . . . . . . . . . . . P-1001, 112 Carmichael, A. J. . . . . . . . . . . . . . . . . . L1-288, 025 Carnalla-Barajas, M. . . . . . . . . . . . . . C2-1356, 167 Caroff, N. . . . . . . . . . . . .C2-080, 007; K-255, 022; . . . . . B-1318, 165; D-1458, 172; L1-1642, 186 Caron, A. . . . . . . . . . . . . . . . . . . . . . . . F-1496, 176 Caron, F. . . . . . . . . . . . . B-1337, 165; B-1338, 165; . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2117, 255 Carrat, F. . . . . . . . . . . . . . . D-173, 013; V-387, 030 Carratalà, J. . . . . . . . . . . .D-180, 013; L1-293, 026; . . . . . . L1-295, 026; L1-298, 026; M-329, 028; . . . . . . . T-340, 029; T-1030, 113; T-1045, 113; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1228, 159 Carreno, J. J.. . . . . . . . . . . K-240, 020; K-1629, 185 Carretero, A. . . . . . . . . . . . . . . . . . . . . K-2091, 252 Carrier, M.. . . . . . . . . . . . . . . . . . . . . . . D-730, 090

213


Presentation Number

Author

Presentation Number

Cars, O. . . . . .A-030, 004; E-798, 094; E-800, 094; . . . . . . . . . . . . . . . . . . . 1149, 141; A-1966, 241

Celik, M. . . . . . . . . . . . . L1-964, 110; A-1941, 240 Celis, A. Y. . . . . . . . . . . . . . . . . . . . . L2-2108, 255

Carton, T. . . . . . . . . . . D-1458, 172; L1-1642, 186 Carvajal, L. P. . . . . . . C2-1389, 169; C2-1909, 237

Cellot, S. . . . . . . . . . . . . . . . . . . . . . . . . V-376, 030

Carvalhaes, C. G. . . . . . . . . . . . . . . . C2-1376, 169

Cen, R. . . . . . . . . . . . . . . . . . . . . . . . . . K-936, 105 Cengiz, A. . . . . . . . . . . . . . . . . . . . . . . A-1941, 240

Carvalho, R. A. . . . . . . . . . . . . . . . . . . C2-716, 088 Carvalho-Assef, A. D. . . . . . . . . . . . . C2-1218, 157

Centrón, D. . . . . . . . . . . C1-074, 006; C2-701, 087

Casadevall, A. . . . . . . . . . . . . . . . . . . . . . 1126, 130

Cercenado, E. . . . . . . . .C2-111, 009; C2-127, 010; . . . . . .C2-130, 010; C2-142, 010; C1-593, 081; . . . . .C2-1358, 167; D-1415, 170; D-1772, 201

Casado, J. L. . . . . . . . . . . .H-217, 018; H-222, 019 Casalino, E. . . . . . . . . . . . . . . . . . . . . L2-2117, 255

Cerf, C. . . . . . . . . . . . . . . . . . . . . . . . . . A-035, 004 Ceriana, P. . . . . . . . . . . . . . . . . . . . . . C2-1217, 157

Casapao, A. M. . . . . . . . . .K-275, 024; K-906, 104; . . . . . . . .K-909, 104; K-946, 106; K-1123, 129; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1985, 244

Ceron, I. . . . . . . . . . . . . . . . . . . . . . . . . K-944, 106

Casadei, G. . . . . . . . . . . . . . . . . . . . . . F-1536, 177

Casari, E. . . . . . . . . . . . . . C2-094, 008; D-159, 011 Casper, C. . . . . . . . . . . . . . . . . . . . . . . . T-353, 029 Caseris, M. . . . . . . . . . . . . . . . . . . . . . V-1073, 117 Cass, R. . . . . . . . . . . . . . . A-042, 004; B-1302, 164 Cassidy, K. . . . . F-843, 099; F-844, 099; F-845, 099 Castagnola, E. . . . . . . . . . . . . . . . . . . . D-1426, 171 Castañeda, X.. . . . . . . . . . .A-610, 082; B-648, 084; . . . . . . . K-945, 106; K-1122, 129; E-1465, 173 Castanheira, M. . . . . . . . . E-189, 015; M-330, 028; . . . . . . . C1-594, 081; C2-691, 087; F-855, 099; . . . . . . .F-856, 099; M-1714, 191; A-1929, 240 Castaño, I. . . . . . . . . . . . . . . . . . . . . . .M-1668, 190 Castel, A. D. . . . . . . . . . . . . . . . . . . . . . H-213, 017 Castellano, A. . . . . . . . . F-2018, 247; F-2020, 247; . . . . . . . . . . . . . . . . . .F-2024, 247; F-2025, 247 Castells, L. . . . . . . . . . . . . . . . . . . . . . . . T-368, 029 Castelo, L. . . . . . . . . . . . . . K-941, 106; K-943, 106 Castillo, J. A. . . . . . . . . . . . . . . . . . . . . H-1573, 180 Castro, A. F.. . . . . . . . . . . . . . . . . . . . . C2-704, 088 Castro, H. C. . . . . . . . . . . . . . . . . . . . . F-1513, 176 Catalan, J. C. . . . . . . . . . . . . . . . . . . . . C1-067, 006 Catalán, P. . . . . . . . . . . . . . . . . . . . . . . V-1242, 160 Cattamanchi, A. . . . . . . . . . . . . . . . . . . . . 530, 068 Cattelan, C. . . . . . . . . . . . . . . . . . . . . . . K-250, 022 Cattoir, V. . . . . . . . . . . . . B-660, 084; D-1441, 171 Cauchon, E.. . . . . . . . . . . . . . . . . . . . . . H-551, 073 Caughlan, R. E. . . . . . . . . . . . . . . . . . C1-1973, 242 Caumes, E. . . . . . . . . . . . . . . . . 402, 033; 493, 058 Cavalcante, F. S. . . . . C2-1387, 169; D-1428, 171; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1907, 237 Cavassini, M. . . . . . . . . . .D-184, 014; H-1566, 179 Cavedon, L. . . . . . . . . . . . . . . . . . . . . . .M-315, 028 Cavusoglu, C. . . . . . . . . . . . . . . . . . . C2-1367, 168 Cayô, R.. . . . . . . . . . . . . D-731, 090; C1-1207, 156 Cazanave, C. . . . . . . . . . . . . . . . . . . . . K-2074, 250 Ceccoli, C. . . . . . . . . . . . . . . . . . . . . . G3-1552, 178 Cederberg, L. E. . . . . . . . . . . . . . . . . . V-1241, 160 Celetti, S. J. . . . . . . . . . . . . . . . . . . . . . K-1927, 239

214

Cerqueiro, C. . . . . . . . . . . . . . . . . . . . G3-1552, 178 Cervera, C. . . . . . . . . . . . .A-610, 082; B-648, 084; . . . . . . .K-945, 106; K-1122, 129;E-1465, 173; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1228, 159 Cervera, T. . . . . . . . . . . . . . . . . . . . . . . . K-263, 023 Cesaro, S.. . . . . . . . . . . . . . . . . . . . . . .M-1234, 159 Cetron, M.. . . . . . . . . . . . . . . . . . . . . . . . 1822, 211 Cevenini, R.. . . . . . . . . . . . . . . . . . . . . . E-207, 016 Ceyhan, M. . . . . . . . . . . L1-964, 110; A-1941, 240 Chachaty, E. . . . . . . . . . . D-772, 092; K-911, 104; . . . . . . . . . . . . . . . . . A-1963, 241; F-2003, 246 Chacon Vargas, K. F. . . . . . . . . . . . . . . . F-833, 098 Chae, J. . . . . . . . . . . . . . . . . . . . . . . . . F-2060, 249 Chae, M. . . . . . . . . . . . . . . . . . . . . . . C2-1913, 237 Chaftari, A. . . . . . . . . . . F-2012, 246; F-2013, 246; . . . . . . . . . . . . . . . . . F-2014, 246; K-2096, 252 Chagnon, F. . . . . . . . . . . . . . . . . . . . . . F-1997, 246 Chaia, J. . . . . . . . . . . . . . . . . . . . . . . . . T-1044, 113 Chaili, S. . . . . . . . . . . . . . . . . . . . . . . . . G-868, 101 Chainier, D. . . . . . . . . . . . . . . . . . . . . . D-1408, 170 Chaiprasert, A. . . . . . . . . . . . . . . . . . . .M-336, 028 Chaisson, R. E. . . . . . . . . . . . . . . . . . . . . 1109, 126 Chaiwarith, R. . . . . . . . . . . . . . . . . . . . D-1406, 170 Chakrabarti, A. . . . . . . . . . . M-332, 028; 1116, 128 Chakrakodi, B. . . . . . . . . . . . . . . . . . . B-1315, 165 Chalana, I. K. . . . . . . . . . . . . . . . . . . . . K-902, 104 Chambers, H. F. . . . . . . . . B-1735, 196; 1111, 127; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1867, 228 Chambers, R. M. . . . . . . . K-240, 020; K-1629, 185 Chamilos, G. . . . . . . . . . . . . . . . . . . . .M-1679, 190 Chamon, R. . . . . . . . .C2-1383, 169; C2-1387, 169; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1907, 237 Champagne, J. . . . . . . . . . . . . . . . . . . C2-1986, 244 Champagne, S. . . . . . . . . D-161, 011; K-1593, 182 Champlin, R. . . . . . . . . . . . . . . . . . . . . . T-356, 029 Chan, A. H. . . . . . . . . . . . . . . . . . . . . . F-1534, 177 Chan, C. Y. . . . . . . . . . . . . . . . . . . . . . E-1992, 245 Chan, E. L. . . . . . . . . . . . . . . . . . . . . . D-1424, 171 Chan, E. W. . . . . . . . . . . . . . . . . . . . . F-2071, 249 Chan, F. . . . . . . . . . . . . . . . . . . . . . . . . E-1480, 174

September 9-12 |

Author

Presentation Number

Chan, J. . . . . . . . . . . . . . . . . . . . . . . . . . . 1172, 148 Chan, M. . . . . . . . . . . . . . . . . . . . . . . . . A-614, 082 Chan, P. . . . . . . . . . . . . . . A-616, 082; A-1247, 161 Chan-Hui, P. . . . . . . . . . . . . . . . . . . . . . G-873, 101 Chan-Tompkins, N. H. . . . . . . . . . . . . . A-619, 082 Chanda, P. . . . . . . . . . . . . . . . . . . . . . . E-1478, 174 Chandorkar, G. . . . . . . . . . . . . . . . . . . . A-641, 083 Chandra, J.. . . . . . . . . . . . . . . . . . . . . . F-2015, 246 Chandra, K. . . . . . . . . . . . K-236, 020; K-1618, 184 Chandran, A. U. . . . . . . . . . . . . . . . . . . K-561, 074 Chang, I. . . . . . . . . . . . . . . . . . . . . . . . A-1247, 161 Chang, K. T. . . . . . . . . . . . . . . . . . . . . D-1450, 172 Chang, P. . . . . . . . . . . . . B-1307, 164; A-1935, 240 Chang, S. . . . . . . . . . . . . C2-097, 008; H-215, 018; . . . . . . . . H-218, 018; H-221, 019; H-226, 019; . . . . . . K-270, 024; H-1578, 180; L1-1654, 188 Chang, S. C. . . . . . . . . . . K-266, 023; K-1607, 183 Chang, S. . . . . . . . . . . . . . H-215, 018; H-218, 018; . . . . . . . L2-309, 027; G-867, 100; V-1238, 160; . . . . . .A-1251, 161; D-1422, 170; H-1578, 180 Chang, Y.. . . . . . . . . . . . . . . . . . . . . . . F-1501, 176 Chang, Y. H. . . . . . . . . . . . . . . . . . . . . T-1032, 113 Chang, Y.. . . . . . . . . . . . . . . . . . . . . . . . . . 426, 038 Changkaew, K.. . . . . . . . . . . . . . . . . . . C2-712, 088 Chantrenne, M. . . . . . . . . . . . . . . . . . . D-1413, 170 Chaparro, C. . . . . . . . . . . . . . . . . . . . . T-1067, 116 Chapman, A. L.. . . . . . . . . . . . . . . . . . L1-287, 025 Chapman, B. A.. . . . . . . . P-994, 112; D-1425, 171 Chappey, C. . . . . . . . . . . . . . . . . . . . . . A-1245, 161 Chapplain, J. . . . . . . . . . . . . . . . . . . . . . K-267, 023 Chapuis, C. . . . . . . . . . . . . . . . . . . . . L1-1221, 158 Charest, H. . . . . . . . . . . . V-389, 030; H-1571, 180 Charles, P. G.. . . . . . . . . . . . . . . . . . . . . . 1882, 232 Charlier, P. . . . . . . . . . . . . . . . . . . . . . . C1-459, 047 Charoin-Pannier, A. . . . . . . . . . . . . . . A-1245, 161 Charpentier, C. . . . . . . . . . . . . . . . . . . . H-886, 102 Charpentier, E. . . . . . . . . . . . . . . . . . . . . 1785, 203 Chastre, J. . . . . . . . . . . . . . . . . . . . . . . . . 1091, 121 Chaturvedula, A. . . . . . . . . . . . . . . . . . . A-611, 082 Chau, F. . . . B-660, 084; B-1305, 164; B-1306, 164 Chaudhry, K. . . . . . . . . . . . . . . . . . . . . . K-902, 104 Chaudhry, R. . . . . . . . . . D-776, 092; C2-1982, 243 Chaussade, H. . . . . . . . . . . . . . . . . . . . . D-177, 013 Chauveaux, D. . . . . . . . . . . . . . . . . . . . K-2074, 250 Chavda, K. D. . . . . . . . . . . . . . . . . . . . C1-589, 081 Chaves, F. . . . . . . . . . . . . . . . . . . . . . . K-2093, 252 Chaves, R. . . . . . . . . . . . . . . . . . . . . . . K-2095, 252 Chayakulkeeree, M. . . . . . . . . . . . . . . . .M-976, 111 Cheatham, S. C. . . . . . . .A-017, 003; L1-282, 025; . . . . . . . . . . . . . . . . . . D-770, 092; F-1520, 177 Cheknis, A. . . . . . . . . . . . . . . . . . . . . . . E-808, 095

AUTHOR INDEX Author

Presentation Number

Chemaly, R. F. . . . . . . . . . . T-356, 029; K-934, 105; . . . . . . . . . . . . . . . . . T-1065, 116; V-1075, 117 Chen, C. . . . . . . . . . . . . . K-936, 105; F-1526, 177; . . . . F-1494, 175; C2-1903, 236; C2-1361, 167 Chen, E. . . . . . . . . . . . . G3-1550, 178; K-921, 105 Chen, H. . . . . . . . . . . . . . . . . . . . . . . . . K-243, 021 Chen, H. J. . . . . . . . . . . . . . . . . . . . . C1-1339, 166 Chen, K. . . . . . . . . . . . . . . . . . . . . . . . . B-057, 005 Chen, L. . . . . . . . . . . . .C1-589, 081; C2-692, 087; . . . . . . E-792, 094; C2-1216, 157; E-1468, 173; . . . . . . . . .K-1625, 184; T-1031, 113; 1141, 137 Chen, L. F.. . . . . . . . . . . . . . . . . . . . . . C2-117, 009 Chen, M. . . . . . . . . . . . . . B-663, 084; P-1005, 112; . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2107, 255 Chen, P. . . . . . . . . . . . . . . . . . . . . . . . . V-1238, 160 Chen, S. . . . . . . . . . . . . . . . . . . . . . . . .M-1680, 190

Author

Presentation Number

Chien-Yuan Chen . . . . . . . . . . . . . . . .M-1669, 190 Chiganer, M. L. . . . . . . . . . . . . . . . . . .M-1690, 190 Chiller, T.. . . . . . . . . . . M-1694, 190; M-1699, 191 Chilton, C. H. . . . . . . . . . . K-474, 048; K-924, 105 Chin, D. N. . . . . . . . . . . . . . . . . . . . . . F-1540, 177 Chin, T. . . . . . . . . . . . . . . . . . . . . . . . . . H-229, 019 Chindamporn, A. . . . . . . . . . . . . . . . . .M-336, 028 Ching, P. . . . . . . . . . . . . . . . . . . . . . . . . K-243, 021 Chirouze, C. . . . . . . . . . . . . . . . . . . . . . K-939, 106 Chittick, G. . . . . . . . . . . . . . . . . . . . . . . T-362, 029 Chiu, C.. . . . . . . . . . . . B-1328, 165; C2-1903, 236 Chiueh, T. . . . . . . . . . . . . . . . . . . . . . C2-1388, 169 Chlebicki, M. P. . . . . . . . . K-235, 020; K-1595, 182 Cho, J. . . . . . . . . . . . . . . . . . . . . . . . . . . D-182, 014 Cho, J. H. . . . . . . . . . . . . . . . . . . . . . . F-1489, 175

Author

Presentation Number

Christensen, J. J. . . . . . . . . . . . . . . . . . D-1444, 171 Christensen, J. . . . . . . . . . . . . . . . . . . . D-1443, 171 Christensen, T.. . . . . . . . . . . . . . . . . . . P-1005, 112 Christensen, P. . . . . . . . . . . . . . . . . . . L1-1652, 187 Christiansen, K. . . . . . . . . . . . . . . . . . . E-1475, 174 Christidou, A. . . . . . . . . . . . . . . . . . . .M-1696, 191 Chu, H. Y. . . . . . . . . . . . . . . . . . . . . . . . T-353, 029 Chu, K. . . . . . . . . . . . . . . . . . . . . . . . . P-1006, 112 Chu, V. H. . . . . . . . . . . . . . . . . . . . . . L1-1644, 186 Chuang, Y.. . . . . . . . . . . K-266, 023; D-1422, 170; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1607, 183 Chuang-Smith, O. N. . . . . . . . . . . . . . F-1517, 176 Chubilleau, C. . . . . . . . . . . . . . . . . . . . . P-996, 112

Chen, S. C. . . . . . . . . . . . . . . . . . . . . . .M-313, 028

Cho, O. . . . . . . . . . . . . . V-1074, 117; K-2079, 250

Chuck, S. K. . . . . . . . . . . . . . . . . . . . . . H-556, 073 Chukwuemeka, A. . . . . . . . . . . . . . . . . . K-260, 023 Chung, C. . . . . . . . . . . . . . . . . . . . . . . C2-089, 008

Chen, S. . . . . . . . . . . . L1-1646, 186; L1-1654, 188; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1249, 161 Chen, T. . . . . . . . . . . . . . . . . . . . . . . . . . F-810, 096 Chen, V.. . . .G-875, 101; M-982, 111; P-1013, 112 Chen, W. . . . . . . . . . . . . . . . . . . . . . . . G-1048, 114

Cho, S.. . . . . . . . . . . . . . . . F-831, 098; F-834, 098 Cho, S. Y. . . . . . . . . . . . . . . . . . . . . . . C2-137, 010

Chung, C. E. . . . . . . . . . . . . . . . . . . . . . A-017, 003 Chung, D. . . . . . . . . . . . . . . . . . . . . . . . T-361, 029

Cho, S.. . . K-1587, 181; K-1588, 181; K-1632, 185 Cho, Y. . . . . . . . . . . . . . . K-908, 104; H-1582, 180 Choe, W. . . . . . . . . . . . . . . . . . . . . . . . F-2060, 249

Chung, D. R. . . . . . . . .C2-137, 010; C2-1366, 167; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1899, 236

Chen, X. Y. . . . . . . . . . . . . . . . . . . . . . F-1500, 176 Chen, Y.. . . . . . . . . . . . . .C2-097, 008; K-270, 024; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1251, 161 Chen, Y. C. . . . . . . . . . . . .K-266, 023; A-640, 083; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1607, 183 Chen, Z. . . . . . . . . . . .C1-1203, 156; A-1283, 162; . . . . . .F-2017, 247; F-2018, 247; F-2018a, 247; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2024, 247 Cheng, A. C. . . . . . . . . . . . K-558, 074; K-952, 108 Cheng, A. . . . . . . . . . . . . K-266, 023; K-1607, 183 Cheng, L. . . . . . . . . . . . . . . . . . . . . . . B-1737, 196 Cheng, S. . . E-792, 094; M-978, 111; M-1056, 115 Cheng, Y.. . . . . . . . . . . . . . . . . . . . . . . . K-936, 105 Chenoweth, E.. . . . . . . . . . . . . . . . . . . . K-926, 105 Cheong, H. . . . . . . . . . . . . . . . . . . . . . . G-872, 101 Cheret, A. . . . . . . . . . . . . . . . . . . . . . . H-1568, 179 Chernov, Y. . . . . . . . . C2-1386, 169; C2-1911, 237 Cherot, J. . . . . . . . . . . . . . . . . . . . . . . . . T-363, 029 Chervin, A. S. . . . . . . . . . . . . . . . . . . . F-1517, 176 Chesneau, O. . . . . . . . . . . . . . . . . . . . C1-1349, 166 Chesnel, L. . . . . . . . . . . . . E-807, 095; F-843, 099; . . . . . . . . . . . . . . . . . . . .F-844, 099; F-845, 099 Chesson, M. . . . . . . . . . . . . . . . . . . . . . A-611, 082 Chi, S. . . . . . . . . . . . . . . . . . . . . . . . . L1-1656, 188 Chiba, M. . . . . . . . . . . . F-2037, 248; F-2038, 248; . . . . . . F-2039, 248; F-2040, 248; F-2044, 248; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2045, 248 Chiba, N. . . . . . . . . . .C2-1353, 167; C2-1354, 167; . . .C2-1990, 244; C2-1991, 244; C2-1977, 243; Chidiac, C. . . . . . . . . . . . . K-249, 022; K-253, 022 Chien, K. . . . . . . . . . . . . . . . . . . . . . . . B-1328, 165

Choi, D.. . . . . . . . . . . . . . . . . . . . . . . . L1-294, 026 Choi, E. . . . . . . . . . . . . . .D-182, 014; B-1309, 165; . . . . . . . . . . . . . . . C2-1975, 243; C2-1978, 243 Choi, J. . . . . . . . . . . . . . . . . . . . . . . . . K-1632, 185 Choi, J. Y. . . . . . . . . . . . . . . . . . . . . . C2-1899, 236 Choi, J. . . . . . . . . . . . . . . H-230, 019; K-916, 104; . . . . . . . . . . . . . . . . . H-1582, 180; K-1632, 185 Choi, S. . . . . T-366, 029; D-739, 091; D-741, 091; . . . . . . . . F-830, 098; K-907, 104; V-1074, 117; . . . . . . V-1239, 160; K-1632, 185; K-2092, 252 Choi, W. . . . . . . . . . . . . . . . . . . . . . . . . G-872, 101 Choi, Y. . . . . . . . . . . . . . . . . . . . . . . . . . K-908, 104 Chong, L. . . . . . . . . . . . . . . . . . . . . . . B-1307, 164 Chong, P. . . . . . . . . . . . . . . . . . . . . . . . .M-990, 111 Chong, Y. . K-907, 104; V-1239, 160; K-2092, 252 Choong, K. . . . . . . . . . . . . . . . . . . . . . L2-307, 027 Chopra, K. . . . . . . . . . . . . . . . . . . . . . . . T-364, 029 Chopra, T. . . . . . . . . . . . . C2-096, 008; K-902, 104 Choquet, C. . . . . . . . . . . . . . . . . . . . . . V-1073, 117 Chotikanatis, K.. . . . . . . . . . . . . . . . . . . E-206, 016 Chou, S.. . . . . . . . . . . . . . . . . . . . . . . . . . 1894, 235 Choudhury, R. . . . . . . . . . . . . . . . . . . . D-1437, 171 Choulaki, C. . . . . . . . . . . . . . . . . . . . . . B-043, 005 Chow, D. S. . . . . . . . . . . . . . . . . . . . . . . A-025, 004 Chow, H. . . . . . . . . . . . . . . . . . . . . . . . . B-053, 005 Chow, J. K. . . . . . . . . . . . . . . . . . . . . . T-1025, 113 Chowdury, P. . . . . . . . . . . . . . . . . . . . . F-1529, 177 Chraiti, M. . . . . . . . . . . . . . . . . . . . . . . K-914, 104 Chrenkova, V. . . . . . . . . . . . . . . . . . . . . T-344, 029

Chung, D. . . . . . . . . . . . K-1587, 181; K-1588, 181 Chung, J. . . . . . . . . . . . . . . . . . . . . . . C2-1215, 157 Chung, K. . . . . . . . . . . . . . . . . . . . . . L2-2112, 255 Chung, P. . . . . . . . . . . . . . . . . . . . . . . . K-1634, 185 Chung, R. T. . . . . . . . . . . . . . . . . . . . . . V-377, 030 Chung, T.. . . . . . . . . . . . . K-277, 024; K-2078, 250 Chuong, C. . . . . . . . . . . . . .F-845, 099; F-846, 099 Church, D.. . . . . . . . . . . . . . 496, 060; D-1448, 172 Church, D. L. . . . . . . . . . . . . . . . . . . . K-1756, 199 Churproong, S. . . . . . . . . . . . . . . . . . . . P-999, 112 Chuvala, L. . . . . . . . . . . B-1302, 164; B-1304, 164 Cianci, J. . . . . . . . . . . . . . . . . . . . . . . . . F-828, 097 Cianciminio-Bordelon, D.. . . . . . . . . . D-1442, 171 Ciccaglioni, A. . . . . . . . . . . . . . . . . . . . . D-165, 012 Ciesielczuk, H. . . . . . . . . . . . . . . . . . . C2-102, 009 Cieslak, P. R. . . . . . . . . . . . . . . . . . . . . . T-345, 029 Cihlar, T. . . . . . . . . . . . . . . . . . . . . . . . . H-892, 103 Cimas, M. . . . . . . . . . . . . . . . . . . . . . . P-1018, 112 Cinotti, R. . . . . . . . . . . . . B-054, 005; B-1335, 165 Ciobanca, P. T. . . . . . . . . . . . . . . . . . . . P-1008, 112 Cirz, R. . . . . A-041, 004; A-042, 004; B-1302, 164 Cisnal, M. . . . . . . . . . . . C2-690, 087; T-1045, 113 Cisneros, J. M. . . . . . . . . . . . . . . . . . . . K-1924, 239 Cisneros, J.. . . . . . . . . . . . . . . . . . . . . . . T-340, 029 Citron, D. M. . . . . . . . . . . . . . . . . . . . . F-854, 099 Ciullo, I. . . . . . . . . . . . . . . . . . . . . . . . . E-796, 094 Clancy, C. . . . . . . . . . . . . . T-348, 029; T-364, 029; . . . . . . . E-792, 094; M-978, 111; T-1031, 113; . . . . . T-1037, 113; M-1056, 115; T-1069, 116; . . . . . . . . . . . . . . . .C2-1216, 157; M-1685, 190

Christensen, C. . . . . . . . . . . . . . . . . . . . K-915, 104

Final Program

215


Presentation Number

Clancy, C. J. . . . . . . . . . . . . T-346, 029; E-786, 094; . . . . . . . E-804, 094; K-1605, 183; K-1622, 184; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1675, 190 Clark, A. . . . . . . . . . . . . . . . . . . . . . . .M-1061, 115 Clark, C. L. . . . . . . . . . . . . . . . . . . . . C1-1971, 242 Clark, K. . . . . . . . . . . . . . . . . . . . . . . . A-1286, 162 Clark, R. . . . . . . . . . . . . . H-228, 019; F-1526, 177 Clarke, L. G. . . . . . . . . . . . . . . . . . . . . K-1622, 184 Clausen, L. N. . . . . . . . . . . . . . . . . . . . . G-876, 101 Clavel, M. . . . . . . . . . . . . . . . . . . . . . C1-1739, 197 Cleary, J. D. . . . . . . . . . . . M-968, 111; M-991, 111 Clemente, W. T. . . . . . . . . . . . . . . . . . K-1606, 183 Clemons, K. V. . . . . . . . . G-875, 101; M-982, 111; . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1013, 112 Clerc, O. . . . . . . . . . . . . . . . . . . . . . . . H-1566, 179 Clifford, R. . . . . . . . . . . . . . . . . . . . . . C2-725, 089 Climax, J. . . . . . . . . . . . . . . . . . . . . . . . F-2009, 246 Clinch, B. . . . . . . . . . . . . . . . . . . . . . . A-1245, 161 Clubb, R. T. . . . . . . . . . . . . . . . . . . . . . F-1534, 177 Cnops, L.. . . . . . . . . . . . . . . . . . . . . . . P-1014, 112 Coakley, P. . . . . . . . . . . . . . . . . . . . . . . C2-692, 087 Coate, B. . . . . . . . . . . . . . . . . . . . . . . . . H-880, 102 Cobb, B. . . . . . . . . . . . . . .T-355, 029; T-1070, 116 Cobo, J. . . . . . . . . . . . . . M-323, 028; M-1700, 191 Cobos, N. . . . . . . . . . . . . . . . . . . . . . . C1-075, 006 Cockerill, F. R. . . . . . . . . . . . . . . . . . . . . . 006, 002 Coelho, C. . . . . . . . . . . . . . . . . . . . . . C1-1740, 197 Coen, P. . . . . . . . . . . . . . . . . . . . . . . . . . D-160, 011 Coetzer, C. T. . . . . . . . . . . . . . . . . . . . P-1021, 112 Coggle, S. V. . . . . . . . . . . . . . . . . . . . . L1-288, 025 Cohen, C. . . . . . . . . . . . . . . . . . . . . . . . H-211, 017 Cohen, H. . . . . . . . . . . . . . . . . . . . . . . L1-962, 110 Cohen, N. D. . . . . . . . . . . . . . . . . . . . C1-1348, 166 Cohen, R. . . . . . . . . . . . .G-864, 100; G-1049, 114 Colafigli, G. . . . . . . . . . . . . . . . . . . . . . . K-898, 104 Colbers, A.. . . . . . . . . . . . . . . . . . . . . . A-1928, 240 Cole, J. . . . . . . . . . . . . . . . . . . . . . . . . . . H-883, 102 Coll, P. . . . . . . . . . . . . . . . . . . . . . . . . . . K-256, 022 Collier, A. C. . . . . . . . . . . . . . . . . . . . . . . 1779, 202 Collins, A. R.. . . . . . . . . . . . . . . . . . . . . B-059, 005 Collins, C. . . . . . . . . . . . . . . . . . . . . . . C2-088, 008 Collins, I. . . . . . . . . . . . . . . . . . . . . . . . F-2016, 247 Collins, R. . . . . . . . . . . . . . . . . . . . . . . . D-771, 092 Colmenero, J. . . . . . . . . . . . . . . . . . . . L1-2102, 254 Colombian Nosocomial Resistance Study Group, . . . . . . . . . . . . . . . . . . C2-694, 087; D-747, 092 Colombo, A. . . . . . . . . . . . . . . . . . . . . T-1035, 113 Colomer, M. . . . . . . . . . . . . . . . . . . . . D-1419, 170 Comer, G. . . . . . . . . . . . . . . . . . . . . . . . . . 492, 057 COMIC Study Group-PROMULGA . . . . . . . . . . . . . . . . M-1232, 159; M-1684, 190

216

Author

Presentation Number

Commons, R. . . . . . . . . . . . . . . . . . . . B-1313, 165 Comolli, J. . . . . . . . . . . . . . . . . . . . . . .M-1060, 115 Compson, J. . . . . . . . . . . . . . . . . . . . . . B-1738, 196 COMRSA Pilot Group. . . . . . . . . . . C2-1380, 169

Author

Presentation Number

Cortet, B.. . . . . . . . . . . . . . . . . . . . . . . . H-231, 019 Corvec, S. . . . . . . . . . . . .C2-080, 007; K-255, 022; . . . . . . . . . . . . . . . . B-1318, 165; C1-1342, 166 Cosgrove, S. E. . . . . . . . . . . . . . . . . . . . K-275, 024

Concha, A. . . . . . . . . . . . . . . . . . . . . . H-1921, 238 Condon, L. M. . . . . . . . . . . . . . . . . . . V-1241, 160

Cosson, P. . . . . . . . . . . . . . . . . . . . . . . B-1333, 165

Conen, A. . . . . . . . . . . . . . . . . . . . . . . C2-082, 007 Conery, A. . . . . . . . . . . . . . . . . . . . . . . F-1538, 177 Confreda, K. L. . . . . . . . . . . . . . . . . . . . E-790, 094

Costa, T. M.. . . . . . . . . . . . . . . . . . . . C2-1377, 169 Coste, J. . . . . . . . . . . . . . . . . . . . . . . . . F-1488, 175

Conklin, B. C. . . . . . . . . . . . . . . . . . . . C1-073, 006 Conly, J. . . . . . . . . . . . . . . 1084, 118; C2-1380, 169 Consolo, S. . . . . . . . . . . . . . . . . . . . . G3-1549, 178 Constantea, N.. . . . . . . . . . . . . . . . . . . P-1008, 112 Conte, U. . . . . . . . . . . .M-1229, 159; M-1683, 190; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1709, 191 Conte, V. . . . . . . . . . . . . . . . . . . . . . . C2-1211, 157 Converse, P. . . . . . . . . . . . . . . . . . . . . . B-1296, 164 Conville, P. S.. . . . . . . . . . . . . . . . . . . . . . . 1858, 22 Conway, B. . . . . . . . . . . . . V-371, 030; H-884, 102 Cook, A. M. . . . . . . . . . . . . . . . . . . . . L1-286, 025 Cook, J. L. . . . . . . . . . . . . . . . . . . . . . . F-2072, 249 Coombs, G. . . . . . . . . . . . . . . . . . . . . C2-1908, 237 Coon, R. . . . . . . . . . . . . . . . . . . . . . . . . V-383, 030 Cooper, D. . . . . . . . . . . . . . . . . . . . . . . . . . 575, 077 Cooper, B. S. . . . . . . . . . . . . . . . . . . . . . . . 571, 076 Cooper, C. B.. . . . . . . . . . . . . . . . . . . . . F-838, 098 Cooper, J. T. . . . . . . . . . . . . . . . . . . . . . T-1025, 113 Cooper, M. A. . . . . . . . C1-062, 006; C1-1743, 197 Corbeil, J.. . . . . . . . . . . . . . . . . . . . . . G3-1541, 178 Corbin, V. . . . . . . . . . . . . . . . . . . . . . . . P-566, 075 Cordero, E. . . . . . . . . . . . . . . . . . . . . . K-1924, 239 Córdoba, S. . . . . . . . . . . . . . . . . . . . . . .M-327, 028 Córdova, L. . . . . . . . . . . . . . . . . . . . . .M-1684, 190 Corey, K. E. . . . . . . . . . . . . . . . . . . . . . . V-377, 030 Corey, L. . . . . . . . . . . . . . . . . . . . . . . . . . 1830, 213 Corkrey, H. . . . . . . . . . . . . . . . . . . . . . . F-846, 099 Cormican, M. . . . . . . . .C2-088, 008; C2-119, 009; . . . . . . . . . . . . . . . . . C2-122, 009; C2-706, 088 Cornejo, P. . . . . . . . . . . . . . . . . . . . . . . C1-067, 006 Cornejo, T. . . . . . . . . . . . . . . . . . . . . . . . K-931, 105 Cornell, K. . . . . . . . . . . . . . . . . . . . . . . P-1019, 112 Cornely, O. A. . . . . . . . .M-338, 028; M-1230, 159; . . . . . M-1234, 159; M-1706, 191; A-1934, 240 Cornet, M.. . . . . . . . . . . . . . . . . . . . . . .M-983, 111 Corrah, T. . . . . . . . . . . . . . . . . . . . . . . L1-288, 025 Corrard, F. . . . . . . . . . . . . . . . . . . . . . . G-1049, 114 Correa, A. . . . . . . . . . . . C2-694, 087; D-747, 092; . . . . . . . . . . . . . . . . . K-903, 104; L2-2108, 255 Corrigan, M. . . . . . . . . . . . . . . . . . . . . F-1493, 175 Corso, A. . . . . . . . . . . . .C2-084, 008; C2-701, 087; . . . . . . D-746, 092; D-759, 092; C2-1217, 157; . . . . . . . . . . . . . . . . F-1491, 175; C2-1910, 237;

September 9-12 |

Costa, G. . . . . . . . . . . . . . . . . . . . . . . . T-1031, 113

Cotellon, G.. . . . . . . . . . . . . . . . . . . . . D-1453, 172 Cottagnoud, M. . . . . . . . . . . . . . . . . . . . B-649, 084 Cottagnoud, P. . . . . . . . . . . . . . . . . . . . . B-649, 084 Cottalorda, J. . . . . . . . . . . . . . . . . . . . . A-1253, 161 Cottell, J. L. . . . . . . . . . . . . . . . . . . . . . C2-710, 088 Cotton, F. . . . . . . . . . . . . . . . . . . . . . . . A-637, 083 Cotton, G. C. . . . . . . . . . . . . . . . . . . . F-2001, 246 Cottreau, J. M.. . . . . . . . . . . . . . . . . . . . K-901, 104 Couet, W. . . . . . . . . . . . . .A-033, 004; A-036, 004; . . . . . . . . . . . A-035, 004; A-037, 004; 502, 061 Couffignal, C. . . . . . . . . . . . . . . . . . . . . A-021, 003 Coughlan, D. . . . . . . . . . . . . . . . . . . . . F-2009, 246 Couillard, M. . . . . . . . . . . . . . . . . . . . . H-1571, 180 Coulange, L. . . . . . . . . . C2-091, 008; C2-719, 089 Courvalin, P. . . . . . . . . .C1-458, 047; C1-676, 086; . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1344, 166 Couture, C. . . . . . . . . . . . . . . . . . . . . . . V-399, 030 Couzigou, C. . . . . . . . . . . . . . . . . . . . . . K-234, 020 Cowling, B. J. . . . . . . . . . . . . . . . . . . . . . 1805, 208 Cox, M. M. . . . . . . . . . . . . . . . . . . . . . G-1053, 114 Coyle, C. M. . . . . . . . . . . . . . .406, 033; 1085a, 199 Coyle, J. R.. . . . . . . . . . . . . . . . . . . . . . . D-750, 092 Coyne, P. . . . . . . . . . . . . . . . . .1823, 211; 493a, 058 Craig, W. . . . . . . . . . . . . .F-857, 099; D-1431, 171; . . . . . . . . . . . . . . . . . A-1947, 241; A-1961, 241 Craigo, J. K. . . . . . . . . . . .F-1490, 175; F-2061, 249 Crandon, J. L. . . . . . . . . . .A-013, 003; A-014, 003; . . A-015, 003; A-625, 083; A-630, 083; A-633, 083 Crank, C. W. . . . . . . . . . . . K-275, 024; K-278, 024 Crarey, E.. . . . . . . . . . . . . . . . . . . . . . . C2-714, 088 Crauwels, H. . . . . . . . . . . . . . . . . . . . . A-1249, 161 Creech, C. B. . . . . . . . . . . . . . . . . . . . . . . . 490, 056 Creely, D.. . . . . . . . . . . . . . . . . . . . . . . . E-197, 015 Cremers, S. . . . . . . . . . . . . . . . . . . . . . . A-026, 004 Cremet, L. . . . . . . . . . . . . . . . . . . . . . . C2-080, 007 Crémieux, A. . . . . . . . . . . . . . . . . . . . . . B-645, 084 Cremona, A. R. . . . . . . . . . . . . . . . . . L1-1637, 186 Crespo, M.. . . . . . . . . . . . . . . . . . . . . . . T-364, 029 Crist, A. E. . . . . . . . . . . . . . . . . . . . . . . E-807, 095 Cristescu, R. . . . . . . . . . . . . . . . . . . . .M-1695, 190 Crofoot, G. . . . . . . . . . . . . . . . . . . . . . . H-555, 073 Crook, D.. . . . . . . . . . . . . . . . . . . . . . . . D-160, 011 Cross, S.. . . . . . . . . . . . . . . . . . . . . . . . B-1738, 196

AUTHOR INDEX Author

Presentation Number

Crowe, S. . . . . . . . . . . . . . . . . . . . . . . . . D-736, 091 Crowe, S. R. . . . . . . . . . . . . . . . . . . . . . D-732, 091 Crowther, G. . . . . . . . . . . . B-662, 084; K-924, 105 Cruciani, M. . . . . . . . . . .H-216, 018; H-1579, 180 Cruz, C. . . . . . . . . . . . . . . . . . . . . . . . . P-1012, 112 Cruzado, J. . . . . . . . . . . . . . . . . . . . . . . T-1030, 113 Cubero, M. . . . . . . . . . . . . . . . . . . . . . C2-690, 087

Author

Presentation Number

Daleno, C. . . . . . . . . . . . . . . . . . . . . . G3-1549, 178 Dalla-Costa, L. M. . . . C2-087, 008; C1-1207, 156 Dalle, D. . . . . . . . . . . . . . . . . . . . . . . . . K-272, 024 Dalle, J. . . . . . . . . . . . . . . T-363, 029; D-1778, 201 Dallow, J. . . . . E-204, 016; E-210, 016; D-769, 092 Damiani, C. . . . . . . . . . . . . . . . . . . . . . .M-333, 028 Damico, P. . . . . . . . . . . . . . . . . . . . . . C2-1398, 169

Cuellar, M. . . . . . . . . . . . . . . . . . . . . .M-1668, 190 Cuenca-Estrella, M. . . . .M-321, 028; M-327, 028; . . . . . . . . . . . . . . . . . . . . . . . . . . . M-1718, 191

Damond, F. . . . . . . . . . . . . . . . . . . . . . . H-886, 102 Dangel, M. . . . . . . . . . . . . . . . . . . . . . . D-167, 012

Cuervo, G. . . . . . . . . . . . . . . . . . . . . . . .M-329, 028

Daniels, K. R. . . . . . . . . . . . . . . . . . . . L1-297, 026

Cuevas, O. . . . . . . . . . . . . . . . . . . . . . . C2-130, 010 Cuhaci, B. . . . . . . . . . . . . . . . . . . . . . . . A-618, 082

Danish Fungaemia Study Group . . . . . .M-318, 028 Dannaoui, E. . . . . . . . . . . . . . . . . . . . .M-1707, 191

Cui, S. . . . . . . . . . . . . . . . . . . . . . . . . . . K-933, 105

Dannemann, B. . . . . . . .A-1258, 161; A-1259, 161; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1260, 161 Dantas, G. . . . . . . . . . . . . . . . . . . . . . . . . . 432, 040 Danziger-Isakov, L. . . . . . . . . . . . . . . G3-1546, 178

Culebras, E. . . . . . . . . . . . . . . . . . . . . . . E-805, 095 Cunha-Bang, C. D. . . . . . . . . . . . . . . . T-1072, 116 Cunningham, M.. . . . . . F-1514, 176; F-2017, 247; . . . . . . . . . . . . . . . . . F-2018, 247; F-2018a, 247 Cunningham, S. . . . . . . . . . . . . . . . . . D-1774, 201 Cunnington, M. C. . . . . . . . . . . . . . . . G-1751, 198 Curello, J.. . . . . . . . . . . . . . . . . . . . . . . . D-754, 092 Curfs, I. . . . . . . . . . . . . . . . . . . . . . . . . .M-334, 028 Curiao, T.. . . . . . . . . . . . . . . . . . . . . . . . D-753, 092 Curlier, E. . . . . . . . . . . . . . . . . . . . . . . . P-566, 075 Curran, M. D. . . . . . . . . . . . . . . . . . . . D-1451, 172 Curtis, N.. . . . . . . . . . . . . . . . . . . . . . . B-1313, 165 Curto, A. . . . . . . . . . . . . . . . . . . . . . . . T-1035, 113 Curto, L. . . . . . . . . . . . . . . . . . . . . . . C1-1206, 156 Cusato, J. . . . . . . . . . . . . A-1769, 200; A-1937, 240 Custodio, J. . . . . . . . . . . . . . . . . . . . . . A-1250, 161 Cutler, C. . . . . . . . . . . . . . . . . . . . . . . . . T-354, 029 Cynamon, M. H. . . . . . . . . . . . . . . . . . E-1995, 245 Czaplewski, L. G. . . . . . . . . . . . . . . . . F-2016, 247

D D’Abramo, A. . . . . . . . . . . . . . . . . . . . . D-165, 012 D’Abrera, V. . . . . . . . . . . . . . . . . . . . . . K-265, 023 D’Avolio, A. . . . . . . . . . A-1769, 200; A-1937, 240 D’Hondt, R. E. . . . . . . . . . . . . . . . . . . . A-011, 003 Da Re, S. . . . . . . . . . . . . . . . . . . . . . . . C1-666, 085 Da Silva, C. O. . . . . . . . . . . . . . . . . . C2-1387, 169 Da Silva, G. J. . . . . . . . . C2-713, 088; P-1012, 112 Dadwal, S. . . . . . . . . . . . . . T-349, 029; T-350, 029; . . . . . . . . . . . . . . . . . . .T-351, 029; T-1039, 113 Dagan, R. . . . . . . . . . . .G-1050, 114; G-1753, 198 Dahoumane, R. . . . . . . . . . . . . . . . . . . . D-173, 013 Dailey, A. L. . . . . . . . . . .D-170, 012; D-1774, 201 Daily, J. P. . . . . . . . . . . . . . . . . . . . . . . . . 1110, 126 Dalarosa, M. G. . . . . . . . . . . . . . . . . . . . A-027, 004 Dale, G. E. . . . . . . . . . . . . . . . . . . . . . . . 1106, 125

Danieli, E. . . . . . . . . . . . . . . . . . . . . . G3-1553, 178

Dao, K. . . . . . . . . . . . . . . . . . . . . . . . . . . 1093, 122 Daoud, Z. . . . . . . . . . . . . . . . . . . . . . . K-1584, 181 Dargis, R. . . . . . . . . . . . . . . . . . . . . . . D-1444, 171 Darini, A. C. . . . . . . . . . . . . . . . . . . . . C2-086, 008 Darling, K. E. . . . . . . . . . . . . . . . . . . . . D-184, 014 Darling, K.. . . . . . . . . . . . . . . . . . . . . . H-1566, 179 Darouiche, R. O. . . . . . . . . . . . . . . . . . K-2097, 252 Das, A.. . . . . . . . . . . . . . . . . . . . . . . . L1-1664, 189 Das, B. K. . . . . . . . . . . . . . . . . . . . . . C2-1982, 243

Author

Presentation Number

Davis, S. L. . . . . . . . . . . . .K-240, 020; K-275, 024; . . . . . . . .K-909, 104; K-946, 106; K-1121, 129; . . . . . K-1123, 129; K-1629, 185; L1-1638, 186 Davis, T.. . . . . . . . . . . . . . . . . . . . . . . C2-1213, 157 Daws, G. M. . . . . . . . . . . . . . . . . . . . . . F-842, 099 Dawson, C. . . . . . . . . . . . . . . . . . . . . . H-1570, 179 Dawson, R. . . . . . . . . . . . . . . . . . . . . . A-1264, 161 Dawurung, J. . . . . . . . . . . . . . . . . . . . . G-1748, 198 Day, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . 1118, 128 Dayaram, Y. . . . . . . . . . . . . . . . . . . . . . . H-880, 102 De Alarcón, A. . . . . . . . . . . . . . . . . . . . K-938, 106 De Anda, C. . . . . . . . L1-1664, 189; L1-1665, 189 De Backer, W. . . . . . . . . . . . . . . . . . . L1-1641, 186 De Barbeyrac, B. . . . . . . . K-248, 022; K-2074, 250 De Benito, I. . . . . . . . . . . . . . . . . . . . . . D-765, 092 De Botton, S.. . . . . . . . . . . . . . . . . . . . . D-772, 092 De Broucker, T. . . . . . . . . . . . . . . . . . C2-1374, 168 De Champs, C. . . . . . . . . . . . . . . . . . . B-1306, 164 De Colsa, A. . . . . . . . . . . . . . . . . . . . G3-1563, 178 De Cueto, M. . . . . . . . . . . . . . . . . . . . C2-111, 009 De Cueto, M. . . . . . . . . . . . . . . . . . . L1-1658, 188 De Dios, S. . . . . . . . . . . . . . . . . . . . . . T-1071, 116 De Gialluly, C.. . . . . . . . . . . . . . . . . . . . D-176, 013 De Greeff, S. C.. . . . . . . . . . . . . . . . . . . D-183, 014 De Groote, M. A. . . . . . . . . . . . . . . . . . F-831, 098 De Gunzburg, J. . . . . . . . . . . . . . . . . . A-1963, 241

Das, D. . . . . . . . . . . . . . . . . . . . . . . . . A-1291, 163 Das, S. . . . . . A-1760, 200; A-634, 083; A-635, 083 Das, S. K.. . . . . . . . . . . . . . . . . . . . . . . C2-715, 088 Datla, S. . . . . . . . . . . . . . C2-096, 008; K-1589, 181

De Gunzburg, J. . . . . . . . . . . . . . . . . . F-2003, 246 De Hoog, S.. . . . . . . . . . . . . . . . . . . . . .M-338, 028

Datta, A. . . . . . . . . . . . . . . . . . . . . . . . B-1736, 196

De Knegt, G. J. . . . . . . . . B-058, 005; A-1268, 161 De la Cadena, E. . . . . . . . C2-694, 087; D-747, 092 De la Cochetière, M. . . D-1458, 172; L1-1642, 186 De la Cruz-Váldez, M. J.. . . . . . . . . . C2-1357, 167 De la Torre, F. . . . . . . . . . . . . . . . . . . . . E-805, 095

Dauchy, F. A. . . . . . . . . . . K-248, 022; K-2074, 250 Daudon, M. . . . . . . . . . . . . . . . . . . . . . . H-889, 103 Dauri, M.. . . . . . . . . . . . . . . . . . . . . . . T-1040, 113 Davenport, J. M. . . . . . . A-1961, 241; A-1962, 241 David, H. M. . . . . . . . . . . . . . . . . . . . . . G-876, 101 David, L. . . . . . . . . . . . . . . . . . . . . . . . . D-729, 090 David, M. . . . . . . . . . . . B-1337, 165; B-1338, 165 Davido, B. . . . . . . . . . . . . . . . . . . . . . . . B-645, 084 Davieau, M. . . . . . . . . . . . . E-203, 016; B-651, 084; . . . . . . . . . . . . . . . . . B-1335, 165; F-2056, 248 Davies, D. . . . . . . . . . . . . . . . . . . . . . . F-2016, 247 Davies, F. . . . . . . . . . . . . . . . . . . . . . . L1-1667, 189 Davies, K. A. . . . . . . . . . . . . . . . . . . . . . D-160, 011 Davies, T. A. . . . . . . . . . . . . . . . . . . . . C1-594, 081 Davies Sala, C.. . . . . . . . . . . . . . . . . . . F-1539, 177 Davis, A. . . . . . . . . . . . . . . . . . . . . . . L1-1659, 189 Davis, K. . . . . . . . . . . . . . . H-211, 017; E-795, 094 Davis, M. M. . . . . . . . . . . . . . . . . . . . . . . . 504, 062 Davis, N. . . . . . . . . . . . . . . . . . . . . . . . . K-902, 104 Davis, S. C. . . . . . . . . . . . . . . . . . . . . . F-1518, 176

Final Program

De Jager-Leclercq, M. G. . . . . . . . . . . L1-965, 110 De Jong, A. . . . . . . . . . . C2-705, 088; C2-709, 088

De Lamballerie, X. . . . . . . . . . . . . . . . . V-387, 030 De Las Peñas, A. . . . . . . . . . . . . . . . . .M-1668, 190 De Lastours, V. . . . . . . . . H-889, 103; H-219, 019; . . . . . . . . . . . . . . . . B-1305, 164; C2-1399, 169 De Lencastre, H. . . . . C2-1365, 167; C1-1740, 197 De Luca, C. . . . . . . . . . . . . . . . . . . . . . . D-159, 011 De Maio, W. . . . . . . . . . . . . . . . . . . . . A-1950, 241 De Marco, B. . . . . . . . . . . . . . . . . . . . . . T-357, 029 De Marez, T. . . . . . . . . .A-1258, 161; A-1259, 161; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1260, 161 De Melker, H. E.. . . . . . . . . . . . . . . . . . D-183, 014 De Moraes-Pinto, M. I. . . . . . . . . . . G3-1557, 178 De Paris, F. . . . . . . . . . . . . . . . . . . . . C2-1375, 168 De Rosa, F. G. . . . . . . . . A-1769, 200; A-1937, 240 De Salas-Cansado, M.. . . . . . . . . . . . . K-1633, 185 De Salvador-Guillouet, F. . . . . . . . . . . A-1253, 161

217


Presentation Number

Author

Presentation Number

Author

Presentation Number

De Serres, G. . . . . . . . . . . V-389, 030; V-1076, 117

Deng, J. . . . . . . . . . . . . . . . . . . . . . . . . F-2072, 249

Diebolt, E. . . . . . . . . . . . . . . . . . . . . . . . H-228, 019

De Steenwinkel, J. E.. . . . . . . . . . . . . . A-1268, 161 De Vedia, L. . . . . . . . C2-1396, 169; C2-1397, 169

Deng, L. . . . . . . . . . . . . . . . . . . . . . . . . K-926, 105 Deng, W. . . . . . . . . . . . . . . . . . . . . . . G3-1562, 178

Diekema, D. . . . . . . . . C2-126, 010; D-1433, 171; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1929, 240

De Vos, D. . . . . . . . . . . . . . . . . . . . . . . P-1014, 112

Deng, Y.. . . . . . . . . . . . . . . . . . . . . . . . F-1526, 177

Diep, B. A.. . . . . . . . . . . . B-645, 084; B-1735, 196

De Vries, M. M. . . . . . . . . . . . . . . . . . K-2086, 252 Dean, C. R. . . . . . . . . . C1-680, 086; C1-1973, 242

Denis, O. . . . . . . . . . . . . . . A-597, 082; A-598, 082 Denisuik, A. . . . . . . . . .C2-103, 009; C2-135, 010; . . . . . . . . C2-149, 010; E-194, 015; E-779, 093 Denmark, R. . . . . . . . . . . . . . . . . . . . . L1-300, 026 Denning, D.. . . . . . . . . . . . . . . . . . . . . . . . 457, 046

Dieterich, D. T. . . . . . . . . . . . . . . . . . . . . . 585, 080 Diezmann, S. . . . . . . . . . . . . . . . . . . . . . . 1870, 229

Dent, C.. . . . . . . . . . . . . . . . . . . . . . . L2-2118, 255

Dimasi, N. . . . . . . . . . . . . . . . . . . . . . . B-1734, 196 Dimopoulos, G. . . . . . . . . . . . . . . . . . . . K-951, 107

Deane, J. . . . . . . . . . . . . .A-008, 003; C2-125, 010; . . . . . . .C2-128, 010; C2-134, 010; E-208, 016; . . . . . . . . D-760, 092; D-764, 092; D-767, 092; . . . . . . . E-778, 093; E-1479, 174; F-1524, 177; . . . . . . . . . . . . . . . . . .F-2046, 248; F-2047, 248 Deb, M. . . . . . . . . . . . . . . . . . . . . . . . C2-1982, 243 Debabov, D. . . . . . . . . . . . . . . . . . . . . . F-2058, 249 Debaugnies, F. . . . . . . . . . . . . . . . . . . . D-1413, 170 DeBess, E. E.. . . . . . . . . . . . . . . . . . . . . T-345, 029 Debiais, F. . . . . . . . . . . . . . . . . . . . . . L1-2104, 254 Decker, M. D. . . . . . . . . . . . . . . . . . . . B-1322, 165 Deconinck, E. . . . . . . . . . . . . . . . . . . .M-1692, 190 Dedhia, H.. . . . . . . . . . . . . . . . . . . . . . A-1289, 163 Dediste, A.. . . . . . . . . . . T-1046, 113; D-1413, 170 Deeks, S. . . . . . . . . . . . . . . . . . . . . . . . . H-553, 073 Deenen, R.. . . . . . . . . . . . . . . . . . . . . . C1-588, 081 Dehio, C. . . . . . . . . . . . . . . . . . . . . . . . . . 1782, 203 Dehn Lunn, A. . . . . . . . . . . . . . . . . . . C2-696, 087 Dejli, J.. . . . . . . . . . . . . . . . . . . . . . . . . P-1021, 112 Dekhnich, A. . . . . . . . C2-1386, 169; C2-1911, 237 Dekkers, O. . . . . . . . . . . . . K-472, 048; K-930, 105 Del Palacio, M. . . . . . . . . . . . . . . . . . . . H-222, 019 Del Pozo, J. . . . . . . . . . . . . . . . . . . . . . K-1612, 184 Del Río, A. . . . . . . . . . . . K-945, 106; K-1122, 129 Del Toro, M. . . . . . . . . . . . . . . . . . . . L1-1658, 188 Del-Rio, A. . A-610, 082; B-648, 084; E-1465, 173 Dela Torre, J. . . . . . . . . . . . . . . . . . . . . . K-942, 106 Delabre, R. M.. . . . . . . . . . . . . . . . . . . . V-387, 030 Delaere, B. . . . . . . . . . . . . . . . . . . . . . L1-1641, 186 Delaney, A. S. . . . . . . . . . . . . . . . . . . . V-1241, 160 Delanghe, P.. . . . . . . . . . . . . . . . . . . . . K-1927, 239 Delgado, J. . . . . . . . . . . . . . . . . . . . . . . T-1071, 116 Del Gorge, C. . . . . . . . . . . . . . . . . . . . F-1523, 177 Delia, P. . . . . . . . . . . . . . . . . . . . . . . . . K-2089, 252 Dellinger, E. . . . . . . . . . . . . . . . . . . . . . . 1879, 231 Delmée, M. . . . . . . . . . . . . . . . . . . . . . . D-156, 011 Dem, P. . . . . . . . . . . . . . . . . . . . . . . . . K-1592, 181 DeMaio, W.. . . . . . . . . . . . . . . . . . . . . A-1951, 241 Demar, M. . . . . . . . . . . . . . . . . . . . . . . P-1011, 112 Demczuk, W.. . . . . . . . . . . . . . . . . . . C2-1360, 167 DeMena, A.. . . . . . . . . . . . . . . . . . . . G3-1552, 178 Demers, A. . . . . . . . . . . . . . . . . . . . . . . D-730, 090 Demeulemeester, A. . . . . . . . . . . . . . . . K-930, 105 Denamur, E. . . . . . . . . . . . . . . . . . . . . B-1305, 164 Deneer, H. . . . . . . . . . . . . . . . . . . . . . . . D-729, 090

218

Denys, G. A. . . . . . . . . C2-1213, 157; F-1524, 177; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1528, 177 Depatureaux, A.. . . . . . . . . . . . . . . . . . . H-886, 102 DePestel, D. D. . . . . . . . . . . . . . . . . . . . K-276, 024 Deprez, G. . . . . . . . . . . . . . . . . . . . . . . . A-637, 083 Desai, A. . . . . . . . . . . . . . . . . . . . . . . . A-1936, 240 Desarbre, E. . . . . . . . . . . . . . . . . . . . . . . . 1797, 206 Descy, J. . . . . . . . . . . . . . . . . . . . . . . . C2-1988, 244

DiFranco-Fisher, J. . . . . . . . . . . . . . . . . E-802, 094 DiGiandomenico, A. . . . F-1529, 177; B-1734, 196 Dilworth, T. . . . . . . . . . . . . . . . . . . . . . E-1472, 174

Dimopoulou, D. . . . . . . B-043, 005; M-1058, 115; . . . . . . . . . . . . . . . . . . . . . . . . . . . M-1696, 191 Dina, J.. . . . . . . . . . . . . . . . . . . . . . . . . . D-178, 013 Dinelli, M. I. . . . . . . . . . . . . . . . . . . . G3-1557, 178 Ding, W. . . . . . . . . . . . . . . . . . . . . . . .M-1695, 190 Dingemanse, J.. . . . . . . . . . . . . . . . . . . A-1273, 162 Dinh, A. . . . . . . . . . . . . P-566, 075; L1-2104, 254

Desessard, C. . . . . . . . . . . . E-203, 016; B-653, 084; . . . . . . B-1335, 165; A-1948, 241; F-2056, 248

Dinleyici, E. C. . . . . . . . . . . . . . . . . . .M-1671, 190 Dionne, M. . . . . . . . . . . G-1047, 114; K-1755, 199

Deshpande, L. M. . . . . .C1-594, 081; C2-691, 087; . . . . . . . . . . . . . . . C1-1343, 166; C1-1745, 197 Deslouches, B. . . . . . . . . .F-1490, 175; F-2061, 249 Dessau, R.B. . . . . . . . . . . . . . . . . . . . . D-1409, 170

Diosque, M.. . . . . . . . . . .G-874, 101; P-1015, 112; . . . . . . . . . . . . . . . . . . . . . . . . . . . . .P-1016, 112 Diot, P.. . . . . . . . . . . . . . . . . . . . . . . . . . A-036, 004 DiPersio, J.. . . . . . . . . . . . . . . . . . . . . . . D-163, 011 DiStefano, D. . . . . . . . . . . . . . . . . . . . . H-551, 073

Dessen, A. . . . . . . . . . . . . . . . . . . . . . . F-2062, 249 DeStefano, F. . . . . . . . . . . . . . . . . . . . . G-1054, 114 Dettenkofer, M. . . . . . . . . . . . . . . . . . . . . 1851, 223 DeVito, J. A. . . . . . . . . . .F-1521, 177; F-1522, 177 Dewhurst, N. F. . . . . . . . K-1590, 181; K-1591, 181 Dhanji, H. . . . . . . . . . . . . . . . . . . . . . . . F-853, 099 Dhar, S. . . . . . . . . . . . . . . . . . . . . . . . . . K-902, 104 Di Bella, A. . . . . . . . . . . . . . . . . . . . . . . D-746, 092 Di Conza, J. . . . . . . . . . .C1-466, 047; C1-678, 086; . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-700, 087 Di Conza, J. A. . . . . . . . . . . . . . . . . . . C1-669, 085 Diéguez, C. . . . . . . . . . . . . . . . . . . . . . H-1921, 238 Di Gregorio, S. . . . . . . . . . . . . . . . . . C2-1397, 169 Di Maggio, T. . . . . . . . . . . . . . . . . . . C1-1205, 156 Di Perri, G. . . . . . . . . . . A-1769, 200; A-1937, 240 Di Pilato, V. . . . . . . . . . . . . . . . . . . . . C1-1205, 156 Diacon, A. . . . . . . . . . . . A-1258, 161; A-1264, 161 Diamantino-Miranda, J. . . . . . . . . . . . . G-866, 100 Diana, M. . . . . . . . . . . . . . . . . . . . . . . D-1426, 171 Diarra, M. S. . . . . . . . . . . . . . . . . . . . C2-1986, 244 Dias, C. H. . . . . . . . . . . . . . . . . . . . . . . K-913, 104 Díaz, D. . . . . . . . . . . . . . . . . . . . . . . . . K-2091, 252 Díaz, L. . . . . . . . . . . . . . . . . . . . . . . . . H-1567, 179 Diaz, L. . . . . . . . . . . . . . . . . . . . . . . . C1-1345, 166 Díaz de Alba, P. . . . . . . . . . . . . . . . . . . C1-683, 086 DiCenzo, R. . . . . . . . . . . . . . . . . . . . . A-1252, 161 Didi, J. . . . . . . . . . . . . . . . . . . . . . . . . . B-1337, 165

September 9-12 |

Disthaporn, P. . . . . . . . . . . . . . . . . . . . E-1477, 174 Diviti, S. . . . . . . . . . . . . . . . . . . . . . . . C2-096, 008 Dixit, V. . . . . . . . . . . . . . . . . . . . . . . . . . V-373, 030 Dixon, R. A. . . . . . . . . . . . . . . . . . . . . F-2001, 246 Djamdjian, L. . . . . . . . . . . . . . . . . . . . C1-072, 006 Djikeng, A. . . . . . . . . . . . . . . . . . . . . . . H-214, 018 Djolbunova, Z.. . . . . . . . . . . . . . . . . . G3-1548, 178 Djossou, F. . . . . . . . . . . . . . . . . . . . . . . P-1011, 112 Djuidje Ngounoue, M. . . . . . . . . . . . . . H-214, 018 Doan, K. A. . . . . . . . . . . . . . . . . . . . . . T-1029, 113 Doan, T.. . . . . . . . . . . . . . . . . . . . . . . . . K-917, 105 Dobson, E. . . . . . . . . . . . . . . . . . . . . . A-1252, 161 Doco-Lecompte, T. . . . . . . . . . . . . . . . . K-939, 106 Dodd, M.. . . . . . . . . . . . . . . . . . . . . . . E-1472, 174 Doerholt, K. . . . . . . . . . . . . . . . . . . . G3-1559, 178 Doern, G. . . . . . . . . . . . . . . . . . . . . . . C2-126, 010 Dohrn, C. . . . . . . . . . . . . . . . . . . . . . . C2-126, 010 Doi, A. M. . . . . . . . . . . . . . . . . . . . . . . C2-685, 087 Doi, N. . . . . . . . . . . . . . . . . . . . . . . . . A-1254, 161 Doi, Y. . . . . . . . 001, 001; C2-112, 009; E-792, 094; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1216, 157 Doit, C. . . . . . . . . . . . . . . . . . . . . . . . . . T-363, 029 Dolande, M. . . . . . . . . . . . . . . . . . . . . .M-327, 028 Dolapci, I. . . . . . . . . . . . . . . . . . . . . . . C2-684, 087 Dole, K. . . . . . . . . . . . . . . . . . . . . . . . . A-1281, 162 Dolivet, G.. . . . . . . . . . . . . . . . . . . . . . L2-302, 027

AUTHOR INDEX Author

Presentation Number

Author

Presentation Number

Author

Presentation Number

Domenech, A. . . . . . . . . . . . . . . . . . . C2-1365, 167

Drew, R. . . . . . . . . . . . .K-1583, 181; M-1703, 191

Dutch Mica Study Group . . . . . . . . . . .M-334, 028

Domingo, J. D. . . . . . . . . . . . . . . . . . G3-1551, 178 Domingo, M.. . . . . . . . . . . . . . . . . . . . . D-751, 092

Drews, S. J. . . . . . . . . . . . . . . . . . . . . . . V-386, 030

Dutkowski, R. . . . . . . . . . . . . . . . . . . . V-1080, 117 Dutronc, H. . . . . . . . . . . . K-248, 022; K-2074, 250

Domingues, R. M.. . . . . . . . . . . . . . . . C1-671, 085

Dreyer, C. . . . . . . . . . . . . . . . . . . . . . . K-2087, 252 Dreze, P. . . . . . . . . . . . . . . . . . . . . . . . B-1312, 165

Dominguez, M. A. . . . . . . . . . . . . . . . D-1775, 201

Driver, V. . . . . . . . . . . . . . . . . . . . . . . . F-2022, 247

Duval, X. . . . . . . . . . . . . . . . . . . . . . . . . K-939, 106

Domínguez, M. . . . . . . . . . . . . . . . . . C2-1395, 169 Dominguez, W. . . . . . . . . . . . . . . . . . G3-1563, 178

Droggari, M. . . . . . . . . . . . . . . . . . . . . . K-245, 021 Dromer, F. . . . . . . . . . . . . . . . . . . . . . .M-1686, 190

Dvorak, T. . . . . . . . . . . . . . . . . . . . . . . F-2012, 246 Dwivedi, S. . . . . . . . . . . . . . . . . . . . . C2-1982, 243

Dominguez-Castellano, A. . . . . . . . . L1-1658, 188 Dominique, S. . . . . . . . . . . . . . . . . . . . .M-974, 111

Dronda, F. . . . . . . . . . . . .H-217, 018; H-1567, 179 Dropa, M. . . . . . . . . . . .C2-106, 009; C1-668, 085; . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1002, 112

Dworkin, J. . . . . . . . . . . . . . . . . . . . . . . K-233, 020 Dwyer, D. E. . . . . . . . . . . . . . . . . . . . . . . . 498, 060

Donald, L. . . . . . . . . . . . . . . . . . . . . . . A-1954, 241 Donald, R. . . . . . . . . . . . . . . . . . . . . . . . . . 575, 077 Donati, D. . . . . . . . . . . . . . . . . . . . . . . T-1035, 113 Donati, M.. . . . . . . . . . . . . . . . . . . . . . . E-207, 016 Donay, J. . . . . . . . . . . . . . . . . . . . . . . . . H-219, 019 Donnellan, M. . . . . . . . . . . . . . . . . . . . . K-469, 048 Donnelly, J. P. . . . . . . . .M-1225, 159; A-1928, 240 Donnelly, J. . . . . . . . . . . . . . . . . . . . . . . . 1887, 233 Donnio, P. . . . . . . . . . . . . . . . . . . . . . . . K-267, 023 Donskey, C. J. . . . . . . . . . . . . . . . . . . . C2-686, 087 Dooley, K. E. . . . . . . . . . . . . . . . . . . . . A-1256, 161 Dorca, J.. . . . . . . . . . . . . .D-180, 013; L1-293, 026; . . . . . . . . . . . . . . . . . L1-295, 026; L1-298, 026 Dorronzoro, A. . . . . . . . . . . . . . . . . . . . E-202, 015 Dortet, L. . . . . . . . . . . .C1-078, 006; C1-587, 081; . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1202, 156 Dos Santos, A. M. . . . . . . . . . . . . . . . G3-1557, 178 Dos Santos, K. R. . . . C2-1387, 169; D-1428, 171; . . . C2-1377, 169; C2-1383, 169; C2-1907, 237 Dotan, I. . . . . . . . . . . . . . . . . . . . . . . . . H-232, 019 Douadi, Y. . . . . . . . . . . . . . . . . . . . . . L1-2106, 254 Douglas, C. M. . . . . . . . . . . . . . . . . . . M-979, 111; . . . . . . . . . . . . . . . . . M-984, 111; M-1057, 115 Douglas, C. . . . . . . . . . M-1676, 190; M-1678, 190 Douglas, C. M. . . . . . . . . . . . . . . . . . .M-1695, 190 Doull, I. J. . . . . . . . . . . . . . . . . . . . . . . F-2064, 249 Douville-Fradet, M. . . . . . . . . . . . . . . . V-389, 030 Dovgan, E. V. . . . . . . . . . . . . . . . . . . . L1-299, 026 Dovzhenko, S. A.. . . . . . . . . . . . . . . . . A-1967, 241 Doyle, D. . . . . . . . . . . . . . . . . . . . . . . . D-1448, 172 Doyon-Reale, N. . . . . . . . . . . . . . . . . .M-1713, 191 Draffan, A. G. . . . . . . . . . . . . . . . . . . . . F-828, 097 Drancourt, M. . . . . . . . . . . . . . . . . . . . . . 1175, 149 Draper, M. P. . . . . . . . . . . . . . . . . . . . . A-1282, 162 Drawz, S. M. . . . . . . . . . . . . . . . . . . . . C1-463, 047 Dreikorn, S. . . . . . . . . . . . . . . . . . . . . . . F-810, 096 Drescher, M. . . . . . . . . . . . . . . . . . . . . . V-398, 030 Dreskin, H. . . . . . . . . . .A-1292, 163; A-1293, 163; . . . . . . . . . . . . . . . . . A-1294, 163; A-1295, 163 Dresser, L. . . . . . . . . . . . K-1590, 181; K-1591, 181 DRESSING2 Study Group, France . . K-1757, 199 Dretler, R. . . . . . . . . . . . . . . . . . . . . . . . H-882, 102

Drouot, E. . . . . . . . . . . . . . . . . . . . . . . . V-392, 030 Droz, S. . . . . . . . . . . . . . . . . . . . . . . . . C2-116, 009 Drulak, M.. . . . . . . . . . . . . . . . . . . . . . . H-877, 102 Drusano, G. . . . . . . . . . . . .A-041, 004; A-042, 004; . . . . . . . . . . . . . . . . . A-1265, 161; E-1993, 245 Drusano, G. L. . . . . . . . . A-011, 003; A-1761, 200 Duarte, L. P. . . . . . . . . . . . . . . . . . . . . K-1603, 183 Duarte, R. . . . . . . . . . . . . . . . . . . . . . . T-1045, 113 Duarte, R. F. . . . . . . . . . . . . . . . . . . . . A-1934, 240 Duarte, R. S. . . . . . . . . . . . . . . . . . . . C2-1375, 168 Dube, G. . . . . . . . . . . . . .T-1034, 113; T-1036, 113 Dubois, V. . . . . . . . . . . . . . . . . . . . . . . C2-719, 089 Dubreucq, L. . . . . . . . . . . . . . . . . . . . . T-1028, 113 Dubuque, J. . . . . . . . . . . . . . . . . . . . . . . V-389, 030 Duchene, E.. . . . . . . . . . . . . . . . . . . . . L1-283, 025 Ducrot, N. . . . . . . . . . . . . . . . . . . . . . . F-2003, 246 Dudley, M. . . . . . . . . . . . . . . . . . . . . . . . 1089, 121 Dudley, M. N. . . . . . . . . . . F-849, 099; F-850, 099; F-851, 099; F-852, 099; F-858, 099; F-848, 099 Duerken, M. . . . . . . . . . . . . . . . . . . . .M-1704, 191 Duffy, E. . . . . . . . . . . . . A-1289, 163; F-1521, 177; . . . . . . . . . . . . . . . . . .F-1522, 177; F-1523, 177 Duffy, S. . . . . . . . . . . . . . . . . . . . . . . .M-1702, 191 Dumford, D. . . . . . . . . . C2-686, 087; C2-720, 089 Dumkow, L. E. . . . . . . . . . . . . . . . . . . . K-240, 020 Dumont, E. F. . . . . . . . .A-1272, 162; A-1276, 162; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1277, 162 Dumpis, U. . . . . . . . . . . . . . . . . . . . . . K-2080, 251 Duncan, F. . . . . . . . . . . . . . . . . . . . . . . . V-371, 030 Dungl, C.. . . . . . . . . . . . . . . . . . . . . . . E-1471, 174 Dunkle, L. . . . . . . . . . . . . . . . . . . . . . . G-1053, 114 Dunne, M.. . . . . . . . . . . .C2-134, 010; K-239, 020; . . . . . . . . . . . . . . . . . . A-623, 082; E-1467, 173 Dunne, W. M. . . . . . . . . . . . . . . . . . . . . D-771, 092 Duong, A. H. . . . . . . . . . . . . . . . . . . . B-1735, 196 Dupon, M.. . . . . . . . . . . .K-248, 022; K-2074, 250; . . . . . . . . . . . . . . . L1-2103, 254; L1-2104, 254 DuPont, H. L. . . . . . . . . . . K-920, 105; K-921, 105 Dupont, H. . . . . . . . . . . . . . . . . . . . . .M-1698, 191 Durand, G. . . . . . . . . . . . .D-745, 092; D-748, 092 Durica, G. . . . . . . . . . . . . . . . . . . . . . . . A-644, 083 Durmaz, R. . . . . . . . . . . . . . . . . . . . . C2-1980, 243

Final Program

Duval, R. E.. . . . . . . . . . . . . . . . . . . . . F-1527, 177

Dyer, J.. . . . . . . . . . . . . . . . . . . . . . . . . . K-265, 023

E Ebrahimi, R. . . . . . . . . . . . . . . . . . . . . . H-556, 073 Echaniz-Aviles, G. . . . . . . . . . . . . . . C2-1356, 167 Echenagusia, A. . . . . . . . . . . . . . . . . . . . D-166, 012 Echenagusia, M. . . . . . . . . . . . . . . . . . . D-166, 012 Eckburg, P. B. . . . . . . . . . E-207, 016; D-760, 092; . . . . . . D-764, 092; A-1949, 241; A-1950, 241; . . . . . .A-1951, 241; A-1952, 241; A-1953, 241; . . . . . . A-1954, 241; A-1955, 241; F-2046, 248; . . . . . . . . . . . . . . . . . .F-2047, 248; F-2054, 248 Eckert, C. . . .K-925, 105; D-154, 011; D-157, 011 Edder, P. . . . . . . . . . . . . . . . . . . . . . . . . K-560, 074 Edelstein, M. . . . . . . . .C2-1386, 169; C2-697, 087; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1911, 237 Edlind, T. D. . . . . . . . . . . . . . . . . . . . . .M-966, 111 Edouard, S. . . . . . . . . . . L1-963, 110; P-1011, 112 Edwards, J.. . . . . . . . . . . . . . . . . . . . . . . . 1117, 128 Edwards, K. M. . . . . . . . . . . . . . 002, 001; 527, 067 Edwards, R. . . . . . . . . . . . . . . . . . . . . . B-1311, 165 Edwards, Jr. J. E. . . . . . . . G-868, 101; M-973, 111 Eells, S. J.. . . . . . . . . . . . . . B-654, 084; B-655, 084 Efstathiou, P. . . . . . . . . . . . . . . . . . . . . . K-245, 021 Egard, M. . . . . . . . . . . . . . . . . . . . . . . L1-291, 026 Egea, A. . . . . . . . . . . . . . . . . . . . . . . . C2-1910, 237 Egea, P. . . . . . . . . . . . . . . . . . . . . . . . . C2-707, 088 Eggimann, P. . . . . . . . . . . . 1115, 128; K-2088, 252 Ehninger, G. . . . . . . . . . . . . . . . . . . . . . T-356, 029 Ehricht, R.. . . . . . . . . . . . . . . . . . . . . . D-1432, 171 Ehrlenbach, S. . . . . . . . . . . . . . . . . . . . F-2058, 249 Eichenseher, F.. . . . . . . . . . . . . . . . . . . F-1516, 176 Eitzinger, C. . . . . . . . . . . . . . . . . . . . . F-2058, 249 Eko, F. O. . . . . . . . . . . . . . . . . . . . . . . E-1994, 245 Ektare, V. . . . . . . . . . . . . . . . . . . . . . . . . K-239, 020 El Garch, F. . . . . . . . . . . C2-705, 088; C2-709, 088 El Lakkis, I. . . . . . . . . . . . . . . . . . . . . . L1-284, 025 El Meouche, I.. . . . . . . . . . . . . . . . . . . B-1337, 165 El-Imad, B. . . . . . . . . . . . . . . . . . . . . . . F-841, 099 El-Mahdy, T. S. . . . . . . . . . . . . . . . . . . C1-077, 006 El-Moamly, A. . . . . . . . . . . . . . . . . . . . V-378, 030 El-Samad, V. . . . . . . . . . . . . . . . . . . . L1-2106, 254

219


Presentation Number

Elagin, S. . . . . . . . . . . . . . . . . . . . . . . . D-1414, 170

Author

Presentation Number

Esposito, S. . . . . . . . . .L2-304, 027; G3-1549, 178; . . . . . . . . . . . . . . .G3-1551, 178; G3-1553, 178

Author

Presentation Number

Fantin, B.. . . . . 433, 040; B-660, 084; B-1305, 164; . . . . . B-1306, 164; C2-1399, 169; K-2087, 252 Farah, R. . . . . . . . . . . . . . . . . . . . . . . . . D-732, 091

Elders, P. J.. . . . . . . . . . . . . . . . . . . . . . C2-104, 009 Elefanti, A. . . . . . . . . . . .E-782, 093; A-1938, 240; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1939, 240

Esteban Moreno, J. . . . . . . . . . . . . . . . L1-958, 109 Esterly, J. . . . . . . . . . . . . . . . . . . . . . . . . K-271, 024

Eley, T. . . . . . . . . . . . . . . . . . . . . . . . . . A-1247, 161

Estes, R.. . . . . . . . . . . . . . . . . . . . . . . . K-2085, 252

Elie, C. . . . . . . . . . . . . M-1686, 190; M-1707, 191 Eliopoulos, G. M. . . . . . . . . . . . . . . . . . . 1194, 154

Etienne, J. . . . . . . . . . . . . . . . . . . . . . . B-1317, 165 Etienne, M. . . . . . . . . . . B-1337, 165; B-1338, 165

Ellery, C. . . . . . . . . . . . . . . . . . . . . . . . A-1264, 161

Euba, G. . . . . . . . . . . . . . . . . . . . . . . . . K-254, 022

Ellington, M. J. . . . . . . . . . . . . . . . . . . D-1451, 172

Evans, C. . . . . . . . . . . . . . . . . . . . . . . . . H-881, 102

Fariñas, M. C. . . . . . . . . D-169, 012; M-1673, 190; . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1018, 112

Elmali, F. . . . . . . . . . . . . . . . . . . . . . . .M-1701, 191 Elman, M. R.. . . . . . . . . . . . . . . . . . . L2-2118, 255

Evans, M. . . . . . . . . . . . . . . . . . . . . . . H-1574, 180 Evdokimova, E. . . . . . . C1-458, 047; C1-1344, 166

Fariñas-Alvarez, C. . . . . . . . . . . . . . . . . D-169, 012 Farinati, A. E. . . . . . . . . . E-202, 015; V-1237, 160

Elsendoorn, A.. . . . . . . . . A-039, 004; L1-963, 110

Everett, M. J. . . . . . . . . . . . . . . . . . . . . A-1959, 241

Farinha, S. . . . . . . . . . . . . . . . . . . . . . . .M-320, 028

Elvers, B. . . . . . . . . . . . . . . . . . . . . . . . . D-183, 014 Emanuel, C.. . . . . . . . . . . . . . . . . . . . . F-2062, 249 Emanuela, C. . . . . . . . . . . . . . . . . . . . C2-1373, 168 Embil, J.. . . . . . . . . . . . . . . . . . . . . . . C2-1380, 169 Embree, J. . . . . . . . . . . . . . . . . . . . . . C2-1360, 167

Everitt, D. . . . . . . . . . . . . . . . . . . . . . . A-1259, 161 Ewing, C. A. . . . . . . . . . . . . . . . . . . . . K-1923, 239 Eworo, A. . . . . . . . . . . . . . . . . . . . . . . T-1026, 113 Eyigun, C. P. . . . . . . . . . . . . . . . . . . . . L1-960, 110 Eyre, D. W. . . . . . . . . . . . . . . . . . . . . . . K-474, 048

Farkas, S. . . . . . . . . . . . . . . . . . . . . . . . F-2020, 247 Farkus, S. . . . . . . . . . . . . . . . . . . . . . . . F-2025, 247 Farley, J. . . . . . . . . . . . . . . . . . . . . . . . . .M-991, 111

Endimiani, A. . . . . . . . . . . C2-116, 009; 1183, 151 Endo, S. . . . . . . . . . . . . C2-114, 009; C2-1901, 236 Englund, J.. . . . . . . . . . . . . . . . . . . . . . . T-353, 029

Ezdon, D. . . . . . . . . . . . . . . . . . . . . . . . A-618, 082

F

Englund, J. A. . . . . . . . . . . . . . . . . . . . . . . 441, 042 Enokizono, K. . . . . . . . . . . . . . . . . . . . D-1438, 171 Enoru, J. . . . . . . . . . . . .A-1949, 241; A-1950, 241; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1951, 241 Enria, D. A. . . . . . . . . . . . . . . . . . . . . . . . 1098, 124 Entenza, J. . . . . . . . . . . . . . . . . . . . . . . . B-046, 005 Epie, F. . . . . . . . . . . . . . . . .F-844, 099; F-845, 099 Erb, S. . . . . . . . . . . . . . . . . . . . . . . . . . . D-167, 012 Ergani, A. . . . . . . . . . . . . . . . . . . . . . . D-1453, 172 Ergonul, O. . . . . . . . . . . . . . . . . . . . . . C2-684, 087 Ermocida, A. . . . . . . . . . . . . . . . . . . . . . D-742, 091 Ernst, B. . . . . . . . . . . . . . . . . . . . . . . . F-2057, 249 Ernst, E. J. . . . . . . . . . . . . . . . . . . . . . . K-1611, 184 Ernst, F. R. . . . . . . . . . . . . . . . . . . . . . L1-292, 026 Ernst, J. . . . . . . . . . . . . . . . . . . . . . . . . . . 1170, 148 Eron, J. . . . . . . . . . . . . . . . . . . . . . . . . . H-229, 019 Erpelding, M. . . . . . . . . . . . . . . . . . . . . K-939, 106 Errecalde, L. . . . . . . . . . . . . . . . . . . . . . D-746, 092 Escribano, P. . . . . . . . . M-1232, 159; M-1684, 190 Eser, B. . . . . . . . . . . . . . . . . . . . . . . . .M-1701, 191 Eshleman, S. H.. . . . . . . . . . . . . . . . . . H-1580, 180 España, A. . . . . . . . . . . .D-1439, 171; D-1440, 171 Español, M. . . . . . . . . . . . . . . . . . . . . . . K-931, 105 Espasa, M. . . . . . . . . . . . . . . . . . . . . . . K-1623, 184 Espedido, B. A. . . . . . . C1-062, 006; C1-1743, 197 Espejo, E. . . . . . . . . . . . . . . . . . . . . . . K-1621, 184 Esper, F. . . . . . . . . . . . . . . .V-385, 030; F-2015, 246 Espinal, P. . . . . . . . . . . B-1327, 165; C2-1900, 236 Espinosa, B. . . . . . . . . . . . . . . . . . . . . . P-1021, 112 Espinosa de los Monteros, L. E. . . . . L1-1653, 187 Espinosa-Silva, Y. . . . . . . . . . . . . . . . . . H-228, 019

220

F-Viladrich, P. . . . . . . . . . . . . . . . . . . . V-1240, 160 Fabre, T. . . . . . . . . . . . . . . . . . . . . . . . . . K-248, 022 Fàbrega, A. . . . . . . . . . . C2-696, 087; B-1329, 165 Faccone, D. . . . . . . . . .C2-084, 008; C2-1217, 157; . . . . . . . . . . . . . . . . F-1491, 175; C2-1910, 237 Fadel, S. A. . . . . . . . . . . . . . . . . . . . . . . K-955, 108 Fairfax, M. . . . . . . . . . . . . . . . . . . . . . . L2-306, 027 Fairhead, H.. . . . . . . . . . . . 1104, 125; F-2065, 249; . . . . . . . . . . . . . . . . . . . . . . . . . . . . .F-2066, 249 Fairhurst, R. M.. . . . . . . . . . . . . . . . . . . . 1200, 155 Fairley, C. K. . . . . . . . . . . . . . . . . . . . . L2-301, 027 Faix, D. . . . . . . . . . . . . . . . . . . . . . . . . . V-383, 030 Fakkas Fernández, M. . . . . . . . . . . . . . . D-169, 012 Fakruddin, M. . . . . . . . . . . . . . . . . . . . C2-711, 088 Falcão, L. D. . . . . . . . . . . . . . . . . . . . C2-1383, 169 Falces, C. . . . . . . . . . . . . . .A-610, 082; B-648, 084; . . . . . . . K-945, 106; K-1122, 129; E-1465, 173 Falci, D. R. . . . . . . . . . . . . . . . . . . . . . . A-027, 004 Falcone, M. . . . . . . . . . . . . . . . . . . . . . . K-938, 106 Falgueras, L. . . . . . . . . . . . . . . . . . . . . K-1623, 184 Fallo, A. . . . . . . . . . . . . . . . . . . . . . . . G3-1552, 178 Falup-Pecurariu, O. . . . . . . . . . . . . . . G3-1551, 178 Famiglietti, A. . . . . . . . . . . . . . . . . . . . D-1455, 172 Famure, O.. . . . . . . . . . . . . . . . . . . . . . . T-365, 029 Fanfair, R. N. . . . . . . . . . . . . . . . . . . . .M-1677, 190 Fang, E. . . . . . . . . . . . . .A-1292, 163; A-1293, 163; . . . . . . . . . . . . . . . . .A-1294, 163; A-1295, 163; . . . . . . . . . . . . . . . L1-1664, 189; L1-1665, 189 Fang, L. . . . . . . . . . . . . . . . . . . . . . . . C2-1380, 169 Fanning, S.. . . . . . . . . . . . . . . . . . . . . .M-1056, 115

September 9-12 |

Faria, N. A. . . . . . . . . . . . . . . . . . . . . C1-1740, 197 Faria-Ramos, I. . . . . . . . . . . . . . . . . . . .M-320, 028 Farias, V. . . . . . . . . . . . . . . . . . . . . . . C2-1375, 168 Fariñas, M. . . . . . . . . . . . . . . . . . . . . . . K-943, 106

Farley, M. M.. . . . . . . . . . . . . . . . . . . . G-1752, 198 Farmakiotis, D. . . . . . . . . . . . . . . . . . .M-1705, 191 Farnsworth, A.. . . . . . . . . . . . . . . . . . . L2-301, 027 Farnum, C. . . . . . . . . . . . . . . . . . . . . . . A-018, 003 Farooqui, A.. . . . . . . . . . . . . . . . . . . . C2-1981, 243 Farrands, A. . . . . . . . . . . . . . . . . . . . . . G-1051, 114 Farrell, D. J. . . . . . . . . . .C2-089, 008; C2-090, 008; . . . . . . . . . . . . . . . . C2-145, 010; C2-1214, 157 Fathima, S. . . . . . . . . . . . . . . . . . . . . . . V-386, 030 Fatima, K. . . . . . . . . . . . . . . . . . . . . . . . H-228, 019 Fattom, A. . . . . . . . . . . . . . . . . . . . . . . . G-869, 101 Fattouh, N. . . . . . . . . . . . . . . . . . . . . . K-1634, 185 Faure, E. . . . . . . . . . . . . . . B-050, 005; B-060, 005 Faure, K. . . . . . . . . . . . . . . B-050, 005; B-060, 005 Fawley, W. N. . . . . . . . . . . . . . . . . . . . . K-474, 048 Fedler, K. A. . . . . . . . . . . . . . . . . . . . . . E-193, 015 Fedyakina, I. . . . . . . . . . . . . . . . . . . . . . V-388, 030 Fegeler, C. . . . . . . . . . . . . . . . . . . . . . C2-1382, 169 Feghoul, L. . . . . . . . . . . . T-363, 029; D-1778, 201 Fehlberg, L. C. . . . . . . . D-731, 090; C1-1207, 156 Feierl, G. . . . . . . . . . . . . . . . . . . . . . . . E-1470, 173 Félix, J.. . . . . . . . . . . . . . . . . . . . . . . . . . H-878, 102 Felton, T. W. . . . . . . . . . M-977, 111; A-1765, 200; . . . . . . A-1942, 240; A-1943, 240; A-1944, 240 Feng, M. . . . . . . . . . . . . . . . . . . . . . . . . H-551, 073 Feng, Q.. . . . . . . . . . . . . . . . . . . . . . . .M-1061, 115 Fenical, W.. . . . . . . . . . . . . . . . . . . . . . F-1514, 176 Fenoll, A. . . . . . . . . . . C2-1358, 167; C2-1365, 167 Fentaw, D. S. . . . . . . . . . . . . . . . . . . . . . D-181, 013 Ferenci, P. . . . . . . . . . . . . . . . . . . . . . . V-1236, 160 Ferguson, E.. . . . . . . . . . F-2006, 246; F-2007, 246; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2008, 246 Ferguson, M. C.. . . . . . . . . . . . . . . . . C2-1377, 169 Ferguson, N. M. . . . . . . . . . . . . . . . . . . . 1854, 225 Ferguson, S. . . . . . . . . . . . . . . . . . . . . . .M-968, 111 Feris Iglesias, J. . . . . . . . . . . . . . . . . . . G-1751, 198

AUTHOR INDEX Author

Presentation Number

Fernandes, C.. . . . . . . . . . . . . . . . . . . L1-1656, 188 Fernandes, P. . . . . . . . . . .E-781, 093; A-1286, 162; . . . . . . . . . . . . . . . . . A-1269, 162; F-1505, 176; Fernández, A. . . . . . . . . . . . . . . . . . . . C1-593, 081 Fernandez, A. . . . . . . . .C1-070, 006; L1-289, 026; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1902, 236 Fernández, I. . . . . . . . . . . . . . . . . . . . . K-1623, 184 Fernandez, P. . . . . . . . . . . . . . . . . . . . . . K-559, 074 Fernandez, S. . . . . . . . C2-1396, 169; C2-1397, 169 Fernández Guerrero, M. . . . . . . . . . . . L1-958, 109 Fernandez-Cruz, A.. . . . . . . . . . . . . . . .K-944, 106; . . . . . D-1411, 170; M-1684, 190; M-1688, 190 Fernández-Hidalgo, N. . . . . . . . . . . . . .K-937, 106; . . . . . . K-938, 106; L1-1644, 186; K-1758, 199 Fernández-Mazarrasa, C. . . . . . . . . . . A-1280, 162 Fernández-Roblas, R. . . . . . . . . . . . . . L1-958, 109 Fernández-Romero, N. . . . . . . . . . . . . D-1452, 172 Fernández-Ruiz, M. . . . . M-329, 028; T-359, 029; . . . . . . . . . . . . . . . . . T-1071, 116; K-2091, 252 Fernández-Sabé, N. . . . . . . . . . . . . . . . . T-368, 029 Fernandez-Sampedro, M. . . . . . . . . . . . D-169, 012 Ferrand, H. . . . . . . . . . . . . . . . . . . . . . L1-957, 109 Ferrándiz, C. . . . . . . . . . . . . . . . . . . . . K-1924, 239 Ferrario, A. . . . . . . . . . . . D-159, 011; K-1601, 182 Ferreira, B. L. . . . . . . . . . . . . . . . . . . . F-1513, 176 Ferreira, D. C. . . . . . . . C2-1387, 169; D-1428, 171 Ferreira, D. . . . . . . . . . . . . . . . . . . . . . . H-878, 102 Ferreira, E. O. . . . . . . . . . . . . . . . . . . . C1-671, 085 Ferreira, I. S. . . . . . . . . . . . . . . . . . . . . F-2011, 246 Ferreira, J. . . . . . . . . . . . . . . . . . . . . . . G-1048, 114 Ferreira, V. . . . . . . . . . . . . . . . . . . . . . . F-1513, 176 Ferrer, A. . . . . . . . . . . . . . . . . . . . . . . . K-1616, 184 Ferrer, C. . . . . . . . . . . . . . . . . . . . . . . . K-1758, 199 Ferretto, R. . . . . . . . . . . . . . . . . . . . . . H-1579, 180 Ferrières, V. . . . . . . . . . . . . . . . . . . . . . P-1007, 112 Ferris, R. . . . . . . . . . . . . . . . . . . . . . . . . H-550, 073 Ferris, W. . . . . . . . . . . . . . . . . . . . . . . . E-1480, 174 Ferry, T. . . . . B-1319, 165; K-249, 022; K-253, 022 Feßler, A. T. . . . . . . . . . . . . . . . . . . . . C1-1350, 166 Feversot . . . . . . . . . . . . . . . . . . . . . . . . T-1026, 113 Fevre, K. . . . . . . . . . . . . . . . . . . . . . . L1-2103, 254 Fey, M.. . . . . . . . . . . . . . . . . . . . . . . . . D-1416, 170 Fiaux, E. . . . . . . . . . . . . B-1337, 165; B-1338, 165 Fick, J. . . . . . . . . . . . . . . . . . . . . . . . . . C1-665, 085 Fielding, R. . . . . . . . . . . . . . . . . . . . . . . V-396, 030 Fierens, F. L. . . . . . . . . . . . . . . . . . . . . . G-859, 100 Fiett, J. . . . . . . . . . . . . . . . . . . . . . . . . . C2-109, 009 Figueiredo, P. . . . . . . . . . . . . . . . . . . . . . H-227, 019 Figueiredo, R. . . . . . . . . . . . . . . . . . . . C2-713, 088 Figueroa, C. . . . . . . . . . . . . . . . . . . . . . . T-361, 029 Figueroa, R. . . . . . . . . . . . . . . . . . . . . . . K-935, 105

Author

Presentation Number

Fikes, S. . . . . . . . . . . . . . . .A-041, 004; A-042, 004; . . . . . . . . . . . . . . . . . A-1265, 161; E-1993, 245 Files, K. . . . . . . . . . . . . . A-1265, 161; E-1993, 245 Filler, S. . . . . B-650, 084,G-868, 101; M-1056, 115 FILPOP Study Group . . . . . . . . . . . . .M-321, 028 Fine, A. . . . . . . . . . . . . . . . . . . . . . . . . . T-342, 029 Finelli, L. . . . . . . . . . . . . . . . . . . . . . . . . . 1733, 195 Fink, P. . . . . . . . . . . . . . . . . . . . . . . . . . G-870, 101 Finks, J. L. . . . . . . . . . . . . . . . . . . . . . . . D-750, 092 Finn, J. . . . . . . . . . . . . . F-2017, 247; F-2018a, 247; . . . . . . . . . . . . . . . . . .F-2018, 247; F-2024, 247 Finn, T. . . . . . . . . . . . . . M-985, 111; M-1059, 115 Fiorella, P. . . . . . . . . . . . . . . . . . . . . . . . D-732, 091 Firsov, A. A. . . . . . . . . . . . . . . . . . . . . A-1967, 241 Fischer, B. G.. . . . . . . . . . . . . . . . . . . .M-1055, 115

Author

Presentation Number

Flores-Treviño, S. M. . . . . . . . . . . . . C2-1370, 168 Flowers, S. A. . . . . . . . . . . . . . . . . . . . .M-970, 111 FluCAN Investigators . . . . . . . . . . . . . . K-952, 108 Fluit, A. C. . . . . . . . . . . . . . . . . . . . . . F-1516, 176 Flume, P. A. . . . . . . . . . . . . . . . . . . . . . . . 1090, 121 Foà, R. . . . . . . . . . . . . . . . . . . . . . . . . . . V-393, 030 Fong, J. . . . . . . . . . . . . . . . . . . . . . . . . K-1585, 181 Fontanals, D. . . . . . . . . K-1623, 184; C2-1358, 167 Fontela, P. S. . . . . . . . . . . . . . . . . . . . . K-1755, 199 Force, E. . . . . . . . . . . . . . . . . . . . . . . . . B-658, 084 Ford, G. . . . . . . . . . . . . . . . . . . . . . . . . A-1956, 241 Ford, S. L. . . . . . . . . . . . . . . . . . . . . . . A-1249, 161 Forestier, C. . . . . . . . . . . . . . . . . . . . . . K-2098, 252 Formighieri, M. S. . . . . . . . . . . . . . . . . C2-087, 008

Fish, D. N.. . . . . . . . . . . . . . . . . . . . . . . . . 475, 049 Fisher, M. . . . . . . . . . . . . . . . . . . . . . . . H-556, 073

Forrest, A. . . . . . . . . . . . . .A-012, 003; A-016, 003; . . . . . . . . A-024, 004; A-027, 004; A-031, 004; . . . . . . . . . E-201, 015;A-605, 082; A-620, 082; . . . . . . . .A-644, 083; E-785, 094; A-1243, 161; . . . . . .A-1244, 161; A-1261, 161; A-1262, 161; . . . . . .A-1263, 161; A-1266, 161; A-1269, 162; . . . . . .A-1270, 162; A-1271, 162; A-1762, 200; . . . . . . . . . . . . . . . . . . . 1861, 227; A-1930, 240

Fisher, N. . . . . . . . . . . . . . . . . . . . . . . . B-1738, 196 Fishman, J. A. . . . . . . . . . . . . . . . . . . . . . . 410, 034

Forrest, G. . . . T-345, 029; D-1432, 171; 1888, 233 Forrester, I. . . . . . . . . . . . . . . . . . . . . . C2-714, 088

Fitzgibbons, L. N. . . . . . . . . . . . . . . . . . T-345, 029 Flach, C. . . . . . . . . . . . . . . . . . . . . . . . C1-665, 085 Flahault, A. . . . . . . . . . . . . . . . . . . . . . . V-387, 030

Forsberg, P. . . . . . . . . . . . . . . . . . . . . . . E-800, 094 Forstner, C. . . . . . . . . . . . . . . . . . . . . . E-1471, 174

Fischer, C. . . . . . . . . . . . . . . . . . . . . . . A-1960, 241 Fischer, G. . . . . . . . . . . . . . . . . . . . . . . .M-338, 028 Fischetti, V. A.. . . . . . . . . . . . . . . . . . . . B-659, 084 Fiscon, M. . . . . . . . . . . . . . . . . . . . . . . . H-216, 018

Flamaing, J. . . . . . . . . . . . . . . . . . . . . L1-1641, 186 Flamm, J. . . . . . . . . . . . . . . . . . . . . . . . . H-556, 073 Flamm, R. K.. . . . . . . . .C2-123, 010; C2-124, 010; . . . . . C2-129, 010; C2-131, 010; C2-132, 010; . . . . . .C2-136, 010; C2-138, 010; C2-139, 010; . . . . . . .C2-145, 010; C2-146, 010; E-186, 015; . . . . . . . . . E-187, 015; E-189, 015; E-193, 015; . . . . . . . . . . . . . . . . . . E-199, 015; F-2050, 248; . . . . . . .F-2051, 248; F-2052, 248; F-2053, 248 Flammini, S. . . . . . . . . . . . . . . . . . . . . . E-796, 094 Flanagan, S. . . . . . . . . . .A-1292, 163; A-1293, 163; . . . . . . . . . . . . . . . . . A-1294, 163; A-1295, 163 Flandin, J. . . . . . . . . . . . . . . . . . . . . . . D-1421, 170 Flarakos, J. . . . . . . . . . . . . . . . . . . . . . . A-1281, 162 Flattery, A.. . . . . . . . . . . . . . . . . . . . . . . F-810, 096 Flecher, E. . . . . . . . . . . . . . . . . . . . . . . . K-267, 023 Fleck, L. . . . . . . . . . . . . . . . . . . . . . . . F-1536, 177 Fleener, S. . . . . . . . . . . . . . . . . . . . . . . .M-981, 111 Fleites, A. . . . . . . . . . . . . . . . . . . . . . C2-1974, 243 Fleming, M. R. . . . . . . . . A-017, 003; F-1520, 177; . . . . . . . . . . . . . . . . . . L1-282, 025; D-770, 092 Flemons, W. W. . . . . . . . . . . . . . . . . . K-1756, 199 Fletcher, C. V. . . . . . . . . . . . . . . . . . . . . . 1128, 131 Flexner, C. W. . . . . . . . . . . . . . . . . . . . . . . 481, 052 Flick, H. . . . . . . . . . . . . . V-398, 030; P-1009, 112 Floeth, M. . . . . . . . . . . . . . . . . . . . . . G3-1547, 178 Florea, D.. . . . . . . . . . . . . . . . . . . . . . . D-1776, 201

Final Program

Fortún, J. . . . . . . . . . . . . . M-323, 028; T-340, 029; . . . . . . D-743, 091; K-2077, 250; M-1700, 191 Fossali, E. . . . . . . . . . . . . . . . . . . . . . G3-1549, 178 Fossler, M. J. . . . . . . . . . . . . . . . . . . . . . A-611, 082 Foster, A. N. . . . . . . . . . . . . . . . . . . . . F-2059, 249 Foster, G. F. . . . . . . . . . . . . . . . . . . . . . V-1236, 160 Fothergill, A. W. . . . . . . . . . . . . . . . . . . . 1179, 150 Foucrier, A. . . . . . . . . . . . . . . . . . . . . . . A-021, 003 Fournier-Wirth, C. . . . . . . . . . . . . . . . F-1488, 175 Fowler, R. C. . . . . . . . . . . . . . . . . . . . . B-1336, 165 Fowler, V. . . . . . .B-1320, 165; 1168, 147; 1808, 209 Fox, R. . . . . . . . . . . . . . M-1676, 190; M-1678, 190 Fox, R. L.. . . . . . . . . . . . . . . . . . . . . . .M-1695, 190 Fragaki, M. . . . . . . . . . . . . . . . . . . . . . . B-043, 005 Fraimow, H. S.. . . . . . . . . . . . . . . . . . . C1-589, 081 Fraisse, T. . . . . . . . . . . . . . . . . . . . . . . . . P-566, 075 Fralich, T.. . . . . . . . . . . . . . . . . . . . . . . . H-556, 073 Franco, M. . . . . . . . . . . . . . . . . . . . . . . . K-256, 022 Francoeur, D. N. . . . . . . . . . . . . . . . . . D-1450, 172 Francois, P.. . . . . . . . . . . . . . . . . . . . . . . . . 425, 038 François, B. . . . . . . . . . . . . . . . . . . . . C1-1739, 197 Frank, I. . . . . . . . . . . . . . . . . . . . . . . . . . . 1893, 235 Frank, U. K. . . . . . . . . . . B-1331, 165; K-2084, 251 Franke, B. . . . . . . . . . . M-1230, 159; M-1706, 191 Fransen, F. . . . . . . . . . . . . . . . . . . . . . L1-1651, 187 Franzblau, S. . . . . . . . . . . . . . . . . . . . . . F-834, 098

221


Presentation Number

Author

Presentation Number

Author

Presentation Number

GAMES . . . .K-941, 106; K-942, 106; K-943, 106; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-944, 106

Franzblau, S. G. . . . . . . . . . F-831, 098; F-835, 098

Fujino, N. . . . . . . . . . . . . . . . . . . . . . . . F-809, 096

Fraser, J. D. . . . . . . . . . . . . . . . . . . . . C2-1908, 237 Frassetto, L. . . . . . . . . . . . . . . . . . . . . . . . 1141, 138

Fujita, T. . . . . . . . . . . . . . . . . . . . . . . . .M-326, 028 Fujiwara, H.. . . . . . . . . . . . . . . . . . . . . . A-038, 004

Frazetto, M. . . . . . . . . . . . . . . . . . . . . . . F-828, 097

Fujiwara, T. . . . . . . . . . . . . . . . . . . . . . . H-550, 073

Gan, J. . . . . . . . . . . . . . . . . . . . . . . . . . A-1246, 161 Gan, V. C. . . . . . . . . . . . . . . . . . . . . . . . P-567, 075

Frederiksen, C. . . . . . . . . . . . . . . . . . . T-1072, 116

Fukase, H. . . . . . . . . . . . . . . . . . . . . . . F-2041, 248

Ganaha, C. . . . . . . . . . . . . . . . . . . . . C2-1397, 169

Fredricks, D. . . . . . . . . . . . . . . . . . . . .M-1676, 190 Freeman, D. . . . . . . . . . . . . . . . . . . . . . A-1953, 241

Fukuzawa, S. . . . . . . . . . . . . . . . . . . . . D-1438, 171 Fulcher, L. C.. . . . . . . . . . . . . . . . . . . . D-1433, 171

Ganaha, M. . . . . . . . . . . . . . . . . . . . . C2-1396, 169 Gandhi, T. . . . . . . . . . . . . . . . . . . . . . . . H-225, 019

Freeman, J.. . . K-474, 048; B-662, 084; K-924, 105 Freeman, J. T.. . . . . . . . . . . . . . . . . . . . C2-689, 087

Fulchini, R. . . . . . . . . . . . . . . . . . . . . . H-1566, 179 Fulke, J. . . . . . . . . . . . . . . . . . . . . . . . . P-1023, 112

Gane, E. . . . . . . . . . . . . . . . . . . . . . . . V-1236, 160

Freeman, R. B.. . . . . . . . . . . . . . . . . . . T-1025, 113

Fulton, S. A. . . . . . . . . . . . . . . . . . . . . A-1257, 161

Frei, C. R. . . . . . . . . . . . . . . . . . . . . . . L1-297, 026 Frei, R.. . . . . . . . . . . . . . . C2-082, 007; D-167, 012

Funatsu, Y.. . . . . . . . . . . . . . . . . . . . . . . A-038, 004 Funke, G.. . . . . . . . . . . . . . . . . . . . . . . . . 1856, 226

Gangneux, J. . . . . . . . . . . . . . . . . . . . . .M-333, 028 Gangneux, J. . . . . . . . . . . . . . . . . . . . . P-1007, 112

Freijs, G. . . . . . . . . . . . . . . . . . . . . . . . K-2080, 251

Furrer, H. . . . . . . . . . . . . . . . . . . . . . . . H-1566, 179

Freire, M. P. . . . . . . . . . . . . . . . . . . . . . K-1603, 183 Freitag, M. . . . . . . . . . . . . . . . . . . . . . C1-1972, 242 French, D. . . . . . . . . . . . . . . . . . . . . . . . K-561, 074

Furustrand Tafin, U. . .C1-1342, 166; M-1719, 191 Furuya, E. Y. . . . . . . . . . . . . . . . . . . . . K-1620, 184 Fux, C. A. . . . . . . . . . . . . . . . . . . . . . . C2-082, 007

French, G. L. . . . . . . . . . . . . . . . . . . . . . . 1803, 208 French Mycosis Study Mycosis . . . . . .M-1686, 190 Frenette, C. . . . . . . . . . . . . . . . . . . . . . K-1755, 199

Fyfe, C. . . . . . . . . . . . . . C1-675, 086; F-1525, 177; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1526, 177

Frere, J. . . . . . . . . . . . . . . . . . . . . . . . G3-1554, 178 Fresco, G. . . . . . . . . . . .M-323, 028; M-1700, 191; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2077, 250 Frey, B.. . . . . . . . . . . . . . . . . . . . . . . . . . F-828, 097 Frey, S. E. . . . . . . . . . . . . . . . . . . . . . . G-1048, 114 Friaes, A. . . . . . . . . . . . . . . . . . . . . . . . C2-151, 010 Frías-Mendivil, M. . . . . . . . . . . . . . . . C2-113, 009 Friberg, L. E. . . . . . . . . . . .A-032, 004; A-033, 004; . . . . . . . . . . . . . . . . . A-1764, 200; A-1966, 241 Frick, D. N. . . . . . . . . . . . . V-370, 030; F-826, 097 Fried, M. W. . . . . . . . . . . . . . . . . . . . . V-1236, 160 Friedland, H. . . . . . . . . . . . . . . . . . . . L1-1659, 189 Friedland, I. . . . . . . . . . . . . . . . . . . . . . . A-641, 083 Friedrich, A. W.. . . . . . . . . . . . . . . . . C2-1382, 169 Friedrich, S. O. . . . . . . . . . . . . . . . . . . A-1264, 161 Frigatto, E. A. . . . . . . . . . . . . . . . . . . C2-1376, 169 Friis-Moeller, A. . . . . . . . . . . . . . . . . . . B-663, 084 Frimat, B. . . . . . . . . . . . . . . . . . . . . . . . A-638, 083 Frimodt-Moeller, N. . . . . . . . . . . . . . . K-1617, 184 Frimodt-Møller, J. . . . . . . . . . . . . . . . . C2-687, 087 Frimodt-Møller, N. . . . . . . . . . . . . . . . A-1965, 241 Fritsch, E. . . . . . . . . . . . . . . . . . . . . . . . K-560, 074 Froissart, A. . . . . . . . . . . . . . . . . . . . . . K-2087, 252 Frost, E. . . . . . . . . . . . . . . . . . . . . . . . . F-1998, 246 Fryszczyn, B. . . . . . . . . . . . . . . . . . . . C1-1204, 156 Fu, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . E-795, 094 Fu, Y. . . . . . . . . . . . . . . . . . . . . . . . . . . . G-868, 101 Fuchs, B. . . . . . . . . . . . . . . . . . . . . . . . F-1538, 177 Fuchs, C. . . . . . . . . . . . . . . . . . . . . . . . L1-291, 026 Fuentes, C.. . . . . . . . . . . . . . . . . . . . . . K-2091, 252 Fujii, C. M. . . . . . . . . . . . . . . . . . . . . . . G-861, 100 Fujikawa, K.. . . . . . . . . . .F-2037, 248; F-2038, 248

222

G G-Reyne, A. . . . . . . . . . . . . . . . . . . . L2-2110, 255 Gaardbo, J. C. . . . . . . . . . . . . . . . . . . . . B-055, 005 Gabastou, J. . . . . . . . . . . . . . . . . . . . . . .M-327, 028 Gaborcik, J. . . . . . . . . . . . . . . . . . . . . . K-1636, 185 Gachot, B. . . . . . . . . . . . . . D-772, 092; K-911, 104 Gagetti, P. . . . . . . . . . . . . . . . . . . . . . C2-1910, 237 Gagnaire, J. . . . . . . . . . . . . . . . . . . . . . B-1319, 165 Gagneur, A. . . . . . . . . . . . . . . . . . . . . . G-1051, 114 Galani, I. . . . . . . . . . . . . . . . . . . . . . . . . E-799, 094 Galani, L. . . . . . . . . . . . . . K-562, 074; E-799, 094 Galanis, E. . . . . . . . . . . . . . . . . . . . . . .M-1233, 159 Galas, M. . . . . . . . . . . . C2-701, 087; C2-1910, 237 Galbois, A.. . . . . . . . . . . . . . . . . . . . . . . D-173, 013 Gale-Rowe, M. . . . . . . . . . . . . . . . . . C2-1380, 169 Gales, A. C. . . . . . . . . . . . . . .420, 037; D-731, 090; . . . . C1-1207, 156; C2-1376, 169; D-1446, 172 Galicia, A. . . . . . . . . . . . . . . . . . . . . . . C1-069, 006 Galiñanes, M. . . . . . . . . . . . . . . . . . . . . K-937, 106 Gallagher, J. C. . . . . . . . . . . . . . . . . . . . K-277, 024 Gallagher, L. . . . . . . . . . . . . . . . . . . . . . V-371, 030 Gallant, J.. . . . . . . . . . . . . . . . . . . . . . . . . . 003, 001 Gallant, J. E. . . . . . . . . . . . . . . . . . . . . . . 1185, 152 Galleni, M. . . . . . . . . . C1-459, 047; C1-1206, 156 Gallien, S. . . . . . . . . . . . . . . . . . . . . . . . P-566, 075 Gallo, R. L. . . . . . . . . . . . . . . . . . . . . . . . . 522, 066 Gálvez, J. . . . . . . . . . . . . . . K-938, 106; K-942, 106 Gálvez-Acebal, J. . . . . . . K-941, 106; L1-1658, 188 Gama, B. . . . . . . . . . . . .C2-127, 010; C2-130, 010; . . . . . . . . . . . . . . . . . .C2-142, 010; M-322, 028 Gamaletsou, M. . . . . . .M-1681, 190; L2-2114, 255

September 9-12 |

Gangneux, F. . . . . . . . . . . . . . . . . . . . . .M-333, 028

Gao, C. . . . . . . . . . . . . . B-1734, 196; B-1734, 196 Gao, W. . . . . . . . . . . . . . . . . . . . . . . . . H-1575, 180 Gao, X. . . . . . . . . . . . . . . . . . . . . . . . . . K-269, 023 Gao, Z. W. . . . . . . . . . . . . . . . . . . . . . F-1500, 176 Garau, J.. . . . . . . . . . . . . L1-290, 026; K-1621, 184; . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1666, 189 Garber, J. . . . . . . . . . . . . . . . . . . . . . . . . A-643, 083 Garbers, S. N. . . . . . . . . . . . . . . . . . . . F-1518, 176 Garcia, C. P.. . . . . . . . . . . . . . . . . . . . . K-1603, 183 Garcia, C. . . . . . . . . . . . C2-1909, 237; K-900, 104 Garcia, H. H.. . . . . . . . . . . . . . . . . . . . . . 1889, 234 Garcia, L. G. . . . . . . . . . . .A-596, 082; A-597, 082; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-599, 082 Garcia, M. C.. . . . . . . . . . . . . . . . . . . . K-1621, 184 Garcia, M. E.. . . . . . . . . . . . . . . . . . . . . K-470, 048 Garcia, P. . . . . . . . . . . . . . . . . . . . . . . . H-1577, 180 García, R. . . . . . . . . . . . . . . . . . . . . . L2-2110, 255 Garcia, Y. T. . . . . . . . . . . . . . . . . . . . . . . K-919, 105 Garcia Alvarez, L. . . . . . . . . . . . . . . . . . K-260, 023 Garcia de la Maria, C. . . . .A-610, 082; B-645, 084; . . . . . . . B-648, 084; K-945, 106; K-1122, 129; . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-1465, 173 Garcia de la Puente, S.. . . . . . . . . . . . G3-1563, 178 García Giménez, S. . . . . . . . . . . . . . . . . G-874, 101 Garcia Vallecillos, C. . . . . . . . . . . . . . . H-1921, 238 Garcia-Castillo, M. . . . . . . . . . . . . . . . . D-753, 092 Garcia-Hermoso, D. . . M-1686, 190; M-1707, 191 García-Reyne, A.. . . . . . . T-368, 029; T-1071, 116; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2091, 252 Garcia-Somoza, D. . . . . L1-293, 026; L1-295, 026 García-Unzueta, M. T. . . . . . . . . . . . .M-1673, 190 Garcia-Vidal, C. . . . . . . .D-180, 013; L1-293, 026; . . . . . . L1-295, 026; L1-298, 026; M-329, 028; . . . . . . . . . . . . . . . . . T-1045, 113; M-1228, 159 Gardella, N. . . . . . . . . C2-1396, 169; C2-1397, 169 Gardiol, C.. . . . . . . . . . . . . . . . . . . . . . . T-352, 029 Garey, K. W. . . . . . . . . . . D-158, 011; M-316, 028; . . . . . . . . . . . .476, 049; K-920, 105; K-921, 105 Garg, H. . . . . . . . . . . . . . . . . . . . . . . . H-1569, 179 Gargallo-Viola, D.. . . . . . . E-204, 016; E-205, 016; . . . . . . . . E-210, 016; D-769, 092; M-980, 111; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1718, 191

AUTHOR INDEX Author

Presentation Number

Author

Presentation Number

Author

Presentation Number

Gargano, J. W. . . . . . . . . . . . . . . . . . . . . . 1819, 210

Geller, B. L. . . . . . . . . . . . . . . . . . . . . C1-1972, 242

Garibotto, C. . . . . . . . . . . . . . . . . . . . . . K-917, 105 Garland, S. M.. . . . . . . . . . . . . . . . . . . L2-301, 027

Geller, D. E. . . . . . . . . . . . . . . . . . . . . . . 1088, 121

Gijon, D. . . . . . . . . . . . . . .D-743, 091; D-753, 092 Gijón, P.. . . . . . . . . . . . . . . . . . . . . . . . . K-263, 023

Gemiarto, A. T. . . . . . . . . . . . . . . . . . . F-2071, 249 Gemmell, C. . . . . . . . . . . . . . . . . . . . . F-1530, 177

Gil, C. . . . . . . . . . . . . . . . . . . . . . . . . . L1-289, 026 Gil, J. . . . . . . . . . . . . . . . . . . . . . . . . . . F-1518, 176

Gentile, A. . . . . . . . . . . . .G-874, 101; P-1015, 112; . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1016, 112 Gentile, G.. . . . . . . . . . . . . V-393, 030; K-898, 104

Gil Anguita, C. . . . . . . . . . . . . . . . . . . H-1921, 238

Garnacho, J. . . . . . . . . . . . . K-948, 107; K-950, 107 Garnacho-Montero, J. . . . . . . . . . . . . . K-1924, 239 Garnica, M. . . . . . . . . . . . . . . . . . . . . .M-1690, 190 Garnier, F. . . . . . . . . . . D-1441, 171; C1-1739, 197 Garraffo, R. . . . . . . . . . . . . . . . . . . . . . A-1253, 161 Garrigós, C. . . . . . . . . . . . . B-647, 084; B-658, 084 Garza-Gonzalez, E.. . . . . . . . . . . . . . C2-1370, 168 Garza-Ramos, U.. . . . . . C1-067, 006; C1-069, 006 Garzón, M. . . . . . . . . . . . . . . . . . . . . L2-2108, 255 Garzoni, C. . . . . . . . . . . . . . . . . . . . . . . T-343, 029 Gasch, O.. . . . . . . . . . . .C1-683, 086; A-1280, 162; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1395, 169 Gaspar, E. B. . . . . . . . . . . . . . . . . . . . . . E-801, 094

Georgakopoulou, T. . . . . . . . . . . . . . . G3-1543, 178 Georgala, A. . . . . . . . . . T-1028, 113; T-1046, 113; . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1413, 170; Georgiadou, S.. . . . . . .M-1679, 190; L2-2114, 255 Gérard, M.. . . . . . . . . . . . . . . . . . . . . . D-1413, 170 Gerding, D. N. K-471, 048; E-808, 095; 1145, 140 Gerdts, V. . . . . . . . . . . . . . . . . . . . . . . . . . 523, 066 Geriak, M. . . . . . . . . . . . . . . . . . . . . . . K-1631, 185 Gericco . . . . . . . . . . . . . . . . . . . . . . . . L1-963, 110

Gaspar, G. G. . . . . . . . . . . . . . . . . . . . C2-086, 008 Gastaminza, G. . . . . . . .D-1439, 171; D-1440, 171

Gershon, A. . . . . . . . . . . . . . . . . . . . . . . . 1826, 212 Gerstoft, J. . . . . . . . . . . . . . . . . . . . . . . H-1916, 238

Gastinne, T. . . . . . . . . . D-1458, 172; L1-1642, 186

Gervaix, A. . . . . . . . . . . . . . . . . . . . . G3-1541, 178 Gestoso, I. . . . . . . . . . . . . . . . . . . . . . . P-1020, 112 Getachew, T. . . . . . . . . . . . . . . . . . . . . . D-181, 013

Gastmeier, P. . . . . . . . . . . . . . . . . . . . . K-1592, 181 Gatanaga, H. . . . . . . . . . . H-223, 019; H-224, 019; . . . . . . . . . . . . . . . . . . .H-888, 103; H-890, 103 Gateff, D. . . . . . . . . . . . . . . . . . . . . . . D-1413, 170 Gatell, J. M. . . . . . . . . . . . .A-610, 082; B-648, 084; . . . . . . . K-945, 106; K-1122, 129; E-1465, 173 Gathe, J.. . . . . . . . . . . . . . . . . . . . . . . . . H-877, 102 Gatti, B.. . . . . . . . . . . . . . . . . . . . . . . . C2-084, 008 Gattu, S. . . . . . . . . . . . . . . . . . . . . . . . K-1589, 181 Gaustad, P.. . . . . . . . . . . . . . . . . . . . . . .M-332, 028 Gauthier, N.. . . . . . . . . . . . . . . . . . . . . . A-638, 083 Gautier, H. . . . . . . . . . . . . . . . . . . . . . . B-653, 084 Gauzit, R. . . . . . . . . . . . . . . . . . . . . . . . K-237, 020 Gavaldà, J. . . . . . . . . . . . . . . . . . . . . . . . K-938, 106 Gavaldá, J. . . . . . . . . . . . . . . . . . . . . . . . T-340, 029 Gavaldà, J. . . . . . . . . . . . . . .T-359, 029; T-368, 029 Gavrish, E. . . . . . . . . . . . . . . . . . . . . . . F-829, 098 Gawronski, K. M. . . . . . . . . . . . . . . . . A-1768, 200 Gayathri, R. . . . . . . . . . . . . . . . . . . . . . . T-367, 029 Gayet-Ageron, A. . . . . . . . . . . . . . . . . K-2083, 251 Gayoso, C. . . . . . . . . . . . . . . . . . . . . . . . K-559, 074 Gayosso-Vázquez, C. . . . . . . . . . . . . . C2-113, 009 Gaytan, J. . . . . . . . . . . . . . . . . . . . . . . . C1-067, 006 Gazzard, B. . . . . . . . . . . . . . . . . . . . . . . H-556, 073 Ge, J. . . . . . . . . . . . . . . . A-1951, 241; F-2054, 248 Ge, Y.. . . . . . .E-203, 016; E-207, 016; D-760, 092; . . . . . . D-764, 092; A-1948, 241; A-1949, 241; . . . . . .A-1950, 241; A-1952, 241; A-1953, 241; . . . . . . A-1954, 241; A-1955, 241; F-2046, 248; . . . . . . . . . . . . . . . . . .F-2047, 248; F-2056, 248 Geerlings, S. E. . . . . . . . . . . . . . . . . . . . . . 542, 071 Gehrer, M. . . . . . . . . . . . . . . . . . . . . . . E-1470, 173 Gellen-Dautremer, J. . . . . . . . . . . . . . . K-2087, 252

Gil-Navarro, M. . . . . . . . . . . . . . . . . . K-1924, 239 Gilbert, A. . . . . . . . . . . . . . . . . . . . . . . . D-751, 092 Gilca, R. . . . . . . . . . . . . . . . . . . . . . . . . V-389, 030 Gilca, V.. . . . . . . . . . . . . . . . . . . . . . . . G-1047, 114 Giles, H. . . . . . . . . . . . . . . . . . . . . . . . P-1023, 112 Gilhuley, K. . . . . . . . . . . . . . . . . . . . . . D-1442, 171 Gilio, A. E. . . . . . . . . . . . . . . . . . . . . . . G-861, 100 Gilis, L. . . . . . . . . . . . . . . . . . . . . . . . . . T-360, 029 Gill, C.. . . . . . . . . . . . . . . . . . . . . . . . . . F-810, 096 Gill, S. R.. . . . . . . . . . . . . . . . . . . . . . . B-1320, 165 Gillis, L. M.. . . . . . . . . . . E-786, 094; K-1605, 183 Gillman, J. . . . . . . . . . . . . . . . . . . . . . . . T-357, 029 Gilmour, M. . . . . . . . . . . . . . . . . . . . C2-1360, 167 Gilsanz, F. . . . . . . . . . . . . . . . . . . . . . . K-1608, 184 Gimenez, M. . . . . . . . . . . . . . . . . . . . . D-1419, 170

Geyer, C. . . . . . . . . . . . . . . . . . . . . . . . C2-115, 009 Ghafur, A. . . . . . . . . . . . . . K-236, 020; P-564, 075; . . . . . . . . . . . . . . . . . P-1003, 112; K-1618, 184

Giourgouli, G. . . . . . . . . . . . . . . . . . . .M-1696, 191 Giraffa, G. . . . . . . . . . . . . . . . . . . . . . . . . . 431, 040 Giralt, E. . . . . . . . . . . . . . . . . . . . . . . . F-2068, 249

Ghanem, K. G. . . . . . . . . . . . . . . . . . . . . . 478, 050

Girardello, R.. . . . . . . . . . . . . . . . . . . C2-1376, 169

Ghannoum, A. M.. . . . . . V-385, 030; F-2015, 246 Ghannoum, M. . . . . . . . . . V-385, 030; F-815, 096; . . . . . . . . . . . . . . . . . M-1062, 115; F-2015, 246

Giraud, C. . . . . . . . . . . . . . . . . . . . . . L1-1224, 158 Giraud, J. . . . . . . . . . . . . . . . . . . . . . . . . P-996, 112 Giraudeau, C. . . . . . . . . . . . . . . . . . . . C2-080, 007

Ghantoji, S. S. . . . . . . . . . K-934, 105; V-1075, 117

Girgenti, D. . . . . . . . . . . . . . . K-259, 023; 575, 077 Girgenti, D. Q. . . . . . . . . . . . . . . . . . . . G-870, 101

Ghassemi, M. . . . . . . . . . . . . . . . . . . . F-2072, 249 Ghebremariam, T. . . . . . . B-650, 084; M-973, 111; . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-1473, 174 Ghebremedhin, B. . . . . . . . . . . . . . . . . C2-108, 009 Ghosh, A. K. . . . . . . . . . . . . . . . . . . . . F-2072, 249 Ghossein, C. . . . . . . . . . . . . . . . . . . . . . A-636, 083 Ghout, I. . . . . . . . . . . . . . . . . . . . . . . . . B-645, 084 Giamarellou, H.. . . . . . . . .K-245, 021; K-246, 021; . . . . . . . . . . . . . . . . . . . K-562, 074; E-799, 094 Giani, T.. . . . . . . . . . . . . E-796, 094; C2-1211, 157 Giannella, M. . . . . . . . . T-1035, 113; T-1040, 113; . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-1041, 113 Giardina, P. . . . . . . . . . . . . . . . . . . . . . . G-870, 101 Gibb, A.. . . . . . . . . . . . . . . . . . . . . . . . . K-927, 105 Gibbons, H. S.. . . . . . . . C1-064, 006; C1-592, 081 Gibert, L.. . . . . . . . . . . . . . . . . . . . . . . B-1337, 165 Gibot, S. . . . . . . . . . . . . . . . . . . . . . . . . P-570, 075 Gibreel, T. . . . . . . . . . . . . . . . . . . . . . . F-1487, 175 Gibson, J. S. . . . . . . . . . . . . . . . . . . . . . C2-708, 088 Giddey, M. . . . . . . . . . . . . B-046, 005; B-659, 084 Giedlin, M. . . . . . . . . . . .H-553, 073; H-1581, 180 Giglio, N.. . . . . . . . . . . . . . . . . . . . . . . . G-874, 101 Giguere, S. . . . . . . . . . . . . . . . . . . . . . C1-1348, 166

Final Program

Girlich, D. . . . . . . . . . . . . .D-745, 092; D-748, 092 Girmenia, C. . . . . . . . . . . . . . . . . . . . . . V-393, 030 Girometti, N.. . . . . . . . . . . . . . . . . . . . K-1619, 184 Giske, C. . . C2-107, 009; E-800, 094; F-2054, 248 Giulieri, S. . . . . . . . . . . . . . . . . . . . . . L1-1221, 158 Giurini, J.. . . . . . . . . . . . . . . . . . . . . . L1-1646, 186 Givon-Lavi, N. . . . . . . .G-1050, 114; G-1753, 198 Glick, Y. . . . . . . . . . . . . . . . . . . . . . . . L1-961, 110 Glossmann, J.. . . . . . . . M-1230, 159; M-1706, 191 Glupczynski, Y. . . . . . . . . . . . . . . . . . . D-1447, 172 GnamNuan, A. . . . . . . . . . . . . . . . . . . . P-998, 112 Gniadkowski, M. . . . . . . . . . . . . . . . . . C2-109, 009 Gobey, J. . . . . . . . . . . . . . . . . . . . . . . . A-1264, 161 Gobin, P. . . . . A-035, 004; A-036, 004; A-037, 004 Godet, C.. . . . . . . . . . . . . A-039, 004; L1-963, 110 Godkin, S. . . . . . . . . . . . . . .T-358, 029; T-362, 029 Goenaga, M. . . . . . . . . . . . . . . . . . . . . . K-943, 106 Goering, R. V. . . . . . . . . . . . . . . . . . . . . K-469, 048 Goetghebeur, M. . . . . . . . . . . . . . . . . . . K-473, 048 Goff, D. A. . . . . . . . . . . .K-275, 024; K-1123, 129; . . . . . . . . . . . . . . . . . K-1636, 185; A-1768, 200

223


Presentation Number

Author

Presentation Number

Author

Presentation Number

Goffinet, N. . . . . . . . . . . . . . . . . . . . . . L1-285, 025

Gonzalez-Lopez, J. . . . . L2-303, 027; K-1616, 184

Goh, C. Y. . . . . . . . . . . . . . . . . . . . . . . A-1959, 241 Goh, S. S. . . . . . . . . . . . . . . . . . . . . . . K-1595, 182

Gonzalez-Ruiz, A.. . . . . . . . . . . . . . . . K-2095, 252

Green, K. A. . . . . . . . C2-1362, 167; C2-1364, 167

Goo, T.. . . . . . . . . . . . . . . . . . . . . . . . . . D-155, 011 Good, C. E. . . . . . . . . . A-1257, 161; C2-1361, 167

Green, M. . . . . . . . . . . . . . . . . . . . . . . E-1475, 174 Green, S. . . . . . . . . . . L1-1663, 189; L1-1665, 189

Goodwin, J. . . . . . . . . . . M-977, 111; A-1765, 200; . . . . . . A-1942, 240; A-1943, 240; A-1944, 240 Goorhuis, A. . . . . . . . . . . . . . . . . . . . . . K-472, 048

Greenberg, D. . . . . . . G-1050, 114; G3-1551, 178; . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-1753, 198

Golan, A. . . . . . . . . . . . . . . . . . . . . . . . .M-339, 028 Gold, J. . . . . . . . . . . . . . . . . . . . . . . . . . A-643, 083 Gold, L. . . . . . . . . . . . . . . . . . . . . . . . . . T-349, 029 Goldberg, L. . . . . . . . . . . . . . . . . . . . . B-1331, 165 Goldblatt, J. . . . . . . . . . . . . . . . . . . . . . B-1311, 165 Goldenthal, K. . . . . . . . . . . . . . . . . . . . G-1053, 114 Goldfarb, J. . . . . . . . . . . . . . . . . . . . . G3-1546, 178 Golding, G. . . . . . . . . . . . . . . . . . . . . C2-1380, 169 Goldman, S. . . . . . . . . . F-2030, 248; F-2031, 248; . . . . . . . . . . . . . . . . . .F-2032, 248; F-2033, 248 Goldstein, B. P. . . . . . . . . . . . . . . . . . . C2-134, 010 Goldstein, E. J. K-471, 048; F-854, 099; 1844, 220 Goletz, G. . . . . . . . . . . . . . . . . . . . . . G3-1547, 178 Golik Mahoney, M. . . . . . . . . . . . . . . . K-1626, 185 Gomez, B. . . . . . . . . . . . . . . . . . . . . . .M-1694, 190 Gomez, D. . . . . . . . . . . . . . . . . . . . . . L1-1653, 187 Gómez, J.. . . . . . . . . . . . . . . . . . . . . . . C2-111, 009 Gomez, S. . . . . . . . . . . C2-084, 008; C2-1217, 157 Gomez-Duarte, O. G. . . . . . . . . . . . . . B-1322, 165 Gómez-GªPedrosa, E. . . . . . . . . . . . . .M-1700, 191 Gomez-Garcia, I. . . . . . . . . . . . . . . . . . D-743, 091 Gómez-García de la Pedrosa, E. . . . . . .M-323, 028 Gómez-Gerique, J. A. . . . . . . . . . . . . .M-1673, 190 Gomez-Gil, R. . . . . . . . . . . . . . . . . . . K-1608, 184 Gomez-Lopez, A. . . . . . . . . . . . . . . . .M-1718, 191 Gomez-Mampaso, E. . . . . . . . . . . . . . . D-743, 091 Gómez-Román, J. . . . . . . . . . . . . . . . . . D-169, 012 Gomme, G. . . . . . . . . . . . . . . . . . . . . . P-1005, 112 Goncharov, A. E. . . . . . . . . . . . . . . . . C2-1385, 169 Gonzaga, D. . . . . . . . . . . . . . . . . . . . . F-1513, 176 Gonzales, E. . . . . . . . . . . . . . . . . . . . . C2-718, 089 Gonzalez, A. . . . . . . . . . . . . . . . . . . . . . D-743, 091 Gonzalez, B. E. . . . . . . . . . . . . . . . . . C2-1361, 167 González, C. . . . . . . . . . . . . . . . . . . . . H-1573, 180 González, E. . . . . . . . . . . . . . . . . . . . . . H-220, 019 Gonzalez, G. . . . . . . . . . . . . . . . . . . . C2-1370, 168 Gonzalez, I. M. . . . . . . . . . . . . . . . . . C2-1915, 237 Gonzalez, J. M. . . . . . . . A-1945, 240; A-1968, 241 González, J. . . . . . . . . . . P-1015, 112; P-1016, 112; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2091, 252 González, M. M. . . . . . . . . . . . . . . . . . H-1576, 180 Gonzalez, M. M. . . . . . . . . . . . . . . . . . C1-461, 047 Gonzalez, N. . . . . . . . . . . . . . . . . . . . G3-1563, 178 Gonzalez, R. . . . . . . . . . . . . . . . . . . . . C1-067, 006 Gónzalez del Vecchio, M. . . . . . . . . . . V-1242, 160 González Díaz, E. . . . . . . . . . . . . . . . C2-1373, 168 González-Alujas, M. T. . . . . . . . . . . . . . K-937, 106 Gonzalez-Diaz, E.. . . . . . . . . . . . . . . C2-1370, 168

224

Green, K. . . . . . . . . . . . . . . . . . . . . . . C2-1363, 167

Goossens, H. . . . . . . . . C2-109, 009; G3-1559, 178

Greenberg, D. P. . . . . . . . . . . . . . . . . . B-1322, 165 Greenfield, J. . . . . . . . . . . . . . . . . . . . . A-1957, 241

Gopalakrishnan, R. . . . . . P-564, 075; P-1003, 112; . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1004, 112

Grégoire, N.. . . . . . . . . . . .A-035, 004; A-036, 004; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-037, 004

Gordeev, M. F.. . . . . . . . .F-1499, 176; F-1502, 176 Gormley, R. . . . . . . . . . . . . . . . . . . . . . G-1048, 114 Gosbell, I. B. . . . . . . . . C1-062, 006; C1-1743, 197 Gose, S. . . . . . . . . . . . . . . . . . . . . . . . . L2-308, 027 Gosset, P. . . . . . . . . . . . . . . . . . . . . . . . . B-050, 005 Gostev, V. V. . . . . . . . . . . . . . . . . . . . C2-1385, 169 Gotoh, N. . . . . . . . . . . . . . . . . . . . . . . F-2039, 248 Gottardi, W. . . . . . . . . . . . . . . . . . . . . F-2058, 249 Gottlieb, D. J. . . . . . . . . . . . . . . . . . . . . . . 547, 072 Gotuzzo, E. . . . . . . . . . . . . . . . . . . . . C2-1909, 237 Goudeau, A. . . . . . . . . . . .D-176, 013; D-177, 013 Gould, E. . . . . . . . . . . . . A-1246, 161; A-1249, 161 Gould, I. M. . . . . . . . . . . . . . . . . . . . . . . . 579, 078 Gould, J. . . . . . . . . . . . . . . . . . . . . . . . F-2066, 249 Gould, J. K. . . . . . . . . . . . . . . . . . . . . . . F-842, 099

Gregoricus, N. . . . . . . . . . . . . . . . . . . . P-1021, 112 Gregory, D. . . . . . . . . . . . . . . . . . . . . . . T-369, 029 Gregson, D. B.. . . . . . . . . . . . . . . . . . . K-1756, 199 Gregson, L. . . . . . . . . . . M-977, 111; A-1765, 200; . . . . . . . . . . . . . . . . . A-1943, 240; A-1944, 240 Grenet, D. . . . . . . . . . . . . . . . . . . . . . . . A-035, 004 Grenier, S. . . . . . . . . . . . . . . . . . . . . . . . D-751, 092 Grenouillet, F. . . . . . . . . . . . . . . . . . . .M-1692, 190 Grif, K. . . . . . . . . . . . . . . . . . . . . . . . . .M-332, 028 Griffith, D. C. . . . . . . . . . . F-848, 099; F-849, 099; . . . . . . . . . F-850, 099; F-851, 099; F-852, 099; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-858, 099 Griffith, E. C. . . . . . . . . . . . . . . . . . . C1-1741, 197 Griffith, M. . . . . . . . . . . . .K-271, 024; A-636, 083; . . . . . . . . . . . . . . . . . B-1323, 165; B-1326, 165; . . . . . . . . . . . . . . . . . K-1614, 184; K-1615, 184

Goulielmos, G. . . . . . . . . . . . . . . . . . . . B-043, 005 Gouliouris, T.. . . . . . . . . . . . . . . . . . . . L1-288, 025

Griffiths, P. . . . . . . . . . . . . . .495, 059; F-2007, 246 Grillot-Courvalin, C. . . . . . . . . . . . . . C1-676, 086

Govender, N. . . . . . . . . . . . . . . . . . . . .M-1699, 191 Govorkova, E. A. . . . . . . . . . . . . . . . . . A-1243, 161

Grimard, D.. . . . . . . . . . . . . . . . . . . . . . V-389, 030 Grimmond, S. M. . . . . C1-062, 006; C1-1743, 197

Gowans, L. K. . . . . . . . . . . . . . . . . . . G3-1546, 178 Gowil, S. . . . . . . . . . . . . . . . . . . . . . . . . F-812, 096 Grabe, D. W. . . . . . . . . . . . . . . . . . . . . . A-606, 082 GRCn°2 EPIDIFF . . . . . . . . . . . . . . . . D-154, 011 Gracon, S. I. . . . . . . . . . . . . . . . . . . . . F-2070, 249 Graeden, E. . . . . . . . . . . . . . . . . . . . . . . V-396, 030 Gragera, B. . . . . . . . . . . . . . . . . . . . . . K-2095, 252 Graham, H. . . . . . . . . . . . . . . . . . . . . . . H-556, 073 Grall, N. . . . . . . . . . . . . . . . . . . . . . . . F-2003, 246 Gramegna, M. . . . . . . . . . . . . . . . . . . . L2-304, 027 Grant, I. H. . . . . . . . . . . . . . . . . . . . . .M-1063, 115 Granwehr, B. . . . . . . . . . . . . . . . . . . . .M-1676, 190 Grare, M.. . . . . . . . . . . . . D-758, 092; F-1527, 177

Grisaru, G. . . . . . . . . . . . . . . . . . . . . G3-1545, 178 Grisold, A. . . . . . . . . . . . P-1009, 112; E-1470, 173; . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1404, 170

Gras, G. . . . . . . . . . . . . .D-177, 013; L1-2103, 254; . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-2104, 254 Gras-Le Guen, C. . . . . . . . . . . . . . . . . L1-285, 025 Grattard, F. . . . . . . . . . . . . . . . . . . . . . . D-178, 013 Grau, I. . . . . . . . . . . . . . . . . . . . . . . . . C2-690, 087 Grau, S. . . . . . . . . . . . . . K-1624, 184; K-1633, 185 Gravett, M. G.. . . . . . . . . . . . . . . . . . . . . . 454, 045 Grayson, L. . . . . . . . . . . . . . . . . . . . . . . T-369, 029 Green, C. . . . . . . . . . . . . . . . . . . . . . . . F-1531, 177

September 9-12 |

Groenefeld, J.. . . . . . . . . . . . . . . . . . . . . K-953, 108 Groll, A. H. . . . . . . . . . . K-953, 108; G3-1547, 178 Gross, U. . . . . . . . . . . . . . . . . . . . . . . . .M-335, 028 Grosset, J. . . . . . . . . . . . . . . . . . . . . . . B-1296, 164 Grossi, P. . . . . . . . . . . . . .T-1035, 113; T-1041, 113 Grossman, T. . . . . . . . . . . . . . . . . . . . . F-1526, 177 Grossman, T. H. . . . . . . .C1-675, 086; E-777, 093; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1525, 177 Groupe des Pédiatres et Microbiologistes de l’Observatoire National des Méningites, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-864, 100 Grulich, A. E. . . . . . . . . . . . . . . . . . . . L2-301, 027 Grundmann, H.. . . . . . . . . . . . . . . . . . . . 1788, 204 Grupo Mexicano De Trabajo En Enfermedad Meningococcica . . . . . . . . . . . . . . L1-1653, 187 Gu, A. M. . . . . . . . . . . . . . . . . . . . . . . . K-268, 023 Gu, B. . . . . . . . . . . . . . . . . . . . . . . . . C2-1401, 169 Gu, X. . . . . . . . . . . . . . . . . . . . . . . . . . C2-083, 008 Gu, Y. . . . . . . F-843, 099; F-844, 099; F-845, 099; . . . . . . F-846, 099; C2-114, 009; C2-1901, 236

AUTHOR INDEX Author

Presentation Number

Author

Presentation Number

Author

Presentation Number

Guay, I. . . . . . . . . . . . . . . . . . . . . . . . . F-1997, 246

Gutierrez, E. . . . . . . . . . . . . . . . . . . . . K-2093, 252

Halim, R.. . . . . . . . . . . . . . . . . . . . . . . . F-828, 097

Gubbay, J. . . . . . . . . . . . . . . . . . . . . . G3-1562, 178 Gudiol, C. . . . . . . . . . . . M-329, 028; T-1045, 113; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1228, 159

Gutierrez, M.. . . . . . . . . . A-009, 003; A-1273, 162 Gutierrez, P. P. . . . . . . . . . . . . . . . . . . . K-1603, 183

Halimi, D. . . . . . . . . . . . . .D-745, 092; D-748, 092

Gutiérrez-Cuadra, M. . . P-1018, 112; M-1673, 190

Gudiol, F.. . . . . . . . . . . . .D-180, 013; L1-298, 026; . . . . . . . . . . . . . . . . . L1-293, 026; L1-295, 026

Hall, C. L. . . . . . . . . . . . .F-2026, 247; F-2027, 247 Hall, D. . . . . . . . . . . . . . . . . . . . . . . . C2-1912, 237

Gudur, U. M.. . . . . . . . . . K-272, 024; K-1589, 181

Gutkind, G. . . . . . . . . . .C1-459, 047; C1-466, 047; . . . . . .C1-678, 086; C1-669, 085; C2-700, 087; . . . . . C2-718, 089; C1-1206, 156; D-1455, 172

Gueit, I. . . . . . . . . . . . . . . . . . . . . . . . . . H-886, 102 Güell, E. . . . . . . . . . . . . . . . . . . . . . . L1-1643, 186 Guembe, M. . . . . . . . . . D-166, 012; M-1688, 190

Gutmann, L. . . . . . . . . . . . . . . . . . . . C2-1359, 167 Guyard, C. . . . . . . . . . . . . . . . . . . . . . . . E-781, 093 Guyer, B. . . . . . . . . . . . . . . . . . . . . . . . . H-556, 073

Guenthard, H. F. . . . . . . . . . . . . . . . . . . V-384, 030

Guzman, B. . . . . . . . . . . . . . . . . . . . . .M-1694, 190

Guerriero, L. . . . . . . . . . D-759, 092; C2-1217, 157 Guerrini, G.. . . . . . . . . . . . . . . . . . . . C2-1398, 169

Guzman, M. . . . . . . . . . K-900, 104; C2-1909, 237 Guzmán-Gómez, L. . . . . . . . . . . . . . . . D-765, 092

Guerry, S. . . . . . . . . . . . . . . . . . . . . . . L2-308, 027

Gygax, S. E.. . . . . . . . . . . . . . . . . . . . . . P-563, 075

Guery, B. . . . . . . . . . . . . . . B-050, 005; B-060, 005

Gyssens, I. C.. . . . . . . . . . . . . . . . . . . . . B-044, 005

Guevara, C. P. . . . . . . . . . . . . . . . . . . . B-1322, 165 Guglielmini, J. . . . . . . . . . . . . . . . . . . . B-1312, 165 Guglietta, A. . . . . . . . . . . . E-204, 016; E-205, 016; . . . . . . . . E-210, 016; D-769, 092; M-980, 111; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1718, 191 Guidet, B. . . . . . . . . . . . . . . . . . . . . . . . D-173, 013 Guillard, T. . . . . . . . . . . . . . . . . . . . . . B-1306, 164 Guillet, J. . . . . . . . . . . . . . . . . . . . . . . . L2-302, 027 Guimard, Y. . . . . . . . . . . . . . . . . . . . . L1-1639, 186 Guinea, J.. . . . . . . . . . .M-1232, 159; M-1684, 190; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1688, 190 Guinea-Ortega, J. V. . . . . . . . . . . . . . . .M-332, 028 Guiot, P. . . . . . . . . . . . . . . . . . . . . . . . L1-291, 026 Guitton, C. . . . . . . . . . . . . . . . . . . . . L1-1224, 158 Gul, H. C. . . . . . . . . . . . . . . . . . . . . . . L1-960, 110 Gulick, R. M. . . . . . . . . . . . . . . . . . . . . . 1188, 152 Gullberg, E. . . . . . . . . . . . . . . . . . . . . . A-1966, 241 Gumpl, E. . . . . . . . . . . . . . . . . . . . . . . D-1412, 170 Gunst, J. D. . . . . . . . . . . . . . . . . . . . . L1-1650, 187 Günthard, H.. . . . . . . . . . . . . . . . . . . . H-1566, 179 Guo, B. N. . . . . . . . . . . . . A-640, 083; F-1503, 176; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1504, 176 Guo, Q. . . . . . . . . . . . . . . . . . . . . . . . C2-1355, 167 Guo, X. . . . . . . . . . . . . . . . . . . . . . . . . . B-047, 005 Guo, Y. . . . . . . . . . . . . . F-1508, 176; K-1634, 185 Gupta, C.. . . . . . . . . . . . . . . . . . . . . . L1-2105, 254 Gupta, R.. . . . . . . . . . . . . . . . . . . . . . . . F-830, 098 Gupta, S. . . . . . . . . . . . . . . . . . . . . . . C2-1982, 243 Gurevich, J. . . . . . . . . . . . . . . . . . . . . . . B-045, 005 Gurevitch, A. S. . . . . . . . . . . . . . . . . . . L1-299, 026 Gurgui, M. . . . . . . . . . . . . K-256, 022; T-340, 029; . . . . . . . . . . . . . . . . . . K-938, 106; K-1621, 184 Gustafson, D. . . . . . . . . .D-170, 012; D-1774, 201 Gustafson, F. . . . . . . . . . . . . . . . . . . . . T-1072, 116 Gustafsson, L. L. . . . . . . . . . . . . . . . . . . H-893, 103 Gutiérrez, A. . . . . . . . . . . . . . . . . . . . . K-1924, 239 Gutiérrez, C. . . . . . . . . . . . . . . . . . . . . H-1567, 179

H

Hall, A. D.. . . . . . . . . . . . . A-601, 082; A-602, 082

Hall, G. S. . . . . . . . . . . . . .D-735, 091; D-771, 092 Hall, L. . . . . . . . . . . . . . . . . . . . . . . . .M-1691, 190 Halliday, C. . . . . . . . . . . . . . . . . . . . . .M-1680, 190 Hallin, M. . . . . . . . . . . . . . . . . . . . . . . . A-598, 082 Halperin, S. A.. . . . . . . . . . . . . . . . . . G3-1542, 178 Hamada, Y. . . . . . . . . . . . . . . . . . . . . . . H-888, 103 Hamandi, B. . . . . . . . . . T-1043, 113; K-1590, 181; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1591, 181 Hamdan, H. . . . . . . . . . . . . . . . . . . . . H-1575, 180 Hamelin, M. . . . . . . . . . . . . . . . . . . . . . V-399, 030 Hamerschlak, N. . . . . . . . . . . . . . . . . .M-1234, 159 Hamilos, G. . . . . . . . . . . . . . . . . . . . . .M-1058, 115

Ha, H. . . . . . . . . . . . . . . . . . . . . . . . . .M-1677, 190 Haaland, R. E. . . . . . . . . . . . . . . . . . . . H-1570, 179 Haas, P. J.. . . . . . . . . . . . . . . . . . . . . . . .M-334, 028 Habeeb, M. A. . . . . . . . . . . . . . . . . . . . F-2054, 248 Haber, P. . . . . . . . . . . . . . . . . . . . . . . . G-1052, 114 Habyarimana, E. . . . . . . . . . . . . . . . . . D-1421, 170 Hachem, R. Y. . . . . . . . . F-2012, 246; F-2013, 246; . . . . . . F-2014, 246; K-2082, 251; K-2096, 252 Hachich, E. . . . . . . . . . . . . . . . . . . . . . C2-717, 088 Hachmann, A. . . . . . . . . . . . . . . . . . . . F-1519, 177 Hackel, M.. . . . . . . . . . .C2-099, 009; C2-100, 009; . . . . . .C2-120, 009; C2-143, 010; C2-141, 010; . . . . . .C2-144, 010; C2-147, 010; C2-148, 010; . . . . . .C2-150, 010; C2-688, 087; C2-721, 089; . . . . . C2-722, 089; C2-724, 089; C2-1210, 157; . . . . . .C2-1352, 167; E-1474, 174; F-1525, 177 Hackstein, H. . . . . . . . . . . . . . . . . . . . . T-341, 029 Haddad, M. . . . . . . . . . . . . . . . . . . . . . H-1574, 180 Hady, W. A.. . . . . . . . . . . . . . . . . . . . . E-1468, 173 Haegele, U. . . . . . . . . . . . . . . . . . . . . . K-2084, 251 Hafkin, B. . . . . . . . . . . . . . . . . . . . . . . E-1486, 174 Hagenaars, J. C. . . . . . . . . . . . . . . . . . . L1-965, 110 Hagihara, K. . . . . . . . . . . . . . . . . . . . . D-1402, 170 Hagihara, M. . . . . . . . . . . .A-014, 003; A-022, 003; . . . . . . . . . . . . . . . . . . .A-023, 004; M-328, 028 Hahka, D. . . . . . . . . . . . . . . . . . . . . . . .M-967, 111 Hai Consortium . . . . . . . . . . . . . . . . . . K-469, 048 Haider, S.. . . . . . . . . . . . . . . . . . . . . . . C2-096, 008 Haihara, M. . . . . . . . . . . . . . . . . . . . . . . A-015, 003 Hainaut, M. . . . . . . . . . . . . . . . . . . . . . D-1413, 170 Hajjar, L. A.. . . . . . . . . . . . . . . . . . . . . K-1603, 183 Hakyemez, I. . . . . . . . . . . . . . . . . . . . . . V-379, 030 Halac, U. . . . . . . . . . . . . . . . . . . . . . . . . V-376, 030 Halasohoris, S.. . . . . . . . .F-1495, 175; F-1522, 177 Hale, D. . . . . . . . . . . . . . . . . . . . . . . . . . K-558, 074

Final Program

Hamilton, M. . . . . . . . . . . . . . . . . . . . B-1736, 196 Hamilton, S. . . . . . . . . . . . . . . . . . . . . . F-828, 097 Hammel, J. P. . . . . . . . . . . . . . . . . . . . . A-1962, 241 Hammerschlag, M. R. . . . . . . . . . . . . . . E-206, 016 Hammerum, A. . . . . . . . . . . . . . . . . . . K-1925, 239 Hammerum, A. M. . . . . . . . . . . . . . . . K-1617, 184 Hammond, S. . . . . . . . . . . . . . . . . . . . . T-354, 029 Hamouda, T. . . . . . . . . . . . . . . . . . . . . . G-869, 101 Hamprecht, A.. . . . . . . . M-338, 028; D-1423, 170 Han, D. . . . . . . . . . . . . . . . . . . . . . . . . . T-366, 029 Han, J. . . . . . . . . . . . . . V-1078, 117; G3-1550, 178 Han, S. . . . . . . . . . . . . . . . H-230, 019; K-916, 104 Hanahoe, B.. . . . . . . . . . C2-119, 009; C2-122, 009 Hance, K.. . . . . . . . . . . . . . . . . . . . . . . D-1410, 170 Hancock, R.. . . . . . . . . . . . . . . . . . . . . . . . 521, 066 Handiwala, L. . . . . . . . . . . . . . . . . . . . . V-397, 030 Hangartner, L. . . . . . . . . . . . . . . . . . . . . V-384, 030 Hannan, T. J. . . . . . . . . . . . . . . . . . . . . . . . 509, 063 Hanselmann, R.. . . . . . . . . . . . . . . . . . A-1289, 163 Hansen, D. S. . . . . . . . . . . . . . . . . . . . C2-687, 087 Hansen, F. . . . . . . . . . . . . . . . . . . . . . . K-1617, 184 Hanson, A. . . . . . . . . . . . . . . . . . . . . . . F-826, 097 Hanson, N. D. . . . . . . . .C1-077, 006; C2-115, 009; . . . . . . . . . . . . . . . . . B-1336, 165; D-1445, 172 Hao, B. . . . . . . . . . . . . . . . . . . . . . . . . .M-978, 111 Hao, J. . . . . . . . . . . . . . . . . . . . . . . . . . . H-892, 103 Harada, S. . . . . . . . . . . . . . . . . . . . . . . F-1509, 176 Harada, Y. . . . . . . . . . . . . . B-048, 005; B-049, 005; . . . . . . . . . . . . . . . . . . .B-657, 084; B-1297, 164 Harbarth, S.. . . . K-560, 074; 572, 076; K-954, 108 Harboe, Z. B.. . . . . . . . . .G-876, 101; H-1916, 238 Harding, M. . . . . . . . . . . . . . . . . . . . . . F-828, 097 Hardouin, J. . . . . . . . . . L1-1642, 186; D-1458, 172 Hardy, D. . . . . . . . . . . . . . . . . . . . . . . . . H-879, 102

225


Presentation Number

Hardy, I.. . . . . . . . . . . . . . . . . . . . . . . . H-1571, 180

Author

Presentation Number

He, Y. . . . . . . F-843, 099; F-844, 099; F-845, 099; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-846, 099

Harrabi, H. . . . . . . . . . . . . . . . . . . . . L1-2103, 254 Harrell, L. . . . . . . . . . . . . . . . . . . . . . . . K-471, 048

Healan, A. M. . . . . . . . . . . . . . . . . . . . A-1257, 161

Harrington, S. M. . . . . . . . . . . . . . . . . . D-735, 091

Heaney, C. . . . . . . . . . . . . . . . . . . . . . C2-1912, 237 Heath, P. T. . . . . . . . . . . . . . . . . . . . . G3-1544, 178

Harriot, M. . . . . . . . . . . . . . . . . . . . . .M-1713, 191 Harris, A. D. . . . . . . . . . . . . . . . . . . . . C2-095, 008 Harris, J. R. . . . . . . . . . . . . . . . . . . . . .M-1677, 190 Harrison, L. H. . . . . . . . . . . . . . . . . . . T-1037, 113 Harrison, S. J. . . . . . . . . . . . . . . . . . . . T-1027, 113 Harrison, T. S. . . . . . . . . . . . . . . . . . . .M-1670, 190 Harrison, T. . . . . . . . . . . . . . . . . . . . . .M-1699, 191 Hart, C. E.. . . . . . . . . . . . . . . . . . . . . . H-1570, 179 Hartling, H. J. . . . . . . . . . . . . . . . . . . . . B-055, 005 Hartman, P. . . . . . . . . . . . . . . . . . . . . . . K-912, 104 Hartmeyer, G. N. . . . . .D-1409, 170; D-1444, 171 Harvey, C. . . . . . . . . . . . . . . . . . . . . . . . H-885, 102 Haschke, M. . . . . . . . . . . . . . . . . . . . . A-1248, 161 Hasegawa, M. . . . . . . . . . . . . . . . . . . C2-1977, 243 Hasegawa, N.. . . . . . . . . . . . . . . . . . . . . A-038, 004 Hashizume, H. . . . . . . . . . . . . . . . . . . F-1509, 176 Hassan, A. . . . . . . . . . . . . .D-171, 012; D-774, 092 Hasse, B. K. . . . . . . . . . . . . . . . . . . . . . . . . 543, 071 Haste, N. . . . . . . . . . . . . . . . . . . . . . . . F-1999, 246 Hatta, M.. . . . . . . . . . . C2-114, 009; C2-1901, 236 Hattori, T. . . . . . . . . . . . . . . . . . . . . . . C2-101, 009 Haulon, S. . . . . . . . . . . . . . . . . . . . . . . K-2089, 252 Hausdorff, W. P. . . . . . . . . . . . . . . . . . . G-859, 100 Havers, S. . . . . . . . . . . . . . . . . . . . . . . C2-689, 087 Havlichek, D. . . . . . . . . . . . . . . . . . . . . A-018, 003 Hawkey, P. . . . . . . . . . . . . . . . . . . . . . . C2-115, 009 Hawkins, K.. . . . . . . . . . . . . . . . . . . . . F-2064, 249 Hawkins, K. R. . . . . . . . . . . . . . . . . . . . D-174, 013 Hawser, S. . . . . . . . . . . .C2-120, 009; C2-133, 010; . . . . . . C2-140, 010; C2-143, 010; C2-721, 089; . . . . . . . . . . . . . . . . . E-1474, 174; F-2067, 249 Haxaire, M. . . . . . . . . . . . . . . . . . . . . . A-1259, 161 Hayakawa, K.. . . . . . . . . .A-034, 004; C2-096, 008; . . . . . . . . .K-262, 023; K-272, 024; E-787, 094; . . . . . . . K-902, 104; K-1589, 181; K-1604, 183 Hayashi, S.. . . . . . . . . . . . . . . . . . . . . . D-1461, 172 Hayashi, Y. . . . . . . . . . . . . . . . . . . . . . D-1402, 170 Hayashida, T. . . . . . . . . . . . . . . . . . . . . . H-890, 103 Hayden, M. . . . . . . . . . . . . . . . . . . . . . . . 1726, 193 Haydon, D. J.. . . . . . . . . . . . . . . . . . . . F-2016, 247 Hayward, A. C. . . . . . . . . . . . . . . . . . L1-1645, 186 Hazen, R. . . . . . . . . . . . . . . . . . . . . . . . H-550, 073 Haznedaroglu, T. . . . . . C2-1367, 168; D-1430, 171 Hazuda, D. . . . . . . . . . . . . . . . . . . . . . . H-551, 073 He, B. . . . . . . . . . . . . . . . . . . . . . . . . . A-1247, 161 He, J. . . . . . . . A-025, 004; A-028, 004; A-029, 004 He, L. . . . . . . . . . . . . . . . . . . . . . . . . C1-1203, 156

226

Author

Presentation Number

Hertz, F. B. . . . . . . . . . . . . . . . . . . . . . K-1617, 184 Herve, K. . . . . . . . . . . . . . . . . . . . . . . . B-1738, 196 Herwaldt, B. L. . . . . . . . . . . . . . . . . . . . . . 450, 044 Herwaldt, L. . . . . . . . . . . . . . . . . . . . . . . . 486, 054 Hester, J. . . . . . . . . . . . . . . . . . . . . . . . . T-361, 029

Heble, D. E. . . . . . . . . . . . . . . . . . . . . . A-612, 082

Heuer, O. . . . . . . . . . . . . . . . . . . . . . . . . . 1789, 204

Hecht, D. W. . . . . . . . . . . . . E-808, 095; 1845, 220 Hecker, S. J. . . . . . . . . . . . . F-848, 099; F-849, 099; . . . . . . . . . F-850, 099; F-851, 099; F-852, 099; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-858, 099 Heffernan, H. . . . . . . . . . . . . . . . . . . C2-1908, 237

Hevener, K. . . . . . . . . . . . . . . . . . . . . . F-2072, 249 Heymann, D. . . . . . . . . . . . . . . . . . . . . . . . 004, 001 Hezode, C. . . . . . . . . . . . . . . . . . . . . . V-1236, 160

Hegde, N. . . . . . . . . . . . . . . . . . . . . . . B-1315, 165

Hickey, R. . . . . . . . . . . . . . . . . . . . . . . . A-618, 082 Hickman, R. A. . . . . . . . . . E-798, 094; E-800, 094

Heilmann, K. . . . . . . . . . . . . . . . . . . . . C2-126, 010 Heim, J. . . . . . . . . . . . . . F-2030, 248; F-2031, 248; . . . . . . . . . . . . . . . . . .F-2032, 248; F-2033, 248 Heimann, S. . . . . . . . . M-1230, 159; M-1706, 191 Heine, H. S.. . . . . . . . . . B-1302, 164; B-1304, 164 Heine, R. . . . . . . . . . . . . . . . . . . . . . . . . . . 455, 045

Hickey, A. J.. . . . . . . . . . . . . . . . . . . . . . . . 437, 041

Hicks, C. . . . . . . . . . . . . . . . . . . . . . . . . H-229, 019 Hidalgo, C. . . . . . . . . . . . . . . . . . . . . . . K-938, 106 Hidalgo Tenorio, C.. . . . . L1-289, 026; K-943, 106; . . . . . . . . . . . . . . . . . . . . . . . . . . . H-1921, 238 Hidri, N. . . . . . . . . . . . . . . . . . . . . . . C1-1739, 197

Heineck, B. L. . . . . . . . . . . . . . . . . . . C2-1905, 236 Heintz, B. . . . . . . . . . . . . . . . . . . . . . . . K-915, 104

Higasa, K. . . . . . . . . . . . . . . . . . . . . . . . H-890, 103 Higgins, P. G. . . . . . . . . . . . . . . . . . . . C1-070, 006

Heise, M. . . . . . . . . . . . . . . . . . . . . . . . . . 1102, 124 Heisig, A. . . . . . . . . . . . . . . . . . . . . . . C1-667, 085 Heisig, P. . . . . . . . . . . . . . . . . . . . . . . . C1-667, 085 Henderson, C. . . . . . . . . . . . . . . . . . . . L2-307, 027 Henderson, H. H. . . . . . . . . . . . . . . . . . P-994, 112

Higgs, C. . . . . . . . . . . . . . . . . . . . . . . . . H-212, 017

Hendrix, C. W. . . . . . . . . . . . . . . . . . . H-1570, 179 Hennessey, Jr. J. P. . . . . . . . . . . . . . . . . . G-868, 101 Henrich, B. . . . . . . . . . . . . . . . . . . . . . C1-588, 081 Henriet, A. . . . . . . . . . . . . . . . . . . . . . . A-036, 004 Henriques, A. . . . . . . . . . . . . . . . . . . . C2-713, 088 Hensgens, M. . . . . . . . . . . K-472, 048; K-930, 105 Hensler, M. . . . . . . . . . . F-1514, 176; F-1999, 246 Hensley, R. . . . . . . . . . . . . . . . . . . . . . D-1416, 170 Hentic, O. . . . . . . . . . . . . . . . . . . . . . . K-2087, 252 Herbrecht, R.. . . . . . . . M-1225, 159; M-1707, 191 Herman, P.. . . . . . . . . . . . . . . . . . . . . .M-1686, 190 Herman, R. . . . . . . . . . . . . . . . . . . . . . C1-459, 047 Hermida, J. . . . . . . . . . . . . . . . . . . . . . . H-217, 018 Hermsen, E. D. . . . . . . . . K-2078, 250; K-922, 105 Hernandez, C. . . . . . . . . . . . . . . . . . . . . D-747, 092 Hernandez, Y. . . . . . . . . . . . . . . . . . . C2-1370, 168 Hernández Ochoa, L. R. . . . . . . . . . . . . F-833, 098 Hernández-Novoa, B. . . . . . . . . . . . . . H-1567, 179 Hernández-Rodríguez, P. A. . . . . . . . C2-1357, 167 Hernández-Salgado, M. . . . . . . . . . . C2-1356, 167 Herradura, P. . . F-843, 099; F-844, 099; F-845, 099 Herrera, M. . . . . . . . . . . . . . . . . . . . . . D-1449, 172 Herrera, M. L. . . . . . . . . . . . . . . . . . . .M-1674, 190 Herrero, M. . . . . . . . . . . . . . . . . . . . . . K-1924, 239 Hershberger, E. . . . . . . . A-641, 083; L1-1638, 186 Hershfield, J. . . . . . . . . . . . . . . . . . . . . F-1522, 177

September 9-12 |

Higuchi, S.. . . . . . . . . . . . . . . . . . . . . . F-2039, 248 Hikosaka, A. . . . . . . . . . . . . . . . . . . . . D-1438, 171 Hilbert, D. W. . . . . . . . . . . . . . . . . . . . . P-563, 075 Hilge, R. . . . . . . . . . . . . . . . . . . . . . . . . H-887, 103 Hill, D. R. . . . . . . . . . . . . . . . . . . . . . . . . . 405, 033 Hill, K. E. . . . . . . . . . . . F-2062, 249; F-2063, 249; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2064, 249 Hilliard, J. . . . . . . . . . . . . . . . . . . . . . . B-1734, 196 Hilliard, J. J. . . . . . . . . . . . . . . . . . . . . . B-1737, 196 Hillman, R. J. . . . . . . . . . . . . . . . . . . . L2-301, 027 Hilty, M. . . . . . . . . . . . . . . . . . . . . . . . C2-116, 009 Hindler, J. A. . . . . . . . . . . . . . . . . . . . . D-1433, 171 Hingwe, A. . . . . . . . . . . . . . . . . . . . . . C2-112, 009 Hino, M. . . . . . . . . . . . . . . . . . . . . . . . D-1402, 170 Hinojosa-Robles, R. M. . . . . . . . . . . C2-1357, 167 Hirai, Y. . . . . . . . . . . . . . . . . . . . . . . . . .M-326, 028 Hirakata, Y. . . . . . . . . . . . . . . . . . . . . . C2-114, 009 Hirosawa, S. . . . . . . . . . . . . . . . . . . . . F-1509, 176 Hirose, A. . . . . . . . . . . . . . . . . . . . . . . D-1402, 170 Hirsch, E. B. . . . . . . . . . K-901, 104; D-1450, 172; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1626, 185 Hirsch, H. . . .T-343, 029; T-355, 029; T-1070, 116 Hirsch, J. . . . . . . . . . . . . . . . . . . . . . . . L1-959, 109 Hirschfield, G.. . . . . . . . . . . . . . . . . . . V-1236, 160 Hirst, G. C. . . . . . . . . . . . . . . . . . . . . . . F-848, 099 Hites, M. C. . . . . . . . . . . . . . . . . . . . . . A-637, 083 Hjort, U. . . . . . . . . . . . . . . . . . . . . . . L1-1652, 187 Hoban, D. . . C2-100, 009; C2-120, 009; C2-141, 010; . . . . . . C2-143, 010; C2-144, 010; C2-147, 010; . . . . . . . C2-148, 010; C2-149, 010; E-191, 015; . . . . . . C2-688, 087; C2-721, 089; C2-722, 089; . . . . .C2-1352, 167; C2-1360, 167; E-1462, 173

AUTHOR INDEX Author

Presentation Number

Hoban, D. J. . . . . . . . . . . . E-194, 015; E-200, 015; . . . . . . . . . . . . . . . . .C2-103, 009; C2-135, 010; . . . . . . E-779, 093; C2-1379, 169; E-1486, 174

Author

Presentation Number

Hoen, B. . . . . . . . . . . . . . . . . . . . . . . . . K-939, 106

Hope, W. W. . . . . . . . . . . . . 411, 035; M-977, 111; . . . . . . A-1942, 240; A-1943, 240; A-1944, 240 Hopkins, S. . . . . . . . . . . E-208, 016; L1-1663, 189; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1958, 241 Hopman, J. . . . . . . . . . . . . . . . . . . . . . . K-244, 021 Hoppe, T.. . . . . . . . . . . . . . . . . . . . . . . D-1423, 170

Hoenigl, M. . . . . . . . . . . . V-398, 030; P-1009, 112; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1404, 170

Horacio, A. . . . . . . . . . . . . . . . . . . . . . . G-866, 100 Horan, J. . . . . . . . . . . . . . . . . . . . . . . . . A-026, 004

Hoet, B. . . . . . . . . . . . . . . . . . . . . . . . . . G-859, 100 Hoetelmans, R. . . . . . . . A-1258, 161; A-1260, 161

Horcajada, J. P.. . . . . . . . .C2-111, 009; K-258, 022; . . . . . . . . . . . . . . . . .K-1624, 184; M-1673, 190 Hori, T. . . . . . . . . . . . . . . . . . . . . . . . . F-1506, 176

Hobbs, M. . . . . . . . . . . . . . . . . . . . . . . P-1023, 112 Hoekstra, C. J. . . . . . . . . . . . . . . . . . . . L1-965, 110

Hoff, P. M.. . . . . . . . . . . . . . . . . . . . . . K-1603, 183 Hoffmeyer, P. . . . . . . . . . . . K-249, 022; K-253, 022 Hofling-Lima, A. L. . . . . . . . . . . . . . . E-1481, 174 Hofmann, P. . . . . . . . . . . . . . . . . . . . . . K-248, 022 Hofmann, W. K. . . . . . . M-335, 028; M-1704, 191 Hogan, P. . . . . . . . . . . . . . . . . . . . . . . .M-1683, 190 Hogevik, H.. . . . . . . . . . . . . . . . . . . . . T-1042, 113 Hokama, L. . . . . . . . . . . . . . . . . . . . . . F-1531, 177 Holden, P. N. . . . . . . . . . . . A-024, 004; E-201, 015 Holder, A. . . . . . . . . . . . . . . . . . . . . . . H-1570, 179 Holguin, D. F. . . . . . . . . . . . . . . . . . . C2-1915, 237 Holland, D. . . . . . . . . . . . . . . . . . . . . . P-1023, 112 Hollegaard, M. . . . . . . . . . . . . . . . . . . . G-876, 101 Holliday, N. . . . . . . . . . . .D-766, 092; E-1463, 173; . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-1467, 173 Hollis-Symynkywicz, M. F. . . . . . . . . . F-1540, 177 Holloway, K. . . . . . . . . . . . . . . . . . . . . K-1635, 185 Holmes, A. . . . . . . . . . . . . . K-260, 023; 1081, 118 Holmes, N. E. . . . . . . . . . . . . . . . . . . . . . 1166, 147 Holst, A. . . . . . . . . . . . . . . . . . . . . . . . G-1752, 198 Holtzer, C.. . . . . . . . . . . . . . . . . . . . . . . H-212, 017 Holzmann, A. . . . . . . . . . . . . . . . . . . . K-1125, 129 Hong, H. . . .T-366, 029; V-1074, 117; V-1239, 160 Hong, J. . . . . . . . . . . . . . C2-1216, 157; E-804, 094 Hong, J. H. . . . . . . . . . . . . . . . . . . . . . . E-792, 094 Hong, K. . G-872, 101; B-1309, 165; C2-1978, 243 Hönigl, M.. . . . . . . . . . . . . . . . . . . . . . . V-395, 030 Honnorat, E. . . . . . . . . . . . . . . . . . . . C2-1374, 168 Honnorat, J. . . . . . . . . . . . . . . . . . . . . L1-1649, 187 Hontz, R. D. . . . . . . . . . . . . . . . . . . . . P-1021, 112 Hood, J. . . . . . . . . . . . . . . . . . . . . . . . . . . 1729, 194 Hook, E. W. . . . . . . . . . . . . . . . . . . . . . D-185, 014 Hooper, D. C. . . . . . . . . . . . . . . 515, 064; 580, 078 Hoopes, J. D. . . . . . . . . . . . . . . . . . . . . . V-383, 030 Hooton, T. M. . . . . . . . . . . . . . . . . . . . . . . 511, 063 Hoover, J. L. . . . . . . . . .A-1270, 162; A-1271, 162; . . . . . . . . . . . . . . . . . A-1275, 162; B-1308, 164 Hoover, R. . . . . . . . . . . .A-1290, 163; A-1956, 241; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1957, 241 Hope, R. . . . . . . . . . . . . . . . . . . . . . . . C2-102, 009 Hope, W. . . . . . . . . . . . . . . A-1765, 200; 1886, 233

Horikoshi, Y. . . . . . . . . . . . . . . . . . . . . D-1429, 171 Horino, A. . . . . . . . . . . . . . . . . . . . . . . D-1456, 172 Horita, Y.. . . . . . . . . . . . . . . . . . . . . . . A-1254, 161 Hornak, V. . . . . . . . . . . . . . . . . . . . . . . . F-810, 096 Hornsey, M.. . . . . . . . . . . . D-761, 092; E-797, 094 Horsney, M.. . . . . . . . . . . . . . . . . . . . . B-1299, 164 Horswill, A. R. . . . . . . . . B-646, 084; F-1517, 176 Horton, L. B.. . . . . . . . . . . . . . . . . . . . C1-462, 047 Horwedel, T. . . . . . . . . . . . . . . . . . . . . T-1068, 116 Hosbul, T. . . . . . . . . . . C2-1394, 169; D-1430, 171 Hose, A. . . . . . . . . . . . . . . . . . . . . . . . . D-155, 011 Hoshino, K. . . . . . . . . . . F-2035, 248; F-2036, 248; . . . . . . F-2037, 248; F-2038, 248; F-2039, 248; . . . . . . F-2040, 248; F-2043, 248; F-2044, 248; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2045, 248 Hosler, J. P. . . . . . . . . . . . . . . . . . . . . . .M-968, 111 Hospital Clinic Endocarditis Study Group, . . . . . . . . . . . . . . . . . . .A-610, 082; B-648, 084; . . . . . . . . . . . . . . . . . . K-945, 106; E-1465, 173 Hossain, Z. . . . . . . . . . . . . . . . . . . . . . C2-711, 088 Hot, C. . . . . . . . . . . . . . . . . . . . . . . . C1-1349, 166 Hothi, J. . . . . . . . . . . . . . . . . . . . . . . . . . K-902, 104 Hotta, G. . . . . . . . . . . . . . K-949, 107; K-1599, 182 Houbraken, J. . . . . . . . . . . . . . . . . . . . .M-332, 028 Hough, G. W. . . . . . . . . . . . . . . . . . . . F-2026, 247 Houhou, N. . . . . . . . . . . . . . . . . . . . . . V-1073, 117 Housman, S. T. . . . . . . . . . A-022, 003; A-023, 004 Houze, S. . . . . . . . . . . . . . . . . . . . . . . . . P-570, 075 How Ooi, M.. . . . . . . . . . . . . . . . . . . . . . 1829, 212 Howard, S.. . . . . . . . . . .A-1765, 200; A-1943, 240; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1944, 240 Howard, S. J. . . . . . . . . . .M-335, 028; M-977, 111; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1942, 240 Howard, W. J. . . . . . . . . . . . . . . . . . . . C2-112, 009 Howson, D. . . . . . . . . . . . . . . . . . . . . . D-1410, 170 Hristea, A. . . . . . . . . . . . C2-110, 009; D-1776, 201 Hryniewicz, W. . . . . . . . . . . . . . . . . . . C2-109, 009 Hsu, C. H. . . . . . . . . . . . . . . . . . . . . . . F-1502, 176 Hsu, L. Y. . . . . . . . . . . . . .E-791, 094; K-896, 104; . . . . . . . . . . . . . . . . . . E-1476, 174; E-195, 015 Hsueh, P. . . . . . . . . . . . . . 1136, 135; C2-1212, 157 Hu, B. . . . . . . . . . . . . . . . . . . . . . . . . . . K-269, 023

Final Program

Author

Presentation Number

Hu, F. . . . . . . . . . . . . . . . . . . . . . . . . C2-1355, 167 Hu, M.. . . . . . . . . . . . . . . . A-028, 004; A-029, 004 Hu, S. . . . . . . . . . . . . . . . . . . . . . . . . . . K-261, 023 Hu, X. X. . . . . . . . . . . . . . . . . . . . . . . . F-1499, 176 Hua, L. . . . V-383, 030; B-1736, 196; B-1737, 196 Huang, C. . . . . . . . . . . . . . . . . . . . . . . . A-613, 082 Huang, E. . . . . . . . . . . . . . . . . . . . . . . F-1508, 176 Huang, H. X. . . . . . . . . . . . . . . . . . . . . F-1502, 176 Huang, J. . . . . . . . . . . . . .F-1503, 176; F-1504, 176 Huang, K. . . . . . . . . . . . . . . . . . . . . . . B-1328, 165 Huang, S. S.. . . . . . . . . . . . . . . . . . . . . . . 1725, 193 Huang, V. . . . . . . . . . . . . A-609, 082; D-1435, 171 Huang, W. . . . . . . . . . . . H-1574, 180; K-1585, 181 Huang, X. . . . . . . . . . . . L1-292, 026; K-1598, 182; . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1661, 189 Huang, Y. Q. . . . . . . . . . .F-1497, 176; F-1498, 176 Huangsaitong, J. . . . . . . . . . . . . . . . . . A-1279, 162 Hubacek, P. . . . . . . . . . . . . . . . . . . . . . . T-344, 029 Huband, M. D. . . . . . . . . . . . . . . . . . C1-1745, 197 Huber, J. . . . . . . . . . . . . . . . . . . . . . . . F-1496, 176 Hubschwerlen, C. . . . C1-1346, 166; C1-1347, 166 Huffnagle, G. B. . . . . . . . . . . . . . . . . . . K-926, 105 Hufton, R. . . . . . . . . . . . . . . . . . . . . . . . F-828, 097 Hughes, D. . . . . . . . . . . . . E-798, 094; F-829, 098; . . . . . . . . . . . . . . . . . A-1764, 200; A-1966, 241 Hughes, M. . . . . . . . . . . . . . . . . . . . . . . V-383, 030 Hugle, T. . . . . . . . . . . . . . . . . . . . . . . . K-2073, 250 Huh, K. . . . . . . . . . . . . . C2-137, 010; K-1587, 181 Huisse, M. G. . . . . . . . . . . . . . . . . . . . . P-570, 075 Hujer, A. M. . . . . . . . . .C2-092, 008; C2-686, 087; . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1209, 156 Hujer, K. M. . . . . . . . . . C2-686, 087; F-2059, 249 Hull, C. M. . . . . . . . . . . . . . . . . . . . . . . V-397, 030 Hull, M.. . . . . . . . . . . . . . . . . . . . . . . . K-1593, 182 Hulten, K. G. . . . . . . . . . . . . . . . . . . C2-1361, 167 Hultgren, S. J. . . . . . . . . . . . . . . . . . . . . . . 512, 063 Humar, A. . . . . . . . . . . . . . . . . . . . . . . . . . 409, 034 Hummel, M. . . . . . . . . . . . . . . . . . . . .M-1704, 191 Humphreys, D. P. . . . . . . . . . . . . . . . . B-1738, 196 Humphries, R. . . . . . . . . K-280, 024; C2-1401, 169 Hung, C. . . . . . . . . . . . . A-1251, 161; G-867, 100; . . . . . . . . H-215, 018; H-218, 018; H-221, 019; . . . . . . .H-226, 019; L2-309, 027; V-1238, 160; . . . . . . . . . . . . . . . . . . . . . . . . . . . . H-1578, 180 Hung, W. C. . . . . . . . . . . . . . . . . . . . C1-1340, 166 Hunstad, D. A. . . . . . . . . . . . . . . . . . . . A-612, 082 Hunt, D. . . . . . . . . . . . . . . . . . . . . . . . F-1526, 177 Hunter, I. . . . . . . . . . . . . . . . . . . . . . . . F-1530, 177 Hurteau, G. . . . . . . . . . . B-1302, 164; B-1304, 164 Hurwitz, J. L. . . . . . . . . . . . . . . . . . . . . V-382, 030 Husain, S. . . M-337, 028; T-365, 029; T-1043, 113; . . . . . . . . . . . . . . . . . T-1067, 116; M-1227, 159

227


Presentation Number

Author

Presentation Number

Author

Presentation Number

Huyard, S. . . . . . . . . . . . . . . . . . . . . . .M-1698, 191

Iqbal, A.. . . . . . . . . . . . . . . . . . . . . . . .M-1670, 190

Jacobs, R. . . . . . . . . . . . . . . . . . . . . . . . A-1292, 163

Huyse, T. . . . . . . . . . . . . . . . . . . . . . . . P-1014, 112 Hwang, Y. Y. . . . . . . . . . . . . . . . . . . . . F-2010, 246

Irani, J. . . . . . . . . . . . . . . . . . . . . . . . . . K-1584, 181 Ireland, C. E. . . . . . . . . . . . A-600, 082; A-603, 082

Jacobson, I. . . . . . . . . . . . . . . . . . . . . . V-1236, 160

Hwei-Fang Tien, . . . . . . . . . . . . . . . .M-1669, 190

Isaacs, D. . . . . . . . . . . . . . . . . . . . . . . . . . 1158, 145

Hyde, L. . . . . . . . . . . . . . . . . . . . . . . . E-1480, 174

Isendahl, J. . . . . . . . . . . . . . . . . . . . . . . C2-107, 009

Jacobus, N. V. . . . . . . . . . . . . . . . . . . . . K-471, 048 Jacoby, G. A. . . . . . . . . . . . . . . . . . . . . . . . 513, 064

Ishibashi, N. . . . . . . . . C2-114, 009; C2-1901, 236 Ishibashi, T. . . . . . . . . . . . . . . . . . . . . . . A-019, 003

I Iacovides, H. . . . . . . . . . . . . . . . . . . . . . A-613, 082

Ishihara, M. . . . . . . . . . . . . A-607, 082; A-608, 082 Ishii, C. . . . . . . . . . . . . . .F-2035, 248; F-2043, 248

Iannetta, M.. . . . . . . . . . . . . . . . . . . . . . D-165, 012 Iannone, R. . . . . . . . . . M-1676, 190; M-1695, 190

Ishii, Y. . . . . . . . . . . . . . .C1-077, 006; K-918, 105; . . . . . . D-1438, 171; D-1459, 172; F-2040, 248

Ibarra, G. . . . . . . . . . . . . . . . . . . . . . . C2-1909, 237

Ishizaka, T.. . . . . . . . . . . . . . . . . . . . . . F-2042, 248 Isloor, S.. . . . . . . . . . . . . . . . . . . . . . . . B-1315, 165

Ibrahim, A. . . . . . . . . . . . .B-650, 084; G-868, 101; . . . . . . .M-973, 111; M-967, 111; E-1473, 174; Ibrahim, K. Y. . . . . . . . . . . . . . . . . . . . K-1603, 183 Ichiki, K. . . . . . . . . . . . .K-1594, 182; M-1687, 190 Ichiyama, S. . . . . . . . . . . . K-949, 107; K-1599, 182 Ichki, K.. . . . . . . . . . . . . . . A-607, 082; A-608, 082 Icyeza, E. R. . . . . . . . . . . . . . . . . . . . . . D-156, 011 Idasa, M. B. . . . . . . . . . . . . . . . . . . . . . E-1994, 245 Idelevich, E. A. . . . . . . . . . . . . . . . . . . E-1483, 174 Ierino, F. . . . . . . . . . . . . . . . . . . . . . . . . T-369, 029 Iglesias, C. . . . . . . . . . . . . . . . . . . . . . . C2-142, 010 Ike, W. E. . . . . . . . . . . . . . . . . . . . . . C2-1898, 236 Ikeda, K. . . . . . . . . . . . . . . . . . . . . . . . . F-825, 097 Ikeuchi, H. . . . . . . . . . . . . . . . . . . . . . K-1594, 182 Ilina, E. . . . . . . . . . . . . . . . . . . . . . . . . C2-697, 087 Imamura, Y. . . . . . . . . . . . . . . . . . . . . . . V-380, 030 Imanaka, R. . . . . . . . . . . . . . . . . . . . . .M-1226, 159 Imöhl, M. . . . . . . . . . . . . . . . . . . . . . . . G-863, 100 Imperial, M. . . . . . . . . . . . . . . . . . . . . C2-085, 008 Inaba, A. . . . . . . . . . . . . . . . . . . . . . . . D-1402, 170 Inagawa, H. . . . . . . . . . . . . . . . . . . . . . . K-897, 104 Indolfi, G. . . . . . . . . . . . . . . . . . . . . . . . . 1800, 207 Inglis, T. J. . . . . . . . . . . . . . . . . . . . . . . C2-708, 088 Ingram, P. R. . . . . . . . . . C2-689, 087; C2-708, 088 Ingrand, P. . . . . . . . . . . . . . . . . . . . . . . . P-996, 112 Inokuma, K.. . . . . . . . . . . . . . . . . . . . . F-2055, 248 Inomata, S. . . . . . . . . . C2-114, 009; C2-1901, 236 Inoue, F. M. . . . . . . . . . . . . . . . . . . . . C2-1376, 169 Inoue, K. . . . . . . . . . . . . . . . . . . . . . . . F-1509, 176 Insunza, A. . . . . . . . . . . . . . . . . . . . . . T-1038, 113 Ioana, M. . . . . . . . . . . . . . . . . . . . . . . . . B-044, 005 Ioannidis, I. . . . . . . . . . . . . . . . . . . . . . . K-562, 074 Ion, M. . . . . . . . . . . . . . . . . . . . . . . . . C2-110, 009 Iorga, B. I. . . . . . . . . . . . C1-066, 006; C1-072, 006 Iori, A. . . . . . . . . . . . . . . . . . . . . . . . . . . V-393, 030 Iorio, N. . . . . . . . . . . . . . . . . . . . . . . . C2-1377, 169 Iorio, N. L. . . . . . . . . .C1-671, 085; C2-1383, 169; . . . . . . . . . . . . . . . C2-1387, 169; C2-1907, 237 Ip, M.. . . . . . . . . . . . . . . . . . . . . . . . . . G-1751, 198

228

Itagaki, M. . . . . . . . . . . . . . . . . . . . . . .M-1226, 159 Iten, A. . . . . K-954, 108; K-956, 108; K-2075, 250 Ito, J. . . . . . . . T-349, 029; T-350, 029; T-351, 029; . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-1039, 113 Ito, Y. . . . . . . . . . . . . . . . . K-949, 107; K-1599, 182 Itoh, K. . . . . . . . . . . . . . .F-2049, 248; F-2055, 248 Itoh, S. . . . . . . . . . . . . . . . . . . . . . . . . . F-2042, 248 ITUBRAS-GEIH-SEIMC Group . . C2-111, 009 Ivanova, R.. . . . . . . . . . . . . . . . . . . . . . . K-943, 106 Iversen, M.. . . . . . . . . . . . . . . . . . . . . . T-1072, 116 Iversen, P. L. . . . . . . . . . . . . . . . . . . . C1-1972, 242 Ivezic-Schoenfeld, Z.. . . . . . . . . . . . .C1-1971, 242; . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1660, 189 Iwanaga, N. . . . . . . . . . . . . . . . . . . . . . . V-380, 030 Iwao, Y. . . . . . . . . . . . . . . . . . . . . . . . C1-1340, 166 Iwata, M. . . . . . . . . . . . . . . . . . . . . . . . D-1438, 171 Iwata, S. . . . . . . . . . . . . .A-038, 004; C2-1354, 167; . . . . . . . . . . . . . . . C2-1977, 243; C2-1990, 244 Iyer, S. . . . . . . . . . . . . C2-1381, 169; C2-1391, 169 Izdebski, R. . . . . . . . . . . . . . . . . . . . . . C2-109, 009 Izikson, R. . . . . . . . . . . . . . . . . . . . . . . G-1053, 114 Izquierdo, M. . . . . . . . . . . . . . . . . . . . . . K-263, 023 Izumi, T. . . . . . . . . . . . . . . . . . . . . . . . F-2041, 248 Izumikawa, K. . . . . . . . . . . B-049, 005; V-380, 030; . . . . . . . . V-400, 030; B-657, 084; B-1297, 164

J Jaber, M. J. . . . . . . . . . . . . . . . . . . . . . . . V-376, 030 Jacinto, P. L.. . . . . . . . . . . . . . . . . . . . C1-1747, 197 Jackson, M. . . . . . . . . . . . . . . . . . . . . . . . 1157, 145 Jackson, P. J. . . . . . . . . . . . . . . . . . . . . . F-2023, 247 Jacob, J. T. . . . . . . . . . . . . . . . . . . . . . . . A-611, 082 Jacob, J. . . . . . . . . . . . . . . . A-027, 004; E-795, 094 Jacob, M. . . . . . . . . . . . . . . . . . . . . . . .M-1061, 115 Jacobs, F. . . . . . . . . . . . . . . . . . . . . . . . . A-637, 083 Jacobs, J.. . . . . . . . . . . . . . . . . . . . . . . . .M-311, 028 Jacobs, M. R. . . . . . . . . .C2-092, 008; C2-720, 089; . . . . . A-1257, 161; C2-1361, 167; F-2059, 249

September 9-12 |

Jacobson, S. . . . . . . . . . . . . . . . . . . . . . . K-928, 105

Jacqmin, H. . . . . . . . . . . . . . . . . . . . . . A-1278, 162 Jacqueline, C.. . . . . . . . . . . B-051, 005; B-054, 005; . . . . . . . . . E-203, 016; B-651, 084; B-653, 084; . . . . . . B-1335, 165; A-1948, 241; F-2056, 248 Jaeger, M.. . . . . . . . . . . . . . . . . . . . . . .M-1055, 115 Jahangiri, S. . . . . . . . . . . . . . . . . . . . . . . F-828, 097 Jahng, M. . . . . . . . . . . . . . . . . . . . . . . . F-2000, 246 Jain, A.. . . . . . . . . . . . . . . . . . . . . . . . . . V-373, 030 Jain, R. . . . . . . . . . . . . . . . . . . . . . . . . . . K-926, 105 Jakielaszek, C. . . . . . . . . . . . . . . . . . . . B-1304, 164 Jakobsen, L. . . . . . . . . . . . . . . . . . . . . . A-1965, 241 Jakubowski, A. . . . . . . . . . . . . . . . . . . . . T-361, 029 Jallad, M. . . . . . . . . . . . . . . . . . . . . . . . K-1584, 181 Jamal, A. J. . . . . . . . . . . . . . . . . . . . . . . . T-365, 029 Jamal, W. . . . . . . . . . . . . . C2-121, 009; D-727, 090 Jambeih, R. . . . . . . . . . . . . . . . . . . . . . L1-284, 025 James, K. D.. . . . . . . . . . . . . . . . . . . . . F-1510, 176 Jamieson, B. . . . . . . . . . . . . . . . . . . . . . A-1286, 162 Jandourek, A. . . . . . . . L1-1659, 189; L1-1661, 189 Janes, R. . . . . . E-204, 016; E-210, 016; D-769, 092 Jang, G. . . . . . . . . . . . . . . . . . . . . . . . C2-1913, 237 Jang, H. . . . . . . . . . . . . . . . . . . . . . . . . B-1298, 164 Jang, J. H. . . . . . . . . . . . . . . . . . . . . . . F-1489, 175 Jang, K. . . . . . . . . . . . . . . . . . . . . . . . . F-1514, 176 Jang, W. . . . . . . . . . . . . . . . . . . . . . . . . . D-755, 092 Janoir, C. . . . . . . . . . . . . . . . . . . . . . . C2-1359, 167 Jansen, K.. . . . . . . . . . . . . . . . . . . . . . . . . . 575, 077 Jansen, K. U. . . . . . . . . . . .D-172, 013; G-870, 101 Janzen, W. P. . . . . . . . . . . . . . . . . . . . . F-1535, 177 Janzon, A. . . . . . . . . . . . . . . . . . . . . . . C1-665, 085 Japan Trichosporonosis Study Group . .M-324, 028 Jarillo-Quijada, M. D. . . . . . . . . . . . . . C2-113, 009 Jarvis, J. . . . . . . . . . . . . . . . . . . . . . . . .M-1699, 191 Jaton, K.. . . . . . . . . . . . . . . . . . . . . . . L1-1221, 158 Javier, C. . . . . . . . . . . . . . . . . . . . . . . . K-2077, 250 Javier, R. . . . . . . . . . . . . L1-289, 026; H-1921, 238 Jayaraman, G. . . . . . . . . . . . . . . . . . . C2-1380, 169 Jayasekara, N.. . . . . . . . . . . . . . . . . . . . K-2081, 251 Jayasundara, K. . . . . . . . . . . . . . . . . . . K-2081, 251 Jayawickrema, S. . . . . . . . . . . . . . . . . . K-2081, 251 Jaydev, F. . . . . . . . . . . . . . . . . . . . . . . . . K-272, 024 Jeffres, M. . . . . . . . . . . . . . . . . . . . . . . D-1434, 171 Jehl, F. . . . . . . . . . . . . . . . . . . . . . . . . . K-2100, 253 Jeng, A. . . . . . . . . . . . . . . . . . . . . . . . . . A-616, 082 Jenkins, S. G. . . . . . . . . . . . . . . . . . . . . . K-471, 048 Jensen, K. S.. . . . . . . . . . . . . . . . . . . . . A-1965, 241

AUTHOR INDEX Author

Presentation Number

Author

Presentation Number

Author

Presentation Number

Jensen, R. H. . . . . . . . . . . . . . . . . . . . .M-1710, 191

Johnson, D. . . . . . . . . . . . . . . . . . . . . . A-1950, 241

Juliano, L. . . . . . . . . . . . . . . . . . . . . . . . D-731, 090

Jensen, S. O. . . . . . . . . . . . . . . . . . . . C1-1743, 197 Jensen, U.. . . . . . . . . . . . . . . . . . . . . . . K-1925, 239

Johnson, J. . . . . . . . . . . .C2-099, 009; C2-141, 010; . . . . . . . . . . . . . . . . .C2-143, 010; C2-147, 010; . . . . . . . . . . . . . . . . . C2-721, 089; C2-722, 089

Jumes, P. . . . . . . . . . . . . . . A-009, 003; A-010, 003 June, C. . . . . . . . . . . . . . . . . . . . . . . . . H-1581, 180

Jensen-Fangel, S. . . . . . . . . . . . . . . . . L1-1650, 187 Jenson, S. O. . . . . . . . . . . . . . . . . . . . . C1-062, 006 Jeong, H. . . . . . . . . . . . . . .F-827, 097; F-2072, 249 Jeong, J. . . . . . . . . . . . . . . K-907, 104; K-2092, 252 Jeong, S.. . . . . . . . . . . . . . . H-230, 019; K-916, 104 Jerse, A. E. . . . . . . . . . . . . . . . . . . . . . . B-1303, 164 Jespersen, B.. . . . . . . . . . . . . . . . . . . . L1-1650, 187 Jespersen, D. J. . . . . . . . . . . . . . . . . . . .M-1693, 190 Jesus, L. A.. . . . . . . . . . . . . . . . . . . . . . K-1606, 183 Jett, S. . . . . . . . . . . . . . . . . . . . . . . . . C1-1742, 197 Jeynes, T. . . . . . . . . . . . . . . . . . . . . . . . . F-828, 097 Ji, D. . . . . . . . . . . . . . . . . . . . . . . . . . . . H-226, 019 Jia, L. . . . . . . . . . . . . . . . . . . . . . . . . . . . K-268, 023 Jian, Z. . . . . . . . . . . . . . . . . . . . . . . . . . C2-083, 008 Jiang, H. . . . . . . . . . . . . . . . . . . . . . . . . H-554, 073 Jiang, J. Q. . . . . . . . . . . . . . . . . . . . . . . F-1502, 176 Jiang, Q.. . . . . . . . . . . . . . . . . . . . . . . . . G-870, 101 Jiang, V. . . A-1950, 241; A-1952, 241; A-1953, 241 Jiang, X. . . . . . . . . . . . . . .F-2002, 246; F-2057, 249 Jiang, Y. . . . . . . . . . . . . . . . . . . . . . . . . K-2096, 252 Jicsinszky, L. . . . . . . . . . . . . . . . . . . . . F-2005, 246 Jih-Luh Tang . . . . . . . . . . . . . . . . . . . .M-1669, 190 Jimenez, F. . . . . . . . . . . . . . . . . . . . . . . . K-940, 106 Jimenez, L. V. . . . . . . . . . . . . . . . . . . L1-1653, 187 Jiménez, O. . . . . . . . . . . . . . . . . . . . . L2-2110, 255 Jiménez de Anta, M. . . . . . . . . . . . . . . C2-696, 087 Jiménez Girón, A. . . . . . . . . . . . . . . . . L1-958, 109 Jiménez-Mejías, E. . . . K-1924, 239; L1-2102, 254 Jiménez-Mejías, M. . . . . C1-683, 086; A-1280, 162 Jiménez-Ortigosa, C.. . . . F-822, 096; M-1715, 191 Jiménez-Parrila, F. . . . . . . . . . . . . . . . . K-1924, 239 Jin, F. . . . . . . . . . . . . . . . . . . . . . . . . . . L2-301, 027 Jin, R. H. . . . . . . . . . . . . . . . . . . . . . . . . H-554, 073 Jing, H. . . . . . . . . . . . . . . . . . . . . . . . . A-1289, 163 J.L. Schmit . . . . . . . . . . . . . . . . . . . . L1-2106, 254 Jo, Y. . . . . . . . . . . . . . . . . . . . . . . . . . . F-2060, 249 Jocham, S. . . . . . . . . . . . . . . . . . . . . . . . K-953, 108 Joffe, A. M. . . . . . . . . . . . . . . . . . . . . . . K-561, 074 Johannsson, B. . . . . . . . . . . . . . . . . . . . K-1611, 184 Johansen, H. K. . . . . . . . . . . . . . . . . . .M-1710, 191 Johansen, M. . . . . . . . . . . . . . . . . . . . . .M-982, 111 Johns, B. . . . . . . . . . . . . . . . . . . . . . . . . H-550, 073 Johnson, A. . . . . . . . . . . C2-100, 009; C2-120, 009 Johnson, A. M. . . . . . . . . . . . . . . . . . L1-1645, 186 Johnson, B. . . . . . . . . . .C2-099, 009; C2-144, 010; . . . . . .C2-147, 010; C2-148, 010; C2-150, 010; . . . . . . . . . . . . . . . . C2-721, 089; C2-1352, 167 Johnson, D. M. . . . . . . . . . . . . . . . . . . F-1512, 176

Johnson, J. R. . . . . . . . . C2-687, 087; L2-2113, 255 Johnson, J. K. . . . . . . . . . . . . . . . . . . . . C2-095, 008 Johnson, J. W. . . . . . . . . . . . . . . . . . . C2-1390, 169 Johnson, L. E. . . . . . . . . . . . . . . . . . . . C2-112, 009 Johnson, L. B. . . . . . . . .K-923, 105; C2-1381, 169; . . . . . . . . . . . . . . . . C2-1391, 169; E-1484, 174 Johnson, L. . . . . . . . . . . . . . . . . . . . . . . T-348, 029 Johnson, M. D. . . . . . . M-1055, 115; M-1703, 191 Johnson, M. E. . . . . . . . . .F-827, 097; F-2072, 249 Johnson, P. . . . . . . . . . . . . . . . . . . . . . . . K-902, 104 Johnson, R. C. . . . . . . . . . . . . . . . . . . C1-1972, 242 Johnson, S. J. . . . . . . . . . . . . . . . . . . . . K-1611, 184 Johnson, S.. . . . . . . . . . . . . . . . . . . . . . K-1583, 181 Johnson, S. J. . . . . . . . . . . . . . . . . . . . . . K-471, 048 Johnston, B. . . . . . . . . . . . . . . . . . . . . . C2-687, 087 Johnstone, J.. . . . . . . . . . . . . . . . . . . . . . K-955, 108 Joly, V. . . . . . . . . . . . . . . . . . . . . . . . . . V-1073, 117 Jones, A. K. . . . . . . . . . C1-680, 086; C1-1973, 242 Jones, B.. . . . . . . . . . . . . . . . . . . . . . . . . V-382, 030 Jones, C. H. . . . . . . . . . . . . . . . . . . . . . . G-870, 101 Jones, L. S.. . . . . . . . . . . A-1276, 162; A-1277, 162 Jones, M. E. . . . . . . . . . . . . . . . . . . . . . .M-331, 028 Jones, R. N. . . . . . . . . . .C2-123, 010; C2-124, 010; . . . . . .C2-129, 010; C2-131, 010; C2-132, 010; . . . . . .C2-136, 010; C2-138, 010; C2-139, 010; . . . . . . .C2-145, 010; C2-146, 010; E-186, 015; . . . . . . . . . E-187, 015; E-189, 015; E-193, 015; . . . . . . . E-199, 015; M-330, 028; C1-594, 081; . . . . . . . . C2-691, 087; F-855, 099; F-856, 099; . . . . . . . 1181, 151; C1-1343, 166; E-1463, 173; . . . . . . .E-1467, 173;F-1510, 176; F-1511, 176; . . . . F-1512, 176; M-1714, 191; C1-1745, 197; . . . . . . . . . . . . . . . . . F-2050, 248; F-2051, 248; . . . . . . . . . . . . . . . . . .F-2052, 248; F-2053, 248 Jones, T. . . . . . . . . . . . . . . . . . . . . . . . . A-1946, 240 Jones-Nelson, O. . . . . . . . . . . . . . . . . . B-1303, 164 Jong, L. . . . . . . . . . . . . . . . . . . . . . . . . F-1531, 177 Joo, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . A-616, 082 Joosten, L. A.. . . . . . . . . . . . . . . . . . . . . B-044, 005 Jordán, M. . . . . . . . . . . . . . . . . . . . . . . . K-256, 022 Jorgensen, D. . . . . . . . . E-1474, 174; L1-1662, 189 Jorgensen, J. H. . . . . . . C2-112, 009; D-1433, 171; . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1449, 172 José M. Aguado . . . . . . . . . . . . . . . . . . .M-312, 028 Joseph, C. . . . . . . . . . . . . . . . . . . . . . . K-2088, 252 Joshi, A. . . . . . . . . . . . . . . . . . . . . . . . . H-1569, 179 Jost, G.. . . . . . . . . . . . . . . . . . . . . . . . . . D-168, 012 Jozwiak, M. . . . . . . . . . . . . . . . . . . . . L1-1224, 158 Juan, C. . . . . . . . . . . . . . . . . . . . . . . . C1-1970, 242 Juenke, J. M. . . . . . . . . . . . . . . . . . . . . . A-017, 003

Final Program

June, C. M. . . . . . . . . . . . . . . . . . . . . . C1-467, 047 Jung, K. . . . . . . . . . . . . . . . . . . . . . . . . P-1006, 112 Jung, S. . . . . . . . . . . . . B-1298, 164; C2-1913, 237 Jung, Y. . . . . . . . . . . . . . . . . . . . . . . . C2-1984, 244 Junie, L. M. . . . . . . . . . . . . . . . . . . . . . P-1008, 112 Jurado, A.. . . . . . . . . . . . . . . . . . . . . . . T-1071, 116 Justesen, U. S. . . . . . . . . . . . . . . . . . . . D-1444, 171 Justinien, E. . . . . . . . . . . . . . . . . . . . . L1-2106, 254 Juve, R. . . . . . . . . . . . . . . . . . . . . . . . . L2-303, 027

K Kaasch, A. . . . . . . . . . . . . . . . . . . . . . C2-1392, 169 Kaatz, G. W. . . . . . . . . .A-627, 083; C1-1341, 166; . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1747, 197 Kabickova, E.. . . . . . . . . . . . . . . . . . . . . T-344, 029 Kadambari, S. . . . . . . . . . . . . . . . . . . G3-1544, 178 Kadlec, K. . . . . . . . . . . .C1-670, 085; C1-679, 086; . . . . . . . . . . . . . . . . . . . . . . . . . . .C1-1350, 166; Kadota, J. . . . . . . . . . . . . . . . . . . . . . . . .M-324, 028 Kaeriyama, M. . . . . . . . . . . . . . . . . . . . . F-809, 096 Kaewpitoon, N. . . . . . . . . . P-998, 112; P-999, 112 Kaewpitoon, S. . . . . . . . . . P-998, 112; P-999, 112 Kafer, J. M. . . . . . . . . . . . . . . . . . . . . C2-1906, 237 Kagan, R.. . . . . . . . . . . . . . . . . . . . . . . H-1575, 180 Kahandawaarachchi, I. . . . . . . . . . . . . K-2081, 251 Kahl, B. C.. . . A-597, 082; A-599, 082; A-596, 082 Kaiser, C. . . . . . . . . . . . . . . . . . . . . . . . . H-229, 019 Kaiser, L. . . . . . . . . . . . . . .K-954, 108; K-956, 108; . . . . . . . . . . . . . . . .T-1064, 116; G3-1556, 178; Kajihara, T. . . . . . . . . . . . . . . . . . . . . . . V-380, 030 Kajiwara, C. . . . . . . . . . . . . . . . . . . . . . . B-056, 005 Kakeya, H. . . . . . . . . . . . . . B-049, 005; V-380, 030; . . . . . . . . .V-400, 030; B-657, 084; B-1297, 164 Kakis, A. . . . . . . . . . . . . . . . . . . . . . . . . K-247, 022 Kaku, M. . . . . . . . . . . . C2-114, 009; C2-1901, 236 Kaku, N. . . . . . . . . . . . . . B-657, 084; B-1297, 164 Kakuta, R. . . . . . . . . . . . . . . . . . . . . . . C2-114, 009 Kalbarczyk, J. . . . . . . . . . . . . . . . . . . . . F-1996, 246 Kallen, A. J. . . . . . . . . . . . . . . . . . . . . . . . 1135, 135 Kalra, A. . . . . . . . . . . . . . . . . . . . . . . . . A-018, 003 Kaltsas, G. . . . . . . . . . . . . . . . . . . . . . L2-2114, 255 Kam, K. M. . . . . . . . . . . . . . . . . . . . . . E-1992, 245 Kam, T. C. . . . . . . . . . . . . . . . . . . . . . . L1-286, 025 Kamal, M. A.. . . . . . . . . . . . . . . . . . . . A-1244, 161 Kamar, N. . . . . . . . . . . . . . . . . . . . . . . . . . 586, 080 Kambal, A. . . . . . . . . . . . . . . . . . . . . C2-1372, 168 Kamihira, S.. . . . . . . . . . . . . . . . . . . . . D-1460, 172

229


Presentation Number

Author

Presentation Number

Author

Presentation Number

Kamiyama, E. . . . . . . . . . . . . . . . . . . . F-2041, 248

Kawai, M. . . . . . . . . . . . . . . . . . . . . . . K-1599, 182

Khan, A. . . . . . . . . . . . . . . . . . . . . . . C2-1981, 243

Kanafani, Z. A. . . . . . . . . . . . . . . . . . L1-1644, 186 Kanagaratnam, B. . . . . . . . . . . . . . . . . C2-122, 009

Kawamata, D. . . . . . . . . . . . . . . . . . . L1-1657, 188

Khan, D. . . . . . . . . . . . . A-1764, 200; A-1966, 241

Kawasuji, T. . . . . . . . . . . . . . . . . . . . . . . H-550, 073

Kanamori, H.. . . . . . . . C2-114, 009; C2-1901, 236

Kawasumi, N. . . . . . . . . . . . . . . . . . . . .M-328, 028 Kaya, B. . . . . . . . . . . . . . . . . . . . . . . . . . V-379, 030

Khan, R. . . . . . . . . . . . . . . . . . . . . . . . . D-776, 092 Khan, S. . . . F-2062, 249; F-2063, 249; F-2064, 249

Kandoussi, H. . . . . . . . . . . . . . . . . . . . A-1247, 161 Kaneko, T. . . . . . . . . . . . . . . . . . . . . . . . F-838, 098 Kang, C. I. . . . . . . . . . .C2-137, 010; C2-1366, 167; . . . . . . . . . . . . . . . . . K-1587, 181; K-1588, 181 Kang, J. . . . . . . . . . . . . . . . . . . . . . . . C2-1975, 243 Kang, S. . . . . . . . . . . . . . . . . . . . . . . . . B-1298, 164 Kania, R. . . . . . . . . . . . . . . . . . . . . . . .M-1686, 190 Kanwar, N.. . . . . . . . . . . . . . . . . . . . . . C2-710, 088 Kanyo, Z. . . . . . . . . . . . . . . . . . . . . . . . F-1522, 177 Kapil, A. . . . . . . . . . . . . . . . . . . . . . . C2-1982, 243 Kaplan, N. . . . . . . . . . . . . . . . . . . . . . . E-1486, 174 Kapoor, N. . . . . . . . . . . . . . . . . . . . . . . . F-824, 097 Kaptue, L. . . . . . . . . . . . . . . . . . . . . . . . H-214, 018 Kar, S. . . . . . . . . . . . . . . . . . . . . . . . . . D-1437, 171 Kara, A. . . . . . . . . . . . . .M-1671, 190; A-1941, 240 Kara, L. . . . . . . . . . . . . . . . . . . . . . . . . . V-375, 030

Khang, C. . . . . . . . . . . . . . . . . . . . . . . . F-846, 099

Kayakiri, N. . . . . . . . . . . . . .F-818, 096; F-819, 096 Kaye, K. . . . . C2-096, 008; 501, 061; C2-1985, 244 Kaye, K. S. . . . . . . . . . . . . .A-034, 004; K-262, 023; . . . . . . . . .K-272, 024; E-787, 094; K-902, 104; . . . . . . . . . . .K-909, K-1121, 129; K-1589, 181; . . . . . . . . . . . . . K-1604, 183; 104; K-1600, 182 Kaynar, L. G. . . . . . . . . . . . . . . . . . . . .M-1701, 191

Khanna, N. . . . . . . . . . . . . . . . . . . . . . . D-776, 092 Khatib, R. . . . . . . . . . C2-1381, 169; C2-1391, 169 Khatri, J. K. . . . . . . . . . . . . . . . . . . . . . . K-272, 024

Kays, M. B. . . . . . . . . . . . A-017, 003; D-770, 092; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1520, 177

Kilfoil, T. . . . . . . . . . . . . . . . . . . . . . . . A-1952, 241 Kilic, A. . . . D-158, 011; M-316, 028; D-1427, 171 Kilic, S. . . . . . . . . . . . . . . . . . . . . . . . C2-1980, 243

Keel, R. A. . . . . . . . . . . . . . . . . . . . . . . . A-020, 003 Keiger, A.. . . . . . . . . . . . . . . . . . . . . . . C2-117, 009 Keim, P. . . . . . . . . . . . . . . . . . . . . . . . . L1-964, 110

Karchmer, A. W. . . . . . . . . 541, 070; L1-1646, 186; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1841, 218 Karginov, V. . . . . . . . . . . . . . . . . . . . . . F-2005, 246

Keitel, W. A. . . . . . . . . . . . . . . . . . . . . . . . 576, 077 Keith, D. . . . . . F-843, 099; F-844, 099; F-845, 099

Katsube, T. . . . . . . . . . . . . . . . . . . . . . . . A-019, 003 Kauffman, C. A. . . . . . . . . . .491, 057; F-1514, 176 Kaufman, S. . . . . . . . . . . . . . . . . . . . . . . D-746, 092 Kauh, A. . . . . . . . . . . . . . . . . . . . . . . .M-1676, 190 Kauh, E. A. . . . . . . . . . . . . . . . . . . . . .M-1695, 190 Kaul, D. R. . . . . . . . . . . . . . . . . . . . . . T-1066, 116 Kaul, R. . . . . . . . . . . . . . . . . . . . . . . . . H-1920, 238 Kavana, M. . . . . . . . . . . . . . . . . . . . . . F-1496, 176

230

Kidney, A. . . . . . . . . . . . . . . . . . . . . . . C2-152, 010

Kazmi, S. U. . . . . . . . . . . . . . . . . . . . C2-1981, 243 Kearney, B. P. . . . . . . . . . . . . . . . . . . . . A-1250, 161

Karagoz, A. . . . . . . . . . . . . . . . . . . . . C2-1980, 243 Karaiskos, I. . . . . . . . . . . . . K-562, 074; E-799, 094 Karakas, A. . . . . . . . . . . . . . . . . . . . . . L1-960, 110

Kasas, S.. . . . . . . . . . . . . . . . . . . . . . . . D-1436, 171 Kashuba, A. D. . . . . . . . . . . . . . . . . . . A-1248, 161 Kasma, M. . . . . . . . . . . . . . . . . . . . . . C2-1900, 236 Kaspar, H. . . . . . . . . . . . . . . . . . . . . . . C1-679, 086 Kasper, D. . . . . . . . . . . . . . . . . . . . . . . . D-728, 090 Katayama, Y. . . . . . . . . . . . . . . . . . . . .M-1226, 159 Katiyar, S. K. . . . . . . . . . . . . . . . . . . . . .M-966, 111 Katsouda, E. . . . . . . . . . . . . . . . . . . . . . K-562, 074

Khodaverdian, V. . . . . . . .F-1515, 176; F-1999, 246 Khot, A.. . . . . . . . . . . . . . . . . . . . . . . . T-1027, 113 Kijsinthopchai, U. . . . . . . . . . . . . . . . . E-1477, 174 Kikuchi, Y.. . H-888, 103; H-223, 019; H-224, 019 Kilayko, M. C. . . . . . . . . . . . . . . . . . . . C2-112, 009

Keck, W. . . . . . . . . . . C1-1346, 166; C1-1347, 166 Keedy, K. . . . . . . . . . . . . . . . . . . . . . . . A-1286, 162

Karlsson, M. O. . . . . . . . . A-033, 004; A-1256, 161 Karp, B. E.. . . . . . . . . . . . . . . . . . . . . . C2-695, 087 Karrer, S. . . . . . . . . . . . . . . . . . . . . . . . K-1125, 129 Karthaus, M. . . . . . . . . . . . . . . . . . . . . .M-338, 028

Khawcharoenporn, T. . . . . . . . . . . . . L2-2116, 255 Khodaparast, L. . . . . . . . . . . . . . . . . . . K-2094, 252

Kazamori, D. . . . . . . . . . .F-2049, 248; F-2055, 248 Kazimierczuk, Z. . . . . . . . . . . . . . . . . . F-1533, 177 Kazma, M. . . . . . . . . . . . . . . . . . . . . . . C2-109, 009

Karadag Oncel, E. . . . . . L1-964, 110; A-1941, 240

Karlowsky, J. A. . . . . . . .C2-135, 010; C2-149, 010; . . . . . . . . . E-191, 015; E-200, 015; E-779, 093; . . . . . . . . . . . . . . . . . E-1462, 173; E-1486, 174; Karlsson, J.. . . . . . . . . . . . . . . . . . . . . . T-1042, 113

Khandker, N. . . . . . . . . . . . . . . . . . . . . . K-902, 104

Kaya, S. . . . . . . . . . . . . . . . . . . . . . . . . D-1405, 170

Kelchlin, P. A. . . . . . . . . . . A-024, 004; E-201, 015 Kelesidis, T. . . . . . . . . . . K-280, 024; C2-1401, 169 Keller, A. . . . . . . . . . . . . . . . . . . . . . . . B-1734, 196 Keller, N. . . . . . . . . . . . . . . . . . . . . . . L1-1640, 186 Kelley, K. L. . . . . . . . . . . . . . . . . . . . . . D-1425, 171 Kelly, D. F. . . . . . . . . . . . . . . . . . . . . . G3-1544, 178 Kelly, P. M. . . . . . . . . . . . . . . . . . . . . . . K-952, 108 Kelly, R. . . . . . . . . . . . . . . . . . . . . . . . . . F-810, 096 Kelly, S. . . . . . . . . . . . . . . . . . . . . . . . . C2-706, 088 Kemp, M. . . . . . . . . . . . . . . . . . . . . . . D-1444, 171 Kenar, L. . . . . . . . . . . . . . . . . . . . . . . C2-1980, 243 Kenfak-Foguena, A. . . . . . . . . . . . . . . . D-184, 014 Kennon, J. . . . . . . . . . . . . . . . . . . . . . . . K-558, 074 Kerff, F. . . . . . . . . . . . . . C1-593, 081; C1-459, 047 Kerkering, T. M. . . . . . . . . . . . . . . . . . . D-162, 011 Kersemaekers, W. . . . . . . . . . . . . . . . . A-1935, 240 Keshavjee, S. . . . . . . . . . . . . . . . . . . . . T-1067, 116 Keslova, P. . . . . . . . . . . . . . . . . . . . . . . . T-344, 029 Kessler, H. . . . . . . . . . . . . . . . . . . . . . . . V-398, 030 Kestler, M. . . . . . . . . . . . . .K-263, 023; K-940, 106; . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1411, 170 Keysary, A.. . . . . . . . . . . . . . . . . . . . . . P-1001, 112 Keystone, J. S. . . . . . . . . . . . . . . . . . . . . . 1891, 234 Khachatryan, A.. . . . . . . . . . . . . . . . . . . K-239, 020

September 9-12 |

Killian, S. . . . . . . . . . . . . . . . . . . . . . . . . D-766, 092 Killian, S. B. . . . . . . . . . E-1463, 173; E-1467, 173 Kim, A. . . . . . . . . . . . . . . . . . . . . . . . . . K-908, 104 Kim, B. . . . . . . . . . . . . . . . . . . . . . . . . . K-908, 104 Kim, C. . . . . . H-230, 019; K-908, 104; K-916, 104 Kim, D. H. . . . . . . . . . . . . . . . . . . . . C2-1899, 236 Kim, E. . . . . . . . . . . . . . . . K-907, 104; K-908, 104 Kim, H. . . . . H-230, 019; K-907, 104; K-908, 104; . . . . . . . K-916, 104; F-1489, 175; H-1582, 180 Kim, I. . . . . . . . . . . . . . . . . . . . . . . . . . . G-872, 101 Kim, J. . . . . . . . . . . . . . A-1255, 161; C1-1343, 166 Kim, J. S. . . . . . . . . . . . . . . . . . . . . . . . . T-365, 029 Kim, J. . . . . . . . . . . . . . . . . H-230, 019; K-916, 104 Kim, K. . . . . .K-908, 104; H-1564, 179; 1874, 230; . . . . . . . . . . . . . . . . C2-1975, 243; K-2076, 250 Kim, M. J. . . . . . . . . . . . . . . . . . . . . . . L1-294, 026 Kim, M. . . . .H-230, 019; K-916, 104; H-1572, 180 Kim, N. . . . . . . . . . . . . . . . . . . . . . . . . . K-908, 104 Kim, S. J. . . . . . . . . . . . . . . . . . . . . . . . T-1043, 113 Kim, S.. . . . . . . . . . . . . . K-1632, 185; F-2060, 249 Kim, S. H. . . . . . . . . . C2-1366, 167; C2-1899, 236 Kim, S.. . . . . H-230, 019; T-366, 029; D-741, 091; . . . . . . . . K-907, 104; K-916, 104; V-1074, 117; . . . . V-1239, 160; C2-1913, 237; C1-1969, 242; . . . . . . . . . . . . . . . . . K-2092, 252; K-2079, 250 Kim, T.. . . . . . . . . . . . . . . . K-907, 104; K-955, 108 Kim, W. . . . . . . . . . . . . . . .D-155, 011; G-872, 101 Kim, Y. S. . . . . . . . . . . . . . . . . . . . . . . L1-294, 026 Kim, Y. . . . . . H-230, 019; T-366, 029; V-372, 030; . . . . . . . . D-741, 091; K-907, 104; K-916, 104; . . . . . . V-1074, 117; V-1239, 160; F-1538, 177; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2092, 252

AUTHOR INDEX Author

Presentation Number

Author

Presentation Number

Author

Presentation Number

Konrardy, M. L. . . . . . . . F-2050, 248; F-2051, 248; . . . . . . . . . . . . . . . . . . F-2052, 248; F-2053, 248

Kimberlin, D. W.. . . . . . . . . . . . . . . . . . . 1828, 212

Ko, A. I. . . . . . . . . . . . . . . . . . . . . . . . . . . 1100, 124

Kimura, K. . . . . . . . . . . . . . . . . . . . . . C2-1989, 244 Kimura, M. . . . . . . . . . . . . . . . . . . . . . . K-897, 104

Ko, K. S. . . . . . . . . . . C2-1366, 167; C2-1899, 236 Kobayashi, M. . . . . . . . . . . . . . . . . . . . . H-550, 073

Kimura, S. . . . . . . . . . . . . . . . . . . . . . . . B-056, 005

Kobayashi, N. . . . . . . . . . . . . . . . . . . . F-2041, 248

Kontoyiannis, D. . . . . . . .M-972, 111; M-979, 111; . . . . . M-984, 111; M-1057, 115; M-1058, 115; . . . . .M-1676, 190; M-1681, 190; M-1705, 191

Kinder, C. . . . . . . . . . . . . . . . . . . . . . . . H-555, 073

Kobayashi, T. . . . . . . . . . . . . . . . . . . . . . H-223, 019 Kobayashi, Y. . . . . . . . . . . . . . . . . . . . . F-1509, 176

Koo, H. L. . . . . K-920, 105; K-921, 105; 1817, 210 Koo, S. . . . . . . . . . . . . . . . . . . . . . . . . .M-1060, 115

Kobela, M. . . . . . . . . . . . . . . . . . . . . . G3-1541, 178 Kobrin, M. B. . . . . . . . . . . . . . . . . . . . A-1967, 241

Koomanachai, P. . . . . . . . . . . . . . . . . . K-1602, 183

Koc, A. N. . . . . . . . . . . . . . . . . . . . . . .M-1701, 191

Koralnik, I. J. . . . . . . . . . . . . . . . . . . . . . T-354, 029 Korbenfeld, D. . . . . . . . . . . . . . . . . . . . . D-746, 092

King, P. . . . . . . . . . . . . . . . .F-848, 099; F-850, 099 King, S. T. . . . . . . . . . . . . . . . . . . . . . . .M-968, 111 Kinoshita, K. . . . . . . . . . . . . . . . . . . . . D-1429, 171 Kipnis, E.. . . . . . . . . . . . . . B-050, 005; B-060, 005 Kiratisin, P. . . . . . . . . . . . . . . . . . . . . . A-1279, 162 Kirchhoff, J. . . . . . . . . . . . . . . . . . . . . . P-1017, 112 Kireev, D.. . . . . . . . . . . . . . . . . . . . . . . F-1535, 177

Köck, R.. . . . . . . . . . . . . . . . . . . . . . . C2-1382, 169 Koeck, R. . . . . . . . . . . . . . . . . . . . . . . G3-1547, 178

Kirkby, N. . . . . . . . . . . . .P-1005, 112; T-1072, 116

Koenig, W. . . . . . . . . . . . . . . . . . . . . . C2-108, 009 Koeth, L. M. . . . . . . . . . . . . . . . . . . . . . E-802, 094

Kirkpatrick, W. R. . . . . . . . B-650, 084; F-823, 096; . . . . . . . . . . . . . . . . M-1674, 190; M-1682, 190 Kish, T. D. . . . . . . . . . . . . . . . . . . . . . . . K-919, 105

Kofteridis, D. P. . . . . . . . .B-043, 005; M-1696, 191 Kogan, A. . . . . . . . . . . . . . . . . . . . . . . L1-962, 110 Koh, H. . . . . . . . . . . . . . . . . . . . . . . . . D-1402, 170

Kishel, J. . . . . . . . . . . . . . . E-807, 095; K-277, 024 Kishony, R. . . . . . . . . . . . . . . . . . . . . . . . 1790, 205

Koh, J. . . . . . . . . . . . . . . . . . . . . . . . . . K-2076, 250

Kissoon, M. . . . . . . . . . . . . . . . . . . . . . . K-281, 024 Kitagawa, M. . . . . . . . . C2-114, 009; C2-1901, 236 Kitagawa, Y.. . . . . . . . . . . . . . . . . . . . .M-1231, 159 Kitajima, I.. . . . . . . . . . . . . . . . . . . . . . D-1461, 172 Kitano, M. . . . . . . . . . . . . . . . . . . . . . . . V-380, 030 Kitzis, M. D. . . . . . . . . . . . . . . . . . . . . . K-234, 020 Kjældgaard, P. . . . . . . . . . . . . . . . . . . . P-1005, 112 Kjær, J. . . . . . . . . . . . . . . . . . . . . . . . . . T-1072, 116 Klaassen, C. H. . . . . . . . . M-332, 028; M-334, 028 Klastersky, J.. . . . . . . . . . . . . . . . . . . . . T-1028, 113 Klein, L. L. . . . . . . . . . . . . . . . . . . . . . . F-831, 098 Klein, M. . . . . . . . . . . . . . . . . . . . . . . . H-1571, 180 Klein, N. J. . . . . . . . . . . . . . . . . . . . . . . . . 1873, 230 Klein, S. . . . . . . . . . . . . . . . . . . . . . . . . C2-093, 008 Klein, U. . . . . . . . . . . . . . . . . . . . . . . . C2-709, 088 Klevens, R.. . . . . . . . . . . . . . . . . . . . . . K-1586, 181 Klinker, K. . . . . . . . . . . . . . . . . . . . . . . . K-274, 024 Klose, H. . . . . . . . . . . . . . . . . . . . . . . . . T-347, 029 Kluge, S. . . . . . . . . . . . . . . . . . . . . . . . . T-347, 029 Klugman, K. P.. . . . . . . . . . .D-172, 013; 1787, 204; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1880, 232 Klumpp, K. . . . . . . . . . . A-1245, 161; V-1080, 117 Kluytmans, J. A.. . . . . . . . E-803, 094; G-870, 101; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1876, 231 Knapp, C. . D-766, 092; E-1463, 173; E-1467, 173 Knebel, W.. . . . . . . . . . . . . . . . . . . . . . . A-634, 083 Knechtel, M. . . . . . . . . . . A-008, 003; F-2065, 249 Knezevic, A. . . . . . . . . . . . . . . . . . . . C1-1347, 166 Knibbe, C. A. . . . . . . . . . . . . . . . . . . . A-1928, 240 Knight, D. . . . . . . . . . . . . . . . . . . . . . . B-1738, 196 Knobel, H. . . . . . . . . . . . . . . . . . . . . . . K-1624, 184 Knoderer, C. A. . . . . . . . . . . . . . . . . . G3-1558, 178 Knudsen, E. . . . . . . . . . . . . . . . . . . . . . D-1444, 171

Koh, S.. . . . . . . . . . . . . . . . . . . . . . . . . D-1402, 170 Koh, T. H. . . . . . . . . . . . . E-195, 015; K-1595, 182 Kohler, I. . . . . . . . . . . . . . . . . . . . . . . . . V-384, 030 Kohler, T. . . . . . . . . . . . . . . . . . . . . . . . B-1333, 165 Kohlhoff, S. A. . . . . . . . . . . . . . . . . . . . E-206, 016 Kohn, D. . . . . . . . . . . . . . . . . . . . . . . G3-1546, 178 Kohno, S. . . . . . . . . . . . . . . B-048, 005; B-049, 005; . . . . . . . . L1-296, 026; V-380, 030; V-400, 030; . . . . . . B-657, 084; M-1231, 159; B-1297, 164; . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1460, 172; Köhrer, K. . . . . . . . . . . . . . . . . . . . . . . C1-588, 081 Koita, I. . . . . . . . . . . . . . . . . . . . . . . . C2-1989, 244 Kojic, E. M. . . . . . . . . . . . . . . . . . . . . . . . 1133, 134 Kokoska, L. . . . . . . . . . . . . . . . . . . . . . F-1532, 177 Köksal . . . . . . . . . . . . . . . . . . . . . . . . . D-1405, 170 Koksal, I. . . . . . . . . . . . . . . . . . . . . . . . . V-394, 030 Kolarovic, M. B. . . . . . . . . . . . . . . . . . V-1237, 160 Koll, B. S. . . . . . . . . . . . . . . . . . . . . . . . . . 573, 076 Kolli, R. . . . . . . . . . . . . . . . . . . . . . . . . . V-370, 030 Kolling, G. L. . . . . . . . . . . . . . . . . . . . . B-047, 005 Komastu, M. . . . . . . . . . . .A-607, 082; A-608, 082; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1687, 190 Komatsu, H. . . . . . . . . . . .H-888, 103; H-890, 103 Komp Lindgren, P. . . . . . . . . . . . . . . . . A-030, 004 Konda, K. . . . . . . . . . . . . . . . . . . . . . . L1-284, 025 Kong, C. J. . . . . . . . . . . . . . . . . . . . . . . L2-308, 027 Kong, D. C. . . . . . . . . . . .K-558, 074; M-1671, 190 Koning, O. H. . . . . . . . . . . . . . . . . . . . L1-965, 110 Konishi, H. . . . . . . . . . . . . . . . . . . . . . .M-326, 028 Konopnicki, D. . . . . . . . . . . . . . . . . . . D-1413, 170 Konradsen, H. . . . . . . . . . . . . . . . . . . . H-1916, 238 Konradsen, H. B. . . . . . . . . . . . . . . . . . . G-876, 101 Konrardy, M. . . . . . . . . . . . . . . . . . . . . F-1511, 176

Final Program

Koopmans, M. M. . . . . . . . . . . . . . . . L1-1222, 158

Korczak, B. . . . . . . . . . .A-1284, 162; E-1474, 174; . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1662, 189 Korean Network for Study on Infectious Diseases (KONSID), . . . . . . . . . . . . . . . . . . C2-137, 010 Korprapun, L. . . . . . . . . . . . . . . . . . . . F-1539, 177 Kort, J. . . . . . . . . . . . . . . . . . . . . . . . . . A-1248, 161 Korytny, A. . . . . . . . . . . . . . . . . . . . . . K-1610, 184 Kosmidis, C. . . . . . . . . . . . . . . . . . . . C1-1747, 197 Kosowska-Shick, K.. . . . . . . . . . . . . . C1-1971, 242 Kostrzewa, M. . . . . . . . . . . . . . . . . . . . D-1777, 201 Kotlovsky, T. . . . . . . . . . C2-109, 009; K-1609, 184 Kotra, H. . . . . . . . . . . . . . . . . . . . . . . . . K-262, 023 Kotsimbos, T.. . . . . . . . . . . . . . . . . . . . . K-952, 108 Kottom, T. J. . . . . . . . . . . . . . . . . . . . . . F-813, 096 Koup, R. . . . . . . . . . . . . . . . . . . . . . . . . . . 577, 077 Kousba, A. . . . . . . . . . . . A-1950, 241; A-1953, 241 Kouyos, R. D. . . . . . . . . . . . . . . . . . . . . K-238, 020 Kovacs, S. J. . . . . . . . . . . A-1281, 162; A-1282, 162 Kovanda, L. L.. . . . . . . . . . . . . . . . . . . .M-331, 028 Kovarik, M. . . . . . . . . . . . . . . . . . . . . . D-1445, 172 Kowalski, D. . . . . . . . . . . . . . . . . . . . . A-1936, 240 Koyama, A. H.. . . . . . . . . . . . . . . . . . . . F-825, 097 Koyamatsu, T. . . . . . . . . . . . . . . . . . . . . D-155, 011 Kozlov, R. . . . . . . . . . . . . . . . . . . . . . . C2-697, 087 Kozlowska, M. . . . . . . . . . . . . . . . . . . . F-1533, 177 Kozyreva, V.. . . . . . . . . . . . . . . . . . . . . C2-697, 087 Kraft, W. K. . . . . . . . . . . . . . . . . . . . . . A-1935, 240 Kralidis, G. . . . . . . . . . . . . . . . . . . . . . . T-343, 029 Krammer, W. . . . . . . . . . . . . . . . . . . . . D-1404, 170 Kranz, D. M. . . . . . . . . . . . . . . . . . . . . F-1517, 176 Krause, P. J. . . . . . . . . . . . . . . . . . . . . . . . . 448, 044 Krause, R. . . . . . . . . . . . . . V-395, 030; V-398, 030; . . . . . . . . . . . . . . . . . P-1009, 112; D-1404, 170 Kreiswirth, B.,N. . . . . . .C1-589, 081; C2-692, 087; . . . . . . . . . . . . . . . . . . E-792, 094; T-1031, 113; . . . . . . . . . . . . . . . . C2-1216, 157; K-1625, 184 Kreller, K. . . . . . . . . . . . . . . . . . . . . . . A-1257, 161 Kremastinou, J. . . . . . . . . . . . . . . . . . G3-1543, 178 Kremer, A. . . . . . . . . . . . . . . . . . . . . . G3-1547, 178 Kremser, L. . . . . . . . . . . . . . . . . . . . . . F-2058, 249 Krepps, M. D. . . . . . . . . C1-064, 006; C1-592, 081

231


Presentation Number

Kriegeskorte, A.. . . . . . . . . . . . . . . . . . E-1483, 174 Kriengkauykiat, J. . . . . . . . T-349, 029; T-350, 029; . . . . . . . . . . . . . . . . . . . T-351, 029; T-1039, 113 Krishna, G. . . . . . . . . . . . . . . . . . . . . . A-1935, 240 Kristiansson, E. . . . . . . . . . . . . . . . . . . C1-665, 085 Kristoffersson, A. N. . . . . . . . . . . . . . . . A-032, 004 Kröger, N. . . . . . . . . . . . . T-347, 029; K-2095, 252 Krogfelt, K. A. . . . . . . . . . . . . . . . . . . . C2-687, 087 Kromke, K. . . . . . . . . . . . . . . . . . . . . . A-1267, 161 Krompa, K. . . . . . . . . . . . . . . . . . . . . . A-1940, 240 Kronborg, G. . . . . . . . . . . . . . . . . . . . . H-1916, 238 Kruse, S. . . . . . . . . . . . . . . . . . . . . . . . K-1592, 181 Ku, C. . . . . . . . . . . . . . . . . A-031, 004; E-795, 094 Ku, N. . . . . . . . . . . . . . . . . H-230, 019; K-916, 104 Kubal, S. A. . . . . . . . . . . . . . . . . . . . . . T-1029, 113 Kubasek, C. . . . . . . . . . . . . . . . . . . . . . D-1446, 172 Kubin, C. J. . . . . . . . . . . . A-026, 004; T-1034, 113; . . . . . . . . . . . . . . . . . .T-1036, 113; K-1620, 184 Kuchipudi, V.. . . . . . . . . C2-096, 008; K-1589, 181 Kuehn, J. . . . . . . . . . . . . . . . . . . . . . . . . K-953, 108 Kuhn, K. . . . . . . . . . . . . . . . . . . . . . . . K-1925, 239 Kuijper, E. . . . . . . . . . . . . . K-472, 048; K-930, 105 Kulawy, R. . . . . . . . . . . . . . . . . . . . . . . . A-011, 003 Kulhanek, G. . . . . . . . . . . . . . . . . . . . . . A-018, 003 Kullar, R. . . . . . . . . . . . . . .K-275, 024; A-643, 083; . . . . . . . K-946, 106; K-1600, 182; K-1631, 185 Kullberg, B. . . . . . . . . . . . M-1055, 115; 1114, 127; . . . . M-1229, 159; M-1683, 190; M-1709, 191; Kumar, A. . . . . . . . . . . . . . C2-703, 088; 1097, 123 Kumar, D. . . . . . . . . . . . . . . . . . . . . . . . E-196, 015 Kumar, G. . . . . . . . . . . . . B-052, 005; A-1253, 161 Kumar, M. . . . . . . . . . . . . . . . . . . . . . . F-2043, 248 Kumar, S. . . . . . . . . . . . . . . . . . . . . . . . . F-812, 096 Kunapuli, A. . . . . . . . . . . . . . . . . . . . . . H-225, 019 Kung, H. C. . . . . . . . . . . . . . . . . . . . . .M-1703, 191 Kunishima, H. . . . . . . . C2-114, 009; C2-1901, 236 Kunze, M. . . . . . . . . . . . . . . . . . . . . . . . D-179, 013 Kupferwasser, D. . . . . . . . . . . . . . . . . . . G-868, 101 Kuramoto, Y. . . . . . . . . . .F-2049, 248; F-2055, 248 Kurosaka, Y.. . . . . . . . . . F-2035, 248; F-2036, 248; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2043, 248 Kurt Azap, O. . . . . . . . . . . . . . . . . . . . C2-684, 087 Kurtinecz, M. . . . . . . . . A-1272, 162; A-1276, 162 Kurtzhals, J. A. . . . . . . . P-1005, 112; P-1017, 112 Kushima, H. . . . . . . . . . . . . . . . . . . . . .M-324, 028 Kusne, S. . . . . . . . . . . . . T-1032, 113; M-1697, 191 Kuster, S. P. . . . . . . . . . . . . . . . . . . . . . . K-955, 108 Kuti, J. L. . . . . . . . . . . . . . .A-018, 003; A-020, 003; . . . . . . . A-022, 003; A-023, 004; A-1287, 163; . . . . . . . . . . . . . . . . . K-1926, 239; A-1964, 241 Kuypers, J. . . . . . . . . . . . . . . . . . . . . . . . T-353, 029

232

Author

Presentation Number

Kwa, A. L. . . . . . . . . . . . . .E-195, 015; K-235, 020; . . . . . . . . E-791, 094; K-896, 104; E-1476, 174; . . . . . .K-1595, 182; K-1613, 184; M-1675, 190 Kwak, E. J. . . . . . . . . . . . . . T-346, 029; T-364, 029; . . . . . .T-1031, 113; T-1037, 113; C2-1216, 157 Kwak, Y. . . . . . . . . . . . C2-725, 089; C2-1914, 237 Kwakwa, H. . . . . . . . . . . . . . . . . . . . . . . H-881, 102 Kwan, B. . . . . . . . . . . . . .F-1514, 176; F-2018, 247 Kwasny, S. M. . . . . . . . . . . . . . . . . . . . . F-816, 096 Kwon, D. B.. . . . . . . . . . . . . . . . . . . . . C1-595, 081 Kwon, H. . . . . . . . . . . . . . . . . . . . . . . C2-1975, 243 Kwon, J. . . . . . . . . . . . . . . . . . . . . . . . . K-1632, 185 Kyaw, M. . . . . . . . . . . . . . . . . . . . . . . . G-1751, 198 Kyo, K.. . . . . . . . . . . . . . . . . . . . . . . . .M-1226, 159 Kyo, T. . . . . . . . . . . . . . . . . . . . . . . . . .M-1226, 159 Kyrpitzi, D. . . . . . . . . . . . . . . . . . . . . .M-1720, 191

L Labella, A. . . . . . . . . . . . . . . . . . . . . . C2-1906, 237 Labori, M. . . . . . . . . . . . L1-293, 026; L1-295, 026; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1228, 159 Labrou, M. . . . . . . . . . . . . . . . . . . . . . B-1300, 164 Lach, D.. . . . . . . . . . . . . . . . . . . . . . . G3-1546, 178 Ladelund, S. . . . . . . . . . . . . . . . . . . . . H-1916, 238 Laerum, O. D. . . . . . . . . . . . . . . . . . . . . B-663, 084 Laeyendecker, O. . . . . . . . . . . . . . . . . . H-1580, 180 Lafaurie, M.. . . . . . . . . . . . . . . . . . . . L2-2109, 255 Laferrière, C. . . . . . . . . . . . . . . . . . . . . . D-730, 090 Lafleur, J. . . . . . . . . . . . . . . . . . . . . . . . F-1496, 176 LaFleur, M. . . . . . . . . . . . F-815, 096; F-1519, 177 Lagacé-Wiens, P.. . . . . .C2-103, 009; C2-135, 010; . . . . . . . . C2-149, 010; E-191, 015; E-194, 015; . . . . . . . . . . . . . . . . . . . E-200, 015; E-779, 093 Lagerbäck, P. . . . . . . . . . . E-800, 094; A-1966, 241 Lagioia, M. . . . . . . . . . . . . . . . . . . . . . . D-159, 011 Lagousi, T. . . . . . . . . . . . . . . . . . . . . . G3-1551, 178 Lai, M.. . . . . . . . . . . . . . . . . . . . . . . . . . H-551, 073 Lajoie, V. . . . . . . . . . . . . . . . . . . . . . . . . V-389, 030 Lake, D.. . . . . . . . . . . . . . . . . . . . . . . .M-1702, 191 Lakshmi, V. P. . . . . . . . . . . . . . . . . . . . . K-236, 020 Lalande, V.. . . . . . . . . . . . .D-154, 011; D-157, 011 Lalezari, J. . . . . . . . . . . . .H-553, 073; H-1581, 180 Lalueza, A. . . . . . . . . . . . . . . . . . . . . L2-2110, 255 Lam, P. . . . . . . . . . . . . . . . . . . . . . . . . . K-955, 108 Lam, T. . . . . . . . . . . . . . F-2017, 247; F-2018, 247; . . . . . . . . . . . . . . . . . F-2018a, 247; F-2024, 247 Lam, T. K. . . . . . . . . . . . . . . . . . . . . . . E-1992, 245 Laman, J. D. . . . . . . . . . . . . . . . . . . . . . B-058, 005 LaMarche, M. . . . . . . . . . . . . . . . . . . . . B-664, 084 Lamberghini, R. . . . . . . . . . . . . . . . . C2-1910, 237 Lambert, A. . . . . . . . . . . . . . . . . . . . . . A-1291, 163

September 9-12 |

Author

Presentation Number

Lammens, C. . . . . . . . . . . . . . . . . . . . . C2-109, 009 Lamp, K. C.. . . . . . . . . . .K-276, 024; K-1635, 185; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2078, 250 Lancett, P. . . . . . . . . . . . . . . . . . . . . . . F-2016, 247 Landecho, M. . . . . . . . . . . . . . . . . . . . K-1612, 184 Landelle, C. . . . . . . . . . . . . . . . . . . . . . . K-929, 105 Landersdorfer, C. B. . . . . . A-011, 003; A-027, 004 Landman, D. . . . . . . . . . . . . F-841, 099; 1130, 132 Landon, E.. . . . . . . . . . . . . . . . . . . . . . . K-279, 024 Landron, C. . . . . . . . . . . . . . . . . . . . . . . A-039, 004 Landry, M. L. . . . . . . . . . . . . . . . . . . . . . . 430, 039 Lange, C. F. . . . . . . . . . . . . . . . . . . . . . F-2070, 249 Langenbach, K. . . . . . . . . . . . . . . . . . . F-2005, 246 Langner-Wegscheider, B. . . . . . . . . . . . V-395, 030 Lanoix, J.P.. . . . . . . . . . . . . . . . . . . . . L1-2106, 254 Lanternier, F. . . . . . . . . M-1686, 190; M-1707, 191 Lao, V. . . . . . . . . . . . . . . . . . . . . . . . . . F-2027, 247 Laouénan, C. . . . . . . . . . . . . . . . . . . . . . A-021, 003 Lapidus, N. . . . . . . . . . . . . . . . . . . . . . . V-387, 030 LaPlante, K. L. . . . . . . . . .K-233, 020; E-790, 094; . . . . . . K-1120, 129; K-1123, 129; E-1464, 173; . . . . . . . . . . . . . . . . . E-1469, 173; K-1628, 185 Lara, A. . . . . . . . . . . . . . . . . . . . . . . . G3-1563, 178 Lara, R. . . . T-368, 029; C1-683, 086; A-1280, 162 Lardeux, M. . . . . . . . . . . . . . . . . . . . . . . D-178, 013 Larios, O.. . . . . . . . . . . . . . . . . . . . . . . . D-729, 090 Larka, C. V. . . . . . . . . . . . . . . . . . . . . . D-1414, 170 Larkins-Ford, J. . . . . . . . . . . . . . . . . . . F-1538, 177 Larosa, F. . . . . . . . . . . . . . . . . . . . . . . .M-1692, 190 Larroque, B.. . . . . . . . . . . . . . . . . . . . . K-2087, 252 Larrosa, N.. . . . . . . . . . C2-1358, 167; K-1616, 184 Larsen, M. V. . . . . . . . . . . . . . . . . . . . . H-1916, 238 Larsson, D. G. . . . . . . . . . . . . . . . . . . . C1-665, 085 LaRue, H. . . . . . . . . . . . . . . . . . . . . . . D-1417, 170 Lasa, I. . . . . . . . . . . . . . . . . . . . . . . . . . C1-672, 085 Lasco, T. M.. . . . . . . . . . . D-158, 011; M-316, 028; . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1450, 172 Lascols, C. . . . . . . . . . . D-1448, 172; C2-724, 089; . . . . . . . . . . . . . . . C1-1209, 156; C2-1210, 157 Lascoux-Combes, C. . . . . . . . . . . . . . . H-1568, 179 Laser, L.. . . . . . . . . . . . . . . . . . . . . . . . . K-238, 020 Lass Floerl, C. . . . . . . . . .M-332, 028; M-337, 028; . . . . . . . . . . . . . . . . M-1227, 159; M-1708, 191 Lasserre, C. . . . . . . . . . . . K-255, 022; B-1318, 165 Lassetter, K. . . . . . . . . . . . . . . . . . . . . . . A-010, 003 Lastovetska, O. . . . . . . C2-089, 008; C2-1214, 157 Lat, A. . . . . . . . . . . . . . . . . . . . . . . . . . K-1620, 184 Latasa, C.. . . . . . . . . . . . . . . . . . . . . . . C1-672, 085 Laterza, F. . . . . . . . . . . . . . . . . . . . . . . L1-963, 110 Latin America Working Group on Bacterial Resistance . . . . . . . . . . . . . . . . . . . . . K-900, 104

AUTHOR INDEX Author

Presentation Number

Author

Presentation Number

Latin American Working Group on Bacterial Resistance . . . . . . . . . . . . . . . . . . . C2-1909, 237

Ledesma, K. R. . . . . . . . . .A-025, 004; A-028, 004; . . . . . . . . . . . . . . . . . . A-029, 004; D-1450, 172

Laudy, A. E.. . . . . . . . . . .F-1533, 177; F-1996, 246 Launay, O. . . . . . . . . . . . . . . . . . . . . . . . V-375, 030

Lee, A. . . . . . . . . . . . . . . . . . . . . . . . . . . A-616, 082 Lee, B. . . . . . . . . . . . . . . . .V-386, 030; T-1069, 116

Author

Presentation Number

Legarth, R. . . . . . . . . . . . . . . . . . . . . . P-1005, 112 Legentil, L. . . . . . . . . . . . . . . . . . . . . . P-1007, 112 Leggio, M. . . . . . . . . . . . . . . . . . . . . . . F-1522, 177

Laupland, K. B. . . . . . . . . . K-1756, 199; 1834, 215

Lee, C. . . B-1324, 165; B-1325, 165; C2-1212, 157

Legoff, J. . . . . . . . . . . . . . . . . . . . . . . . . D-178, 013 Legout, L. . . . . . . . . . . . . . . . . . . . . . . K-2089, 252

Laurence, B.. . . . . . . . . . . . . . . . . . . . L1-1656, 188 Laurent, F. . . . . . . . . . . . . . 1174, 149; B-1317, 165; . . . . . . . . . . . . . . . . B-1319, 165; C1-1739, 197 Laurent, M. . . . . . . . . . . . . . . . . . . . . . F-2003, 246 Laurent, V.. . . . . . . . . . . . . . . . . . . . . . . P-568, 075

Lee, D.. . . . . . . . . . . . . K-1632, 185; C2-1975, 243

Leguerrier, A. . . . . . . . . . . . . . . . . . . . . K-267, 023

Lee, E. . . . . . . . . . . . . . . . . . . . . . . . . . . D-734, 091 Lee, F. . . . . . . . . . . . . . . . . . . . . . . . . . . T-357, 029 Lee, G.. . . . . . . . . . . . . . .H-553, 073; H-1581, 180

Lehner, B. . . . . . . . . . . . . . . . . . . . . . . C2-093, 008 Lehoux, D. . . . . . . . . . . . . . . . . . . . . . . A-620, 082 Lehrnbecher, T. . . . . . . . . . . . . . . . . . .M-1708, 191

Laussucq, S. . . . . . . . . . . . . . . . . . . . . L1-1661, 189

Lee, G. C. . . . . . . . . . . . . . . . . . . . . . . . E-794, 094 Lee, H. . . . . . . . . . . . . . . . . . . . . . . . C2-1903, 236

Lauten, M.. . . . . . . . . . . . . . . . . . . . . . .M-335, 028 Lautenbach, E. . . . . . . . . . . . . . . . . . . . . . 487, 055

Leib, S. . . . . . . . . . . . . . . . . . . . . . . . . . B-649, 084 Leibovitz, E. . . . . . . . . . M-339, 028; G-1050, 114

Lee, H. J. . . . . . . . . . . . . . . A-031, 004; E-795, 094

Leistner, R. . . . . . . . . . . . . . . . . . . . . . K-1592, 181

Lee, H. . . . . . . . F-827, 097; M-967, 111; B-1309, . . . . . . . . . . . . E-1473, 174; 165; C2-1978, 243 Lee, J.. . . . . . . . . . . . . . . . . . . . . . . . . . . G-872, 101

Leite, T. M. . . . . . . . . . . . . . . . . . . . . . . K-913, 104 Leitner, E. . . . . . . . . . . . D-1404, 170; E-1470, 173 Leiva, L. M.. . . . . . . . . . . . . . . . . . . . . A-1945, 240

Lautenschlager, I. . . . . . . .T-355, 029; T-1070, 116 Lauzon, D.. . . . . . . . . . . . . . . . . . . . . . . V-389, 030 Lavergne, V.. . . . . . . . . . . . . . . . . . . . . . D-751, 092 Lavigne, J. . . . . . . . . . . . . K-255, 022; B-1318, 165; . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1327, 165 Lavín, B. A. . . . . . . . . . . . . . . . . . . . . .M-1673, 190 Lavoie, L. . . . . . . . . . . . . . . . . . . . . . . . K-473, 048 Law, D. . . . . . . . . . . . . . . . . . . . . . . . . . . 1869, 229 Lawrence, L. . . . . . . . . . A-1956, 241; A-1957, 241

Lee, J. J. . . . . . . . . . . . . . C1-068, 006; C1-595, 081 Lee, J.. . . . . D-182, 014; G-872, 101; B-1309, 165; . . . C2-1978, 243; C2-1978, 243; C2-1975, 243 Lee, J. H. . . . . . . . . . . . . C1-068, 006; C1-595, 081 Lee, K. . . . . . . . . . . . . . . . H-218, 018; H-221, 019; . . . . . . . . . . . . . . . . . . . H-226, 019; V-372, 030 Lee, L. K. . . . . . . . . . . . . . . . . . . . . . . H-1569, 179 Lee, M. . . . . . . . . . . . . . . . . . . . . . . . C2-1212, 157

Lawrence, L. E. . . . . . . . .E-208, 016; A-1290, 163; . . . . . . . . . . . . . . . . L1-1663, 189; A-1958, 241

Lee, N. Y. . . . . . . . . . . . . . . . . . . . . . . C2-137, 010

Lawson, C. . . . . . . . . . . . . . . . . . . . . . . A-040, 004 Lawson-Ayayi, S.. . . . . . . . . . . . . . . . . . K-248, 022

Lee, R. T. . . . . . . . . . . . . . . . . . . . . . . . H-1569, 179 Lee, R. . . . . . . . . . . . . . . . . . . . . . . . . . . F-815, 096

Laxminarayan, R. . . . . . . . . . . . . . . . . P-1024, 112 Lazarovitch, T. . . . . . . . . . . . . . . . . . . . . E-787, 094

Lee, R. E. . . . . . . . . . .A-1267, 161; C1-1741, 197; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-832, 098 Lee, R. . . . . . . . . . . . . . . . . . . . . . . . . C2-1213, 157 Lee, S. . . . . . . . . . . . . . . F-2018, 247; F-2018a, 247 Lee, S. J. . . . . . . . . . . . . . . . . . . . . . . . F-2017, 247 Lee, S. A. . . . . . . . . . . . . . . . . . . . . . . . F-2000, 246

Le, A.. . . . . . . . . . . . . . . . . . . . . . . . . . L1-959, 109 Le, B. M. . . . . . . . . . . . . . . . . . . . . . . . . T-357, 029 Le, H. N. . . . . . . . . . . . . . . . . . . . . . . . B-1735, 196 Le, T. H. . . . . . . . . . . . . . . . . . . . . . . .M-1677, 190 Le Gal, S. . . . . . . . . . . . . . . . . . . . . . . .M-333, 028 Le Goff, J. . . . . . . . . . . . . T-363, 029; D-1778, 201 Le Joubioux, A. . . . . . . . . . . . . . . . . . . . A-638, 083 Le Mabecque, V. . . . . . . . B-653, 084; A-1948, 241 Le Moal, G.. . . . . . . . . . . A-039, 004; L1-963, 110 Le Saux, N. . . . . . . . . . . . . . . . . . . . . G3-1542, 178 Le Strat, Y. . . . . . . . . . . . . . . . . . . . . . . V-375, 030 Le Vacon, F.. . . . . . . . . D-1458, 172; L1-1642, 186 Leakey, A. . . . . . . . . . . . . . E-204, 016; E-210, 016 Leal, J. R.. . . . . . . . . . . . . . . . . . . . . . . K-1756, 199 Learn, D. B.. . . . . . . . . . . . . . . . . . . . . A-1955, 241 Leavitt, R. . . . . . . . . . . . . . . . . . . . . . . . H-885, 102 Lebeaux, D. . . . . . . . . . . . . . . . . . . . . . K-2087, 252 LeClaire, A. . . . . . . . . . . . . . . . . . . . . . . D-155, 011 Leclercq, R. . . . . . . . . . D-1441, 171; L2-2117, 255 Lecompte, T. . . . . . . . . . . . . . . . . . . . . . T-343, 029 Ledeboer, N. A. . . . . . . . . . .D-728, 090; 1131, 133; . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1777, 201 Ledergerber, B. . . . . . . . . . . . . . . . . . . . V-384, 030

Lee, S. H. . . . . . . . . . . . C1-068, 006; C1-595, 081 Lee, S. . . . . . .T-366, 029; D-741, 091; K-907, 104; . . . . . . P-1006, 112; V-1074, 117; V-1239, 160; . . . H-1564, 179; C2-1978, 243; C2-1984, 244; . . . . . . F-2024, 247; K-2076, 250; K-2092, 252 Lee, V. . . . . . . . . . . . . . . . . . . . . . . . . . F-2010, 246 Lee, W. . . . . . . . . . . . . . . . E-195, 015; V-372, 030; . . . . . . E-791, 094; C2-1212, 157; E-1476, 174; . . . . . . . . . . . . . . . . . K-1595, 182; K-1613, 184 Lee, Y. J. . . . . . . . . . . . . . . . . . . . . . . . . T-361, 029 Lee, Y. . . . . . T-366, 029; D-732, 091; D-741, 091; . . . . . . . . . . . . . . . . . . K-907, 104; V-1074, 117; . . . . . . . . . . . . . . . . V-1239, 160; C2-1984, 244 Leeds, J. . . . . . . . . . . . . . . . . . . . . . . . . . B-664, 084 Leelaporn, A.. . . . . . . . . . . . . . . . . . . . E-1477, 174 Leelarasamee, A. . . . . . . . . . . . . . . . . . E-1477, 174 Lefebvre, B. . . . . . . . . . . . C2-085, 008; D-751, 092 Leflon, V. . . . . . . . . . . . . . . . . . . . . . . L2-2109, 255 Leflon-Guibout, V. . . . . . . . . . . . . . . . K-2087, 252 Lefort, A.. . . . . . . . . . . . B-660, 084; L2-2109, 255; . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2117, 255

Final Program

Lekkakou, D. . . . . . . . . . . . . . . . . . . . . . E-799, 094 Lellek, H. . . . . . . . . . . . . . . . . . . . . . . . T-347, 029 Lemaire, N. . . . . . . . . . . . . . . . . . . . . . . A-638, 083 Lemaire, S. . A-596, 082; A-599, 082; F-2029, 247 Lemaire, X. . . . . . . . . . . . . . . . . . . . . . L1-957, 109 Lemaitre, T. . . . . . . . . . . . . . . . . . . . . . G-1051, 114 LeMay, M.. . . . . . . . . . . . . . . . . . . . . . F-2034, 248 Lemeunier, L. . . . . . . . . . . . . . . . . . . . . H-231, 019 Lempers, V. J. . . . . . . . . . . . . . . . . . . . A-1928, 240 Len, O. . . . . . . . . . . . . . . . . . . . . . . . . . T-368, 029 Leneva, I. A. . . . . . . . . . . . . . . . . . . . . . V-388, 030 Leo, Y. . . . . . . . . . . . . . . . . P-569, 075; P-567, 075 Leon, F. . . . . . . . . . . . . . . . . . . . . . . . . F-1488, 175 Leonard, D. A. . . . . . . . . . . . . . . . . . . C1-467, 047 Leonard, S. N. . . . . . . . . . A-622, 082; K-1123, 129 Leone, A. . . . . . . . . . . . . . . . . . . . . . . . K-1125, 129 Leonildi, A. . . . . . . . . . . . . . . . . . . . . . . E-796, 094 Leopold, T. N. . . . . . . . . . . . . . . . . . . . P-1010, 112 Leoz, M. . . . . . . . . . . . . . . . . . . . . . . . . H-886, 102 Lepak, A. . . . . . . . . . . . . . F-857, 099; A-1270, 162; . . . . . .A-1271, 162; A-1929, 240; A-1930, 240; . . . . . A-1931, 240; A-1932, 240; A-1947, 241 Lepak, A. J. . . . . . . . . . . . . . . . . . . . . . D-1431, 171 Lepe, J. . . C1-683, 086; A-1280, 162; K-1924, 239 Lepelletier, D. . . . . . . . . . K-255, 022; B-1318, 165 Lepeule, R. . . . . . . . . . V-1073, 117; L2-2109, 255 Lephart, P. . . . . . . . . . . . . K-902, 104; L2-306, 027 Lephart, P. R. . . . . . . . . . .K-262, 023; K-272, 024; . . . . . . . . T-367, 029; E-787, 094; K-1589, 181; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1604, 183 Lepist, I. . . . . . . . . . . . . . . . . . . . . . . . . H-892, 103 Lepoutre, A. . . . . . . . . . . . . . . . . . . . C2-1359, 167 Lepri, A. C. . . . . . . . . . . . . . . . . . . . . . T-1072, 116 Lerman, Y.. . . . . . . . . . C2-109, 009; C2-1900, 236 Leroy, J. . . . . . . . . . . . . . . . . . . . . . . . .M-1692, 190 Leroy, O. . . . . . . . . . . . . . . . . . . . . . . . K-2089, 252

233


Presentation Number

Author

Presentation Number

Author

Presentation Number

Leruez, M.. . . . . . . . . . . . . . . . . . . . . . . V-387, 030

Liew, Y. . . . . . . . . . . . . . . . . . . . . . . . . K-1595, 182

Liu, M. . . . . . . . . . . . . . . G-875, 101; M-973, 111

Lesho, E. . . . . . . . . . . . C2-725, 089; C2-1914, 237 Leung, V. . . . . . . . . . . . . . . . . . . . . . . . . D-161, 011

Lightstone, F.. . . . . . . . . F-2017, 247; F-2018, 247; . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2018a, 247

Levasseur, P.. . . . . . . . . . . . . . . . . . . . . A-1760, 200

Lightwood, D. . . . . . . . . . . . . . . . . . . . B-1738, 196 Liguori, S. . . . . . . . . . . . . . . . . . . . . . G3-1554, 178 Lilly, M. . . . . . . . . . . . . . . . . . . . . . . . . . F-828, 097

Liu, S. . . . F-838, 098; V-1078, 117; G3-1550, 178 Liu, W. . . . .A-041, 004; A-042, 004; C2-083, 008; . . . . . . . H-215, 018; H-218, 018; L2-309, 027; . . . . . . . . F-810, 096; G-867, 100; V-1238, 160; . . . . . . . . . . . . . . . . . . . . . . . . . . . . H-1578, 180 Liu, X. . . . . . . . . . . . . . . . . . . . . . . . . . . K-933, 105 Liu, Y. . . . . . . . . . . . . . . .A-010, 003; C2-083, 008; . . . . . . . . . . . . . . . C2-1212, 157; C2-1987, 244

Levin, E. . . . . . . . . . . . . . . . . . . . . . . . L1-961, 110 Levine, D. P. . . . . . . . . . K-275, 024; L1-1638, 186; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1730, 194 Levitt, P. S. . . . . . . . . . . . . . . . . . . . . . C1-464, 047

Lim, C. H.. . . . . . . . . . . . . . . . . . . . . . L1-294, 026 Lim, C. . . . . . . . . . . . . . . . . . . . . . . . . K-1613, 184

Levrard, M. . . . . . . . . . . . . . . . . . . . . .M-1698, 191

Lim, C. J. . . . . . . . . . . . . . . . . . . . . . . . . K-558, 074

Levy, C. . . . . . . . . . . . . . .G-864, 100; G-1049, 114 Lévy, S. . . . . . . . . . . . . . . . . . . . . . . . . . V-375, 030

Lim, C. S. . . . . . . . . . . . . M-990, 111; F-2071, 249 Lim, S. . . . . . . . . . . . . . . . . . . . . . . . . C2-1913, 237

Lévy-Bruhl, D. . . . . . . . . . . . . . . . . . . . V-375, 030

Lim, T. P. . . . E-195, 015; E-791, 094; E-1476, 174

Lew, D. . . . . . . . . . . . . . . . K-249, 022; K-253, 022 Lew, I. . . . . . . . . . . . . . . . . . . . . . . . . . K-1598, 182 Lewinski, M. A. . . . . . . . . . . . . . . . . . D-1433, 171 Lewis, J. S. . . . . . . . . . . . . . . . . . . . . . . C2-112, 009 Lewis, K. . . . . . . . . . . . . . . F-815, 096; F-829, 098; . . . . . . . . . . . . . . . . . .F-1519, 177; F-1536, 177

Lim, W. P. . . . . . . . . . . . . . . . . . . . . . . . A-614, 082 Limaye, A. P. . . . . . . . . . . . . . . 1815, 209; 407, 034 Limper, A. H. . . . . . . . . . . . . . . . . . . . . F-813, 096 Lin, A. . . . . . . . . . . . . . . K-1590, 181; K-1591, 181

Lewis, P. . . . . . . . . . . . . . . . . . . . . . . . G-1052, 114 Lewis, R. E. . . . . . . . . . .M-984, 111; M-1057, 115; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1679, 190 Lewis, R. . . . . . . . . . . . . . . . . 414, 035; M-972, 111 Lewis, R. E. . . . . . . . . . . .M-979, 111; K-1619, 184 Li, C. R. . . . . . . . . . . . . . . . . . . . . . . . F-1499, 176 Li, C. . . . . . . . . . . . . . . . . . . . . . . . . . . A-1763, 200 Li, D. . . . . . . . . . . . . . . . A-1289, 163; A-1956, 241 Li, G. Q. . . . . . . . . . . . . . . . . . . . . . . . F-1499, 176 Li, H.. . . . . . . . . . . . . . . . . . . . . . . . . . C2-083, 008 Li, J. . . . . . . . .A-024, 004; A-027, 004; A-031, 004; . . . . . . . . . . . 500, 061; A-634, 083; A-635, 083; . . . . . . . . . E-785, 094; E-795, 094; K-933, 105; . . . . . . F-1505, 176; M-1695, 190; A-1760, 200 Li, K. . . . . . . . . . . . . . . . . . . . . . . . . . . . V-370, 030 Li, Q. . . . . . . . . . . . . . . . . F-838, 098; D-1454, 172 Li, S. . . . . . . . . . . . . . . . . . . . . . . . . . . B-1296, 164 Li, T. . . . . . . . . . . . . . . . . . . . . . . . . . . . F-846, 099 Li, W. . . . . . . . . . . . . . . . . K-268, 023; K-936, 105 Li, X. . . . . . A-009, 003; F-810, 096; M-1061, 115; . . . . . F-2017, 247; F-2018, 247; F-2018a, 247; . . . . . . . . . . . . . . . . . F-2022, 247; F-2024, 247; Li, Y. . . . . . C2-083, 008; C2-083, 008; T-365, 029; . . . . . . . . . F-845, 099; F-846, 099; K-933, 105; . . . . . A-1248, 161; F-1498, 176; L1-1659, 189 Li, Z. . . . . . . . . . . . . . . . . . . . . . . . . . . . K-933, 105 Liao, C. . . . . . . . . . . . . C2-1212, 157; D-1420, 170 Liao, G. . . . . . . . . . . . . . M-984, 111; M-1057, 115 Liappis, A. P. . . . . . . . . . . . . . . . . . . . . . H-213, 017 Liberator, P. . . . . . . . . . . . . . . 575, 077; G-870, 101 Libman, M. D. . . . . . . . . . . . . 403, 033; 1140, 137 Lichtner, M. . . . . . . . . . D-742, 091; C2-1373, 168 Liebenstein, T. . . . . . . . . . . . . . . . . . . . . A-621, 082 Liebo, R. V. . . . . . . . . . . . . . . . . . . . . . V-1241, 160 Liew, Y. X. . . . . . . . . . . . . . . . . . . . . . . . K-896, 104

234

Livak, B. . . . . . . . . . . . . . . . . . . . . . . . . H-883, 102 Livermore, D. M. . . . . . . . E-192, 015; F-853, 099; . . . . . . . . . . . . . . . . . . . 1196, 154; F-2048, 248 Livermore, J. . . . . . . . . . M-977, 111; A-1765, 200; . . . . . . A-1942, 240; A-1943, 240; A-1944, 240 Livshiz-Riven, I. . . . . . . . . . . . . . . . . . .M-339, 028 Lizasoain, M.. . . . . . . . . T-1071, 116; K-2091, 252

Lin, B. . . . . . . . . . . . . . . . . . . . . . . . . . . F-828, 097

Lloyd, T. . . . . . . . . . . . . . . . . . . . . . . . . K-561, 074 Lloyd-Smith, E. . . . . . . . K-1593, 182; D-161, 011

Lin, C. . . . . . . . . . . . . . . . . . . . . . . . . . C2-097, 008

Lloyld, T. . . . . . . . . . . . . . . . . . . . . . . . D-1448, 172

Lin, S. . . . . . . . . . . . . . . . . . . . . . . . . . A-1251, 161

Lo, S. . . . . . . . . . . . . . . . C2-089, 008; C2-090, 008 Lob, S. . . . . . . . . . . . . . .C2-100, 009; C2-141, 010; . . . . . . . . . . . . . . . . . C2-688, 087; C2-722, 089

Lin, T. . . . . . . . . . . . . . . . . . . . . . . . . . . V-397, 030 Lin, Y. T. . . . . . . . . . . . . . . . . . . . . . . C1-1339, 166 Lina, B. . . . . . . . . . . . . . . . . . . . . . . . . V-1080, 117 Lina, G. . . . . . . . . . . . . . . . . . . . . . . . . B-1735, 196 Liñares, J.. . . . . . . . . . . . .B-658, 084; C2-690, 087; . . . . . . . . . . . . . . .C2-1358, 167; C2-1365, 167; . . . . . . . . . . . . . . . C2-1395, 169; C2-1974, 243 Lincopan, N. . . . . . . . . .C2-106, 009; C2-704, 088; . . . . . . .C2-716, 088; C2-717, 088; E-784, 094; . . . . . . . . E-788, 094; E-801, 094; K-1606, 183; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2004, 246 Lindner, H. . . . . . . . . . . . . . . . . . . . . . F-2058, 249 Ling, L. . . . . . . . . . . . . . . . . . . . . . . . . . F-829, 098 Ling, M. L. . . . . . . . . . . . . . . . . . . . . . K-1595, 182 Linhares, A. R. . . . . . . . . . . . . . . . . . . . D-749, 092 Linkin, D. . . . . . . . . . . . . . . . . . . . . . . . D-744, 091 Lionakis, M. . . . . . . . . . . . . . . . . . . . . . . . 548, 072 Lionakis, M. S. . . . . . . . . . . . . . . . . . .M-1055, 115 Liou, L. . . . . . . . . . . . . . . . . . . . . . . . . . G-871, 101 Lipkin, C. B. . . . . . . . . . . . . . . . . . . . . L1-292, 026 Lipkin, W. I. . . . . . . . . . . . . . . . . . . . . . . 1190, 153 Lipsky, B. A. . . . . . . . . . . . . . . . . . . . . . . . 540, 070 Lischka, P. . . . . . . . . . . . . . . . . . . . . . . . T-356, 029 Lista, N.. . . . . . . . . . . C2-1396, 169; C2-1397, 169 Little, S. . . . . . . . . . . . . . . . . . . . . . . . . F-2028, 247 Litwin, J. . . . . . . . . . . . . . . . . . . . . . . . A-1958, 241 Liu, B. Y. . . . . . . . . . . . . . . . . . . . . . . . . E-795, 094 Liu, C. . . . . K-247, 022; K-261, 023; C2-1212, 157 Liu, D. . . . . . . . . . . . . . . . . . . . . . . . . . A-1284, 162 Liu, E. M. . . . . . . . . . . . . . . . . . . . . . . C1-065, 006 Liu, G. . . . . . . . . . . . . . . . . . . . . . . . . . F-2031, 248 Liu, J. . . . . F-832, 098; V-1078, 117; C1-1203, 156; . . . . . A-1267, 161; F-1498, 176; G3-1550, 178

September 9-12 |

Lobo, L. A. . . . . . . . . . . . . . . . . . . . . . C1-671, 085 Loboda, A.. . . . . . . . . . . . . . . . . . . . . .M-1695, 190 Locher, H. H. . . . . . . C1-1346, 166; C1-1347, 166 Lock, J. L. . . . . . . . . . . . . . . . . . . . . . . L1-286, 025 Locke, J.. . . . . . . . . . . . . .F-1514, 176; F-2025, 247 Lodise, T. P. . A-020, 003; A-606, 082; K-1123, 129 Loeb, M. . . . . . . . . . . . . . . . . . . . . . . . . K-955, 108 Loebner-Olesen, A.. . . . . . . . . . . . . . . K-1617, 184 Loecken, A. . . . . . . . . . . . . . . . . . . . . . . K-953, 108 Loessner, M. J.. . . . . . . . . . . . . . . . . . . F-1516, 176 Logan, A.. . . . . . . . . . . . . . . . . . . . . . . F-2016, 247 Lohse, A. W. . . . . . . . . . . . . . . . . . . . . . . 1820, 210 Loizidou, A. . . . . . . . . . T-1028, 113; D-1413, 170 Loman, N. J. . . . . . . . . . . . . . . . . . . . . . . . 424, 038 Lomas, J. M. . . . . . . . . . . . . . . . . . . . . . K-938, 106 Lomas, J. . . . . . . . . . . . . . . . . . . . . . . . . K-941, 106 Lomovskaya, O.. . . . . . . . . F-855, 099; F-848, 099; . . . . . . . . . F-849, 099; F-850, 099; F-851, 099; . . . . . . . . . . . F-852, 099; F-858, 099; 1837, 216 Loneragan, G. H. . . . . . . . . . . . . . . . . C2-710, 088 Long, F. . . . . . . . . . . . . . . . . . . . . . . . . F-2002, 246 Long, L.. . . . . . . . . . . . . . . . . . . . . . . . . F-815, 096 Longcor, J. . . . . . . . . . . . .E-208, 016; A-1289, 163; . . . . .A-1290, 163; L1-1663, 189; A-1956, 241; . . . . . . . . . . . . . . . . . A-1957, 241; A-1958, 241 Longley, N. . . . . . . . . . . . . . . . . . . . . .M-1699, 191 Longo, G. . . . . . . . . . . . . . . . . . . . . . . D-1436, 171 Longshaw, C.. . . . . . . . . . K-924, 105; B-1299, 164 Longuet, P. . . . . . . . . . . . . . . . . . . . . . V-1073, 117 Loo, A. . . . . . . . . . . . . . . . . . . . . . . . . . A-636, 083 Loo, V. G. . . . . . . . . . . . . . . . . . . . . . . . . 1847, 221

AUTHOR INDEX Author

Presentation Number

Author

Presentation Number

Author

Presentation Number

Lucero, C. . . . . . . . . . . . C2-701, 087; D-746, 092; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1910, 237

Macedo, A. . . . . . . . . . . T-1044, 113; D-1403, 170 Macesic, N. . . . . . . . . . . . . . . . . . . . . . . K-952, 108

López, J.. . . . . . . . . . . . . . . . . . . . . . . . . K-938, 106

Lucet, J. C.. . . . . . . . . . K-1757, 199; L2-2117, 255 Luciano, K. A. . . . . . . . . . . . . . . . . . . . E-1485, 174

López, Y. . . . . . . . . . . . . .E-205, 016; C1-681, 086; . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-682, 086 Lopez del Hierro, M. . . . . . . . . . . . . . H-1921, 238

Lückermann, M. . . . . . . . . . . . . . . . . . A-1960, 241

MacGowan, A. P. . . . . . . .A-628, 083; A-629, 083; . . . . . . . . A-631, 083; A-642, 083; D-763, 092; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-793, 094

Ludden, C. . . . . . . . . . .C2-119, 009; C2-122, 009; . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-706, 088

MacGregor, T. R.. . . . . . . . . . . . . . . . . A-1248, 161 Machado, A. M. . . . . . . . . . . . . . . . . C2-1376, 169

Lueangniyomkul, A. . . . . . . . . . . . . . . . H-894, 103 Luisa Moro, M. . . . . . . . . . . . . . . . . . . . . 1155, 144 Lukacs, N. . . . . . . . . . . . . . . . . . . . . . . . G-869, 101

Machalek, D. A. . . . . . . . . . . . . . . . . . L2-301, 027

Looke, D. F.. . . . . . . . . . . . . . . . . . . . . . . 1192, 153 Lopez, E. . . . . . . . . . . . . . . . . . . . . . . G3-1552, 178 Lopez, G. . . . . . . . . . . . . . . . . . . . . . . H-1917, 238

Lopez Furst, M.. . . . . C2-1396, 169; C2-1397, 169 López Jiménez, J. . . . . . . . . . . . . . . . . . A-1934, 240 Lopez Ruz, M. . . . . . . . . . . . . . . . . . . H-1921, 238 López-Cerero, L. . . . . . . . . . . . . . . . . . C2-707, 088

Lukehart, S. A. . . . . . . . . . . . . . . . . . . B-1301, 164

López-Contreras, J. . . . . . . . . . . . . . . . . K-256, 022

Lumbreras, C. . . . . . . . . . T-359, 029; T-1071, 116; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2091, 252

López-Cortés, L. . . . . . . . . . . . . . . . . L1-1658, 188 López-Medrano, F. . . . . . . T-359, 029; K-938, 106; . . . . . T-1071, 116; K-2091, 252; L2-2110, 255 Lopez-Roa, P. . . . . . . . . .T-1026, 113; V-1242, 160 López-Rojas, R.. . . . . . . . . . . . . . . . . . B-1329, 165 López-Vélez, R.. . . . . . . . . . . . . . . . . . . . 1087, 119 Lora, J. . . . . . . . . . . . . . . . . . . . . . . . . L1-2102, 254 Lora-Tamayo, J.. . . . . . . . . K-254, 022; B-647, 084 Lorentz, S. . . . . . . . . . . . . . . . . . . . . . . L1-959, 109 Lorenzo, I. G. . . . . . . . . . . . . . . . . . . . C1-067, 006 Loriau, J. . . . . . . . . . . . . . . . . . . . . . . . . K-234, 020 Lortholary, O. . . . . . . . M-1686, 190; M-1707, 191 Losinno Juan, Ramirez Santiago, Blanco Miriam, Cazzola Laura, Firpo Soledad, Yebara Analia, . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1637, 186

Lundgren, J. D. . . . . . . . . . . . . . . . . . . T-1072, 116 Lung, M. . . . . . . . . . . . . . . . . . . . . . . . . K-931, 105 Lunniss, C. J. . . . . . . . . . . . . . . . . . . . . F-2016, 247 Luo, C. . . . . . . . . . . . . . . . . . . . . . . . . C1-673, 085 Luo, G. . . . . . . . . . . . . . . B-650, 084; E-1473, 174 Luo, R. . . . . . . . . . . . . . . . . . . . . . . . . L1-292, 026 Luo, X.. . . . . . . . . . . . . . . . . . . . . . . . . B-1303, 164 Luque, A.. . . . . . . . . . . . . . . . . . . . . . . A-1252, 161 Luse, A. . . . . . . . . . . . . . . . . . . . . . . . . K-2080, 251 Lustig, S. . . . K-249, 022; K-253, 022; B-1319, 165 Lustig, U.. . . . . . . . . . . . . . . . . . . . . . . A-1764, 200 Luther, M. K. . . . . . . . . E-1464, 173; E-1469, 173 Lutsar, I. . . . . . . . . . . .G3-1559, 178; G-1750, 198 Luttick, A. . . . . . . . . . . . . . . . . . . . . . . . F-828, 097

Lou, Y.. . . . . . . . . . . . . . . . . . . . . . . . . A-1246, 161 Loughborough, A. . . . . . . . . . . . . . . . . . K-281, 024

Luzzaro, F. . . . . . . . . . . D-757, 092; C2-1211, 157; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1897, 236

Louie, A. . . . .A-011, 003; A-041, 004; A-042, 004; . . . . . . A-1265, 161; A-1761, 200; E-1993, 245 Louie, T. . . . . . . . . . . . . . . . . . . . . . . . . . 1146, 140

Ly, N. S.. . . . . A-016, 003; A-024, 004; E-785, 094 Lye, D. C. . . . P-567, 075; P-569, 075; A-614, 082; . . . . . . . . . K-896, 104; K-899, 104; K-910, 104 Lyerly, D. M. . . . . . . . . . . .D-162, 011; D-163, 011 Lynch, D. T.. . . . . . . . . . . . . . . . . . . . . . D-170, 012 Lynskey, N. . . . . . . . . . . . . . . . . . . . . . B-1311, 165 Lyon, G. M.. . . . . . . . . . M-337, 028; M-1227, 159 Lyon, K. C. . . . . . . . . . . . . . . . . . . . . G3-1558, 178 Lyra, Y. C. . . . . . . . . . . . . . . . . . . . . . . D-1428, 171

Lounis, N. . . . . . . . . . . . . . . . . . . . . . . A-1259, 161 Loveless, V. . . . . . . . . . . . . . . . . . . . . . A-1267, 161 Low, D. E. . . . . . . . . . . .C2-089, 008; C2-090, 008; . . . . .K-281, 024; C2-1214, 157; C2-1363, 167; . . . . . . . . . . . . . . . C2-1362, 167; C2-1364, 167 Low, D. . . . . . . . . . . . . . . . . . . . . . . . G3-1562, 178 Lowe, D. . . . . . . . . . . . . K-1590, 181; K-1591, 181 Lowman, W. . . . . . . . . . . . . . . . . . . . . . D-773, 092 Loyse, A. . . . . . . . . . . . . . . . . . . . . . . .M-1670, 190 Loza, E. . . . . . . . . . . . . . M-323, 028; M-1700, 191 Lu, C. . . . . G-867, 100; V-1238, 160; A-1251, 161 Lu, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . K-936, 105 Lu, M. . . . . . . . . . . . . . . . . . . . . . . . . . . H-551, 073 Lu, N. . . . . . . . . . . . . . . . . . . . . . . . . . A-1767, 200 Lu, R. J. . . . . . . . . . . . . . . . . . . . . . . . . . H-554, 073 Lu, X. . . . . . . . . . . . . . . . K-905, 104; F-1499, 176 Lu, Y.. . . . . . . . . . . . . . . . . . . . . . . . . . . F-834, 098 Lubritz, G.. . . . . . . . . . . . . . . . . . . . . G3-1547, 178 Lucas, E. . . . . . . . . . . . . . . . . . . . . . . G3-1563, 178 Lucas, M. J. . . . . . . . . . . . . . . . . . . . . L1-1223, 158

M M Protein Study Group . . . . . . . . . . . B-1312, 165 M’zali, F. . . C2-091, 008; D-164, 012; C2-719, 089 Ma, J. . . . . . . . . . . . . . . . . . . . . . . . . . . F-1502, 176 Ma, L. . . . . . . . . . . . . . . . . . . . . . . . . . A-1934, 240 Ma, Z. . . . . . . F-834, 098; F-835, 098; F-836, 098; . . . . . . . . . F-837, 098; F-838, 098; F-839, 098; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-840, 098 MacDonald, J. . . . . . . . . . . . . . . . . . . C2-1380, 169 MacDonald, N. C.. . . . . . . . . . . . . . . . . K-240, 020 MacDougall, C. . . . . . . . . D-754, 092; K-1923, 239 MacDougall, L. . . . . . . . . . . . . . . . . . .M-1233, 159

Final Program

MacKenzie, B. . . . . . . . . . . . . . . . . . . . B-1738, 196 MacKenzie, C. R. . . . . . . . . . . . . . . . . C1-588, 081 Mackenzie, R. . . . . . . . . . . . . . . . . . . G3-1562, 178 Mackey, J. . . . . . . . . . . . . . . . . . . . . . . L1-284, 025 Macmullin, G. . . . . . . . . . . . . . . . . . . G3-1562, 178 MacMullin, G. . . . . . . . . . . . . . . . . . C2-1214, 157 MacNeill, M. . . . . . . . . . . . . . . . . . . . . C2-090, 008 Macri, A. . . . . . . . . . . . . . . . . . . . . . . . D-1776, 201 Madero, R.. . . . . . . . . . . . . . . . . . . . . . K-1608, 184 Madhi, S. A. . . . . . . . . . . . . . . . . . . . . . D-172, 013 Madhura, D. . . . . . . . . . . . . . . . . . . . . A-1267, 161 Madrid, N.. . . . . . . . . . . . . . . . . . . . . . H-1567, 179 Madsen, H. A. . . . . . . . . . . . . . . . . . . . . G-862, 100 Maehara, C. . . . . . . . . . . . . . . . . . . . . . D-1438, 171 Maertens, J. . . . . . . . . . M-1225, 159; M-1676, 190 Maffia, P. . . . . . . . . . . . . . . . . . . . . . . . F-1491, 175 Magalhães, A. G.. . . . . . . . . . . . . . . . . K-1601, 182 Magarian Blander, J. . . . . . . . . . . . . . . . . . 417, 036 Maggi, G. . . . . . . . . . . . . . . . . . . . . . . K-1608, 184 Magill, S. . . . . . . . . . . . . . . . . . . . . . . . . . 1806, 208 Magri, A. S. . . . . . . . . . . . . . . . . . . . . . K-1603, 183 Magulick, J. P. . . . . . . . . . . . . . . . . . . . L1-297, 026 Mahajan, S. . . . . . . . . . . .T-1065, 116; V-1075, 117 Mahamat, A. . . . . . . . . . . . . . . . . . . . . P-1011, 112 Maharjan, B. . . . . . . . C2-1368, 168; C2-1369, 168 Mahbub, K. R.. . . . . . . . . . . . . . . . . . . C2-711, 088 Maher, K.. . . . . . . . . . . . . . . . . . . . . . . C2-705, 088 Mahjoub, Y. . . . . . . . . . . . . . . . . . . . . .M-1698, 191 Mahoney, A. D. . . . . . . . . . . . . . . . . . . . . . 531, 068 Maia, J. . . . . . . . . . . . . . . . . . . . . . . . . .M-320, 028 Maier, S. J. . . . . . . . . . . . . . . . . . . . . . . P-1021, 112 Maietta, R. . . . . . . . . . . . . . . . . . . . . . A-1282, 162 Maiga, M. . . . . . . . . . . . . . . . . . . . . . . . D-739, 091 Maillart, E. . . . . . . . . . . . . . . . . . . . . . . A-637, 083 Mailles, A. . . . . . . . . . C2-1374, 168; L1-1649, 187 Maiolo, E. . . . . . . . . . . . . . . . . . . . . . . .M-974, 111 Maki, D. . . . . . . . . . . . . . . . . . . . . . . . . . 1138, 136 Maki, H. . . . . . . . . . . . . F-1506, 176; F-1507, 176 Maki, K. . . . . . . . . . . . . . . F-817, 096; F-818, 096; . . . . . . . . . . F-819, 096; F-820, 096; F-821, 096 Makidon, P. E.. . . . . . . . . . . . . . . . . . . . G-869, 101 Makristathis, A.. . . . . . . . . . . . . . . . . . H-1918, 238 Malachy, A. . . . . . . . . . . . . . . . . . . . . . L1-962, 110

235


Presentation Number

Malagnino, V. . . . . . . . . . . . . . . . . . . . . D-165, 012 Malani, P. N. . . . . . . . . . . . . . . . . . . . . . . . 488, 055 Malaysian Candidaemia Study (MaCaS) Group, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-947, 107 Malczynski, M. . . . . . . . B-1323, 165; B-1326, 165; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1614, 184 Malfatti, M. A. . . . . . . . . . . . . . . . . . . F-2027, 247 Malhotra, M. K. . . . . . . . . . . . . . . . . . . K-240, 020 Malhotra-Kumar, S. . . . . . . . . . . . . . . C2-109, 009 Mallegol, J. . . . . . . . . . . . . . . . . . . . . . . E-781, 093 Malmberg, C. . . . . . . . . . E-798, 094; A-1966, 241 Malouin, F. . . . . . . . . . . .F-1997, 246; F-1998, 246 Mamizuka, E. . . . . . . . . . C2-717, 088; E-784, 094 Manavathu, E. . . . . . . . . . . . . . . . . . . .M-1716, 191 Manavathu, E. K. . . . . . . M-986, 111; M-987, 111 Manca, N. . . . . . . . . . . . . . . . . . . . . . . L2-304, 027 Manca, S.. . . . . . . . . . . . . . . . . . . . . . . . K-561, 074 Mancos, P. . . . . . . . . . . . . . . . . . . . . . . K-2086, 252

Author

Presentation Number

Author

Presentation Number

Marchaim, D. . . . . . . . . .A-034, 004; C2-096, 008; . . . . . . . . . K-262, 023; K-272, 024; T-367, 029; . . . . . . . .E-787, 094; K-902, 104; K-1589, 181; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1604, 183 Marchak, M. . . . . . . . . . . . . . . . . . . . . F-2019, 247 Marchand, C. L. . . . . . . .F-1495, 175; F-1522, 177

Marti, S. . . . . . . . . . . . . . . . . . . . . . . C2-1974, 243 Martin, C. . . . . . . . . . . D-1413, 170; C1-1739, 197

Marchand, S. . . . . . . . . . . . A-036, 004; A-037, 004 Marchandin, H. . . . . . . . . . . . . . . . . . . F-1488, 175

Martín, R. . . . . . . . . . . . . . . . . . . . . . C2-1395, 169

Marchetti, O. . . . . . . . .L1-1221, 158; M-1225, 159

Maritza, P. . . . . . . . . . . . . . . . . . . . . . . C2-718, 089 Martin-Davila, P.. . . . . . . M-323, 028; D-743, 091; . . . . . . . . . . . . . . . . .M-1700, 191; K-2077, 250 Martín-Gandul, C. . . . . C1-683, 086; A-1280, 162

Marchillo, K. . . . . . . . . . .F-857, 099; D-1431, 171; . . . . . . A-1931, 240; A-1932, 240; A-1947, 241 Marchou, B.. . . . . . . . . . . . . . . . . . . . L1-2103, 254

Martin, E. T. . . . . . . . . . K-272, 024; C2-1985, 244 Martin, I. . . . . . . . . . . . . . . . . . . . . . . C2-1360, 167 Martín, J. . . . . . . . . . . . . . . . . . . . . . . . . H-217, 018 Martin, S. I. . . . . . . . . . . . . . . . . . . . . . T-1066, 116

Marco, F. . . . . . . . . . . . . . .A-610, 082; B-648, 084; . . . . . . . K-945, 106; K-1122, 129; E-1465, 173 Marcus, G.. . . . . . . . . . . . . . . . . . . . . . . T-367, 029 Mardekian, J. . . . . . . . . . . . . . . . . . . . . . K-259, 023 Mares, M. . . . . . . . . . . . . . . . . . . . . . . . F-811, 096

Martin-Lopez, A. . . . . . . . . . . . . . . . . . K-470, 048 Martin-Mazuelos, E. . . . . . . . . . . . . . . . K-950, 107 Martín-Rabadán, P. . . . . . D-166, 012; E-806, 095; . . . . . . . . . . . . . . . . M-1688, 190; K-2090, 252 Martínez, A. A. . . . . . . . . . . . . . . . . . . H-1573, 180

Maretty, L.. . . . . . . . . . . . . . . . . . . . . . P-1017, 112

Martinez, D. . . . . . . . . . . . . . . . . . . . . .M-315, 028

Mändar, R. . . . . . . . . . . . . . . . . . . . . . L2-310, 027 Mandrekar, J. N. . . . . . . . . D-170, 012; B-652, 084 Manfrin, V. . . . . . . . . . . . . . . . . . . . . . H-1579, 180

Margolis, D. . . . . . . . . . . H-895, 103; A-1249, 161 Margolskee, D. . . . . . . . . . . . . . . . . . . . T-358, 029 Margot, N.. . . . . . . . . . . . . . . . . . . . . . . H-552, 073

Martínez, E. . . . . . . . . . . . . . . . . . . . . . . . 446, 043 Martínez, G. . . . . . . . . . . . . . . . . . . . . .M-327, 028 Martínez, J. . . . . . . . . . . . . . . . . . . . . . C1-075, 006

Mariani, L. . . . . . . . . . . . . . . . . . . . . . . D-168, 012

Mangano, A. . . . . . . . . . . . . . . . . . . . . . B-045, 005 Mangin, E. . . . . . . . . . . . . . . . . . . . . . . A-010, 003

Maricela Valerio . . . . . . . . . . . . . . . . . .M-312, 028 Marijanovic, N. . . . . . . . . . . . . . . . . . L1-1667, 189

Mangus, R. S. . . . . . . . . . . . . . . . . . . . T-1029, 113 Manjuba, C.. . . . . . . . . . . . . . . . . . . . . C2-107, 009

Marimón, J. . . . . . . . . . . . . . . . . . . . . C2-1358, 167 Marín, M. . . . . . . . . . . .C2-127, 010; C2-130, 010; . . . . . .C2-142, 010; D-1411, 170; D-1415, 170 Marin, M. . . K-470, 048; K-944, 106; D-1772, 201

Martinez, M. . . . . . . . . . . G-875, 101; M-982, 111; . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1013, 112 Martinez, M. B.. . . . . . . . . . . . . . . . . . . G-861, 100 Martinez, R. . . . . . . . . . . . . . . . . . . . . C2-086, 008

Mankatitham, W. . . . . . . . . . . . . . . . . . H-894, 103 Mankertz, J. . . . . . . . . . . . . . . . . . . . . . C1-679, 086 Manku, M. . . . . . . . . . . . . . . . . . . . . . F-2009, 246 Manoharan, A. . . . . . . . . . . . . . . . . . . . E-196, 015 Manonelles, G. . . . . . . . . . . . . . . . . . G3-1552, 178 Manos, P. . . . . . . . . . . . . . . . . . . . . . . L1-1663, 189 Manosuthi, S. . . . . . . . . . . . . . . . . . . . . H-894, 103 Manosuthi, W. . . . . . . . . . . . . . . . . . . . H-894, 103 Manousaka, S. . . . . . . . . . . . . . . . . . . . B-1300, 164 Manoussakis, M. . . . . . . . . . . . . . . . . L2-2114, 255 Mansi, I. A. . . . . . . . . . . . . . . . . . . . . . L1-297, 026 Mansouri, M. D. . . . . . . . . . . . . . . . . . K-2097, 252 Mantella, A.. . . . . . . . . . . . . . . . . . . . C1-1205, 156 Manuel, O. . T-343, 029; T-352, 029; L1-1221, 158 Manuel, S. . . . . . . . . . . . . . . . . . . . . . . . K-956, 108 Manzoor, H. . . . . . . . . . . . . . . . . . . . C2-1981, 243 Manzur, A. . . . . . . . . . . . . . . . . . . . . . .M-329, 028 Maor, Y.. . . . . . . . . . . . L1-962, 110; L1-1640, 186 Maraki, S. . . . . . . . . . . . . . . . . . . . . . .M-1696, 191 Marathe, B. M. . . . . . . . . . . . . . . . . . . A-1243, 161 Marathe, N. . . . . . . . . . . . . . . . . . . . . . C1-665, 085 Marbury, T. A-010, 003; A-1294, 163; A-1295, 163 Marcelli, C. . . . . . . . . L1-2103, 254; L1-2104, 254 March, F. . . . . . . . . . . . . . . . . . . . . . . . . K-931, 105

236

Mario Fernández-Ruiz . . . . . . . . . . . . .M-312, 028 Marlenee, N. . . . . . . . . . .F-2022, 247; F-2033, 248 Marmolin, E. S. . . . . . . . . . . . . . . . . . . D-1444, 171 Marocco, R. . . . . . . . . . . . . . . . . . . . . . . D-740, 091 Marques, E. A. . . . . . . . . . . . . . . . . . . . D-731, 090 Márquez, J. A. . . . . . . . . . . . . . . . . . . . K-1924, 239 Marr, K. . . . . . . . . . . . . . . . . . . . . . . . .M-1676, 190 Marra, A. R. . . . . . . . . . . . . . . . . . . . . C2-685, 087 Marra, A. . . . . . . . . . . . .A-1289, 163; A-1290, 163; . . . . . . . . . . . . . . . . . . F-1522, 177; F-1523, 177 Marra, C. M. . . . . . . . . . . . . . . . . . . . . B-1301, 164 Marra, C. . . . . . . . . . . . . . . . . . . . . . . . A-1937, 240 Marrie, T. J. . . . . . . . . . . . . . . . . . . . . . . . 1883, 232 Marriel, M. . . . . . . . . . . . . . . . . . . . . . D-1403, 170 Marriott, D. J. . . . . . . . . . . . K-947, 107; 1164, 146 Marsault, É. . . . . . . . . . . .F-1997, 246; F-1998, 246 Marsh, J. . . . . . . . . . . . . . . . . . . . . . . . T-1037, 113 Marshall, S. . . . . . . . . . . C2-686, 087; C2-692, 087 Marshall, S. M. . . . . . . . . . . . . . . . . . . C2-720, 089 Marshall, S. H. . . . . . . . C2-092, 008; C1-590, 081 Martelin, R. . . . . . . . . . . . .D-745, 092; D-748, 092 Marth, E.. . . . . . . . . . . . . . . . . . . . . . . E-1470, 173 Marti, A. . . . . . . . . . . . . . . . . . . . . . . . . K-940, 106 Marti, N. . . . . . . . . . . . . M-980, 111; M-1718, 191

September 9-12 |

Martinez, S. . . . . . . . . . . . . . . . . . . . . . . K-258, 022 Martinez Alarcon, J. . . . . . . . . . . . . . . T-1041, 113 Martinez de Salazar, P. . . . . . . . . . . . . K-1616, 184 Martínez-Lacasa, X. . . . . . . . . . . . . . . . K-938, 106 Martinez-Leyva, G.. . . . . . . . . . . . . . G3-1563, 178 Martínez-Longoria, C. . . . . . . . . . . . C2-1357, 167 Martínez-Martínez, L. . . . . . . . . . . . .C2-105, 009; . . . . . . . . . .C2-111, 009; D-169, 012; 516, 064; . . . . . . . C1-683, 086; D-765, 092; A-1280, 162 Martinez-Selles, M.. . . . . . . . . . . . . . . . K-942, 106 Martinez-Yelamos, S. . . . . . . . . . . . . . V-1240, 160 Martinho, G. . . . . . . . . . . . . . . . . . . . . T-1044, 113 Martins, A. F. . . . . . . . . . . . . . . . . . . C2-1905, 236 Martins, M. A. . . . . . . . . . . . . . . . . . . .M-311, 028 Martins, V. P. . . . . . . . . . . . . . . . . . . . . K-1601, 182 Martiny, D. . . . . . . . . . . . . . . . . . . . . . D-1413, 170 Marty, F. M. . . . . . . . . . . T-354, 029; M-1060, 115 Marty, N. . . . . . . . . . . . . . . . . . . . . . . . . D-758, 092 Maryland MDRO Prevention Collaborative, . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-095, 008 Masaisa, F. . . . . . . . . . . . . . . . . . . . . . . . D-775, 092 Masarwa, S. . . . . . . . . . . . . . . . . . . . . . . K-557, 074 Mascara, G. P. . . . . . . . . . . . . . . . . . . . . A-619, 082 Mascarenhas, L. A. . . . . . . . . . . . . . . . K-1601, 182 Mascellino, M. T.. . . . . . . . . . . . . . . . . . D-165, 012 Maseda, E.. . . . . . . . . . . . . . . . . . . . . . K-1608, 184 Mason, K. L. . . . . . . . . . . . . . . . . . . . . . B-661, 084 Massias, L.. . . . . . . . . . . . . A-021, 003; B-645, 084

AUTHOR INDEX Author

Presentation Number

Author

Presentation Number

Masson, L. . . . . . . . . . . . . . . . . . . . . . C2-1986, 244

McBride, S. . . . . . . . . . . . . . . . . . . . . . P-1023, 112

Massongo, M. . . . . . . . . . . . . . . . . . . . K-2089, 252 Massot, M. . . . . . . . . . . . . . . . . . . . . L1-1639, 186

McCabe, I.. . . . . . . . . . . . . . . . . . . . . . . K-260, 023

Mastroianni, C. M. . . . . . . . . . . . . . . . D-165, 012; . . . . . . . . . . . . . . . . . . .D-740, 091; D-742, 091 Mastroianni, C. . . . . . . . . . . . . . . . . . C2-1373, 168 Masuda, T. . . . . . . . . . . . . . . . . . . . . . . F-1509, 176 Mataseje, L. F. . . . . . . . . . . . . . . . . . . . C2-085, 008 Mateos, J.. . . . . . . . . . . . . . . . . . . . . . . . K-559, 074 Mateu, L.. . . . . . . . . . . . . . . . . . . . . . . D-1419, 170 Mathai, D. . . . . . . . . . . . . . . . . . . . . . . . E-196, 015 Matheron, S. . . . . . . . . . . . . . . . . . . . . . P-570, 075 Matias, N. A. . . . . . . . . . . . . . . . . . . . L1-1653, 187 Matos, J. A. . . . . . . . . . . . . . . . . . . . . . . K-257, 022 Matrakool, L. . . . . . . . . . . .P-998, 112; P-999, 112 Matsa, S. . . . . . . . . . . . . . . . . . . . . . . . F-1505, 176 Matsui, K. . . . . . . . . . . . .F-1506, 176; F-1507, 176 Matsui, M.. . . . . . . . . . D-1456, 172; C2-1904, 236 Matsumoto, S. . . . . . . . . . . F-817, 096; F-818, 096; . . . . . . . . . F-819, 096; F-820, 096; F-821, 096; . . . . . . . . . F-822, 096; F-823, 096; M-981, 111 Matsumoto, T. . . . . . . . . . . . . . . . . . . L1-1657, 188 Matsumura, Y. . . . . . . . . . K-949, 107; K-1599, 182 Matsuo, Y. . . . . . . . . . . . . . . . . . . . . . . . A-019, 003 Matsushima, A. . . . . . . . . K-949, 107; K-1599, 182 Matsushita, S. . . . . . . . . . . . . . . . . . . . D-1429, 171

Presentation Number

Meinz, M. . . . . . . . . . . . . . . . . . . . . . . . F-810, 096 Meis, J. F.. . . . . . . . . . . . . M-332, 028; M-334, 028

McCammon, J. A. . . . . . . . . . . . . . . . . F-1534, 177 McCauley, J. . . . . . . . . . . . . . . . . . . . . A-1761, 200

Mejstrikova, E. . . . . . . . . . . . . . . . . . . . T-344, 029

McClean, S.. . . . . . . . . . . . . . . . . . . . . B-1334, 165 McClellan, I. . . . . . . . . . . . . . . . . . . . . K-1631, 185

Melano, R. G. . . . . . . . .C2-089, 008; C2-090, 008; . . . . . . C1-589, 081; E-781, 093; C2-1214, 157 Mélard, A. . . . . . . . . . . . . . . . . . . . . . . H-1568, 179

McComsey, G. A. . . . . . . . . . . . . . . . . . . 1152, 143 McConnell, M. . . . . . . . . . . . . . . . . . .M-1677, 190 McCormick, D. . . . . . . . . . T-356, 029; V-391, 030 McCoy, C. . . . . . . . . . . . . . . . . . . . . . . . D-163, 011 McCracken, M. . . . . . C2-1379, 169; C2-1380, 169 McCray, P. B.. . . . . . . . . . . . . . . . . . . . B-1322, 165 McCullough, A. E. . . . . . . . . . . . . . . . T-1032, 113 McDermott, L. A. . . . . . . . . . . . . . . . . . K-471, 048 McDermott, P.. . . . . . . . . . . . . . . . . . . C2-714, 088 McElmeel, M. L.. . . . . . . . . . . . . . . . . D-1433, 171 McEwen, A. . . . . . . . . . . . . . . . . . . . . A-1956, 241 McGann, P. . . . . . . . . . C2-725, 089; C2-1914, 237 McGeer, A. . . . . . . . . . .K-281, 024; C2-1362, 167; . . . . . . . . . . . . . . . C2-1363, 167; C2-1364, 167 McGill, R. L.. . . . . . . . . . . . . . . . . . . . . A-619, 082 McGregor, J. C. . . . . . . . . . . . . . . . . . L2-2118, 255 McIntosh, S. D. . . . . . . . . . . . . . . . . . . . H-213, 017 McKenney, D. . . . . . . . . . . . . . . . . . . . . B-664, 084 McKinnell, J. A. . . . . . . . . B-654, 084; B-655, 084 McKinnell, J. . . . . . . . . . . . . . . . . . . . . . A-042, 004 McLellan, D. G. . . . . . . . . . . . . . . . . . . K-265, 023

Matta, L. . . . . . . . . . . . . . . . . . . . . . . L2-2108, 255 Matte, G. R. . . . . . . . . .C2-106, 009; C1-668, 085; . . . . . . . . . . . . . . . . . C2-716, 088; P-1002, 112 Matte, M. H. . . . . . . . . .C2-106, 009; C1-668, 085; . . . . . . . . . . . . . . . . . C2-716, 088; P-1002, 112

McLin, V. A. . . . . . . . . . . . . . . . . . . . G3-1556, 178 McMillan, D. . . . . . . . . . . . . . . . . . . . B-1312, 165

Mattis, D. M. . . . . . . . . . . . . . . . . . . . F-1517, 176

McRoberts, J. P. . . . . . . . A-602, 082; C2-1985, 244

Maurer-Stroh, S. . . . . . . . . . . . . . . . . . H-1569, 179 Maury, E.. . . . . . . . . . . . . . . . . . . . . . . . D-173, 013

Mdluli, K. . . . . F-834, 098; F-835, 098; F-836, 098 Meads, A. . . . . . . . . . . . . . . . . . . . . . L1-1667, 189 Mear, J. . . . . . . . . . . . . . . . . . . . . . . . . . B-060, 005 Méar, J. B. . . . . . . . . . . . . . . . . . . . . . . . B-050, 005 Medeiros, M. . . . . . . . . . . . E-784, 094; E-788, 094; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-801, 094 Mediavilla, J. R. . . . . . . . . . . . . . . . . . . C1-589, 081 Medina, J. . . . . . . . . . . L1-290, 026; L1-1666, 189 Medina, V. . . . . . . . . . . . . . . . . . . . . . L1-1653, 187 Medlock, M. . . . . . . . . . A-1290, 163; A-1958, 241 Meex, C. . . . . . . . . . . . . . . . . . . . . . . C2-1988, 244 Mehboob, S. . . . . . . . . . . . . . . . . . . . . F-2072, 249

Maury, N. . . . . . . . . . . . . . . . . . . . . . . . K-560, 074 Mavraganis, P. . . . . . . . . . . . . . . . . . . G3-1543, 178 Mavridou, E. . . . . . . . . . . . . . . . . . . . . A-1938, 240 Mavrou, I. . . . . . . . . . . . . . . . . . . . . . . . K-245, 021 Max, B. . . . . . . . . . . . . . . . . . . . . . . . . . H-883, 102 May, D. . . . . . . . . . . . . . . . . . . . . . . . . K-1583, 181 May, R. . . . . . . . . . . . . . . . . . . . . . . . L2-2112, 255 May, T.. . . . . . . . . . . . . . . . . . . . . . . . . L2-302, 027 May-Hadford, J. . . . . . . . . . . . . . . . . . . V-386, 030 Maya, J. J. . . . . . . . . . . . . D-747, 092; K-903, 104; . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2108, 255 Mayer, C. . . . . . . . . . . . . . . . . . . . . . . . . H-891, 103 Mayhew, A. . . . . . . . . . . L1-287, 025; L1-288, 025 Mazel, D.. . . . . . . . . . . . . . . . . . . . . . . B-1330, 165 Mc Clanahan, R. . . . . . . . . . . . . . . . . . A-1950, 241 Mc Garry, E. . . . . . . . . . . . . . . . . . . . . C2-119, 009 Mc Intyre, G. F.. . . . . . . A-1961, 241; A-1962, 241 McBride, K.. . . . . . . . . L1-290, 026; L1-1666, 189

Author

McLeod, D. . . . . . . . . . . . . . . . . . . . . . . F-847, 099

Mehra, P. . . . . . . . . . . L1-1663, 189; L1-1665, 189 Mehtar, S. . . . . . . . . . . . . . . . . . . . . . . . . . 484, 053 Meibohm, B. . . . . . . . . . . . . . . . . . . . . A-1267, 161 Meier, F. A. . . . . . . . . . . . . . . . . . . . . . D-1416, 170 Meije, Y. . . . . . . . . . . . . . M-323, 028; T-340, 029; . . . . . . . . . . . . . . . . .M-1700, 191; K-2077, 250 Meini, M. R. . . . . . . . . . . . . . . . . . . . . C1-461, 047 Meinke, P. T. . . . . . . . . . . . . . . . . . . . . F-1496, 176

Final Program

Melander, C. . . . . . . . . . . . . . . . . . . . . F-2069, 249

Melbarde-Kelmere, A.. . . . . . . . . . . . . K-2080, 251 Melchers, M. J. . . . . . . . . . E-190, 015; E-198, 015; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-803, 094 Melchers, W. J. . . . . . . . .M-319, 028; M-988, 111; . . . . . . . . . . . . . . . . . .M-989, 111; A-1933, 240 Meletiadis, J. . . . . . . . . . .E-782, 093; A-1938, 240; . . . . . . . . . . . . . . . . . A-1939, 240; A-1940, 240 Melhem, M. . . . . . . . . . . . . . . . . . . . . .M-327, 028 Melhem, M. S. . . . . . . . . . . . . . . . . . . .M-311, 028 Melhem, M. . . . . . . . . . A-1961, 241; A-1962, 241 Melin, P. . . . . . . . . . . . . . . . . . . . . . . C2-1988, 244 Mellado, E. . . . . . . . . . . . . . . . . . . . . . .M-321, 028 Melo, L. C. . . . . . . . . . . . . . . . . . . . . . C2-704, 088 Melo-Cristino, J. . . . . . . C2-151, 010; G-866, 100; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-865, 100 Mena, A. . . . . . . . . . . . . . . . . . . . . . . . . A-011, 003 Mendelman, P.. . . . . . . . . . . . . . . . . . . G-1048, 114 Mendes, R. E. . . . . . . . .C2-132, 010; C2-139, 010; . . . . . C2-691, 087; C1-1343, 166; F-1510, 176; . . . . . F-1511, 176; F-1512, 176; C1-1745, 197; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1906, 237 Mendez, I. A. . . . . . . . . . . . . . . . . . . C2-1915, 237 Méndez, J. . . . . . . . . . . . . . . . . . . . . . . . K-559, 074 Mendez, J. . . . . . . . . . . . . . . . . . . . . . L1-1643, 186 Mendez, M. . . . . . . . . . . . . . . . . . . . . . A-1767, 200 Mendez-Vigo, L. . . . . . . . . . . . . . . . . . K-2078, 250 Mendonça, N. . . . . . . . . . . . . . . . . . . . C2-713, 088 Mendoza, Y. . . . . . . . . . . . . . . . . . . . . H-1573, 180 Menegas, D. . . . . . . . . . . . . . . . . . . . G3-1543, 178 Menezes, L. C. . . . . . . . . . . . . . . . . . . D-1412, 170 Mengoli, C. . . . . . . . . . . .H-216, 018; H-1579, 180 Mengoni, F. . . . . . . . . . . . .D-740, 091; D-742, 091 Menichetti, F. . . . . . . . . . . . . . . . . . . . . E-796, 094 Mentese, A. . . . . . . . . . . . V-394, 030; D-1405, 170 Mentré, F. . . . . . . . . . . . . A-021, 003; A-1963, 241 Mera, R. M.. . . . . . . . . . . . . . . . . . . . . . G-862, 100 Merad, M. . . . . . . . . . . . . . . . . . . . . . . . K-911, 104 Mercado, D.. . . . . . . . . . . . . . . . . . . . .M-1694, 190 Mercier, R. C. . . . . . . . E-1472, 174; C1-1742, 197 Mercuri, P. . . . . . . . . . . . . . . . . . . . . . . C1-459, 047 Meriem, S. . . . . . . . . . . . . . K-250, 022; K-251, 022 Merin, C.. . . . . . . . . . . . . . . . . . . . . . . L1-289, 026 Merino, I. . . . . . . . . . . . . . . . . . . . . . . C2-111, 009 Merino, M. . . . . . . . . . . . . . . . . . . . . C2-1902, 236 Merino, P. . . . . . . . . . . . . E-805, 095; P-1020, 112

237


Presentation Number

Author

Presentation Number

Author

Presentation Number

Merlet, A. . . . . . . . . . . . . . . . . . . . . . . K-2074, 250 Merlin, J. . . . . . . . . . . . . . . . . . . . . . . . L2-302, 027

Miles, P. . . . . . . . . . . . . . . . . . . . . . . . . . D-736, 091 Milillo, M. . . . . . . . . . . . . . . . . . . . . . C2-1914, 237

Mitchell, A. P. . . . . . . . . . . . . . . . . . . .M-1056, 115 Mitchell, A. M. . . . . . . . . . . . . . . . . . . B-1314, 165

Miller, A. . . . . . . . . . . . . . . . . . . . . . . . . . . 575, 077

Mert, G. . . . . . . . . . . . . . . . . . . . . . . . L1-960, 110

Miller, B. . . . . . . . . . . . . . . . . . . . . . . . . A-641, 083

Mitchell, G. . . . . . . . . . . .F-1997, 246; F-1998, 246 Mitchell, J. . . . . . . . . . . . . . . . . . . . . . . . A-618, 082

Mertz, D.. . . . . . . . . . . . . K-955, 108; K-1927, 239

Miller, D. . . . . . . . . . . . . . . . . . . . . . . C2-1400, 169 Miller, E. . . . . . . . . . . . . . . . . . . . . . . . . F-841, 099

Merkier, A. K. . . . . . . . . . . . . . . . . . . . C1-074, 006

Meshay, M. . . . . . . . . . . . . . . . . . . . . . . A-618, 082 Mesquita, N. M. . . . . . . . . . . . . . . . . . . K-257, 022 Messaritakis, I.. . . . . . . . . . . . . . . . . . . . B-043, 005 Messer, S. A. . . . . . . . . . M-1714, 191; M-330, 028 Mestres, C. A. . . . . . . . . . .A-610, 082; B-648, 084; . . . . . . . K-945, 106; K-1122, 129; E-1465, 173 Metan, G. . . . . . . . . . . . . . . . . . . . . . .M-1701, 191 Metcalf, C.. . . . . . . . . . . . . F-843, 099; F-844, 099; . . . . . . . . . . . . . . . . . . . .F-845, 099; F-846, 099 Metchock, B. . . . . . . . . . . . . . . . . . . . . . D-737, 091 Metzger, S. . . . . . . . . . . . . . . . . . . . . . D-1410, 170 Meugnier, H. . . . . . . . . . . . . . . . . . . . . B-1319, 165 Meya, D. . . . . . . . . . . . . . . . . . . . . . . .M-1699, 191 Meyer, E. . . . . . . . . . . . . . . . . . . . . . . . K-1592, 181 Meyer, L. . . . . . . . . . . . . H-1568, 179; K-2073, 250 Meyer, W. . . . . . . . . . . . . . . . . . . . . . . .M-336, 028 Meyer, W. A. . . . . . . . . . . . . . . . . . . . . H-1575, 180 Meyers, J. . . . . . . . . . . . . . . . . . . . . . . . . H-211, 017 Meylan, P. . . T-343, 029; T-352, 029; L1-1221, 158 Meyvisch, P.. . . . . . . . . .A-1259, 161; A-1258, 161; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1260, 161 Meza, A. . . . . . . . . . . . . . . . . . . . . . . . C1-069, 006 Meza, J. L. . . . . . . . . . . . . . . . . . . . . . . . K-922, 105 Meziane-Cherif, D. . . . C1-458, 047; C1-1344, 166 Michael, G. B. . . . . . . . . . . . . . . . . . . . C1-670, 085 Michail, G. . . . . . . . . . . . . . . . . . . . . . B-1300, 164 Michallet, M.. . . . . . . . . . . . . . . . . . . . . T-360, 029 Michelet, C.. . . . . . . . . . . . . . . . . . . . . . K-267, 023 Michowicz, A. . . . . . . . . . . . . . . . . . . .M-1670, 190 Micic, D. . . . . . . . . . . . . . . . . . . . . . . . . K-926, 105 Micol, J. . . . . . . . . . . . . . . . . . . . . . . . . . D-772, 092 Micozzi, A. . . . . . . . . . . . . V-393, 030; K-898, 104 Microbiology and Pediatric Pneumococcal Working Group. . . . . . . . . . . . . . . . . G-866, 100 Middeldorp, J. M. . . . . . . . . . . . . . . . . . . 1724, 192 Miegeville, A. F. . . . . . . .B-653, 084; A-1948, 241; . . . . . . . . . . . . . . . . . . . . . . . . . . . . .F-2056, 248 Miesel, L.. . . . . . . . . . . . . . . . . . . . . . . F-1496, 176 Migiyama, Y. . . . . . . . . . . . B-048, 005; B-049, 005; . . . . . . . . . . . . . . . . . . B-657, 084; B-1297, 164 Migliavacca, R. . . . . . . C2-094, 008; C2-1897, 236 Miida, H.. . . . . . . . . . . . . . . . . . . . . . . F-2042, 248 Mikamo, H. . . . . . . . . . . . . . . L2-305, M-325, 028; . . . . . . . . . . . . . M-328, 028; 027; C2-693, 087; . . . . M-1231, 159; A-1288, 163; C2-1989, 244; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2045, 248 Milanelo, L. . . . . . . . . . . . . .P-993, 112; P-995, 112

238

Miller, L. A.. . . . . . . . . . . . . . . . . . . . . . G-862, 100

Mitchell, J. D. . . . . . . . . . . . . . . . . . . . . . . 536, 069 Mitchell, R. . . . . . . . . . . . . . . . . . . . . . L2-306, 027 Mitchell, T. J. . . . . . . . . . . . . 519, 065; B-1314, 165

Miller, L. . . . . . . . . . . . . .F-1495, 175; F-1522, 177 Miller, M. K. . . . . . . . . . . . . . . . . . . . . G-1749, 198 Miller, M. J. . . . . . . . . . . . . . . . . . . . . . . . 1794, 206

Mitev, G. M. . . . . . . . . . . . . . . . . . . . C1-1972, 242 Mithal, S.. . . . . . . . . . . . F-1494, 175; F-1495, 175

Miller, M. . . . . . . . . . . . . H-552, 073; H-551, 073; . . . . . . . . . . . . . . . . . . . . . . . . . . . . H-1574, 180

Mitsuyasu, R.. . . . . . . . . .H-553, 073; H-1581, 180 Mittal, S. . . . . . . . . . . . . . . . . . . . . . . . . F-812, 096

Miller, T. E. . . . . . . . . . . . . . . . . . . . . . . P-563, 075

Miura, Y. . . . . . . . . . . . . . . . . . . . . . . L1-1657, 188

Millett, W.. . . . . . . . . . . . . . . . . . . . . . . F-829, 098

Miyairi, I.. . . . . . . . . . . . . . . . . . . . . . . . D-175, 013 Miyake, T. . . . . . . . . . . . . . . . . . . . . . . F-1509, 176 Miyata, I. . . . . . . . . . . . . . . . . . . . . . . . . D-175, 013

Milligan, D. . . . . . . . . . . F-2030, 248; F-2031, 248; . . . . . . . . . . . . . . . . . .F-2032, 248; F-2033, 248 Millon, L. . . . . . . . . . . . . . . . . . . . . . .M-1692, 190 Mimoz, O. . . A-035, 004; A-037, 004; K-1757, 199 Min, W. J. . . . . . . . . . . . . . . . . . . . . . . . H-554, 073 Minami, H. . . . . . . . . . . . . . . . . . . . . . D-1461, 172 Minassian, S. L. . . . . . . .A-1292, 163; A-1293, 163; . . . . . . . . . . . . . . . . . A-1294, 163; A-1295, 163 Minea, B. . . . . . . . . . . . . . . . . . . . . . . . . F-811, 096 Minenza, N. . . . . . . . . . . . . . . . . . . . . C2-723, 089 Ming Yao . . . . . . . . . . . . . . . . . . . . . . .M-1669, 190 Mingbunjerdsuk, P. . . . . . . . . . . . . . . . H-1565, 179 Mingorance, J. . . . . . . . . . . . . . . . . . . . D-1452, 172 Mininger, C. . . . . . . . . . . . . . . . . . . . . B-1308, 164 Minkowski, A. . . . . . . . . . . . . . . . . . . . . F-836, 098 Minodier, P. . . . . . . . . . . . . . . . . . . . . G3-1554, 178 Minotti, C. . . . . . . . . . . . . . . . . . . . . . . K-898, 104 Miquelarena, A. . . . . . . . . . . . . . . . . . . . E-202, 015 Mira, J. P. . . . . . . . . . . . . . . .P-568, 075; P-570, 075 Miragaia, M. . . . . . . . . . . . . . . . . . . . C1-1740, 197 Mirambell, A. . . . . . . . . . . . . . . . . . . . K-1616, 184 Miranda, A. S. . . . . . . . . . . . . . . . . . . . D-1403, 170 Miranda, I. M. . . . . . . . . . . . . . . . . . . . .M-320, 028 Mireia Puig . . . . . . . . . . . . . . . . . . . . . .M-312, 028 Mirelis, B. . . . . . . . . . . . . . . . . . . . . . . . K-931, 105 Miro, E. . . . . . . . . . . . . . . . . . . . . . . . . C1-593, 081 Miró, E. . . . . . . . . . . . . . . . . . . . . . . . . K-1621, 184 Miró, J. . . . . . . . . . . . . . . . . . . . . . . . . . K-943, 106 Miro, J. M.. . . . . . . . . . . . . A-610, 082; B-645, 084; . . . . . . . . . B-648, 084; K-941, 106; K-945, 106; . . . . . . . . . . . . . . . . . K-1122, 129; E-1465, 173 Miron, L. . . . . . . . . . . . . . . . . . . . . . . . . F-811, 096 Mischnik, A. . . . . . . . . . . . . . . . . . . . . C2-093, 008 Mishali, H. . . . . . . . . . . . . . . . . . . . . . K-1609, 184 Mishra, N. N. . . . . . . . . . . . . . . . . . . C1-1744, 197 Misset, B.. . . . . . . . . . . . . . . . . . . . . . . . K-234, 020 Mitcham, J. . . . . . . . . . . . . . . . . . . . . . . G-873, 101

September 9-12 |

Mitsuyama, J.. . . . . . . . . . C2-693, 087; F-809, 096

Miyazaki, T. . . . . . . . . . . . . . . . . . . . . . . V-380, 030 Mizushima, D.. . . . . . . . . . . . . . . . . . . . H-224, 019 Moaddab, M.. . . . . . . . . . . . . . . . . . . L2-2111, 255 Moeck, G. . . . . . . . . . . . .C2-128, 010; A-620, 082; . . . . . . . . . . . . . . . . . . D-762, 092; E-1463, 173 Moellering, Jr. R. C. . . . . . . . . . . . . . . . . 1112, 127 Moffat, J. . . . . . . . . . . . . . . . . . . . . . . . F-1537, 177 Mohamed, J. A. . . . . . . . F-2013, 246; K-2096, 252 Mohazabnia, P. . . . . . . . . . . . . . . . . . . . T-357, 029 Mohin, S.. . . . . . . . . . . . . . . . . . . . . . . . K-272, 024 Mohsina, K. . . . . . . . . . . . . . . . . . . . . . C2-711, 088 Moir, D.. . . . . . . . . . . . . . . . . . . . . . . . . . 1103, 125 Moise, P. A. . . . . . . . . . . . . . . . . . . . . . . K-276, 024 Moisi, D. . . . . . . . . . . . . . . . . . . . . . . . H-1571, 180 Mojica, M. F. . . . . . . . . .C1-590, 081; C2-694, 087; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-747, 092 Mok, S. . . . . . . . . . . . . . . . . . . . . . . . . . A-611, 082 Moldovan, O. . . . . . . . . . . . . . . . . . . . D-1776, 201 Molero, L. . . . . . . . . . . . L1-293, 026; L1-295, 026 Molina, J. . . .H-219, 019; H-889, 103; K-1924, 239 Molini, B. J. . . . . . . . . . . . . . . . . . . . . . B-1301, 164 Molinos, S. . . . . . . . . . . . . . . . . . . . . . D-1419, 170 Molitorisz, S. . . . . . . . . . . . . . . . . . . . . . P-994, 112 Moll, F. L. . . . . . . . . . . . . . . . . . . . . . . L1-965, 110 Moller, K. . . . . . . . . . . . . . . . . . . . . . . . B-055, 005 Mollerach, M. . . . . . . C2-1396, 169; C2-1397, 169 Molstad, D. . . . . . . . . . . A-1289, 163; F-1523, 177 Molteni, C. . . . . . . . . . . . . . . . . . . . . . . D-757, 092 Mommeja-Marin, H. . . . . .T-358, 029; T-362, 029 Monaco, A. . . . . . . . . . . . . . . . . . . . . . . B-045, 005 Monahan, C. . . F-843, 099; F-844, 099; F-845, 099 Mondino, S.. . . . . . . . . . . . . . . . . . . . C2-1377, 169 Monecke, S. . . . . . . . . . . D-1432, 171; D-1440, 171 Mongodin, E. F. . . . . . . . . . . . . . . . . . B-1320, 165 Monllau, J. . . . . . . . . . . . . . . . . . . . . . . . K-256, 022

AUTHOR INDEX Author

Presentation Number

Monnet, D. L. . . . . . . . . . . . . . . . . . . . . . 1789, 204 Montakantikul, P. . . . . . . . . . . . . . . . . A-1279, 162 Montalto, M. . . . . . . . . . . . . . . . . . . . L1-1667, 189 Montassier, E. . . . . . . . . L1-283, 025; L1-285, 025; . . . . . . . . . . . . . . . . D-1458, 172; L1-1642, 186 Monteiro, F.. . . . . . . . . . . . . . . . . . . . . D-1428, 171 Monteiro, J. . . . . . . . . . . . . . . . . . . . . . D-1446, 172

Author

Presentation Number

Moreno, S. . . . . . . . . . . . . H-217, 018; H-222, 019; . . . . . . . M-323, 028; D-743, 091; H-1567, 179; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1700, 191 Moreno-Bofarull, A. . . . . . . . . . . . . . . . E-205, 016 Morera, M. A. . . . . . . . . . . . . . . . . . . . K-1621, 184 Morfin, R. . . . . . . . . . . . . . . . . . . . . . . C1-067, 006 Morfin Otero, M. . . . . . . . . . . . . . . . C2-1373, 168

Montejo, M. . . . . . . . . . . . T-340, 029; T-368, 029; K-938, 106; K-941, 106; K-943, 106; K-948, 107

Morfin-Otero, R.. . . . . . . . . . . . . . . . C2-1370, 168 Mori, M. . . . . . . . . . . . . . . . . . . . . . . . D-1461, 172

Montelaro, R. C. . . . . . . .F-1490, 175; F-2061, 249

Mori, N. . . . . . . . . . . . . . . . . . . . . . . . . K-918, 105

Montero, M. . . . . . . . . . . . . . . . . . . . . K-1624, 184 Montgomery, K. . . . . . . . . . . . . . . . . . F-2023, 247

Moriarty, S. R. . . . . . . . . . . . . . . . . . . . . A-623, 082 Morigi, M.. . . . . . . . . . . . . . . . . . . . . . . . 1799, 207

Monti, F. . . . . . . . . . . . .C2-133, 010; C2-140, 010; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2067, 249 Montinaro, V. . . . . . . . . . . . . . . . . . . . L2-304, 027

Morikawa, H. . . . . . . . . . . F-818, 096; F-820, 096

Monto, A. . . . . . . . . . . . . . . . . . . . . . . V-1080, 117 Montoya, C. M.. . . . . . . . . . . . . . . . . L2-2108, 255 Montoya, J. G. . . . . . . . . M-337, 028; M-1227, 159 Montrucchio, C. . . . . . . . . . . . . . . . . . A-1769, 200 Moodley, A. . . . . . . . . . . . . . . . . . . . . .M-1670, 190 Mooi, F. R. . . . . . . . . . . . D-183, 014; B-1322, 165 Moon, J. S.. . . . . . . . . . . . . . . . . . . . . . P-1006, 112 Moon, S. . . . . . . . . . . . . . . T-366, 029; K-907, 104; . . . . . . . . . . . . . . . . . .V-1074, 117; V-1239, 160 Mooney, L. . . . . . . . . . . . . . . . . . . . . . A-1960, 241 Moore, A. . . . . . . . . . . . . . . . . . . . . . . B-1738, 196 Moore, C. . . . . . . . . . . . . . . . . . . . . . . A-1289, 163 Moore, E. . . . . . . . . . . . . . . . . . . . . . . C1-665, 085 Moore, R. . . . . . . . . . . . . . . . . . . . . . . H-1580, 180 Mootien, J. Y. . . . . . . . . . . . . . . . . . . . L1-291, 026 Mora-Rillo, M. . . . . . . . . . . . . . . . . . . D-1452, 172 Moradi, P. W. . . . . . . . . . . . . . . . . . . . .M-981, 111 Moradpour, D.. . . . . . . . . . . . . . . . . . . . D-184, 014 Morales, C. . . . . . . . . . . . . . . . . . . . . . P-1000, 112 Morales, E. . . . . . . . . . . . . . . . . . . . . . K-2093, 252 Morales, J. M. . . . . . . . . . . . . . . . . . . . . T-359, 029 Morales, R. . . . . . . . . . . . . . . . . . . . . .M-1694, 190 Morales Ramirez, J. . . . . . . . . . . . . . . . . H-891, 103 Moraru, R.. . . . . . . . . . . . . . . . . . . . . . . F-811, 096 Mordechai, E. . . . . . . . . . . . . . . . . . . . . P-563, 075 Mordino, J. . . . . . . . . . . . . . . . . . . . . . K-1626, 185 Moreau, P. . . . . . . . . . . D-1458, 172; L1-1642, 186 Moreillon, P. . . . . . . . . . . B-046, 005; B-1316, 165; . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1746, 197 Morency-Potvin, P. . . . . . . . . . . . . . . . . D-730, 090 Moreno, A. . . . . . . . . . . . H-217, 018; H-222, 019; . . . . . . . . . T-340, 029; A-610, 082; B-648, 084; . . . . . . . . K-943, 106; K-941, 106; K-945, 106; . . . . . . K-1122, 129; M-1228, 159; E-1465, 173 Moreno, D. . . . . . . . . . . .K-912, 104; K-1597, 182; . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1655, 188 Moreno, M. . . . . . . . . . . . . . . . . . . . . . . K-942, 106

Morillo, A.. . . . . . . . . . . . . . . . . . . . . . T-1043, 113 Morinaga, Y. . . . . . . . . . . . B-048, 005; B-049, 005; . . . . . . . B-657, 084; B-1297, 164; D-1460, 172 Moriyama, B.. . . . . . . . . . . . . . . . . . . .M-1681, 190 Morizot, G. . . . . . . . . . . . . . . . . . . . . .M-1686, 190 Moro, P. . . . . . . . . . . . . . . . . . . . . . . . . G-1052, 114 Morobe, I. . . . . . . . . . . . . . . . . . . . . . . C2-101, 009 Morosini, M. . . . . . . . . . . . E-205, 016; D-753, 092 Morozumi, M. . . . . . .C2-1353, 167; C2-1354, 167; . . . C2-1990, 244; C2-1991, 244l; C2-1977, 243 Morrill, H. J. . . . . . . . . . . . . . . . . . . . . . K-233, 020 Morris, D. . . . . . . . . . . .C2-088, 008; C2-119, 009; . . . . . . C2-122, 009; C2-706, 088; A-1294, 163

Author

Presentation Number

Mozley, P. D. . . . . . . . . . . . . . . . . . . . .M-1695, 190 Mpanaka, I. . . . . . . . . . . . . . . . . . . . . L2-2114, 255 Mu, J.. . . . . . . . . . . . . . . . . . . . . . . . . C2-1212, 157 Muccioli, G. . . . . . . . . . . . . . . . . . . . . A-1291, 163 Mueller, A.. . . . . . . . . . . . . . . . . . . . . C2-1914, 237 Mueller, B. A. . . . . . . . . . . . . . . . . . . . . A-606, 082 Mueller, N. . . . . . . . . . . . . . . . . . . . . . . T-343, 029 Mueller, W. . . . . . . . . . . . . . . . . . . . . . .M-977, 111 Muhammed, T. . . . . . . . . . . . . . . . . . . G-1748, 198 Mühlemann, K. . . . . . . . . . . . . . . . . . . C2-116, 009 Mukabayire, O. . . . . . . . . . . . . . . . . . . D-1421, 170 Mukankwiro, T. . . . . . . . . . . . . . . . . . . D-1421, 170 Mukherjee, P. K. . . . . . . . V-385, 030; F-2015, 246 Mukherjee, S. . . . . . . . . . . V-370, 030; F-826, 097 Mukhi, S.. . . . . . . . . . . . . . . . . . . . . . . . V-386, 030 Mukonzo, J. . . . . . . . . . . . . . . . . . . . . . . H-893, 103 Mulanovich, V. E. . . . . . T-1065, 116; V-1075, 117 Mulet, X. . . . . . . . . . . . . . . . . . . . . . . C1-1970, 242 Mullane, K. M. . . . . . . . . 1193, 154; M-1676, 190; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2085, 252 Mullany, P. . . . . . . . . . . . . . . . . . . . . . C2-1983, 243 Mulleman, D. . . . . . . . . . . . . . . . . . . L1-2103, 254 Mullen, V. . . . . . . . . . . . . . . . . . . . . . C1-1972, 242 Muller, A. E. . . . . . . . . . . . . . . . . . . . . . A-624, 083 Muller, E. . . . . . . . . . . . . . . . . . . . . . . . . 1142, 138

Morris, M. I. . . . . . . . . . . . . . . . . . . . . T-1033, 113

Muller-Serieys, C. . . . . . . . . . . . . . . . . . B-645, 084

Morrissey, I. . . . . . . . . . . . . E-204, 016; E-210, 016; . . . . . . . C2-705, 088; C2-709, 088; D-769, 092 Mortelmans, K. . . . . . . . . . . . . . . . . . . F-1531, 177 Mortensen, E. M. . . . . . . . . . . . . . . . . L1-297, 026 Mortin, L. I. . . . . . . . . . . . . . . . . . . . . . F-846, 099 Morton, C. . . . . . . . . . . . .F-828, 097; F-2016, 247 MOSAR WP5 & WP2 Study Groups, . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-109, 009 Moscatelli, A. . . . . . . . . . . . . . . . . . . . D-1426, 171 Moser, W. . . . . . . . . . . . . . . . . . . . . . . .M-977, 111 Moshos, J. . . . . . . . . . . . . K-262, 023; K-1589, 181 Moskvitina, E. . . . . . . . . . . . . . . . . . . C2-1386, 169 Moss, R. . . . . . . . . . . . . . . V-381, 030; V-382, 030 Motlagh, H.. . . . . . . . . . . . . . . . . . . . .M-1062, 115 Motyl, M. R. . . . . . . . . M-1714, 191; M-1715, 191 Motyl, M. . . A-008, 003; D-767, 092; A-1763, 200 Moundipa, P. F. . . . . . . . . . . . . . . . . . . . H-214, 018 Moura, R. . . . . . . . . . . . . . . . . . . . . . . C2-717, 088 Mourer, M. . . . . . . . . . . . . . . . . . . . . . F-1527, 177 Mouton, J. W. . . . . . . . . . . B-044, 005; E-190, 015; . . . . . . . . E-198, 015; M-332, 028; A-624, 083; . . . . . . . . E-782, 093; E-803, 094; M-988, 111; . . . . . . . . M-989, 111; 1127, 131; A-1933, 240; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1938, 240 Moyà, B. . . . . . . . . . . . . . . . . . . . . . . C1-1970, 242 Moyaert, H. . . . . . . . . . . C2-705, 088; C2-709, 088

Mullis, C. E. . . . . . . . . . . . . . . . . . . . . H-1580, 180 Mulvey, M. . . . . . . . . . .C2-085, 008; C2-103, 009; . . . . . . . . . . . . . . . C2-1379, 169; C2-1380, 169

Final Program

Munar, M. . . . . . . . . . . . . . . . . . . . . . . . A-643, 083 Muniain, M. . . . . . . . . . . . . . . . . . . . L1-1658, 188 Munier, A. . . . . . . . . . . . H-219, 019; C2-1399, 169 Munita, J. M. . . . . . . . . . . . . . . . . . . . C1-1345, 166 Muñoz, K. A.. . . . . . . . . A-1292, 163; A-1293, 163 Muñoz, P. . . .K-940, 106; K-941, 106; K-942, 106; . . . . . . . . K-943, 106; K-944, 106; K-948, 107; . . . . . .T-1026, 113; T-1041, 113; M-1232, 159; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1684, 190 Muñoz, P. . . . . . . . . . . . . . . T-340, 029; 1163, 146; . . . . . . . . . . . . . . . . . . . V-1242, 160; 1809, 209 Muñoz-Fernández, M. . . . . . . . . . . . . H-1567, 179 Munoz-Price, L. . . . . . . . . . . . . . . . . . . . 1154, 144 Munyaradzi, S. . . . . . . . . . . . . . . . . . . A-1767, 200 Muppavarapu, K. . . . . . . . C2-096, 008; K-272, 024 Murakami, H. . . . . . . . . . . . . . . . . . . . D-1438, 171 Muraleedharan, C.. . . . . . . . . . . . . . . . C2-703, 088 Murgolo, N. J. . . . . . . . . . . . . . . . . . . .M-1695, 190 Muriel T. Mafura, Theresa Hunt . . . . C2-1979, 243 Murillo, O. . . . . . . . . . . . . K-254, 022; B-647, 084; . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-2102, 254 Murphy, C. . . . . . . . . . . . . . . . . . . . . . . F-846, 099 Murphy, D. G. . . . . . . . . . . . . . . . . . . . H-1571, 180

239


Presentation Number

Murphy, E. . . . . . . . . . . . . . . . . . . . . . . G-870, 101 Murphy, P. M. . . . . . . . . .B-057, 005; M-1055, 115 Murphy, T. M. . . . . . . . . . . . . . . . . . . . F-2028, 247 Murray, B. E. . . . . . . . C1-1345, 166; C2-1389, 169 Murray, K. P. . . . . . . . . . . . . . . . . . . . . K-1121, 129 Murray, R. W. . . . . . . . . . . . . . . . . . . . C1-670, 085 Musemakweri, A. . . . . . . . . . . . . . . . . . D-775, 092 Mushtaq, S. . . . . . . . . . . .C2-152, 010; E-192, 015; . . . . . . . . . . . . . . . . . . .F-853, 099; F-2048, 248 Mutesa, L. . . . . . . . . . . . . . . . . . . . . . . . D-775, 092 Muthusamy, A. . . . . . . . . . . . . . . . . . . . K-262, 023 Mutters, N. T. . . . . . . . . . . . . . . . . . . . C2-093, 008 Muvunyi, C. . . . . . . . . . . . . . . . . . . . . . D-775, 092 Myc, A. . . . . . . . . . . . . . . . . . . . . . . . . . G-869, 101 Myers, C. . . . . . . . . . . . . . . . . . . . . . . . . V-383, 030 Myers, D.. . . . . . . . . . . . . . . . . . . . . . C1-1343, 166 Myers, D. E. . . . . . . . . . K-1120, 129; K-1628, 185 Mykietiuk, A. . . . . . . . .M-329, 028; C2-1398, 169 Mylonakis, E. . . . . . . . . . . F-1538, 177; 1868, 229 Mynatt, R. P. . . . . . . . . . . . . . . . . . . . . . K-909, 104 Myrvold, R. . . . . . . . . . . F-2062, 249; F-2063, 249; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2064, 249

N

Presentation Number

Nacache, F. . . . . . . . . . . . . . . . . . . . . . C2-716, 088 Nacy, C. A. . . . . . . . . . . . . . . . . . . . . . . . . 435, 041 Nadel, S. . . . . . . . . . . . . . . . . . . . . . . G3-1544, 178 Naderer, O. J. . . . . . . . . .A-1275, 162; A-1276, 162; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1277, 162 Nadimpalli, M. . . . . . . . . . . . . . . . . . C2-1912, 237 Naeem, T. . . . . . . . . . . . . . . . . . . . . . C2-1372, 168 Nagano, N. . . . . . . . . . . . . . . . . . . . . C2-1989, 244 Nagano, Y. . . . . . . . . . . . . . . . . . . . . . C2-1989, 244 Nagao, M. . . . . . . . . . . . . K-949, 107; K-1599, 182 Nagaoka, K. . . . . . . . . . . . . B-048, 005; B-049, 005; . . . . . . . . . . . . . . . . . . B-657, 084; B-1297, 164 Nagashima, M. . . . . . . . . . . . . . . . . . . L1-296, 026 Nagel, J. . . . . . . . . . . . . . . H-225, 019; T-1068, 116 Nagl, M. . . . . . . . . . . . . . . . . . . . . . . . F-2058, 249 Nahmgunn, H. . . . . . . . . . . . . . . . . . . . A-038, 004 Naik, R. . . . . . . . . . . . . . . . K-264, 023; K-904, 104 Nailor, M. D. . . . . . . . . . . . . . . . . . . . . K-1926, 239 Nair, D. . . . . . . . . . . . . . . . . . . . . . . . C2-1982, 243 Nair, R. . . . . . . . . . . . . . . . . . . . . . . . C2-1384, 169 Najvar, L. K. . . . . . . . . . . . B-650, 084; F-823, 096; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1682, 190 Nakagawa, S. . . . . . . . . . . . . . . . . . . . . C2-693, 087 Nakai, H. . . . . . . . . . . . . . . . . . . . . . . . F-1506, 176

Author

Presentation Number

Nakai, T. . . . . F-817, 096; F-818, 096; F-819, 096; . . . . . . . . . . . . . . . . . . . .F-820, 096; F-821, 096

Nero, T. . . . . . . . . . . . . . . . . . . . . . . . . . F-828, 097

Nakajima, C. . . . . . . . .C2-712, 088; C2-1368, 168; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1369, 168

Netea, M. G. . . . . . . . . . .B-044, 005, M-1055, 115 NETWORK Group . . . . . . . . . . . . . . T-1040, 113

Nakajima, K. . . . . . . . . . . .A-607, 082; A-608, 082; . . . . . .K-1594, 182; K-1627, 185; M-1687, 190 Nakamae, H. . . . . . . . . . . . . . . . . . . . . D-1402, 170 Nakamae, M. . . . . . . . . . . . . . . . . . . . . D-1402, 170 Nakamura, R. . . . . . . . . . . . . . . . . . . . F-1507, 176 Nakamura, S. . . . . . . . . . . . . . . . . . . . . . V-380, 030 Nakane, T. . . . . . . . . . . . . . . . . . . . . . . D-1402, 170 Nakashima, H.. . . . . . . . . . . . . . . . . . . . E-780, 093 Nam, H. . . . . . . . . . . . . . . . . . . . . . . C2-1913, 237 Nam, S. . . . . . . . . . . . . . . . . . . . . . . . . F-1514, 176 Nannini, E. C. . . . . . . . . . . . . . . . . . . C2-1389, 169 Nanno, S. . . . . . . . . . . . . . . . . . . . . . . . D-1402, 170

Net, O.. . . . . . . . . . . . . . . . . . . . . . . . . K-1924, 239

Neuzil, K. M.. . . . . . . . . . . . . . . . . . . . . . . 526, 067 Nevarez Moorillón, G. V. . . . . . . . . . . . F-833, 098 Neves, F. C. . . . . . . . . . . . . . . . . . . . . . K-1606, 183 Neves, P. R. . . . . . . . . . . . . E-784, 094; E-801, 094 Nevez, G.. . . . . . . . . . . . . . . . . . . . . . . .M-333, 028 Nevrekar, S. N. . . . . . . . . . . . . . . . . . . T-1029, 113 Newland, J. G. . . . . . . . . . . . . . . . . . . . . . . 479, 051 Newton, D. W. . . . . . . . . . . . . . . . . . . . . . 497, 060 Neyret, P. . . . . . . . . . . . . . . K-249, 022; K-253, 022 Ndjomou, J. . . . . . . . . . . . . . . . . . . . . . . F-826, 097 Ng, K. Y. . . . . . . . . . . . . . . . . . . . . . . . H-1569, 179

Napolitano, L. . . . . . . . . . . . . . . . . . . . H-1574, 180

Ng, K. . . . . . . . . . . . . . . . . . . . . . . . . . . K-561, 074

Napravnik, S. . . . . . . . . . . . . . . . . . . . . . H-229, 019 Narbey, D. . . . . . . . . . . . . . . . . . . . . . . L1-291, 026 Nardell, E. . . . . . . . . . . . . . . . . . . . . . . . . . 529, 068

Ng, O. T. . . . . . . . . . . . . . . . . . . . . . . . H-1569, 179 Ng, S. B. . . . . . . . . . . . . . . . . . . . . . . . A-1959, 241 Ng, T. M. . . . . A-614, 082; K-899, 104; K-910, 104

Nardi, S. . . . . . . . . . . . . . . . . . . . . . . . . H-216, 018 Nash, A.. . . . . . . . . . . . . . . . . . . . . . . . F-1515, 176 Nast, C. C.. . . . . . . . . . . . . . . . . . . . . . . B-646, 084

Ngamskulrungroj, P. . . . . . . . . . . . . . . .M-336, 028 Nguon, S.. . . . . . . . . . . . . . . . . . . . . . . F-1532, 177 Nguyen, B.. . . . . . . . . . . . .D-165, 012; H-885, 102 Nguyen, C. . . . . . . . . . . . . . . . . . . . . . . K-915, 104 Nguyen, D. T. . . . . . . . . . . . . . . . . . . .M-1711, 191

Nastasa, V. . . . . . . . . . . . . . . . . . . . . . . . F-811, 096

Naas, T. . . . . . . . . . . . . .C1-066, 006; C1-072, 006; . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1453, 172 Naber, K. G. . . . . . . . . . . . . . . . . . . . . A-1285, 162

240

Author

Nath, G. . . . . . . . . . . . . . . . . . . . . . . . . V-373, 030 Nation, R. L. . . . . . . . . . . .A-024, 004; A-027, 004; . . . . . . . . . A-031, 004; E-785, 094; E-795, 094 Nauclér, P. . . . . . . . . . . . . . . . . . . . . . . C2-107, 009 Naughton, T. . . . . . . . . . . . . . . . . . . . . K-1611, 184 Navarro, F. . . . . . . . . . . . C1-593, 081; K-1621, 184 Navarro, G. . . . . . . . . . . . . . . . . . . . . . K-1623, 184 Navarro San Francisco, C. . . . . . . . . . . D-1452, 172 Navas, D. . . . . . . . . . . . . . . . . . . . . . . . L1-285, 025 Navas, E. . . . .H-217, 018; D-743, 091; K-943, 106 Navon-Venezia, S. . . . . . . . . . . . . . . . . . K-557, 074 Nawfal, R. . . . . . . . . . . . . . . . . . . . . . . K-1584, 181 Nayak, R. . . . . . . . . . . . . . . . . . . . . . . C2-1219, 157 Naylor, C. . . . . . . . . . . . . . . . . . . . . . . . B-047, 005 Ndjomou, J. . . . . . . . . . . . . . . . . . . . . . . V-370, 030 Ndzerem, E. . . . . . . . . . . . . . . . . . . . . . H-212, 017 Neary, B. . . . . . . . . . . . . . . . . . . . . . . .M-1699, 191 Neely, M. . . . . . . . . . . . . . . . . . . . . . . . . A-636, 083 Nelson, B. . . . . . . . . . . . . . . . . . . . . . . F-1537, 177 Nelson, K. . . . . . . . . . . . F-2017, 247; F-2018, 247; . . . . . F-2018a, 247; F-2020, 247; F-2023, 247; . . . . . . . . . . . . . . . . . .F-2024, 247; F-2026, 247 Nelson, L. . . . . . . . . . . . . . . . . . . . . . . L1-959, 109 Nelson, M. P. . . . . . . . . . . . . . . . . . . . . . A-612, 082 Nelson-Piercy, C.. . . . . . . . . . . . . . . . . . . . 452, 045 Nembot, G. . . . . . . . . . . . . . . . . . . . . . H-1568, 179 Neofytos, D. . . . . . . . . . . . . . . . . . . . .M-1676, 190 NeoMero Consortium . . . . . . . . . . . . . G-1750, 198

September 9-12 |

Nguyen, J. . . . . . . . . . . . . . . . . . . . . . . . V-383, 030 Nguyen, J. C. . . . . . . . . . . . . . . . . . . . . . K-234, 020 Nguyen, J. . . . . . . . . . . . . . . . . . . . . . . . K-915, 104 Nguyen, M. H. . . . . . . . . . T-346, 029; E-786, 094; . . . . . . . . E-792, 094; E-804, 094; K-1605, 183; . . . . . . . . . . . . . . . . .K-1622, 184; M-1675, 190 Nguyen, M. . . . . . . . . . . . T-364, 029; M-978, 111; . . . . . .T-1031, 113; T-1037, 113; M-1056, 115; . . . . . T-1069, 116; C2-1216, 157; M-1685, 190 Nguyen, N. . . . . . . . . . . . M-967, 111; M-992, 111 Nguyen, Q. A. . . . . . . . . . . . . . . . . . . . . K-947, 107 Nguyen, S. . . . . . . . . . . . . . . . . . . . . . . . F-816, 096 Nguyen, T. . . . . . . . . . . . A-1963, 241; F-2003, 246; . . . . . . F-2017, 247; F-2018, 247; F-2018a, 247 Nguyen, T. A. . . . . . . . . . . . . . . . . . . .M-1677, 190 Nguyen-Van-Tam, J. . . . . . . . . . . . . . . V-1080, 117 NIAID Influenza Research Collaboration, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-383, 030 Nica, M. . . . . . . . . . . . . . . . . . . . . . . . C2-110, 009 Nicco, E. . . . . . . . . . . . . . . . . . . . . . . . .M-317, 028 Nichol, G. . . . . . . . . . . . . . . . . . . . . . . . H-553, 073 Nichol, K. . . . . . . . . . . C2-135, 010; C2-1379, 169 Nichol, K. . . . . . . . . . . . . . . . . . . . . . C2-1360, 167 Nicholls, D. L. . . . . . . . . . .A-628, 083; A-629, 083; . . . . . . . . . . . . . . . . . . . A-631, 083; A-642, 083 Nichols, A.. . . . . . . . . . . . . . . . . . . . . . . K-247, 022 Nichols, K. R. . . . . . . . . . . . . . . . . . . G3-1558, 178

AUTHOR INDEX Author

Presentation Number

Nichols, W. . . . . . . . . . . . .A-632, 083; A-634, 083; . . . . . . . . . . . . . . . . . . A-635, 083; A-1760, 200 Nichols, W. W. . . . . . . . . . . . . . . . . . . . E-187, 015 Nicholson, B. . . . . . . . . . . . . . . . . . . . . C2-117, 009

Author

Presentation Number

Author

Presentation Number

Nolla, J. . . . . . . . . . . . . . . . . . . . . . . . L1-2102, 254

Obi, C. L. . . . . . . . . . . . . . . . . . . . . . . C2-101, 009

Nomoto, A. . . . . . . . . . . . . . . . . . . . . . F-1509, 176 Nomura, N. . . . . . . . . . . . C2-693, 087; F-809, 096

Obunge, O. K. . . . . . . . . . . . . . . . . . . C2-1371, 168

Nonato, B. . . . . . . . . . . . . . . . . . . . . . C2-1376, 169

Ochi, T. . . . . . . . . . . . . . . . . . . . . . . . .M-1226, 159 Oda, K. . . . . . . . . . . . . . . . . . . . . . . . . . V-390, 030

Nicholson, S. . . . . . . . . . . . . . . . . . . . . . K-924, 105

Nonnenmacher, C. . . . . . . . . . . . . . . . K-2100, 253

Oda, S.. . . . . . . . . . . . . . . . . . . . . . . . .M-1231, 159

Nickerson, E. . . . . . . . . . . . . . . . . . . . . L1-288, 025 Nicol, M. . . . . . . . . . . . . . . . . . . . . . . . C2-723, 089

Nordmann, P.. . . . . . . . . .A-042, 004; C1-061, 006; . . . . . .C1-063, 006; C1-066, 006; C1-071, 006; . . . . . .C1-072, 006; C1-078, 006; C1-465, 047; . . . . . . C1-587, 081; C1-591, 081; D-745, 092; . . . . . .D-748, 092; C1-1202, 156; D-1453, 172 Nørgaard, M. . . . . . . . . . . . . . . . . . . . . . G-876, 101

Odeigah, P. . . . . . . . . . . . . . . . . . . . . C2-1371, 168

Nicolas-Chanoine, M. . . . . . . . . . . . . . . . . 510, 063 Nicolau, D. P.. . . . . . . . . . .A-013, 003; A-014, 003; . . . . . . . . A-015, 003; A-018, 003; A-020, 003; . . . . . . . . . . A-022, 003; A-023, 004; 539, 070; . . . . . . . . A-625, 083; A-630, 083; A-633, 083; . . . . . . . A-1287, 163; 1793, 205; K-1926, 239; . . . . . . . . . . . . . . . . . A-1964, 241; F-2021, 247 Nicoletti, A. G. . . . . . . . . . . . . . . . . . C1-1207, 156 Nicoletti, G.. . . . . . . . . . . . . . . . . . . . . C1-594, 081 Nicolle, L. E. . . . . . . . . . . . . . . . . . . . . . . . 544, 071 Nieberg, P. . . . . . . . . . . . . . . . . . . . . . . K-1586, 181 Nielsen, E. I. . . . . . . . . . A-1764, 200; A-1966, 241 Nielsen, L. E.. . . . . . . . . . . . . . . . . . . . C2-725, 089 Nielsen, X. . . . . . . . . . . . D-1443, 171; D-1444, 171 Nierenberg, N. E. . . . . . . . . . . . . . . . . T-1025, 113 Nieves, D. J. . . . . . . . .G3-1560, 178; G3-1561, 178 Niimi, H. . . . . . . . . . . . . . . . . . . . . . . . D-1461, 172 Nikaido, H. . . . . . . . . . . . . . . . . . . . . . . . 1835, 216 Nikitin, I.. . . . . . . . . . . . . . . . . . . . . . . V-1236, 160 Nikolaidis, P. . . . . . . . . . . . . . . . . . . . . K-2095, 252 Nilkamhang, S. . . . . . . . . . . . . . . . . . . . H-894, 103 Nimrichter, L. . . . . . . . . . . . . . . . . . . . . . 1721, 192 Ninet Bescher, B. . . . . . . . . . . . . . . . . G3-1541, 178 Ninot, S. . . . .A-610, 082; B-648, 084; K-945, 106; . . . . . . . . . . . . . . . . . K-1122, 129; E-1465, 173 Niranjan, V. . . . . . . . . . . . . . . . . . . . . . A-1245, 161 Nishide, M. . . . . . . . . . . . . . . . . . . . . . . F-825, 097 Nishijima, K. . . . . . . . . . . . . . . . . . . . . . H-223, 019 Nishijima, T. H-224, 019; H-888, 103; H-890, 103 Nishikawa, H. . . . . . . . . . . . . . . . . . . . . F-809, 096 Nishimoto, M. . . . . . . . . . . . . . . . . . . . D-1402, 170 Nishimura, M. . . . . . . . . . . . . . . . . . . . . B-056, 005 Nist, A. . . . . . . . . . . . . . . . . . . . . . . . . V-1080, 117 Niubó, J. . . . . . . . . . . . . . . . . . . . . . . . V-1240, 160 Nizet, V.. . . . . . .418, 036; 1087c, 120; F-1514, 176; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1999, 246 Njihia, J.. . . . . . . . . . . . . . . . . . . . . . . C2-1380, 169 Njoku, J. C. . . . . . . . . . . . . . . . . . . . . . . K-922, 105 No, D. . . . . . . . . . . . . . . . . . . . . . . . . C1-1348, 166 Nobre, V. . . . . . . . . . . . .T-1044, 113; D-1403, 170; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1606, 183 Noel, A. R. . . . . . . . . . . . .A-628, 083; A-629, 083; . . . . . . . . A-631, 083; A-642, 083; D-763, 092; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-793, 094 Nogueira, K. S. . . . . . . . . . . . . . . . . . C1-1207, 156 Nolan, T. . . . . . . . . . . . . . . . . . . . . . . . . F-851, 099

Noritake, K. . . . . . . . . . . . . . . . . . . . . . F-2042, 248 North, J.. . . . . . . . . . . . . . . . . . . . . . . . . F-815, 096 Norton, S. A. . . . . . . . . . . . . . . . . . . . . . . 1086, 119 Nosanchuk, J.. . . . . . . . . . . . . . . . . . . . . . . 549, 072 Notermans, D. . . . . . . . . . . . . . . . . . . . . D-183, 014 Nottingham, M. . . . . . . . . . . . . . . . . . . F-847, 099 Nouch, S. . . . . . . . . . . . . . . . . . . . . . . . . V-371, 030 Nouér, S. A. . . . . . . . . . .K-1601, 182; M-1690, 190 Noureddine, M. . . . . . . . . . . . . . . . . . . . K-938, 106 Noury, P. . . . . . . . . . . . . . . . . . . . . . . . C2-091, 008 Nouwen, J. L.. . . . . . . . . . . . . . . . . . . . . B-058, 005

Oderinde, B. S. . . . . . . . . . . . . . . . . . . G-1748, 198 Odugbemi, T.. . . . . . . . . . . . . . . . . . . . C2-108, 009 Oelschlaeger, P. . . . . . . . . . . . . . . . . . . C1-065, 006 Oethinger, M. . . . . . . . . . . . . . . . . . . . D-1432, 171 Offenstadt, G. . . . . . . . . . . . . . . . . . . . . D-173, 013 Offermann, D. . . . . . . . . . . . . . . . . . . . F-2016, 247 Offermann, L. . . . . . . . . . . . . . . . . . . . F-2016, 247 Ogwal-Okeng, J. . . . . . . . . . . . . . . . . . . H-893, 103 Oh, D. . . . . . . . . . . . . . . . . H-230, 019; K-916, 104 Oh, H. . . . . . . . . . . . . . . . . . . . . . . . . . . K-916, 104 Oh, M.. . . . . . . . . . . . . . . . . . . . . . . . . . K-908, 104 Ohba, S.. . . . . . . . . . . . . . . . . . . . . . . . F-1509, 176 Ohgami, K. . . . . . . . . . . . . . . . . . . . . . . G-871, 101 Ohno, T. . . . . . . . . . . . . . . . . . . . . . . C2-1989, 244

Novack, V. . . . . . . . . . . . . . . . . . . . . . . . H-232, 019 Novakova, J. . . . . . . . . . . . . . . . . . . . . . F-1532, 177

Ohuchi, N. . . . . . . . . . . . . . . . . . . . . . C1-460, 047 Ojemhen, O. . . . . . . . . C2-121, 009; C2-1378, 169 Ojielska, M. . . . . . . . . . . . . . . . . . . . . . . P-566, 075

Novick, R. P. . . . . . . . . . . . . . . . . . . . C2-1906, 237 Novick, S. . . . . . . . . . . . . . . . . . . . . . . P-1022, 112

Oka, S.. . . . . H-223, 019; H-224, 019; H-888, 103; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . H-890, 103

Novick, S. J. . . . . . . . . . . . . . . . . . . . . . A-1275, 162 Novikov, A. . . . . . . . . . . M-985, 111; M-1059, 115

Okada, A. . . . . . . . . . . . . . .F-818, 096; F-819, 096 Okada, K. . . . . . . . . . . . . . . . . . . . . . . .M-326, 028 Okada, T. . . . . . . . . . . . . . . . . . . . . . . C2-1977, 243

Nucci, M.. . . . . . . . . . . .M-329, 028; M-1234, 159; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1690, 190 Nucleo, E. . . . . . . . . . . C2-094, 008; C2-1897, 236 Nuermberger, E. . . . . . . . . . . . . . . . . . . F-836, 098 Nukaga, M. . . . . . . . . . . C1-076, 006; C1-460, 047 Nunes, L. S. . . . . . . . . . . . . . . . . . . . . C2-1375, 168 Nuñez, J. M. . . . . . . . . . . . . . . . . . . . . K-1624, 184 Nutman, T. B. . . . . . . . . . . . . . . . . . . . . . 1890, 234 Nyberg, J. . . . . . . . . . . . . . . . . . . . . . . . . A-032, 004 Nyc, O. . . . . . . . . . . . . . . . . . . . . . . . . . T-344, 029

O O’Brien, W. . . . . . . . . . . . E-777, 093; F-1525, 177; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1526, 177 O’Connor, L. . . . . . . . . .A-1765, 200; A-1942, 240; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1944, 240 O’Connor, R. D. . . . . . . . . . . . . . . . . C1-1969, 242 O’Day, T. . . . . . . . . . . . . . . . . . . . . . . . B-1736, 196 O’Dowd, V. . . . . . . . . . . . . . . . . . . . . . B-1738, 196 O’Hanley, P. . . . . . . . . . . .F-1524, 177; F-1528, 177 O’Riordan, W. D. . . . . . . . . . . . . . . . L1-1663, 189 Obed, M. . . . . . . . . . . . . . . . . . . . . . . C2-1398, 169 Obel, N.. . . . . . . . . . . . . . . . . . . . . . . . H-1916, 238

Final Program

Okade, H. . . . . . . . . . . . . . . . . . . . . . . C2-693, 087 Okamura, H. . . . . . . . . . . . . . . . . . . . . D-1402, 170 Okamura, N. . . . . . . . . . . . . . . . . . . . . . E-780, 093 Okatani, T.. . . . . . . . . . . . . . . . . . . . . .M-1226, 159 Oksenhendler, E. . . . . . . . . . . . . . . . . . . . 1107, 126 Okumura, R. . . . . . . . . . F-2037, 248; F-2038, 248; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2045, 248 Okusanya, O. O. . . . . . . .A-620, 082; A-1261, 161; . . . . . .A-1262, 161; A-1263, 161; A-1266, 161; . . . . . . A-1269, 162; A-1270, 162; A-1271, 162 Olaru, I. D. . . . . . . . . . . . . . . . . . . . . . C2-110, 009 Oldach, D. . . . . . . . . . . . A-1286, 162; A-1269, 162 Olesen, B. . . . . . . . . . . . . . . . . . . . . . . C2-687, 087 Olin, J. T. . . . . . . . . . . . . . . . . . . . . . . . . V-397, 030 Oliva, A. . . . . . . . . . . . . . . . . . . . . . . . . D-165, 012 Oliveira, D. E. . . . . . . . . . . . . . . . . . . . C1-668, 085 Oliveira, L. G. . . . . . . . . . . . . . . . . . . G3-1557, 178 Oliveira, N. N. . . . . . . . . . . . . . . . . . . . C2-704, 088 Oliveira, S.. . . . . . . . . . . . . . . . . . . . . . C2-717, 088 Oliveira, V. G. . . . . . . . . . . . . . . . . . . C2-1376, 169 Oliver, A. . . . . . . . . . . . . .C1-593, 081; A-011, 003; . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1970, 242 Olivier, L. . . . . . . . . . . . . . . . . . . . . . . K-2098, 252

241


Presentation Number

Author

Presentation Number

Author

Presentation Number

Olivo, M. . . . . . . . . . . . . . . . . . . . . . . .M-1674, 190

Ovbiagele, B. . . . . . . . . . . . . . . . . . . . . . H-228, 019

Palomar, M. . . . . . . . . . . . . . . . . . . . . . K-1758, 199

Olsen, D. B.. . . . . . . . . . . . . . . . . . . . . F-1496, 176 Olsen, K. M. . . . . . . . . . . . . . . . . . . . . . K-922, 105

Ovetchkine, P. . . . . . . . . . . . . . . . . . . G3-1554, 178 Oxbrow, M. . . . . . . . . . . . . . . . . . . . . . B-1738, 196

Palomino, J. . . . . . . . . . . . . . . . . . . . . . K-1924, 239

Olson, J. A. . . . . . . . . . . . M-992, 111; M-967, 111

Ozkaya Parlakay, A. . . . . L1-964, 110; A-1941, 240

Olyaei, A. . . . . . . . . . . . . . . . . . . . . . . . A-643, 083

Ozkutuk, N.. . . . . . . . . . . . . . . . . . . . C2-1367, 168

Palù, G. . . . . . . . . . . . . . .H-216, 018; H-1579, 180 Palzkill, T. G. . . . . . . . . C1-462, 047; C1-1204, 156

Omer, S. B. . . . . . . . . . . . . . . . . . . . . . . . 1151, 142 ONERBA . . . . . . . . . . . . . . . . . . . . . . . K-237, 020

Ozsurekci, Y. . . . . . . . . . L1-964, 110; A-1941, 240 Ozyurt, M. . . . . . . . .C2-1367, 168; C2-1394, 169; . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1430, 171

Ong, A. T. . . . . . . . . . . . . . . . . . . . . . . .M-313, 028 Ong, V. . . . . . . . . . . . . . .F-2026, 247; F-2027, 247 Onio, A.. . . . . . . . . . . . . . . . . . . . . . . C2-1379, 169 Onishi, J. . . . . . . . . . . . . . . . . . . . . . . . . F-810, 096 Ono, E. . . . . . . . . . . . . . . . . . . . . . . . G3-1557, 178 Onodera, Y. . . . . . . . . . . .F-2038, 248; F-2039, 248 Onsomearng, S. . . . . . . . . . . . . . . . . . . .M-976, 111 Onsøyen, E. . . . . . . . . . . . . 1105, 125; F-2062, 249; . . . . . . . . . . . . . . . . . . F-2063, 249; F-2064, 249 Onufrak, N. . . . . . . . . . . . . A-615, 082; A-617, 082 Onyejepu, N. . . . . . . . . . . . . . . . . . . . C2-1371, 168 Oosting, M. . . . . . . . . . . . . . . . . . . . . . . B-044, 005 Opperman, T. J. . . . . . . . . . . . . . . . . . . . F-816, 096 OPTIPRIM ANRS Study Group . . . H-1568, 179 Or, Y. S. . . . . . . . . . . . . . . . . . . . . . . . . B-1303, 164 Oramasionwu, C. U. . . . . . . . . . . . . . . L1-297, 026 Orcajo, J. . . . . . . . . . . . . . . . . . . . . . . . . K-940, 106 Orellana, M. A. . . . . . . . . . . . . . . . . . . K-2093, 252 Orenstein, R. . . . . . . . . . . . . . . . . . . . .M-1697, 191 Oresco, C. P. . . . . . . . . . . . . . . . . . . . . C2-704, 088 Origüen, J. . . . . . . . . . . . T-1071, 116; K-2091, 252 Oriol, I. . . . . . . . . . . . . . . . . . . . . . . . . V-1240, 160 Orlando, G. . . . . . . . . . . . . . . . . . . . . . L2-304, 027 Orlov, B. . . . . . . . . . . . . . . . . . . . . . . . L1-962, 110 Ortatatli, M. . . . . . . . . . . . . . . . . . . . C2-1980, 243 Orth, D.. . . . . . . . . . . . . . . . . . . . . . . . F-2058, 249 Ortiz, G. . . . . . . . . . . . . . . . . . . . . . . . K-1621, 184 Ortíz, J. . . . . . . . . . . . . . . . . . . . . . . . . . D-743, 091 Osherov, N. . . . . . . . . . . M-985, 111; M-1059, 115 Osmolski, J. R.. . . . . . . . . . . . . . . . . . . . E-808, 095 Osorio, L. E. . . . . . . . . . . . . . . . . . . . . . K-903, 104 Østergaard, L. . . . . . . . . . . . . . . . . . . L1-1650, 187 Osterhaus, A.. . . . . . . . . . . . . . . . . . . . V-1080, 117 Ostermann, H. . . . . . . L1-290, 026; L1-1666, 189 Ostrowsky, B.. . . . . . . . . . . . . . . . . . . . K-1634, 185 Otelea, D. . . . . . . . . . . . . . . . . . . . . . . D-1776, 201 Oteo, J. . . . . . . . . . . . . . . C1-593, 081; K-942, 106 Otero, D. . . . . . . . . . . . . . . . . . . . . . . . K-1601, 182 Otero, J. . . . . . . . . . . . . . . . . . . . . . . . . K-2093, 252 Otvagin, I. V. . . . . . . . . . . . . . . . . . . . . L1-299, 026 Ouachée, M. . . . . . . . . . . . . . . . . . . . . . T-363, 029 Ouakki, M. . . . . . . . . . . . . . . . . . . . . . V-1076, 117 Ouertatani-Sakouhi, H. . . . . . . . . . . . B-1333, 165

242

P Paccaly, A. . . . . . . . . . . . . . . . . . . . . . . A-1255, 161 Pace, S. . . . . . . . . . . . . . . . . . . . . . . . . A-1769, 200 Pacheco, R. . . . . . . . . . . . D-747, 092; K-903, 104; . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2108, 255 Pachon, D. P. . . . . . . . . . . . . . . . . . . . C2-1915, 237 Pachón, J.. . . . . . . . . . . . . . . . . . . . . . . B-1329, 165 Packham, D. . . . . . . . . . . . . . . . . . . . .M-1680, 190 Paderu, P. . . . . . . . . . . . . F-822, 096; M-1678, 190; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1715, 191 Padilla, B. . . . . . . . . . . . . K-948, 107; V-1242, 160 Paesmans, M.. . . . . . . . . .T-1028, 113; T-1046, 113 Pagadala, S. R. . . . . . . . . . . . . . . . . . . . . F-847, 099 Pagani, L. . .C2-094, 008; K-929, 105; K-954, 108; . . . . .K-956, 108; C2-1211, 157; C2-1897, 236; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2075, 250 Pagani, N. . . . . . . . . . . . . . . . . . . . . . . A-1769, 200 Paganini, H.. . . . . . . . . . . . . . . . . . . . C2-1910, 237 Page, M. G. . . . . . . . . . . . . . . . . . . . . . . F-842, 099 Pahissa, A. . . . T-340, 029; T-368, 029; K-931, 105; . . . . . . . . K-937, 106; K-938, 106; K-1758, 199 Pai, M. . . . . . . . . . . . . . . . . . . . . . . . . . K-1755, 199 Paige, D. . . . . . . . . . . . . . . . . . . . . . . . A-1264, 161 Painter, R. E. . . . . . . . . . . . . . . . . . . . . F-1496, 176 Painter, T.. . . . . . . . . . . . . . . . . . . . . . . L2-306, 027 Painter, W.. . . . . . . . . . . . . .T-358, 029; T-362, 029 Paiva, L. F. . . . . . . . . . . . . . . . . . . . . . . K-1606, 183 Paixao, M. . . . . . . . . . . . . . . . . . . . . . .M-1690, 190 Pajot, O. . . . . . . . . . . . . . . . . . . . . . . . . A-021, 003 Palavecino, E. L. . . . . . . . . . . . . . . . . C2-1390, 169 Palefsky, J. . . . . . . . . . . . . . . . . . . . . . . . . 1134, 134 Palella, F. . . . . . . . . . . . . . . . . . . . . . . . . H-556, 073 Palla, M. . . . . . . . . . . . . . K-262, 023; K-1589, 181 Pallares, E. . . . . . . . . . . . . . . . . . . . . . . . D-743, 091 Pallarés, M. . . . . . . . . . . . . . . . . . . . . . C2-111, 009 Pallares, R. . . . . . . . . . . . . . . . . . . . . . . C2-690, 087 Pallecchi, L. . . . . . . . . . C2-700, 087; C1-1205, 156 Pallen, M. J. . . . . . . . . . . . . . . . . . . . . . . . . 423, 038 Palma, P. . . . . . . . . . . . . . . . . . . . . . . . H-1921, 238 Palmeiro, J. K. . . . . . . . C2-087, 008; C1-1207, 156 Palmer, H. R. . . . . . . . . . . . . . . . . . . . L2-2111, 255 Palmer, J. T. . . . . . . . . . . . . . . . . . . . . . F-2016, 247

September 9-12 |

Palomo, F. S. . . . . . . . . . . . . . . . . . . . . D-1412, 170

Pamulapati, C. . . . . . . . . . . . . . . . . . . . A-1243, 161 Pan, S. . . . . . . . . . . . . . . K-270, 024; L1-1654, 188 Panagea, T.. . . . . . . . . . . . . . . . . . . . . . . K-246, 021 Pancholi, P. . . . . . . . . . . . . . . . . . . . . . . D-756, 092 Panchumarthi, V. R. . . . . . . . . . . . . . . . K-920, 105 Panda, S. . . . . . . . . . . . . . . . . . . . . . . . D-1437, 171 Pandey, B. D. . . . . . . . C2-1369, 168; C2-1368, 168 Pandori, M. . . . . . . . . . . . . . . . . . . . . . L2-308, 027 Pandya, M. . . . . . . . . . . . . . . . . . . . . . F-2043, 248 Panesso, D. . . . . . . . . . . . . . . . . . . . . C1-1345, 166 Pang, J.. . . . . . . . . . . . . . F-1499, 176; C2-698, 087 Pankey, G. A.. . . . . . . . . . . . . . . . . . . .M-1717, 191 Pannaraj, P. S. . . . . . . . . . . . . .1160, 145; 1801, 207 Paño, J.. . . . . . . . . . . . . . . . . . . . . . . . . . K-943, 106 Paño-Pardo, J. R. . . . . . . . . . . . . . . . . . D-1452, 172 Pantel, A. . . . . . . . . . . . . . . . . . . . . . . . B-1327, 165 Papadakis, J.. . . . . . . . . . . . . . . . . . . . . . B-043, 005 Papadomichelakis, E.. . . . . . . . . . . . . . . K-245, 021 Papalia, M.. . . . . . . . . . . C1-074, 006; D-1455, 172 Papanicolaou, G. . . . . . . . . T-361, 029; T-362, 029 Papasavas, P. K. . . . . . . . . . . . . . . . . . . A-1287, 163 Papatheodorou, P. . . . . . . . . . . . . . . . . F-1537, 177 Papenburg, J. . . . . . . . . . . . . . . . . . . . . V-1076, 117 Papoutsaki, V. . . . . . . . . . . . . . . . . . . . . E-799, 094 Papp-Wallace, K. M. . . .C1-076, 006; C1-460, 047; . . . . . . . C1-463, 047; C1-464, 047; F-847, 099 Pappas, P. G. . . . . . . . . . . . . 546, 072; M-1225, 159 Papy, E. . . . . . . . . . . . . . . . . . . . . . . . . L1-957, 109 Paquet, A. . . . . . . . . . . . . . . . . . . . . . . H-1574, 180 Paradiso, P. R. . . . . . . . . . . . . . . . . . . . . . 1884, 232 Paran, Y. . . . . . . . . . . . . M-985, 111; M-1059, 115 Paranhos-Baccala, G. . . . . . . . . . . . . . . D-172, 013 Paraschiv, S. . . . . . . . . . . . . . . . . . . . . . D-1776, 201 Pare, J. . . . . . . . . . . . . . . . . . . . . . . . . . K-1122, 129 Paret, G. . . . . . . . . . . . . . . . . . . . . . . G3-1545, 178 Parienti, J. J. . . . . . . . . L1-2104, 254; L2-2117, 255 Parisi, S. G. . . . . . . . . . . .H-216, 018; H-1579, 180 Park, B. . . . . . . . . . . . . . . . . . . . . . . . .M-1677, 190 Park, C. . . . . . . . . . . . . . . . . . . . . . . . C2-1975, 243 Park, H. . . . . . . . . . . . . . . . . . . . . . . . . . T-366, 029 Park, J. . . . . T-366, 029; K-908, 104;C2-1215, 157; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1256, 161 Park, K. . . . D-755, 092; D-741, 091; K-2092, 252; . . . . . . . K-907, 104; V-1239, 160; B-1298, 164 Park, S. . . . . . . . . . . . . . V-1074, 117; V-1239, 160 Park, S. Y. . . . . . . . . . . . . . . . . . . . . . . C2-137, 010

AUTHOR INDEX Author

Presentation Number

Park, S. . . . . .T-366, 029; D-741, 091; K-907, 104; . . . . . V-1074, 117; V-1239, 160; C2-1216, 157; . . . . . . K-1587, 181; K-1588, 181; K-1632, 185 Park, Y. . . . D-755, 092; C2-112, 009; F-2060, 249 Parker, M. . . . . . . . . . . . . . . . . . . . . . . . F-828, 097 Parquin, F. . . . . . . . . . . . . . . . . . . . . . . . A-035, 004 Parsons, T. L. . . . . . . . . . . . . . . . . . . . . H-1570, 179 Pascale, J. M. . . . . . . . . . . . . . . . . . . . . H-1573, 180 Pascual, A. . . . . . . . . . . .C1-683, 086; C2-707, 088; . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1658, 188 Pascual, M. . . . . . . . . . . . . . . . . . . . . . . T-352, 029 Pascual, V. . . . . . . . . . . . . . . . . . . . . . . K-1621, 184 Pasculle, W. . . . . . . . . . . . . . . . . . . . . C2-1216, 157 Paskalis, H. . . . . . . . . . . . . . . . . . . . . . . K-562, 074 Pasqualotto, A. C. . . . . . M-337, 028; M-1227, 159 Pasquau Liaño, J. . . . . . . L1-289, 026; H-1921, 238 Passadore, L. F. . . . . . . . . . . . . . . . . . . . G-861, 100 Passet, V. . . . . . . . . . . . . . . . . . . . . . . . C2-088, 008 Pasteran, F. . . . . . . . . . . C2-084, 008; D-746, 092; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1217, 157 Patel, D.. . . . . . . . . . . . . T-367, 029; C1-1341, 166; . . . . . . . . . . . . . . . . C1-1747, 197; K-1923, 239 Patel, G. A. . . . . . . . . . . . . . . . . . . . . . K-1630, 185 Patel, H.. . . . . . . . . . . . . . . . . . . . . . . . A-1960, 241 Patel, J.. . . . . . . . . . . . . . . . . H-883, 102; 1177, 150 Patel, K. . . . . . . . . . . . . . . . . . . . . . . . . . F-827, 097 Patel, N.. . . . . . . . . . . . . . A-606, 082; K-1123, 129 Patel, P. . . . . . . . . . . . . . A-1246, 161; A-1272, 162 Patel, R. . . . . .D-170, 012; K-471, 048; B-652, 084; . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1774, 201 Patel, S. . . . . . . . . . . . . . . . . . . . . . . . . . K-281, 024 Patel, S. N.. . . . . . . . . . .C2-089, 008; C2-090, 008; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1214, 157 Patel, S. . . . . . . . . . . . . . . . . . . . . . . . . . K-946, 106 Paterson, D. . . . . . . . . . . . . . . .1113, 127; 1184, 151 Paterson, D. L.. . . . . . . .C2-112, 009; C2-689, 087; . . . . . . . . . C2-692, 087; E-795, 094; 1810, 209 Pathan, R. . . . . . . . . . . . . . . . . . . . . . . K-2095, 252 Patriarca, P. . . . . . . . . . . . . . . . . . . . . . G-1053, 114 Patricia Muñoz . . . . . . . . . . . . . . . . . . .M-312, 028 Pattabiraman, N. . . . . . . . . . . . . . . . . . C1-673, 085 Patterson, T. F. . . . . . . . . . . . . 456, 046; B-650, 084; . . . . . . F-823, 096; M-1225, 159; M-1674, 190; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1682, 190 Patti, R. M. . . . . . . . . . . . . . . . . . . . . . . E-807, 095 Pau, C. P. . . . . . . . . . . . . . . . . . . . . . . . H-1570, 179 Paukner, S. . . . . . . . . . L1-1660, 189; C1-1971, 242 Pauli, E. . . . . . . . . . . . . . . . F-839, 098; F-840, 098 Pavell, A. M. . . . . . . . . . . . . . . . . . . . . . K-278, 024 Pavez, M. . . . . . . . . . . . . . . . . . . . . . . . C2-717, 088 Pavie, J. . . . . . . . . . . . . . . . . . . . . . . . . . H-886, 102 Pavliakova, D. . . . . . . . . . . . . . . . . . . . . G-870, 101 Pavlovic, J. . . . . . . . . . . . . . . . . . . . . . . . T-369, 029

Author

Presentation Number

Author

Presentation Number

Pawlak, J. . . . . . . . . . . . . . . . . . . . . . . . E-1484, 174

Perez, G. . . . . . . . . . . . . . . . . . . . . . . . . B-045, 005

Paxton, L. A. . . . . . . . . . . . . . . . . . . . . H-1570, 179

Perez, J. A. . . . . . . . . . . . . . . . . . . . . . . A-1968, 241

Payne, L. J.. . . . . . . . . . . . .F-842, 099; F-2066, 249 Paz, C. . . . . . . . . . . . . . . . . . . . . . . . . . L2-303, 027

Pérez, J. . . . . . . . . . . . . . . T-340, 029; K-1621, 184 Pérez, M. . . . . . . . . . . . . . . . . . . . . . . .M-1688, 190

Pazhoor, A. . . . . . . . . . . . . . . . . . . . . . . D-727, 090

Pérez C. M. . . . . . . . . . . .P-1015, 112; P-1016, 112

Pean, Y. . . . . . . . . . . . . . . . . . . . . . . . . . K-237, 020 Pearce, D. D. . . . . . . . . . . . . . . . . . . . . . H-228, 019

Perez Gomez, H. . . . . . . . . . . . . . . . . C2-1373, 168 Perez Granda, M. . . . . . . . . . . . . . . . . K-2101, 253

Pearlman, H. . . . . . . . . . . . . . . . . . . . . A-1936, 240 Pearson, A.. . . . F-843, 099; F-844, 099; F-845, 099 Pearson, J. . . . . . . . . . . . . . . . . . . . . . . E-1475, 174

Pérez Tanoira, R. . . . . . . . . . . . . . . . . . L1-958, 109

Pease, J. . . . . . . . . . . . . . . . . . . . . . . . . B-1311, 165 Peck, K. R.. . . . . . . . . .C2-1366, 167; C2-137, 010; . . . . . . . . . . . . . . . . . K-1587, 181; K-1588, 181 Pedrero, S. . . . . . . . . . . . . . . . . . . . . . . . K-254, 022 Pedrosa, M. . . . . . . . . . . . . . . . . . . . . . . D-732, 091 Peet, N. P. . . . . . . . . . . . . . . . . . . . . . . . F-816, 096 Peetermans, W. E. . . . . . . . . . . . . . . . L1-1641, 186 Peffault Delatour, R. . . . . . . . . . . . . . . D-1778, 201 Pegg, K. M. . . . . . . . . . . . . . . . . . . . . . C1-065, 006 Peghin, M. . . . . . . . . . . . . . . . . . . . . . .M-1228, 159 Peirano, G.. . . . . . . . . . .K-561, 074; C2-1210, 157; . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1448, 172 Peiris, M. . . . . . . . . . . . . . . . . . . . . . . . . . 1732, 195 Peláez, T. . . . M-321, 028; K-470, 048; E-806, 095; . . . . . . . . . . . . . . . . M-1684, 190; M-1688, 190 Peleg, A. Y. . . . . . . . . . . . . . . . . . . . . . . K-558, 074 Pelegrín, I. . . . . . . . . . . . . . . . . . . . . . . . B-658, 084 Pelegrin, I. . . . . . . . . . . . . . . . . . . . . . . V-1240, 160 Pellett, P. . . . . . . . . . . . . . . . . . . . . . . G3-1546, 178 Peltier, J.. . . . . . . . . . . . . B-1337, 165; B-1338, 165 Pemán, J. . . . M-321, 028; M-329, 028; K-950, 107 Peña, C. . . . . . . . . . . . . . . . . . . . . . . . . . K-938, 106 Peng, H. Y. . . . . . . . . . . . . . . . . . . . . . . H-554, 073 Peng, L. F. . . . . . . . . . . . . . . . . . . . . . . . V-377, 030 Peng, W. . . . . . . . . . . . . . . . . . . . . . . . C2-083, 008 Penman, A. . . . . . . . . . . . . . . . . . . . . . . D-185, 014 Penteado, S. . . . . . . . . . . . . . . . . . . . . . . K-913, 104 Peoples, A. . . . . . . . . . . . . . . . . . . . . . . . F-829, 098 Peppercorn, A. . . . . . . . . . . . . . . . . . . . A-1246, 161 Percin, D.. . . . . . . . . . . . . . . . . . . . . . C2-1980, 243 Perego, C. . . . . . . . . . . . . . . . . . . . . . . . K-934, 105 Pereira, D. . . . . . . . . . . . . . . . . . . . . . . F-1505, 176 Pereira, J. . . . . . . . . . . . . . . . . . . . . . . . K-1603, 183 Pereira, M. . . . . . . . . . . . .T-1034, 113; T-1036, 113 Pereira, P. S. . . . . . . . . . . . . . . . . . . . . C2-1218, 157 Pereira, R. H.. . . . . . . . . . . . . . . . . . . . . D-731, 090 Peres, M. M. . . . . . . . . . . . . . . . . . . . . . D-746, 092 Perez, A. . . . . . . . . . . . . . . . . . . . . . . . C1-672, 085 Perez, C. E. . . . . . . . . . . . . . . . . . . . . . P-1000, 112 Perez, C. . . . . . . . . . . . . . . . . . . . . . . . F-1518, 176 Perez, F. . . C2-092, 008; C2-692, 087; C2-720, 089

Final Program

Pérez-Elías, M. . . . . . . . . .H-217, 018; H-222, 019 Pérez-Llarena, F. . . . . . . C1-070, 006; C1-593, 081 Pérez-Trallero, E. . . . . . . . . . . . . . . . C2-1358, 167 Perfect, J. . . . . . . . . . . . .M-977, 111; M-1055, 115; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1703, 191 Pericas, J. M. . . . . . . . . . . .A-610, 082; B-648, 084; . . . . . . . K-945, 106; K-1122, 129; E-1465, 173 Perilli, V. . . . . . . . . . . . . . . . . . . . . . . . T-1040, 113 Perin, S. . . . . . . . . . . . . . . . . . . . . . . . . . P-566, 075 Périn-Dureau, F. . . . . . . . . . . . . . . . . . . A-035, 004 Perkhofer, S. . . . . . . . . . . . . . . . . . . . .M-1708, 191 Perkins, M. . . . . . . . . . . . . . . . . . . . . . . . . 534, 069 Perlin, D. S. . . . . . . . . . . F-822, 096; C2-1216, 157; . . . . .M-1678, 190; M-1710, 191; M-1715, 191 Perotti, M. . . . . . . . . . . . . . . . . . . . . . . D-1426, 171 Perovic, O. . . . . . . . . . . . . . . . . . . . . . . . D-773, 092 Perreten, V. . . . . . . . . . . . . . . . . . . . . . C2-116, 009 Perri, M. B. . . . . . . . . . . . . . . . . . . . . . . K-912, 104 Perrier, A. . . . . . . . . . . . . . . . . . . . . . . . K-956, 108 Perrone, R.. . . . . . . . . . . . . . . . . . . . . . A-1247, 161 Persing, D. H. . . . . . . . . . . . . . . . . . . . . K-469, 048 Pesano, R. . . . . . . . . . . . . . . . . . . . . . . H-1575, 180 Pescetto, L. . . . . . . . . . . . . . . . . . . . . . D-1426, 171 Pesho, M.. . . . . . . . . . . . . . . . . . . . . . . F-1515, 176 Peskova, P. . . . . . . . . . . . . . . . . . . . . . .M-1720, 191 Pessacq, P. . . . . . . . . . . . . . . . . . . . . . C2-1398, 169 Pessoa, D. . . . . . . . . . . . . . . . . . . . . . . P-1012, 112 Pestana, A. . . . . . . . . . . . . . . . . . . . . . . C2-717, 088 Pestel-Caron, M. . . . . . . B-1337, 165; B-1338, 165 Peters, G. . . . . . . . . . . . . . . . . . . . . . . . E-1483, 174 Peters, R. P. . . . . . . . . . . . . . . . . . . . . . . G-870, 101 Petersen, C. . . . . . . . . . . . . . . . . . . . . . A-1255, 161 Petersen, I. . . . . . . . . . . . . . . . . . . . . . L1-1645, 186 Peterson, E. J. . . . . . . . . . . . . . . . . . . . F-1535, 177 Peterson, M. L. . . . . . . . . . . . . . . . . . . F-1517, 176 Petit, G. . . . . . . . . . . . . . . . . . . . . . . . . G-1051, 114 Peto, T. E. . . . . . . . . . . . . . . . . . . . . . . . K-474, 048 Petraitiene, R. . . . . . . . . . . . . . . . . . . . .M-981, 111 Petraitis, V. . . . . . . . . . . . . . . . . . . . . . .M-981, 111 Petraityte, E. . . . . . . . . . . . . . . . . . . . . .M-981, 111 Petri, W. A. . . . . . . . . . . . . . . B-047, 005; 507, 062 Petrikkos, G. . . . . . . . . . . . K-245, 021; K-246, 021

243


Presentation Number

Petroni, A. . . . . . . . . . . .C2-084, 008; C2-701, 087; . . . . . . . . . . . . . . . . . D-759, 092; C2-1217, 157 Petropoulos, C. . . . . . . . . . . . . . . . . . . H-1574, 180 Petrosillo, N. . . . . . . . . . . . . . . . . . . . . T-1040, 113 Petschulies, M. . . . . . . . . . . . . . . . . . . C1-667, 085 Pettit, N. . . . . . . . . . . . . . . . . . . . . . . . . K-279, 024 Peves Rios, W. . . . . . . . . . . . . . . . . . . G3-1553, 178 Pfaff, P. . . . . . . . . . . . C1-1346, 166; C1-1347, 166 Pfaller, M. . . . . . . . . . . . . . . . . . . . . . . A-1929, 240 Pfaller, M. A. . . . . . . . . . M-330, 028; M-1714, 191 Pfeffer, K. . . . . . . . . . . . . . . . . . . . . . . C1-588, 081 Pfeiffer, C. . . . . . . . . . . . . . . . . . . . . . . D-1432, 171 Phan, L. T. . . . . . . . . . . . . . . . . . . . . . . B-1303, 164 Phee, L. . . . . D-761, 092; E-797, 094; B-1299, 164 Phillips, P. . . . . . . . . . . . . . . . . . . . . . .M-1233, 159 Piazza, A.. . . . . . . . . . . C2-094, 008; C2-1897, 236 Picazo, J. J. . . . . . . . . . . . . E-805, 095; P-1020, 112

Author

Presentation Number

Author

Presentation Number

Pitrak, D. L. . . . . . . . . . . . . . . . . . . . . K-2085, 252

Poonwan, N. . . . . . . . . . . . . . . . . . . . . .M-336, 028

Pitre, M. . . . . . . . . . . . . K-1590, 181; K-1591, 181 Pitt, G. R. . . . . . . . . . . . . . . . . . . . . . . F-2016, 247

Poppen, P. J. . . . . . . . . . . . . . . . . . . . . . . H-213, 017

Pitta, T. . . . . . . . . . . . . . . . . . . . . . . . .M-1702, 191 Pittet, D. . . . .K-560, 074; K-914, 104; K-929, 105; . . . . . . . .K-954, 108; K-956, 108; K-2075, 250; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2083, 251 Pittet, L. F. . . . . . . . . . . . . . . . . . . . . G3-1556, 178 Pizzorno, M. A. . . . . . . . . . . . . . . . . . . V-1079, 117 Planche, T. D. . . . . . . . . D-160, 011; K-1754, 199; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1759, 199 Planes, A. M.. . . . . . . . . . K-937, 106; K-1758, 199 Plantier, J. C. . . . . . . . . . . . . . . . . . . . . . H-886, 102 Plantinga, T. S. . . . . . . . .B-044, 005; M-1055, 115 Plata, A.. . . . . . . . . . . . . . . K-938, 106; K-943, 106 Plata, K. B. . . . . . . . . . . . . . . . . . . . . . E-1478, 174 Platt, R. W. . . . . . . . . . . . . . . . . . . . . . K-1755, 199

Popoiu, M.. . . . . . . . . . . . . . . . . . . . . . C2-110, 009 Porcher, R. . . . . . . . . . . . . .H-219, 019; H-889, 103 Porter, K. . . . . . . . . . . . . . . . . . . . . . . . . F-828, 097 Portillo, M. E. . . . . . . . . . . . . . . . . . . . . K-258, 022 Portinari, R. . . . . . . . . . . . . . . . . . . . . . . T-357, 029 Portnoy, Y. A. . . . . . . . . . . . . . . . . . . . A-1967, 241 Porto, A. P.. . . . . . . . . . . . . . . . . . . . . . C1-669, 085 Portu, J. . . . . . . . . . . . . . . . . . . . . . . . . . K-942, 106 Pos, K. M. . . . . . . . . . . . . . . . . . . . . . . . . 1836, 216 Posfay-Barbe, K. M. . . . . G3-1556, 178; 1083, 118 Poskly, B. . . . . . . . . . . . . . . . . . . . . . . . C2-112, 009 Postelnick, M. . . . . . . . . . . . . . . . . . . . . K-271, 024 Pote, L. A. . . . . . . . . . . . . . . . . . . . . . . T-1029, 113

Piet, J. R. . . . . . . . . . . . . . . . . . . . . . . L1-1651, 187

Plouzeau, C. . . . . . . . . . . . . . . . . . . . . . A-039, 004 Plovsing, R. P. . . . . . . . . . . . . . . . . . . . . B-055, 005

Potel, G. . . . . B-051, 005; B-054, 005; E-203, 016; . . . . . . . L1-283, 025; L1-285, 025; B-651, 084; . . . . . . B-653, 084; L1-1224, 158; B-1335, 165; . . . . .D-1458, 172; L1-1642, 186; A-1948, 241; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2056, 248 Potoski, B. A.. . . . . . . . . . K-275, 024; K-1123, 129 Potron, A. C1-061, 006; C1-063, 006; C1-591, 081

Pietersma, F. . . . . . . . . . . . . . . . . . . . . F-1516, 176 Pignatari, A. C. . . . . . . C2-685, 087; D-1412, 170; . . . . . . . . . . . . . . . . D-1446, 172; E-1481, 174

Ploy, M. . . . . . . . . . . . . C1-666, 085; D-1408, 170; . . . . . . . . . . . . . . . . D-1441, 171; C1-1739, 197

Pouch, S. M. . . . . . . . . . .T-1034, 113; T-1036, 113 Poudel, A. . . . . . . . . . C2-1368, 168; C2-1369, 168

Po-Ren Hsueh . . . . . . . . . . . . . . . . . . .M-1669, 190 Pockros, P. J. . . . . . . . . . . . . . . . . . . . . V-1236, 160

Poudyal, A. . . . . . . . . . . . . . . . . . . . . . . E-795, 094 Poulakou, G. . . . . . . . . . . . . . . . . . . . . . K-245, 021 Poulsen, S. D. . . . . . . . . . . . . . . . . . . . . B-055, 005

Piddock, L. J. . . . . . . . . . . . . . . . . . . . . C1-674, 086 Pierard, D. . . . . . . . . . . . . . . . . . . . . . . F-2029, 247 Pierrotti, L. C. . . . . . . . . . . . . . . . . . . . K-1603, 183

Pigrau, C. . . . . . . . . . . . . . . . . . . . . . . K-1758, 199 Pilewski, J. . . . . . . . . . . . . . . . . . . . . . . . T-364, 029 Pillai, D. . . . . . . . . . . . . . . . . . . . . . . G3-1562, 178 Pillar, C.. . . A-008, 003; F-2019, 247; F-2065, 249 Pillet, S. . . . . . . . . . . . . . . . . . . . . . . . . . D-178, 013 Pilligua-Lucas, M. . . . . . . . . . . . . . . . . B-1303, 164 Pilotte, J. . . . . . . . . . . . . . . . . . . . . . . . . D-751, 092 Pina-Vaz, C. . . . . . . . . . . M-320, 028; F-1492, 175 Pina-Vaz, I. . . . . . . . . . . . . . . . . . . . . . F-1492, 175 Pinho, M. D. . . . . . . . . . . . . . . . . . . . . C2-151, 010 Pini, B.. . . . . . . . . . . . . . D-757, 092 C2-1211, 157 Pinilla, B. . . . . . . . . . . . . . . . . . . . . . . . . K-944, 106 Pino, M. . . . . . . . . . . . . C1-466, 047; C1-678, 086 Pinsky, B. A. . . . . . . . . . . .T-355, 029; T-1070, 116 Pintado, V. M-323, 028; M-1700, 191; K-2077, 250 Piontkowsky, D.. . . . . . . . . . . . . . . . . . . H-879, 102 Pipa, E. . . . . . . . . . . . . . . . . . . . . . . . G3-1543, 178 Pippo, T. . . . . . . . . . . . . . . . . . . . . . . . . G-874, 101 Piret, J. . . . . . . . . . . . . . . . . . . . . . . . . . . V-392, 030 Píriz, M. . . . . . . . . . . . . . . . . . . . . . . . K-1623, 184 Pisano, J. . . . . . . . . . . . . . . . . . . . . . . . . K-279, 024 Piscitelli, S. . . . . . . . . . . . . . . . . . . . . . A-1249, 161 Piselli, P. . . . . . . . . . . . . . . . . . . . . . . . T-1040, 113 PISOT study group . . . . . . . . . . . . . . . T-1041, 113 Pitman, M. C. . . . . . . . . . . . . . . . . . . . C2-689, 087 Pitout, J. D. . . . . . . . . . .K-561, 074; C2-1210, 157; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .D-1448, 172

244

Playford, E. G. . . . . . . . . . . . . . . . . . . .M-313, 028 Plevneshi, A. . . . . . . .C2-1362, 167; C2-1363, 167; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1364, 167

Podczervinski, S. . . . . . . . . . . . . . . . . . . T-353, 029 Podnecky, N. . . . . . . . . . .F-2022, 247; F-2033, 248 Poggio, J. . . . . . . . . . . . . . . . . . . . . . . C2-1398, 169 Pogue, J. M. . . . . . . . . . . . .A-034, 004; K-272, 024; . . . . . . . . .E-787, 094; K-902, 104; K-906, 104; . . . . . . . . . . . . . . . . . . K-909, 104; K-1604, 183 Poinhos, R. . . . . . . . . . . . . . . . . . . . . . . H-227, 019 Poiree, S. . . . . . . . . . . . . . . . . . . . . . . .M-1707, 191 Poirel, L. . . . . . . . . . . . .C1-061, 006; C1-063, 006; . . . . . .C1-071, 006; C1-078, 006; C1-465, 047; . . . . . . . . . C1-587, 081; C1-591, 081; 514, 064; . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1202, 156 Poirier, A. . . . . . . . . . . . . . . . . . . . . . . . V-389, 030 Polgreen, P. M. . . . . . . . . . . . . . . . . . . K-1611, 184 Polisetty, R. . . . . . . . . . . . . . . . . . . . . . . A-618, 082 Politikos, I.. . . . . . . . . . . . . . . . . . . . . . . T-354, 029 Pollard, A. J. . . . . . . . . . . . 440, 042; G3-1544, 178 Polzoni, M. . . . . . . . . . . . . . . . . . . . . . T-1040, 113 Pomar, V. . . . . . . . . . . . . . . . . . . . . . . . . K-256, 022 Pommier, S. . . . . . . . . . . . . . . . . . . . . . F-2016, 247 Pomraning, K. R. . . . . . . . . . . . . . . . . C1-1972, 242 Ponce, B. . . . . . . . . . . . . . . . . . . . . . . L2-2110, 255 Pong, S. . . . . . . . . . . . . . . . . . . . . . . . G3-1562, 178 Pong-Porter, S. . . . . . C2-1362, 167; C2-1364, 167 Ponniah, M. P. . . . . . . . . . . . . . . . . . . .M-1713, 191 Pontikos, M. . . . . . . . . . . . . . . . . . . . . .M-972, 111 Pool, B. . . . . . . . . . . . . . . . . . . . . . . . . . F-828, 097

September 9-12 |

Poupet, H. . . . . . . . . . . . . . . . . . . . . . . D-1441, 171 Pournaras, S. . . . . . . . . . . . . . . . . . . . . B-1300, 164 Poutanen, S. M. . . . . . . . .K-281, 024; K-1590, 181; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1591, 181 Poutsiaka, D. D.. . . . . . . . . . . . . . . . . . T-1025, 113 Poveda, E. . . . . . . . . . . . . . . . . . . . . . . H-1576, 180 Póvoa, H. C. . . . . . . . . . . . . . . . . . . . C2-1383, 169 Powderly, B. . . . . . . . . . . . . . . . . . . . . . . . 1807, 209 Powell, L. C. . . . . . . . . . .F-2063, 249; F-2064, 249 Power, P. . . . . . . . . . . . .C1-459, 047; C1-466, 047; . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1206, 156 Powers, R. A. . . . . . . . . . . . . . . . . . . . . C1-467, 047 Poxton, I. . . . . . . . . . . . . . . . . . . . . . . . . K-927, 105 Poyart, C.. . . . . . . . . . . . . . . . . . . . . . . D-1441, 171 Poynten, I. M. . . . . . . . . . . . . . . . . . . . L2-301, 027 Poza, M. . . . . . . . . . . . C1-672, 085; C2-1902, 236 Pozzetto, B. . . . . . . . . . . . . . . . . . . . . . . D-178, 013 Prabhakara, S. . . . . . . . . . . . . . . . . . . . B-1315, 165 Praestgaard, J. . . . . . . . . .B-664, 084; A-1281, 162; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1282, 162 Pranatharthi, C. . . . . . . . . . . . . . . . . . . . T-367, 029 Prasad, R. . . . . . . . . . . . . . . . . . . . . . . .M-975, 111 Prattes, J. . . . . . . . . . . . . . . . . . . . . . . . . V-398, 030 Prazuck, T. . . . . . . . . . . . . . . . . . . . . . L1-1639, 186 Prendergast, A. . . . . . . . . . . . . . . . . . . . . 1872, 230

AUTHOR INDEX Author

Presentation Number

Author

Presentation Number

Prentice, A. M. . . . . . . . . . . . . . . . . . . . . . 505, 062

Qiu, F. . . . . . . . . . . . . . . . . . . . . . . . . . . K-922, 105

Press, E. G. .E-786, 094; E-804, 094; M-1675, 190 Press, R. A. . . . . . . . . . . . . . . . . . . . . . . K-273, 024

Qiu, Y. L.. . . . . . . . . . . . . . . . . . . . . . . F-1502, 176 Quach, C. . . . . . . . . . . . . . . . . . . . . . . K-1755, 199

Author

Presentation Number

Railkar, R. . . . . . . . . . .M-1676, 190; M-1678, 190; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1695, 190 Rainey, G. . . . . . . . . . . . . . . . . . . . . . . B-1734, 196 Raiz, S. . . . . . . . . . . . . . . . . . . . . . . . . G-1050, 114

Preston, L. . . . . . . . . . . . . . . . . . . . . . . C2-725, 089

Quale, J. . . . . . . . . . . . . . . . . . . . . . . . . . F-841, 099

Prevalence of Multiresistant Microorganisms (PMM)Study Group. . . . . . . . . . . C2-1382, 169 Prevots, R. . . . . . . . . . . . . . . . . . . . . . . .M-314, 028

Que, Y. A. . . . . . . . . . . . . B-046, 005; K-2088, 252

Raji, M. A.. . . . . . . . . . C2-121, 009; C2-1378, 169

Queiroz-Telles, F. . . . . . . . . . . . . . . . .M-1234, 159 Quelet, S.. . . . . . . . . . . . . . . . . . . . . . . . V-375, 030

Rajuri, S. D.. . . . . . . . . . . . . . . . . . . . . . K-272, 024 Rallu, F. . . . . . . . . . . . . .D-730, 090; G3-1554, 178

Price, D.. . . . . . . . . . . . . . . . . . . . . . . . F-2016, 247

Quentin, C. . . . . . . . . . . . . . . . . . . . . . C2-091, 008 Quentin, R. . . . . . . . . . . . . . . . . . . . . . . D-176, 013

Ramalho, P. A. . . . . . . . . . . . . . . . . . . . F-1492, 175 Ramalingam, K.. . . . . . . . . . . . . . . . . . F-2010, 246

Price, L. L.. . . . . . . . . . . . . . . . . . . . . . T-1025, 113 Prieto, S. . . . . . . . . . . C2-1396, 169; C2-1397, 169

Quentin-Noury, C. . . . . . . . . . . . . . . . C2-719, 089

Raman, K. . . . . . . . . . . . . . . . . . . . . . . K-1926, 239

Prince, W. T. . . . . . . . . . . . . . . . . . . . L1-1660, 189

Quereda, C. . . . . . . . . . . . . . . . . . . . . . . H-217, 018 Quesada, M. . . . . . . . . C2-1358, 167; D-1419, 170

Ramanathan, S. . . . . . . . . . . . . . . . . . . A-1250, 161

Principe, L. . . . . . . . . . . . . . . . . . . . . . . D-757, 092 Principi, N. . . . . . . . . G3-1549, 178; G3-1553, 178

Quesnell, R. . . . . . . . . . . . . . . . . . . . . . F-2034, 248

Price, C. S. . . . . . . . . . . .G-1054, 114; D-1410, 170

Pritchard, M. F. . . . . . . . .F-2063, 249; F-2064, 249 Pritt, B. S. . . . . . . . . . . . . . . . D-174, 013; 447, 044 Priyadarshini, K. . . . . . . . . . . . . . . . . . K-1618, 184 Prochaska, R. R. . . . . . . E-1463, 173; E-1467, 173 Procop, G. W. . . . . . . . . . . . . . . . . . . . . D-735, 091 Proctor, R. A.. . . . . . . . . . .A-596, 082; A-597, 082; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-599, 082 Prokocimer, P. . . . . . . . .A-1292, 163; A-1293, 163; . . . . .A-1294, 163; A-1295, 163; L1-1664, 189; . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1665, 189 PROMULGA . . . . . . . . . . . . . . . . . . .M-1688, 190 Prósper, L. . . . . . . . . . . . . . . . . . . . . . . H-1576, 180 Prueller, F. . . . . . . . . . . . . . . . . . . . . . . D-1404, 170 Pryor, M. . . . . . . . . . . . . . . . . . . . . . . . . F-828, 097 Puchades, F. . . . . . . . . . . . . . . . . . . . . . .M-329, 028 Pugh, M. V. . . . . . . . . . . . . . . . . . . . . . L1-297, 026 Pugliese, F.. . . . . . . . . . . . . . . . . . . . . . T-1040, 113 Puig, C. . . . . . . . . . . . . . . . . . . . . . . . C2-1974, 243 Puig, L. . . . . . . . . . . . . . . . . . . . . . . . . . K-258, 022 Puig, M.. . . . . T-368, 029; K-948, 107; K-950, 107 Puimé, A.. . . . . . . . . . . . . . . . . . . . . . . .M-327, 028 Pujol, M. . . . . . . . . . . . . K-254, 022; C2-1395, 169 Pulluru, H.. . . . . . . . . . . . . . . . . . . . . . . A-034, 004 Punab, M. . . . . . . . . . . . . . . . . . . . . . . L2-310, 027 Punt, N. . . . . . . . . . . . . . . . . . . . . . . . . . A-624, 083 Pupaibool, J. . . . . . . . . . . . . . . . . . . . . . F-813, 096 Puro, V. . . . . . . . . . . . . . . . . . . . . . . . . T-1040, 113 Putney, K. . . . . . . . . . . . . . . . . . . . . . L2-2111, 255 Puzniak, L. A. . . . . . . . . K-1120, 129; K-1628, 185 Pym, A. . . . . . . . . . . . . . . . . . . . . . . . . A-1258, 161 Pyrgos, V.. . . . . . . . . . . . . . . . . . . . . . . .M-314, 028

Q Qi, C.. . . . B-1323, 165; B-1326, 165; K-1614, 184 Qiang, C. . . . . . . . . . . . . . . . . . . . . . . . . K-933, 105 Qin, X.. . . . . . . . . . . . . . . . . . . . . . . . . B-1332, 165

Quick, M. . . . . . . . . . . . . . . . . . . . . . C2-1384, 169 Quiles, M. G. . . . . . . . . . . . . . . . . . . . D-1412, 170 Quinart, A. . . . . . . . . . . . . . . . . . . . . . . D-164, 012 Quinn, C. L. . . . . . . . . . . . . . . . . . . . . F-1517, 176 Quinn, J. P. . . . . . . . . . . C2-694, 087; D-747, 092; . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1745, 197 Quinn, T. C. . . . . . . . . . . . . . . . . . . . . H-1580, 180 Quinson, A. . . . . . . . . . . . . . . . . . . . . . . H-877, 102 Quintanilla, N. . . . . . . . . . . . . . . . . . . K-2093, 252 Quintero, R. . . . . . . . . . . . . . . . . . . . C2-1914, 237 Quinteros, M. G.. . . . . . . . . . . . . . . . . . E-202, 015 Quintiliani, R. . . . . . . . . . . . . . . . . . . . . A-020, 003 Qureshy, M. S.. . . . . . . . . . . . . . . . . . C2-1981, 243

R Raab-Traub, N. . . . . . . . . . . . . . . . . . . . . 1722, 192 Raad, I. I. . . . . . . . . . . . . F-2012, 246; F-2013, 246; . . . . . . F-2014, 246; K-2082, 251; K-2096, 252 Raanani, E. . . . . . . . . . . . . . . . . . . . . . L1-962, 110 Rabaud, C.. . . . . . . . . . . . . K-237, 020; P-566, 075 Rabiais, S. . . . . . . . . . . . . . . . . . . . . . . . H-878, 102 Rabinovich, R. . . . . . . . . . . . . . . . . . . . . . 1824, 211 Rabinovitch, M. D. . . . . . . . . . . . . . . . V-1241, 160 Raboud, J. M. . . . . . . . . . . . . . . . . . . . H-1920, 238 Racine, F. . . . . . . . . . . . . . . . . . . . . . . . A-1763, 200 Radice, M. . . . . . . . . . . .C1-074, 006; C2-700, 087; . . . . . . . . . . . . . . . . . C2-718, 089; D-1455, 172 Radigan, E. . . . . . . . . . . . . . . . . . . . . . K-1585, 181 Rae, W. . . . . . . . . . . . . . . . . . . . . . . . .M-1670, 190 Rafailovich, M. H. . . . . . . . . . . . . . . . . . P-997, 112 Rafalskiy, V. V. . . . . . . . . . . . . . . . . . . . L1-299, 026 Raffay, A. . . . . . . . . . . . . . . . . . . . . . . . C2-079, 007 Raggam, R. B. . . . . . . . . . V-398, 030; D-1404, 170 Raghubir, N. . . . . . . . . . . . . . . . . . . . . C2-150, 010 Rahav, G. . . . . . . . . . . . L1-962, 110; L1-1640, 186 Rahim, Z. M. . . . . . . . . . . . . . . . . . . C2-1369, 168 Rahman, M. . . . . . . . . . . . . . . . . . . . . . H-228, 019

Final Program

Ramasubramanian, V. . . . . P-564, 075; P-565, 075; . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1003, 112 Rambaud, C. . . . . . . . . . . . . . . . . . . . . . D-157, 011 Ramírez, I. . . . . . . . . . . . . . . . . . . . . . . T-1026, 113 Ramirez, M.. . . . . . . . . .C1-074, 006; C2-151, 010; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-866, 100 Ramírez, M.. . . . . . . . . . .G-865, 100; D-1455, 172 Ramonet, M. . . . . . . . . . .P-1015, 112; P-1016, 112 Ramos, A. . . . . . . . . . . . . . . . . . . . . . . . T-340, 029 Ramos, E. . . . . . . . . . . . . . . . . . . . . . . . G-873, 101 Ramphal, R.. . . . . . . . . . . . . . . . . . . . . . K-274, 024 Ramsay, C.. . . . . . . . . . . . . . . . . . . . . . . . 1729, 194 Rana, S. W. . . . . . . . . . . . . . . . . . . . . . C2-703, 088 Rane, H. S. . . . . . . . . . . . . . . . . . . . . . F-2000, 246 Ranfaing, J. . . . . . . . . . . . . . . . . . . . . . B-1317, 165 Rao, E. P. . . . . . . . . . . . . . . . . . . . . . . . F-2043, 248 Rao, G. G. . . . . . . . . . . . . .A-016, 003; A-024, 004; . . . . . . . . . . . . . . . . . . A-1243, 161; E-785, 094 Rao, K.. . . . . . . . . . . . . . . . . . . . . . . . . . K-926, 105 Raoult, D. . . . . . . . . . . . . . . .P-1011, 112; 449, 044 Rapoport, M. . . . . . . . . . . C2-084, 008; D-746, 092 Raporport, M. . . . . . . . . . . . . . . . . . . C2-1217, 157 Rasigade, J. P.. . . . . . . . . B-1317, 165; B-1319, 165 Rasmussen, A. . . . . . . . . . . . . . . . . . . . T-1072, 116 Ratanasalink, W. . . . . . . . . . . . . . . . . . . P-998, 112 Rath, B. . . . . . . . . . . . . . A-1245, 161; G-1749, 198 Rath, P. M. . . . . . . . . . . . . . . . . . . . . . .M-335, 028 Rathi, C. . . . . . . . . . . . . . . . . . . . . . . . A-1267, 161 Ravic, M. . . . . . . . . . . . . . . . . . . . . . . . F-1530, 177 Ravn, P. . . . . . . . . . . . . . . . . . . . . . . . . H-1919, 238 Rawal, M. . . . . . . . . . . . . . . . . . . . . . . .M-975, 111 Rawlings, M. . . . . . . . . . . . . . . . . . . . . . H-881, 102 Rawte, P. . . . . . . . . . . . . . . . . . . . . . . . C2-090, 008 Ray, A. J. . . . . . . . . . . . . . C2-720, 089; H-892, 103 Raymond, F. . . . . . . . . . . . . . . . . . . . G3-1541, 178 Rayner, C. R. . . . . . . . . .A-1245, 161; A-1243, 161; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1244, 161 Rearden, P.. . . . . . . . . . . . . . . . . . . . . .M-1060, 115 Rearte, A. . . . . . . . . . . . .P-1015, 112; P-1016, 112 Redding, S. W. . . . . . . . . . . . . . . . . . .M-1674, 190

245


Presentation Number

Reddy, K. R. . . . . . . . . . . . . . . . . . . . . . F-848, 099 Reddy, M. . . . . . . . . . . . . . . . . . . . . . . A-1243, 161 Reddy, S. . . . . . . . . . . . . . . . . . . . . . . L2-2112, 255 Reese, K. A. . . . . . . . . . . . . . . . . . . . . C1-1972, 242 Reeve, M. . . . . . . . . . . . A-1956, 241; A-1289, 163 Rege, S. . . . . . . . . . . . . . . . . . . . . . . . L1-2105, 254 Regnouf-de-Vains, J. . . . . . . . . . . . . . . F-1527, 177 Reguera, J. . . . . . . . . . . . . . . . . . . . . . . . K-942, 106 Reiberger, T. . . . . . . . . . . . . . . . . . . . . H-1918, 238 Reid, D. . . . . . . . . . . . . . . . . . . . . . . . . D-1442, 171 Reif, S. . . . . . . . . . . . . . . . . . . . . . . . . G3-1545, 178 Reigadas, E. . . . . . . . . . . E-806, 095; M-1232, 159; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2090, 252

Author

Presentation Number

Ritchie, S. R. . . . . . . . G3-1555, 178; C2-1908, 237

Rezai, M. . . . . . . . . . . . . . . . . . . . . . . L1-1647, 186

Rittenhouse, S. . . . . . . . A-1275, 162; B-1308, 164

Rezende de Castro, R. . . . . . . . . . . . . . D-1447, 172 Rhéaume, C. . . . . . . . . . . . . . . . . . . . . . V-399, 030

Ritz, D. . . . . . . . . . . . . . . . . . . . . . . . C1-1347, 166

Riahi, F. . . . . . . . . . . . . . . . . . . . . . . . . C2-126, 010

Rivero Rodriguez, M. . . . . . . . . . . . . . H-1921, 238 Rizk, M. . . . . . . . . . . . . . . . . . . . . . . . . A-008, 003 Rizk, M. L. . A-009, 003; A-010, 003; A-1763, 200

Ribeiro, V. B. . . . . . . . . . . . . . . . . . . . . . D-749, 092 Ribera, A. . . . . . . . . . . . . . . . . . . . . . . . K-254, 022

Reinstrup, L. . . . . . . . . . . . . . . . . . . . . P-1005, 112 Reinwald, M. . . . . . . . . . M-335, 028; M-1704, 191

Ricagni, L. . . . . . . . . . . . . . . . . . . . . . . D-1426, 171 Ricardo, E.. . . . . . . . . . . . . . . . . . . . . . .M-320, 028

Reis, H. . . . . . . . . . . . . . . . . . . . . . . . .M-1690, 190

Riccobono, E. . . . . . . . . . . . . . . . . . . C1-1205, 156 Rice, C. M. . . . . . . . . . . . . . . . . . . . . . . . . 005, 002 Rich, P. . . . . . . . . . . . . . . . . . . . . . . . .M-1670, 190

Rene, A.. . . . . . . . . . . . . . . . . . . . . . . . F-2010, 246 Renner, E. . . . . . . . . . . . . . . . . . . . . . . T-1043, 113 Renteria, M. . . . . . . . . .C2-099, 009; C2-150, 010; . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-721, 089 Renzi, G. . . . . . . . . . . . . . . . . . . . . . . . . K-560, 074 Repetto, V. . . . . . . . . . . . . . . . . . . . . . . C2-094, 008 Resch, G. . . . . . . . . . . . . . B-659, 084; B-1316, 165 Reseau des Observatoires Regionaux du Pneumocoque . . . . . . . . . . . . . . . . . . . . . . . C2-1359, 167 Ressina, S. . . . . . . . . . . . . . . . . . . . . . . C1-588, 081 Reuland, E. A. . . . . . . . . . . . . . . . . . . . C2-104, 009 Reus, S. . . . . . . . . . . . . . . . . . . . . . . . . . K-941, 106 Revale, S. . . . . . . . . . . . . . . . . . . . . . . . C1-678, 086 Revelly, J. . . . . . . . . . . . . . . . . . . . . . . . K-2088, 252 Revest, M. . . . . . . . . . . . . . . . . . . . . . . . K-267, 023 Rey, A. . . . . . . . . . . . . . . . . . . . . . . . . . F-1523, 177 Reyes, A. . . . . . . . . . . . . . . . . . . . . . . L2-2115, 255 Reyes, J. . . . . . . . . . . . . .K-900, 104; C1-1345, 166; . . . . . . . . . . . . . . . C2-1389, 169; C2-1909, 237 Reyna, F. . . . . . . . . . . . . . . . . . . . . . . . C1-067, 006 Reynaud, A. . . . . . . . . . . .C2-080, 007; K-255, 022; . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1318, 165 Reynolds, D. K. . . . . . . . . . . . . . . . . . . A-1244, 161

246

Rivas, N. . . . . . . . . . . . . . . . . . . . . . . G3-1552, 178 Rivat, S. . . . . . . . . . . . . . . .D-745, 092; D-748, 092 Rivera, J. I. . . . . . . . . . . . . . . . . . . . . . . C2-112, 009 Rivera, L. . . . . . . . . . . . . . . . . . . . . . . . G-1751, 198 Rivera Chavira, B. R.. . . . . . . . . . . . . . . F-833, 098

Reimnitz, P. . . . . . . . . . . . . . . . . . . . . . . B-044, 005

Rempel, H. . . . . . . . . . . . . . . . . . . . . C2-1986, 244 Remy, J. M. . . . . . . . . . . .F-1521, 177; F-1522, 177 Renders, N. H. . . . . . . . . . . . . . . . . . . L1-965, 110

Riteau, B. . . . . . . . . . . . . . . . . . . . . . . . . V-399, 030

Rhee, M. . . . . . . . . . . . . . .T-350, 029; H-555, 073; . . . . . . . .H-879, 102; H-891, 103; A-1250, 161 Rhomberg, P. R. . . . . . .C2-124, 010; C2-131, 010; . . . . . . . . C2-146, 010; E-193, 015; F-855, 099; . . . . . . . F-856, 099; E-1463, 173; E-1467, 173; . . . . . . . . . . . . . . . . . .F-1511, 176; F-1512, 176

Reiner, N. . . . . . . . . . . . . . . . . . . . . . . . . 1723, 192 Reingold, A. . . . . . . . . . . . . . . . . . . . . . . . 532, 068

Rello, J. . . . . . . . . . . . . . . . . . . . . . . . . . K-951, 107 Remont, L. . . . . . . . . . . . . . . . . . . . . C2-1988, 244

Presentation Number

Reynolds, J. L. . . . . . . . . . . . . . . . . . . . C2-695, 087 Reynolds, R. . . . . . . . . . . . . . . . . . . . . C2-152, 010

Ribaud, P. . . . . . . . . . . . . . . . . . . . . . .M-1707, 191 Ribeiro, M. O. . . . . . . . . . . . . . . . . . . C2-1375, 168 Ribeiro, S. S. . . . . . . . . . . . . . . . . . . . C2-1907, 237

Reisenberg, K. . . . . . . . . . . . . . . . . . . . K-1610, 184 Reitzel, R. . . . . . . . . . . . F-2012, 246; F-2014, 246; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2082, 251 Relich, R.. . . . . . . . . . . . . . . . . . . . . . C2-1213, 157 Reller, M. E. . . . . . . . . . . . . . . . . . . . . . . 1101, 124

Author

Richard, M. . . . . . . . . . . . . T-356, 029; V-391, 030 Richardson, C. . . . . . . . . . . . . . . . . . . . G-1048, 114 Richaud, C. . . . . . . . . . . . . . . . . . . . . . . B-660, 084 Riche, A. . . . . . . . . . . . . . . . . . . . . . . . L1-963, 110 Richmond, G. J.. . . . . . . . . . . . . . . . . . . H-879, 102 Richter, S. S. . . . . . . . . . C2-112, 009; C2-126, 010 Riebe, K. M. . . . . . . . . . . . . . . . . . . . . D-1777, 201 Riederer, K. . . . . . . . . C2-1381, 169; C2-1391, 169 Rieger, A.. . . . . . . . . . . . . . . . . . . . . . . H-1918, 238 Riesenberg, K. . . . . . . . . H-232, 019; L1-961, 110; . . . . . . . . . . . . . . . . . . . . . . . . . . . . .P-1022, 112 Rigassio-Radler, D. . . . . . . . . . . . . . . . L1-300, 026 Rigaut, D. . . . . . . . . . . . C2-705, 088; C2-709, 088 Riggins, R. . . . . . . . . . . . B-1302, 164; B-1304, 164 Riggs, M. . . . . . . . . . . . . . . . . . . . . . . . . A-634, 083 Righi, E. . . . . . . . . . . . . .M-317, 028; T-1035, 113 Rijnsburger, M. C. . . . . . . . . . . . . . . . . C2-104, 009 Rijs, T. . . . . . . . . . . . . . . . . . . . . . . . . . .M-319, 028 Riley, L. W. . . . . . . . . . . . . . . . . . . . . . C2-110, 009 Rincón, G. . . . . . . . . . .C2-700, 087; C2-1389, 169; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1909, 237 Ring, C. . . . . . . . . . . . . . . K-926, 105; T-1068, 116 Rini, J. F. . . . . . . . . . . . . . . . . . . . . . . .M-1063, 115 Rinsky, J. . . . . . . . . . . . . . . . . . . . . . . C2-1912, 237 Rio Marques, L. . . . . . . . . . . . . . . . . . D-1436, 171 Rios, F.. . . . . . . . . . . . . . . . . . . . . . . . . K-2093, 252 Riosa, S. . . . . . . . . . . . . . . . . . . . . . . . . E-1478, 174 Rioux, C. . . . . . . . . . . . . . . . . . . . . . . . V-1073, 117 Risso, F. . . . . . . . . . . . . . . . . . . . . . . . . D-1426, 171 Ritchie, G. . . . . . . . . . . . . . . . . . . . . . . . D-161, 011

September 9-12 |

Rivera, A.. . . . . . . . . . . . . . . . . . . . . . . K-1621, 184

Rizzardini, G. . . . . . . . . . . . . . . . . . . . L2-304, 027 RLN . . . . . . . . . . . . . . . . . . . . . . . . . . .M-327, 028 Robb, A. . . . . . . . . . . . . . . . . . . . . . . . K-2095, 252 Robbins, W.. . . . . . . . . . . . . . . . . . . . . . H-879, 102 Roberson, M.. . . . . . . . . . . . . . . . . . . . . G-873, 101 Robert, J. . . . . . . . . . . . . . . . . . . . . . . . . K-237, 020 Robert-Gangneux, F. . . . . . . . . . . . . . . P-1007, 112 Roberts, A. P.. . . . . . . . . . . . . . . . . . . C2-1979, 243 Roberts, J. . . . . . . . . . . . L2-301, 027; F-2007, 246; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2008, 246 Roberts, M. C.. . . . . . . . . . . . . . . . . . C1-1348, 166 Roberts, S. A. . . . . . . G3-1555, 178; C2-1908, 237 Robertson, L.. . . . . . . . . . . . . . . . . . . . D-1414, 170 Robichaud, S. . . . . . . . . . . . . . . . . . . . . D-729, 090 Robin, S. . . . . . . . . . . . . . . . . . . . . . . . . P-996, 112 Robinson, T. . . . . . . . . . . . . . . . . . . . . F-2005, 246 Robledo, I. E. . . . . . . . . . . . . . . . . . . . . E-789, 094 Roblot, F. . . . . . . . . . . . . .A-039, 004; L1-963, 110; . . . . . . . . . . . . . . . . . P-996, 112; L1-2104, 254 Robson, J. M.. . . . . . . . . . . . . . . . . . . . L2-307, 027 Roca, I. . . C1-075, 006; B-1329, 165; D-1775, 201 Roca, J. . . . . . . . . . . . . . . . . . . . . . . . . T-1030, 113 Rocchetti, T. T. . . . . . . . . . . . . . . . . . . D-1412, 170 Rocchi, S. . . . . . . . . . . . . . . . . . . . . . .M-1692, 190 Rocha, J. L. . . . . . . . . . . .C2-087, 008; K-913, 104; . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2113, 255 Rocha, V. C. . . . . . . . . . . . . . . . . . . . . D-1403, 170 Rocher, I. . . . . . . . . . . . . . . . . . . . . . . . K-1755, 199 Rochstroh, A. C. . . . . . . . . . . . . . . . . . C2-685, 087 Rock, J. A. . . . . . . . . . . . . . . . . . . . . . . L1-294, 026 Rock, J. . . . . . F-843, 099; F-844, 099; F-845, 099; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-846, 099 Rockstroh, J. . . . . . . . . . . . . . . . . . . . . . H-885, 102 Roda, J. . . . . . . . . . . . . . . . . . . . . . . . . . K-944, 106 Rodgers, M. A. . . . . . . . . . . . . . . . . . . . V-377, 030 Rodier, M. . . . . . . . . . . . . . . . . . . . . . . . T-363, 029 Rodil, R. . . . . . . . . . . . . . . . . . . . . . . . K-1612, 184 Rodkey, E. . . . . . . . . . . . . . . . . . . . . . . C1-463, 047

AUTHOR INDEX Author

Presentation Number

Author

Presentation Number

Author

Presentation Number

Rodrigo, C. . . . . . . . . . . . . . . . . . . . . . D-1419, 170

Rojas, L. . . . . . . . . . . . . . . . . . . . . . . .M-1688, 190

Rougemont, M. . . . . . . . . . . . . . . . . . . H-1566, 179

Rodrigues, A. G. . . . . . . . M-320, 028; F-1492, 175 Rodrigues, A.. . . . . . . . . . . . . . . . . . . . C2-107, 009

Rojas, N. . . . . . . . . . . C2-1909, 237; C2-1915, 237 Rojo, A. . . . . . . . . . . . . .D-1439, 171; D-1440, 171

Round, J. . . . . . . . . . . . . . . . . . . . . . . . . . . 415, 036

Rodrigues, C.. . . . . . . . . . . . . . . . . . . . . . . 419, 037

Rojtman, A. . . . . . . . . . . . . . . . . . . . . . K-1625, 184 Rollins, L. O. . . . . . . . . . . . . . . . . . . . .M-1693, 190 Rolo, D. . . . . . . . . . . . . . . . . . . . . . . . C2-1365, 167

Roussel, P. . . . . . . . . . . . F-2030, 248; F-2031, 248; . . . . . . . . . . . . . . . . . .F-2032, 248; F-2033, 248

Rodrigues, F. . . . . . . . . . . . . . . . . . . . G3-1551, 178 Rodriguez, C. A. . . . . . . A-1945, 240; A-1968, 241 Rodríguez, C. . . . . . . . . . . . . . . . . . . .M-1232, 159 Rodriguez, C. . . . . . . . . . . . . . . . . . . . C2-701, 087 Rodríguez, C. . . . . . . . . . . . . . . . . . . . . D-765, 092 Rodriguez, E.. . . . . . . . . . C1-067, 006; G-871, 101 Rodriguez, F. . . . . . . . . . . . . . . . . . . . . C1-683, 086 Rodríguez, H. . . . . . . . . . . . . . . . . . . . . K-944, 106 Rodriguez, J. . . . . . . . . . . . . . . . . . . . . A-1761, 200 Rodríguez, J. . . . . . . . . .M-1700, 191; K-2077, 250 Rodriguez, N. . . . . . . . . . . . . . . . . . . C2-1370, 168 Rodríguez, V. . . . . . . . . . . . . . . . . . . . . C1-067, 006 Rodriguez Cuns, G.. . . . . . . . . . . . . . C2-1988, 244 Rodriguez Noriega, E. . . . . . . . . . . . . C2-1373, 168 Rodriguez Valdez, L. M. . . . . . . . . . . . . F-833, 098 Rodriguez-Baño, J. . . . C1-683, 086; C2-707, 088l . . . . . . . . . . . . . . . . K-1633, 185; L1-1658, 188 Rodríguez-Carballeira, M. . . . . . . . . . K-1621, 184 Rodríguez-Créixems, M. . . . . . . . . . . .C2-127, 010; . . . . . . . . D-726, 090; K-943, 106; K-940, 106; . . . . . . K-944, 106; D-1411, 170; D-1415, 170; . . . . . M-1684, 190; D-1772, 201; K-2090, 252

Rolo, J. . . . . . . . . . . . . . . . . . . . . . . . . C1-1740, 197 Rolston, K. V. . . . . . . . . . . . . . . . . . . . . K-252, 022 Román, E. . . . . . . . . . . . . . . . . . . . . . . C2-105, 009 Romanelli, R.. . . . . . . . . T-1044, 113; K-1606, 183 Romanov, A. . . . . . . . C2-1386, 169; C2-1911, 237

Rowe, J. . . . . . . . . . . . . . . . . . . . . . . . . F-2009, 246

Romero, F. . . . . . . . . . . . . . . . . . . . . . . .M-322, 028

Rouzioux, C. . . . . . . . . . . . . . . . . . . . . H-1568, 179 Rowlinson, M. . . . . . . . . . .D-732, 091; D-736, 091 Roy, C. . . . . . . . . . . . . . . . . . . . . . . . . . . P-568, 075

Romero, J. . . . . F-843, 099; F-844, 099; F-845, 099

Rozemeijer, W. . . . . . . . . . . . . . . . . . . . G-870, 101

Romero-Gómez, M. P. . . . . . . . . . . . . D-1452, 172 Romney, M. . . . . . . . . . . . D-161, 011; K-1593, 182

Ruane, P. . . . . . . . . . . . . . .H-556, 073; H-879, 102 Rubi, J.. . . . . . . . . . . . . . . . . . . . . . . . . . D-743, 091 Rubino, C. M. . . . . . . . . A-1961, 241; A-1962, 241

Rondinaud, E. . . . . . . . . C1-063, 006; C1-591, 081 Ronit, A. . . . . . . . . . . . . . . . . . . . . . . . . B-055, 005 Roques, P. . . . . . . . . . . . . . . . . . . . . . . . T-363, 029 Roquilly, A. . . . . . . . . . . . . B-051, 005; B-054, 005; . . . . . . . . . . . . . . . . . . B-651, 084; B-1335, 165 Rosato, A. . . . . . . . . . . . . . . . . . . . . . . E-1478, 174 Rosato, R. . . . . . . . . . . . . . . . . . . . . . . E-1478, 174 Rose, W. . . . . . . . . . . . . . .A-621, 082; A-626, 083; . . . . . C1-677, 086; C1-1351, 166; E-1482, 174

Rodriguez-French, A. . . . . . . . . . . . . . . H-220, 019 Rodríguez-Hernández, M. J. . . . . . . . . K-1924, 239 Rodríguez-López, F. . . . . . . . . . . . . . . A-1280, 162 Rodríguez-Martínez, J. . C1-683, 086; A-1280, 162 Rodriguez-Noriega, E. . . . . . . . . . . . C2-1370, 168

Rosenthal, J.. . . . . . . . . . . . . . . . . . . . L1-1645, 186 Rosenthal, M. E. . . . . . . . . . . . . . . . . . K-1625, 184

Rodriguez-Sanchez, B. . .D-726, 090; D-1772, 201 Rodríguez-Tudela, J. . . . . . . . . . . . . . . .M-327, 028 Rodvold, K. A.. . . . . . . . . . . . . . . . . . . A-1277, 162 Roeger, F.. . . . . . . . . . . . . . . . . . . . . . .M-1708, 191 Roger, M.. . . . . . . . . . . . . . . . . . . . . . . H-1571, 180 Roger, P.. . . . . . . . . . . . . . A-1253, 161; B-052, 005 Rogers, A. . . . . . . . . . . . . . . . . . . . . . . H-1575, 180 Rogers, B. A. . . . . . . . . . C2-689, 087; C2-708, 088 Rogers, L. M. . . . . . . . . . . . . . . . . . . . . B-661, 084 Rogers, P. D. . . . . . . . . . .M-969, 111; M-970, 111; . . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-971, 111 Rogers, P. . . . . . . . . . . . . . . . . . . . . . . . . G-871, 101 Rohde, H. . . . . . . . . . . . . . . . . . . . . . . . T-347, 029 Rohrer, R. J. . . . . . . . . . . . . . . . . . . . . . T-1025, 113 Roig, G. . . . . . . . . . . . . . . . . . . . . . . . . L2-303, 027 Roilides, E. . . . . . . . . .M-1681, 190; M-1720, 191; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1875, 230 Rojas, E. . . . . . . . . . . . . . . . . . . . . . . . . G-870, 101 Rojas, L. J. . . . . . . . . . . . . C2-694, 087; D-747, 092

Routy, J. . . . . . . . . . . . . . . . . . . . . . . . . H-1571, 180 Roux, F. L. . . . . . . . . . . . . . . . . . . . . . . B-1330, 165 Rouyer, C. . . . . . . . . . . . . . . . . . . . . . . K-2089, 252

Rosen, S. R. . . . . . . . . . . . . . . . . . . . . . K-1620, 184 Rosenbach, M.. . . . . . . . . . . . . . . . . . . . F-810, 096 Rosenblatt, J. . . . . . . . . . F-2012, 246; F-2014, 246; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2082, 251

Rodriguez-Pardo, D. . . . . K-931, 105; K-1758, 199 Rodríguez-Rosales, G.. . . . . . . . . . . . . . D-166, 012

Rousseau, C. . . . . . . . . . . . . . . . . . . . . . V-376, 030

Rosenblatt, J. E. . . . . . . . . . . . . . . . . . . . D-170, 012

Roset, A. . . . . . . . . . . . . . . . . . . . . . . L1-2102, 254 Rosetti, A. S. . . . . . . . . . . . . . . . . . . . . . E-801, 094 Rosli, R. . . . . . . . . . . . . . . . . . . . . . . . . .M-990, 111 Ross, H. . . . . . . . . . . . . . . . . . . . . . . . . T-1043, 113 Ross, J. E. . . . . . . . . . . C2-139, 010; C1-1343, 166 Ross, L. L. . . . . . . . . . . . . .H-882, 102; H-895, 103 Ross, T. . . . . . . . . . . . . . . . . . . . . . . . . K-1756, 199 Rossello, E. . . . . . . . . . . . . . . . . . . . . .M-1228, 159 Rossi, F. . . . . . . . . . . . . . . . . . . . . . . . . K-1603, 183 Rossi, R. . . . . . . . . . . . . . . . . . . . . . . . . D-742, 091 Rosso, F. . . . . . . . . . . . . . . . . . . . . . . L2-2108, 255 Rossolini, G. M. . . . . . . .C2-700, 087; E-796, 094; . . . C1-1205, 156; C2-1211, 157; C2-1897, 236 Rotger, A. . . . . . . . . . . . . . . . . . . . . . . . K-940, 106 Roth, A. L. . . . . . . . . . . . . . . . . . . . . . D-1445, 172 Roth, S. . . . . . . . . . . . . . . . . . . . . . . . . A-1255, 161 Rotimi, O. . . . . . . . . . . . . . . . . . . . . . . C2-121, 009 Rotimi, V. . . . . . . . . . . . . C1-071, 006; D-727, 090 Rotrying, F. . . . . . . . . C2-1396, 169; C2-1397, 169 Rotstein, C. . . . . . . . . . . .T-1043, 113; T-1067, 116

Final Program

Rubinovitch, B. . . . . . . . . . . . . . . . . . . . K-557, 074 Rubinstein, E. . . . . . . . . . . . . 578, 078; A-639, 083 Rubio, A. . . . . . . . . . . . . . . . . . . . . . . C1-1744, 197 Rucinski, S. L. . . . . . . . . . . . . . . . . . . . . D-170, 012 Rude, T. H. . . . . . . . . . . . . . . . . . . . . . B-1320, 165 Rudin, S. . C2-092, 008; C2-686, 087; C2-692, 087 Rudnick, W. . . . . . . . C2-1363, 167; C2-1364, 167 Ruebsamen-Schaeff, H.. . . T-356, 029; V-391, 030 Ruggiero, M. . . . . . . . . C1-466, 047; C1-1206, 156 Ruhnke, M. . . . . . . . . .M-1229, 159; M-1683, 190; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1709, 191 Ruhwald, M. . . . . . . . . . . . . . . . . . . . . H-1919, 238 Ruimy, R.. . . . . . . . . . . L1-957, 109; C2-1399, 169 Ruiz, A. . . . . . . . . . . . . . .D-726, 090; D-1772, 201 Ruiz, B. . . . . . . . . . . . . . . . . . . . . . . . . C2-105, 009 Ruiz, G. . . . . . . . . . . . . . . . . . . . . . . . . K-1608, 184 Ruiz, I. . . . . . . . . . . . . . . . . . . . . . . . . .M-1228, 159 Ruiz, J. . . . . . .K-938, 106; K-941, 106; K-942, 106; . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-992, 111 Ruiz, S. . . . . . . . . . . . . . . . . . . . . . . . . C2-092, 008 Ruiz, Y. . . . . . . . . . . . . . . . . . . . . . . . .M-1702, 191 Ruiz de Alegría, C. . . . . C1-683, 086; A-1280, 162 Ruiz-Camps, I. . . . . . . . . . . . . . . . . . . .M-312, 028 Ruiz-Garbajosa, P. . . . . . . C2-111, 009; D-753, 092 Rujiragul, R. . . . . . . . . . . . .P-998, 112; P-999, 112 Rumbo-Feal, S. . . . . . . . . . . . . . . . . . C2-1902, 236 Rummel, M. . . . . . . . . . . . . . . . . . . . . . T-341, 029 Runnegar, N. . . . . . . . . . . . . . . . . . . . . C2-689, 087 Ruperto, F. . . . . . . . . . . . . . . . . . . . . . . T-1040, 113 Rupp, M. E.. . . . . . . . . . . . . . . . . . . . . . K-922, 105 Rutgersson, C. . . . . . . . . . . . . . . . . . . . C1-665, 085 Ruvinsky, S. D. . . . . . . . . . . . . . . . . . . . B-045, 005 Ryan, K.. . . . . . . . . . . . E-1472, 174; C1-1742, 197 Ryan, R.. . . . . . . . . . . . . . . . . . . . . . . . . H-880, 102 Rybak, J. M.. . . . . . . . . . . . . . . . . . . . . E-1466, 173

247


Presentation Number

Author

Presentation Number

Author

Presentation Number

Sannes-Lowery, K. S. . . . . . . . . . . . . C2-1361, 167

Rybak, M.,J.. . . . . . . . . . . .K-272, 024; K-275, 024; . . . . . . . . A-600, 082; A-601, 082; A-602, 082; . . . . . . . . A-603, 082; A-626, 083; A-627, 083; . . . . . . . . .K-906, 104; K-909, 104; K-946, 106; . . . . . .K-1121, 129; K-1123, 129; K-1600, 182; . . . . . . L1-1638, 186; 1165, 147; C2-1985, 244

Salata, R. A.. . . . . . . . . . . V-385, 030; A-1257, 161; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2015, 246

Ryu, G. . . . . . . . . . . . . . . . . . . . . . . . . . D-734, 091 Rzotkiewicz, S. . . . . . . . . . . . . . . . . . . P-1001, 112

Salem, E. . . . . . . . . . . . . . . . . . . . . . . . K-1584, 181

Santiago, C. . . . . . . . . . . . . . . . . . . . . . L1-289, 026

Salerno, G.. . . . . . . . . . . .F-2032, 248; F-2033, 248 Salez, N. . . . . . . . . . . . . . . . . . . . . . . . . V-387, 030

Santiago, L. . . . . . . . . . . . . . . . . . . . . . . H-882, 102

S Sá-Leão, R. . . . . . . . . . . . . . . . . . . . . C2-1365, 167 Saad, N. . . . . . . . . . . . . . . . . . . . . . . . . A-1766, 200 Sabé, N. . . . . . . . . . . . . . . . . . . . . . . . . T-1030, 113 Sabet, M. . . . . F-848, 099; F-851, 099; F-852, 099; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-858, 099 Sabo, J. P. . . . . . . . . . . . . . . . . . . . . . . . A-1248, 161 Sadarangani, M. . . . .G3-1542, 178; G3-1544, 178 Sader, H. S. . . . . . . . . . .C2-123, 010; C2-124, 010; . . . . . .C2-129, 010; C2-131, 010; C2-132, 010; . . . . . .C2-136, 010; C2-138, 010; C2-145, 010; . . . . . . . .C2-146, 010; E-186, 015; E-189, 015; . . . . . . . . . E-187, 015; E-193, 015; E-199, 015; . . . . . . F-2050, 248; F-2051, 248; F-2052, 248; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2053, 248; Saez Llorenz, X. . . . . . . . . . . . . . . . . . G-1751, 198 Safdar, A. . . . . . . . . . . . . . . . . . . . . . . . . K-273, 024 Saga, T. . . . . . . . . . . . . . . K-918, 105; D-1459, 172 Sagermann, M. . . . . . . . . . . . . . . . . . . . B-053, 005 Saginur, R. . . . . . . . . . . . . . . . . . . . . . . E-1480, 174 Sagisaka, M. . . . . . . . . . . . . . . . . . . . L1-1657, 188 Saha, S. . . . . . . . . . . . . . . . . . . . . . . . . G-1751, 198 Saha-Chaudhuri, P. . . . . . . . . . . . . . . .M-1703, 191 Sahi, S. K. . . . . . . . . . . . . . . . . . . . . . . B-1301, 164 Sahli, S. . . . . . . . . . . . . . . . . . . . . . . . . .M-983, 111 Sahm, D. . . . . . . . . . . . . .A-008, 003; C2-125, 010; . . . . . . .C2-128, 010; C2-134, 010; E-208, 016; . . . . . . . . D-760, 092; D-764, 092; D-767, 092; . . . . . . .E-778, 093; G-862, 100; L1-1660, 189; . . . . . . E-1479, 174; F-1524, 177; F-1521, 177; . . . . . . . F-1528, 177; F-2046, 248; F-2047, 248 Sahner, D. . . . . . . . . . . . . . . . . . . . . . . F-1531, 177 Saidel-Odes, L. . . . . . . . H-232, 019; L1-961, 110; . . . . . . . . . . . . . . . . . P-1022, 112; K-1610, 184 Saiman, L. . . . . . . . . . . . . . . . . . . . . . . . . 1839, 217 Saint-Jean, M. . . . . . . . . . . . . . . . . . . . . D-730, 090 Saito, S. . . . . . . . . . . . . . . . . . . . . . . . . D-1461, 172 Sakata, H. . . . . . . . . . C2-1354, 167; C2-1990, 244 Sakata, K.. . . . . . . . . . . . . . . . . . . . . . . F-2055, 248 Sakellariou, C. . . . . . . . . . . . . . . . . . . . K-1592, 181 Sakoulas, G.. . . . . . . . . . . .K-275, 024; A-601, 082; . . . . . . . A-626, 083; E-1482, 174; K-1631, 185 Sakwinska, O. . . . . . . . B-1316, 165; C1-1746, 197 Salama, N. N. . . . . . . . . . . . . . . . . . . . . A-606, 082 Salas-Venero, C. . . . . . . . . . . . . . . . . . . D-169, 012

248

Salcedo, M. . . . . . . . . . . . . . . . . . . . . . T-1026, 113

Sans, D. . . . . . . . . . . . . . . . . . . . . . . . . . D-730, 090 Santalucía, M. . . . . . . . . . . . . . . . . . . . . E-202, 015

Saleem, R. . . . . . . . . . . . . . . . . . . . . . . . D-727, 090 Saleh-Mghir, A.. . . . . . . . . . . . . . . . . . . B-645, 084

Santarsiero, B. . . . . . . . . . . . . . . . . . . . F-2072, 249 Santella, G. . . . . . . . . . . . . . . . . . . . . . C2-700, 087

Salfinger, M. . . . . . . . . . . .D-732, 091; D-736, 091

Santilli, S. . . . . . . . . . . . . . V-393, 030; K-898, 104 Santos, A. . . . . . . . . . . . . . . . . . . . . . . . H-227, 019

Salgado-Pabon, W. . . . . . . . . . . . . . . . F-1517, 176 Salgueiro, V. C. . . . . . C2-1383, 169; C2-1907, 237

Santos, M. . . . . . . . . . . . . . . . . . . . . . . . H-227, 019 Santos, P. . . . . . . . . . . . . . . . . . . . . . . L1-1659, 189

Salimnia, A. . . . . . . . . . . . . . . . . . . . . . L2-306, 027 Salimnia, H. . . . . . . . . . . . . . . . . . . . . L2-306, 027 Salstrom, S. . . . . . . . . . . . . . . . . . . . . . . D-163, 011

Santos, R. . . . . . . . . . . . L1-287, 025; L1-288, 025

Saltigeral, P. . . . . . . . . . . . . . . . . . . . . G3-1563, 178 Salvado, M. . . . . . . . . . . . . . . . . . . . . . . K-258, 022 Salvatore, M. J. . . . . . . . . . . . . . . . . . . F-1496, 176 Salvioni, A. . . . . . . . . . . . . . . . . . . . . . F-1999, 246 Samayoa, B. . . . . . . . . . . . . . . . . . . . . .M-1694, 190 Sambanthamoorthy, K. . . . . . . . . . . . . C1-673, 085 Sambhara, S. . . . . . . . . . . . . . . . . . . . . D-1435, 171 Sambol, S. . . . . . . . . . . . . . . . . . . . . . . . E-808, 095 Samonis, G. . . . . . . . . . . B-043, 005; M-1058, 115; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1696, 191 Sampsonas, F. . . . . . . . . . . . . . . . . . . .M-1679, 190 Samri, A. . . . . . . . . . . . . . . . . . . . . . . . H-1568, 179 Samson, R. A. . . . . . . . . . . . . . . . . . . . .M-332, 028 Samuel, L. P. . . . . . . . . . . . . . . . . . . . . D-1416, 170 San Juan, R. . . . . . . . . . . . . . . . . . . . . . K-2091, 252 San Miguel, A. . . . . . . . . . . . . . . . . . . . D-164, 012 San Roman, M. D. . . . . . . . . . . . . . . . . A-024, 004 San-Juan, R. . . . . . . . . . . . . . . . . . . . . T-1071, 116 Sanche, S. . . . . . . . . . . . . . . . . . . . . . . . D-729, 090 Sánchez, A. . . . . . . . . . . C1-067, 006; C1-069, 006 Sánchez, C. . . . . . . . . . . . . . . . . . . . . .M-1688, 190 Sanchez, I. . . . . . . . . . . . . . . . . . . . . . . L1-289, 026 Sanchez, M.. . . . . . . . . . . . . . . . . . . . . K-2093, 252 Sanchez-Alemán, M.. . . . . . . . . . . . . C2-1356, 167 Sánchez-Carrillo, C. . . . C2-127, 010; D-726, 090; . . . . . . D-1415, 170; D-1772, 201; K-2090, 252 Sánchez-Ortega, I. . . . . . . . . . . . . . . . T-1045, 113 Sánchez-Patán, F. . . . . . . . . . . . . . . . . L1-958, 109 Sánchez-Sousa, A. . . . . . . . . . . . . . . . . .M-323, 028 Sandberg-Schaal, A. . . . . . . . . . . . . . . . . 1144, 139 Sanders, R. L. . . . . . . . . . . V-381, 030; V-382, 030 Sandid, M.. . . . . . . . . . . .L1-284, 025; T-1066, 116 Sandri, A. M.. . . . . . . . . . . . . . . . . . . . . A-027, 004 Sanfeliu, I. . . . . . . . . . . . . . . . . . . . . . . K-1623, 184 Sanguinetti, M. . . . . . . . . . . . . . . . . . . . F-814, 096 Sanjuan-Padrón, L. . . . . . . . . . . . . . . . C2-113, 009 Sanjurjo, M. . . . . . . . . . . . . . . . . . . . . .M-1232, 159

September 9-12 |

Santos, S. R. . . . . . . . . . . . . . . . . . . . . . G-861, 100 Santos-Preciado, J. I. . . . . . . . . . . . . . . C2-113, 009 Sanz, F. . . . . . . . . . . . . . . . . . . . . . . . . K-2093, 252 Sanz, J. . . . . . . . . . . . . . . . . . . . . . . . . . H-1576, 180 Saosri, P. . . . . . . . . . . . . . . . . . . . . . . . . P-998, 112 Saravolatz, L. D. . . . . . . . . . . . . . . . . . E-1484, 174 Saravolatz, S. . . . . . . . . . . . . . . . . . . . . E-1484, 174 Sarkar, A. . . . . . . . . . . . . . . . . . . . . . . . . F-827, 097 Sarmati, L.. . . . . . . . . . . . . . . . . . . . . . H-1579, 180 Sarmento, A. . . . . . . . . . . . . . . . . . . . . . H-227, 019 Sarmiento, E.. . . . . . . . . . . . . . . . . . . . T-1026, 113 Sarmiento, I. . . . . . . . . . . . . . . . . . . . . . D-762, 092 Saroufim, C. . . . . . . . . . . . . . . . . . . . L1-2106, 254 Sarraz-Bournet, B.. . . . . . . . . . . . . . . . K-2089, 252 Sarriá, C. . . . . . . . . . . . . . . . . . . . . . . . H-1576, 180 Sasano, M. . . . . . . . . . . . . . . . . . . . . . C2-1901, 236 Sasikala, S. . . E-195, 015; E-791, 094; E-1476, 174 Sass, N. . . . . . . . . . . . . . . . . . . . . . . . G3-1557, 178 Satana, D. . . . . . . . . . . . . . . . . . . . . . C2-1367, 168 Sathapollatchaphum, A. . . . . . . . . . . . . P-998, 112 Sathyendran, V. . . . . . . . . . . . . . . . . . . P-1023, 112 Sato, A. . . . . . . . . . . . . . . . . . . . . . . . . . H-550, 073 Sato, J. L. . . . . . . . . . . . . . . . . . . . . . . G3-1557, 178 Sato, M. . . . . . . . . . . . . . . . . . . . . . . . . C2-717, 088 Sattar, A. . . . . . . . . . . . . . .F-842, 099; F-1530, 177 Satyanarayana, G. . . . . . . . . . . . . . . . . . T-354, 029 Satzke, C. . . . . . . . . . . . . . . . . . . . . . . . . . 520, 065 Sauermann, R. . . . . . . . . . . . . . . . . . . . . E-783, 093 Saunders, M. . . . . . . . . . . . . . . . . . . . . F-1530, 177 Sauvage, E. . . . . . . . . . C1-459, 047; C1-1206, 156 Sauvageon, H. . . . . . . . . . . . . . . . . . . . . H-889, 103 Sauvan, V. . . . . . . . . . . . . . . . . . . . . . . . K-954, 108 Sauzullo, I. . . . . . . . . . . . . .D-740, 091; D-742, 091 Savard, R. . . . . . . . . . . . . . . . . . . . . . . . V-389, 030 Savchenko, A. . . . . . . . C1-458, 047; C1-1344, 166 Savelkoul, P.. . . . . . . . . . . C2-104, 009; G-870, 101 Savinelli, S. . . . . . . . . . . . . . . . . . . . . C2-1373, 168 Sawa, R.. . . . . . . . . . . . . . . . . . . . . . . . F-1509, 176

AUTHOR INDEX Author

Presentation Number

Author

Presentation Number

Author

Presentation Number

Sawamura, H. . . . . . . . C2-1989, 244; F-2045, 248

Schwab, F. . . . . . . . . . . . . . . . . . . . . . . K-1592, 181

Sawani, M. . . . . . . . . . . . . . . . . . . . . . C2-703, 088 Sax, H. . . . . . . . . . . . . . . K-1125, 129; K-2083, 251 Sayah-Jeanne, S. . . . . . . A-1963, 241; F-2003, 246

Schwaber, M. J. . . . . . . . .K-557, 074; K-1609, 184; . . . . . . . . . . . . . . . . . . . . . .1727, 193; 1833, 215 Schwameis, R. . . . . . . . . . . . . . . . . . . . . E-783, 093

Scaggiante, R. . . . . . . . . . . . . . . . . . . . H-1579, 180

Schwardt, O. . . . . . . . . . . . . . . . . . . . . F-2057, 249

Scaglione, E. . . . . . . . . . . . . . . . . . . . C2-1398, 169 Scala, A.. . . . . . . . . . . . . . . . . . . . . . . G3-1549, 178

Schwartz, J. A. . . . . . . . . .M-967, 111; A-1944, 240 Schwarz, S. P.. . . . . . . . .C1-670, 085; C1-679, 086; . . . . . . C1-1350, 166; 1865, 228; C2-1987, 244 Schweins, R. . . . . . . . . . . . . . . . . . . . . F-2007, 246 Schweizer, F. . . . . . . . . . . C2-135, 010; E-779, 093

Sengeløv, H. . . . . . . . . . . . . . . . . . . . . T-1072, 116

Schweizer, H. P. . . . . . . . .F-2022, 247; F-2033, 248

Senol, E. . . . . . . . . . . . . . . . . . . . . . . .M-1671, 190 Senthur Nambi, P. . . . . . . P-564, 075; P-1003, 112

Scangarella-Oman, N. . . . . D-766, 092; E-802, 094 Schaefer, E. A. . . . . . . . . . . . . . . . . . . . . V-377, 030 Schaefer, J. . . . . . . . . . . . . . . . . . . . . . C1-1969, 242 Schaffer, K. . . . . . . . . . . . . . . . . . . . . . B-1334, 165 Schaible, B. . . . . . . . . . . . . . . . . . . . . . B-1334, 165 Schaible, D. . . . . . . . . . . . . . . . . . . . . . . H-880, 102 Scharenberg, M. . . . . . . . . . . . . . . . . . F-2057, 249 Scharikow, L. . . . . . . . . . . . . . . . . . . . C2-1360, 167 Scharmen, A. . . . . . . . . . . . . . . . . . . . . . A-018, 003 Scheel, C.. . . . . . . . . . . . . . . . . . . . . . .M-1694, 190 Scheetz, M. . . . . . . . . . . .A-636, 083; B-1323, 165; . . . . . . B-1326, 165; K-1614, 184; K-1615, 184 Scheifele, D. W.. . . . . . . . . . . . . . . . . G3-1542, 178

Schweizer, M. . . . . . . . . . . . . . . . . . . . . . 1877, 231 Science, M. . . . . . . . . . . . . . . . . . . . . . . K-955, 108

Semorile, L. . . . . . . . . . . . . . . . . . . . . . F-1491, 175 Sen, L. . . . . . . . . . . . . . . . . . . . . . . . . . . B-045, 005 Senn, G. . . . . . . . . . . . . . . . . . . . . . . . K-1125, 129 Sennati, S. . . . . . . . . . . . . . . . . . . . . . . C2-700, 087 Senneville, E. . . . . . . . . . H-231, 019; L1-957, 109; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2089, 252

Seo, S. M. . . . . . . . . . C1-1341, 166; C1-1747, 197 Seo, Y. . . . . . . . . . . . . . . . . . . . . . . . . . . G-872, 101

Scott, R.. . . . . 524, 066; A-1284, 162; E-1474, 174; . . . . . . F-1494, 175; F-1495, 175; F-1493, 175; . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1662, 189 Scotto, M. . . . . . . . . . . . . . . . . . . . . . . D-1773, 201

Seoung, S. K. . . . . . . . . . . . . . . . . . . . . L1-294, 026 Seow, H. . . . . . . . . . . . . . . . . . . . . . . . .M-990, 111

Scrivo, R. . . . . . . . . . . . . . . . . . . . . . . . . D-740, 091 Scully, I. . . . . . . . . . . . . . . . . . . . . . . . . . . . 575, 077

Schellekens, J. F. . . . . . . . . . . . . . . . . . . D-183, 014 Scherrer, A. U. . . . . . . . . . . . . . . . . . . . . V-384, 030 Scheutz, F. . . . . . . . . . . . . . . . . . . . . . . C2-687, 087 Schindler, B. D. . . . . . C1-1341, 166; C1-1747, 197

Sears, P. . . . . . . . . . . . . . . . . . . . . . . . . A-1274, 162 Sears, W. . . . . . . . . . . . . . . . . . . . . . . L1-1663, 189 Seas, C. . . . . . . . . . . . . . K-900, 104; C2-1909, 237

Schindler, M. . . . . . . . . . . K-929, 105; K-2075, 250 Schipper, K. . . . . . . . . . . . . . . . . . . . . L1-1651, 187 Schlaeffer, F. . . . . . . . . . H-232, 019; L1-961, 110; . . . . . . . . . . . . . . . . . P-1022, 112; K-1610, 184 Schlamm, H. . . . . . . . .M-1225, 159; M-1229, 159; . . . . . . . . . . . . . . . . M-1683, 190; M-1709, 191 Schlecht, H. P. . . . . . . . . . . . . . . . . . . . . A-618, 082 Schlievert, P. M.. . . . . . . . . . . . . . . . . . F-1517, 176

Seber, E. . . . . . . . . . . . . . . . . . . . . . . C2-1367, 168 Seclén, E.. . . . . . . . . . . . . . . . . . . . . . . H-1576, 180

Schmidt, S. S. . . . . . . . . . . . . . . . . . . . . B-652, 084 Schmitt, B.. . . . . . . . . . . . . . . . . . . . . . D-1774, 201 Schmitt-Hoffmann, A. . . . . . . . . . . . . . F-842, 099 Schnegg, A. . . . . . . . . . . . . . . . . . . . . . . D-184, 014 Schoenen, F. J. . . . . . . . . . . . . . . . . . . . . V-370, 030 Schöni-Affolter, F. . . . . . . . . . . . . . . . . H-1566, 179 Schonning, K. . . . . . . . . . . . . . . . . . . . . B-663, 084 Schrengenberger, K.. . . . . . . . . . . . . . . . D-167, 012 Schrenzel, J. . . . . . . . . . . . . . K-560, 074; 1176, 149 Schroeder, S. . . . . . . . C1-1346, 166; C1-1347, 166 Schubel, L.. . . . . . . . . . . . . . . . . . . . . . . K-939, 106 Schubert, R.. . . . . . . . . . . . . . . . . . . . .M-1708, 191 Schuck, V. . . . . . . . . . . . . . . . . . . . . . . . A-632, 083 Schuetz, A. N. . . . . . . . . . . . . . . . . . . . . . 1182, 151 Schurtz, G. . . . . . . . . . . . . . . . . . . . . . . B-050, 005 Schutten, M. . . . . . . . . . . . . . . . . . . . . V-1080, 117

Selton-Suty, C. . . . . . . . . . . . . . . . . . . . K-939, 106

Scott, H. M. . . . . . . . . . . . . . . . . . . . . C2-710, 088

Seah, C. . . . . . . . . . . . . . . . . . . . . . . . . . E-781, 093 Seales, D. . . . . . . . . . . . . . . . . . . . . . . . D-1424, 171

Schmaltz, C. A. . . . . . . . . . . . . . . . . . . . K-257, 022 Schmidt, C. . . . . . . . . . . . . . . . . . . . . . . G-868, 101 Schmidt, S. . . . . . . . . . . . . . . . . . . . . .M-1708, 191

Sellman, B. . . . . . . . . . . F-1529, 177; B-1734, 196; . . . . . . . . . . . . . . . . . B-1736, 196; B-1737, 196

Secor, W. E.. . . . . . . . . . . . . . . . . . . . . . P-563, 075 Seddon, J.. . . . . . . . . . . . . . . . . . . . . . . A-1274, 162 Sedlacek, P. . . . . . . . . . . . . . . . . . . . . . . T-344, 029 Sedlinieks, K.. . . . . . . . . . . . . . . . . . . . K-2080, 251 Sedunary, R. . . . . . . . . . . . . . . . . . . . . T-1027, 113 Seeber, K.. . V-398, 030; P-1009, 112; D-1404, 170 Segado, A. . . . . . . . . . . . . . . . . . . . . . . . K-944, 106 Segner, R. E. . . . . . . . . . . . . . . . . . . . . . D-170, 012 Segolodi, T. M. . . . . . . . . . . . . . . . . . . H-1570, 179 Segonds, C. . . . . . . . . . . . . . . . . . . . . . . D-758, 092 Segreti, J. . . . . . . . . . . . . . . . . . . . . . . . . K-275, 024 Segura, F. . . . . . . . . . . . . . . . . . . . . . . . K-1623, 184 Segura, I. . . . . . . . . . . . . . . . . . . . . . . . H-1921, 238 Seidl, K. . . . . . . . . . . . . . . B-646, 084; K-1125, 129 Seifarth, W. . . . . . . . . . . . . . . . . . . . . . .M-335, 028 Seifert, H. . . . . . . . . . . . .A-030, 004; C1-070, 006; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1392, 169 Seitz, A. E. . . . . . . . . . . . . . . . . . . . . . .M-314, 028 Seixas, M. . . . . . . . . . . . . . . . . . . . . . C2-1383, 169 Sekaly, R. . . . . . . . . . . . . . . . . . . . . . . . . H-553, 073 Seki, L. M.. . . . . . . . . . . . . . . . . . . . . C2-1218, 157 Seki, M. . . . . . . . . . . . . . . . V-380, 030; V-400, 030 Seki, T.. . . . . . . . . . . . . . . . . . . . . . . . . . H-550, 073 Selenge, B. . . . . . . . . . . . . . . . . . . . . . . C1-068, 006

Final Program

Sepúlveda, M. J.. . . . . . . . . . . . . . . . . . H-1576, 180 Sereno, R. . . . . . . . . . . . . . . . . . . . . . . C2-713, 088 Sergent, O. . . . . . . . . . . . . . . . . . . . . . P-1007, 112 Serra, J. . . . . . . . . . . . . . . . . . . . . . . . . L2-303, 027 Serra, M. . . . . . . . . . . . . . . . . . . . . . . L1-1643, 186 Serrano-Villar, S. . . . . . . .H-217, 018; H-1567, 179 Serres, G. D. . . . . . . . . . . . . . . . . . . . . G-1047, 114 Seto, W. . . . . . . . . . . . . . . . . K-243, 021; 1085, 118 Severynse-Stevens, D. . . . . . . . . . . . . . . F-837, 098 Seville, M. . . . . . . . . . . . . . . . . . . . . . .M-1697, 191 Seville, T. M. . . . . . . . . . . . . . . . . . . . . T-1032, 113 Seward, J. F. . . . . . . . . . . . . . . . . . . . . . . . . 442, 042 Sexton, D. J.. . . . . . . . . . . . . . . . . . . . . C2-117, 009 Seybold, U. . . . . . . . . . . . . . . . . . . . . . . H-887, 103 Seydi, A. . . . . . . . . . . . . . . . . . . . . . . .M-1698, 191 Seyedmousavi, S. . . . . . . .M-989, 111; M-988, 111; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1933, 240 Sfair, S. . . . . . . . . . . . . . . . . . . . . . . . . C2-087, 008 Sferrazza, S. . . . . . . . . . . . . . . . . . . . . G3-1553, 178 Shade, C. . . . . . . . . . . . . . . . . . . . . . . . H-1916, 238 Shadiack, A. M.. . . . . . . . . F-837, 098; F-839, 098; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-840, 098 Shaefer, M. . . . . . . . . . . . .H-882, 102; H-895, 103 Shafiee, A. . . . . . . . . . . . . . . . . . . . . . . . F-810, 096 Shafran, S. D. . . . . . . . . . . . . . . . . . . . . . . 401, 033 Shah, A. P. . . . . . . . . . . . . . . . . . . . . . . T-1029, 113 Shah, D. N. . . D-158, 011; K-920, 105; K-921, 105 Shah, D. J. . . . . . . . . . . . . . . . . . . . . . . V-1075, 117 Shah, D. P. . . . . . . . . . . . . . . . . . . . . . . T-1065, 116 Shah, D.. . . . . . . . . . . . . . . . . . . . . . . . F-1528, 177 Shah, P. K. . . . . . . . . . . . . . . . . . . . . . . T-1065, 116 Shah, S. . . . . . . . . . . . . . . . . . . . . . . . . . K-904, 104 Shahani, S.. . . . . . . . . . . . . . . . . . . . . . K-1589, 181 Shaheen, B. W. . . . . . . . . . . . . . . . . . C2-1219, 157 Shahrooei, M. . . . . . . . . . . . . . . . . . . . K-2094, 252

249


Presentation Number

Author

Presentation Number

Author

Presentation Number

Shakib, S.. . . . . . . . . . . . . . . . . . . . . . . A-1272, 162

Shlaes, D.. . . . . . . . . . . . . . . . . . . . . . . . . 1148, 141

Simiele, M. . . . . . . . . . . A-1769, 200; A-1937, 240

Shalit, P.. . . . . . . . . . . . . . . . . . . . . . . . . H-879, 102 Shallcross, L. . . . . . . . . . . . . . . . . . . . L1-1645, 186

Shlykova, D. S. . . . . . . . . . . . . . . . . . . A-1967, 241 Shoham, M.. . . . . . . . . . .F-1515, 176; F-1999, 246

Simitsopoulou, M. . . . . . . . . . . . . . . . .M-1720, 191 Simjee, S. . . . . . . . . . . . . C2-705, 088; C2-709, 088

Shamblaw, D. . . . . . . . . . .H-555, 073; H-556, 073

Shoji, T. . . . . . . . . . . . . . . . . . . . . . . . . D-1429, 171

Simkins, J. . . . . . . . . . . . . . . . . . . . . . . T-1033, 113

Shang-Yi Huang . . . . . . . . . . . . . . . . .M-1669, 190

Shopsin, B. . . . . . . . . . . . . . . . . . . . . C2-1906, 237 Short, E. . . . . . . . . . . . . . . . . . . . . . . . . K-271, 024

Simner, P.. . . . . . . . . . . .C2-103, 009; M-1691, 190

Shortridge, D. . . . . . . . . . . . . . . . . . . . . E-197, 015 Shouche, Y. . . . . . . . . . . . . . . . . . . . . . C1-665, 085 Shouji, M. . . . . . . . . . . . . . . . . . . . . . C2-1353, 167

Simó, M. . . . . . . . . . . . . . . . . . . . . . . . K-1621, 184 Simões, A. S. . . . . . . . . . . . . . . . . . . . C2-1365, 167 Simoes, B. . . . . . . . . . . . . . . . . . . . . . .M-1234, 159

Shoyinka, A. . . . . . . . . . .K-912, 104; K-1597, 182; . . . . . . . . . . . . . . . .L1-1655, 188; M-1713, 191 Shrivastava, D.. . . . . . . . . . . . . . . . . . . . F-812, 096

Simon, F. . . . T-363, 029; H-886, 102; D-1778, 201 Simon, J. . . . . . . . . . . . . . . . . . . . . . . . . G-869, 101

Shani, E. . . . . . . . . . . . . . . . . . . . . . . . .M-339, 028 Shannon, S. K.. . . . . . . . . . . . . . . . . . . . D-170, 012 Shapiro, M. . . . . . . . . . . . . . . . . . . . . . K-1609, 184 Sharff, K. A. . . . . . . . . . . . . . . . . . . . . D-1432, 171 Sharland, M. . . . . . . . . . . .480, 051; G3-1559, 178; . . . . . . . . . . . . . . . . . K-1754, 199; K-1759, 199 Sharma, M. . . . . . . . . C2-1381, 169; C2-1391, 169 Sharma, R.. . . . . . . . . . . . . . . . . . . . . . K-1630, 185 Sharma, S. . . D-733, 091; F-824, 097; D-1437, 171 Sharma-Kuinkel, B. K. . . . . . . . . . . . . B-1320, 165 Shapiro, M. . . . . . . . . . . . . . . . . . . . . . K-1609, 184 Sharp, A. . . . . . . . . . . . . M-977, 111; A-1942, 240; . . . . . . A-1943, 240; A-1944, 240; A-1765, 200 Sharp, Z. . . . . . . . . . . . . . . . . . . . . . . . . D-739, 091 Shaw, E.. . . . . . . . . . . . . . . . . . . . . . . . C2-111, 009 Shaw, K.. . . . . . . . . . . . . . E-778, 093; E-1479, 174; . . . . . . . . F-1514, 176; 1864, 228; F-2017, 247; . . . . . .F-2018, 247; F-2018a, 247; F-2020, 247; . . . . . . F-2022, 247; F-2023, 247; F-2024, 247; . . . . . . . . . . . . . . . . . .F-2025, 247; F-2028, 247 Shelton, E.. . . . . . . . . . . . . . . . . . . . . . . T-369, 029 Shelton, M. . . . . . . . . . . . . . . . . . . . . . T-1037, 113 Shemes, S. . . . . . . . . . C2-1381, 169; C2-1391, 169 Shen, J. . . . . . . . . . . . . . . . . . . . . . . . C2-1987, 244 Shen, Z. . . . . . . . . . . . . . . . . . . . . . . . C2-1987, 244 Sherrill, R. G. . . . . . . . . . . . . . . . . . . . F-1510, 176 Sheth, P. M. . . . . . . . . . . . . . . . . . . . . . C2-089, 008 Shetty, N.. . . . . . . . . . . . . . . . . . . . . . . . D-160, 011 Shi, D. . . . . . . . . . . . . . . . . . . . . . . . . . . K-933, 105 Shi, L. . . . . . . . . . . . . . G3-1550, 178; V-1078, 117 Shi, Y. G. . . .A-640, 083; F-1503, 176; F-1504, 176 Shi, Y. . . . . . . . . . . . . . . A-1283, 162; B-1737, 196 Shibasaki, M.. . . . . . . . . . . . . . . . . . . . F-1509, 176 Shibayama, K. . . . . . . . D-1456, 172; C2-1904, 236 Shibue, Y. . . . . . . . . . . . . . . . . . . . . . . . B-056, 005 Shields, R. . . . . . . . . . . . . . T-346, 029; T-348, 029; . . . . . . . . . E-792, 094; E-786, 094; E-804, 094; . . . . . . .T-1031, 113; T-1037, 113; T-1069, 116; . . . . .C2-1216, 157; K-1605, 183; K-1622, 184; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1675, 190 Shigemura, N. . . . . . . . . . .T-1037, 113; T-364, 029 Shimada, J.. .E-780, 093; F-1506, 176; F-1507, 176 Shimizu, T. . . . . . . . . . . . . . . . . . . . . . F-2041, 248 Shin, G. . . . . . . . . . . . . . . . . . . . . . . . . H-1582, 180 Shin, J. . . . . . . . . . . . . . . . . . . . . . . . . . B-1298, 164 Shinabarger, D. . . . . . . . . A-008, 003; F-2065, 249; Shirazi, F.. . . . . . . . . . . . . . . . . . . . . . . .M-972, 111 Shire, N. M-1676, 190; M-1678, 190; M-1695, 190

250

Shriver, Z. H.. . . . . . . . . . . . . . . . . . . . V-1077, 117 Shu, W. . . . . . . . . . . . . . . . . . . . . . . . . F-1540, 177 Shubert, C. . . . . . . . . . . . . . . . . . . . . . . E-197, 015 Shukla, S. K. . . . . . . . . . . V-373, 030; C1-677, 086; . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1351, 166 Shulman, S. T. . . . . . . . . . . . . . . . . . . . . . . 582, 079 Shultz, J. . . . . . . . . . . . . . . . . . . . . . . . . K-274, 024 Shutt, K. A. . . . . . . . . . . . . . . . . . . . . . C2-112, 009 Siafakas, N. . . . . . . . . . . A-1939, 240; A-1940, 240 Sidhu, M. . . . . . . . . . . . . . . . . . . . . . . . D-172, 013 Sidhu, S. . . . . . . . . . . . . . . . . . . . . . . . F-1537, 177 Sidjabat, H. E. . . . . . . . . . . . . . . . . . . . C2-708, 088 Sidorenko, S. V. . . . . . . . . . . . . . . . . . C2-1385, 169 Siebert, H. . . . . . . . . . . . . . . . . . . . . . . C2-090, 008 Siegmund, C.. . . . . . . . . . . . . . . . . . . . F-2067, 249 Siegrist, C. . . . . . . . . . . . . . . . . . . . . . G3-1556, 178 Sierra, J. . . . . . . . . . . . . C2-1395, 169; D-1775, 201 Sikes, D. . . . . . . . . . . . . . . . . . . . . . . . . D-737, 091 Silbert, S. . . . . . . . . . . . . . . . . . . . . . . . D-1446, 172 Silk, B. . . . . . . . . . . . . . . . . . . . . . . . . . . . 1816, 210 Silks, L. . . . . . . . . . . . . . . . . . . . . . . . . . F-830, 098 Silva, D. N. . . . . . . . . . . . . . . . . . . . . . C1-671, 085 Silva, E. . . . . . . . . . . . . . . . . . . . . . . . . . H-889, 103 Silva, K. . . . . . . . . . . . . . . . . . . . . . . . . C2-717, 088 Silva, M. J. . . . . . . . . . . . . . . . . . . . . . . . H-878, 102 Silva, M. G. . . . . . . . . . . . . . . . . . . . . C2-1375, 168 Silva, R. M. . . . . . . . . . . . . . . . . . . . . . C2-685, 087 Silva-Costa, C. . . . . . . . . . . . . . . . . . . C2-151, 010 Silva-Sanchez, J. . . . . . . C1-067, 006; C1-069, 006 Silveira, F. . . . . . . . . . . . T-364, 029; C2-1216, 157; . . . . . . . . . . . . . . . . . .T-1031, 113; T-1037, 113 Silver, S. . . . . . . . . . . . . . . . . . . . . . . . . . H-213, 017 Silverman, J.. . . . . . . . . . . . F-843, 099; F-844, 099; . . . . . . . . . . . . . . . . . . . .F-845, 099; F-846, 099 Silvia, A. . . . . . . . . . . . . . . . . . . . . . . . A-1264, 161 SIMA-P Study Group . . . . . . . . . . . . . P-570, 075 Simenauer, A. . . . . . . . .C2-125, 010; C2-128, 010; . . . . . . . C2-134, 010; D-760, 092; D-764, 092; . . . . . . . .D-767, 092; E-1479, 174; E-778, 093; . . . . . . . F-1524, 177; F-2046, 248; F-2047, 248

September 9-12 |

Simó, G. . . . . . . . . . . . . . . . . . . . . . . . . D-166, 012

Simon, D. J. . . . . . . . . . . . . . . . . . . . . . B-1303, 164

Simoneau, E. . . . . . . . . . . . . . . . . . . . . . V-389, 030 Simpson, R. . . . . . . . . . . . . . . . . . . . . . . A-619, 082 Sims, K. . . . . . . . . . . . . . . . . . . . . . . . . A-1247, 161 Singer, L. G. . . . . . . . . . .T-1043, 113; T-1067, 116 Singh, C. . . . . . . . . . . . . . . . . . . . . . . . E-1478, 174 Singh, D. V. . . . . . . . . . . C2-715, 088; D-1437, 171 Singh, J. . . . . . . . . . . . G3-1560, 178; G3-1561, 178 Singh, K. S. . . . . . . . . . . K-278, 024; L2-2116, 255 Singh, M.. . B-656, 084; F-841, 099; C1-1969, 242 Singh, N. . . . . . . . . . . . . M-337, 028; M-1227, 159 Singh, S. . . . . . . . . . . . . . F-810, 096; F-1496, 176 Singh-Moodley, A. . . . . . . . . . . . . . . . . D-773, 092 Singhal, S. . . . . . . . . . . . . . . . . . . . . . . F-2043, 248 Singhal, T. . . . . . . . . . . . . . K-264, 023; K-904, 104 Singleton, S. F.. . . . . . . . . . . . . . . . . . . F-1535, 177 Siopi, M. . . . . . . . . . . . . A-1938, 240; A-1939, 240 Sipsas, N. . . . . . . . . . . .M-1681, 190; L2-2114, 255 SIREVA-Mexico Network . . . . . . . . C2-1356, 167 Sirijatuphat, R. . . . . . . . . . . . . . . . . . . K-1602, 183 Siripanichgon, K.. . . . . . . . . . . . . . . . . C2-712, 088 SITIP Lyme Disease Study Group, G3-1553, 178 Siu, L. . . . . . . . . . . . . . . . . . . . . . . . . . B-1321, 165 Sivagnanam, S. . . . . . . . . . . . . . . . . . .M-1680, 190 Sivaramakrishnn, H. . . . . . . . . . . . . . . . F-824, 097 Skalweit, M. J. . . . . . . . . . . . . . . . . . . . C1-073, 006 Skana, F. . . . . . . . . . . . . . . . . . . . . . . .M-1692, 190 Sklaney, M. . . . . . . . . . . . . . . . . . . . . . E-1995, 245 Sklar, P. . . . . . . . . . . . . . . . . . . . . . . . . . H-885, 102 Skory, C. . . . . . . . . . . . . . . . . . . . . . . . .M-973, 111 Skov, M. N. . . . . . . . . . . . . . . . . . . . . . D-1444, 171 Skov, R. . . . . . . . . . . . . . . . . . . . . . . . . H-1916, 238 Skultans, V. . . . . . . . . . . . . . . . . . . . . . K-2080, 251 Slain, D.. . . . . . . . . . . . . . . . . . . . . . . . . K-928, 105 Slaughter, J. . . . . . . . . . . . . . . . . . . . . . . E-197, 015 Slaughter, S.. . . . . . . . . . . . . . . . . . . . . D-1432, 171 Slavin, M. A. . . . . . . . . . M-315, 028; T-1027, 113; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1225, 159 Slee, A. M.. . . . . . . . . . . . . . . . . . . . . . F-2028, 247

AUTHOR INDEX Author

Presentation Number

Slim, J. . . . . . . . . . . . . . . . . . . . . . . . . . . K-902, 104 Slinger, R. . . . . . . . . . . . . . . . . . . . . . . E-1480, 174 Sliwinski, J. . . . . . . . . . . . . . . . . . . . . . E-1472, 174 Slobod, K. . . . . . . . . . . . . . . . . . . . . . . G-1751, 198 Small, C. B. . . . . . . . . . . . . . . . . . . . . . . H-895, 103 Smani, Y. . . . . . . . . . . . . . . . . . . . . . . . B-1329, 165 Smart, J. I. . . . . . . . . . . . . . . . . . . . . . . .M-331, 028

Author

Presentation Number

Son, T. . . . . . . . . . . . . . . . . . . . . . . . . . . T-361, 029 Sønderholm, M. . . . . . . . . . . . . . . . . . T-1072, 116 Song, C.. . . . . . . . . . . . . . . . . . . . . . . . K-1595, 182

Author

Presentation Number

Spencer, J. . . . . . . . . . . . . . . . . . . . . . . C1-465, 047 Spicer, J. O. . . . . . . . . . . . . . . . . . . . . . G-1752, 198 Spiess, B. . . . . . . . . . . . . M-335, 028; M-1704, 191 Spigelman, M. . . . . . . . . . . . . . . . . . . . . . . 537, 069

Song, J. H. . . . . . . . . . C2-1366, 167; C2-1899, 236 Song, J. . . . . . . . . . . . . . K-1588, 181; K-1587, 181

Spikermann, J. . . . . . . . . . . . . . . . . . . . . F-842, 099

Song, J. H. . . . . . . . . . . . . . . . . . . . . . . C2-137, 010

SPILF . . . . . . . . . . . . . . . . . . . . . . . . . . K-237, 020

Song, J. . . . . H-230, 019; G-872, 101; K-916, 104; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2072, 249

SMART Study Group in China . . . . . C2-702, 087 Smeesters, P. R. . . . . . . . B-1312, 165; B-1313, 165

Song, K. . . . . . . . . . . . . . . . . . . . . . . . . . K-908, 104

Spiro, D. . . . . . . . . . . . . . . . . . . . . . . . . H-214, 018 Spoering, A.. . . . . . . . . . . . . . . . . . . . . . F-829, 098 Spoulou, V. . . . . . . . . . . . . . . . . . . . . G3-1551, 178

Smelhaus, V. . . . . . . . . . . . . . . . . . . . . . T-344, 029

Song, W. . . . . . . . . . . . . . . . . . . . . . . . . K-933, 105 Song, Y. L.. . . . . . . . . . . . . . . . . . . . . . T-1039, 113

Sprenger, C. R. . . . . . . . . . . . . . . . . . . . A-623, 082

Smith, A. . . . . . . . . . . . . . . . . . . . . . . . B-1314, 165 Smith, C. P. . . . . . . . . . . . . . . . . . . . . . F-1518, 176 Smith, C. . . . . . . . . . . . . . A-018, 003; A-1290, 163 Smith, D. W. . . . . . . . . . . . . . . . . . . . . F-1520, 177 Smith, D. K. . . . . . . . . . . . . . . . . . . . . H-1570, 179 Smith, D. M. . . . . . . . . . . . . . . . . . . . . . G-869, 101 Smith, K. Y. . . . . . . . . . . . . . . . . . . . . . . H-883, 102 Smith, M. . . . . . . . . . . . . . . . . . . . . . . . D-773, 092 Smith, M. I.. . . . . . . . . . . . . . . . . . . . . . . . 506, 062 Smith, P. F. . . . . . . . . . . . . . . . . . . . . . A-1244, 161 Smith, R. M. . . . . . . . . . . . . . . . . . . . .M-1677, 190 Smith, T. . . . . . . . . . . . . . . . . . . . . . . C2-1384, 169 Smith, T. C. . . . . . . . . . . . . . . . . . . . . . . . 1191, 153 Smith, T. J.. . . . . . . . . . . . . . . . . . . . . . L1-300, 026 Smollan, G. . . . . . . . . . . . . . . . . . . . . . . K-557, 074 Smolyakov, R. . . . . . . . . . H-232, 019; P-1022, 112 Smyth, D. S. . . . . . . . . . . . . . . . . . . . C2-1906, 237 Snelders, E. . . . . . . . . . . . . . . . . . . . . . .M-319, 028 Snydman, D. R. . . . . . . . . .K-471, 048; E-807, 095; . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-1025, 113 Sobel, J. D.. . . . . . . . . . . . . 1162, 146; L2-306, 027 Soborg, C. . . . . . . . . . . . . . . . . . . . . . . H-1919, 238 Sobrino, B.. . . . . . . . . . . . . . . . . . . . . L1-2102, 254 Soentjens, P. H. . . . . . . . . . . . . . . . . . . P-1014, 112 Soerensen, P. . . . . . . . . . . . . . . . . . . . L1-1652, 187 Søgaard, O. S. . . . . . . . . . . . . . . . . . . L1-1650, 187 Soge, O. O. . . . . . . . . C1-1348, 166; C2-1898, 236 Sohnle, P. . . . . . . . . . . . . . . . . . . . . . . . . D-153, 011 Sokol, B. . . . . . . . . . . . . . . . . . . . . . . . F-2015, 246 Sola, C. . . . . . . . . . . . . . . . . . . . . . . . C2-1910, 237 Solé, M. . . . . . . . . . . . . . C1-075, 006; C2-696, 087 Soler Bistué, A. . . . . . . . . . . . . . . . . . . F-1539, 177 Solis, N. . . . . . . . . . . . . . . . . . . . . . . . .M-1056, 115 Sollazzi, L. . . . . . . . . . . . . . . . . . . . . . . T-1040, 113 Soloff, R. . . . . . . . . . . . . . . . . . . . . . . . . G-871, 101 Solon, E. . . . . . . . . . . . . . . . . . . . . . . . A-1949, 241 Solórzano-Sánchez, F. . . . . . . . . . . . . C2-1356, 167 Soltani, B. . . . . . . . . . . . . . . . . . . . . . L1-1656, 188 Somily, A. M. . . . . . . . . . . . . . . . . . . C2-1372, 168 Son, B. . . . . . . . . . . . . . . . . . . . . . . . . . F-2060, 249

Song, Y. . . . . . . . . . . . . . . . H-230, 019; K-916, 104 Sönmez, M. . . . . . . . . . . . . . . . . . . . . . D-1405, 170 Sönmez Yıldırım, S.. . . . . . . . . . . . . . . D-1405, 170 Sonthisombat, P. . . . . . . . . . . . . . . . . . A-1279, 162 Soo, V. W. . . . . . . . . . . . . . . . . . . . . . . . . 1784, 203 Sood, S. . . . . . . . . . . . . . . . . . . . . . . . C2-1982, 243 Soon, R. L. . . . . . . . . . . . .A-016, 003; A-024, 004; . . . . . . . . E-201, 015; A-605, 082; A-1762, 200 Sorbello, A. . . . . . . . . . . . . . . . . . . . . . . T-342, 029 Sorde, R. . . . . . . . . . . . . . . . . . . . . . . . K-1758, 199 Sordelli, N. . . . . . . . . . . . . . . . . . . . . G3-1552, 178 Sordillo, E.. . . . . . . . . . . . . . . . . . . . . . C2-112, 009 Sørensen, H. T. . . . . . . . . . . . . . . . . . . . G-876, 101 Sørensen, S. S. . . . . . . . . . . . . . . . . . . . T-1072, 116 Soriano, A.. . . . . . . . . . . . . . . . . . . . . . K-1633, 185 Soriano, V. . . . . . . . . . . . . . . 482, 052; H-1576, 180 Sorlí, L. . . . . . . . . . . . . . . K-258, 022; K-1624, 184 Sorrell, T. C. . . . . . . . . . . . . . . . . . . . . .M-313, 028 Sørum, H. . . . . . . . . . . . . . . . . . . . . . . B-1330, 165 Sotier, M.. . . . . . . . . . . . . . . . . . . . . . . . B-660, 084 Soto-Noguerón, A. . . . . . . . . . . . . . . C2-1356, 167 Sotorrio, V. . . . . . . . . . . . . . . . . . . . . . L1-289, 026 Soubani, A. O. . . . . . . . . . . . . . . . . . . . . K-902, 104 Soubih, E. . . . . . . . . . . . . . . . . . . . . . . F-1514, 176 Soulama-Mouze, C. . . . . . . . . . . . . . . F-2067, 249 Souli, M. . . . . E-799, 094; K-245, 021; K-246, 021 Souza, A. G. . . . . . . . . . . . . . . . . . . . C2-1376, 169 Souza, C. A. . . . . . . . . . . . . . . . . . . . .M-1234, 159 Sowedan, A.. . . . . . . . . . . . . . . . . . . . . F-2064, 249 Soy, D. . . . . . .A-610, 082; B-648, 084; K-945, 106; . . . . . . . . . . . . . . . . . K-1122, 129; E-1465, 173 Spagnuolo, P. . . . . . . . . V-1078, 117; G3-1550, 178 Spalla, M. . . . . . . . . . . . . . . . . . . . . . . C2-094, 008 SPANC Research Team . . . . . . . . . . . L2-301, 027 Spaulding, A. R. . . . . . . . . . . . . . . . . . F-1517, 176 Specklin, J. . . . . . . . . . . . . . . . . . . . . . C1-1346, 166 Spector, S. A. . . . . . . . . . . . . . . . . . . . . H-1917, 238 Spellberg, B. . . . . . . . . . . . . . . . . . . . . . . 1795, 206 Spelman, D. . . . . . . . . . . . . . . . . . . . . . . K-558, 074 Spencer, D. . . . . . . . . . . . . . . . . . . . . . . H-881, 102

Final Program

Spreen, W. . . . . . . . . . . . . . . . . . . . . . . A-1249, 161 Spudich, S. S. . . . . . . . . . . . . . . . . . . . . . . 444, 043 Squassi, I.. . . . . . . . . . . . . . . . . . . . . . G3-1552, 178 Squires, K. . . . . . . . . . . . . . . . . . . . . . . . H-882, 102 Sripa, B. . . . . . . . . . . . . . . . . . . . . . . . . . P-999, 112 Sriprakash, K. . . . . . . . . . . . . . . . . . . . B-1312, 165 Sriskandan, S. . . . . . . . . . . . . . . . . . . . B-1311, 165 Srivastava, M. . . . . . . . . . . . . . . . . . . . . V-373, 030 Stachowiak, J. . . . . . . . . . . . . . . . . . . . . K-934, 105 Stahl, J. . P-566, 075; C2-1374, 168; L1-1649, 187 Stapert, L. . . . . . . . . . . . . . . . . . . . . . . F-2019, 247 Staphylococcus Study Group. . . . . . . . C2-130, 010 Stappers, M. H. . . . . . . . . . . . . . . . . . . . B-044, 005 Starke, J. R. . . . . . . . . . . . . . . . . . . . . . . . 1798, 207 Starner, T. . . . . . . . . . . . . . . . . . . . . . . B-1322, 165 Stary, J.. . . . . . . . . . . . . . . . . . . . . . . . . . T-344, 029 Starzyk, K. A. . . . . . . . . . . . . . . . . . . . G-1749, 198 STCS. . . . . . . . . . . . . . . . . . . . . . . . . . . T-343, 029 Ste-Croix, H.. . . . . . . . . . . . . . . . . . . .M-1711, 191 Steckbeck, J. D. . . . . . . . .F-1490, 175; F-2061, 249 Steckelberg, J. M. . . . . . . . . . . . . . . . . . B-652, 084 Stecken, L.. . . . . . . . . . . . . . . . . . . . . . . D-164, 012 Steed, M. E. . A-600, 082; A-603, 082; A-627, 083 Steen, J. A. . . . . . . . . . . C1-062, 006; C1-1743, 197 Steenbergen, J. . . . . . . . . . . . . . . . . . . L1-2105, 254 Steer, A. . . . . . . . . . . . . . . . . 583, 079; B-1312, 165 Steering Comittee . . . . . . . . . . . . . . . . . P-566, 075 Stefanik, D. . . . . . . . . . . . . . . . . . . . . C2-1392, 169 Stein, D. S. . . . . . . . . . . A-1281, 162; A-1282, 162 Stein, D. . . . . . . . . . . . . . . . . . . . . . . . H-1581, 180 Stein, G. E. . . . . . . . . . . . . . . . . . . . . . . A-018, 003 Steinhouse, K. . . . . . . . . . . . . . . . . . . . . V-396, 030 Steinke, L. M. . . . . . . . . . . . . . . . . . . . . K-909, 104 Stepan, G. . . . . . . . . . . . . . . . . . . . . . . . H-552, 073 Stephens, J. T. . . . . . . . . .F-1524, 177; F-1528, 177 Stephens, J. . . . . . . . . . . . . . . . . . . . . . . K-239, 020 Sternik, L. . . . . . . . . . . . . . . . . . . . . . . L1-962, 110 Stevens, D. A. . . . . . . . . . G-875, 101; M-982, 111; . . . . . . . . . . . . . . . . . . . .P-1013, 112; 1852, 224 Stevens, V. . . . . . . . . . . . . . A-615, 082; A-617, 082

251


Presentation Number

Stewardson, A. . . . . . . . . K-560, 074; K-2083, 251 Stewart, J. . . . . . . . . . . . . . . . . . . . . . C2-1912, 237 Stewart, K.. . . . . . . . . . . . . . . . . . . . . . . H-884, 102 Stibich, M.. . . . . . . . . . . . . . . . . . . . . . . K-934, 105 Stidham, M. . . . . . . . . . F-2017, 247; F-2018, 247; F-2018a, 247 Stilwell, M. G. . . . . . . . . . . . . . . . . . . . C2-136, 010 Stoch, S. A. . . . . . . . . . . . . . . . . . . . . . . A-009, 003 Stock, A. H.. . . . . . . . . . . D-770, 092; F-1520, 177 Stock, P. . . . . . . . . . . . . . . . . . . . . . . . . . . . 443, 043 Stoelben, S. . . . . . . . . . . . . T-356, 029; V-391, 030 Stogios, P. J. . . . . . . . . . C1-458, 047; C1-1344, 166 Stojanov, M. . . . . . . . . B-1316, 165; C1-1746, 197 Stokes, N. . . . . . . . . . . . . . . . . . . . . . . F-2016, 247 Stoltz, R. . . . . . . . . . . . . . . . . . . . . . . . A-1255, 161 Stover, C. . . . . . . . . . . . . B-1734, 196; B-1736, 196 Stover, C. K. . . . . . . . . . . . . . . . . . . . . B-1737, 196 Stover, K. . . . . . . . . . . . . . M-991, 111; M-968, 111 Stover, K. . . . . . . . . . . . . . . . . . . . . . . . F-1529, 177 Straub, R. J. . . . . . . . . . . . . . . . . . . . . . A-1275, 162 Strauss, G. E.. . . . . . . . . . . . . . . . . . . . .M-981, 111 Stray, K. . . . . . . . . . . . . . . . . . . . . . . . . . H-892, 103 Streinu-Cercel, A. . . . . . . . . . . . . . . . . D-1776, 201 Streit, J. M. . . . . . . . . . . . . E-186, 015; E-199, 015; . . . . . . . . . . . . . . . . . E-1463, 173; E-1467, 173 Strohmaier, K. . . . . . . . . . . . . . . . . . . . . H-885, 102 Strommer, S. . . . . . . . . . . . . . . . . . . . . . E-783, 093 Strugeon, E.. . . . . . . . . . . . . . . . . . . . . C1-666, 085 Strukova, E. N. . . . . . . . . . . . . . . . . . . A-1967, 241 Struminger, B. . . . . . . . . . . . . . . . . . . .M-1677, 190 Strutton, D. . . . . . . . . . . . . . . . . . . . . . . K-259, 023 Stryjewski, M. . . . . . . C2-1396, 169; C2-1397, 169 Stubbings, W. . . . . . . . . . . . . . . . . . . . . F-842, 099 Su, P. . . . . . . . . . . . . . . . . . . . . . . . . . . F-2072, 249 Su, Y. . . . . . . . . . . . . . . . . .G-867, 100; H-218, 018 Suarez, J. . . . . . . . . . . . . M-337, 028; M-1227, 159 Suárez, M. . . . . . . . . . . . . . . . . . . . . . .M-1688, 190 Suaya, J. A. . . . . . . . . . . . . . . . . . . . . . . G-862, 100 Subich, D. . . . . . . . . . . . . . . . . . . . . . . A-1293, 163 Subramoney, V. . . . . . . . . . . . . . . . . . . A-1244, 161 Such, K. A. . . . . . . . . . . . . . . . . . . . . . .M-981, 111 Suckling, C. . . . . . . . . . . . . . . . . . . . . . F-1530, 177 Sudan, A. . . . . . . . . . . . . . . . . . . . . . . . A-1943, 240 Suefuji, K. . . . . . . . . . . . C1-680, 086; F-1540, 177 Suematsu, H. . . . . . . . . C2-1989, 244; F-2045, 248 Suetens, C.. . . . . . . . . . . . . . . .1789, 204; 1804, 208 Sugimoto, K. . . . . . . . . . . . . . . . . . . . . F-2049, 248 Sugita, T. . . . . . . . . . . . . . . . . . . . . . . . .M-328, 028 Sugumar, M. . . . . . . . . . . . . . . . . . . . . . E-196, 015 Suh, B. . . . . . . . . . . . . . . . . . . . . . . . . L1-1656, 188 Suh, Y. . . . . . . . . . . . . . . . . . . . . . . . . . K-2079, 250

252

Author

Presentation Number

Sukasem, C.. . . . . . . . . . . . . . . . . . . . . . H-894, 103 Suleman, M. . . . . . . . . . . . . . . . . . . . . P-1007, 112 Sullivan, D. C. . . . . . . . . . . V-374, 030; P-994, 112; . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1425, 171 Sumillera, M.. . . . . . . . . . . . . . . . . . . . . D-169, 012 Sun, C.. . . . . . . . . . . . . . . . . . . . . . . . . F-1526, 177 Sun, D. . . . . . . F-848, 099; F-849, 099; F-850, 099 Sun, H. . . .K-266, 023; A-1281, 162; A-1282, 162; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1607, 183 Sun, Q. . . . . . . . . . . . . . . . . . . . . . . . . . K-933, 105

Author

Presentation Number

Syriou, V. . . . . . . . . . . . . . . . . . . . . . . L2-2114, 255 Syrogiannopoulos, G. . . . . . . . . . . . . G3-1551, 178 Szeszs, M. W. . . . . . . . . . . . . . . . . . . . .M-311, 028 Szpunar, S. . . . . . . . . . . . . . . . . . . . . . . . K-923, 105 Sztark, F. . . . . . . . . . . . . . . . . . . . . . . . . D-164, 012 Szucs, T. D. . . . . . . . . . . . . . . . . . . . . . . G-860, 100 Szymonifka, M. . . . . . . . . . . . . . . . . . . F-1496, 176

T

Sundaragiri, P. R. . . . . . . . . . . . . . . . . . . K-272, 024

Tabata, H. . . . . . . . . . . . . . . . . . . . . . . D-1461, 172

Sundareshan, V. . . . . . . . . . . . . . . . . . . E-1485, 174 Sunder, S. . . . . . . . . . . . . D-176, 013; D-177, 013; . . . . . . . . . . . . . . . . L1-963, 110; L1-1639, 186

Tabone, T. . . . . . . . . . . . . . . . . . . . . . . L2-301, 027 Tabrizi, S. N. . . . . . . . . . . . . . . . . . . . . L2-301, 027

Sundsmo, J. S. . . . . . . . . . . . . . . . . . . . . B-053, 005 Sunesara, I. . . . . . . . . . . . . . . . . . . . . . . D-185, 014 Sung, H. . . .T-366, 029; V-1074, 117; V-1239, 160 Sungkanuparph, S. . . . . .H-894, 103; H-1565, 179 Sunkara, G. . . . . . . . . . . A-1281, 162; A-1282, 162 Suominen, H. . . . . . . . . . . . . . . . . . . . .M-315, 028 Supparatpinyo, K. . . . . . . . . . . . . . . . . D-1406, 170 Supple, M. E. . . . . . . . . . . . . . . . . . . . . A-622, 082 Sureshkumar, D. . . . . . . . P-565, 075; P-1004, 112 Surgers, L. . . . . . . . . . . . . . . . . . . . . . . . D-154, 011 Surin, R. . . . . . . . . . . . . . . . . . . . . . . . . A-637, 083 Surmont, F. . . . . . . . . . . . . . . . . . . . . L1-1641, 186 Surska, M. . . . . . . . . . . . . . . . . . . . . . . K-2080, 251 Sutcliffe, J. A. . . . . . . . . .C1-675, 086; E-777, 093; . . . . . . . . . . . . . . . . . .F-1525, 177; F-1526, 177 Sutherland, C. J. . . . . . . . . . . . . . . . . . . . 1099, 124 Suthienkul, O. . . . . . . . . . . . . . . . . . . . C2-712, 088 Suwantarat, N.. . . . . . . . . . . . . . . . . . . C2-686, 087 Suzuki, E. . . . . . . . . . . . . . . . . . . . . . . F-2041, 248 Suzuki, S.. . . . . . . . . . . D-1456, 172; C2-1904, 236 Suzuki, Y. . . . . . . . . . . . . C2-712, 088; F-825, 097; . . . . . . . . . . . . . . . C2-1368, 168; C2-1369, 168 Svanas, G. W. . . . . . . . . . . . . . . . . . . . D-1414, 170 Svanborg, C. M. . . . . . . . . . . . . . . . . . . . . 508, 063 Svensson, E.. . . . . . . . . . . . . . . . . . . . . A-1256, 161 Sverdlov, O. . . . . . . . . . . . . . . . . . . . . . A-1247, 161 Swamydas, M. . . . . . . . . . . . . . . . . . . .M-1055, 115 Swanson, R. . . . . . . . . . . . . . . . . . . . . .M-1229, 159 Swayne, R. L. . . . . . . . . . . . . . . . . . . . D-1451, 172 Sweeney, M. T. . . . . . . . C1-670, 085; F-2034, 248 Swiatlo, E. . . . . . . . . . . . . . . . . . . . . . . . D-185, 014 Swietochowska, E. . . . . . . . . . . . . . . . . F-1533, 177 Swift, M. . . . . . . . . . . . .A-1265, 161; A-1761, 200; . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-1993, 245 Swigart, W. E. . . . . . . . . . . . . . . . . . . . L1-286, 025 Swyers, L. . . . . . . . . . . . . . . . . . . . . . . D-1417, 170 Sykes, L. . . . . . . . . . . . . E-1463, 173; E-1467, 173 Symmons, D. . . . . . . . . . . . . . . . . . . . . . . 1092, 122

September 9-12 |

Taccone, F. S.. . . . . . . . . . . . . . . . . . . . . A-637, 083 Tack, K. J. . . . . . . . . . . . . . . . . . . . . . L1-1660, 189 Tagarao, M. A.. . . . . . . . . . . . . . . . . . . D-1433, 171 Tagliaferri, E.. . . . . . . . . . . . . . . . . . . . . E-796, 094 Taguebue, J. . . . . . . . . . . . . . . . . . . . . G3-1541, 178 Tahir, N. . . . . . . . . . . . . . E-195, 015; E-1476, 174 Tailor, F.. . . . . . . . . . . . . . C2-103, 009; E-194, 015 Taishi, T. . . . . . . . . . . . . . . . . . . . . . . . . H-550, 073 Tajima, T.. . . . . . . . . . . . . . . . . . . . . . C2-1977, 243 Takagi, E. H. . . . . . . . . . . . . . . . . . . . . . G-861, 100 Takahashi, Y. . . . . . . . . . . .A-607, 082; A-608, 082; . . . . . . F-1509, 176; K-1594, 182; K-1627, 185; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1687, 190 Takakura, S. . . . . . . . . . . K-949, 107; M-1231, 159; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1599, 182 Takano, M. . . . . . . . . . . . . . . . . . . . . . . H-890, 103 Takano, T. . . . . . . . . . . . . . . . . . . . . . C1-1340, 166 Takasaki, W. . . . . . . . . . . . . . . . . . . . . F-2042, 248 Takeda, S. . . . F-817, 096; F-818, 096; F-819, 096; . . . . . . . . . . . . . . . . . . . .F-820, 096; F-821, 096 Takemoto, S. . . . . . . . . . . . K-247, 022; K-261, 023 Takemura, H.. . . . . . . . . . . . . . . . . . . . . E-780, 093 Takesue, Y.. . . . . . . . . . . . .A-607, 082; A-608, 082; . . . . . M-1231, 159; K-1594, 182; K-1627, 185; . . . . . . . . . . . . . . . . M-1687, 190; F-2044, 248 Takubo, S. . . . . . . . . . . . . . . . . . . . . . . K-1627, 185 Talbot, G. H. . . . . . . . . . . . . . . . . . . . . A-1952, 241 Talreja, D. . . . . . . . . . . . . . . . . . . . . . . C2-703, 088 Tam, V. H. . . . . . . . . . . . . .A-025, 004; A-028, 004; . . . . . . . . . . . A-029, 004; 503, 061; A-614, 082; . . . . . . . . . K-896, 104; 1096, 123; D-1450, 172 Tamaru, A.. . . . . . . . . . . . . . . . . . . . . C2-1369, 168 Tamayo-Legorreta, E. M. . . . . . . . . . . C1-069, 006 Tambyah, P. A. . . . . . . . . . . . . . . . . . . . . 1137, 135 Tan, C. M. . . . . . . . . . . . . . . . . . . . . . . F-1496, 176 Tan, D. H. . . . . . . . . . . . . . . . . . . . . . . H-1920, 238 Tan, M. . . . . . . . . . . . . . . . . . . . . . . . . . D-163, 011 Tan, S. . . . . . . . . . . . . . . . . . . . . . . . . . . T-354, 029 Tan, T. Y. . . . E-195, 015; E-791, 094; E-1476, 174

AUTHOR INDEX Author

Presentation Number

Author

Presentation Number

Author

Presentation Number

Thienphrapa, W. . . . . . . .F-1514, 176; F-1999, 246 Thigpen, M. C. . . . . . . . . . . . . . . . . . . H-1570, 179

Tan, T. T. . . . . . . . . . . . . . . E-195, 015; E-791, 094

Tector, A. J. . . . . . . . . . . . . . . . . . . . . . T-1029, 113

Tan, Y. . . . . . . . . . . . . . . . . . . . . . . . . . .M-990, 111 Tanaka, A. . . . . . . . . . . . . . . . . . . . . . . . V-380, 030 Tanaka, S. K. . . . . . . . . . . . . . . . . . . . . A-1281, 162

Tedone, N. . . . . . . . . . . . . . . . . . . . . . . . T-360, 029 Tegtmeier, B. . . . . . . . . . . . T-349, 029; T-350, 029; . . . . . . . . . . . . . . . . . . .T-351, 029; T-1039, 113

Tanedjeu, K. S. . . . . . . . . . . . . . . . . . . P-1010, 112

Teh, B. W. . . . . . . . . . . . . . . . . . . . . . . T-1027, 113

Tang, W. . . . . . . . . . . . . . . . . . . . . . . . H-1581, 180 Tang, W. W. . . . . . . . . . . . . . . . . . . . . . H-553, 073

Teixeira, A. L. . . . . . . . . . . . . . . . . . . . D-1403, 170 Teixeira, F. L.. . . . . . . . . . . . . . . . . . . . C1-671, 085

Tang, Y. . . . . . . . . . . . . . . . . . . . . . . . . D-1442, 171 Tängdén, T. . . . . . . . . . . . . . . . . . . . . . . E-800, 094

Teixeira, G. . . . . . . . . . . . . . . . . . . . . . T-1044, 113

Thomas, D. . . . . . . . . . . F-2006, 246; F-2007, 246; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2008, 246

Teixidó, M. . . . . . . . . . . . . . . . . . . . . . F-2068, 249 Tektonidou, M. . . . . . . . . . . . . . . . . . L2-2114, 255

Thomas, D. W. . . . . . . . F-2062, 249; F-2063, 249; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2064, 249

Telles, J. . . . . . . . . . . . . . . . . . . . . . . . . . D-172, 013

Thomas, H. R.. . . . . . . . . . . . . . . . . . .M-1060, 115 Thomas, J. . . . . . . . . . . . . F-828, 097; M-1062, 115

Tangkoskul, T. . . . . . . . . . . . . . . . . . . . .M-976, 111 Tankovic, J. . . . . . . . . . . . . . . . . . . . . . . D-173, 013 Tanner, B. . . . . . . . . . . . . . . . . . . . . . . . K-934, 105

Temme, L. . . . . . . . . . . . . . . . . . . . . . . . H-881, 102 Templeton, D. J. . . . . . . . . . . . . . . . . . L2-301, 027

Thom, K. A. . . . . . . . . . . . . . . . . . . . . C2-095, 008 Thomaides-Brears, H. . . . . . . . . . . . . . F-2016, 247 Thomas, B. M. . . . . . . . . . . . . . . . . . . . F-824, 097 Thomas, C. . . . . . . . . . . . . . . . . . . . . . . K-260, 023

Tansek, R. . . . . . . . . . . . . . K-262, 023; K-902, 104 Tantalo, L. C. . . . . . . . . . . . . . . . . . . . B-1301, 164 Tanudra, M. A. . . . . . . . . . . . . . . . . . . . A-632, 083

Templeton, K. . . . . . . . . . . . . . . . . . . . . K-927, 105

Thomas, S.. . . . . . . . . . . . . . . . . . . . . . G-1752, 198 Thomas, T. A. . . . . . . . . . . . . . . . . . . . . A-026, 004

Ten Kate, M. T. . . . . . . . . B-058, 005; A-1268, 161 Tenero, D. . . . . . . . . . . . . . . . . . . . . . . A-1272, 162

Thomas, V. . . . . . . . . . . C2-705, 088; C2-709, 088 Thomas, Y. . . . . . . . . . . . . . . . . . . . . . . K-956, 108

Tanzi, E. . . . . . . . . . . . . . . . . . . . . . . . L2-304, 027 Taori, S. . . . . . . . . . . . . . . . . . . . . . . . . . K-927, 105 Tapiero, B. . . . . . . . . . . . . . . . . . . . . . G3-1554, 178

Teng, C. B. . . . . . . . . . . . . . . . . . . . . . . K-899, 104 Teng, L. J. . . . . . . . . . C1-1339, 166; C1-1340, 166 Tenover, F. C. . . . . . . . . . . . . . . . . . . . . K-469, 048

Thompson, D. . . . . . . . . . . . . . . . . . . .M-1233, 159 Thompson, E. . . . . . . . . . . . . . . . . . . . P-1023, 112 Thompson, J. . . . . . . . . . . . . . . . . . . . . . F-810, 096

Taraboulos-Klein, T. . . . . . . . . . . . . . . .M-339, 028

Teo, J.. . . . . . . . . . . . . . . K-1595, 182; K-1613, 184

Taracila, M. . . . . . . . . . C1-463, 047; C1-1209, 156 Taracila, M. A.. . . . . . . . . . . . . . . . . . . C1-590, 081 Taramasso, L.. . . . . . . . . . . . . . . . . . . . .M-317, 028 Tarazi, Z. . . . . . . . . . . . . . . F-848, 099; F-851, 099; . . . . . . . . . . . . . . . . . . . .F-852, 099; F-858, 099

Teófilo, E. . . . . . . . . . . . . . . . . . . . . . . . H-878, 102 Teperman, L. W. . . . . . . . . . . . . . . . . . . K-273, 024

Thomson, K. . . . . . . . . . . . . . . . . . . . . . . 1173, 149 Thomson, K. S. . . . . . . . . . . . . . . . . . . . E-789, 094 Thongyen, S. . . . . . . . . . . . . . . . . . . . . . H-894, 103 Thorn, M. . . . . . . . . . . . . . . . . . . . . . . A-1958, 241 Thorne, C. . . . . . . . . . . . . . . . . . . . . . . . . 1150, 142

Tanner, C. . . . . . . . . . . . . . . . . . . . . . . . D-736, 091

Tari, L. W. . . . . . . . . . . . F-2017, 247; F-2018, 247; . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2018a, 247 Tarquinio, K. M. . . . . . . . . . . . . . . . . . . E-790, 094 Tascini, C. . . . . . . . . . . . . . . . . . . . . . . . E-796, 094 Taseera, K. . . . . . . . . . . . . . . . . . . . . . .M-1699, 191 Tashiro, T. . . . . . . . . . . . . . . . . . . . . . . . V-380, 030 Tasina, E.. . . . . . . . . . . . . . . . . . . . . . .M-1720, 191 Tasneen, R. . . . . . . . . . . . . . . . . . . . . . . F-836, 098 Tate, H. . . . . . . . . . . . . . . . . . . . . . . . . C2-714, 088 Tateda, K. . . . . . . . . . . . .B-056, 005; C1-077, 006; . . . . . . .L1-296, 026; K-918, 105; D-1438, 171; . . . . . . . . . . . . . . . . . D-1459, 172; F-2040, 248 Tato, M.. . . . . . . . . . . . . .E-205, 016; C1-681, 086; . . . . . . . . . . . . . . . . . . C1-682, 086; D-753, 092 Tattevin, P. . . . . . . . . . . . . . . . . . . . . . . . B-645, 084 Tavakkol, A. . . . . . . . . . . . . . . . . . . . . A-1946, 240 Tavares, P. . . . . . . . . . . . . . . . . . . . . . . .M-320, 028 Tawa, P. . . . . . . . . . . . . . . . . . . . . . . . . . H-551, 073 Tayade, A. . . . . . . . . . . . . P-565, 075; P-1004, 112; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1618, 184 Taylor, C. T. . . . . . . . . . . . . . . . . . . . . . B-1334, 165 Taylor, J. J. . . . . . . . . . . . . . . . . . . . . . . . D-756, 092 Taylor, S. . . . . . . . . . . . . . . . . . . . . . . . P-1023, 112 Tebas, P. . . . . H-556, 073; 1153, 143; H-1581, 180; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1780, 202 Tebini, A.. . . . . . . . . . . . . . . . . . . . . . . T-1035, 113 Teboul, J. . . . . . . . . . . . . . . . . . . . . . . L1-1224, 158

Teppler, H.. . . . . . . . . . . . . . . . . . . . . . . H-885, 102 Terada, Y.. . . . . . . . . . . . . . . . . . . . . . . D-1402, 170 Terakubo, S.. . . . . . . . . . . . . . . . . . . . . . E-780, 093 Terrades, R. . . . . . . . . . . . . . . . . . . . . . K-1624, 184 Terranova, L. . . . . . . . . . . . . . . . . . . . G3-1553, 178

Thorne, G. M. . . . . . . . . . . . . . . . . . . L1-2105, 254

Terrault, N. . . . . . . . . . . . . . . . . . . . . . . . . 584, 080 Tersen, I. . . . . . . . . . . . . . . . . . . . . . . . . K-234, 020 Teruya, K. . . . . . . . . . . . . . . . . . . . . . . . H-224, 019 Tessier, C. . . . . . . . . . . . . . . . . . . . . . . K-2087, 252 Tessier, P. R.. . . . . . . . . . . . . . . . . . . . . F-2021, 247 Tessitore, L. . . . . . . . . . . . . . . . . . . . . . T-1040, 113 Testro, A. . . . . . . . . . . . . . . . . . . . . . . . . T-369, 029 Tetiurka, B. . . . . . . . . . . . . . . . . . . . . . G-1749, 198 Teunis, P. . . . . . . . . . . . . . . . . . . . . . . . . D-183, 014 Texereau, M. . . . . . . . . . . . . . . . . . . . . L1-963, 110 Thamlikitkul, V. . . . . . . . E-209, 016; K-1602, 183 Thang, P. . . . . . . . . . . . . . . . . . . . . . . .M-1677, 190 Tharpe, W. . . . . . . . . . . . . . . . . . . . . . . T-357, 029 The Canadian Antimicrobial Resistance Alliance (CARA) . . . . . . . . . . . . . . . . . . . . . . E-194, 015 The Design Study Group . . . . . . . . . . . E-803, 094 The Fungiscope ECMM/ISHAM Working Group, . . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-338, 028 The HUG Infection Control Team . . . . K-914, 104 Theiler, G. . . . . . . . . . . . . . . . . . . . . . . . V-395, 030

Thuot, A.. . . . . . . . . . . . . . . . . . . . . . . . V-389, 030 Thursky, K. . . . . . . . . . . . M-315, 028; T-1027, 113 Thuy, C.. . . . . . . . . . . . . . . . . . . . . . . .M-1677, 190

Thein, T. . . . . . . . . . . . . . . P-567, 075; P-569, 075 Theodoridou, M. . . . . . . . . . . . . . . . . G3-1543, 178 Theusch, J. . . . . . . . . . . . . . . . . . . . . . . K-2085, 252 Thévenin, M.. . . . . . . . . . . . . . . . . . . . K-2088, 252

Final Program

Thornton, C. R.. . . . . . . . . . . . . . . . . .M-1682, 190 Thumamo, B. P.. . . . . . . . . . . . . . . . . . E-1994, 245

Thwaites, G. . . . . . . . . . . . . . . 499, 060; 1811, 209 Thys, Y. . . . . . . . . . . . . . . . . . . . . . . . . . B-044, 005 Tian, Y. . . . . . . . . . . . . . . . . . . . . . . . . . H-552, 073 Tibbetts, R. J. . . . . . . . . . . . . . . . . . . . D-1416, 170 Ticchioni, M.. . . . . . . . . . . . . . . . . . . . . B-052, 005 Tickler, I. A. . . . . . . . . . . . . . . . . . . . . . K-469, 048 Tiengrim, S. . . . . . . . . . . .E-209, 016; M-976, 111 Tierno, P. M. . . . . . . . . . . . . . . . . . . . . . K-273, 024 Tijet, N. . C2-089, 008; C2-090, 008; C2-1214, 157 Timke, M. . . . . . . . . . . . . . . . . . . . . . . D-1777, 201 Timmer, W. . . . . . . . . . . . . . . . . . . . . . A-1273, 162 Timmins, G. . . . . . . . . . . . D-739, 091; F-830, 098 Timmler, B. . . . . . . . . . . . . . . . . . . . . . . V-391, 030 Timsit, J. F. . . . P-568, 075; 574, 076; K-1757, 199 Tinelli, M. . . . . . . . . . . . . . . . . . . . . . L2-304, 027 Ting, L. . . . . . . . . . . . . . A-1281, 162; A-1282, 162 Tinturier, F. . . . . . . . . . . . . . . . . . . . . .M-1698, 191 Tipton, M.. . . . . . . . . . . . . . . . . . . . . . . H-229, 019 Tisdel, N. L. . . . . . . . . . . . . . . . . . . . . . D-158, 011 Tishler, D. S. . . . . . . . . . . . . . . . . . . . . A-1287, 163 Tisi, G. . . . . . . . . . . . . . . . . . . . . . . . . L2-304, 027

253


Presentation Number

Tiwari, R. . . . . . . . . . . . . . . . . . . . . . . F-2034, 248 Tjoeng, C. . . . . . . . . . . . . . . . . . . . . . . . V-381, 030 Tkaczyk, C. . . . . . . . . . . B-1736, 196; B-1737, 196 Tkhilaishvili, T. . . . . . . . . . . . . . . . . . . . K-251, 022 Toba, S. . . . . . . . . . . . . . M-324, 028; M-1712, 191 Tobudic, S.. . . . . . . . . . . . . . . . . . . . . . E-1471, 174 Todhunter, S. . . . . . . . . . . . B-662, 084; K-924, 105 Tokimatsu, I. . . . . . . . . . . . . . . . . . . . . .M-324, 028 Tokuda, K. . . . . . . . . . . C2-114, 009; C2-1901, 236 Tokui, T. . . . . . . . . . . . . . . . . . . . . . . . F-2041, 248 Toledano, R. . . . . . . . . . . . . . . . . . . . . . H-232, 019 Toledo, P. . . . . . . . . . . . . . . . . . . . . . . . . K-913, 104 Toleman, M. A. . . . . . . . C1-064, 006; C1-592, 081

Author

Presentation Number

Traczewski, M. M.. . . . . . E-188, 015; D-768, 092; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-771, 092 Tragiannidis, A. . . . . . . . . . . . . . . . . . G3-1547, 178 Traglia, G. . . . . . . . . . . . C1-074, 006; D-1455, 172 Trampuz, A.. . . . . . . . . . . D-168, 012; K-250, 022; . . . . . K-251, 022; C1-1342, 166; D-1436, 171; . . . . . . . .M-1719, 191; 1840, 218; F-2011, 246; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2073, 250 Tramsen, L. . . . . . . . . . . . . . . . . . . . . .M-1708, 191

Tsuji, B. T. . . . . . . . . . . . . .A-016, 003; A-024, 004; . . . . . . . . . A-031, 004; E-201, 015;A-605, 082; . . . . . . . . . . . . . . . . . . E-785, 094; A-1762, 200 Tsuji, M. . . . . . . . . . . . . . A-019, 003; F-1507, 176

Tsukamoto, T. . . . . . . . . . . . . . . . . . . . . K-915, 104

Tran, T. T. . . . . . . . . . . . . . . . . . . . . . C1-1345, 166 Trang, M.. . . . . . . . . . . . . . . . . . . . . . . . A-012, 003

Tremblay, C. L. . . . . . . . . . . . . . . . . . . H-1571, 180 Trevillyan, J.. . . . . . . . . . . . . . . . . . . . . . T-369, 029

Trautner, B. W. . . . . . . . . . . . . . . . . . . . . . 545, 071 Treanor, J. J. . . . . . . . . . .G-1048, 114; G-1053, 114 Tremblay, C. . . . . . . . . . . . . . . . . . . . . . D-751, 092

Tomishima, M. . . . . . . . . . .F-818, 096; F-820, 096

Trigoso, C. . . . . . . . . . . . . . . . . . . . . . C1-1205, 156 Trikic, M. . . . . . . . . . . . . . . . . . . . . . . K-1633, 185

Tomizuka, K. . . . . . . . . . . . . . . . . . . . . . G-871, 101 Tong, X.. . . . . . . . . . . . . A-1245, 161; V-1080, 117 Topham, D. . . . . . . . . . . . . . . . . . . . . . G-1048, 114

Trindade, W. . . . . . . . . . . . . . . . . . . . . T-1044, 113 Tripathi, S.. . . . . . . . . . . . . . . . . . . . . .M-1061, 115 Trivedi, A. . . . . . . . . . . . . . . . . . . . . . . A-1267, 161

Topp, E. . . . . . . . . . . . . . . . . . . . . . . . C2-1986, 244 Toran, J. . . . . . . . . . . . . . . . . . . . . . . . . . E-202, 015 Torelli, G. . . . . . . . . . . . . . . . . . . . . . . . V-393, 030

Trivedi, I. . . . . . . . . . . . . . . . . . . . . . . . . K-926, 105

254

Tsuchiya, K. . . . . . . . . . . . . . . . . . . . . . . H-890, 103 Tsuchiya, Y. . . . . . . . . . . . . . . . . . . . . . F-2042, 248

Tran, M. . . . . . . . . . . . . . . . . . . . . . . . . A-018, 003 Tran, T. . . . . . . . . . . . . . . . . . . . . . . . . F-1531, 177

Tomasz, A.. . . . . . . . . . . . . . . . . . . . . . . . 1881, 232 Tomatis, P. E.. . . . . . . . . . . . . . . . . . . . C1-461, 047 Tomayko, J. . . . . . . . . . . . . . . . . . . . . . A-1272, 162

Torresi, J. . . . . . . . . . . . . . . . . . . . . . . . . T-369, 029 Tortajada, M. . . . . . . . . . . . . . . . . . . . G3-1551, 178 Tórtola, M. T. . . . . . . . . . . . . . . . . . . . K-1616, 184 Tosini, W. . . . . . . . . . . . . . . . . . . . . . . . V-375, 030 Tossonian, H. . . . . . . . . . . V-371, 030; H-884, 102 Totet, A. . . . . . . . . . . . . . . . . . . . . . . . .M-333, 028 Totrov, M. . . . . . . . . . . . . . . . . . . . . . . . F-848, 099 Totsuka, K. . . . . . . . . . . . . . . . . . . . . . .M-326, 028 Totty, H. R. . . . . . . . . . . . . . . . . . . . . . . D-162, 011 Touger-Decker, R. . . . . . . . . . . . . . . . . L1-300, 026 Tovilo, K. . . . . . . . . . . . . . . . . . . . . . . . . V-398, 030 Townsend, R.. . . . . . . . . . . . . . . . . . . . A-1936, 240 Townsend, S. M. . . . . . . . . . . . . . . . . . F-1518, 176 Toyama, K. . . . . . . . . . . . . . . . . . . . . . F-2041, 248 Toyama, M. . . . . . . . . . . . . . . . . . . . . C2-1989, 244 Toyoda, Y. . . . . . . . . . . . . .T-1037, 113; T-364, 029

Tsuchida, T. . . . . . . . . . . . .A-607, 082; A-608, 082; . . . . . . . . . . . . . . . . .K-1627, 185; M-1687, 190

Tsujimoto, K. . . . . . . . . . . . . . . . . . . . . . F-825, 097 Tsukada, K. . . . . . . . . . . . .H-224, 019; H-888, 103

Traore, O. . . . . . . . . . . . . . . . . . . . . . . K-2098, 252

Torre-Cisneros, J. . . . . . . . . . . . . . . . . . T-340, 029 Torres, E. . . . . . . . . . . . . . . . . . . . . . . . C2-707, 088 Torres, V. J. . . . . . . . . . . . . . . . . . . . . C2-1906, 237

Presentation Number

Tran, D. . . . . . . . . . . . . . . . . . . . . . . . . . K-955, 108

Tolmasky, M. . . . . . . . . . . . . . . . . . . . . F-1539, 177 Tomas, M. K-559, 074; C1-672, 085; C2-1902, 236 Tomaselli, S. G. . . . . . . . . .A-628, 083; A-629, 083; . . . . . . . . . . . . . . . . . . . A-631, 083; A-642, 083

Torelli, R.. . . . . . . . . . . . . . . . . . . . . . . . F-814, 096 Tornos, P. . . . . . . . . . . . . . . . . . . . . . . . . K-937, 106 Torok, M. E. . . . . . . . . . L1-287, 025; L1-288, 025 Toronto Invasive Bacterial Diseases Network, . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1363, 167

Author

Trojani, C. . . . . . . . . . . . . . . . . . . . . . . . B-052, 005 Troncoso, F. . . . . . . . . . . . . . . . . . . . . C1-1206, 156 Trottier, B. . . . . . . . . . . . . . . . . . . . . . . H-1571, 180 Trouillet, J. . . . . . . . . . . . . . . . . . . . . . L1-1224, 158 Trouillet, S. . . . . . . . . . . B-1317, 165; B-1319, 165 Truitt, B. . . . . . . . . . . . . . . . . . . . . . . . F-1515, 176 Truong, L. . . . . . . . . . . . . . . . . . . . . . . . F-827, 097 Truong, L. X. . . . . . . . . . . . . . . . . . . . .M-1677, 190 Trustman, N. . . . . . . . . . . . . . . . . . . . . . K-241, 020 Truu, J.. . . . . . . . . . . . . . . . . . . . . . . . . L2-310, 027 Trzoss, M. . . . . . . . . . . . F-2017, 247; F-2018, 247; . . . . . . . . . . . . . . . . . F-2018a, 247; F-2024, 247 Tsai, H. Y. . . . . . . . . . . . . . . . . . . . . . .M-1669, 190 Tsai, M. . . . . . . . . . . . . . .H-1578, 180; H-221, 019 Tsai, S. . . . . . . . . . . . . . . . . . . . . . . . . . B-1307, 164 Tsai, Y. . . . . . . . . . . . . . . . . . . . . . . . . . B-1321, 165 Tsakris, A. . . . . . . . . . . . . . . . . . . . . . . B-1300, 164 Tsang, R. . . . . . . . . . . . . . . . . . . . . . . G3-1542, 178 Tsao, S. . . . . . . . . . . . . . . . . . . . . . . . C2-1388, 169 Tsapepas, D. . . . . . . . . . .T-1034, 113; T-1036, 113 Tse, B. Y. . . . . . . . . . . . . . . . . . . . . . . . C2-081, 007 Tsen, H. . . . . . . . . . . . . . . . . . . . . . . . . C2-698, 087 Tsimiklis, C. . . . . . . . . . . . . . . . . . . . . . D-751, 092 Tsiodras, S. . . . . . . . . . . K-280, 024; C2-1401, 169 Tsivkovski, R. . . . . . . . . . . F-848, 099; F-849, 099; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-852, 099

September 9-12 |

Tubach, F. . . . . . . . . . . . . . .P-568, 075; P-570, 075 Tubau, F. . . . . K-254, 022; B-647, 084; B-658, 084; . . . . . C1-683, 086; A-1280, 162; C2-1395, 169 Tucker, S. . . . . . . . . . . . . . . . . . . . . . . . . F-828, 097 Tucker, S. P. . . . . . . . . . . . . . . . . . . . . . F-2016, 247 Tuduri, E. . . . . . . . . . . . . . . . . . . . . . . . D-746, 092 Tulkens, P. M. . . . . . . . . . .A-596, 082; A-597, 082; . . . . . . . A-598, 082; A-599, 082; A-1278, 162; . . . . . . . . .A-1291, 163; 1860, 227; F-2029, 247 Tulliano, G. . . . . . . . . . . . . . . . . . . . . . . K-273, 024 Tulumba, S. . . . . . . . . . . . . . . . . . . . . . D-1442, 171 Tumietto, F. . . . . . . . . . . . . . . . . . . . . . K-1619, 184 Tuohy, M. J. . . . . . . . . . . . .D-735, 091; D-771, 092 Tuon, F. F. . . . . . . . . . . . .C2-087, 008; K-913, 104; . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2113, 255 Tupps, M. . . . . . . . . . . . . . . . . . . . . . . T-1068, 116 Turano, H. G. . . . . . . . . . E-801, 094; F-2004, 246 Turenne, C. Y. . . . . . . . . . . . . . . . . . . . . . 1857, 226 Turlej-Rogacka, A. . . . . . . . . . . . . . . . C2-107, 009 Turner, C. . . . . . . . . . . . . . . . . . . . . . . B-1311, 165 Turner, S. J. . . . . . . . . . . .A-605, 082; M-1671, 190 Turteltaub, K. W.. . . . . . . . . . . . . . . . . F-2027, 247 Tverdek, F. P. . . . . . . . . . . . . . . . . . . . .M-1705, 191 Ty, P. . . . . . . . . . . . . . . . . . . . . . . . . . . . K-932, 105 Tyagi, S. . . . . . . . . . . . . . . . . . . . . . . . . B-1296, 164 Tyring, S. K. . . . . . . . . . . . . . . . . . . . . . V-397, 030 Tyrrell, L.. . . . . . . . . . . . . . . . . . . . . . . . . 1896, 235 Tyski, S. . . . . . . . . . . . . . .F-1533, 177; F-1996, 246 Tyson, K. . . . . . . . . . . . . . . . . . . . . . . . B-1738, 196 Tzanakaki, G. . . . . . . . . . . . . . . . . . . G3-1543, 178 Tzuman, O. . . . . . . . . . . . . . . . . . . . . . . E-787, 094

U Ubukata, K. . . . . . . . .C2-1353, 167; C2-1354, 167; . . C2-1977, 243; C2-1990, 244; C2-1991, 244 Uchida, S. . . . . . . . . . . . . . F-817, 096; F-818, 096; . . . . . . . . . . F-819, 096; F-820, 096; F-821, 096 Uchino, M. . . . . . . . . . . . . . . . . . . . . . K-1594, 182 Uçkay, I.. . . . .K-249, 022; K-929, 105; K-253, 022; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2075, 250 Ueda, T. . . . .A-607, 082; A-608, 082; M-1687, 190

AUTHOR INDEX Author

Presentation Number

Ueng-Arporn, N.. . . . . . . . .P-998, 112; P-999, 112 Ueno, T. . . . . . . . . . . . . . . . . . . . . . . . . D-1461, 172 Uhl, J. R. . . . . . . . . . . . . . . . . . . . . . . .M-1691, 190 UK Childhood Meningitis Study Group, . . . . . . . . . . . . . . . . . . . . . . . . . . . G3-1544, 178

Author

Presentation Number

Valery, A. . . . . . . . . . . . . . . . . . . . . . . L1-1639, 186 Valesini, G. . . . . . . . . . . . . . . . . . . . . . . D-740, 091 Valette, M. . . . . . . . . . . . . . . . . . . . . . . K-2089, 252 Valhidate Study Group . . . . . . . . . . . . L2-304, 027

Author

Presentation Number

Van Praet, S. . . . . . . . . . . . . . . . . . . . . D-1413, 170 Van Soolingen, D. . . . . . . . . . . . . . . . . A-1268, 161 Van Wart, S. A. . . . . . . .A-1244, 161; A-1961, 241; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1962, 241

Vallé, M. . . . . . . . . . . . . C2-705, 088; C2-709, 088 Vallejo, A. . . . . . . . . . . . . H-222, 019; D-743, 091; . . . . . . . . . . . . . . . . . . . . . . . . . . . . H-1567, 179

Vandenberg, O. . . . . . . . . . . . . . . . . . . D-1413, 170

Vallejo, M. E.. . . . . . . . . D-747, 092; L2-2108, 255 Vallejo, N. . . . . . . . . . . . . . . . . . . . . . . . K-938, 106

Vander, K. . . . . . . . . . . . . . . . . . . . . . . . V-398, 030

Umejiburu, U. . . . . . . . . . . . . . . . . . . . C2-121, 009 Ummels, L. . . . . . . . . . . . . . . . . . . . . . . K-244, 021

Vallier, B. C. . . . . . . . . . . . . . . . . . . . . C1-467, 047

Vandevoorde, C. . . . . . . . . . . . . . . . . . . A-621, 082 Vandewalle, B. . . . . . . . . . . . . . . . . . . . . H-878, 102

Umoh, N. O. . . . . . . . . . . . . . . . . . . . . E-1994, 245

Valsamakis, A. . . . . . . . . . . . .429, 039; T-1070, 116 Valverde, A. . . . . . . . . . . . . . . . . . . . . . . D-753, 092

Ullmann, A. J. . . . . . . . . . . . . . . . . . . . . . 1161, 146 Ullum, H. . . . . . . . . . . . . . . . . . . . . . . . B-055, 005 Ulrika, F. . . . . . . . . . . . . . . . . . . . . . . . .M-974, 111 Umeh, O.. . . . . . . . . . . . . . . . . . . . . . . . A-641, 083

Umulisa, N. . . . . . . . . . . . . . . . . . . . . . D-1421, 170 Unal, G. . . . . . . . . . . . . . . . . . . . . . . . . . H-886, 102 Underwood, M. . . . . . . . . . . . . . . . . . . . H-550, 073 Uoyama, S.. . . . . . . . . . . .F-2035, 248; F-2043, 248 Upadhyay, D. J. . . . . . . . . . . . . . . . . . . F-2043, 248 Updike, C. A. . . . . . . . . . . . . . . . . . . . . E-804, 094 Upputuri, V.. . . . . . . . . . . . . . . . . . . . . K-1589, 181 Upton, A.. . . . . . . . . . . . . . . . . . . . . . . A-1259, 161 Upton, A. M. . . . . . . . . . . . . . 438, 041; F-834, 098; . . . . . . . . . F-835, 098; F-836, 098; F-837, 098; . . . . . . . . . . . . . . . . . . . .F-839, 098; F-840, 098 Upton, M. . . . . . . . . . . . . . . . . . . . . . . F-1487, 175 Urban, C. . . . . . . . . . . . . . . A-014, 003; A-015, 003 Urbancic, K.. . . . . . . . . . . . . . . . . . . . . . T-369, 029 Urueña, A. . . . . . . . . . . . .G-874, 101; P-1015, 112; . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1016, 112 Usonis, V.. . . . . . . . . . . . . . . . . . . . . . G3-1551, 178 Utili, R. . . . . . . . . . . . . . . . . . . . . . . . . K-2095, 252 Utley, S. S. . L1-282, 025; D-770, 092; F-1520, 177 Utrarachkij, F. . . . . . . . . . . . . . . . . . . . C2-712, 088 Uwimana, I. M. . . . . . . . . . . . . . . . . . . D-1421, 170 Uzun Sümer, A. . . . . . . . . . . . . . . . . . . D-1405, 170

V Vabret, A.. . . . . . . . . . . . . . . . . . . . . . . . D-178, 013 Vachée, A. . . . . . . . . . . . . . . . . . . . . . . L1-957, 109 Vager, D. L. . . . . . . . . . . .M-986, 111; M-987, 111; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1716, 191 Vaid, N. . . . . . . . . . . . . . . . . . . . . . . . C2-1380, 169 Vaillant, V. . . . . . . . . . . . . . . . . . . . . . L1-1649, 187 Vaishnav, R. . . . . . . . . . . . . . . . . . . . . . . K-242, 020 Vakalis, N. . . . . . . . . . . . . . . . . . . . . . . . E-799, 094 Valachis, A. . . . . . . . . . . .B-043, 005; M-1696, 191 Valdes, J. . . . . . . . . . . . . . . . . . . . . . . . F-1518, 176 Vale Silva, L. . . . . . . . . . . . . . . . . . . . . . F-814, 096 Valentin, T. . . . . . . . . . . . . V-395, 030; V-398, 030; . . . . . . . . . . . . . . . . . P-1009, 112; D-1404, 170 Valerio, M. . . . . . . . . . . . . .K-944, 106; K-950, 107; . . . . . T-1026, 113; M-1232, 159; M-1684, 190

Valour, F. . . . . . . . . . . . . . . . . . . . . . . . B-1319, 165

Van Bambeke, F. . . . . . . . .A-596, 082; A-597, 082; . . . . . . . . . . A-598, 082; A-599, 082; 1143, 139; . . . . . . A-1278, 162; A-1291, 163; F-2029, 247 Van Benthem, B. . . . . . . . . K-472, 048; K-930, 105 Van Broeck, J. . . . . . . . . . . . . . . . . . . . . D-156, 011 Van Caeseele, P. . . . . . . . . . . . . . . . . . . C2-085, 008 Van Damme, P. . . . . . . . . . . . . . . . . . L1-1641, 186 Van de Beek, D. . . . . . L1-1222, 158; L1-1223, 158; . . . . . . . . . . . . . . . L1-1648, 187; L1-1651, 187

Vandenbroucke-Grauls, C. M. . . . . . . C2-104, 009 Vandenesch, F. . . . . . . . . B-1317, 165; B-1319, 165 Vandevoorde, A. . . . . . . . . . . . . . . . . . A-1260, 161

Vandewoude, K.. . . . . . . . . . . . . . . . . . . K-951, 107 VanHecker, J. . . . . . . . . . A-1932, 240; D-1431, 171 Vanier, G.. . . . . . . . . . . . . . . . . . . . . . . F-2023, 247 Vanjak, D. . . . . . . . . . . . . . . . . . . . . . L2-2109, 255 VanNiewenhze, M. . . . . . . . . . . . . . . C1-1969, 242 VanSchooneveld, T. C.. . . . . . . . . . . . . . K-922, 105 VanScoy, B. . . A-011, 003; A-041, 004; A-042, 004 Vanstone, G. L. . . . . . . . . . . . . . . . . . . C2-081, 007 Vargas, H. . . . . . . . . . . . . . . . . . . . . . L2-2108, 255 Vargas-Shiraishi, O.. . G3-1560, 178; G3-1561, 178

Van den Akker, F. . . . . . . . . . . . . . . . . C1-463, 047 Van den Berg, S. . . . . . . . . . . . . . . . . . . B-058, 005 Van der Ende, A. . . . . L1-1222, 158; L1-1648, 187; . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1651, 187

Varkey, R. . . . . . . . . . . . . . . . . . . . . . . F-1529, 177 Varon, A. . . . . . . . . . . . . . . . . . . . . . . .M-1690, 190 Varon, E. . . . . . . . . . . . . . H-219, 019; G-864, 100; . . . . . . . . . . . . . . . . C2-1359, 167; G-1049, 114 Varona-Bobadilla, H. J. . . . . . . . . . . . . C2-113, 009 Vasaikar, S. D. . . . . . . . . . . . . . . . . . . . C2-101, 009

Van der Graaf, P. H. . . . . . . . . . . . . . .A-1261, 161; . . . . . . . . . . . . . . . . . A-1262, 161; A-1263, 161

Vasicek, E. M. . . . . . . . . . . . . . . . . . . . .M-971, 111 Vasoo, S. . . . . . . . . . . . . . . . . . . . . . . L2-2116, 255

Van der Ley, P. . . . . . . . . . . . . . . . . . . L1-1651, 187 Van der Linden, M. . . . . . . . . . . . . . . . . G-863, 100 Van der Velden, W. J.. . . . . . . . . . . . . . A-1928, 240 Van Duin, D. . . . . . . . . . . . . . . . . . . . . C2-692, 087 Van Dyk, D. . . . . . . . . . . . . . . . . . . . . F-1537, 177 Van Eldere, J. . . . . . . . . . . . . . . . . . . . . K-2094, 252 Van Esbroeck, M. . . . . . . . . . . . . . . . . P-1014, 112 Van Grunderbeeck, N.. . . . . . . . . . . . . . A-638, 083 Van Hal, S. J. . . . . . . . . C1-062, 006; C1-1743, 197 Van Heeswijk, R. . . . . . .A-1258, 161; A-1259, 161; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1260, 161

Vaudaux, C. . . . . . . . . . . . . . . . . . . . . . . K-560, 074 Vaudry, W. . . . . . . . . . . . . . . . . . . . . . G3-1542, 178

Van de Vegt, D. . . . . . . . . . . . . . . . . . . . K-244, 021 Van Delden, C. . . . . . . . . T-343, 029; B-1333, 165

Van Herck, K. . . . . . . . . . . . . . . . . . . L1-1641, 186 Van Iersel, M. P. . . . . . . A-1934, 240; A-1935, 240 Van Ingen, J. . . . . . . . . . . . . . . . . . . . . . . 1180, 150 Van Keulen, M. . . . . . . . . . . . . . . . . . . C2-104, 009 Van Laethem, V. . . . . . . . . . . . . . . . . . T-1028, 113 Van Laethem, Y. . . . . . . . . . . . . . . . . L1-1641, 186 Van Lunzen, J. . . . . . . . . . . . . . . . . . . . . H-556, 073 Van Marm, S. . . . . . . . . . . . . . . . . . . . F-1516, 176 Van Melderen, L.. . . . . . . . . . . . . . . . . B-1312, 165 Van Mil, C. . . E-190, 015; E-198, 015; E-803, 094 Van Petersen, A. S. . . . . . . . . . . . . . . . L1-965, 110

Final Program

Vay, C. . . . . . . . . . . . . . . C1-074, 006; D-1455, 172 Vázquez, G. J. . . . . . . . . . . . . . . . . . . . . E-789, 094 Vazquez, J. A. . . . . . . . . .M-986, 111; M-987, 111; . . . . . E-1466, 173; K-1629, 185; L1-1638, 186; . . . . L1-1653, 187; M-1713, 191; M-1716, 191 Vazquez, L. . . . . . . . . . . . . . . . . . . . . . C1-067, 006 Vázquez, M. . . . . . . . . . . . . . . . . . . . . C1-067, 006 Vehreschild, J. . . . . . . . .M-338, 028; M-1230, 159; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1706, 191 Vehreschild, M. J. . . . . .M-338, 028; M-1230, 159; . . . . . . . . . . . . . . . . M-1234, 159; M-1706, 191 Velasco, C. . . . . . . . . . . . . . . . . . . . . . L1-1658, 188 Velasco, E. . . . . . . . . . . . . . . . . . . . . . .M-1234, 159 Velazquez-Meza, M. . . . . . . . . . . . . . C2-1356, 167 Velegraki, A. . . . . . . . . . . . . . . . . . . . .M-1720, 191 Veliz, O.. . . C2-084, 008; D-746, 092; F-1491, 175 Vellozzi, C. . . . . . . . . . . . . . . . . . . . . . G-1052, 114 Velmahos, V. . . . . . . . . . . . . . . . . . . . . K-1923, 239 Veloso, T. R.. . . . . . . . . . . . . . . . . . . . . . B-046, 005 Vema-Varapu, C. . . . . . . . . . . . . . . . . . A-1247, 161 Vente, A. . . . . . . . . . . . . A-1959, 241; A-1960, 241

255


Presentation Number

Author

Presentation Number

Author

Presentation Number

Venter, A.. . . . . . . . . . . . . . . . . . . . . . . A-1264, 161

Viney, J. . . . . . . . . . . . . . . . . . . . . . . . . B-1311, 165

Wagner, G. . . . . . . . . . . . . . . . . . . . . . T-1064, 116

Venugopal, A. A. . . . . . . . . . . . . . . . . . . K-923, 105 Venugopalan, V. . . . . . . . . . . . . . . . . . . . K-241, 020

Vingsbo Lundberg, C. . . . . . . . . . . . . . A-1965, 241 Vinje, J. . . . . . . . . . . . . . . . . . . . . . . . . P-1021, 112

Wagner, J. . . .A-009, 003; A-010, 003; V-398, 030; . . . . . . P-1009, 112; D-1404, 170; K-1615, 184 Wagner, M. . . . . . . . . . . . . . . . . . . . . . . K-473, 048

Vera-Cabrera, L. . . . . . . . . . . . . . . . . C2-1357, 167

Vinnard, C. . . . . . . . . . . . . . . . . . . . . . . D-744, 091

Verbrugh, H. A.. . . . . . . . . . . . . . . . . . . B-058, 005

Viola, G. M. . . . . . . . . . . . . . . . . . . . . . K-252, 022

Verdaguer, R. . . . . . . . . . . . . . . . . . . . L1-2102, 254 Verdijk, R. M. . . . . . . . . . . . . . . . . . . . . B-058, 005

Virgilio, F. . . . . . . . . . . . . . . . . . . . . . . . G-874, 101 Virmaux, M. . . . . . . . . . . . . . . . . . . . . .M-333, 028

Verduin, K. . . . . . . . . . . . . . . . . . . . . . .M-334, 028 Vergidis, P. . . . . . . . . . . . . . . . . . . . . . . . B-652, 084

Vironneau, P. . . . . . . . . . . . . . . . . . . . .M-1686, 190 Viscidi, R. . . . . . . . . . . . . . . . . . . . . . . . T-354, 029

Vergison, A. . . . . . . . . . . . . . . . 439, 042; 1159, 145

Viscoli, C. . . . . . . . . . . . . . . . . . . . . . . .M-317, 028

Verhaegen, J. . . . . . . . . . . . . . . . . . . . L1-1641, 186 Verhoeven, P. O. . . . . . . . . . . . . . . . . . . D-178, 013

Vishwanathan, K. . . . . . . . . . . . . . . . . . A-632, 083 Viswananthan, R. . . . . . . . . . . . . . . . . F-1515, 176

Vermeiren, C. . . . . . . . . . . . . . . . . . . C2-1214, 157

Viswanathan, K. . . . . . . . . . . . . . . . . . V-1077, 117

Vernardaki, A. . . . . . . . . . . . . . . . . . . G3-1543, 178 Vernet, G. . . . . . . . . . . . . . . . . . . . . . . . D-172, 013 Versporten, A. . . . . . . . . . . . . . . . . . . G3-1559, 178

Vitali, L. . . . . . . . . . . . . . . . . . . . . . . . C2-086, 008 Viu, D.. . . . . . . . . . . . . . . . . . . . . . . . . L2-303, 027 Vivas, M. . . . . . . . . . . . . . . B-647, 084; B-658, 084

Versteeg, D. . . . . . . . . . . . . . . . . . . . . . .M-319, 028 Verweij, P. E. . . . . . . . . . . M-319, 028; E-782, 093; . . . . . . .M-988, 111; M-989, 111; A-1933, 240; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1938, 240 Vesga, O. . . . . . . . . . . . . A-1945, 240; A-1968, 241

Vivier-Darrigol, M. . . . . . . . . . . . . . . . . P-996, 112 Vizzotti, C. . . . . . . . . . . .G-874, 101; P-1015, 112; . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1016, 112 Vlachou, A. . . . . . . . . . . . . . . . . . . . . L2-2114, 255

Veuthey, M. . . . . . . . . . . . . K-250, 022; K-251, 022 Veverka, M. M. . . . . . . . . . . . . . . . . . G3-1558, 178

Vogelaers, D. . . . . . . . . . . . . . . . . . . . . . K-951, 107 Vogler, A. J. . . . . . . . . . . . . . . . . . . . . . L1-964, 110 Voirol, P. . . . . . . . . . . . . . . . . . . . . . . . K-2088, 252

Viale, P. . . . . . . . . . . . . . . . . . . . . . . . . K-1619, 184 Viana, P. O. . . . . . . . . . . . . . . . . . . . . G3-1557, 178 Viani, R. M. . . . . . . . . . . . . . . . . . . . . H-1917, 238 Vianna, R. M. . . . . . . . . . . . . . . . . . . . T-1029, 113 Viasus, D. . . . . . . . . . . . .D-180, 013; L1-293, 026; . . . . . . . . . . . . . . . . . L1-295, 026; L1-298, 026 Vibhakar, S. . . . . . . . . . . . . . . . . . . . . . . H-883, 102 Vidal, B. . . . . . . . . . . . . . . . . . . . . . . . . K-234, 020 Vidyalakshmi, P. . . . . . . . . P-564, 075; P-565, 075; . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1004, 112 Viget, N. . . . . . . . . . . . . . . . . . . . . . . . . H-231, 019 Vignaud, J. . . . . . . . . . . . . . . . . . . . . . . D-1408, 170 Vikram, H. . . . . . . . . . . T-1032, 113; M-1697, 191 Vila, A. J. . . . . . . . . . . . . . . . . . . . . . . . C1-461, 047 Vila, J. . . . .C1-075, 006; E-205, 016; C1-681, 086; . . . . . . .C1-682, 086; C2-696, 087; K-931, 105; . . . . . .B-1327, 165; B-1329, 165; D-1775, 201; . . . . . . . . . . . . . . . . C2-1900, 236; F-2068, 249 Vila-Farrés, X. . . . . . . . . . . . . . . . . . . . F-2068, 249 Vilacosta, I. . . . . . . . . . . . . . . . . . . . . . . K-938, 106 Vilchez, R. . . . . . . . . . . . . .T-355, 029; T-1070, 116 Villa, A. . . . . . . . . . . . . . . . . . . . . . . . . T-1026, 113 Villareal, V. A. . . . . . . . . . . . . . . . . . . . . V-377, 030 Villegas, M. V. . . . . . . . .C2-092, 008; C1-590, 081; . . . . . . . C2-694, 087; D-747, 092; K-903, 104; . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2108, 255 Villers, D. . . . . . . . . . . . . . . . . . . . . . L1-1224, 158 Vincent, W. . . . . . . . . . . . . . . . . . . . . . . K-241, 020 Vindel, A. . . . . . . . . . . . . . . . . . . . . . . D-1415, 170

256

Vlake, A. W. . . . . . . . . . . . . . . . . . . . . L1-965, 110

Voit, S. . . . . . . . . . . . . . . . . . . . . . . . . . K-1586, 181 Volkow, P. . . . . . . . . . . . . . . . . . . . . . . C1-067, 006 Von Eiff, C. . . . . . . . . . . . . . . . . . . . . . E-1483, 174 Von Kries, R. . . . . . . . . . . . . . . . . . . . . . G-863, 100 Von Sonnenburg, F. . . . . . . . . . . . . . . . . . 1825, 211 Voss, A. . . . . . . . 485, 054; K-244, 021; E-803, 094 Vossier, L. . . . . . . . . . . . . . . . . . . . . . . F-1488, 175 Vouillamoz, J.. . . . . . . . . . . B-046, 005; B-659, 084 Vu, T. . . . . . . . . . . . . . . . . . . . . . . . . . . B-1312, 165 Vu-Cantero, D. . . . . . . . . . . . . . . . . . . . T-343, 029 Vugia, D. J. . . . . . . . . . . . . . . . . . . . . . . . 1728, 194 Vuichard, D. . . . . . . . . . . . . . . . . . . . . H-1566, 179 Vullo, V. . . . . . . . . . . . . . . D-165, 012; D-740, 091; . . . . . . . . . . . . . . . . . D-742, 091; C2-1373, 168

W Waako, P. . . . . . . . . . . . . . . . . . . . . . . . . H-893, 103 Wachino, J. . . . . . . . . . . . . . . . . . . . . . D-1456, 172 Wack, M. F. . . . . . . . . . . . . . . . . . . . . . F-1520, 177 Wada, Y. . . . . . . . . . . . . . .A-607, 082; A-608, 082; . . . . . . . . . . . . . . . . . . . . . . . . . . . .M-1687, 190 Waddell, S. T. . . . . . . . . . . . . . . . . . . . F-1496, 176 Wagener, M. . . . . . . . . . M-337, 028; M-1227, 159 Wagenlehner, C. . . . . . . . . . . . . . . . . . A-1285, 162 Wagenlehner, F. M. . . . . . . . . . . . . . . . A-1285, 162 Wagner, D. M.. . . . . . . . . . . . . . . . . . . L1-964, 110

September 9-12 |

Wagner-Eibel, U. . . . . . . . . . . . . . . . . E-1470, 173 Wahlers, K. . . . . . . . . . . . . . . . . . . . . . .M-338, 028 Wainaina, J. N. . . . . . . . . . . . . . . . . . . . D-153, 011 Wainberg, M. A. . . . . . . . . . . . . . . . . . H-1571, 180 Wajima, T. . . . . . . . . . . .A-019, 003; C2-1990, 244; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1991, 244 Walchak, R. C. . . . . . . . . . . . . . . . . . .M-1691, 190 Walia, S. K. . . . . . . . . . . . . . . . . . . . . . C2-703, 088 Walk, S. T. . . . . . . . . . . . . K-926, 105; T-1068, 116 Walker, C. . . . . . . . . . . . . . . . . . . . . . . .M-977, 111 Walker, I. . . . . . . . . . . . . . . . . . . . . . . . . H-881, 102 Walker, J. R.. . . . . . . . . . . . . . . . . . . . . C1-680, 086 Walkty, A. . . . . . . . . . . .C2-135, 010; C2-149, 010; . . . . . . . . . E-191, 015; E-200, 015; E-779, 093 Wallace, C. J. . . . . . . . . . . . . . . . . . . . . C1-590, 081 Wallace, R. J. . . . . . . . . . . . . . . . . . . . . . . 1859, 226 Wallengren, K.. . . . . . . . . . . . . . . . . . . B-1296, 164 Wallis, R. S. . . . . . . . . . . A-1257, 161; A-1264, 161 Wallner, C. . . . . . . . . . . . . . . . . . . . . . P-1009, 112 Walmsley, S. . . . . . . . . . . . . . . . . . . . . . H-882, 102 Walmsley, S. L. . . . . . . . . . 1849, 222; H-1920, 238 Wals, P. D. . . . . . . . . . . . . . . . . . . . . . . G-1047, 114 Walsh, C. T. . . . . . . . . . . . . . . . . . . . . . . . . 007, 002 Walsh, T. . . . . . . . . . . . . .M-972, 111; M-981, 111; . . . . . . . . . . . . . . . . . . . M-1681, 190; 1853, 224 Walsh, T. . . . . . . . . . . . . . . . . . . . . . . .M-1720, 191 Walsh, T. R. . . . . . . . . . . C1-064, 006; C1-592, 081 Walti, L. N. . . . . . . . . . . . D-168, 012; K-250, 022; . . . . . . . . . . . . . . . . . . K-251, 022; K-2073, 250 Wang, B. . . . . F-834, 098; F-843, 099; F-844, 099; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-845, 099 Wang, C. J. . . . . . . . . . . . . . . . . . . . . . . H-554, 073 Wang, H. L. . . . . . . . . . . . . . . . . . . . . F-1498, 176 Wang, H. . . . . . . . . . . . . . G-868, 101; F-1496, 176 Wang, J. . . . A-027, 004; A-031, 004; C2-097, 008; . . . . . . . . . . . . . . . . . K-270, 024; L1-1654, 188 Wang, L. . . . . . . . . . . . . . 1189, 153; C2-1393, 169 Wang, M. X. . . . . . . . . . . . . . . . . . . . . . H-554, 073 Wang, M. G. . . . . . . . . . . . . . . . . . . . . . A-640, 083 Wang, M. . . . . . . . . . . B-1332, 165; C2-1355, 167 Wang, N. . . . . . . . . . . . . . . . . . . . . . . . F-1517, 176 Wang, P.. . . . . . . . . . . . . . . . . . . . . . . C2-1355, 167 Wang, Q. . . . . . . . . . . . . . . . . . . . . . . . F-1498, 176 Wang, S. . . .K-278, 024; H-553, 073; H-1581, 180 Wang, W. . . . . . . . . . C2-1388, 169; D-1422, 170; . . . . . . . F-1497, 176; F-1498, 176; F-1501, 176 Wang, X. K. . . . . . . . . . . . . . . . . . . . . . F-1499, 176

AUTHOR INDEX Author

Presentation Number

Wang, Y. . . . K-268, 023; C2-702, 087; F-834, 098; . . . . . F-835, 098; C2-1987, 244; L2-2107, 255 Wang, Z. . . . . . . . . . . . . . . . . . . . . . . . F-1501, 176 Warburton, P. . . . . . . . . . . . . . . . . . . C2-1983, 243 Ward, D. . . . . . . . . . . . . . . . . . . . . . . . . H-555, 073 Wardyn, S. . . . . . . . . . . . . . . . . . . . . . C2-1384, 169 Wareham, D. . . . . . . . . . C2-102, 009; D-761, 092; . . . . . . . . . . . . . . . . . . E-797, 094; B-1299, 164 Wargin, W. . . . . . . . . . . . . .F-839, 098; F-840, 098 Warn, P. . . . . . . . . . . . . . . F-842, 099; F-1530, 177; . . . . . . A-1943, 240; A-1944, 240; F-2066, 249 Warner, M. . . . . . . . . . . . E-192, 015; F-2048, 248 Warrener, P. . . . . . . . . . . F-1529, 177; B-1734, 196 Washington, C. . . . . . . . . . . . . . . . . . C2-1361, 167 Waskin, H. . . . . . . . . . . . . . . . . . . . . . A-1935, 240 Waskins, H. . . . . . . . . . . . . . . . . . . . . . A-1934, 240 Watabe, R. . . . . . . . . . . . . . . . . . . . . . . F-1509, 176 Watanabe, K. . . . . . . . . . . .H-223, 019; H-888, 103 Waterman, P. . . . . . . . . C2-725, 089; C2-1914, 237 Waters, C. . . . . . . . . . . . . . . . . . . . . . .M-1062, 115 Watson, S. . . . . . . . . . . . . . . . . . . . . . . . K-265, 023 Watters, A. A. . . . . . . . . . . . . . . . . . . . F-1510, 176 Watts, J. . . . . . . . . . . . . . . . . . . . . . . . . F-2034, 248 Watts, J. L.. . . . . . . . . . . . . . . . . . . . . . C1-670, 085 Wawrzak, Z. . . . . . . . . . . . . . . . . . . . C1-1344, 166 Webber, M. A. . . . . . . . . . . . . . . . . . . . C1-674, 086 Weber, A. T.. . . . . . . . . . . . . . . . . . . . . B-1336, 165 Weber, M. M. . . . . . . . . . . . . . . . . . . .M-1691, 190 Weber, P. D.. . . . . . . . . . . . . . . . . . . . . D-1773, 201 Wei, H. . . . . . . . . . . . . . . . . . . . . . . . . . K-933, 105 Wei, X.. . . . . . . . . . . . . . . . . . . . . . . . . A-1250, 161 Weigert, R. . . . . . . . . . . . . . . . . . . . . . K-2074, 250 Weinberger, M. . . . . . . . . . . . . . . . . . . P-1001, 112 Weiner, E. M. . . . . . . . . . . . . . . . . . . . F-1534, 177 Weintraub, E. S. . . . . . . . . . . . . . . . . . G-1054, 114 Weiser, M. . . . . . . . . . . . . . . . . . . . . . . . T-343, 029 Weiss, P.. . . . . . . . . . . . . . . . . . . . . . . . . B-653, 084 Weiß, S. . . . . . . . . . . . . . . . . . . . . . . . C1-1350, 166 Weissman, S. . . . . . . . . . . . . . . . . . . . . C2-115, 009 Weist, K. . . . . . . . . . . . . . . . . . . . . . . . . . 1789, 204 Wellems, T. E. . . . . . . . . . . . . . . . . . . . . . 1199, 155 Weller, S. . . . . . . . . . . . . . . . . . . . . . . . A-1246, 161 Wells, C. . . . . . . . . . . . . . . . . . . . . . . . A-1255, 161 Wells, T.. . . . . . . . . . . . . . . . . . . . . . . . . . 1201, 155 Wen-Chien Chou . . . . . . . . . . . . . . . .M-1669, 190 Wendel, A. F.. . . . . . . . . . . . . . . . . . . . C1-588, 081 Wendel, S. K.. . . . . . . . . . . . . . . . . . . . H-1580, 180 Wengenack, N. L. . . . . . . . . . . . . . . . .M-1691, 190 Wennerås, C. . . . . . . . . . . . . . . . . . . . . T-1042, 113 Wenning, L. . . . . . . . . . . . . . . . . . . . . A-1763, 200 Wenzel, P. . . . . . . . . . . . . . . . . . . . . . C2-1214, 157

Author

Presentation Number

Author

Presentation Number

Wereszczynski, J. . . . . . . . . . . . . . . . . . F-1534, 177

Willis, L. . . . . . . . . . . . . . . . . . . . . . . G3-1544, 178

Werner, P. . . . . . . . . . . . . . . . . . . . . . C2-1382, 169 Werth, B. J. . . . . . . . . . . . .A-600, 082; A-602, 082; . . . . . . . . . A-603, 082; A-626, 083; A-627, 083 Wertheim, H. F. . . . . . . . . . . . . . . . . . P-1024, 112

Wilmer, A.. . . . . . . . . . . . D-161, 011; K-1593, 182 Wilson, A. N. . . . . . . . . . . . . . . . . . . . . K-262, 023 Wilson, A. . . . . . . . . . . . . . . . . . . . . . .M-1062, 115

Wessels, M. . . . . . . . . . . . . . . . . . . . . . . . . 581, 079

Wilson, D. . . . . . . . . . . . . . . . . . . . . . .M-1670, 190

Westbrook, S. D. . . . . . . . . . . . . . . . . .M-1674, 190 Westphal, J. . . . . . . . . . . . . . . . . . . . . . K-2100, 253 Wever, P. C. . . . . . . . . . . . . . . . . . . . . . L1-965, 110

Wilson, G. . . . . . . . . . . . . . . . . . . . . . . C2-699, 087 Wilson, L. E. . . . . . . . . . . . . . . . . . . . . C2-095, 008

Weyer, K. . . . . . . . . . . . . . . . . . . . . . . . . . . 535, 069

Wilson, A. C. . . . . . . . . . . . . . . . . . . G3-1558, 178

Win, T. . . . . . . . . . . . . . . . . . . . . . . . . . F-841, 099

Wheat, L. J. . . . . . . . . . . . . . . . . . . . . . T-1066, 116

Windau, A. R. . . . . . . . C2-1361, 167; F-2059, 249 Windsor, H.. . . . . . . . . . . . . . . . . . . . . . E-207, 016

Whichard, J. M.. . . . . . . . . . . . . . . . . . C2-695, 087 Whitcomb, J. . . . . . . . . . . . . . . . . . . . . H-1574, 180

Wing, S. . . . . . . . . . . . . . . . . . . . . . . C2-1912, 237

White, K.. . . . . . . . . . . . .H-556, 073; H-1574, 180 White, P. . . . . . . . . . . . . . . . . . . . . . . . . K-277, 024 Whitlam, J. . . . . . . . . . . . . . . . . . . . . . . T-369, 029 Whitley, R. J. . . . . . . . . . . . . . . . . . . . . V-1080, 117 WHONET-Argentina Group . . . . . . C2-701, 087 Wi, Y. . . . . . . . . . . . . . . . . . . . . . . . . . K-1587, 181 Wible, M. . . . . . . . . . . . . . . . . . . . . . C2-1906, 237 Wickes, B. . . . . . . . . . . . . . . . . . . . . . . D-1449, 172 Wickes, B. L.. . . . . . . . . . . . . . . . . . . .M-1674, 190 Wickham, K. . . . . . . . . . . . . . . . . . . . . . D-163, 011 Widen, R. . . . . . . . . . . . . . . . . . . . . . . D-1446, 172 Widmer, A. F. . . . . . . . . C2-082, 007; D-167, 012; . . . . . . . . . . . . . . . . . . . . . .1139, 136; 1878, 231 Wiederhold, N. P. . . . . . . . . . 412, 035; B-650, 084; . . . . . . .F-823, 096; M-1674, 190; M-1682, 190 Wielens, J. . . . . . . . . . . . . . . . . . . . . . . . F-828, 097 Wiener, A. . . . . . . . . . . . . . . . . . . . . . . . K-953, 108 Wienzek-Lischka, S. . . . . . . . . . . . . . . . T-341, 029 Wiesman, W. P. . . . . . . . . . . . . . . . . . . F-1518, 176 Wikman, P. . . . . . . . . . . . . . . . . . . . . . . D-743, 091 Wilcox, M. . . . . . . . . . . . D-160, 011; K-474, 048; . . . . . . . . . . B-662, 084; K-924, 105; 1846, 221 Wildhaber, B. E. . . . . . . . . . . . . . . . . G3-1556, 178 Wilkins, P. P. . . . . . . . . . . . . . . . . . . . . . . 1892, 234 Wilkinson, A. . . . . . . . . .F-2065, 249; F-2066, 249 Wilkinson, T. . . . . . . . . . . . . . . . . . . . . A-1943, 240 Will, S. . . . . . . . . . . . . . . . . . . . . . . . . .M-335, 028 Willey, B. . . . . . . . . . . . . .C2-085, 008; K-281, 024; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1214, 157 Williams, A. J. . . . . . . . . . . . . . . . . . . . G-1748, 198 Williams, A. . . . . . . . . . . . . . . . . . . . . . B-664, 084 Williams, G. . . . . . . . . . . .A-630, 083; A-631, 083; . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1761, 200 Williams, J. D. . . . . . . . . . . . . . . . . . . . . F-816, 096 Williams, K. . . . . . . . . . . . . . . . . . . . . . F-836, 098 Williamson, D. A. . . . G3-1555, 178; C2-1908, 237 Williamson, J. C. . . . . . . . . . . . . . . . . C2-1390, 169 Williamson, P. R.. . . . . . . . . . . . . . . . . .M-314, 028 Willis, D. . . . . . . . . . . . . . . . . . . . . . . . . D-736, 091

Final Program

Wine, B. . . . . . . . . . . . . . .H-882, 102; H-895, 103 Winkle, P. . . . . . . . . . . . . . . . . . . . . . . A-1250, 161 Winkler, M. . . . . . . . . . . . . . . . . . . . . . . F-847, 099 Winkler, M. L. . . . . . . C1-463, 047; C1-1209, 156 Winner, J. . . . . . . . . . . . . . . . . . . . . . . . D-153, 011 Winthrop, K. L.. . . . . . . . . . . . . . . . . . . T-345, 029 Wipasa, J.. . . . . . . . . . . . . . . . . . . . . . . D-1406, 170 Wirth, V. . . . . . . . . . . . . . . . . . . . . . . . . F-828, 097 Wise, E.. . . . . . . . . . . . . . . . . . . . . . . . B-1311, 165 Wiskirchen, D. E. . . . . . . . . . . . . . . . . . A-013, 003 Wisniewski, T. . . . . . . . . . . . . . . . . . . . . D-153, 011 Wisplinghoff, H. . . . . . M-1230, 159; D-1423, 170; . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-1706, 191 Witmer, M. . . . . . . . . . . . . . . . . . . . . . . H-551, 073 Woei Tsay . . . . . . . . . . . . . . . . . . . . . .M-1669, 190 Woerther, P. . . . . . . . . . . . . . . . . . . . . . . D-772, 092 Wohl, D. . . . . . . . . . . . . . . . . . . . . . . . . H-895, 103 Wohlert, S. . . . . . . . . . . . . . . . . . . . . . A-1960, 241 Wolfe, A. . . . . . . . . . . . . . . . . . . . . . . . . K-561, 074 Wolff, F.. . . . . . . . . . . . . . . . . . . . . . . . . A-637, 083 Wolff, M.. . . . A-021, 003; P-568, 075; P-570, 075; . . . . . . . . . . . . . . . . M-1707, 191; L2-2117, 255 Wolfhagen, M. . . . . . . . . . . . . . . . . . . .M-334, 028 Wollenberg, L.. . . . . . . . . . . . . . . . . . . . A-016, 003 Wollenhaupt, M. . . . . . . A-1245, 161; G-1749, 198 Wong, A. . . . . . . . . . . . . . . . . . . . . . . . . K-243, 021 Wong, C. K. . . . . . . . . . . . . . . . . . . . . . K-909, 104 Wong, J. . . . . . . . . . . . . . . . . . . . . . . . . K-1636, 185 Wong, J. G. . . . . . . . . . . . . . . . . . . . . . . P-567, 075 Wong, K. . . . . . . . . . .C2-1362, 167; C2-1363, 167; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1364, 167 Wong, S. . . . . . . . . . . . . F-1537, 177; F-2018, 247; . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2018a, 247 Wong, T. . . . . . . . . . . . . D-161, 011; C2-1380, 169 Wong-Beringer, A. . . . . . . . K-932, 105; 1167, 147; . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1586, 181 Wongkulab, P. . . . . . . . . . . . . . . . . . . . D-1406, 170 Woo, J. . . . . . . D-741, 091; T-366, 029; K-907, 104; . . . . . . V-1074, 117; V-1239, 160; K-2092, 252 Wood, S. . . . . . . . . . . . . . . . . . . . . . . . A-1956, 241

257


Presentation Number

Author

Woodford, N. . . . . . . . C2-102, 009; D-1451, 172; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1786, 204

Y

Woods, A. L. . . . . . . . . . . . . . . . . . . . C1-1973, 242 Woods, C. W. . . . . . . . . . . . . . . . . . . . C2-117, 009 Woodward, M. J. . . . . . . . . . . . . . . . . C1-1208, 156 Workowski, K. . . . . 445, 043; 477, 050; H-879, 102 Worley, S. . . . . . . . . . . . . . . . . . . . . . G3-1546, 178 Wormser, G. P. . . . . . . . . . . . . . . . . . . . . . 451, 044 Wren, M. . . . . . . . . . . . . . . . . . . . . . . . . D-160, 011 Wright, C. . . . . . . . . . . . .F-2063, 249; F-2064, 249 Wright, D. W. . . . . . . . . . . . . . . . . . . . . . 1796, 206 Wright, G. . . . . . . . . . . . . . . . . . . . . . . . . . 434, 040 Wright, K. . . . . . . . . . . . . . . . . . . . . . . K-1620, 184 Wroe, A. . . . . . . . . . . . . . . . . . . . . . . . . K-927, 105 Wu, C. . . . . . . . . . . . . . . . . . . . . . . . . C2-1987, 244 Wu, G.. . . . . . . . . . . . . . . . . . . . . . . . . A-1766, 200 Wu, H. . . . . . . . . . . . . . . . . . . . . . . . . . H-554, 073 Wu, J. F.. . . . . . . . . . . . . .F-1503, 176; F-1504, 176 Wu, J.. . . C2-118, 009; C2-1384, 169; A-1763, 200 Wu, J. F.. . . . . . . . . . . . . . . . . . . . . . . . . A-640, 083 Wu, J.. . . . . . . . . . . . . . . . . . . . . . . . . . A-1283, 162 Wu, P. . . . . . . . . . . . . . . . . . . . . . . . . . L2-309, 027 Wu, S. . . . . . . . . . . . . . . . . . . . . . . . . C2-1903, 236 Wu, U. . . . . . . . . . . . . . . . . . . . . . . . . . C2-097, 008 Wu, X. J. . . .A-640, 083; F-1503, 176; F-1504, 176 Wu, X. . . . .C1-068, 006; C1-595, 081 A-1283, 162 Wu, Y. . . . . . . . . . . . . . . . . . . . . . . . . . A-1289, 163 Wyles, D. L. . . . . . . . . . . . . . . . . . . . . . . 1781, 202

X Xercavins, M.. . . . . . . . . C2-111, 009; K-1621, 184 Xerinda, S. . . . . . . . . . . . . . . . . . . . . . . . H-227, 019 Xiao, X. . . . . . . . . . . . . . . . . . . . . . . . . F-1526, 177 Xiao, Y. . . . . . . . . . . . . . . . . . . . . . . . . . . . 422, 037 Xie, D. . . . . . . . . . . . . . . . . . . . . . . . . . . H-554, 073 Xie, L. . . . . . . . . . . . . . . C1-680, 086; F-1540, 177 Xie, Y. . . . . . . . . . . . . . . . . . . . . . . . . . . H-554, 073 Xiong, Y. . . . . . . . . . . . . . G-868, 101; E-1474, 174 Xiong, Y. Q.. . . . . . . . . . . . B-646, 084; B-654, 084; . . . . . . . . . . . . . . . . . . B-655, 084; E-1468, 173 Xu, H. . . . . . . . . . . . . . . . . . . . . . . . . . . K-268, 023 Xu, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . F-834, 098 Xu, T. . . . . . . . . . . . . . . . . . . . . . . . . . .M-1061, 115 Xu, W. . . . . . . . . . . . . . M-1056, 115; M-1061, 115 Xu, Y.. . . . . . . . . . . . . . V-1078, 117; G3-1550, 178 Xu, Y. H. . . . . . . . . . . . . . . . . . . . . . . . F-1498, 176 Xu, Y.. . . . . . . . . . . . . . C2-702, 087; L2-2107, 255 Xue, B. . . . A-1261, 161; A-1262, 161; A-1263, 161 Xue, M. . . . . . . . . . . . . . . . . . . . . . . . . . K-239, 020

258

Presentation Number

Author

Presentation Number

Yılmaz, G. . . . . . . . . . . . . . . . . . . . . . . D-1405, 170

Yao, C. . . . . . . . . . . . . . . . . . . . . . . . . . . H-554, 073 Yapar, M. . . . . . . . . . . . . . . . . . . . . . . . . D-158, 011 Yasuhiro, K. . . . . . . . . . . . . . . . . . . . . . A-1955, 241

Yakubchyk, Y. A. . . . . . . . . . . . . . . . . . . P-997, 112 Yamada, A. . . . . . . . . . . . . . . . . . . . . C2-1989, 244

Yasui, K.. . . . . . . . . . . . . . . . . . . . . . . . D-1438, 171 Yau, C. . . . . . . . . . . . . . . . . . . . . . . . . . . K-243, 021

Yamada, E.. . . . . . . . . . . . . . . . . . . . . . . F-809, 096

Yazaki, A.. . . . . . . . . . . . .F-2049, 248; F-2055, 248 Yazdanpanah, Y. . . . . . . L1-957, 109; V-1073, 117; . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2117, 255

Yamada, K. . . . . . . . . . . . . B-048, 005; B-049, 005; . . . . . . . . . . . . . . . . . . B-657, 084; B-1297, 164 Yamada, M. . . . . . . . . . C2-114, 009; D-1460, 172; . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1901, 236 Yamada, R. . . . . . . . . . . . . . . . . . . . . . . H-890, 103 Yamagishi, Y. . . . . . . . . . L2-305, 027; M-325, 028; . . . . . . M-328, 028; C2-693, 087; A-1288, 163; . . . . . . . . . . . . . . . . C2-1989, 244; F-2045, 248 Yamaguchi, K. . . . . . . . . . . . . . . . . . . . . B-056, 005 Yamaguchi, T. . . . . . . . . . . . . . . . . . . L1-1657, 188 Yamamoto, M. . . . . . . . . . K-949, 107; K-1599, 182 Yamamoto, T.. . . . . . . . . . . . . . . . . . . C1-1340, 166 Yamamoto, Y. . . . . . . . . . . B-049, 005; V-380, 030; . . . . . . . . . . . . . . . . . . B-657, 084; B-1297, 164

Ye, X. Y. . . . . . . . . . . . . . . . . . . . . . . . . . A-640, 083 Ye, X. . . . . . . . . . . . . . . . . . . . . . . . . . . B-1332, 165 Ye, Z. . . . . . . . . . . . . . . C1-677, 086; C1-1351, 166 Yeaman, M. . . . . . . . . . . . . . . . . . . . . . . G-868, 101 Yeang, M. . . . . . . . . . . . . . . . . . . . . . . . P-569, 075 Yebenes, J. . . . . . . . . . . . . . . . . . . . . . L1-1643, 186 Yen-Lieberman, B. . . . . . . . . . . . . . . G3-1546, 178 Yeni, P. . . . . . . . . . . . . . . . . . . . . . . . . . V-1073, 117 Yeni, P. G. . . . . . . . . . . . . . . . . . . . . . . . . 1186, 152 Yesilkaya, A. . . . . . . . . . . . . . . . . . . . . C2-684, 087 Yew, W. W. . . . . . . . . . . . . . . . . . . . . . E-1992, 245

Yamane, K. . . . . . . . . . . . . . . . . . . . . . D-1456, 172 Yamano, Y.. . . . . . . . . . . .F-1506, 176; F-1507, 176 Yamasaki, H. . . . . . . . . . . . . . . . . . . . . . F-825, 097

Yi, J.. . . . . . . . . . . . . . . . H-1564, 179; K-2076, 250

Yamashita, K.. . . . . . . . . . . . . . . . . . . . . F-809, 096

Yilmaz, H. . . . . . . . . . . . . . . . . . . . . . . . V-394, 030 Yilmaz, S. . . . . . . . . . . . . . . . . . . . . . . D-1427, 171 Yin, M. T. . . . . . . . . . . . . A-026, 004; K-1620, 184

Yan, J.. . . . . . . . . . . . . . . . . . . . . . . . . . C2-118, 009 Yan, Q.. . . . . . . . . . . . . . . . . . . . . . . . . . K-936, 105 Yan, Y. . . . . . . . . . . . . . . . . . . . . . . . . . . H-551, 073 Yanagihara, K. . . . . . . . . . . B-048, 005; B-049, 005; . . . . . . . . V-380, 030; B-657, 084; B-1297, 164; . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1460, 172 Yanai, N. . . . . . . . . . . . . . . . . . . . . . . G3-1545, 178 Yañez, L. . . . . . . . . . . . . . . . . . . . . . . . T-1038, 113 Yang, C. . . . . . . . . . . . . .C2-097, 008; L2-309, 027; . . . . . . . . . . . . . . . . . H-1578, 180; K-1607, 183 Yang, F. . . . . . . . . . . . . . . . . . . . . . . . C2-1355, 167 Yang, H.. . . . . . . . . . . . . . . . . . . . . . . C2-1215, 157 Yang, J.. . . . . . . . . . . . . . . .H-221, 019; G-867, 100 Yang, J. B. . . . . . . . . . . . . . . . . . . . . . . F-1489, 175 Yang, J.. . . . . . . . . . . . . . . . . . . . . . . . . . K-933, 105 Yang, K. . . . . . . . . . . . . . . A-016, 003; A-1243, 161 Yang, L. . . . . . . . . . . . . . . . . . . . . . . . . . H-229, 019 Yang, N. . . . . . . . . . . . . B-1309, 165; C2-1978, 243 Yang, P. L. . . . . . . . . . . . . . . . . . . . . . . . V-377, 030 Yang, Q.. . . . . . . . . . . . C2-702, 087; L2-2107, 255 Yang, S. . . . . . . . . . . . . . . . . . . . . . . . . E-1468, 173 Yang, T. . . . . . . . . . . . . . . . F-839, 098; F-840, 098 Yang, X. Y. . . . . . . . . . . . . . . . . . . . . . . F-1499, 176 Yang, Z. . . . . . . . . . . . . . . H-215, 018; V-1238, 160 Yankelev, S. . . . . . . . . . . . . . . . . . . . . L1-2105, 254 Yano, H.. . . . . . . . . . . . C2-114, 009; C2-1901, 236 Yansouni, C. P.. . . . . . . . . . . . . . . . . . . P-1014, 112 Yant, S. . . . . . . . . . . . . . . . . . . . . . . . . . H-892, 103

September 9-12 |

Yildirim, A. . . . . . . . . . . . . . . . . . . . . .M-1701, 191 Yilmaz, G. . . . . . . . . . . . . . . . . . . . . . . . V-394, 030

Yin, N.. . . . . . F-843, 099; F-844, 099; F-845, 099; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-846, 099 Yin, X. . . . . . . . . . . . . . . . . . . . . . . . . . A-1250, 161 Yip, C. W. . . . . . . . . . . . . . . . . . . . . . . E-1992, 245 Yoneyama, A.. . . . . . . . . . . . . . . . . . . . . K-897, 104 Yong, C.. . . . . . . . . . . . . . . . . . . . . . . . A-1248, 161 Yoo, J.. . . . . . . . . . . . . . C2-1215, 157; K-1632, 185 Yoon, B. . . . . . . . . . . . . . . . . . . . . . . . . . H-213, 017 Yoon, E. J. . . . . . . . . . . . . . . . . . . . . . . C1-676, 086 Yoon, M. J.. . . . . . . . . . . .K-276, 024; K-1635, 185; K-2078, 250 Yoshida, M. . . . . . . . . . . . F-825, 097; D-1402, 170 Yoshida, O. . . . . . . . . . . .F-1506, 176; F-1507, 176 Yoshimura, T.. . . . . . . . . . . . . . . . . . . . D-1402, 170 Yoshinaga, T. . . . . . . . . . . . . . . . . . . . . . H-550, 073 Yoshizawa, S. . . . . . . . . . . . . . . . . . . . . . K-918, 105 Yoshizumi, A. . . . . . . . . C1-077, 006; D-1438, 171 You, X. F. . . . . . . . . . . . . . . . . . . . . . . . F-1499, 176 You, X. . . . . . . . . . . . . . . . . . . . . . . . . . F-2002, 246 Young, B. . . . . . . . . . . . . . . . . . . . . . . . . H-882, 102 Young, C.. . . . . . . . . . . . . . . . . . . . . . . . D-185, 014 Young, K. . . . . . . . . . . . . .A-008, 003; C2-724, 089; . . . . . . . D-767, 092; M-979, 111; M-984, 111; . . . . . . M-1057, 115; F-1496, 176; A-1763, 200 Young, M. . . . . . . . . . . . . . . . . . . . . . . H-1575, 180 Young, V. B.. . . . . . . . . . . . . . . . . . . . . . K-926, 105

AUTHOR INDEX Author

Presentation Number

Author

Presentation Number

Yousef, A. E. . . . . . . . . . . . . . . . . . . . . F-1508, 176

Zeuzem, S.. . . . . . . . . . . . . . . . . . . . . . V-1236, 160

Yu, G. . . . . . . . . . . . . . . .F-1999, 246; F-1515, 176 Yu, H. H. . . . . . . . . . . . . . . . . . . . . . . . . E-795, 094

Zha, J. . . . . . . . . . . . . . . . . . . . . . . . . . F-1529, 177

Yu, H. . . . . . . . . . . . . . . . . . . . . . . . . . . K-259, 023

Zhai, L. . . . . . . . . . . . . . . . . . . . . . . . . . B-663, 084 Zhai, Q. Q. . . . . . . . . . . . . . . . . . . . . . F-1499, 176

Yu, J. C. . . . .A-640, 083; F-1503, 176; F-1504, 176

Zhanel, G. . . . . . . . . . . . . . A-040, 004; A-639, 083

Yu, J. . . . . . . . . . . . . . . . . D-755, 092; A-1283, 162 Yu, M. . . . . . . . . . . . . . . . . . . . . . . . . . . K-926, 105

Zhanel, G. G. . . . . . . . .C2-103, 009; C2-135, 010; . . . . . . . .C2-149, 010; E-191, 015; E-194, 015; . . . . . . .E-200, 015; E-779, 093; C2-1360, 167; . . . . . C2-1379, 169; E-1462, 173; E-1486, 174 Zhang, H. . . . . . . . . . . . . . . . . . . . . . L2-2107, 255

Yu, M. A.. . . . . . . . . . . . . . . . . . . . . . . T-1068, 116 Yuan, H. . . . . . . . . . . . . F-1499, 176; F-1500, 176; . . . . . . .F-1501, 176; F-1502, 176; F-1503, 176; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1504, 176 Yuan, Z. Y.. . . . . . . . . . . F-1500, 176; F-1501, 176; . . . . . . . . . . . . . . . . . .F-1503, 176; F-1504, 176 Yuichi, K.. . . . . . . . . . . . . . . . . . . . . . . F-2037, 248 Yumoto, S. . . . . . . . . . . . . . . . . . . . . . . D-1438, 171 Yun, H. . . . . . . . . . . . . . . . . . . . . . . . . . G-875, 101 Yung, C.. . . . . . . . . . . . . . . .P-567, 075; P-569, 075 Yung, S. C.. . . . . . . . . . . . . . . . . . . . . . . B-057, 005 Yungyuen, T. . . . . . . . . . . . . . . . . . . . . E-1477, 174 Yuste, J. R. . . . . . . . . . . . D-1439, 171; D-1440, 171

Z Zabner, J. . . . . . . . . . . . . . . . . . . . . . . . B-1322, 165 Zadeikis, N. . . . . . . . . . . . . . . . . . . . . . A-1936, 240

Zhang, J. . . . . . . . . . . . . . A-640, 083; F-1503, 176; . . . . . . F-1504, 176; F-2017, 247; F-2018, 247; . . . . . .F-2018a, 247; A-1283, 162; F-2024, 247 Zhang, K. J. . . . . . . . . . . . . . . . . . . . . . F-1503, 176 Zhang, L.. . . . . . . . . . . . . . . . . . . . . . . . F-838, 098 Zhang, M. . . . . . . . . . . V-1078, 117; G3-1550, 178 Zhang, Q. . . . . . . . . . . . . . . . . . . . . . C2-1987, 244 Zhang, S. . . . . F-843, 099; F-844, 099; F-845, 099; . . . . . . . . . . . . . . . . . . . . F-846, 099; 1843, 219 Zhang, T. . . . . . . . . . . . . . . . . . . . . . . . . H-554, 073 Zhang, W. X.. . . . . . . . . . . . . . . . . . . . F-1499, 176 Zhang, W. . . . . . . . . . . . . . . . . . . . . . . F-2002, 246

Zahar, J. R. . . . . . . . . . . . . . . . . . . . . L2-2109, 255 Zainah, H. . . . . . . . . . . . . . . . . . . . . . .M-1716, 191 Zaiss, N. H. . . . . . . . . . . . . . . . . . . . . . . D-179, 013 Zambardi, G. . E-197, 015; D-745, 092; D-748, 092 Zambon, M. . . . . . . . . . . . . . . . . . . . . . . 1895, 235

Zhao, H. . . . . . . . . . . . . . .H-882, 102; H-895, 103 Zhao, H. X. . . . . . . . . . . . . . . . . . . . . . . H-554, 073 Zhao, J. . . . . . . . . . . . . . . . H-885, 102; K-933, 105

Zamorano, L.. . . . . . . . C1-593, 081; C1-1970, 242

Zhao, J. J. . . . . . . . . . . . . . .K-262, 023; K-275, 024; . . . . . . . . . . . . . . . . . . K-902, 104; K-1121, 129 Zhao, L.. . . . . . . . . . . . . . . . . . . . . . . . C2-095, 008 Zhao, P. . . . . . . . . . . . . . . . . . . . . . . . . . D-172, 013 Zhao, X.. . . . . . . . . . . . . . . . . . . . . . . . . . 1791, 205

Zampiero, A. . . . . . . . . . . . . . . . . . . . G3-1553, 178 Zander, E. . . . . . . . . . . . . . . . . . . . . . . C1-070, 006 Zanetti, G.. . . . . . . . . . . . . . . . . . . . . . K-2088, 252 Zapico, S.. . . . . . . . . . . . . . . . . . . . . . . .M-321, 028 Zaragoza, R. . . . . . . . . . . . K-948, 107; K-950, 107 Zarfel, G.. . . . . . . . . . . . . . . . . . . . . . . E-1470, 173 Zariri, A. . . . . . . . . . . . . . . . . . . . . . . L1-1651, 187 Zarrouk, V. . . . . . . . . . . . . . . . . . . . . . K-2087, 252 Zavascki, A. P. . . . . . . . . . A-027, 004; D-749, 092; . . . . . . . . . . . . . . . . . K-913, 104; C2-1905, 236 Zeder, A. J. . . . . . . . . . . . . . . . . . . . . . . H-887, 103 Zeidan, J. . . . . . . . . . . . . . . . . . . . . . . . . H-553, 073 Zeitlinger, M. A. . . . . . . . . . . . . . . . . . . E-783, 093 Zelenitsky, S. . A-040, 004; A-613, 082; A-639, 083 Zerr, D. M. . . . . . . . . . . . . . . . . . . . . . . . 1827, 212 Zerva, L. . . E-782, 093; A-1939, 240; A-1940, 240 Zervos, M. . . . . . . . . . . . . . . . . . . . . . . . K-276, 024 Zervos, M. J. . . . . . . . . . . .A-609, 082; K-912, 104; . . . . . . . . . . . . . . . . K-1597, 182; L1-1655, 188

Presentation Number

Zimmermann, H. . . . . . . . T-356, 029; V-391, 030 Zimmermann, S. . . . . . . . . C2-093, 008; 1132, 133 Zingg, W. . . . . K-914, 104; K-929, 105; 1082, 118; . . . . . . . . . . 1802, 208; 1838, 217; K-2075, 250 Zinkernagel, A. . . . . . . . . . . . . . . . . . . K-1125, 129 Zinner, S. H. . . . . . . . . . . . . . . . . . . . . A-1967, 241 Zinsou, R. . . . . . . . . . . . . . . . . . . . . . . B-1737, 196 Ziochos, H. . . . . . . . . . . . . . . . . . . . . . C1-062, 006 Zito, E. . . . . . . . . . . . . . . . . . . . . . . . . . . . 575, 077 Zollner-Schwetz, I. . . . . . . V-395, 030; V-398, 030; . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1009, 112 Zollos, D.. . . . . . . . . . . . D-766, 092; E-1463, 173; . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-1467, 173 Zorreguieta, A. . . . . . . . . . . . . . . . . . . F-1539, 177 Zou, P. . . . . . . . . . . . . . . . . . . . . . . . . . . K-905, 104 Zoulim, F. . . . . . . . . . . . . . . . . . . . . . . . . . 428, 039 Zuerenko, G. . . . . . . . . . . . . . . . . . . . . . A-008, 003 Zurita, J. . . . . . . . . . . . . . . . . . . . . . . . . K-900, 104 Zurita, S. . . . . . . . . . . . . . . . . . . . . . . . .M-327, 028

Zhang, Y. Y.. . . . . . . . . . F-1497, 176; F-1503, 176; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1504, 176 Zhang, Y. . . . . . . . . . . . . . F-827, 097; A-1264, 161; . . . . . . . . . . . . . . . . . B-1332, 165; F-2072, 249 Zhang, Y. Y.. . . . . . . . . . . . . . . . . . . . . . A-640, 083 Zhang, Y. . . . . . . . . . . . . . . . . . . . . . . . A-1283, 162

Zampaloni, C. . . . . . . . .C2-133, 010; C2-140, 010; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2067, 249

Author

Zhao, Y. . . . . . . . . . . . . . . E-792, 094; T-1031, 113; . . . . . C2-1216, 157; M-1678, 190; F-2002, 246 Zhong, D. F. . . . . . . . . . .F-1500, 176; F-1501, 176 Zhou, D. . . . . . . . . . . . . . . A-634, 083; A-635, 083 Zhou, H. . . . . . . . . . . . . . . . . . . . . . . . . K-936, 105 Zhou, J. L. . . . . . . . . . . . . . . . . . . . . . . F-1501, 176 Zhou, Q. . . . . . . . . . . . . . . . . . . . . . . . . K-269, 023 Zhou, Y. J. . . . . . . . . . . . . . . . . . . . . . . . A-640, 083 Zhu, D. M. . . . . . . . . . . . . . . . . . . . . . F-1497, 176 Zhu, D. . . . . . . . . . . . . B-1332, 165; C2-1355, 167; . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2036, 248 Zhu, J. Z. . . . . . . . . . . . . A-1276, 162; A-1277, 162 Zhu, L. . . . . . . . . . . . . . . . . . . . . . . . . .M-982, 111 Zhu, Q. . . . . . . . . . . . . . . . . . . . . . . . . . K-268, 023 Zhu, T.. . . . F-827, 097; A-1261, 161; A-1262, 161; . . . . . . . . . . . . . . . . . A-1263, 161; A-1264, 161 Zimmerman, O. . . . . . . M-985, 111; M-1059, 115

Final Program

259

> NOTES

260

September 9-12 |

KEYWORD INDEX

animal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-991 animal efficacy . . . . . . . . . . . . . . . . . F-842, F-1523

13-valent Pneumococcal Conjugate Vaccine . . . . . . . . . . . . . . . . . . . . . . . . . G-864, G-1049 13C-isonizid . . . . . . . . . . . . . . . . . . . . . . . . . F-830

adherence. . . . . . . . .H-211, H-212, P-565, H-884, . . . . . . . . . . . . . . . . . . . . . . . . B-1322, C2-1400 adhesin . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1332

16S rRNA methylase . . . . . . . . . . . . . . . . . C1-1203

adjusted dosage . . . . . . . . . . . . . . . . . . . . . . . A-610

16S-23S rRNA gene . . . . . . . . . . . . . . . . . . D-1443 16S-rRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . D-743

ADME . . . . . . . . . . . . . . . . . . . . . . F-839, A-1267 adolescent . . . . . . . . . . . . . . . . . . . . . . . . . . A-1292

antagonism . . . . . . . . . . . . . . . . . . . . . . . . . . E-782

18S rRNA . . . . . . . . . . . . . . . . . . . . . . . . . M-1062

adsorbent . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1963

2-pyridone . . . . . .F-2030, F-2031, F-2032, F-2033

adult. . . . . . . . . . . . . . . . . . . M-322, P-566, K-956

anthropology . . . . . . . . . . . . . . . . . . . . . . . . K-2080 anti-influenzal agents . . . . . . . . . . . . . . . . . . V-388

A A549 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-780

AdvanSureTM Mycobacteria GenoBlot Assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-734 adverse drug effects . . . . . . . . . . . . . . . . . . L1-1661 adverse event . . L1-284, G-1052, L1-1664, K-2075 aetiology . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1649

animal model . . . . . . . . . . . G-875, M-980, P-1013, . . . .B-1307, D-1431, A-1948, F-2035, F-2043, . . . . . . . . . . . . . . . . . . . . . . . . . F-2056, K-2097

anti-M2e mAb . . . . . . . . . . . . . . . . . . . . . . . G-873 anti-MRSA antibiotics . . A-038, E-1466, E-1472, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1514 anti-phagocytosis . . . . . . . . . . . . . . . . . . . . . B-1325 anti-staphylococcal . . . . . . . . . . . . . . . . . . . . B-656 anti-TNF. . . . . . . . . . . . . . . . . . . . . . . . . . . . D-740

AAC(6’)-Ib-cr . . . . . . . . . D-759, C2-700, B-1306 abacavir . . . . . . . . . . . . . . . . . . . . . . H-882, H-895

affirm test . . . . . . . . . . . . . . . . . . . . . . . . . . L2-306

AbaR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1899

AFM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1436

anti-tuberculosis treatment . . . . . . . . . . . . . A-1264

ABC transporter . . . . . . . . . . . . . . . . . . . . . M-975 abdominal . . . . . . . . . . . . . . . . . . . . . . . . . M-1685 abdominal prosthetic aortic graft . . . . . . . . . . K-263

AFN-1252 . . . . . . . . . . . . . . . . . . . . . . . . . . E-1486 Africa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-107 Africa Middle East . . . . . . . . . . . . . . . . . . . C2-150

ABSSSI . . . . . C2-1396, K-1598, L1-1663, A-1957

age . . . . . . . . . . . . . . . . . . . . H-556, H-880, H-879 AGR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1906 agricultural azole antifungals . . . . . . . . . . . . M-320

antibacterial . . . . . . A-628, A-642, D-768, F-1497, . . . . F-1498, F-1499, F-1501, F-1502, F-1503, . . . .F-1504, F-1515, F-1527, F-1528, L1-1662 antibacterial activity . . . . . F-1488, F-1533, F-2044, . . . . . . . . . . . . . . . . . . . . . . . . . F-2045, F-2062

accessory gene regulator. . . . . . . . . . . . . . . C2-1395 accident and emergency . . . . . . . . . . . . . . . . . K-242 ACH490 . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1302 Achromobacter . . . . . . . . . . . . . . . . . . . . . . . . D-1455 Achromobacter xylosoxidans . . . . . . . . . . . . . . C1-074 AcinetobacterA-030, B-049, C1-071, E-789, F-2039 Acinetobacter baumannii . . . A-024, C1-069, D-171, . . . . . . . K-559, C1-676, E-784, E-786, E-785, . . E-787, E-788, F-841, K-899, K-902, K-905, . . . B-1327, B-1329, D-1422, K-1602, K-1604, . . . . . . . . . K-1605, K-1606, K-1607, C2-1897, . . . . . . C2-1898, C2-1899, C2-1902, C2-1903, . . C2-1904, C2-1905, F-2010, F-2043, F-2067 Acinetobacter baumannii multidrug-resistant . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-202 Acinetobacter spp. . . . . . . . . . . . . . . C1-458, C2-1901 acne . . . . . . . . . . . . . . . . . . . . . . . . . D-776, F-2009 activation . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-052 active surveillance . . . . . . . . . . . . . . . . . . . L1-1641 activity . . . . . . . . . . . . . . . .F-1510, F-1511, F-1512 acute respiratory infection . . . . . . . . . . . . . G3-1548 acute bacterial skin and skin structure infections . . . . . . . . . . . . . . . . . . . . . . . . . A-1961, A-1962 acute HIV . . . . . . . . . . . . . . . . . . . . . . . . . .H-1568 acute illness severity . . . . . . . . . . . . . . . . . . . . K-910 acute laryngitis. . . . . . . . . . . . . . . . . . . . . . . L1-299 acute myocardial infarction . . . . . . . . . . . . . .H-228 acyclovir 5%/ hydrocortisone 1% cream. . . . . V-397 adenosine deaminase . . . . . . . . . . . . . . . . . . . D-182 adenovirus . . . . . . . . . . . . . . . . . . . . D-1778, T-363 adequacy . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2091

AIC316 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-391 AIDS . . . . . . . . . . . . . . . . . . . . . . . .H-220, A-1253 airsamplers . . . . . . . . . . . . . . . . . . . . . . . . . . . K-244 albumin . . . . . . . . . . . . . . . . . . . . . . D-180, P-1022 algorithm . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-286 alliaceus . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-321 allogeneic hematopoietic stem cell transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-360 alpha toxin . . . . . . . . . . . . . . . . . . . . . . . . . . B-1736 alternate dosing strategies . . . . . . . . . . . . . . A-1928 AmBisome. . . . . . . . . . . . . . . . . . . . . . . . . . P-1013 Amikacin . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1647 Aminoglycoside resistance . . . . . . . . . . . . . . . A-042 Aminoglycosides . . . . . . . . .A-038, C1-458, E-779 Amp C beta lactamase producing bacteria . . D-774 Amp C Etest . . . . . . . . . . . . . . . . . . . . . . . . . D-774 AmpC . . . . . . . . . . . . . . . . C2-079, C2-103, F-855 AmpC ơ-lactamases . . . . . . . . . . . . . . . . . . C2-082 amphotericin B . . . . . . . . . H-220, M-977, M-982, . . . . . . . . . . .M-992, M-1225, A-1939, A-1940 Amphotericin B colloidal dispersion . . . . . . P-1000 Ampicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . K-274 Ampicillin + Ceftriaxone . . . . . . . . . . . . . . . . K-938 Ampicillin + Gentamicin. . . . . . . . . . . . . . . . K-938 Ampicillin plus Ceftriaxone . . . . . . . . . . . . . K-945 anaerobes . . . . . . . . . . . . . . .B-048, C1-671, F-854, . . . . . . . . . . . . . . . . . . . . . . . . . D-1774, F-2045 ANAEROBIC QC . . . . . . . . . . . . . . . . . . . . E-188 anal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-301 anal intraepitelial neoplasia . . . . . . . . . . . . .H-1921 anidulafungin. . . . . . . . . M-311, M-989, M-1229, . . . . . . . . . . . . . . . . . . . . . . . . M-1683, M-1709

Final Program

antibacterial combination . . . . . . . . E-793, E-1485 antibacterial mode of action . . . . . . . . . . . . F-2062 antibacterial time-kill activity E-783, E-789, E-804 antibio-resistance . . . . . . . . . . . . . . . . . . . . . P-1010 antibiofilm . . . . . . . . . . . . . . . . . . . . . . . . . . C1-673 antibiogram . . . L1-282, D-756, D-1441, C2-1980 antibioresistance . . . . . . . . . . . . . . . . . . . . . . K-470 antibiotic . . . . . . L1-287, L1-288, F-2030, F-2031, . . . . . . . . . . . . . . . . . . . . . . . . . F-2032, F-2033 antibiotic combinations . . . . . . . . . . . . . . . . . A-030 antibiotic consumption . . . K-234, L1-285, K-1595 antibiotic resistance . . . . C1-065, C2-106, C2-152, . . . . B-654, C1-666, C1-467, C2-684, C2-725, . . . G-866, P-1002, P-1024, G-1050, C1-1204, . . . . . . . . C2-1399, D-1451, K-1636, C1-1972, . . . . . . . . . . . . . . . C2-1979, C2-1986, L2-2117 antibiotic resistance genes . . . . . . .C1-074, D-1454 antibiotic susceptibility . . . D-756, D-771, E-1480 antibiotic use . . . K-1613, K-237, L2-2118, P-1024 antibiotics . . . . . . L1-291, A-638, K-935, B-1330, . . . . F-1500, K-1591, G-1750, F-2003, K-2075 antibiotics resistance . . . . . . . . . C2-1353, C2-1401 antibody . . . . . . . . P-994, P-1016, V-1077, B-1738 antibody response . . . . . . . . . . . . . . . . . . . .H-1580 antibody-dependent enhancement . . . . . . . B-1734 antifungal. . . . . . . . M-317, M-331, F-810, F-816, . . . . . . . . F-818, F-819, F-820, M-976, M-982, . . . M-983, M-1061, M-1714, A-1930, A-1936 antifungal activity . . . . . . . . . . . . . .M-974, F-1533 antifungal agent . . . . . . . . . . . . . . . . . . . . . . . F-809 antifungal combination therapy . . . . . . . . . M-1711 antifungal combinations . . . . . . . . . . . . . . M-1719 antifungal drug response prediction. . . . . . M-1695 antifungal drugs . . . . . . . . . . . . . . . . . . . . . . A-1946 antifungal prophylaxis . . . . . . . . . . . . . . . . M-1711

261

> Keyword INDEX antifungal stewardship . . . . . . . . . . . . . . . . M-1232

Asia/Pacific rim . . . . . . . . . . . . . . . . . . . . . . C2-689

bacterial . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1221

antifungal surveillance . . . . . . . . . . . . . . . . . M-330 antifungal susceptibility . . . . . . . . . . M-318, M-971

ASP9726 . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-822 Aspergillosis . . . . F-823, G-875, M-981, M-1060, . M-1225, M-1226, M-1676, M-1701, M-1704

bacterial identification . . . . D-729, D-730, D-1461

antifungal susceptibility testing . . . . . . . . . . M-311 antifungal therapy . . . . .M-338, M-1063, G3-1559 antifungals . . . . . . . . . . . . . . . . . . . .T-349, M-1232 antigen . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-1693

Aspergillus . . . . . . . . M-319, M-330, M-337, T-343, . . . . . . . . . T-347, F-817, F-818, F-819, F-821, . . . . . . . . .M-1227, M-1681, M-1714, A-1930, . . . . . . . . . . . . . . . . . . . . . . . . . A-1932, A-1940

antigen antibody combination assay . . . . . .H-1582

Aspergillus calidoustus . . . . . . . . . . . . . . . . . . . F-809

antigen expression . . . . . . . . . . . . . . . . . . . . . G-870 antigenemia . . . . . . . . . . . . . . . . . . . . . . . . . . T-355

Aspergillus fumigatus . . . . . . M-335, M-987, M-989, . . . . . . . . . . . . . . . . .A-1938, M-1716, M-1719 Aspergillus terreus . . . . . . . . . . . . . . . . . . . . . M-332

bacterial infection . . . . . C2-1384, K-2075, T-1040 bacterial meningitis . . . . . . . . . .L1-1222, L1-1223, . . . . . . . L1-1224, G3-1543, L1-1648, L1-1652 bacterial resistance . . . . . . . . . . . . . . . . . . . . A-1967 bacterial topoisomerases . . . . . . . .F-2017, F-2018a bactericidal . . . . . . . . . . . .F-1514, F-1516, F-1531 bactericidal activity . . . . . . . . . . . . . E-210, A-1264 Bacteroides . . . . . . . . . . . . . . . . . . . . . . . . . . C2-140 Bacteroides spp. . . . . . . . . . . . . . . . . . . . . . . . . E-805 bactobilia . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1608

antimicrobial . . . . . . . . . . C2-706, F-810, A-1284, . . . . . . . . . . . . . . . . . . . . . . . . . F-2001, K-2097 antimicrobial activity . . . . .F-1492, F-1532, F-1996

assessment . . . . . . . . . . . . . . . . . . . . . . . . . . K-2083

BAL30072. . . . . . . . . . . . . . . . . . . . . . . . . . A-1285

antimicrobial agents. . . . . . . . K-252, F-825, F-831, . . . . . . . . . . . . .F-833, P-1019, F-2010, F-2061

Asunaprevir . . . . . . . . . . . . . . . . . . . . . . . . . A-1247 Asymptomatic bacteriuria. . . . . . . . . . . . . . . L2-2114

antimicrobial coated endotracheal . . . . . . . . F-2014 antimicrobial consumption . . . . . . . . . . . . . K-1925 antimicrobial peptide . . . . . . B-656, F-829, F-1487, . . . . . . . . . . . .F-1489, F-1490, F-2060, F-2068

Atazanavir . . . . . . . H-882, H-888, H-889, A-1251 Atlantic salmon innate immunity . . . . . . . . B-1330

bariatric surgery . . . . . . . . . . . . . . . . . . . . . . . K-265 barrier . . . . . . . . . . . . . . . . . . . . . . . F-2015, V-385 BC-3781 . . . . . . . . . . . . . . . . . . C1-1971, L1-1660 benzamil hydrochloride . . . . . . . . . . . . . . . . F-2000

antimicrobial resistance . . . . . . . . . C2-137, K-280, . . . . L2-308, K-558, C2-698, C2-705, C2-709, . . . . . . . . . . . C2-713, D-750, D-775, C2-1362, . . . . . . . . C2-1364, D-1449, G3-1562, K-1924 antimicrobial stewardship . . . . . . . . K-233, K-241, . . . . . . . . . . . . . . . . . . . . . . . . . K-1923, K-1924 antimicrobial stewardship program . . . . . . . . K-235 antimicrobial susceptibility . . . . . . . D-181, E-209, . . . . . . . . . . . . . . . C2-1356, C2-1978, L2-2107 antimicrobial susceptibility testing . . . . . . . D-736, . D-754, D-755, D-765, D-766, E-802, E-806, . . . . . . . . . C2-1360, D-1423, D-1441, E-1463, . . . . . . . . . . . . . . . . . . . . . . . . . E-1467, F-2021 antimicrobial therapy . . . . . . . . . . . . K-272, K-1927 antimicrobial utilization . . . . . . . . . . . . . . . K-1923 antimicrobials . . . . . . . . L1-299, F-1513, M-1696 antiretroviral drugs . . . . . . . . . . . . . . . . . . . .H-894 antiretroviral therapy . . . . . .H-211, H-225, H-886, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . H-1565 antisense . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1539 antisense antibiotic . . . . . . . . . . . . . . . . . . C1-1972 antiseptic . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2058 antiviral . . . . . . . . . . T-367, V-377, V-382, A-1246 antiviral activity . . . . . . . . . . . . . . . . . . . . . . . F-824 antiviral therapy . . . . . . . . . . . . . . . . . . . . . . . V-373 anxiety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-232 apo E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-372 apoptosis . . . . . . . . . . . . . . . . . . . . . M-972, M-978 arasertaconazole . . . . . . . . . . . . . . . M-980, M-1718 arbovirus . . . . . . . . . . . . . . . . . . . . . . P-567, P-569 Argentina. . . . . G-874, P-1015, P-1016, C2-1217, . . . . . . . . . . . . . . . . . . . . . . . C2-1398, C2-1910 argyrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1973 ART-naïve patients, ART experienced patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-1572 aseptic failure . . . . . . . . . . . . . . . . . . . . . . . . . K-258

262

Asplenia . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1648

ATLAS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-928 atopic dermatitis . . . . . . . . . . . . . .D-1439, D-1440 ATP-binding cassette . . . . . . . . . . . . . . . . C1-1349 AUC/MIC . . . . . . . . . . . . . . . . . . . . . . . . . A-1768 Austria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1009 authochtonous . . . . . . . . . . . . . . . . . . . . . . . P-1009 autoantibody . . . . . . . . . . . . . . . . . . . . . . . . D-1406 autoimmune rheumatic diseases . . . . . . . . L2-2114 automation . . . . . . . . . . . . . . . . . . . . . . . . . . D-727 avibactam . . . . . . . . . E-190, E-194, A-633, A-634, . . . . . . . . . . . . . . . . . . . . . . . . . . A-635, A-1760 Azadirachta indica . . . . . . . . . . . . . . . . . . . . . F-812 Azithromycin. . . . . . . . . . . . . . . . . . . . . . . . L1-296 Azithromycin extended release formulation . .V-400 azole . . . . . . . . . . . . . . . . . M-319, F-815, M-1711 azole resistance . . . M-334, F-814, M-988, M-969

B ơ-D-glucan . . . . . . . . . . . . . . . . . . . . . . . . M-1687 ơ-lactamase inhibitor . . . . . . . . . . . . . . . . . . . F-855 ơ-lactams . . . . . . . . . . . . . . . . . . . . . . . . . . . E-1478 ơ-lactams resistance mechanisms . . . . . . . C1-1970 B-cell malignancies . . . . . . . . . . . . . . . . . . . T-1042 B. pseudomallei . . . . . . . . . . . . . . . . . . . . . . . . F-2022 BAC libraries . . . . . . . . . . . . . . . . . . . . . . . C2-1983 Bacillus anthracis . . . . . . . . . . . . . . . . . . . . . . C2-1980 bacteremia . . . . . B-058, C2-110, C2-127, C2-152, . . . . . . . K-241, K-248, K-272, K-276, L1-297, . . . . . . . B-650, C2-690, D-772, K-897, K-898, . K-899, K-901, K-909, K-913, K-915, L1-961, . . . . T-1030, T-1031, T-1039, T-1045, D-1419, . . . K-1592, K-1597, K-1601, K-1619, K-1624, .K-1630, K-1635, L1-1638, L1-1642, L1-1658, . . K-1759, C2-1901, K-2086, K-2091, L2-2110 bacteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-711 bacteria resistance . . . . . . . . . . . . . . . . . . . . . K-911

September 9-12 |

beta lactam i . . . . . . . . . . . . . . . . . . . . . . . . . E-196 beta-cyclodextrin . . . . . . . . . . . . . . . . . . . . . F-2005 beta-glucan . . . . . . . . . . . . . . . . . . . . . . . . M-1701 beta-hemolytic streptococci . . . . . . E-778, L1-1644 beta-lactam . . . . . . . . . . . . . . . . . . . . . . . . . C1-460 beta-lactam resistance . . . . . . . . . . C1-463, F-2069 beta-lactam/beta-lactamase inhibitor . . . . . C2-694 beta-lactamase . . . . . . . . . . . . . . . C1-065, C1-076, C2-079, C1-460, C1-462, C1-463, C1-464, C1466, D-753, F-847, D-1449, C1-1204, C1-1209, C2-1902 beta-lactamase inhibitor . . . . . . . . . A-008, A-009, . . . . . . . . A-010, E-189, E-190, E-198, E-199, . . .C2-724,F-847, F-848, F-849, F-850, F-851, . . . . . . . F-852, F-853, F-858, A-1761, A-1763 beta-lactams. . . . . . . . . . . . . . . . . . . F-842, C2-149 Betaherpesviruses . . . . . . . . . . . . . . . . . . . G3-1546 biliary endoscopy . . . . . . . . . . . . . . . . . . . . . K-1608 binary toxin . . . . . . . . . . . . . . . . . . . . . . . . . . K-933 bioavailability. . . . . . . . . . . . . . . . . . . . . . . . A-1247 biodefense . . . . . . . . . . . . . . . . . . . F-1522, F-1525 biodistribution . . . . . . . . . . . . . . . . . . . . . . . A-1267 biofilm . . . . . . . . . . B-057, D-171, A-598, C1-666, . . . . . C1-673, C1-674, C1-677, E-777, E-790, . . . . . M-974, M-986, M-987, B-1318, B-1337, . . . B-1338, C1-1351, F-1492, F-1493, F-1518, . . M-1713, M-1716, M-1720, F-2000, F-2013, . . . . . . . . . . . F-2062, F-2064, F-2069, K-2094 biomarkers . . . . . . . P-570, D-163, K-926, D-1403, . . . . . . . . . . . . . . . . H-1567, M-1673, M-1676 biosynthesis . . . . . . . . . . . . . . . . . . . . . . . . . F-1508 biowarfare Pathogen . . . . . . . . . . . . . . . . . . F-1495 bis-amidine . . . . . . . . . . . . . . . . . . . . . . . . . . F-816 BK virus. . . . . . . . . . . . . . . . . . . . . . . T-354, T-360 BKV IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-361 BKV viruria . . . . . . . . . . . . . . . . . . . . . . . . . . T-361 blood . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-393

KEYWORD INDEX

blood culture . . . . .D-727, D-728, K-911, D-1408, . . . . . . . . . .D-1413, D-1414, D-1416, D-1417, . . . . . . . . . . . . . . . . . . . . . . . . .D-1423, K-1759

CA-MRSA . . . . . . . . . B-056, C2-1379, C2-1398, . . . . . . . . . . . . . . . . . . . . . . . L1-1654, L1-1657 CABP . . . . . . . . . . . . . . . C2-146, A-1286, F-1525

cardiac allograft vasculopathy . . . . . . . . . . . T-1071

blood stream infection and pneumonia . . . . . K-912 bloodstream infection . . . . K-271, P-569, C2-685, . . . . . . . D-726, K-896, K-900, K-914, T-1045, . . K-1123, D-1412, G3-1547, K-1590, K-1591, . . K-1609, K-1610, K-1615, L1-1656, K-1756, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1907 blurred vision . . . . . . . . . . . . . . . . . . . . . . . . . V-395 board game . . . . . . . . . . . . . . . . . . . . . . . . . K-2081

CAD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-229 Cadazolid . . . . . B-662, E-808, A-1273, C1-1346, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1347 Caenorhabditis elegans. . . . . . . . . . . B-1327, F-1538

cardiovascular disease . . . . . . . . . . . . . . . . . .H-230 carriage . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1912

Bolivia . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1205 bolus infusion . . . . . . . . . . . . . . . . . . . . . . . K-1612 bone and joint infection . . . . . . . . . B-1319, K-2076 bone cell invasion. . . . . . . . . . . . . . . . . . . . . B-1319 bone infection . . . . . . . . . . . . . . . . . . . . . . . . B-052 bone mineral density . . . . . . . . . . . . . . . . . . .H-231 booster doses . . . . . . . . . . . . . . . . . . . . . . . . G-1047 bordetell pertussis . . . . . . . . . . . . . . . . . . . . B-1322 Bordetella pertussis . . . . . . . . . . . . . . . . . . . G3-1563 Borrelia burgdorferi . . . . . . . . . . . . . . . . . . . . G3-1553 bovine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1315 bovine respiratory disease . . . . . . . C1-670, F-2034 bovis group streptococci. . . . . . . . . . . . . . . . D-1444 Brazil . . . . . . . . . . . . . . .C2-106, C2-716, C1-1207 breakpoints . . . . . . . . . . . . . . . . . . . . . . . . . . D-746 breast infection . . . . . . . . . . . . . . . . . . . . . . . K-252 broad spectrum . . . . . . . . . . . . . . . . E-191, F-1536 broad spectrum antibacterial agents. . . . . . . F-2017 broad-spectrum antimicrobial . . . . . . . . . . . F-2019 broad-spectrum beta-lactams . . . . . . . . . . . . A-637 broad-spectrum cephalosporin . . . . . . . . . . . F-843 broiler and layer chicken . . . . . . . . . . . . . . . P-1010 broiler chicken . . . . . . . . . . . . . . . . . . . . . . C2-1986 Bronchial epithelial cells . . . . . . . . . . . . . . . . A-597 Bronchoalveolar lavage . .A-1277, M-1701, K-1926 brucella . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-961 brucellosis . . . . . . . . . . . . . . . . . . . . . . . . . . L1-960 BSI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1452 bundle . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-1231 Buprenorphine. . . . . . . . . . . . . . . . . . . . . . . A-1250 Burkholderia . . . . . C1-460, K-904, K-1616, F-2033 Burkholderia cepacia complex . . . . . . . . . . . . . . . D-731 Burkhlolderia pseudomallei . . . . . . . . . . . . . . . P-1004

C c-di-GMP . . . . . . . . . . . . . . . . . . . . . . . . . . C1-673 C-reactive protein . . . . . . . . . . . . . . . . . . . . D-1402 C. albicans . . . . . . . . . . . . . . . . . . . . . M-970, A-1945 C. difficile–associated disease . . . . . . . . . . . . . B-663 C. glabrata . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-323 C. parapsilosis . . . . . . . . . . . . . . . . M-1058, M-1684

cagA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1981 calcaneal . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2074 Campylobacter. . . . . . . . . . . . . . . . .C2-714, D-1457 Canada . . . . . . . . . . . . . . . . . . . . . C2-085, C2-090

cardiac device infections . . . . . . . . . . . . . . . . D-165 cardiovascular . . . . . . . . . . . . . . . . . . . . . . . C2-140

case-control study . . . . . . . . . . . . . . . . . . . . M-313 caspofungin . . . . . . . . . . . M-968, M-978, M-1671 cassette chromosome recombinases (ccr) . . C1-1740 catheter . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2091 catheter related infection . . . . . . . K-1757, K-2088, . . . . . . . . . . . . . . . . . . K-2090, K-2097, K-2098

cancer . . . . . . .K-953, V-1075, G3-1546, G3-1547

catheter tip colonization . . . . . . . . . . . . . . . . D-167

Candida . . . M-330, F-814, K-949, M-978, M-979, . . . . . . . . M-1056, M-1229, M-1231, M-1674, . . . . . . . . M-1675, M-1683, M-1685, M-1700, . . . . . . . . . M-1709, M-1718, M-1720, A-1931 Candida albicans . . . . . . . . B-050, M-968, M-971, . . . . . . . . . . M-990, M-1696, M-1713, F-2000 Candida glabrata . . . . . . . . .M-316, F-822, M-985, . .M-1059, E-1466, M-1668, M-1717, A-1929

catheter-related bacteremia . . . . . . K-1758, K-2095 catheter-related bloodstream infection . . . . .K-948, . . . . . . . . . . . K-949, M-1688, K-1757, K-2087, . . . . . . . . . . . . . . . . . . . . . . . . . K-2090, K-2093 Cationic antimicrobial peptides . . . . . . . . . . F-2061 cationic peptide . . . . . . . . . . . . . . . . . . . . . . F-1491

Candida parapsilosis . . . . . . . . . . . . . . . . . . . M-326 Candida spp. . . . . . M-325, M-339, F-820, K-943, . . . . . . . . . . . . . . . . . . M-969, M-974, M-1715 Candida tropicalis . . . . . . . . . . . . . . . . . . . . . . M-967 candidemia . . . . . . . . . . . . M-311, M-312, M-313, . . . . . . M-317, M-323, M-325, M-329, T-349, . . . . . K-947, K-948, K-950, M-1230, M-1684, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-1700 candidiasis . . . . . . . . . . . M-980, M-1055, M-1229, . . . . . . . . . . . . . . . . . . . . . . . . M-1683, M-1709 candiduria . . . . . . . . . . . . . . . . . . . . . . . . . M-1673 CAP . . . . . . . . . . . . . . . . . . . . . . . L1-290, L1-294 capsular types. . . . . . . . . . . . . . . C2-1354, C2-1990 capybara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-993 carbapenem . . . . . . C1-071, E-193, K-234, K-237, . . . . . . .L1-289, C1-595, E-780, E-803, F-853, . . . . . . . . . . . . . . . . . . K-901, K-1615, C2-1899 carbapenem resistance . . . C2-096, D-751, T-1034, . . . . . . . . . . . . . . . . B-1336, C2-1897, C2-1901 carbapenem-hydrolyzing Class D ơ-lactamase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-068 carbapenem-resistant Enterobacteriaceae . . . . . . . . . . . . . C2-092, C2-095, K-234, D-750, . . . . . . . . . . . . . . . . C2-1211, C2-1215, K-1613 carbapenem-resistant Klebsiella pneumoniae . . . . . . . A-014, K-557, E-792, K-1609, K-1623 carbapenem/beta-lactamase inhibitor . . . . . . F-856 carbapenemase . . . . . . . . C1-061, C1-063, C1-067, . . . C1-069, C1-070, C1-078, C2-083, C2-084, . . . C2-085, C2-088, C2-093, C2-097, C2-118, . . . C2-121, C1-464, C1-587, C1-588, C1-591, . . D-745, D-746, D-748, E-800, F-849, F-850, . . . . . . . . .D-1447, D-1453, D-1448, C2-1213, . . . . . . . . . . . . . . . . C2-1216, C2-1905, F-2054 carbapenems . . . . . . . . . . . . . . . . . . . . . . . . C1-594 carbon monoxide . . . . . . . . . . . . . . . . . . . . . . F-830 carbon monoxide dehydrogenase . . . . . . . . . . D-739 carcinogenic Human Liver Fluke . . . . . . . . . P-999

Final Program

CAUTI . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2112 CAZ-AVI . . . . . . . . . . . . . . . . . . . . A-632, A-1760 CB-183,315. . . . . . . . . . . . . . . . . . . . . . . . . . E-807 CC11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1218 CCHF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-394 CCR5/CXCR4 . . . . . . . . . . . . . . . . . . . . . .H-1577 ccrAB . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1393 CDAD . . . . . . . . . . . . C1-1346, C1-1347, F-1530 cefazolin . . . . . . . . . . . . . . . . . . . . A-609, C2-1389 cefepime . . . . . . . . . . . . . . . . . . . . .C1-073, D-747 cefepime-tazobactam . . . . . . . . . . . . E-196, K-1618 cefoperazone/sulbactam . . . . . . . . . . . . . . . . . A-640 ceftaroline . . . . . . . . A-625, A-627, A-629, A-630, . . . . . A-631, C2-126, C2-127, C2-130, E-188, . . . . . . . . . . . . . . . . . . . D-771, K-909, D-1433 ceftaroline fosamil . . . . . . . . . . . . . . . . . . . L1-1661 ceftaroline-avibactam . . . . . . . . . . . . . . . . . . E-191 ceftazidime . . . . . . C1-076, E-190, A-631, A-633, . . . . . . . . . . . . . . . . . . . . .A-634, A-635, A-636 ceftazidime-avibactam . . . . . . . . . . . . . . . . . . E-187 ceftobiprole . . . . . . . . . . . . . . . . . . . A-624, A-624a ceftolozane. . . . . . . . E-198, E-200, E-201, A-641, . . . . . . . . . . . . . . . . . . . . . . . . A-1762, C1-1970 ceftriaxone . . . . . . . . . . . . . . . . . . . . . . . . . . . A-613 ceftriaxone resistance . . . . . . . . . . . . . . . . . . C2-695 cell defense . . . . . . . . . . . . . . . . . . . . . . . . . . A-599 cell division . . . . . . . . . . . . . . . . . . . . . . . . . F-1539 cell fractionation . . . . . . . . . . . . . . . . . . . . . A-1291 cell wall . . . . . . . . . . . . . . . . . . . . C1-1969, M-984 cell wall stiffness . . . . . . . . . . . . . . . . . . . . . D-1436 cell wall thickness . . . . . . . . . . . . . . . . . . . C1-1742 cellular immunity . . . . . . . . . . . . . . . . . . . . M-1708 CEM-101 . . . . . . . . . . . . . . . . . . . . . . . . . . . E-781 central line associated infection . . . . . . . . . . K-2085 central line-associated blood stream infection . . . . . . . . . . . . . . . . . . . . . . . . . . K-914, T-1044

263

> Keyword INDEX central nervous system infection . . . . . . . . L1-1650 central venous catheter . . . . . . . . . T-1044, K-2092 cephalosporin. . . . . . . . . C2-123, C2-124, C2-129, . . . . . . C2-131, E-199, L2-308, D-755, F-844, . . . . . . . . . . . . . . . . . . . . . . . . . F-845, L1-1659 cephamycinase . . . . . . . . . . . . . . . . . . . . . . . C1-075

clinical epidemiology . . . . . K-259, M-312, M-313, . . . . . . . . . . . . . . . . . . . D-161, H-887, M-1702 clinical features . . . . . . . . . . . . . . . . . . . . . . . K-905 clinical impact . . . . . . . . . . . . . . . . . . . . . . . M-320 clinical isolates . . . . . . . . . . . . . . . . . . . . . . . F-2037

cerebral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-568

clinical presentation . . . . . . . . . . . . . . . . . . . . V-398 clinical samples . . . . . . . . . . . . . . . . . . . . . . M-335

cerebrospinal fluid . . . . . . D-168, P-1023, M-1704 cervical cancer . . . . . . . . . . . . . . . . . . . . . . . L2-302 cetylpyridinium chloride . . . . . . . . . V-385, F-2015

clinical trial . . . .L1-299, H-877, V-1236, A-1272, . . . . . . . . . . . . . . . . . A-1285, F-2041, L1-1660

cfr . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1745

Clofazimine . . . . . . . . . . . . . . . . . . . . . . . . . A-1259

cfr gene . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1987 chagas’ disease . . . . . . . . . . . . . . . . . . . . . . . P-1013

clonal complex . . . . . . . . . . . . . . . . . . . . . . C2-1361 clonal complex 30 . . . . . . . . . . . . . . . . . . . . B-1320

characteristics . . . . . . . . . . . . . . . . . . . . . . . K-2073

clonal set . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-690 clonal virus. . . . . . . . . . . . . . . . . . . . . . . . . .H-1568

charcoal . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2003 charcoal-containin blood media . . . . . . . . . D-1409 chart review . . . . . . . . . . . . . . . . . . . . . . . . . L1-292 chemokine . . . . . . . . . . . . . . . . . . . . . . . . . . . B-057 chemokine receptor . . . . . . . . . . . . . . . . . . M-1055 chemotherapy . . . . . . . . . . . . . . . . . . . . . . . D-1458 chicken . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-714 child . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G3-1556 childhood. . . . . . . . . . . . . . . . . . . . . . . . . . G3-1555 children . . . . . . . . . V-390, G-864, K-953, V-1076, . . . . . .G3-1542, G3-1545, G3-1547, G3-1551, . . . . . . . .G3-1552, G3-1559, G-1749, A-1941, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1974 Chinese clinical isolates . . . . . . . . . . . . . . . . F-2036 Chlamydia trachomatis . . . . E-206, L2-305, L2-309 Chlamydophila . . . . . . . . . . . . . . . . . . . . . . . . E-207 chlorhexidine . . . . . . . . . . . . . . . . . . . . . . . C2-1914 chlorine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-243 Chromobacterium violaceum . . . . . . . . . . . . . F-2071 chromogenic test . . . . . . . . . . . . . . . . . . . . . . D-753 chronic cardiopulmonary disease . . . . . . . . . . G-872 chronic kidney disease . . . . . . . . . . . . . . . . . . K-235 chronic liver disease . . . . . . . . . . . . . . . . . . . . V-373 chronic Q-fever . . . . . . . . . . . . . . . . . . . . . . L1-965 Ciprofloxacin . . . . . . . . .C2-714, A-1968, C2-1982 Ciprofloxacin PK/PD . . . . . . . . . . . . . . . . . A-1965 Ciprofloxacin resistance . . . . . . . . . . . . . . . . C2-686 circulating DNA . . . . . . . . . . . . . . . . . . . . M-1692 CLABSI . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1755 class 1 integron . . . . . . . .C1-666, C2-712, C2-719 class C beta-lactamase . . . . . . . . . . . . . . . . . C1-073 class D beta-lactamase . . . . . . . . . . C1-074, C1-467 class D carbapenemase . . . . . . . . . . . . . . . . C1-595 clavulanic acid . . . . . . . . . . . . . . . . . . . . . . C1-1206 clearing device . . . . . . . . . . . . . . . . . . . . . . M-1062 Clinafloxacin . . . . . . . . . . . . . . . . . . . . . . . . F-2034 Clindamycin . . . . . . . . . . . . . . . . D-1431, L1-2106 clinical and environmental isolates . . . . . . . C1-668 clinical characteristics . . . . . . . . . . . . . . . . . . K-920

264

clinical studies . . . . . . . . . . . . . . . K-1618, L1-1659

clonality . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1606 clones . . . . . . . . . . . . . . . . . . . . . . C2-117, C2-1910 Clostridium difficile . . . . . . . . D-153, D-154, D-156, . D-157, D-158, D-159, D-162, D-163, K-469, . . K-470, K-471, K-472, K-473, K-474, B-662, . . B-664, E-807, E-808, K-919, K-922, K-924, . . K-925, K-926, K-929, K-930, K-931, K-932, . . . . . . . K-933, K-934, K-935, K-936, T-1029, . . . . . . . . . . . . . . . . . A-1274, C1-1347, F-1530 Clostridium difficile infection. . . . . . . .D-155, D-160, . . . . . . . . D-161, K-917, K-918, K-920, K-921, . . . . . . . . . . . . . . . . . . . . K-923, K-928, T-1068 Clostridium difficile toxin . . K-918, F-1537, B-1738 Clostridium perfringens . . . . . . . . . . . . . . . . F-2005 cloxacillin plus vancomycin . . . . . . . . . . . . . . B-648 CLSI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-752 CLSI 2012 breakpoints . . . . . . . . . . . . . . . . . D-747 CMI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1658 CMV . . . . . . . . . . . . . D-174, T-340, T-356, T-358 CMV resistance . . . . . . . . . . . . . . . . . . . . . . T-1072 CMX001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-362 CMY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-075 CMY-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-710 co-infection . . . . . . . . . . . . . . . . . . . . . . . . . . V-386 co-localization . . . . . . . . . . . . . . . . . . . . . . C1-1350 co-receptor tropism . . . . . . . . . . . . . . . . . . .H-1575 co-selection . . . . . . . . . . .C1-670, C2-708, C1-135 coagulase negative staphylococci . . . . . . . . . C2-1399 Cobicistat . . . . . . . . . . . . . . . . . . . . . . . . . . .H-892 Coccidioidomycosis . . . . . . . . . . . M-1697, M-1702 Coenzyme A . . . . . . . . . . . . . . . . . . . . . . . . F-1540 cohort . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-1043 cohort study . . . . . . . . . . . . . . . . . . . . . . . . . . V-387 coli . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-102 colistin . . . . . A-031, A-032, A-033, A-034, A-035, . . A-036, A-037, K-562, D-761, E-793, E-796, . . . . . .E-797, E-804, P-1024, B-1299, K-1602, . . . . . . . . . . . . . . . . . . .F-2006, F-2007, F-2008 colistin combinations . . . . . E-786, E-792, K-1605, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1607

September 9-12 |

colonization . . . . C2-096, D-166, K-560, C2-1974, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2112 colonization resistance . . . . . . . . . . . . . . . . . F-2003 colorectal cancer . . . . . . . . . . . . . . . . . . . . . F-1519 combination. . . . A-031, B-1298, E-1482, A-1930, . . . . . . . . . . . . . . . . . . . . . . . . . A-1944, F-2067 combination therapy . . . . . . E-195, V-388, A-601, . . . . . . . . A-626, D-756, E-791, E-795, F-821, . . . . . . . . . . . . . . . . . . . . . . . . . . K-922, E-1476 commensal bacteria . . . . . . . . . . . . . . . . . . C2-1399 commensal enterobacteria . . . . . . . . . . . . . . B-1305 community. . . . . . . . . . . .K-930, C2-112, C2-1380 community hospitals . . . . . . . . . . . C2-117, K-1923 community onset infections . . . . . . . . . . . . . T-1041 community-acquired . . . . . . . . . . . . . . . . . . C2-082 community-acquired bacterial pneumonia . . . . . . . . . . . . . . . . . . C2-145, L1-292, A-1269 community-acquired ESBL-E . . . . . . . . . . C2-104 community-acquired infections . . . . . . . . . . K-1754 community-acquired pneumonia . . . . . . . . . D-180, . . . . . . . . . . . . . . . . . L1-291, L1-298, G3-1549 community-associated . . . . . . . . . . K-920, C2-1908 community-onset. . . . . K-1587, L1-1645, L2-2113 companion animals . . . . . . . . . . . . . . . . . . C2-1219 comparative effectiveness. . . . . . . . . . . . . . . K-1628 complicated bloodstream infections. . . . . . . D-1411 complicated skin and skin structure infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-044 complications. . . . . . . . . . . . . . . . . . . . . . . . V-1078 conjugate vaccine . . . . . . . . . . . . . . . . . . . . G3-1543 conjugated vaccines . . . . . . . . . . . . . . . . . . . . G-865 conjugative plasmid . . . . . . . . . . . . . . . . . . C2-1987 contamination . . . . . . . . . . . . . . . . . . . . . . . . K-904 continuous infusion . . . . . . . . . . . . . . . . . . . . A-614 contributable mortality . . . . . . . . . . . . . . . . . K-921 copper . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-245 corals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-715 corticosteroids . . . . . . . . . . . . . . . . . . . . . . M-1697 cost-effectiveness . . . . . . . . . D-153, G-860, G-874, . . . . . . . . . . . . . . . . . . . . . . . . D-1424, M-1671 cost-effectiveness analysis . . . . . . . . . . . . . . K-1633 cost-of-illness-analysis. . . . . . . . . . . . . . . . M-1230 costs . . . . . . . . . . . . . . . . . . . . . . M-1706, L2-2115 Cotrimoxazole . . . . . . . . . . . . . . . . . . . . . . . K-2077 Coxiella burnetti . . . . . . . . . . . . . . . . . . . . . . . P-1012 Coxsackie Bs . . . . . . . . . . . . . . . . . . . . . . . . G-1748 Cpl-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-659 CR-Acinetobacter baumannii . . . . . . . . . . . C2-1900 Creatine phosphokinase . . . . . . . . . . . . . . . K-1626 creep . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1376 critical care. . . . . . . . . . . . . . . . . . . . . . . . . . . A-037 critically ill patients . . . . . . . . . . . . A-027, L1-1224 cross infection . . . . . . . . . . . . . . . . . . . . . . . K-1754 cross protection . . . . . . . . . . . . . . . . . . . . . . . B-053

KEYWORD INDEX

Cryptococcal antigen (CrAg) . . . . . . . . . . M-1699 Cryptococcal meningitis . . . . . . . . H-220, M-1670 Cryptococcosis. . . . . . . . M-336, M-1233, M-1677, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-1699 Cryptococcus . . . . . M-331, M-976, M-977, M-1693, . . . . . . . . . . . . . . . . . .A-1942, A-1943, A-1944 Cryptococcus gattii . . . . . . . . . . . . . . . T-345, M-1233 Cryptococcus neoformans . . . . . . . . . . . . . . . . M-314 crystal structure . . . . . . . . . . . . . . . . . . . . . . C1-465 cSSTI . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1666 CTX-M. . . . . . C1-072, C2-108, C2-113, C2-116, . . . . . . . . C2-119, C2-704, C1-1204, C1-1205, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1589 CTX-M expression . . . . . . . . . . . . . . . . . . . C2-115 CTX-M-15 . . . . . . . . . . . . . . . . . . . . . . . . . C2-110 CTX-M-2 . . . . . . . . . . . . . . . . . . . . . . . . . . C2-106 CTX-M-5 . . . . . . . . . . . . . . . . . . . . . . . . . . C2-697 CTXM . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1451 culture . . . . . . . . . . . . . . . . . . . . . . . D-174, E-1994 curli . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-674 cutaneous leishmaniasis . . . . . . . . . . . . . . . . P-1000 CVC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2013 CXCL8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1311 cyclic peptide . . . . . . . . . . . . . . . . . . . . . . . . F-1509 cystic fibrosis . . . . . . . . . . . A-035, A-036, C2-080, . . . . . A-597, A-643, E-1480, K-1616, F-2063, . . . . . . . . . . . . . . . . . . . . . . . . . F-2064, F-2070 Cytochromes P450 . . . . .A-1248, A-1254, A-1951 Cytokines . . . . . . . . B-055, B-056, B-058, B-1307 Cytomegalovirus . . . . H-224, T-355, T-362, T-365, . . . . . . . . T-366, T-368, T-369, V-393, T-1070, . . . . . . . . . . . . . . . . . . . . . . . . . T-1071, V-1242 Cytotoxin. . . . . . . . . . . . . . . . . . . . . . . . . . . B-1317

D Dalbavancin . . . . . . . . . . . . C2-138, A-623, E-1467 Daptomycin . . . . . . . K-275, K-276, K-278, K-279, . . K-280, A-598, A-600, A-601, A-602, A-603, . . A-604, A-605, A-606, B-649, B-653, B-654, . B-658, B-659, B-660, E-797, K-944, K-1121, . C2-1392, C1-1345, D-1438, E-1464, E-1465, . . . E-1468, E-1469, E-1476, E-1478, E-1482, . . L1-1638, K-1626, K-1631, K-1634, K-1635, . . K-1636, C1-1744, F-2011, K-2078, K-2085, . . . . . . . . . K-2095, K-2098, L1-2105, L2-2111 Daptomycin and p-glicoprotein . . . . . . . . . A-1769 Daptomycin non-susceptibility . . . . . . . . . C1-1743 Daptomycin nonsusceptible. . . . . . . . . . . . . . A-626 Daptomycin pharmacogenomic . . . . . . . . . . A-1769 Daptomycin pharmacokinetic . . . . . . . . . . . A-1769 Darunavir . . . . . . . . . . . . . . . . . . . . . . . . . . .H-889 DAS181 . . . . . . . . . . . . . . . . . . . . . . V-381, V-382 day 3 clinical response . . . . . . . . . . . . . . . . . K-1598 day 4 clinical Response . . . . . . . . . . . . . . . . L1-292 de-escalation . . . . . . . . . . . . . . . . . . K-271, L1-283

decision rule. . . . . . . . . . . . . . . . . . . . . . . . . . K-917 decolonization . . . . . . . . . . . . . . . . . K-267, T-1069 Dectin-1 . . . . . . . . . . . . . . . . . . . . . . . . . . M-1057 Decubitus . . . . . . . . . . . . . . . . . . . . . . . . . L1-2103 defined daily dose . . . . . . . . . . . . . . . . . . . . M-326 Delafloxacin . . . . E-208, A-598, L1-1663, A-1956, . . . . . . . . . . . . . . . . . . . . . . . . . A-1957, A-1958

doripenem . . . . . . . . A-013, A-014, A-015, A-016, . . . . . . . . A-017, A-018, A-019, A-020, A-024, . . . . . . . . . . . . . . . . . . . . E-786, E-803, K-1605 dose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-615 dose selection . . . . . . . . . . . . . . . . . . . . . . . . . A-029 dosing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-638 double umbilical cord blood transplant . . . . . T-354

delayed cerebral thrombosis . . . . . . . . . . . . L1-1223 demography . . . . . . . . . . . . . . . . . . . . . . . . . K-1925

doxycycline . . . . . . . . . . . . . . . . . . . . . . . . . P-1003 drosophila . . . . . . . . . . . . . . . . . . . . . . . . . . M-979 drug distribution . . . . . . . . . . . . . . . . . . . . . F-2026

dental medicine . . . . . . . . . . . . . . . . . . . . . . K-2084

drug interactions . . . . . . . . . . . . . . . . . . . . . A-1935

depression . . . . . . . . . . . . . . . . . . . . . . . . . . .H-232 Dermatophytes . . . . . . . . . . . . . . . . . . . . . . A-1946

drug regimen . . . . . . . . . . . . . . . . . . . . . . . . K-2100

dessication . . . . . . . . . . . . . . . . . . . . . . . . . . . K-559

drug resistance testing . . . . .V-374, D-737, D-1776 drug resistance, bacterial . . . . . . . . . . . . . . . K-1754

Delamanid . . . . . . . . . . . . . . . . . . . . . . . . . . A-1255

device-associated infections . . . . . . . . . . . . . . K-252 dexamethasone . . . . . . . . . . . . . . . . . . . . . L1-1222 diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1373 diabetic foot . . . . . . . . . . . . . . . . . . . . . . . . L1-1646 diacetyl rhein . . . . . . . . . . . . . . . . . . . . . . . . F-1532 diagnosis . . . . . . . . D-154, D-156, D-157, D-165, . . . . . . . D-166, D-176, D-177, D-183, D-185, . . . . D-741, P-1005, T-1026, M-1690, M-1692 diagnosis of schistosome hybdrid cluster . . . P-1014 diagnostic . . . . . . . . . . . . . . . . . . . . . . . . . . . D-160 diagnostic methods . . . . . . . . . . . M-1060, M-1694 diagnostic performance . . . . . . . . . . . . . . . . D-1425 diagnostic tests . . . . . . . . . . . . . . . . L1-298, D-169 dialysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-617 diarrhea . . . . . . . . . . . . . . . . . . . . . . . K-469, K-935 difficult-to-identify bacteria . . . . . . . . . . . . D-1772 Dihydropteroate synthase . . . . . . . . . . . . . . M-333 Dioctacecyldimethylammonium bromide . . .E-784, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-801 Dioctadecyldimethylammonium bromide bicelles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2004 direct-acting antivirals . . . . . . . . . . . . . . . . . V-1237 direct-testing . . . . . . . . . . . . . . . . . . . . . . . . . D-164 disease severity. . . . . . . . . . . . . . . . . . . . . . . . D-163 disinfectant . . . . . . . . . . . . . . . . . . . . . . . . . . F-825 disk conservation . . . . . . . . . . . . . . . . . . . . . . D-758 disk diffusion . . . . . . . . . . . . . . . . . . D-760, D-762 disk diffusion method . . . . . . . . . . . . . . . . . . D-758 DNA binding . . . . . . . . . . . . . . . . . . . . . . . . F-826 DNA gyrase. . . . .F-2018, F-2023, F-2026, F-2027 DNA gyrase, topoisomerase IV . . . . . . . . . . F-2028 DNA microarray . . . . . . . . . . . . . . . . . . . . . . K-255 DNA schistososome detection . . . . . . . . . . P-1014 DNA synthesis inhibitor . . . . . . . . . . . . . . . F-2019 DNA-Microarray . . . . . . . . . . . . . . . . . . . . D-1440 dnaQ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-667 Dolutegravir . . . . . . . . . . . . . . . . . . . . . . . . A-1249

Final Program

drug resistance . .F-1531, H-1574, L1-1654, E-1994

drug susceptibilities . . . . . . . . . . . . . . . . . . . M-987 drug-drug interaction . . . . . . . . . . A-1248, A-1254 DS-8587 . . . . . . F-2035, F-2036, F-2037, F-2038, . . . . F-2039, F-2040, F-2041, F-2042, F-2043, . . . . . . . . . . . . . . . . . . . . . . . . . F-2044, F-2045 duration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-615 Dutch community . . . . . . . . . . . . . . . . . . . . C2-104

E e-test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-164 E. coli . . . . . . . . . C2-100, C2-103, C2-687, C2-688, . . . . . C2-702, C2-710, C2-712, K-898D-1452, . . . . .K-1586, F-2025, F-2040, F-2049, F-2057 E. coli AmpC infection . . . . . . . . . . . . . . . . K-1621 early sepsis . . . . . . . . . . . . . . . . . . . . . . . . . L1-1647 Easter and Western Europe . . . . . . . . . . . . . C2-141 Eastern Europe . . . . . . . . . . . . . . . C2-136, C2-143 EBV surveillance . . . . . . . . . . . . . . . . . . . . . . T-352 Echinocandin . . . . . M-323, F-817, F-818, F-819, . . . . . F-821, F-823, M-981, M-1058, M-1675, . . . . . . . . . . . . . . . . . M-1720, A-1928, A-1929 Echinocandin resistance . . . . . . . . . . . . . . . M-967 Echinocandin susceptibility . . . . . . . . . . . . M-1710 Echinococcus . . . . . . . . . . . . . . . . . . . . . . . . . P-1018 ECHO and THRIVE . . . . . . . . . . . . . . . . . .H-880 Echocardiography . . . . . . . . . . . . . . . . . . . L1-1640 ECOFF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-187 economic evaluation . . . . . . . . . . . . K-239, K-1592 EDP-420 . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1303 Efavirenz . . . . . . . . . . . . . H-883, A-1255, A-1256 Effective dose . . . . . . . . . . . . . . . . . . . . . . . F-2056 effectiveness . . . . . . . . . . . . . . . . . . . . . . . . . . G-872 efficacy . . . . . . . . . . . H-555, B-664, F-817, F-2016 efficacy and safety . . . . . . . . . . . . . . . . . . . . K-1631 efficacy and tolerability . . . . . . . . . . . . . . . . .H-878 efflux . . . . . . . C1-675, C1-680, C2-696, C1-1341, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1747 efflux inhibitor . . . . . . . . . . . . . . . . . . . . . . . C1-674

265

> Keyword INDEX efflux inhibitors . . . . . . . . . . . . . . . . . . . . . . . F-814

enzyme mechanism . . . . . . . . . . . . . . . . . . C1-1344

efflux pumps . . . C1-672, C2-684, C2-692, F-1996 elderly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1293

Eosinophil peroxidase . . . . . . . . . . . . . . . . . F-1528 epidemic . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-363

electronic surveillance . . . . . . . . . . . . . . . . . K-1756

epidemic plasmid . . . . . . . . . . . . . . . . . . . . C1-1205

elisa . . . . . . . . . . . . . . . . . . . . . . . . D-183, M-1694

epidemiologic trends . . . . . . . . . . . . . . . . . . C2-725 epidemiology . . . . . . . . . C2-083, C2-095, C2-105, . . . . . .H-213, K-257, L1-293, L2-307, M-314, . . . . . M-318, M-327, M-336, K-472, C2-699, . K-908, K-930, K-947, P-994, P-1001, P-1012, . . V-1241, G3-1543, K-1593, K-1616, K-1621, . K-1622, L1-1639, L1-1645, G-1751, K-1758, . . . . . . . D-1775, C2-1905, C2-1908, C2-1985

elongation factor G . . . . . . . . . . . . . . . . . . C1-1973 Elvitegravir . . . . . . . . . . . . . . . . . . . . . . . . . A-1250 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-879 embolism . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1637 emergence of drug resistance . . . . . . . . . . . . C2-094 emergency department . . . . . . . . . L1-285, L1-286 Emericella sp . . . . . . . . . . . . . . . . . . . . . . . . . . F-812 Empyema . . . . . . . . . . . . . . . . . . . . . . . . . . C2-148 Encephalitis . . . . . . . . V-1239, C2-1374, G3-1545, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1649 end stage renal disease . . . K-235, K-1597, L1-1650 EndA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1535 Endocarditis . . . . . A-039, K-277, K-937, L1-962, . . . . . . . . L1-963, D-1411, L1-1637, L1-1638, . . . . . . . .L1-1639, L1-1640, L1-1644, M-1680 Endocarditis and biofilms . . . . . . . . . . . . . . . B-646 Endolysin . . . . . . . . . . . . . . . . . . . . . . . . . . F-1516 Endotracheal tube . . . . . . . . . . . . . . . . . . . M-1062 engineered antimicrobial peptides . . . . . . . . F-2061 enhanced combination effect . . . . . . . . . . . . . E-798 Enoyl reductase . . . . . . . . . . . . . . . . . . . . . . F-2072 Enterobacter. . . . . . . . . . . . . . . . . . . C1-683, A-1280 Enterobacter species . . . . . . . . . . . . . . . . . . . C2-105 enterobacteria . . . . . . . . . . . . . . . . . . . . . . . . D-759 Enterobacteriaceae . . . . . . C2-079, C2-083, C2-084, . . . C2-090, C2-093, C2-096, C2-097, C2-152, . . . . . . . E-191, E-195, C1-587, A-629, A-630, . . . . .C1-672, C2-694, C2-704, D-745, D-748, . . . . . . . .D-749, D-771, D-772, K-901, K-903, . . . . . . . . T-1035, C1-1202, C2-1214, D-1448, . . . . . . . . . . . . . . . . . . . . . . . . F-2053, L2-2116 Enterobacteriaceae species . . . . . . . . . . . . . . . . E-798 Enterococci . . . .E-778, K-944, C1-1345, C2-1986 Enterococcus . . . . . . . . K-273, K-274, K-275, K-277, . . . . . . . . . . . . . . . . . . . . . . . . . . K-278, K-1632 Enterococcus faecalis . . . . . . . .K-938, K-945, E-1465, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1637 Enterococcus faecium . . . . . . . . . . . . . . . . . . . . B-660 Enterococcus spp. . . . . . . . . . . . . . . . . . . . . . C2-1987 Enterococcus . . . . . . . . . . . . . . . . . . . . . . . . . E-1464 Enterotoxigenic Bacteroides fragilis. . . . . . . . F-1519 Enterotoxins . . . . . . . . . . . . . . . . . . . . . . . . D-1439 environment . . . . . . . . . . . . . . . . . . . . . . . . C2-716 environment disinfectant . . . . . . . . . . . . . . . . K-243 environmental . . . . . . . . . . . . . . . . . . . . . . . C2-717 environmental colonization . . . . . . . . K-245, K-246 environmental decontamination . . . . . . . . . . K-934 environmental factors . . . . . . . . . . . . . . . . M-1228 enzyme immunoassay . . . . . . . . . D-1407, M-1693

266

extended-spectrum beta-lactamase . . . . . . C2-118, . . . . . . . . . C2-703, C1-1203, K-1588, L2-2108 extended-spectrum cephalosporins . . . . . . . C1-590

F FAB001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2067 FabI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-1486 familial predeliction . . . . . . . . . . . . . . . . . . . C2-699 fatty acid . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2009 FDG-PET/CT . . . . . . . . . . . . . . . . . . . . . . L1-965

Epithelial lining fluid. . . . .A-025, A-1277, A-1933 Epsilon toxin . . . . . . . . . . . . . . . . . . . . . . . . F-2005

Febrile neutropenia . . . . .T-1028, T-1046, D-1402, . . . . . . . . . . . . . . . . . . . . . . . . .D-1403, D-1405

Epstein-Barr virus . . . . . . . . . . . . . . . . . . . . V-1241

fecal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1963 Ferrioxamine . . . . . . . . . . . . . . . . . . . . . . . . M-973 FIC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-203 FIC index . . . . . . . . . . . . . . . . . . . . . . . . . . . E-782 Fidaxomicin . . . . . . K-471, K-473, K-932, A-1274, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1346

Ergosterol . . . . . . . . . . . . . . . . . . . . . . . . . . M-970 Erm41 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-735 Ertapenem . . . . . . . . . . . . . .A-013, A-014, K-1585 ESBL. . . . . . . . C1-071, C2-100, C2-101, C2-103, . . . C2-108, C2-109, C2-105, C2-107, C2-112, . . . . . . C2-114, C2-147, E-186, E-194, E-196, . . . C1-462, C2-691, C2-701, C2-704, C2-718, . . . . . . . . D-752, D-773, E-798, E-803, F-855, . . . . . . . T-1035, C1-1202, C1-1207, C1-1208, . . . D-1447, K-1583, K-1584, K-1586, K-1590, . . . . . . . . . . . . . . . . . . . . . . . . . K-1591, F-2054 ESBL enterobacteria . . . . . . . . . . . . . . . . . . C2-117 ESBL-producing Enterobacteriaceae . . . . . . . .K-560, . . . . . . . . . . . D-754, D-755, K-1585, L2-2113 ESBL-producing Escherichia coli . . . . . . . . C2-689, . . . K-1587, K-1589, K-1592, K-1617, L2-2109 Escherichia . . . . . . . . . . . . . . . . . . . . . . . . . . C2-102 Escherichia coli . . . . . . . . C1-075, C2-080, C2-094, . . . . . C2-111, C2-113, C2-114, E-197, E-201, . . L1-283, C2-685, C2-686, C2-1219, B-1305, . . . . . . . . . . F-1540, K-1588, A-1965, L2-2108 ESKAPE pathogens . . . . . . . . . . . . K-233, T-1030 essential oils . . . . . . . . . . . . . . . . . . . . . . . . . . F-833 Etest . . . . . . . . . . D-765, E-799, D-1433, K-1604 Ethanol . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2098 Etiology . . . . . . . . . . . . . . . . . . . . . . . . . . . G3-1544 Eucast . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-757 Europe . . . . . . L1-290, C2-147, C2-1352, L1-1666 evaluation . . . . . . . . . . . . . . . . . . . . . P-567, K-910 evolution . . . . . . . . . . . . . . . . . . . . C1-461, M-966 exam gloves . . . . . . . . . . . . . . . . . . . . . . . . . K-2082 excision . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1746 exotic birds. . . . . . . . . . . . . . . . . . . . . . . . . . . P-995 experimental endocarditis . . . . . . . . A-610, B-645, . . . . . . . . . . . . . . . . . . . . . . . . . . . B-648, K-943 experimental meningitis . . . . . . . . . . . . . . . . B-649 exposure . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1934 exposure-response . . . . . . . . . . . . . . . . . . . . A-1933 extended spectrum cephalosporins . . . . . . . . D-753 extended infusion . . . . . . .A-643, A-1766, A-1767 extended spectrum beta lactamase . . . . . . . . C2-121

September 9-12 |

Fimbriae . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1322 FimH antagonists . . . . . . . . . . . . . . . . . . . . F-2057 Finafloxacin . . . . . . . . . . . . . . . . . . A-1959, A-1960 first-line therapy . . . . . . . . . . . . . . . . . . . . . K-2095 FKS mutations . . . . . . . . . . . . . . M-1675, M-1710 FKS1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-979 Flouroketolide . . . . . . . . . . . . . . . . . . . . . . . A-1286 Fluconazole . . . . . . F-811, M-970, M-971, M-985, . . . . . . . . . . . . . . . . . . . . . . . . . A-1943, A-1945 Fluconazole resistant . . . . . . . . . . . . . . . . . M-1059 Fluorocycline . . . . . . . . . . . . . . . . . . . . . . . . . E-777 Fluoroquinolone . . . . . . . C2-125, E-209, C1-665, . . . . . C2-708, D-760, D-764, L1-957, A-1949, . . . A-1951, A-1952, A-1953, A-1954, A-1955, . . . .A-1957, A-1959, A-1960, F-2037, F-2038, . . . . F-2046, F-2047, F-2048, F-2049, F-2054, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2055 Fluoroquinolone resistance . . . . C1-667, C2-1355, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1400 Fluroketolide . . . . . . . . . . . . . . . . . . . . . . . . F-1505 food . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-925 food chain . . . . . . . . . . . . . . . . . . . . . . . . . . C2-707 food contamination . . . . . . . . . . . . . . . . . . . . K-560 food of animal origin . . . . . . . . . . . . . . . . . . C2-713 foodborne pathegon. . . . . . . . . . . . . . . . . . . F-1494 foreign body osteomyelitis . . . . . . . . . . . . . . . B-652 foreign-body infection . . . . . . . . . . . . . . . . . . B-647 Foscavir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-358 Fosfomycin . . . . A-602, B-647, C1-1203, C2-087, . . . . . . . . . . . . E-793, A-1279, E-1477, K-1602 FQs . . . . . . . . . . . . . . . . . .F-2050, F-2051, F-2052 Francisella tularensis . . . . . . . . . . . . . L1-964, F-2072 French guiana . . . . . . . . . . . . . . . . . . . . . . . P-1011 ftsI mutations . . . . . . . . . . . . . . . . . . . . . . C2-1975 full genome sequence . . . . . . . . . . . . . . . . . . C1-678 Fungaemia . . . . . . . . . . . . . . . . . . . . . . . . . . M-318

KEYWORD INDEX

fungal. . . . . . . . . . . . . . . M-327, M-1688, M-1691 fungal diseases . . . . . . . . . . . . . . . . . . . . . . M-1063 fungal infections . . . . . . . . . M-338, T-343, T-345, . . . . . . . . . . . . . . . . . . . . . . . . .M-1060, T-1066 Fungemia-fungicidal . . . . . . . . . . . . . . . . . . . F-816 Furanoside . . . . . . . . . . . . . . . . . . . . . . . . . . P-1007 Fusariosis . . . . . . . . . . . . . . . . . . . M-1234, M-1690 fusC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1339 fusidic acid . . . . . . . . . . . . . . . . . . . . . . . . . C1-1339 fusidic acid resistance. . . . . . . . . . . . . . . . . C2-1394 fusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-554

G Galactomannan . . . . . . . T-1067, M-1226, M-1690 Galleria mellonella . . . . . . B-1323, B-1326, K-1614 Ganciclovir . . . . . . . . . . . . . . . . . . . . . . . . . . T-358 gastric band . . . . . . . . . . . . . . . . . . . . . . . . . . K-265 Gastroenteritis . . . . . . . . . . . . . . . . . . . . . . . D-1457 gastrointestinal illness . . . . . . . . . . . . . . . . . P-1021 GDH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-157 Genadine antiseptic . . . . . . . . . . . . . . . . . . . K-2082 gender stratification . . . . . . . . . . . . . . . . . . . .H-882 gene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-101 gene regulation . . . . . . . C1-671, C1-676, C1-677, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1351 generic antibiotics . . . . . . . . . . . . . . . . . . . . . B-645 genetic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-876 genetic elements . . . . . . . . . . . . . . . . . . . . . .H-894 genetic identification . . . . . . . . . . . . . . . . . . D-1460 genetic resistance elements . . . . . . . . . . . . C2-1383 genetic variation . . . . . . . . . . . . . . . . . . . . . B-1309 GeneXpert . . . . . . . . . . . . . . . . . . . . . . . . . . D-1427 GenomEra . . . . . . . . . . . . . . . . . . . . . . . . . . D-1415 genomics . . . . . . . . . . . . . . . . . . . . .K-474, H-1569 genotypes . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1358 genotypic algorithm. . . . . . . . . . . . . . . . . . .H-1574 genotypic resistance . . . . . . . . . . . . . . . . . . . .H-215 genotypic tools. . . . . . . . . . . . . . . . . . . . . . .H-1576 genotyping . . . . . . . . . . . . . . . . . . .H-214, C2-1980 Gentamicin . . . . . . . . . . . . . . . . . . . . . . . . . . A-039 geographic information system . . . . . . . . . . . P-998 geriatrics . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-954 Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-863 GES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-718 Ghrelin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-394 GIM-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-588 global suppressor . . . . . . . . . . . . . . . . . . . . C1-1209 glucan synthase enzyme. . . . . . . . . . . . . . . . . F-822 glucan synthesis . . . . . . . . . . . . . . . . . . . . . M-1057 Glutamate dehydrogenase . . . . . . . . . . . . . . . D-156 Glyceryl trinitrate . . . . . . . . . . . . . . . . . . . . F-2012

Glycopeptides . . . . . . . . . F-1506, F-1507, F-1510, . . . . . . . . . . . . . . . . . . . . . . . . . F-1511, F-1512 gold nanoparticle . . . . . . . . . . . . . . . . . . . . . F-2002 Gonorrhea . . . . . . . . . . . . . . . . . . . . . . . . . . F-2052

heart failure . . . . . . . . . . . . . . . . . . . . . . . . . M-991 heart transplant . . . . . . . . . . . . . . . . T-364, T-1071 helicase-primase . . . . . . . . . . . . . . . . . . . . . . V-391 Helicobacter . . . . . . . . . . . . . . . . . . . M-328, K-897

grafts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-164 gram-negative . . . . . . . . . A-040, C2-150, F-1522, . . . . . . . . . . . . . . . . . . . . . . . . . F-2023, K-2079 gram negative bacilli . . . . . . K-561, E-802, K-896, . . . . . . . . . . . . . . . . . . . . . . . . . A-1270, A-1271

Helicobacter pylori . . . . . . . . . . . . . . . . . . . . . C2-1981

gram-negative antibacterial agents . . . . . . F-2018a

hematopoietic cell transplantation . . . T-362, T-1065 hematopoietic stem cell transplant . . V-393, T-1045 hematopoietic stem cell transplantation . . . . T-367, . . . . . . . . . . . . . . . . . . . . . . . . . T-1038, T-1044

gram-negative bacteremia . . . . . . . . . . . . . . . K-916 gram-negative bacteria . . . . . . . . . C2-151, D-766, . . . . . . . . . . . . K-897, F-2002, F-2046, F-2069 gram-positive . . . . . . . . . . . . . . . . C2-132, C2-133, . . . . . . . . . . . C2-138, F-1497, F-1498, F-1499, . . . . . . . . . . . .F-1500, F-1501, F-1503, F-1521 gram-positive cocci . . . . . . . . . . . .D-1433, D-1438 gram-positive organisms . . C2-134, C2-151, F-2047 group B streptococci . . . . . . . . . C2-1988, C2-1989 group B streptococcus . . . . . . . . . . . . . . . . . . G-1751 growth curves . . . . . . . . . . . . . . . . . . . . . . . A-1940 GS-7340 . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-552 GSK1322322. . . . . . . . . . . . . . . . . A-1276, A-1277 GSK2251052. . . . . . . . . . E-802, A-1270, A-1271, . . . . . . . . . . . . . . . . . . . . . . . . . A-1272, B-1304 guidelines. . . . . . . . . . . . . . . . . . . . . . . . . . . L1-298 gyrA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-696 Gyrase . . . . . . . . . . . . . . . .F-2016, F-2024, F-2025 Gyrase B . . . . . . . . . . . . . . . . . . . . F-2020, F-2022 Gyrase inhibitor. . . . . . . . . . . . . . . F-2021, F-2029

H H. influenzae . . . . . . . . . . . . . . . . . . . . . . . C2-1975 H1N1 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . B-045 H1N1 influenza. . . . . . . . . . . . . . . . . . . . . . . V-398 HA-MRSA . . . . . . . . . . . . . . . . . . . . . . . . C2-1379 HAART . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-230 Haemophilus spp. . . . . . . . . . . . . . . . . . . . . . . . C2-145 halogenobenzimidazoles . . . . . . . . . . . . . . . . . F-1533 hamster . . . . . . . . . . . . . . . . . . . . . F-1530, B-1738 hand hygiene . . . . . . . . . . . . . . . . C2-1915, K-2083 handwashing compliance . . . . . . . . . . . . . . . K-2080 HBV vaccine . . . . . . . . . . . . . . . . . . . . . . . . . V-375 HCMV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-392 HCV . . . . . . . . . . . . . . . . . . . . . . . . . V-370, V-371 HCV infection . . . . . . . . . . . . . . . . . . . . . . . V-372 health related quality of life . . . . . . . . . . . . . L1-300 healthcare . . . . . . . . . . . . . . . . . . . . . . . . . . C2-122 healthcare-associated infection . . . . K-245, K-246, K-947 healthcare-associated infections. . . . . . . . . . K-2084 healthcare-associated pneumonia . . . . . . . . K-2100 healthy children . . . . . . . . . . . . . . . . . . . . . . G-1049

Final Program

hematologic disease . . . . . . . . . . . . . . . . . . . D-1403 hematological malignancy . . . . . . . . . . . . . M-1669 hematology . . . . . . . . . . . . . . . . . . . . . . . . . . K-898

Hemodialysis . . . . . . A-606, A-618, A-636, K-923, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1630 Hemodialysis catheter . . . . . . . . . . . . . . . . . K-2093 Hemorrhagic cystitis . . . . . . . . . . . . . . . . . . . T-360 hepatic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1295 hepatic impairment . . . . . . . . . . . . . . . . . . . A-1260 hepatitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-885 hepatitis A vaccination . . . . . . . . . . P-1015 P-1016 Hepatitis B . . . . . . . . . . . . . V-374, V-379, G-1047 Hepatitis B virus . . . . . . . . . . . . . . . . H-218, V-373 Hepatitis C . . B-053, T-364, V-379, F-828, A-1248 Hepatitis C virus . . . D-185, H-215, T-368, V-377, . . . . . . . F-826, F-827, G-871, V-1236, V-1237 Hepatitis E . . . . . . . . . . . . . . . . . . . . . . . . . . V-376 Hepatitis E virus . . . . . . . . . . . . . . . D-184, V-1238 hepatotoxicity . . . . . . . . . . . . . . . . . . . . . . . .H-221 herpes simplex virus. . . . . . . . D-185, T-342, T-367, . . . . . . . . . . . . . . . . . . . F-824, V-1239, H-1920 hetero-VISA . . . . . . . . . . . . . . . . . . . . . . . . D-1434 heterocycle . . . . . . . . . . . . . . . . . . . . . . . . . . F-1526 heterogeneous macrolide resistance . . . . . . . D-1430 heteroresistance . . . . . . . . . . . . . . . M-985, D-1435 heterosubtypic antibodies . . . . . . . . . . . . . . . V-384 Hexaplex PCR. . . . . . . . . . . . . . . . . . . . . . . D-1437 HHV-6 . . . . . . . . . . . . . . . . . . . . . T-351¸G3-1546 high level mupirocin resistance . . . . . . . . . C2-1394 high resolution melt. . . . . . . . . . . . . . . . . . . . D-735 high throughput screening. . F-827, F-831, F-1536 high-inoculum effect . . . . . . . . . . . . . . . . . C2-1389 high-throughput compound screening . . . . F-1535 histone acetyltransferase . . . . . . . . . . . . . . . . F-813 histopathology . . . . . . . . . . . . . . . . . . . . . . . M-967 histoplasma . . . . . . . . . . . . . . . . . . . . . . . . M-1694 HIV . . . . . . H-212, H-213, H-219, H-225, H-227, . . . . . . . H-228, H-231, H-232, H-550, H-552, . . . . . . . H-554, M-336, V-371, H-877, H-883, . . . . . . . . .A-1253, C2-1373, H-1567, H-1570, . . . . . . . . . H-1577, H-1580, H-1581, H-1582, . . . . . . . . . .H-1916, H-1919, H-1920, H-1921 HIV co-receptor . . . . . . . . . . . . . . . . . . . . .H-1569 HIV complications . . . . . . . . . . . . . . . . . . . .H-887 HIV drug mutation . . . . . . . . . . . . . . . . . . .H-1572

267

> Keyword INDEX implantable port device . . . . . . . . . . . . . . . . K-2087 improved bioavailability . . . . . . . . . . . . . . . . F-1489

HIV infection . . . . H-224, H-229, H-230, A-1252

human metapneumovirus . . . . . . . . . . . . . . . V-399

HIV infections/complications . . . . . H-217, H-888 HIV infections/immunology . . . . . . . . . . . . .H-553

human papillomavirus (HPV) . . . . . . . . . . . L2-301 human pharmacokinetics . . . . . . . . . . . . . . . A-1273

in vitro . . . . . . . . . . . . . . . E-1995, F-1510, F-1512

HIV low-level viremia . . . . . . . . . . . . . . . . .H-1566

human-use antibiotics . . . . . . . . . . C2-705, C2-709

in vitro activity . . . . . . . . . .F-1506, F-2019, F-2049

HIV testing . . . . . . . . . . . . . . . . . H-1571, H-1581

hVISA . . . . . . . . . . . . . . K-1123, C2-1381, E-1469

in vitro antifungal susceptibility. . . . . . . . . M-1669

HIV therapy . . . . . H-553, H-556, H-884, H-894, . . . . . . . . . . . . . . . . . . . . . . . . H-1565, H-1579

hVISA/VISA/VRSA . . . .A-626, A-627, C1-1743 Hydatid disease . . . . . . . . . . . . . . . . . . . . . . P-1018

in vitro model . . . . . . . . . . . . . . . . A-1967, F-2014

HIV tropism . . . . . . . . . . . . . . . . . . . . . . . .H-1576

hydrazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-844

HIV undetectability . . . . . . . . . . . . . . . . . .H-1566

hydrochoerus hydrochaeris . . . . . . . . . . . . . . P-993 hyperbilirubinemia . . . . . . . . . . . . . . . . . . . A-1251

HIV-1 . . . . . . . . . . . . . . . . . . . . . . H-1917, H-885 HIV-1 resistance . . . . . . . . . . . . . . . . . . . . .H-1571 HIV-1 treatment . . . . . . . . . . . . . . . . . . . . . .H-878

hypermucoviscosity phenotype . . . . . . . . . . B-1324 hypermutant . . . . . . . . . . . . . . . . . . . . . . . . . A-011

HIV-1 tropism . . . . . . . . . . . . . . . . . . . . . .H-1579

hypersensitivity . . . . . . . . . . . . . . . . . . . . . . .H-895

HIV-1 viral load . . . . . . . . . . . . . . . . . . . . .H-1579 HIV-O . . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-886

hyperthermia . . . . . . . . . . . . . . . . . . . . . . . . M-972 hypoxia . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1334

HIV-positive . . . . . . . . . . . . . . . . . . . . . . . . .H-556 HIV/AIDS . . . . . . . . . H-1564, M-1677, M-1699

I

HIV/AIDS-TB . . . . . . . . . . . . . . . . . . . . . . .H-893 HIV/HCV co-infection . . . . . . . . . H-214, H-216, . . . . . . . . . . . . . . . . . . . . . . . . . . H-217, H-884 HLA testing . . . . . . . . . . . . . . . . . . . . . . . . .H-895

ICU . . . . . . . . . . C2-144, H-227, M-1698, K-2088 ICU mortality . . . . . . . . . . . . . . . . . . . . . . . . K-951

hMPV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-386 hollow-fiber model . . . . . . . . . . . . . . . . . . . . A-632 homeless . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-959 homosexual men . . . . . . . . . . . . . . L2-301, V-1238

identification of mycobacteria to the species . .D-734

hospital . . . . . . . . . . . . . . . . . . . . . . . H-213, P-566 hospital acquired infection (HAI) . . K-238, K-908, . . . . . . . . . . . . . . . . . . . . . K-952, K-927, K-936 hospital health workers . . . . . . . . . . . . . . . . . D-744 hospital-acquired MRSA . . . . . . . . . . . . . C2-1911 hospital-acquired pneumonia . . . . . . B-054, A-640 hospitalization . . . . . . . . . . H-211, L1-290, V-389, . . . . . . . . G3-1551, K-1598, L1-1661, L1-1666 hospitalization cost . . . . . . . . . . . . . . . . . . . . D-159 host defense . . . . . . . . . . . . . . . . . . . . . . . . . . B-651 host defense protein. . . . . . . . . . . . E-1474, F-1493, . . . . . . . . . . . . . . . . . . . . . . . . . F-1494, F-1495 host responses . . . . . . . . . B-051, B-1335, M-1708 housekeeping . . . . . . . . . . . . . . . . . . . . . . . . . V-383 HPV . . . . . . . . . . . . . . . . . . . . . . . L2-304, H-1921 HPV 16 . . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-302 HPV infection . . . . . . . . . . . . . . . . . . . . . . . L2-304 HPV prevention . . . . . . . . . . . . . . . . . . . . . L2-304 HRM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1445 HSCT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-361 HSV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-307 HSV-shedding. . . . . . . . . . . . . . . . . . . . . . . . V-391 human . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1315 human ADME . . . . . . . . . . . . . . . . . . . . . . A-1956 human alpha-defensins 1-3 . . . . . . . . . . . . . F-1488 human blood biomarkers . . . . . . . . . . . . . . M-1695 human immunodeficiency virus . . . . . . . . . . .H-223 human immunodeficiency virus type 1 . . . .H-1918

268

ICU patients . . . . . . . . . . . . . . . . . . . . . . . . V-1242 identification . . . D-727, D-1410, D-1444, D-1777 IGRA . . . . . . . . . . . . . . . . . . . . . . . D-740, D-742 IL-10R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-871 Ilicicolin H . . . . . . . . . . . . . . . . . . . . . . . . . . F-810 imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-568 imaging techniques . . . . . . . . . . . . . . . . . . . L1-960 imipenem. . . . . . . . A-009, A-021, C1-070, E-192, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-724 imipenem-sulbactam sinergy . . . . . . . . . . . . . E-202 Imipenem/MK-7655 . . . . . . . . . . . . . . . . . . . D-767 immune memory . . . . . . . . . . . . . . . . . . . . . G-1047 immune response . . . . . . . . B-055, H-222, G-1054, . . . . . . . . . . . . . . . . . . . . . . . . H-1565, H-1567 immunization . . . . . . . . . . . . . . . . . . B-046, V-384 immunization status . . . . . . . . . . . . . . . . . . . P-996 immunoassay . . . . . . . . . . . . . . . . . . . . . . . . . D-184 immunocompromised . . . . . . . . . . . . . . . . . . T-349 immunocompromised host . . . . . . . . T-344, V-376 immunocompromised patients . . . . . V-397, K-902 immunogenicity . . . . . . . . . . . . . . . . . . . . . . . G-867 immunologic progression. . . . . . . . . . . . . . .H-1578 immunological failure . . . . . . . . . . . . . . . . .H-1564 immunology . . . . . . . . . . . . . . . . . . . . . . . . . B-661 immunomodulation . . . . . . . .B-048, B-050, B-657, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1297 immunopharmacology . . . . . . . . . . . . . . . . . M-984 immunosuppressor exposure . . . . . . . . . . . G3-1557 IMP-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1215 IMP-27 . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-090 IMP-36 . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-067 impaired hepatic function . . . . . . . . . . . . . . A-1283

September 9-12 |

in vitro PK/PD model . . . . . .A-022, A-023, A-621 in vitro susceptibility . . . . . . . . . . . . D-770, F-1520 in vitro time-kill curve . . . . . . . . . . . . . . . . . A-1764 in vivo . . . . . . . . . . . . . . . . . . . . . . . B-664, K-1617 in vivo efficacy . . . . . . . . . . B-656, F-1507, F-2055 in-hospital mortality . . . . . . . . . . . . . . . . . . .H-228 inactivation . . . . . . . . . . . . . . . . . . . . . . . . . . E-780 Inc I1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-707 incidence . . . . . . K-273, T-344, C2-1363, L1-1643 incompatibility types . . . . . . . . . . . . . . . . . . C1-589 India . . . . C1-063, C2-099, K-236, P-564, P-565, . . . . . . . . . . . . . . . . . . . . . . . . . P-1004, K-1618 Indian S.aureus . . . . . . . . . . . . . . . . . . . . . . . B-1315 inducible-resistance . . . . . . . . . . . . . . . . . . . D-1431 infants . . . . . . . . . . . . . . . . . . . . .A-1245, G3-1561 infection. . . . . . . . K-263, T-1026, T-1027, T-1043, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1380 infection control . . . . . . . . D-155, D-751, D-1442, . . . . . . . . . . . . . . . . . . . . . . . . . K-1611, K-2081 infection model . . . . . . . . . . . . . . . . . . . . . . F-1487 infectious disease . . . . . . . . . . . . . . . . . . . . . . P-564 infective endocarditis . . . . . . K-939, K-940, K-941, . . . . . . . K-942, K-944, K-945, K-946, K-1122, . . . . . . . . . . . . . . . . . . E-1464, E-1465, F-1517 inflammation . . . . . . . . . . . . . . . . . . . . . . . . B-1307 inflammatory bowel disease . . . . . . . . . . . . . F-1519 influenza . . . . V-380, V-384, V-385, V-389, V-390, . . . . . . . V-400, K-952, K-955, K-956, G-1053, . . . . . . . . . V-1079, A-1243, A-1246, G3-1549, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G3-1550 influenza A . . . . . . . . . . . . . . . . . . . G-873, V-1077 influenza A virus H1N1 subtype . . . . . . . . . . V-387 influenza A viruses. . . . . . . . . . . . . . . . . . . . . V-388 influenza H1N1. . . . . . . . . . . . . . . . . . . . . G3-1548 influenza like illness . . . . . . . . . . . . . . . . . . . . V-398 influenza vaccine . . T-359, G-872, K-953, G-1052 informatics . . . . . . . . . . . . . . . . . . . . . . . . . . M-315 infusion duration . . . . . . . . . . . . . . . . . . . . . A-1761 INH. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-959 inhibition . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-066 inhibitor. . . . .F-813, F-826, F-857, V-370, F-2016 inhibitor resistant phenotype . . . . . . . . . . . . C2-694 injection drug users . . . . . . . . . . . . . . . . . . . . V-371 innate immunity . . . . . . . . . . . . . . . . B-054, B-059 inoculum . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-253 inoculum effect . . . . . . . . . . . . . . . . . . . . . . A-1764 Inquilinus limosus . . . . . . . . . . . . . . C1-466, C1-678 insertion sequence . . . . . . . . . . . . . . . . . . . . C1-064

KEYWORD INDEX

integrase . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-550

Israel . . . . . . . . . . . . . . . . . . . . . . . C2-099, L1-961

Lactococcus lactis . . . . . . . . . . . . . . . . . . . . . B-046

integrase inhibitor . . . . . . . . . . . . . . . . . . . . A-1252 integrase mutations . . . . . . . . . . . . . . . . . . .H-1574

Italy . . . . . . . . . . . . . . . . . . . . . . . C1-594, C2-1211 Itraconazole . . . . . . . . . . . . . . . . . . . . . . . . . M-991

Lactoferrin. . . . . . . . . . . . . . . . . . . . . . . . . . . D-162 LAMP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1456

integrative and conjugative element. . . . . . . C1-670

ITS region . . . . . . . . . . . . . . . . . . . . . . . . . . . D-734

latent tuberculosis . . . . . . . . . . . . . . . . . . . . T-1032

integron . . . . . . . . . . . . . .C1-068, C2-101, D-1408

ITS region sequence analysis . . . . . . . . . . . . D-1443

latent tuberculosis infection . . . . . . .D-744, T-1033, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-1917 lateral flow device . . . . . . . . . . . . . . . . . . . M-1682

intensive care unit . . . . . . . . A-021, K-270, K-950, . . . . . . . . . . . . . . . . . . . . . . . . M-1230, K-2080 interactions . . . . . . . . . . . . . . . . . . . . . . . . . . D-769

J

Latin America . . . . . . . . . . . . . . . . . . . . . . C2-1909

interferon . . . . . . . . . . . . . . . . . . . . H-216, D-1407

Japan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-223

Legionella pneumonia . . . . . . . . . . . L1-293, L1-295

interferon-Ƣ release assay . . . . . . . . . . . . . . . . D-744 interferon-gamma . . . . . . . . . . . . . . . . . . . . D-1406

JNJ-Q2 . . . . . . . . . . . . . . . . . . . . . A-1961, A-1962

Legionella pneumophila . . . . . . . . . . . . . . . . . B-1297 Leishmania . . . . . . . . . . . . . . . . . . . . . . . . . P-1007

interferon-gamma release assay . . . D-741, H-1918

K

Leishmaniasis . . . . . . . . . . H-222, P-1007, P-1020

interferon-Î³ release assay . . . . . . . . . . . . . .H-1919 intergenus transfer . . . . . . . . . . . . . . . . . . . . C1-679 internalization . . . . . . . . . . . . . . . . . . . . . . . B-1334 interventional study . . . . . . . . . . . . . . . . . . . . V-375 intestinal microbiota . . . . . . . . . . D-1458, L1-1642 intra-abdominal . . . . . . . . . . . . . . . C2-100, C2-141 intra-abdominal candidiasis . . . . . . . . . . . . M-1056 intra-abdominal infection . . . . . . . C2-702, F-2044 intracellular . . . . . . . . . . . . . . . . . . . . . . . . . F-2029 intracellular activity . . . . . . . . . . . . . . . . . . . . E-781 intracellular infection . . . . . . . . . . . . . . . . . . . A-596 intracranial pressure . . . . . . . . . . . . . . . . . . L1-1652 intraluminal catheter biofilm . . . . . . . . . . . . F-2012 intravenous . . . . . . . . . . . . . . . . . . . . . . . . . A-1276 intravenous immunoglobulin . . . . . . . . . . . . B-1735 invasive aspergillosis . . . M-988, M-1226, M-1228, . . . . . . . . . . . . . . . . M-1678, M-1682, M-1695 invasive candidiasis . . . . . . . . . . . . . . . . . . M-1687 invasive fungal disease . . . . . . . . . . . . . . . . . . T-344 invasive fungal infection . . . . . . . . . M-315, K-951, . . . . . . . . . . . . . . . . . . . . . . . . M-1232, M-1703 invasive infection . . . . L1-1646, C1-1739, C2-1991 invasive pneumococcal disease . . C2-1353, C2-1354 invasive pneumococcal infections . . . . . . . . . G-861 invasive pulmonary aspergillosis . . . . . . . . . . K-951 invasive streptococcal infections . . . . . . . . G3-1554 invasive zygomycosis . . . . . . . . . . . . . . . . . . M-973 IPAF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-060 IPD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-863 IPDM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-613 iron . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1017 iron chelator . . . . . . . . . . . . . . . . . . . . . . . . M-976 IS1216V-flanked composite mobile element . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1340 IS6110 sequence . . . . . . . . . . . . . . . . . . . . . . D-733 IS91-like elements . . . . . . . . . . . . . . . . . . . . C1-669 ISAba1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-070 isavuconazole . . . .M-331, M-332, A-1931, A-1936 ISCR1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-669 ISCR1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-693 isolation . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1611

Lenalidomide . . . . . . . . . . . . . . . . . . . . . . . T-1027 K. oxytoca . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-691 K. pneumoniae . . . . . . . . C2-108, C2-120, C2-702, . . . . . . . . . . . . . . . . . . . . . . . . . B-1324, B-1325 kidney transplant . . . . . . . . . . . . . . . . . . . . . T-1036 kidney transplant recipients . . . . . . . . . . . . . T-1035 kidney transplantation . . . . . . . . . . . . . . . . . . T-359 kidney tubular dysfunction . . . . . . . . . . . . . .H-890 kinetics . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1206 kirby – Bauer’s disk diffusion . . . . . . . . . . . . . D-181 Klebsiella . . . . . . . A-041, A-042, C1-061, C2-1216, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1586 Klebsiella oxytoca . . . . . . . . . . . . . . . . . . . . . C1-593 Klebsiella pneumoniae . . . C1-062, C2-086, C2-087, . . . C2-088, C2-091, C2-690, C2-692, C2-693, . . . . . . . .C2-717, E-800, F-841, F-846, K-913, . . . . . . . . . .T-1034, C2-1215, B-1321, K-1588, . . . . . . . . . . . . . . . . . . . . . . . . . K-1620, F-2059 Klebsiella pneumoniae carbapenemase-2 . . . C2-1212 Klebsiella pneumoniae-producing Carbapenemase . . . . . . . . . . . . . . . . . . . . . . . . . K-1619, K-1625 Klebsiella producing carbapenemase . . . . . .B-1323, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1614 KPC . . . . . . . . . A-013, C1-066, C2-086, C2-089, .C1-589, D-747, D-748, D-749, E-789, E-796, . . F-849, F-850, F-856, F-857, K-903, T-1031, . . C2-1213, D-1445, D-1446, D-1450, F-2059 KPC Carbapenemases . . . A-015, C2-087, C2-094, . . . . . . . . . E-192, E-794, F-848, F-851, F-852, . . . . . . . . . . . . . . F-853, F-858, K-913, B-1300 KPC carrier . . . . . . . . . . . . . . . . . . . . . . . . . C2-095 KPC Klebsiella pneumoniae . . . . . . . . . . . . . . B-1326 KPC spread . . . . . . . . . . . . . . . . . . C2-092, C2-716 KPC-2 . . . . . . . . . . . . . . . . . . . . . . C1-464, C2-717 KPC-producing K. pneumoniae. . . . . . . . . . C2-1218 KPC-type . . . . . . . . . . . . . . . . . . . . . . . . . C2-1211 KPI-10 . . . . . . . E-207, A-1949, A-1950, A-1951, . . . .A-1952, A-1953, A-1954, A-1955, F-2048

L L20B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-1748 laboratory detection . . . . . . . . . . . . . . . . . . . D-1448 lactate . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1221

Final Program

Leptospirosis . . . . . . . . . . . . . . . . . . . . . . . . P-1009 Letermovir . . . . . . . . . . . . . . . . . . . . . . . . . . . T-356 lettuce . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-703 Levofloxacin . . . . . . . . . . . B-649, A-1963, A-1964 Lincosamides . . . . . . . . . . . . . . . . . . . . . . . C1-1349 Linezolid . . . . . . B-655, C2-139, C2-142, K-1120, . . . . . . . . . . A-1261, A-1263, A-1287, A-1288, . . . . . . . . C1-1343, E-1471, E-1479, C1-1745, Linezolid resistant . . . . . . . . . . . . . . . . . . . C2-1401 Lipid formulations of Amphotericin B . . . M-1705 lipids . . . . . . . . . . . . . . . . . . . . . . . V-377, C1-1744 lipoglycopeptide. . . . . . . . .C2-132, C2-134, A-621 lipopolysaccharide . . . . . . . . . . . . . . . . . . . L1-1651 liposomal Amphotericin B . . . . . . M-988, A-1941, . . . . . . . . . . . . . . . . . . . . . . . . M-1671, M-1707 Listeria monocytogenes . . . . . . . . . . F-1997, L1-1222 liver cirrhosis . . . . . . . . . . . . . . . . . . . . . . . M-1698 liver transplant . . . . . . . . . . . . . . . . . . . . . . . . T-368 liver transplantation . . . . . . . . . . . T-1040, G3-1556 livestock and poultry . . . . . . . . . . . C2-705, C2-709 loading dose . . . . . . . . . . . . . . . . . . . . . . . . . . A-607 locked nucleic acid (LNA). . . . . . . . . . . . . . D-1454 long-acting . . . . . . . . . . . . . . . . . . . . . . . . . .H-554 long-term care facilities . . . . . . . . . . . K-557, K-558 long-term functional outcome . . . . . . . . . . L1-2103 long-term oral suprressive antibiotic therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2077 LpxC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-680 LPXTG-protein . . . . . . . . . . . . . . . . . . . . . B-1316 LTBI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-959 lung . . . . . . . . . . . . . . . . . . . . . . . . . . B-060, B-651 lung transplant . . . . . . . . . . . A-035, M-337, T-364, . . . . M-1227, T-1037, T-1064, T-1067, T-1069 Lyme disease . . . . . . . . . . . . . . . . . . . . . . . G3-1553 lymphocyte . . . . . . . . . . . . . . . . . . . . . . . . M-1679 lytA real-time PCR . . . . . . . . . . . . . . . . . . . . D-172

M M. fortuitum . . . . . . . . . . . . . . . . . . . . . . . . . E-1995

269

> Keyword INDEX M. tuberculosis . . . . . . . . . . . . . . . .D-733, C2-1368

Methicillin resistant. . . . . . . . . . . . . . . . . . . T-1037

macroarray . . . . . . . . . . . . . . . . . . . . . . . . . . C2-698 macrolide . . . . . . . . . . . . . . B-048, B-049, C2-1988

Methicillin-sensitive Staphylococcus aureus . . K-1125 Methicillin-susceptible Staphylococcus aureus . . . . . . . . . . . A-609, B-1319, C2-1389, K-1122

Macrolide resistance . . . . L1-296, D-175, B-1301, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1977 Macrolide resistance genes . . . . . . . . . . . . C1-1348 Macrophage . . . . B-661, M-984, M-1055, M-1057

Metronidazole . . . . . . . . . . . . . . . . . P-563, P-1019 Metronidazole and vancomycin . . . . . . . . . . . K-922

monoclonal . . . . . . . . . . . . . . . . . . . . . . . . . B-1736 monoclonal antibody . . . . . T-342, G-871, A-1278, . . . . . . . . . . . . . . . . . . F-1529, B-1734, B-1737 Monosulfactam . . . . . . . . . . . E-193, F-841, F-842 monte carlo . . . . . . . . . . . . . . . . . . . . . . . . . . A-605

MIC creep . . . . . . . . . . . . . . . . . . C2-1390, E-1481

Monte Carlo simulation . . . A-012, A-016, A-019, . . . . . . . . . . . . . . . . . . . A-624a, A-644, A-1280 Moraxella osloensis. . . . . . . . . . . . . . . . . . . . . C2-1979 Morinidazole . . . . . . . . . . . . . . . . . . . . . . . . A-1283 Morpholino . . . . . . . . . . . . . . . . . . . . . . . . C1-1972 morphology switching . . . . . . . . . . . . . . . . . M-990

MALDI-ToF . . . D-726, D-728, D-731, D-1423, . . . . . . . . . . . . . . . . . . . . . . . . .D-1772, D-1777

MIC determination . . . . . . . . . . . . . . . . . . . . D-761 MIC testing. . . . . . .E-804, D-763, D-764, D-766, . . . . . . . . . . . . . . . . . . .D-768, E-1463, E-1467

mortality . . . . . . . . C2-097, D-160, H-227, K-254, . . . . . . . K-472, K-912, K-923, K-955, K-1603, . . . . . . . . . . . . . . . L1-1639, L1-1643, G-1753

MALDI-ToF MS . . . . . . . D-729, D-730, D-1773, . . . . . . . . . . . . . . . . . . . . . . . . .D-1774, D-1775

Micafungin . . . . . . . . . . . . M-326, M-328, M-334, . . . . . . . . . . . . . . . . . . . . . . .G3-1560, G3-1561

mortality risk factors . . . . . . K-896, K-907, K-942, . . . . . . . . . . . . . . . . . . . . . K-943, K-948, K-950

Manuka propolis . . . . . . . . . . . . . . . . . . . . . F-2071 Maraviroc . . . . . . . . . . . . . . . . . . . . . . . . . .H-1576 marker . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-743 mass sequencing . . . . . . . . . . . . . . . . . . . . . L2-310 mass spectrometry . . . . . D-1413, M-1691, D-1776

mice infections. . . . . . . . . . . . . . . . . . . . . . . B-1300

mortality-morbidity . . . . . . . . . . . . H-229, L1-1641 Mouse . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-1056

Mexico. . . . . . . . . . . . . . . . . . . . L1-1653, L2-2115

magnetic isotope effect . . . . . . . . . . . . . . . . . F-830

MHT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-749

magnetic resonance imaging . . . . . . . . . . . M-1670

MIC . . . . . . . . . . D-736, K-907, F-1508, M-1715, . . . . . . . . . . . .F-2020, F-2024, F-2036, F-2047

MAKI . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-1700 Malaria . . . .P-568, P-570, P-998, P-1005, P-1017 Malaria guidelines . . . . . . . . . . . . . . . . . . . . . P-565

mathematical modeling . . . . . . . . . . V-396, A-1966 MBL . . . . . . . . . . . . . . . . . . . . . . . . B-045, C1-590 MDR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2030 MDR acinetobacter . . . . . . . A-022, A-023, K-562, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-902 MDR TB. . . . . . . . . . . . . . . . . . . . . . . . . . . A-1259 measles. . . . . . . . . . . . . . . . . . . . . . . P-566, V-1073 meat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1913 mecA gene . . . . . . . . . . . . . . . . . . . . . . . . . . D-1437 mecA variant . . . . . . . . . . . . . . . . . . . . . . . C1-1739 mechanicstic model . . . . . . . . . . . . . . . . . . . A-1763 mechanism of action . . . . . F-824, M-1061, F-2007 mechanism-based inhibitors . . . . . . . . . . . . C1-459 mechanism-based models / dr . . . . . . . . . . . . A-011 mediatinitis . . . . . . . . . . . . . . . . . . . . . . . . . . K-267 medical education . . . . . . . . . . . . C2-1915, K-2081 medication therapy management. . . . . . . . . .H-212 mef(A), erm(X) . . . . . . . . . . . . . . . . . . . . . C1-1348 Melioidosis . . . . . . . . . . . . . . . . . . . . . . . . . P-1004 Meningitis . . . . . B-658, M-977, P-1023, L1-1221, . . . . . . . . V-1239, G3-1541, G3-1544, A-1942, . . . . . . . . . . . . . . . . . . . . . . . . . A-1943, A-1944 Meningococcal . . . . . . . . . . . . . . . . . . . . . G3-1542 Meningococcal disease . . . . . . . . . . . . . . . L1-1653 Meningoencephalitis . . . . . . . . . . . P-1006, V-1240 Meropenem . . . . . . . . . . . . . . . . . . . A-012, K-1612 metabolism . . .A-1281, A-1284, A-1950, C2-1979 metabolites . . . . . . . . . . . . . . . . . . . . . . . . . A-1950 Metallo-beta-lactamase . . . . . . . . C1-065, C1-077, . . . . . . . . . . C1-461, C1-465, C1-588, C1-593, . . . . . . . . . . . . . . . . . . C1-594, D-745, D-1451 Metallo-carbapenemase . . . . . . . . . . . . . . . . C2-091 Methadone . . . . . . . . . . . . . . . . . . . . . . . . . A-1250

270

micro-pattern . . . . . . . . . . . . . . . . . . . . . . L2-2112 microarray . . . . . . . . . . D-1416, D-1432, C2-1983 microbiological diagnosis. . . . . . . . . . . . . . L1-2104 microbiology . . . . . . . . . . . . . . . . . . . . . . . . . K-261 microbiology laboratory. . . . . . . . . . . . . . . . . D-729 microcalorimetry . . . . . . . . . . . . . . . . . . . . M-1719 microdosing . . . . . . . . . . . . . . . . . . . . . . . . . F-2027 microparticles . . . . . . . . . . . . . . . . . . . . . . . F-2011 microRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . B-059 microsporidia . . . . . . . . . . . . . . . . . . . P-993, P-995 microtitre tray . . . . . . . . . . . . . . . . . . . . . . . . D-763 midazolam . . . . . . . . . . . . . . . . . . . . . . . . . . A-1936 mimic . . . . . . . . E-1474, F-1493, F-1494, F-1495 minimum inhibitory concentration . . . . . . . . D-737 Minocycline . . . . . . . . . . . . . . . . . . . . . . . . . C2-133 Mitochondria . . . . . . . . . . . . . . . . . . . . . . . A-1291 Mitochondrial function . . . . . . . . . . . . . . . . M-968 mixed species biofilm . . . . . . . . . . . . . . . . . . E-1466 mixed treatment comparison . . . . . . . . . . . . .H-878 MK-1439 . . . . . . . . . . . . . . . . . . . . . . . . . . .H-551 MK-3118 . . . . . . . . . . . . . . . . . . M-1714, M-1715 MK-7655 . . . . . . . . . . . . . . . . . . . . . . . . . . . E-192 MLST . . . . . . . . . . . . . . .K-936, D-1459, C2-1904 MLST epidemiology . . . . . . . . . . . . . . . . . C2-1353 mode of action . . . . . . . . . . . . . . . . . . . . . . . F-2038 model host . . . . . . . . . . . . . . . . . . . . . . . . . . F-1538 modeling . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2070 modified hodge test . . . . . . . . . . . . . . . . . . . D-1450 molds . . . . . . . . . . . . . . . . . . . . . . . M-321, M-1680 molecular characterization . . . . . . . . . . . . . C2-1378 molecular diagnostics. . . . . D-155, D-732, D-1418, . . . . . . . . . . . . . . . . . . . . . . . . D-1419, M-1668 molecular epidemiology . . . . . . . . D-161, C2-1216, . . . . . . . B-1309, C2-1377, C2-1384, C2-1396, . . C2-1397, H-1571, K-1599, K-1625, C2-1911 molecular typing . . . . . .L2-309, C2-1210, B-1312, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1388

September 9-12 |

mouse lung infection model . . . . . . . . . . . . F-2028 mouse model . . . . V-399, B-663, M-1058, A-1275, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1308 mRNA half life . . . . . . . . . . . . . . . . . . . . . . C2-115 MRSA . . . . . . . . B-057, C2-123, C2-124, C2-127, . . . . . C2-129, C2-130, C2-131, E-186, E-208, . . . . . . . . A-596, A-605, A-608, A-622, B-646, . . . . . . . B-647, B-650, B-653, C1-677, D-773, . . F-843, F-846, G-868, K-900, K-907, K-946, . . T-1069, A-1290, B-1317, C1-1351, C2-1377, . . . . . . C2-1378, C2-1379, C2-1380, C2-1382, . . . . . . C2-1385, C2-1383, C2-1386, C2-1388, . C2-1396, C2-1397, D-1415, D-1424, D-1426, . . D-1429, D-1435, D-1425, D-1427, D-1434, . . . E-1462, E-1470, E-1472, E-1473, E-1476, . . . E-1471, E-1477, E-1480, E-1482, E-1484, . . . . E-1485, F-1496, F-1506, F-1507, F-1509, . . . .F-1518, F-1521, K-1593, K-1594, K-1595, . . . K-1597, K-1599, K-1601, K-1634, K-1627, . . . . . . . L1-1646, L1-1654, L1-1655, L1-1656, . . . . . . . .L1-1657, L1-1665, B-1737, C1-1739, . . . . . . C1-1742, C1-1743, C1-1744, C1-1746, . . . . . . . D-1775, C2-1907, C2-1908, C2-1910, . . . . . . . C2-1912, C2-1913, C2-1914, F-2001, . . . . . . . . . . . . . . . . . . . . . . . . . F-2032, K-2076 MRSA bacteremia . . . . K-1121, C2-1391, D-1418, . . . . . . . . . . . . . . . . . . K-1600, K-1636, A-1768 MRSA complicated skin and soft tissue infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1633 MRSA diagnosis . . . . . . . . . . . . . .D-1414, D-1432 MRSA pneumonia . . . . . . . . . . . . K-1120, K-1628 MRSA treatment. . . . . . . .F-1515, F-1517, F-1999 MRX-I . . . . . . . F-1497, F-1498, F-1499, F-1500, . . . . . . . . . . . .F-1501, F-1502, F-1503, F-1504 MSSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-613 MSSA and MRSA . . . . . . . . . . . . . . . . . . . . B-648 Mucin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-049 Mucocutanea . . . . . . . . . . . . . . . . . . . . . . . . P-1020 Mucormycosis . . . . . . . . .T-347, M-1679, M-1686, . . . . . . . . . . . . . . . . M-1692, M-1707, M-1708 Mucositis . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1458

KEYWORD INDEX

multi-azole resistance . . . . . . . . . . . . . . . . M-1712 multi-drug resistant pathogens . . . . D-770, F-1520 multi-locus sequence typing . . . C2-114, G3-1562, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1991 multi-resistant . . . . . . . . . . . . . . . . . . . . . . . . K-561

N N. meningitidis serogroup . . . . . . . . . . . . . L1-1653 Nanoantibiotic . . . . . . . . . .F-2006, F-2007, F-2008 Nanoemulsion . . . . . . . . . . G-869, F-2010, F-2070

Nitroimidazole . . . . . F-834, F-835, F-837, F-838, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-840 NK cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-051 non-albicans Candida spp . . . . . . . . . . . . . M-1696

multi-resistant TB . . . . . . . . . . . . . . . . . . . C2-1367 multidisciplinar professionals. . . . . . . . . . . . P-1002

nanoparticle . . . . . . . . . . . . . . . . . . . . . . . . . . P-997

non-critically ill . . . . . . . . . . . . . . . . . . . . . . . A-637 non-fermenter . . . . . . . . . . . . . . . . F-2050, F-2053

nanosphere. . . . . . . . . . . . . . . . . . . . . . . . . . D-1417

non-immunosuppressed . . . . . . . . . . . . . . . V-1242

multidrug cross-resistance . . . . . . . . . . . . . . M-320

nasal carriers . . . . . . . . . . . . . . . . . . . . . . . C2-1383 nasal colonization . . . . . . . . . . . . . . . . . . . C2-1377 Nasopharyngeal . . . . . . . . . . . . . . . . . . . . . . . V-383

non-nucleoside reverse transcriptase inhibitor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-551 non-ß-lactams . . . . . . . . . . . . . . . . . . . . . . . E-1470

multidrug efflux . . . . . . . . . . . . . . . . . . . . . . C1-676 multidrug resistance. . . . . . C2-149, E-195, M-975, . . . . . . . . C1-1340, C2-1369, K-1587, K-1610, . . . . . . . . . . K-1624, C2-1898, F-2055, K-2096 multidrug-resistant Acinetobacter spp . . . . . . K-1607 multidrug-resistant bacteria . . . . . . . K-246, E-801, . . . . . . . . . . . . . . . . . . . . . . . . . F-1527, K-1608

Nasopharyngeal carriage . . . . . . .G-1049, C2-1975 nationwide matched cohort study . . . . . . . L1-1650 native antimicrobial peptide . . . . . . . . . . . . F-1488 natural product . . . . . . . . . . . . . . . . . . . . . . . F-829

multidrug-resistant gram-negative C1-062, F-2018 multidrug-resistant gram-negative bacilli . . . K-558 multifaceted prevention program. . . . . . . . . .K-240, . . . . . . . . . . . . . . . . . . . . . . . . . K-1629, K-2088

natural products . . . . . . . . . . . . . . . . . . . . . . . F-825

Multilocus sequence typing . . . . . . . . . . . . . C2-118

NDM-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1900 NDM-producing . . . . . . . . . . . . . . . . . . . . . . E-795 NDV-3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-868

multiple antibiotic resistance . . . . . . . . . . . . C1-671 multiplex PCR. . . . . . . . . D-178, D-1432, M-1668 multiplex real time PCR . . . . . . . . . . . . . . M-1674 multiplex real-time PCR . . . . . . . . . . . . . . . D-1449 multiplication . . . . . . . . . . . . . . . . . . . . . . . G-1748 mupirocin . . . . . . . . . . . . . . . . . . . . . . . . . . E-1484 mupirocin resistance . . . . . . . . . . K-1595, C2-1914 murine model . . . . . . . . . . . . . . . . . . . . . . . . B-660 murine tuberculosis . . . . . . . . . . . . . . . . . . . A-1268 mutant prevention concentration. . . . . . . . . A-1274 mutants . . . . . . . . . . . . . . . . . . . . . M-333, C1-681 mutation . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1343 mutations . . . . . . . . . . . C1-682, C2-1370, H-1573 MXP-4509 . . . . . . . . . . . . . . . . . . . . . . . . . . F-811 Mycobacteria . . . . . . . . . . . . . . . . . . . . . . . . D-1777 Mycobacterial infections . . . . . . . . . . . . . . . . K-265 Mycobacterium . . . . . . . . . . . . . C2-1370, C2-1375 Mycobacterium abscessus . . . . . . . . . . . . . . . . . . K-266 Mycobacterium avium . . . . . . . . . . . . . . . . . B-1310 Mycobacterium chelonae-abscessus complex D-735 Mycobacterium massiliense . . . . . . . . . . . . . . . . K-266 Mycobacterium tuberculosis . . . . . . . . . D-736, F-829, . . . . . F-832, F-833, A-1257, A-1261, A-1262, . . A-1263, C2-1369, C2-1371, D-1776, E-1994 Mycobacterium tuberculosis complex . . . . . . . D-732, . . . . . . . . . . . . . . . . . . . . . . . . .D-737, C2-1367 Mycoplasma . . . . . . . . . . . . . . . . . . .D-176, E-207 Mycoplasma pneumoniae . . . . . . . . . . D-175, B-1309, . . . . . . . . . . . . . . . . . . . . . . . C2-1977, C2-1978 Myeloma . . . . . . . . . . . . . . . . . . . . . . . . . . . T-1027 Myeloperoxidase . . . . . . . . . . . . . . . . . . . . . F-1524

natural resistance . . . . . . . . . . . . . . . . . . . . . V-1237 NDM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-561 NDM-1 . . . . . . . C1-064, C2-091,C1-592, F-2048

nebulisation . . . . . . . . . . . . . . . . . . . . A-036, A-037 necrotizing pneumonia . . . . . . . . . . . . . . . . B-1735 neglected tropical diseases . . . . . . . . . . . . . . . P-569 Neisseria gonorrhoeae. . . . . . . . . . . .L2-303, L2-308, . . . . . . . . . . . . . . . . . . . . . . . . . . E-781, B-1303 Neisseria meningitidis . . . . . . . . . C2-1982, L1-1651 nemonoxacin . . . . . . . . . . . . . . . . . . . . . . . . . E-206 neonatal . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-1751 neonatal intensive care unit . . . . . . K-1125, K-1599 neonatal invasive infection . . . . . . . . . . . . . C2-1990 neonate immunity . . . . . . . . . . . . . . . . . . . G3-1557 neonates . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-339 neonatology . . . . . . . . . . . . . . . . . . . . . . . . . G-1750 Nepal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1368 Nephropathia epidemica . . . . . . . . . . . . . . . . V-395 Nephrotoxicity . . . A-034, A-616, A-617, G3-1558, . . . . . . . . . . . . . . . . . . . . . . . . K-1629, L1-1655 nested polymerase chain reaction . . . . . . . . . D-733 Neuraminidase inhibitor . . . . . . . . . . . . . . . . V-390 Neuropsychology . . . . . . . . . . . . . . . . . . . . . G-1054 Neurosugical& onco . . . . . . . . . . . . . . . . . . . K-236 Neurotoxicosis . . . . . . . . . . . . . . . . . . . . . . G3-1548 Neutropenia . . . . . .A-018, H-217, T-1025, K-1632 Neutropenic fever . . . . . . . . . . . . . . . . . . . . T-1038 Nevirapine extended release . . . . . . . . . . . . .H-877 new Delhi metallo-ơ-lactamase. . . . . . . . . C2-1219 new OXA variant. . . . . . . . . . . . . . . . . . . . . D-1455 newborn. . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1387 Ngaoundere-Cameroon . . . . . . . . . . . . . . . . P-1010 NICU . . . . . . . . . . . . . . . . . . . . . . M-339, D-1429

Final Program

Nontuberculous mycobacteria . . . . . . . . . . . . F-831 norovirus . . . . . . . . . . . . . . . . . . . . P-1021, G-1048 North America . . . . . . . . . . . . . . . C2-144, C2-722 Northeastern Thailand . . . . . . . . . . . . . . . . . P-999 nosocomial infection . . . . . . . . . . . . . . . . . . . K-956 nosocomial meningitis . . . . . . . . . . . . . . . . . . K-562 nosocomial pneumonia . . . . . . . . . . . . . . . . A-624a novel gendine. . . . . . . . . . . . . . . . . . . . . . . . K-2096 novel non-antibiotic catheter lock . . . . . . . . F-2012 novel scaffold . . . . . . . . . . . . . . . . . F-1514, F-2018 NS3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-370 NS3/4A protease . . . . . . . . . . . . . . . . . . . . . . F-827 NS5b polymerase. . . . . . . . . . . . . . . . . . . . . . F-828 NSAID . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1996 NTHi . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1974 nursery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-1051 NXL104 . . . . . . . . . . . . . . .C2-149, E-194, A-630

O O25b:ST131 . . . . . . . . . . . . . . . . . C2-119, C2-122 obesity . . . . . . . . . . . A-017, A-612, A-637, A-638, . . . . . . . . . . . . . . . . . . . . . . . . . A-1287, K-1628 older adults . . . . . . . . . . . . . . . . . . . . . . . . . K-1600 OLT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-1025 Omadacycline . . . . . . . . . . . . . . . . A-1281, A-1282 omega loop . . . . . . . . . . . . . . . . . . . . . . . . . C1-072 Omiganan . . . . . . . . . . . . . . . . . . . . . . . . . . F-1491 OmpA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1329 once daily dose. . . . . . . . . . . . . . . . . . . . . . L1-1647 Oncohematological patients . . . . . . . . . . . . M-312 oncology . . . . . . . . . . . . . . . . . . . . . T-353, K-1603 oncology patients . . . . . . . . . . . . . .D-1412, K-2087 Ontario, Canada . . . . . . . . . . . . . . . . . . . . C2-1214 Onychomycosis . . . . . . . . . . . . . . . . . . . . . . A-1946 OPAT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-284 operation room . . . . . . . . . . . . . . . . . . . . . . . K-244 Opisthorchis viverrini . . . . . . . . . . . . . . . . . . . . P-999 opportunistic infection . . . . . . . . . . . H-222, T-342 Opsonophagocytosis . . . . . . . . . . . T-1042, A-1278 optimal design . . . . . . . . . . . . . . . . . . . . . . . . A-032 oral pathogens . . . . . . . . . . . . . . . . . . . . . . . F-2015 oral treatment . . . . . . . . . . . . . . . . . . . . . . . T-1028

271

> Keyword INDEX oritavancin . . . . . . C2-128, A-620, D-762, E-1462, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-1463 Oropharyngeal. . . . . . . . . . . . . . . . . . . . . . . . V-383 Oropharyngeal candidiasis . . . . . . .F-815, M-1674 Oropharyngeal squamous cell carcinoma . . L2-302 oseltamivir . . . . A-1243, A-1244, A-1245, G-1749, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-1080 Oseltamivir phosphate . . . . . . . . . . . . . . . . . . V-400

pattern recognition receptors . . . . . . . . . . . . . B-044

phenotypes. . . . . . . . . . . . . . . . . . . . . . . . . C2-1388

PBPK model . . . . . . . . . . . . . . . . . . . . . . . . . A-033

phenylboronic acid. . . . . . . . . . . . . . . . . . . . D-1450 phorbol myristate acetate. . . . . . . . . . . . . . . . A-599

PCR . . . . . . . . . . . D-173, D-174, D-176, D-177, . . . . T-347, C1-665, D-1415, D-1425, D-1445, . . . . . . . . . . . . . . . . . D-1447, K-1594, M-1704 PCR ESI TOF Mass spectrometry . . . . . . . D-1778 PCR multiplex. . . . . . . . . . . . . . . . . . . . . . . D-1428 PCR-ribotypin . . . . . . . . . . . . . . . . . . . . . . . K-933

Osteoarticular infection . K-929, M-1681, L1-2106 Osteomyelitis . . . B-653, B-1317, A-1768, K-2074, . . . . . . . . . . . . . . . . . . . . . . . . K-2078, L1-2102

PCV10 vaccine . . . . . . . . . . . . . . . . . . . . . . . G-861 PCV13. . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1364

Osteoporosis . . . . . . . . . . . . . . . . . . . . . . . . .H-231

PDH1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-1059

otitis media . . . . . . . . . . . . . . . . . . . . . . . . . G-1050 otitis media . . . . . . . . . . . . . . . . . . . . . . . . . . D-181

pediatric . . . . . . . . . . A-019, B-045, M-322, V-376, . . . . . . . . . A-612, A-1244, G3-1544, G3-1558, . . . . . . . . . . . . . . . . . . . . . . G3-1560, C2-1977 pediatric infections . . . . . . . . . . . . . . . . . . . G-1752 pediatric population . . . . . . . . . . . . . . . . . . G3-1550

Otomycosis . . . . . . . . . . . . . . . . . . . . . . . . . M-322 outbreak . . .T-353, K-904, K-954, V-1073, K-1125, . . . . . . . . C2-1375, D-1421, K-1623, C2-1902 outcome . . . . . . . . . M-317, M-324, D-180, K-931, . . . . . . . . . . . . . . . .G3-1542, K-1601, C2-1906 outpatient . . . . . K-239, L1-287, L1-288, L2-2118 OXA-143 . . . . . . . . . . . . . . . . . . . . . . . . . . K-1606 OXA-163 . . . . . . . . . . . . . . . . . . . . . . . . . . C2-084 OXA-210 . . . . . . . . . . . . . . . . . . . . . . . . . . C1-068 OXA-23 . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1900

PCV7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1354

PEI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1492 penicillin . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1989 peptide Deformylase . . . . . . . . . . . . . . . . . . A-1276 peptide structure and function . . . . . . . . . . . F-1490 PER-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1207 peramivir . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-380

OXA-239 . . . . . . . . . . . . . . . . . . . . . . . . . . C1-069 OXA-240 . . . . . . . . . . . . . . . . . . . . . . . . . . C1-595

percutaneous needle biopsy . . . . . . . . . . . . L1-2104 performance evaluation . . . . . . . . . . . . . . . .H-1582 peripheral line . . . . . . . . . . . . . . . . . . . . . . . K-2086

OXA-48 . . . . . C1-061, C1-063, C1-066, C2-093, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-591 OXA-48-like . . . . . . . . . . . . . . . . . . . . . . . . D-1453

peritonitis . . . . . . . . . . . . . . . . . . . . . . . . . M-1685 persistence . . . . . . . . . . . . . . . . . . . B-1337, B-1338

Oxacillinases . . . . . . . . . . . . . . . . . . . . . . . . . E-788 Oxazolidinone . . . B-651, E-778, A-1289, A-1290, . . . . . . . . . . . . . . . . . . A-1291, E-1479, F-1502 Ozenoxacin . . . . . . E-204, E-205, E-210, C1-681, . . . . . . . . . . . . . . . . . . . . . . . . . .C1-682, D-769

P P-glycoprotein . . . . . . . . . . . . . . . . . . . . . . . M-982 P. aeruginosa . . . . . A-632, C2-718, B-1308, F-2060 PA-824 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-836 PAE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2024 paediatric infections . . . . . . . . . . . . . . . . . . . . G-859 Paenibacterin . . . . . . . . . . . . . . . . . . . . . . . . F-1508 Palivizumab . . . . . . . . . . . . . . . . . . . . . . . . . . T-357 pandemic influenza . . . . . . . . . . . . . . . . . . . V-1078 pandrug resistance . . . . . . . . . . . . . . E-791, F-2068 Parainfluenza . . . . . . . . . . . . . . . . . . . . . . . . . V-382 parasite infections . . . . . . . . . . . . . . P-997, P-1006 parasites . . . . . . . . . . . . . . . . P-994, P-997, P-1019 parenteral nutrition . . . . . . . . . . . . . . . . . . . K-1758 pathogen . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1457 pathogenesis . . . . . . . . . . . . . . . . . B-1310, B-1329 pathogenomics. . . . . . . . . . . . . . . . . . . . . . . B-1314 pathogens . . . . . . . . . . . . . . . . . . . . . . . . . . F-1524

272

persistent bacteremia . . . . . . . . . . .D-1420, K-2092 persistent candidemia . . . . . . . . . . . . . . . . M-1669 pertussis . . . . . . . . . . . . . . . . . . . . .D-183, G3-1563 PET/CT . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-940 phage display . . . . . . . . . . . . . . . . . . . . . . . . F-1537 phage open-reading frames typing method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1429 pharmacodynamics . . . . . . . A-025, A-030, A-041, . . . . . . . A-624, A-642, A-629, A-631, M-989, . . . A-1762, A-1765, A-1931, A-1932, A-1942, . . . . . . . . . . . . . . . . . . . . . . . . . A-1947, A-1967 pharmacokinetic . . . . . . . . . A-025, A-628, H-893, . . . . . . . . . . . . . . . . . .A-1252, A-1928, A-1948 pharmacokinetic/Pharmacodynamic (PK/PD) . . . . . . A-038, A-606, A-620, A-1243, A-1269, . . . A-1270, A-1271, A-1275, A-1288, B-1308, . . . .A-1760, A-1763, A-1961, A-1962, F-2035 pharmacokinetics . . . . . . . . . A-009, A-010, A-017, . .A-018, A-026, A-027, A-618, A-640, A-634, . . . . A-641, M-992, A-1245, A-1256, A-1258, . . . A-1260, A-1272, A-1279, A-1282, A-1283, . . . A-1949, A-1952, A-1953, A-1956, A-1960, . . . . . . . . . . . . . . . . . . .F-2026, F-2027, F-2041 pharmacy driven . . . . . . . . . . . . . . . . . . . . . . K-241 phase 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-381 phase II . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-294 phase II clinical trial . . . . . . . . . . . . . . . . . L1-1662 phase-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-873

September 9-12 |

Phosphopantetheine adenylyltransferase . . . F-1540 phototoxicity . . . . . . . . . . . . . . . . . . . . . . . . A-1955 phylogenetic analysis . . . . . . . . . . . . . . . . . . .H-214 phylogeography . . . . . . . . . . . . . . . . . . . . . . L1-964 physiopathology. . . . . . . . . . . . . . . . . . . . . . . P-570 PICC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2096 pigeons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-995 pikromycin. . . . . . . . . . . . . . . . . . . . . . . . . . F-1505 pilus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-865 Piperacillin/tazobactam . . . . E-197, K-242, A-643, . . . . . . . . . . . A-644, C2-721, C2-722, K-1590, . . . . . . . . . . . . . . . . . . . . . . . . . A-1766, A-1767 PK/PD modeling . . . . . . . . A-012, A-636, A-644, . . . . . . . . . . . . . . . . . . A-1266, A-1764, F-2006 PK/PD target attainment . . . . . . . . . A-040, A-639 PK/PD-index-effect relationship . . . . . . . . . A-624 plasmid . . . . . . C1-064, C1-591, C1-679, C2-697, . . . . . . . . .C2-703, C2-711, C1-1208, C1-1745 plasmid epidemiology . . . . . . . . . . . . . . . . . C2-092 plasmid-mediated . . . . . . . . . . . . . . . . . . . . C2-082 plasmid-mediated AmpC . . . . . . . . . . . . . . C2-081 plasmid-mediated quinolone resistance . . . . D-1456 plasmids . . . . . . . . . . . . . . . . . . . . . C1-592, C2-710 Plazomicin . . . . . . . . A-041, A-042, E-779, B-1302 Plazomycin . . . . . . . . . . . . . . . . . . . . . . . . . . A-040 Pleuromutilin. . . . . . . . . . . . . . . L1-1660, C1-1971 Plex-ID . . . . . . . . . . . . . . . . . . . . . . . . . . . M-1691 Plusbacin . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1969 PML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-341 PMQR . . . . . . . C1-683, C2-700, C2-701, D-759 PMX30063 . . . . . . . . . . A-1284, E-1474, L1-1662 Pneumococcal bacteremia . . . . . . . . . . . . . . . G-862 Pneumococcal resistance . . . . . . . . . . . . . . . . G-861 Pneumococcal conjugate vaccine . . . G-859, G-860, . . . . . . . . . . . . . G-863, G-866, G-867, G-1050 Pneumococcal disease . . . G-859, G-876, L1-1641, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-1916 Pneumococcal meningitis . . . . . . . . . . . . . . . G-864 Pneumococcal pneumonia . . . . . . . . D-172, G-862 Pneumococcal polysaccharide vaccine . . . . . . G-867 Pneumococcal surveillance . . . . . . . . . . . . C2-1364 Pneumococcal vaccine . . . . . . . . . T-1042, C2-1357 Pneumococci . . . . . . . . . . . . . . . C2-1365, C2-1366 Pneumococcus . . . . . . . B-1314, C2-1356, C2-1362 Pneumocystis jirovecii . . . . . . . . . . . . . . . . . . . M-333 Pneumocystis jirovecii pneumonia. . . . H-221, H-226 Pneumonia. . . . . . C2-146, D-173, H-226, L1-289, . . . . . . . . . . L1-297, A-641, T-1041, G3-1551, . . . B-1737, G-1753, C2-1906, F-2066, K-2101 PNU-100480 . . . . . . . . . . A-1264, A-1265, E-1993 PNU-100480 (Sutezolid) . . . . . . . A-1262, A-1263

KEYWORD INDEX

PNU100480 . . . . . . . . . . . . . . . . . . . . . . . . E-1992

prosthetic-related infection . . . . . . . K-255, B-1318

point mutation . . . . . . . . . . . . . . . . . . . . . . C2-1984 Polyene+azole combination . . . . . . . . . . . . . A-1939

protease inhibitor. . . . . . . . . H-215, H-883, H-888 protease-activated receptor . . . . . . . . . . . . . . V-399

Quinolone resistance . . . C2-696, C2-701, B-1305, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1306 Quinolone resistance-determining region . C2-1355

Polymerase chain reaction (PCR) . . . . . . . . . T-355

protein design . . . . . . . . . . . . . . . . . . . . . . . V-1077

Quinolones . . . . . . . . . . . . . . . . . . . . . . . . C2-1981

Polymyxin . . . . . . . . . . . . . . . . . . . . . . . . . . . E-795

Proteomics . . . . . . . . . . . . . . . . . . . . . . . . . . . K-559

Quorum sensing . . . . . . . .M-990, B-1333, F-2071

Polymyxin B . . . . . . A-023, A-024, A-026, A-027, . . . . . A-028, C2-086, E-785, K-1620, M-1717

Proteus Mirabilis . . . . . . . . . . . . . . . . . . . . . K-1610 Proviral DNA . . . . . . . . . . . . . . . . . . . . . . .H-1575

Polymyxin E . . . . . . . . . . . . . . . . . . . . . . . . . E-790

Pseudomonas . . . . B-060, C1-465, D-746, A-1765, . . . . . . . . . . . . . . . . . C1-1973, F-2064, F-2066

population . . . . . . . . . . . . . . . . . . . . . . . . . . L2-303 population analysis . . . . . . . . . . . . C2-1387, E-197 population pharmacodynamic analysis . . . . . A-016 population pharmacokinetics . . . . . . A-020, A-021, . . . . . A-611, A-619, A-1244, A-1287, A-1964 porin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-792 Posaconazole . . . . .T-346, T-350, A-1932, A-1933, . . . . . . . . . .A-1934, A-1935, M-1703, M-1706 post-antibiotic effect . . . . . . A-008, F-832, A-1959 poultrry . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-706 pre-emptive therapy. . . . . . . . . . . . . . . . . . . T-1067 pre-exposure prophylaxis . . . . . . . . . . . . . . .H-1570 pre-kidney transplant recipients . . . . . . . . . T-1033 prediction model . . . . . . . . . . . . . . . . . . . . . K-1583 predictive performance . . . . . . . . . . . . . . . . . A-614 predictive tools. . . . . . . . . . . . . . . . . . . . . . . . K-910 predictive value . . . . . . . . . . . . . . . . . . . . . . D-1408 predictor of mortality. . . . . . . . . . . . . . . . . . . K-916 predictors of clinical success . . . . . . . . . . . . K-1120 preemptive therapy . . . . . . . . . . . . . . . . . . . .H-224 preemptive treatment. . . . . . . . . . . . . . . . . . . T-366 prescribing pattern . . . . . . . . . . . . . . . . . . . . . K-242 prevalence . . . . C2-104, C2-107, C2-692, D-1434, . . . . . . . . . . . . . . . . . . . . . . . C2-1897, C2-1913 prevention . . . . . . . . . . . . . . . . . . . K-2084, K-2101 prevention programme . . . . . . . . . K-1757, K-2093 primary care settings . . . . . . . . . . . . . . . . . . . D-775 primary HIV infection . . . . . . . . . . . . . . . .H-1578 primary infection . . . . . . . . . . . . . . . . . . . . M-1697 probiotics . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-300 procalcitonin . . . . . . . . . . . . . . . . . .K-926, D-1402 prognosis . . . . . . . . K-254, K-937, K-939, M-1679 prognostic . . . . . . . . . . . . . . . . . . . . . . . . . . K-2074 prognostic factors . . . . . . . . . . . . . . . . . . . . . P-567 prolonged infusion . . . . . . . . . . . . . . . . . . . . K-1612 propensity score . . . . . . . . . . . . . . . . . . . . . . K-1600 Prophylaxis . . . . K-261, T-1038, M-1703, M-1706 Propionibacterium . . . . . . . . . . . . . . . . . . . . . . D-776 Propionibacterium acnes . . . . . . . . .D-170, C1-1342 prospective study . . . . . . . . . . . . . . . . . . . . M-1707 prostate biopsy . . . . . . . . . . . . . . . . . . . . . . . C2-686 prosthesis infection . . . . . . . . . . . . . . . . . . . K-2077 prosthetic joint infection . . . . . . . . . D-169, K-248, . . K-249, K-250, K-251, K-253, K-254, K-256, . . . . . . . . . . . . K-257, K-258, K-2078, L1-2105

Pseudomonas aeruginosa . . . . A-008, A-015, B-050, . . . . . . B-051, C1-067, C1-078, A-633, A-639, . . . C1-680, C2-719, C2-720, C2-721, C2-722, . . . . . C2-723, C2-724, C2-725, D-757, E-790, . . .E-193, E-199, E-791, F-843, F-846, K-903, . . . . M-986, A-1278, B-1333, B-1334, B-1335, . . . . B-1336, B-1337, B-1338, F-1529, K-1624, . . . . . . . . . M-1716, A-1766, B-1734, C1-1970, . . . . . F-1998, F-2004, F-2021, F-2063, F-2065 Pseudomonas aeruginosa . . . . . . . . . . . . . . .PTK 0796 . . . . . . . . . . . . . . . . . . . . . . . . . A-1281, A-1282 public health epidemiology . . . . . . .C2-695, D-750 public health interventions . . . . . . . . . . . . . . G-860 public health involvement . . . . . . . . . . . . . . P-1002

R rabbit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-981 race . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-881 Radezolid. . . . . . . . . . . . . . . . . . . . C2-142, A-1290 rainfall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-293 Raltegravir . . . . . . . . . . . . . . . . . . . .H-885, A-1253 rapid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1410 rapid detection . . . . . . . . C1-078, C1-587 C1-1202 rapid diagnostic . . . . . . . . . . . . . . . . . . . . . . D-1461 rapid test . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1426 RDW. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-916 reactivation . . . . . . . . . . . . . . . . . . . . . . . . . . T-351 reactive oxygen species . . . . . . . . . . . . . . . . . . A-599 readmission . . . . . . . . . . . . . . . . . . . . . . . . . . K-240

pulmonary complication . . . . . . . . . . . . . . . .H-226 pulmonary penetration . . . . . . . . . . . . . . . . A-1964 pulse-field gel electrophoresis . . . . . . . . . . . C2-723 pulsed xenon ultraviolet . . . . . . . . . . . . . . . . . K-934

ready-to-eat raw vegetables . . . . . . . . . . . . . . K-925 real time PCR . . . . . . . . . . . . . . . . . . . . . . . . D-159 real time-RT-PCR . . . . . . . . . . . . . . . . . . . T-1064 real-time multiplex PCR . . . . . . . . . . . . . . . D-1411

Puumala virus . . . . . . . . . . . . . . . . . . . . . . . . V-395 PVL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1657 Pyelonephritis . . . . . . . . . . . . . . . . . . . . . . . B-1306

real-time PCR . . . .C2-081, D-158, D-175, D-179, . . . . . . . . . . . P-1005, T-1070, D-1412, D-1442

Pyogenic spondylodiscitis . . . . . . . . . . . . . . K-2076 Pyrazinamide . . . . . . . . . . . . . . . . . . . . . . . . B-1296 Pyrazolium . . . . . . . . . . . . . . . . . . . . . . . . . . F-845 Pyrosequence . . . . . . . . . . . . . . . . . . . . . . . . D-1460 Pyrosequencing . . . . . . D-1446, D-1459, C2-1904 Pyrrolocytosine . . . . . . . . . . . . . . . . . . . . . . F-2059

Q Q fever. . . . . . . . L1-962, L1-963, P-1001, P-1011, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1012 qepA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1456 QNR . . . . . . . . . . . . . . . .C1-683, C2-693, C2-700 QNRgenes . . . . . . . . . . . . . . . . . . . . . . . . . . C1-665 qPCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1453 QTc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1958 quad . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-879 quality control . . . . . . . . . . . . . . . . . D-767, D-768 QuantiFERON . . . . . . . . . . . . . . . . . . . . . . T-1033 QuantiFERON-TB Gold In-Tube . . . . . . .H-1917 quantitative PCR (qPCR) . . . . . . . . . . . . . . D-1454 quantitative real time PCR . . . . . . . . . . . . . D-1422 Quinolone . . . . . . . .E-203, E-206, E-208, B-1298, . . . L1-1663, A-1947, A-1948, A-1958, F-2056

Final Program

recA gene . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-731 recombinant . . . . . . . . . . . . . . . . . . . . . . . . . G-1053 recombinant virus . . . . . . . . . . . . . . . . . . . . . V-392 recombinase activity. . . . . . . . . . . . . . . . . . . C1-669 recovery . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-1564 recurrence . . . . . . . K-924, K-932, T-1068, K-1619 recurrent . . . . . . . . . . . . . . . . . . . . . . . . . . M-1684 recurrent CDI . . . . . . . . . . . . . . . . . . . . . . . . K-927 recurrent herpes simplex labialis . . . . . . . . . . V-397 reduced cytotoxicity . . . . . . . . . . . . . . . . . . . F-1489 regional antibiogram . . . . . . . . . . . . . . . . . . . K-233 registry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-338 regulation. . . . . . . . . . . . . . . . . . . . C1-672, M-966 rejection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-359 renal . . . . . . . . . . . . . . . . . . .T-365, H-891, A-1294 renal dysfunction . . . . . . . . . . . . . . . . . . . . . . A-607 renal elimination . . . . . . . . . . . . . . . . . . . . . . A-028 renal function. . . . . . . . . . . . . . . . . . . . . . . . . A-635 renal impairment . . . . . . . . . A-029, A-621, H-887, . . . . . . . . . . . . . . . . . . . . . . . . . .H-889, K-1631 renal injury . . . . . . . . . . . . . . . . . . . . . . . . M-1673 renal insufficiency . . . . . . . . . . . . . . . . . . . . . A-010 renal replacement therapy . . . . . . . . . . . . . . . A-619 renal transplant . . . . . . . . . . . . . . T-1034, G3-1557 renal transport . . . . . . . . . . . . . . . . . . . . . . . .H-892 renal uptake . . . . . . . . . . . . . . . . . . . . . . . . . . A-028

273

> Keyword INDEX repeat testing . . . . . . . . . . . . . . . . . . . . . . . . . D-153

rotavirus vaccine . . . . . . . . . . . . . . . . . . . . . . G-874

serology . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1008

reproducibility . . . . . . . . . . . . . . . . . . . . . . . . D-758 reservoir . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-1568

rpoB mutations . . . . . . . . . . . . . . . . . . . . . C2-1395 RPX2003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-854

seroprevalence . . . . . . . . . . . D-184, V-379, V-1241

residential-care . . . . . . . . . . . . . . . . . . . . . . C2-119

RSV . . . . . . . . . . . . T-357, G-869, V-1075, V-1076

resistance . . . . . C2-080, C2-102, C2-122, C2-135, . . . . . C2-136, K-238, K-278, L2-303, M-319, . . . . . . . M-321, M-327, M-335, V-381, V-392, . . . . . . . C1-461, P-563, A-604, A-628, A-642, . . . . . C1-681, C2-706, C2-708, D-776, E-779, . . . . . . E-805, F-857, T-1036, V-1079, V-1080, . . . . . . C1-1208, C1-1341, C1-1342, C1-1345, . . . . . . C2-1357, C2-1359, C2-1370, C2-1371, . . . D-1416, D-1421, F-1526, H-1573, K-1615, . .K-1620, K-1622, K-1634, M-1718, C1-1741, . . . A-1765, K-1925, A-1929, A-1938, A-1968, . . . . . . .C2-1982, C2-1983, C2-1988, C2-1989

RT-PCR . . . . . . . . . . . . . . . . . . . . . . . . . . G3-1563

serotypes . . . H-219, C2-1356, C2-1358, C2-1359, . . . . . . C2-1360, C2-1363, C2-1366, G3-1541

resistance development . . . . . . . . . . . . . . . . . A-011 resistance Frequency . . . . . . . . . . . . . . . . . . F-2025 resistance genes . . . . . . . . . . . . . C1-1350, C2-1903 resistance mechanisms . . . . . . . . . . . . . . . . . D-1430 resistance mutation . . . . . . . . . . . . . . . . . . . .H-218 resistance selection. . . . . .A-600, A-1966, C1-1971 resistant . C2-125, V-394, C1-682, F-820,C2-1978 resistant Acinetobacter baumannii . . . . . . . . . K-1603 resistant microorganisms . . . . . . . . . D-772, T-1046 resistant pathogens . . . . . . . . . . . . . . . . . . . K-1611 respiratory . . . . . . . . . . . . . . . . . . . . . D-177, V-386 respiratory infections . . . . .D-179, T-1065, F-1523, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2051 respiratory syncytial virus . . . . . . . . . . . . . . . T-353 respiratory tract infection . . . . . . . . . . . . . G3-1549 respiratory viruses . . . . . . . . . . . . . V-389, M-1228 retapamulin . . . . . . . . . . . . . . . . . . . . . . . . . E-1484 retrospective analysis . . . . . . . . . . V-1078, G3-1550 RGM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1375 rhodamine 6G . . . . . . . . . . . . . . . . . . . . . . M-1712 Rhodococcus . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1348 Ribavirin . . . . . . . . . . . . . . . . . . . . . H-216, V-1075 ribosome . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1343 ribotype 027 . . . . . . . . . . . . . . . . . . . . . . . . . K-924 Rickettsia conorii . . . . . . . . . . . . . . . . . . . . . . P-1022 Rickettsia typhi . . . . . . . . . . . . . . . . . . . . . . . P-1022 Rifabutin . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1257 Rifampicin . . . . . . . . . . . . . . . . . . . . . . . . . . . K-929 Rifampicin Dosage . . . . . . . . . . . . . . . . . . . A-1268 Rifampin . . . . . B-652, L1-1224, A-1261, A-1262, . . . . . . . . . . . . . . . . C1-1342, K-2089, L1-2106 Rilpivirine . . . . . . . . . . . . . . . . . . . .A-1249, H-880 risk factors . . . . . . . . K-263, V-387, K-949, K-955, . . . . .K-899, T-1040, K-1583, K-1613, K-1621, . . . . . . . . G-1753, C2-1903, H-1916, L2-2110, risk index . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-921 Rituximab . . . . . . . . . . . . . . . . . . . . . . . . . . . T-341 RNA biomarker . . . . . . . . . . . . . . . . . . . . . M-1678 rnase P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1539

274

Rtt109 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-813 RX-04 . . . . . . . . . . . . . . . . . . . . . . F-1521, F-1522

S S. aureus infection . . . . . . . . . . . . . . . . . . . . . G-870 S. pneoumoniae . . . . . . . . . . . . . . . . L1-1648, F-2028 S. pyogenes . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-1462 S/GSK1265744 . . . . . . . . . . . . . . . .H-550, A-1249 Sacroiliitis . . . . . . . . . . . . . . . . . . . . . . . . . . L1-960 safety . . . . . . . . . . H-555, H-891, L1-957, P-1017, . . . . . . . A-1289, G3-1560, G3-1561, G-1749, . . . . . . . . . . . . . . . . . . . . . . . . . A-1934, A-1941 safety pharmacology . . . . . . . . . . . . . . . . . . F-2042 Salmonella . . . . .C2-695, C2-697, C2-713, D-1421, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1328 Salmonella enteritidis . . . . . . . . . . . . . . . . . . . C2-698 salvage therapy. . . . . . . . . . . . . . . . . . . . . . .H-1566 sampling bias . . . . . . . . . . . . . . . . . . . . . . . . K-1759 SAR . . . . . . . . . . . . . . . . . . . . . . . . . . F-844, F-845 SASP . . . . . . . . . . . . . . . . . . . . . . . F-2065, F-2066 SCCmec . . .B-1316, C2-1385, C2-1393, C1-1746 SCCmec type . . . . . . . . . . . . . . .C2-1386, D-1428 Scedosporium . . . . . . . . . . . . . . . . . . . . . . . . T-348 Schistosomiasis . . . . . . . . . . . . . . . . . . . . . . P-1014 score. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-295 screening . . . . . . . . . . . . . . . . . . . .T-1039, M-1677 screening methods . . . . . . . . . . . . . . D-751, P-1008 scrub typhus. . . . . . . . . . . . . . . . . . . D-182, P-1003 SCV . . . . . . . . . . . . . . . . . . . . . . . . . . A-596, A-597 second-line therapy . . . . . . . . . . . . . . . . . . C2-1367 secondary pneumococcal pneumonia . . . . . . . V-380 secretions subglottic . . . . . . . . . . . . . . . . . . . K-2101 see-saw effect . . . . . . . . . . . . . . . . . . A-627, E-1478 select agents . . . . . . . . . . . . . . . . . . . . . . . . . F-2023 selection . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1617 semi-synthesis . . . . . . . . . . . . . . . . . . . . . . . F-1509 semiquantitative roll-plate method . . . . . . . . D-167 Sentry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-691 Sepsis . . .B-055, L1-286, L1-289, P-1003, D-1413, . . D-1461, K-1635, L1-1643, G-1750, L2-2117 Septic arthritis . . . . . . . . . . . . . . . . . . . . . . . K-2073 Septicaemia . . . . . . . . . . . . . . . . . . . . . . . . . D-1404 Septicemia . . . . . . . . . . . . . . . . . . . . . . . . . . . K-905 sequence type 11 . . . . . . . . . . . . . . . . . . . . C2-1212 serial testing performance . . . . . . . . . . . . . .H-1918 Serine-carbapenemase . . . . . . . . . . . . E-189, F-856 seroepidemiology . . . . . . . . . . . . . . . . . . . . . V-1238

September 9-12 |

serotype 19A . . . . . . . . . . . . . . . C2-1357, C2-1361

Serratia marescens . . . . . . . . . . . . . . . . . . . . C2-085 serum levels . . . . . . . . . . . . . . . . . . . . . . . . . . T-350 severe hospital-acquired pneumonia . . . . . . V-1074 severity. . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1667 sexual intercourse . . . . . . . . . . . . . . . . . . . . . L2-310 sexually transmitted infection . . . . . . . . . . . L2-309 Shigella . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-699 shoulder . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-170 SHV-12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-707 Sialic acid. . . . . . . . . . . . . . . . . . . . . . . . . . . B-1325 signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . M-983 SILAC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1328 silver nanoparticles . . . . . . . . . . . . . . . . . . . F-2001 simulation human pharmacokinetics . . . . . . . A-022 single nucleotide polymorphisms . . .B-044, H-890 Sinusitis . . . . . . . . . . . . . . . . . . . . . . . . . . . M-1686 SIRS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1404 Sitafloxacin . . . . . . . . . . . . . . . . . . . . . . . . . L2-305 site-directed mutagenesis. . . . . . . . . . . . . . C1-1206 skin and skin structure infections . . . . . . . C2-134, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1398 skin and soft tissue infections . . . K-239, G3-1555, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1667 skin infection . . . . . . . L1-1659, L1-1664, L1-1665 skin structure infections . . . . . . . . . . . . . . . . C2-123 small colony variants . . . . . . . . . . . M-986, E-1483 smallpox. . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-396 SMART . . . . . . . . . . . . . . . . . . . . C2-120, C2-688 smear positive . . . . . . . . . . . . . . . . . . . . . . C2-1372 Socioeconomic disparities . . . . . . . . . . . . . . G-1752 sodium oxychlorosene . . . . . . . . . . . D-770, F-1520 sodium salicylate . . . . . . . . . . . . . . . . . . . . . B-1324 softgel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1247 solid organ transplant . . . . . T-345, T-366, T-1026, . . . . . . . . . . . . . . . . . . . . . . . . . T-1066, T-1068 solid organ transplantation . . . . . . . . . . . . . T-1041 solid tumor . . . . . . . . . . . . . . . . . . . . . . . . . . K-911 solid-state NMR . . . . . . . . . . . . . . . . . . . . C1-1969 Solithromycin . . A-1269, A-1286, B-1301, F-1505 Sonication . . . . . . . D-165, D-167, D-168, K-1623 Sortase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1534 SOT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-340 southwest Nigeria . . . . . . . . . . . C2-1378, C2-1898 SP2078 . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1511 spa type . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1382 Spain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-1018 sparse sampling schedule . . . . . . . . . . . . . . . . A-032 specie specific marker . . . . . . . . . . . . . . . . . D-1455

KEYWORD INDEX

species identification . . . . . . . . . . . . . . . . . . D-1443 Spectinamides . . . . . . . . . . . . . . . . . . . . . . . A-1267 Spectinomycin . . . . . . . . . . . . . . . . . . . . . . . . F-832 spectrum of activity . . . . . . . . . . . . . . . . . . . . D-760

streptogramins . . . . . . . . . . . . . . . . . . . . . . C1-1349 Streptomycin . . . . . . . . . . . . . . . . . L1-958, B-1321 structural characterization . . . . . . . . . . . . . . C1-467

systemic candidiasis . . . . . . . . . . . . . . . . . . M-1698

T

structure. . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-462 structure-activity relationship . . . . . . . . . . . F-1490

T-2307 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-809

spread . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1212 spread of resistance genes . . . . . . . . . . . . . . C1-668

structure-based drug design . . . . . .F-2017, F-2018a

T-lymphocytes . . . . . . . . . . . . . . . . . . . . . . . . B-052 target . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-983

sputum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-172

subspecialty . . . . . . . . . . . . . . . . . . . . . . . . . . P-564 substrate specificity . . . . . . . . . . . . . . . . . . . M-975 Sulfonamide . . . . . . . . . . . . . . . . . . . . . . . C1-1741

spine SSI . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-261

SpyCEP. . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1311 SSI . . . . . . . . . . . . . . . . . . . . K-247, K-262, K-1594 ST131 . . . . . . . C2-110, C2-111, C2-112, C2-115, . . . . . . . . . . . C2-116, C2-687, K-1584, F-2040 ST258 . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1217 ST59 CA-MRSA . . . . . . . . . . . . . . . . . . . C1-1340 stable isotope . . . . . . . . . . . . . . . . . . . . . . . . . D-739 Staphylococcal cassette chromosomal mec . . C1-1740 Staphylococci . . C2-130, C2-1393, D-1441, L1-2105 Staphylococcus . . . . . . . . . B-1314, D-1417, E-1479, . . . . . . . . . . . . . . . . . . . . . . . . F-1516, L1-2102 Staphylococcus aureus . . . . . . . . B-043, B-046, B-058, . . . . . . . C2-126, K-249, K-253, K-259, K-267, . . A-620, A-625, B-650, B-657, D-762, E-783, . . K-900, K-906, K-908, K-909, K-915, K-937, . . .T-1037, B-1316, B-1318, B-1320, C1-1339, . . . . . . C1-1341, C2-1376, C2-1381, C2-1382, . . . . . . C2-1384, C2-1390, C2-1391, C2-1394, . . D-1414, D-1419, D-1420, D-1428, D-1430, . . . D-1439, D-1440, D-1459, E-1468, E-1483, . . . . E-1486, F-1487, F-1513, F-1534, F-1538, . . . . . . . G3-1555, L1-1645, L1-1658, M-1713, . . . . . . . . B-1735, B-1736, C1-1740, C1-1741, . . . . . . C1-1747, C2-1909, C2-1912, C2-1915, . . . . . . . . . . . . . . . . . . .F-1997, F-1998, F-2029 Staphylococcus aureus - ST398 . . . . . . . . . . . . . K-255 Staphylococcus aureus bacteremia . . . . . . . . . . K-2092 Staphylococcus epidermidis . . . . . . . . . . . . . . . K-2094 Staphylococcus spp.. . . . . C2-128, C2-1401, D-1437, . . . . . . . . . . . . . . . . . . . . . . . . . K-2085, K-2089 statins . . . . . . . . . . . . . . . L1-297, M-329, K-1626 STD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1303 stem cell transplantation . . . . . . . . . T-363, D-1778 stewardship . . . . . .H-225, K-1926, K-240, L1-282 stochastic mutations . . . . . . . . . . . . . . . . . . A-1266 stool toxin . . . . . . . . . . . . . . . . . . . . . . . . . . . D-162 strain type . . . . . . . . . . . . . . . . . . . . . . . . . . . K-931 strain typing. . . . . . . . . . . . . . . . . . . M-316, K-469 Streptococcus agalactiae . . . . . . . . . . . . . . . . C2-1990 Streptococcus pneumoniae . . . . . . . . . C2-145, C2-146, H-219, L1-296, B-658, G-862, G-865, G-866, . . . . . . . A-1275, C2-1352, C2-1355, C2-1358, . . . . . . C2-1359, C2-1360, C2-1361, C2-1363, . . . C2-1365, C2-1366, F-1535, G3-1541, G3Streptococcus pseudopneumoniae . . . . . . . . . . C2-1365 Streptococcus pyogenes . . . . .B-661, B-1311, B-1312, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1991 Streptococcus viridans . . . . . . . . . . . . . . . . . L1-1640 Streptococcus. . . . . . . . . . . . . . . . . . . . . . . . . . . B-1313

structure-function . . . . . . . . . . . . . C1-076, C1-458

target surveillance . . . . . . . . . . . . . . . . . . . . . K-268 target trough level . . . . . . . . . . . . . . . . . . . . . A-608

sulphur contaning acetamide as anticandidal agent . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-812

Tazobactam . . . . . . C1-073, E-198, E-200, E-201, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1762 TB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1254

suPAR . . . . . . . . . . . . . . . . . . . . . .D-1404, D-1405

TB/HIV . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1371

Superantigens . . . . . . . . . . . . . . . . B-1313, F-1517 superficial culture . . . . . . . . . . . . . . . . . . . . M-1688

TBA-354 . . . . F-834, F-835, F-836, F-837, F-838, . . . . . . . . . . . . . . . . . . . . . . . . . . . F-839, F-840 TDM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1627 Tecovirimat . . . . . . . . . . . . . . . . . . . . . . . . . . V-396 Tedizolid . . . . . C2-142, A-1292, A-1293, A-1294, . . . . . . . . . A-1295, L1-1664, L1-1665, E-1995 Teicoplanin . . . . . . . . . . . . . . . . . . . . A-607, A-608

suppression . . . . . . . . . . . . . . . . . . . . . . . . . .H-881 surface properties . . . . . . . . . . . . . . . . . . . . . F-2063 surfactant . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-783 surgery . . . . . . . . . . . K-939, K-941, K-942, L1-962 surgical infection . . . . . . . . . . K-256, K-259, K-262 surgical management . . . . . . . . . . . . . . . . . M-1686 surgical prophylaxis . . . . . . . . . . . . . . K-236, K-247 surgical site infection (SSI) . . . . . . . . K-266, K-269 surgical wound . . . . . . . . . . . . . . . . . . . . . . . . K-262 surgical wound infection . . . . . . . . . . . . . . . . K-268 surveillance . . . C2-089, C2-124, C2-125, C2-126, . . . C2-129, C2-131, C2-132, C2-135, C2-136, . . . . . C2-137, C2-138, C2-139, E-204, K-237, . . . . . . .M-315, D-773, K-914, K-952, P-1021, . .C2-1213, C2-1362, D-1424, H-1573, K-1755 surveillance cultures . . . . . . . . . . . . . . . . . . . F-1524 susceptibility . . . . . . . . . C2-688, C2-120, C2-135, . . . . . . . .E-200, L1-282, K-471, E-808, F-854, . . . . . . . . . . . G-876, D-1410, E-1483, E-1992 susceptibility testing . . . . . . . . . . . . . E-205, D-728 Sutezolid . . . . . . . . . . . . . . . . . . . . A-1265, E-1993 sutures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-269 swine respiratory disease . . . . . . . . . . . . . . . F-2034 Switzerland . . . . . . . . . . . . . . . . . . . . . . . . . C2-116 SXT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-715 SXT transfer . . . . . . . . . . . . . . . . . . . . . . . . B-1330 syndromic diagnosis. . . . . . . . . . . . . . . . . . . . D-178 synergism . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-796 synergist. . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1496 synergistic effects . . . . . . . . . . . . . . . . . . . . . . E-788 synergy. . . . . A-031, A-622, E-782, E-799, E-800, . . . . . . . . . . . F-815, E-1472, L1-1655, F-2009 synergy studies . . . . . . . . . . E-797, B-1299, F-1527, . . . . . . . . . . . . . . . . . . . . . . . . .M-1717, F-2060 synovial fluid . . . . . . . . . . . . . . . . . . . . . . . . K-2073 synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-838 synthetic antibodies . . . . . . . . . . . . . . . . . . . F-1537 Syphilis . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1301 systematic review . . . . . . . . . . . . . . . . . . . . . . A-034

Final Program

Telavancin . . . . . A-622, B-1299, E-1468, E-1469, . . . . . . . . . . . . . . . . E-1470, L1-1656, C1-1742 temporal trends . . . . . . . . . . . . . . . . . . . . . . C2-687 Tenofovir . . . . . . . .H-218, H-890, H-892, H-1570 Tenofovir Prodrug . . . . . . . . . . . . . . . . . . . . .H-552 TEST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-148 Tetracycline . . . . . . . . . . . . . . . . . . . . . . . . . F-1526 Tetracycline Resistance . . . . . . . . . . . . . . . . C1-675 Tetracycline resistance genes . . . . . . . . . . . . C2-712 Thailand . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-998 therapeutic . . . . . . . . . . . . . . . . . . . . . . . . . . L1-958 therapeutic drug monitoring . . . . . . . T-346, T-350 therapeutic equivalence . . . . . . . . . A-1945, A-1968 therapy . . . . . . . . . . . . . . . . L1-287, L1-288, T-341 Thermomyces lanuginosus . . . . . . . . . . . . . . . M-1680 thorough QT/QTc study. . . . . . . . . . . . . . . . A-623 three dimensional extract test, . . . . . . . . . . . . D-774 tick transmitted disease . . . . . . . . . . . . . . . G3-1553 Tigecycline . . . . . . . . . . C2-099, C2-133, C2-140, . . . C2-141, C2-143, C2-144, C2-147, C2-148, . . . . . . C2-150, B-652, C2-721, D-765, E-784, . . . . . E-785, E-799, A-1280, C2-1352, F-2004 Tigecycline combinations . . . . . . . . . . . . . . B-1300 Tigecycline MIC . . . . . . . . . . . . . . . E-787, K-1604 Tigecycline resistance . . . . . . . . . . . C2-151, E-787 time-killing assay . . . . . . . . . . . . . . . . E-202, D-761 time kill . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-2022 time to detection . . . . . . . . . . . . . . . . . . . . . D-1409 time to positivity of blood culture . . . . . . . . D-1420 time-kill curves . . . . . . . . . . . . . . . . . . . . . . . E-203 time-kill study . . . . . . . . . . . . . . . . . . . . . . . . E-794 tissue culture plate . . . . . . . . . . . . . . . . . . . . . D-171 TLA-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-072

275

> Keyword INDEX TMC207 . . . . . A-1256, A-1257, A-1258, A-1259, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1260 Tn1721 transposon . . . . . . . . . . . . . . . . . . . C1-668 Tn4401 . . . . . . . . . . . .C1-589, C2-1217, C2-1218 tolerability . . . . . . . . . . . . . . . . . . . . . . . . . . A-1273 tolerance . . . . . . . . . . . . . . . . . . . . . . . . . . M-1705

U U-480 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1266 Uganda . . . . . . . . . . . . . . . . . . . . . . . . . . . . .H-893 ultrasonography . . . . . . . . . . . . . . . . . . . . . . P-1008

Vancomycin-Resistent Enterococci (VRE) . . .K-272, . . K-275, K-277, K-279, K-281, A-600, A-601, . . . . A-602, B-655, T-1039, C1-1344, D-1436, . . . . . . . . . . . . . . . . .D-1442, K-1632, C2-1985 Vancomycin-susceptible Enterococcus faecium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1984

uncomplicated cystitis . . . . . . . . . . . . . . . . . . D-775

VAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1926

toll like receptor agonist . . . . . . . . . . . . . . . . B-054

unusual microorganisms . . . . . . . . . . . . . . . K-2090

Tomatidine . . . . . . . . . . . . . . . . . . F-1997, F-1998

variable number tandem repeat . . . . . . . . . . C2-723 Varicella vaccine. . . . . . . . . . . . . . . . . . . . . G3-1554

Topical microbicide . . . . . . . . . . . . . . . . . . . F-1528 Topoisomerase . . . . . . . . . . . . . . . . C1-667, F-2039

upper respiratory infection. . . . . . . . . . . . . . L1-300 UppS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1496 urinary . . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2111

Topoisomerase inhibitors. . . . . . . . . . . . . . . F-2031

urinary tract infections. . . . . . . . . . . . . . . . . C2-113

Varicella-zoster virus . . . . . . . . . . . . . . . . . . V-1240 Vascular graft infection . . . . . . . . . . . . . . . . K-2089

totally implantable venous access ports . . . . . D-166 toxicity . . . . . . . . . . . . . . . . . . . . . . A-1954, F-2008

urinary bactericidal activity (UBT) . . . . . . . A-1285

Veillonella . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-806

urinary screening . . . . . . . . . . . . . . . . . . . . . K-1927 urinary tract infection . . . . C2-111, K-274, K-280, . . . .L1-283, C2-684, C2-689, T-1036, B-1331, . . . . . . . . .B-1332, A-1965, L2-2107, L2-2108, . . . . . . . L2-2110, L2-2113, L2-2115, L2-2116, . . . . . . . . . . . . . . . . . . . . . . . L2-2117, L2-2118 urinary tract infections/colonizations . . . . L2-2109

Ventilator associated pneumonia . . . . . . . . . F-2014 Verapamil . . . . . . . . . . . . . . . . . . . . . . . . . . F-2013 Vertebral osteomyelitis . . . . . . . .K-2079, L1-2103, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-2104

toxicology . . . . . . . . . . . . . . . . . . . . . . . . . . F-2042 toxin. . . . . . . . . . . . . . . . . . . . . . . .M-1063, F-1999 toxin genes . . . . . . . . . . . . . . . . . . . . . . . . . . . D-158 Toxoplasma gondii. . . . . . . . . . . . . . . . . . . . . .H-223 TP-271 . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1525 TR-701 FA . . . . . . . . . . . . . . . . . . . . . . . . . A-1292 TR-701FA. . . . . . . . . . . .A-1293, A-1294, A-1295 TR/L98H mutation . . . . . . . . . . . . . . . . . . M-334 trans-enamine . . . . . . . . . . . . . . . . . . . . . . . C1-459 transmission. . . . . . . . . . . . . . . . . . . . . . . . . C2-109 transplant . . . .K-273, M-337, T-348, T-351, T-357, . . . . . . . . . . . . . . . . . . T-1029, T-1031, M-1227 transplantation . . . . . . T-343, T-346, T-352, T-356, . . . . . . T-365, T-1030, T-1032, T-1043, T-1072 transposon . . . . . . . . . . . . . . . . . . . . . . . . . . C1-679 treatment . . . . . . . . . D-154, K-250, K-251, K-256, . . . . . . . . . . . . . . . . . . K-917, M-1234, V-1236 treatment failure . . . . . . . . . . . . . . . . . . . . . . K-249 treatment strategy . . . . . . . . . . . . . . . . . . . . . K-238 triazoles . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1513 Trichomonas vaginalis . . . . . . . . . . . . . . . . . . . . P-563 Trichosporon asahii . . . . . . . . . . . . . . . . . . . . M-1712 trichosporonemia . . . . . . . . . . . . . . . . . . . . . M-324 trimethoprim/sulfametoxazole. . . . . .H-221, A-603 tropism . . . . . . . . . . . . . . . . . . . . H-1577, H-1578 TST . . . . . . . . . . . . . . . . . . . . . . . . . D-740, D-742 Tuberculosis . . . . . . D-739, D-741, D-742, D-743, . . . F-834, F-835, F-836, F-837, F-839, F-840, . . . L1-957, L1-958, A-1255, A-1258, A-1265, . . . . . . . B-1296, C2-1372, C2-1373, C2-1374, . . . . . . . . . G3-1552, E-1992, E-1993, H-1919 Tularemia. . . . . . . . . . . . . . . . . . . . . . . . . . . F-1531 Turkey . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-964 Tween80 . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-763 type 2 diabetes . . . . . . . . . . . . . . . . . . . . . . . . B-043 type B influenza . . . . . . . . . . . . . . . . . . . . . . V-1080 type-three secretion . . . . . . . . . . . . . . . . . . . F-1529 typing . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1747

urine concentrations . . . . . . . . . . . . . . . . . . M-992 uropathogenic E. coli . . . . . E-777, B-1331, B-1332 USA100 pvl+ . . . . . . . . . . . . . . . . . . . . . . . C2-1907 USA300. . . . . . . . . . . . . . . . . . . . . B-056, C2-1909 USA600 MRSA . . . . . . . . . . . . . . . . . . . . . . K-912 UTI . . . . . . . . . . . . . . . . . . . . . . . . F-2057, K-1927

V vaccination . . . . . . . . . . . . . . . . . . . . . . . . . . . P-996 vaccination coverage . . . . . . . . . . . . P-996, G-1051 vaccination promotion . . . . . . . . . . . . . . . . . G-1051 vaccine . . . B-053, G-868, G-869, G-875, G-1048, G-1053, G-1054, K-2094 vaccine acceptability . . . . . . . . . . . . . . . . . . . V-375 vaccine development . . . . . . . . . . . . . . . . . . . G-870 vaccine safety . . . . . . . . . . . . . . . . . . . . . . . . G-1052 vaginal co-infections . . . . . . . . . . . . . . . . . . L2-306 vaginal microbiota . . . . . . . . . . . . . . . . . . . . L2-310 vaginitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-306 Valganciclovir . . . . . . . . . . . . . . . . . T-369, T-1025 validation . . . . . . . . . . . . . . . . . . . . . . . . . . . K-1756 vanA gene . . . . . . . . . . . . . . . . . . . K-281, C2-1985 vanA-type . . . . . . . . . . . . . . . . . . . . . . . . . C2-1984 Vancomycin . . . . . . C2-128, K-247, K-473, A-609, . .A-610, A-611, A-612, A-614, A-616, A-617, . . A-618, A-619, B-645, B-646, B-659, E-807, . . K-906, , K-919, K-1123, C2-1376, C2-1390, . . C2-1395, D-1435, E-1473, E-1477, E-1481, . . . . . . . . . .G3-1558, K-1627, K-1629, K-1630 Vancomycin MIC . . . . . K-946, K-1122, C2-1391, . . . . . . . . . . . . . . . . . C2-1392, E-1471, E-1485 Vancomycin MIC creep. . . . . . . . K-1121, C2-1392 Vancomycin nephrotoxicity . . . . . . . . . . . . . . A-615

Varicella zoster virus vaccine . . . . . . . . . . . G3-1556

Vibrio owensii . . . . . . . . . . . . . . . . . . . . . . . . . C2-715 Vibrio vulnificus . . . . . . . . . . . . . . . . . . . . . . . B-1298 VIM-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1214 VIM-2 carbapenemase . . . . . . . . . . . . . . . . C2-719 VIM-28 . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-077 VIM-type metallo-beta-lactamase . . . . . . . C2-720 viral diagnostics . . . . . . . . . . . . . . . . . . . . . . V-1076 viral infection . . . . . . . . . . . . B-059, K-954, V-1074 viral load . . . . . . . . . . . . . . . . . . . . H-1575, T-1070 viral loads. . . . . . . . . . . . . . . . . . . . . . . . . . . . V-372 viral suppression . . . . . . . . . . . . . . . . . . . . .H-1580 viridans group streptococci . . . . . . . . . . . . . . A-604 virological failure . . . . . . . . . . . . . . . . . . . . . T-1072 virological outcome . . . . . . . . . . . . . . . . . . . A-1251 virological response . . . . . . . . . . . . . . . . . . . .H-886 virtual screening. . . . . . . . . . . . . . . . . . . . . . F-1534 virulence . . . . .C2-1210, B-1310, B-1321, B-1323, . . . . B-1326, B-1327, B-1328, B-1333, B-1336, . . . . . . . . . . . . . . . . . . . . . . . . . F-1515, K-1614 virulence factor . . . . . . . .C2-685, B-1312, B-1331, . . . . . . . . B-1335, C2-1400, D-1452, G3-1554, . . . . . . . . . . . . . . . . . . . . . . . . . F-1999, F-2058 virus . . . . . . . . . . . . . . . . . T-1064, T-1065, V-1073 virus like particle . . . . . . . . . . . . . . . . . . . . . G-1048 VISA . . . . . . . . A-603, K-906, C2-1381, C2-1387, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-1473 visual symptoms. . . . . . . . . . . . . . . . . . . . . M-1670 vitamin D receptor . . . . . . . . . . . . . . . . . . . . B-043 VITEK 2 . . . . . . . . . . . . . . . . . . . . . . . . . . M-1710 Voriconazole . . . . M-324, F-811, A-1938, A-1939, . . . . . . . . . . . . . . . . . . . . . . . . M-1225, M-1234 Voriconazole P-Glycoprotein . . . . . . . . . . . A-1937 Voriconazole pharmacogenomics. . . . . . . . . A-1937 Voriconazole therapeutic drug monitoring . A-1937 VRE . . . . . . . K-270, K-276, K-281, B-654, B-655 VRE colonization . . . . . . . . . . . . . . . . . . . . . K-271 VZV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-307

276

September 9-12 |

KEYWORD INDEX

W water . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-711 water based method . . . . . . . . . . . . . . . . . . . K-2082 whole genome sequencing . . . . . . .C1-062, B-1320, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1651 whole genomes . . . . . . . . . . . . . . . . . . . . . . C1-592 wound . . . . . . . . . . . . . . . . . . . . . . C2-143, F-1518

X X-ray crystallography. . . . . . . . . . . . . . . . . . C1-459 X-ray structure. . . . . . . . . . . . . . . C1-463, C1-1344 XDR-TB . . . . . . . . . . . . . . . . . . . . . . . . . . C2-1368

Y Y. pestis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1302 yeast . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M-966 Yersinia pestis . . . . . . . . . . . . . . . . . . . . . . . . B-1304 yield . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1409 young adult . . . . . . . . . . . . . . . . . . . . . . . . C2-1372

Z Zabofloxacin . . . . . . . . . . . . . . . . . . . . . . . . L1-294 Zanamivir . . . . . . . . . . . . . . . . . . . V-1079, A-1246 Zoonosis . . . . . . . . . . . . . . . . . . . . L1-963, P-1001 Zygomycosis . . . . . . . . . . . . . . . . . . . . . . . . M-973

Final Program

277

> NOTES

278

September 9-12 |

ORAL SESSIONS

ICAAC 2012

Program Grid Special Sessions and Lectures

> Sunday AM

> Sunday PM

> Monday PM

> Tuesday PM

> Wednesday AM

Interactive ID Fellows Session

031 Literature Review

120 ICAAC Live

209 ID Quiz

Plenary Session

001 Infectious Diseases 101: For Fellows Age 18-88 Room 104 7:00 a.m. - 9:00 a.m.

002 Opening Keynote Session Hall E 9:30 a.m. - 11:30 a.m.

Room 103 1:45 p.m. - 3:45 p.m.

Poster Summary Session 032 Early New Antimicrobial Agents Room 104 1:45 p.m. - 3:45 p.m.

This Week in Microbiology with Vincent Racaniello Esplanade Ballroom 303 2:00 p.m. - 4:00 p.m.

130 ICAAC Lecture Room 103 4:30 p.m. - 5:30 p.m.

Esplanade Ballroom 308 2:00 p.m. - 4:00 p.m.

213 Cubist-ICAAC Award Lecture Room 103 4:30 p.m. - 5:30 p.m.

225 The Use of Social Media and New Technologies in Healthcare Room 130 8:00 a.m. - 9:00 a.m

Symposium 130a ICAAC-GCACMID Symposium Room 102 5:45 p.m. - 7:15 p.m.

Final Program

279

> Program Grid Oral Sessions Oral Sessions- Category A

Antimicrobial Pharmacokinetics, Pharmacodynamics and General Pharmacology

> Sunday PM

> Monday AM

> Monday PM

> Tuesday AM

> Tuesday PM

> Wednesday AM

Symposium

Meet-the-Experts

Symposium

Meet-the-Experts

Slide Session

Symposium

035 Pharmacodynamics of Antifungal Agents Esplanade Ballroom 306 4:00 p.m. - 6:00 p.m.

049 Surgical Prophylaxis: Dosage Recommendations, Tissue Penetration, and Pharmacokinetic Considerations Esplanade Ballroom 305 7:00 a.m. - 8:15 a.m.

Meet-the-Experts 061 Targeting Gram-Negative Superbugs with Polymyxins: From Lab-Bench to Bedside

121 Aerosol Drug Delivery: Getting Anti-Infective Agents to the Lung

139 Intra- and Extracellular Activities of AntiInfective Agents

Room 130 2:00 p.m. - 4:00 p.m.

Esplanade Ballroom 310 7:00 a.m. - 8:15 a.m.

Meet-the-Experts 131 Top Papers in Anti-Infective and Antiretroviral PK/PD Esplanade Ballroom 310 5:45 p.m. - 7:00 p.m.

200 Maximizing PK/ PD Modeling for Dosing, Prevention of Resistance and Clinical Outcomes

227 Use of Pharmacokinetics/Pharmacodynamics for Risk Reduction of Adverse Events

Room 102 1:30 p.m. - 4:00 p.m.

Room 103 9:15 a.m. - 11:15 a.m.

Symposium 147 Vancomycin: What Do We Know Now About Pharmacokinetics/ Pharmacodynamics? Esplanade Ballroom 306 8:30 a.m. - 10:30 a.m.


Oral Sessions- Category B

Therapy in Animal Models, Pathogenesis of Infectious Diseases, Molecular Basis for Pathogenicity, and Host Defenses

> Sunday PM

> Monday AM

> Monday PM

> Tuesday AM

Symposium

Symposium

Symposium

Symposium

036 Microbial Factors Modulating Host Responses: New Frontiers Esplanade Ballroom 309 4:00 p.m. - 6:00 p.m.

062 Malnutrition, Microbiome & Mucosal Immunity Esplanade Ballroom 308 8:30 a.m. - 10:30 a.m.

Symposium 063 Pathogenesis, Diagnosis and Treatment of Urinary Tract Infection

122 Bacterial and Viral Infections in Patients Treated with Novel Biologic Agents: What Do I Need to Know? Esplanade Ballroom 300 2:00 p.m. - 4:00 p.m.

Room 130 8:30 a.m. - 10:30 a.m.

148 New Concepts in Tuberculosis: Pathogenesis, Diagnostics, Treatment, and Prevention Esplanade Ballroom 308 8:30 a.m. - 10:30 a.m.

Symposium 192 Virulence Bags: Extracellular Vesicles that Modify Host-Pathogen Interactions Esplanade Ballroom 302 11:15 a.m. - 12:45 p.m.

Slide Session 196 Novel Antibody Therapy of Difficult Infections Esplanade Ballroom 310 11:15 a.m. - 12:45 p.m.

280

September 9-12 |

> Tuesday PM

> Wednesday AM

ORAL SESSIONS Oral Sessions- Cateogry C1

Antibacterials: Mechanisms of Action, Biochemistry and Genetics of Resistance (Antibacterial, not Viral or Fungal)

> Sunday PM

> Monday AM

Symposium

Symposium

037 Multidrug Resistance in Emerging Countries

064 PlasmidMediated Quinolone Resistance



Slide Session 047 Structure/ Function Esplanade Ballroom 300 4:00 p.m. - 6:30 p.m.

> Monday PM

> Tuesday AM

> Tuesday PM

> Wednesday AM

Symposium

Symposium

Symposium

149 Novel Techniques for the Diagnostic of the Emerging Antibiotic Resistances Esplanade Ballroom 302 8:30 a.m. - 10:30 a.m.

Slide Session 081 Carbapenemase in Enterobacteriaceae and P. aeruginosa

Slide Session 156 Extended Spectrum ơ-Lactamases

Room 122 11:15 a.m. - 12:45 p.m.

Room 121 8:30 a.m. - 11:00 a.m.

203 Bacterial Communication and Resistance Esplanade Ballroom 300 2:00 p.m. - 4:00 p.m.

228 Resistance in Beyond MecA Esplanade Ballroom 302 9:15 a.m. - 11:15 a.m.

Meet-the-Experts 214 Top 10 ơ-Lactamase Papers in 2012 Esplanade Ballroom 305 5:45 p.m. - 7:00 p.m.

Slide Session 197 Resistance in Staphylococcus aureus Room 122 11:15 a.m. - 12:45 p.m.

Oral Sessions- Category C2

Antibacterials: Surveys and/or Molecular Epidemiology of Resistance and Resistance Genes, Strains or Serotypes (Bacterial, not Viral or Fungal Resistance)

> Sunday PM

> Monday AM

> Monday PM

> Tuesday AM

> Tuesday PM

> Wednesday AM

Symposium

Symposium

Symposium

Meet-the-Experts

Symposium

Meet-the-Experts

038 Whole Genome Sequencing and Molecular Epidemiology: The New Frontier? Esplanade Ballroom 308 4:00 p.m. - 6:00 p.m.

065 Population Dynamics in Streptococcus pneumoniae Esplanade Ballroom 310 8:30 a.m. - 10:30 a.m.

123 Antibiotic Combinations against Gram-Negatives in the XDR Era: From Bench to Bedside Room 122 2:00 p.m. - 4:00 p.m.

140 : The Management of Severe and Recurrent Infections Esplanade Ballroom 308 7:00 a.m. - 8:15 a.m.

Slide Session Meet-the-Experts 132 Detecting, Controlling, and Treating Carbapenemase-Producing Enterobacteriaceae

157 Carbapenemases Go Global Esplanade Ballroom 300 8:30 a.m. - 11:00 a.m.


204 Global Spread of Antimicrobial Resistance: Mechanisms of Spread, Surveillance, and Control Room 121 2:00 p.m. - 4:00 p.m.

Meet-the-Experts 215 Surveillance of Antimicrobial Resistance: Potential Sources of Bias Esplanade Ballroom 309 5:45 p.m. - 7:00 p.m.

220 Anaerobes and Surveillance: Neglected or Not? Esplanade Ballroom 302 7:00 a.m. - 8:15 a.m.

Slide Session 236 Acinetobacter: Challenges and Continued Emergence Room 132 9:15 a.m. - 11:45 a.m.

Slide Session 237 MRSA: Pervasive, Persistent, and Pathogenic Esplanade Ballroom 305 9:15 a.m. - 11:45 a.m.

Final Program

281

> Program Grid Oral Sessions Oral Sessions- Category D

Laboratory Tests for Diagnosing Infections; Methods for Antibacterial Susceptibility Testing

> Sunday PM

> Monday AM

> Monday PM

> Tuesday AM

> Tuesday PM

> Wednesday AM

Symposium

Meet-the-Experts

Symposium

Symposium

Slide Session

Meet-the-Experts

039 Best Practices: Diagnosis of Viral Causes of Hepatitis Esplanade Ballroom 305 4:00 p.m. - 6:00 p.m.

050 Syphilis Diagnostics: Traditional Versus “New” Algorithm Room 122 7:00 a.m. - 8:15 a.m.


124 Epidemiology and Diagnosis of Febrile Illness in the Era of Global Climate Change

150 Antimicrobial Susceptibility Update Room 120 8:30 a.m. - 10:30 a.m.

Room 102 2:00 p.m. - 4:00 p.m.

201 Diverse Applications of Mass Spectrometry in Clinical Microbiology Room 120 1:30 p.m. - 4:00 p.m.

Room 103 8:30 a.m. - 10:30 a.m.



Meet-the-Experts

060 Cases in Clinical Microbiology

221 Optimal Diagnostic Testing for Clostridium difficile in Clinical Practice

133 MALDI-ToF and PCR/ESI Mass Spectrometry: Implementation and Impact on Patient Care

226 Challenges in the Diagnosis and Clinical Interpretation of Infections with Gram-Positive Rods

Room 121 5:45 p.m. - 7:00 p.m.

Room 104 9:15 a.m. - 11:15 a.m

Oral Sessions- Category E

In Vitro Antibacterial Susceptibility Studies and Drug-Combination Interactions

> Sunday PM

> Monday AM

> Monday PM

Symposium 040 Origins and Ecology of Antibiotic Resistance

> Tuesday AM

> Tuesday PM

Symposium

Symposium

151 Laboratory Approaches for Detection, Characterization, and Reporting of Important Resistance Mechanisms in Gram-Negatives


Room 132 8:30 a.m. - 10:30 a.m.

282

September 9-12 |

205 Selecting Antibiotic Resistant Mutants in the Laboratory: How Best to Mimic the Real World? Esplanade Ballroom 302 2:00 p.m. - 4:00 p.m.

> Wednesday AM

ORAL SESSIONS Oral Sessions-Category F

New Antimicrobial Agents (i.e. pre-US IND or prior to the start of any clinical therapeutic studies) and New Research Technologies

> Sunday PM

> Monday AM

> Monday PM

> Tuesday AM

> Tuesday PM

> Wednesday AM

Symposium

Symposium

Symposium

Meet-the-Experts

Symposium

Symposium

041 New Treatments for Mycobacterium tuberculosis Infections Room 122 4:00 p.m. - 6:00 p.m.

066 Host Defense (Antimicrobial) Peptides: Major Players in Health and Novel Therapeutics

125 Alternative Approaches to Inhibiting GramNegative Bacteria Esplanade Ballroom 308 2:00 p.m. - 4:00 p.m.


141 Too Few New Anti-GramNegative Agents: How to Change the Landscape?

206 Iron Transport and Homeostasis: Are There Opportunities for New Drugs?

Room 122 7:00 a.m. - 8:15 a.m.


229 New Approaches in the Treatment of Fungal Infections Esplanade Ballroom 309 9:15 a.m. - 11:15 a.m

Meet-the-Experts 216 Meeting the Challenge of Efflux from Gram-Negative Bacteria Esplanade Ballroom 302 5:45 p.m. - 7:00 p.m.

Oral Sessions- Category G

Adult and Pediatric Vaccine Studies and Pediatric Infections

> Sunday PM

> Monday AM

> Monday PM

> Tuesday AM

> Tuesday PM

> Wednesday AM

Symposium

Meet-the-Experts

Slide Session

Meet-the-Experts

Symposium

Symposium

042 Vaccine Conquests and Challenges Room 120 4:00 p.m. - 6:00 p.m.

051 Antibiotic Shortages, Antibiotic Stewardship and the Sick Child Esplanade Ballroom 309 7:00 a.m. - 8:15 a.m.

Symposium

114 Vaccines: Innovations, Impact and Safety Room 121 1:30 p.m. - 4:00 p.m.

142 Healthy Mother, Healthy Baby Esplanade Ballroom 309 7:00 a.m. - 8:15 a.m.


067 Hot Topics in Vaccines

145 Interactive Cases in Pediatric Infectious Diseases

Room 120 8:30 a.m. - 10:30 a.m.

Room 103 8:30 a.m. - 10:30 a.m.

Symposium

207 Hot Topics in Pediatric Infectious Disease: 2012 Room 122 2:00 p.m. - 4:00 p.m.

230 Interplay between Pathogen and Host: From Immune Deficiency to Infectious Disease Room 122 9:15 a.m. - 11:15 a.m.

Slide Session

077 Vaccine Innovations

198 Global Pediatrics

Esplanade Ballroom 305 11:15 a.m. - 12:45 p.m.


Final Program

283

> Program Grid Oral Sessions Oral Sessions- Category H

HIV/AIDS and Other Retroviruses, Including Resistance

> Sunday PM

> Monday AM

> Monday PM

> Tuesday AM

Symposium

Meet-the-Experts

Symposium

Meet-the-Experts

043 Update on HIVAssociated Co-Morbidities Room 121 4:00 p.m. - 6:00 p.m.

052 How Do I Treat HCV in HIV/ HCV Co-Infected Patients?

126 Current Issues in HIV-Associated Opportunistic Diseases

143 Management of Antiretroviral Therapy-Induced Bone Toxicity

Room 121 7:00 a.m. - 8:15 a.m.


Room 121 7:00 a.m. - 8:15 a.m.

Slide Session 073 New Antiretroviral Therapy: Bench to Bedside Room 104 8:30 a.m. - 11:00 a.m.

Meet-the-Experts 134 Prevention of Anal Cancer in HIV-Infection: From Early Detection to Vaccination

> Tuesday PM

> Wednesday AM Meet-the-Experts 222 Can We Safely Simplify Antiretroviral Therapy in TreatmentExperienced Patients?

Symposium


152 What’s New in Antiretroviral Therapy

Slide Session 238 Common Pathogens: Still a Problem in HIV-I

Room 130 8:30 a.m. - 10:30 a.m.


Room 102 9:15 a.m. - 11:45 a.m.

Oral Sessions- Category H2

Antiretroviral Agents for Treatment and Prevention Including Preclinical and All Phases of Clinical Trials and Resistance

> Sunday PM

> Monday AM

> Monday PM

> Tuesday AM

> Tuesday PM Interactive Symposium 202 Advances in HIV and HCV Management Room 103 2:00 p.m. - 4:00 p.m.

284

September 9-12 |

> Wednesday AM

ORAL SESSIONS Oral Sessions- Cateogry K

Healthcare-Associated and Surgical Infections and Clinical Epidemiology

> Sunday PM

> Monday AM

> Monday PM

> Tuesday AM

> Tuesday PM

> Wednesday AM

Slide Session

Meet-the-Experts


Meet-the-Experts

Symposium

Meet-the-Experts

048 Difficulties of Clostridium difficile Room 254 4:00 p.m. - 6:30 p.m.

053 Infection Prevention and Control in Lowand -MiddleResource Settings Esplanade Ballroom 308 7:00 a.m. - 8:15 a.m.

Meet-the-Experts 054 Top Papers in Infection Prevention and Control, 2011-2012 Room 120 7:00 a.m. - 8:15 a.m.

Symposium

118 Evidence-Based Infection Prevention and Control: Answering Key Questions

138a MDRO Control: What to Do When Basic Prevention Measures Don’t Work?

Room 104 2:00 p.m. - 4:00 p.m.

Room 102 7:00 a.m. - 8:15 a.m.

Slide Session 129 Staphylococcus aureus: Tough Bug, Tough Treatment Room 132 2:00 p.m. - 4:00 p.m.

Meet-the-Experts

068 Preventing Spread of M. tuberculosis in Healthcare Facilities

136 Preventing Line-Associated Bloodstream Infection: Which Measures are Essential?

Room 122 8:30a.m. - 10:30 a.m.


Slide Session 074 MultidrugResistant Organisms and Catheter-Related Infections Room 254 8:30 a.m. - 11:00 a.m.


208 Are Prevalence Surveys Still Useful for HealthcareAssociated Infection Surveillance? Esplanade Ballroom 305 2:00 p.m. - 4:00 p.m.

144 Antimicrobial Resistance and Antimicrobial Stewardship in NonHospital Settings Room 120 7:00 a.m. - 8:15 a.m.

Symposium 193 Regional Approaches to Prevention of Healthcare-Associated Antimicrobial Resistance

Room 120 7:00 a.m. - 8:15 a.m.

Symposium Meet-the-Experts

Meet-the-Experts

223 Environmental Cleaning and Infection Prevention

217 Challenging Issues in Pediatric Infection Prevention and Control Room 122 5:45 p.m. - 7:00p.m.

231 A Multifaceted Approach to Preventing Surgical Site Infections Room 121 9:15 a.m. - 11:15 a.m.

Slide Session Meet-the-Experts 218 Issues in the Diagnosis and Management of Prosthetic Joint Infections

239 Antimicrobial Stewardship: Perils of Prescribing Esplanade Ballroom 310 9:15 a.m. - 11:45 a.m



Slide Session 199 Bloodstream Infections: Catheters, Cultures and Counts Room 121 11:15 a.m. - 12:45 p.m.

076 Challenges in Infection Control Room 104 11:15 a.m. - 12:45 p.m.

Final Program

285

> Program Grid Oral Sessions Oral Sessions- Category L

Clinical Treatment and Outcome Trials Involving Adult Community-Acquired Infections, Including Obstetrical-Gynecological and Sexually Transmitted Infections

> Sunday PM

> Monday AM

> Monday PM

> Tuesday AM

Symposium

Meet-the-Experts

Symposium

Symposium

044 An Update on Novel and Important Tickborne Diseases Room 102 4:00 p.m. - 6:00 p.m.

055 Challenging Infections in Older Adults Esplanade Ballroom 310 7:00 a.m. - 8:15 a.m.

127 New Issues in the Management of MultidrugResistant (MDR) Endocarditis Esplanade Ballroom 305 2:00 p.m. - 4:00 p.m.

Symposium 069 New Issues in the Management of MDR/XDR TB Esplanade Ballroom 306 8:30 a.m. - 10:30 a.m.

> Tuesday PM

> Wednesday AM

153 Dangerous Pets and Other Animals Room 102 8:30 a.m. - 10:30 a.m.

Symposium 154 What Every Clinician Should Know About Emerging New Antimicrobials Esplanade Ballroom 305 8:30 a.m. - 10:30 a.m.

Symposium Symposium

078 50 Years of Fluoroquinolones: Past, Present and Future

194 Emerging and Current Challenges in Injecting Drug Users

Room 132 11:15 a.m. - 12:45 p.m.

Room 102 11:15 a.m. - 12:45 p.m.

Symposium 079 An Update on Streptococcal Pharyngitis and Rheumatic Fever Esplanade Ballroom 302 11:15 a.m. - 12:45 p.m.

Oral Sessions- Category L1

Clinical Trials of Adults with Community-Acquired Infections

> Sunday PM

> Monday AM

> Tuesday AM

> Tuesday PM

> Wednesday AM

> Wednesday PM

Meet-the-Experts

Slide Session

Symposium

Symposium

Symposium

056 Difficult to Manage Cutaneous Infections in Adults and Children

158 New Insights in Bacterial Meningitis Esplanade Ballroom 309 8:30 a.m. - 11:00 a.m.


Symposium 070 New Insights in Diabetic Foot Infections and Osteomyelitis Room 121 8:30 a.m. - 10:30 a.m.

286

September 9-12 |

210 Potluck: The Latest on Foodborne Infections Room 132 2:00 p.m. - 4:00 p.m.

232 What’s New with Pneumococcus?

045 An Update on Perinatal Infections


Room 130 4:00 p.m. - 6:00 p.m.

ORAL SESSIONS Oral Sessions- Category L2

STD, Urinary Tract and Ob-Gyn Infections

> Sunday PM

> Monday AM

> Monday PM

> Tuesday AM

> Tuesday PM

> Wednesday AM

Symposium 071 An Update on the Treatment and Prevention of UTIs Room 102 8:30 a.m. - 10:30 a.m

Oral Sessions- Category M

Mycology, Including Resistance and Mechanisms of Action of Antifungals

> Sunday PM

> Monday AM

> Monday PM

> Tuesday AM

> Tuesday PM

> Wednesday AM

Symposium

Meet-the-Experts

Slide Session


Meet-the-Experts

Meet-the-Experts

046 Mycology 2012: Top Papers Room 132 4:00 p.m. - 6:00 p.m.

057 Fungal Infections Involving the Eye Room 102 7:00 a.m. - 8:15 a.m.

115 Sleuthing in Mycology Esplanade Ballroom 310 1:30p.m. - 4:00 p.m.

Symposium Symposium 072 Research in Mycology: Hot Topics Room 132 8:30 a.m. - 10:30 a.m.

128 Fungal Infections in High-Risk Groups: Current and Future Strategies for Control

146 Challenging Cases in Mycology

219 How Can the Mycology Lab Work for You?

Room 104 8:30 a.m. - 10:30 a.m.

Room 121 5:45p.m. -7:00 p.m.

Slide Session 159 Mycology for the Bedside Room 122 8:30 a.m. -1:00 a.m.

224 Fungal Infections of the Central Nervous System Room 121 7:00 a.m. - 8:15 a.m.

Symposium 233 Controversies in Clinical Mycology Esplanade Ballroom 300 9:15 a.m. - 11:15 a.m.


Final Program

287

> Program Grid Oral Sessions Oral Sessions- Category P

Global Health, Travel Medicine and Parasitology

> Sunday PM

> Monday AM

> Monday PM

> Tuesday AM

> Tuesday PM

> Wednesday AM


Meet-the-Experts


Symposium

Symposium

Symposium

033 What’s Hot Where it’s Hot: Interactive Cases in Tropical Medicine Room 103 4:00 p.m. - 6:00 p.m.

058 Top Ten Papers in Travel and Tropical Medicine Esplanade Ballroom 306 7:00 a.m. - 8:15 a.m.

Slide Session 075 Parasitology, Global Health and Travel Medicine Esplanade Ballroom 309 8:30 a.m. - 11:00 a.m.

119 Clinical Problem Solving: Interactive Cases in Travel and Tropical Medicine

155 Update on Drug Resistance in Malaria

211 Global Health as an Academic Discipline



234 Best Practices for Serologic Testing in Selected Parasitic Diseases Room 254 9:15 a.m. - 11:15 a.m.

Room 103 2:00 p.m. - 4:00 p.m.

Meet-the-Experts 137 Controversies in Pre-Travel Preparation Room 122 5:45 p.m. - 7:00 p.m.

Oral Sessions- Category T

Transplantation Infectious Diseases

> Sunday PM

> Monday AM

> Monday PM

> Tuesday AM

> Tuesday PM

> Wednesday AM

Slide Session 116 Infections in Transplant Recipients Room 120 1:30 p.m. - 4:00 p.m.

Oral Sessions- Category V

Virology (Non-HIV), Including Resistance, and Non-HIV Viral Opportunistic Infections in HIV-Infected Patients

> Sunday PM

> Monday AM

> Monday PM

> Tuesday AM

> Tuesday PM

> Wednesday AM


Meet-the-Experts

Slide Session

Slide Session

Symposium

Symposium

034 Transplantation and the ID Physician: Management Strategies for the 21st Century Room 104 4:00 p.m. - 6:00 p.m.

288

059 Persistent Herpes Virus Viremia: What Does it Mean? Esplanade Ballroom 300 7:00 a.m. - 8:15 a.m.

117 Respiratory Viruses and Measles

160 Hepatitis and Herpes Viruses


Room 254 8:30 a.m. - 11:00 a.m.

Meet-the-Experts

080 Hot Topics in Viral Hepatitis

138 New Strategies for Transplantation of HIV Infected Individuals

Room 130 11:15 a.m. - 12:45 p.m.


Symposium

September 9-12 |

Symposium 195 Influenza: Beyond the Headlines Room 130 11:15 a.m. - 12:45 p.m.

212 Viruses and the Central Nervous System: Diagnostic, Treatment and Recent Outbreaks Room 130 2:00 p.m. - 4:00 p.m.

235 Recognizing and Managing Antiviral Resistance Room 120 9:15 a.m. - 11:15 a.m.

POSTER SESSIONS Poster Session- Category A

Antimicrobial Pharmacokinetics, Pharmacodynamics and General Pharmacology Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Tuesday 11:15 a.m. - 1:15 p.m.

Wednesday 9:15 a.m. - 11:15 a.m.

Halls A-C

Halls A-C

Halls A-C

Halls A-C

003 PK/PD of Carbapenems With or Without Beta-Lactamase Inhibitors

082 Glycopeptides and Lipopeptides: What’s New in PK/PD and Safety

161 Clinical Pharmacology of Antiviral and AntiTuberculosis Agents

240 Antifungals: Improving PK/PD and Safety

004 Polymyxins and Aminoglycosides: Optimizing PK/PD and Dosing

083 Improving Pharmacodynamics of Beta-Lactams and Beta-Lactamase Inhibitors

162 Clinical Pharmacology of Novel Anti-Infective Agents

241 Toxicokinetics and PK/PD of New and Old Fluoroquinolones

163 Pharmacokinetics/ Pharmacodynamics of New and Old Oxazolidinones

Poster Session- Category B

Therapy in Animal Models, Pathogenesis of Infectious Diseases, Molecular Basis for Pathogenicity, and Host Defenses Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Tuesday 11:15 a.m. - 1:15 p.m.

Halls A-C

Halls A-C

Halls A-C

005 Immune Response to Microbial Infection

084 Antimicrobial Therapy in Animal Models I

164 Antimicrobial Therapy in Animal Models II


165 Microbial Determinants of Virulence

Poster Session- Category C1

Antibacterials: Mechanisms of Action, Biochemistry and Genetics of Resistance (Antibacterial, not Viral or Fungal) Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Tuesday 11:15 a.m. - 1:15 p.m.


Halls A-C

Halls A-C

Halls A-C

Halls A-C

006 Carbapenemases and Expanded Spectrum ơLactamases: Enterobacteriaceae, S. aeruginosa, A. bumannii

085 Genetics and Resistance

166 Resistance to Staphylococcus and Other Gram-Positive

242 Mechanisms of Resistance to Novel Compounds

086 Resistance by Efflux/ Quinolone Resistance

Poster Session- Category C2

Antibacterials: Surveys and/or Molecular Epidemiology of Resistance and Resistance Genes, Strains or Serotypes (Bacterial, not Viral or Fungal Resistance) Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Tuesday 11:15 a.m. - 1:15 p.m.


Halls A-C

Halls A-C

Halls A-C

Halls A-C

007 AmpCs: Not Going Away!

087 Diverse Resistance Issues in Enterobacteriaceae

167 Characterization of Streptococcus pneumoniae in the Era of Antibiotics and Vaccines

243 Antimicrobial Resistance of Miscellaneous Bacteria

008 Carbapenemases: Will They Ever End! 009 ESBLs: Still Relevant

088 Food, Animals and Environment Reservoirs for Gram-Negative Organisms

168 Drug-Resistant Mycobacterium tuberculosis

244 Streptococcus and Enterococus

010 Multi-Center Surveillance Studies

089 Pseudomonas aeruginosa: An Overview of Survelliance Data

169 MRSA: A Bug with International Appeal and Great Sense

Final Program

289

> Program Grid Poster Sessions Poster Session- Category D

Laboratory Tests for Diagnosing Infections; Methods for Antibacterial Susceptibility Testing Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Tuesday 11:15 a.m. - 1:15 p.m.

Halls A-C

Halls A-C

Halls A-C

011 Clostridium difficile Diagnosticss

090 MALDI-ToF Mass Spectrometry and Identification and Susceptibility Testing

170 Detection of Bacteremia and Biomarkers for Sepsis

012 Diagnosis of Infections of Implantable Devices and Biofilms 013 Diagnosis of Respiratory Tract Infections

091 Mycobacteria: Diagnostics and Susceptibility Testing 092 Phenotypic Susceptibility Testing Methods

014 Serologic Methods for Detection of Infectious Diseases


171 Diagnosis, Characterization and Antimicrobial Susceptibility Testing: Gram-Positive Cocci 172 Molecular Methods for Pathogen Identification and Resistance Detection

Poster Session- Category E

In Vitro Antibacterial Susceptibility Studies and Drug-Combination Interactions Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Tuesday 11:15 a.m. - 1:15 p.m.


Halls A-C

Halls A-C

Halls A-C

Halls A-C

015 In Vitro Activity of BetaLactamase Inhibitor Combinations

093 Cornucopia of In Vitro Activity

173 In Vitro Activity of Lipoglycopeptides and Related Compounds

245 In Vitro Activity for Mycobacteria

016 In Vitro Activity of Fluoroquinolones

094 In Vitro Activity Against Multidrug-Resistant GramNegative Bacteria

174 In Vitro Activity Versus Staphylococcal

095 In Vitro Activity Versus Anaerobes

Poster Session- Category F

New Antimicrobial Agents (i.e. pre-US IND or prior to the start of any clinical therapeutic studies) and New Research Technologies Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Tuesday 11:15 a.m. - 1:15 p.m. Halls A-C

Halls A-C

096 New Antifungal Agents

175 Antimicrobial Peptides and Peptidomimetics

246 New Ways with Old Friends: Repurposing and Novel Formulations

097 New Antiviral Agents 098 New Approaches in Mycobacterial Therapy 099 Targeting the Bacterial Cell Wall: New Beta-Lactams and Beta-Lactamase Inhibitor Combinations

290


Halls A-C

September 9-12 |

176 Compounds and Approaches for Combating Gram-Positive Infections 177 Novel Antimicrobial Approaches and Agents

247 Novel Inhibitors of Bacterial GyrB/ParE Topoisomerase Subunits 248 Quinolones and Beyond 249 Targeting Gram-Negative Pathogens

POSTER SESSIONS Poster Session- Category G

Adult and Pediatric Vaccine Studies and Pediatric Infection Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Tuesday 11:15 a.m. - 1:15 p.m.


Tuesday 11:15 a.m. - 1:15 p.m.


Halls A-C

100 Impact of Expanded Valent: Pneumococcal Vaccines 101 Updates in Vaccines

Poster Session- Category G3

Studies Relating to Aspects of Pediatric Infections Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Halls A-C

178 Pediatrics

Poster Session- Category H

HIV/AIDS and Other Retroviruses, Including Resistance Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Tuesday 11:15 a.m. - 1:15 p.m.

Halls A-C

Halls A-C

Halls A-C

017 Adherence to HIV Therapy and Care

102 Antiretroviral Therapy Outcomes Including Select Populations

179 HIV-I Pathogenesis and Predictors of Antiretroviral Response in Treatment and Prevention

018 Hepatitis B and C Coinfection in HIV

103 Safety and Toxicity of Antiretroviral Therapy

019 Opportunistic Infections and Co-Morbid Conditions in HIV-I


180 HIV-I Resistance, Tropism and Novel Laboratory Methods

Poster Session- Category K

Healthcare-Associated and Surgical Infections and Clinical Epidemiology Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Tuesday 11:15 a.m. - 1:15 p.m.


Halls A-C

Halls A-C

Halls A-C

Halls A-C

020 Antibiotic Stewardship and Usage

104 Blood Stream Infections

181 Extended-Spectrum ơ-Lactamase Enterobacteriaceae

250 Bone Infections

105 Clostridium difficile Infections 021 Infection Control and the Environment

106 Endocarditis

022 Prosthetic Joint Infections

107 Fungal Infections

023 Surgical Site Infections

108 Influenza

024 Vancomyoin-Resistant Enterococci

251 Hand Hygiene 182 MRSA Infections 183 Resistant Acinetobacter Infections 184 Resistant Gram-Negative Infections

252 Vascular Catheter and Device Related Infections 253 Ventilator-Associated Pneumonia

185 Use of Vancomycin, Daptomycin and/or Linezolid

Final Program

291

> Program Grid Poster Sessions Poster Session- Category L1

Clinical Trials of Adults with Community-Acquired Infections Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Tuesday 11:15 a.m. - 1:15 p.m.


Halls A-C

Halls A-C

Halls A-C

Halls A-C

025 Antimicrobial Stewardship and OPAT

109 An Update on Tuberculosis

186 Endocarditis and Other Invasive Infections

254 Bone and Joint Infections

110 Zoonotic Infections 026 Respiratory Tract Infection

187 Meningitis and Central Nervous System Infections 188 Methicillin-Resistant Staphylococcus aureus: Clinical Aspects 189 Novel Agents and Insights in Skin and Soft Tissue Infections

Poster Session- Category L2

STD, Urinary Tract and Ob-Gyn Infections Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Tuesday 11:15 a.m. - 1:15 p.m.


Halls A-C

Halls A-C

027 Studies in Sexually Transmitted Infection

255 Urinary Tract Infection

Poster Session- Category M

Mycology, Including Resistance and Mechanisms of Action of Antifungals Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Tuesday 11:15 a.m. - 1:15 p.m.

Halls A-C

Halls A-C

Halls A-C

028 Fungal Epidemiology

111 Experimental Mycology

190 Clinical Mycology I 191 Clinical Mycology II

292

September 9-12 |


POSTER SESSIONS Poster Session- Category P

Global Health, Travel Medicine and Parasitology Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Tuesday 11:15 a.m. - 1:15 p.m.


Tuesday 11:15 a.m. - 1:15 p.m.


Halls A-C

112 Global Health, Parasitology and Travel Medicine

Poster Session- Category T

Transplantation Infectious Diseases Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Halls A-C

Halls A-C

029 Infections in Transplant Recipients: Viruses and Fungi

113 Infections in Transplant Recipients and Patients with Malignancies

Poster Session- Category V

Virology (Non-HIV), Including Resistance, and Non-HIV Viral Opportunistic Infections in HIV-Infected Patients Sunday 11:30 a.m. - 1:30 p.m.

Monday 11:15 a.m. - 1:15 p.m.

Tuesday 11:15 a.m. - 1:15 p.m.


Halls A-C

030 Non-HIV Virology

Final Program

293

> NOTES

294

September 9-12 |

> Notes

Late-breakers

> Notes

LATE-BREAKER SCIENTIFIC SESSIONS 003 (A) Poster Session

C2-097b First Identification of OXA-48 Carbapenemase-Producing

Enterobacteriaceae (CPE) in the United States

PK/PD of Carbapenems With or Without Beta-Lactamase Inhibitors Sunday, 11:30 AM - 1:30 PM . . . . . . . . . . . . . . . . . . . . . Halls A-C Presentation: A-022a Efficacy of Humanized Carbapenem Exposures against New

Delhi Metallo-Beta-Lactamase (NDM-1) Producing Enterobacteriaceae in a Murine Infection Model D. E. Wiskirchen1, P. Nordmann 2, J. L. Crandon3, D. P. Nicolau 3; 1Univ. of St. Joseph, Sch. of Pharm., Hartford, CT, 2Hosp. Bicetre, Paris, France, 3 Anti-Infect. Res. & Devel., Hartford Hosp., Hartford, CT.

-----------------------------------------------------------------------005 (B) Poster Session Immune Response to Microbial Infection Sunday, 11:30 AM - 1:30 PM . . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: B-060a TPA Alu I/D SNP Associates with Bacterial Osteomyelitis E. Valle-Garay 1, A. H. Montes 1, V. Carcaba 2, J. A. Carton 2, V. Asensi2;1Oviedo Univ. Med. Sch., Oviedo, Spain, 2Hosp. Univ. Central de Asturias, Oviedo Univ. Med Sch., Oviedo, Spain. B-060b Epithelial Innate Immune Response to Acinetobacter bauman-

nii Challenge: Why Some are More Vulnerable to Infection? Z. Feng 1, X. Jia 1, M. Adams 2, R. A. Bonomo3, A. Weinberg 1;1Sch. of Dental Med., Case Western Reserve Univ., Cleveland, OH, 2Sch. of Med., Case Western Reserve Univ., Cleveland, OH, 3Louis Stokes Cleveland Dept. of VA Med. Ctr., Cleveland, OH. B-060c Serum Annexin A2 Levels in Acute Brucellosis N. Aktug Demir 1, S. Ozcimen 2, S. Sumer 3, A. Arpaci 4, O. Ural 5, A. C. Inkaya 6; 1State Hosp. of Adiyaman, Adiyaman, Turkey, 2Numune State Hosp., Konya, Turkey, 3Selcuk Univ. Selcuklu Faculty of Med., Konya, Turkey, 4Adiyaman Univ. Faculty of Med., Adiyaman, Turkey, 5Selcuk Univ. Selcuku Faculty of Med., Konya, Turkey, 6Hacettepe Univ. Faculty of Med., Ankara, Turkey.

-----------------------------------------------------------------------008 (C2) Poster Session Carbapenemases: Will They Ever End! Sunday, 11:30 AM - 1:30 PM . . . . . . . . . . . . . . . . . . . . . Halls A-C

A. J. Mathers1, K. Hazen2, A. Yeh1, J. Carroll1, H. Cox1, C. Sifri 1; 1Univ. of Virginia, Charlottesville, VA, 2Duke, Durham, NC.

-----------------------------------------------------------------------009 (C2) Poster Session ESBLs: Still Relevant Sunday, 11:30 AM - 1:30 PM . . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: C2-121a Emergence of blaCTX-M Resistance Determinants in the

Bovine E. coli Reservoir, Northwest United States

M. A. Davis, L. Jones, N. Suthar, D. V. Meyers, W. Sischo, T. E. Besser; Washington State Univ., Pullman, WA. C2-121b CMY2 and CTXM15 Producing Salmonella Typhi, India N. Taneja1, S. B. Appannanavar 1, A. Kumar 1, G. Verma 1, Y. Kumar2; 1 Postgraduate Inst. of Med. Ed. and Res., Chandigarh, India, 2CRI Kasauli, Kasauli, India.

-----------------------------------------------------------------------026 (C2) Poster Session Respiratory Tract Infection Sunday, 11:30 AM - 1:30 PM . . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: L1-300a Severe Community-Acquired Pneumonia Requiring Inten-

sive Care Unit Admission H. Erdem1, H. Turkan 2, A. Cilli 3, L. Gorenek 1, O. Oncul 1, CAP in the ICU Study Group; 1GATA Haydarpasa Hosp., Istanbul, Turkey, 2GATA Hosp., Ankara, Turkey, 3Akdeniz Univ., Sch. of Med., Antalya, Turkey. L1-300b Ceftaroline Fosamil (CPT-F) Use Patterns in Hospitalized

Adult Patients with Community-Acquired Bacterial Pneumonia (CABP): A Retrospective Analysis of a Large U.S. Hospital Database X. Huang1, E. Beresford 1, H. D. Friedland 2; 1Forest Res. Inst., Inc., Jersey City, NJ, 2Cerexa Inc., Oakland, CA. L1-300c Community-Acquired Pneumonia (CABP) Due to Methi-

cillin-Resistant Staphyloccus aureus (MRSA) and Treatment with Ceftaroline: Experience from the CAPTURE Study A. Jandourek1, A. Cunningham 2, G. Udeani 3, Y. Li 1, H. Friedland 1; 1 Cerexa, Inc., Oakland, CA, 2Covenant Med. Ctr., Lubbock, TX, 3 Christus Spohn Hosp., Corpus Christi, TX.

Presentations: C2-097a Detection of Carbapenem-Resistant Providencia rettgeri

Producing Metallo-ß-Lactamase NDM-1 in Mexico H. Barrios 1, E. Garza-González 2, E. Tamayo 1, U. Garza-Ramos 1, J. M. Llaca-Díaz 2, A. Camacho-Ortiz 2, S. Guzmán-López 3, J. Silva-Sánchez1; 1 INSP, Cuernavaca, Mexico, 2Hosp. Univ. Dr. JE González, Monterrey, Mexico, Fac. de Medicina, UANL, Monterrey, Mexico.

Final Program

295

> Late-Breaker SCIENTIFIC SESSIONS -----------------------------------------------------------------------029 (T) (V) Poster Session Infections in Transplant Recipients: Viruses and Fungi Sunday, 11:30 AM - 1:30 PM . . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: T-369a Evaluation of Novel Program Aimed at Screening Solid Or-

gan Transplant Recipients for Emerging CMV Infection C. D. Cunha-Bang, S. S. Sørensen, H. Sengeløv, M. Iversen, F. Gustafsson, A. Rasmussen, N. Kirkby, J. Kjær, R. S. Brandt, C. Matthews, L. Peters, O. Kirk, J. Hilsted, J. Grarup, J. D. Lundgren, MATCH Program Study Group; Rigshospitalet, Copenhagen, Denmark. T-369b Risk Factors for Adenovirus Infection and Disease in Pediat-

ric Hematopoietic Stem Cell Transplant Patients L. Feghoul 1, J. Dalle 2, S. Chevret 1, M. Ouachée 1, M. Fahd 2, A. Baruchel 2 , F. Simon 1, J. Le Goff1; 1Univ Paris Diderot, Hosp. Saint-Louis, Paris, France, 2Univ. Paris Diderot, Hosp. Robert Debré, Paris, France.

-----------------------------------------------------------------------030 (V) Poster Session Non HIV Virology Sunday, 11:30 AM - 1:30 PM . . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: V-400a Method Development and Improvement of Human Papillo-

mavirus (HPV) Detection and Genotyping S. F. Ambaye; Orebro Univ., Orebro, Sweden. V-400b Characterization of a Monoclonal Antibody Specific to

Monkeypox Ortholog of A27L Protein: Specificity is Conferred by a Single Amino Acid Difference Within the Heparin Binding Site L. Hughes1, J. Goldstein 1, J. Pohl 1, J. W. Hooper 2, M. S. Keckler 1, M. Townsend 1, D. Bagarozzi 1, I. Damon 1, K. Karem 1; 1CDC, Atlanta, GA, 2 USAMRIID, Frederick, MD. V-400c Hepatitis C Virus (HCV) Induces Epidermal Growth Factor

Receptor (EGFR) Activation via CD81 Binding for Viral Internalization and Entry J. Diao, H. Pantua, H. Ngu, L. Komuves, L. Diehl, G. Schaefer, S. Kapadia; Genentech, San Francisco, CA. V-400d Prior Receipt of 2008-09 Trivalent Inactivated Influenza Vac-

cine Increases Pandemic H1N1 Severity in Ferrets: Randomized Double-Blind Placebo-Controlled Experiment D. M. Skowronski1, M. E. Hamelin 2, G. De Serres 3, N. Z. Janjua 1, G. Li 1 , X. Bouhy 2, C. Couture 4, S. Lavigne 4, G. Boivin 2; 1BC Ctr. for Disease Control, Vancouver, Canada, 2Ctr. Hosp. Univ. de Québec, Québec, Canada, 3 Inst. Natl. de Santé Publique du Québec, Québec, Canada, 4Inst. Univ. de Cardiologie et Pneumologie de Québec, Québec, Canada. V-400e A Cell Based High-Throughput Screening Approach for the

Discovery of New Inhibitors of Respiratory Syncytial Virus W. Severson1, D. Chung 1, B. Moore 2, D. S. Matharu 3, J. E. Golden 3, C. Maddox 2, L. Rasmussen 2, M. I. Sosa 4, S. Ananthan 2, E. White 2, C. Jonsson 1; 1Univ. of Louisville, Louisville, KY, 2Southern Res. Inst., Birmingham, AL, 3Univ. of Kansas, Lawrence, KS, 4Southern Res. Inst., Birmingham, KY.

296

September 9-12 |

V-400f The Role of Glycosylation in HCV Resistance to Broadly

Neutralizing Antibodies H. Pantua, J. Diao, M. Ultsch, M. Hazen, K. Takeda, S. Date, T. K. Cheung, Q. Phung, P. Hass, D. Arnott, J. Hongo, R. Kelley, C. Eigenbrot, S. Kapadia; Genentech, South San Francisco, CA.

-----------------------------------------------------------------------073 (H) Slide Session New Antiretroviral Therapy: Bench to Bedside Monday, 8:30 AM - 11:00 AM . . . . . . . . . . . . . . . . . . Room 104 Presentations: H-556a Discovery of a Novel HIV-1 Nucleotide Competing RT

Inhibitor Series S. Tremblay, BSc - Research Associate, A. Pelletier, MSc - Research Associate, M. Ribadeneira, PhD - Associate Director, C. Sturino, PhD - Associate Director, S. Mason, PhD - Associate Director, L. Lamorte, PhD - Research Scientist, R. Bethell, PhD - Vice President, D. Rajotte, PhD - Senior Principal Scientist; Boehringer Ingelheim Ltd., R&D, Laval, Canada. H-556b Dolutegravir (DTG; S/GSK1349572) + Abacavir/Lami-

vudine Once Daily Statistically Superior to Tenofovir/Emtricitabine/Efavirenz: 48-Week Results - SINGLE (ING114467) S. Walmsley, MD - Professor of Medicine1, A. Antela, MD - Doctor 2, N. Clumeck, MD - Professor 3, D. Duiculescu, MD - Doctor 4, A. Eberhard, MD - Doctor 5, F. Gutiérrez, MD - Doctor 6, L. Hocqueloux, MD - Doctor 7, F. Maggiolo, MD - Doctor 8, U. Sandkovsky, MD - Assistant Professor of Medicine 9, C. Granier, DESS - Manager, Statistics 10, B. Wynne, MD - Physician Project Leader 10, K. Pappa, PharmD - Clinical Investigation Leader 10; 1Univ Hlth. Network, Toronto, Canada, 2Hosp. Clin. Univ., Santiago de Compostela, Spain, 3Ctr. Hosp. Univ. Saint-Pierre, Brussels, Belgium, 4Infectious Tropical Diseases Hosp., Bucharest, Romania, 5MVZ Karlsplatz HIV Res., Clin. Care Ctr., Munich, Germany, 6Hosp. Univ. de Elche, Alicante, Spain, 7 Ctr. Hosp. Regional d’Orléans, Orléans, France, 8Antiviral Therapy Unit Ospedali Riuniti, Bergamo, Italy, 9Univ. Nebraska Med Ctr., Omaha, NE, 10 GlaxoSmith-Kline, Research Triangle Park, NC. H-556c Simplification to Abacavir/Lamivudine (ABC/3TC) +

Atazanavir (ATV) from Tenofovir/Emtricitabine (TDF/FTC) + ATV/Ritonavir (RTV, /r) Maintains Viral Suppression and Improves Bone Biomarkers D. Wohl, MD - Associate Professor1, L. Bhatti, MD - Director HIV/HepC Clin. 2, C. B. Small, MD - Associate Professor 3, H. Edelstein, MD - Associate Professor 4, H. Zhao, PhD – Manager Stats 5, D. A. Margolis, MD – Clinical Division Director 5, L. L. Ross, MS - Senior Invest 5, M. S. Shaefer, PharmD - Director Medical Affairs NA 6; 1AIDS Clin. Trials Unit, UNC CH, Chapel Hill, NC, 2AIDS Healthcare Fndn., Beverly Hills, CA, 3New York Med. Coll., Vahalla, NY, 4Alameda County Med. Ctr., Oakland, CA, 5GlaxoSmithKline, Research Triangle Park, NC, 6ViiV Healthcare, Research Triangle Park, NC.

LATE-BREAKER SCIENTIFIC SESSIONS -----------------------------------------------------------------------074 (K) Slide Session

-----------------------------------------------------------------------086 (C1) Poster Session

Multidrug-Resistant Organisms and Catheter-Related Infections

Resistance by Efflux/Quinolone Resistance

Monday, 8:30 AM - 11:00 AM . . . . . . . . . . . . . . . . . . Room 254

Monday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentation: C1-683a Structural Determinants of QnrS1 Resistance

Presentations: K-562a Peptide Nucleic Acid Fluorescence In Situ Hybridization

(PNA FISH) Screening for Detection of Central Venous Catheter Related Bloodstream Infections in Patients Undergoing Hemodialysis J. Wagner, MD - Research Assistant, G. Schilcher, MD - Research Assistant, M. Hönigl, MD - Research Assistant, T. Valentin, MD - Research Assistant, W. Ribitsch, MD - Research Assistant, I. Zollner-Schwetz, MD - Assoc. Prof., J. Horina, MD - Professor, A. Rosenkranz, MD - Professor, R. Krause, MD Professor; Med. Univ. Graz, Graz, Austria. K-562b One-Step 2% Chlorhexidine in 70% Isopropyl Alcohol

(CHX-OH) Compared to 4-Step Povidone Iodine (PVI) Scrub, Rinse, Dry and 5% PVI-OH for Preventing Central Line-Associated Bloodstream Infection (CLABSI) J. J. Parienti, MD, PhD - Physician, A. Seguin, MD - Physician, B. Sauneuf, MD - Physician, N. Terzi, MD - Physician, X. Valette, MD - Physician, R. Masson, MD - Physician, C. Daubin, MD - Physician, J. Dutheil, MS - Research Assistant, F. Fournel, MS - Research Assistant, F. Chaillot, MS - Research Assistant, V. Cattoir, MD, PhD - Physician, D. du Cheyron, MD, PhD Physician; CHU Caen, Caen, France. K-562c First Evidence of a Hospital-Wide Multidisciplinary and

Multimodal Intervention Program to Reduce Central Venous Catheter (CVC) Related Bloodstream Infections (CRBSI) W. Zingg, MD - Senior Registrar, B. Walder, MD - Senior Registrar, V. Cartier, MD - Senior Registrar, S. Touveneau, RN - Nurse, M. Theriault, RN - Senior Registrar, D. Pittet, MD, MS - Professor; Univ. of Geneva Hosp., Geneva, Switzerland.

-----------------------------------------------------------------------085 (C1) Poster Session Genetics and Resistance Monday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentation: C1-673a Debunking the Myth of the Bifunctional Aminoglycoside

(6’) Acetyltransferase Ie/Aminoglycoside (2”) Phosphotransferase Ia Enzyme H. Frase, M. Toth, N. T. Antunes, S. B. Vakulenko; The Univ. of Notre Dame, Notre Dame, IN.

M. M. Tavio1, G. A. Jacoby 2, D. C. Hooper 1; 1Massachusetts Gen. Hosp., Boston, MA, 2Lahey Clinic, Burlington, MA.

-----------------------------------------------------------------------090 (D) Poster Session MALDI-ToF Mass Spectrometry and Identification and Susceptibility Testing Monday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: D-731a Detection of SPM-1-Producing Pseudomonas aeruginosa (Pa)

and CHDL-Producing Acinetobacter baumannii (Acb) Using Liquid Chromatography Mass Spectrometry (LCMS) and MALDIToF MS C. G. Carvalhaes, R. Cayô, D. M. Assis, E. R. Martins, L. Juliano Neto, M. A. Juliano, A. C. Gales; UNIFESP, Sao Paulo, Brazil. D-731b Species-Specific Bacteriophage Amplification for Enhanced

MALDI-ToF MS Bacterial Diagnostics C. R. Cox, C. R. McAlpin, K. J. Voorhees; Colorado Sch. of Mines, Golden, CO. D-731c MALDI-ToF-MS Based Typing of Multidrug-Resistant

Klebsiella pneumoniae Isolates for Advanced Microbial Source Tracking L. Putignani 1, A. Karger, F. Di Girolamo 1, B. Bettin 2, A. Masotti 1, F. Del Chierico 1, A. Carattoli 3, M. P. Balice 4, M. Ballardini 4, P. Bernaschi 4,1, E. Bordi 4, D. Capozzi 4, M. Carletti 1,4, A. Giordano 4, S. Maiorano 4, M. Meledandri 4, G. Parisi 4, A. Tamburro 4, A. Tarasi 4, A. Capone5,4, N. Petrosillo 5,4 1 ; Bambino Gesù Children’s Hosp., IRCCS, Italy, Rome, Italy, 2Federal Res. Inst. for Animal Hlth., Riems, Germany, Riems, Germany, 3Publ. Hlth. Inst., Rome, Italy, Rome, Italy, 4SEERBIO, Rome, Italy, 5Spallanzani Hosp., Rome, Italy.

-----------------------------------------------------------------------092 (D) Poster Session Phenotypic Susceptibility Testing Methods

Monday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: D-776a ESBL/AmpC Co-Detection Simplified: A New Look at an

Existing ESBL Detection Technique K. De, I. R. Kaur, N. P. Singh; Univ. Coll. of Med. Sci., Delhi, India.

Final Program

297

> Late-Breaker SCIENTIFIC SESSIONS D-776b Comparison of Phenotypic Screening Methods for Detection

of Extended-Spectrum ơ-Lactamase Producers among Pediatrics with Bloodstream Infections in a Saudi Hospital M. A. Abo-Shadi, A. A. Al-Johani; Faculty of Sci.-Taibah Univ., Al-Madinah, Saudi Arabia. D-776c Efflux Detection in Meropenem (MEM) Resistant Pseudomo-

nas (P.) aeruginosa Isolates

-----------------------------------------------------------------------094 (E) Poster Session In Vitro Activity against Multidrug-Resistant GramNegative Bacteria Monday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentation: E-804a In Vitro Activity of Plazomicin against Molecularly Charac-

terized ESBL-, AmpC-, and KPC-Producing Escherichia coli (EC) and Klebsiella pneumoniae (KPN) Obtained Across Canada: 2007 - June 2012 1,2

1,2

1,2

A. Denisuik , H. J. Adam , A. J. Walkty , P. Lagacé-Wiens , J. A. Karlowsky 1,2, D. J. Hoban 1,2, G. G. Zhanel 1; 1Univ. of Manitoba, Winnipeg, Canada, 2Diagnostic Services of Manitoba, Winnipeg, Canada.

-----------------------------------------------------------------------096 (F) Poster Session New Antifungal Agents Monday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentation: F-823a Antifungal Activity of Aldimines Derived from 2-Aminophe-

nol against Cryptococcus neoformans and Cryptococcus gattii T. F. F. Magalhães, D. L. da Silva, C. M. da Silva, C. V. B. Martins, L. J. Nogueira, A. de Fátima, M. A. R. Stoianoff, J. A. G. Ferreira; Univ. Fed. de Minas Gerais, Belo Horizonte, Brazil.

-----------------------------------------------------------------------097 (F) Poster Session New Antiviral Agents

Presentation: F-858a Time-Dependent Inhibition of NDM-1, VIM-2, & IMP-1

Metallo-ơ-Lactamases By 3-(4-Chloromethylstyryl)-(6r,7r)-7(Phenylacetamido)-Ceph-3-EM-4-Carboxylic Acid L. D. Sutton1, S. Yu 1, A. Vosbeek 1, M. Aitha 2, M. W. Crowder 2; 1Sopharmia Inc., St. Joseph, MO, 2Miami Univ., Oxford, OH.

-----------------------------------------------------------------------101 (C2) Poster Session Updates in Vaccines Monday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: G-876a Effectiveness of the Pneumococcal Haemophilus Influenzae

Protein D Conjugate Vaccine (PHiD-CV10) against Outpatient Antimicrobial Prescriptions: FinIP Trial A. A. Palmu 1, J. Jokinen 2, H. Nieminen 1, E. Ruokokoski 2, T. Puumalainen 3, T. M. Kilpi 2; 1Natl. Inst. for Hlth. and Welfare, Tampere, Finland, 2Natl. Inst. for Hlth. and Welfare, Helsinki, Finland, 3GlaxoSmithKline Vaccines, Espoo, Finland. G-876b Greater Risk of Measles with Earlier Age of 1st Dose in Ado-

lescents Who Received Two Pediatric Doses of Vaccine Beginning From 12 Months of Age: Further Evidence from Quebec G. De Serres1, F. Defay 1, N. Boulianne 1, M. Landry 2, M. Ouakki 1, N. Brousseau 3, B. J. Ward4, D. M. Skowronski5; 1Inst. Natl. de Santé Publique du Québec, Québec, Canada, 2MSSS, Montréal, Canada, 3ASSS Mauricie et Ctr. du Québec, Trois-Rivières, Canada, 4McGill Univ., Montréal, Canada, 5 BCCDC, Vancouver, Canada.

-----------------------------------------------------------------------102 (H) Poster Session Antiretroviral Therapy Outcomes Including Select Populations Monday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentation:

Monday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentation: F-828a AVI-7288 Provides Significant Survival Benefit When

Administered up to Four Days After Marburg Virus Infection in Cynomolgus Macaques P. L. Iversen1, T. K. Warren2, J. Wells2, J. Charleston 1, A. C. Shurtleff 2, P. Sazani 1, R. Davies 1, L. Welch 2, N. L. Garza2, A. Heald 1, S. Bavari 2; 1 Sarepta Therapeutics., Cambridge, MA, 2USAMRIID, Fredrick, MD.

298

Targeting the Bacterial Cell Wall: New Beta-Lactams and Beta-Lactamase Inhibitor Combinations Monday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C

C. A. Thoms-Rodriguez1, A. M. Nicholson 1, N. Christian 1, B. M. Willey 2, T. Mazzulli; Deputy Chief Microbiologist 2,3; 1The Univ. of the West Indies, KGN, Jamaica, 2Mount Sinai Hosp., Toronto, Canada, 3The Univ. of Toronto, Toronto, Canada.

1

-----------------------------------------------------------------------099 (F) Poster Session

September 9-12 |

H-886a 18 Month Efficacy and Safety of the New WHO Option B+

Regimen in the Prevention Breast Feeding Transmission of HIV-1 in Zambia M. Ngoma 1, A. Misir 2, W. Mutale 1, R. Pilon 3, M. S. Silverman4; 1Univ. of Zambia, Lusaka, Zambia, 2Univ. of Ottawa, Ottawa, Canada, 3Hlth. Canada, Ottawa, Canada, 4Univ. of Toronto, Ajax, Canada.

LATE-BREAKER SCIENTIFIC SESSIONS -----------------------------------------------------------------------112 (P) Poster Session

-----------------------------------------------------------------------117 (V) Slide Session

Global Health, Parasitology and Travel Medicine

Respiratory Viruses and Measles

Monday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C

Monday, 1:30 PM - 4:00 PM . . . . . . . Esplanade Ballroom 309

Presentation:

Presentation:

P-1023a Adult Respiratory Distress Syndrome Secondary to Babesiosis P. Singh, N. Kaur, S. Cherian; SUNY Upstate Med. Univ., Syracuse, NY.

-----------------------------------------------------------------------113 (T) Poster Session Infections in Transplant Recipients and Patients with Malignancies Monday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C

V-1080a Anti-Viral Treatment of Influenza in Infants Under 1 Year

of Age M. O. Loveless, MD, MHA - Virology Medical Director1, P. Spagnuolo 2, M. Zhang3, S. Liu3, J. Liu3, Y. Xu1, E. Chen1, J. Han1, L. Shi3; 1Genentech, Inc., South San Francisco, CA, 2Case Western Reserve Univ., Cleveland, OH, 3 Sch. of Publ. Hlth. and Tropical Med., Tulane Univ., New Orleans, LA.

-----------------------------------------------------------------------160 (V) Slide Session Hepatitis and Herpes Viruses

Presentations: T-1046a Evaluation of the Effect of Number of Transplantations on

Tigecycline Susceptibility Patterns in Enterococcal Blood Isolates from Hematopoetic Stem Cell Transplant (HSCT) Recipients: A 5-yr Restrospective Study of 400 HSCT Recipients (2007-2011) S. K. Apewokin1, A. Pande 1, S. Zainab 1, A. Restrepo 1, N. Ahmad 2, M. Grazziutti 1; 1Univ, of Arkansas for Med Sci., Little Rock, AR, 2Univ of Arkansas for Med. Sci., Little Rock, AR. T-1046b Fidaxomicin in the Treatment of Clostridium difficile-Associ-

ated Diarrhea (CDAD) in Transplant Recipients Y. Dubrovskaya, D. S. Clutter, M. Merl, J. Zain, L. Teperman, R. Press, A. Safdar; NYU Langone Med. Ctr., New York, NY.

Tuesday, 8:30 AM - 11:00 AM . . . . . . . . . . . . . . . . . . Room 254 Presentation: V-1242a Age-Specific Prevalence of Epstein-Barr Virus (EBV) Anti-

body (Ab) in U.S. Children: Results from the National Health and Nutrition Examination Surveys (NHANES) 2003-2010 H. H. Balfour, Jr, MD - Professor1, F. Sifakis, MPH, PhD - Director, Epidemiology ID, Vaccines 2, J. A. Sliman, MD - Associate Medical Director 2, J. A. Knight, BA - Associate Scientist 1, D. O. Schmeling, BS - Scientist 1, W. Thomas, PhD - Associate Professor 1; 1Univ. of Minnesota, Minneapolis, MN, 2 MedImmune, LLC, Gaithersburg, MD.

-----------------------------------------------------------------------114 (C2) Slide Session Vaccines: Innovations, Impact and Safety Monday, 1:30 PM - 4:00 PM . . . . . . . . . . . . . . . . . . . . Room 121 Presentations: G-1054a Effectiveness of the 10-Valent Pneumococcal Non-Typeable

Haemophilus influenzae Protein D Conjugate Vaccine against Acute Otitis Media T. Vesikari, MD - Professor1, A. Forstén, MD - Head of Study Clinics, Physician Coordinator 1, I. Seppä, MD - Clinical Investigator 1, T. Puumalainen, MD - Head of Medical Affairs 2, A. Soininen, PhD - Senior CRA 2, P. Lommel, MS - Manager Bio-Statistician 3, M. Hezareh, PhD - Clinical Development Manager 3, M. Moreira, MD - Clinical Development Manager 3, D. Borys, MD - Director Clinical Development 3, L. Schuerman, MD - Clinical Development Manager 3; 1Univ. of Tampere, Tampere, Finland, 2GlaxoSmithKline, Espoo, Finland, 3GlaxoSmithKline Vaccines, Wavre, Belgium. G-1054b Incidence of Invasive Pneumococcal Disease in Children

Declines Further Following PCV13 Introduction S. I. Pelton, MD - Professor of Pediatrics and Epidemiology1, I. Yildirim, MD - Research Scholar 1, K. Hsu, MD - Assistant Professor of Pediatrics 1, A. Silverio, BA - Research Associate 2, and MA DPH; 1BUSM, Boston, MA, 2 BMC, Boston, MA.

Final Program

299

> Late-Breaker SCIENTIFIC SESSIONS -----------------------------------------------------------------------161 (A) Poster Session

-----------------------------------------------------------------------164 (B) Poster Session

Clinical Pharmacology of Antiviral and Anti-Tuberculosis Agents

Antimicrobial Therapy in Animal Models II

Tuesday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C

Tuesday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentation: B-1308a Efficacy of Intravenous Plazomicin in the African Green

Presentations: A-1268a Long Half-Life is a Key Feature for High Potency of

AIC316 against HSV-2 J. T. Schiffer1, A. Wald 1, D. McCormick 2, B. Timmler 2, H. RubsamenSchaeff 2, A. Birkmann 2; 1Fred Hutchinson Cancer Res. Ctr., Seattle, WA, 2 Aicuris, Wuppertal, Germany. A-1268b First Single Intravenous Dose Escalation Data in Volun-

teers for Letermovir: A Novel Anti-Human Cytomegalovirus Drug Entering Phase 3 D. Kropeit1, J. Scheuenpflug 1, K. Erb-Zohar 2, H. Stobernack 1, D. McCormick 3, M. Richard, MD - CMO 1, H. Zimmermann 1, H. Rübsamen-Schaeff 1; 1AiCuris, Wuppertal, Germany, 2Clinphase, Hanau, Germany, 3DMPK Solutions Ltd., Nottingham, United Kingdom. A-1268c Investigation of the Effect of Oral Letermovir Administra-

tion; A Novel Anti-Human Cytomegalovirus Drug Entering Phase 3, on the Pharmacokinetics of a Single Oral Dose of P-GP (MDR1) Substrate Digoxin in Volunteers J. Scheuenpflug 1, D. Kropeit1, K. Erb-Zohar 2, J. G. W. Theis 3, H. Stobernack 1, D. McCormick 4, M. Richard 1, H. Zimmermann 1, H. RübsamenSchaeff 1; 1AiCuris, Wuppertal, Germany, 2Clinphase, Hanau, Germany, 3 InHeCon, Bergisch Gladbach, Germany, 4DMPK Solutions Ltd, Nottingham, United Kingdom. A-1268d The Blood Bactericidal Activity of PNU-100480 (Sutezolid,

U-480) and its Major Active Metabolite PNU-101603 (U-603) in Patients with Pulmonary TB: Insight from PK/PD Modeling T. Zhu, G. Nucci, R. S. Wallis; Pfizer Inc., Groton, CT.

Monkey (AGM) Inhalational Plague Model W. Mega1, R. Cirz 2, R. Cass 2, N. Reyes 2, M. Valderas 1, R. Sherwood 1; 1 LRRI, Albuquerque, NM, 2Achaogen, Inc., South San Francisco, CA.

-----------------------------------------------------------------------165 (B) Poster Session Microbial Determinants of Virulence Tuesday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentation: B-1338a Development of Anthrax in a Macaque Model after Inges-

tion of Bacillus anthracis Spores Z. Llewellyn 1, N. Richardson-Harman 2, J. Mann 1, R. May 1, B. Yamamoto 1, J. Toomey 1, J. Boydston 1, D. Karaolis 3, S. Cendrowski3; 1Southern Res. Inst., Birmingham, AL, 2Alpha StatConsult, Damascus, MD, 3Natl. Biodefense Analysis and Countermeasures Ctr., Frederick, MD.

-----------------------------------------------------------------------166 (C1) Poster Session Resistance to Staphylococcus and Other Gram-Positive Tuesday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations:

-----------------------------------------------------------------------163 (A) Poster Session

C1-1351a Meca-Independent High-Level, Beta-Lactam Resistance

Pharmacokinetics/Pharmacodynamics of New and Old Oxazolidinones

C1-1351b Whole-Genome Analysis of a Daptomycin-Susceptible

Tuesday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentation: A-1295a Lack of MAO Inhibition by Tedizolid Phosphate in Clinical

and Nonclinical Studies S. Flanagan, S. Minassian, E. Fang, K. Bartizal, P. Prokocimer; Trius Therapeutics, San Diego, CA.

300

September 9-12 |

in Staphylococcus aureus Strains Passaged in Ceftobiprole and Ceftaroline L. Chan, H. Chambers; Univ. of California, San Francisco, CA.

Enterococcus faecium and its Daptomycin-Resistant Variant Arising During Therapy T. T. Tran 1,2, D. Panesso 1,3, H. Gao 4, J. H. Roh 1, J. M. Munita 1,5, J. Reyes 1,3, L. Diaz 1,3, E. A. Lobos 4, Y. Shamoo 6, N. N. Mishra 7,8, A. S. Bayer 7,8, B. E. Murray 1, G. M. Weinstock 4, C. A. Arias1,3; 1Univ. of Texas Med. Sch., Houston, TX, 2Univ. of Houston Coll. of Pharm., Houston, TX, 3Univ. El Bosque, Bogota, Colombia, 4Washington Univ., St. Louis, MO, 5Univ. del Desarrollo Sch. of Med., Santiago, Chile, 6Rice Univ., Houston, TX, 7LA Biomedical Res Inst. at Harbor - UCLA, Torrance, CA, 8Geffen Sch. of Med. UCLA, Los Angeles, CA.

LATE-BREAKER SCIENTIFIC SESSIONS -----------------------------------------------------------------------169 (C2) Poster Session

-----------------------------------------------------------------------176 (F) Poster Session

MRSA: A Bug with International Appeal and Great Sense

Compounds and Approaches for Combating GramPositive Infections



Presentations: C2-1401a The Molecular Characteristic of Methicillin-Resistant

Presentation:

Staphylococcus aureus Isolated from Children in Shanghai, China

F-1518a New Mechanism of Action for Macrolide and Ketolide Anti-

J. H. Cao, G. H. Li, X. G. Xu, D. M. Zhu; Huashan Hosp. Fudan Univ., Shanghai, China.

biotics is to Reduce Fidelity of Translation P. Gupta, N. Vazquez-Laslop, A. Mankin; Univ. of Illinois, Chicago, IL.

C2-1401b Spread of USA300-Like MRSA Colonization in a Postpar-

tum Maternal and Neonatal Care Center in Korea M. Ji, H. Sung, E. A. Kim, M. Kim; Univ. Ulsan and Asan Med. Ctr., Seoul, Korea, Republic of.

-----------------------------------------------------------------------172 (D) Poster Session Molecular Methods for Pathogen Identification and Resistance Detection

F-1540b Nanoscale Analysis of the Effects of a New Antibacterial,

Cx1, on a Multidrug-Resistant Pseudomonas aeruginosa

Assay Able to Identify Staphylococcus aureus Harboring the New MecC Gene as Well as the Classical MecA Gene in Cultures and Clinical Materials J. Tasse 1, A. Kearns 2, A. Larsen 3, G. Edwards 4, B. Pichon 2, R. Skov 3, F. Laurent1; 1French Natl. Reference Ctr. for Staphylococci, Hospices Civils de Lyon, Lyon, France, 2Hlth. Protection Agency, London, United Kingdom, 3 Serum Staten Inst., Copenhagen, Denmark, 4Scottish MRSA Reference Lab., NHS Greater Glasgow and Clyde, Stobhill Hosp., Glasgow, United Kingdom.

-----------------------------------------------------------------------175 (F) Poster Session Antimicrobial Peptides and Peptidomimetics Presentations: F-1495a In Vivo Activity of Novel Aggregating Peptide in Staphylo3

N. G. Bednarska , I. Vogel , F. Rousseau , J. Schymkowitz , J. Van Eldere ; 1 KU Leuven, Leuven, Belgium, 2VIB SWITCH Lab., KU Leuven, Leuven, Belgium, 3UZ Leuven, Leuven, Belgium. F-1495b Exploring the Inhibitory Potential of Antimicrobial Peptide

X. Feng, K. Sambanthamoorthy, D. V. Zurawski, C. Paranavitana; Walter Reed Army Inst. of Res., Silver Spring, MD.

F-1540c A Phase I, Double-Blind, Randomised, Placebo-Controlled,

Dose Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of NVB302 Administered Orally to Healthy Volunteers S. Febbraro 1, A. Hancock 2, A. Boyd 3, M. J. Dawson2; 1Simbec Res. Limited, Merthyr Tydfil, United Kingdom, 2Novacta Biosystems Limited, Welwyn Garden City, United Kingdom, 3Boyd Consulting Limited, Crewe, United Kingdom.

Pediatrics

coccal Sepsis and Abscess Infection

LL-37 and its Fragments, that Prevent Biofilm Formation of Multidrug-Resistant A. baumannii

C. Formosa 1,2,3, M. Grare 4, R. E. Duval3,5, E. Dague 1,2; 1CNRS, LAAS, Toulouse, France, 2Univ. de Toulouse; UPS, INSA, INP, ISAE; UT1, UTM, LAAS, ITAV, Toulouse, France, 3SRSMC, UMR 7565, Univ. de Lorraine CNRS, Nancy, France, 4Lab. de Bactériologie-Hygiène, IFB, CHU Toulouse Purpan, Toulouse, France, 5ABC Platform, Nancy, France.

-----------------------------------------------------------------------178 (G3) Poster Session


2

Presentations:

J. Kim, Y. Joo, D. Cho, P. Heo, D. Kweon; Sungkyunkwan Univ., Suwon, Korea, Republic of.

D-1461a Evaluation of the First and Unique Commercial Molecular

2


Bacterial Persisters Based on Fluorescence

Presentation:

1

Novel Antimicrobial Approaches and Agents

F-1540a High Throughput Screening Method for Drugs against


1

-----------------------------------------------------------------------177 (F) Poster Session

Tuesday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: G3-1563a Evaluation of Viral Coinfections in Hospitalized and

Non-Hospitalized Children with Respiratory Infections Using Microarrays S. Kouni1, P. Karakitsos 2, A. Chranioti 2, M. Theodoridou Papagrigoriou 1, A. Michos 1; 1Univ. of Athens, Aghia Sophia Children’s Hosp., Athens, Greece, 2Univ. Hosp. Attikon, Athens, Greece.

Final Program

301

> Late-Breaker SCIENTIFIC SESSIONS G3-1563b Prophylactic Valacyclovir to Prevent Outbreaks of

Men Who Have Sex with Men (MSM) and Association with the Size of Intracellular HIV-1 Reservoir (ANRS EP49)

J. Anderson; Boynton Hlth. Service, Univ. of Minnesota, Minneapolis, MN.

J. Ghosn1, A. Delobelle 2, M. Leruez-Ville 3, C. Beaudoux 2, L. Mascard 3, A. Canestri 1, R. Landman 4, D. Zucman 5, D. Ponscarme 6, A. Rami 7, J. Viard 8, B. Spire 9, H. Lecuyer 3, D. Costagliola 2, C. Rouzioux, PharmD 3, M. SuzanMonti 9; 1Bicetre Hosp., Paris, France, 2INSERM UPMC UMR S943, Paris, France, 3Necker Hosp., Paris, France, 4Bicaht Hosp., Paris, France, 5Foch Hosp., Suresnes, France, 6St. Louis Hosp., Paris, France, 7Lariboisiere Hosp., Paris, France, 8Hotel Dieu Hosp., Paris, France, 9INSERM UMR S912, Marseille, France.

-----------------------------------------------------------------------179 (H) Poster Session HIV-I Pathogenesis and Predictors of Antiretroviral Response in Treatment and Prevention Tuesday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: H-1570a Poor CD4+ T-Cell Restoration Linked to Residual HIV-1

Reverse Transcription Under Anti-Retroviral Therapy K. C. Psomas1,2, C. Mettling 3, J. Reynes 1, P. Corbeau 2; 1Infectious Diseases Dept., Univ. Hosp. of Montpellier, Montpellier, France, 2Inst. of Human Genetics, CNRS UPR 1142, Montpellier, France, 3Inst. of Human Genetics CNRS UPR 1142, Montpellier, France. H-1570b The CD4/CD8 Ratio as a Marker of T-Cell Activation/

Exhaustion in HIV-Infected Children and Young Adults on AntiRetroviral Therapy T. Sainz1, S. Serrano-Villar 2, L. Díaz 1, M. González-Tomé 3, M. Mellado 4, J. Ramos 5, S. Moreno 1, M. Muñoz-Fernández 1; 1Hosp. Gregorio Marañón, Madrid, Spain, 2Hosp. Ramón y Cajal, Madrid, Spain, 3Hosp. Doce de Octubre, Madrid, Spain, 4Hosp. Carlos III, Madrid, Spain, 5Hosp. de Getafe, Madrid, Spain. H-1570c HIV Impairs Human Alveolar Macrophage Innate Immune

-----------------------------------------------------------------------180 (H) Poster Session HIV-I Resistance, Tropism and Novel Laboratory Methods Tuesday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: H-1582a Use of Next-Generation Sequencing Platforms to Deter-

mine HIV-1 Coreceptor Tropism M. E. Quinones-Mateu1,2, J. Archer 3, J. Weber 4, R. Gibson 2, E. Paxinos 5, E. Arts 2, D. L. Robertson 3, L. Mimms 6; 1UHCMC, Cleveland, OH, 2 CWRU, Cleveland, OH, 3Univ. of Manchester, Manchester, United Kingdom, 4Inst. of Organic Chemistry and Biochemistry, Prague, Czech Republic, 5 Pacific Biosciences, Menlo Park, CA, 6Quidel, San Diego, CA. H-1582b Evaluation of a Prototype Instrument-Free, Point of Care

Functions

Test for the Measurement of CD4+ T-Cells in Management of HIV Infection

H. C. Mwandumba1,2, K. C. Jambo 1, D. Banda 1, R. S. Heyderman 1,2, D. G. Russell 3; 1Malawi-Liverpool-Wellcome Trust Clinical Res. Programme, Blantyre, Malawi, 2Liverpool Sch. of Tropical Med., Liverpool, United Kingdom, 3Cornell Univ., Ithaca, NY.

D. A. Anderson1, S. Crowe 1, M. Garcia 1, N. Barnes 1, A. Landay 2, T. Denny 3; 1Burnet Inst., Melbourne, Australia, 2Rush Univ., Chicago, IL, 3 Duke Univ., Durham, NC.

H-1570d Elimination of HIV-1 Infected Cells by Radiolabeled Anti-

body to GP41 in a Human Blood Brain Barrier Model A. McFarren1, D. Tsukrov 2, D. Williams 2, L. Lopez 2, S. Kitchen 3, M. Gorny 4, S. Zolla-Pazner 4, A. Morgenstern 5, F. Bruchertseifer 5, A. Casadevall 2, J. Berman 2, E. Dadachova 2; 1Children’s Hosp. at Montefiore, Bronx, NY, 2Albert Einstein Coll. of Med., Bronx, NY, 3UCLA David Geffen Sch. of Med., Los Angeles, CA, 4NYU, New York, NY, 5Inst. for Transuranium Elements, Karlsruhe, Germany. H-1570e Killing of ART-Treated HIV-Infected Human Lympho-

cytes by Radioimmunotherapy D. I. Tsukrov1, A. McFarren 2, D. Williams 1, L. Lopez 1, S. Kitchen 3, M. Gorny 4, S. Zolla-Pazner 4, A. Morgenstern 5, F. Bruchertseifer 5, J. Berman 1, A. Casadevall 1, E. Dadachova 1; 1Albert Einstein Coll. of Med., Bronx, NY, 2 Children’s Hosp. at Montefiore, Bronx, NY, 3UCLA David Geffen Sch. of Med., Los Angeles, CA, 4NYU, New York, NY, 5Inst. for Transuranium Elements, Karlsruhe, Germany.

302

H-1570f Prevalence of HIV-1 Seminal Shedding in HIV-1 Infected

Primary Herpes Gladiatorum at a 28-Day Wrestling Camp: A 10 Year Review

September 9-12 |

-----------------------------------------------------------------------186 (C2) Poster Session Endocarditis and Other Invasive Infections Tuesday, 11:15 AM - 1:15 PM . . . . . . . . . . . . . . . . . . . . Halls A-C Presentation: L1-1647a Efficacy and Safety of TP-434 versus Ertapenem in Com-

plicated Intra-Abdominal Infection (cIAI) P. Horn1, G. Cesnauskas 2, M. Ramesh 3, S. Walpole 1, J. Sutcliffe 1, J. Solomkin 4; 1Tetraphase Pharmaceuticals, Watertown, MA, 2Kaunas Hosp., Kaunas, Lithuania, 3Victoria Hosp., Bangalore, India, 4Univ. Cincinnati, Cincinnati, OH.

LATE-BREAKER SCIENTIFIC SESSIONS -----------------------------------------------------------------------189 (C2) Poster Session

-----------------------------------------------------------------------238 (H) Slide Session

Novel Agents and Insights in Skin and Soft Tissue Infections

Common Pathogens: Still a Problem in HIV-I


Wednesday, 9:15 AM - 11:45 AM . . . . . . . . . . . . . . . Room 102 Presentation: H-1921a HIV/HCV Coinfected and HCV Monoinfected Patients

Presentations: L1-1667a Ceftaroline (CPT) Fosamil Real World Use Patterns in

Hospitalized Adult Patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI): A Retrospective Analysis of a Large US Hospital Database X. Huang1, S. Chen 1, E. Beresford 1, H. D. Friedland 2; 1Forest Res. Inst., Inc., Jersey City, NJ, 2Cerexa Inc., Oakland, CA. L1-1667b Effect of a Single Prior Dose Short Acting Antibiotic on

Clinical Efficacy in a Phase 2b Exploratory Study of Delafloxacin (DLX) Compared to Vancomycin (VAN) and Linezolid (LNZ) in Adults with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) J. Longcor, L. Lawrence, S. Hopkins, E. Duffy; Rib-X Pharmaceuticals, Inc., New Haven, CT. L1-1667c Objective Measures of Clinical Efficacy in a Phase 2b

Exploratory Study of Delafloxacin Compared to Vancomycin and Linezolid in Adults with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) J. Longcor, L. Lawrence, S. Hopkins; Rib-X Pharmaceuticals, Inc., New Haven, CT.

-----------------------------------------------------------------------197 (C1) Slide Session

Have Similar Early HCV Viral Kinetics with the Potent HCV Nucleotide Polymerase Inhibitor Sofosbuvir (SOF) M. Rodriguez-Torres, MD - Principle Investigator 1, M. Gonzales, MD Investigator 1, J. Rodriguez, PhD - Investigator 1, S. Rossi, PharmD - Senior Director, Clinical Research2, G. Shen, PhD - Manager, Biostatistics 2, A. Mathias, PhD - Director, Clinical Pharmacology 2, B. Symonds, PharmD - Vice President, Clinical Research 2; 1Fundacion de Investigacion de Diego, San Juan, PR, 2Gilead Sci., Foster City, CA.

-----------------------------------------------------------------------240 (A) Poster Session Antifungals: Improving PK/PD and Safety Wednesday, 9:15 AM - 11:15 AM . . . . . . . . . . . . . . . . Halls A-C Presentation: A-1946a Phase 1B Study of the Pharmacokinetics (PK) and Safety

of Posaconazole (POS) IV in Patients (Pts) at Risk for Invasive Fungal Infection (IFI) J. Maertens 1, O. Cornely 2, A. Ullmann 3, W. Heinz 4, G. Krishna 5, M. Caceres 5, N. Kartsonis 5, H. Waskin5, M. N. Robertson5; 1Univ. Hosp. Gasthuisberg, Leuven, Belgium, 2Univ. Hosp. Cologne, Cologne, Germany, 3 Johannes Gutenberg Univ., Mainz, Germany, 4Julius-Maximilians-Univ. Würzburg, Würzburg, Germany, 5Merck, Whitehouse Station, NJ.

Resistance in Staphylococcus aureus Tuesday, 11:15 AM - 12:45 PM . . . . . . . . . . . . . . . . . Room 122 Presentation: C1-1747a Identification of Novel Factors Affecting Methicillin-Re-

sistance and the Cell Wall Stress Stimulon in Staphylococcus aureus V. Dengler, MA or MS - PhD candidate1, M. M. Senn, PhD - Postdoc 1, C. Quiblier, MS - PhD Candidate 1, B. Berger-Bächi, PhD - Professor 1, N. McCallum, PhD - Postdoc 1,2; 1Univ. of Zurich, Zurich, Switzerland, 2Univ. of Sydney, Sydney, Australia.

Final Program

303

> Late-Breaker SCIENTIFIC SESSIONS -----------------------------------------------------------------------242 (C1) Poster Session

-----------------------------------------------------------------------249 (F) Poster Session

Mechanisms of Resistance to Novel Compounds

Targeting Gram-Negative Pathogens

Wednesday, 9:15 AM - 11:15 AM . . . . . . . . . . . . . . . . Halls A-C

Wednesday, 9:15 AM - 11:15 AM . . . . . . . . . . . . . . . . Halls A-C

Presentation:

Presentations:

C1-1973a Identification of the Antibiotic TA Binding Pocket in Type

II Signal Peptidase and Target Based Producer Strain Resistance

ella pneumoniae Using the Murine Thigh Infection Model

Y. Xiao, D. Wall; Univ. of Wyoming, Laramie, WY.

L. Lamb, J. L. Crandon, D. P. Nicolau; Ctr. for Anti-Infect. Res. & Dev., Hartford Hosp., Hartford, CT.

-----------------------------------------------------------------------246 (F) Poster Session New Ways with Old Friends: Repurposing and Novel Formulations Wednesday, 9:15 AM - 11:15 AM . . . . . . . . . . . . . . . . Halls A-C Presentations: F-2015a Rescuing Obsolete Antibiotics: Structural Basis of Inhibi-

tion of Aminoglycoside-Modifying Enzymes by Protein Kinase Inhibitors P. J. Stogios1, E. Evdokimova 1, P. Spanogiannopoulos 2, N. Todorovic 2, A. Capretta 2, G. D. Wright 2, A. Savchenko 1; 1Univ. of Toronto, Toronto, Canada, 2McMaster Univ., Hamilton, Canada. F-2015b NanoDisk-Amphotericin B is Superior to Liposomal Am-

photericin B in a Murine Model of Disseminated Aspergillosis B. L. Burgess1,2, Y. He 2, B. Luo 1, R. O. Ryan 1,2, S. F. Carroll 1, T. M. Forte, PhD - Staff Scientist 1,2, M. N. Oda 1,2; 1Lypro Biosciences, Berkeley, CA, 2 Children’s Hosp. Oakland, Oakland, CA.

-----------------------------------------------------------------------248 (F) Poster Session Quinolones and Beyond Wednesday, 9:15 AM - 11:15 AM . . . . . . . . . . . . . . . . Halls A-C Presentations: F-2056a DS-8587, a New Generation of Broad Spectrum Quinolone:

In Vivo Anti-Anaerobe Activity in a New Murine Model of Liver Abscess Due to Fusobacterium necrophorum Via Injection into Caudal Vein 1

1

2

2

1

K. Nagaoka , K. Yanagihara , Y. Kurosaka , K. Hoshino , S. Kohno ; 1 Nagasaki Univ. Graduate Sch. of Biomedical Sci., Nagasaki, Japan, 2Daiichi Sankyo, Co., Ltd., Tokyo, Japan. F-2056b DS-8587, a New Generation of Broad Spectrum Quino-

lones: In Vitro Antibacterial Activity against Clinical Isolates from Aspiration Pneumonia J. Fujita1, F. Higa 1, I. Nakasone 1, N. Yamane 1, M. Chiba 2, R. Okumura 2, K. Hoshino 2; 1Univ. of the Ryukyus, Okinawa, Japan, 2Daiichi Sankyo, Co., Ltd., Tokyo, Japan.

304

F-2072a Pharmacodynamic Assessments of RX-P873 against Klebsi-

September 9-12 |

F-2072b Identification and Characterization of Small-molecule

Inhibitors of Escherichia coli RecBCD DNA Repair Enzyme Using a Transcreener Adenosine 5’-O-Diphosphate Assay M. A. Chapman1, G. R. Smith 2, S. F. Singleton 1; 1Univ. of North Carolina at Chapel Hill, Chapel Hill, NC, 2Fred Hutchinson Cancer Res. Ctr., Seattle, WA.

-----------------------------------------------------------------------251 (K) Poster Session Hand Hygiene

Wednesday, 9:15 AM - 11:15 AM . . . . . . . . . . . . . . . . Halls A-C Presentation: K-2084a Hand Hygiene Compliance (HHC) Results Using Before-

After (B-A) Auditing Appear Inaccurate Compared to the WHO 5 Moments Auditing Tool (5M) in Intense Care Settings K. Ryan 1, P. L. Russo 1, D. Williams 1, K. Heard 1, K. Bellis 1, S. Havers 1, M. L. Grayson1,2; 1Hand Hygiene Australia, Victoria, Australia, 2Univ. of Melbourne, Melbourne, Australia.

-----------------------------------------------------------------------255 (L2) Poster Session Urinary Tract Infection Wednesday, 9:15 AM - 11:15 AM . . . . . . . . . . . . . . . . Halls A-C Presentations: L2-2118a Plazomicin Safety and Efficacy in Patients with Complicat-

ed Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) V. Riddle1, D. Cebrik 2, E. Armstrong 3, R. Cass 3, T. Clobes 3, K. Hillan 3; 1 Ind. Consultant, Crofton, MD, 2Axistat, San Francisco, CA, 3Achaogen Inc., S. San Francisco, CA. L2-2118b A Multi-Faceted Intervention to Reduce Rates of Cath-

eter-Associated Urinary Tract Infections in a Resource-Limited Setting L. G. Tillekeratne1, D. R. Linkin 1,2, M. Obino 3, A. Omar 3, M. Wanjiku 3, D. Holtzman 1, J. Cohn 1,2; 1Hosp. of the Univ. of Pennsylvania, Philadelphia, PA, 2Perelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA, 3Sch. of Med., Univ. of Nairobi, Nairobi, Kenya.

LATE-BREAKER AUTHOR INDEX Author

Presentation Number

A

Author

Presentation Number

Author

Presentation Number

Bettin, B. . . . . . . . . . . . . . . . . . . . . . . . D-731c, 090

Cherian, S.. . . . . . . . . . . . . . . . . . . . . P-1023a, 112

Bhatti, L. . . . . . . . . . . . . . . . . . . . . . . . H-556c, 073 Birkmann, A. . . . . . . . . . . . . . . . . . . . A-1268a, 161

Cheung, T. K. . . . . . . . . . . . . . . . . . . . .V-400f, 030 Chevret, S. . . . . . . . . . . . . . . . . . . . . . . T-369b, 029

Adam, H. J. . . . . . . . . . . . . . . . . . . . . . E-804a, 094 Adams, M.. . . . . . . . . . . . . . . . . . . . . . B-060b, 005

Boivin, G. . . . . . . . . . . . . . . . . . . . . . . V-400d, 030

Chiba, M. . . . . . . . . . . . . . . . . . . . . . F-2056b, 248

Bonomo, R. A.. . . . . . . . . . . . . . . . . . . B-060b, 005

Cho, D. . . . . . . . . . . . . . . . . . . . . . . . F-1540a, 177

Ahmad, N.. . . . . . . . . . . . . . . . . . . . . T-1046a, 113

Bordi, E. . . . . . . . . . . . . . . . . . . . . . . . D-731c, 090 Borys, D. . . . . . . . . . . . . . . . . . . . . . . G-1054a, 114

Chranioti, A. . . . . . . . . . . . . . . . . . . G3-1563a, 178 Christian, N. . . . . . . . . . . . . . . . . . . . . D-776c, 092

Aktug Demir, N. . . . . . . . . . . . . . . . . . B-060c, 005 Al-Johani, A. A. . . . . . . . . . . . . . . . . . D-776b, 092 Ambaye, S. F.. . . . . . . . . . . . . . . . . . . . V-400a, 030

Bouhy, X. . . . . . . . . . . . . . . . . . . . . . . . V-400d, 030 Boulianne, N.. . . . . . . . . . . . . . . . . . . . G-876b, 101

Chung, D. . . . . . . . . . . . . . . . . . . . . . . V-400e, 030 Cilli, A. . . . . . . . . . . . . . . . . . . . . . . . L1-300a, 026

Boyd, A.. . . . . . . . . . . . . . . . . . . . . . . F-1540d, 177

Cirz, R. . . . . . . . . . . . . . . . . . . . . . . . B-1308a, 164

Ananthan, S. . . . . . . . . . . . . . . . . . . . . V-400e, 030

Boydston, J. . . . . . . . . . . . . . . . . . . . . B-1338a, 165 Brandt, R. S. . . . . . . . . . . . . . . . . . . . . T-369a, 029

Clobes, T.. . . . . . . . . . . . . . . . . . . . . L2-2118a, 255 Clumeck, N. . . . . . . . . . . . . . . . . . . . . H-556b, 073

Brousseau, N.. . . . . . . . . . . . . . . . . . . . G-876b, 101

Clutter, D. S. . . . . . . . . . . . . . . . . . . . T-1046b, 113

Bruchertseifer, F. . . . .H-1570d, 179, H-1570e, 179 Bruno, D.. . . . . . . . . . . . . . . . . . . . . . T-1072a, 116 Burgess, B. L. . . . . . . . . . . . . . . . . . . F-2015b, 246

Cohn, J. . . . . . . . . . . . . . . . . . . . . . . L2-2118b, 255 Corbeau, P. . . . . . . . . . . . . . . . . . . . . H-1570a, 179 Cornely, O. . . . . . . . . . . . . . . . . . . . . A-1946a, 240

Abo-Shadi, M. A. . . . . . . . . . . . . . . . . D-776b, 092

Aitha, M. . . . . . . . . . . . . . . . . . . . . . . . F-858a, 099

And Ma Dph, . . . . . . . . . . . . . . . . . . G-1054b, 114 Anderson, B. J.. . . . . . . . . . . . . . . . . G3-1563b, 178 Anderson, D. A. . . . . . . . . . . . . . . . . H-1582b, 180 Antela, A. . . . . . . . . . . . . . . . . . . . . . . H-556b, 073 Antunes, N. T. . . . . . . . . . . . . . . . . . . C1-673a, 085 Apewokin, S. K.. . . . . . . . . . . . . . . . . T-1046a, 113 Appannanavar, S. B. . . . . . . . . . . . . . C2-121b, 009

Costagliola, D. . . . . . . . . . . . . . . . . . . H-1570f, 179 Couture, C. . . . . . . . . . . . . . . . . . . . . . V-400d, 030 Cox, C. R. . . . . . . . . . . . . . . . . . . . . . . D-731b, 090

C

Archer, J. . . . . . . . . . . . . . . . . . . . . . . H-1582a, 180 Arias, C. A. . . . . . . . . . . . . . . . . . . . C1-1351b, 166 Armstrong, E. . . . . . . . . . . . . . . . . . L2-2118a, 255

Caceres, M. . . . . . . . . . . . . . . . . . . . . A-1946a, 240 Camacho-Ortiz, A. . . . . . . . . . . . . . . C2-097a, 008

Arnott, D. . . . . . . . . . . . . . . . . . . . . . . .V-400f, 030 Arpaci, A. . . . . . . . . . . . . . . . . . . . . . . B-060c, 005

Canestri, A. . . . . . . . . . . . . . . . . . . . . H-1570f, 179 Cao, J. H. . . . . . . . . . . . . . . . . . . . . . C2-1401a, 169

Arts, E. . . . . . . . . . . . . . . . . . . . . . . . H-1582a, 180 Asensi, V. . . . . . . . . . . . . . . . . . . . . . . . B-060a, 005 Assis, D. M.. . . . . . . . . . . . . . . . . . . . . D-731a, 090

Cap In The Icu Study Group, . . . . . . L1-300a, 026 Capone, A.. . . . . . . . . . . . . . . . . . . . . . D-731c, 090 Capozzi, D. . . . . . . . . . . . . . . . . . . . . . D-731c, 090

B

Cox, H. . . . . . . . . . . . . . . . . . . . . . . . C2-097b, 008 Crandon, J. L. . . . . . . . . . . . . . . . . . . . A-022a, 003 Crandon, J. L. . . . . . . . . . . . . . . . . . . F-2072a, 249 Crowder, M. W. . . . . . . . . . . . . . . . . . F-858a, 099 Crowe, S. . . . . . . . . . . . . . . . . . . . . . . H-1582b, 180 Cunha-Bang, C. D. . . . . . . . . . . . . . . . T-369a, 029 Cunningham, A. . . . . . . . . . . . . . . . . L1-300c, 026

Capretta, A. . . . . . . . . . . . . . . . . . . . . F-2015a, 246

D

Bagarozzi, D. . . . . . . . . . . . . . . . . . . . . V-400b, 030 Balfour, H. H. . . . . . . . . . . . . . . . . . . V-1242a, 160

Carattoli, A.. . . . . . . . . . . . . . . . . . . . . D-731c, 090 Carcaba, V. . . . . . . . . . . . . . . . . . . . . . B-060a, 005 Carletti, M. . . . . . . . . . . . . . . . . . . . . . D-731c, 090 Carroll, J. . . . . . . . . . . . . . . . . . . . . . . C2-097b, 008

Da Silva, C. M. . . . . . . . . . . . . . . . . . . F-823a, 096 Da Silva, D. L.. . . . . . . . . . . . . . . . . . . F-823a, 096

Balice, M. P.. . . . . . . . . . . . . . . . . . . . . D-731c, 090 Ballardini, M. . . . . . . . . . . . . . . . . . . . D-731c, 090 Banda, D.. . . . . . . . . . . . . . . . . . . . . . H-1570c, 179 Barnes, N. . . . . . . . . . . . . . . . . . . . . . H-1582b, 180 Barrios, H. . . . . . . . . . . . . . . . . . . . . . C2-097a, 008 Bartizal, K.. . . . . . . . . . . . . . . . . . . . . A-1295a, 163 Baruchel, A.. . . . . . . . . . . . . . . . . . . . . T-369b, 029 Bavari, S. . . . . . . . . . . . . . . . . . . . . . . . F-828a, 097 Bayer, A. S. . . . . . . . . . . . . . . . . . . . C1-1351b, 166 Beaudoux, C. . . . . . . . . . . . . . . . . . . . H-1570f, 179 Bednarska, N. G. . . . . . . . . . . . . . . . . F-1495a, 175 Bellis, K. . . . . . . . . . . . . . . . . . . . . . . K-2084a, 251 Beresford, E. . . . . . . . . . . . . . . . . . . L1-1667a, 189 Beresford, E. . . . . . . . . . . . . . . . . . . . L1-300b, 026 Berger-Bächi, B. . . . . . . . . . . . . . . . C1-1747a, 197 Berman, J. . . . . . . . . .H-1570d, 179, H-1570e, 179 Bernaschi, P. . . . . . . . . . . . . . . . . . . . . D-731c, 090 Besser, T. E. . . . . . . . . . . . . . . . . . . . . C2-121a, 009 Bethell, R. . . . . . . . . . . . . . . . . . . . . . . H-556a, 073

Carroll, S. F.. . . . . . . . . . . . . . . . . . . . F-2015b, 246 Cartier, V. . . . . . . . . . . . . . . . . . . . . . . K-562c, 074 Carton, J. A. . . . . . . . . . . . . . . . . . . . . B-060a, 005 Carvalhaes, C. G. . . . . . . . . . . . . . . . . D-731a, 090 Casadevall, A. . . . . . .H-1570d, 179, H-1570e, 179 Cass, R. . . . . . . . . . . . . . . . . . . . . . . . B-1308a, 164 Cass, R. . . . . . . . . . . . . . . . . . . . . . . L2-2118a, 255 Cattoir, V. . . . . . . . . . . . . . . . . . . . . . . K-562b, 074 Cayô, R.. . . . . . . . . . . . . . . . . . . . . . . . D-731a, 090 Cebrik, D. . . . . . . . . . . . . . . . . . . . . L2-2118a, 255 Cendrowski, S.. . . . . . . . . . . . . . . . . . B-1338a, 165 Cesnauskas, G. . . . . . . . . . . . . . . . . L1-1647a, 186 Chaillot, F.. . . . . . . . . . . . . . . . . . . . . . K-562b, 074 Chambers, H. . . . . . . . . . . . . . . . . . C1-1351a, 166 Chan, L. . . . . . . . . . . . . . . . . . . . . . C1-1351a, 166 Chapman, M. A. . . . . . . . . . . . . . . . . F-2072b, 249 Charleston, J. . . . . . . . . . . . . . . . . . . . . F-828a, 097 Chen, E. . . . . . . . . . . . . . . . . . . . . . . V-1080a, 117 Chen, S. . . . . . . . . . . . . . . . . . . . . . . L1-1667a, 189

Diaz, L. . . . . . . . . . . . . . . . . . . . . . . . H-1570b, 179 Dadachova, E. . . . . . .H-1570d, 179, H-1570e, 179 Dague, E.. . . . . . . . . . . . . . . . . . . . . . .F-1540c, 177 Dalle, J. . . . . . . . . . . . . . . . . . . . . . . . . T-369b, 029 Damon, I. . . . . . . . . . . . . . . . . . . . . . . V-400b, 030 Date, S. . . . . . . . . . . . . . . . . . . . . . . . . .V-400f, 030 Daubin, C. . . . . . . . . . . . . . . . . . . . . . . K-562b, 074 Davies, R. . . . . . . . . . . . . . . . . . . . . . . F-828a, 097 Davis, M. A. . . . . . . . . . . . . . . . . . . . C2-121a, 009 Dawson, M. J. . . . . . . . . . . . . . . . . . . F-1540d, 177 De, K. . . . . . . . . . . . . . . . . . . . . . . . . . D-776a, 092 de Fátima, A. . . . . . . . . . . . . . . . . . . . . F-823a, 096 De Serres, G. . . . . . . . . . G-876b, 101, V-400d, 030 Defay, F.. . . . . . . . . . . . . . . . . . . . . . . . G-876b, 101 Del Chierico, F. . . . . . . . . . . . . . . . . . . D-731c, 090 Delobelle, A. . . . . . . . . . . . . . . . . . . . H-1570f, 179 Dengler, V.. . . . . . . . . . . . . . . . . . . . C1-1747a, 197 Denisuik, A. . . . . . . . . . . . . . . . . . . . . E-804a, 094 Denny, T. . . . . . . . . . . . . . . . . . . . . . . H-1582b, 180

Final Program

339

> Late-Breaker AUTHOR INDEX Author

Presentation Number

Author

Presentation Number

Author

Presentation Number

Di Girolamo, F. . . . . . . . . . . . . . . . . . . D-731c, 090

Garza-González, E.. . . . . . . . . . . . . . C2-097a, 008

Hoshino, K. . . . . . . . . . F-2056a, 248, F-2056b, 248

Diao, J.. . . . . . . . . . . . . . . V-400c, 030, V-400f, 030 Diaz, L. . . . . . . . . . . . . . . . . . . . . . . C1-1351b, 166

Garza-Ramos, U.. . . . . . . . . . . . . . . . C2-097a, 008 Ghosn, J. . . . . . . . . . . . . . . . . . . . . . . H-1570f, 179

Hsu, K. . . . . . . . . . . . . . . . . . . . . . . . G-1054b, 114 Huang, D. B. . . . . . . . . . . . . . . . . . . . F-1540b, 177

Diehl, L. . . . . . . . . . . . . . . . . . . . . . . . V-400c, 030

Gibson, R. . . . . . . . . . . . . . . . . . . . . . H-1582a, 180

Huang, X. . . . . . . . . . . . . . . . . . . . . . L1-300b, 026

Dijkshoorn, L. . . . . . . . . . . . . . . . . . C2-1905a, 236

Giordano, A. . . . . . . . . . . . . . . . . . . . . D-731c, 090

Huang, X. . . . . . . . . . . . . . . . . . . . . L1-1667a, 189

Du Cheyron, D. . . . . . . . . . . . . . . . . . K-562b, 074 Dubrovskaya, Y.. . . . . . . . . . . . . . . . . T-1046b, 113

Golden, J. E. . . . . . . . . . . . . . . . . . . . . V-400e, 030 Goldstein, J. . . . . . . . . . . . . . . . . . . . . . V-400b, 030

Hughes, L.. . . . . . . . . . . . . . . . . . . . . . V-400b, 030

Duffy, E. . . . . . . . . . . . . . . . . . . . . . L1-1667b, 189 Duiculescu, D. . . . . . . . . . . . . . . . . . . . H-556b, 073

González-Tomé, M. . . . . . . . . . . . . . H-1570b, 179 Gonzales, M. . . . . . . . . . . . . . . . . . . . H-1921a, 238

I

Durso, R. . . . . . . . . . . . . . . . . . . . . . . F-1540b, 177

Gorenek, L. . . . . . . . . . . . . . . . . . . . . L1-300a, 026

Inkaya, A. C. . . . . . . . . . . . . . . . . . . . . B-060c, 005

Dutheil, J. . . . . . . . . . . . . . . . . . . . . . . K-562b, 074 Duval, R. E.. . . . . . . . . . . . . . . . . . . . F-1540c, 177

Gorny, M. . . . . . . . . .H-1570d, 179, H-1570e, 179 Granier, C.. . . . . . . . . . . . . . . . . . . . . . H-556b, 073

Iversen, M.. . . . . . . . . . . . . . . . . . . . . . T-369a, 029 Iversen, P. L. . . . . . . . . . . . . . . . . . . . . F-828a, 097

Grare, M.. . . . . . . . . . . . . . . . . . . . . . .F-1540c, 177

E Eberhard, A. . . . . . . . . . . . . . . . . . . . . H-556b, 073 Edelstein, H. . . . . . . . . . . . . . . . . . . . . H-556c, 073 Edwards, G.. . . . . . . . . . . . . . . . . . . . D-1461a, 172 Eigenbrot, C. . . . . . . . . . . . . . . . . . . . . .V-400f, 030 Erb-Zohar, K. . . . . . . A-1268b, 161, A-1268c, 161 Erdem, H. . . . . . . . . . . . . . . . . . . . . . L1-300a, 026 Evdokimova, E. . . . . . . . . . . . . . . . . . F-2015a, 246

F

Grarup, J. . . . . . . . . . . . . . . . . . . . . . . . T-369a, 029 Grayson, M. L. . . . . . . . . . . . . . . . . . K-2084a, 251 Grazziutti, M. . . . . . . . . . . . . . . . . . . T-1046a, 113 Gupta, P. . . . . . . . . . . . . . . . . . . . . . . F-1518a, 176 Gustafsson, F. . . . . . . . . . . . . . . . . . . . T-369a, 029 Gutiérrez, F.. . . . . . . . . . . . . . . . . . . . . H-556b, 073 Guzmán-López, S. . . . . . . . . . . . . . . C2-097a, 008

H Hönigl, M.. . . . . . . . . . . . . . . . . . . . . . K-562a, 074 Hamelin, M. E. . . . . . . . . . . . . . . . . . . V-400d, 030

Fahd, M. . . . . . . . . . . . . . . . . . . . . . . . T-369b, 029 Fang, E. . . . . . . . . . . . . . . . . . . . . . . . A-1295a, 163

Han, J. . . . . . . . . . . . . . . . . . . . . . . . . V-1080a, 117 Hancock, A.. . . . . . . . . . . . . . . . . . . . F-1540d, 177

Febbraro, S. . . . . . . . . . . . . . . . . . . . . F-1540d, 177 Feghoul, L. . . . . . . . . . . . . . . . . . . . . . T-369b, 029

Hass, P. . . . . . . . . . . . . . . . . . . . . . . . . .V-400f, 030 Havers, S. . . . . . . . . . . . . . . . . . . . . . K-2084a, 251 Hazen, K. . . . . . . . . . . . . . . . . . . . . . C2-097b, 008 Hazen, M. . . . . . . . . . . . . . . . . . . . . . . .V-400f, 030 He, Y. . . . . . . . . . . . . . . . . . . . . . . . . F-2015b, 246 Heald, A. . . . . . . . . . . . . . . . . . . . . . . . F-828a, 097 Heard, K. . . . . . . . . . . . . . . . . . . . . . . K-2084a, 251 Heinz, W. . . . . . . . . . . . . . . . . . . . . . A-1946a, 240 Heo, P. . . . . . . . . . . . . . . . . . . . . . . . . F-1540a, 177 Heyderman, R. S. . . . . . . . . . . . . . . . H-1570c, 179 Hezareh, M. . . . . . . . . . . . . . . . . . . . G-1054a, 114 Higa, F. . . . . . . . . . . . . . . . . . . . . . . . F-2056b, 248 Hillan, K.. . . . . . . . . . . . . . . . . . . . . L2-2118a, 255 Hilsted, J.. . . . . . . . . . . . . . . . . . . . . . . T-369a, 029 Hoban, D. J. . . . . . . . . . . . . . . . . . . . . E-804a, 094 Hocqueloux, L. . . . . . . . . . . . . . . . . . . H-556b, 073 Holtzman, D. . . . . . . . . . . . . . . . . . L2-2118b, 255 Hongo, J. . . . . . . . . . . . . . . . . . . . . . . . .V-400f, 030 Hooper, D. C. . . . . . . . . . . . . . . . . . . C1-683a, 086 Hooper, J. W.. . . . . . . . . . . . . . . . . . . . V-400b, 030 Hopkins, S. . . . . . . .L1-1667b, 189, L1-1667c, 189 Horina, J. . . . . . . . . . . . . . . . . . . . . . . . K-562a, 074 Horn, P. . . . . . . . . . . . . . . . . . . . . . . L1-1647a, 186

Feng, X. . . . . . . . . . . . . . . . . . . . . . . . F-1495b, 175 Feng, Z. . . . . . . . . . . . . . . . . . . . . . . . . B-060b, 005 Ferreira, J. A. . . . . . . . . . . . . . . . . . . . . F-823a, 096 Fishetti, V. A. . . . . . . . . . . . . . . . . . . F-1540b, 177 Flanagan, S. . . . . . . . . . . . . . . . . . . . . A-1295a, 163 Formosa, C. . . . . . . . . . . . . . . . . . . . . .F-1540c, 177 Forstén, A. . . . . . . . . . . . . . . . . . . . . . G-1054a, 114 Forte, T. M. . . . . . . . . . . . . . . . . . . . . F-2015b, 246 Fournel, F. . . . . . . . . . . . . . . . . . . . . . . K-562b, 074 Frase, H. . . . . . . . . . . . . . . . . . . . . . . C1-673a, 085 Friedland, H. D. . . . . . . . . . . . . . . . L1-1667a, 189 Friedland, H. D. . . . . .L1-300b, 026, L1-300c, 026 Fujita, J. . . . . . . . . . . . . . . . . . . . . . . . F-2056b, 248

G Gales, A. C. . . . . . . . . . . . . . . . . . . . . . D-731a, 090 Gao, H. . . . . . . . . . . . . . . . . . . . . . . C1-1351b, 166 Garcia, M. . . . . . . . . . . . . . . . . . . . . . H-1582b, 180 Garcia-Reyne, A.. . . . . . . . . . . . . . . . T-1072a, 116 Garza, N. L. . . . . . . . . . . . . . . . . . . . . F-828a, 097

340

September 9-12 |

J Jacoby, G. A. . . . . . . . . . . . . . . . . . . . C1-683a, 086 Jambo, K. C. . . . . . . . . . . . . . . . . . . . H-1570c, 179 Jandourek, A. . . . . . . . . . . . . . . . . . . . L1-300c, 026 Janjua, N. Z. . . . . . . . . . . . . . . . . . . . . V-400d, 030 Ji, M. . . . . . . . . . . . . . . . . . . . . . . . . C2-1401b, 169 Jia, X. . . . . . . . . . . . . . . . . . . . . . . . . . . B-060b, 005 John, G. . . . . . . . . . . . . . . . . . . . . . . . T-1072a, 116 Jokinen, J. . . . . . . . . . . . . . . . . . . . . . . G-876a, 101 Jones, L.. . . . . . . . . . . . . . . . . . . . . . . C2-121a, 009 Jonsson, C.. . . . . . . . . . . . . . . . . . . . . . V-400e, 030 Joo, Y. . . . . . . . . . . . . . . . . . . . . . . . . F-1540a, 177 Juliano, M. A. . . . . . . . . . . . . . . . . . . . D-731a, 090 Juliano Neto, L. . . . . . . . . . . . . . . . . . . D-731a, 090

K Kapadia, S.. . . . . . . . . . . . . . . . . . . . . . V-400c, 030 Kapadia, S.. . . . . . . . . . . . . . . . . . . . . . .V-400f, 030 Karakitsos, P. . . . . . . . . . . . . . . . . . . G3-1563a, 178 Karaolis, D. . . . . . . . . . . . . . . . . . . . . B-1338a, 165 Karem, K. . . . . . . . . . . . . . . . . . . . . . . V-400b, 030 Karger, A. . . . . . . . . . . . . . . . . . . . . . . D-731c, 090 Karlowsky, J. A. . . . . . . . . . . . . . . . . . . E-804a, 094 Kartsonis, N. . . . . . . . . . . . . . . . . . . . A-1946a, 240 Kaur, I. R. . . . . . . . . . . . . . . . . . . . . . . D-776a, 092 Kaur, N. . . . . . . . . . . . . . . . . . . . . . . . P-1023a, 112 Kearns, A. . . . . . . . . . . . . . . . . . . . . . D-1461a, 172 Keckler, M. S. . . . . . . . . . . . . . . . . . . . V-400b, 030 Kelley, R. . . . . . . . . . . . . . . . . . . . . . . . .V-400f, 030 Khan, B. . . . . . . . . . . . . . . . . . . . . . . F-1540b, 177 Kilpi, T. M. . . . . . . . . . . . . . . . . . . . . . G-876a, 101 Kim, E. A. . . . . . . . . . . . . . . . . . . . . C2-1401b, 169 Kim, J. . . . . . . . . . . . . . . . . . . . . . . . . F-1540a, 177 Kim, M. . . . . . . . . . . . . . . . . . . . . . . C2-1401b, 169 Kirk, O. . . . . . . . . . . . . . . . . . . . . . . . . T-369a, 029


Presentation Number

Author

Kirkby, N. . . . . . . . . . . . . . . . . . . . . . . T-369a, 029

M

Kitchen, S. . . . . . . . . .H-1570d, 179, H-1570e, 179 Kjær, J. . . . . . . . . . . . . . . . . . . . . . . . . . T-369a, 029

Presentation Number

Author

Presentation Number

Mutale, W. . . . . . . . . . . . . . . . . . . . . . H-886a, 102 Mwandumba, H. C. . . . . . . . . . . . . . H-1570c, 179

Maddox, C. . . . . . . . . . . . . . . . . . . . . . V-400e, 030

N

Kohno, S. . . . . . . . . . . . . . . . . . . . . . . F-2056a, 248

Maertens, J. . . . . . . . . . . . . . . . . . . . . A-1946a, 240 Magalhães, T. F. . . . . . . . . . . . . . . . . . . F-823a, 096

Komuves, L.. . . . . . . . . . . . . . . . . . . . . V-400c, 030 Kouni, S. . . . . . . . . . . . . . . . . . . . . . G3-1563a, 178

Maggiolo, F.. . . . . . . . . . . . . . . . . . . . . H-556b, 073

Nagaoka, K. . . . . . . . . . . . . . . . . . . . . F-2056a, 248

Maiorano, S. . . . . . . . . . . . . . . . . . . . . D-731c, 090

Krause, R. . . . . . . . . . . . . . . . . . . . . . . K-562a, 074 Krishna, G. . . . . . . . . . . . . . . . . . . . . A-1946a, 240

Mankin, A. . . . . . . . . . . . . . . . . . . . . F-1518a, 176 Mann, J. . . . . . . . . . . . . . . . . . . . . . . . B-1338a, 165

Nakasone, I. . . . . . . . . . . . . . . . . . . . . F-2056b, 248 Ngoma, M. . . . . . . . . . . . . . . . . . . . . . H-886a, 102

Kropeit, D.. . . . . . . . . A-1268b, 161, A-1268c, 161

Margolis, D. A. . . . . . . . . . . . . . . . . . . H-556c, 073

Nicholson, A. M. . . . . . . . . . . . . . . . . . D-776c, 092

Kumar, A. . . . . . . . . . . . . . . . . . . . . . C2-121b, 009 Kumar, Y.. . . . . . . . . . . . . . . . . . . . . . C2-121b, 009

Martins, C. V. . . . . . . . . . . . . . . . . . . . F-823a, 096 Martins, E. R. . . . . . . . . . . . . . . . . . . . D-731a, 090

Nicolau, D. P.. . . . . . . . . . . . . . . . . . . . A-022a, 003 Nicolau, D. P.. . . . . . . . . . . . . . . . . . . F-2072a, 249

Kurosaka, Y.. . . . . . . . . . . . . . . . . . . . F-2056a, 248

Mascard, L. . . . . . . . . . . . . . . . . . . . . H-1570f, 179

Nieminen, H.. . . . . . . . . . . . . . . . . . . . G-876a, 101

Kweon, D. . . . . . . . . . . . . . . . . . . . . . F-1540a, 177

Mason, S.. . . . . . . . . . . . . . . . . . . . . . . H-556a, 073 Masotti, A. . . . . . . . . . . . . . . . . . . . . . D-731c, 090 Masson, R.. . . . . . . . . . . . . . . . . . . . . . K-562b, 074 Match Program Study Group . . . . . . . T-369a, 029 Matharu, D. S.. . . . . . . . . . . . . . . . . . . V-400e, 030

Nogueira, L. J. . . . . . . . . . . . . . . . . . . . F-823a, 096 Nordmann, P.. . . . . . . . . . . . . . . . . . . . A-022a, 003 Nucci, G. . . . . . . . . . . . . . . . . . . . . . . A-1268d, 161

Knight, J. A. . . . . . . . . . . . . . . . . . . . V-1242a, 160

L Lagacé-Wiens, P.. . . . . . . . . . . . . . . . . E-804a, 094 Lamb, L. . . . . . . . . . . . . . . . . . . . . . . F-2072a, 249 Lamorte, L. . . . . . . . . . . . . . . . . . . . . . H-556a, 073 Landay, A. . . . . . . . . . . . . . . . . . . . . . H-1582b, 180 Landman, R. . . . . . . . . . . . . . . . . . . . H-1570f, 179 Landry, M.. . . . . . . . . . . . . . . . . . . . . . G-876b, 101 Larsen, A. . . . . . . . . . . . . . . . . . . . . . D-1461a, 172 Lattes, R. . . . . . . . . . . . . . . . . . . . . . . T-1072a, 116 Laurent, F. . . . . . . . . . . . . . . . . . . . . . D-1461a, 172 Lavigne, S. . . . . . . . . . . . . . . . . . . . . . . V-400d, 030 Law, C. . . . . . . . . . . . . . . . . . . . . . . . F-1540b, 177 Lawrence, L. . . . . . .L1-1667b, 189, L1-1667c, 189 Le Goff, J. . . . . . . . . . . . . . . . . . . . . . . T-369b, 029 Lecuyer, H. . . . . . . . . . . . . . . . . . . . . H-1570f, 179 Lee, H. . . . . . . . . . . . . . . . . . . . . . . . F-1540b, 177 Leruez-Ville, M. . . . . . . . . . . . . . . . . H-1570f, 179 Li, G. H. . . . . . . . . . . . . . . . . . . . . . C2-1401a, 169 Li, G. . . . . . . . . . . . . . . . . . . . . . . . . . . V-400d, 030 Li, Y. . . . . . . . . . . . . . . . . . . . . . . . . . L1-300c, 026 Linkin, D. R. . . . . . . . . . . . . . . . . . . L2-2118b, 255 Liu, J. . . . . . . . . . . . . . . . . . . . . . . . . . V-1080a, 117 Liu, S. . . . . . . . . . . . . . . . . . . . . . . . . V-1080a, 117 Llaca-Díaz, J. M. . . . . . . . . . . . . . . . . C2-097a, 008 Llewellyn, Z. . . . . . . . . . . . . . . . . . . . B-1338a, 165 Lobos, E. A. . . . . . . . . . . . . . . . . . . C1-1351b, 166 Lommel, P. . . . . . . . . . . . . . . . . . . . . G-1054a, 114 Longcor, J. . . . . . . . . . . . . . . . . . . . . L1-1667b, 189 Longcor, J. . . . . . . . . . . . . . . . . . . . . L1-1667c, 189 Lopez, L. . . . . . . . . . .H-1570d, 179, H-1570e, 179 Loveless, M. O . . . . . . . . . . . . . . . . . V-1080a, 117 Lundgren, J. D. . . . . . . . . . . . . . . . . . . T-369a, 029 Luo, B.. . . . . . . . . . . . . . . . . . . . . . . . F-2015b, 246

Mathers, A. J. . . . . . . . . . . . . . . . . . . C2-097b, 008 Mathias, A. . . . . . . . . . . . . . . . . . . . . H-1921a, 238 Matthews, C. . . . . . . . . . . . . . . . . . . . . T-369a, 029 May, R. . . . . . . . . . . . . . . . . . . . . . . . B-1338a, 165 Mazzulli, T. . . . . . . . . . . . . . . . . . . . . . D-776c, 092 McAlpin, C. R. . . . . . . . . . . . . . . . . . . D-731b, 090 McCallum, N. . . . . . . . . . . . . . . . . . C1-1747a, 197 McCormick, D. . . . . . A-1268a, 161, A-1268b, 161, . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1268c, 161 McFarren, A. . . . . . . H-1570d, 179, H-1570e, 179, . . . . . . . . . . . . . . . . . . . . . . . . . . . H-1570d, 179 Mega, W.. . . . . . . . . . . . . . . . . . . . . . B-1308a, 164 Meledandri, M. . . . . . . . . . . . . . . . . . . D-731c, 090 Mellado, M.. . . . . . . . . . . . . . . . . . . . H-1570b, 179 Merl, M. . . . . . . . . . . . . . . . . . . . . . . T-1046b, 113 Metan, G. . . . . . . . . . . . . . . . . . . . . C2-1905a, 236 Mettling, C.. . . . . . . . . . . . . . . . . . . . H-1570a, 179 Meyers, D. V.. . . . . . . . . . . . . . . . . . . C2-121a, 009 Michos, A. . . . . . . . . . . . . . . . . . . . . G3-1563a, 178 Mimms, L.. . . . . . . . . . . . . . . . . . . . . H-1582a, 180 Minassian, S. . . . . . . . . . . . . . . . . . . . A-1295a, 163 Mishra, N. N. . . . . . . . . . . . . . . . . . C1-1351b, 166 Misir, A. . . . . . . . . . . . . . . . . . . . . . . . H-886a, 102 Montejo, M. . . . . . . . . . . . . . . . . . . . T-1072a, 116 Montes, A. H. . . . . . . . . . . . . . . . . . . . B-060a, 005 Moore, B. . . . . . . . . . . . . . . . . . . . . . . V-400e, 030 Moreira, M. . . . . . . . . . . . . . . . . . . . . G-1054a, 114 Moreno, S. . . . . . . . . . . . . . . . . . . . . . H-1570b, 179 Morgenstern, A. . . . .H-1570d, 179, H-1570e, 179 Muñoz-Fernández, M. . . . . . . . . . . . H-1570b, 179 Munita, J. M. . . . . . . . . . . . . . . . . . . C1-1351b, 166 Munoz, P. . . . . . . . . . . . . . . . . . . . . . T-1072a, 116 Murray, B. E. . . . . . . . . . . . . . . . . . . C1-1351b, 166

Final Program

Ngu, H. . . . . . . . . . . . . . . . . . . . . . . . . V-400c, 030

O Obino, M. . . . . . . . . . . . . . . . . . . . . L2-2118b, 255 Oda, M. N. . . . . . . . . . . . . . . . . . . . . F-2015b, 246 Okumura, R. . . . . . . . . . . . . . . . . . . . F-2056b, 248 Omar, A. . . . . . . . . . . . . . . . . . . . . . L2-2118b, 255 Oncul, O.. . . . . . . . . . . . . . . . . . . . . . L1-300a, 026 Ouachée, M. . . . . . . . . . . . . . . . . . . . . T-369b, 029 Ouakki, M. . . . . . . . . . . . . . . . . . . . . . G-876b, 101 Ozcimen, S. . . . . . . . . . . . . . . . . . . . . . B-060c, 005

P Palmu, A. A. . . . . . . . . . . . . . . . . . . . . G-876a, 101 Pande, A. . . . . . . . . . . . . . . . . . . . . . . T-1046a, 113 Panesso, D. . . . . . . . . . . . . . . . . . . . C1-1351b, 166 Pantua, H. . . . . . . . . . . . . . . . . . . . . . . V-400c, 030 Pantua, H. . . . . . . . . . . . . . . . . . . . . . . .V-400f, 030 Pappa, K. . . . . . . . . . . . . . . . . . . . . . . . H-556b, 073 Paranavitana, C.. . . . . . . . . . . . . . . . . F-1495b, 175 Parienti, J. . . . . . . . . . . . . . . . . . . . . . . K-562b, 074 Parisi, G. . . . . . . . . . . . . . . . . . . . . . . . D-731c, 090 Paton, B. . . . . . . . . . . . . . . . . . . . . . . A-1946a, 240 Paxinos, E. . . . . . . . . . . . . . . . . . . . . . H-1582a, 180 Pelletier, A. . . . . . . . . . . . . . . . . . . . . . H-556a, 073 Pelton, S. I. . . . . . . . . . . . . . . . . . . . . G-1054b, 114 Peters, L. . . . . . . . . . . . . . . . . . . . . . . . T-369a, 029 Petrosillo, N. . . . . . . . . . . . . . . . . . . . . D-731c, 090 Phung, Q. . . . . . . . . . . . . . . . . . . . . . . .V-400f, 030 Pichon, B. . . . . . . . . . . . . . . . . . . . . . D-1461a, 172 Pilon, R. . . . . . . . . . . . . . . . . . . . . . . . H-886a, 102 Pittet, D. . . . . . . . . . . . . . . . . . . . . . . . K-562c, 074 Pohl, J. . . . . . . . . . . . . . . . . . . . . . . . . . V-400b, 030

341

> Late-Breaker AUTHOR INDEX Author

Presentation Number

Author

Ponscarme, D. . . . . . . . . . . . . . . . . . . H-1570f, 179

S

Press, R. . . . . . . . . . . . . . . . . . . . . . . . T-1046b, 113 Prokocimer, P. . . . . . . . . . . . . . . . . . . A-1295a, 163

Presentation Number

Author

Presentation Number

Soininen, A.. . . . . . . . . . . . . . . . . . . . G-1054a, 114

Sørensen, S. S. . . . . . . . . . . . . . . . . . . . T-369a, 029

Solomkin, J. . . . . . . . . . . . . . . . . . . . L1-1647a, 186 Sosa, M. I. . . . . . . . . . . . . . . . . . . . . . . V-400e, 030

Putignani, L. . . . . . . . . . . . . . . . . . . . . D-731c, 090

Safdar, A. . . . . . . . . . . . . . . . . . . . . . . T-1046b, 113 Sainz, T. . . . . . . . . . . . . . . . . . . . . . . . H-1570b, 179

Spanogiannopoulos, P. . . . . . . . . . . . . F-2015a, 246

Puumalainen, T.. . . . . . G-1054a, 114, G-876a, 101

Sambanthamoorthy, K. . . . . . . . . . . . F-1495b, 175

Psomas, K. C. . . . . . . . . . . . . . . . . . . H-1570a, 179

Spagnuolo, P. . . . . . . . . . . . . . . . . . . . V-1080a, 117

Sandkovsky, U. . . . . . . . . . . . . . . . . . . H-556b, 073

Spire, B. . . . . . . . . . . . . . . . . . . . . . . . H-1570f, 179 Stobernack, H.. . . . . . A-1268b, 161, A-1268c, 161

Sariguzel, F. M. . . . . . . . . . . . . . . . . C2-1905a, 236 Sauneuf, B. . . . . . . . . . . . . . . . . . . . . . K-562b, 074

Stogios, P. J. . . . . . . . . . . . . . . . . . . . . F-2015a, 246 Stoianoff, M. A.. . . . . . . . . . . . . . . . . . F-823a, 096

Quiblier, C. . . . . . . . . . . . . . . . . . . . C1-1747a, 197

Sauve, K. . . . . . . . . . . . . . . . . . . . . . . F-1540b, 177

Sturino, C. . . . . . . . . . . . . . . . . . . . . . . H-556a, 073

Quinones-Mateu, M. E. . . . . . . . . . . H-1582a, 180

Savchenko, A. . . . . . . . . . . . . . . . . . . F-2015a, 246 Sazani, P. . . . . . . . . . . . . . . . . . . . . . . . F-828a, 097

Sumer, S. . . . . . . . . . . . . . . . . . . . . . . . B-060c, 005 Sumerkan, B. . . . . . . . . . . . . . . . . . . C2-1905a, 236

Schaefer, G. . . . . . . . . . . . . . . . . . . . . . V-400c, 030

Sung, H. . . . . . . . . . . . . . . . . . . . . . C2-1401b, 169

Scheuenpflug, J. . . . . . A-1268b, 161, A-1268c, 161 Schiffer, J. T. . . . . . . . . . . . . . . . . . . . A-1268a, 161 Schilcher, G. . . . . . . . . . . . . . . . . . . . . K-562a, 074 Schmeling, D. O. . . . . . . . . . . . . . . . . V-1242a, 160 Schneider, B. . . . . . . . . . . . . . . . . . . . F-1540b, 177

Sutcliffe, J. . . . . . . . . . . . . . . . . . . . . L1-1647a, 186 Suthar, N. . . . . . . . . . . . . . . . . . . . . . C2-121a, 009 Sutton, L. D. . . . . . . . . . . . . . . . . . . . . F-858a, 099

Q

R Rübsamen-Schaeff, H. . . . . . . . . . . .A-1268b, 161, . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1268c, 161 Rajotte, D. . . . . . . . . . . . . . . . . . . . . . . H-556a, 073 Ramesh, M. . . . . . . . . . . . . . . . . . . . L1-1647a, 186 Rami, A. . . . . . . . . . . . . . . . . . . . . . . H-1570f, 179 Ramos, J. . . . . . . . . . . . . . . . . . . . . . . H-1570b, 179 Rasmussen, A. . . . . . . . . . . . . . . . . . . . T-369a, 029 Rasmussen, L. . . . . . . . . . . . . . . . . . . . V-400e, 030 Restrepo, A. . . . . . . . . . . . . . . . . . . . . T-1046a, 113 Reyes, J. . . . . . . . . . . . . . . . . . . . . . . C1-1351b, 166 Reyes, N. . . . . . . . . . . . . . . . . . . . . . . B-1308a, 164 Reynes, J. . . . . . . . . . . . . . . . . . . . . . . H-1570a, 179 Ribadeneira, M. . . . . . . . . . . . . . . . . . . H-556a, 073 Ribitsch, W.. . . . . . . . . . . . . . . . . . . . . K-562a, 074 Richard, M. . . . . . . . . A-1268b, 161, A-1268c, 161 Richardson-Harman, N. . . . . . . . . . . B-1338a, 165 Riddle, V.. . . . . . . . . . . . . . . . . . . . . L2-2118a, 255 Robertson, D. L. . . . . . . . . . . . . . . . . H-1582a, 180 Robertson, M. N. . . . . . . . . . . . . . . . A-1946a, 240 Rodriguez, J. . . . . . . . . . . . . . . . . . . . H-1921a, 238 Rodriguez-Torres, M. . . . . . . . . . . . . H-1921a, 238 Roh, J. H. . . . . . . . . . . . . . . . . . . . . C1-1351b, 166 Rosenkranz, A. . . . . . . . . . . . . . . . . . . K-562a, 074 Ross, L. L. . . . . . . . . . . . . . . . . . . . . . . H-556c, 073 Rossi, S. . . . . . . . . . . . . . . . . . . . . . . . H-1921a, 238 Rousseau, F. . . . . . . . . . . . . . . . . . . . . F-1495a, 175 Rouzioux, C. . . . . . . . . . . . . . . . . . . . H-1570f, 179 Rubsamen-Schaeff, H. . . . . . . . . . . . A-1268a, 161 Ruokokoski, E. . . . . . . . . . . . . . . . . . . G-876a, 101 Russell, D. G. . . . . . . . . . . . . . . . . . . H-1570c, 179 Russo, P. L. . . . . . . . . . . . . . . . . . . . . K-2084a, 251 Ryan, K.. . . . . . . . . . . . . . . . . . . . . . . K-2084a, 251 Ryan, R. O. . . . . . . . . . . . . . . . . . . . . F-2015b, 246

342

Schuch, R. . . . . . . . . . . . . . . . . . . . . . F-1540b, 177 Schuerman, L. . . . . . . . . . . . . . . . . . . G-1054a, 114 Schymkowitz, J. . . . . . . . . . . . . . . . . . F-1495a, 175 Seguin, A. . . . . . . . . . . . . . . . . . . . . . . K-562b, 074 Sengeløv, H. . . . . . . . . . . . . . . . . . . . . T-369a, 029 Senn, M. M. . . . . . . . . . . . . . . . . . . C1-1747a, 197 Seppã, I.. . . . . . . . . . . . . . . . . . . . . . . G-1054a, 114 Serrano-Villar, S. . . . . . . . . . . . . . . . . H-1570b, 179 Severson, W. . . . . . . . . . . . . . . . . . . . . V-400e, 030 Shaefer, M. S. . . . . . . . . . . . . . . . . . . . H-556c, 073 Shamoo, Y. . . . . . . . . . . . . . . . . . . . C1-1351b, 166 Shen, G. . . . . . . . . . . . . . . . . . . . . . . H-1921a, 238 Sherwood, R.. . . . . . . . . . . . . . . . . . . B-1308a, 164 Shi, L. . . . . . . . . . . . . . . . . . . . . . . . . V-1080a, 117 Shurtleff, A. C. . . . . . . . . . . . . . . . . . . F-828a, 097 Sifakis, F. . . . . . . . . . . . . . . . . . . . . . . V-1242a, 160 Sifri, C. . . . . . . . . . . . . . . . . . . . . . . . C2-097b, 008 Silva-Sánchez, J. . . . . . . . . . . . . . . . . C2-097a, 008 Silverio, A. . . . . . . . . . . . . . . . . . . . . . G-1054b, 114 Silverman, M. S. . . . . . . . . . . . . . . . . . H-886a, 102 Simon, F. . . . . . . . . . . . . . . . . . . . . . . . T-369b, 029 Singh, N. P. . . . . . . . . . . . . . . . . . . . . . D-776a, 092 Singh, N. . . . . . . . . . . . . . . . . . . . . . . T-1072a, 116 Singh, P.. . . . . . . . . . . . . . . . . . . . . . . P-1023a, 112 Singleton, S. F.. . . . . . . . . . . . . . . . . . F-2072b, 249 Sischo, W. . . . . . . . . . . . . . . . . . . . . . C2-121a, 009 Skov, R. . . . . . . . . . . . . . . . . . . . . . . . D-1461a, 172 Skowronski, D. M. . . . . . . . . . . . . . . . G-876b, 101 Skowronski, D. M. . . . . . . . . . . . . . . . V-400d, 030 Sliman, J. A.. . . . . . . . . . . . . . . . . . . . V-1242a, 160 Small, C. B. . . . . . . . . . . . . . . . . . . . . . H-556c, 073 Smith, G. R. . . . . . . . . . . . . . . . . . . . F-2072b, 249

September 9-12 |

Suzan-Monti, M. . . . . . . . . . . . . . . . H-1570f, 179 Symonds, B.. . . . . . . . . . . . . . . . . . . . H-1921a, 238

T Takeda, K. . . . . . . . . . . . . . . . . . . . . . . .V-400f, 030 Tamayo, E.. . . . . . . . . . . . . . . . . . . . . C2-097a, 008 Tamburro, A. . . . . . . . . . . . . . . . . . . . . D-731c, 090 Taneja, N. . . . . . . . . . . . . . . . . . . . . . C2-121b, 009 Tarasi, A. . . . . . . . . . . . . . . . . . . . . . . . D-731c, 090 Tasse, J. . . . . . . . . . . . . . . . . . . . . . . . D-1461a, 172 Tavio, M. M. . . . . . . . . . . . . . . . . . . . C1-683a, 086 Teperman, L. . . . . . . . . . . . . . . . . . . . T-1046b, 113 Terzi, N. . . . . . . . . . . . . . . . . . . . . . . . K-562b, 074 Theis, J. G. . . . . . . . . . . . . . . . . . . . . A-1268c, 161 Theodoridou Papagrigoriou, M. . . . G3-1563a, 178 Theriault, M. . . . . . . . . . . . . . . . . . . . . K-562c, 074 Thomas, W. . . . . . . . . . . . . . . . . . . . . V-1242a, 160 Thoms-Rodriguez, C. A.. . . . . . . . . . . D-776c, 092 Tillekeratne, L. G. . . . . . . . . . . . . . . L2-2118b, 255 Timmler, B. . . . . . . . . . . . . . . . . . . . . A-1268a, 161 Todorovic, N.. . . . . . . . . . . . . . . . . . . F-2015a, 246 Toomey, J. . . . . . . . . . . . . . . . . . . . . . B-1338a, 165 Torre Cisneros, J. . . . . . . . . . . . . . . . . T-1072a, 116 Toth, M. . . . . . . . . . . . . . . . . . . . . . . C1-673a, 085 Touveneau, S. . . . . . . . . . . . . . . . . . . . K-562c, 074 Townsend, M. . . . . . . . . . . . . . . . . . . . V-400b, 030 Tran, T. T. . . . . . . . . . . . . . . . . . . . . C1-1351b, 166 Tremblay, S. . . . . . . . . . . . . . . . . . . . . . H-556a, 073 Tsukrov, D. I. . . . . . . . . . . . . . . . . . . . H-1570e, 179 Tsukrov, D. . . . . . . . . . . . . . . . . . . . . H-1570d, 179 Turkan, H. . . . . . . . . . . . . . . . . . . . . . L1-300a, 026


Presentation Number

U Udeani, G. . . . . . . . . . . . . . . . . . . . . . L1-300c, 026 Ullmann, A. . . . . . . . . . . . . . . . . . . . . A-1946a, 240 Ultsch, M. . . . . . . . . . . . . . . . . . . . . . . .V-400f, 030 Ural, O. . . . . . . . . . . . . . . . . . . . . . . . . B-060c, 005

V Vakulenko, S. B. . . . . . . . . . . . . . . . . C1-673a, 085 Valderas, M.. . . . . . . . . . . . . . . . . . . . B-1308a, 164 Valentin, T. . . . . . . . . . . . . . . . . . . . . . K-562a, 074 Valette, X. . . . . . . . . . . . . . . . . . . . . . . K-562b, 074 Valle-Garay, E. . . . . . . . . . . . . . . . . . . B-060a, 005 Van Der Reijden, T. . . . . . . . . . . . . . C2-1905a, 236 Van Eldere, J. . . . . . . . . . . . . . . . . . . . F-1495a, 175 Vazquez-Laslop, N. . . . . . . . . . . . . . . F-1518a, 176 Verma, G. . . . . . . . . . . . . . . . . . . . . . C2-121b, 009 Vesikari, T. . . . . . . . . . . . . . . . . . . . . . G-1054a, 114 Viard, J. . . . . . . . . . . . . . . . . . . . . . . . H-1570f, 179 Vogel, I. . . . . . . . . . . . . . . . . . . . . . . . F-1495a, 175 Voorhees, K. J. . . . . . . . . . . . . . . . . . . . D-731b, 090 Vosbeek, A. . . . . . . . . . . . . . . . . . . . . . F-858a, 099

W Wagner, J. . . . . . . . . . . . . . . . . . . . . . . K-562a, 074 Wald, A. . . . . . . . . . . . . . . . . . . . . . . A-1268a, 161 Walder, B. . . . . . . . . . . . . . . . . . . . . . . K-562c, 074 Walkty, A. J.. . . . . . . . . . . . . . . . . . . . . E-804a, 094 Wall, D. . . . . . . . . . . . . . . . . . . . . . . C1-1973a, 242 Wallis, R. S. . . . . . . . . . . . . . . . . . . . . A-1268d, 161 Walmsley, S. . . . . . . . . . . . . . . . . . . . . H-556b, 073 Walpole, S. . . . . . . . . . . . . . . . . . . . L1-1647a, 186 Wanjiku, M. . . . . . . . . . . . . . . . . . . L2-2118b, 255 Ward, B. J. . . . . . . . . . . . . . . . . . . . . . . G-876b, 101 Warren, T. K. . . . . . . . . . . . . . . . . . . . . F-828a, 097 Waskin, H. . . . . . . . . . . . . . . . . . . . . A-1946a, 240 Weber, J. . . . . . . . . . . . . . . . . . . . . . . H-1582a, 180 Weinberg, A. . . . . . . . . . . . . . . . . . . . . B-060b, 005 Weinstock, G. M. . . . . . . . . . . . . . . C1-1351b, 166 Welch, L. . . . . . . . . . . . . . . . . . . . . . . . F-828a, 097 Wells, J. . . . . . . . . . . . . . . . . . . . . . . . . F-828a, 097 White, E.. . . . . . . . . . . . . . . . . . . . . . . V-400e, 030 Willey, B. M. . . . . . . . . . . . . . . . . . . . . D-776c, 092 Williams, D. . . . . . . H-1570d, 179, H-1570e, 179, . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2084a, 251 Wiskirchen, D. E. . . . . . . . . . . . . . . . . A-022a, 003 Wittekind, M. . . . . . . . . . . . . . . . . . . F-1540b, 177

Author

Presentation Number

Author

Presentation Number

Wynne, B. . . . . . . . . . . . . . . . . . . . . . . H-556b, 073

X Xiao, Y. . . . . . . . . . . . . . . . . . . . . . . C1-1973a, 242 Xu, X. G. . . . . . . . . . . . . . . . . . . . . . C2-1401a, 169 Xu, Y.. . . . . . . . . . . . . . . . . . . . . . . . . V-1080a, 117

Y Yamamoto, B. . . . . . . . . . . . . . . . . . . B-1338a, 165 Yamane, N. . . . . . . . . . . . . . . . . . . . . F-2056b, 248 Yanagihara, K. . . . . . . . . . . . . . . . . . . F-2056a, 248 Yeh, A. . . . . . . . . . . . . . . . . . . . . . . . . C2-097b, 008 Yildirim, I. . . . . . . . . . . . . . . . . . . . . . G-1054b, 114 Yu, S. . . . . . . . . . . . . . . . . . . . . . . . . . . F-858a, 099

Z Zain, J. . . . . . . . . . . . . . . . . . . . . . . . . T-1046b, 113 Zainab, S. . . . . . . . . . . . . . . . . . . . . . T-1046a, 113 Zhanel, G. G. . . . . . . . . . . . . . . . . . . . E-804a, 094 Zhang, M. . . . . . . . . . . . . . . . . . . . . . V-1080a, 117 Zhao, H. . . . . . . . . . . . . . . . . . . . . . . . H-556c, 073 Zhu, D. M. . . . . . . . . . . . . . . . . . . . C2-1401a, 169 Zhu, T.. . . . . . . . . . . . . . . . . . . . . . . . A-1268d, 161 Zimmermann, H. . . . A-1268b, 161, A-1268c, 161 Zingg, W. . . . . . . . . . . . . . . . . . . . . . . K-562c, 074 Zolla-Pazner, S. . . . . .H-1570d, 179, H-1570e, 179 Zollner-Schwetz, I. . . . . . . . . . . . . . . . K-562a, 074 Zucman, D. . . . . . . . . . . . . . . . . . . . . H-1570f, 179 Zurawski, D. V. . . . . . . . . . . . . . . . . . F-1495b, 175

Wohl, D. . . . . . . . . . . . . . . . . . . . . . . . H-556c, 073 Wright, G. D. . . . . . . . . . . . . . . . . . . F-2015a, 246

Final Program

343

> NOTES

344

September 9-12 |

LATE-BREAKER KEYWORD INDEX

2

breast feeding. . . . . . . . . . . . . . . . . . . . . . . . H-886a

efflux . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-776c

Brucellosis . . . . . . . . . . . . . . . . . . . . . . . . . . B-060c

emergence . . . . . . . . . . . . . . . . . . . . . . . . . C2-121a enterococcus . . . . . . . . . . . . . . . . . . . . . . . T-1046a

2-aminophenol . . . . . . . . . . . . . . . . . . . . . . F-823a

A aac(6’)-aph(2’’) . . . . . . . . . . . . . . . . . . . . . . C1-673a

C

Enterococcus faecium . . . . . . . . . . . . . . . . . C1-1351b epidemiology . . . . . . . . . . . . . . . . . . . . . . G3-1563a

CAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-300a

Epithelia . . . . . . . . . . . . . . . . . . . . . . . . . . . B-060b Epstein-Barr virus . . . . . . . . . . . . . . . . . . . V-1242a ertapenem . . . . . . . . . . . . . . . . . . . . . . . . . . A-022a

abacavir, H-556c Abacavir/Lamivudine . . . . . . . . . . . . . . . . H-556b

Carbapenemases . . . . . . . . . . . . . . . . . . . . C2-097a Carbapenem-Resistant Klebsiella pneumoniae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-097b

ABSSSI . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1667a

catheter . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-562a

Acinetobacter baumannii . . . . . . C2-1905a, F-1495b

catheter-related bloodstream infection . . . . K-562c

acute otitis media . . . . . . . . . . . . . . . . . . . G-1054a adenovirus . . . . . . . . . . . . . . . . . . . . . . . . . . T-369b

cattle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-121a CCR5 antagonists . . . . . . . . . . . . . . . . . . . H-1582a

adult respiratory distress syndrome . . . . . . P-1023a

CD4/CD8 ratio. . . . . . . . . . . . . . . . . . . . .H-1570b ceftaroline fosamil . . . . . . . . . . L1-1667a, L1-300b

fidelity . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1518a fluoro-quinolone . . . . . . . . . . . . . . . . . . . . F-2056a

cell wall stress stimulon . . . . . . . . . . . . . . C1-1747a central catheter infection . . . . . . . . . . . . . . . K-562b

fluoroquinolone . . . . . . . . . . . . . . . . . . . . L1-1667b frameshift . . . . . . . . . . . . . . . . . . . . . . . . . F-1518a

African green monkey . . . . . . . . . . . . . . . . B-1308a aggregation . . . . . . . . . . . . . . . . . . . . . . . . F-1495a alcohol . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-2084a aminoglycosides . . . . .L2-2118a, F-2015a, C1-673a AmpC . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-776a amphotericin B . . . . . . . . . . . . . . . . . . . . . F-2015b Annexin A2 . . . . . . . . . . . . . . . . . . . . . . . . . B-060c anthrax. . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1338a

cephalosporin. . . . . . . . . . . . . . . . . . . . . . . L1-300c children . . . . . . . . . . . . . . . . . . . . . . . . . . . G-1054b chlorexidine . . . . . . . . . . . . . . . . . . . . . . . . . K-562b cIAI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1647a

antianaerobic activity . . . . . . . . . . . . . . . . . F-2056a antibacterial activity . . . . . . . . . . . . . . . . . . F-1495a antibacterial mode of action . . . . . . . . . . . F-1540c

class B metallo beta-lactamase. . . . . . . . . . . F-858a clinical data . . . . . . . . . . . . . . . . . . . . . . . L1-1667b clinical results . . . . . . . . . . . . . . . . . . . . . L1-1667c clinical trial . . . . . . . . . . . . . . . . . . . . . . . L1-1647a

antibiotic . . . . . . . . . . . . . . . . . . . . . . . . . L1-1667c

Clostridium difficile infection . . . T-1046b, F-1540d

antibiotic resistance . . .F-2072b, C1-673a, F-2015a antibiotic TA . . . . . . . . . . . . . . . . . . . . . . C1-1973a antibiotic . . . . . . . . . . . . . . . . . . . . . . . . . L1-1667b antibody . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-400f

CMV . . . . . . . . . . . . . . . . . . . . . A-1268b, A-1268c CMY-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . C2-121b coinfection . . . . . . . . . . . . . . . G3-1563a, H-1921a

antifungal. . . . . . . . . . . . . . . . . . . . . . . . . . . F-823a antimicrobial . . . . . . . . . . . . . . . . . . . . . . . F-1540b antimicrobial therapy . . . . . . . . . . . . . . . . . G-876a antiretroviral therapy , H-1570e antiviral . . . . . . . . . . . A-1268b, A-1268c, H-1921a antiviral treatment . . . . . . . . . . . . . . . . . . . A-1268a anti-virals . . . . . . . . . . . . . . . . . . . . . . . . . . V-1080a aspiration pneumonia . . . . . . . . . . . . . . . . F-2056b atomic force microscopy . . . . . . . . . . . . . . F-1540c AVI-7288 . . . . . . . . . . . . . . . . . . . . . . . . . . F-828a

B babesiosis . . . . . . . . . . . . . . . . . . . . . . . . . . P-1023a bacteremia . . . . . . . . . . . . . . . . . . . . . . . . . F-1540b bacterial persistence . . . . . . . . . . . . . . . . . . F-1540a bacteriophage amplification . . . . . . . . . . . . . D-731b beta-lactam resistance . . . . . . . . . . . . . . . C1-1351a biomarker . . . . . . . . . . . . . . . . . . . . . . . . . . H-556c bloodstream infections . . . . . . . . . . . . . . . . . D-776b boronic acid . . . . . . . . . . . . . . . . . . . . . . . . . D-776a brain . . . . . . . . . . . . . . . . . . . . . . . . . . . . H-1570d

community-acquired bacterial pneumonia. . . L1-300b community-acquired pneumonia . . . . . . . . L1-300c community-associated MRSA . . . . . . . . C2-1401b conjugated vaccines . . . . . . . . . . . . . . . . . . . G-876a CRBSI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . K-562a Cryptococcus infections . . . . . . . . . . . . . . . . . F-823a CTX-M. . . . . . . . . . . . . . . . . . . . . . . . . . . C2-121a CTX-M-15 . . . . . . . . . . . . . . . . . . . . . . . . C2-121b cUTI . . . . . . . . . . . . . . . . . . . . . . . . . . . . L2-2118a Cytomegalovirus . . . . . . . . . . . . . . . . . . . . . T-369a

D Daptomycin . . . . . . . . . . . . . . . . . . . . . . . C1-1351b deep sequencing. . . . . . . . . . . . . . . . . . . . H-1582a defensin . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-060b dolutegravir . . . . . . . . . . . . . . . . . . . . . . . . .H-556b doripenem . . . . . . . . . . . . . . . . . . . . . . . . . . A-022a DS-8587 . . . . . . . . . . . . . . . . . . . . . . . . . . F-2056b

E E. coli . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E-804a efficacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-1054a

Final Program

ESBL. . . . . . . . . . . . . . . . . . . . . . . D-776a, E-804a extended-spectrumơ-lactamase . . . . . . . . . D-776b

F

G gastrointestinal . . . . . . . . . . . . . . . . . . . . . B-1338a

H hand hygiene . . . . . . . . . . . . . . . . . . . . . . . K-2084a HCV . . . . . . . . . . . . . . . H-1921a, V-400c , V-400f healthcare-associated infection . . K-562c, L2-2118b hemodialysis . . . . . . . . . . . . . . . . . . . . . . . . K-562a herpes gladiatorum . . . . . . . . . . . . . . . . . G3-1563b herpes simplex virus. . . . . . . . . . . . . . . . . . A-1268a high throughput screening. . . . . . . . . . . . . F-1540a high-throughput compound screening . . . F-2072b HIV . . . . . . . . . . . . . . . H-1570d, H-556a, H-886a HIV coreceptor tropism . . . . . . . . . . . . . . H-1582a HIV infection . . . . . . . . . . . . . . . . . . . . . . H-1570c HIV Infections/immunology. . .H-1570a, H-1582b HIV testing . . . . . . . . . . . . . . . . . . . . . . . . H-1570a HIV therapy . . . . . . . . . . . . . . . . . . . . . . . . H-556a HIV viral load . . . . . . . . . . . . . . . . . . . . . . H-1570f HIV/AIDS . . . . . . . . . . . . . . . . . . . . . . . . H-1570e hospital database . . . . . . . . . . . . . . . . . . . . L1-300b hospitalization . . . . . . . . . . . . . . . . . . . . . L1-1667a human alveolar macrophages . . . . . . . . . . . H-1570c

I ICU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-300a immunoactivation . . . . . . . . . . . . . . . . . . .H-1570b immunosenescence . . . . . . . . . . . . . . . . . .H-1570b infants . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-1080a infection control . . . . . . . . . . . . . . . . . . . . K-2084a influenza . . . . . . . . . . . . . . . . . . . . . . . . . . V-1080a influenza A . . . . . . . . . . . . . . . . . . . . . . . . . V-400d

345

> Late-Breaker

KEYWORD INDEX

influenza vaccine . . . . . . . . . . . . . . . . . . . . . V-400d innate immunity . . . . . . . . . . . . . . . . . . . . . B-060b intravenous . . . . . . . . . . . . . . . . . . . . . . . . A-1946a invasive aspergillosis . . . . . . . . . . . . . . . . . F-2015b invasive Pneumococcal disease . . . . . . . . . G-1054b

K

objective end points . . . . . . . . . . . . . . . . . L1-1667c

O option B+. . . . . . . . . . . . . . . . . . . . . . . . . . . H-886a

sepsis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1495a

OXA-48 . . . . . . . . . . . . . . . . . . . . . . . . . . C2-097b

sexual transmission . . . . . . . . . . . . . . . . . . H-1570f SPM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-731a Spondylitis . . . . . . . . . . . . . . . . . . . . . . . . . . B-060c

OXA-like enzymes . . . . . . . . . . . . . . . . . C2-1905a

Klebsiella pneumoniae MDR. . . . . . . . . . . . . D-731c

OXA-type . . . . . . . . . . . . . . . . . . . . . . . . . . D-731a

P

Linezolid . . . . . . . . . . . . . . . . . . . . . . . . . . A-1295a LL-37, LL-30, LL-20 . . . . . . . . . . . . . . . . F-1495b

paediatrics . . . . . . . . . . . . . . . . . . . . . . . . . . D-776b Panton-Valentine leukocidin . . . . . . . . . . C2-1401b

LspA . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1973a

pathogenesis . . . . . . . . . . . . . . . . . B-060a, V-400c PCV13. . . . . . . . . . . . . . . . . . . . . . . . . . . . G-1054b

M

pediatric . . . . . . . . . . . . . . . . . . . . . . . . . . . . T-369b persister inhibitors . . . . . . . . . . . . . . . . . . . F-1540a

MALDI-ToF MS bacterial diagnostics . . . D-731b MAO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1295a Marburg virus . . . . . . . . . . . . . . . . . . . . . . . F-828a

pharmacokinetic . . . . A-1268b, A-1268c, A-1946a Phase-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . F-1540d PK/PD . . . . . . . . . . . . . . . . . . . . . . . . . . . A-1268d

mathematical modeling . . . . . . . . . . . . . . . A-1268a Measles . . . . . . . . . . . . . . . . . . . . . . . . . . . G-876b

plague . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1308a plasmid epidemiology . . . . . . . . . . . . . . . . C2-097b

mecA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1461a mecC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-1461a mechanism. . . . . . . . . . . . . . . . . . . . . . . . . . V-400c

Plazomicin . . . . . . . . . .B-1308a, E-804a, L2-2118a pneumococcal conjugate vaccine . . . . . . . . G-1054a pneumococci . . . . . . . . . . . . . . . . . . . . . . . . G-876a

metallo-ß-lactamases . . . . . . . . . . . . . . . . . . F-858a

PNU-100480 . . . . . . . . . . . . . . . . . . . . . . . A-1268d point-of-care . . . . . . . . . . . . . . . . . . . . . . .H-1582b Posaconazole . . . . . . . . . . . . . . . . . . . . . . . A-1946a

methicillin resistance . . . . . . . . . . . . . . . . C1-1747a methicillin-resistant Staphylococcus aureus . . . . . . . . . . . . . . . . . . . . . . C2-1401a, L1-300c MIC, Biofilm . . . . . . . . . . . . . . . . . . . . . . F-1495b microarrays . . . . . . . . . . . . . . . . . . . . . . . G3-1563a MOA . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-1973a molecular characteristic . . . . . . . . . . . . . . C2-1401a molecular epidemiology . . . . . . . . . . . . . . C2-1905a monkeypox . . . . . . . . . . . . . . . . . . . . . . . . . V-400b monoclonal antibody . . . . . . . . . . . . . . . . . . V-400b MS MALDI-ToF . . . . . . . . . . . . . . . . . . . D-731c multidrug-resistant gram-negative . . . . . . F-1540c multifaceted prevention program. . . . . . . . . K-562c multiple sequencing primers . . . . . . . . . . . . V-400a murine model . . . . . . . . . . . . . . . . . . . . . . F-2056a Mycobacterium tuberculosis . . . . . . . . . . . . . A-1268d

N nanoparticle . . . . . . . . . . . . . . . . . . . . . . . . F-2015b NDM-1 . . . . . . . . . . . . . . . . . . . . C2-097a, A-022a NHP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-1338a non-fermentative bacilli. . . . . . . . . . . . . . . . D-731a NVB302 . . . . . . . . . . . . . . . . . . . . . . . . . . F-1540d

346

Salmonella typhi . . . . . . . . . . . . . . . . . . . . . C2-121b screening . . . . . . . . . . . . . . . . . . . . . . . . . . . T-369a semen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . H-1570f

osteomyelitis . . . . . . . . . . . . . . . . . . . . . . . . B-060a outbreak . . . . . . . . . . . . . . . . . . . . . . . . . . . . G-876b

Klebsiella pneumoniae . . . . . . . . . . . . . . . . . F-2072a

L

S

Povidone Iodine. . . . . . . . . . . . . . . . . . . . . . K-562b proteolytic function . . . . . . . . . . . . . . . . . . H-1570c Providencia rettgeri . . . . . . . . . . . . . . . . . . . C2-097a pyrosequencing . . . . . . . . . . . . . . . . . . . . . . V-400a

Q QnrS1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . C1-683a

R radioimmunotherapy . . . . . . . . H-1570d, H-1570e RecBCD . . . . . . . . . . . . . . . . . . . . . . . . . . F-2072b resistance . . . . . . . . . . . . . . . . . . . D-776c, C1-683a resistance selection. . . . . . . . . . . . . . . . . . C1-1351a respiratory syncytial virus . . . . . . . . . . . . . . V-400e reverse-transcriptase . . . . . . . . . . . . . . . . . . H-556a rifampin . . . . . . . . . . . . . . . . . . . . . . . . . . . T-1072a RX-P873 . . . . . . . . . . . . . . . . . . . . . . . . . . F-2072a

September 9-12 |

seroepidemiology . . . . . . . . . . . . . . . . . . . . V-1242a

Staphylococcus aureus . . . . . . . . .C1-1747a, D-1461a, . . . . . . . . . . . . . . . . . . . . . . F-1540b, C1-1351a stem cell transplantation . . . . . . . .T-369b, T-1046a Streptococcus milleri group. . . . . . . . . . . . . . F-2056b structure-activity relationship . . . . . . . . . . C1-683a structure-function . . . . . . . . . . . . . F-2015a, V-400f sulfonylpyrrolidine . . . . . . . . . . . . . . . . . . . . V-400e Swine Influenza . . . . . . . . . . . . . . . . . . . . . . V-400d

T Tedizolid . . . . . . . . . . . . . . . . . . . . . . . . . . A-1295a tenofovir . . . . . . . . . . . . . . . . . . . . . . . . . . . H-556c therapeutic . . . . . . . . . . . . . . . . . . . . . . . . . . F-828a TP-434 . . . . . . . . . . . . . . . . . . . . . . . . . . L1-1647a TPA polymorphism . . . . . . . . . . . . . . . . . . . B-060a translation . . . . . . . . . . . . . . . . . . . . . . . . . F-1518a transplant . . . . . . . . . . . . . . . . . . T-1072a, T-1046b transplantation. . . . . . . . . . . . . . . . . . . . . . . T-369a treatment . . . . . . . . . . . . . . . . . . . . . . . . . . T-1046b treatment-nieve . . . . . . . . . . . . . . . . . . . . . .H-556b tuberculosis . . . . . . . . . . . . . . . . . . . . . . . . T-1072a Turkey . . . . . . . . . . . . . . . . . . . . . . . . . . . . L1-300a Tygecycline . . . . . . . . . . . . . . . . . . . . . . . . T-1046a type-specific real-time PCR . . . . . . . . . . . . V-400a typing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-731c

U urinary tract infection . . . . . . . . . . . . . . . L2-2118b

V vaccine effectiveness . . . . . . . . . . . . . . . . . . G-876b valacyclovir . . . . . . . . . . . . . . . . . . . . . . . G3-1563b VIM-type Metallo-Beta-Lactamase . . . . . . F-858a virus binding . . . . . . . . . . . . . . . . . . . . . . . . V-400b

W wrestling . . . . . . . . . . . . . . . . . . . . . . . . . G3-1563b

NOTES

Final Program

347

> NOTES

348

September 9-12 |

NOTES

Final Program

349

> NOTES

350

September 9-12 |

NEW LEVELS OF LEARNING WITH

ICAAC: The Digital Video Library Features Over 200 Hours of ICAAC 2012 Presentations ◗ Full-motion videos, PDF slides and MP3 audio

of many sessions

◗ CME credits above what you can earn at the

conference

◗ Convenient online and mobile viewing —

◗ Portable DVD-ROM for on-the-go access*

iPad®, iPhone® and Android™ devices *DVD-ROM will ship 6 weeks after the meeting

SPECIAL DISCOUNTS WITH ONSITE PURCHASE! ■

South Lobby Virtual Meeting Booth

■

Exhibit Hall Booth #1115

www.icaac.org/dvl

Save t he Date !

Final Program

Final Program

Suggest Documents

Final Program

final program

Final Program

final program

Final Program

final program

FINAL PROGRAM

final program

final program

Final Program

Final Program

Final Program

final program

final program

final program

Final Program

Download Final Program

Final Technical Program

final program - saric.us

final program

final program

Final Program - IFS2018

final program

FINAL PROGRAM - miccai 2013